<SEC-DOCUMENT>0001055726-23-000010.txt : 20230301
<SEC-HEADER>0001055726-23-000010.hdr.sgml : 20230301
<ACCEPTANCE-DATETIME>20230301163533
ACCESSION NUMBER:		0001055726-23-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230301
DATE AS OF CHANGE:		20230301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INOVIO PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001055726
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				330969592
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14888
		FILM NUMBER:		23694199

	BUSINESS ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		8584103134

	MAIL ADDRESS:	
		STREET 1:		6769 MESA RIDGE RD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INOVIO BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20050404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL CORP
		DATE OF NAME CHANGE:	20011116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GENETRONICS BIOMEDICAL LTD
		DATE OF NAME CHANGE:	19980213
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ino-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:d5376b60-4920-4297-91b8-ae15a0711c84,g:73741ec8-2e2b-4617-87f5-1b9c1ea3fbd1,d:02d4bef15c6d4619b17bfe55828c95c8--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20221231" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ino-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N180LTEtMS0xLTQ5ODI4_b9716ae4-dfeb-46d7-a56f-cd66648ab15b">false</ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N182LTEtMS0xLTQ5ODI4_0fdfed36-a2bd-416f-9772-c74b20717e1b">2022</ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N183LTEtMS0xLTQ5ODI4_82035183-9a8a-4b72-aeec-6b72050aad3f">FY</ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N185LTEtMS0xLTQ5ODI4_f24b663c-fd71-48ca-bb55-c55839a2d05d">0001055726</ix:nonNumeric><ix:nonNumeric contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy0wLTEtMS01MDQxMQ_8a092680-f934-40f5-bab2-8b87b0b9ccf7">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="i6a09be2c6e5c4d808f21c4869c433b68_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i6a09be2c6e5c4d808f21c4869c433b68_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2">P2Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i7bbe89ce4a474b04b398872bd94f43bc_D20190219-20190228" decimals="7" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjMvZnJhZzo2ZDZmY2FhZmI2M2M0MDlkOGExMmFiOGY3ZWYzYWRkMy90YWJsZTpmZDgyN2IxNDJiYzU0YmQxYjQ2N2M5MWJkOTJmOTczYS90YWJsZXJhbmdlOmZkODI3YjE0MmJjNTRiZDFiNDY3YzkxYmQ5MmY5NzNhXzItMS0xLTEtNDk4Mjg_2686e1ba-ee3e-41e9-8714-58f98394d693">0.1858045</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i5f047558dce94087b1f897876f14e1f3_D20220101-20221231" decimals="INF" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjE3L2ZyYWc6ZDY2NGU5YzdjMjRjNDE3YmExYzExYzM0ZjAzZTJmMzIvdGV4dHJlZ2lvbjpkNjY0ZTljN2MyNGM0MTdiYTFjMTFjMzRmMDNlMmYzMl85ODk1NjA0NjQ5OTkx_ae0a3ea2-2ea2-4a7a-97c8-36d404e7d3f2">50</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ino-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34f3ee93005e44e4818bc81e3c428fc3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i68aed334af06455c9f43334dc07c928f_I20230224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6327975f86354d84adb2cb38dcd5ea52_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i462df0bfe2224796bd3e4784559e9ff7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28fdf7ad489d4fce8f004f820b342526_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c2c1a9b72144f0a92349e7cf9e5a446_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie31c91acde4741fe900e7a84f2b0ad34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ecffdec9a64e498429f8977ea52114_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3a7a0113a6439694f0af4a15e4c7dc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idae06434a74c4378bb8e66fbb38683a8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91313ea012fb4e29a82373b1216240c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20b1cb6ae6442cfb1dd54c81a7d71f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7dc4c4c9f63349128d1754e94f5cc9e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d6cb11719d041f090cfb6c6b041e892_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i718af9ccd104415fbf64c9d32f74bb1e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8942a4a67cba41659b89e7b8521ab8eb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bb91b86850c4019853cfafe96543ff8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if583dbf110944d9b91969553df66a181_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad2ce681ebaa453d8289a854900c32fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77f6191d42744cbe9b446139968001a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc077e8d5154506ba48d33c68a71bfe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9c9e86d4a54a01b3a0e8c79d8927b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf7e09219084016a812c88d9977fa5a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i110d8cff3e7c4910b2e0c84f0f9c65de_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7da2f113135949f6b69b0f0304007c14_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13cf002a66c44d39492fe34b336faf0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71c1abee2354fad9e808f4f24fbcbd2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11369143520413d8c7da3da06fc56b1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib23b8d6624644da386cf1e538d1bd8af_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16ffc786c3c84f7ba4e698ca14539948_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ad082f8bde4a7a92524043edf853c1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75216b6319924276935aa28bd9bb7dcf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01a55d99d9834376b29d04025a363045_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4459abbf67aa4910bb765838712d9fe5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4028d9e38f094f768bb1e9452fc45472_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cf453e9844f4d6fa74be581ed00a513_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fd95af3528440b39f64c721172b95b3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ba6177eb6b8472495d2e2a45d024f63_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8666bf368748449bb6e324e42d8b1d21_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8501fb06a5774680b79276ad409fed15_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0151eb300ba9417ca13398ee631e0a11_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6a118a9cde4fde96c5f7c1ae0848ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4439b6c598d454e8b8ff9ceb6d62287_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if998a11fda824693a82b5630eee5944a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ed40a3258c4619b0d384f1c875f1b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7a2f2ae8ab40ccae727491f64f50ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6173a75999554213bd9ef6b178b3c5a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78e8ed6c44394b9d8730b7f657680c0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf99a57f4f0543779cb105cb89a2a1ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e327b57b7e447c8aadc23b5385ebe2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i564f8e98e6a4437d87441f8dad2ebdb9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1bdec8a908c4594afd92ff4781d3366_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i989ec83114ba4070a4bd52566656d740_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ff864730ea642239a8163e8e1918732_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f77b689e902453898c3df44adad4187_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6cae987a41b4492a9781bcec7e5cea0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i851b409487e4421e97a148072ac742ed_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ino:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6a09be2c6e5c4d808f21c4869c433b68_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c4af40c177746a9860d90e560bd8e93_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5c26fff9c54ee6aeec015bd77060ea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia738364cb3704782bff4583a29069493_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf4c53fa971d4d039d0b3f9f50813d00_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i778adc9858e4413284de317978f1491e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f6a30b1663b4a28822ba910bb5f0d2b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i385f8bc5e1ef496fa5bf4b77f4ac4c8d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i905fef709da24983a7a134952ad5cd76_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c357726a9834da5b7f9e01126ab1934_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i793c2cf60aba4213b7dda26b6bd1d0bf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2234c920452e4ca5a201f3f44924f639_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea03f1cc4604b918e8a86d38eb57330_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9983d93acb00482e8d0d425200e8a260_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acef92df1eb4002905dc17370558309_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26efa4ca4234676aff27081710a3c9f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b5b9fd187a54c0e8a75c5406595c067_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b6db699219044e993eb9ea5a3b6b102_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7e112a8d0b4389b6475906e5e25f9a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c6268345f84faf98df07aa08e09d50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i666a23e01c6442398866e53b58f368d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cb872fefb714074b5880db078069e39_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie489748523ab48ef9c00350ee420a2ad_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib54af4db6f934822936c9df96da62d29_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacebae33d2f744a48bfe3f27c87963b5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c2ca730669f40a3b880aad76ef47eb8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec30835ff64649d1af8bee1755bb6747_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0233517f0744b4d84dbc2857651922e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8427d8144b8a45508082c0e9224f6b9a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if216a168540f4767a05cedea2727d91b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3508c7fdd5df49c9b3d412117527967f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba97b678f2164b7dab82b6edbc9c7f26_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605c60f66d234792a11598c1cdedabc7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d452e7c90114add826a2726068eca7b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39566c733fd24bfebb62337eb808c542_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcac4af5c7b542f9afc5cb5e93d18b8e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia146e47921c744fc956b2120c6439daf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd3d9ccb223c4b51adcc34fee442e12e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i950175750d8f45f99adff0b9d015b817_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i990e94fbd63b4cd8aa841335ddf7a196_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa2ff55b5b64c87ac5b7a3c20a2340a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e0c5185d2f4ec88fb795922202c563_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96a3222a554c43c892ad45d36bed2135_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b4cbfef541641c29b555849b7baa86b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e6793803cc44808ce478887c3e8548_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i022f7c48f8c449e0984cc5c418c9249f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4c58350d8dd4037a4eeb106f14f84bb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a04772ad7c34b45b0fea6aab0e11b68_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24234386041445bca5cb6066f1a957bc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa7c00e7c454fc0aadae3a3b369359e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id150bf83ee8f48f998faaca40b1a30ec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0c56d581394886b4899de7fc50e0e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e1e7149a8c6422490e7e06c70d28310_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a71317f6eea40f7b6476ead84dae594_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic78b5c6c0e794855951b9ce333c34e4d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if01705c616d24d9da3e0014282dd5837_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a901e2e495476b83006c89b06314cf_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5a02ab98d44b87a3c2fe66c95e090a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i677b7c07452f40d7bb6f5a339c25fa59_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05af6b16800c4f969cf22fdff24b2acd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d52f8c0138d4608b9e0be15696a4efd_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2001c79602b4f5b85e822a75b982b64_D20180411-20180411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-11</xbrli:startDate><xbrli:endDate>2018-04-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b72b34cbaa4c96b0e773c47a774b68_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea847db8af964a5a95a30170013066a4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1c6e230bbb4305a74e7bd299517f02_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624d921570e54646b679bccfad2456ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19d08d5f004243748735e0364a7ac6f0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5dd47e2e24e8451fbedb25fb61279123_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6e68fd9d7034356a5daff34bafca427_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fb8532210c34bb3b02229812e1d6ccf_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d6c481f47d4e698f05a3589d8d4a5f_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82d467a9444a402eab652428f5f340aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i953055247fb0438694e88e83fe092f34_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e7ae79d83454d1a94162dfaaf181c92_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0972fde3981d46cb86a06b579ea816d4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i526c4d9267ea40f59d929793e9e609e6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i650513b7b0b042eba217f78ede5cb81f_D20181001-20181031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i743b9e9db9bf47abb1bdc985839a7e95_D20190801-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd06dc6be4e490f8fbf48221de75ab1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93c96775125a4f49bee81002302c8881_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fb85cb9a30245a59734675d97301f64_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0715a0fcc3914e2c86a2471c1d0415ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2137a35c3759425c9f6105f0eb18daad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife18dab7106f4cfab95e7efa34dda590_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83eec1d80cf54e79a405e0ac8c7c3446_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c86a87fced4537bffa81e5585402dd_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3e8f8ce3eb145728468142b2b4b4151_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ef3b95e79d94359931733a1d9c874ae_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87dc46031834cbabb9a823d652b3f5f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdb55475f21c4c86a9e26fd186d37d72_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd5f4f4bdca146dda0cf7316b5eddc03_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a8536568e6643a3826b271bb765d299_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115835ccef2c4c728f65ff50b203bbd4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieed26bae30344c0d930f02e46a10d2c3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045659d16234450a8682a7768426647b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6069d61346224762a4acb6d0319cd34b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c404065aa374228af041779ee4cc690_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i394eb6bee034494f9c9496c6ce256993_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00707a03b34c4fcbbec4fec91c975908_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe96ffbd0e984b259b36f75c11046687_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib38202672cc64d6990a3e920cb9cc97e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1224aeba242c41d5ab7db7226ed80399_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id37d05cb9f5d42caa6e09898a3f84573_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3fca8c2d78840729b4acd29bd42d46b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8231f8423e648e3831733a20c3b6e00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie753e892040f46cfa5eaaf24a0aa310d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>ino:position</xbrli:measure></xbrli:unit><xbrli:context id="i5b2add8fd23e494f887f27eb874b2134_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib18c28bf3960424a854d14b13675393f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93622c19682e47a18bd389447a17beb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d28cb507a504198a57d5181ce08ac8f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib904a495e82646c380154c25b095b55a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07066c0990e24538bc05caed189f78fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3648b2d58fe42268eae0877934e1081_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b37d006f03d47b3b8e7c0a1873c00f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb9dfd820dc743fda9f61d926e90be25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc86246d2a124c419654fa1e9bf8dc32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86004616beac41238cc173e85e423ddf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i477c90290ae74d219ed8ba9ff7390f90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dc9d150f733431f97498d614ee4a8db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i186cb4d8d2d24f43bf75c63e229647ae_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i619f71a84cc54c479c772df5eeaf3bb8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01197e4e2ce54a9f9c6f4e01fa548a46_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72d5d82697444dd38fb5e557609c0c36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c8775bf17fa47f3b938211c08019c26_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d1f385cc4944c44a2038acebc25f9cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9de6860abc2a4ad68642fef0b295cbfb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48fb0a0d192947be932e34702459a178_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4be9cf58cb4a4d05880ed751b4f5ec5b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84830cf68b7443bca9c062e649dd83d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37194e785fbe427fa670a663c8578ab1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e279598e344efcb34f380149832910_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49986e2e16ef472cb8df7bab0e9e2546_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3867bd2a43024f87bb44709b985fcf7d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06eace206e6e4294aa395dafbbaf4688_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fceb1189d5448b79ca2bbb77264e050_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23d3f92702014f969ac3d1af800214f7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f4ae7cd847f4617951fb8ff3f3100f1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ffb3a787b3b45cd813aa7b2f5ed87b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd4592471329482e8c0661f6abdb0594_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i936b53682ed8485d8ce3260a62f5541a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2013fc31e88d4b0bb859d16c236f4634_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0608f84c1ca4f2990271fa5a4b1c79b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91447d855fe3401ebf5c16b61ccf4a0f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0971090c3254e23a37a6a1c85cbf09d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i176930b6d6c643fa8db9ce1084359b5d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28e0a92a960d49f88d849ddf682a08b5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67083206a9594573bb4dbe4cb68aa3af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49b293969cc040c983dd1f2e97563558_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6c675487b97442eb5c6a91aff241fcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3448daba76f24eb6a3f805c849575a5e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d198f1f030e444294b8ea36f6116b09_I20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77a209b559d5422f82009bd955139f3d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b1117d2331b42a9a95485f3c02170c5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6b301ab495414cb544cfeec3509fd4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i482ffaf143e145b29a6c013341ec65b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8a8f742a37148a19cfc04478fa8b852_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4852db4bcad84553977888af623d132e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i373cde7a8abc406eb292a0ab2cbe85ec_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0234d350c34dfeac832494bdf5206c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ea35c5c90b42d78cff73917a5896b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3891a2d892d444ab2b6d75d1e90d526_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1443f3e411954434acd4f1bcdb1ca5a3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie89ddab5935542b39c5b4ea28140cb13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24e8db3eab40498a818ac04516b22b71_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e498a11c93d46d08d441fc1e554b563_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedaf8cf0acdd46ffa0621f524655250d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib41ca5add1234f08a9091fcbd9f51b00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87ff63586a45468dad886c18594fa0da_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99b74bae4f344e8cbf89dd04418411bf_I20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bbe89ce4a474b04b398872bd94f43bc_D20190219-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-19</xbrli:startDate><xbrli:endDate>2019-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>ino:day</xbrli:measure></xbrli:unit><xbrli:context id="ibda181353d814282bfd46ddc089e9aed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1242ebcd358e4468bb5a2b7b601e0e98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i063303991a5041809d8211c86ef7e0d7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316205765748470e9cebde8ab78a5ae1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8ef7a9972a45d68c3268ee6c9acbc2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="i189926960d2b4b1c89848491c1ce2245_D20191226-20191226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-26</xbrli:startDate><xbrli:endDate>2019-12-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11da8ee96782442db68b426be9a9c645_D20210317-20210317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-17</xbrli:startDate><xbrli:endDate>2021-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7044f94f6dec495687d4bb1d5e39219b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f47b0a510ab4c979a96d6c6c04992e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29af49ccbb494cac8290ea49a3d605f0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i665787c5dd50498ba18daa109d1fa1ce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36e51ec971e349c587d471174bf94e10_D20211109-20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-09</xbrli:startDate><xbrli:endDate>2021-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fca5b2439d74d788e0d439a6f383003_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3109c39c7dfe480a826f059e43510271_D20210125-20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-25</xbrli:startDate><xbrli:endDate>2021-01-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i256486c034e74959bea28a09407f168f_I20210125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95c79bb8b10c435bb78e5dfe4b84d8d3_I20160513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i333db47ca7594db8809bb340e9af167b_I20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieaecf1d1bad04443b82d7b4be5e89ad5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4bb1b79238d54150bdfc9c781bd5fc1b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36807b22af264de2a3e9c80926cea5b8_I20220624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a0cabe1550b4ee2905d7e3e21009431_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae9a3aca7b5e4544b7ec63dc9e3b7fdf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10ba30993b07407997027cb283263b45_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf2749e9d9094ef991e679e1b9cc83fe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0768a9275ad64e93b52e47eba8d93b74_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1455c9a790944d63a8c0009471f82bcb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b4f24c6cfc0434db99f876f8856c535_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i107f49b9f6cb4502ac08563229ac6d5f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide5ec322e22c4863b4ec3beac0c62440_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f6468c1ea34497783cc0f8b7387f0fb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1288bd631248f7b04452e9589385b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ce9a943aa164c8c8f02796513f3578c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdb2a873738e472696885e376b3e567b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10ced5af10f440b0bebf5936fd97f874_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcb4a7e1962b43df901c999bf8eb65ec_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb960975b9964654908d00a526851994_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i432ab502425b494c81d8825eac83ad96_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87e0aa1271764f94a354dfcb830960c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8bf9009e8e749869810035ae3b924e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc9a82ce6304c689c1c2e03e7569363_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefc5ac42f1b746c1aebd94bf8240f755_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0bfc9c5f8ce490dac127867d5e5bd45_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f047558dce94087b1f897876f14e1f3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d81dec2251d43bc8eec87ebd45ccbbe_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="if9eb27232eb94ef4b6dc9ca0783ab193_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850961a8bdd6418e89855c3fe22af042_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e5bfcb200d2499cbfc64d230771e3f2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ino:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ib9df2365f9454744b557f8f6b5aa3936_I20210309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84820f5d4e9a4ac2a3cac63e01a7c45c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if12b9cf6eeaa4f20aa6799810ad465db_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i650dedeab35546edb17b1d6256119449_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfaee2d1c32b4607a08c7c73282b04f4_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic954d78339b94180a278d80e6ec99f23_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:KoreanStateIncomeTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i071ac54a560b456dab72ccae0e2af24a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c37010c9d245c2a4349d20fc492085_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d82d3ec063a42378ab880fcb038f565_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbb0e730795e49dd91d896275f2661e3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2be958cfc18849ac8a625b235decac6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c5b7985c2de404f91adb16157f71c16_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20e06ec8473a49698ac1e8cad9679f61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i817aab3e5a42474f970fce9fc4e1a2fa_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7448c2b34ba40ff87e0d9cf69208bc4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957537cf7fde4f90a792a8cc73b50b9c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6b5e86588ce4204ad22f6367761229d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64432e8f98434affba895ba9830ae610_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70087078e10b48ae9664922295bdecd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8718060c67641f5a4518ae2471cec53_D20160301-20160331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-03-01</xbrli:startDate><xbrli:endDate>2016-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia687677e1a354cffa7a0cefe22646f85_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i566a6c987fa446498049b5aff48c2020_D20161101-20161130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-11-01</xbrli:startDate><xbrli:endDate>2016-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0abccea943c4509ba78bb57e68e1da5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb7ba3207c4249c49792d6993d00f3d2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65f278575cc40f2a1b542d1f3241a97_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e671e6067184545b7d91d89a7ca3096_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c216752c5f4440ea912be5dd36dbc5c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b843063dda44b569897c0fcac97eea1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4aaa62817594ece850f89f4ae127ddf_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44df340754904d60b387ac967f2fee31_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15e530f73df34c398e566264b204a2d4_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i560af3a39c4c40d3874fed14c6721a9f_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7f0c3c89e134e6891c4524576f4fe89_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i876fc07681a44ee487cf4e512393be2a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i312c32046c954040884f45e992037d33_D20200601-20200601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69253dc5f01644e79d35a7205adbc9bd_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6407ce5393843909b745480c6ca2554_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb50f5b639ee412d94255ce7d570a547_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if32e8f4ea58f4ce98e067ea7e1754cba_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c7c8026b35043069ab11881210ac603_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i270dcf1d2c4b423d889baab7dc6a12bc_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b0650a02db7416e902fd5464a19fe1b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53479a023482480fa55a43efd0b59aab_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1281c7cd4bf4b6394985b10e622fc01_I20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i610a9153ce62445cb06cc24f93ac3001_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i523a6b123f304bd09e5c0ae91b9adde5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i988b6f75b9e6460c956d40049e2a8e51_D20220301-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2572a2fffba544ef9e41966fc1155177_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98148ffac5c843dab35c796318d95e41_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c7588fc83b4e679b3d9caf40ad0d04_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i339d243acc4a4538ae743f7ea71e863b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-31</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>ino:employee</xbrli:measure></xbrli:unit><xbrli:context id="if1a9994a0e9c42d682a6382e17a889cd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b1cb2986d5240299edf1d6dd0ab9f19_I20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5c59f2516940b1ba2ee6b6fca25969_D20230201-20230228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001055726</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI5_20eb05e5-8e85-4bcd-bba7-9968f435e9fe">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6YmNlZjUxNzllNDFiNDQzYWI2MDMwZmZiMmMzZmMzNGYvdGFibGVyYW5nZTpiY2VmNTE3OWU0MWI0NDNhYjYwMzBmZmIyYzNmYzM0Zl8wLTAtMS0xLTQ5ODI4_d7c4d15f-42ae-4755-b05e-dbba1690743d">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> FOR THE FISCAL YEAR ENDED <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8xMjQ_6f719939-fe1f-478f-9251-381ea99466a7"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8xMjQ_b27b99ab-c232-4484-9746-d1ccaf5c59ea">DECEMBER 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.465%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZDdjM2MwNjdiM2JhNDY0MmJlNTM1YmJkNzYxYTc4MDIvdGFibGVyYW5nZTpkN2MzYzA2N2IzYmE0NjQyYmU1MzViYmQ3NjFhNzgwMl8wLTAtMS0xLTQ5ODI4_e90f4e8f-d378-4eb4-af65-e1bf5e2bd191">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">COMMISSION FILE NO.&#160;<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIz_0c004c70-2dcc-4383-b975-f2afbc4d8563">001-14888</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ino-20221231_g1.jpg" alt="ino-20221231_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:204px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDMw_846ff1c3-7c2f-41e7-a6a4-432ba562bb91">INOVIO PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18wLTAtMS0xLTQ5ODI4_37f41a45-10f9-4118-926d-11cf759a17f7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18wLTItMS0xLTQ5ODI4_d4943833-51f4-461f-9f27-037ccc16073e">33-0969592</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfNA_010c30b0-2dd5-4190-a7c8-7ee2c730b259">660 W. Germantown Pike</ix:nonNumeric>, <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfOA_218d6cac-71d8-4dcd-8767-6df8068e1276">Suite 110</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfMTE_6e58c372-d816-47ec-8731-e0f501d1138a">Plymouth Meeting</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfMTU_c4d5d95b-3cce-4f1a-98f8-a5d83c795c7f">Pennsylvania</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTItMS0xLTQ5ODI4_ef284de3-cfbe-4213-a324-bdb5604d96b8">19462</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">REGISTRANT&#8217;S TELEPHONE NUMBER, INCLUDING AREA CODE: (<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI0_e2db9a3a-6e25-452c-a576-8fccd2999142">267</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI1_9b2c64c1-f1b1-4e2b-9c52-c1f31595bb77">440-4200</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(B) OF THE ACT:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.936%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.799%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6Nzg3OGU1MzJjYmU2NDgxMDk3MmZlMzUzYmEyNDg1NTkvdGFibGVyYW5nZTo3ODc4ZTUzMmNiZTY0ODEwOTcyZmUzNTNiYTI0ODU1OV8xLTAtMS0xLTQ5ODI4_e8cba96d-62d3-43dd-b7a0-b15d402bda46">COMMON STOCK, $0.001 PAR VALUE</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6Nzg3OGU1MzJjYmU2NDgxMDk3MmZlMzUzYmEyNDg1NTkvdGFibGVyYW5nZTo3ODc4ZTUzMmNiZTY0ODEwOTcyZmUzNTNiYTI0ODU1OV8xLTEtMS0xLTQ5ODI4_d626b998-2978-4e19-9fbe-75b4602b1194">INO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6Nzg3OGU1MzJjYmU2NDgxMDk3MmZlMzUzYmEyNDg1NTkvdGFibGVyYW5nZTo3ODc4ZTUzMmNiZTY0ODEwOTcyZmUzNTNiYTI0ODU1OV8xLTItMS0xLTQ5ODI4_c1c80e8c-a87e-4d4f-a171-705160f47ad9">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT: NONE</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV85ODk1NjA0NjU0NDgx_492936d3-9a6a-4c76-a913-e4cc1659d5ac">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI2_740d9940-baac-40de-885f-9598758c69e1">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI3_f5d167f1-e314-4717-97a6-2fe9a91b2ba8">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIw_8b731d02-e78b-40ca-9c78-c6872089a281">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#168;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZjQwMzU4ZjExMGZkNGRiMGE2NmI3OTc4MDZhZmI3NWEvdGFibGVyYW5nZTpmNDAzNThmMTEwZmQ0ZGIwYTY2Yjc5NzgwNmFmYjc1YV8zLTAtMS0xLTYwMzYz_0d3e85cb-6f16-4316-9e96-3f502a8a3a32">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZjQwMzU4ZjExMGZkNGRiMGE2NmI3OTc4MDZhZmI3NWEvdGFibGVyYW5nZTpmNDAzNThmMTEwZmQ0ZGIwYTY2Yjc5NzgwNmFmYjc1YV8zLTQtMS0xLTQ5ODI4_f11fd50d-1a2d-4998-a5d5-1ba2fc96e7c7">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZjQwMzU4ZjExMGZkNGRiMGE2NmI3OTc4MDZhZmI3NWEvdGFibGVyYW5nZTpmNDAzNThmMTEwZmQ0ZGIwYTY2Yjc5NzgwNmFmYjc1YV80LTQtMS0xLTYwMzYx_e1d9330b-7181-4a5e-a63b-990e33b6c5d1">&#168;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIx_ba6f5bdb-55a5-4310-ae35-2a5aa1667877">&#9744;</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. &#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8xMDk5NTExNjMyMjY4_b908d060-314d-48e3-94a7-88d27cb9e970">x</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity (which consists solely of shares of Common Stock) held by non-affiliates of the Registrant as of June&#160;30, 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="i34f3ee93005e44e4818bc81e3c428fc3_I20220630" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8yNzQ1_e28e81e5-b6ed-4f2b-a893-e9ba580009fe">425.5</ix:nonFraction> million based on $1.73 per share, the closing price on that date of the Registrant&#8217;s Common Stock on the Nasdaq Global Select Market.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of shares outstanding of the Registrant&#8217;s Common Stock, $0.001 par value, was <ix:nonFraction unitRef="shares" contextRef="i68aed334af06455c9f43334dc07c928f_I20230224" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8yOTYw_244b464a-c665-4e85-9808-614540584f63">260,131,986</ix:nonFraction> as of February&#160;24, 2023.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIy_e29300bf-0c8c-4fc7-b435-72097de1238c" escape="true"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2022.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_10">PART I</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_10">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_13">ITEM&#160;1. BUSINESS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_16">ITEM&#160;1A. RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_16">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_19">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_19">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_22">ITEM&#160;2. PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_22">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_25">ITEM&#160;3. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_25">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_28">ITEM&#160;4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_28">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_31">PART II</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_31">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_34">ITEM&#160;5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_34">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_37">ITEM&#160;6. [RESERVED]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_37">53</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_40">ITEM&#160;7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_40">54</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_58">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_58">62</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_61">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_61">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_64">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_64">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_67">ITEM&#160;9A. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_67">63</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_73">ITEM 9B. OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_73">7</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_76">ITEM 9C.  </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_76">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_76">73</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_79">PART III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_79">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_82">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_82">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_85">ITEM&#160;11. EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_85">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_88">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_88">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_91">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_91">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_94">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_94">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_97">PART IV</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_97">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_100">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_100">66</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_103">ITEM 16. FORM 10-K SUMMARY</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_103">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_106">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_106">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_109">CONSOLIDATED FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_109">1</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_13"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K (including the following section regarding Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations), or this Annual Report, contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates&#8221; and similar expressions or variations of such words are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading &#8220;Risk Factors&#8221; below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report includes trademarks and registered trademarks of INOVIO Pharmaceuticals, Inc. Products or service names of other companies mentioned in this Annual Report may be trademarks or registered trademarks of their respective owners. References herein to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;INOVIO&#8221; or the &#8220;Company&#8221; refer to INOVIO Pharmaceuticals, Inc. and its subsidiaries. References herein to &#8220;DNA medicines&#8221; refers to our product candidates in development for diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Risk Factors</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks, including risks that may prevent us from achieving our business objectives or may adversely affect our business, financial condition, results of operations, cash flows and prospects. These risks are discussed more fully in Part I, Item 1A., Risk Factors herein. These risk factors include, but are not limited to, the following: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary smart device technology.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional capital to develop our DNA medicines and proprietary smart device technology, which may prove difficult and costly to obtain.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are currently pursuing third-party sponsored and funded development of this candidate, but there can be no assurance that it will ever receive regulatory approval as a vaccine booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">DNA medicines are a novel approach to treating and preventing disease, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we and the contract manufacturers upon whom we rely fail to produce our proprietary smart devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary smart devices and DNA medicine candidates.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have agreements with government agencies, which are subject to termination and uncertain future funding, which could have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may be harmed if our restructuring plans do not achieve the anticipated results or cause undesirable consequences.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face intense and increasing competition and steps taken by our competitors, such as the introduction of a new, disruptive technology may impede our ability to successfully commercialize our DNA medicines, if approved.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.</span></div><div style="padding-left:4.5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. Our goal is to advance our diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, our DNA medicine candidates have shown the ability to generate immune responses, especially CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and memory T-cell responses against targeted pathogens and cancers, via our precisely designed plasmids. These plasmids are delivered into cells using our investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our lead candidates are focused on diseases associated with HPV. In 2022, we announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated Recurrent Respiratory Papillomatosis (RRP). In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces our belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Characteristics of DNA Medicines </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines are optimized DNA plasmids containing a gene encoding for a target protein which is expressed once DNA medicines are delivered into cells. Characteristics of our DNA medicines include:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">T Cell Responses: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have demonstrated the ability to generate high levels of T cell (CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and memory) response along with antibody response. CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T cell responses are thought to play an important role in clearing tumors or infected cells.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Tolerability: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines appear to be well-tolerated when evaluated against multiple disease targets. Our DNA medicines have been administered over 15,000 times across more than 5,000 participants to date.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Ability to Readminister: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have been used in clinical trials to boost immune response via repeat administration, offering the possibility for boosting without any concerns of generating an anti-vector response. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Versatility:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our gene encoding technology can target any disease or condition that is strongly associated with an antigen or protein.   </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.07pt">Stability of Product: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines have been shown to be stable at room temperature for extended periods and do not require frozen storage or shipping. Certain of our DNA plasmids under development have been room temperature stable for over 6 months.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.17pt">Design and Manufacture: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DNA medicines can be rapidly designed and scaled. Ease of manufacture may provide a cost advantage. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;padding-left:10.5pt">Delivery Mechanism:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> Cell membranes can hinder the entry of large molecules such as DNA plasmids. To overcome this barrier, delivery mechanisms such as electroporation are used to increase cellular uptake.  </span></div><div style="margin-top:5pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Our DNA Medicines Platform</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our DNA medicines platform consists of DNA plasmids and our investigational proprietary smart device, CELLECTRA, which is used to deliver the DNA plasmids into the cell. These two components combine to create a versatile platform that has the potential to target any disease or condition that is associated with a specific antigen or protein.   </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> - DNA Plasmid Design Technology</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our precisely designed DNA plasmids are circular double-stranded DNA that have been optimized using our proprietary SynCon technology to express the target antigen or protein. In the areas of HPV-related diseases, cancer, and infectious diseases, the expressed proteins are the antigens that are strongly associated with the target disease. The expressed antigens, in turn, elicit antigen-specific antibody and T cell responses. We first identify one or more antigens that we believe are the best targets for directing the immune system toward a particular tumor or infectious disease. We then apply our SynCon design process, which analyzes the genetic make-up of the selected antigens from multiple variants of a tumor or strains of a virus. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each antigen, SynCon technology creates a new genetic sequence that represents a nucleotide consensus sequence of the targeted antigen. In doing so, we believe we can create a differentiated SynCon sequence to help the immune system better recognize the target antigen and potentially variations of the target antigen. We have generated immune responses, including CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and memory T cells, with SynCon-designed DNA medicines against various tumor-associated antigens, as well as against different strains of certain infectious diseases in human clinical trials. Because the engineered SynCon sequences are substantially similar to the original sequences, without matching them exactly, we believe they are patentable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a SynCon sequence is engineered, it is then inserted into a circular DNA plasmid with its own promoter. Promoters serve a vital role in &#8220;promoting&#8221; the expression of the target antigen once the DNA medicine has entered the cell. Through our SynCon technology, our DNA plasmids have been optimized to enable high expression in human cells. We believe these design capabilities allow us to better target appropriate immune system mechanisms and produce a higher level of antigen expression compared to traditional approaches, potentially enhancing the overall ability to induce the desired immune response.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plasmids are then manufactured in a bacterial fermentation process using scalable manufacturing technology. We have recently developed a high-yield manufacturing process which we anticipate using to manufacture our DNA medicines. The manufactured DNA medicines are designed to be stable under normal environmental conditions for extended periods of time. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Delivery Technology </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large molecules, like DNA plasmids, tend to be hindered by the cell membrane from entering the cell. To overcome this hurdle and allow for an efficient cellular uptake of our DNA plasmids, we have developed the CELLECTRA delivery technology, which delivers the DNA medicines directly into cells either intramuscularly (IM) or intradermally (ID). CELLECTRA devices use brief electrical pulses to reversibly open small pores in the cell membrane, allowing DNA plasmids to enter. Through this process, the cellular uptake of the DNA plasmids can be substantially increased compared to the injection of DNA plasmids alone. This improved cellular uptake has enabled the immune responses and efficacy results observed in our clinical trials to date.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CELLECTRA device portfolio currently consists of three models. CELLECTRA 2000 can perform both IM and ID injections and has been used in numerous clinical trials to date. CELLECTRA 5PSP is our new IM device utilizing a prefilled drug cartridge. CELLECTRA 5PSP has been used in our Phase 3 trials (REVEAL1/REVEAL2) for cervical high-grade squamous intraepithelial lesions (HSIL). We are also planning to use CELLECTRA 5PSP for the planned Phase 3 trial for INO-3107, our DNA medicines candidate for RRP. Finally, CELLECTRA 3PSP is our next-generation ID delivery device developed with support from the U.S. Department of Defense, which is ready for large volume production and application submission to regulatory agencies for review and approval. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CELLECTRA devices are validated and manufactured under Current Good Manufacturing Practices (cGMP). We have filed device master files with the U.S. Food and Drug Administration (FDA) covering the use of CELLECTRA smart devices in human clinical trials. CELLECTRA 2000 and 5PSP models have received CE mark certification in the EU.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for administration of our DNA medicines is illustrated in the following graphic. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><img src="ino-20221231_g2.jpg" alt="ino-20221231_g2.jpg" style="height:265px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA Medicines and HPV-related Diseases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human papillomavirus (HPV) is a sexually-transmitted, persistent viral infection with one or more high-risk genotypes that can lead to warts, precancerous lesions and cancers, such as RRP, cervical, head and neck, anal and vulvar dysplasias, which are abnormal precancerous cells, and cancers. Approximately 90% of all HPV infections clear naturally and do not result in disease. However, for those not able to clear the virus naturally, persistent infection can lead to cancer and other debilitating, life-threatening diseases affecting quality of life.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV types fall into two groups. Low-risk HPV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.g., HPV 6 and HPV 11) may lead to benign growths (warts or papillomas) that can develop into conditions such as RRP. High-risk (HR) HPV </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.g., HPV 16 and HPV 18) may lead to cell changes and lesions (i.e., precancerous dysplasia) that can become malignant and lead to cervical cancer. HPV causes nearly all cervical cancers and many cancers of the vagina, vulva, penis, anus, rectum, and oropharynx.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While there are currently vaccines available to prevent HPV infection, challenges with acceptance, accessibility, and patient compliance have resulted in many vaccine-eligible people remaining unvaccinated and at risk. It is estimated that even in the United States, only 50-60% of the eligible population has been vaccinated against HPV. In addition, current preventive HPV vaccines cannot treat or protect those already infected with the same HPV genotypes. As a result, there is still an urgent need for the development of HPV therapies that can treat existing infections and prevent the development of HPV-related diseases. The current standard of care for many HPV-related diseases, including cervical dysplasia, cancer, and RRP, is surgery. These surgeries can be invasive and may be needed repeatedly because the underlying HPV infection is not eliminated. This is especially true for chronic diseases such as RRP and anal dysplasia. In addition to surgery, other options are being explored to treat HPV-related diseases, including the usage of checkpoint inhibitors and other immunotherapies.    </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the key characteristics of DNA medicines that we believe are important for the treatment of HPV-related diseases are listed in the following graphic:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><img src="ino-20221231_g3.jpg" alt="ino-20221231_g3.jpg" style="height:246px;margin-bottom:5pt;vertical-align:text-bottom;width:645px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our DNA Medicines in Development</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chart below provides an overview of our DNA medicines pipeline. Each of the programs identified are described in more detail below.</span></div><div style="margin-top:5pt"><img src="ino-20221231_g4.jpg" alt="ino-20221231_g4.jpg" style="height:325px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-3107 for HPV-related Recurrent Respiratory Papillomatosis (RRP)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRP is a life-long, rare disease characterized by the growth of tumors in the respiratory tract primarily caused by HPV-6 and/or HPV-11 genotypes. Although mostly benign, such papillomas can cause severe, sometimes life-threatening airway obstruction and respiratory complications. A distinguishing aspect of RRP is the tendency for the papilloma to recur after surgical procedures to remove them. If RRP develops in the lungs, affected individuals can potentially experience recurrent pneumonia, chronic lung disease (bronchiectasis) and, ultimately, progressive pulmonary failure. In extremely rare cases, RRP can develop into squamous cell carcinoma. Additional symptoms of RRP can include a hoarse voice, difficulty in sleeping and swallowing, and chronic coughing. RRP symptoms are usually more severe in children than in adults.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incidence and prevalence of RRP is variable and depends on several factors that vary based on geographic location. There are estimated to be approximately 14,000 active cases and approximately 1.8 new cases per 100,000 adults in the United States each year. Global data for RRP is even more scarce, but available studies show a burden of disease in almost every country studied, ranging from an incidence of 0.18 cases per 100,000 adults in Lesotho to 0.54 per 100,000 adults in Norway and 0.02 cases per 100,000 children in Australia to 2.8 per 100,000 children in Thailand. The average yearly cost of treatment for RRP is estimated to be approximately $72,000. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced preliminary results from an open-label, multicenter Phase 1/2 trial evaluating the efficacy, safety, tolerability and immunogenicity of INO-3107, a DNA medicine candidate targeting HPV-6 and HPV-11 associated RRP.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For this trial, adult patients first underwent surgical removal of their papilloma(s) and then received up to four doses of INO-3107, once every three weeks. The study protocol also included the administration of INO-9112, which encodes for human interleukin-12 (IL-12) to help enhance the immune response. The primary endpoint of this trial was safety and tolerability. Interim results from the trial showed INO-3107 to be well-tolerated with all patients completing the trial follow-up. Treatment-emergent adverse events (TEAEs) observed in the trial were generally low-grade, with 86% of patients experiencing at least one TEAE, most of which were Grade 1. Three patients (14%) experienced a Grade 3 TEAE, but none were deemed related to treatment with INO-3107. The most commonly reported TEAEs were injection site pain (38%) and fatigue (19%). While two serious adverse events were reported, these were also deemed unrelated to INO-3107.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial also assessed the efficacy of INO-3107. Preliminary results from the initial cohort of 21 patients showed a statistically significant reduction in the number of RRP surgical interventions in the year following the administration of INO-3107 compared with the year prior to treatment, which was the clinical endpoint of the trial. Of the 21 patients, 16 (76%) had a decrease in surgical interventions in the year following the administration of INO-3107 relative to the number of surgeries in the year prior to the trial. Of those 16 patients, six required no surgical intervention during the trial period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was a median decrease of three surgical interventions (95% CI 1, 3) across the initial cohort. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the trial, INO-3107 generated cellular responses against both HPV 6 and HPV 11, spanning both CD4 and CD8 T cells, including killer T cells. T-cell activity against HPV 6 and HPV 11 was present at the study end, which was 43 weeks after completion of treatment, and is indicative of a persistent cellular memory response. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-3107 was granted Orphan Drug Designation (ODD) by the FDA in July 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we announced positive preliminary results from the second cohort of our Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated RRP in adults. In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 patients (91%) had a reduction in surgical interventions in the year following initial treatment, with measurement beginning at Day 0, the start of trial therapy. Of these 10 patients, four did not require surgery. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year prior to treatment, the number of surgical interventions for these 11 patients ranged between 2 and 8, and the median was 5.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment with INO-3107 induced cellular responses against both HPV 6 and HPV 11, inducing both activated CD4 and activated lytic CD8 T cells. T cell responses were also observed at Week 52, which was 43 weeks after final treatment with INO-3107, indicating a persistent cellular memory response.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-3107 was well-tolerated in the trial, with all 11 patients completing the trial follow-up. Treatment-emergent adverse events (TEAE) observed in the trial were generally low-grade, with five patients (46%) experiencing at least one TEAE; four patients (36%) reported at least one related TEAE, all of which were Grade 1 or 2. The only adverse events reported by more than one patient were injection site pain (two patients) and headache (two patients). The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 for the Treatment of HPV-related Cervical HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cervical HSIL is a pre-cancerous condition caused by HPV infection. While most genital HPV infections are cleared naturally by the body's own immune system, persistent cervical infection with one or more HR-HPV genotypes can eventually lead to cervical high-grade dysplasia (HSIL) and eventually to cervical cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current management options for cervical HSIL are limited and are associated with potential unwanted side effects. The &#8220;watch-and-wait&#8221; process associated with low-grade squamous intraepithelial lesions (LSIL, formerly called low-grade dysplasia or CIN 1), and in some young women with CIN2, can be a stressful approach. The current standard of care for cervical HSIL is surgery, which involves ablating or cutting into a women&#8217;s cervix to remove the pre-cancerous lesions. These treatments may lead to short-term adverse effects including excess bleeding, and infection, or to longer-term reproductive risks such as pre-term birth, miscarriage, and perhaps infertility. Recurrence of high-grade precancerous lesions can occur after surgery because surgery does not clear the underlying HPV infection.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there is no approved immunotherapy or drug available to treat persistent HPV infection or cervical HSIL. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VGX-3100 is designed to generate T cell immune responses against the E6 and E7 oncogenic proteins of high-risk HPV types 16 and 18 that can be present in both precancerous and cancerous cells transformed by these HPV types. E6 and E7 are oncogenes that play an integral role in transforming HPV-infected cells into precancerous and cancerous cells, thus making them appealing targets for T cell-directed immunotherapy. The goal of VGX-3100 is to stimulate the body's immune system to generate a T cell response to kill the cells producing the E6/E7 protein. The potential of such immunotherapy would be to treat HSIL caused by these HPV types. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed randomized, blinded, placebo-controlled Phase 2b and Phase 3 clinical trials of VGX-3100 compared to placebo, in women with HPV-16 and HPV-18 cervical HSIL. In the Phase 2b trial, women treated with VGX-3100 were more likely to demonstrate resolution of cervical HSIL and HPV clearance from cervical lesions than those women receiving placebo. In addition, antigen-specific T cell levels in women treated with VGX-3100 were greater than those treated with placebo. All women were monitored for an additional 52 weeks following the primary endpoint to assess for safety; VGX-3100 was well-tolerated and there were no safety concerns observed. Immune endpoints were also assessed and women whose lesions regressed also had higher frequencies of HPV-specific CD8+ T cells which co-expressed key molecules important in the T cell killing cascade and directly correlated with clinical efficacy. To our knowledge, this Phase 2b trial was the first study from which data was published indicating a direct correlation between antigen-specific CD8+ T cells generated in vivo and clinical efficacy.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 Immune Correlates and Biomarker Signatures </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing a biomarker signature for our VGX-3100 program. In May 2019, we entered into a collaboration with QIAGEN N.V. to co-develop a liquid biopsy-based diagnostic for this biomarker signature to identify women with HPV-16/18 cervical HSIL most likely to respond to VGX-3100. In February 2021, we announced an extension of our partnership with QIAGEN with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">next-generation sequencing technology to complement our therapies. QIAGEN is utilizing the Illumina NextSeq&#8482; 550Dx platform for this biomarker, the first development based on a partnership QIAGEN and Illumina entered into in October 2019. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced that we and QIAGEN had identified candidate biomarker signatures for VGX-3100 with the intent of selecting a final signature of a pre-treatment in vitro diagnostic to meet the specific characteristics desired to identify women with HPV-16/18 cervical HSIL most likely to respond to VGX-3100. This biomarker, if validated, may have the potential to identify those women who are more likely to have a favorable treatment outcome, specifically the regression of cervical HSIL and viral clearance.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 Trials (REVEAL1 and REVEAL2)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Phase 3 program, named REVEAL, consists of a primary trial (REVEAL1; HPV-301) and confirmatory trial (REVEAL2; HPV-303). The REVEAL trials are prospective, randomized (2:1), double-blind, placebo-controlled trials evaluating adult women with HPV 16/18 positive biopsy-proven cervical HSIL (CIN 2/3). The primary endpoint is regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix, which was a secondary endpoint that was achieved in our Phase 2b trial. Overall, the Phase 3 trials are evaluating cervical tissue changes at approximately 9 months after beginning a three-dose regimen of VGX-3100 administered at months 0, 1 and 3.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we announced the results of the REVEAL1 trial of VGX-3100. The trial protocol-defined intention to treat (ITT) population (N=201) included all randomized participants regardless of availability of endpoint data and defines those without endpoint data as non-responders. There were eight such participants (seven in the treatment group, one in the placebo group) in the ITT population.  Including participants with missing endpoint data, the percentage of participants meeting the primary endpoint was 22.5% (31/138) in the treatment group, versus 11.1% (7/63) in the placebo group (p=0.029; 95%CI: -0.4,21.2), which was not statistically significant. All secondary endpoints were achieved except for regression of cervical HSIL alone (95%CI: -0.6,24.5). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the protocol-defined mITT population (N=193), which included all participants with endpoint data, VGX-3100 achieved the primary and secondary endpoints among all evaluable participants. For the primary endpoint of histopathological regression of HSIL and virologic clearance of HPV-16 and/or HPV-18 at week 36, the percentage of responders was 23.7% (31/131) in the treatment group, versus 11.3% (7/62) in the placebo group (p=0.022; 95%CI: 0.4,22.5), which was statistically significant. All secondary efficacy endpoints were achieved in this population. These endpoints were: a) regression of cervical HSIL to normal tissue combined with HPV16/18 viral clearance, b) regression of cervical HSIL alone, c) regression of cervical HSIL to normal tissue, and d) HPV 16/18 viral clearance alone. There were no treatment-related serious adverse events (SAEs) and most adverse events (AEs) were self-resolving and were considered to be mild to moderate, consistent with earlier clinical trials. The data from REVEAL1 was presented at the 2021 American Society for Colposcopy and Cervical (ASCCP) annual scientific meeting, and at the 34th International Papillomavirus Conference (IPVC) in November 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed the 52-week safety follow-up of participants in REVEAL1 and showed that VGX-3100 remained well-tolerated through Week 88. In addition, participants treated with VGX-3100 who met the primary endpoint at Week 36 remained clear of HPV-16 and/or HPV-18 at Week 88.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REVEAL2 is our second Phase 3 trial with VGX-3100. In April 2022, the trial protocol was amended to utilize a biomarker-selected population as the primary population, based on prior analysis of REVEAL1 results suggesting that this investigational biomarker had the potential to identify women more likely to respond to treatment with VGX-3100.  We announced that this trial would no longer be considered to be a pivotal trial and would not lead to a BLA filing for a biomarker-selected population, as the FDA advised us that the biomarker-positive population would not be sufficient to support approval of a potential marketing application for VGX-3100. The FDA recommended using REVEAL2 as an exploratory trial and that conducting one or two additional well-controlled trials in the biomarker-selected population would be more likely to provide evidence to support approval of a marketing application.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial participants in REVEAL2 included 203 women, 18 years of age or older, who had histologically-confirmed cervical HSIL associated with HPV-16 and/or HPV-18, but who were otherwise healthy. Participants received either VGX-3100 or placebo at 0, 4 and 12 weeks (randomized 2:1). The primary endpoint, as amended, was the percentage of biomarker-selected participants with regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A secondary endpoint was the percentage of all participants with regression and virologic clearance.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we announced data from our REVEAL2 trial. Statistical significance was not achieved in the investigational biomarker-selected population for the endpoint of lesion regression and viral clearance. However, statistical significance was achieved in the all-participants population for the endpoint of lesion regression and viral clearance.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of participants in the investigational biomarker-selected population meeting the endpoint was 28.6% (6/21) in the treatment group, versus 0% (0/4) in the placebo group (p=0.115; difference in percentage 28.6, 95%CI: -24.6, 50.4), which was not statistically significant. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The result of the all-participants population of 203 participants (134 participants in the treatment group, 69 in the placebo group) was statistically significant, with 27.6% (37/134) of the participants meeting the endpoint in the treatment group, versus 8.7% (6/69) in the placebo group (p=0.001; difference in percentage 18.9, 95%CI: 7.8, 28.6).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, in the all-participants population of REVEAL2, viral clearance was observed in 37.3% (50/134) in the treatment group versus 8.7% (6/69) in the placebo group. Given the importance of viral clearance in removing the underlying cause of the HPV-related diseases, this data may have positive implications in our other HPV-related programs.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ad hoc integrated efficacy analysis of the results for both REVEAL1 and REVEAL2 shows statistical significance in the biomarker-selected and all-participants populations for lesion regression and viral clearance. For the combined biomarker-selected population of 92 participants (68 participants in the treatment group, 24 in the placebo group), the percentage of participants meeting the primary endpoint was 54.4% (37/68 in the treatment group, versus 12.5% (3/24) in the placebo group (p=&lt;0.001; difference in percentage 41.9, 95%CI: 20.4, 57.0). For the combined all-participants population of 404 participants (272 participants in the treatment group, 132 in the placebo group), the percentage of participants meeting the primary endpoint was 25.0% (68/272 in the treatment group, versus 9.8% (13/132) in the placebo group (p=&lt;0.001; difference in percentage 15.2, 95%CI: 7.4, 22.1).    </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both REVEAL1 and REVEAL2, VGX-3100 was well-tolerated. There were no treatment-related serious adverse events and most adverse events were considered to be mild to moderate.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This combined data set will be used as supportive data in any future regulatory interactions involving VGX-3100. We will continue to evaluate the results to determine next steps for VGX-3100 in our HPV programs. We plan to submit the data for publication in a peer-reviewed journal later this year.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Anal or Perianal HSIL </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-16 and HPV-18 can also cause precancerous lesions of the anus (anal HSIL).  Left untreated, anal HSIL may progress to cancer.  Spontaneous regression of anal HSIL is observed in approximately 20% of patients. Persistent infection with one or more high-risk HPV genotypes is responsible for a large portion of anal cancer. In the United States, about 55% to 80% of anal HSIL cases are associated with HPV-16/18, and worldwide about 80% of anal HSIL cases are associated with HPV-16/18. In the United States, over 90% of anal cancer is attributable to HPV, and about 87% of those HPV anal cancers are attributable to HPV-16/18 specifically. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no validated screening tests or a general consensus for screening recommendations for anal HSIL. Treatment usually consists of repeated ablation, most commonly radiofrequency ablation (RFA), resections or laser therapy. However, recurrence rates are high, up to 49% one year after treatment, as ablation does not clear the underlying HPV infection, resulting in an unmet medical need. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 2 clinical trial (HPV-203) to evaluate VGX-3100 in participants who are HIV-negative with histologically confirmed anal or perianal HSIL, or anal intraepithelial neoplasia (AIN), associated with HPV-16 and/or HPV-18. This open-label trial enrolled 24 participants who received three doses of VGX-3100 delivered by our CELLECTRA-5PSP device. The primary endpoint of the trial was histologic clearance of the high-grade lesions and virologic clearance of the HPV-16/18 virus in anal/perianal tissue samples. In December 2020, we announced Phase 2 efficacy results from this trial. One-half of participants treated with VGX-3100 (11/22) showed resolution of HPV-16/18-associated anal HSIL at six months following the start of treatment. VGX-3100 was well-tolerated in the trial. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Phase 2 anal HSIL trial described above, a separate ongoing Phase 2 trial sponsored by the AIDS Malignancy Consortium (AMC-103) is evaluating VGX-3100 in participants with histologically confirmed anal or perianal HSIL associated with HPV-16 and/or HPV-18 who are HIV-positive. This open-label single-arm trial plans to enroll approximately 90 participants who will receive up to four doses of VGX-3100 delivered by CELLECTRA-5PSP smart device. The primary endpoint of the trial is histological regression of high-grade anal lesions to low-grade SIL or normal histology. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGX-3100 for the Treatment of Vulvar HSIL</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HPV-16 and HPV-18 can also cause precancerous and cancerous lesions of the vulva. These precancerous lesions, or vulvar HSIL, have less than a 5% rate of spontaneous or natural regression and there are no FDA-approved treatments. Surgery, the most common treatment, is associated with high rates of disease recurrence and can cause disfigurement, long-term pain, and psychological distress for women who undergo the procedure. Non-surgical options such as the off-label use of topical imiquimod are also available. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 2 trial (HPV-201) to evaluate the efficacy of VGX-3100 in participants with vulvar HSIL.  This randomized, open-label Phase 2 clinical trial assessed the efficacy of VGX-3100 in 33 women with vulvar HSIL. VGX-3100 was administered with our CELLECTRA -5PSP smart device. The primary endpoint of the trial was histologic clearance of high-grade lesions and virologic clearance of the HPV virus in vulvar tissue samples. The trial also evaluated the safety and tolerability of VGX-3100. In January 2021, we announced efficacy results from this trial. A 25% or more reduction in HPV-16/18-associated vulvar HSIL was observed for 63% of trial participants (12 of 19) treated with VGX-3100 at six </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months post-treatment. Three of the 20 participants with histology data (15%) resolved their vulvar HSIL and had no HPV-16/18 virus detectable in the healed area. VGX-3100 was well-tolerated in the Phase 2 trial. </span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-5401 for the Treatment of Glioblastoma Multiforme (GBM) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Glioblastoma multiforme (GBM) is the most common aggressive type of brain cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the median age at diagnosis is 65 years, and the incidence rate increases thereafter. Prognosis is extremely poor, and a limited number of new therapies have been approved over the last 10 years; median overall survival for U.S. patients receiving standard of care therapy is approximately 10 months and the five-year survival is 6.8% for all ages combined. The annual incidence of GBM is estimated to be approximately 12,000 cases per year and increasing. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate INO-5401 is an immunotherapy consisting of three DNA plasmids encoding for three tumor-associated antigens: human Telomerase Reverse Transcriptase (hTERT), Wilms Tumor gene-1 (WT1) and Prostate-Specific Membrane Antigen (PSMA). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed a Phase 1/2 immuno-oncology trial of INO-5401 and INO-9012 (IL-12 plasmid) in participants with newly diagnosed GBM, in combination with cemiplimab (Libtayo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a PD-1 inhibitor developed by Regeneron Pharmaceuticals. This open-label trial began in 2018 and enrolled 52 newly diagnosed GBM participants. The primary endpoint was safety and tolerability, and the trial also evaluated immunogenicity and efficacy (Overall Survival, or OS). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we presented OS data at the 2022 American Society of Clinical Oncology (ASCO) from GBM-001 Phase 2 trial.  Median OS duration in patients with an unmethylated MGMT promoter (Cohort A) was 17.9 months, which compares favorably to historical comparisons (14.6-16 months). Median OS data in patients with a  MGMT methylated promoter (Cohort B), was 32.5 months, which compares favorably to historical comparisons (23.2-25 months). Overall, INO-5401 + INO-9012 demonstrated tolerability and immunogenicity when administered with Libtayo and RT/TMZ (radiation and temozolomide) to newly diagnosed GBM patients. Notably, INO-5401 elicited antigen-specific T cells that may infiltrate GBM tumors. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">INO-5151 (INO-5150 + INO-9012) for the Treatment of Prostate Cancer </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-5151 consists of DNA plasmids targeting Prostate Specific Antigen (PSA) and Prostate Specific Membrane Antigen (PSMA), combined with INO-9112, the IL-12 plasmid, for the treatment of prostate cancer. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we announced a clinical collaboration with Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) as part of which INO-5151 is being combined with an immune modulator (CDX-301, FLT3 ligand, a dendritic cell mobilizer) and a PD-1 immune checkpoint inhibitor (nivolumab) in participants with metastatic castration-resistant prostate cancer (mCRPC), in a PICI-sponsored platform trial (PORTER). This combination trial is an open-label, non-randomized, exploratory platform trial designed to assess the safety and antitumor activity of multiple immunotherapy-based combinations in participants with mCRPC who have received prior secondary androgen inhibition. The trial evaluated biomarkers of immune activity and clinical outcomes using a multi-omic, multi-parameter approach. Under the agreement, PICI designed and conducted the clinical trial, working in collaboration with its established network of clinical academic and industry cancer centers, with funding support from CRI. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, at the Society for Immunotherapy of Cancer (SITC) 2022 annual meeting, PICI announced that while the treatment with INO-5151 induced antigen-specific T cell responses, the combination therapy of INO-5151 + nivolumab + CDX-301 was not deemed to have sufficient clinical activity by the study sponsors and will not be expanded for further study. </span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Infectious Disease Product Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4800 for COVID-19 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2/3 Clinical Trial &#8211; INNOVATE </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we announced the discontinuance of all internally funded COVID-19 vaccine programs for INO-4800. The decision followed a comprehensive review of  market conditions and global demand for COVID-19 vaccines. In May 2022, we announced the discontinuance of our INNOVATE program, which was focused on developing INO-4800 as a primary vaccine candidate against COVID-19. At that time, our intention was to continue our efforts to develop INO-4800 as a heterologous booster  vaccine. However, in October 2022, we announced the discontinuance of these heterologous booster vaccine efforts for INO-4800 as market conditions continued to shift. While we believe that INO-4800 has attributes that could be beneficial as a potential vaccine and/or booster vaccine against COVID-19, such as its ability to elicit immune responses at the humoral and cellular level, including driving cross-reactive T cell responses against multiple variants of concern, our decision was driven by external factors. These included epidemiological trends, including reduced number of severe COVID-19 cases, difficulty in conducting heterologous booster trials in highly vaccinated populations, market conditions such as vaccine oversupply, lower </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">forecast projections for vaccine doses in the future, and vaccine fatigue, and changes in regulatory timelines and requirements, as well as diminishing government financial support.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2/3 Clinical Trial &#8211; SOLIDARITY TRIAL VACCINES (STV)</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-4800 is one of two initial COVID-19 vaccine candidates included in the World Health Organization (WHO) sponsored Solidarity Trial Vaccines, which is designed to evaluate the efficacy and safety of promising new candidate vaccines selected by an independent vaccine prioritization advisory group composed of leading scientists and experts. Our decision to discontinue our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine does not affect the evaluation of INO-4800 in this trial.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">INO-4800 in China </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborator Advaccine has completed enrollment of its 200-participant homologous and 267-participant heterologous booster vaccine trials in China. The trials are designed to evaluate safety, tolerability and immunogenicity of INO-4800 as a homologous booster where INO-4800 was administered as the primary vaccine and as a heterologous booster where an inactivated vaccine was administered as the primary vaccine. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19 dMAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using our SynCon technology, we are able to create a precisely designed DNA plasmid that encodes for a specific monoclonal antibody (mAb). We refer to these DNA plasmids as our dMAb product candidates. We deliver the plasmid directly into cells of the body using our CELLECTRA smart delivery system, enabling the electroporated cells to manufacture those mAbs in vivo (i.e. by the body itself), unlike conventional mAb technology that requires manufacture outside of the body. We believe this approach provides potentially significant advantages in terms of design simplicity, rapidity of execution and lower production costs. We expect to design dMAb product candidates not only for new disease targets that are not currently addressable with conventional recombinant mAbs, but also targets of existing, commercially available mAb products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we, along with a team of scientists from The Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University, received a $37.6 million grant from the U.S. Defense Advanced Research Projects Agency (DARPA), a research and development agency of the DoD and the JPEO-CBRND, to use our dMAb technology to develop anti-SARS-CoV-2-specific dMAbs that function as both a therapeutic and preventive treatment for COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of DARPA's two-year grant, the consortium constructed COVID-19 dMAb candidates mirroring AstraZeneca's traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Wistar announced the dosing of the first participant in a Phase 1, open-label, single-center, 24-person dose escalation trial to evaluate the safety, tolerability and pharmacokinetic profile of two of our mAb product candidates , administered IM followed immediately by electroporation using our CELLECTRA 2000 device in a 1- and 2-dose regimen (Days 0 and 3) in healthy adults (NCT05293249).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4201 for Ebola Virus Disease</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ebola virus causes one of the most virulent viral diseases, with case fatality rates averaging approximately 50% but approaching up to 90% in past outbreaks in areas with no or under-developed health care. Ebola can spread through human-to-human transmission by direct contact with the blood, secretions, organs or bodily fluids of an infected individual and with surfaces or materials that contain the contaminated fluids of an infected person, such as bedding and clothing. It is capable of causing death within 2 to 21 days of exposure. In November 2019, the first conditional approval was issued for a preventive vaccine against Ebola virus. This approval was from the European Medicines Agency (EMA) for the vaccine ERVEBO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. That same month, the WHO pre-qualified that vaccine for use in high-risk countries. In the next month, the FDA approved that vaccine. However, there are no proven effective therapeutic treatments for Ebola. In addition, various experimental approaches have already been associated with undesirable side effects and limited ability to scale manufacturing.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, we announced complete enrollment of a 46-participant Phase 1b trial in which our DNA medicine candidate INO-4201 was assessed as a heterologous booster in healthy volunteers previously vaccinated with rVSV-ZEBOV (ERVEBO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), an FDA- and EMA- approved viral vector-based Ebola vaccine (NCT04906629). To date, INO-4201 has been well-tolerated and has not demonstrated systemic SAEs, such as fever, joint pain, and low white blood cell counts, that have been reported in association with some viral vector-based Ebola vaccines currently in development.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we announced results from the Phase 1b trial. INO-4201 was well-tolerated and boosted humoral responses in 100% (36 of 36) of treated participants. We and our collaborators plan to publish the data in a peer-reviewed journal and provide updates on the next steps for INO-4201.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4700 for Middle East Respiratory Syndrome (MERS)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Middle East Respiratory Syndrome (MERS) is a viral respiratory illness first reported in Saudi Arabia in 2012. MERS appears to have been transmitted from an animal reservoir to humans, but human to human transmission has been confirmed. In 2018, we announced a collaboration with CEPI under which CEPI would fund up to $56 million of costs to support our pre-clinical and clinical advancement through Phase 2 of our vaccine candidate INO-4700. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We dosed and completed enrollment for the first part (dose finding stage) of the Phase 2 trial (192 participants) of INO-4700. The multi-center Phase 2 trial was a randomized, double-blinded, placebo-controlled trial designed to evaluate the safety, tolerability, and immunogenicity of INO-4700 administered with CELLECTRA 2000 in approximately 500 healthy adult participants (NCT04588428).</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trial was conducted at sites in Jordan, Lebanon, and Kenya.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on initial analysis of data from the studies, we and CEPI agreed to discontinue development of INO-4700 for MERS in November 2022. Although INO-4700 was well-tolerated by participants in our clinical trials and generated immune responses, the two-dose regimen did not meet CEPI's selection criteria for further development. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4500 for Lassa Fever</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lassa fever, also known as Lassa hemorrhagic fever, is an acute viral disease which occurs mostly in West Africa. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, we completed enrollment of a 220 participant Phase 1b trial for our vaccine candidate INO-4500 in Accra, Ghana, which was the first vaccine clinical trial for Lassa Fever conducted in West Africa, where the viral illness is endemic. The trial was funded by CEPI. The dosing regimen involved two intradermal vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg doses. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, we announced that we and CEPI agreed to discontinue development of INO-4500 for Lassa Fever, following initial analyses of data from studies. Although INO-4500 was well tolerated by participants in our clinical trials and generated immune responses, the two-dose regimen did not meet CEPI's selection criteria for further development. </span></div><div style="margin-top:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and Alliances</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most material collaboration arrangements are summarized below.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, we entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, we granted to Advaccine the exclusive right to develop, manufacture and commercialize our vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without our express prior written consent. As part of the collaboration, Advaccine also granted to us a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain instances, we will have the right to convert the exclusive license to a non-exclusive license in the licensed territories, other than Greater China, unless Advaccine agrees to pay us its full share of development costs in excess of a specified maximum. Notwithstanding the foregoing, Advaccine will be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred in conducting the trial in Greater China. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Agreement, Advaccine made an upfront payment to us of $3.0 million in January 2021. In addition to the upfront payment, we are entitled to receive up to an aggregate of $200.0 million, payable upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. In December 2020 we earned a $2.0 million milestone payment based on the enrollment of the first participant in the Phase 2 clinical trial for the product in the Advaccine territory. We are also entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay us an annual maintenance fee of $1.5 million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, we will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, we may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by us to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to us, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or 18 months&#8217; written notice thereafter; provided that we may accelerate the effectiveness of such termination to the extent permitted by law.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio</span></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an Amended and Restated License and Collaboration Agreement with Beijing Apollo Saturn Biological Technology Limited, a corporation organized under the laws of China, or ApolloBio. Under the terms of this License and Collaboration Agreement, which became effective in March 2018, we granted to ApolloBio the exclusive right to develop and commercialize VGX-3100, our DNA immunotherapy product candidate designed to treat pre-cancers caused by HPV, within the agreed upon territories - Greater China (defined as China, Hong Kong, Macao and Taiwan). As part of the collaboration, ApolloBio will fund all clinical development costs within the licensed territory.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the upfront payment that we received in 2018, we are entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of VGX-3100 in accordance with the Amended and Restated License and Collaboration Agreement. In the event that VGX-3100 is approved for marketing in these territories, we will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the low- to mid-teens, subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the last-to-expire patent covering the licensed products in the specified territory. The License and Collaboration Agreement, once effective, will continue in force until ApolloBio has no remaining royalty obligations. In December 2021, ApolloBio dosed its first participant in a separate Phase 3 trial in China (HPV-303CHN). </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we develop and seek to ultimately commercialize our product candidates, we face and will continue to encounter competition with an array of existing or development-stage drug and immunotherapy approaches targeting diseases we are pursuing. We are aware of various established enterprises, including major pharmaceutical companies, broadly engaged in vaccine/immunotherapy research and development. These include AbbVie, AstraZeneca, BioNTech, Bristol-Myers Squibb, GlaxoSmithKline plc, Janssen Pharmaceuticals (part of J&amp;J), Merck, Moderna, Novartis, Pfizer, Roche, and Sanofi-Aventis.  There are also various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, including but not limited to CureVac, Dynavax, GeneOne, Genexine, Hookipa, Imunon, Iovance, Nektar, Nykode, Precigen, Translate Bio, Vir Biotechnology, and Zydus. If these companies are successful in developing their technologies, it could materially and adversely affect our business and our future growth prospects. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is working to develop a treatment based on a Gorilla adenovirus vector. Genexine and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">production and immune responses to prevent or treat various diseases. These competitive technologies have shown promise, but they each also have their unique obstacles to overcome. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Viral Vaccine Delivery </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This technology utilizes a virus as a carrier, or vector, to deliver genetic material into target cells.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The method is efficient for delivering immunotherapy antigens and has the advantage of mimicking real viral infection so that the recipient will mount a broad immune response against the immunotherapy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential limitation of the technology stems from problems with unwanted immune responses against the viral vector, limiting its use to patients who have not been previously exposed to the viral vector and making repeated administration difficult. In addition, complexity and safety concerns increase their cost and complicate regulatory approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lipid DNA/RNA Delivery</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of lipid formulations have been developed that increase the effect of DNA/RNA immunotherapies. These work by either increasing uptake of the DNA/RNA into cells or by acting as an adjuvant, alerting the immune system. While there has been significant progress in this field, including emergency use authorization of COVID-19 mRNA vaccines in 2020, lipid nanoparticle delivery of mRNA may have thermal stability issues as well as the potential of adverse events from the lipid nanoparticle formulations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">DNA Immunotherapy Delivery with Electroporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other companies with electroporation intellectual property and devices. We believe we have competitive advantages over other companies focused on electroporation for multiple reasons: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We have an extensive history and experience in developing the methods and devices that optimize the use of electroporation in conjunction with DNA-based agents. This experience has been validated with multiple sets of interim data from clinical trials assessing DNA-based immunotherapies and vaccines against cancers and infectious disease.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We have a broad product line of electroporation instruments designed to enable DNA delivery, including our intradermal and intramuscular devices. </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We have been proactive in filing for patents, as well as acquiring and licensing additional patents, to expand our global patent estate. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to ours. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position will be affected by the disease indications addressed by our product candidates and those of our competitors, the timing of market introduction for these products and the stage of development of other technologies to address these disease indications. For us and our competitors, proprietary technologies, the ability to complete clinical trials on a timely basis and with the desired results, and the ability to obtain timely regulatory approvals to market these product candidates are likely to be significant competitive factors. Other important competitive factors will include efficacy, safety, ease of use, reliability, availability and price of products and the ability to fund operations during the period between technological conception and commercial sales. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other regulatory agencies may expand current requirements for public disclosure of DNA-based product development data, which may harm our competitive position with foreign and United States companies developing DNA-based products for similar indications. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercialization and Manufacturing</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the broad potential applications of our technologies, we intend to develop and commercialize products both on our own and through our collaborators and licensees. We intend to develop and commercialize products in well-defined specialty markets, such as HPV-related diseases, infectious diseases, and cancer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where appropriate, we intend to rely on strategic marketing and distribution alliances.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our plasmids can be produced in commercial quantities through uniform methods of fermentation and processing that are applicable to all plasmids. We believe we will be able to obtain sufficient supplies of plasmids for all foreseeable clinical investigations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and other proprietary rights are essential to our business. We file patent applications to protect our technologies, inventions and improvements to our inventions that we consider important to the development of our business. We file for patent registration extensively in the United States and in key foreign markets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our patent filings include claims covering various features of our products and product candidates, including composition, methods of manufacture and use, our patents do not provide us with complete protection, or guarantee, against the development of competing products. In addition, some of our know-how and technology are not patentable. We thus also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position. We also require employees, consultants, advisors and collaborators to enter into confidentiality agreements, but such agreements may provide limited protection for our trade secrets, know-how or other proprietary information.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, our patent portfolio included approximately 100 issued U.S. patents and approximately 80 U.S. patent applications as well as approximately 800 issued foreign counterpart patents and approximately 700 counterpart foreign patent applications. These are comprised, in part, of:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">two U.S. patent applications and approximately 40 counterpart foreign patent applications, directed to treatment of RRP;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">seven issued U.S. patents and five U.S. patent applications, as well as approximately 80 issued foreign counterpart patents and approximately 50 counterpart foreign patent applications, directed to treatment of GBM;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">approximately 70 issued U.S. patents and approximately 50 U.S. patent applications, as well as approximately 400 issued foreign counterpart patents and approximately 500 counterpart foreign patent applications, directed to our other earlier-stage product candidates; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">approximately 30 issued U.S. patents and approximately 20 U.S. patent applications, as well as approximately 30 issued foreign counterpart patents and approximately 125 counterpart foreign patent applications, directed to our device delivery systems.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pending patent applications directed to treatment of RRP, if issued, would expire between about 2040 and 2043. Our issued patents directed to treatment of GBM expire between about 2027 and 2037 and our pending patent applications, if issued, would expire between about 2027 and 2040. Our issued patents directed to our other product candidates expire between about 2023 and 2036 and our pending patent applications, if issued, would expire between about 2027 and 2042. Our issued patents directed to our device delivery systems expire between about 2023 and 2036 and our pending patent applications, if issued, would expire between about 2023 and 2042.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual patent terms extend for varying periods of time, depending upon the date of filing of the patent application, the date of patent issuance, and the legal term of patents in the countries in which they are obtained. In most countries in which we file patent applications, including the United States, the patent term is 20 years from the date of filing of the first non-provisional patent application to which priority is claimed. In some instances, a patent term can be extended under certain circumstances, such as patent term extension or patent term adjustment; alternatively, a patent term may be shortened, for example in the United States, if a patent is terminally disclaimed over an earlier-filed patent. Protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to protect our intellectual property rights adequately our competitors might gain access to our technology and our business would thus be harmed. In addition, defending our intellectual property rights might entail significant expense. Any of our intellectual property rights may be challenged by others or invalidated through administrative processes or litigation through the courts. In addition, our patents, or any other patents that may be issued to us in the future, may not provide us with any competitive advantages, or may be challenged by third parties. Furthermore, legal standards relating to the validity, enforceability and scope of protection of intellectual property rights are uncertain. Effective patent, trademark, copyright and trade secret protection may not be available to us in each country where we operate. The laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and domestic and international mechanisms for enforcement of intellectual property rights in those countries may be inadequate. Accordingly, despite our efforts, we may be unable to prevent third parties from infringing upon or misappropriating our intellectual property or otherwise gaining access to our technology. We may be required to expend significant resources to monitor and protect our intellectual property rights. We may initiate claims or litigation against third parties for infringement of our proprietary rights or to establish the validity of our proprietary rights. Any such litigation, whether or not it is ultimately resolved in our favor, would result in significant expense to us and divert the efforts of our technical and management personnel.</span></div><div style="margin-top:5pt;text-indent:23.15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be rights we are not aware of, including applications that have been filed but not published that, when issued, could be asserted against us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These third parties could bring claims against us, and that would cause us to incur substantial expenses and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development, manufacturing or sales of the product or biologic </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose or be required to seek a license from the third party. These licenses may not be available on acceptable terms, or at all. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also impact our collaborators, which would also impact the success of the collaboration and therefore us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Important legal issues remain to be resolved as to the extent and scope of available patent protection for biologic products, including vaccines, and processes in the United States and other important markets outside the United States, such as Europe and Japan. Foreign markets may not provide the same level of patent protection as provided under the United States patent system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that litigation or administrative proceedings may be necessary to determine the validity and scope of certain of our and others&#8217; proprietary rights.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any such litigation or proceeding may result in a significant commitment of resources in the future and could force us to interrupt our operations, redesign our products or processes, or negotiate a license agreement, all of which would adversely affect our revenue. Furthermore, changes in, or different interpretations of, patent laws in the United States and other countries may result in patent laws that allow others to use our discoveries or develop and commercialize our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that the patents we obtain or the unpatented technology we hold will afford us significant commercial protection.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level and in other countries extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products, or biologics, and medical devices, such as our product candidates. Generally, before a new biologic or medical device can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Combination Products in the United States</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities, and frequently by different centers at the FDA. These products are known as combination products. Specifically, under regulations issued by the FDA, a combination product may be:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a product comprised of two or more regulated components that are physically, chemically, or otherwise combined or mixed and produced as a single entity;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">two or more separate products packaged together in a single package or as a unit and comprised of drug and device products;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device or biological where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any investigational drug, device, or biological packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products comprising an electroporation device for delivery of a biologic. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product, which means the mode of action expected to make the greatest contribution to the overall intended therapeutic effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, if the primary mode of action of a device-biologic combination product is attributable to the biologic product, that is, if it acts by means of a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, or analogous product, the FDA center responsible for premarket review of the biologic product would have primary jurisdiction for the combination product. We believe that all of our product candidates will have a biologic primary mode of action, with the device component reviewed under a Device Master File.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Biological Product Development</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biologics under FDCA, and the Public Health Service Act, or PHSA, and their implementing regulations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates must be approved by the FDA through the Biologics License Application, or BLA, process before they may be legally marketed in the United States. The process required by the FDA before a biologic may be marketed in the United States generally involves the following:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of extensive nonclinical, sometimes referred to as pre-clinical laboratory tests, pre-clinical animal studies and formulation studies in accordance with applicable regulations, including the FDA&#8217;s Good Laboratory Practice, or GLP, regulations;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices, or GCPs, to establish the safety and efficacy of the proposed product candidate for its proposed indication;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of a BLA;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the product is produced to assess compliance with the FDA&#8217;s current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality, purity and potency;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential FDA audit of the pre-clinical and/or clinical trial sites that generated the data in support of the BLA; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the BLA prior to any commercial marketing or sale of the product in the United States. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data required to support a BLA is generated in two distinct development stages: pre-clinical and clinical. The pre-clinical development stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which support subsequent clinical testing. The conduct of the pre-clinical studies must comply with federal regulations, including GLPs. The sponsor must submit the results of the pre-clinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a product candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the product candidate to healthy participants under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCPs, which include the requirement that all research participants provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, participant selection and exclusion criteria, and the parameters to be used to monitor participant safety and assess efficacy.  Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial participant or his or her legal representative and must monitor the clinical trial until completed.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Sponsors of certain clinical trials of FDA-regulated products, including biologics, are required to register and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclose specified clinical trial information, which is publicly available at www.clinicaltrials.gov.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally conducted in three sequential phases that may overlap, known as Phase 1, Phase 2 and Phase 3 clinical trials. Phase 1 clinical trials generally involve a small number of healthy volunteers who are initially exposed to a product candidate. The primary purpose of these clinical trials is to assess the action, side effect tolerability and safety of the product candidate and, if possible, to gain early evidence on effectiveness. Phase 2 clinical trials typically involve studies in patients to determine the dose required to produce the desired benefits. At the same time, safety and preliminary evaluation of efficacy is assessed. Phase 3 clinical trials generally involve large numbers of patients at multiple sites, in multiple countries (from several hundred to several thousand participants) and are designed to provide the data necessary to demonstrate the efficacy of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. Phase 3 clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. Generally, two adequate and well-controlled Phase 3 clinical trials are required by the FDA for approval of a BLA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may grant conditional approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials, such as these post-approval trials, to further assess the biologic&#8217;s safety and effectiveness after BLA approval.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important rate increase of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated intervals based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BLA and FDA Review Process</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following trial completion, trial data is analyzed to assess safety and efficacy. The results of pre-clinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed labeling for the product and information about the manufacturing process and facilities that will be used to ensure product quality, results of analytical testing conducted on the chemistry of the product candidate, and other relevant information. The BLA is a request for approval to market the biologic for one or more specified indications and must contain proof of safety, purity, potency and efficacy, which is demonstrated by extensive pre-clinical and clinical testing. The application includes positive findings from pre-clinical and clinical trials as well as ambiguous or negative results. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee, which is adjusted on an annual basis. PDUFA also imposes an annual program fee for approved products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a BLA has been accepted for filing, which occurs, if at all, 60 days after the BLA&#8217;s submission, the FDA&#8217;s goal is to review BLAs within ten months of the filing date for standard review or six months of the filing date for priority review, if the application is for a product intended for a serious or life-threatening condition and the product, if approved, would provide a significant improvement in safety or effectiveness. The review process is often significantly extended by FDA requests for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional information or clarification. If not accepted for filing, the sponsor must resubmit the BLA and begin the FDA&#8217;s review process again, including the initial 60-day review to determine if the application is sufficiently complete to permit substantive review.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the BLA submission is accepted for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective for its intended use, and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, strength, quality, purity and potency. The FDA may refer applications for novel drug product candidates or drug product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during the review process. The review and evaluation of a BLA by the FDA is extensive and time consuming and may take longer than originally planned to complete, and we may not receive a timely approval, if at all.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. In addition, before approving a BLA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant and time-consuming requirements related to clinical trials, pre-clinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the FDA will ultimately approve a product for marketing in the United States and we may encounter significant difficulties or costs during the review process. If a product receives marketing approval, the approval may be significantly limited to specific populations, severities of allergies, and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling or may condition the approval of the BLA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved products. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess the product&#8217;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to assure the safe use of the product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve the BLA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Marketing Requirements</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new product, a manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, also known as off-label use, limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may prescribe legally available drugs and biologics for off-label uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the product or its labeling or changes of the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, once a product is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. The FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. Moreover, the constituent parts of a combination product retain their regulatory status, for example, as a biologic or device, and as such, we may be subject to additional requirements in the Quality System Regulation, or QSR, applicable to medical devices, such as design controls, purchasing controls, and corrective and preventive action. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. cGMP regulations require, among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. BLA holders using contract manufacturers, laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute products manufactured, processed or tested by them. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, REMS and post-marketing surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coverage and Reimbursement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and vaccines. Accordingly, a pharmaceutical company&#8217;s ability to commercialize its products successfully depends in part on the extent to which private health insurers, other third-party payors, and governmental authorities, including Medicare and Medicaid, establish appropriate coverage and reimbursement levels for its product candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors generally require that products be approved for marketing by the FDA.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are available. The process for obtaining coverage for a product or service is separate from the process to obtain the associated reimbursement. Reimbursement levels can affect the adoption of products and services by physicians and patients. Additionally, products used in connection with medical procedures may not be reimbursed separately, but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for a product or the treatment or procedure in which the product is used may not be available.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for drug products and vaccines can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for drug products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time consuming and costly which may require the provision of scientific and clinical support for the use of the product to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and continue to be, a number of legislative and regulatory changes to the healthcare system that impact the ability to sell pharmaceutical products profitably. In the United States, the federal government enacted the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Created a licensure framework for follow on biologic products.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain judicial and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties, starting January 1, 2019, for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax, and, effective January 1, 2021, also eliminated the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Further, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and by creating a newly established manufacturer discount program. It is unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. In addition, other legislative changes have been proposed and adopted since the ACA was enacted. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute will remain in effect until 2031 unless additional Congressional action is taken. Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, the U.S. Department of Health and Human Services, or HHS, released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential legislative policies that Congress could pursue to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Laws</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to the business of a pharmaceutical company. The laws that may affect a pharmaceutical company&#8217;s ability to operate include:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or the purchasing, ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors) and other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pharmaceutical company will need to spend substantial time and money to ensure that its business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that its business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If a pharmaceutical company&#8217;s operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to it, it may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm and the curtailment or restructuring of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Regulations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances, including radioactive compounds and infectious disease agents, used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Customers and Research and Development</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we derived 94% of our revenue from the procurement contract with the DoD that we entered into in June 2020. During the year ended December 31, 2021, we derived 43% of our revenue from the procurement contract with the DoD and 14% of our revenue from our collaborator Plumbline Life Sciences, a company of which we are an approximately 19% stockholder. During the year ended December 31, 2020, we derived 68% of our revenue from Advaccine and 18% of our revenue from Plumbline Life Sciences.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, virtually all of our activities have consisted of research and development efforts related to developing our electroporation technologies and immunotherapies. Research and development expense consists of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Our research and development expense was $187.7 million in 2022, $249.2 million in 2021 and $94.2 million in 2020. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our revenue for the years ended December&#160;31, 2022, 2021 and 2020 was earned in the United States. All of our long-lived assets are located in the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462, and our main telephone number is (267) 440-4200. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.inovio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the information contained in this Annual Report, information about us can be found on our website. Our website and information included in or linked to our website are not part of this Annual Report.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make our annual report on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, or the Exchange Act, available free of charge on our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or the SEC. The SEC maintains an Internet site (www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, including us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding our corporate governance, including the charters of our audit committee, our nomination and corporate governance committee and our compensation committee, our Code of Business Conduct and Ethics, our Corporate Governance Guidelines, and information for contacting our board of directors is available on our website.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct and Ethics includes our Code of Ethics applicable to our Chief Executive Officer and Chief Financial Officer, who also serves as our principal accounting officer. Any amendments to or waivers of the Code of Ethics will be promptly posted on our website or in a report on Form 8-K, as required by applicable law.</span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Resources</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 14, 2023, we employ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed 184 p</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eople on a full-time basis. Of the tot</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">al, 136 were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in product research, which includes research and development, quality assurance, clinical, engineering and manufacturing, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 48 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were in general and administrative functions, which includes corporate development, information technology, legal, commercial, investor relations, finance and corporate administration. Approximately one-half of our workforce is comprised of women and approximately one-half is comprised of individuals with ethnically diverse backgrounds. In addition, four of the eight members of our board of directors are women. None of our employees are subject to collective bargaining agreements. We con</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sider our relationship with our employees to be good. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete in the highly competitive biotechnology industry. Attracting, developing and retaining talented people in research, quality assurance, clinical, engineering, manufacturing and other positions is crucial to executing our strategy and our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to compete effectively. Our ability to recruit and retain such talent depends on several factors, including compensation and benefits, talent development and career opportunities, and work environment. To that end, we invest in our employees to be an employer of choice.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Engagement</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we work to make an impact on how healthcare is delivered, we believe it is critical that our employees are informed and engaged. We communicate frequently and transparently with our employees through a variety of communication methods, including video and written communications, town hall meetings, employee surveys and our company intranet, and acknowledge individual contributions to INOVIO through several rewards and recognition initiatives. We believe these engagement efforts keep employees informed about our strategy, culture and purpose and motivated to do their best work. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety and Wellness</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The physical health, financial well-being, life balance and mental health of our employees is vital to our success. In 2021, we launche</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d a Company-wide comprehensive wellness program inclusive of financial, physical, and mental well-being.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The environmental, health and safety team stays abreast of local, regional and global concerns and trends and ensures safety procedures are in place to mitigate workplace injuries and safety risks. Employees are required to complete training in various safety procedures for the laboratories and manufacturing facilities and specialized safety training based on particular job duties. Designated Safety Officers and response teams oversee safety-related initiatives and a safety committee provides input on safety procedures, practices, and policies. Employees are required to wear personal protective equipment relevant for their particular job duties. Occupational injuries at the workplace are extremely low and are always investigated to determine if any environmental or other changes need to be implemented.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should carefully consider the following factors regarding information included in this Annual Report. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any of the following risks actually occur, our business, financial condition and operating results could be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses in recent years, expect to incur significant net losses in the foreseeable future and may never become profitable.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced significant operating losses over the last several years. As of December 31, 2022 our accumulated deficit was $1.5 billion. We have generated limited revenues, primarily consisting of license revenue, grant funding and interest income. We expect to continue to incur substantial additional operating losses for at least the next several years as we advance our clinical trials and research and development activities. We may never successfully commercialize our DNA medicine candidates or proprietary smart device technology and thus may never have any significant future revenues or achieve and sustain profitability.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited sources of revenue and our success is dependent on our ability to develop our DNA medicines and proprietary smart device technology.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not sell any products and may not have any other products commercially available for several years, if at all. Our ability to generate future revenues depends heavily on our success in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developing and securing United States and/or foreign regulatory approvals for our DNA medicine candidates, including securing regulatory approval for conducting clinical trials with DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">developing our proprietary smart device technology; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercializing any products for which we receive approval from the FDA and foreign regulatory authorities. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our proprietary smart device and DNA medicine candidates will require extensive additional clinical study and evaluation, regulatory approval in multiple jurisdictions, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote our proprietary smart device and DNA medicine candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities. If we do not receive regulatory approval for and successfully commercialize any products, we will not generate any revenues from sales of proprietary smart device and DNA medicine products, and we may not be able to continue our operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A small number of licensing partners and government contracts currently account for a substantial portion of our revenue. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive, and in the past we have derived, a significant portion of our revenue from a limited number of licensing partners and government grants and contracts. Revenue can fluctuate significantly depending on the timing of upfront and event-based payments and work performed. If we fail to sign additional future contracts with major licensing partners and the government, if a contract is delayed or deferred, or if an existing contract expires or is canceled and we fail to replace the contract with new business, our revenue would be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional capital to develop our DNA medicines and proprietary smart device technology, which may prove difficult and costly to obtain.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting the costly and time-consuming research, pre-clinical studies and clinical testing necessary to obtain regulatory approvals and bring our DNA medicine candidates and proprietary smart device technology to market will require a commitment of substantial funds in excess of our current capital. Our future capital requirements will depend on many factors, including, among others:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress of our current and new product development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope and results of our pre-clinical and clinical testing; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost involved in obtaining regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of prosecuting, enforcing and defending against patent infringement claims and other intellectual property rights; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competing technological and market developments; and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and the related costs to establish and maintain collaborative and other arrangements with third parties to assist in potentially bringing our products to market. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional financing may not be available on acceptable terms, or at all. Domestic and international capital markets have from time to time experienced heightened volatility, particularly in light of geopolitical turmoil, inflation and rising interest rates, making it more difficult in many cases to raise capital through the issuance of equity securities. Volatility in the capital markets can also negatively impact the cost and availability of credit, creating illiquid credit markets and wider credit spreads. Concern about the stability of the markets generally and the strength of counterparties specifically has led many lenders and institutional investors to reduce, and in some cases cease to provide, funding to borrowers. To the extent we are able to raise additional capital through the sale of equity securities, or we issue securities in connection with another transaction in the future, the ownership position of existing stockholders could be substantially diluted. If additional funds are raised through the issuance of preferred stock or debt securities, these securities are likely to have rights, preferences and privileges senior to our common stock and may involve significant fees, interest expense, restrictive covenants and the granting of security interests in our assets. Rising interest rates could also increase the costs of any debt financing we may obtain. Raising capital through a licensing or other transaction involving our intellectual property could require us to relinquish valuable intellectual property rights and thereby sacrifice long-term value for short-term liquidity.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to successfully address ongoing liquidity requirements would have a substantially negative impact on our business. If we are unable to obtain additional capital on acceptable terms when needed, we may need to take actions that adversely affect our business, our stock price and our ability to achieve cash flow in the future, including possibly surrendering our rights to some technologies or product opportunities, delaying our clinical trials or curtailing or ceasing operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Development, Manufacturing and Regulatory Approval</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain FDA approval of our product candidates, we will not be able to commercialize them in the United States.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our proprietary smart device and DNA medicine candidates in the United States. If we fail to obtain FDA approval to market our proprietary smart device and DNA medicine candidates, we will be unable to sell our products in the United States, which will significantly impair our ability to generate any revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This regulatory review and approval process, which includes evaluation of preclinical studies and clinical trials of our products as well as the evaluation of our manufacturing processes and our third-party contract manufacturers' facilities, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-controlled clinical trials that our proprietary smart device and DNA medicine candidates are both safe and effective for each indication for which approval is sought. To the extent that our DNA medicine candidates are manufactured at multiple sites or using different processes, we will also need to demonstrate comparability across the manufacturing batches in order to obtain regulatory approval. Satisfaction of the approval requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the product. We do not know if or when we might receive regulatory approvals for our proprietary smart device and any of our DNA medicine candidates currently under development. Moreover, any approvals that we obtain may not cover all of the clinical indications for which we are seeking approval, or could contain significant limitations in the form of narrow indications, warnings, precautions or contra-indications with respect to conditions of use. In such event, our ability to generate revenues from such products would be greatly reduced and our business would be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the approval process and may either refuse to consider our application for substantive review or may form the opinion after review of our data that our application is insufficient to allow approval of our proprietary smart device and DNA medicine candidates. If the FDA does not consider or approve our application, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our application. Depending on the extent of these or any other studies, approval of any applications that we submit may be delayed by several years, or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be successful or considered sufficient by the FDA for approval or even to make our applications approvable. If any of these outcomes occur, we may be forced to abandon one or more of our applications for approval, which might significantly harm our business and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our product candidates or any product we may seek to develop in the future will ever obtain the appropriate regulatory approvals necessary for us or our collaborators to commence product sales. Any delay in obtaining, or an inability to obtain, applicable regulatory approvals would prevent us from commercializing our products, generating revenues and achieving and sustaining profitability. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval in the United States, we may never receive approval or commercialize our products outside of the United States, and the same risk applies for products approved outside the United States, with respect to regulatory approval in the United States.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any proprietary smart device and DNA medicine candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approval procedures vary among countries and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries might differ from that required to obtain FDA approval, and the regulatory approval process in other countries may include all of the risks detailed above regarding FDA approval in the United States as well as other risks. Furthermore, regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. Failure to obtain regulatory approval in other countries or any delay or setback in obtaining such approval could have the same adverse effects detailed above regarding FDA approval in the United States. Such effects include the risks that our DNA medicine candidates may not be approved for all indications requested, which could limit the uses of our DNA medicine candidates and have an adverse effect on their commercial potential or require costly, post-marketing follow-up studies. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive and can take many years to complete, and its outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Results from one study may not be reflected or supported by the results of similar studies. Results of an animal study may not be indicative of results achievable in human studies. Human-use equipment and DNA medicine candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. The time required to obtain approval by the FDA and similar foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials, depending upon numerous factors. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change. We have not obtained regulatory approval for any human-use products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to complete the clinical trial process for many reasons, including the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our proprietary smart device or product candidate is safe and effective for any indication; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of clinical or statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in enrolling a sufficient number of participants in clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary smart device or DNA medicine candidates' clinical and other benefits outweigh their safety risks; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that our proprietary smart device or product candidate presents an advantage over existing therapies, or over placebo in any indications for which the FDA requires a placebo-controlled trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our DNA medicine candidates may not be sufficient to support the submission of a new drug application or other submission or to obtain regulatory approval in the United States or elsewhere; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities or that of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could result in increased costs to us and delay or limit our ability to generate revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Delays in the commencement, conduct or completion of clinical testing could significantly affect our product development costs. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. In addition, ongoing clinical trials may not be completed on schedule, or at all, and could be placed on a hold by the regulators for various reasons. The commencement and completion of clinical trials can be delayed for a number of reasons, including delays related to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a clinical trial;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adverse results from third party clinical trials involving gene-based therapies and the regulatory response thereto;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">future bans or stricter standards imposed on clinical trials of gene-based therapy;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">manufacturing sufficient quantities of our proprietary smart device and DNA medicine candidates for use in clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining Internal Review Board, or IRB, approval to conduct a clinical trial at a prospective site;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">slower than expected recruitment and enrollment of patients to participate in clinical trials for a variety of reasons, including competition from other clinical trial programs for similar indications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">conducting clinical trials with sites internationally due to regulatory approvals and meeting international standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">retaining patients who have initiated a clinical trial but may be prone to withdraw due to side effects from the therapy, lack of efficacy or personal issues, or who are lost to further follow-up;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">collecting, reviewing and analyzing our clinical trial data; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">global unrest, including geopolitical risks emanating from countries such as Russia and China, global pathogen outbreaks or pandemics, terrorist activities, and economic and other external factors beyond our control.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to clinical trials of product candidates for rare diseases, such as our clinical trial of INO-3107 for the treatment of recurrent respiratory papillomatosis, or RRP, we may encounter difficulties in recruiting a sufficient number of patients to enroll in the trial due to the small number of patients with the disease. Because RRP is caused by specific HPV types, 6 and 11, and there is currently no standard protocol for diagnostic/screening of RRP patients unless there are symptoms of respiratory distress, it may be difficult to identify and diagnose patients for whom INO-3107 may be a potential treatment. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trials may also be delayed as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or other regulatory authorities due to a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inspection of the clinical trial operations or trial sites by the FDA or other regulatory authorities resulting in the imposition of a clinical hold;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unforeseen safety issues; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we experience delays in completion of, or if we terminate, any of our clinical trials, the commercial prospects for our proprietary smart device and our DNA medicine candidates may be harmed and our ability to generate product revenues will be delayed or eliminated altogether. For example, in November 2022 we announced the discontinuation of the development programs for our product candidates INO-4700 for MERS and INO-4500 for Lassa Fever. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Further, delays in the commencement, conduct or completion of clinical trials may adversely affect the trading price of our common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">None of our DNA medicine candidates have been approved for sale, and we may never develop commercially successful DNA medicine products.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our DNA medicines programs are in various stages of research and development, and currently include DNA medicine candidates in discovery, preclinical studies and Phase 1, 2 and 3 clinical trials. There are limited data regarding the efficacy of DNA medicine candidates compared with conventional vaccines, and we must conduct a substantial amount of additional research and development before the FDA or any comparable foreign regulatory authority will approve any of our DNA medicine candidates. The success of our efforts to develop and commercialize our DNA medicine candidates could be delayed or fail for a number of reasons. For example, we could experience delays in product development and clinical trials. Our DNA medicine candidates could be found to be ineffective or unsafe, or otherwise fail to receive necessary regulatory clearances to proceed with further clinical development or to be approved for marketing. Our products, even if they are deemed to be safe and effective by regulatory authorities, could be difficult to manufacture on a large scale or uneconomical to market, or our competitors could develop superior products more quickly and efficiently or more effectively market their competing products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, adverse events, or the perception of adverse events, relating to vaccine and immunotherapy candidates and delivery technologies may negatively impact our ability to develop commercially successful products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism. These and other claims may influence public perception of the use of vaccine and immunotherapy products and could result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approval of our potential products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We previously expended significant resources on the development of a COVID-19 vaccine candidate. We are now only pursuing development in collaboration with third parties, as both a primary and heterologous booster vaccine, but there can be no assurance that our candidate will ever receive regulatory approval as a primary vaccine or a booster in any country, whether by Emergency Use Authorization or otherwise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, we expended significant resources on the clinical development of a COVID-19 vaccine candidate, INO-4800. We were previously conducting a Phase 2/3 clinical trial of INO-4800 called INNOVATE. Based on regulatory feedback and the competitive landscape for COVID-19 vaccines, in 2022 we discontinued the INNOVATE trial and pursued a strategy to develop our COVID-19 vaccine as a potential heterologous booster following administration of other primary vaccines. Following an assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines, in the fourth quarter of 2022 we discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are no longer conducting any active clinical trials of INO-4800 and do not expect that it will ever receive regulatory approval in the United States. Our collaborator, Advaccine, is continuing the clinical development of INO-4800 in a Phase 2 clinical trial in China and may seek an Emergency Use Authorization, or EUA, from regulatory authorities in China and other countries in Asia for the use of INO-4800 as a heterologous booster. However, any such decision would be made by Advaccine, and there is no guarantee that Advaccine will apply for an EUA or other similar authorization or, if it does apply, that Advaccine will be able to obtain such authorization. An EUA may not be available if countries are no longer in a state of public health emergency, in which case full approval would need to be sought.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our COVID-19 vaccine candidate continues to be evaluated as part of the World Health Organization&#8217;s Solidarity Trial Vaccines. Depending on the results of that trial, we could also pursue a strategy of seeking EUA for the vaccine candidate in other countries outside of the United States. Even if an EUA or other authorization is ultimately granted, we will rely on the applicable regulatory authority policies and guidance governing vaccines authorized in this manner in connection with the marketing and sale of our vaccine candidate. If these policies and guidance change unexpectedly and/or materially or if we misinterpret them, potential sales of our product could be adversely impacted. Regulatory authorities may also terminate an EUA if safety issues or other concerns about our product arise or if we or Advaccine fail to comply with the conditions of authorization. If we or Advaccine apply for an EUA or similar authorization from regulatory authorities outside of the United States, the failure to obtain such authorization or the termination of such an authorization, if obtained, would adversely impact our and Advaccine&#8217;s ability to market and sell our COVID-19 vaccine.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">DNA medicines are a novel approach to treating and preventing disease, and negative perception of the efficacy, safety, or tolerability of any investigational medicines we develop could adversely affect our ability to conduct our business, advance our investigational medicines, or obtain regulatory approvals.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No DNA medicines have been granted EUA or have been approved to date by the FDA. Adverse events in clinical trials of our investigational medicines or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of DNA medicine, or other products that are perceived to be similar to DNA medicines, such as those related to other nucleic acid based vaccines such as mRNA vaccines, gene therapy or gene editing, could result in a decrease in the perceived benefit of one or more of our programs, increased regulatory scrutiny, decreased confidence by patients and clinical trial collaborators in our investigational medicines, and less demand for any product that we may develop. Our pipeline of DNA medicine candidates could result in a greater quantity of reportable adverse events, including suspected unexpected serious adverse reactions, other reportable negative clinical outcomes, manufacturing reportable events or material clinical events that could lead to clinical delay or hold by the FDA or applicable regulatory authority or other clinical delays, any of which could negatively impact the perception of one or more of our programs, as well as our business as a whole. In addition, responses by U.S., state, or foreign governments to negative public perception may result in new legislation or regulations that could limit our ability to develop any investigational medicines or commercialize any approved products, obtain or maintain regulatory approval, or otherwise achieve profitability. More restrictive statutory regimes, government regulations, or negative public opinion would have an adverse effect on our business, financial condition, results of operations, and prospects and may delay or impair the development of our investigational medicines and commercialization of any approved products or demand for any products we may develop.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and the contract manufacturers upon whom we rely fail to produce our proprietary smart devices and DNA medicine candidates in the volumes that we require on a timely basis, or at all, or if these contractors fail to comply with their obligations to us or with stringent regulations, we may face delays in the development and commercialization of our proprietary smart device and DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture some components of our proprietary smart devices and utilize the services of contract manufacturers to manufacture the remaining components of these devices. We also rely on third party contract manufacturers to produce our DNA medicine candidates for use in our clinical trials and potentially for commercial distribution, if any product candidate is approved by regulatory authorities. The manufacture of these devices and our DNA medicine candidates requires significant expertise and capital investment, including the development of advanced manufacturing techniques and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">process controls. Manufacturers often encounter difficulties in production, particularly in scaling up for commercial production. These problems include difficulties with production costs and yields, quality control, including stability of the equipment and DNA medicine candidates and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our manufacturers were to encounter any of these difficulties or our manufacturers otherwise fail to comply with their obligations to us, our ability to provide our proprietary smart device to our partners and to supply DNA medicine candidates for clinical trials or to commercially launch a product would be jeopardized. For example, we previously relied on VGXI to manufacture DNA plasmids for our DNA medicine candidates, including INO-4800. In 2020, VGXI notified us that they would be unable to produce the necessary plasmids to meet this timeline due to a lack of manufacturing capacity. As a result, we had to engage several additional third-party contract manufacturers. However, there can be no assurance that we will be able to secure adequate additional manufacturing capacity for any of our DNA medicine candidates on commercially reasonable terms. Our inability to secure sufficient manufacturing capacity, or our inability to transfer necessary manufacturing know-how to third parties, would adversely affect our commercialization plans and could also harm our reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any delay or interruption in the supply of clinical trial supplies for our DNA medicine candidates could delay the completion of our clinical trials, increase the costs associated with maintaining our clinical trial program and, depending upon the period of delay, require us to commence new trials at significant additional expense or terminate the trials completely. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, all manufacturers of our products must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the generation and maintenance of records and documentation. Manufacturers of our products may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. We have little control over our manufacturers' compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of any product is compromised due to our or our manufacturers' failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our products, entail higher costs or result in our being unable to effectively commercialize our products. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis, pursuant to provided specifications and at commercially reasonable prices, we may be unable to meet demand for our products and would lose potential revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are combination products regulated under both the biologic and device regulations of the Public Health Service Act and Federal Food, Drug, and Cosmetic Act. Third-party manufacturers may not be able to comply with cGMP regulations, regulations applicable to biologic/device combination products, including applicable provisions of the FDA&#8217;s drug cGMP regulations, device cGMP requirements embodied in the quality system regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are dependent on single-source suppliers for some of the components and materials used in, and the processes required to develop, our product candidates and investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on single-source suppliers for some of the components and materials used in, and manufacturing processes required to develop and commercialize, our product candidates and investigational medicines. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs, or that they will not be purchased by one of our competitors or another company that may not be interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes, and finished goods exposes us to several risks, including disruptions in supply, price increases, or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials, and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions which would damage our business, financial condition, results of operations, and prospects.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we have to switch to a replacement supplier, the manufacture and delivery of our product candidates or investigational medicines could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers for any of the components or processes used in our product candidates or investigational medicines, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single-source components and materials used in our product candidates, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to supply our investigational medicines.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our reliance on these suppliers, service providers, and manufacturers subjects us to a number of risks that could harm our reputation, business, and financial condition, including, among other things:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays to the development timelines for our development candidates or investigational medicines;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of supply resulting from modifications to or discontinuation of a supplier&#8217;s operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues, or a supplier&#8217;s variation in a component;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">a lack of long-term supply arrangements for key components with our suppliers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">inability to obtain adequate supply in a timely manner, or to obtain adequate supply on commercially reasonable terms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">difficulty and cost associated with locating and qualifying alternative suppliers for our components in a timely manner;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">production delays related to the evaluation and testing of components from alternative suppliers, and corresponding regulatory qualifications;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delay in delivery due to our suppliers&#8217; prioritizing other customer orders over ours;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage to our reputation caused by defective components produced by our suppliers; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fluctuation in delivery by our suppliers due to changes in demand from us or their other customers.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our products receive regulatory approval, they may still face future development and regulatory difficulties.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if United States regulatory approval is obtained, regulators may still impose significant restrictions on a product's indicated uses or marketing or impose ongoing requirements for potentially costly post-approval studies. This governmental oversight may be particularly strict with respect to gene-based therapies. Our products will also be subject to ongoing FDA requirements governing the labeling, packaging, storage, advertising, promotion, record keeping and submission of safety and other post-market information. For example, the FDA strictly regulates the promotional claims that may be made about medical products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of drug treatment made in the physician&#8217;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. However, companies may in certain circumstances share truthful and not misleading information that is otherwise consistent with the product&#8217;s FDA approved labeling. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, regulations. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturer or us, including requiring withdrawal of the product from the market or suspension of manufacturing. If we, our DNA medicine candidates, or the manufacturing facilities for our DNA medicine candidates fail to comply with applicable regulatory requirements, a regulatory agency may: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issue Warning Letters or untitled letters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose civil or criminal penalties; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend regulatory approvals; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspend any ongoing clinical trials; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refuse to approve pending applications or supplements to applications filed by us; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose restrictions on operations, including costly new manufacturing requirements; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seize or detain products or require us to initiate a product recall. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing some of our investigational DNA medicines and sometimes using new endpoints or methodologies for the treatment of diseases in which there is little clinical experience. As a result, the FDA or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no pharmacologic therapies approved to treat the underlying causes of many diseases that we currently attempt to address or may address in the future. There has been limited clinical trial experience for the development of pharmaceuticals to treat these rare diseases in general, and we are not aware of a registrational trial that led to approval of a drug to treat these diseases. There have been some historical trials with other agents which may have utilized clinical endpoints that are less applicable to our efforts that address the underlying defect. As a result, the design and conduct of clinical trials of investigational medicines for the treatment of these disorders and other disorders may take longer, be more costly, or be less effective as part of the novelty of development in these diseases. For example, our product candidate INO-3107 is being developed for RRP, a rare condition for which there are no approved non-surgical treatments. In particular, there are challenges associated with agreeing to a primary endpoint with the FDA for the treatment of RRP where no precedent exists.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we or our strategic collaborators may conduct for our programs. Further, even if we do achieve the pre-specified criteria, our trials may produce results that are unpredictable or inconsistent with the results of the more traditional efficacy endpoints in the trial. The FDA also could give overriding weight to other efficacy endpoints over a primary endpoint, even if we achieve statistically significant results on that endpoint, if we do not do so on our secondary efficacy endpoints. The FDA also weighs the benefits of a product against its risks and the FDA may view the efficacy results in the context of safety as not being supportive of licensure. Other regulatory authorities in Europe and other countries may make similar findings with respect to these endpoints.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have obtained Orphan Drug Designation for one of our DNA medicine candidates. As part of our business strategy, we may continue to seek Orphan Drug Designation for additional DNA medicine candidates, and we may be unsuccessful in obtaining new designations or may be unable to obtain or maintain the benefits associated with Orphan Drug Designation, including the potential for orphan drug exclusivity.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained Orphan Drug Designation from the FDA for INO-3107 for the treatment of RRP. We have sought and may continue to seek Orphan Drug Designation for one or more of our other DNA medicine candidates, although we may be unsuccessful in doing so. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years, except in limited circumstances. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have obtained Orphan Drug Designation for INO-3107 for the treatment of RRP, and even if we obtain Orphan Drug Designation for our other DNA medicine candidates in specific indications, we may not be the first to obtain marketing approval of these DNA medicine candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our DNA medicine candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our DNA medicine candidates, we may never receive such designations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">A breakthrough therapy designation or fast track designation by the FDA for a drug may not lead to a faster development or regulatory review or approval process, and it would not increase the likelihood that the drug will receive marketing approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may seek a breakthrough therapy designation for one or more of our investigational medicines. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the regulatory submission.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Designation as a breakthrough therapy is at the discretion of the FDA. Accordingly, even if we believe that one of our investigational medicines meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a drug may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. Even if we are successful in obtaining accelerated approval in the United States or under comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we may not successfully complete required post-approval trials, such trials may not confirm the clinical benefit of our drug, or approval of the drug may be withdrawn. In addition, even if one or more of our investigational medicines qualify as breakthrough therapies, the FDA may later decide that the investigational medicine no longer meets the conditions for qualification or it may decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Reliance on Third Parties</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose or are unable to secure collaborators or partners, or if our collaborators or partners do not apply adequate resources to their relationships with us, our product development and potential for profitability will suffer. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into, and may continue to enter into, distribution, co-promotion, partnership, sponsored research and other arrangements for development, manufacturing, sales, marketing and other commercialization activities relating to our products. For example, in the past we have entered into license and collaboration agreements to develop, obtain regulatory approval for and commercialize our DNA medicine candidates for specified indications, including in jurisdictions outside of the United States. The amount and timing of resources applied by our collaborators are largely outside of our control. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our current or future collaborators breaches or terminates our agreements, or fails to conduct our collaborative activities in a timely manner, our commercialization of products could be diminished or blocked completely. We may not receive any event-based payments, milestone payments or royalty payments under our collaborative agreements if our collaborative partners fail to develop products in a timely manner or at all. It is possible that collaborators will change their strategic focus, pursue alternative technologies or develop alternative products, either on their own or in collaboration with others. Further, we may be forced to fund programs that were previously funded by our collaborators, and we may not have, or be able to access, the necessary funding. The effectiveness of our partners, if any, in marketing our products will also affect our revenues and earnings.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to enter into new collaborative agreements. However, we may not be able to successfully negotiate any additional collaborative arrangements and, if established, these relationships may not be scientifically or commercially successful. Our success in the future depends in part on our ability to strategically enter into agreements with other organizations. This can be difficult due to internal and external constraints placed on these organizations. Some organizations may have insufficient administrative and related infrastructure to enable collaborations with many companies at once, which can extend the time it takes to develop, negotiate, implement and execute a collaboration. Once news of discussions regarding possible collaborations are known in the medical community, regardless of whether the news is accurate, failure to announce a collaborative agreement or the entity's announcement of a collaboration with another entity may result in adverse speculation about us, resulting in harm to our reputation and our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disputes could also arise between us and our existing or future collaborators, as to a variety of matters, including financial and intellectual property matters or other obligations under our agreements. These disputes could be both expensive and time-consuming and may result in delays in the development and commercialization of our products or could damage our relationship with a collaborator. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have agreements with government agencies, which are subject to termination and uncertain future funding, which could have a negative impact on our ability to develop certain of our pipeline candidates and/or require us to seek alternative funding sources to advance product candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into agreements with government agencies, such as the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases, DARPA, Medical CBRN Defense Consortium and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, or DoD, and we intend to continue entering into these types of agreements in the future. Our business is partially dependent on the continued </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance by these government agencies of their responsibilities under these agreements, including adequate continued funding of the agencies and their programs. We have no control over the resources and funding that government agencies may devote to these agreements, which may be subject to annual renewal and which generally may be terminated by the government agencies at any time. For example, in April 2021 we were notified by the DoD that it discontinued funding for the Phase 3 segment of our INNOVATE trial, which resulted in increased expenditures by us.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies may fail to perform their responsibilities under these agreements, which may cause them to be terminated by the government agencies. In addition, we may fail to perform our responsibilities under these agreements. Many of our government agreements are subject to audits, which may occur several years after the period to which the audit relates. If an audit identifies significant unallowable costs, we could incur a material charge to our earnings or reduction in our cash position. As a result, we may be unsuccessful entering, or ineligible to enter, into future government agreements. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we and our collaborators may not be able to obtain regulatory approval for or commercialize our DNA medicine candidates.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators have entered into agreements with CROs to provide monitors for and to manage data for our on-going clinical programs. We and the CROs conducting clinical trials for our proprietary smart device and DNA medicine candidates are required to comply with current good clinical practices, or GCPs, regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or the CROs conducting clinical trials of our DNA medicine candidates fail to comply with applicable GCPs, the clinical data generated in the clinical trials may be deemed unreliable and the FDA may require additional clinical trials before approving any marketing applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any relationships with CROs terminate, we or our collaborators may not be able to enter into arrangements with alternative CROs. In addition, these third-party CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our on-going clinical programs or perform trials efficiently. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could harm our competitive position. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements, or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our DNA medicine candidates. As a result, our financial results and the commercial prospects for our DNA medicine candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. Cost overruns by or disputes with our CROs may significantly increase our expenses.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We enter into various contracts in the normal course of our business in which we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">agree to indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically agree to indemnify the institution and related parties from losses arising from claims relating to the products, processes or services made, used, sold or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sub licensees&#8217; exercise of rights under the agreement. With respect to our commercial agreements, we have agreed to indemnify our vendors from any third-party product liability claims that could result from the production, use or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we typically agree to indemnify them from claims arising from the good faith performance of their services.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage or not covered by insurance, our business, financial condition and results of operations could be adversely affected. Similarly, if we are relying on a collaborator or other third party to indemnify us and the collaborator or other third party is denied insurance coverage or otherwise does not have assets available to indemnify us, our business, financial condition and results of operations could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of Our DNA Medicine Candidates</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have only a small marketing organization and no sales organization. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, if approved, we may not be able to generate product revenues.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have only a small commercial organization to support pre-commercial activities for our proprietary smart device and DNA medicine candidates, if approved, and we do not currently have a sales organization. In order to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize any products, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. We contemplate establishing our own sales force or seeking third-party partners to sell our products. The establishment and development of our own sales force to market any products we may develop will be expensive and time-consuming and could delay any product launch, and we may not be able to successfully develop this capability. We will also have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. To the extent we rely on third parties to commercialize our approved products, if any, we will receive lower revenues than if we commercialized these products ourselves. In addition, we may have little or no control over the sales efforts of third parties involved in our commercialization efforts. In the event we are unable to develop our own marketing and sales force or collaborate with a third-party marketing and sales organization, we would not be able to commercialize our DNA medicine candidates which would negatively impact our ability to generate product revenues. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If products for which we receive regulatory approval do not achieve broad market acceptance, the revenues that we generate from their sales will be limited.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our proprietary smart device and DNA medicine candidates for which we obtain marketing approval from the FDA or other regulatory authorities will depend upon the acceptance of these products by both the medical community and patient population. Coverage and reimbursement of our DNA medicine candidates by third-party payors, including government payors, generally is also necessary for optimal commercial success. The degree of market acceptance of any of our approved products will depend on a number of factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to provide acceptable evidence of safety and efficacy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the relative convenience and ease of administration, including the acceptance and usage of our proprietary smart device by the medical community; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any actual or perceived adverse side effects; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in a product's FDA-approved labeling, including, for example, potential &#8220;black box&#8221; warnings; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative treatments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and cost effectiveness; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our or any future collaborators' sales and marketing strategies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the public perception of new therapies and the reputational challenges that the vaccine industry is facing related to the growing momentum of the anti-vaccine movement;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain sufficient third-party coverage and adequate reimbursement; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of patients to pay out of pocket in the absence of third-party coverage. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our proprietary smart device and DNA medicine candidates are approved but do not achieve an adequate level of acceptance by physicians, healthcare payors and patients, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our DNA medicine candidates may require significant resources and may never be successful. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to uncertainty relating to coverage and reimbursement policies which, if not favorable to our DNA medicine candidates, could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients in the United States and elsewhere generally rely on third-party payors to reimburse part or all of the costs associated with their prescription drugs and medical treatments. Accordingly, our ability to commercialize our proprietary smart device and DNA medicine candidates successfully will depend in part on the extent to which governmental authorities, including Medicare and Medicaid, private health insurers and other third-party payors establish appropriate coverage and reimbursement levels for our DNA medicine candidates and related treatments. As a threshold for coverage and reimbursement, third-party payors in the United States generally require that drug products and vaccines have been approved for marketing by the FDA. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. Coverage decisions may not favor new products when more established or lower cost therapeutic alternatives are already available. Even if we obtain coverage for a given product, the associated reimbursement rate may not be adequate to cover our costs, including research, development, intellectual property, manufacture, sale and distribution expenses, or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless reimbursement is adequate to cover all or a significant portion of the cost of our drug products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our products, if approved, will be provided under the supervision of a physician. When used in connection with medical procedures, our DNA medicine candidates may not be reimbursed separately but their cost may instead be bundled as part of the payment received by the provider for the procedure only. Separate reimbursement for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or separately reimburse for our DNA medicine candidates or procedures using our DNA medicine candidates, could reduce physician utilization of our products once approved.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement policies for products can differ significantly from payor to payor as there is no uniform policy of coverage and reimbursement for products among third-party payors in the United States. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant trend in the U.S. healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and services. Third-party payors are increasingly challenging the effectiveness of and prices charged for medical products and services. Moreover, the U.S. government, state legislatures and foreign governmental entities have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and coverage and requirements for substitution of generic products for branded prescription drugs. We may not be able to obtain third-party payor coverage or reimbursement for our products in whole or in part.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee and Operational Matters</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may be harmed if our restructuring plans do not achieve the anticipated results or cause undesirable consequences.</span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022 and again in January 2023, we undertook restructuring plans that resulted in a total reduction in headcount of approximately 79 employees and a significant majority of our contractors. Restructuring plans may yield unintended consequences, such as attrition beyond our intended reduction in workforce and reduced employee morale, which may cause our employees who were not affected by the reduction in workforce to seek alternate employment. During the second half of 2022, we experienced increased attrition after conducting the first reduction in force. Additional attrition could impede our ability to meet our operational goals, which could have a material adverse effect on our financial performance. In addition, as a result of the reductions in our workforce, we may face an increased risk of employment litigation. </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, employees whose positions have been or will be eliminated in connection with these restructuring plans may seek future employment with our competitors. Although all our employees are required to sign a confidentiality agreement with us at the time of hire, we cannot be certain that the confidential nature of our proprietary information will be maintained in the course of such future employment. We cannot be certain that any of our restructuring efforts will be successful, or that we will be able to realize the cost savings and other anticipated benefits from our current or any future restructuring plans. In addition, if we continue to reduce our workforce, it may adversely impact our ability to respond rapidly to any new growth or revenue opportunities. Any restructuring activities we undertake may take longer than expected and may require changes to our business that we are unable to implement. If we are unsuccessful in implementing our cost saving initiatives and restructuring plans or if we do not achieve our expected results, our results of operations and cash flows could be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently subject to litigation and may become subject to additional litigation, which could harm our business, financial condition and reputation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have actions brought against us by stockholders relating to past transactions, changes in our stock price or other matters. For example, numerous purported shareholder class action complaints have been filed against us, naming us and our directors and executive officers as defendants, and alleging that we made materially false and misleading statements regarding the development of INO-4800 in violation of certain federal securities laws. Although we have settled the current class action securities litigation, there can be no guarantee that we will not become subject to similar claims in the future. We may also become party to litigation with third parties as a result of our business activities. In 2020, we filed a lawsuit against one of our contract manufacturers, who then filed a counterclaim against us alleging that we had breached our contract with them, among other claims. There can be no assurance that we will ultimately prevail in the ongoing litigation matters described in this report or in future litigation matters. These and any potential future actions against us could give rise to substantial damages, which could have a material adverse effect on our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with litigation could harm our business, financial condition and reputation, as litigation is often costly, time-consuming and disruptive to business operations. The defense of our existing and potential future lawsuits could also result in diversion of our management's time and attention away from business operations, which could harm our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have experienced changes to our senior leadership team, which creates uncertainty and could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced changes to our senior leadership team over the past year. Our former President and Chief Executive Officer, Dr. J. Joseph Kim, who served in those roles since 2009, resigned in May 2022, and Dr. Jacqueline Shea, previously our Chief Operating Officer, was appointed to those roles. Although Dr. Shea has served with our Company since 2019, the management transition had the potential to create uncertainty and disrupt our operations and relationships with employees, suppliers and partners and result in operational inefficiencies, decreased employee morale and productivity and increased turnover. Any departure at a senior level could be particularly disruptive given that we are already experiencing leadership transitions and, to the extent we experience additional turnover, competition for top management is high such that it may take some time to find a candidate that meets our requirements. In addition, our competitors may seek to use this management transition and the related potential disruptions to gain a competitive advantage over us. If we are unable to successfully navigate the transition of our chief executive officer, our business could suffer.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon key personnel who may terminate their employment with us at any time and we may need to hire additional qualified personnel in order to obtain financing, pursue collaborations or develop or market our DNA medicine candidates. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers, including personnel with expertise in clinical trials, government regulation, manufacturing, marketing and other areas. Competition for qualified personnel is intense among companies, academic institutions and other organizations. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and DNA medicine candidates. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, including the global COVID-19 pandemic.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, in 2020 a number of governmental orders and other public health guidance measures were implemented across much of the United States, including in the locations of our offices, laboratories, clinical trial sites and third parties on whom we rely. As a result, our expected clinical development timelines were negatively impacted. These or similar events could result in future business and manufacturing disruption, or in reduced operations, any of which would materially affect our business, financial condition and results of operations. The COVID-19 pandemic also caused supply chain disruptions and supply shortages globally. As a result, we experienced delays and disruptions in obtaining clinical supplies, manufacturing supplies and components, and had to secure new vendors for certain supplies and components at higher prices. There can be no assurance that we will not encounter similar difficulties in the future.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spread of COVID-19, which caused a broad impact globally, could also affect us economically. While the potential economic impact brought by COVID-19 may be difficult to assess or predict, it has resulted in significant disruption of global financial markets, which could reduce our ability to access capital. Although we raised significant funds from the sale of our common stock in the public markets during the pandemic, there can be no guarantee that we will be able to continue to so, which could negatively affect our future liquidity.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future health epidemics could adversely affect our clinical trial operations, including our ability to initiate and conduct our planned trials on their expected timelines and to recruit and retain participants and principal investigators and site staff who, as healthcare providers, may have heightened exposure if an outbreak occurs in their geography. Trial participants may not be able to or may not feel safe going into healthcare facilities, which is necessary for the collection and completion of data samples for our clinical trials. Further, future epidemics could also result in delays in our clinical trials due to prioritization of hospital resources toward the disease, restrictions in travel, potential unwillingness of participants to enroll in trials, participants withdrawing from trials following enrollment as a result of contracting disease or other health conditions. In addition, we rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our preclinical studies and clinical trials, and the outbreak may affect their ability to devote sufficient time and resources to our programs or to travel to sites to perform work for us. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face intense and increasing competition and steps taken by our competitors such as the introduction of a new, disruptive technology may impede our ability to successfully commercialize our DNA medicines, if approved. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our competitors develop products with efficacy or safety profiles significantly better than our product candidates and introduce new, disruptive technology, we may not be able to commercialize our products, if approved, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or product candidates obsolete or noncompetitive, or result in treatments or cures superior to ours.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors and potential competitors include large pharmaceutical companies broadly engaged in vaccine/immunotherapy research and development, such as Janssen Pharmaceuticals (part of J&amp;J), Sanofi-Aventis, GlaxoSmithKline plc, Merck, Pfizer, Roche, AbbVie, Novartis, Bristol-Myers Squibb, and AstraZeneca, as well as various development-stage biotechnology companies involved in different vaccine and immunotherapy technologies, such as CureVac, Dynavax, Genexine, Hookipa, Iovance, Nektar, Nykode, Precigen, Translate Bio, Zydus, and Vir Biotechnology. These companies have significantly greater financial and other resources and greater expertise than us in research and development, securing government contracts and grants to support research and development efforts, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and marketing. This may make it easier for them to respond more quickly than us to new or changing opportunities, technologies or market needs. Many of these competitors operate large, well-funded research and development programs and have significant products approved or in development. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck and GlaxoSmithKline have commercialized preventive vaccines against HPV to protect against cervical cancer. Some companies are seeking to treat early HPV infections or low-grade cervical dysplasia. Loop Electrosurgical Excision Procedure, commonly known as LEEP, is a surgical procedure and is the current standard of care for treating high-grade cervical dysplasia. In RRP caused by HPV subtypes 6 and 11, Precigen is working to develop a treatment based on a gorilla adenovirus vector. Advaxis, Genexine, and Gilead Sciences have therapeutic cervical cancer product candidates under development. Many companies are pursuing different approaches to pre-cancers and cancers we are targeting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also compete more specifically with companies seeking to utilize antigen-encoding DNA delivered with electroporation or other delivery technologies such as viral vectors or lipid vectors to induce in vivo generated antigen production and immune responses to prevent or treat various diseases. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small biotechnology companies may also prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies or through acquisition or development of intellectual property rights. Our potential competitors also include academic institutions, governmental agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for product and clinical development and marketing. Research and development by others may seek to render our technologies or products obsolete or noncompetitive. See &#8220;Business&#8212;Competition&#8221; for additional information on our competitive landscape. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to successfully acquire, develop and market additional product candidates or approved products would impair our ability to grow.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire, in-license, develop and/or market additional products and product candidates. The success of these actions depends partly upon our ability to identify, select and acquire promising product candidates and products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, future acquisitions may entail numerous operational and financial risks, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management's time and attention to develop acquired products or technologies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of securities to pay for acquisitions; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher than expected acquisition and integration costs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, any product candidate that we acquire may require additional development efforts prior to commercial sale, including extensive clinical testing and approval by the FDA and applicable foreign regulatory authorities. All product candidates are prone to risks of failure typical of product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including for 35 days from December 2018 to January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely to a large extent upon sophisticated information technology systems to operate our businesses, some of which are managed, hosted provided and/or used for third-parties or their vendors. We collect, store and transmit large amounts of confidential information (including personal information and pseudonymized information), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. A significant breakdown, invasion, corruption, destruction, interruption, or unavailability of critical information technology systems or infrastructure, by our workforce, others with authorized access to our systems or unauthorized persons could negatively impact operations. Hardware, software, or applications we develop or obtain from third parties may contain defects in design or manufacture or other supply chain problems that could unexpectedly compromise our information and network security. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our or our third-party providers' systems, portable media or storage devices. We could also experience a business interruption, theft of confidential information or reputational damage from industrial espionage attacks, malware or other cyber-attacks (including ransomware), which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. While we have invested in the protection of data and information technology, there can be no assurance that our efforts will prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. In addition, as the regulatory environment related to information security, data collection and use, and privacy becomes increasingly rigorous, with new and constantly changing requirements applicable to our business, compliance with those requirements could also result in additional costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure and, if successful claims are brought against us, we may incur substantial liability.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our proprietary smart device and DNA medicine candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. For example, pharmaceutical companies have been subject to claims that the use of some pediatric vaccines has caused personal injuries, including brain damage, central nervous system damage and autism, and these companies have incurred material costs to defend these claims. If we cannot successfully defend ourselves against product liability claims, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our DNA medicine candidates; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of related litigation; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distraction of management's attention from our primary business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to commercialize our products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained product liability insurance coverage for our clinical trials, but our insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, large judgments have been awarded in class action lawsuits based on products that had unanticipated side effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could adversely affect our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent our products' commercial success. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the United States and certain foreign jurisdictions there have been, and we anticipate there will continue to be, a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell any of our products profitably. In the United States, the federal government enacted healthcare reform legislation, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA. Among the ACA&#8217;s provisions of importance to the pharmaceutical industry are that it:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposed an annual excise tax of 2.3% on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions, although the effective rate paid may be lower. However, the 2020 federal spending package permanently eliminated, effective January 1, 2020, this ACA-mandated medical device tax;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price, or AMP;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted or injected;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expanded the entities eligible for discounts under the Public Health program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established a Center for Medicare &amp; Medicaid Innovation at the Centers for Medicare &amp; Medicaid Services, or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; and</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.75pt">created a licensure framework for follow on biologic products.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been executive, judicial, and Congressional challenges to certain aspects of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties for not complying with the ACA&#8217;s individual mandate to carry qualifying health insurance coverage for all or part of a year. In addition, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage was eliminated, along with the health insurer tax. On June 17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. On August 16, 2022, President Biden signed the Inflation Reduction Act of 2022, or IRA, into law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA also eliminates the "donut hole" under the Medicare Part D program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost and creating a new manufacturer discount program. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the ACA and our business. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Budget Control Act of 2011 included reductions to Medicare payments to providers of 2% per fiscal year, which, due to subsequent legislative amendments to the statute will remain in effect until 2031, unless Congressional action is taken. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 4% in the final fiscal year of this sequester. The American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers, including hospitals, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. For example, at the federal level, in July 2021, the Biden administration released an executive order, &#8220;Promoting Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. In addition, the IRA, among other things (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare and (ii) imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. These provisions will take effect progressively starting in fiscal year 2023, although they may be subject to legal challenges. It is currently unclear how the IRA will be implemented but it is likely to have a significant impact on the pharmaceutical industry. In addition, the Biden administration released an additional executive order on October 14, 2022, directing HHS to report on how the Center for Medicare and Medicaid Innovation can be further leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to make and implement healthcare reforms may adversely affect: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price we believe is fair for our products; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenues and achieve or maintain profitability; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely approval of our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with applicable healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain federal, state, local and foreign healthcare laws and regulations pertaining to fraud and abuse, transparency, patients' rights, and privacy are applicable to our business. The laws that may affect our ability to operate include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, people from soliciting, receiving or providing remuneration, directly or indirectly, to induce or reward either the referral of an individual, or ordering, or leasing of an item, good, facility or service, for which payment may be made by a federal healthcare program such as Medicare or Medicaid. The intent standard under the federal healthcare program Anti-Kickback Statute was amended by the ACA to a stricter standard such that a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the ACA codified case law that a claim including items or services resulting from a violation of the federal healthcare program Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the civil False Claims Act, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which prohibits, among other things, executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal healthcare program Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and related regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain individuals and entities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, created under the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with certain exceptions, to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">chiropractors), other healthcare professionals (such as physicians assistants and nurse practitioners) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDCA, which among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. Foreign Corrupt Practices Act, which, among other things, prohibits companies issuing stock in the U.S. from bribing foreign officials for government contracts and other business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, state and local laws requiring the registration of pharmaceutical sales and medical representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional state and local laws such as laws in California and Massachusetts, which mandate implementation of compliance programs, compliance with industry ethics codes, and spending limits, and other state and local laws, such as laws in Vermont, Maine, and Minnesota which require reporting to state governments of gifts, compensation, and other remuneration to physicians. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shifting regulatory environment, along with the requirement to comply with multiple jurisdictions with different compliance and/or reporting requirements, increases the possibility that a company may run afoul of one or more laws.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, which require strict compliance in order to offer protection, it is possible that governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable healthcare laws. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, imprisonment, integrity and/or other oversight obligations, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Any such penalties could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and our third-party manufacturers must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our and our third-party manufacturers' activities involve the controlled storage, use and disposal of hazardous materials, including the components of our DNA medicine candidates and other hazardous compounds. We and our manufacturers are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In the event of an accident, state or federal authorities may curtail the use of these materials and interrupt our business operations. If we are subject to any liability as a result of our or our third-party manufacturers' activities involving hazardous materials, our business and financial condition may be adversely affected. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We have entered into collaborations with Chinese companies and conduct certain research and development activities in China. Uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, a trade war, political unrest or unstable economic conditions in China could materially adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a license and collaboration agreement with a China-based company ApolloBio, pursuant to which ApolloBio has the exclusive right to develop and commercialize VGX-3100 in China, Hong Kong, Macao and Taiwan. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value. In addition, the Chinese legal system is based in part on government policies and internal rules, some of which are not published on a timely basis or at all, and which may have a retroactive effect. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Because Chinese administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are exposed to the possibility of disruption of our research and development activities in the event of changes in the policies of the United States or Chinese governments, political unrest or unstable economic conditions in China. For example, China's "zero COVID" policy has caused delays in Advaccine&#8217;s conduct of clinical trials for INO-4800 in China under our collaboration with them, which has in turn resulted in delays in obtaining clinical data to evaluate the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety and potential efficacy of INO-4800. Further, the threat of a trade war between the United States and China could lead to supply chain disruptions or increased costs for clinical materials manufactured in China that are necessary for our development efforts. These interruptions or failures could then impede commercialization of our DNA medicine candidates and impair our competitive position. We may also be exposed to fluctuations in the value of the local currency in China. These uncertainties may impede our ability to enforce the contracts we have entered into and our ability to continue our research and development activities and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, principal investigators, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, and consultants. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the EU and other jurisdictions; provide accurate information to the FDA, the EMA, and other regulatory authorities; comply with healthcare fraud and abuse laws and regulations in the United States and abroad; or report financial information or data accurately or disclose unauthorized activities to us. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. Sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations, and prospects, including the imposition of significant fines or other sanctions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee litigation and unfavorable publicity could negatively affect our future business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our employees may, from time to time, bring lawsuits against us regarding injury, creating a hostile work place, discrimination, wage and hour disputes, sexual harassment, or other employment issues. In recent years there has been an increase in the number of discrimination and harassment claims generally. Coupled with the expansion of social media platforms and similar devices that allow individuals access to a broad audience, these claims have had a significant negative impact on some businesses. Certain companies that have faced employment- or harassment-related lawsuits have had to terminate management or other key personnel, and have suffered reputational harm that has negatively impacted their business. If we were to face any employment-related claims, our business could be negatively affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It is difficult and costly to generate and protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success will depend in part on obtaining and maintaining patent, trademark, trade secret, and other intellectual property protection relating to our proprietary smart device and DNA medicine candidates, as well as successfully defending these intellectual property rights against third-party challenges. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. The laws and regulations regarding the breadth of claims allowed in biotechnology patents have evolved over recent years and continues to undergo review and revision, both in the United States and abroad. The biotechnology patent situation outside the United States can be even more uncertain depending on the country. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our licensed patents, our patents or in third-party patents, nor can we predict the likelihood of our patents surviving a patent validity challenge. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our intellectual property rights is uncertain, because legal decision-making can be unpredictable, thereby often times resulting in limited protection, which may not adequately protect our rights or permit us to gain or keep our competitive advantage, or resulting in an invalid or unenforceable patent. For example: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or the parties from whom we have acquired or licensed patent rights, may not have been the first to file the underlying patent applications or the first to make the inventions covered by such patents; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the named inventors or co-inventors of patents or patent applications that we have licensed or acquired may be incorrect, which may give rise to inventorship and ownership challenges; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may develop similar or alternative technologies, or duplicate any of our products or technologies that may not be covered by our patents, including design-arounds; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pending patent applications may not result in issued patents; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents covering our products and technologies may not provide us with any competitive advantages or have any commercial value; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be challenged and invalidated, or rendered unenforceable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governments in the United States or abroad may prevent us from enforcing patents on our vaccines, which could prevent us from excluding competitors from those markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issued patents may be subject to reexamination, which could result in a narrowing of the scope of claims or cancellation of claims found unpatentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop or acquire additional proprietary technologies that are patentable; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trademarks may be invalid or subject to a third party's prior use; or </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enforce our patent rights will depend on our ability to detect infringement, and litigation to enforce patent rights may not be pursued due to significant financial costs, diversion of resources, and unpredictability of a favorable result or ruling. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend, in part, on our licensors and collaborators to protect a portion of our intellectual property rights. In such cases, our licensors and collaborators may be primarily or wholly responsible for the maintenance of patents and prosecution of patent applications relating to important areas of our business. If any of these parties fail to adequately protect these products with issued patents, our business and prospects would be harmed significantly. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may rely on trade secrets to protect our technology, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our trade secrets to competitors. Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our licensors fail to obtain or maintain patent protection or trade secret protection for our DNA medicine candidates or our technologies, third parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate revenues and attain profitability. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, U.S. and other policymakers have proposed reforming the patent laws and regulations of their countries. In September 2011 the America Invents Act (the Act) was signed into law. The Act changed the current &#8220;first-to-invent&#8221; system to a system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. The Act also created a procedure to challenge newly issued patents in the patent office via post-grant proceedings and new inter parties reexamination proceedings. These changes may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our product sales, business and results of operations. The changes may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other companies may have or may acquire intellectual property rights that could be enforced against us. If they do so, we may be required to alter our technologies, pay licensing fees or cease activities. If our products or technologies infringe the intellectual property rights of others, they could bring legal action against us or our licensors or collaborators claiming damages and seeking to enjoin any activities that they believe infringe their intellectual property rights. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because patent applications can take many years to issue, and there is a period when the application remains undisclosed to the public, there may be currently pending applications unknown to us or reissue applications that may later result in issued patents upon which our products or technologies may infringe. There could also be existing patents of which we are unaware that our products or technologies may infringe. In addition, if third parties file patent applications or obtain patents claiming products or technologies also claimed by us in pending applications or issued patents, we may have to participate in interference or derivation proceedings in the United States Patent and Trademark Office to determine priority or derivation of the invention. If third parties file oppositions in foreign countries, we may also have to participate in opposition proceedings in foreign tribunals to defend the patentability of our filed foreign patent applications. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a third party claims that we infringe its intellectual property rights, it could cause our business to suffer in a number of ways, including: </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become involved in time-consuming and expensive litigation, even if the claim is without merit, the third party's patent is invalid or we have not infringed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may become liable for substantial damages for past infringement if a court decides that our technologies infringe upon a third party's patent; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be enjoined by a court to stop making, selling or licensing our products or technologies without a license from a patent holder, which may not be available on commercially acceptable terms, if at all, or which may require us to pay substantial royalties or grant cross-licenses to our patents; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to redesign our products so that they do not infringe upon others' patent rights, which may not be possible or could require substantial investment or time. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events occur, our business could suffer and the market price of our common stock may decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not yet registered our trademarks in all of our potential markets, and failure to secure those registrations could adversely affect our business.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademark applications may not be allowed for registration, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to an Investment in Our Common Stock</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our common stock may not be sustained.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed on the Nasdaq Global Select Market, we cannot be certain that an active trading market for our shares will continue to be sustained. If an active market for our common stock is not sustained, it may be difficult for investors in our common stock to sell shares without depressing the market price for the shares or to sell the shares at all.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock has been and may continue to be volatile, and an investment in our common stock could decline substantially in value. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In light of our small size and limited resources, as well as the uncertainties and risks that can affect our business and industry, our stock price has been and may continue to be highly volatile and has been and may in the future be subject to substantial drops, with or even in the absence of news affecting our business. Period to period comparisons are not indicative of future performance. The following factors, which are not exhaustive, in addition to the other risk factors described in this report, and the potentially low volume of trades in our common stock, may have a significant impact on the market price of our common stock, some of which are beyond our control: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments concerning any research and development, clinical trials, manufacturing, and marketing efforts or collaborations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuating public or scientific interest in the potential for our vaccines or other DNA medicine candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our announcement of significant acquisitions, strategic collaborations, joint ventures or capital commitments; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological innovations; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new products or services that we or our competitors offer; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, conduct and/or outcome of intellectual property and/or litigation matters; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial or other estimates by securities analysts or other reviewers or evaluators of our business; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions or trends in bio-pharmaceutical or other healthcare industries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments in the United States and other countries; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceptions of gene-based therapy; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the economic performance and/or market valuations of other biotechnology and medical device companies; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our capital structure;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales or other transactions by executive officers or directors involving our common stock; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in accounting principles; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">global unrest including geopolitical risks emanating from countries such as Russia and China, terrorist activities, and economic and other external factors; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease pandemics, including COVID-19. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock market in general can experience relatively large price and volume fluctuations from time to time. In particular, the market prices of securities of smaller biotechnology and medical device companies have experienced dramatic fluctuations that often have been unrelated or disproportionate to the operating results of these companies. Continued market fluctuations could result in extreme volatility in the price of our common stock, which could cause a decline in the value of our common stock. In addition, price volatility may increase if the trading volume of our common stock remains limited or declines.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We have broad discretion in the use of our cash, cash equivalents, and investments, and may not use them effectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the application of our cash, cash equivalents, and investments, and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. For example, our operating expenses during the period from 2020 to 2022 significantly increased due to development and manufacturing activities for our COVID-19 vaccine program, for which we discontinued internal funding in the fourth quarter of 2022. We may not deploy our current capital resources effectively. The failure by our management to apply our funds effectively could result in financial losses that could have a material adverse impact on our business, cause the price of our common stock to decline, and delay the development of our investigational medicines. Pending their use, we may invest our cash, cash equivalents, and investments in a manner that does not produce income or that loses value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation contains provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the authority of our board of directors to issue shares of undesignated preferred stock and to determine the rights, preferences and privileges of these shares, without stockholder approval; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all stockholder actions must be effected at a duly called meeting of stockholders and not by written consent; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the elimination of cumulative voting. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors, including to delay or impede a merger, tender offer or proxy contest involving our company. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never paid cash dividends on our common stock and we do not anticipate paying dividends in the foreseeable future. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have paid no cash dividends on our common stock to date, and we currently intend to retain our future earnings, if any, to fund the development and growth of our business. In addition, the terms of any future debt or credit facility may preclude or limit our ability to pay any dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of potential gain for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Sections 382 and 383 of the revised Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity by certain significant shareholders over a rolling three year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our share ownership, some of which would be outside our control. If our ability to use our net operating losses and other tax attributes is limited by ownership changes, we may be unable to utilize a material portion of our net operating losses and other tax attributes to offset our future taxable income. In addition, there is also a risk that due to changes in laws and regulations, such as alternative minimum taxes or suspensions on the use </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of net operating losses, or other unforeseen reasons, our existing net operating losses could expire or otherwise become unavailable to offset future income tax liabilities.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly operating results may fluctuate significantly.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in the level of expenses related to our proprietary smart device, DNA medicine candidates or future development programs; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses related to corporate transactions, including ones not fully completed; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addition or termination of clinical trials or funding support; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement lawsuit in which we may become involved; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any legal claims that may be asserted against us or any of our officers; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments affecting our proprietary smart device and DNA medicine candidates or those of our competitors; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">debt service obligations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the fair value of our investments, including investments in affiliated entities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these arrangements; and </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any of our DNA medicine candidates receive regulatory approval, the levels of underlying demand for our products. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations and liquidity needs could be materially affected by market fluctuations and general economic conditions. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be materially affected by economic conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, global pathogen outbreaks or pandemics, including COVID-19, and the availability and cost of credit have in the past and may continue to contribute to increased volatility and diminished expectations for the economy and the markets going forward. Market upheavals may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected. Our future cost of equity or debt capital and access to the capital markets could be adversely affected, and our stock price could decline. There may be disruption or delay in the performance of our third-party contractors and suppliers. If our contractors, suppliers and partners are unable to satisfy their contractual commitments, our business could suffer. In addition, we maintain significant amounts of cash and cash equivalents at one or more financial institutions that are in excess of federally insured limits, and we may experience losses on these deposits. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that equity research analysts publish about us and our business, and we have limited research coverage by equity research analysts. Equity research analysts may elect not to initiate or continue to provide research coverage of our common stock, and such lack of research coverage may adversely affect the market price of our common stock. Even if we have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The issuance of additional stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation authorizes us to issue up to 600,000,000 shares of common stock and up to 10,000,000 shares of preferred stock with such rights and preferences as may be determined by our board of directors. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock or securities convertible into our common stock from time to time in connection with a financing, acquisition, investment, our stock incentive plans or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs and demands upon management as a result of being a public company.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the United States, we incur significant legal, accounting and other costs that could negatively affect our financial results. In addition, changing laws, regulations and standards relating to corporate governance and public disclosure, including regulations implemented by the SEC and stock exchanges, may increase legal and financial compliance costs and make some activities more time-consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management's time and attention from revenue-generating activities to compliance activities. If notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory authorities may initiate legal proceedings against us and our business may be harmed.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these rules might also make it more difficult for us to obtain some types of insurance, including director and officer liability insurance, and we might be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these events could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, on committees of our board of directors or as members of senior management.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws could adversely affect our business and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax regimes to which we are subject or under which we operate are unsettled and may be subject to significant change. In December 2017, tax legislation commonly known as the Tax Cuts and Jobs Act was enacted, which significantly revised the Internal Revenue Code of 1986, as amended, or the Code. The Tax Cuts and Jobs Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35 percent to a flat rate of 21 percent, limitation of the tax deduction for interest expense to 30 percent of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80 percent of current-year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the federal tax law is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the federal tax law. The issuance of additional regulatory or accounting guidance related to the Tax Act, or changes proposed or implemented by the current U.S. presidential administration or otherwise, could materially affect our tax obligations and effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our research, development candidates, investigational medicines, and the diseases our development candidates and investigational medicines are being developed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business, resulting in potential regulatory actions against us. For example, participants may use social media channels to comment on their experience in an ongoing blinded clinical trial or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our development candidates and investigational medicines. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own no real property and have no plans to acquire any real property in the future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">San Diego Leases</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2013, we entered into a lease, or the First San Diego Lease, for office space in San Diego, California. The term of the First San Diego Lease commenced on December 1, 2013. The initial term of the First San Diego Lease is ten years, with an option to extend the term by five years, subject to specified conditions. In June 2015, we amended the First San Diego Lease to increase the total leased space to 31,207 square feet and occupy the entire building. The commencement of the amended First San Diego Lease was in January 2016. As of December 31, 2022, rent payments under the First San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. We had an option to terminate the First San Diego Lease on December 1, 2019, which we did not exercise.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, we entered into an office lease, or the Second San Diego Lease, for a second property in San Diego, California. The total space under the Second San Diego Lease is approximately 51,000 square feet. We are using the facility for office, manufacturing and research and development purposes. The term of the Second San Diego Lease commenced on June&#160;1, 2017. The initial term of the Second San Diego Lease is ten years, with a right to terminate on November&#160;30, 2023, subject to specified conditions.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Second San Diego Lease. As of December 31, 2022, rent payments under the Second San Diego Lease include base rent with an annual increase of approximately 3 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $95,000. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Plymouth Meeting Lease </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, we entered into a lease, or the Plymouth Meeting Lease, for our corporate headquarters in Plymouth Meeting, Pennsylvania. We occupied the space in June 2014. The initial term of the Plymouth Meeting Lease was 11.5 years, with a right to extend the term by five years, subject to specified conditions. We use the space for office purposes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The base rent adjusts periodically throughout the term of the Plymouth Meeting Lease. As of December 31, 2022, rent payments under the Plymouth Meeting Lease include base rent with an annual increase of approximately 2 percent, and additional monthly fees to cover our share of certain facility expenses, including utilities, property taxes, insurance and maintenance. In addition, we have paid a security deposit of $49,000. In July 2015, we amended the Plymouth Meeting Lease to increase the total leased space to 27,583 square feet. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, we entered into another amendment to the Plymouth Meeting Lease to increase the total leased space to 57,361 square feet and extend the lease term through December 31, 2029. In connection with this amendment, we paid the landlord an additional security deposit of $75,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, we entered into two agreements to sublease a total of approximately 13,500 square feet in our Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our current and future planned facilities will be adequate to meet our operating needs for the foreseeable future. Should we need additional space, we believe we will be able to secure additional space at commercially reasonable rates.</span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Securities Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Securities Class Action Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming us and J. Joseph Kim, our former President and Chief Executive Officer, as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our development of a vaccine for COVID-19 in our public disclosures in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. On June 18, 2020, the court appointed Manuel Williams to serve as lead plaintiff. On August 3, 2020, Mr. Williams filed a consolidated complaint, naming us and three of our officers as defendants. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 21, 2020, Mr. Williams and another purported stockholder, Andrew Zenoff filed a first amended complaint, naming us and three of our officers as defendants. Defendants filed a motion to dismiss plaintiff&#8217;s first amended complaint on November 5, 2020. On February 16, 2021, the court issued an order granting in part, and denying in part, Defendants&#8217; motion to dismiss. The court granted Defendants&#8217; motion to dismiss, and dismissed with prejudice, the claims premised on the April 30 and June 30, 2020 statements. The court denied Defendants&#8217; motion to dismiss as to the remaining statements. On March 9, 2021, Defendants filed their answer to the complaint. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, we will pay $30.0 million in cash and $14.0 million in shares of our common stock to settle all outstanding claims. Our insurance carriers have paid the $30.0 million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement, and on January 18, 2023, the court entered an order granting final approval of the settlement, as set forth in a stipulation of settlement. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, pursuant to the securities class action settlement, we issued 7,000,000 shares of common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the expiration of the appeal period or resolution of an appeal if one is filed, we will make another contribution of common stock to the settlement fund with a value of approximately $2.1 million. The number of shares will be calculated based on the average trading price of our common stock for the 10 trading days preceding the determination date pursuant to the terms of the securities class action settlement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class action complaint. The lawsuit accuses our board of directors of failing to exercise reasonable and prudent supervision over our management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of us as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v. Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name our current directors as defendants. The Devarakonda complaint also names one of our former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, we filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GeneOne Litigation</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against us, alleging that we had breached the CELLECTRA Device License Agreement, or the Agreement, between us and GeneOne. We terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from us. On January 29, 2021, we filed preliminary objections to the complaint. On August 23, 2021, the Court overruled our preliminary objections to the complaint. On September 13, 2021, we filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement, and assert claims for breach of contract and declaratory judgment. The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs. On October 18, 2021, GeneOne filed its answer to our counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to aggressively prosecute the claims set forth in our counterclaims against GeneOne and to vigorously defend ourselves against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock, par value $0.001 per share, began trading on the Nasdaq Global Select Market on September 15, 2014 under the symbol "INO," having previously traded on the NYSE MKT exchange. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 24, 2023, we had approximately 100 common stockholders of record. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing price per share of our common stock on February 24, 2023 was $1.28, as reported on the Nasdaq Global Select Market.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payment of any dividends on our common stock is within the discretion of our board of directors. We have never paid cash dividends on our common stock and the board of directors does not expect to declare cash dividends on the common stock in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the performance of our common stock with the performance of the NYSE American Index, the S&amp;P SuperCap Biotechnology index and the Nasdaq Composite Index for the five years ended December 31, 2022. The graph assumes a $100 investment on December 31, 2017 in our common stock and in each index, with the reinvestment of all dividends, if any.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-align:center;text-indent:22.5pt"><img src="ino-20221231_g5.jpg" alt="ino-20221231_g5.jpg" style="height:400px;margin-bottom:5pt;vertical-align:text-bottom;width:558px"/></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*$100 invested on 12/31/17 in stock or index, including reinvestment of dividends.<br/>Fiscal year ended December 31.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/21</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12/22</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inovio Pharmaceuticals, Inc.&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NYSE American</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nasdaq Composite</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P SuperCap Biotechnology Index</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The stock price performance included in this graph is not necessarily indicative of future stock price performance. The performance graph is furnished solely to accompany this Form 10-K annual report and shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Parties </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;RESERVED</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements, as defined in Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue,&#8221; the negative of such terms or other comparable terminology. These statements are only predictions. Actual events or results may differ materially.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable based on our current expectations and projections, we cannot guarantee future results, levels of activity, performance or achievements. Moreover, neither we, nor any other person, assume responsibility for the accuracy and completeness of the forward-looking statements. We are under no obligation to update any of the forward-looking statements after the filing of this Annual Report to conform such statements to actual results or to changes in our expectations.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes and other financial information appearing elsewhere in this Annual Report. Readers are also urged to carefully review and consider the various disclosures made by us which attempt to advise interested parties of the factors which affect our business, including without limitation the disclosures made in Item&#160;1A of Part&#160;I of this Annual Report under the caption &#8220;Risk Factors.&#8221;</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk factors that could cause actual results to differ from those contained in the forward-looking statements include but are not limited to: our history of losses; our lack of products that have received regulatory approval; uncertainties inherent in clinical trials and product development programs, including but not limited to the fact that pre-clinical and clinical results may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve desired results, that preclinical studies and clinical trials may not commence, have sufficient enrollment or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies, that results from an animal study may not be indicative of results achievable in human studies, that clinical testing is expensive and can take many years to complete, that the outcome of any clinical trial is uncertain and failure can occur at any time during the clinical trial process, and that our proprietary smart device technology and DNA medicine candidates may fail to show the desired safety and efficacy traits in clinical trials; the availability of funding; the ability to manufacture our DNA medicine candidates; the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or our collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that we and our collaborators hope to develop; our ability to receive development, regulatory and commercialization event-based payments under our collaborative agreements; whether our proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity; and the impact of government healthcare laws and proposals.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_43"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. Our goal is to advance our diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, our DNA medicine candidates have shown the ability to generate immune responses, especially CD4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CD8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">+</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and memory T-cell responses against targeted pathogens and cancers, via our precisely designed plasmids. These plasmids are delivered into cells using our investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our lead candidates are focused on diseases associated with HPV. In 2022, we announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces our belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, our DNA medicines for Ebola HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head &amp; neck, cervical, anal, penile, vulvar, and vaginal; other HPV-related disorders, such as RRP; and GBM.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our DNA medicine candidates are in the research and development phase. We have not generated any revenues from the sale of any products, and we do not expect to generate any such revenues for at least the next several years. We earn revenue from license fees and milestone revenue and collaborative research and development agreements and contracts. Our DNA medicine candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All DNA medicine candidates that we advance to clinical testing will require regulatory approval prior to commercial use, and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had an accumulated deficit of $1.5 billion. We expect to continue to incur substantial operating losses in the future due to our commitment to our research and development programs, the funding of preclinical studies, clinical trials and regulatory activities and the costs of general and administrative activities. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">VGX-3100 Update</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REVEAL2 is our second Phase 3 trial with VGX-3100.  In April 2022, the trial protocol was amended to utilize a biomarker-selected population as the primary population, based on prior analysis of REVEAL1 results suggesting that this investigational biomarker had the potential to identify women more likely to respond to treatment with VGX-3100. We announced that this trial would no longer be considered to be a pivotal trial and would not lead to a BLA filing for a biomarker-selected population, as the FDA advised us that the biomarker-positive population would not be sufficient to support approval of a potential marketing application for VGX-3100. The FDA recommended using REVEAL2 as an exploratory trial and that conducting one or two additional well-controlled trials in the biomarker-selected population would be more likely to provide evidence to support approval of a marketing application.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial participants in REVEAL2 included 203 women, 18 years of age or older, who had histologically-confirmed cervical HSIL associated with HPV-16 and/or HPV-18, but who were otherwise healthy. Participants received either VGX-3100 or placebo at 0, 4 and 12 weeks (randomized 2:1). The primary endpoint, as amended, was the percentage of biomarker-selected participants with regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 in the cervix.  A secondary endpoint was the percentage of all participants with regression and virologic clearance.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we announced data from our REVEAL2 trial. Statistical significance was not achieved in the investigational biomarker-selected population for the endpoint of lesion regression and viral clearance. However, statistical significance was achieved in the all-participants population for the endpoint of lesion regression and viral clearance.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of participants in the investigational biomarker-selected population meeting the primary endpoint was 28.6% (6/21) in the treatment group, versus 0% (0/4) in the placebo group (p=0.115; difference in percentage 28.6, 95%CI: -24.6, 50.4), which was not statistically significant.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The result of the all-participants population of 203 participants (134 participants in the treatment group, 69 in the placebo group) was statistically significant, with 27.6% (37/134) of the participants meeting the endpoint in the treatment group, versus 8.7% (6/69) in the placebo group (p=0.001; difference in percentage 18.9, 95%CI: 7.8, 28.6).</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, in the all-participants population of REVEAL2, viral clearance was observed in 37.3% (50/134) in the treatment group versus 8.7% (6/69) in the placebo group. Given the importance of viral clearance in removing the underlying cause of the HPV-related diseases, this data may have positive implications in our other HPV-related programs.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ad-hoc integrated efficacy analysis of the results for both REVEAL1 and REVEAL2 achieved statistical significance in the biomarker-selected and all-participants populations for lesion regression and viral clearance. For the combined biomarker-selected population of 92 participants (68 participants in the treatment group, 24 in the placebo group), the percentage of participants meeting the primary endpoint was 54.4% (37/68 in the treatment group, versus 12.5% (3/24) in the placebo group (p=&lt;0.001; difference in percentage 41.9, 95%CI: 20.4, 57.0). For the combined all-participants population of 404 participants (272 participants in the treatment group, 132 in the placebo group), the percentage of participants meeting the primary endpoint was 25.0% (68/272 in the treatment group, versus 9.8% (13/132) in the placebo group (p=&lt;0.001; difference in percentage 15.2, 95%CI: 7.4, 22.1).    </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both REVEAL1 and REVEAL2, VGX-3100 was well-tolerated. There were no treatment-related serious adverse events and most adverse events were considered to be mild to moderate.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This combined data set will be used as supportive data in future regulatory interactions involving VGX-3100. We will continue to evaluate the results to determine next steps for VGX-3100 in our HPV programs. We plan to submit the data for publication in a peer-reviewed journal later this year.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">INO-4800 Update</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 27, 2022, we announced that we have discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The decision was based on our assessment of the current global demand for COVID-19 vaccines, changes in regulatory timelines and requirements, diminishing government financial support, and the overall growing uncertainty related to opportunities for heterologous booster vaccines.  </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INO-4800 continues to be evaluated as part of the World Health Organization&#8217;s Solidarity Trial Vaccines and we continue preclinical development of a potential pan-COVID-19 vaccine candidate. In addition, our clinical collaborator Advaccine is continuing to develop INO-4800 as a potential COVID-19 heterologous booster vaccine in Greater China using its own resources.</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reductions in Force</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, we committed to and communicated a corporate reorganization plan, including a reduction in force, or the Reduction. The purpose of the Reduction was to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, we reduced overall headcount by approximately 24 employees, which represented 11% of our full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3 million. We expect to incur a one-time pre-tax charge of approximately $1.1 million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, we undertook a separate reorganization and reduced overall headcount by approximately 55 employees, which represented 18% of our full-time employees. We also terminated agreements with approximately 86% of our contractors. We incurred a one-time pre-tax charge of $1.6 million in the third quarter of 2022 related to these actions, consisting primarily of one-time severance payments upon termination, continued benefits and outplacement services. </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Class Action Settlement </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, the United States District Court for the Eastern District of Pennsylvania, or the Court, entered an order, or the Order, granting final approval for the settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The settlement includes $30.0 million in cash and $14.0 million in shares of our common stock to settle all outstanding claims. Our insurance carriers have paid the cash component of the settlement and we will therefore not incur any material cash expenses associated with the litigation, other than legal fees and related expenses, which were approximately $11.0 million through December 31, 2022. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, pursuant to the securities class action settlement, we issued 7,000,000 shares of common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the expiration of the appeal period or resolution of an appeal if one is filed, we will make another contribution of common stock to the settlement fund with a value of approximately $2.1 million. </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC defines critical accounting policies as those that are, in management&#8217;s view, important to the portrayal of our financial condition and results of operations and require management&#8217;s judgment. Our discussion and analysis of our financial condition and results of operations are based on our audited consolidated financial statements, which have been prepared in accordance with U.S.&#160;GAAP. Our significant accounting policies are outlined in Note 2 to the consolidated financial statements included in this report.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses. We base our estimates on experience and on various assumptions that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates. We believe the following accounting policies to be critical to the judgments and estimates used in the preparation of our consolidated financial statements:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreements and Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess whether our collaboration agreements are subject to Accounting Standards Codification ("ASC") Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and we conclude that our collaboration partner is not a customer, we present such payments as a reduction of research and development expense. If payments from our collaboration partner to us represent consideration from a customer, then we account for those payments within the scope of Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, Revenue from Contracts with Customers (&#8220;Topic 606&#8221;). </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercial goals; and (iv) royalties on net sales of licensed products. At contract inception, we assess the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are performance obligations. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, we must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. We evaluate each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price. Differences in the allocation of the transaction price between delivered and undelivered performance obligations can impact the timing of revenue recognition but do not change the total revenue recognized under any agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaboration arrangements that include license fees, we recognize revenues from non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaboration arrangements that include milestone payments (variable consideration), we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. This assessment is based on our past experience with our collaboration partner, market insight and partner communication. Milestone payments that are not within our or our collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment and could be material.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For collaboration arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, we recognize revenue in the period the underlying sales occur. To date, we have not recognized any royalty revenue resulting from any of our collaborative arrangements.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses - Clinical Trial Accruals</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our activities have largely consisted of research and development efforts related to developing proprietary smart device technologies, DNA medicine candidates and dMABs. For clinical trial expenses, judgments used in estimating accruals rely on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to our results of operations. </span></div><div><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding recent accounting pronouncements is contained in Note&#160;2 to the consolidated financial statements, included elsewhere in this report.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial data for the years ended December&#160;31, 2022, 2021 and 2020 is presented in the following table and the results of these periods are used in the discussion thereafter.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.664%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.112%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,  </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2022 vs. 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)          2021 vs. 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity<br/></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,262,268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,487,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,636,462)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,650,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,240,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,245,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,589,821)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,994,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,185,285&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,752,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,247,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,432,932&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,504,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">277,835,788&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">302,992,677&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,493,264&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,156,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,499,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(267,573,520)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(301,217,919)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(124,082,044)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,644,399&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177,135,875)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,782,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,311,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,418,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,234&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,253,952)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,936,447)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,702,450)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,766,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,670,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,670,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,899,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(553,570)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,556,658&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,346,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,110,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,846,172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,222,838)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,695,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,623,334)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,918,335)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,861,584)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(704,896)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,204,955)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,048,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,121,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,121,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,177,043)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,177,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,762,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,762,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277,652,852)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,571,471&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,334,019)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(434,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,584,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,730,826)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150,223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(279,818,065)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,658,710)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,474,914)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,840,645&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136,183,796)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,063,757)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss attributed to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(279,818,065)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303,658,710)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166,411,157)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,840,645&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,247,553)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Not meaningful</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2022 and 2021 </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue was primarily derived under collaborative arrangements and contracts, including arrangements with affiliated entities, for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The $8.5 million increase in revenue was primarily due to higher revenue earned from our Procurement Contract with the DoD.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for full-time research and development employees, facilities expenses, overhead expenses, cost of laboratory supplies, clinical trial and related clinical manufacturing expenses, fees paid to contract research organizations and other consultants, and outside expenses. We utilize a labor reporting system to record employee compensation on a project-by-project basis. Unallocated research and development expenses include engineering and device-related expenses that are not allocable to a specific project, as well as stock-based compensation, other employee-related expenses that are not related to a specific project, and facilities and depreciation expenses.    </span></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development costs are expensed as incurred. Non-refundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following tables summarize our research and development expense by product candidate for the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-4800 and other Covid-19</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,587&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VGX-3100</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-3107</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">INO-5401 and other Immuno-oncology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other research and development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Engineering and device-related </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,702)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,817&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,558&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,741)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,589)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24.5pt"><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $61.6 million overall decrease in research and development expenses year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$45.9 million in lower drug manufacturing and outside services related to INO-4800;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$21.9 million of costs related to the acquisition and installation of manufacturing equipment for INO-4800 during 2021 that did not recur in 2022;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$15.6 million in lower engineering services and expensed equipment related to our CELLECTRA 3PSP device and array automation project; </span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$11.8 million in lower clinical study, outside services and immunology expenses related to VGX-3100;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.9 million in lower expensed inventory related to the CELLECTRA 2000 device; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$4.6 million in lower employee stock-based compensation primarily from lower weighted average grant date fair values for the awards granted during 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$29.2 million of lower contra-research and development expense recorded from grant agreements; and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$14.4 million of increased drug manufacturing costs related to our COVID-19 variant studies and DARPA COVID-19 dMAb grant.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contributions received from current grant agreements and recorded as contra-research and development expense were $24.5 million and $53.7 million for the years ended December&#160;31, 2022 and 2021, respectively. The decrease year over year was primarily due to decreases of $21.0 million, $5.8 million, $3.3 million and $3.2 million earned under the DoD 3PSP device development grant, CEPI grants related to INO-4800 and device development activities, reimbursements from Advaccine and the CEPI Lassa and MERS grant, respectively. These decreases were offset by an increase of $5.3 million, earned primarily under the sub-grant through Wistar for DARPA COVID-19 dMAb. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses, which include business development expenses, the amortization of intangible assets and patent expenses, were $90.2 million for the year ended December&#160;31, 2022 as compared to $53.8 million in 2021.  The $36.4 overall increase year over year was primarily the result of:</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:23.5pt">$44.0 million related to the class action securities litigation settlement, which was reduced by $30.0 million of insurance recoveries, resulting in a net $14.0 million expense, which is the value of our common stock to be issued in connection with the settlement;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$14.3 million in higher legal expenses, primarily related to litigation matters;</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$6.9 million in severance expenses related to the separation of our former President and Chief Executive Officer in May 2022, including $4.2 million of stock-based compensation expense related to equity award modifications (see Note 10 to our consolidated financial statements included in this report for additional information); and</span></div><div style="margin-top:5pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">$1.6 million in overall higher employee compensation.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the employee&#8217;s requisite service period. Total employee stock-based compensation cost for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December&#160;31, 2022 and 2021 was $22.2 million and $25.0 million, of which $8.8 million and $13.4 million was included in research and development expenses and $13.4 million and $11.6 million was included in general and administrative expenses, respectively. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1.4 million increase in interest income for the year ended December&#160;31, 2022 as compared to 2021 was primarily due to higher interest rates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $682,000 decrease in interest expense for the year ended December&#160;31, 2022 as compared to 2021 was primarily due to lower non-cash interest expense related to the $78.5 million aggregate principal amount of our 6.50% convertible senior notes due 2024 as a result of the adoption of ASU&#8209;2020-06, and no interest expense recorded on the convertible promissory notes issued in December 2019 due to their full conversion into shares of our common stock in March 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loss on Investment in Affiliated Entity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss on investment in affiliated entity resulted from the declines in the fair market value of our investment in PLS of $1.9 million and $554,000 for the years ended December&#160;31, 2022 and 2021, respectively. We record our investment in PLS at its market value based on the closing price of the shares on the Korea New Exchange Market at each balance sheet date, with changes in fair value reflected in the consolidated statements of operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Unrealized Loss on Available-for-Sale Equity Securities </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized loss on available-for-sale equity securities for the years ended December&#160;31, 2022 and 2021 was $7.8 million and $3.2 million, respectively, which resulted from a change in the fair market value of the investments.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share in Net Loss of Geneos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The share in net loss of Geneos represents our share of Geneos' losses during the period after deconsolidation in June 2020. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred operating losses and accordingly have not recorded a provision for U.S. income taxes for any of the periods presented. Utilization of net operating losses and tax credits are subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended, or IRC. As of December&#160;31, 2022, we had net operating loss carry forwards for U.S. federal, California and Pennsylvania income tax purposes of $920.6 million, $210.3 million and $89.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. We also had U.S. federal and state research and development tax credits of $40.5 million and $4.7 million, respectively, net of the federal research and development credits that will expire due to IRC Section&#160;383 limitations. The net operating losses and credits began to expire during 2022.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2021 and 2020</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a comparison of the years ended December 31, 2021 and 2020, you may refer to Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 1, 2022.</span></div><div><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our primary uses of cash have been to finance research and development activities including clinical trial activities for the advancement of DNA medicine candidates. Since inception, we have satisfied our cash requirements principally from proceeds from the sale of equity securities, indebtedness and grants and government contracts.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had cash and short-term investments of $253.0 million and working capital of $218.4 million, as compared to $401.3 million and $382.7 million as of December&#160;31, 2021, respectively. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $216.2 million and $215.7 million for the years ended December&#160;31, 2022 and 2021, respectively. The variance was primarily due to the timing and changes in working capital balances, offset by decreased operating expenses.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities was $109.6 million and $(175.3) million for the years ended December&#160;31, 2022 and 2021, respectively. The variance was primarily the result of timing differences in short-term investment purchases, sales and maturities.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financing Activities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $81.8 million and $211.5 million for the years ended December&#160;31, 2022 and 2021, respectively. The variance was primarily due to the proceeds from the January 2021 underwritten public offering, partially offset by an increase in the proceeds from the sale of common stock under the Sales Agreement (defined below) in 2022 compared to 2021. </span></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, we entered into an ATM Equity Offering</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) under which we may offer and sell, from time to time at our sole discretion, shares of our common stock with aggregate gross proceeds of up to $300.0 million, through the Sales Agents.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms and conditions of the Sales Agreement, the Sales Agents may sell the common stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221;. The Sales Agents will use commercially reasonable efforts to sell the common stock from time to time, based upon instructions from us, including any price, time or size limits or other customary parameters or conditions we may impose. We will pay the Sales Agents a commission of up to three percent (3.0%) of the gross sales proceeds of any common stock sold through the Sales Agents under the Sales Agreement, and we have provided the Sales Agents with certain indemnification rights. During the year ended December 31, 2022, we sold </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,445,743</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock under the Sales Agreement for aggregate net proceeds of $83.0 million. During the year ended December 31, 2021, we sold 6,955,341 shares of common stock under the Sales Agreement for aggregate net proceeds of $47.7 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, we sold 66,064,887 shares of common stock for aggregate net proceeds of $454.5 million under previous ATM sales agreements.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, we closed an underwritten public offering of 20,355,000 shares of our common stock at a public offering price of $8.50 per share. The net proceeds, after deducting the underwriters' discounts and commissions and other estimated offering expenses payable by us, were $162.1&#160;million. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2022, stock options to purchase 118,694 shares of common stock were exercised for aggregate net proceeds of $283,000, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $1.4 million. During the year ended December&#160;31, 2021, stock options to purchase 1,310,263 shares of common stock were exercised for aggregate net proceeds of $6.7 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.6 million. During the year ended December&#160;31, 2020, stock options to purchase 2,178,252 shares of common stock were exercised for aggregate net proceeds of $12.3 million, which proceeds were offset by tax payments made related to net share settlement of RSU awards of $4.0 million.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Requirements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had an accumulated deficit of $1.5 billion and we expect to continue to operate at a loss for some time. The amount of the accumulated deficit will continue to increase, as it will be expensive to continue research and development efforts. Our current cash resources, including amounts that we may be able to obtain through sales of common stock under our &#8220;at the market&#8221; equity facility, will not be sufficient to complete the clinical development of any of our product candidates, and we anticipate that additional financing will be required in order to commercialize and generate revenues from the sale of any product candidates that receive regulatory approval. If these activities are successful and if we receive approval from the FDA to market our DNA medicine candidates, then we will need to raise additional funding to market and sell the approved products and equipment. In addition to the potential issuance of equity or debt securities in order to raise capital, we are also evaluating potential collaborations as an additional way to fund our operations. We believe that our current cash and short-term investments are sufficient to meet our planned working capital requirements for at least the next twelve months from the date of this report. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, in January 2023 and July 2022, we undertook corporate reorganization plans to decrease our expenses, extend our cash runway, and maintain a streamlined organization to support key clinical programs that we expect to drive our long-term growth. Also, in October 2022, we announced that we have discontinued our internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. We expect these actions to reduce our operating expenses incrementally and extend our cash runway into the first quarter of 2025, without giving effect to any further capital raising activities, whether under the Sales Agreement or otherwise. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, future minimum payments due under our contractual obligations are set forth in the table below. We expect to be able to satisfy these obligations, both in the short-term and in the longer-term, with cash on hand and proceeds from sales of our common stock under the Sales Agreement. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less than<br/>1&#160;year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1&#160;&#8211;&#160;3&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3&#160;&#8211;&#160;5&#160;years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;than<br/>5&#160;years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible senior notes (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,015,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,090,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,113,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,665,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing commitments (3)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,515,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,515,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Amounts represent remaining contractual amounts due under our Notes, including interest based on the fixed rate of 6.5% per year. Although these Notes mature in March 2024, they may be converted into shares of our common stock prior to maturity if certain conditions are met. We may also redeem the Notes prior to their maturity if certain conditions are met. Any redemption prior to maturity would result in repayments of the principal amounts sooner than the scheduled repayments as indicated in the table. See Note 9, Convertible Debt, to the consolidated financial statements in this report for additional information.</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) We have entered into operating leases for our facilities, which expire from 2023 to 2029, and operating leases for office equipment, which expire in 2024. In the fourth quarter of 2019, we entered into two subleases for a portion of our Plymouth Meeting corporate headquarters facility with one period through March 31, 2025 and the other month-to-month after December 31, 2022. As of December&#160;31, 2022, we expect to receive aggregate future minimum lease payments totaling $434,000 (non-discounted) over the duration of the sublease agreements, which expected payments are not included in the table above.&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Remaining purchase obligations from supply agreements with contract manufacturers.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are a party to a variety of agreements pursuant to which we may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, consolidated results of operations or financial condition.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_58"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to increase the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. We mitigate default risk by investing in short-term investment-grade securities. During the year ended December&#160;31, 2022, there was a pronounced increase in prevailing interest rates in the United States, which contributed to a loss of $7.8 million in the market value of our investment portfolio during the period.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate on our indebtedness is fixed and not subject to fluctuations in interest rates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and most transactions during the year ended December&#160;31, 2022 were made in United States dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations, with the exception of certain cash and cash equivalents held in South Korea that are denominated in South Korean Won and the valuation of our equity investment in PLS, which is denominated in South Korean Won and then translated into United States dollars. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain transactions are denominated primarily in foreign currencies, including South Korean Won, Euros, British Pounds and Canadian Dollars. These transactions give rise to monetary assets and liabilities that are denominated in currencies other than the U.S. dollar. The value of these monetary assets and liabilities are subject to changes in currency exchange rates from the time the transactions are originated until settlement in cash. As a result, our financial results could be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets where we conduct business.</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative purposes and do not engage in exchange rate hedging or hold or issue foreign exchange contracts for trading purposes. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Risk</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor. Although inflation has increased generally in the United States in recent months, we do not believe that inflation has had a material effect on our business, financial condition or results of operations during the year ended December&#160;31, 2022. </span></div><div style="margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;8 is incorporated by reference to our Consolidated Financial Statements and the Report of Independent Registered Public Accounting Firm beginning at page&#160;F-1 of this report.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, which are designed to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules&#160;and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer, or CEO, and Chief Financial Officer, or CFO, as appropriate to allow timely decisions regarding required disclosures. </span></div><div style="margin-top:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an evaluation carried out as of the end of the period covered by this Annual Report, under the supervision and with the participation of our management, including our CEO and CFO, our CEO and CFO have concluded that, as of the end of such period, our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934) were effective as of December&#160;31, 2022 at the reasonable assurance level.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Internal Control Over Financial Reporting</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting and Attestation Report of Registered Public Accounting Firm</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, management, with the participation of the Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in &#8220;Internal Control&#8212;Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the assessment, management determined that we maintained effective internal control over financial reporting as of December&#160;31, 2022.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm regarding the effectiveness of internal control over financial reporting as required by Section 404(b) of the Sarbanes-Oxley Act of 2002. Management&#8217;s report was not subject to attestation by our registered public accounting firm pursuant to rules of the SEC that permit smaller reporting companies to provide only management&#8217;s report in this Annual Report.</span></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4.5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have not been any changes in our internal control over financial reporting that occurred during the fourth quarter of our fiscal year ended December&#160;31, 2022, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B. &#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_76"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.            DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160;&#160;&#160;&#160;DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;10 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2022 fiscal year, under the captions &#8220;Election of Directors&#8221; and &#8220;Executive Officers and Other Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160;&#160;&#160;EXECUTIVE COMPENSATION</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;11 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2022 fiscal year, under the captions &#8220;Compensation Discussion and Analysis,&#8221; &#8220;Executive Compensation,&#8221; &#8220;Compensation of Directors&#8221; and &#8220;Director Compensation Table.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;12 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2022 fiscal year, under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and &#8220;Equity Compensation Plan Information.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director independence and other information required by this Item&#160;13 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2022 fiscal year, under the captions &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Election of Directors.&#8221;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item&#160;14 is hereby incorporated by reference from our definitive proxy statement, to be filed pursuant to Regulation&#160;14A within 120&#160;days after the end of our 2022 fiscal year, under the caption &#8220;Ratification of Appointment of Registered Public Accounting Firm.&#8221;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_100"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statements</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated financial statements required to be filed hereunder are indexed on Page&#160;F-1 hereof.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules not listed herein have been omitted because the information required to be set forth therein is not applicable or is included in the Financial Statements or notes thereto.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Exhibits</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report on Form&#160;10-K:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468dex31.htm">Certificate of Incorporation with all amendments (incorporated by reference to Exhibit&#160;3.1 of the registrant&#8217;s Form S-3 registration statement, filed on July 23, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000095012311076829/w84047exv3w2.htm">Amended and Restated Bylaws of Inovio Pharmaceuticals, Inc. dated August&#160;10, 2011 (incorporated by reference to Exhibit&#160;3.2 to the registrant&#8217;s Form&#160;8-K current report filed on August&#160;12, 2011).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Indenture, dated as of February 19, 2019, by and between the registrant and U.S. Bank National Association, as trustee (incorporated by reference to Exhibit 4.1 to the registrant&#8217;s current report on Form 8-K filed with the SEC on February 20, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312519045422/d695922dex41.htm">Form of Note representing the registrant&#8217;s 6.50% Convertible Senior Notes due 2024 (included as Exhibit A to the Indenture filed as Exhibit 4.1).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino-12312019x10xkex49.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (incorporated by reference to Exhibit 4.9 to the registrant&#8217;s annual report on Form 10-K filed with the SEC on March 12, 2020)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">10.1&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_31.htm">R&amp;D Alliance Agreement dated December&#160;19, 2005 by and between Ganial Immunotherapeutics,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by Novation and Amendment Agreement by and between VGX Pharmaceuticals, Inc., Ganial Immunotherapeutics, Inc., and Onconox (incorporated by reference to Exhibit&#160;10.31 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">10.2&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_39.htm">R&amp;D Collaboration and License Agreement dated December&#160;18, 2006 by and between VGX International,&#160;Inc. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated October&#160;31, 2007 and as amended by Second Amendment dated August&#160;4, 2008 (incorporated by reference to Exhibit&#160;10.39 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">10.3&#8224;&#160;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_50.htm">Patent License Agreement dated April&#160;27, 2007 by and between The Trustees of the University of Pennsylvania and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment dated June&#160;12, 2008 (incorporated by reference to Exhibit&#160;10.50 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">10.4&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_34.htm">License Agreement dated May&#160;9, 2007 by and between Baylor University and VGX Pharmaceuticals,&#160;Inc. (incorporated by reference to Exhibit&#160;10.34 as filed with the registrant&#8217;s registration statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">10.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">ATM Equity Offering</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm">SM</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312518175305/d593417d8k.htm"> Sales Agreement dated November 9, 2021 by and among Inovio Pharmaceuticals, Inc., </a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000062/ino-93021x10xqex101.htm">BofA Securities, Inc., RBC Capital Markets, LLC and Oppenheimer &amp; Co. Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrants Form 10-Q quarterly report for the quarter ended September 30, 2021 filed on November 9, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">10.6&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312510122273/dex102.htm">License and Collaboration Agreement dated March&#160;24, 2010 between Inovio Pharmaceuticals, Inc. and VGX International, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended March&#160;31, 2010 filed on May&#160;17, 2010).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.241%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">10.7&#8224;</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511298587/d237108dex101.htm">Collaborative Development and License Agreement dated October 7, 2011 between VGX International, Inc. and Inovio Pharmaceuticals, Inc., as amended by First Amendment dated August 21, 2013, and Second Amendment dated October 7, 2013 (incorporated by reference to Exhibit 10.1 as filed with the registrant&#8217;s Form 10-Q quarterly report for the quarter ended September&#160;30, 2011 filed on November&#160;7, 2011).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016x10qexhibit101.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000040/ino-3312016xexhibit102.htm">Collaborative Research Agreement dated March 14, 2016 by and between The Wistar Institute of Anatomy and Biology, a Commonwealth of Pennsylvania nonprofit corporation, and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended March 31, 2016 filed on May 9, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">10.10&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572618000014/ino-12312017x10kex1012.htm">Amended and Restated License and Collaboration Agreement, dated December 29, 2017, by and between Inovio Pharmaceuticals, Inc. and Beijing Apollo Saturn Biological Technology Limited (incorporated by reference to Exhibit 10.12 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2017 filed on March 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000055/ino-63021x10xqex101.htm">10.11&#8224;&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572621000055/ino-63021x10xqex101.htm">Amended and Restated Collaboration and License Agreement dated June 7, 2021 between Inovio Pharmaceuticals, Inc. and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (incorporated by reference to Exhibit 10.1 as filed with the registrants Form 10-Q quarterly report for the quarter ended June 30, 2021 filed on August 9, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572613000005/ino-3312013x10qex101.htm">Lease dated April 9, 2013 by and between BMR-Wateridge LP and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to registrant's quarterly report for the quarter ended March 31, 2013, filed on May 10, 2013).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">Lease Agreement dated as of March 5, 2014 between Brandywine Operating Partnership L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.36 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2014 filed on March 17, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000003/ino-12312013x10kex1036.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000067/ino-9302016x10qex101.htm">Office Lease Agreement dated October 10, 2016 by and between 6759 Mesa Ridge Road Holdings, LLC and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2016 filed on November 9, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">Sublease dated June 21, 2017 between Accolade, Inc. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex102.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000036/ino-6302017x10qex101.htm">Second Amendment to the Lease Agreement dated June 22, 2017 between Brandywine Operating Partnership, L.P. and Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 as filed with the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2017 filed on August 8, 2017).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm">10.17+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000104746909000344/a2190045zex-10_43.htm">Employment Agreement dated March&#160;31, 2008 by and between J. Joseph Kim, Ph.D. and VGX Pharmaceuticals,&#160;Inc., as amended by First Amendment of Employment Agreement dated March&#160;31, 2008 (incorporated by reference to Exhibit&#160;10.43 as filed with the registrant&#8217;s Registration Statement on Form&#160;S-4 (File No.&#160;333-156035) on April&#160;27, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm">10.18+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1041.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and J. Joseph Kim, PhD. (incorporated by reference to Exhibit&#160;10.41 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572622000049/ino-63022x10qex101.htm">10.19+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572622000049/ino-63022x10qex101.htm">Separation Agreement, dated as of May 10, 2022, by and between the registrant and J. Joseph Kim (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572622000049/ino-63022x10qex101.htm">incorporated</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572622000049/ino-63022x10qex101.htm"> by reference to Exhibit 10.1 </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572622000049/ino-63022x10qex101.htm">of the registrant's Form 10-Q quarterly report for the quarter ended June 30, 2022 filed on August 9, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572622000049/ino-63022x10qex101.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">10.20+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312511068803/dex105.htm">Employment Agreement dated as of December&#160;27, 2010 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.5 to the registrant&#8217;s Form 10-K report for the year ended December&#160;31, 2010 filed on March&#160;16, 2011).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">10.21+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000144530513000665/ino-12312012x10kex1042.htm">First Amendment to Employment Agreement dated as of December&#160;31, 2012 between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit&#160;10.42 of the registrant&#8217;s Form 10-K annual report for the year ended December&#160;31, 2012 filed on March&#160;18, 2013).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">10.22+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572614000013/ino930201410qex102.htm">Second Amendment to Employment Agreement dated November 7, 2014 by and between Inovio Pharmaceuticals, Inc. and Peter Kies (incorporated by reference to Exhibit 10.2 of the registrant's Form 10-Q quarterly report for the quarter ended September 30, 2014 filed on November 10, 2014).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">10.23+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino1231209x10kex1026.htm">Employment Agreement dated March 8, 2019 between Inovio Pharmaceuticals, Inc. and Jacqueline E. Shea (incorporated by reference to Exhibit 10.26 of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">10.24+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572620000012/ino12312019x10kex1027.htm">Employment Agreement dated as of March 4, 2019 between Inovio Pharmaceuticals, Inc. and Laurent M. Humeau (incorporated by reference to Exhibit 10.27 of the registrant's Form 10-K annual report for the year ended December 31, 2019 filed on March 12, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">10.25</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465909050590/a09-18452_1ex10d1.htm">Form of Indemnification Agreement for Directors and Officers of Inovio Pharmaceuticals, Inc. (incorporated by reference to Exhibit&#160;10.1 to the registrant&#8217;s Form&#160;10-Q quarterly report for the quarterly period ended June&#160;30, 2009, filed on August&#160;19, 2009).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">10.26+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000033/ino-12312015x10kex1012.htm">Amended and Restated 2007 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit 10.12 to the registrant's Form 10-K report for the year ended December 31, 2015 filed on March 14, 2016).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">10.27+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000110465907039528/a07-14196_1ex4d4.htm">Form of Incentive and Non-Qualified Stock Option Grants under the 2007 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit&#160;4.4 to the registrant&#8217;s Registration Statement on Form&#160;S-8 filed on May&#160;14, 2007).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">10.28+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572616000036/ino-2016xproxy.htm">Inovio Pharmaceuticals, Inc. 2016 Omnibus Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the registrant's Form 8-K filed on May 10, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">10.29+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1055.htm">Form of Incentive Stock Option Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.55 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">10.30+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1056.htm">Form of Nonqualified Stock Option Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.56 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">10.31+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm">Form of Restricted Stock Unit</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000105572617000013/ino-12312016x10kex1054.htm"> Award Agreement under 2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.54 as filed with the registrant's Form 10-K annual report for the year ended December 31, 2016 filed on March 15, 2017.)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">10.32+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex991.htm">Inovio Pharmaceuticals, Inc. 2022 Inducement Plan (incorporated by reference to Exhibit 99.1 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">10.33+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex992.htm">Form of Option Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.2 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">10.34+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1055726/000119312522186278/d902697dex993.htm">Form of RSU Grant Package under 2022 Inducement Plan (incorporated by reference to Exhibit 99.3 of the registrant&#8217;s Form S-8 registration statement, filed on June 30, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex211.htm">Subsidiaries of the registrant (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex231.htm">Consent of Independent Registered Public Accounting Firm (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.702%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.854%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.237%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_106">24.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_106">Power of Attorney (included on signature page).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex311.htm">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex312.htm">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex321.htm">32.1&#94;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ino-12312022x10kex312.htm">Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Designates management contract, compensatory plan or arrangement.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Confidential treatment has been granted for certain portions omitted from this exhibit (indicated by asterisks) pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The confidential portions of this exhibit have been separately filed with the Securities and Exchange Commission.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain confidential portions of this exhibit (indicated by asterisks) were omitted because the identified confidential portions are not material and are of the type that the registrant treats as private or confidential. </span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#94;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">These certifications are being furnished solely to accompany this Annual Report pursuant to 18 U.S.C. Section 1350, and are not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</span></div><div style="padding-left:24.75pt;text-indent:-22.5pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March&#160;1, 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JACQUELINE E. SHEA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea<br/>President, Chief Executive Officer and Director                                                                                         (On Behalf of the Registrant)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jacqueline E. Shea and Peter Kies, and each of them severally, his or her true and lawful attorney-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead, in any and all capacities, to do any and all things and execute any and all instruments that such attorney may deem necessary or advisable under the Securities Exchange Act of 1934 and any rules, regulations and requirements of the United States Securities and Exchange Commission in connection with the Annual Report on Form&#160;10-K and any and all amendments hereto, as fully for all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all said attorneys-in-fact and agents, each acting alone, and his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.403%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JACQUELINE E. SHEA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jacqueline E. Shea</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;SIMON X. BENITO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Simon X. Benito</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;PETER KIES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Peter Kies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ROGER D. DANSEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Roger D. Dansey</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/    ANN C. MILLER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ann C. Miller</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JAY SHEPARD</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jay Shepard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;DAVID B. WEINER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">David B. Weiner</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;WENDY L. YARNO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Wendy L. Yarno</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;LOTA S. ZOTH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lota S. Zoth</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC.</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_112"></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_115">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTIvZnJhZzozZjExNTIwM2EwMDk0YTE4ODFhMDJlN2UwZTA1Zjc5Ny90YWJsZTo5MDcxMmM2YTkzMDg0NjIzOGE2NzgxZTM2ODIyNDc2Ni90YWJsZXJhbmdlOjkwNzEyYzZhOTMwODQ2MjM4YTY3ODFlMzY4MjI0NzY2XzEtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmZGE2NTA3NDczMmY0YmQ2YTYyZWEyNWQ1ZWUxMDkwM183MQ_34873fca-f2c6-4952-b19b-e95b74a066cb">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_115">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_118">Consolidated Balance Sheets </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_118">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_121">Consolidated Statements of Operations </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_121">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_124">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_124">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_127">Consolidated Statements of Stockholders' Equity </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_127">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_130">Consolidated Statements of Cash Flows </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_130">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_133">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i02d4bef15c6d4619b17bfe55828c95c8_133">9</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To the Shareholders and the Board of Directors of Inovio Pharmaceuticals, Inc. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the consolidated balance sheets of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Accrual of Clinical Trial Expenses</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Description of the Matter</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During 2022, the Company incurred $187.7 million for research and development expenses and as of December 31, 2022 accrued $10.6 million for clinical study costs. A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including clinical research organizations (&#8220;CROs&#8221;). External costs to be paid to CROs are accrued and expensed based upon actual work completed in accordance with signed agreements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Auditing management&#8217;s accounting for accrued clinical study costs is especially challenging because the evaluation is dependent upon a high-volume of data and input exchanged between clinical personnel and third-party service providers, such as the number of sites activated, the number of patients enrolled, and the number of patient visits, which is tracked in spreadsheets and other end user computing programs.</span></div><div><span><br/></span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">How We Addressed the Matter in our Audit</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We obtained an understanding of the accounting for accrued clinical trial expenses including management&#8217;s process for measuring estimated accrued clinical study costs such as patient enrollment and total cost incurred to date from third-parties.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To test the completeness of the Company&#8217;s accrued clinical trial expenses, we obtained from third-parties confirmation of patient enrollment and direct service cost to date for significant clinical trials. We attended internal clinical trial and project status meetings with accounting personnel and the clinical project manager to understand the status of significant clinical trial activities. To assess the appropriate measurement of accrued clinical trial expenses, we inspected key terms, timelines of completion, activities and costs for a sample of vendor contracts, including amendments, and compared these to management&#8217;s analyses used in tracking the progress of service agreements. We also tested a sample of subsequent payments by agreeing the invoice to the original accrual and the invoice payments to bank statements. </span></div></td></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.220%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTUvZnJhZzo3NzgxZGQ4ODA5MWI0NzA5YWE1NTgzZGE0NTA5M2I3Ny90YWJsZTo1Mjg3ODUyN2Y1ZjY0ZGZkODI0ZTZhNzEyODU0ZDlmZS90YWJsZXJhbmdlOjUyODc4NTI3ZjVmNjRkZmQ4MjRlNmE3MTI4NTRkOWZlXzAtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjoyZmFkYzZlODkxNGU0M2ZkYTg5ZDVkYjQ4NzZhMzgzOF84_c4191747-dae1-4d75-bf7b-94d6fe9f31fe">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 2002.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTUvZnJhZzo3NzgxZGQ4ODA5MWI0NzA5YWE1NTgzZGE0NTA5M2I3Ny90YWJsZTo1Mjg3ODUyN2Y1ZjY0ZGZkODI0ZTZhNzEyODU0ZDlmZS90YWJsZXJhbmdlOjUyODc4NTI3ZjVmNjRkZmQ4MjRlNmE3MTI4NTRkOWZlXzMtMC0xLTEtNDk4Mjg_0ef37232-a434-4d2f-81aa-a9630030a2ce">San Diego, California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQtMS0xLTEtNDk4Mjg_c8082895-42cd-4756-ba78-87dec6f318ca">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQtMy0xLTEtNDk4Mjg_4a5dc3f2-9dee-4cf5-9c62-d91b81298d66">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUtMS0xLTEtNDk4Mjg_dc77be86-dff5-43dd-b475-28b9aa14f96e">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUtMy0xLTEtNDk4Mjg_876d739a-368b-4275-9253-d795fa5a6757">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzYtMS0xLTEtNDk4Mjg_4ea6af40-5770-4124-8d86-7c2857603496">1,701,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzYtMy0xLTEtNDk4Mjg_ed519a5d-c90f-46b2-b985-4fad0382a84d">5,466,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzctMS0xLTEtNDk4Mjg_0f3eb9ec-27b9-4b5a-b20a-be5d6bbf744b">10,036,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzctMy0xLTEtNDk4Mjg_7661a919-b5fa-4dd8-a88f-fe30225aaa67">2,565,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzgtMS0xLTEtNDk4Mjg_9305df2b-c844-4dfb-9d5a-38a5bc822c9f">50,130,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzgtMy0xLTEtNDk4Mjg_1fb4e562-dae2-41a5-8793-4d931d76a21e">38,836,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzktMS0xLTEtNDk4Mjg_dd911609-0bc6-4a3f-8d3f-a6ee9532e8d4">375,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzktMy0xLTEtNDk4Mjg_40442027-ae0b-403d-a37b-a092d7786e35">261,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzExLTEtMS0xLTQ5ODI4_790194d3-ada0-4194-a7dc-92d019370b93">315,242,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzExLTMtMS0xLTQ5ODI4_0c1b2f81-ec6c-4469-b482-d51207d148a0">448,444,945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzEzLTEtMS0xLTQ5ODI4_59d76d5a-f7bd-452a-a926-fe993483682d">7,727,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzEzLTMtMS0xLTQ5ODI4_41f3d143-d4bc-4625-bf50-1e1e26015b97">17,453,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in affiliated entity </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE0LTEtMS0xLTQ5ODI4_3bef2783-dad7-4022-8453-18bb37dbe538">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE0LTMtMS0xLTQ5ODI4_df2c732d-4e68-4b3c-95dc-a12730fdb9f1">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE2LTEtMS0xLTQ5ODI4_d4fd1dc7-991b-4890-9bbf-485ca8b49597">2,129,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE2LTMtMS0xLTQ5ODI4_03d52296-651b-4ee2-b22d-0137b072dfa3">2,626,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE3LTEtMS0xLTQ5ODI4_4cee51c5-06d8-4073-8dea-45e26b97447e">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE3LTMtMS0xLTQ5ODI4_cec4320c-5e95-4614-b236-e9ce131af478">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE4LTEtMS0xLTQ5ODI4_178cbb2f-1bb5-4a6a-987d-25dd19c14aaf">10,228,207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE4LTMtMS0xLTQ5ODI4_b7b5898e-7545-4643-938f-c9a2f52fe9c6">11,571,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE5LTEtMS0xLTQ5ODI4_73857de9-f551-4aba-b347-a99bd6eabd20">684,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE5LTMtMS0xLTQ5ODI4_ddf4bab0-0e09-4996-a34d-99d9b3641af2">1,425,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIwLTEtMS0xLTQ5ODI4_1c34be04-4bc5-4152-aca9-14735a28e39a">348,533,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIwLTMtMS0xLTQ5ODI4_ceb0870e-50b8-4c2a-a8db-4242475b1a63">495,941,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIzLTEtMS0xLTQ5ODI4_9f853293-54ea-43c7-b727-72dc373e8647">79,686,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIzLTMtMS0xLTQ5ODI4_db96d59b-0489-4b91-91be-6fc9df401bb6">47,644,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses due to affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI0LTEtMS0xLTQ5ODI4_c7cb83aa-c919-40f8-8518-d9d5f6fa1590">1,220,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI0LTMtMS0xLTQ5ODI4_67d7385e-94dd-4a61-bef2-744bfd78f20e">548,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI1LTEtMS0xLTQ5ODI4_6baf465f-6a5e-4907-a43f-9cca8e1e5783">10,594,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="ino:AccruedClinicalTrialExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI1LTMtMS0xLTQ5ODI4_4cfba382-acd6-409c-b754-6d96696222a1">10,326,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI2LTEtMS0xLTQ5ODI4_f99cfa65-bb1b-4aa0-98f2-a3248aa7332e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI2LTMtMS0xLTQ5ODI4_2318a6d8-ef75-40a9-a7e7-d392d2fb593f">21,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI5LTEtMS0xLTQ5ODI4_c24dd478-12c4-419b-b9c2-0f54710667e3">2,803,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI5LTMtMS0xLTQ5ODI4_53386a9c-e92f-495e-9d02-6bfeec438a25">2,603,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMwLTEtMS0xLTQ5ODI4_abda950d-9fdd-4124-bb9f-4ac8622cb387">2,475,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="ino:DeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMwLTMtMS0xLTQ5ODI4_d550d8ae-cc8d-44e3-892b-8be5e0c5d19c">4,559,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant funding liability from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMxLTEtMS0xLTQ5ODI4_38f3e88d-4425-4611-98c2-e21c64bdd7ce">87,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="ino:DeferredGrantFundingFromAffiliateCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMxLTMtMS0xLTQ5ODI4_f99a8500-619c-4d58-a162-7b6e1c810c0c">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMyLTEtMS0xLTQ5ODI4_e55b6969-ae3b-4aa7-b786-b77ce92285a4">96,868,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMyLTMtMS0xLTQ5ODI4_ebf6d47e-dd4c-45fa-83af-c782e8057a97">65,741,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMzLTEtMS0xLTQ5ODI4_a38fd2c7-7563-4680-98e3-de5718f1b2a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMzLTMtMS0xLTQ5ODI4_c35c28ea-0dae-4da8-bd95-b9228c6837ec">64,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzM1LTEtMS0xLTQ5ODI4_d9dde24f-bf4c-4a66-8b83-1c3f82ae288c">16,614,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28fdf7ad489d4fce8f004f820b342526_I20211231" decimals="0" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzM1LTMtMS0xLTQ5ODI4_965cd22a-a10e-41a5-baea-5bbbc31a1ba2">14,959,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQwLTEtMS0xLTQ5ODI4_f74bdbc3-3758-4d2e-ad3e-c7e77bc3fbb0">12,655,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQwLTMtMS0xLTQ5ODI4_e0ae24a9-7185-4024-947c-07e9bf5fe71f">15,459,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQxLTEtMS0xLTQ5ODI4_ac63f78f-1b55-4309-bb67-fdc435645a7c">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQxLTMtMS0xLTQ5ODI4_4daa5e7b-8459-4aa6-8ccb-1a61db4d391d">32,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQzLTEtMS0xLTQ5ODI4_9bfa8908-5b41-4f7d-8f3c-71bcfe4416f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQzLTMtMS0xLTQ5ODI4_a5792fa8-4554-45cb-9393-d0bbcbefa2a1">14,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ0LTEtMS0xLTQ5ODI4_af06df78-13d0-41d4-a9df-cbc405c13364">126,170,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ0LTMtMS0xLTQ5ODI4_748a7910-84b5-465e-ab00-a683f9e2fa5e">96,272,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ1LTEtMS0xLTQ5ODI4_be41e7d3-351a-4bbd-b4f6-a6a69e79ea27"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ1LTMtMS0xLTQ5ODI4_19327a90-808c-460c-a213-523ac00950bb"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfMzA_084b8abe-3eb6-4748-8897-5c1581753291"><ix:nonFraction unitRef="usdPerShare" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfMzA_4f27ec57-466c-44ea-800a-caff131d0cc1">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfNTM_06153425-1042-4778-acc8-fb06af83c28e"><ix:nonFraction unitRef="shares" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfNTM_d28432e6-bc63-412a-a782-94c02266438b">10,000,000</ix:nonFraction></ix:nonFraction>, issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_00bfdd30-1eee-4935-8ca9-a91f15a7c507"><ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_e65cd6c5-3550-4217-b5db-e9d5ceb9bc3b"><ix:nonFraction unitRef="shares" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_f0043209-b6f9-444b-b417-668e3403e866"><ix:nonFraction unitRef="shares" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_f22b2c37-ab84-4c1d-9f23-24ccfacf28f4">9</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at December&#160;31, 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTEtMS0xLTQ5ODI4_2128af53-895d-4483-ad53-824612f6e3ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTMtMS0xLTQ5ODI4_f189feaf-f1ba-433e-933f-fa01ecc157b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock&#8212;par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMjc_0f44bad0-fdce-4746-b092-ea70a3062fa2"><ix:nonFraction unitRef="usdPerShare" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMjc_b0dbc841-7623-4e94-a53f-91d5a374df92">0.001</ix:nonFraction></ix:nonFraction>; Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfNTA_525ffb8c-0fc7-4f1f-b5cc-fe3295ba3cf9"><ix:nonFraction unitRef="shares" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfNTA_ea8d0bc4-952e-478a-a1e1-6a3e1c65647b">600,000,000</ix:nonFraction></ix:nonFraction> at December 31, 2022 and 2021, issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTA4_245f099f-ec82-4040-99c3-b745c9a23667"><ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTA4_ad72fc5f-2315-42f4-b23f-c8aae75a46e7">253,091,319</ix:nonFraction></ix:nonFraction> at December&#160;31, 2022 and <ix:nonFraction unitRef="shares" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTM2_59ffc067-85f2-4875-b053-dbf4e2fd5275"><ix:nonFraction unitRef="shares" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTM2_eb09d194-4a3d-46b6-a6c0-1d7edb449889">217,382,887</ix:nonFraction></ix:nonFraction> at December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTEtMS0xLTQ5ODI4_e03e7961-d771-487f-a5bf-c28627c967d4">253,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTMtMS0xLTQ5ODI4_de8de84d-8cfd-4d72-b1a5-b4eca4fd6a64">217,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ5LTEtMS0xLTQ5ODI4_0f20047a-4e1d-44b1-8d01-0b7122df76b3">1,710,656,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ5LTMtMS0xLTQ5ODI4_6ddf9883-2774-4fc2-8bc4-c0b453723045">1,609,589,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUwLTEtMS0xLTQ5ODI4_62e4b242-ed85-44a4-9e8f-de0f9dd6de6e">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUwLTMtMS0xLTQ5ODI4_ac1a87a5-4e2c-4813-9bfc-99563400951e">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUxLTEtMS0xLTQ5ODI4_522ca994-322b-42ae-a52e-7a8abadf9c40">698,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUxLTMtMS0xLTQ5ODI4_bf20707d-c271-4c90-b2fd-43f4380cb879">282,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUyLTEtMS0xLTQ5ODI4_829fb864-0db8-494d-aedc-99514f253c52">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUyLTMtMS0xLTQ5ODI4_edb3a3de-80dc-427d-aef9-686d6cfde112">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzU1LTEtMS0xLTQ5ODI4_483d2ce3-97f7-4ba6-b992-78cad0c06840">348,533,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzU1LTMtMS0xLTQ5ODI4_f8ac67a9-03de-4ee4-a4ea-81480e192713">495,941,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:15pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:55.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from collaborative arrangements and other contracts, including affiliated entity</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzktMS0xLTEtNDk4Mjg_c8a8bdd2-2c9e-47d2-8bd7-a9bf76321d7c">10,262,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzktMy0xLTEtNDk4Mjg_05a31d7f-8e64-417b-ac95-f297136fee68">1,774,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzktNS0xLTEtNDk4Mjg_e383d37e-b1af-4a9c-8848-fe160ecea811">7,411,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzExLTEtMS0xLTQ5ODI4_98fa0456-9aa3-4f6e-b4a2-fb233bcc074f">187,650,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzExLTMtMS0xLTQ5ODI4_ffc5a166-47a9-4d53-aa33-4eb7a6975e21">249,240,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzExLTUtMS0xLTQ5ODI4_a57548df-8518-4e19-bec1-f2067df4f425">94,245,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzEyLTEtMS0xLTQ5ODI4_8f596a14-4252-423b-81ac-15101c520941">90,185,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzEyLTMtMS0xLTQ5ODI4_9f20c840-4764-4954-88de-fe5ce236fa72">53,752,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzEyLTUtMS0xLTQ5ODI4_d13daed2-4c59-468c-b938-cf21b42dc23e">37,247,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE1LTEtMS0xLTQ5ODI4_5f483f79-2360-4fdb-9749-0dd0c7263d23">277,835,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE1LTMtMS0xLTQ5ODI4_1e2d3d01-641a-443f-9b6e-0be4c476d66e">302,992,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE1LTUtMS0xLTQ5ODI4_dcc52791-d864-436c-b90b-07a5482ae5ae">131,493,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE2LTEtMS0xLTQ5ODI4_19fc4305-1bf9-472f-a113-8ca3e8e7ba2e">267,573,520</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE2LTMtMS0xLTQ5ODI4_c1bb5523-4a3e-4954-a66b-de2cfd351607">301,217,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE2LTUtMS0xLTQ5ODI4_97fa2df3-e971-4ccd-be0e-4fc7917ab879">124,082,044</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE4LTEtMS0xLTQ5ODI4_768fc702-d184-40ec-9386-ca1e6a5ca730">4,782,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE4LTMtMS0xLTQ5ODI4_aa7c0a69-4876-4437-8341-43493acb3af2">3,363,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE4LTUtMS0xLTQ5ODI4_0d5631b5-204d-46a4-9a0c-5a7e3c252337">3,311,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE5LTEtMS0xLTQ5ODI4_a98bf224-32eb-4f04-9901-61f4470f0d0f">1,253,952</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE5LTMtMS0xLTQ5ODI4_6e1485d9-7f2b-45d1-8f94-0dd9b4918623">1,936,447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE5LTUtMS0xLTQ5ODI4_6514e5b8-5066-423e-80ab-dbdf3c4234e0">8,702,450</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIxLTEtMS0xLTQ5ODI4_80a703a0-20dd-448f-8613-047ee35546fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIxLTMtMS0xLTQ5ODI4_0d1a3379-f489-4d87-8ce6-ecb937b0912d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIxLTUtMS0xLTQ5ODI4_338fccd8-60a1-4f93-9b0e-d443313e17b2">75,670,977</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Loss) gain on investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIyLTEtMS0xLTQ5ODI4_6fb35fb7-3fa9-4fdd-a536-f9ee08eccf30">1,899,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIyLTMtMS0xLTQ5ODI4_2ea27889-2dc6-40d3-9573-d59a6f034649">553,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIyLTUtMS0xLTQ5ODI4_a6ebda71-c130-41ad-94bf-1641ca73755e">36,556,658</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized (loss) gain on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIzLTEtMS0xLTQ5ODI4_d88b958b-9ed0-460a-bb97-55af18d28be6">7,846,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIzLTMtMS0xLTQ5ODI4_be5da5f4-b353-47ef-bbed-f50fbccd19a5">3,222,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIzLTUtMS0xLTQ5ODI4_b485e2ca-2084-4544-a0f1-fdf6be98fc67">1,695,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI0LTEtMS0xLTQ5ODI4_16ad1459-8b2a-405c-86f6-7cb75423df08">3,861,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI0LTMtMS0xLTQ5ODI4_8ea1bd96-8bd2-41eb-9bff-bf29c5eb11f9">343,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI0LTUtMS0xLTQ5ODI4_f7b27aaa-cef1-47c2-a19e-99a18abac1a1">704,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI1LTEtMS0xLTQ5ODI4_98c413b1-5eba-409f-b842-ba76dd021a74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI1LTMtMS0xLTQ5ODI4_e064518f-7d96-4ba9-aa5d-06d937724c2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI1LTUtMS0xLTQ5ODI4_eab95407-55d0-4307-953d-080eb269314a">4,121,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2c1a9b72144f0a92349e7cf9e5a446_D20220101-20221231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI2LTEtMS0xLTQ5ODI4_440df533-9a0e-4dba-8ec1-46449d925fa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie31c91acde4741fe900e7a84f2b0ad34_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI2LTMtMS0xLTQ5ODI4_b60ad391-c69a-4835-b8df-a956780a171a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46ecffdec9a64e498429f8977ea52114_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI2LTUtMS0xLTQ5ODI4_831c96dd-8eb7-4d10-abd5-ad11fc805a39">8,177,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3a7a0113a6439694f0af4a15e4c7dc_D20220101-20221231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI3LTEtMS0xLTQ5ODI4_306fb038-e1dd-422d-896d-e6b943740010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae06434a74c4378bb8e66fbb38683a8_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI3LTMtMS0xLTQ5ODI4_3d1accbd-edf6-48a6-a228-eb3587e7b142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI3LTUtMS0xLTQ5ODI4_c7176b8a-2c16-4ffc-a931-dbe20ba031ef">8,762,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss before share in net loss of Geneos</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI4LTEtMS0xLTQ5ODI4_90021400-01ad-4d21-a9bb-3a6c105da58c">277,652,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI4LTMtMS0xLTQ5ODI4_704f1675-a083-4d2a-8a0d-a539d0081636">303,224,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI4LTUtMS0xLTQ5ODI4_66ff74c4-f3ae-424c-a07d-5faabdf53308">162,890,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in net loss of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMwLTEtMS0xLTQ5ODI4_24985add-2cfc-43b3-a4d8-222141372959">2,165,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMwLTMtMS0xLTQ5ODI4_1a89afce-d42c-48c2-9802-02aa759c7ba6">434,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMwLTUtMS0xLTQ5ODI4_4de3f94e-f200-45c9-82c8-7289c7db7730">4,584,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMxLTEtMS0xLTQ5ODI4_fd05bbb7-13f0-453d-9ca4-a130866ed2f1">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMxLTMtMS0xLTQ5ODI4_76f0ce08-1057-41cf-b120-0ff38740d8a4">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMxLTUtMS0xLTQ5ODI4_ec104b82-7445-4183-8f1e-0d87d74d2fab">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMyLTEtMS0xLTQ5ODI4_860de164-9663-4a69-8d78-1d1727d5702d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMyLTMtMS0xLTQ5ODI4_6a56022f-3e1a-4b2c-8070-7695c4f21ef2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMyLTUtMS0xLTQ5ODI4_dd47785d-324c-4283-a3c2-fb609b23b393">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMzLTEtMS0xLTQ5ODI4_f2a7b68e-3a60-487a-8160-6c03e2d995b6">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMzLTMtMS0xLTQ5ODI4_cdfa73d4-549a-406b-b811-6cd919ad0405">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMzLTUtMS0xLTQ5ODI4_19e5c0dd-2c09-4b6d-ad26-2a8b80dad117">166,411,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTEtMS0xLTQ5ODI4_300e9f43-2af6-460f-b1d6-6a4c6524dfab"><ix:nonFraction unitRef="usdPerShare" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTEtMS0xLTQ5ODI4_7cc2c40d-0028-4a33-9c03-7797dee3a8b3">1.17</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTMtMS0xLTQ5ODI4_8e0a2a3f-29d5-4eac-9938-44dc32e4675a"><ix:nonFraction unitRef="usdPerShare" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTMtMS0xLTQ5ODI4_e09e4fb1-7c3b-41d9-a4b7-a78da7c827a0">1.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTUtMS0xLTQ5ODI4_730f99b5-44b6-4b7d-8b9d-a7593d1a84ea"><ix:nonFraction unitRef="usdPerShare" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTUtMS0xLTQ5ODI4_9b8a9ebd-f9cb-481f-89f2-e4422072067b">1.07</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of common shares outstanding </span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTEtMS0xLTQ5ODI4_839782d8-6ede-4eb7-8a93-4a2c54807d7d"><ix:nonFraction unitRef="shares" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTEtMS0xLTQ5ODI4_8ddb2f59-67e0-4417-8f07-a923c772b228">238,622,188</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTMtMS0xLTQ5ODI4_23d6de9e-abcc-4f38-841a-331d08666c11"><ix:nonFraction unitRef="shares" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTMtMS0xLTQ5ODI4_8f4b0058-420f-446f-ab12-a338a8a731d8">208,829,801</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTUtMS0xLTQ5ODI4_9dc57524-d3ba-459b-88c9-e8f9e8dc3c81"><ix:nonFraction unitRef="shares" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTUtMS0xLTQ5ODI4_fddcb1c1-bfc7-4d28-8fe4-f9bb5293d608">155,126,857</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzItMS0xLTEtNDk4Mjg_d917662d-55d9-495a-95b2-81fb958a81b5">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzItMy0xLTEtNDk4Mjg_fe479f12-f233-4f5b-a783-369786257872">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzItNS0xLTEtNDk4Mjg_59af82b0-a36f-434a-b484-a202d114fc76">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzUtMS0xLTEtNDk4Mjg_0693f379-8d26-47f5-ba3d-485901649227">25,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzUtMy0xLTEtNDk4Mjg_a085897a-6042-4768-a5ae-2123bb1d9c7f">30,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzUtNS0xLTEtNDk4Mjg_ab561479-30f4-4421-9146-430af6f7bc93">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Unrealized (loss) gain on short-term investments, net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzYtMS0xLTEtNDk4Mjg_ac695975-80ba-4e38-abca-32a7ce292ad5">390,949</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzYtMy0xLTEtNDk4Mjg_5d054d2e-3e39-462e-9d2d-d200ba21c069">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzYtNS0xLTEtNDk4Mjg_73024634-442a-4338-be61-eb4c999dbb6e">755,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzctMS0xLTEtNDk4Mjg_9914dd41-8ac8-4951-90b8-ce7b05901c35">280,234,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzctMy0xLTEtNDk4Mjg_b8542b1e-cbaf-43d8-954b-ac37d1dcd2a2">303,684,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzctNS0xLTEtNDk4Mjg_a6f750e3-0406-4407-b14d-c866a31d8203">168,203,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzgtMS0xLTEtNDk4Mjg_fdb52f7d-c704-4bd5-b12d-73d6556a6fca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzgtMy0xLTEtNDk4Mjg_e7ed07ae-7e97-479e-bfaa-bde9ee35c770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzgtNS0xLTEtNDk4Mjg_646b4fd0-74c8-47bb-915e-d202a82b22bb">1,063,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzktMS0xLTEtNDk4Mjg_e8f98191-4fdf-4799-86ff-93c5f292142c">280,234,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzktMy0xLTEtNDk4Mjg_697b19bb-f3d5-4c38-b88f-987ded181de1">303,684,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzktNS0xLTEtNDk4Mjg_0f38115a-0ca7-471d-9b72-5bd37ec056a8">167,139,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_127"></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.891%"><tr><td style="width:1.0%"></td><td style="width:25.010%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.292%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.459%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>interest</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>stockholders&#8217;<br/>equity</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of&#160;shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Number<br/>of shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i91313ea012fb4e29a82373b1216240c7_I20191231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTEtMS0xLTQ5ODI4_c5856ee2-6124-4abd-b4a1-ee65a5af2be0">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91313ea012fb4e29a82373b1216240c7_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTMtMS0xLTQ5ODI4_af62a1a0-5c40-4ebf-b879-e702571a39d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic20b1cb6ae6442cfb1dd54c81a7d71f1_I20191231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTUtMS0xLTQ5ODI4_9ab3999c-d162-4314-8980-8f3c89e622c1">101,361,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20b1cb6ae6442cfb1dd54c81a7d71f1_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTctMS0xLTQ5ODI4_25f102e1-4687-40f7-9ee5-137470f3083b">101,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc4c4c9f63349128d1754e94f5cc9e5_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTktMS0xLTQ5ODI4_ebc781d0-b7dd-42c7-9b8d-e7caaf1b3b39">742,646,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d6cb11719d041f090cfb6c6b041e892_I20191231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTExLTEtMS00OTgyOA_f8287650-8941-40b9-bce2-2f5637f333de">739,785,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i718af9ccd104415fbf64c9d32f74bb1e_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTEzLTEtMS00OTgyOA_f56ea3e3-5c40-45fd-aae8-d43d7f314d1b">472,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8942a4a67cba41659b89e7b8521ab8eb_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTE1LTEtMS00OTgyOA_c81c6b50-aad6-4bdf-a8ab-b86c995d14b0">1,969,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb91b86850c4019853cfafe96543ff8_I20191231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTE3LTEtMS00OTgyOA_763660b5-eadb-4d84-8479-371cfe2db3e6">5,404,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTUtMS0xLTQ5ODI4_ec5e6934-10c3-4463-8094-7acc5d8cd5af">66,064,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTctMS0xLTQ5ODI4_9d0c38ff-dc50-40a3-8d21-aaa81cd32167">66,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTktMS0xLTQ5ODI4_4f8f88fe-a82d-4d04-bfa0-09579edd224d">454,420,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTE3LTEtMS00OTgyOA_0bff0151-3a01-4ec0-aa04-1cdced834aa6">454,486,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of preferred stock to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iad2ce681ebaa453d8289a854900c32fa_D20200101-20201231" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTEtMS0xLTQ5ODI4_bcc13deb-48d8-40d3-b5cf-9800c5b408e3">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTUtMS0xLTQ5ODI4_cc4c61f7-47b1-4d40-a798-ec13bbe6baaf">5,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTctMS0xLTQ5ODI4_e88a62bf-17b8-40fa-8cab-9e51daa73dae">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTktMS0xLTQ5ODI4_e88e0800-e0c7-4ad1-b00b-849762e5ec23">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTE3LTEtMS00OTgyOA_38d89961-9521-493f-a3c9-226815674bcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of senior notes to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77f6191d42744cbe9b446139968001a6_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTUtMS0xLTQ5ODI4_69c2d66d-dc93-4019-8fc0-69562b2df9f5">11,535,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77f6191d42744cbe9b446139968001a6_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTctMS0xLTQ5ODI4_df104e3a-5895-49ca-825a-05219a14722b">11,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc077e8d5154506ba48d33c68a71bfe_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTktMS0xLTQ5ODI4_f6286daa-7531-4a4c-8152-ae3d746c19bb">43,682,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTE3LTEtMS00OTgyOA_98fba71d-6583-4e65-b17f-93f0a32f1fed">43,694,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of August 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb9c9e86d4a54a01b3a0e8c79d8927b3_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTUtMS0xLTQ5ODI4_7670b213-8e81-4a4a-8097-27bb0c6607a8">4,962,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9c9e86d4a54a01b3a0e8c79d8927b3_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTctMS0xLTQ5ODI4_8fa3adf2-48e8-4c75-815c-85a9287a4f29">4,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bf7e09219084016a812c88d9977fa5a_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTktMS0xLTQ5ODI4_a954e3f3-ccfd-43bb-b35b-34b1d268a33c">102,666,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110d8cff3e7c4910b2e0c84f0f9c65de_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTE3LTEtMS00OTgyOA_9a7bb0c8-6009-4b0f-be3f-1a096ad4cdc8">102,671,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTUtMS0xLTQ5ODI4_e051bbad-d926-4af9-8bc8-a9a75e94e38c">2,922,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTctMS0xLTQ5ODI4_50ae6f4f-95bb-4f8e-bdd0-aea0a5efc6f3">2,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTktMS0xLTQ5ODI4_a757625b-c9db-44de-be2b-a149e90d27ca">8,238,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTE3LTEtMS00OTgyOA_c2bdb784-44ca-4a31-9f1a-6eae890fff59">8,241,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk3LTktMS0xLTQ5ODI4_02515031-58c3-49c2-9cd4-a403da09d4bd">15,655,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231" decimals="0" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk3LTE1LTEtMS00OTgyOA_f96c2141-69a6-4982-9e09-f4617366753f">8,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk3LTE3LTEtMS00OTgyOA_6bc99159-7c27-4c43-8b1b-3e3cc0f752ad">15,647,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest in Geneos, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk4LTE1LTEtMS00OTgyOA_a4903fa4-cab2-4af1-9571-54c45529e088">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk4LTE3LTEtMS00OTgyOA_5ac9a533-cb37-474c-aa14-97f65736027c">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk5LTE1LTEtMS00OTgyOA_4203f8b7-331c-45e1-9a66-f9999eeb4a87">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk5LTE3LTEtMS00OTgyOA_dfd7959e-85b0-44f9-abc6-14f138e547ef">3,181,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7da2f113135949f6b69b0f0304007c14_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMC0xMS0xLTEtNDk4Mjg_b1fe953e-b1e0-4ea0-bed8-228522664bf5">166,411,157</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMC0xNS0xLTEtNDk4Mjg_241a692c-62ca-4315-b616-858d13bd9d98">1,063,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMC0xNy0xLTEtNDk4Mjg_f2e0f747-ba01-42b7-8f5d-1b0a681b2e33">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231" decimals="0" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMS05LTEtMS00OTgyOA_f89d904f-3455-4a8a-a64a-6e4700318873">96,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231" decimals="0" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMS0xNS0xLTEtNDk4Mjg_bfbc14d9-4d0f-4f43-bee7-2c9087757d75">96,269</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMS0xNy0xLTEtNDk4Mjg_a30c0dd4-1ff0-4bbc-928b-c2b0ac152338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id13cf002a66c44d39492fe34b336faf0_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMi0xMy0xLTEtNDk4Mjg_dd583126-0d1a-4ee6-9fcb-a82860d64189">755,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMi0xNy0xLTEtNDk4Mjg_bdede4d8-6906-4aa2-965f-6824ddf74370">755,963</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id13cf002a66c44d39492fe34b336faf0_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMy0xMy0xLTEtNDk4Mjg_3e4b5143-191c-48b4-b65f-6f6ce1b3241d">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMy0xNy0xLTEtNDk4Mjg_cffef8de-f6e5-449d-b8c0-6c196a9abecc">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if71c1abee2354fad9e808f4f24fbcbd2_I20201231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xLTEtMS00OTgyOA_0acfdd63-39a8-4c53-bebd-ed854bae860c">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71c1abee2354fad9e808f4f24fbcbd2_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0zLTEtMS00OTgyOA_ecc39816-f78f-460c-88d1-fbb7084463bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id11369143520413d8c7da3da06fc56b1_I20201231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC01LTEtMS00OTgyOA_aad729ad-ce1a-4ca3-a372-e41119eb3e4b">186,851,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id11369143520413d8c7da3da06fc56b1_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC03LTEtMS00OTgyOA_320f8d17-8f7f-47b6-ae48-f0386dca9eb2">186,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib23b8d6624644da386cf1e538d1bd8af_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC05LTEtMS00OTgyOA_32219911-d2a1-4480-8fda-602bb42fbf79">1,367,406,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i16ffc786c3c84f7ba4e698ca14539948_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xMS0xLTEtNDk4Mjg_85376520-6471-40aa-9149-7ed92249b14a">906,196,812</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10ad082f8bde4a7a92524043edf853c1_I20201231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xMy0xLTEtNDk4Mjg_7b5b9b5f-a0d4-4bc8-a52c-b2ed0d417254">256,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75216b6319924276935aa28bd9bb7dcf_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xNS0xLTEtNDk4Mjg_51a3849f-5d98-4e19-a79b-03d2c2619606">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xNy0xLTEtNDk4Mjg_a2961049-378a-4973-92a3-1d1dd492e3ed">461,140,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS01LTEtMS00OTgyOA_4b3699ab-0ca3-4615-99a3-09337298f24a">27,310,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS03LTEtMS00OTgyOA_30934935-ab7e-4ea4-8d3e-a5ee0a4d8832">27,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS05LTEtMS00OTgyOA_8868b90e-8199-405d-8a2b-625a8920de47">209,414,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS0xNy0xLTEtNDk4Mjg_b486b0cd-351e-42e2-a44a-fb24ba743031">209,441,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of December 2019 Bonds to common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi01LTEtMS00OTgyOA_4c9ddfe2-ba74-46bf-ba52-f9ff72a3445c">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi03LTEtMS00OTgyOA_0d146f63-da8b-4cf9-964b-53badf05ac81">1,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi05LTEtMS00OTgyOA_81635230-d215-4f87-8d7c-4cb0137e082e">4,376,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi0xNy0xLTEtNDk4Mjg_276781ed-56d2-4da9-bcc7-adba12152153">4,377,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy01LTEtMS00OTgyOA_4fcf2984-68e9-47c8-a6cc-fe683956d80d">2,211,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy03LTEtMS00OTgyOA_e1c255da-6346-41cc-9584-5f5bc573b40f">2,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy05LTEtMS00OTgyOA_f8fc1a6d-cd1e-4626-a404-f0ccaa60abd4">2,055,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy0xNy0xLTEtNDk4Mjg_245649b6-2566-456d-b6df-aadcf70982d8">2,057,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOC05LTEtMS00OTgyOA_f261eb91-7e42-4aa1-abe4-d26e5eeee87c">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOC0xNy0xLTEtNDk4Mjg_b4efa0b7-e864-4551-85f1-7795c39db917">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i01a55d99d9834376b29d04025a363045_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOS0xMS0xLTEtNDk4Mjg_d2ac61fe-feab-47cb-a7bb-e96279a6d2ec">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOS0xNy0xLTEtNDk4Mjg_a64a7608-0764-4945-9a32-7e5e17da3847">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4459abbf67aa4910bb765838712d9fe5_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMC0xMy0xLTEtNDk4Mjg_cbf9b339-514c-4195-86ea-28caf38ea73f">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMC0xNy0xLTEtNDk4Mjg_1175e119-999d-4357-b9c6-04ffe6ab5358">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4459abbf67aa4910bb765838712d9fe5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMS0xMy0xLTEtNDk4Mjg_ca198c56-d0d5-4e30-b67f-832f596ce686">30,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMS0xNy0xLTEtNDk4Mjg_b760d162-1422-492c-b2a7-c941a515e858">30,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4028d9e38f094f768bb1e9452fc45472_I20211231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xLTEtMS00OTgyOA_120bd7c0-767a-42a4-ac12-05bd4264e846">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4028d9e38f094f768bb1e9452fc45472_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0zLTEtMS00OTgyOA_1f0116b8-4471-4e20-8b40-8a949af77548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cf453e9844f4d6fa74be581ed00a513_I20211231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi01LTEtMS00OTgyOA_19a90259-7e66-4ce7-81b5-4c294a1d240e">217,382,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cf453e9844f4d6fa74be581ed00a513_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi03LTEtMS00OTgyOA_b3d924b6-d13d-4c2d-bd9a-268461e044d0">217,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fd95af3528440b39f64c721172b95b3_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi05LTEtMS00OTgyOA_1d89d9f5-b3db-49e7-b982-205f9a6e5dfe">1,609,589,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ba6177eb6b8472495d2e2a45d024f63_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xMS0xLTEtNDk4Mjg_3b9155b3-7c62-49ad-ab44-3cb472aa6150">1,209,855,522</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8666bf368748449bb6e324e42d8b1d21_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xMy0xLTEtNDk4Mjg_f20d5994-685c-4c06-80ab-ea67fb963e6a">282,236</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8501fb06a5774680b79276ad409fed15_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xNS0xLTEtNDk4Mjg_38330682-a89a-4d4a-b5e7-f5a7d68de956">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xNy0xLTEtNDk4Mjg_6df1ac17-4e5d-4787-a255-651e974504a6">399,669,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy0wLTEtMS01MDQxMQ_8a092680-f934-40f5-bab2-8b87b0b9ccf7">Cumulative adjustment from adoption of ASU 2020-06</span></span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0151eb300ba9417ca13398ee631e0a11_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy05LTEtMS01MDQxMQ_71b06893-ec63-4eb9-b5c4-bb29d85efc74">3,294,019</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6a118a9cde4fde96c5f7c1ae0848ec_I20211231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy0xMS0xLTEtNTA0MTE_01352c9b-6084-4450-9e78-266416f34adc">1,825,803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4439b6c598d454e8b8ff9ceb6d62287_I20211231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy0xNy0xLTEtNTA0MTE_435ec549-6aef-44b2-9955-07f038c62bf5">1,468,216</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for cash, net of financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC01LTEtMS01MDQxMQ_ab4328f9-a0ee-4b9f-af5e-3cfb0b27e1c4">34,445,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC03LTEtMS01MDQxMQ_b1945f4a-b3c7-4933-88e2-bb4f20349e6a">34,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC05LTEtMS01MDQxMQ_2e30c184-0e86-4b77-8c3a-2caccb85fdf9">82,920,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC0xNy0xLTEtNTA0MTE_dc469f0f-166a-42f2-a8a2-b781dd70187d">82,955,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options for cash and vesting of RSUs, net of tax payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS01LTEtMS01MDQxMQ_514bd483-63b3-4e4e-9115-be849e1d1661">1,262,689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS03LTEtMS01MDQxMQ_ec1e95b6-89ec-414e-bc01-e98356eae121">1,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS05LTEtMS01MDQxMQ_76413546-a42f-4463-8eb0-be160772d06a">1,115,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS0xNy0xLTEtNTA0MTE_eff79bd1-2927-405e-858d-bc93114d3dcf">1,114,609</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNi05LTEtMS01MDQxMQ_47b7a3c6-c917-4db6-bbe5-11164480ca38">22,555,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNi0xNy0xLTEtNTA0MTE_68976d34-4edf-4fbe-8383-51b25f492786">22,555,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if998a11fda824693a82b5630eee5944a_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNy0xMS0xLTEtNTA0MTE_aabe1fe0-881a-4548-ae8d-5f3b7a7a65a4">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNy0xNy0xLTEtNTA0MTE_e748d082-c313-4056-9408-0de0636e33f9">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized loss on short-term investments, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75ed40a3258c4619b0d384f1c875f1b3_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOC0xMy0xLTEtNTA0MTE_358a2d02-ad3d-44a8-8b66-c4d2e5064795">390,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOC0xNy0xLTEtNTA0MTE_2126d825-75a6-4274-99f5-3ec291b15fe7">390,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75ed40a3258c4619b0d384f1c875f1b3_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOS0xMy0xLTEtNTA0MTE_5a4a647c-0c95-4144-a6cb-a226807f98cc">25,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOS0xNy0xLTEtNTA0MTE_741456c6-4701-4533-adad-e1b871bfae2c">25,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b7a2f2ae8ab40ccae727491f64f50ef_I20221231" decimals="INF" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xLTEtMS01MDQzMA_d2d21293-de1c-4bd8-970d-633f5bd25378">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7a2f2ae8ab40ccae727491f64f50ef_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0zLTEtMS01MDY5OQ_f3d7f690-6bdb-4bfe-bd9b-6b09d3cafcfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6173a75999554213bd9ef6b178b3c5a6_I20221231" decimals="INF" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC01LTEtMS01MDY5OQ_977a5049-6d63-4464-b45d-81947a1ec126">253,091,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6173a75999554213bd9ef6b178b3c5a6_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC03LTEtMS01MDY5OQ_bc2ce551-321b-4f92-8d7b-d3483cf3848a">253,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78e8ed6c44394b9d8730b7f657680c0a_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC05LTEtMS01MDY5OQ_a1989926-7c50-4004-85e5-dff4ca78f018">1,710,656,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf99a57f4f0543779cb105cb89a2a1ff_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xMS0xLTEtNTA2OTk_5fa2c7ae-f851-482f-92d7-5e7d2f6d0613">1,487,847,784</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e327b57b7e447c8aadc23b5385ebe2b_I20221231" decimals="0" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xMy0xLTEtNTA2OTk_9fe472fc-66c3-4b67-aed1-afe7243580a3">698,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i564f8e98e6a4437d87441f8dad2ebdb9_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xNS0xLTEtNTA2OTk_bfa94d26-bb49-432f-84b1-a693bee4c229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xNy0xLTEtNTA2OTk_dc1db29f-15d9-4a6c-ae7a-f2ce59abbae2">222,362,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_130"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.803%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.779%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Year ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMtMS0xLTEtNDk4Mjg_6203f9ea-3a5f-4bc1-89ac-2fa4e150290b">279,818,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMtMy0xLTEtNDk4Mjg_e87ff291-8be4-4531-bbbe-b8c5ace36fc3">303,658,710</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMtNS0xLTEtNDk4Mjg_76619cc1-7c03-47d0-8742-43323b74e870">167,474,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUtMS0xLTEtNDk4Mjg_dc5d0e2e-424d-496f-b155-bc85aac2d44d">3,656,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUtMy0xLTEtNDk4Mjg_e8fc6c86-7262-4da7-baac-1a0b5368b02d">3,040,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUtNS0xLTEtNDk4Mjg_8b26a64c-350e-4809-88e0-f2c72e98977e">3,038,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYtMS0xLTEtNDk4Mjg_b15f0d8b-d2cf-4758-b66e-4ea8dcc505b6">496,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYtMy0xLTEtNDk4Mjg_42858842-2853-4a2d-8fb7-03dde7b36fe7">520,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYtNS0xLTEtNDk4Mjg_ae978564-3802-495d-bed1-2b264471ec0f">547,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzctMS0xLTEtNDk4Mjg_41998943-eb95-454a-821e-12d6ba99c3fc">1,342,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzctMy0xLTEtNDk4Mjg_6e30417f-2747-439c-99fd-0125330c80bb">1,170,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzctNS0xLTEtNDk4Mjg_6099a463-386b-4438-b787-fe1d5559e7e2">1,041,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzktMS0xLTEtNDk4Mjg_6195750f-04c3-4a1b-87cc-3437009c7768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzktMy0xLTEtNDk4Mjg_a84b97f9-bedd-4873-952f-206a6748c91b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzktNS0xLTEtNDk4Mjg_f0f2a97d-ce0d-49be-b01d-0326e16a61d0">75,670,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzExLTEtMS0xLTQ5ODI4_3c4e930a-46fe-469b-a5d4-f103d59d6600">22,555,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzExLTMtMS0xLTQ5ODI4_26b9d408-58de-44c2-8fc1-1525a4947832">26,336,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzExLTUtMS0xLTQ5ODI4_0e9fcddb-b8dc-4925-906e-66c34cba8c3b">15,647,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="ino:NonCashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEyLTEtMS0xLTQ5ODI4_9fd816b5-f28b-4c41-8ca5-ac19ade9bdd4">186,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="ino:NonCashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEyLTMtMS0xLTQ5ODI4_11988b06-ad24-4ce0-9ea6-64211c3a17a2">858,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:NonCashInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEyLTUtMS0xLTQ5ODI4_25a7e138-47ff-4cc9-98d2-6366664c3942">4,077,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of (discounts) premiums on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEzLTEtMS0xLTQ5ODI4_3706a11f-7c89-4aa2-83a9-814e0ea07ba4">1,320,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEzLTMtMS0xLTQ5ODI4_aab6641f-f533-44f2-9202-a33f8ec0dbee">1,633,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEzLTUtMS0xLTQ5ODI4_2fda6231-deb4-4501-9f3a-d9ed987e412c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE4LTEtMS0xLTQ5ODI4_cfd46bba-bca9-4c5d-850e-f31a730ce9f1">4,029,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE4LTMtMS0xLTQ5ODI4_af67ebe9-940d-485f-8f11-ae4b2f1f3b1e">5,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE4LTUtMS0xLTQ5ODI4_8120516a-9ea9-4f6d-aa90-b3c3ab940ae1">588,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of receivable with shares of common stock from affiliated entity (PLS)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE5LTEtMS0xLTQ5ODI4_0e38b0c4-4e89-40f1-90f5-7f23f89b2cf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE5LTMtMS0xLTQ5ODI4_30e271b3-2583-4a72-a6c6-25172b6da0da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE5LTUtMS0xLTQ5ODI4_2ddc6e6b-a0f4-49aa-aff8-c251bb82c7b1">1,713,770</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIwLTEtMS0xLTQ5ODI4_7ba4c8eb-dd89-4f57-ba3e-ebc4388e2794">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIwLTMtMS0xLTQ5ODI4_7a12291b-a3a6-48a4-a4f9-4be58de2dec7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIwLTUtMS0xLTQ5ODI4_cbd16ac9-4f1e-442a-a397-d8502a4c1908">4,121,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on remeasurement of investment in Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTEtMS0xLTU2ODg0_88ceb2a7-2946-42c9-939d-b5403d241acf">165,215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTMtMS0xLTU2ODg0_2c24632d-8e2a-41d3-80bd-6c4b62753bff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:GainLossOnRemeasurementOfEquityMethodInvestment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTUtMS0xLTU2ODg0_58a82949-b5ef-4f9f-b87a-5981dd6a38d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on disposal of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTEtMS0xLTQ5ODI4_7a6cdddb-e7a9-46b7-b017-66cf45f36e10">1,074,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTMtMS0xLTQ5ODI4_a3aa0929-c743-471f-83cc-57d3c194dae8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTUtMS0xLTQ5ODI4_d787f55b-2a83-4ecd-b0b2-ae2977e48a76">26,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on equity investment in affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIyLTEtMS0xLTQ5ODI4_12b0c61c-4682-4934-960c-a0b01a47c3ef">1,899,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIyLTMtMS0xLTQ5ODI4_882970bc-6f38-4eb1-b673-681e91d2f401">553,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:ChangeInValueOfInvestmentsInAffiliatedCompany" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIyLTUtMS0xLTQ5ODI4_6744b07e-bc10-41b0-9dbb-3fff2575ecb9">36,556,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share of net loss in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIzLTEtMS0xLTQ5ODI4_e12e9436-a8da-4124-9742-b8d80419b250">2,165,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIzLTMtMS0xLTQ5ODI4_0e8a88cf-c03f-4f4f-a4ad-c720979f6670">434,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIzLTUtMS0xLTQ5ODI4_b1e27db3-244c-4cb8-bced-6e2a528d1e97">4,584,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on extinguishment of convertible August 2019 bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1bdec8a908c4594afd92ff4781d3366_D20220101-20221231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI0LTEtMS0xLTQ5ODI4_76e25cf2-f324-4205-965a-0a145cc6429c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i989ec83114ba4070a4bd52566656d740_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI0LTMtMS0xLTQ5ODI4_c578b882-01fd-4b62-a611-bd4157238ffa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i110d8cff3e7c4910b2e0c84f0f9c65de_D20200101-20201231" decimals="0" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI0LTUtMS0xLTQ5ODI4_4a2c047a-d7b9-4545-aa9e-67bf6da8138d">8,177,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on extinguishment of convertible senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3a7a0113a6439694f0af4a15e4c7dc_D20220101-20221231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI1LTEtMS0xLTQ5ODI4_1d13fa42-59ac-432e-af17-bc49462557a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idae06434a74c4378bb8e66fbb38683a8_D20210101-20211231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI1LTMtMS0xLTQ5ODI4_5b3dcb8f-2ceb-4f01-ac38-8ef2f2a3a16c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231" decimals="0" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI1LTUtMS0xLTQ5ODI4_f5671f48-873b-4e72-9b7f-fee5d30fb21e">8,762,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized loss (gain) on available-for-sale equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI2LTEtMS0xLTQ5ODI4_3811752c-6cfc-44b3-b611-5d3c28fb4481">7,846,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI2LTMtMS0xLTQ5ODI4_4b64bf51-e79a-470c-9243-bce36ed88a46">3,222,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI2LTUtMS0xLTQ5ODI4_4707f562-7bf0-4278-a368-70a76e9a433f">1,695,497</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized transaction (gain) loss on foreign-currency denominated debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI4LTEtMS0xLTQ5ODI4_5a434442-1f45-4268-ae7d-4d44fb0515e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI4LTMtMS0xLTQ5ODI4_c2bfaba7-095e-49e6-8dd0-78fce293366d">176,927</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI4LTUtMS0xLTQ5ODI4_ee99e65c-dacf-4a9c-bfd5-f246a9a201af">15,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, including from affiliated entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMwLTEtMS0xLTQ5ODI4_a46069d4-2058-426c-9142-5e3f68906bda">3,706,172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMwLTMtMS0xLTQ5ODI4_1bc0a671-9c53-4a7f-b7df-3ebb9390cb9f">11,031,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMwLTUtMS0xLTQ5ODI4_eb0451c9-c906-481a-9445-0d1f2701cecb">17,015,471</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMyLTEtMS0xLTQ5ODI4_60f65030-2dc4-473e-9161-c69e7d7cba33">5,336,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMyLTMtMS0xLTQ5ODI4_571332a8-f2a8-4b76-867d-959c4037d38d">6,343,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMyLTUtMS0xLTQ5ODI4_8149b1b9-568d-41c4-9832-6e0edb8483ad">38,475,465</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM1LTEtMS0xLTQ5ODI4_ce60bd0a-f9aa-499c-9470-53f5ebce1a88">741,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM1LTMtMS0xLTQ5ODI4_a502fe41-743b-4059-9a8a-264666e005c7">24,531,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM1LTUtMS0xLTQ5ODI4_04fe943e-3372-40ec-ac5c-65450f610843">23,285,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses, including from affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM2LTEtMS0xLTQ5ODI4_e1edf69e-5874-4a41-a2bc-c0910a024b59">32,606,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM2LTMtMS0xLTQ5ODI4_0a423dac-1c57-45a7-9a25-3f2f3d03212b">26,140,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM2LTUtMS0xLTQ5ODI4_ed7a6599-8884-43a0-ae23-138eae0a854c">3,251,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM3LTEtMS0xLTQ5ODI4_0be0ca66-5c4b-4cb2-aa40-8e3e7f205f94">267,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM3LTMtMS0xLTQ5ODI4_696e4648-bb28-4780-bfa7-c84d1b5fc5cd">375,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:IncreaseDecreaseInAccruedClinicalTrialExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM3LTUtMS0xLTQ5ODI4_820202b6-d77c-4c3b-8cc0-ecce005ddf52">5,962,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM5LTEtMS0xLTQ5ODI4_a8593787-5c76-4bcd-b851-1e583b855c03">85,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM5LTMtMS0xLTQ5ODI4_1d9b75d1-d960-4c27-82f9-216fa1070410">39,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM5LTUtMS0xLTQ5ODI4_2484c659-6c20-4ddc-a11f-1f24f47d9585">62,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQyLTEtMS0xLTQ5ODI4_dc22c966-94b0-4f4e-8ff5-1c882546fe41">2,603,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQyLTMtMS0xLTQ5ODI4_dabc439e-e29a-4a65-b3c3-d07b69765e5d">2,329,394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQyLTUtMS0xLTQ5ODI4_7696a4e4-eb64-4762-a546-840131338498">2,091,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Grant funding liability, including from affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQzLTEtMS0xLTQ5ODI4_d0123958-893a-4236-bb74-7f818d50ad7a">2,034,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQzLTMtMS0xLTQ5ODI4_09f9d43a-5102-4095-b1ea-3ec194c455dd">2,973,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:IncreaseDecreaseinDeferredGrantFundingCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQzLTUtMS0xLTQ5ODI4_c9af0bd2-fb23-4d21-85dc-a7fe80702db3">624,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ1LTEtMS0xLTQ5ODI4_a2d69375-a389-4b9f-808f-c51bcbe260d0">14,826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ1LTMtMS0xLTQ5ODI4_ecb56052-8f98-46fa-b80a-5dc2ed0c3811">42,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ1LTUtMS0xLTQ5ODI4_3ed2d96f-aaef-470f-aed6-0551126ca1c9">20,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ2LTEtMS0xLTQ5ODI4_253866f8-6fbe-4911-b643-7a5a80c82d18">216,215,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ2LTMtMS0xLTQ5ODI4_1771d5ad-ead9-4605-a6a8-913e97b71559">215,708,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ2LTUtMS0xLTQ5ODI4_4d2cd02c-668c-4710-8452-134d34d3338d">177,979,046</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ4LTEtMS0xLTQ5ODI4_aa525832-43b2-47ed-8962-19117d2d4610">248,528,843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ4LTMtMS0xLTQ5ODI4_016cb69a-d698-40ab-aee5-6d3e60002c0e">348,953,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ4LTUtMS0xLTQ5ODI4_4690b3bf-527f-49e8-af02-d096ce2cf794">156,216,677</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of or maturity of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ5LTEtMS0xLTQ5ODI4_e3e86ff5-a587-4550-925b-5888143e06ed">361,083,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ5LTMtMS0xLTQ5ODI4_8ea53be9-a5d0-40b1-b7e2-4cf1075e0bca">174,839,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ5LTUtMS0xLTQ5ODI4_20bce427-4f16-47b3-b1bf-a2b623a72ac0">62,991,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of capital assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUwLTEtMS0xLTQ5ODI4_008d6551-7013-457c-bfe3-2742d2e47cd6">969,153</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUwLTMtMS0xLTQ5ODI4_8adadd1e-33fd-4c08-9391-f488f16adb93">1,231,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUwLTUtMS0xLTQ5ODI4_e59f8fd2-a016-4017-b149-f47ceaba0720">1,520,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of investment of GeneOne</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUxLTEtMS0xLTQ5ODI4_4d8ad1a0-fff0-4fe6-b0ae-752c7cd0d0fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUxLTMtMS0xLTQ5ODI4_a9117750-a304-409e-b87f-07267fa87f01">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUxLTUtMS0xLTQ5ODI4_6b77ec8b-9029-4e01-95f0-f0971178c407">40,125,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Decrease in cash resulting from the deconsolidation of Geneos</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUyLTEtMS0xLTQ5ODI4_e08bfa79-d386-4599-8189-ba989fba25f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUyLTMtMS0xLTQ5ODI4_761702b2-e7f2-400b-beb0-b2a774264cec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUyLTUtMS0xLTQ5ODI4_ef868b8c-373f-434d-8029-fe41ed9905ed">2,774,851</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investment in Geneos</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUzLTEtMS0xLTQ5ODI4_2e2ca8fd-ec67-4c98-9175-3561e1ae3a05">1,999,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUzLTMtMS0xLTQ5ODI4_88547f7b-11d7-4878-a208-89b2fab6c12c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUzLTUtMS0xLTQ5ODI4_9a90194d-c681-460f-b7db-609a2e867ede">1,399,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU1LTEtMS0xLTQ5ODI4_ba5409fa-d65c-4925-b189-7f9c2a71a30c">109,585,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU1LTMtMS0xLTQ5ODI4_614b0fc0-606b-42a9-8452-43dbbff61a56">175,344,484</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU1LTUtMS0xLTQ5ODI4_a8402be5-b726-4240-821f-f75fe8c36118">58,795,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU5LTEtMS0xLTQ5ODI4_71a0310b-45dc-4101-a6aa-4002aba6f320">82,955,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU5LTMtMS0xLTQ5ODI4_6170cef8-ee58-4b7f-af78-e6d73498ee83">209,441,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU5LTUtMS0xLTQ5ODI4_bfc37512-5b49-41d2-84e4-e324aa8d0ad4">454,486,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYwLTEtMS0xLTQ5ODI4_e8d1f72e-dbb6-487e-b0fe-965c7b37bed4">283,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYwLTMtMS0xLTQ5ODI4_adc62ce5-b9c2-445e-9cf5-970c91a2d574">6,668,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:ProceedsfromStockOptionandWarrantExercises" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYwLTUtMS0xLTQ5ODI4_1c6c4223-4b69-4d30-b94b-232893a5da78">12,269,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYxLTEtMS0xLTQ5ODI4_d8f46bdd-b94b-4107-b89d-45b630b0f56d">1,397,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYxLTMtMS0xLTQ5ODI4_fdeb4488-bc3e-41fb-b9ef-cd507a64bf71">4,611,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYxLTUtMS0xLTQ5ODI4_34de17ec-8210-4078-bf7f-6fd862ae5ccb">4,028,177</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYyLTEtMS0xLTQ5ODI4_f98e26c2-ce3e-4578-8ea7-b1841f4a0d42">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYyLTMtMS0xLTQ5ODI4_686160f5-406f-4022-bf43-7304875a58d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromMinorityShareholders" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYyLTUtMS0xLTQ5ODI4_af57941c-e6e5-47be-b190-b3facf9df942">2,379,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from Geneos issuance of note payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYzLTEtMS0xLTQ5ODI4_d7d101f0-0ad7-486e-950e-0c3bb5cd1283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYzLTMtMS0xLTQ5ODI4_668b9b1e-0760-46a1-ba18-29baaa1432bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYzLTUtMS0xLTQ5ODI4_b1c0ca12-6983-404b-9fb4-d9aca1e70f11">171,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY0LTEtMS0xLTQ5ODI4_09d3d657-c845-4eda-9843-4e2b98c130c1">81,840,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY0LTMtMS0xLTQ5ODI4_3a427b7d-068e-4922-8f2c-76a0acd232a5">211,498,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY0LTUtMS0xLTQ5ODI4_9d1fc798-283c-4112-a591-ecd3beeb8655">465,279,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY1LTEtMS0xLTQ5ODI4_fae68d20-3582-45ab-891b-f1b3a7497774">25,556</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY1LTMtMS0xLTQ5ODI4_2e265f0f-2d67-4d61-a6f3-e65caedde87f">30,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY1LTUtMS0xLTQ5ODI4_ef71e9f8-b2e6-4bee-a800-2f76df2c042a">27,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Decrease) increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY2LTEtMS0xLTQ5ODI4_b5cb4b15-629c-42f8-89b6-3c18963e412b">24,814,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY2LTMtMS0xLTQ5ODI4_c14833bd-4fa9-498c-b4c2-13dbb544ab20">179,584,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY2LTUtMS0xLTQ5ODI4_3b870f0d-f684-4375-a409-0ae1d5517cb2">228,532,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY3LTEtMS0xLTQ5ODI4_49088c69-8dd4-4404-96b9-d2f4d356c2eb">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY3LTMtMS0xLTQ5ODI4_bcd5ec4f-efba-41b3-8f48-85d650232ff6">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb91b86850c4019853cfafe96543ff8_I20191231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY3LTUtMS0xLTQ5ODI4_8068b2b1-ce73-4e18-8dc0-7652e81e37b0">22,196,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY4LTEtMS0xLTQ5ODI4_5376536a-2cc1-480b-bbfe-34fdb4008805">46,329,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY4LTMtMS0xLTQ5ODI4_980f5454-b1f6-4a09-9a47-0c26b270e04d">71,143,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231" decimals="0" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY4LTUtMS0xLTQ5ODI4_f63eb5a4-6007-4e70-86b8-10eff593a5aa">250,728,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts accrued for purchases of property and equipment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzcyLTEtMS0xLTQ5ODI4_90876dac-f428-45bf-a0f1-fca30ddbedb7">108,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzcyLTMtMS0xLTQ5ODI4_f31a477d-a8d5-4832-bc91-0701c8d10eb0">204,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzcyLTUtMS0xLTQ5ODI4_782bc2aa-0799-4967-85a7-07ff6aad2ce8">136,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzczLTEtMS0xLTQ5ODI4_7242f4b9-d215-4c50-9726-91145b749071">1,066,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzczLTMtMS0xLTQ5ODI4_5908d2d3-eae6-4b69-8083-381e454b9adb">1,077,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzczLTUtMS0xLTQ5ODI4_f5e930c9-6d66-4996-86ba-e20880407330">4,624,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in prepaid expenses and other current assets related to fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3Xzc0LTEtMS0xLTQ5ODI4_5d7b4720-69e2-4ea6-8f13-50b6f30e6263">6,071,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3Xzc0LTMtMS0xLTQ5ODI4_2514ece6-44e5-442b-8dd2-da5983a1b5d1">7,709,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3Xzc0LTUtMS0xLTQ5ODI4_b1d33482-2600-4565-89e4-86347225f356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inovio Pharmaceuticals, Inc.</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_136"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzYvZnJhZzpmY2E0NmI3YWE3Yzk0YjBkYTdiN2M2YmM1NjgyNjBkNS90ZXh0cmVnaW9uOmZjYTQ2YjdhYTdjOTRiMGRhN2I3YzZiYzU2ODI2MGQ1XzM1NjU_190a9a2b-dbb8-4552-8cf4-8ded465e1321" continuedAt="i5cbc5ecf301f499d91b14df55e860ebc" escape="true">The Company</ix:nonNumeric></span></div><ix:continuation id="i5cbc5ecf301f499d91b14df55e860ebc"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company&#8217;s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, the INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidates are focused on diseases associated with HPV.  In 2022, INOVIO announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for Ebola; HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head &amp; neck; other HPV-related disorders, such as RRP; and GBM.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     2. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MjY2_14c8b3c9-c6ad-4ebb-a858-ce35f758f927" continuedAt="i9b6d1699e59540b9a58126a300de818f" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9b6d1699e59540b9a58126a300de818f" continuedAt="iba484dec2caf41a4900919feed1be1b9"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjcz_bc67cc8a-5402-464b-9177-dcbc3065b787" continuedAt="i328b435d712a4b2a9390f6fbc1ba9d99" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM1MjA_1aed2210-5544-4891-b79d-53b6a0760cdd">279.8</ix:nonFraction> million for the year ended December&#160;31, 2022. The Company had working capital of $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="ino:WorkingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM1OTQ_5e75c988-b151-4069-a30e-b0509f075692">218.4</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-8" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM2Mjc_a02c584f-cf17-4e33-a83e-61b542200e6d">1.5</ix:nonFraction> billion as of December&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5OTU_e0118d15-552c-46d2-95d1-6c3beadd4fcc">253.0</ix:nonFraction> million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODEyMzY_c34a70c4-41ab-4084-b410-893ccd7e1d55">83.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODEyMjE_fcf0904c-7c94-412f-b4e6-d52f83514536">47.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib6cae987a41b4492a9781bcec7e5cea0_D20200101-20201231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0OTg5OTI_bb0c43b5-4ab1-4999-adb6-dfe2e594b02f">454.5</ix:nonFraction>&#160;million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i851b409487e4421e97a148072ac742ed_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzQ2MjA_6af8cc8d-9841-4114-a93c-c7926b2d3e5b">162.1</ix:nonFraction>&#160;million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y also issued convertible notes and bonds in a series of private placement transactions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iba484dec2caf41a4900919feed1be1b9" continuedAt="id37669d16d104ce9adc5a1ac2e3f9def"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i328b435d712a4b2a9390f6fbc1ba9d99" continuedAt="icbe43dc99f074b8f9df7d8d27590b422">liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</ix:continuation></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icbe43dc99f074b8f9df7d8d27590b422">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjg4_0d7be64f-b83e-47e7-986a-0c6c2a820704" continuedAt="i5197e471195d4e628f1bf3215436fd9e" escape="true">Consolidation</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5197e471195d4e628f1bf3215436fd9e">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.</ix:continuation> </span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzg4_30075b1b-0938-49a8-8919-7336327920fe" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as <ix:nonFraction unitRef="segment" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzEwMjEz_807ec1cb-797d-4e62-b1e5-7cc980860f62">one</ix:nonFraction> segment operating primarily within the United States.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzM1_3254c615-01eb-44a7-b6b1-50a236bef0c9" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MjY4_981986e8-9ea8-448c-a863-37a589c5dfc1" continuedAt="i96f54e59adaa498fb813cef539b0ddce" escape="true">Concentration of Credit Risk</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i96f54e59adaa498fb813cef539b0ddce">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDE0_538c9dfe-08e5-4653-8e08-8c836d6f3f4e" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzY3_6a6c8d70-1852-4619-a39a-45023a7c4a11" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2022 and 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzQ1_6391a896-1758-4d20-8b2d-f9a2bf2e44ba" continuedAt="i33bbc4086e14464b8cf8a251a95ef4ca" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2022 and 2021. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id37669d16d104ce9adc5a1ac2e3f9def" continuedAt="i3a391333d117488890dc7630fd83d879"><div style="margin-top:5pt;text-indent:24.75pt"><ix:continuation id="i33bbc4086e14464b8cf8a251a95ef4ca" continuedAt="i5c29c7f0687642ec8232323a658d292d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5c29c7f0687642ec8232323a658d292d">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDIz_fd360ae3-16ba-47f3-a215-74edc63fd482" continuedAt="i51eb8ecc66424c37ab079a8c71a78fa2" escape="true">Accounts Receivable</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i51eb8ecc66424c37ab079a8c71a78fa2">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NDk3_1189da54-59bf-43c4-9074-470d6aa33ea0"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NDk3_d9d470e4-2d7d-4ca0-a5ad-1a55a9c3a9c4">No</ix:nonFraction></ix:nonFraction> allowance for doubtful accounts was deemed necessary at December&#160;31, 2022 and 2021.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzY5_7c0cfad3-f7cb-4269-ac38-a57261dbafb0" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca">three</span> to <ix:nonNumeric contextRef="i8c4af40c177746a9860d90e560bd8e93_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzM3_3f57e01c-182c-4d9d-a71c-77e9552d1df1">five years</ix:nonNumeric>. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjkx_e86aefed-2e56-46a1-b328-b27d731205f3" continuedAt="ifc56bc446694403bbad714edf1853a1e" escape="true">Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifc56bc446694403bbad714edf1853a1e">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.</ix:continuation> The Company has not recognized any losses on long-lived assets through December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzA1_948f130b-5c69-4a10-81cd-fd6978e8301d" continuedAt="i940b395d98c24a05bfde199aa9d088ea" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2">two</span> to <ix:nonNumeric contextRef="i8c4af40c177746a9860d90e560bd8e93_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjEx_c8d2eb9c-a239-4d8d-a3eb-907daf366eaf">18</ix:nonNumeric> years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2022 and 2021, the Company&#8217;s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkx_a3bf0792-67d8-4456-a9cd-62a668fe1b92">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDk4_4a7a12fe-f3da-4078-a687-f154d28a8913">2.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2022.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i3a391333d117488890dc7630fd83d879" continuedAt="idd69367a2577432c87b30e564f3cf39a"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i940b395d98c24a05bfde199aa9d088ea">cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.</ix:continuation> See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzgz_26e60bd0-708d-4d3a-ab2b-ee1747ee4b4f" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIwNDIx_6cdc1bfb-8a8a-4afa-a953-387840211cce">299.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIwNDI4_febadfd0-8cdb-4a52-a79d-7f96ff71965f">237.2</ix:nonFraction> million at December&#160;31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIxOTkwMjMzMTE0OTM_a4453ab9-1a3c-4ec8-9a22-b17442f3fdf8" continuedAt="i2be601928b114b07a9bf400214a56b1a" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue, in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIxOTkwMjMzMTE0OTQ_d3beef48-92ca-43c5-8c5b-d5ec07d46b89" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div></ix:nonNumeric><ix:continuation id="i2be601928b114b07a9bf400214a56b1a" continuedAt="i27645005e5f041a38279cf80d0028f51"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idd69367a2577432c87b30e564f3cf39a" continuedAt="ib5b61820654b4da4a1ff4f6df9175981"><ix:continuation id="i27645005e5f041a38279cf80d0028f51"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div></ix:continuation><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="ino:GrantRevenuePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzU4_4b92dca3-2663-419a-8818-c87b9bd809ba" continuedAt="i1d3ed7f0ef6b455f892d77ed26ab31a2" escape="true">Grants</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="i1d3ed7f0ef6b455f892d77ed26ab31a2" continuedAt="i011cb34304da4ca1aa4a315e07243d22"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i011cb34304da4ca1aa4a315e07243d22">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzA3_b2017f45-dff5-4278-a800-82e77f060f5d" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzM4_1fb84def-6c6f-4ba4-9d65-9891a5a7d87b" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div></ix:nonNumeric><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzI3_79fb72ab-d4c7-4f06-9c3e-46f8eb269581" continuedAt="ibfba68de84fb4648a76a5871a41329ff" escape="true">Equity Investments</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:27pt"><ix:continuation id="ibfba68de84fb4648a76a5871a41329ff" continuedAt="iab43936ccbf74d5a8b8204c41c300f71"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iab43936ccbf74d5a8b8204c41c300f71"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</ix:continuation>&#160;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib5b61820654b4da4a1ff4f6df9175981" continuedAt="i640aabee67014aad9a6d218f19bf1e28"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzA4_5b1fdae2-4f59-4c58-9943-d683776a6d0f" continuedAt="i8517cd315b3748418ceb67714e1f6309" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i8517cd315b3748418ceb67714e1f6309">Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.</ix:continuation> </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDEx_9982eefa-7669-4da9-87ec-c0b8a2fb0178" continuedAt="i5c6fc36437ce49359cd1c5dc45c9f9d2" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:4.5pt;text-indent:27pt"><ix:continuation id="i5c6fc36437ce49359cd1c5dc45c9f9d2" continuedAt="icf32ebc072894f6e8f187033eefcb3d3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icf32ebc072894f6e8f187033eefcb3d3">For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.</ix:continuation> </span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDI1_ce4444d2-08ae-4e4c-84ea-43d5894b718b" escape="true"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b5c26fff9c54ee6aeec015bd77060ea_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzItMS0xLTEtNDk4Mjg_29bad806-38ac-494d-b5b2-f67dc00d4a75">12,221,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia738364cb3704782bff4583a29069493_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzItMy0xLTEtNDk4Mjg_93fd9b73-867c-45b5-b243-6158d66232cd">10,488,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf4c53fa971d4d039d0b3f9f50813d00_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzItNS0xLTEtNDk4Mjg_1f576281-75af-4a37-9a17-9ad59f99d3d2">8,906,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i778adc9858e4413284de317978f1491e_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzQtMS0xLTEtNDk4Mjg_b22f20c0-8320-4609-9ee1-7a39bb421091">2,556,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8f6a30b1663b4a28822ba910bb5f0d2b_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzQtMy0xLTEtNDk4Mjg_073942c4-3dd9-445c-b34a-8056e41398d0">2,448,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i385f8bc5e1ef496fa5bf4b77f4ac4c8d_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzQtNS0xLTEtNDk4Mjg_d8a90a1c-c3c2-4b36-b2fc-0afb73542d7b">2,558,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i905fef709da24983a7a134952ad5cd76_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzUtMS0xLTEtNDk4Mjg_bc0e2c49-0797-4162-8243-3005e049635e">111,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c357726a9834da5b7f9e01126ab1934_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzUtMy0xLTEtNDk4Mjg_aa19d084-bfd7-441d-8aad-cd851e3f3e3b">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i793c2cf60aba4213b7dda26b6bd1d0bf_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzUtNS0xLTEtNDk4Mjg_f91579cd-1243-4868-81e2-f418fc4cf0db">663,353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2234c920452e4ca5a201f3f44924f639_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzYtMS0xLTEtNDk4Mjg_5bac15a4-ce61-49c4-b04f-bb69dcfa9c62">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ea03f1cc4604b918e8a86d38eb57330_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzYtMy0xLTEtNDk4Mjg_b46d99a9-f338-4eb0-9036-00860b8e0c55">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9983d93acb00482e8d0d425200e8a260_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzYtNS0xLTEtNDk4Mjg_86a12d75-332e-4d23-8e04-fe491c90475d">3,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4acef92df1eb4002905dc17370558309_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzctMS0xLTEtNDk4Mjg_ccfae5ae-4cc5-4023-821d-04a3cb37990a">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic26efa4ca4234676aff27081710a3c9f_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzctMy0xLTEtNDk4Mjg_3d40c084-ee49-4db0-bcc9-f4fd3032c531">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b5b9fd187a54c0e8a75c5406595c067_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzctNS0xLTEtNDk4Mjg_f8c68f65-5611-43df-becf-7535191ac277">3,049,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0b6db699219044e993eb9ea5a3b6b102_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzktMS0xLTEtNDk4Mjg_d51771ff-a3fc-4b74-90b0-0df3fee5beb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e7e112a8d0b4389b6475906e5e25f9a_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzktMy0xLTEtNDk4Mjg_37220e81-53fa-429e-99c5-90b404b482bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38c6268345f84faf98df07aa08e09d50_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzktNS0xLTEtNDk4Mjg_ec0655cc-fdfc-4d32-97ca-92b813cbc7e0">1,009,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzEwLTEtMS0xLTQ5ODI4_1ec45027-dab8-4701-b76f-8c03332f5fe1">17,943,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzEwLTMtMS0xLTQ5ODI4_594b6bf9-4fdf-4af5-85d3-f663dcec824d">16,654,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzEwLTUtMS0xLTQ5ODI4_6a1c6e4f-bf94-4fd8-814b-7128a7463a64">16,190,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzcw_c7a71750-f751-4fab-935a-2c302330a51f" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:CompensationRelatedCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzc4_0eb1d75e-944b-4c6c-92a1-34989d01a921" continuedAt="i228001f875d549bf916cf4199db9f47f" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i640aabee67014aad9a6d218f19bf1e28"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i228001f875d549bf916cf4199db9f47f" continuedAt="i594f62c8d4054327ad1cc90a52665659">date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i594f62c8d4054327ad1cc90a52665659">The Company recognizes forfeitures as they occur.</ix:continuation> </span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzMy_f6d6b04b-3adb-4017-a43a-231a2d02acf0" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzItMS0xLTEtNDk4Mjg_04f3d56c-0097-4d88-ba85-0517aa0a8e04">2.05</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzItMy0xLTEtNDk4Mjg_e903fa72-63e9-4d0d-b48d-74e3d6b64769">0.91</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzItNS0xLTEtNDk4Mjg_ce587f9a-344a-4fc7-93c4-99b37775010b">0.63</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzMtMS0xLTEtNDk4Mjg_8369eb14-0c41-472a-8986-64d39952045a">94</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzMtMy0xLTEtNDk4Mjg_2724b47c-52da-42e9-8f04-0abc4c5e6672">93</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzMtNS0xLTEtNDk4Mjg_f08546a5-e896-46cb-a028-265c9922db93">78</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzQtMS0xLTEtNDk4Mjg_0b9f1be4-1c02-42db-a0e9-8752e5d79b50">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzQtMy0xLTEtNDk4Mjg_bd773674-2fc2-48c7-b6a3-acdce7587d05">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzQtNS0xLTEtNDk4Mjg_ba62b967-bfa2-4e18-b717-417ad771a9af">6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzUtMS0xLTEtNDk4Mjg_d8d756b3-f12e-44d9-af70-c8a3c015d1de">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzUtMy0xLTEtNDk4Mjg_681d595a-4b01-4ca3-a028-a051e261081e">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzUtNS0xLTEtNDk4Mjg_d5d3176a-c014-480c-ad05-3d292d1e9c1c">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:52.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.741%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzItMS0xLTEtNDk4Mjg_a8ba89ea-5c8a-42ac-b70d-284cb74e1659">1.96</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzItMy0xLTEtNDk4Mjg_66bb99d8-bf35-4030-9568-e6bc891165b2">1.45</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzItNS0xLTEtNDk4Mjg_f98c4111-73bb-4937-8f9b-213d69d13e5c">0.82</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzMtMS0xLTEtNDk4Mjg_fb9a9c68-ccba-471f-9940-d006a2ec2e4b">87</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzMtMy0xLTEtNDk4Mjg_e82eae8c-b72d-4bd2-be4d-9e877b129928">87</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzMtNS0xLTEtNDk4Mjg_efa06eb1-74c2-4546-9898-a50cb6179ed7">76</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzQtMS0xLTEtNDk4Mjg_e3ea1e8b-be85-4922-b191-0ea5f103ad8a">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzQtMy0xLTEtNDk4Mjg_78a26f7c-8b94-40c5-a75d-29870d4b2dd8">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzQtNS0xLTEtNDk4Mjg_39ae1195-88b5-45ac-bc9a-eed5b42cdf33">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzUtMS0xLTEtNDk4Mjg_7d5e722c-d92d-414e-bc54-02c994c94c76">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzUtMy0xLTEtNDk4Mjg_1c71ff39-48a1-43a9-9164-b2d8a4827a93">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzUtNS0xLTEtNDk4Mjg_5abf7554-ec9c-45c6-995c-e09d9653356f">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjg3_e8bdbab2-3d97-4bfd-832f-dfb5dd06a4c0" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcxMzU_d7cf9543-8bca-4b3d-b7c7-184845e4243d">1.8</ix:nonFraction>&#160;million, a decrease in additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcxNjI_942e3057-ac7b-4d3b-9efd-4e123e556efb">3.3</ix:nonFraction>&#160;million, and an increase in convertible senior notes of $<ix:nonFraction unitRef="usd" contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101" decimals="-5" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcxODk_ff38ecaa-17ff-4e99-907a-9b9470bb9825">1.5</ix:nonFraction>&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="ib54af4db6f934822936c9df96da62d29_I20221231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcyMTY_bfb59b9b-6b20-4c49-93a3-f5ff5d62940a">1.5</ix:nonFraction>&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_142"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzExNjE_7d439786-ea92-4d97-8386-2046e2e80706" continuedAt="ic9da2480cc5e48ae9195b35faeed4169" escape="true">Revenue Recognition and Concentration of Credit Risk</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="ic9da2480cc5e48ae9195b35faeed4169" continuedAt="ieaef20683400453ba5e5d60187ea304d">During the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized revenue from various license and other agreements. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzExNjI_e760ea9c-c5fc-469f-a7fd-a29a3b1bd22c" continuedAt="i77e2c289470b4e2093416dba71e3b2ac" escape="true">The following table indicates the percentage of total revenues in excess of 10% with any single customer:</ix:nonNumeric></ix:continuation></span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ieaef20683400453ba5e5d60187ea304d"><div><ix:continuation id="i77e2c289470b4e2093416dba71e3b2ac"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.828%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.945%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.967%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.201%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacebae33d2f744a48bfe3f27c87963b5_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtMS0xLTEtNDk4Mjg_a4aaf5bd-bda7-4822-bff4-30d3831dc8c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4c2ca730669f40a3b880aad76ef47eb8_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtMy0xLTEtNDk4Mjg_43f088fe-6cff-441a-b3b1-98a84935c6d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec30835ff64649d1af8bee1755bb6747_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtNS0xLTEtNDk4Mjg_6719a287-f1c3-4a21-b189-27832d715bb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib0233517f0744b4d84dbc2857651922e_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtNy0xLTEtNDk4Mjg_7836313a-7f9f-4981-b52e-f69a9e08176e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8427d8144b8a45508082c0e9224f6b9a_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtOS0xLTEtNDk4Mjg_47f6eb0c-eb73-4673-932c-8a40e585fba4">5,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if216a168540f4767a05cedea2727d91b_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtMTEtMS0xLTQ5ODI4_a7a03454-3ae6-4d71-a08e-028333b000b2">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3508c7fdd5df49c9b3d412117527967f_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtMS0xLTEtNDk4Mjg_29456713-6a49-4a8e-be1a-fcb341c15223">33,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba97b678f2164b7dab82b6edbc9c7f26_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtMy0xLTEtNDk4Mjg_ad39d1af-6399-4ce8-aabc-d99129206c2d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605c60f66d234792a11598c1cdedabc7_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtNS0xLTEtNDk4Mjg_5de2a4d3-bc4c-49d7-8c2b-7cf64770a420">245,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d452e7c90114add826a2726068eca7b_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtNy0xLTEtNDk4Mjg_24a28440-29e3-4ffd-8948-f94cfe42c892">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39566c733fd24bfebb62337eb808c542_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtOS0xLTEtNDk4Mjg_eefaadfc-af92-4f7d-b352-7f29565cbcd9">1,370,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifcac4af5c7b542f9afc5cb5e93d18b8e_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtMTEtMS0xLTQ5ODI4_3d83edac-bdda-4477-9aeb-ee79f1fd88c4">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia146e47921c744fc956b2120c6439daf_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtMS0xLTEtNDk4Mjg_d5b4b6e8-3bba-445c-b96d-d1a591f99dd8">9,591,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd3d9ccb223c4b51adcc34fee442e12e_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtMy0xLTEtNDk4Mjg_4d29a5f7-5123-4dbd-8902-09c77686f4e0">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950175750d8f45f99adff0b9d015b817_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtNS0xLTEtNDk4Mjg_00fddf64-adc1-41ed-9ad8-ec99ab01b43d">754,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i990e94fbd63b4cd8aa841335ddf7a196_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtNy0xLTEtNDk4Mjg_6cceec16-e03f-41bf-855c-09845c4424d1">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaa2ff55b5b64c87ac5b7a3c20a2340a_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtOS0xLTEtNDk4Mjg_c4aa2774-5234-437a-8061-fb10d5347148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3e0c5185d2f4ec88fb795922202c563_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtMTEtMS0xLTQ5ODI4_2c4b5989-cefb-406c-838e-5d199ef67be7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a3222a554c43c892ad45d36bed2135_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtMS0xLTEtNDk4Mjg_1191d842-91d1-43a4-aed4-96cc9b7a57d5">636,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b4cbfef541641c29b555849b7baa86b_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtMy0xLTEtNDk4Mjg_867d2fe3-49ef-4877-9287-68df2e39832b">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87e6793803cc44808ce478887c3e8548_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtNS0xLTEtNDk4Mjg_cdf7ef71-1c0b-409f-86a9-c98df264c3d6">774,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i022f7c48f8c449e0984cc5c418c9249f_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtNy0xLTEtNDk4Mjg_38d16470-7496-41c2-9be0-58eb0034eeef">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4c58350d8dd4037a4eeb106f14f84bb_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtOS0xLTEtNDk4Mjg_9ef0b230-2b83-4362-a1d6-c57728e0fb0a">1,040,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7a04772ad7c34b45b0fea6aab0e11b68_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtMTEtMS0xLTQ5ODI4_60006bd6-860d-42b1-ba79-1b1f1a3b8477">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctMS0xLTEtNDk4Mjg_e416e211-0741-491e-b872-55995d6b31fb">10,262,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24234386041445bca5cb6066f1a957bc_D20220101-20221231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctMy0xLTEtNDk4Mjg_78a7a5f5-cd52-4afc-8075-5fee38abeb42">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctNS0xLTEtNDk4Mjg_a426fc56-7c7b-4cd6-8622-d34e7777681b">1,774,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7aa7c00e7c454fc0aadae3a3b369359e_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctNy0xLTEtNDk4Mjg_c21fa1ec-5926-411c-9336-f5db6a84726f">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctOS0xLTEtNDk4Mjg_4a7a4cec-9e0d-4d94-b9a7-963f6f908342">7,411,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id150bf83ee8f48f998faaca40b1a30ec_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctMTEtMS0xLTQ5ODI4_82e57218-e5f0-4dec-9b10-6040c453ba7c">100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the total revenue recognized during the year ended December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzM1Mw_f71d3380-2444-430d-9c2a-7cfff00aa414">14,000</ix:nonFraction> was in deferred revenue as of December 31, 2021. During the year ended December 31, 2021, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzQ3Ng_52e53778-7f5b-4765-87a6-26d60635158e">46,000</ix:nonFraction> that was included in deferred revenue at December 31, 2020. Performance obligations are generally satisfied within 12 months of the initial contract date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. As of December&#160;31, 2021, $<ix:nonFraction unitRef="usd" contextRef="icb0c56d581394886b4899de7fc50e0e5_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzgwOQ_da32bf35-4f5c-456a-94f0-d4e95805f9f0">3.6</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="i1e1e7149a8c6422490e7e06c70d28310_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzgxNg_80463e5e-23cd-4e15-a276-dded3b1f0328">65</ix:nonFraction>%, and $<ix:nonFraction unitRef="usd" contextRef="i2a71317f6eea40f7b6476ead84dae594_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzE2NDkyNjc0NDI4NTY_5ffaf116-f47d-4d26-a2d0-1c229c0eaa32">1.9</ix:nonFraction> million, or <ix:nonFraction unitRef="number" contextRef="ic78b5c6c0e794855951b9ce333c34e4d_D20210101-20211231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzE2NDkyNjc0NDI4NjU_28e900f2-baa2-4c9c-89b1-9d9909a5923c">34</ix:nonFraction>%, of the Company's accounts receivable was attributable to the DoD and CEPI MERS grants, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</span></div></ix:continuation><div><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIxOTI1_432d2ad8-e239-4e54-977e-8992ea86e7c2" continuedAt="i360caaf26f0947c8afaf269459b6d734" escape="true">Collaborative Agreements </ix:nonNumeric></span></div><ix:continuation id="i360caaf26f0947c8afaf269459b6d734" continuedAt="idcc5f2e6d1574214ab2e4b2bcff16839"><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. On October 27, 2022, the Company announced that it had discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $<ix:nonFraction unitRef="usd" contextRef="if01705c616d24d9da3e0014282dd5837_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzI2ODU_1d2b6b14-9674-4140-891a-059e00564397">3.0</ix:nonFraction>&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzI3OTg_7fb43bd1-1ad0-4f2a-9988-75bb469be88f">200.0</ix:nonFraction>&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for <ix:nonNumeric contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzM2OTY_c9d9b67d-d399-4706-b3d3-d7840bfbf8a4">ten years</ix:nonNumeric> after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $<ix:nonFraction unitRef="usd" contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231" decimals="-5" name="us-gaap:CostMaintenance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzQwODk_bac4a79d-00f8-439f-9a12-4f3807d3422b">1.5</ix:nonFraction>&#160;million for a period of <ix:nonNumeric contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231" name="ino:AnnualMaintenancePeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzQxMDg_a7134d7e-fa7e-45a8-b03b-c689b415e8d0">five years</ix:nonNumeric>, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="idcc5f2e6d1574214ab2e4b2bcff16839" continuedAt="i458c7eef8d654a07885e9b5eab5395f3"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU3NTA_af08d52d-7fbb-43eb-bacb-0c70ea2afc3b">18</ix:nonNumeric> months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $<ix:nonFraction unitRef="usd" contextRef="if01705c616d24d9da3e0014282dd5837_D20210101-20210131" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzY1MDE_055799c4-348f-40f1-b584-623c5e48bcc5">3.0</ix:nonFraction>&#160;million upfront payment received in January 2021 plus a $<ix:nonFraction unitRef="usd" contextRef="i85a901e2e495476b83006c89b06314cf_D20210101-20211231" decimals="-5" name="ino:CollaborationAgreementPaymentEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzY1NjI_d4ba425f-760c-47db-ad97-46a132e393b5">2.0</ix:nonFraction>&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $<ix:nonFraction unitRef="usd" contextRef="i85a901e2e495476b83006c89b06314cf_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2Xzc0MzQ_97443b16-f8ed-4270-84e9-cae7a0f8c881">5.0</ix:nonFraction>&#160;million was allocated to the license performance obligation. The Company recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i6d5a02ab98d44b87a3c2fe66c95e090a_D20220101-20221231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NjY5MjY_55572b0e-0ada-4904-bb7c-666e0e10e3af">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i677b7c07452f40d7bb6f5a339c25fa59_D20210101-20211231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzY5MjU_57703263-6d2f-484f-9bf7-ad41bfe4a6e8">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i05af6b16800c4f969cf22fdff24b2acd_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzY5MDg_59044bfb-d549-4e72-b046-900a905bfe0d">5.0</ix:nonFraction>&#160;million of revenue for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the years ended December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020, respectively, under the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility was assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022, 2021 and 2020 the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzU3MTk_2ac16d5e-ef01-4bbd-b640-88bd3fa812d1">1.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i85a901e2e495476b83006c89b06314cf_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NjY5NzQ_a3ed51b8-bf32-49d4-acd5-7768c52022b6">4.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9d52f8c0138d4608b9e0be15696a4efd_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcyNzI_4458b4c9-67a9-45db-bca3-b0abe0209e22">0</ix:nonFraction>, respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231" decimals="-5" name="ino:CollaborationAgreementAdditionalRevenueToBeAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzEwMjI1_2e596b96-a58a-4bea-9879-26d6f9204c59">20.0</ix:nonFraction> million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for <ix:nonNumeric contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231" name="ino:CollaborationAgreementRoyaltyPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzEwNzcx_7ecbeedf-1c6f-47a0-b12b-94b5aa3ca000">10</ix:nonNumeric> years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning <ix:nonNumeric contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231" name="ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzExMzkz_82238cf0-5b66-4fda-8a23-b76ed661a3fe">one year</ix:nonNumeric> after the effective date for any reason upon <ix:nonNumeric contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231" name="ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzExNDQx_9d4fa542-5b1b-43eb-aef1-5141269509fe">90</ix:nonNumeric> days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there has been no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i458c7eef8d654a07885e9b5eab5395f3" continuedAt="iefa9f405b7f5407e8d6799ea2df3d2f8"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ia2001c79602b4f5b85e822a75b982b64_D20180411-20180411" decimals="-6" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE1Nzky_611b7dd5-6f9a-4eb7-8cef-b0c7650d86ad">56</ix:nonFraction> million of costs over a <ix:nonNumeric contextRef="ia2001c79602b4f5b85e822a75b982b64_D20180411-20180411" name="ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIxOTIx_21c3576a-277e-4335-a4d7-c69e29df45f6">five-year</ix:nonNumeric> period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2022, 2021 and 2020, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i90b72b34cbaa4c96b0e773c47a774b68_D20220101-20221231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzU3NTg_4fd49cbc-7d30-4417-9feb-a8fdfebe01ea">6.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="iea847db8af964a5a95a30170013066a4_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNTE_c423d23c-91a7-495c-b29f-634a011c38e4">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e1c6e230bbb4305a74e7bd299517f02_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementsUpfrontPaymentReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNTk_c18380e2-29d9-4fc9-ad97-fe0db0aae127">6.4</ix:nonFraction> million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2022 and 2021, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i624d921570e54646b679bccfad2456ed_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2Mjc4_a428302c-4207-4e27-b140-4b4a120840c9">1.7</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i19d08d5f004243748735e0364a7ac6f0_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcwODE_b7673394-879a-4857-b58c-bb65bada0a15">1.9</ix:nonFraction>&#160;million, respectively, on the consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $<ix:nonFraction unitRef="usd" contextRef="i5dd47e2e24e8451fbedb25fb61279123_D20200101-20200131" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDQ3_ff90ea3b-5e8f-4f37-859a-b365bdd071aa">9.0</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="ic6e68fd9d7034356a5daff34bafca427_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NjEz_fd1dca69-31a6-44fb-92de-c6f916d5db34">6.9</ix:nonFraction>&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i6fb8532210c34bb3b02229812e1d6ccf_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2Nzkx_500ba907-26b2-4cb2-9025-9bd3e6dd1c27">5.0</ix:nonFraction>&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $<ix:nonFraction unitRef="usd" contextRef="i59d6c481f47d4e698f05a3589d8d4a5f_D20200401-20200430" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2OTcy_749d42fe-3df8-4be7-845f-e0851daa1f35">1.3</ix:nonFraction>&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $<ix:nonFraction unitRef="usd" contextRef="i82d467a9444a402eab652428f5f340aa_D20220101-20221231" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3MDkx_3c676adf-9a01-45d3-aeb3-024e8abe5bbe">1.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i953055247fb0438694e88e83fe092f34_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3MDk4_d151a1aa-516d-49c1-a501-3d8c504eb3da">6.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6e7ae79d83454d1a94162dfaaf181c92_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNjU_4f4022f8-a92f-4ed9-9787-c1ba25d7f370">10.0</ix:nonFraction> million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i0972fde3981d46cb86a06b579ea816d4_I20221231" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3MjU4_57de9447-cc1c-429f-b8f3-a1ee4d758607">2.3</ix:nonFraction>&#160;million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="i526c4d9267ea40f59d929793e9e609e6_I20211231" decimals="-5" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzY5NTU_95024dc6-23aa-4b37-95be-f33acf16d89f">1.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800, respectively</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="i650513b7b0b042eba217f78ede5cb81f_D20181001-20181031" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3NTE1_f0b4a96a-1106-4efa-b9f5-e375374d3a3b">2.2</ix:nonFraction>&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $<ix:nonFraction unitRef="usd" contextRef="i743b9e9db9bf47abb1bdc985839a7e95_D20190801-20190830" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3ODc4_5ba04997-b6fb-4522-a776-d0616f30a544">1.1</ix:nonFraction>&#160;million for the project. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i5fd06dc6be4e490f8fbf48221de75ab1_D20220101-20221231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3OTUz_71abed3d-a8af-44ce-b63f-57b041494b4c">233,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i93c96775125a4f49bee81002302c8881_D20210101-20211231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3OTYw_c208d5d2-beda-4e0c-891d-7361816d9bb0">182,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i0fb85cb9a30245a59734675d97301f64_D20200101-20201231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNzU_dba8fd68-4cf4-42cf-b11e-63310770f28d">463,000</ix:nonFraction>, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i0715a0fcc3914e2c86a2471c1d0415ed_I20221231" decimals="-3" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4MDgw_367bea6b-f822-4b66-b3a1-d2b31277dbc8">153,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i2137a35c3759425c9f6105f0eb18daad_I20211231" decimals="-3" name="us-gaap:GrantsReceivable" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxODg_4b7cccea-1dd1-45db-892f-9cd42a829547">384,000</ix:nonFraction> recorded as deferred grant funding on the consolidated balance sheet related to the grant, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $<ix:nonFraction unitRef="usd" contextRef="ife18dab7106f4cfab95e7efa34dda590_D20200301-20200331" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4MjM3_e36a3d94-f979-46a8-9cc4-28bfe3b90afb">5.0</ix:nonFraction>&#160;million to accelerate the development of the CELLECTRA 3PSP device for the intradermal delivery of INO-4800. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i83eec1d80cf54e79a405e0ac8c7c3446_D20220101-20221231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4Mzk3_d71c2554-e40d-49d2-8083-0c241cde7e75">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="ia5c86a87fced4537bffa81e5585402dd_D20210101-20211231" decimals="-3" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4NDA0_b16452a7-2657-4559-bfe0-c6f6262e88ca">893,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="id3e8f8ce3eb145728468142b2b4b4151_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementFundingToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcyMTY_a7eb44a7-1ca5-4527-862f-c32f15050b6e">4.1</ix:nonFraction> million, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $<ix:nonFraction unitRef="usd" contextRef="i0ef3b95e79d94359931733a1d9c874ae_D20200601-20200630" decimals="-5" name="ino:CollaborativeAgreementFundingReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE5NDEw_f671c17f-3125-4d1a-b2c6-23dd7d97372f">54.5</ix:nonFraction>&#160;million. The Company determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib87dc46031834cbabb9a823d652b3f5f_D20220101-20221231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU0OTc1NTg0OTYwMw_dbfb44f5-45ff-4db8-ac62-1af5e46de26c">6.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibdb55475f21c4c86a9e26fd186d37d72_D20210101-20211231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU0OTc1NTg0OTYwOA_4e1275f9-88fa-4077-8160-17e652c401af">27.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idd5f4f4bdca146dda0cf7316b5eddc03_D20200101-20201231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU0OTc1NTg0OTYxNg_02c29d01-7d14-465d-99e8-5343c2ba1cdb">21.2</ix:nonFraction> million, respectively, as contra-research and development expense related to the OTA agreement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The total purchase price under the Procurement Contract was $<ix:nonFraction unitRef="usd" contextRef="i0ef3b95e79d94359931733a1d9c874ae_D20200601-20200630" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIwMjcw_1dc7c278-91b1-4ab2-97da-ea625c68167a">16.8</ix:nonFraction>&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $<ix:nonFraction unitRef="usd" contextRef="i0a8536568e6643a3826b271bb765d299_D20220101-20220131" decimals="-5" name="ino:CollaborativeArrangementFixedPriceContractAmountAwarded" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzM5NjU_1fb5218a-e86c-4aee-a3a2-e0874125149e">10.7</ix:nonFraction>&#160;million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2022, 2021 </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="iefa9f405b7f5407e8d6799ea2df3d2f8" continuedAt="id73dd9161f174d938114691cc37547e9">and 2020</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="id73dd9161f174d938114691cc37547e9">, the Company recorded revenue of $<ix:nonFraction unitRef="usd" contextRef="i115835ccef2c4c728f65ff50b203bbd4_I20221231" decimals="-5" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzQxODI_901e8144-ac93-4435-bfc3-33ea5ad8bd25">9.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ieed26bae30344c0d930f02e46a10d2c3_I20211231" decimals="-3" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIxMDc1_45f4832e-a166-45f2-ba81-136bd6fd17fc">755,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i045659d16234450a8682a7768426647b_I20201231" decimals="-3" name="ino:CollaborativeArrangementRevenueFromTheProcurementContract" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcyMjY_6d0beff7-69ea-4c38-a819-cfa1f9fc4bce">0</ix:nonFraction>, respectively, from the Procurement Contract.</ix:continuation> </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MDY_1835ff9c-ff66-488f-9ee6-f4875b6ceb99" continuedAt="i2783c16f405b4306a218c57f662ed56a" escape="true"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MDY_9729f0ce-bd38-4638-b954-85345ca405b5" continuedAt="ief74b7cae64a463eb50088822479c648" escape="true">Short-term Investments and Fair Value Measurements</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i2783c16f405b4306a218c57f662ed56a" continuedAt="i8e90e1ccb8fe4d8e8ef20620125c5d02"><ix:continuation id="ief74b7cae64a463eb50088822479c648" continuedAt="icafac94dbf574c66b3e2e5c04764f97e"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MTA_34ae57db-b7c3-4794-a1f3-b65c469c18b1" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2022 and 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItMy0xLTEtNDk4Mjg_43ff01fd-f004-4a83-8909-f5fdb4c79fa1">117,036,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItNS0xLTEtNDk4Mjg_17ab3dca-5e01-4574-8265-ce60850e8ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItNy0xLTEtNDk4Mjg_d507da42-9623-4d99-a517-679c75ed422a">9,373,514</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItOS0xLTEtNDk4Mjg_6086c2ce-8c9b-4186-b0f4-264a4b52b464">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i8c404065aa374228af041779ee4cc690_D20220101-20221231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtMS0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpiY2QxMzQ5MzBhZTA0NGRiYWYxMTJmZGQ3NTEwYTI0Y18xNA_a6adfec0-a531-4be9-ab6f-b3c88e9659b7">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtMy0xLTEtNDk4Mjg_8689c49e-d8aa-4d99-b46f-99628bcd890c">95,001,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtNS0xLTEtNDk4Mjg_913003a2-0faf-4b5f-a407-eeb16c2480d4">7,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtNy0xLTEtNDk4Mjg_89a11a16-5942-48e1-8e00-0a75f78ca191">44,266</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtOS0xLTEtNDk4Mjg_69df9559-f2f1-48f8-985f-5843c1b53f4b">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i00707a03b34c4fcbbec4fec91c975908_D20220101-20221231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtMS0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmMDZiY2JjYjdmMTM0Y2E3OTQ4NjcwYzY1Y2JmYzQyMl8xNA_c2a5600b-1455-4a5b-b81f-d0a1087deb09">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtMy0xLTEtNDk4Mjg_cd514f55-dfe9-468e-92ff-99b8f33a882e">2,977,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtNS0xLTEtNDk4Mjg_b41df0a5-b882-4921-ba49-108235ff208a">13,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtNy0xLTEtNDk4Mjg_036daac9-f070-4fac-83fb-344db210af5a">320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtOS0xLTEtNDk4Mjg_83664b30-9117-4839-9a9a-1887d97907de">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtMy0xLTEtNDk4Mjg_4f91267c-8bf1-44b3-82d6-f93a423146f7">1,435,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtNS0xLTEtNDk4Mjg_0428e72d-806d-42cc-b4c1-a4c2896d14f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtNy0xLTEtNDk4Mjg_ed10c567-8319-4962-b0cb-0562977ab5f1">384,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtOS0xLTEtNDk4Mjg_0c8c6008-3663-47d0-a475-92ff15a5194e">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtMy0xLTEtNDk4Mjg_cac30a69-6681-4460-8b96-1f12c6bd7794">216,450,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtNS0xLTEtNDk4Mjg_34667d3f-7230-43a4-a4fd-7afbb2e57016">21,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtNy0xLTEtNDk4Mjg_356ec45f-f08e-4b2e-be78-9d740971a784">9,802,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtOS0xLTEtNDk4Mjg_929d3c92-dc2b-4647-9477-051ccacee056">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:25.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.812%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItMy0xLTEtNDk4Mjg_77ef70b2-7289-4094-ac45-43948c8847a5">192,966,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItNS0xLTEtNDk4Mjg_4b44f34a-ca36-4f04-b2f2-0994f84fb066">87,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItNy0xLTEtNDk4Mjg_65728a37-b865-43fc-9632-a422c6e4348d">1,614,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItOS0xLTEtNDk4Mjg_23ea6208-bd0f-41dc-82de-01e06f83c8d2">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMS0xLTEtNTExNzUvdGV4dHJlZ2lvbjozYmZmNzBiYzM3Y2E0NmYzOTNmNjgxNDQ3ODM5MzUwZF8xNA_bc8a4d84-a22f-4d6c-93a3-7af07685e886">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMy0xLTEtNTExODM_5804c07b-7de0-4a35-9a36-5006f24c3156">94,193,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNS0xLTEtNTExODM_d26889b4-bb22-46cb-988e-648d3f44fd8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNy0xLTEtNTExODM_f2534e1e-d070-4cf6-bd62-f38c142cd5c0">9,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtOS0xLTEtNTExODM_6440b558-85b3-4332-aef7-1d54a54ae082">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMS0xLTEtNDk4MjgvdGV4dHJlZ2lvbjplNGJlMWY5ZjE4ZjE0N2NjYmFlMTBkY2M1YjIxMTJjNV8xNA_bc8a4d84-a22f-4d6c-93a3-7af07685e886">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMy0xLTEtNDk4Mjg_7609be73-8307-48c3-8c04-be22103989fe">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNS0xLTEtNDk4Mjg_9c2f9086-c0c2-41a2-a707-d076a7eb12df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNy0xLTEtNDk4Mjg_e5661e56-198e-4c8f-affc-bd8edf7cc2b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtOS0xLTEtNDk4Mjg_a69fb821-6e05-49b0-9bbb-baaf8a612642">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than <ix:nonNumeric contextRef="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231" name="ino:DebtSecuritiesAvailableforSaleContractualMaturity" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtMS0xLTEtNTExNjQvdGV4dHJlZ2lvbjo0MGFhMWQzOWM1OWM0N2UyYTE0ZmExZDNjODY4MjI1ZF8xNA_bc8a4d84-a22f-4d6c-93a3-7af07685e886">1</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtMy0xLTEtNDk4Mjg_c76855ff-1724-4df5-b5e2-f836bae0c598">2,976,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtNS0xLTEtNDk4Mjg_3c4c78dc-e7ce-4c00-bd6b-08f92add510e">15,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtNy0xLTEtNDk4Mjg_e741bb74-7dbc-4b89-98af-8f2337f9e027">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtOS0xLTEtNDk4Mjg_1adfbb00-f773-468b-9dbd-25668977c916">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtMy0xLTEtNDk4Mjg_1686770b-7747-4792-840f-1f54119675cb">1,608,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtNS0xLTEtNDk4Mjg_f75e2448-c446-484a-b096-819247ae9e36">4,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtNy0xLTEtNDk4Mjg_b3f0895d-41f7-400d-8559-7a518931ecd3">23,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtOS0xLTEtNDk4Mjg_41dc341b-9f76-42f3-8033-3b1756455d7d">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtMy0xLTEtNDk4Mjg_41ca6f92-05c0-4e47-b95c-d48f047377a9">331,712,413</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtNS0xLTEtNDk4Mjg_5e127820-b974-42bc-bd40-d3251809c556">107,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtNy0xLTEtNDk4Mjg_8d2ca605-1e32-478b-96d2-e6af3501530e">1,648,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtOS0xLTEtNDk4Mjg_41ded366-ee13-4b60-926d-2ff6c7bc0826">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzI2Mw_f90e96a2-d733-4885-abfc-27d039865890">21,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzI3MA_e4b41839-3506-4cc8-827d-590153352051">394,000</ix:nonFraction>, respectively, and gross realized loss on investments of $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzMzMA_1016880c-dd91-419e-ab61-219ab1c30519">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzMzNw_07b3da82-392e-405a-8c2f-9664e419462e">399,000</ix:nonFraction>, respectively. During the years ended December&#160;31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MA_54886739-4ab3-40a7-a056-b0569a36edbe">7.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4Nw_034e874b-ad3e-4c0a-b249-371d08956289">3.2</ix:nonFraction>&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2022,&#160;2021&#160;and&#160;2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2022, the Company had&#160;<ix:nonFraction unitRef="position" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzgwNw_fe5d90b2-9d68-456e-92ff-12316edda021">29</ix:nonFraction>&#160;available-for-sale securities in a gross unrealized loss position, of which <ix:nonFraction unitRef="position" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4Xzg4Ng_f93234a8-d299-4098-bdeb-5c6ca808606a">21</ix:nonFraction> with an aggregate total unrealized loss of $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzkzMg_56bd724e-8f72-4956-bcd4-3597b6eb55a6">8.7</ix:nonFraction> million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2022&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MDU_48f5e875-c159-4701-94b0-979d438abd04" continuedAt="i100287dbc05b45ba8e52fbebbfb79cad" escape="true"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8e90e1ccb8fe4d8e8ef20620125c5d02" continuedAt="i3e8f7786171549f683637e7afa8597af"><ix:continuation id="icafac94dbf574c66b3e2e5c04764f97e" continuedAt="i3b4fc62102a64d66b55d67b311ee0fa0"><ix:continuation id="i100287dbc05b45ba8e52fbebbfb79cad"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:38.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.059%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b2add8fd23e494f887f27eb874b2134_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtMS0xLTEtNDk4Mjg_f0ddbcd8-4080-4dc0-83bb-4799cb77db87">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib18c28bf3960424a854d14b13675393f_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtMy0xLTEtNDk4Mjg_330ca55e-ada2-4218-bdd2-c36c1c6f77e2">107,662,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93622c19682e47a18bd389447a17beb8_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtNS0xLTEtNDk4Mjg_f28c2953-7459-4be8-a4db-ed1f8df384b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d28cb507a504198a57d5181ce08ac8f_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtNy0xLTEtNDk4Mjg_2e2db9c0-d02d-4669-8498-adb6bfb14a5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib904a495e82646c380154c25b095b55a_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktMS0xLTEtNDk4Mjg_ad73eca8-4b22-4acd-9645-0ed14305530d">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07066c0990e24538bc05caed189f78fb_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktMy0xLTEtNDk4Mjg_0aeb8c08-c3ce-4fc8-9b5b-e92f2959fc13">94,964,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3648b2d58fe42268eae0877934e1081_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktNS0xLTEtNDk4Mjg_7d7443ff-fa37-4848-a235-83a182efbc55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b37d006f03d47b3b8e7c0a1873c00f5_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktNy0xLTEtNDk4Mjg_30e5063e-d8b1-4cf6-8dab-0424e48d5817">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb9dfd820dc743fda9f61d926e90be25_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTEtMS0xLTQ5ODI4_c3277ede-2e2f-416f-90b7-c1ec44918dbb">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc86246d2a124c419654fa1e9bf8dc32_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTMtMS0xLTQ5ODI4_f59de93a-cdd6-4092-a3b5-afb6891fa1c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86004616beac41238cc173e85e423ddf_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTUtMS0xLTQ5ODI4_abc23289-21cb-468b-8370-7a1f9ee48e0b">2,990,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i477c90290ae74d219ed8ba9ff7390f90_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTctMS0xLTQ5ODI4_217d8478-a6a8-46cd-a25e-124341451b48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc9d150f733431f97498d614ee4a8db_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTEtMS0xLTQ5ODI4_761cba9e-0f87-42d4-b45a-44cf2b729778">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186cb4d8d2d24f43bf75c63e229647ae_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTMtMS0xLTQ5ODI4_2de28432-1474-4326-b646-bd435ff2ba1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i619f71a84cc54c479c772df5eeaf3bb8_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTUtMS0xLTQ5ODI4_291ca98d-ddf8-4a63-9bb1-618245bada5a">1,051,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01197e4e2ce54a9f9c6f4e01fa548a46_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTctMS0xLTQ5ODI4_9f6026c2-0ab9-4d63-b935-c3309616d838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d5d82697444dd38fb5e557609c0c36_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTEtMS0xLTQ5ODI4_ff727309-2a88-4886-a973-c8d2c3da8186">206,669,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8775bf17fa47f3b938211c08019c26_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTMtMS0xLTQ5ODI4_6897ebe1-2714-40d0-b77c-7c6a3d5d0985">202,627,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTUtMS0xLTQ5ODI4_6fe9953e-bd42-4f79-9186-d287211e5789">4,042,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d1f385cc4944c44a2038acebc25f9cb_I20221231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTctMS0xLTQ5ODI4_be3483de-fd6e-4986-a6de-8c74f15a9ec9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d5d82697444dd38fb5e557609c0c36_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTEtMS0xLTQ5ODI4_7d929e9b-ef03-4783-9257-d482c8521c1f">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8775bf17fa47f3b938211c08019c26_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTMtMS0xLTQ5ODI4_ecd1529f-47c5-474d-86cd-98b27aa1f47d">2,007,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTUtMS0xLTQ5ODI4_9f84d99a-6cca-4f29-8046-9844cfbb0c68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d1f385cc4944c44a2038acebc25f9cb_I20221231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTctMS0xLTQ5ODI4_6f4867f0-a0b6-4524-bd9e-3895fdb67d43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d5d82697444dd38fb5e557609c0c36_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTEtMS0xLTQ5ODI4_86836882-b922-411e-8e20-cf746f17aea2">208,676,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8775bf17fa47f3b938211c08019c26_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTMtMS0xLTQ5ODI4_2f81eaaa-c885-4d17-a73e-409c33188645">204,634,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTUtMS0xLTQ5ODI4_15666ef7-7149-4bd0-88e2-db92e5ebea85">4,042,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d1f385cc4944c44a2038acebc25f9cb_I20221231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTctMS0xLTQ5ODI4_242088cd-f607-41c4-aa9e-54c14c13d305">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.762%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9de6860abc2a4ad68642fef0b295cbfb_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMS0xLTEtNDk4Mjg_81c48efe-fc8e-4f69-9138-4b3ef1769878">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fb0a0d192947be932e34702459a178_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMy0xLTEtNDk4Mjg_874181aa-ef7f-49df-9287-b4d92b7de6a7">191,439,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be9cf58cb4a4d05880ed751b4f5ec5b_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNS0xLTEtNDk4Mjg_eb19bc73-f673-4844-be4c-737626df5c85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84830cf68b7443bca9c062e649dd83d6_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNy0xLTEtNDk4Mjg_8c409a84-292e-486b-8fc8-3e8ffc31e981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37194e785fbe427fa670a663c8578ab1_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMS0xLTEtNTEyOTQ_c27d122e-f401-4a18-9859-5a0acc1cf1ff">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e279598e344efcb34f380149832910_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMy0xLTEtNTEyOTQ_e82c69a8-8223-44c6-abed-4951b88ac57f">94,183,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49986e2e16ef472cb8df7bab0e9e2546_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNS0xLTEtNTEyOTQ_ace4d29c-e7da-4033-9005-93671d88598d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3867bd2a43024f87bb44709b985fcf7d_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNy0xLTEtNTEyOTQ_bbdbba86-ca29-49a0-812d-b2d093df3405">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06eace206e6e4294aa395dafbbaf4688_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTEtMS0xLTUxMjk0_52f178a7-65df-4adb-a753-e0b096266bfa">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fceb1189d5448b79ca2bbb77264e050_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTMtMS0xLTUxMjk0_6c293b24-1e7c-488c-bd01-c16226064e77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23d3f92702014f969ac3d1af800214f7_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTUtMS0xLTUxMjk0_69d879c7-e489-47ad-a5e7-b12de697d5af">39,967,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f4ae7cd847f4617951fb8ff3f3100f1_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTctMS0xLTUxMjk0_8afb408b-5f07-4cfc-a3cd-b781666d7b51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ffb3a787b3b45cd813aa7b2f5ed87b8_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTEtMS0xLTQ5ODI4_b7d30711-b229-4dca-bba7-ee6584670536">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd4592471329482e8c0661f6abdb0594_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTMtMS0xLTQ5ODI4_57e57b4f-ca0a-4ba2-86a2-4a343316abc8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i936b53682ed8485d8ce3260a62f5541a_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTUtMS0xLTQ5ODI4_0491efb9-3a08-4345-bdde-0d097db73699">2,991,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2013fc31e88d4b0bb859d16c236f4634_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTctMS0xLTQ5ODI4_877d1df2-7915-4808-b05e-d978f92ed684">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0608f84c1ca4f2990271fa5a4b1c79b_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTEtMS0xLTQ5ODI4_74f96529-68f5-4a81-b5a5-eba760b6b4cf">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91447d855fe3401ebf5c16b61ccf4a0f_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTMtMS0xLTQ5ODI4_4bcccb66-9dc0-4e37-8d91-84d3b8a07d14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0971090c3254e23a37a6a1c85cbf09d_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTUtMS0xLTQ5ODI4_02492979-02a5-4471-b22a-ab6845d2d2e3">1,588,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176930b6d6c643fa8db9ce1084359b5d_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTctMS0xLTQ5ODI4_a175bbef-5cf0-4127-b5b2-99e8d1797cd9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e0a92a960d49f88d849ddf682a08b5_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTEtMS0xLTQ5ODI4_d23ac57e-ecff-47d8-8ffd-16c3952f2534">330,170,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67083206a9594573bb4dbe4cb68aa3af_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTMtMS0xLTQ5ODI4_04871afb-8720-4df8-bb6e-a1c3e4cec01c">285,622,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b293969cc040c983dd1f2e97563558_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTUtMS0xLTQ5ODI4_14f36ce6-4fa5-403d-b5f4-f54d57d9e01c">44,547,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c675487b97442eb5c6a91aff241fcf_I20211231" decimals="0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTctMS0xLTQ5ODI4_deaca99b-76d5-41d5-8dbb-7bcc908e5bc5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e0a92a960d49f88d849ddf682a08b5_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTEtMS0xLTQ5ODI4_fb11422d-55cc-4a82-aa87-1efc5e56ae44">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67083206a9594573bb4dbe4cb68aa3af_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTMtMS0xLTQ5ODI4_f630d869-33b8-423b-af1c-c3f56be37111">3,906,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b293969cc040c983dd1f2e97563558_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTUtMS0xLTQ5ODI4_2b60ac3b-fc67-4598-b8f5-6b5fcc67ce37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c675487b97442eb5c6a91aff241fcf_I20211231" decimals="0" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTctMS0xLTQ5ODI4_dce25bf6-65db-4779-9fcb-4a20360f2954">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28e0a92a960d49f88d849ddf682a08b5_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTEtMS0xLTQ5ODI4_d1621bc6-3b0f-4680-8f3e-4741c25a36ca">334,077,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67083206a9594573bb4dbe4cb68aa3af_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTMtMS0xLTQ5ODI4_0f784224-25f8-42e9-8c59-12a0fdbab0ed">289,529,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49b293969cc040c983dd1f2e97563558_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTUtMS0xLTQ5ODI4_601e463e-35d5-44d5-9b38-d8ca86be333c">44,547,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6c675487b97442eb5c6a91aff241fcf_I20211231" decimals="0" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTctMS0xLTQ5ODI4_0a342ae3-8f8b-4f8e-a67e-9ac43e948812">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in <ix:nonFraction unitRef="shares" contextRef="i3448daba76f24eb6a3f805c849575a5e_I20221231" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzI5NDA_ddec8c81-fd8e-4a90-8b0a-5969b0426a98">597,808</ix:nonFraction> common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3e8f7786171549f683637e7afa8597af" continuedAt="if99d45cedf01454db6c262e24452803b"><ix:continuation id="i3b4fc62102a64d66b55d67b311ee0fa0" continuedAt="ice886741d5a148d5b6bd664101e75d9a">service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.</ix:continuation></ix:continuation></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if99d45cedf01454db6c262e24452803b"><ix:continuation id="ice886741d5a148d5b6bd664101e75d9a">There were no Level 3 assets held as of December&#160;31, 2022 and 2021.</ix:continuation></ix:continuation> </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 6. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzUxMg_3ec8c714-319f-4407-b7e4-ba754ab99408" continuedAt="i58f7c96ce16c410d828bfd922e737656" escape="true">Certain Balance Sheet Items</ix:nonNumeric></span></div><ix:continuation id="i58f7c96ce16c410d828bfd922e737656" continuedAt="i564d47b26eb4465f9f44a950279b5148"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzUxMw_bbbb2c58-4f3f-4fdd-8459-2b4f10aa99b9" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMS0xLTEtNTEzMzM_0d0761a9-9a75-4290-b321-a04082b38b47">30,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMy0xLTEtNTEzMzM_8756008f-c684-44b9-bca3-3af127714348">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMS0xLTEtNDk4Mjg_99befb13-7ce0-4a76-b954-1dcaa83dc10d">1,401,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="ino:PrepaidManufacturingExpensesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMy0xLTEtNDk4Mjg_e10f2cd6-d32b-4b1a-b579-932e6943d3f1">27,474,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzItMS0xLTEtNDk4Mjg_8d8965c9-cd28-4ddd-9ade-da252f33fdee">18,729,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzItMy0xLTEtNDk4Mjg_364ce9db-1375-4f31-ade6-ba227ac96bf5">11,362,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzQtMS0xLTEtNDk4Mjg_4b8d90d8-9404-4405-aa03-3d525a3210dc">50,130,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzQtMy0xLTEtNDk4Mjg_c8220ed0-4d66-4dc9-a570-ae24498ae2c0">38,836,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzEwOTk1MTE2Mjk1OTY_9684544a-1aad-4bcd-b372-fd721b7aded7" continuedAt="i0111e50544ed462c96eb93ab123c9d4a" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzEtMS0xLTEtNTE0MjQ_2df9a530-2e02-4667-9047-b2628e5ed954">19,862,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzEtMy0xLTEtNTE0MjQ_ee5993ad-9215-4fe5-af5f-4291fc097f93">27,424,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzItMS0xLTEtNTE0MjQ_9c8fcb9d-fd5b-441c-85e3-a31294933152">12,574,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzItMy0xLTEtNTE0MjQ_a1091c49-b775-438d-b372-f5154cca8f9e">16,112,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzMtMS0xLTEtNTE0MjQ_9af89996-729d-4b3c-ac1c-42ac1c35b628">44,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:LitigationReserveCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzMtMy0xLTEtNTE0MjQ_636f6d0e-d8af-4562-ac8a-aa0d3ba387b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzQtMS0xLTEtNTE0MjQ_7b85e0a1-10eb-4d93-92f8-68b479b8204f">3,249,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzQtMy0xLTEtNTE0MjQ_2d37011b-7e0d-4ed8-864f-1faa6cdc391e">4,106,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzUtMS0xLTEtNTI1ODM_51bb133f-c98f-4a72-83e2-5c51aa01e9ab">79,686,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzUtMy0xLTEtNTI1ODM_85b05681-a604-41ac-9b3f-06128ff888c4">47,644,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i564d47b26eb4465f9f44a950279b5148" continuedAt="ie01cb784ea544302a06245e482dc534a"><ix:continuation id="i0111e50544ed462c96eb93ab123c9d4a" continuedAt="i0c6926bd950340788ab7e656f66934ef">(a)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.91pt"><ix:continuation id="ie01cb784ea544302a06245e482dc534a"><ix:continuation id="i0c6926bd950340788ab7e656f66934ef">In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221; The final judicial order for the settlement was issued in January 2023. The settlement consists of $<ix:nonFraction unitRef="usd" contextRef="i4d198f1f030e444294b8ea36f6116b09_I20220731" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzE2NDkyNjc0NDMzMjA_c51a94ff-957e-4b12-829d-7530b46f3aff">30.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="i4d198f1f030e444294b8ea36f6116b09_I20220731" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzE2NDkyNjc0NDMzNDk_e7ac27b7-b31e-4b13-91f8-20cee76ada60">14.0</ix:nonFraction>&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $<ix:nonFraction unitRef="usd" contextRef="i77a209b559d5422f82009bd955139f3d_D20220101-20221231" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzE2NDkyNjc0NDMzNzM_e59ab9a6-7e8d-4be8-8bcc-c0d5708eeb3f">252,000</ix:nonFraction> of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.</ix:continuation></ix:continuation> </span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="text-indent:-18pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_154"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzQ1NA_fc215da3-2eb3-4207-951d-cd625ed23a68" continuedAt="ic7827ace13694a9aaaa763d4ddd98841" escape="true">Fixed Assets</ix:nonNumeric></span></div><ix:continuation id="ic7827ace13694a9aaaa763d4ddd98841" continuedAt="i7a458b3a6ade4787aadb059f12006595"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzQ1OA_5fd19f0d-48ff-427e-85e4-66213dfaaeba" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzItMS0xLTEtNDk4Mjg_57bb9d37-cfe5-4f09-913a-7ae1d4800669">15,803,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzItMy0xLTEtNDk4Mjg_ccd77303-3e90-485b-9046-82dd86ac0c2b">10,036,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzItNS0xLTEtNDk4Mjg_814994c1-98c0-4c22-9260-604086c03010">5,767,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1117d2331b42a9a95485f3c02170c5_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzQtMS0xLTEtNDk4Mjg_6ceab958-6d39-4079-ab31-03bec93b7702">5,300,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b1117d2331b42a9a95485f3c02170c5_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzQtMy0xLTEtNDk4Mjg_99b98570-204e-441f-b58a-6cfca6e7242a">4,295,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b1117d2331b42a9a95485f3c02170c5_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzQtNS0xLTEtNDk4Mjg_daf7167e-f9b0-4fcc-8e29-bbc9364b7330">1,004,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzUtMS0xLTEtNDk4Mjg_0b55c98b-9790-46da-928f-ffbf3aa39040">2,827,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzUtMy0xLTEtNDk4Mjg_17330190-73e3-40dc-9b98-06ecade12227">2,803,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzUtNS0xLTEtNDk4Mjg_4da92ad8-a24a-468e-b73b-cd3c416f152c">23,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6b301ab495414cb544cfeec3509fd4_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzYtMS0xLTEtNDk4Mjg_7917b458-5b26-4d50-a76d-a7b2fc9076ea">5,360,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3b6b301ab495414cb544cfeec3509fd4_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzYtMy0xLTEtNDk4Mjg_299a03fd-bdc9-4050-b8f0-06a30be31388">4,428,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6b301ab495414cb544cfeec3509fd4_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzYtNS0xLTEtNDk4Mjg_eebe4cef-e7ac-477c-9097-ea31ea77484f">932,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzctMS0xLTEtNDk4Mjg_d2db9091-ff02-44c8-8b0a-990f05e3c0a8">29,291,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzctMy0xLTEtNDk4Mjg_17e429b4-060d-4ca1-ae74-a8dd19c5e7fa">21,563,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzctNS0xLTEtNDk4Mjg_bc740997-ad6d-44b8-ae17-a4db7d850f04">7,727,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482ffaf143e145b29a6c013341ec65b1_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzktMS0xLTEtNDk4Mjg_d9bc9686-2260-44e7-b918-ac93c827e133">15,803,108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i482ffaf143e145b29a6c013341ec65b1_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzktMy0xLTEtNDk4Mjg_9193785d-9f70-480a-b201-7d8cd6f3b5e3">8,258,608</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i482ffaf143e145b29a6c013341ec65b1_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzktNS0xLTEtNDk4Mjg_2bb60851-a286-4dd0-b94d-39698f4ba0c4">7,544,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a8f742a37148a19cfc04478fa8b852_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEwLTEtMS0xLTQ5ODI4_2572cadf-6883-4332-8a3c-205f9209bd22">12,392,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8a8f742a37148a19cfc04478fa8b852_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEwLTMtMS0xLTQ5ODI4_3debc3d7-e91b-4050-aee9-0cdce9a258aa">4,279,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a8f742a37148a19cfc04478fa8b852_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEwLTUtMS0xLTQ5ODI4_bc85f2fe-8bcd-4789-9863-40124ae6c8ac">8,113,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4852db4bcad84553977888af623d132e_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzExLTEtMS0xLTQ5ODI4_1452f280-eb59-4636-a611-e1d600184542">2,827,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4852db4bcad84553977888af623d132e_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzExLTMtMS0xLTQ5ODI4_8642db1f-4e5b-4e94-bdf3-96b502c838ad">2,599,643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4852db4bcad84553977888af623d132e_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzExLTUtMS0xLTQ5ODI4_1c497549-0172-45a0-b11b-c9cbcff552d3">227,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEyLTEtMS0xLTQ5ODI4_2a985bf1-0c8e-4473-b115-e428647208b3">5,374,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEyLTMtMS0xLTQ5ODI4_6aaae577-7101-4e44-9ce9-1c0c5a36c713">3,806,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEyLTUtMS0xLTQ5ODI4_2f649793-8165-487c-ab9c-b75d5dc8eb7e">1,567,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEzLTEtMS0xLTQ5ODI4_a87340bd-35a0-43b9-bb70-a16d4b4c7357">36,397,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEzLTMtMS0xLTQ5ODI4_09660ce1-d2df-4f16-a089-bd0b31246dc3">18,944,378</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEzLTUtMS0xLTQ5ODI4_4fec220e-34a5-4f5f-a53f-5a4a2ecde48d">17,453,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7a458b3a6ade4787aadb059f12006595">Depreciation expense for the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzE2NQ_2d596de7-9b98-4d21-94f8-6faffdf3bc86">3.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzE2OQ_491d5194-be95-477b-b7bc-d6613b66d4dd">3.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzE3Ng_de6e691a-829b-4180-a633-b99212781679">3.0</ix:nonFraction> million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" name="ino:PropertyPlantAndEquipmentDisposedOfBySale" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzU0OTc1NTgxNDc0OQ_5344a417-d2af-48e9-a850-49f298f549d6">6.1</ix:nonFraction>&#160;million and disposed of fixed assets with a net book value of $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentDisposals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzU0OTc1NTgxNTI0Ng_63a92eb3-5e2e-4a0b-94ca-c4058dd4d4e5">1.1</ix:nonFraction>&#160;million. The Company has recorded a receivable from the sale of these assets of $<ix:nonFraction unitRef="usd" contextRef="i373cde7a8abc406eb292a0ab2cbe85ec_I20221231" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzU0OTc1NTgxNTY5Nw_cf886cd8-a5e6-42cf-a53f-a130e2ec8ce0">6.1</ix:nonFraction>&#160;million, which is included in prepaid expenses and other current assets on the consolidated balance sheet.</ix:continuation></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5Xzc1MQ_11a460f4-e85f-4e08-a2b4-980c88840d3e" continuedAt="id85ee9b4996f4a0780679c79ee089d86" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="id85ee9b4996f4a0780679c79ee089d86"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5Xzc1Mw_fb3385c8-32b8-40f5-bc3c-b9d11e51f421" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.874%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtMy0xLTEtNDk4Mjg_4b80c062-7760-49fe-a77e-fc6d515b2d73">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtNy0xLTEtNDk4Mjg_b520636a-cf21-48c9-9b89-ecbf068c97c9">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:GoodwillGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtOS0xLTEtNDk4Mjg_d24a913a-6a11-4810-b317-beecf10ecd17">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtMTMtMS0xLTQ5ODI4_3256805b-a4df-4728-9979-c70d95ec8301">10,513,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7e0234d350c34dfeac832494bdf5206c_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMS0xLTEtNDk4Mjg_55b96ae1-9bf7-4ecd-a370-a783fe6f9cbb">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ea35c5c90b42d78cff73917a5896b8_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMy0xLTEtNDk4Mjg_c6d42cae-543f-41ae-8c85-5c94094dc802">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77ea35c5c90b42d78cff73917a5896b8_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtNS0xLTEtNDk4Mjg_7898cc07-09bb-48ec-baa5-62ac86212d2c">1,323,761</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ea35c5c90b42d78cff73917a5896b8_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtNy0xLTEtNDk4Mjg_cf4e751f-4127-4a55-a055-9114b8d4e9d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3891a2d892d444ab2b6d75d1e90d526_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtOS0xLTEtNDk4Mjg_2bc6640f-4352-436d-a37f-9a72f831b589">1,323,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3891a2d892d444ab2b6d75d1e90d526_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMTEtMS0xLTQ5ODI4_bb1b0758-089f-448b-82bc-0b7027a5a2ed">1,305,600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3891a2d892d444ab2b6d75d1e90d526_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMTMtMS0xLTQ5ODI4_f89e9f75-9584-43f4-a469-516c564374eb">18,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1443f3e411954434acd4f1bcdb1ca5a3_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMS0xLTEtNDk4Mjg_c2075cff-e692-4e7d-b642-0ee5bc082eb6">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ddab5935542b39c5b4ea28140cb13_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMy0xLTEtNDk4Mjg_b660eab2-e7f1-421d-bb60-3be74d4e6f72">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie89ddab5935542b39c5b4ea28140cb13_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktNS0xLTEtNDk4Mjg_f37da9eb-e2c9-407d-bee2-bcddf498cc99">2,988,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie89ddab5935542b39c5b4ea28140cb13_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktNy0xLTEtNDk4Mjg_d6154a40-8d8b-4ea1-955f-f63854f86f95">2,111,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e8db3eab40498a818ac04516b22b71_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktOS0xLTEtNDk4Mjg_77b1cc80-0990-48c7-a9c9-f095787f46a4">5,100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i24e8db3eab40498a818ac04516b22b71_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMTEtMS0xLTQ5ODI4_78b8f711-d434-41c9-b9ec-ca1267a4f476">2,735,556</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24e8db3eab40498a818ac04516b22b71_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMTMtMS0xLTQ5ODI4_2419fa10-fbbb-42b0-adf1-1c09fea2b5ad">2,364,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5e498a11c93d46d08d441fc1e554b563_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTEtMS0xLTQ5ODI4_351d6c33-1425-47aa-9e80-f676c81b9aea">18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedaf8cf0acdd46ffa0621f524655250d_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTMtMS0xLTQ5ODI4_ae04f5af-a629-4f10-ad57-d2ee4dc80a40">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iedaf8cf0acdd46ffa0621f524655250d_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTUtMS0xLTQ5ODI4_dc816905-3a7d-4bbe-8c59-d464e06f2485">4,031,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedaf8cf0acdd46ffa0621f524655250d_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTctMS0xLTQ5ODI4_234395ff-6f0e-4616-b3ee-00f7ff778888">18,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41ca5add1234f08a9091fcbd9f51b00_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTktMS0xLTQ5ODI4_95294b41-3b92-4d9d-a5fb-cb403582cffc">4,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib41ca5add1234f08a9091fcbd9f51b00_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTExLTEtMS00OTgyOA_f1ca5308-9578-4a53-82f1-03386e2b16de">3,806,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41ca5add1234f08a9091fcbd9f51b00_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTEzLTEtMS00OTgyOA_2a812863-9feb-400f-8c48-4eb1b2620499">243,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87ff63586a45468dad886c18594fa0da_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTEtMS0xLTQ5ODI4_020df3fe-b045-4601-b6b1-b468a67a9017">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTMtMS0xLTQ5ODI4_2c431c60-ee1d-4547-88d7-fc964d2693fa">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTUtMS0xLTQ5ODI4_50c12251-7ed1-48fd-bba7-596ec6e8cb93">8,343,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTctMS0xLTQ5ODI4_c2556b98-69f5-48cd-8460-ef8546bcc879">2,129,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTktMS0xLTQ5ODI4_1ac578d7-8042-4fd7-b5fb-3ea44021499a">10,473,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTExLTEtMS00OTgyOA_6bf7bd04-f292-4b3e-9edd-a89b6b7909e9">7,847,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTEzLTEtMS00OTgyOA_75cd0960-c32b-4122-a433-655f269981c6">2,626,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTMtMS0xLTQ5ODI4_3eaab947-95e9-4225-944e-bcbfb4450baf">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTUtMS0xLTQ5ODI4_7d8729d6-da7a-430c-9824-1757a59aa35b">8,343,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTctMS0xLTQ5ODI4_c13a4c9b-388d-451a-b462-b37672121f08">12,643,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="ino:GoodwillAndIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTktMS0xLTQ5ODI4_133ee9de-a513-49d5-8120-d2fd01fce3d5">20,987,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTExLTEtMS00OTgyOA_54facf22-01a1-4194-a159-47eab4a42b12">7,847,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="0" name="ino:GoodwillAndIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTEzLTEtMS00OTgyOA_1149465d-375a-4571-ae54-53e985c42144">13,139,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets was $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzQzMQ_d398f03c-1532-49bb-9fb0-d83352c4b243">496,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzQzNQ_943da8c9-e68d-4e8a-bc58-ea7ffa37e2a0">520,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzQ0Mg_40da039e-6ab2-4992-bab6-9c1ecd6f727e">547,000</ix:nonFraction> for the years ended December&#160;31, 2022, 2021 and 2020, respectively. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5Xzc0MQ_04152144-af79-49ab-8966-5f7135b5915f" continuedAt="i74c69f349aae4077809a3e45ea8e743b" escape="true">Amortization expense related to intangible assets at December&#160;31, 2022 is expected to be incurred as follows: </ix:nonNumeric></span></div><ix:continuation id="i74c69f349aae4077809a3e45ea8e743b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:86.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzEtMS0xLTEtNDk4Mjg_a0e6e44e-6772-46af-9c4a-37b925aee308">273,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzItMS0xLTEtNDk4Mjg_e1862e92-af04-42bf-89ca-51fbc3391fd7">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzMtMS0xLTEtNDk4Mjg_835cf008-4cee-41ff-8922-d374dc83caee">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzQtMS0xLTEtNDk4Mjg_eb2dee55-f953-42dd-a21d-7864b8b7f457">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzUtMS0xLTEtNDk4Mjg_1db66301-69dc-40aa-a36d-4b131bd044f5">253,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzYtMS0xLTEtNDk4Mjg_77f8f7dc-d60d-47c2-8528-3f95ad874303">845,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzctMS0xLTEtNDk4Mjg_68f90ebc-003d-4dfe-8a04-5627652f7025">2,130,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzYwNg_6b6eaddc-4272-4da6-8d56-d9ef9bb1f2c8"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzYwNg_94276916-9ac0-4012-9bef-a92b3ee91776"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzYwNg_eaec98fd-b54e-4f5a-8b50-84b8118d1389">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment or impairment indicators present and <ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzY1Nw_2870a618-8d3c-44db-8f69-f2cf270b0daa"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzY1Nw_5523e799-c240-491b-9998-2bc0f4b5ada7"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzY1Nw_f23b7292-4a54-40d7-b07e-7650d30b624b">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> losses were recorded during the years ended December&#160;31, 2022, 2021 and 2020.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_160"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNjkx_5a5e4123-8cf3-4e55-b0f8-229de0fade06" continuedAt="i1270ed223d3c497fa85b4bd3129a8af7" escape="true">Convertible Debt</ix:nonNumeric></span></div><ix:continuation id="i1270ed223d3c497fa85b4bd3129a8af7" continuedAt="i786a4caa24174c73b81160424ca20297"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $<ix:nonFraction unitRef="usd" contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEzNg_5d90e705-59bf-4978-956e-53c8f30ffecb">78.5</ix:nonFraction> million aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE3Mw_beb7dace-d3aa-477c-83b1-a3759d3935da">6.50</ix:nonFraction>% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i786a4caa24174c73b81160424ca20297" continuedAt="i642cc691582e47f58eb5954f3722d118"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i7bbe89ce4a474b04b398872bd94f43bc_D20190219-20190228" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQwNQ_f67394e8-1de1-4527-971f-2e267286b31e">75.7</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of <ix:nonFraction unitRef="number" contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzYxNA_59b9b10d-286c-4aa7-b3e0-b8233f622c99">6.50</ix:nonFraction>% per annum. The Notes mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE0MTI_9e70e447-eeeb-4194-98e6-5d2ae7e96c39">5.38</ix:nonFraction> per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds <ix:nonFraction unitRef="number" contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2MzY_78886632-3b01-43fb-83f7-17538c008885">130</ix:nonFraction>% of the conversion price on (i) each of at least <ix:nonFraction unitRef="day" contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2ODc_2a6d3f15-b8e3-4c32-80be-a976613c0e42">20</ix:nonFraction> trading days (whether or not consecutive) during the <ix:nonFraction unitRef="day" contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE3NDM_895bbd86-257b-4d64-950f-fcd77a265e4a">30</ix:nonFraction> consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to <ix:nonFraction unitRef="number" contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzIwMTQ_a87a7b0d-b9cf-4817-a911-f86235d9e927">100</ix:nonFraction>% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $<ix:nonFraction unitRef="usd" contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301" decimals="-5" name="us-gaap:DebtInstrumentUnamortizedDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg3ODM_445ee423-b85c-48f4-ac60-9365b58ebedc">16.3</ix:nonFraction>&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of <ix:nonFraction unitRef="number" contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4MDQ_e0388afe-2cd6-43b5-b552-ffd96f3d42f0">13.1</ix:nonFraction>%. In addition, the Company allocated $<ix:nonFraction unitRef="usd" contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4MjA_7a07a606-3b09-488d-9891-c649d323e615">592,000</ix:nonFraction> of debt issuance costs to the equity component and the remaining debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i1242ebcd358e4468bb5a2b7b601e0e98_I20221231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4NDM_4ff6907d-43f2-4769-81c1-b38d66431a3a">2.2</ix:nonFraction>&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4NzA_c6ba9928-d938-4655-8a79-5050f1ff2556">1.8</ix:nonFraction>&#160;million, a decrease to additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101" decimals="-5" sign="-" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4OTc_4019ff5b-348e-4b33-81c7-dc86da5c7d2e">3.3</ix:nonFraction>&#160;million, and an increase to convertible senior notes of $<ix:nonFraction unitRef="usd" contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101" decimals="-5" name="us-gaap:ConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg5MjQ_0d67149f-2b00-409b-9a97-1caa54e7801e">1.5</ix:nonFraction>&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNjky_5a82b38a-bb40-4d26-bd7f-59fd0f88a258" escape="true"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231" decimals="0" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzAtMS0xLTEtNDk4Mjg_dc858921-cca6-48ed-8957-fb0e2ae6bca3">78,500,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231" decimals="0" name="ino:DebtInstrumentConvertibleDebtConvertedAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzEtMS0xLTEtNDk4Mjg_cff7e2a9-1d86-4370-8bbc-313878af6483">62,085,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231" decimals="0" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzMtMS0xLTEtNDk4Mjg_51f8bc39-9d48-4718-b0f1-6018f95c13c9">155,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231" decimals="0" name="ino:DebtinstrumentAccruedInterest" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzQtMS0xLTEtNDk4Mjg_ae978f0c-7f7b-4515-8377-213ffc6a5d5a">355,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzUtMS0xLTEtNDk4Mjg_61ce4271-e1d1-40d3-aa87-598e8f5f1ffa">16,614,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i063303991a5041809d8211c86ef7e0d7_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ2NTY_7de89442-577b-4685-a22b-35693960df1b">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i316205765748470e9cebde8ab78a5ae1_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ2NjM_5cc593be-0bf1-4dd7-8a9b-57c31fe76a9e">1.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1b8ef7a9972a45d68c3268ee6c9acbc2_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NjYxMDI_c25f3ec8-666d-4af6-913b-cec6dadabba0">6.9</ix:nonFraction>&#160;million, respectively, of interest expense related to the Notes, of which $<ix:nonFraction unitRef="usd" contextRef="i063303991a5041809d8211c86ef7e0d7_D20220101-20221231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ3MzI_04672d7b-1922-4e10-814e-3aa51c7aca22">1.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i316205765748470e9cebde8ab78a5ae1_D20210101-20211231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ3Mzk_674fe883-464c-42a2-a3b0-d89117806093">1.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1b8ef7a9972a45d68c3268ee6c9acbc2_D20200101-20201231" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NjYxMTY_54360d7d-4af7-4f53-8acf-8378e186fa49">4.1</ix:nonFraction>&#160;million, respectively, related to the contractual interest coupon. </span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNjg5_e84e5910-04e3-4c0c-8309-6be2cfa0e397" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of <ix:nonFraction unitRef="number" contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ5NDE_5c09b974-9135-41ac-a2f0-e7bea9d1864a">6.5</ix:nonFraction>% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:85.869%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.346%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTpkZDFjYzg4NTZkYTc0Zjc1ODg0ZjE4MTI3YWQxMGQwNC90YWJsZXJhbmdlOmRkMWNjODg1NmRhNzRmNzU4ODRmMTgxMjdhZDEwZDA0XzQtMi0xLTEtNDk4Mjg_4dc4a109-c269-476f-9c15-2c4b156ba6b3">1,067,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231" decimals="0" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTpkZDFjYzg4NTZkYTc0Zjc1ODg0ZjE4MTI3YWQxMGQwNC90YWJsZXJhbmdlOmRkMWNjODg1NmRhNzRmNzU4ODRmMTgxMjdhZDEwZDA0XzUtMi0xLTEtNDk4Mjg_0d0b1951-db8f-4e2e-a966-e46e4cf71e19">16,948,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231" decimals="0" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTpkZDFjYzg4NTZkYTc0Zjc1ODg0ZjE4MTI3YWQxMGQwNC90YWJsZXJhbmdlOmRkMWNjODg1NmRhNzRmNzU4ODRmMTgxMjdhZDEwZDA0XzctMi0xLTEtNDk4Mjg_505864ce-f8dd-4523-be8d-2a3b5ba2e6ce">18,015,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i642cc691582e47f58eb5954f3722d118" continuedAt="i39cf049d8c5248f69a0705aa74533f57"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of <ix:nonFraction unitRef="krw" contextRef="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk0MDk_a3d52b58-0c9b-435c-b296-3b5f05fc2533">4.7</ix:nonFraction> billion KRW (USD $<ix:nonFraction unitRef="usd" contextRef="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk0MzU_7dae63a7-35d3-45d6-a1bd-44d103c254d6">4.1</ix:nonFraction> million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $<ix:nonFraction unitRef="usd" contextRef="i189926960d2b4b1c89848491c1ce2245_D20191226-20191226" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk1NzQ_7c1fa1b1-5c76-4d44-ad53-1f2f94258123">4.0</ix:nonFraction> million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrue interest at a coupon rate of <ix:nonFraction unitRef="number" contextRef="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk3MjU_4d44778b-d4d1-4c48-9dc3-d4b774fb4a80">1.00</ix:nonFraction>% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i11da8ee96782442db68b426be9a9c645_D20210317-20210317" decimals="INF" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk5NTc_08eecca6-aea5-4413-90f4-6aad497a226c">1,009,450</ix:nonFraction> shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the $<ix:nonFraction unitRef="usd" contextRef="i11da8ee96782442db68b426be9a9c645_D20210317-20210317" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NjU0NTc_a5817880-d1ba-4e3e-9b9a-057eef837685">4.4</ix:nonFraction>&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.</span></div></ix:continuation><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i39cf049d8c5248f69a0705aa74533f57">During the year ended December 31, 2021,&#160;the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i7044f94f6dec495687d4bb1d5e39219b_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyMzE1_67c26474-a3fc-4e23-bacf-5a4ceb228796">50,000</ix:nonFraction> of interest expense related to the December 2019 Bonds, of which $<ix:nonFraction unitRef="usd" contextRef="i7044f94f6dec495687d4bb1d5e39219b_D20220101-20221231" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNDA1_0f571def-af44-4e4e-98d1-38c11bb474a1">9,000</ix:nonFraction> related to the contractual interest coupon. The effective interest rate of the December 2019 Bonds was <ix:nonFraction unitRef="number" contextRef="i5f47b0a510ab4c979a96d6c6c04992e4_I20211231" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEwOTk1MTE2NTIyNDM_600427d2-23e6-4a23-9013-6506095bcbfd">6.2</ix:nonFraction>%.</ix:continuation> </span></div><div><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_169"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMzQ_5c572dc2-6e7e-4d80-9f7e-f8114494260e" continuedAt="ib5613f5df8fb464c9585901d089b2a51" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><div style="margin-top:3pt"><span><br/></span></div><ix:continuation id="ib5613f5df8fb464c9585901d089b2a51" continuedAt="i1bd914cf796246edbd6e99650e5a1805"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMzI_ba01d555-94f9-4586-8ecf-c2a1cf7d7663" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:47.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $<ix:nonFraction unitRef="usdPerShare" contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjplNmNiN2UwMmM5ZTY0MjRiOGMyMWZhZmQwZTExZmYxNV8zNA_906f3e9e-254e-49cb-94ae-681f6cabd7ae">0.001</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtMS0xLTEtNDk4Mjg_914a58bc-ba99-4d0e-a394-98febfe6d71a">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtMy0xLTEtNDk4Mjg_2b9a1b3f-86f3-4834-973e-292dcaed362e">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtNS0xLTEtNDk4Mjg_afb59a50-ad20-42e0-98ca-a6349f086b52">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i665787c5dd50498ba18daa109d1fa1ce_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtNy0xLTEtNDk4Mjg_bcfc9fc5-042f-4254-8529-b64b701c8fbe">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $<ix:nonFraction unitRef="usdPerShare" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="2" name="ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ5OA_ec585d93-cc8c-4532-854f-6e05a0f0883a">27.20</ix:nonFraction> per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of <ix:nonFraction unitRef="shares" contextRef="i665787c5dd50498ba18daa109d1fa1ce_I20211231" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYxMQ_40b9d309-a96b-421d-9a5d-c58f496c239f">3,309</ix:nonFraction> shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i36e51ec971e349c587d471174bf94e10_D20211109-20211109" decimals="INF" name="ino:StockSalesAgreementMaximumAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMg_b6332542-0159-49a8-88f0-2f0e89ee59f1">300.0</ix:nonFraction>&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to <ix:nonFraction unitRef="number" contextRef="i36e51ec971e349c587d471174bf94e10_D20211109-20211109" decimals="INF" name="ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEwMzM_1d585038-1230-4e21-bf36-d2da4bafb147">3.0</ix:nonFraction>% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December&#160;31, 2022 and 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEyMDE_4ae7fe84-e23e-433d-b7e2-f10b7fe77375">34,445,743</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231" decimals="INF" name="ino:StockSaleAgreementAggregateNumberofSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwNDczMTM5Njk5NjA_c481009b-2fa0-42bb-a99a-fd2703cdd91d">6,955,341</ix:nonFraction> shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEzMTQ_71cb4144-6cb2-465e-8c9c-15cd6c1d4c7b">2.44</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231" decimals="2" name="ino:StockSaleAgreementWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwNDczMTM5Njk5NzE_cdde8d2f-56db-457a-8962-227352793857">6.96</ix:nonFraction> per share, respectively, resulting in aggregate net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEzNjc_8825c93c-9009-4a0a-af59-97710ce4cd5a">83.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231" decimals="-5" name="ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwNDczMTM5Njk5Nzg_c0c717e3-cd01-49bf-8daf-69280b33986d">47.7</ix:nonFraction>&#160;million, respectively. As of December&#160;31, 2022 there was $<ix:nonFraction unitRef="usd" contextRef="i2fca5b2439d74d788e0d439a6f383003_I20221231" decimals="-5" name="ino:StockSalesAgreementRemainingAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE0MDU_c25ae84d-0e59-4c7c-b9b3-d4f3d3e6f134">167.4</ix:nonFraction>&#160;million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of <ix:nonFraction unitRef="shares" contextRef="i3109c39c7dfe480a826f059e43510271_D20210125-20210125" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE1Mzc_e6cf88d3-df9c-4ed7-9ff8-963515ffa29c">20,355,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i256486c034e74959bea28a09407f168f_I20210125" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE1OTM_5f7e54d0-b9b9-4611-aaa2-0b7926b8273b">8.50</ix:nonFraction> per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="i3109c39c7dfe480a826f059e43510271_D20210125-20210125" decimals="-5" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE3MzQ_034594bf-6351-4583-9072-48770669a2fd">162.1</ix:nonFraction>&#160;million. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December&#160;31, 2022, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was <ix:nonFraction unitRef="shares" contextRef="i95c79bb8b10c435bb78e5dfe4b84d8d3_I20160513" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQwODE_00de8ced-6dbc-4002-8ffe-a123e95fbace">22,000,000</ix:nonFraction> shares. On the first business day of each calendar year, the maximum number of shares is increased by&#160;<ix:nonFraction unitRef="shares" contextRef="i95c79bb8b10c435bb78e5dfe4b84d8d3_I20160513" decimals="INF" name="ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQxOTM_013442ee-b21b-47a7-a7b6-52b47c34c417">2,000,000</ix:nonFraction> shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by <ix:nonFraction unitRef="shares" contextRef="i333db47ca7594db8809bb340e9af167b_I20220101" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ0Nzc_174360b8-3a27-4515-b547-5a24300bb7af">2,000,000</ix:nonFraction>. At December&#160;31, 2022, the Company had <ix:nonFraction unitRef="shares" contextRef="ieaecf1d1bad04443b82d7b4be5e89ad5_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ1MDQ_367ffc3f-8c40-472c-8833-7e19a8e7b12a">3,831,240</ix:nonFraction> shares of common stock available for future grant under the 2016 Incentive Plan, <ix:nonFraction unitRef="shares" contextRef="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231" decimals="INF" name="ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ1ODg_cabb89b8-ae9a-4808-a3c0-d8e918e5226d">2,446,257</ix:nonFraction> shares underlying outstanding but unvested service-based RSUs, options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="ieaecf1d1bad04443b82d7b4be5e89ad5_I20221231" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ2OTM_1fa14d6f-60b7-4bce-b234-7307bc5f9e14">10,132,969</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i4bb1b79238d54150bdfc9c781bd5fc1b_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU0OTc1NTgyOTY4MA_aa9cc838-abca-4fa8-8b53-5ac09101a7a6">111,941</ix:nonFraction> shares of performance-based RSUs outstanding under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1bd914cf796246edbd6e99650e5a1805" continuedAt="i5c247b70d497456c9c5529c5ed1379de"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan generally vest over <ix:nonNumeric contextRef="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ4NTA_60d9257a-a42e-4f14-a4c5-483dcf465f46">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ4OTI_e5ce08b3-5af5-4943-be3b-559b5becf050">ten years</ix:nonNumeric>. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed <ix:nonFraction unitRef="shares" contextRef="i36807b22af264de2a3e9c80926cea5b8_I20220624" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQwOTI_67ab54c4-85a3-4516-a794-41677018f2de">2,000,000</ix:nonFraction> shares. At December&#160;31, 2022 the Company had <ix:nonFraction unitRef="shares" contextRef="i6a0cabe1550b4ee2905d7e3e21009431_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQxNTg_74c414fb-ef0d-45e5-84f8-406a07c0fc26">1,703,750</ix:nonFraction> shares of common stock available for future grant under the 2022 Inducement Plan, <ix:nonFraction unitRef="shares" contextRef="i6a0cabe1550b4ee2905d7e3e21009431_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQxNzc_8d14c756-c697-426b-829c-a3d4e354c131">110,000</ix:nonFraction> shares underlying outstanding but unvested RSUs and options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="i6a0cabe1550b4ee2905d7e3e21009431_I20221231" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQxOTQ_d9d96cff-9b6a-41d6-a98a-eb4fe4429445">186,250</ix:nonFraction> shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2022, the Company had options outstanding to purchase <ix:nonFraction unitRef="shares" contextRef="iae9a3aca7b5e4544b7ec63dc9e3b7fdf_I20221231" decimals="INF" name="us-gaap:CommonStockOtherSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzUxNzU_d8be44cd-b38c-4301-a3dd-9b5f3bdd74ab">1,902,329</ix:nonFraction> shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over <ix:nonNumeric contextRef="i10ba30993b07407997027cb283263b45_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzUzMDE_4addf0c5-7c8c-4ca6-b5c2-076b6152d431">three years</ix:nonNumeric> and have a maximum contractual term of <ix:nonNumeric contextRef="i10ba30993b07407997027cb283263b45_D20220101-20221231" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzUzNDM_a83ea593-24ba-4be9-b719-bff16e9f6901">ten years</ix:nonNumeric>. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1MTY_e50732e0-7d9e-4aa2-8428-d2cef3200b5c">22.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1MjA_fbf74ab1-7604-414d-a9ed-3b92d17c5ed0">25.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1Mjc_5473398a-9b7e-4c19-b2db-653022a68eba">14.5</ix:nonFraction> million, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="idf2749e9d9094ef991e679e1b9cc83fe_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1NTQ_3a45dd48-e68e-4a13-ac19-816dbc0952f7">8.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i0768a9275ad64e93b52e47eba8d93b74_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1NTg_6706aaa8-d84a-4d28-8970-6a1428baaaff">13.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1455c9a790944d63a8c0009471f82bcb_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1NjU_263992d0-d3c0-4432-8999-0182fa7ff29a">8.0</ix:nonFraction> million was included in research and development expenses and $<ix:nonFraction unitRef="usd" contextRef="i5b4f24c6cfc0434db99f876f8856c535_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU2MzA_38f64348-938c-4bf3-befa-e3cb6c6f9f98">13.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i107f49b9f6cb4502ac08563229ac6d5f_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU2MzQ_f84b6036-5c15-45c8-b274-9bc108a9666f">11.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide5ec322e22c4863b4ec3beac0c62440_D20200101-20201231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU2NDE_7049d88a-0cc0-4bd6-8d41-18bb0dc14dea">6.5</ix:nonFraction> million was included in general and administrative expenses, respectively. The Company entered into a Separation Agreement with its former President and Chief Executive Officer on May 10, 2022, under which outstanding RSUs as of the separation date were fully vested, and one-half of the RSUs were settled in the Company's common stock and the remainder settled in cash. The officer's stock options will continue to vest over a certain period and will remain exercisable until <ix:nonNumeric contextRef="i4f6468c1ea34497783cc0f8b7387f0fb_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU0OTc1NTgzMDIyNQ_d55f7ad0-2501-4610-bc08-56d8ef75a1be">five years</ix:nonNumeric> after the separation date. Stock-based compensation for the year ended December 31, 2022 included a $<ix:nonFraction unitRef="usd" contextRef="i4f6468c1ea34497783cc0f8b7387f0fb_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU0OTc1NTgzMDMzNw_610fab21-9e06-4aeb-9232-871364e4e500">4.2</ix:nonFraction>&#160;million charge related to these RSU and stock option modifications.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, there was $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU3NDg_fbdbd1f7-0983-4e37-9f3a-a0e1525a8ceb">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU3NjM_94461588-c4cc-4b24-b7b1-e287e21a4c46">16.5</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU5Mjg_c6d77726-4e41-46fd-be77-e9a0a447dbe3">1.6</ix:nonNumeric> years and <ix:nonNumeric contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU5NDE_dc758dbf-93d7-4ea8-a112-6b426f17c7cc">2.0</ix:nonNumeric> years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, there was $<ix:nonFraction unitRef="usd" contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU5OTY_8ee876e6-0650-4980-a4e6-c421a829761b">7.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2ce9a943aa164c8c8f02796513f3578c_I20211231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwMTE_4e5630ac-b835-4184-ad06-dcd63007e74b">13.4</ix:nonFraction> million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYxODU_83cd5488-6526-45b5-9b35-457db004d0c7">1.7</ix:nonNumeric> years and <ix:nonNumeric contextRef="i10ced5af10f440b0bebf5936fd97f874_D20210101-20211231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYxOTg_9959580e-4000-463e-9586-07c6cae9f38b">1.8</ix:nonNumeric> years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="ibcb4a7e1962b43df901c999bf8eb65ec_D20220101-20221231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY0OTQ_65b18c74-8b67-4147-bcb6-665a88181f2c">1.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ieb960975b9964654908d00a526851994_D20210101-20211231" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY0OTg_f9ed27b7-edbf-4e34-acea-cd65b052f13f">1.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i432ab502425b494c81d8825eac83ad96_D20200101-20201231" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY1MDU_8734b66c-e58f-429a-ba10-5c664f1a46a4">1.2</ix:nonFraction> million, respectively. As of December&#160;31, 2022, options to purchase <ix:nonFraction unitRef="shares" contextRef="i87e0aa1271764f94a354dfcb830960c2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY1NjY_bc069e49-88c1-4e60-9042-4feef70e5515">665,875</ix:nonFraction> shares of common stock granted to non-employees remained outstanding.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxNTQ_af1e3817-46eb-495b-9869-01c30215d6fe" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:26.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpkNzY5YjNhMTczNzM0ZmFlYTZkMDk1ODYyM2FhZjA1NF80_cbab3fa3-7e59-4ff2-9706-ff16f4eee891">1.56</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpkNzY5YjNhMTczNzM0ZmFlYTZkMDk1ODYyM2FhZjA1NF83_937095eb-b718-4f6b-9a07-b09009a8d9bd">3.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMi0xLTEtNDk4Mjg_990164e4-6ebb-4d4b-b188-c3c922967f4d">830,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItNC0xLTEtNDk4Mjg_a2504b37-9920-4444-84ee-b51bdb044e64">8.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItNi0xLTEtNDk4Mjg_2abd9e40-38e3-4cc8-a122-a0ca1f054feb">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItOC0xLTEtNDk4Mjg_a666d6be-75f1-4adf-a1ea-aabe63818396">247,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMTAtMS0xLTQ5ODI4_2e3148fa-118e-4c87-b346-f4e4b56db7ec">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo3NjdmNGI5YzJkYWY0Nzk1OWNhMThjZTVkMTZlY2Q1Ml80_2a4433cc-f0d3-4e0a-aca7-b2cc652fd2fb">3.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo3NjdmNGI5YzJkYWY0Nzk1OWNhMThjZTVkMTZlY2Q1Ml83_19749d15-3122-43be-98ea-ec3fca32e537">6.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMi0xLTEtNDk4Mjg_e3d56264-fa5d-4ed8-be1a-1d419a695142">5,461,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtNC0xLTEtNDk4Mjg_09b7415e-d9b6-4798-afc3-5550e062c26b">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtNi0xLTEtNDk4Mjg_48d59019-5c08-4624-9109-0c7597e3af08">3.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtOC0xLTEtNDk4Mjg_1e24c0e9-b0a4-45d9-9e50-2bd64d32a89f">3,059,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMTAtMS0xLTQ5ODI4_b2e0fe95-7d8d-42da-ac87-254067a708b7">3.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo2NjFjOGEzMTI3NDQ0ZGYxOTQ2NDhiYjg4ZjgzM2E3MF80_cb5f5885-00ca-41a2-91ae-af587e3258c0">6.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo2NjFjOGEzMTI3NDQ0ZGYxOTQ2NDhiYjg4ZjgzM2E3MF83_152f7280-d87b-4c3a-b409-51ecbe7f3dcc">9.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMi0xLTEtNDk4Mjg_6db86a4d-0ff5-4193-bc28-f00d04623e6d">3,349,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtNC0xLTEtNDk4Mjg_7b6c8908-a6ba-433f-a9d5-3678626fc66f">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtNi0xLTEtNDk4Mjg_43c3c8f2-2c70-43f5-af59-9d665432f8a6">7.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtOC0xLTEtNDk4Mjg_dbdbca7a-941b-40fa-b998-9c381ed2d2b4">2,861,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMTAtMS0xLTQ5ODI4_d34de8aa-9500-4bd3-b8e8-0a11d7412d0e">7.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmZWI4YWMxZWFiYTc0M2JmODYzMGE5YjVjZTY0ZDMwZF80_f00ed651-7bdc-479c-b828-ea378833e89b">9.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmZWI4YWMxZWFiYTc0M2JmODYzMGE5YjVjZTY0ZDMwZF83_1663eaa1-cc8c-48a5-8ff6-4cfda8f9c07d">12.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMi0xLTEtNDk4Mjg_1e2fec3e-0fb8-4612-a1f3-5aa18bf0dbb7">1,930,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtNC0xLTEtNDk4Mjg_5af54aad-de83-4cb8-abb9-d0aacd4af1ea">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtNi0xLTEtNDk4Mjg_a4259a2d-4e37-4957-944c-b303a35316d7">10.97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtOC0xLTEtNDk4Mjg_9d5921ee-9370-43e3-99b2-a008b4da402f">1,080,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMTAtMS0xLTQ5ODI4_a11e6de2-a294-4daa-a45d-ad37be690331">10.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjozM2ViOGUxNmU2Mzg0MzAxYWI2Y2VlZDEyMGM3Y2IwNV80_9fa41c40-05b7-454d-a043-2620320cacfc">12.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjozM2ViOGUxNmU2Mzg0MzAxYWI2Y2VlZDEyMGM3Y2IwNV83_bdb7770b-ab46-472a-9c82-00d92835ca03">15.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMi0xLTEtNDk4Mjg_1878f5bc-f82c-46ea-a227-6c23173748e4">580,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtNC0xLTEtNDk4Mjg_769e0796-282d-4f75-983b-d58539fa4197">4.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtNi0xLTEtNDk4Mjg_6d4b0ac5-43d8-495d-b66b-3ea1cc7c260f">13.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtOC0xLTEtNDk4Mjg_efc2ffc0-49ea-409f-b366-5a49c0154462">529,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMTAtMS0xLTQ5ODI4_faaa21e5-95fc-41d5-9894-6c69ea7ec655">13.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjphMWMzNmQ5YWIzMmY0YjZkYmY0ZDk0MTYwN2I3NjM2Y180_1d09771b-3787-46e2-b42f-ff30cabb5b28">15.01</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjphMWMzNmQ5YWIzMmY0YjZkYmY0ZDk0MTYwN2I3NjM2Y183_102e2241-a764-44d8-b50a-003acbf99f75">25.62</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMi0xLTEtNDk4Mjg_4e8ff5ad-c467-4e5f-9a8c-52a90f7a76b3">68,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctNC0xLTEtNDk4Mjg_1400e8a4-50b9-4620-a20c-54075776759b">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctNi0xLTEtNDk4Mjg_3b4a183a-c374-4acd-94b1-43624e703f29">21.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctOC0xLTEtNDk4Mjg_b9d873f6-e0a9-498a-a6a3-d50b3da7f547">51,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMTAtMS0xLTQ5ODI4_72d0d982-b479-43c8-a633-df6ebb294ea2">21.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtMi0xLTEtNDk4Mjg_877dfb9c-fe3d-4a96-bd3c-b259d9ceb2c6">12,221,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtNC0xLTEtNDk4Mjg_681036f4-b309-41a4-9256-54c3aa38a1ae">6.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtNi0xLTEtNDk4Mjg_9b3722e4-f50c-4774-9d0e-5cf12ed42803">6.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtOC0xLTEtNDk4Mjg_cfcb87ff-b83e-4da9-8455-193502f1fedb">7,829,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtMTAtMS0xLTQ5ODI4_436e39ad-d909-4585-a73f-66d96ac858d6">6.79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the aggregate intrinsic value of options outstanding was $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY4MDQ_6f604086-4f25-4285-95db-f096055b46e9">0</ix:nonFraction>, the aggregate intrinsic value of options exercisable was $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY4NjU_818a72fb-5a2d-40a9-8de2-0d49238aad2c">0</ix:nonFraction>, and the weighted average remaining contractual term of options exercisable was <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY5NDg_02d4b09e-03e4-497b-b174-6c03ff8cf714">5.7</ix:nonNumeric> years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the aggregate intrinsic value of unvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcwNDc_81d6e8ef-4738-4a47-a81f-eece43c873a1">4.0</ix:nonFraction> million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcxNjU_6d045c75-e116-4070-9793-fdf5122e6cb2">4.6</ix:nonFraction> million.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5c247b70d497456c9c5529c5ed1379de"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, options to purchase <ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcyMTc_a2564ebd-c871-4002-bd94-e282a0fbff57">12,221,548</ix:nonFraction> shares of common stock and <ix:nonFraction unitRef="shares" contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231" decimals="INF" name="ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcyNDc_81981505-df6d-452c-b379-ac3f25d77483">2,556,257</ix:nonFraction> RSUs were expected to vest.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMzg_1465f8f2-7de6-47cc-a541-9ca5e12e0572" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2022 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:70.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzktMS0xLTEtNDk4Mjg_57301473-ac1c-4bf9-82d9-7f7547e4f862">10,488,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzktMy0xLTEtNDk4Mjg_14eeffdf-be55-446d-bfc9-8ecc31c7652e">7.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEwLTEtMS0xLTQ5ODI4_f865f185-6348-4c11-b1d1-92e51216a7ae">4,623,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEwLTMtMS0xLTQ5ODI4_68b0924c-67f0-4086-9696-9c88455f0946">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzExLTEtMS0xLTQ5ODI4_2df2d03c-6d5c-4847-a82d-2390d26c82d4">118,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzExLTMtMS0xLTQ5ODI4_877582cf-d033-4d8c-8b31-d7baa6d99f4b">2.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEyLTEtMS0xLTQ5ODI4_5d930982-bf4e-4da3-bd8b-8b3062b25d2c">2,772,199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEyLTMtMS0xLTQ5ODI4_b79dc2c6-6639-4e05-85a4-336b5f5526a4">7.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEzLTEtMS0xLTQ5ODI4_9517acdc-fb97-4878-b62c-2a3f23919834">12,221,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEzLTMtMS0xLTQ5ODI4_dd60a67e-6a2f-4fc8-8397-3e9478f0a2c9">6.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxNDQ_87c06c14-d17f-4774-8f96-ac6236c00014" escape="true"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2022 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2ce9a943aa164c8c8f02796513f3578c_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzktMS0xLTEtNDk4Mjg_7b41dc18-015e-4a86-ae8b-2a7c8b35353b">2,448,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzEwLTEtMS0xLTQ5ODI4_6be178ac-ae5b-4e4d-9d05-1ba4f81d1970">2,485,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzExLTEtMS0xLTQ5ODI4_42389e54-ad9a-4b37-baa1-9cb719cf70ee">1,618,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzEyLTEtMS0xLTQ5ODI4_0a51546c-ab78-44b5-9a06-74cb31b4e215">760,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzEzLTEtMS0xLTQ5ODI4_e28edb07-1049-409c-b244-67f0c9d9a3f5">2,556,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc1NzQ_192dde16-950e-4bdf-aee4-7aca15864ca3">8.47</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc1ODU_e4b1ad14-1286-43c9-b502-9adc671b0b11">77,250</ix:nonFraction> options which expired during the year ended December&#160;31, 2022, $<ix:nonFraction unitRef="usdPerShare" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc2NDk_39857aa9-0191-4f6f-848c-351355a76e52">4.56</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc2NjA_f72a8655-2364-4b83-a6a3-2ffc399f4595">7,000</ix:nonFraction> options which expired during the year ended December&#160;31, 2021 and $<ix:nonFraction unitRef="usdPerShare" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc3Mjc_67f9d65c-5d15-44e3-998d-2d6f05259b9e">4.44</ix:nonFraction> for the <ix:nonFraction unitRef="shares" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc3Mzg_37f4368a-560e-4353-8fd2-6195262572de">78,750</ix:nonFraction> options which expired during the year ended December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $<ix:nonFraction unitRef="usdPerShare" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc4NTk_fdc5719c-e33c-49ba-9e62-2774f94fa818">2.34</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc4NjM_2cbdab14-e5be-4592-ad6b-f4a90419b90d">7.61</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc4NzA_7b280af8-46c3-43b6-968f-6c6e1079ced8">6.87</ix:nonFraction> for options granted during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $<ix:nonFraction unitRef="usdPerShare" contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgwMDU_b919fd61-f09c-4076-a2ee-a92943ff0e59">3.12</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i10ced5af10f440b0bebf5936fd97f874_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgwMDk_bc2ab615-6397-42ae-a5f8-0228100d15c4">10.37</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ia0bfc9c5f8ce490dac127867d5e5bd45_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgwMTY_e5376d28-f768-480e-8376-ea9312dba609">9.12</ix:nonFraction> per share for RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgxNTE_66b08f30-7085-41fa-a224-0218a298bfab">283,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgxNTU_d3716a0a-3e25-4fb8-b5ee-3ed012c2e440">6.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgxNjI_f73e3c0c-6ab0-4e39-b2d6-64a0db2ca0f0">12.3</ix:nonFraction> million in proceeds from the exercise of stock options during the years ended December&#160;31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgzMzI_bfeafa3b-95ac-462d-9258-5aef779252b7">81,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgzMzY_7d659431-32c3-410d-a759-92ca91737a87">7.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgzNDM_a3b43739-a73b-4792-b43b-efef5c63281d">14.2</ix:nonFraction> million during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">had</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzg0NTE_3711d807-261b-4df2-9af2-adbc6e6207f6">111,941</ix:nonFraction></span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">performance-based RSUs outstanding, which were granted to key employees in August 2020. The underlying performance milestones of the RSUs were not probable of achievement as of December&#160;31, 2022, and no stock-based compensation expense has been recognized to date for the performance-based RSUs.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_175"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzExNzMz_3470a003-de16-4b60-b333-4904664fd250" continuedAt="i5f7506f8d1ef4749889fdfa28ff434e7" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i5f7506f8d1ef4749889fdfa28ff434e7" continuedAt="iba18032a0f3f41cfa036aacea8d0e689"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately <ix:nonFraction unitRef="sqft" contextRef="i0d81dec2251d43bc8eec87ebd45ccbbe_D20220101-20221231" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1Xzc5_50449d97-8040-48fd-a5ff-b859cd9d8162">82,200</ix:nonFraction> square feet of office, laboratory, and manufacturing space in San Diego, California and <ix:nonFraction unitRef="sqft" contextRef="if9eb27232eb94ef4b6dc9ca0783ab193_D20220101-20221231" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE3MA_8b4c054d-774d-4286-a90c-3c41f74ff07a">57,360</ix:nonFraction> square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2022 of <ix:nonNumeric contextRef="i850961a8bdd6418e89855c3fe22af042_I20221231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzMzMQ_d6bfd022-dc7b-4bc5-9c26-b2f8ed268699">0.9</ix:nonNumeric> years to <ix:nonNumeric contextRef="i4e5bfcb200d2499cbfc64d230771e3f2_I20221231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzMzNw_388ce4eb-58b4-4138-9a10-4c1abad959c3">7.0</ix:nonNumeric> years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iba18032a0f3f41cfa036aacea8d0e689" continuedAt="if8c2b9cf7f8d470e8b0efe67afa14ff1"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzExNzM5_0dcb0216-eab9-44f8-b8ab-b10e7b187891" escape="true"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.351%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzEtMS0xLTEtNDk4Mjg_2d294132-bdda-4065-936a-8779495297c9">4,089,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzItMS0xLTEtNDk4Mjg_b4e3bd4f-426e-43e2-b0a7-cf84b5b8c2b3">3,050,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzMtMS0xLTEtNDk4Mjg_e985e0e8-d63a-49fc-9334-ba89a08fd583">3,063,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzQtMS0xLTEtNDk4Mjg_e2eea168-1760-4069-935f-748daed526a7">3,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzUtMS0xLTEtNDk4Mjg_b355a433-c821-44e8-8cf7-af7f76c1ef36">2,526,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzYtMS0xLTEtNDk4Mjg_177b4bec-dd56-4083-8916-8699e312004b">4,223,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzctMS0xLTEtNDk4Mjg_be5abb0c-bdbd-493b-82bc-fdfda6abbf86">20,090,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzgtMS0xLTEtNDk4Mjg_da13c952-40e8-4483-b413-5dd634f9a8d2">4,630,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzktMS0xLTEtNDk4Mjg_ba5fde3b-0f77-428d-a8ab-61b3293a40aa">15,460,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzEwLTEtMS0xLTQ5ODI4_68d33410-097e-4721-ba68-eac5270c2dc0">2,804,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzExLTEtMS0xLTQ5ODI4_bb079b90-6597-45e3-8223-da9c245acb83">12,656,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzEzLTEtMS0xLTQ5ODI4_7cd1ac86-d990-4a11-90c2-9ed8a19c4e63">5.9</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzE0LTEtMS0xLTQ5ODI4_1a1b7607-7c6a-4235-a011-ed929d6eb6be">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIwMDE_035dda03-e79d-41a6-80e2-1b13b5888120">3.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIwMDU_d99ce2f7-f998-4975-bcb0-edcdc13c1a15">3.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-5" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIwMTI_fbebed43-f9d7-4468-9fc8-7c977d1e5cb2">3.4</ix:nonFraction> million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into <ix:nonFraction unitRef="agreement" contextRef="i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231" decimals="INF" name="ino:LesseeNumberOfLeaseAgreementsEnteredInto" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIyOTQ_1d4b03c4-b858-4101-a868-82175fa1cc4e">two</ix:nonFraction> agreements to sublease a total of approximately <ix:nonFraction unitRef="sqft" contextRef="i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231" decimals="0" name="ino:LesseeOperatingLeaseAreaofLandUnderLease" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIzNDU_8ed2292b-d2f2-40f4-bb5f-94da61ca0f5f">13,500</ix:nonFraction> square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, the Company will pay $<ix:nonFraction unitRef="usd" contextRef="ib9df2365f9454744b557f8f6b5aa3936_I20210309" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE2NDkyNjc0NzA5MzI_54db302d-1b70-421b-b1c1-cc60248a17a6">30.0</ix:nonFraction>&#160;million in cash and $<ix:nonFraction unitRef="usd" contextRef="ib9df2365f9454744b557f8f6b5aa3936_I20210309" decimals="-5" name="ino:LossContingencyEstimateOfPossibleLossValueOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE2NDkyNjc0NzA5NjE_229cac92-b389-4f9f-bca3-412ab9a3bfb4">14.0</ix:nonFraction>&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers have paid the $<ix:nonFraction unitRef="usd" contextRef="ib9df2365f9454744b557f8f6b5aa3936_I20210309" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE2NDkyNjc0NzA5OTA_7513df16-f944-44e3-9c00-d5450c87d02c">30.0</ix:nonFraction>&#160;million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement. See Note 16 for events subsequent to December 31, 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if8c2b9cf7f8d470e8b0efe67afa14ff1" continuedAt="i0f4b571451754f7da87f55e44b649be5"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action complaint described above. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0f4b571451754f7da87f55e44b649be5">operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3Mjk_caa53f53-57f8-4a0d-9322-06523821bdbf" continuedAt="iaf2697ba80d14f12b1656b4de73dfed7" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="iaf2697ba80d14f12b1656b4de73dfed7" continuedAt="ifd749c2762b9440aa739816e82f31b67"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3MjM_f72f3fa1-9737-43bc-8533-1a0ddbe7c199" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzItMS0xLTEtNDk4Mjg_618aee11-8344-4c61-97c1-56b7206d800a">277,440,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzItMy0xLTEtNDk4Mjg_da6a2cca-9059-4d9f-9811-88e6c7d85dc2">302,614,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzItNS0xLTEtNDk4Mjg_ef703400-9a84-4b88-943a-6b72939a1867">162,664,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzMtMS0xLTEtNDk4Mjg_fe149952-a51e-42ba-95f4-3acf9dd2e417">211,249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzMtMy0xLTEtNDk4Mjg_3b6eac19-3810-4fe5-a4d8-deb405c508a1">610,320</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzMtNS0xLTEtNDk4Mjg_b2125e29-3d84-4753-8395-024f991769eb">225,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzQtMS0xLTEtNDk4Mjg_d4983b88-718f-46ff-9edf-32cf22f32799">277,652,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzQtMy0xLTEtNDk4Mjg_3cd74d49-b09d-488d-9e86-4f2c446a7dec">303,224,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="0" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzQtNS0xLTEtNDk4Mjg_726554ba-908a-4757-b3d3-4569395c4086">162,890,304</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzYxOQ_1152d0ef-f311-4333-a961-8b6591039a51"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzYxOQ_2cb7f959-8992-49b2-9904-97051734aed7"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzYxOQ_40a28e52-f02f-4ac4-a421-8f07fa377959">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for or benefit from income taxes for the years ended December 31, 2022, 2021 and 2020. </span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3MDM_07aabb33-a4bf-4c25-9e17-0aac00c2f15e" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzItMS0xLTEtNDk4Mjg_e84d1f54-b2a4-4e6f-9a7c-44dd4d11ed76">58,307,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzItMy0xLTEtNDk4Mjg_e4e01e98-9669-46e5-a7f8-790377c1396b">63,677,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzItNS0xLTEtNDk4Mjg_3b90f034-a940-4715-8e81-a71f91eb69de">34,207,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzMtMS0xLTEtNDk4Mjg_9c2db69a-deeb-4637-ac5d-9f4457f5476a">3,601,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzMtMy0xLTEtNDk4Mjg_02001f18-f736-40a3-b499-e46f9cd16bb1">3,447,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzMtNS0xLTEtNDk4Mjg_ec3b8544-6c5a-4681-a391-8567e90d22a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzUtMS0xLTEtNDk4Mjg_335f48cd-7947-4299-8f35-4130d463e3c3">61,065,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzUtMy0xLTEtNDk4Mjg_81e977e0-d7e0-486b-bec5-f6f02b670fd4">77,424,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzUtNS0xLTEtNDk4Mjg_b5986848-baec-48ff-a5a4-d83483db3c3a">21,428,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzYtMS0xLTEtNDk4Mjg_059fffb7-258a-456f-b786-1c41a856d69a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzYtMy0xLTEtNDk4Mjg_08ecc5b0-6c4f-4556-9372-bb5d2497a2b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzYtNS0xLTEtNDk4Mjg_f9519ba0-f02f-4baf-bf6e-c26796fa6a28">14,450,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzctMS0xLTEtNDk4Mjg_8bd9026c-80f0-4b86-a838-f2e06f7ff679">7,534,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzctMy0xLTEtNDk4Mjg_f9a049ec-42fa-461f-8a41-8ed76d81d8f1">16,523,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" sign="-" name="ino:IncomeTaxReconciliationStatuteLimitations" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzctNS0xLTEtNDk4Mjg_001fcc55-8ec5-41fd-8fd2-893c2b6d9601">2,650,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzktMS0xLTEtNDk4Mjg_39d418f5-b38b-40b6-8c96-e8a93c25689c">2,913,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzktMy0xLTEtNDk4Mjg_c1f7813a-2ec8-4c6d-b067-3866ab406309">483,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzktNS0xLTEtNDk4Mjg_76e9614f-3bec-4e7b-bf90-a253a73563be">1,953,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEwLTEtMS0xLTQ5ODI4_b06cf8e9-d665-494a-85ba-8f205afe15fc">2,291,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEwLTMtMS0xLTQ5ODI4_022aa5e0-fd30-4d7f-b26b-d150ea02c258">6,509,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEwLTUtMS0xLTQ5ODI4_b85dc7df-5417-422b-8825-040695c6b1d2">1,068,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzExLTEtMS0xLTQ5ODI4_f69b3f9f-bf60-4dbd-87f3-0f1234201b67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzExLTMtMS0xLTQ5ODI4_94576f9b-8e88-41a9-a999-34938d14e355">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzExLTUtMS0xLTQ5ODI4_8a36c196-c38d-459d-a15d-9bec2bafd54f">853,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEyLTEtMS0xLTQ5ODI4_9b153e67-f434-4ec7-ae0b-de7dffc01b03">1,459,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEyLTMtMS0xLTQ5ODI4_71b48378-469a-4e61-82dd-8782da6f4a07">616,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEyLTUtMS0xLTQ5ODI4_0587ae19-b97c-413c-b26b-5f78cc565e2c">468,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEzLTEtMS0xLTQ5ODI4_9f47c217-1e5a-4955-847f-defe7ffa4102">1,337,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEzLTMtMS0xLTQ5ODI4_11458519-009a-4371-aa1a-354e069b8d56">542,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" sign="-" name="ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEzLTUtMS0xLTQ5ODI4_a2e25d99-1f96-4cb0-8766-20d5076552e7">368,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE0LTEtMS0xLTQ5ODI4_3bf296b7-12ab-4ce3-bc25-31e6dd7ff9e5">187,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE0LTMtMS0xLTQ5ODI4_bace0f59-0b27-48f7-ac7d-431c119b8c33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE0LTUtMS0xLTQ5ODI4_838d1aee-73ff-46a4-bcab-4b09eb04ba13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE1LTEtMS0xLTQ5ODI4_8717fe93-8b13-4f36-8941-e2c138554bdb">8,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE1LTMtMS0xLTQ5ODI4_e30047ba-de54-4a9b-ae3d-525ed11c2f2d">24,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE1LTUtMS0xLTQ5ODI4_14378fa0-47d2-4ba7-8098-f48d822f9265">9,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE2LTEtMS0xLTQ5ODI4_2d298072-4cc5-4c29-867e-f986af57789f">3,246,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE2LTMtMS0xLTQ5ODI4_219aabff-be19-4701-9719-bca4e23f9a4f">819,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE2LTUtMS0xLTQ5ODI4_42ac875b-9fb7-4ebe-90cc-929a1731073f">920,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE3LTEtMS0xLTQ5ODI4_e1cd16eb-5eb8-4fe4-8e9f-e177ef3bfff3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE3LTMtMS0xLTQ5ODI4_218a737a-3432-4500-8201-0ac6d961df62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="ino:ComprehensiveIncomeLossTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE3LTUtMS0xLTQ5ODI4_eed3550a-6837-43c5-b28c-d61856db1940">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY2OTU_5f62d1dc-47e7-41de-a165-7b42f7b604b4" continuedAt="i8758d1306f5e4f8c99cac0e3b168169f" escape="true">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are shown below:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ifd749c2762b9440aa739816e82f31b67" continuedAt="ibc50e62e862f4778b38ad49385706975"><div style="margin-top:5pt"><ix:continuation id="i8758d1306f5e4f8c99cac0e3b168169f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzMtMS0xLTEtNDk4Mjg_14fd245c-8e01-4651-87cc-8383ca7aeb5f">41,252,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzMtMy0xLTEtNDk4Mjg_9341be56-fe4c-4eae-8410-2fef5ad67f92">4,200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzQtMS0xLTEtNDk4Mjg_3a7891c7-1014-4251-b31c-be06e6843c98">212,768,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzQtMy0xLTEtNDk4Mjg_f47e3e52-9a5f-47dd-9315-6e26e9f5e7b3">197,144,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzUtMS0xLTEtNDk4Mjg_cef223f4-801c-4ea0-8f21-6ff5bcf1c4b8">26,442,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzUtMy0xLTEtNDk4Mjg_3179c13c-74bd-4ca6-87f4-856fb6288d35">23,005,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzYtMS0xLTEtNDk4Mjg_f4d5fbd7-be46-45f2-95dc-5af94222c4ea">538,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzYtMy0xLTEtNDk4Mjg_c37bde72-7e25-449a-a8e9-13bba8276370">987,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzgtMS0xLTEtNDk4Mjg_7d5b885d-6f0a-4b8c-bfca-d97707141626">3,945,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzgtMy0xLTEtNDk4Mjg_685e5862-de68-4736-b415-4e7f940aa00c">3,599,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzktMS0xLTEtNDk4Mjg_4f682f91-b51a-4984-be21-d73d8c1ff73e">559,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="ino:DeferredTaxAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzktMy0xLTEtNDk4Mjg_98d398a1-cae5-492a-8c3c-906685571169">637,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="ino:DeferredTaxAssetInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzExLTEtMS0xLTQ5ODI4_32c7bc75-5d55-4a49-959e-7c565fdaa926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="ino:DeferredTaxAssetInterestExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzExLTMtMS0xLTQ5ODI4_b6b80488-fa32-4c98-94c5-2a3f3a55502e">83,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEyLTEtMS0xLTQ5ODI4_6b2f71bc-229c-4f87-96de-cb522393bfc3">1,569,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEyLTMtMS0xLTQ5ODI4_e358aef7-9bbb-46cf-ba66-3b3b65676a22">750,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEzLTEtMS0xLTQ5ODI4_137e73b0-558b-42e8-9c3d-6134729d6e7f">3,247,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="ino:DeferredTaxAssetsOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEzLTMtMS0xLTQ5ODI4_e9ce9901-0763-4cc9-b950-fcfe6abffd16">3,793,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE0LTEtMS0xLTQ5ODI4_5b7c9592-5740-47ee-a27f-e3c8b62a693a">57,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE0LTMtMS0xLTQ5ODI4_be9d0064-fe20-476c-8145-ad00b16df4e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE1LTEtMS0xLTQ5ODI4_ad45c261-fa5c-42f4-a535-5835804f473f">11,062,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE1LTMtMS0xLTQ5ODI4_718df49d-da2c-4904-8b78-8c3ed2595713">5,973,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE2LTEtMS0xLTQ5ODI4_6b193dd6-1d5b-4d40-bc8c-0bba00984660">301,439,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE2LTMtMS0xLTQ5ODI4_c6c31523-07d7-4f18-aa4d-52c2d8a5bfb1">240,171,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE3LTEtMS0xLTQ5ODI4_650ab7ec-e6f1-4bcf-8231-6e8fb3da2726">299,124,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE3LTMtMS0xLTQ5ODI4_41c169ae-6d31-40ed-9b8c-2092c095eed2">237,205,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE4LTEtMS0xLTQ5ODI4_fc71af34-e6c7-45e7-aec6-7c1486e3a2a2">2,315,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE4LTMtMS0xLTQ5ODI4_2c5105a4-7482-49e2-8bce-d0beda15ecdc">2,966,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIwLTEtMS0xLTQ5ODI4_0bba33be-337e-43b8-890d-1fe678d882ad">199,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIwLTMtMS0xLTQ5ODI4_13dcacfa-5668-4f35-8026-c6cc2fef89dc">194,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIyLTEtMS0xLTQ5ODI4_0c42b622-5462-4d9c-b076-d4c5047dfc89">2,148,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIyLTMtMS0xLTQ5ODI4_f537df5c-154a-4e0c-8eb5-f5ae9cfa0e72">2,430,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="ino:DeferredTaxLiabilitiesFinancingArrangementDiscount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIzLTEtMS0xLTQ5ODI4_c2905af6-6821-4f1b-a56d-a67d184bb5e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="ino:DeferredTaxLiabilitiesFinancingArrangementDiscount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIzLTMtMS0xLTQ5ODI4_b1d8a518-0c72-4b8d-87b2-6a1997c0a4ff">321,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI1LTEtMS0xLTQ5ODI4_a0cbfb80-85d1-45b0-b7f6-684e0284dff0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI1LTMtMS0xLTQ5ODI4_2a39b1aa-bb41-46e9-af41-2274716aa164">53,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTEtMS0xLTYwMzM1_1913eadd-0482-4775-a50d-c894c348466a">2,347,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTMtMS0xLTYwMzM3_a4bca52c-6663-4e71-9cb6-443c647ca9a1">2,998,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTEtMS0xLTQ5ODI4_fb5a2bc1-24c1-4c95-afc5-b38eb0b9edce">32,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTMtMS0xLTQ5ODI4_4447da7b-1482-4f99-8fb7-eb90b78453ea">32,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i84820f5d4e9a4ac2a3cac63e01a7c45c_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzE4MTM_23bff36b-d9b5-44d4-9f26-d16cd9c3697a">920.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="if12b9cf6eeaa4f20aa6799810ad465db_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzE4MTc_d2e7f53d-6ad6-4d0f-bda1-18bfe7fd7ce5">210.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i650dedeab35546edb17b1d6256119449_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzE4MjQ_7a460b05-d9ae-46e9-9c89-7ffc8a2eb645">89.6</ix:nonFraction> million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $<ix:nonFraction unitRef="usd" contextRef="icfaee2d1c32b4607a08c7c73282b04f4_I20181231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzIwMTY_fa11742a-1364-49ed-b0db-35c039eb82e4">625.4</ix:nonFraction> million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2022, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2022, respectively, unless previously utilized. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also had Korean NOL carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ic954d78339b94180a278d80e6ec99f23_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzIzNzM_dd18b20d-196c-4be2-b9fd-c8e829fc577e">1.0</ix:nonFraction> million as of December 31, 2022. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2022, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i071ac54a560b456dab72ccae0e2af24a_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzI2Njc_c4cb46c2-a3e9-41bb-805f-805c7fe813db">40.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzI2NzQ_332c0894-d591-49d0-bfd6-64bb6a8f7d35">4.7</ix:nonFraction> million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY2OTc_d0385e5a-fb69-4f2a-97c5-0dc55a1e687c" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtMS0xLTEtNDk4Mjg_e6d934d1-1dd8-4833-bbe4-43f231d26cd5">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtMy0xLTEtNDk4Mjg_31b5fa12-b574-4979-9bd9-c5866c79b146">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtNS0xLTEtNDk4Mjg_e28f447d-3d3e-49cf-a059-474a13596351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtNy0xLTEtNDk4Mjg_badfd5ec-2574-4fe8-989e-f311924c8f4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinTwoYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtOS0xLTEtNDk4Mjg_732abad1-b93d-42ff-b43b-0eead0f005bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtMS0xLTEtNDk4Mjg_a40a93de-04c1-4842-a9ca-e9c537ff4f5c">18.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtMy0xLTEtNDk4Mjg_780d6fe1-d348-4492-ad14-d23f8b359b6d">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinThreeYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtNS0xLTEtNDk4Mjg_aec17fcc-45c2-4717-a6d8-c48adca2f060">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInThreeYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtNy0xLTEtNDk4Mjg_e03ef20c-01c3-4146-ac20-78b6e665b240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInThreeYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtOS0xLTEtNDk4Mjg_9609ed01-4d38-4ac9-83ee-67d1da7a4baa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtMS0xLTEtNDk4Mjg_9aef4c5b-17c9-4729-b1b1-bd973e9a6f5f">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtMy0xLTEtNDk4Mjg_18a70f3e-5e82-40e9-8988-a062b25ab848">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFourYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtNS0xLTEtNDk4Mjg_911fd7b9-806c-434e-bfb1-116c95517082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInFourYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtNy0xLTEtNDk4Mjg_c68cbdde-7687-4db5-b246-90c07f058de8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInFourYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtOS0xLTEtNDk4Mjg_815c48ef-4fdd-4a28-a1db-143dddbb0de2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMS0xLTEtNTgyNzU_a03a6c8b-bad2-44c9-aa04-83acc26069f1">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMy0xLTEtNTgyNzU_5393acf9-24bb-4527-8c72-f2c31914938d">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringinFiveYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNS0xLTEtNTgyNzU_d58c701d-b3de-4005-9b30-0c8165d47cdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinFiveYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNy0xLTEtNTgyNzU_b370adef-72af-4eaa-ac75-698efd7ab62c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringinFiveYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtOS0xLTEtNTgyNzU_96632591-fa1b-4ac9-a14c-758ed5a6a54c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInSixYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMS0xLTEtNDk4Mjg_538ce952-30a3-4f4f-be9d-1010d3fc7bd3">249.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInSixYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMy0xLTEtNDk4Mjg_45fcfdaa-912a-4670-837f-4a4f63f65f22">277.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsExpiringInSixYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNS0xLTEtNDk4Mjg_cda2dbba-1f12-47be-ac49-873ca35ad87f">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInSixYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNy0xLTEtNDk4Mjg_c3c5cc8f-9402-413a-b1c9-0078210599f3">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardExpiringInSixYears" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtOS0xLTEtNDk4Mjg_cf880bb2-4d22-4512-b968-0b571fb4ddc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctMS0xLTEtNDk4Mjg_12fd41df-27f7-4bf6-a81e-0710441fa79f">625.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctMy0xLTEtNDk4Mjg_b32aac25-34e4-45c9-8b4b-addff6d4b773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231" decimals="-5" name="ino:OperatingLossCarryforwardsIndefinitelyCarryforward" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctNS0xLTEtNDk4Mjg_4892b4d7-b2ea-4b00-88e9-290b271e8b33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctNy0xLTEtNDk4Mjg_132e765b-24b9-4e12-9d3b-11a3bc414011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="ino:TaxCreditCarryforwardCarryforwardIndefinitely" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctOS0xLTEtNDk4Mjg_d385e6e3-81c7-4b65-a01d-9e6202eefa59">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtMS0xLTEtNDk4Mjg_386525bf-afd9-4ee8-8cda-7f109db2833e">920.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtMy0xLTEtNDk4Mjg_bf0cf124-19de-4a17-acfd-363d6d1d094e">299.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtNS0xLTEtNDk4Mjg_44a48b2d-c1ac-4587-8f7e-ef64fbaf43ed">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtNy0xLTEtNDk4Mjg_3ac435cb-6885-4acd-9280-ac64ea3d2e05">40.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtOS0xLTEtNDk4Mjg_be83d35b-4aaa-43b7-8ae1-fedf02fb3f1a">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:24.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibc50e62e862f4778b38ad49385706975"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2022. As a result of the analysis, the Company estimates that approximately $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="ino:TaxBenefitsExpired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzMzNzI_a928095a-00f5-4dd2-a404-758e4f41ebbd">8.3</ix:nonFraction> million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2022, 2021 and 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act did not have a material impact on the Company's financial statements for the years ended December 31, 2022, 2021 or 2020.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3Mjg_fb54c792-e4e1-4b6f-b486-fa19065a7fe4" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzItMS0xLTEtNDk4Mjg_3ec718eb-1680-453e-bd98-805514f2cd47">18,819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzItMy0xLTEtNDk4Mjg_452a3ae3-d224-4008-a8d3-15b7867e6c9a">12,210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bb91b86850c4019853cfafe96543ff8_I20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzItNS0xLTEtNDk4Mjg_a7f1c564-936d-4827-8c11-bf79c1369b82">11,204,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzMtMS0xLTEtNDk4Mjg_f901e3fd-12d3-4806-9b09-3e77417587e3">2,902,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzMtMy0xLTEtNDk4Mjg_d2516d6c-1121-4dfc-bb8f-a083a16625d6">6,602,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzMtNS0xLTEtNDk4Mjg_8a14c0d8-c07d-447b-a096-ac905797fcd0">1,043,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzQtMS0xLTEtNDk4Mjg_74060f18-5b85-4797-b1b3-58e16a73781d">582,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzQtMy0xLTEtNDk4Mjg_c4f9ccb9-d7c1-4b01-b199-b72ff19ba43e">7,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzQtNS0xLTEtNDk4Mjg_cb567e05-3f6c-4ba0-97b0-af9208d237e2">27,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-3" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzUtMS0xLTEtNDk4Mjg_31bdea95-8b93-4845-9e2f-2012e83b5dc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-3" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzUtMy0xLTEtNDk4Mjg_2fb4b374-98df-4323-9a69-aa7999564739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-3" sign="-" name="ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzUtNS0xLTEtNDk4Mjg_51003ed3-c411-4f55-89bd-2642b10fea1e">64,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzYtMS0xLTEtNDk4Mjg_b319d769-b9b4-4dbc-bfcb-5748e2793c35">21,139,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzYtMy0xLTEtNDk4Mjg_14f20953-a00c-4458-9f04-889ece7447a6">18,819,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzYtNS0xLTEtNDk4Mjg_82dee665-6971-4b09-bae4-7b50fad0d80f">12,210,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzU0Nzk_7bd3a889-0194-4586-b6cd-8b5b33614b0a">19.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzU0ODM_d971dde3-0139-4f3d-9545-21d37c3114da">17.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzU0OTA_cab691af-9cd7-408c-863d-62acebfccd82">10.9</ix:nonFraction> million as of December&#160;31, 2022, 2021 and 2020, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2019 and state and local income tax examinations before 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div></ix:continuation><div><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_181"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzU0MA_6ea4a334-a417-4a3f-983b-cbac636c940e" continuedAt="i98a0eaf0c83144ffb80af01000b62312" escape="true">401(k) Plan</ix:nonNumeric></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i98a0eaf0c83144ffb80af01000b62312">The Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches <ix:nonFraction unitRef="number" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzI2MA_115cafbe-7b35-4541-9db1-8c41356a1095">50</ix:nonFraction>% of its employees&#8217; contributions, up to <ix:nonFraction unitRef="number" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzMwMg_4e3b3ca3-8dc0-4573-b44c-40c361871a4a">6</ix:nonFraction>% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $<ix:nonFraction unitRef="usd" contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzQ1Nw_ed6f3897-d217-48d1-99b6-f3719699e1d1">1.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzQ2MQ_96c6bf9f-24f8-45d4-b07a-48621fcfaf18">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzQ3Ng_a276ac72-04e5-401d-99b4-4af3db3ab657">1.1</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_184"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM2MjE_7ed9cfa6-1597-4f28-a58e-d0785770e29f" continuedAt="if8fc3f3c9d2d4e9c8c6135b43af3272e" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="if8fc3f3c9d2d4e9c8c6135b43af3272e" continuedAt="i14df98a843114ca68cc93dbeac618fc6">Plumbline Life Sciences, Inc.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i14df98a843114ca68cc93dbeac618fc6"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned <ix:nonFraction unitRef="shares" contextRef="i20e06ec8473a49698ac1e8cad9679f61_I20211231" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3Xzg0_99754574-c623-407c-87b0-a424de973812"><ix:nonFraction unitRef="shares" contextRef="i817aab3e5a42474f970fce9fc4e1a2fa_I20221231" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3Xzg0_bf54f0f6-24f4-4d50-989d-4446f7084856">597,808</ix:nonFraction></ix:nonFraction> shares of common stock in PLS as of December 31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a <ix:nonFraction unitRef="number" contextRef="i817aab3e5a42474f970fce9fc4e1a2fa_I20221231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE5OA_074d43c6-99cb-41fe-a52d-2659677082f4">18.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i20e06ec8473a49698ac1e8cad9679f61_I20211231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzIwNQ_2ef34878-019f-4da2-a064-895f76d42e5a">18.9</ix:nonFraction>% ownership interest, respectively. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2022,  2021 and 2020, the Company recognized revenue from PLS of $<ix:nonFraction unitRef="usd" contextRef="id7448c2b34ba40ff87e0d9cf69208bc4_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzQ4Nw_416b4437-af86-4689-95d5-1a8be09c4d65">34,000</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="i957537cf7fde4f90a792a8cc73b50b9c_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzQ5NA_67a75f72-1fdc-4c0a-baf7-f7106c0d3395">245,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie6b5e86588ce4204ad22f6367761229d_D20200101-20201231" decimals="-5" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDU5MjQ_604fa521-3c57-49bb-bf54-2ab0f46912eb">1.4</ix:nonFraction> million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i64432e8f98434affba895ba9830ae610_I20221231" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzU4OQ_0893cc6f-1d2d-4260-8ca5-6a6fccf028c9">59,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i70087078e10b48ae9664922295bdecd6_I20211231" decimals="-3" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzU5Ng_4b64b2c3-0d20-4be7-81eb-78cb821f3c6d">25,000</ix:nonFraction>, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $<ix:nonFraction unitRef="usd" contextRef="ib8718060c67641f5a4518ae2471cec53_D20160301-20160331" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzEyNDk_559bbfe0-e065-4a5c-884e-abaa96e879a3">3.1</ix:nonFraction> million during the <ix:nonNumeric contextRef="ib8718060c67641f5a4518ae2471cec53_D20160301-20160331" name="ino:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM2MTg_0eaac8ee-aac2-4ae7-aa0e-62c7bbf90e6c">five-year</ix:nonNumeric> term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the exclusive right to in-license new intellectual property developed under this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, which have been completed as of September 30, 2022, the Company is reimbursing Wistar a total of $<ix:nonFraction unitRef="usd" contextRef="ia687677e1a354cffa7a0cefe22646f85_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementExpensesToReimburse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE4OTE_64c1ac2b-f860-4ab6-b8f1-82b228304996">1.9</ix:nonFraction>&#160;million for all direct and indirect costs incurred in the conduct of the collaborative research.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company rece</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived a&#160;$<ix:nonFraction unitRef="usd" contextRef="i566a6c987fa446498049b5aff48c2020_D20161101-20161130" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE5Nzg_6ad22f11-cc38-4aa9-baac-8ee1e05ef77d">6.1</ix:nonFraction> million&#160;sub-grant through Wistar to develop a d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MAb</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against the Zika infectio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n, with funding through December 2021. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases, with funding through February 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $<ix:nonFraction unitRef="usd" contextRef="ia0abccea943c4509ba78bb57e68e1da5_D20200101-20201231" decimals="-5" name="ino:CollaborativeAgreementAwardedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzIyODk_080248d8-701a-474c-935e-3fb3e512f52a">10.7</ix:nonFraction>&#160;million sub-grant through Wistar, which was amended in 2021 to $<ix:nonFraction unitRef="usd" contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231" decimals="-5" name="ino:CollaborativeAgreementAmendedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzIzNDc_7414b03c-a799-438c-9a40-8a150494097c">13.6</ix:nonFraction>&#160;million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $<ix:nonFraction unitRef="usd" contextRef="ibb7ba3207c4249c49792d6993d00f3d2_D20220101-20221231" decimals="-5" name="ino:CollaborativeAgreementAwardedOptionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI1NDQ_bee5094b-915f-4672-9760-b5ca8f8a5e71">6.0</ix:nonFraction>&#160;million in funding through March 2024, of which $<ix:nonFraction unitRef="usd" contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231" decimals="-5" name="ino:CollaborativeAgreementAwardedExercisedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI1OTE_f7b998db-3404-4598-89ff-97532593a598">3.3</ix:nonFraction>&#160;million has been exercised as of December 31, 2022. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2022 and 2021, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ib65f278575cc40f2a1b542d1f3241a97_D20220101-20221231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI4Nzg_b5c693f0-c5e8-4729-9198-4a48f9d4170a">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia687677e1a354cffa7a0cefe22646f85_D20210101-20211231" decimals="-5" name="ino:GrantProceedsReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI4ODU_6466b188-a23a-4b56-aaea-eb03321debe4">3.0</ix:nonFraction> million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="ibb7ba3207c4249c49792d6993d00f3d2_D20220101-20221231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMyMzE_98110ec9-d347-4e8d-85cd-8a15171aef89">1.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3e671e6067184545b7d91d89a7ca3096_D20210101-20211231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMyNDY_8d3034d8-74f9-4faa-9fca-1f7a086fdadb">2.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia0abccea943c4509ba78bb57e68e1da5_D20200101-20201231" decimals="-5" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDU5OTA_b8de6292-a3e2-4c6c-bd9a-8c455de1513c">2.3</ix:nonFraction>&#160;million, respectively. At December&#160;31, 2022 and 2021, the Company had an accounts receivable balance of $<ix:nonFraction unitRef="usd" contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMzMzY_317f49bd-3e40-4c34-bd27-ec2b697296af">9.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231" decimals="-5" name="us-gaap:AccountsReceivableRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMzNDM_215193db-253c-491b-9750-d47c89d83757">2.6</ix:nonFraction> million, respectively, and an accounts payable and accrued liability balance of $<ix:nonFraction unitRef="usd" contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM0MTg_7a789330-58f9-4643-8d47-9752fff23f3a">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM0MjU_af72c170-92ec-4f3e-a010-9671ae1085d7">548,000</ix:nonFraction>, respectively, related to Wistar. As of December&#160;31, 2022 and 2021, the Company had a prepaid expense balance of $<ix:nonFraction unitRef="usd" contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM1MTc_aba5483e-bfaf-4004-bdbd-8ac249b012d4">375,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDYxMTg_40c9837c-51f7-4403-9b22-5ee04d07589a">261,000</ix:nonFraction>, respectively, and recorded $<ix:nonFraction unitRef="usd" contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM1MzM_cfa59128-64e5-4c15-a47e-601aad19df81">88,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231" decimals="-3" name="ino:DeferredGrantFundingFromAffiliate" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDYxMDk_43e5e843-2bbe-40e9-9334-e9b70dac5527">37,000</ix:nonFraction>, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div></ix:continuation><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzk4NzM_f86cf012-311c-4e27-a69d-320569043bb9" continuedAt="i39e6775456af438fbc3d04df71f6cfec" escape="true">Geneos Therapeutics, Inc. </ix:nonNumeric></span></div><ix:continuation id="i39e6775456af438fbc3d04df71f6cfec" continuedAt="i8c86f374bed2460a9998bcab651612e2"><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="ie4aaa62817594ece850f89f4ae127ddf_D20190201-20190228" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzM3OA_40d8fb8f-f38a-4778-9368-31d35365a271">1.2</ix:nonFraction>&#160;million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i44df340754904d60b387ac967f2fee31_I20190228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzUwNw_4382f73f-4ff3-4518-882e-a44de223dfab">61</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="i15e530f73df34c398e566264b204a2d4_I20200131" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzc5OQ_58adbfda-039d-4c80-8b87-f177a9cf206d">800,000</ix:nonFraction>. Following this transaction, the Company held&#160;<ix:nonFraction unitRef="number" contextRef="i560af3a39c4c40d3874fed14c6721a9f_I20200131" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg3MA_6e26c562-4e5e-4f68-bfe3-217c02734c7f">52</ix:nonFraction>%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $<ix:nonFraction unitRef="usd" contextRef="ic7f0c3c89e134e6891c4524576f4fe89_I20200630" decimals="-3" name="ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzExMjE_e4b1b2f9-28f3-4410-b065-c39e78a32dda">800,000</ix:nonFraction>. Following this transaction, the Company owned <ix:nonFraction unitRef="number" contextRef="i876fc07681a44ee487cf4e512393be2a_I20200630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzExNzE_40c8d2f2-b996-433b-adc0-d904849776f9">47</ix:nonFraction>% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8c86f374bed2460a9998bcab651612e2" continuedAt="i4ad76fdb84854f0bb18c407c3f2e10ff"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $<ix:nonFraction unitRef="usd" contextRef="i312c32046c954040884f45e992037d33_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE4Mzk_fa3daeb1-a725-458d-b769-497fabd96e7f">4.1</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i312c32046c954040884f45e992037d33_D20200601-20200601" decimals="-5" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE4NTI_4ebb0421-5596-41d6-be34-77c3260493f8">2.4</ix:nonFraction>&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value. </span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and is therefore recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i69253dc5f01644e79d35a7205adbc9bd_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzY4NjE_c434ee42-dc3b-46cb-80a8-4b2d9806d9f7">1.4</ix:nonFraction>&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="ia6407ce5393843909b745480c6ca2554_I20201130" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzc0OTY_68fe8697-937c-42a8-91ae-9057b26bcc48">36</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2021 was $<ix:nonFraction unitRef="usd" contextRef="ibb50f5b639ee412d94255ce7d570a547_D20210101-20210331" decimals="-5" name="ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg1MzE_344bd77f-5249-4da2-8ddf-df5947ca6a99">1.5</ix:nonFraction>&#160;million; however, only $<ix:nonFraction unitRef="usd" contextRef="ibb50f5b639ee412d94255ce7d570a547_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg1NDk_472a931a-bb9f-476b-ba06-faa394269294">434,000</ix:nonFraction> was recorded, reducing the Company's total investment in Geneos to $<ix:nonFraction unitRef="usd" contextRef="if32e8f4ea58f4ce98e067ea7e1754cba_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg2MTk_9d8d39a2-9bc1-485b-b9da-1a07c96f8ee9">0</ix:nonFraction>. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f the total amount, $<ix:nonFraction unitRef="usd" contextRef="i6c7c8026b35043069ab11881210ac603_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg2Mzk_4d8031a3-1b29-4e1e-986b-17c544b514b3">819,000</ix:nonFraction> was allocated to the equity method investment, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i270dcf1d2c4b423d889baab7dc6a12bc_I20210331" decimals="0" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg3MjY_748ad1cb-d4e4-4478-af68-4488789110e2">0</ix:nonFraction> as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The remaining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9b0650a02db7416e902fd5464a19fe1b_D20210101-20210331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg3NjU_0581f488-12f7-4f9f-8d29-9e002cede3b2">4.2</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss was allocated to the Company&#8217;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $<ix:nonFraction unitRef="usd" contextRef="i53479a023482480fa55a43efd0b59aab_I20210331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg5MzU_5461c892-58b9-405c-9005-c9cd227345dc">0</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="ib1281c7cd4bf4b6394985b10e622fc01_I20210228" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzkzNTI_91bd26c4-9a7f-49e2-97c2-0ca50fb269db">35</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $<ix:nonFraction unitRef="usd" contextRef="i610a9153ce62445cb06cc24f93ac3001_D20220301-20220331" decimals="-5" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ1ODU_5435344a-1276-431d-8f82-ae60df74c9b6">2.0</ix:nonFraction>&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately <ix:nonFraction unitRef="number" contextRef="i523a6b123f304bd09e5c0ae91b9adde5_I20220331" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2MDM_e3873f96-bf24-4b5d-8509-1f53778a34dd">28</ix:nonFraction>% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4ad76fdb84854f0bb18c407c3f2e10ff"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $<ix:nonFraction unitRef="usd" contextRef="i988b6f75b9e6460c956d40049e2a8e51_D20220301-20220331" decimals="-3" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2MTc_1fb92d67-c5a3-416b-8134-94288c4eac67">165,000</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzIxOTkwMjMyNzg1NDg_925b4f6e-e544-45f8-bf9e-906d9d5cbf4c" escape="true"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $<ix:nonFraction unitRef="usd" contextRef="i988b6f75b9e6460c956d40049e2a8e51_D20220301-20220331" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2NDA_cd223e46-5b3e-4dc0-8b0d-d3a52ea4229f">2.2</ix:nonFraction>&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $<ix:nonFraction unitRef="usd" contextRef="i2572a2fffba544ef9e41966fc1155177_I20220331" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2NTc_b8ead2d4-ff37-4441-9f41-2c9f0416c567">0</ix:nonFraction> as of December 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98148ffac5c843dab35c796318d95e41_I20211231" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzEtMi0xLTEtNTI2Mjk_0b2d27ed-3a98-468d-8385-7c107290be7c">1,999,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8c7588fc83b4e679b3d9caf40ad0d04_D20220101-20221231" decimals="0" name="us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzItMi0xLTEtNTI2Mjk_5b50771e-a002-4fc5-a28f-c069797892f7">165,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8c7588fc83b4e679b3d9caf40ad0d04_D20220101-20221231" decimals="0" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzMtMi0xLTEtNTI2Mjk_991bad5d-668b-419f-bed3-a02ecb8b7d3b">2,165,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i339d243acc4a4538ae743f7ea71e863b_I20221231" decimals="0" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzQtMi0xLTEtNTI2Mjk_f2f99ecf-46a5-48b9-b706-b1c353508e17">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $<ix:nonFraction unitRef="usd" contextRef="i339d243acc4a4538ae743f7ea71e863b_I20221231" decimals="0" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjU1MzE_1970aee7-2a50-4c82-912f-91759f4ebb57">0</ix:nonFraction> and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology.   </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div></ix:continuation><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="i02d4bef15c6d4619b17bfe55828c95c8_193"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzMw_d3e57f90-e30b-4c11-bc84-d135bc55785b" continuedAt="i283d04f3c09140919628055b8f80cbd4" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="i283d04f3c09140919628055b8f80cbd4"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the Company committed to and communicated a corporate reorganization plan, including a reduction in force (the &#8220;Reduction&#8221;). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company reduced its overall headcount by approximately <ix:nonFraction unitRef="employee" contextRef="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131" decimals="0" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM2OA_525a3c12-fae8-4a6e-9167-04f1a36a0a43">24</ix:nonFraction> employees, which represented <ix:nonFraction unitRef="number" contextRef="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM3Mg_8fbce565-2a7f-4ccc-b17b-4e9c58d4aa8f">11</ix:nonFraction>% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $<ix:nonFraction unitRef="usd" contextRef="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131" decimals="-5" name="ino:RestructuringAndRelatedCostExpectedAnnualSavings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM3Nw_6b64b349-fab7-47ce-976b-f882afb381c2">4.3</ix:nonFraction>&#160;million. The Company expects to incur a one-time pre-tax charge of approximately $<ix:nonFraction unitRef="usd" contextRef="if1a9994a0e9c42d682a6382e17a889cd_I20230331" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM5MQ_1d4b0dfb-2c5b-4022-8334-0803b1897b76">1.1</ix:nonFraction>&#160;million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. The Company expects such costs to be the only direct expense of the Reduction. The Company expects all charges associated with the Reduction to be incurred during the quarter ending March 31, 2023, with related cash payments expected to be paid out in the first half of 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 18, 2023, the court for the securities class action (see Note 11) entered an order granting final approval of the settlement, as set forth in a stipulation of settlement. In February 2023, pursuant to the securities class action settlement, the Company issued <ix:nonFraction unitRef="shares" contextRef="i1b1cb2986d5240299edf1d6dd0ab9f19_I20230228" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMjQ3NA_248c3646-c91b-48b6-b58f-6fc6d691f475">7,000,000</ix:nonFraction> shares of common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the expiration of the appeal period or resolution of an appeal if one is filed, the Company will make another contribution of common stock to the settlement fund with a value of approximately $<ix:nonFraction unitRef="usd" contextRef="i1b1cb2986d5240299edf1d6dd0ab9f19_I20230228" decimals="-5" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyNDUzMA_95e2c8cb-5b4e-4a05-9592-e1e52585489f">2.1</ix:nonFraction>&#160;million. The number of shares will be calculated based on the average trading price of the common stock for the <ix:nonFraction unitRef="day" contextRef="ife5c59f2516940b1ba2ee6b6fca25969_D20230201-20230228" decimals="INF" name="ino:CommonStockSharesIssuedSharePriceConsecutiveTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMzk1Mw_14a53d0e-eb06-413b-98bd-e1f2632cff88">10</ix:nonFraction> trading days preceding the determination date pursuant to the terms of the securities class action settlement.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-34</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ino-12312022x10kex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i5c79eae9c9ea4ea88b288673ac8fd775_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INOVIO PHARMACEUTICALS, INC. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.917%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.594%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Subsidiary Name(1)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Jurisdiction of Organization</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;padding-left:11.25pt;text-indent:-9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inovio Asia, LLC</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ino-12312022x10kex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8def2d622f774c328551be013a33bdbe_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Registration Statement (Form S-3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. 333- 236202) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Registration Statement (Form S-3 No. 333-252256) of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Registration Statement (Form S-8 Nos. 333-142938, 333-150769, 333-161559, 333-166906, 333-174353, 333-181532, 333-192318, 333-196325, 333-209155, and 333-216061) pertaining to the 2007 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Registration Statement (Form S-8 Nos. 333-216059, 333-223776, 333-230337, 333-231872, 333-236201, 333-253736 and 333-263167) pertaining to the 2016 Omnibus Incentive Plan, as amended, of Inovio Pharmaceuticals, Inc.,</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Registration Statement (Form S-8 No. 333-265944) pertaining to the Inovio Pharmaceuticals, Inc. 2022 Inducement Plan,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our reports dated March&#160;1, 2023, with respect to the consolidated financial statements of Inovio Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Inovio Pharmaceuticals, Inc. for the year ended December 31, 2022.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">March&#160;1, 2023</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ino-12312022x10kex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2e304d53b0da4f2fa39fa8f0d6511688_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CEO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jacqueline E. Shea, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JACQUELINE E. SHEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ino-12312022x10kex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic6f97ac56ace426f9d2c3842d1b4ec55_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of CFO Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Exchange Act Rules&#160;13a-15(e) and 15d-15(e) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">as Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;302 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Peter Kies, certify that&#58; </font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this annual report on Form&#160;10-K of Inovio Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15(d)-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ino-12312022x10kex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7e5a787df7984c27ad0f3b40f2ea3182_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1 </font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. Section&#160;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As Adopted Pursuant to </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of the Sarbanes-Oxley Act of 2002 </font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ending December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), each of the undersigned, in the capacities and on the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to his knowledge&#58; </font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:9pt;padding-left:63pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:4.349%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.176%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JACQUELINE E. SHEA</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jacqueline E. Shea</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">President, Chief Executive Officer and Director</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Executive Officer)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;P</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">ETER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> K</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">IES&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Peter Kies</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Principal Financial and Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ino-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5376b60-4920-4297-91b8-ae15a0711c84,g:73741ec8-2e2b-4617-87f5-1b9c1ea3fbd1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ino="http://www.inovio.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.inovio.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ino-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.inovio.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.inovio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompany" roleURI="http://www.inovio.com/role/TheCompany">
        <link:definition>0000010 - Disclosure - The Company</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRisk" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk">
        <link:definition>0000012 - Disclosure - Revenue Recognition and Concentration of Credit Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreements" roleURI="http://www.inovio.com/role/CollaborativeAgreements">
        <link:definition>0000013 - Disclosure - Collaborative Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurements" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements">
        <link:definition>0000014 - Disclosure - Short-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItems" roleURI="http://www.inovio.com/role/CertainBalanceSheetItems">
        <link:definition>0000015 - Disclosure - Certain Balance Sheet Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssets" roleURI="http://www.inovio.com/role/FixedAssets">
        <link:definition>0000016 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssets" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets">
        <link:definition>0000017 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebt" roleURI="http://www.inovio.com/role/ConvertibleDebt">
        <link:definition>0000018 - Disclosure - Convertible Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.inovio.com/role/StockholdersEquity">
        <link:definition>0000019 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.inovio.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.inovio.com/role/IncomeTaxes">
        <link:definition>0000021 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlan" roleURI="http://www.inovio.com/role/A401kPlan">
        <link:definition>0000022 - Disclosure - 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.inovio.com/role/RelatedPartyTransactions">
        <link:definition>0000023 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsInc" roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc">
        <link:definition>0000024 - Disclosure - Geneos Therapeutics, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.inovio.com/role/SubsequentEvents">
        <link:definition>0000025 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000027 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskTables" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables">
        <link:definition>0000028 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsTables" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables">
        <link:definition>0000029 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsTables" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables">
        <link:definition>0000030 - Disclosure - Certain Balance Sheet Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsTables" roleURI="http://www.inovio.com/role/FixedAssetsTables">
        <link:definition>0000031 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsTables" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables">
        <link:definition>0000032 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtTables" roleURI="http://www.inovio.com/role/ConvertibleDebtTables">
        <link:definition>0000033 - Disclosure - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.inovio.com/role/StockholdersEquityTables">
        <link:definition>0000034 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables">
        <link:definition>0000035 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.inovio.com/role/IncomeTaxesTables">
        <link:definition>0000036 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncTables" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables">
        <link:definition>0000037 - Disclosure - Geneos Therapeutics, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000038 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
        <link:definition>0000039 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails">
        <link:definition>0000041 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails">
        <link:definition>0000042 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails">
        <link:definition>0000043 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeAgreementsDetails" roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails">
        <link:definition>0000044 - Disclosure - Collaborative Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>0000045 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
        <link:definition>0000046 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000047 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails">
        <link:definition>0000048 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails">
        <link:definition>0000049 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FixedAssetsDetails" roleURI="http://www.inovio.com/role/FixedAssetsDetails">
        <link:definition>0000050 - Disclosure - Fixed Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails">
        <link:definition>0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1">
        <link:definition>0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNarrativeDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails">
        <link:definition>0000052 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails">
        <link:definition>0000053 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtNarrativeDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails">
        <link:definition>0000054 - Disclosure - Convertible Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtBalanceOfConvertibleDebtDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails">
        <link:definition>0000055 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleDebtScheduleofMaturitiesDetails" roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails">
        <link:definition>0000056 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofPreferredStockDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails">
        <link:definition>0000057 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>0000058 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionsOutstandingDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails">
        <link:definition>0000059 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails">
        <link:definition>0000060 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails">
        <link:definition>0000061 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>0000062 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails">
        <link:definition>0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1">
        <link:definition>0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofPretaxLossfromOperationsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails">
        <link:definition>0000064 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails">
        <link:definition>0000065 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000066 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000067 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
        <link:definition>0000068 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails">
        <link:definition>0000069 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="A401kPlanDetails" roleURI="http://www.inovio.com/role/A401kPlanDetails">
        <link:definition>0000070 - Disclosure - 401(k) Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails">
        <link:definition>0000071 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncNarrativeDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails">
        <link:definition>0000072 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeneosTherapeuticsIncPreferredStockInvestmentDetails" roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails">
        <link:definition>0000073 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.inovio.com/role/SubsequentEventsDetails">
        <link:definition>0000074 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ino_ApolloBioMember" abstract="true" name="ApolloBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CEPIMERSMember" abstract="true" name="CEPIMERSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAmendedAmount" abstract="false" name="CollaborativeAgreementAmendedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseinDeferredGrantFundingCurrent" abstract="false" name="IncreaseDecreaseinDeferredGrantFundingCurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinThreeYears" abstract="false" name="OperatingLossCarryforwardsExpiringinThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementRevenueFromTheProcurementContract" abstract="false" name="CollaborativeArrangementRevenueFromTheProcurementContract" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFourMember" abstract="true" name="RangeOfExercisePricesFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredTaxAssetsIntangibleAssets" abstract="false" name="DeferredTaxAssetsIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesFiveMember" abstract="true" name="RangeOfExercisePricesFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" abstract="false" name="CollaborativeAgreementPeriodFromEffectiveDateForTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DNAEncodedMonoclonalAntibodyTechnologyMember" abstract="true" name="DNAEncodedMonoclonalAntibodyTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" abstract="false" name="CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SeriesAOnePreferredStockMember" abstract="true" name="SeriesAOnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SanDiegoCaliforniaMember" abstract="true" name="SanDiegoCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_December2019ConvertibleBondsMember" abstract="true" name="December2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesIncMember" abstract="true" name="PlumblineLifeSciencesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_INO4800Member" abstract="true" name="INO4800Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" abstract="true" name="McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DoDMember" abstract="true" name="DoDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays" abstract="false" name="CommonStockSharesIssuedSharePriceConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingReceived" abstract="false" name="CollaborativeAgreementFundingReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_RangeOfExercisePricesThreeMember" abstract="true" name="RangeOfExercisePricesThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_GeneosTherapeuticsInc.Member" abstract="true" name="GeneosTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_FormerPresidentAndChiefExecutiveOfficerMember" abstract="true" name="FormerPresidentAndChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CoalitionforEpidemicPreparednessInnovationsMember" abstract="true" name="CoalitionforEpidemicPreparednessInnovationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AccruedClinicalTrialExpenseCurrent" abstract="false" name="AccruedClinicalTrialExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" abstract="false" name="OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CELLECTRA3PSPProprietarySmartDeviceMember" abstract="true" name="CELLECTRA3PSPProprietarySmartDeviceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementPaymentEarned" abstract="false" name="CollaborationAgreementPaymentEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_KoreanStateIncomeTaxAuthorityMember" abstract="true" name="KoreanStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" abstract="false" name="SaleOfStockSalesProceedsOfAnyCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringInSixYears" abstract="false" name="OperatingLossCarryforwardsExpiringInSixYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2007IncentivePlanMember" abstract="true" name="A2007IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_GainLossOnRemeasurementOfEquityMethodInvestment" abstract="false" name="GainLossOnRemeasurementOfEquityMethodInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" abstract="false" name="ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_StockSalesAgreementRemainingAuthorizedAmount" abstract="false" name="StockSalesAgreementRemainingAuthorizedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInThreeYears" abstract="false" name="TaxCreditCarryforwardExpiringInThreeYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AllOtherCustomersMember" abstract="true" name="AllOtherCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_WorkingCapital" abstract="false" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInSixYears" abstract="false" name="TaxCreditCarryforwardExpiringInSixYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_August2019ConvertibleBondsMember" abstract="true" name="August2019ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_TheWistarInstituteMember" abstract="true" name="TheWistarInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardCarryforwardIndefinitely" abstract="false" name="TaxCreditCarryforwardCarryforwardIndefinitely" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantRevenuePolicyTextBlock" abstract="false" name="GrantRevenuePolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DepartmentOfDefenceMember" abstract="true" name="DepartmentOfDefenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_EmployeesAndDirectorsMember" abstract="true" name="EmployeesAndDirectorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_DeferredTaxAssetsOperatingLeaseLiability" abstract="false" name="DeferredTaxAssetsOperatingLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" abstract="false" name="NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_LossContingencyEstimateOfPossibleLossValueOfShares" abstract="false" name="LossContingencyEstimateOfPossibleLossValueOfShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtSecuritiesAvailableforSaleContractualMaturity" abstract="false" name="DebtSecuritiesAvailableforSaleContractualMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_DeferredTaxAssetInterestExpense" abstract="false" name="DeferredTaxAssetInterestExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SARSCoV2COVID19VaccineMember" abstract="true" name="SARSCoV2COVID19VaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" abstract="true" name="AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_ServiceBasedRestrictedStockUnitsMember" abstract="true" name="ServiceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_A2022InducementPlanMember" abstract="true" name="A2022InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_RangeOfExercisePricesTwoMember" abstract="true" name="RangeOfExercisePricesTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedOptionAmount" abstract="false" name="CollaborativeAgreementAwardedOptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_CollaborativeAgreementsUpfrontPaymentReceived" abstract="false" name="CollaborativeAgreementsUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtinstrumentAccruedInterest" abstract="false" name="DebtinstrumentAccruedInterest" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedAmount" abstract="false" name="CollaborativeAgreementAwardedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A2016IncentivePlanMember" abstract="true" name="A2016IncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringInFourYears" abstract="false" name="TaxCreditCarryforwardExpiringInFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PLSaffiliatedentityMember" abstract="true" name="PLSaffiliatedentityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_StockSalesAgreementMaximumAuthorizedAmount" abstract="false" name="StockSalesAgreementMaximumAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" abstract="false" name="IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AnnualMaintenancePeriod" abstract="false" name="AnnualMaintenancePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" abstract="false" name="StockPurchaseAgreementCommitmentOfAdditionalInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LassaFeverAndMERSVaccineMember" abstract="true" name="LassaFeverAndMERSVaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesTable" abstract="true" name="AccountsPayableAndAccruedExpensesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" abstract="false" name="DeferredTaxLiabilitiesFinancingArrangementDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsGross" abstract="false" name="GoodwillAndIntangibleAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeArrangementFixedPriceContractAmountAwarded" abstract="false" name="CollaborativeArrangementFixedPriceContractAmountAwarded" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RangeOfExercisePricesOneMember" abstract="true" name="RangeOfExercisePricesOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ProceedsfromStockOptionandWarrantExercises" abstract="false" name="ProceedsfromStockOptionandWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinTwoYears" abstract="false" name="TaxCreditCarryforwardExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GoodwillAndIntangibleAssetsNet" abstract="false" name="GoodwillAndIntangibleAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncreaseDecreaseInAccruedClinicalTrialExpense" abstract="false" name="IncreaseDecreaseInAccruedClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_GrantProceedsReceived" abstract="false" name="GrantProceedsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborationAgreementAdditionalRevenueToBeAchieved" abstract="false" name="CollaborationAgreementAdditionalRevenueToBeAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" abstract="false" name="PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NonCashInterestExpense" abstract="false" name="NonCashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" abstract="false" name="SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_TaxCreditCarryforwardExpiringinFiveYears" abstract="false" name="TaxCreditCarryforwardExpiringinFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementFundingToBeReceived" abstract="false" name="CollaborativeAgreementFundingToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateNumberofSharesIssued" abstract="false" name="StockSaleAgreementAggregateNumberofSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFourYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFourYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" abstract="false" name="CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseInOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" abstract="false" name="NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_ChangeInValueOfInvestmentsInAffiliatedCompany" abstract="false" name="ChangeInValueOfInvestmentsInAffiliatedCompany" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_AdvaccineMember" abstract="true" name="AdvaccineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_TaxBenefitsExpired" abstract="false" name="TaxBenefitsExpired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_StockSaleAgreementWeightedAveragePricePerShare" abstract="false" name="StockSaleAgreementWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ino_PrepaidManufacturingExpensesCurrent" abstract="false" name="PrepaidManufacturingExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" abstract="false" name="EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" abstract="false" name="ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_CaliforniaIncomeTaxAuthorityMember" abstract="true" name="CaliforniaIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliateCurrent" abstract="false" name="DeferredGrantFundingFromAffiliateCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PlumblineLifeSciencesMember" abstract="true" name="PlumblineLifeSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ino_AccountsPayableAndAccruedExpensesLineItems" abstract="true" name="AccountsPayableAndAccruedExpensesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" abstract="false" name="StockSaleAgreementAggregateProceedsFromIssuanceOfStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" abstract="false" name="ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" abstract="false" name="ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_IncomeTaxReconciliationStatuteLimitations" abstract="false" name="IncomeTaxReconciliationStatuteLimitations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PropertyPlantAndEquipmentDisposedOfBySale" abstract="false" name="PropertyPlantAndEquipmentDisposedOfBySale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsIndefinitelyCarryforward" abstract="false" name="OperatingLossCarryforwardsIndefinitelyCarryforward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeNumberOfLeaseAgreementsEnteredInto" abstract="false" name="LesseeNumberOfLeaseAgreementsEnteredInto" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ino_BillAndMelindaGatesFoundationMember" abstract="true" name="BillAndMelindaGatesFoundationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinTwoYears" abstract="false" name="OperatingLossCarryforwardsExpiringinTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_OperatingLossCarryforwardsExpiringinFiveYears" abstract="false" name="OperatingLossCarryforwardsExpiringinFiveYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_A6.50ConvertibleSeniorNotesDue2024Member" abstract="true" name="A6.50ConvertibleSeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_ConvertibleBondsMember" abstract="true" name="ConvertibleBondsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_SeriesA2OnePreferredStockMember" abstract="true" name="SeriesA2OnePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_DeferredGrantFundingFromAffiliate" abstract="false" name="DeferredGrantFundingFromAffiliate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DeferredGrantFundingCurrent" abstract="false" name="DeferredGrantFundingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_ComprehensiveIncomeLossTaxExpenseBenefit" abstract="false" name="ComprehensiveIncomeLossTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_DebtInstrumentConvertibleDebtConvertedAmount" abstract="false" name="DebtInstrumentConvertibleDebtConvertedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_PennsylvaniaStateIncomeTaxAuthorityMember" abstract="true" name="PennsylvaniaStateIncomeTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_PlymouthMeetingPennsylvaniaMember" abstract="true" name="PlymouthMeetingPennsylvaniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_RestructuringAndRelatedCostExpectedAnnualSavings" abstract="false" name="RestructuringAndRelatedCostExpectedAnnualSavings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_UnderwrittenPublicOfferingMember" abstract="true" name="UnderwrittenPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CertainBalanceSheetItemsAbstract" abstract="true" name="CertainBalanceSheetItemsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ino_RangeOfExercisePricesSixMember" abstract="true" name="RangeOfExercisePricesSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborativeAgreementAwardedExercisedAmount" abstract="false" name="CollaborativeAgreementAwardedExercisedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_LesseeOperatingLeaseAreaofLandUnderLease" abstract="false" name="LesseeOperatingLeaseAreaofLandUnderLease" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="ino_SalesAgreementMember" abstract="true" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_CollaborationAgreementRoyaltyPeriod" abstract="false" name="CollaborationAgreementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ino_CollaborativeAgreementExpensesToReimburse" abstract="false" name="CollaborativeAgreementExpensesToReimburse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ino_MutualFundsMember" abstract="true" name="MutualFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_BiojectMember" abstract="true" name="BiojectMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ino_NonEmployeeMember" abstract="true" name="NonEmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ino-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5376b60-4920-4297-91b8-ae15a0711c84,g:73741ec8-2e2b-4617-87f5-1b9c1ea3fbd1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff501e7d-f008-41cd-be28-fea00764e6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f7f1cd47-8e7a-4080-abb2-16586c33bb9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff501e7d-f008-41cd-be28-fea00764e6bb" xlink:to="loc_us-gaap_CommonStockValue_f7f1cd47-8e7a-4080-abb2-16586c33bb9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6aef42f6-c04b-4f89-9870-cc74de52c210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff501e7d-f008-41cd-be28-fea00764e6bb" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6aef42f6-c04b-4f89-9870-cc74de52c210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5b21d6a6-01ff-450e-a0a0-aa64bad594b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff501e7d-f008-41cd-be28-fea00764e6bb" xlink:to="loc_us-gaap_PreferredStockValue_5b21d6a6-01ff-450e-a0a0-aa64bad594b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5115b112-c65d-484c-886f-69eff82bef35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff501e7d-f008-41cd-be28-fea00764e6bb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5115b112-c65d-484c-886f-69eff82bef35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_567f9486-22f8-40e4-8a82-01fed4267b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_ff501e7d-f008-41cd-be28-fea00764e6bb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_567f9486-22f8-40e4-8a82-01fed4267b8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0e988166-10e7-4467-8dd9-1c9dc0d7e3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_dabaad88-f7ba-4871-9387-189bbae1e0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0e988166-10e7-4467-8dd9-1c9dc0d7e3f6" xlink:to="loc_us-gaap_StockholdersEquity_dabaad88-f7ba-4871-9387-189bbae1e0b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_852119a4-e39b-4977-8066-bb3542010830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0e988166-10e7-4467-8dd9-1c9dc0d7e3f6" xlink:to="loc_us-gaap_Liabilities_852119a4-e39b-4977-8066-bb3542010830" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b9444c0e-40d9-4a22-a2b7-e59c9f8d730b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0e988166-10e7-4467-8dd9-1c9dc0d7e3f6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b9444c0e-40d9-4a22-a2b7-e59c9f8d730b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b56d11ba-1cc9-453b-8e65-b679d21ca9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b56d11ba-1cc9-453b-8e65-b679d21ca9b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_ce98c861-a8e5-40fb-a598-ee72fef1f8eb" xlink:href="ino-20221231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_ce98c861-a8e5-40fb-a598-ee72fef1f8eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f24541fb-dd92-47ef-9b41-71662e4adb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f24541fb-dd92-47ef-9b41-71662e4adb3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_7e5f2786-a21c-4a14-bf10-d483de3d049b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_7e5f2786-a21c-4a14-bf10-d483de3d049b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_812fb4f2-c55f-4e9e-b567-825b6d41089e" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:to="loc_ino_DeferredGrantFundingCurrent_812fb4f2-c55f-4e9e-b567-825b6d41089e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_95849872-5d25-4047-be68-32ac51ee545b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_95849872-5d25-4047-be68-32ac51ee545b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b834ecd-510d-4c6d-94c8-8eaf1f300b68" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_6cce7ab8-c539-4d2b-a004-c84d73726526" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_4b834ecd-510d-4c6d-94c8-8eaf1f300b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_b25c462b-fd75-4e46-8793-2e21b8d4ed39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_530f2474-aa31-4bae-a8fc-8748b0c4f0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b25c462b-fd75-4e46-8793-2e21b8d4ed39" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_530f2474-aa31-4bae-a8fc-8748b0c4f0cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7fe98bc-7f7a-4be0-91cb-612f4a56781c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b25c462b-fd75-4e46-8793-2e21b8d4ed39" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7fe98bc-7f7a-4be0-91cb-612f4a56781c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_2046db8c-25f1-4a8c-9cdc-6b65810919ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b25c462b-fd75-4e46-8793-2e21b8d4ed39" xlink:to="loc_us-gaap_ShortTermInvestments_2046db8c-25f1-4a8c-9cdc-6b65810919ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_8fe02e75-eef2-4561-8c17-b15ad1beec35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b25c462b-fd75-4e46-8793-2e21b8d4ed39" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_8fe02e75-eef2-4561-8c17-b15ad1beec35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_745780fb-947f-4b81-a379-29f93fced1e0" xlink:href="ino-20221231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b25c462b-fd75-4e46-8793-2e21b8d4ed39" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_745780fb-947f-4b81-a379-29f93fced1e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a66d9de7-e52c-4269-b57a-70eff9ce13d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_b25c462b-fd75-4e46-8793-2e21b8d4ed39" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a66d9de7-e52c-4269-b57a-70eff9ce13d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8069d5ff-c700-40ff-a337-1e369aa55c40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8bf40ee7-b621-4e51-afed-5e992f531cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8069d5ff-c700-40ff-a337-1e369aa55c40" xlink:to="loc_us-gaap_LiabilitiesCurrent_8bf40ee7-b621-4e51-afed-5e992f531cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9d5226b4-7d98-4661-9fb9-6eee71d2252f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8069d5ff-c700-40ff-a337-1e369aa55c40" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9d5226b4-7d98-4661-9fb9-6eee71d2252f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_49f0f528-7a40-4770-9d89-879c258fae46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8069d5ff-c700-40ff-a337-1e369aa55c40" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_49f0f528-7a40-4770-9d89-879c258fae46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02ad0a8d-8928-4b94-9b12-ae6a562d0458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8069d5ff-c700-40ff-a337-1e369aa55c40" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_02ad0a8d-8928-4b94-9b12-ae6a562d0458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f07dd400-523a-4d48-9465-84d7ef9ed2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8069d5ff-c700-40ff-a337-1e369aa55c40" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f07dd400-523a-4d48-9465-84d7ef9ed2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_55e6667e-6645-43c3-82f6-a2ffdbde6bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8069d5ff-c700-40ff-a337-1e369aa55c40" xlink:to="loc_us-gaap_ConvertibleDebt_55e6667e-6645-43c3-82f6-a2ffdbde6bc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_25aa4974-95ea-47cf-84c0-2c6d2e1760ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:to="loc_us-gaap_AssetsCurrent_25aa4974-95ea-47cf-84c0-2c6d2e1760ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_67207d23-e096-41ad-a4e5-f220c93657c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_67207d23-e096-41ad-a4e5-f220c93657c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_40f3621a-9756-44ce-8dbe-902d554db770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_40f3621a-9756-44ce-8dbe-902d554db770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_88ff066d-9410-4ffd-b107-e5d8d87abfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_88ff066d-9410-4ffd-b107-e5d8d87abfe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7415d707-83c2-4c6e-a397-60bef1fd33cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_7415d707-83c2-4c6e-a397-60bef1fd33cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_52745ccc-4c65-4784-9017-49df671dcd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:to="loc_us-gaap_Goodwill_52745ccc-4c65-4784-9017-49df671dcd8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a9f7248-af9f-47d9-aad4-158c0f3e173f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_372fda4a-72d2-4e84-a761-2abd6f791ec6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2a9f7248-af9f-47d9-aad4-158c0f3e173f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f8db6795-00a0-42eb-a05b-f639ec53a6af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_f8db6795-00a0-42eb-a05b-f639ec53a6af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_d3a99bc7-0afb-4f18-b2ea-751aff1868b1" xlink:href="ino-20221231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_d3a99bc7-0afb-4f18-b2ea-751aff1868b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_0ca42904-fc1d-4a57-9a91-38b1de4d89a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_InterestIncomeOperating_0ca42904-fc1d-4a57-9a91-38b1de4d89a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_7a314559-8965-40d6-b958-752af6269f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_InterestExpense_7a314559-8965-40d6-b958-752af6269f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_0b8b59e2-87a9-431a-838c-686f08876cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_0b8b59e2-87a9-431a-838c-686f08876cf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1ce0e89a-0e8a-4f5a-aa09-d818c272f02a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1ce0e89a-0e8a-4f5a-aa09-d818c272f02a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b329cc82-6f1f-4772-880d-5d0b844144f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_OperatingIncomeLoss_b329cc82-6f1f-4772-880d-5d0b844144f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d5a0c0d3-6aa9-4c3a-97f5-c87dd2d4aeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d5a0c0d3-6aa9-4c3a-97f5-c87dd2d4aeb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_20964853-81d9-48a0-9285-22075f1550ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_bedd3136-13de-4ee0-b7e3-d5506643bdf3" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_20964853-81d9-48a0-9285-22075f1550ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_80a79df1-f05b-4320-95c9-1527eab47532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d769e3c-5acd-4efd-a31c-db7140cb45f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_80a79df1-f05b-4320-95c9-1527eab47532" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1d769e3c-5acd-4efd-a31c-db7140cb45f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7597359b-52db-46db-9640-144b0e7f7cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_80a79df1-f05b-4320-95c9-1527eab47532" xlink:to="loc_us-gaap_OperatingExpenses_7597359b-52db-46db-9640-144b0e7f7cc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c517e876-6489-4290-9990-a5238592f0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bc530c75-8aa0-48d1-8950-177d278958b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c517e876-6489-4290-9990-a5238592f0e4" xlink:to="loc_us-gaap_ProfitLoss_bc530c75-8aa0-48d1-8950-177d278958b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5d8e1402-9e53-42a6-a158-0fba622bff85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c517e876-6489-4290-9990-a5238592f0e4" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5d8e1402-9e53-42a6-a158-0fba622bff85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6c45b463-2048-4f3e-8da4-7105d9ff0dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_dea3c39f-e654-4166-b076-8cf383cb7e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6c45b463-2048-4f3e-8da4-7105d9ff0dc5" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_dea3c39f-e654-4166-b076-8cf383cb7e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_14ba982d-f0a0-4d01-9d6c-2c956f565213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6c45b463-2048-4f3e-8da4-7105d9ff0dc5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_14ba982d-f0a0-4d01-9d6c-2c956f565213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6a5e8668-4562-4184-8ddc-bbc9c5b5d64a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_de210d56-684b-4d65-8fd7-6df51278bb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_6a5e8668-4562-4184-8ddc-bbc9c5b5d64a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_de210d56-684b-4d65-8fd7-6df51278bb26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61737e41-252f-43f3-be64-620709b3b85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_6a5e8668-4562-4184-8ddc-bbc9c5b5d64a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61737e41-252f-43f3-be64-620709b3b85a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_e5ca87db-2063-4697-a072-b1a16257205e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_02725a92-2fec-499b-92bf-189627cb904d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e5ca87db-2063-4697-a072-b1a16257205e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_02725a92-2fec-499b-92bf-189627cb904d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e8d7fbb5-f257-469a-a46a-fd9588fd0503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_e5ca87db-2063-4697-a072-b1a16257205e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e8d7fbb5-f257-469a-a46a-fd9588fd0503" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be0cd494-5d9c-4dfa-a410-0f747e2ffeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6bb21cf0-c4b0-416e-b549-c03a19145b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be0cd494-5d9c-4dfa-a410-0f747e2ffeef" xlink:to="loc_us-gaap_ProfitLoss_6bb21cf0-c4b0-416e-b549-c03a19145b4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7790f54f-78c6-4429-957a-a88654809154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be0cd494-5d9c-4dfa-a410-0f747e2ffeef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_7790f54f-78c6-4429-957a-a88654809154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3185be40-58cf-4843-9933-d94998d0dd97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_be0cd494-5d9c-4dfa-a410-0f747e2ffeef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3185be40-58cf-4843-9933-d94998d0dd97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8046b4eb-9184-4323-9416-1a0e0ec95893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_210a2273-ebde-4279-89de-9c7663262324" xlink:href="ino-20221231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8046b4eb-9184-4323-9416-1a0e0ec95893" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_210a2273-ebde-4279-89de-9c7663262324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c1594187-91d7-4252-b77c-b9740a0b9cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8046b4eb-9184-4323-9416-1a0e0ec95893" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c1594187-91d7-4252-b77c-b9740a0b9cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_d025b97b-b248-4077-a5fc-dd6c3153f5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8046b4eb-9184-4323-9416-1a0e0ec95893" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_d025b97b-b248-4077-a5fc-dd6c3153f5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_c699450d-1e8d-4aa2-a9ff-b6d738f6c452" xlink:href="ino-20221231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8046b4eb-9184-4323-9416-1a0e0ec95893" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_c699450d-1e8d-4aa2-a9ff-b6d738f6c452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_e07e7aab-3e3c-486f-b1f9-88b6f925e303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8046b4eb-9184-4323-9416-1a0e0ec95893" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_e07e7aab-3e3c-486f-b1f9-88b6f925e303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_d73554b0-5aa1-4cfb-967c-37ce58814fad" xlink:href="ino-20221231.xsd#ino_NonCashInterestExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_ino_NonCashInterestExpense_d73554b0-5aa1-4cfb-967c-37ce58814fad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d73f373f-a94e-432a-a0c2-52ebe35114d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_Depreciation_d73f373f-a94e-432a-a0c2-52ebe35114d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c9107be-cd13-4d6c-bbd6-1c54fff09c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2c9107be-cd13-4d6c-bbd6-1c54fff09c14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_9ab0eb0a-8619-4482-a100-4ca4a8d642c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_9ab0eb0a-8619-4482-a100-4ca4a8d642c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_1b69a306-1a48-4550-895d-cfbfa8b79eee" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_1b69a306-1a48-4550-895d-cfbfa8b79eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_05d00686-0ba7-4b91-8fc1-97263573724c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_05d00686-0ba7-4b91-8fc1-97263573724c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_35380f73-0020-47c4-9dcb-31fd381e84f5" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_35380f73-0020-47c4-9dcb-31fd381e84f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_552d81cd-25b8-414f-a454-f887a296211d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_552d81cd-25b8-414f-a454-f887a296211d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_069409ea-3c2a-4c4d-81d1-e10352993082" xlink:href="ino-20221231.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_069409ea-3c2a-4c4d-81d1-e10352993082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8d56def4-52c2-469f-991c-d57e728a930b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8d56def4-52c2-469f-991c-d57e728a930b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_83ac9371-9ac1-4193-b96c-c58c3a0125af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_83ac9371-9ac1-4193-b96c-c58c3a0125af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_36318c63-a056-4fdc-9c60-538c1f9ae72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_36318c63-a056-4fdc-9c60-538c1f9ae72f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2aa18752-3740-4888-9a97-9d60deba707c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_2aa18752-3740-4888-9a97-9d60deba707c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b1e57c94-ed25-4c25-8f92-0c40faf055b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b1e57c94-ed25-4c25-8f92-0c40faf055b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_b91f7bd2-c3b6-49cf-9138-4b7a39e70ba5" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_b91f7bd2-c3b6-49cf-9138-4b7a39e70ba5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0c9105ca-2af1-43b6-b035-a77a7507245c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_0c9105ca-2af1-43b6-b035-a77a7507245c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_09bc377c-e65e-4694-b325-3b9f33fb356a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_09bc377c-e65e-4694-b325-3b9f33fb356a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_60ba241d-9fe3-4ecd-b827-b545d96fd7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_60ba241d-9fe3-4ecd-b827-b545d96fd7d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c365d2bb-67f6-4cc0-bf25-12eb57e5cfe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c365d2bb-67f6-4cc0-bf25-12eb57e5cfe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_d138159f-1c06-4291-a224-60a488dc67e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_d138159f-1c06-4291-a224-60a488dc67e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_2f658f34-7844-49f9-b19b-1b5f49e6144e" xlink:href="ino-20221231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_2f658f34-7844-49f9-b19b-1b5f49e6144e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bdba11fa-5e9f-4509-b86c-13882a5aa294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_ProfitLoss_bdba11fa-5e9f-4509-b86c-13882a5aa294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2a3376cd-298d-4b17-a391-92a1c255c34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_2a3376cd-298d-4b17-a391-92a1c255c34a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_408d1934-569a-48a8-a9d0-9f1675ad8f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_408d1934-569a-48a8-a9d0-9f1675ad8f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fd6a9029-6df1-407e-a13e-4b8cc0733561" xlink:href="ino-20221231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:calculationArc order="25" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_fd6a9029-6df1-407e-a13e-4b8cc0733561" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_a48d23b2-b14a-4e00-8607-e75b7bd4ae4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:calculationArc order="26" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_a48d23b2-b14a-4e00-8607-e75b7bd4ae4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6da668b2-42ce-4af2-a168-bd393cf197c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="27" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a6f66be3-ceed-473a-ba95-74d74113d233" xlink:to="loc_us-gaap_ShareBasedCompensation_6da668b2-42ce-4af2-a168-bd393cf197c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3631bdc-22aa-496b-85e9-2cc1760f2ec5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_502e8a17-8f72-48fb-9ec7-b6581f237545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3631bdc-22aa-496b-85e9-2cc1760f2ec5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_502e8a17-8f72-48fb-9ec7-b6581f237545" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f411a316-9406-471c-b458-19aa91db18d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3631bdc-22aa-496b-85e9-2cc1760f2ec5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f411a316-9406-471c-b458-19aa91db18d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b05dfad-c1da-417f-a0ed-48fed284b5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3631bdc-22aa-496b-85e9-2cc1760f2ec5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7b05dfad-c1da-417f-a0ed-48fed284b5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23c79820-2aec-41ab-b8b3-787fd5e53ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d3631bdc-22aa-496b-85e9-2cc1760f2ec5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_23c79820-2aec-41ab-b8b3-787fd5e53ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b9221dd-d07b-4d36-8ed7-9e5426a9b9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_0bc95d62-47a2-4a74-a769-3e38934df29e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b9221dd-d07b-4d36-8ed7-9e5426a9b9fb" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_0bc95d62-47a2-4a74-a769-3e38934df29e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_14a41c69-e5eb-4c58-8fae-d635a6f0aacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b9221dd-d07b-4d36-8ed7-9e5426a9b9fb" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_14a41c69-e5eb-4c58-8fae-d635a6f0aacb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74074ba6-ff2a-4875-ac53-e7f6c93df233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b9221dd-d07b-4d36-8ed7-9e5426a9b9fb" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_74074ba6-ff2a-4875-ac53-e7f6c93df233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7a1daf98-cfec-4796-8341-0369914ee6c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b9221dd-d07b-4d36-8ed7-9e5426a9b9fb" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_7a1daf98-cfec-4796-8341-0369914ee6c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_af12200f-8db7-414e-8641-ebf72d59b9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b9221dd-d07b-4d36-8ed7-9e5426a9b9fb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_af12200f-8db7-414e-8641-ebf72d59b9a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_fa1fd32b-8e5b-46e5-8bed-7f77df19b800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b9221dd-d07b-4d36-8ed7-9e5426a9b9fb" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_fa1fd32b-8e5b-46e5-8bed-7f77df19b800" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e631b4df-de93-4403-97e5-03827c003a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75dfbc62-4c51-4d21-ae1e-a1c748bc71b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e631b4df-de93-4403-97e5-03827c003a14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_75dfbc62-4c51-4d21-ae1e-a1c748bc71b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bec36729-b71e-46d5-a380-67026647d1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e631b4df-de93-4403-97e5-03827c003a14" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_bec36729-b71e-46d5-a380-67026647d1dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bbded3a-2d13-490b-90c7-e1f9b2c73a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e631b4df-de93-4403-97e5-03827c003a14" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6bbded3a-2d13-490b-90c7-e1f9b2c73a40" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4f7c224c-ed7a-45c0-a541-2439db63b26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6ccecea5-514e-4105-a5af-20b9a1ccc2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f7c224c-ed7a-45c0-a541-2439db63b26e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6ccecea5-514e-4105-a5af-20b9a1ccc2ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_1849a8e6-d290-478d-bccb-add82c44f583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4f7c224c-ed7a-45c0-a541-2439db63b26e" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_1849a8e6-d290-478d-bccb-add82c44f583" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84faff3d-783e-4ab8-b378-bf266abeb117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_2622bb65-b1bf-405c-b093-4096ef6755f5" xlink:href="ino-20221231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84faff3d-783e-4ab8-b378-bf266abeb117" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_2622bb65-b1bf-405c-b093-4096ef6755f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_16da4541-8122-4ea4-9a41-db1a406521c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84faff3d-783e-4ab8-b378-bf266abeb117" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_16da4541-8122-4ea4-9a41-db1a406521c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_db61c200-3bd0-46a8-8a6a-ecac1bfdb4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_84faff3d-783e-4ab8-b378-bf266abeb117" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_db61c200-3bd0-46a8-8a6a-ecac1bfdb4cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_380633b8-293f-413e-b813-fc5c4c10c468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_c65319d1-3f59-47e1-91e1-eaad8684faae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_380633b8-293f-413e-b813-fc5c4c10c468" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_c65319d1-3f59-47e1-91e1-eaad8684faae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_ca919908-5f3d-4fa1-84cc-7d3fe6b61e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_380633b8-293f-413e-b813-fc5c4c10c468" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_ca919908-5f3d-4fa1-84cc-7d3fe6b61e6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_12b34a94-53ef-46b9-b908-9dc40ed4bf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_380633b8-293f-413e-b813-fc5c4c10c468" xlink:to="loc_us-gaap_AccruedSalariesCurrent_12b34a94-53ef-46b9-b908-9dc40ed4bf9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_b0782543-6bdb-4747-8d9c-a8d997bb5c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_380633b8-293f-413e-b813-fc5c4c10c468" xlink:to="loc_us-gaap_LitigationReserveCurrent_b0782543-6bdb-4747-8d9c-a8d997bb5c3f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#FixedAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ac14bb9d-86be-4124-a408-86f86ab957eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c96c592d-630f-4803-82f2-f1bcce615506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ac14bb9d-86be-4124-a408-86f86ab957eb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c96c592d-630f-4803-82f2-f1bcce615506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ea232bf-aeec-42f0-8f0f-dfaf34aec1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ac14bb9d-86be-4124-a408-86f86ab957eb" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ea232bf-aeec-42f0-8f0f-dfaf34aec1b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_937bbed5-8dc0-4fdc-a101-e75f6270b152" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_80d2618c-54de-4ebe-bd89-28df0f231151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_937bbed5-8dc0-4fdc-a101-e75f6270b152" xlink:to="loc_us-gaap_Goodwill_80d2618c-54de-4ebe-bd89-28df0f231151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1a88b1f-d4de-437a-b237-0c55ae61600b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_937bbed5-8dc0-4fdc-a101-e75f6270b152" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e1a88b1f-d4de-437a-b237-0c55ae61600b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e58d8ec6-fd9c-489a-a986-6868ef0d40cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fc57bb4-f8fe-4480-b593-39676b1a2f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e58d8ec6-fd9c-489a-a986-6868ef0d40cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9fc57bb4-f8fe-4480-b593-39676b1a2f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6afda08d-7dd4-4cb0-a3f8-98e975bbf709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e58d8ec6-fd9c-489a-a986-6868ef0d40cd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6afda08d-7dd4-4cb0-a3f8-98e975bbf709" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_2a854dd1-548a-4185-a8c6-7d8798549f94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_caea585a-40ca-4e7f-a34f-6358828b866d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Goodwill_2a854dd1-548a-4185-a8c6-7d8798549f94" xlink:to="loc_us-gaap_GoodwillGross_caea585a-40ca-4e7f-a34f-6358828b866d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_06153b3e-da84-4f86-be5c-048d6aa5b43f" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_16af6136-e35a-41e4-a916-77f795401cbe" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_06153b3e-da84-4f86-be5c-048d6aa5b43f" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_16af6136-e35a-41e4-a916-77f795401cbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8333f87c-839e-45a0-b463-540ce5405681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet_06153b3e-da84-4f86-be5c-048d6aa5b43f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_8333f87c-839e-45a0-b463-540ce5405681" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2e15cc9-6980-44b0-a7a0-4e305570acee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_179540ff-458e-428e-b833-323d74688298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2e15cc9-6980-44b0-a7a0-4e305570acee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_179540ff-458e-428e-b833-323d74688298" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e6da8841-66d7-4b6b-88f3-5925f8726af4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2e15cc9-6980-44b0-a7a0-4e305570acee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e6da8841-66d7-4b6b-88f3-5925f8726af4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_82cacbb6-a6c5-4833-8961-2f8531c950d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2e15cc9-6980-44b0-a7a0-4e305570acee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_82cacbb6-a6c5-4833-8961-2f8531c950d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_27342024-448d-4dda-8194-1e50a55e9f55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2e15cc9-6980-44b0-a7a0-4e305570acee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_27342024-448d-4dda-8194-1e50a55e9f55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b4cfa100-b547-40df-ada9-3398bea1a162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2e15cc9-6980-44b0-a7a0-4e305570acee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b4cfa100-b547-40df-ada9-3398bea1a162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f997c30a-e255-4ee2-9b40-3051ce873194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c2e15cc9-6980-44b0-a7a0-4e305570acee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_f997c30a-e255-4ee2-9b40-3051ce873194" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3bfd4b48-da3f-4ce0-a72f-b97d0d6a5e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_80c86bb6-9687-4e54-b658-b88e94b95597" xlink:href="ino-20221231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3bfd4b48-da3f-4ce0-a72f-b97d0d6a5e70" xlink:to="loc_ino_DebtinstrumentAccruedInterest_80c86bb6-9687-4e54-b658-b88e94b95597" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9442a8d2-30fe-4748-a98b-e128992042df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3bfd4b48-da3f-4ce0-a72f-b97d0d6a5e70" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9442a8d2-30fe-4748-a98b-e128992042df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_3868363b-6cbc-4c15-bf2a-a53a3b7721f8" xlink:href="ino-20221231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3bfd4b48-da3f-4ce0-a72f-b97d0d6a5e70" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_3868363b-6cbc-4c15-bf2a-a53a3b7721f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_ee908abf-b7a7-4e31-8623-8ac58074de99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_3bfd4b48-da3f-4ce0-a72f-b97d0d6a5e70" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_ee908abf-b7a7-4e31-8623-8ac58074de99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_80098888-a6ef-45db-8788-87b4fbdc5dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f000089f-5880-43ac-b72e-6d7bc960199b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80098888-a6ef-45db-8788-87b4fbdc5dea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f000089f-5880-43ac-b72e-6d7bc960199b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d21ff12b-1c67-40d9-9c02-f885671f5227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_80098888-a6ef-45db-8788-87b4fbdc5dea" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_d21ff12b-1c67-40d9-9c02-f885671f5227" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0a3821fb-e8fe-4ca5-be71-575ca356951a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9619365a-0f6d-4496-9eaa-74233ae122ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0a3821fb-e8fe-4ca5-be71-575ca356951a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9619365a-0f6d-4496-9eaa-74233ae122ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_99f54d63-4a65-45e4-aded-ec3610abdbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_0a3821fb-e8fe-4ca5-be71-575ca356951a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_99f54d63-4a65-45e4-aded-ec3610abdbcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16d9d631-56b4-428f-bdd5-ba81507a5a49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_074ea005-bc1a-4eff-8342-7728f3ebc9de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16d9d631-56b4-428f-bdd5-ba81507a5a49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_074ea005-bc1a-4eff-8342-7728f3ebc9de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0b9524a8-ac2e-4c97-8130-8e23b7359f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16d9d631-56b4-428f-bdd5-ba81507a5a49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0b9524a8-ac2e-4c97-8130-8e23b7359f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_18fbef2f-7164-4db5-816d-f2a059c84328" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16d9d631-56b4-428f-bdd5-ba81507a5a49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_18fbef2f-7164-4db5-816d-f2a059c84328" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_71595b37-362d-4549-8416-e84955e7bb29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16d9d631-56b4-428f-bdd5-ba81507a5a49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_71595b37-362d-4549-8416-e84955e7bb29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2316cf0d-17fd-4cb3-be1d-d955b971930b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16d9d631-56b4-428f-bdd5-ba81507a5a49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2316cf0d-17fd-4cb3-be1d-d955b971930b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_4333c62d-a744-4956-897b-1d848fe37bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16d9d631-56b4-428f-bdd5-ba81507a5a49" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_4333c62d-a744-4956-897b-1d848fe37bc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bb1dc313-1b30-4a4b-8ec3-abaff97538ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d4a34f0-a913-4c16-b216-3908559e0dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bb1dc313-1b30-4a4b-8ec3-abaff97538ba" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3d4a34f0-a913-4c16-b216-3908559e0dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2ef3eb26-19e2-42b9-96c5-9b6b2a49664c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bb1dc313-1b30-4a4b-8ec3-abaff97538ba" xlink:to="loc_us-gaap_OperatingLeaseLiability_2ef3eb26-19e2-42b9-96c5-9b6b2a49664c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29313e69-b1a3-4941-908e-eb9de5070f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0970f69c-92b8-4de6-b81e-adc1b9f7c4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29313e69-b1a3-4941-908e-eb9de5070f13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0970f69c-92b8-4de6-b81e-adc1b9f7c4d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bcf9868b-91f2-451c-af30-1a0508fa8241" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_29313e69-b1a3-4941-908e-eb9de5070f13" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_bcf9868b-91f2-451c-af30-1a0508fa8241" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:href="ino-20221231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_025307df-603b-4a77-8a1a-ddb271234f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_025307df-603b-4a77-8a1a-ddb271234f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4860cffb-7f93-4859-b085-0dc5c98852a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_4860cffb-7f93-4859-b085-0dc5c98852a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_176109d4-0eb5-4552-b524-c3abf1834e68" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_176109d4-0eb5-4552-b524-c3abf1834e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_32462d00-15fa-4294-9ce5-17234b91ba1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_32462d00-15fa-4294-9ce5-17234b91ba1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_ff5f7335-8517-40a5-b694-14f8b95d08c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_ff5f7335-8517-40a5-b694-14f8b95d08c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_5a53fedd-c669-431c-914a-8a485dfa5469" xlink:href="ino-20221231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_5a53fedd-c669-431c-914a-8a485dfa5469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b6837acd-5564-4640-afd3-ef50fa97858a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_b6837acd-5564-4640-afd3-ef50fa97858a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_e5c86bb0-3fc3-46b9-abfb-bca9577f3d69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_e5c86bb0-3fc3-46b9-abfb-bca9577f3d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2c9a2a51-4683-49dd-b245-96ca613431e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2c9a2a51-4683-49dd-b245-96ca613431e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_31eb136a-e213-4a98-9b58-794a2433b9d2" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_31eb136a-e213-4a98-9b58-794a2433b9d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1008c7e9-ecf1-4ca2-8c80-63dd2bb80bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_1008c7e9-ecf1-4ca2-8c80-63dd2bb80bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_602806b7-aa1d-49a3-bdae-16bd78395299" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_602806b7-aa1d-49a3-bdae-16bd78395299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_ec7d1758-c0a6-4ae5-afde-5ea7c140e8d1" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_782dbc11-b0eb-4b11-8df4-fe2b828e382a" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_ec7d1758-c0a6-4ae5-afde-5ea7c140e8d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1ac86a50-2c48-4015-bf40-9fdb98974bce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1ac86a50-2c48-4015-bf40-9fdb98974bce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2c0d7f54-0be6-4ae9-96a6-83c7078f36c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2c0d7f54-0be6-4ae9-96a6-83c7078f36c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_c06f06a9-b366-44e0-a447-5f10547543e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_c06f06a9-b366-44e0-a447-5f10547543e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e6be48af-fae9-4a2f-bf8a-28f86ae314a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e6be48af-fae9-4a2f-bf8a-28f86ae314a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ff91a3a0-9be3-40a2-adc3-5b3620fb3453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_ff91a3a0-9be3-40a2-adc3-5b3620fb3453" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_d08a326a-cbc4-456b-9aca-ac42a3e17032" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_d08a326a-cbc4-456b-9aca-ac42a3e17032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_1cd5abcd-6ace-4a8e-8556-8c1444f4d133" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_1cd5abcd-6ace-4a8e-8556-8c1444f4d133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_13d0350f-c333-44e4-9ebe-b2cb4f7dc417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_13d0350f-c333-44e4-9ebe-b2cb4f7dc417" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_65a901c6-6c39-469e-bd0a-bf5ecd2fc696" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_65a901c6-6c39-469e-bd0a-bf5ecd2fc696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_b3e6378c-3937-49df-bfca-c06355ff4a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_b3e6378c-3937-49df-bfca-c06355ff4a78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_90c72901-7401-4e9d-828f-3cf39cf264e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_3a5c387b-843a-4187-abee-ca1c81e3a024" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_90c72901-7401-4e9d-828f-3cf39cf264e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2f283beb-c4a8-458a-b1cb-eaab3a3e81d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c0099df7-ffcf-4d37-9f5c-37a381daba44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2f283beb-c4a8-458a-b1cb-eaab3a3e81d1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_c0099df7-ffcf-4d37-9f5c-37a381daba44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0da5b498-4344-48b8-846a-120d105e2898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_2f283beb-c4a8-458a-b1cb-eaab3a3e81d1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0da5b498-4344-48b8-846a-120d105e2898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_38f36610-2920-4e2d-acd0-cfb826d733c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9b2a43b6-5291-47d2-8f3f-0922600db862" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_38f36610-2920-4e2d-acd0-cfb826d733c2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9b2a43b6-5291-47d2-8f3f-0922600db862" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_d57fe938-acde-44d2-b977-99b8f3183212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_38f36610-2920-4e2d-acd0-cfb826d733c2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_d57fe938-acde-44d2-b977-99b8f3183212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e921eed0-e1d4-4e9d-8454-abc229714652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_99d06618-08f4-428b-8158-3fca67128eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e921eed0-e1d4-4e9d-8454-abc229714652" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_99d06618-08f4-428b-8158-3fca67128eda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_647cff23-d6af-4886-a6f1-88041c81e4bd" xlink:href="ino-20221231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e921eed0-e1d4-4e9d-8454-abc229714652" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_647cff23-d6af-4886-a6f1-88041c81e4bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8b6dab7e-854a-40e5-b015-eaf46c90f13a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e921eed0-e1d4-4e9d-8454-abc229714652" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8b6dab7e-854a-40e5-b015-eaf46c90f13a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_247373d9-688a-48f3-95e2-3b170376d217" xlink:href="ino-20221231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_e921eed0-e1d4-4e9d-8454-abc229714652" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_247373d9-688a-48f3-95e2-3b170376d217" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:calculationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_f9744b14-1d27-4a78-b377-527ec8a2b76e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f55244b7-2c71-440a-ab95-74c71ed12973" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_f9744b14-1d27-4a78-b377-527ec8a2b76e" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f55244b7-2c71-440a-ab95-74c71ed12973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_724727f3-8812-4768-a924-d1c96e4c63f3" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_f9744b14-1d27-4a78-b377-527ec8a2b76e" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_724727f3-8812-4768-a924-d1c96e4c63f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_e164f7b5-43ec-4c9a-8815-c4374846a619" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_f9744b14-1d27-4a78-b377-527ec8a2b76e" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_e164f7b5-43ec-4c9a-8815-c4374846a619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_7f0bc7f9-f56d-473c-9250-d37e478d527d" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_f9744b14-1d27-4a78-b377-527ec8a2b76e" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_7f0bc7f9-f56d-473c-9250-d37e478d527d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_98da7e56-9e86-41f8-8f49-0c17200f70f7" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_f9744b14-1d27-4a78-b377-527ec8a2b76e" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_98da7e56-9e86-41f8-8f49-0c17200f70f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInSixYears_ef96466f-2693-486f-ba44-6b4a5bc6ab70" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringInSixYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLossCarryforwards_f9744b14-1d27-4a78-b377-527ec8a2b76e" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInSixYears_ef96466f-2693-486f-ba44-6b4a5bc6ab70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_3c0774b1-fe63-4561-a400-33c113619f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_57069738-4ca7-49d6-bb6e-be67d3a34407" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_3c0774b1-fe63-4561-a400-33c113619f1d" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_57069738-4ca7-49d6-bb6e-be67d3a34407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_21e0e973-40fb-4ad1-9088-49c74ed57c3e" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_3c0774b1-fe63-4561-a400-33c113619f1d" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_21e0e973-40fb-4ad1-9088-49c74ed57c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_29b6626d-45d7-4b9e-ad9c-1d9fcd201f75" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_3c0774b1-fe63-4561-a400-33c113619f1d" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_29b6626d-45d7-4b9e-ad9c-1d9fcd201f75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_9a4eda7d-600c-46ba-8313-f7b70ed70de6" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_3c0774b1-fe63-4561-a400-33c113619f1d" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_9a4eda7d-600c-46ba-8313-f7b70ed70de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_c2c61360-39e4-460c-a713-308797aa1307" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_3c0774b1-fe63-4561-a400-33c113619f1d" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_c2c61360-39e4-460c-a713-308797aa1307" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInSixYears_29220872-6118-43fd-8234-c905c6d750e8" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInSixYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_3c0774b1-fe63-4561-a400-33c113619f1d" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInSixYears_29220872-6118-43fd-8234-c905c6d750e8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ino-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5376b60-4920-4297-91b8-ae15a0711c84,g:73741ec8-2e2b-4617-87f5-1b9c1ea3fbd1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i1433c897b36d4d19bf9c060f5c0bd6c2_ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:to="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fcfd8189-7b06-41d5-b51d-91a056990430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fcfd8189-7b06-41d5-b51d-91a056990430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f4518558-9add-454c-88ef-313c5e9de36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_ShortTermInvestments_f4518558-9add-454c-88ef-313c5e9de36e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39a985be-f7b5-437c-9a00-fe85c949b5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39a985be-f7b5-437c-9a00-fe85c949b5e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_5569800c-1409-4bd8-b3b0-144578f1b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_5569800c-1409-4bd8-b3b0-144578f1b3ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c9f5296-b7c8-44b2-a2cd-f57252037895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c9f5296-b7c8-44b2-a2cd-f57252037895" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_bad93ddd-5b45-4c02-8738-e461dab4c72f" xlink:href="ino-20221231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_bad93ddd-5b45-4c02-8738-e461dab4c72f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_08c8f693-f157-491a-85b3-9a445feee2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_AssetsCurrent_08c8f693-f157-491a-85b3-9a445feee2da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_504194c7-023a-4070-bce5-ba7f460844c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_504194c7-023a-4070-bce5-ba7f460844c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b6dbda27-cddd-4849-a820-73c5e6ea9543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b6dbda27-cddd-4849-a820-73c5e6ea9543" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a1d32a1-882c-4284-8a9e-cb58f9eb0b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a1d32a1-882c-4284-8a9e-cb58f9eb0b1d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12844d3f-295e-4717-a935-e194361af89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_Goodwill_12844d3f-295e-4717-a935-e194361af89b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7cd5c88-c398-4e7d-8163-c7e7d44d8c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7cd5c88-c398-4e7d-8163-c7e7d44d8c65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9db4aec0-6d00-483d-ac09-cfed07b988f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9db4aec0-6d00-483d-ac09-cfed07b988f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_69888162-841c-4f32-9555-034f29d7460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_Assets_69888162-841c-4f32-9555-034f29d7460d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_56284ef0-448b-4681-831d-aabd7ffa09f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_56284ef0-448b-4681-831d-aabd7ffa09f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_bcd65c83-e62f-4348-b74f-b61da98709f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_bcd65c83-e62f-4348-b74f-b61da98709f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_2dc5a66e-5da9-4b69-8b20-c1e9a1eeb6f1" xlink:href="ino-20221231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_2dc5a66e-5da9-4b69-8b20-c1e9a1eeb6f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b9e87397-18ea-46df-beb6-a701a3e060db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b9e87397-18ea-46df-beb6-a701a3e060db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b8b4b89-80a9-4ca7-9ba9-a0a53cee8830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b8b4b89-80a9-4ca7-9ba9-a0a53cee8830" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_38d5609b-621f-4943-8387-417347f8385f" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_ino_DeferredGrantFundingCurrent_38d5609b-621f-4943-8387-417347f8385f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63fe9595-8e87-4bcc-9ec9-9fcc2aa124c4" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63fe9595-8e87-4bcc-9ec9-9fcc2aa124c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_87dade5e-3757-4cdb-a6b8-d894515c9dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_LiabilitiesCurrent_87dade5e-3757-4cdb-a6b8-d894515c9dff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_71fd0d94-334c-4adb-a743-29b801426ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_71fd0d94-334c-4adb-a743-29b801426ec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_d0609647-63f4-45e7-81cc-c559cdad7333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_ConvertibleDebt_d0609647-63f4-45e7-81cc-c559cdad7333" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9feea21-7b79-4195-a0b3-8dbeec6f27ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9feea21-7b79-4195-a0b3-8dbeec6f27ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_700e1d03-5392-4869-b474-ec8c6dfec257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_700e1d03-5392-4869-b474-ec8c6dfec257" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2998fb90-ec99-4601-8c05-ffbc9dbf3aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2998fb90-ec99-4601-8c05-ffbc9dbf3aa2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ac65b0d-6029-4530-a05a-c80275e00766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_Liabilities_5ac65b0d-6029-4530-a05a-c80275e00766" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d49ccfe-2c5f-4551-b1f0-0e638c10c8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d49ccfe-2c5f-4551-b1f0-0e638c10c8fc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a6d9dbfe-e80f-4c3c-bf14-f5db282e1660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_PreferredStockValue_a6d9dbfe-e80f-4c3c-bf14-f5db282e1660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3a0cdf12-ae58-4983-8e0c-9cb536ff4fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_CommonStockValue_3a0cdf12-ae58-4983-8e0c-9cb536ff4fb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_00c13deb-848d-4eb3-b520-8ae0bfe1862d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_AdditionalPaidInCapital_00c13deb-848d-4eb3-b520-8ae0bfe1862d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9074fbf7-d5ab-40b1-a44b-4540a9d2e219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9074fbf7-d5ab-40b1-a44b-4540a9d2e219" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9596fafb-15e9-41a9-9097-b475a0f0989b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9596fafb-15e9-41a9-9097-b475a0f0989b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02f64a17-19d7-4c2d-bc67-5c6d500271c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_StockholdersEquity_02f64a17-19d7-4c2d-bc67-5c6d500271c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_724ec278-c832-47be-b86d-46e32cb00751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_724ec278-c832-47be-b86d-46e32cb00751" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a8710c67-34ff-412b-ae69-47d8ffea0e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:to="loc_us-gaap_StatementTable_a8710c67-34ff-412b-ae69-47d8ffea0e77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3998a3fc-05e2-41a7-a847-1482e6d872dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a8710c67-34ff-412b-ae69-47d8ffea0e77" xlink:to="loc_us-gaap_DebtInstrumentAxis_3998a3fc-05e2-41a7-a847-1482e6d872dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3998a3fc-05e2-41a7-a847-1482e6d872dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3998a3fc-05e2-41a7-a847-1482e6d872dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3998a3fc-05e2-41a7-a847-1482e6d872dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_03ffc6b8-ebb7-4766-8b4d-04238eba7b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3998a3fc-05e2-41a7-a847-1482e6d872dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_03ffc6b8-ebb7-4766-8b4d-04238eba7b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_628d9e4b-b628-473f-9d68-49a4eb2dab88" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_03ffc6b8-ebb7-4766-8b4d-04238eba7b43" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_628d9e4b-b628-473f-9d68-49a4eb2dab88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i160502230e974ebda960682644d1d6a7_ConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d6b66eb0-794e-4a73-afc0-748b7931a503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_RevenuesAbstract_d6b66eb0-794e-4a73-afc0-748b7931a503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_717446a3-8418-4de6-88b9-2e7d225e1711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_d6b66eb0-794e-4a73-afc0-748b7931a503" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_717446a3-8418-4de6-88b9-2e7d225e1711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ed30cd14-49c6-4a44-abb8-efdebbf891c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ed30cd14-49c6-4a44-abb8-efdebbf891c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c1030fa4-b6f2-4b62-b8c2-d98af2b89c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c1030fa4-b6f2-4b62-b8c2-d98af2b89c33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9921af2a-dec7-413b-87fe-199bc26b503d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:to="loc_us-gaap_OperatingExpenses_9921af2a-dec7-413b-87fe-199bc26b503d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c1b54cc8-f2ac-4514-93cf-1ed8720461e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_OperatingIncomeLoss_c1b54cc8-f2ac-4514-93cf-1ed8720461e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_30d5bea6-1097-43e6-bb11-cacab53d570f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_InterestIncomeOperating_30d5bea6-1097-43e6-bb11-cacab53d570f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f86c0ae6-209e-4360-b149-b84d5727d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_InterestExpense_f86c0ae6-209e-4360-b149-b84d5727d9dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3709a127-97be-4516-be15-10f80088cffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3709a127-97be-4516-be15-10f80088cffb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_771b2ae4-89ce-49e6-a4db-1a0acfe964f5" xlink:href="ino-20221231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_771b2ae4-89ce-49e6-a4db-1a0acfe964f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8c734ae7-5fb3-411f-bb71-0799c07f7585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8c734ae7-5fb3-411f-bb71-0799c07f7585" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_29e57f33-fa4f-471c-8d44-5a24ad2586b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_29e57f33-fa4f-471c-8d44-5a24ad2586b3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_30a1ce6f-2249-436d-8d05-24947db1fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_30a1ce6f-2249-436d-8d05-24947db1fbed" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a12e33d-f0cf-422f-b2dc-ae03bdd2b9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a12e33d-f0cf-422f-b2dc-ae03bdd2b9b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_98d638ad-6d6f-4574-ab85-e86bbfe36e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_98d638ad-6d6f-4574-ab85-e86bbfe36e71" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_256b078d-cfea-4a81-a69e-b9bbb993a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_256b078d-cfea-4a81-a69e-b9bbb993a09b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c16a25df-d410-4851-9409-828a8b2bb7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_ProfitLoss_c16a25df-d410-4851-9409-828a8b2bb7ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_451017b8-f882-4363-948f-30c5748ad426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_451017b8-f882-4363-948f-30c5748ad426" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70715d7e-3e14-4de1-a413-052868273d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_NetIncomeLoss_70715d7e-3e14-4de1-a413-052868273d3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0bd66108-a83d-435e-9f52-fb1823ff2107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:to="loc_us-gaap_EarningsPerShareBasic_0bd66108-a83d-435e-9f52-fb1823ff2107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5d3431d4-ba0e-425f-bb07-e0b2239f230d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5d3431d4-ba0e-425f-bb07-e0b2239f230d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb1754ff-effc-49e9-8a83-b4b7fc357176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb1754ff-effc-49e9-8a83-b4b7fc357176" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_529eb9ee-e381-4959-845a-dc2cc5d7b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_529eb9ee-e381-4959-845a-dc2cc5d7b2bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3d1aa109-0523-4427-a5ce-c7ccd1bc4313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_StatementTable_3d1aa109-0523-4427-a5ce-c7ccd1bc4313" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e08749b8-e088-4a48-a02e-56bcc96851fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3d1aa109-0523-4427-a5ce-c7ccd1bc4313" xlink:to="loc_us-gaap_DebtInstrumentAxis_e08749b8-e088-4a48-a02e-56bcc96851fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e08749b8-e088-4a48-a02e-56bcc96851fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_e08749b8-e088-4a48-a02e-56bcc96851fd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e08749b8-e088-4a48-a02e-56bcc96851fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_e08749b8-e088-4a48-a02e-56bcc96851fd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_01518598-a75b-4d2f-9b3a-170188fbf0d7" xlink:href="ino-20221231.xsd#ino_ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:to="loc_ino_ConvertibleBondsMember_01518598-a75b-4d2f-9b3a-170188fbf0d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_362f8bc9-edfc-4ec3-a6b0-55b1e7fd2c14" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_362f8bc9-edfc-4ec3-a6b0-55b1e7fd2c14" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ib5f7eb95957140c69911597d4c1a33f0_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1274e265-d324-4b72-8632-ab7d8280571d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1274e265-d324-4b72-8632-ab7d8280571d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_50947185-5a46-4d8c-a9a4-515d414dfb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_SharesIssued_50947185-5a46-4d8c-a9a4-515d414dfb9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5bfb5209-20e2-4cbd-9a34-bd07db45c83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5bfb5209-20e2-4cbd-9a34-bd07db45c83b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc636399-5348-48d4-b8af-ab0e0fbcf9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc636399-5348-48d4-b8af-ab0e0fbcf9ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8436f329-aace-4e13-b796-1df546e3c582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8436f329-aace-4e13-b796-1df546e3c582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bdfba070-4e93-412f-9eee-260885de07fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bdfba070-4e93-412f-9eee-260885de07fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_00836eb0-7b38-40c4-a2d0-5f9a4c010792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_00836eb0-7b38-40c4-a2d0-5f9a4c010792" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_be42e8a4-085f-48fa-b267-8ce7006badf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_be42e8a4-085f-48fa-b267-8ce7006badf1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_04da6c7f-dbc7-4ef7-9c2d-51441b637d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_04da6c7f-dbc7-4ef7-9c2d-51441b637d28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acebe1ad-b34d-4f7c-8f97-778a36cbcb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acebe1ad-b34d-4f7c-8f97-778a36cbcb11" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_7ab68419-ab37-4493-8735-7b53326afb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_7ab68419-ab37-4493-8735-7b53326afb26" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4190e5e7-60fb-4d2d-a2d5-b0175ad99b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4190e5e7-60fb-4d2d-a2d5-b0175ad99b87" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0c066ff9-ce65-4edc-bc70-d2a6388af10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_ProfitLoss_0c066ff9-ce65-4edc-bc70-d2a6388af10b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47b2abef-49e4-47dc-ba3a-c44f6cb88c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47b2abef-49e4-47dc-ba3a-c44f6cb88c2c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_242d91a8-452b-47e6-bf0d-b5000d28743b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_242d91a8-452b-47e6-bf0d-b5000d28743b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4c46b7d6-fb36-4f22-81ea-3f3129fdf938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4c46b7d6-fb36-4f22-81ea-3f3129fdf938" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_690c6a53-735a-46d8-84bf-32d1d8eaa0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64827119-f3b7-492d-a2b7-496cf76baa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1274e265-d324-4b72-8632-ab7d8280571d" xlink:to="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aafccd50-dc24-4621-aa79-18ec3e544dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aafccd50-dc24-4621-aa79-18ec3e544dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aafccd50-dc24-4621-aa79-18ec3e544dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aafccd50-dc24-4621-aa79-18ec3e544dbb" xlink:to="loc_us-gaap_EquityComponentDomain_aafccd50-dc24-4621-aa79-18ec3e544dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aafccd50-dc24-4621-aa79-18ec3e544dbb" xlink:to="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4388213a-ca2e-41db-9d0e-1d65b12306da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_PreferredStockMember_4388213a-ca2e-41db-9d0e-1d65b12306da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5665d357-21d2-48f5-a9c6-f392fbf51b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_CommonStockMember_5665d357-21d2-48f5-a9c6-f392fbf51b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fe4258c2-da90-4b62-b88b-5f9fc34d49aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fe4258c2-da90-4b62-b88b-5f9fc34d49aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_88f14530-af32-4ac4-9012-2e4ab63b8aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_RetainedEarningsMember_88f14530-af32-4ac4-9012-2e4ab63b8aa1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89268b24-48bc-4ad1-b107-f14c56402f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89268b24-48bc-4ad1-b107-f14c56402f06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f0db2c5a-8a10-4444-88de-01639cb81e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f0db2c5a-8a10-4444-88de-01639cb81e3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_457c6963-6ed2-4aa6-894e-5ee836e500c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_457c6963-6ed2-4aa6-894e-5ee836e500c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_457c6963-6ed2-4aa6-894e-5ee836e500c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_457c6963-6ed2-4aa6-894e-5ee836e500c7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_457c6963-6ed2-4aa6-894e-5ee836e500c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_457c6963-6ed2-4aa6-894e-5ee836e500c7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_09c1a817-2e31-4d93-b573-0721441d27f9" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_09c1a817-2e31-4d93-b573-0721441d27f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_05ffb3e6-74c4-43ad-b9f8-e182afda366b" xlink:href="ino-20221231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:to="loc_ino_August2019ConvertibleBondsMember_05ffb3e6-74c4-43ad-b9f8-e182afda366b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_13473bdb-bd3b-4b22-87c0-075726e1d78e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_13473bdb-bd3b-4b22-87c0-075726e1d78e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_13473bdb-bd3b-4b22-87c0-075726e1d78e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_13473bdb-bd3b-4b22-87c0-075726e1d78e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_13473bdb-bd3b-4b22-87c0-075726e1d78e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5bcc6797-48f8-4af1-ba90-f054afc1198f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_13473bdb-bd3b-4b22-87c0-075726e1d78e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5bcc6797-48f8-4af1-ba90-f054afc1198f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_17cee506-a402-4c7c-b61a-6507bfda2056" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5bcc6797-48f8-4af1-ba90-f054afc1198f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_17cee506-a402-4c7c-b61a-6507bfda2056" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i335880b52bfc4d2e9fdbdcebddab9ccc_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13dc57f0-2bfe-40ad-a60a-ad7299a67e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_ProfitLoss_13dc57f0-2bfe-40ad-a60a-ad7299a67e47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cdea279e-74eb-4ae7-81b1-402a0d7cb15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_Depreciation_cdea279e-74eb-4ae7-81b1-402a0d7cb15a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7337d1fe-1ff8-466a-98be-44506f5c617c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7337d1fe-1ff8-466a-98be-44506f5c617c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c9661e6e-7bac-462c-bb67-9cbe2521d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c9661e6e-7bac-462c-bb67-9cbe2521d7c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_aa78ff0c-bc1a-4866-99f6-ff692832e3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_aa78ff0c-bc1a-4866-99f6-ff692832e3f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e4440b16-7602-4fc5-8578-926da05e9a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_ShareBasedCompensation_e4440b16-7602-4fc5-8578-926da05e9a57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_bbb4ef95-8373-407a-beaf-9cd1ada67bed" xlink:href="ino-20221231.xsd#ino_NonCashInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_NonCashInterestExpense_bbb4ef95-8373-407a-beaf-9cd1ada67bed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_50ba13b4-5d91-4dc5-aab1-7e22aaf31602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_50ba13b4-5d91-4dc5-aab1-7e22aaf31602" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_4b4377dc-6b76-43f3-b9dd-374ef612d57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_4b4377dc-6b76-43f3-b9dd-374ef612d57d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_eae4b988-e9f6-433e-bea6-336b016a0dc4" xlink:href="ino-20221231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_eae4b988-e9f6-433e-bea6-336b016a0dc4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_7d25fd7c-4bc3-474d-8431-c5e74eee69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_7d25fd7c-4bc3-474d-8431-c5e74eee69d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_92e82da2-acdd-4d3b-80cd-252b3f3c72b9" xlink:href="ino-20221231.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_92e82da2-acdd-4d3b-80cd-252b3f3c72b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_81e67174-d99b-4ec4-b3b5-4369bef7c9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_81e67174-d99b-4ec4-b3b5-4369bef7c9c4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cfe72195-d9f5-4820-bc1e-85430fbdeb9f" xlink:href="ino-20221231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cfe72195-d9f5-4820-bc1e-85430fbdeb9f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_95a53aee-d8d5-418e-b01f-332865e5142a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_95a53aee-d8d5-418e-b01f-332865e5142a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1976fc08-9132-41e0-a29a-7306569801cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1976fc08-9132-41e0-a29a-7306569801cb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c32ba4b9-426a-404a-ac55-eed831c11b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c32ba4b9-426a-404a-ac55-eed831c11b1d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a1a167eb-f770-49bc-8eac-dd562ecaaf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a1a167eb-f770-49bc-8eac-dd562ecaaf79" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eaa96e4f-76f5-4396-9943-a9f036ff5eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eaa96e4f-76f5-4396-9943-a9f036ff5eee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_606f7989-0e63-4194-aaa6-4b6a9ad809b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_606f7989-0e63-4194-aaa6-4b6a9ad809b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5858a853-c690-4cf0-a5dd-628461b16625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5858a853-c690-4cf0-a5dd-628461b16625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_128a229c-40ed-43b7-9bca-baaca55a6b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_128a229c-40ed-43b7-9bca-baaca55a6b92" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_995ba839-5411-4c84-a00f-1ec3d610464b" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_995ba839-5411-4c84-a00f-1ec3d610464b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_65d28f39-200a-480e-9350-43cb899b0101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_65d28f39-200a-480e-9350-43cb899b0101" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_cb242e88-96f5-4bbf-9baa-aa2f2c20f3f5" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_cb242e88-96f5-4bbf-9baa-aa2f2c20f3f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_66a41765-9052-4783-9152-300b7e5ccf5b" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_66a41765-9052-4783-9152-300b7e5ccf5b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_aa819f0e-24c3-4390-8f99-735b1e9643f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_aa819f0e-24c3-4390-8f99-735b1e9643f9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d2e6162-1c65-4da7-8d30-e971f086e725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d2e6162-1c65-4da7-8d30-e971f086e725" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_37030ed3-e77f-4ef7-80da-93aec0e4caf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_37030ed3-e77f-4ef7-80da-93aec0e4caf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_070f4fa4-e87d-4525-b140-1f35d7733b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_070f4fa4-e87d-4525-b140-1f35d7733b91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7b44668-93db-4b55-8510-51a3870672c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7b44668-93db-4b55-8510-51a3870672c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_50f0966e-d93f-4f3f-a408-faf6b4050607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_50f0966e-d93f-4f3f-a408-faf6b4050607" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_3ac7ae0d-edc1-4c41-8a70-0ebe1715626f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_3ac7ae0d-edc1-4c41-8a70-0ebe1715626f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1537dfd9-e776-4aad-bd30-97737a3ee020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1537dfd9-e776-4aad-bd30-97737a3ee020" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a1c68a2-9a29-47bc-8f40-e719afc85040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a1c68a2-9a29-47bc-8f40-e719afc85040" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b87ef9f2-d577-4a04-89fb-d682b998cc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b87ef9f2-d577-4a04-89fb-d682b998cc87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_59aed24f-3652-49c5-abea-66a4dc1c27dd" xlink:href="ino-20221231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_59aed24f-3652-49c5-abea-66a4dc1c27dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_517fb8ce-bdf1-4bd0-bc56-0e0d17f4efe5" xlink:href="ino-20221231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_517fb8ce-bdf1-4bd0-bc56-0e0d17f4efe5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_e2f85ea8-3735-42f8-8667-1e749efc6406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_e2f85ea8-3735-42f8-8667-1e749efc6406" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_dd134344-2788-4a02-8852-1e1ba1159938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_dd134344-2788-4a02-8852-1e1ba1159938" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20f62bb9-69df-4861-b7be-d4d53e24c9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20f62bb9-69df-4861-b7be-d4d53e24c9b8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22ef15dc-e534-44f6-a127-9ca8db92913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22ef15dc-e534-44f6-a127-9ca8db92913a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58638712-289f-4ba4-ba58-a2eb1687e829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58638712-289f-4ba4-ba58-a2eb1687e829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49de7372-5d52-4413-ab65-154126a1e778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49de7372-5d52-4413-ab65-154126a1e778" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09b0cc2f-b2d7-4f19-b6f9-05823937a071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a4b74c9d-d6bf-466c-b59b-fcdad75ecbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a4b74c9d-d6bf-466c-b59b-fcdad75ecbd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e3a10b23-8326-43a4-a6bc-3d22b8271be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:to="loc_us-gaap_InterestPaidNet_e3a10b23-8326-43a4-a6bc-3d22b8271be5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_b1670552-daf7-4c4e-bc48-9da55fa33a4f" xlink:href="ino-20221231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:to="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_b1670552-daf7-4c4e-bc48-9da55fa33a4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a75dbe3-23ee-4e53-92f7-890216c29ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_StatementTable_6a75dbe3-23ee-4e53-92f7-890216c29ddc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_897fe42b-896a-4199-9131-0e0d014a9f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6a75dbe3-23ee-4e53-92f7-890216c29ddc" xlink:to="loc_us-gaap_DebtInstrumentAxis_897fe42b-896a-4199-9131-0e0d014a9f36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_897fe42b-896a-4199-9131-0e0d014a9f36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_897fe42b-896a-4199-9131-0e0d014a9f36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_897fe42b-896a-4199-9131-0e0d014a9f36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_897fe42b-896a-4199-9131-0e0d014a9f36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_bae4153f-b653-4fef-ba20-1dd7bb56576f" xlink:href="ino-20221231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:to="loc_ino_August2019ConvertibleBondsMember_bae4153f-b653-4fef-ba20-1dd7bb56576f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_712222f0-66f5-4308-b98e-3254e6cf5d51" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_712222f0-66f5-4308-b98e-3254e6cf5d51" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i0b5a0cc23c25436c87a7f163b0e25411_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_093d3be7-bfc8-4470-9a1e-b5d431b3017b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_NetIncomeLoss_093d3be7-bfc8-4470-9a1e-b5d431b3017b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_4b268fe7-1ea7-4e2c-8963-fde2d6d05427" xlink:href="ino-20221231.xsd#ino_WorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_ino_WorkingCapital_4b268fe7-1ea7-4e2c-8963-fde2d6d05427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8db7453a-3974-444e-b3ea-66e4a66da01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8db7453a-3974-444e-b3ea-66e4a66da01a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d9d59ca-a610-46c2-8915-f7768ff60767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d9d59ca-a610-46c2-8915-f7768ff60767" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0a27cd69-4b7b-4461-98d8-7d92baa14015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0a27cd69-4b7b-4461-98d8-7d92baa14015" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e8d20571-45d6-48ec-8883-7c15518550f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e8d20571-45d6-48ec-8883-7c15518550f6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9bfc1bd6-18a6-4319-90fa-adc4c74ce2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9bfc1bd6-18a6-4319-90fa-adc4c74ce2a0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f056aaeb-7942-4447-8e3e-5f16213e6028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f056aaeb-7942-4447-8e3e-5f16213e6028" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_335c7117-f54d-4a3e-854e-8917356a6716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_335c7117-f54d-4a3e-854e-8917356a6716" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6aa3b70e-34bd-4079-9741-785845daa086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6aa3b70e-34bd-4079-9741-785845daa086" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2679b466-3816-42eb-9a06-e17e85ba41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2679b466-3816-42eb-9a06-e17e85ba41f7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c931086-cf09-4e52-8186-96847f76b6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c931086-cf09-4e52-8186-96847f76b6ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1c931086-cf09-4e52-8186-96847f76b6ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c931086-cf09-4e52-8186-96847f76b6ae" xlink:to="loc_us-gaap_ClassOfStockDomain_1c931086-cf09-4e52-8186-96847f76b6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cdbbe21a-351b-4706-98ae-b50cb479c8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c931086-cf09-4e52-8186-96847f76b6ae" xlink:to="loc_us-gaap_ClassOfStockDomain_cdbbe21a-351b-4706-98ae-b50cb479c8c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8527f5a8-f512-4084-9e1e-9974a9b83ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cdbbe21a-351b-4706-98ae-b50cb479c8c1" xlink:to="loc_us-gaap_CommonStockMember_8527f5a8-f512-4084-9e1e-9974a9b83ec6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_8c25a328-bfee-4c93-adb6-e81d113ba82d" xlink:href="ino-20221231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:to="loc_ino_SalesAgreementMember_8c25a328-bfee-4c93-adb6-e81d113ba82d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_227a1db3-767b-4113-a30a-5988ecd5fb4e" xlink:href="ino-20221231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_227a1db3-767b-4113-a30a-5988ecd5fb4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:to="loc_srt_RangeAxis_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a" xlink:to="loc_srt_RangeMember_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a" xlink:to="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3e6df31-9195-4e48-a049-40a7e89dd038" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:to="loc_srt_MinimumMember_b3e6df31-9195-4e48-a049-40a7e89dd038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d3b9f5c-13c4-4ade-9bc9-fe4f1da406fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:to="loc_srt_MaximumMember_5d3b9f5c-13c4-4ade-9bc9-fe4f1da406fd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended" id="i042e2fc02cf646f3bd333db3d9f35623_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16ec8e50-c92d-4997-bab1-ff71e8250f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_890b0ef4-d9c0-45c9-aa35-1c83819f1cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16ec8e50-c92d-4997-bab1-ff71e8250f30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_890b0ef4-d9c0-45c9-aa35-1c83819f1cc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16ec8e50-c92d-4997-bab1-ff71e8250f30" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f7f0f71-a629-4e38-8394-5b40d243496e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f7f0f71-a629-4e38-8394-5b40d243496e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f7f0f71-a629-4e38-8394-5b40d243496e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f7f0f71-a629-4e38-8394-5b40d243496e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4f7f0f71-a629-4e38-8394-5b40d243496e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f7f0f71-a629-4e38-8394-5b40d243496e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5b2de695-92b5-4230-af00-ac92e0981b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5b2de695-92b5-4230-af00-ac92e0981b87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_2d1418d6-4e0c-4855-91ca-e0b2a66ecc1f" xlink:href="ino-20221231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_2d1418d6-4e0c-4855-91ca-e0b2a66ecc1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56619617-feea-418f-b8ca-63d97c93bcff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56619617-feea-418f-b8ca-63d97c93bcff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_41b07f2a-21c3-4a48-bfe9-133542be77db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_41b07f2a-21c3-4a48-bfe9-133542be77db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_13a8ba97-bdaa-4ef9-ba97-f2ef6b9e20ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_13a8ba97-bdaa-4ef9-ba97-f2ef6b9e20ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_811454a3-6464-4748-96ec-3667c515e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:to="loc_us-gaap_DebtInstrumentAxis_811454a3-6464-4748-96ec-3667c515e63f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_811454a3-6464-4748-96ec-3667c515e63f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_811454a3-6464-4748-96ec-3667c515e63f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_811454a3-6464-4748-96ec-3667c515e63f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_811454a3-6464-4748-96ec-3667c515e63f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d634fd93-d085-40f8-bb8b-fa8395b34bb5" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d634fd93-d085-40f8-bb8b-fa8395b34bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_1231fbfc-2c2f-415d-aad6-1787ddd449ed" xlink:href="ino-20221231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:to="loc_ino_December2019ConvertibleBondsMember_1231fbfc-2c2f-415d-aad6-1787ddd449ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended" id="i6a8763ac4a3b4046a0a238a0f3cf9e55_SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_520ad937-1ce5-4f01-946f-68ed4511509d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:href="ino-20221231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_520ad937-1ce5-4f01-946f-68ed4511509d" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7460aa11-5853-4eaf-9b9d-86631058bc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7460aa11-5853-4eaf-9b9d-86631058bc72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_014bb679-7429-47ba-ad29-b59490b0c7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_014bb679-7429-47ba-ad29-b59490b0c7c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89e46480-85c6-4510-8c73-061fe176e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89e46480-85c6-4510-8c73-061fe176e07c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_782beff3-d6f4-4e04-97a9-7118c6cecf08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_782beff3-d6f4-4e04-97a9-7118c6cecf08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_520ad937-1ce5-4f01-946f-68ed4511509d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:to="loc_srt_TitleOfIndividualAxis_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_6363d49a-21d3-48ae-8d76-a4b09593cd1e" xlink:href="ino-20221231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:to="loc_ino_EmployeesAndDirectorsMember_6363d49a-21d3-48ae-8d76-a4b09593cd1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_5ba58a49-9edd-423a-8fa0-f5bce15894c4" xlink:href="ino-20221231.xsd#ino_NonEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:to="loc_ino_NonEmployeeMember_5ba58a49-9edd-423a-8fa0-f5bce15894c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a7083d8-931b-4867-b6f4-0ea7c324724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:to="loc_us-gaap_AwardTypeAxis_3a7083d8-931b-4867-b6f4-0ea7c324724d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a7083d8-931b-4867-b6f4-0ea7c324724d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3a7083d8-931b-4867-b6f4-0ea7c324724d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a7083d8-931b-4867-b6f4-0ea7c324724d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fd1e142-4c7b-424c-9bae-df2168cbfd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3a7083d8-931b-4867-b6f4-0ea7c324724d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fd1e142-4c7b-424c-9bae-df2168cbfd6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5d616728-e0ea-455c-becb-405a6fa4ea81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fd1e142-4c7b-424c-9bae-df2168cbfd6f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5d616728-e0ea-455c-becb-405a6fa4ea81" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended" id="i23fafbbab57d4145ad67e0629d8afed7_SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1f4a968-f468-44f2-a5cf-7219918fb767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1f4a968-f468-44f2-a5cf-7219918fb767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f22f1162-b39d-4f89-8174-10e2e45ecaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f22f1162-b39d-4f89-8174-10e2e45ecaa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_17ed9831-2fc8-4dba-8e4f-1e4033422127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_ConvertibleDebt_17ed9831-2fc8-4dba-8e4f-1e4033422127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2dda849a-30f9-4973-a988-876e0b044630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2dda849a-30f9-4973-a988-876e0b044630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_697abcb2-7597-4310-ad67-945cf811b3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_697abcb2-7597-4310-ad67-945cf811b3cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ebd0b6a2-2e24-46df-8f1a-a60f707fc008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_697abcb2-7597-4310-ad67-945cf811b3cc" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ebd0b6a2-2e24-46df-8f1a-a60f707fc008" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ebd0b6a2-2e24-46df-8f1a-a60f707fc008_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ebd0b6a2-2e24-46df-8f1a-a60f707fc008" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ebd0b6a2-2e24-46df-8f1a-a60f707fc008_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5bdd64b3-0574-463e-afe6-1e023c603f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ebd0b6a2-2e24-46df-8f1a-a60f707fc008" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5bdd64b3-0574-463e-afe6-1e023c603f9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a481b1f1-a7d8-4e78-b8e3-73f98784cc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_5bdd64b3-0574-463e-afe6-1e023c603f9e" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a481b1f1-a7d8-4e78-b8e3-73f98784cc0a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended" id="iec3d90ea80824a1da7f4ed11f203eb88_RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_207b7c85-93b0-472a-a23c-2a967f564039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_207b7c85-93b0-472a-a23c-2a967f564039" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_89bb1035-19d8-4798-b321-02f129de77fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_89bb1035-19d8-4798-b321-02f129de77fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_76707195-c06c-44fa-8e8a-c3a396fc0582" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:to="loc_srt_MajorCustomersAxis_76707195-c06c-44fa-8e8a-c3a396fc0582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_76707195-c06c-44fa-8e8a-c3a396fc0582_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_76707195-c06c-44fa-8e8a-c3a396fc0582" xlink:to="loc_srt_NameOfMajorCustomerDomain_76707195-c06c-44fa-8e8a-c3a396fc0582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_76707195-c06c-44fa-8e8a-c3a396fc0582" xlink:to="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_d685b20d-ac1a-41f2-b794-3b2f18d442fa" xlink:href="ino-20221231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_AdvaccineMember_d685b20d-ac1a-41f2-b794-3b2f18d442fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_ea0c14bb-2c6b-4139-951d-ffbea6228ea9" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_ea0c14bb-2c6b-4139-951d-ffbea6228ea9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_63fdaf7e-978c-4c3f-8840-6dac7b4501bf" xlink:href="ino-20221231.xsd#ino_DoDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_DoDMember_63fdaf7e-978c-4c3f-8840-6dac7b4501bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_c4d61ccc-83d8-406d-bf70-44db512ef213" xlink:href="ino-20221231.xsd#ino_AllOtherCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_AllOtherCustomersMember_c4d61ccc-83d8-406d-bf70-44db512ef213" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2d59e23a-41f5-44a4-b4a6-108bf9d9de45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2d59e23a-41f5-44a4-b4a6-108bf9d9de45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2d59e23a-41f5-44a4-b4a6-108bf9d9de45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2d59e23a-41f5-44a4-b4a6-108bf9d9de45" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2d59e23a-41f5-44a4-b4a6-108bf9d9de45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05d1205f-3fcd-462c-9fbf-b75f7453258e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2d59e23a-41f5-44a4-b4a6-108bf9d9de45" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05d1205f-3fcd-462c-9fbf-b75f7453258e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7aadfc19-5ee5-40b4-a055-1739a2a43da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05d1205f-3fcd-462c-9fbf-b75f7453258e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7aadfc19-5ee5-40b4-a055-1739a2a43da4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4653aa1-9d7e-4691-b006-c4deef87e69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4653aa1-9d7e-4691-b006-c4deef87e69e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e4653aa1-9d7e-4691-b006-c4deef87e69e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4653aa1-9d7e-4691-b006-c4deef87e69e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e4653aa1-9d7e-4691-b006-c4deef87e69e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_97bcff58-60fe-407c-84cf-c2a56a077416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4653aa1-9d7e-4691-b006-c4deef87e69e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_97bcff58-60fe-407c-84cf-c2a56a077416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ba80c357-d396-4180-960b-6fc50afcbc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_97bcff58-60fe-407c-84cf-c2a56a077416" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ba80c357-d396-4180-960b-6fc50afcbc9c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="extended" id="i8e999930834a4e6ebc0c0e24c05c0c03_RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11bf396a-d124-4c90-aa0a-9a5424d2d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11bf396a-d124-4c90-aa0a-9a5424d2d75e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_4dc49229-a121-470c-a76a-e1e0a577e509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:to="loc_us-gaap_AccountsReceivableNet_4dc49229-a121-470c-a76a-e1e0a577e509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ae794d6c-c271-4b95-9c1d-7e8207738f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ae794d6c-c271-4b95-9c1d-7e8207738f3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3d7eb849-fd46-43a6-bb82-9d33afd991a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:to="loc_srt_MajorCustomersAxis_3d7eb849-fd46-43a6-bb82-9d33afd991a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3d7eb849-fd46-43a6-bb82-9d33afd991a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3d7eb849-fd46-43a6-bb82-9d33afd991a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_3d7eb849-fd46-43a6-bb82-9d33afd991a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3d7eb849-fd46-43a6-bb82-9d33afd991a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_824cb900-f698-4362-8b20-e13bd1acf9b2" xlink:href="ino-20221231.xsd#ino_DoDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:to="loc_ino_DoDMember_824cb900-f698-4362-8b20-e13bd1acf9b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CEPIMERSMember_6a23c899-d740-4c51-a447-28fc0df14bf4" xlink:href="ino-20221231.xsd#ino_CEPIMERSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:to="loc_ino_CEPIMERSMember_6a23c899-d740-4c51-a447-28fc0df14bf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0e7bedfc-df7f-482e-be90-f2752f9d9851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0e7bedfc-df7f-482e-be90-f2752f9d9851" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_855d5a3f-6450-4914-9c7f-5e0f760dc3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0e7bedfc-df7f-482e-be90-f2752f9d9851" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_855d5a3f-6450-4914-9c7f-5e0f760dc3cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e43c279-5301-4c9d-8523-ddccf2810687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e43c279-5301-4c9d-8523-ddccf2810687" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8e43c279-5301-4c9d-8523-ddccf2810687_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e43c279-5301-4c9d-8523-ddccf2810687" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8e43c279-5301-4c9d-8523-ddccf2810687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca299e33-a6bf-4edc-9676-e54191f4309a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e43c279-5301-4c9d-8523-ddccf2810687" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca299e33-a6bf-4edc-9676-e54191f4309a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_87bda4d2-6c86-437f-a38d-e6767e54549d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca299e33-a6bf-4edc-9676-e54191f4309a" xlink:to="loc_us-gaap_AccountsReceivableMember_87bda4d2-6c86-437f-a38d-e6767e54549d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CollaborativeAgreementsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended" id="i7ca15c2b92c145ec952206da12a5ee8e_CollaborativeAgreementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_a6a39fc2-4495-456a-89c2-2a4012680733" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_a6a39fc2-4495-456a-89c2-2a4012680733" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_294ed76b-378a-4330-ae21-fee7fdb5fc61" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_294ed76b-378a-4330-ae21-fee7fdb5fc61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_dba5cd37-bf24-4268-9f3f-a137bf2797ca" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_dba5cd37-bf24-4268-9f3f-a137bf2797ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_5a4a5bce-cae0-4126-bd43-bf554d4cb1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_CostMaintenance_5a4a5bce-cae0-4126-bd43-bf554d4cb1bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_a5fc88d7-d1f0-4c36-83f7-debdf518902d" xlink:href="ino-20221231.xsd#ino_AnnualMaintenancePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_AnnualMaintenancePeriod_a5fc88d7-d1f0-4c36-83f7-debdf518902d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_6aeb2824-3e5b-4389-a070-34b426ce9fac" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_6aeb2824-3e5b-4389-a070-34b426ce9fac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_c7d332b8-d308-48fd-bbaa-fad70e48ed66" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_c7d332b8-d308-48fd-bbaa-fad70e48ed66" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3bafce94-0773-4f4e-aba8-504153fb75ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3bafce94-0773-4f4e-aba8-504153fb75ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_52772973-13fc-4ff9-951d-cc27ca99bb6a" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_52772973-13fc-4ff9-951d-cc27ca99bb6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_ac4c6999-b54c-4808-91de-ab42679d36ad" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_ac4c6999-b54c-4808-91de-ab42679d36ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_1338fc70-fcbc-4fc7-a64e-27caa7afff4a" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_1338fc70-fcbc-4fc7-a64e-27caa7afff4a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_8da5c01b-8642-4504-895f-d401b9acc927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_AccountsReceivableNet_8da5c01b-8642-4504-895f-d401b9acc927" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_912ed3ac-c59e-48e9-b478-eff4a60bf27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_GrantsReceivable_912ed3ac-c59e-48e9-b478-eff4a60bf27d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_04202e90-ac97-4e08-a6c9-57bc27b46cda" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_04202e90-ac97-4e08-a6c9-57bc27b46cda" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_675b618d-10d2-4064-902b-a6a6a2d5d6d5" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_675b618d-10d2-4064-902b-a6a6a2d5d6d5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_4af7ce5f-776a-426d-9a4b-6e420be3330e" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_4af7ce5f-776a-426d-9a4b-6e420be3330e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_d843c05f-6145-4785-8a2b-928f4d4d15c2" xlink:href="ino-20221231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_GrantProceedsReceived_d843c05f-6145-4785-8a2b-928f4d4d15c2" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_srt_CounterpartyNameAxis_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_ea99363f-2244-42a2-837b-b498f385ee8b" xlink:href="ino-20221231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_AdvaccineMember_ea99363f-2244-42a2-837b-b498f385ee8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_f9b50035-4c74-43e1-bd92-81ef7c2f891b" xlink:href="ino-20221231.xsd#ino_ApolloBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_ApolloBioMember_f9b50035-4c74-43e1-bd92-81ef7c2f891b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_5b69834d-1180-49af-8ce1-9b3155a5b415" xlink:href="ino-20221231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_5b69834d-1180-49af-8ce1-9b3155a5b415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_29220cf1-be92-4490-99aa-25a9b1c10b0e" xlink:href="ino-20221231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_29220cf1-be92-4490-99aa-25a9b1c10b0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_dcbd6b7c-4687-4725-97de-51e42e1e2deb" xlink:href="ino-20221231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_DepartmentOfDefenceMember_dcbd6b7c-4687-4725-97de-51e42e1e2deb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_764e1641-20ad-45fc-972a-f2c914d0fad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_764e1641-20ad-45fc-972a-f2c914d0fad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_cdf2c7ea-2041-4906-8851-68ffff8d8981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_764e1641-20ad-45fc-972a-f2c914d0fad5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_cdf2c7ea-2041-4906-8851-68ffff8d8981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_srt_MajorCustomersAxis_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f9693f6b-e768-484d-b413-ed9c925d1c55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_f9693f6b-e768-484d-b413-ed9c925d1c55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_3b384ba5-57cd-493d-9c16-5136a10e38e4" xlink:href="ino-20221231.xsd#ino_AdvaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_f9693f6b-e768-484d-b413-ed9c925d1c55" xlink:to="loc_ino_AdvaccineMember_3b384ba5-57cd-493d-9c16-5136a10e38e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53b891f3-2d12-48af-a299-9340bfd42edf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_srt_ProductOrServiceAxis_53b891f3-2d12-48af-a299-9340bfd42edf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_53b891f3-2d12-48af-a299-9340bfd42edf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_53b891f3-2d12-48af-a299-9340bfd42edf" xlink:to="loc_srt_ProductsAndServicesDomain_53b891f3-2d12-48af-a299-9340bfd42edf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_53b891f3-2d12-48af-a299-9340bfd42edf" xlink:to="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f21949a7-9f3f-4606-869d-a02ef8d8d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_us-gaap_LicenseMember_f21949a7-9f3f-4606-869d-a02ef8d8d1a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_14776411-db0d-497f-a825-1dd2ae37fa50" xlink:href="ino-20221231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_14776411-db0d-497f-a825-1dd2ae37fa50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_5e94e756-5522-4574-9e9e-6b2fb956066c" xlink:href="ino-20221231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_5e94e756-5522-4574-9e9e-6b2fb956066c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_35aef405-fd72-493f-9b41-971bd2f9fdf1" xlink:href="ino-20221231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_35aef405-fd72-493f-9b41-971bd2f9fdf1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_e91e24df-f33b-4133-8f8a-f0a0e861da1e" xlink:href="ino-20221231.xsd#ino_INO4800Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_INO4800Member_e91e24df-f33b-4133-8f8a-f0a0e861da1e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_c99f6dea-3892-4181-974b-55ae2e959cfa" xlink:href="ino-20221231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_c99f6dea-3892-4181-974b-55ae2e959cfa" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended" id="i5660499ee9fb405e9a0db807271ea4c3_ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_eaf7b2e6-28c2-4b36-b5d3-8a230eb5784f" xlink:href="ino-20221231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_eaf7b2e6-28c2-4b36-b5d3-8a230eb5784f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3e58d07-d822-49c4-8888-4311bcc85859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3e58d07-d822-49c4-8888-4311bcc85859" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae8241-12b6-4829-8139-f6c125831450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae8241-12b6-4829-8139-f6c125831450" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed94f280-8d96-4ed8-aa27-62ca2e8f7679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed94f280-8d96-4ed8-aa27-62ca2e8f7679" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd791276-b735-4a48-90a0-bb19d506b983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd791276-b735-4a48-90a0-bb19d506b983" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_746bb208-1923-44cf-b78d-de44b74c49a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_746bb208-1923-44cf-b78d-de44b74c49a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_746bb208-1923-44cf-b78d-de44b74c49a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_746bb208-1923-44cf-b78d-de44b74c49a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_746bb208-1923-44cf-b78d-de44b74c49a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_746bb208-1923-44cf-b78d-de44b74c49a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_91177d3e-40c9-4bed-9202-b240ab3d9d5d" xlink:href="ino-20221231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_ino_MutualFundsMember_91177d3e-40c9-4bed-9202-b240ab3d9d5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_d5c4db98-310c-4459-abfe-cdea036544df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_d5c4db98-310c-4459-abfe-cdea036544df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_aad75328-15bd-4326-8203-bb86e8cd47b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_CommercialPaperMember_aad75328-15bd-4326-8203-bb86e8cd47b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6ccd742a-a846-46fe-b580-2355badb2269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6ccd742a-a846-46fe-b580-2355badb2269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4276c094-103c-4f56-b7ca-275c0be9e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4276c094-103c-4f56-b7ca-275c0be9e1d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_287cdf75-44c8-4b08-805d-6c8662fccafe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:to="loc_srt_RangeAxis_287cdf75-44c8-4b08-805d-6c8662fccafe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_287cdf75-44c8-4b08-805d-6c8662fccafe_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_287cdf75-44c8-4b08-805d-6c8662fccafe" xlink:to="loc_srt_RangeMember_287cdf75-44c8-4b08-805d-6c8662fccafe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d403ccf3-77c2-446e-971f-6e5126a360b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_287cdf75-44c8-4b08-805d-6c8662fccafe" xlink:to="loc_srt_RangeMember_d403ccf3-77c2-446e-971f-6e5126a360b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_27842c60-a650-4106-a3d1-d3eac13a39b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d403ccf3-77c2-446e-971f-6e5126a360b6" xlink:to="loc_srt_MaximumMember_27842c60-a650-4106-a3d1-d3eac13a39b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i071d0a0e1690453bafd5d7f592493a58_ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e27bc61d-e011-485b-bdbd-ffaad3c4e0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e27bc61d-e011-485b-bdbd-ffaad3c4e0c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fea2648d-0099-42fe-89e6-12b8b4294476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fea2648d-0099-42fe-89e6-12b8b4294476" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0b0ff870-67de-4f27-a0c7-4884d8a6fb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0b0ff870-67de-4f27-a0c7-4884d8a6fb40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_54013d67-5138-4d19-9235-7ce0bfcba3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_54013d67-5138-4d19-9235-7ce0bfcba3aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_d090a791-ff60-4cc2-8ae2-9dd3a227ee12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_d090a791-ff60-4cc2-8ae2-9dd3a227ee12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_edfd9b4d-3052-4665-947b-65f9370df8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_edfd9b4d-3052-4665-947b-65f9370df8ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_17c0606c-682c-4fff-8cb6-715a91572189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_17c0606c-682c-4fff-8cb6-715a91572189" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a5afe94-441f-4130-9308-2a9b7b70f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a5afe94-441f-4130-9308-2a9b7b70f99b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a5afe94-441f-4130-9308-2a9b7b70f99b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a5afe94-441f-4130-9308-2a9b7b70f99b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5a5afe94-441f-4130-9308-2a9b7b70f99b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed692db1-72cf-46b2-a9eb-20939592dcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a5afe94-441f-4130-9308-2a9b7b70f99b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed692db1-72cf-46b2-a9eb-20939592dcfe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a2752594-410b-4046-afd0-10ddb7fbbde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed692db1-72cf-46b2-a9eb-20939592dcfe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a2752594-410b-4046-afd0-10ddb7fbbde2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bb641a84-23cc-4c06-bd9a-d069d5ef6532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:to="loc_us-gaap_InvestmentTypeAxis_bb641a84-23cc-4c06-bd9a-d069d5ef6532" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_bb641a84-23cc-4c06-bd9a-d069d5ef6532_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_bb641a84-23cc-4c06-bd9a-d069d5ef6532" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_bb641a84-23cc-4c06-bd9a-d069d5ef6532_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_af200f3e-5276-46ae-ad4d-7ccd4c7652a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_bb641a84-23cc-4c06-bd9a-d069d5ef6532" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_af200f3e-5276-46ae-ad4d-7ccd4c7652a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1da6edb6-e93b-4685-93d9-4cccd4e64b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_af200f3e-5276-46ae-ad4d-7ccd4c7652a7" xlink:to="loc_us-gaap_CommonStockMember_1da6edb6-e93b-4685-93d9-4cccd4e64b90" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="id8394b1c35c0444aa403cac19c295939_ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24b5e3a-2a53-4c3e-be62-af89eb30be82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24b5e3a-2a53-4c3e-be62-af89eb30be82" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a521316-883b-4db7-9018-d41017bd4d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a521316-883b-4db7-9018-d41017bd4d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_63f2a597-b546-44fa-9f30-f597bb6e6c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_63f2a597-b546-44fa-9f30-f597bb6e6c59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_224f69fd-262b-4d25-be39-9e635fcff3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_224f69fd-262b-4d25-be39-9e635fcff3f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24b5e3a-2a53-4c3e-be62-af89eb30be82" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3cbd532-75c2-4cad-83e3-9265dcecc763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3cbd532-75c2-4cad-83e3-9265dcecc763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3cbd532-75c2-4cad-83e3-9265dcecc763_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3cbd532-75c2-4cad-83e3-9265dcecc763" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c3cbd532-75c2-4cad-83e3-9265dcecc763_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b70b8524-72dd-406a-8c97-8bb1b8960b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3cbd532-75c2-4cad-83e3-9265dcecc763" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b70b8524-72dd-406a-8c97-8bb1b8960b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f8a1449e-dee8-457c-9157-0172938f1109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b70b8524-72dd-406a-8c97-8bb1b8960b4a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f8a1449e-dee8-457c-9157-0172938f1109" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e24dacd-1cc6-4cb8-93d8-2452f31e1469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e24dacd-1cc6-4cb8-93d8-2452f31e1469" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e24dacd-1cc6-4cb8-93d8-2452f31e1469_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e24dacd-1cc6-4cb8-93d8-2452f31e1469" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8e24dacd-1cc6-4cb8-93d8-2452f31e1469_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e24dacd-1cc6-4cb8-93d8-2452f31e1469" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_8cc0556e-6dd7-4c22-9428-4f50773ecfec" xlink:href="ino-20221231.xsd#ino_MutualFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_ino_MutualFundsMember_8cc0556e-6dd7-4c22-9428-4f50773ecfec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_3202189e-4f62-4357-b065-903326447c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_3202189e-4f62-4357-b065-903326447c03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c4186217-9344-4577-b29a-0a644af0a5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_CommercialPaperMember_c4186217-9344-4577-b29a-0a644af0a5ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ccb28076-680b-47f9-8706-bc8401077058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ccb28076-680b-47f9-8706-bc8401077058" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_599d53b1-ab55-4c19-8491-fc13ea4f7ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_599d53b1-ab55-4c19-8491-fc13ea4f7ea5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbb12af9-5de1-40bc-87d1-b5542a8d18e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbb12af9-5de1-40bc-87d1-b5542a8d18e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbb12af9-5de1-40bc-87d1-b5542a8d18e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbb12af9-5de1-40bc-87d1-b5542a8d18e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bbb12af9-5de1-40bc-87d1-b5542a8d18e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbb12af9-5de1-40bc-87d1-b5542a8d18e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ecd90e49-eea8-4a11-b700-86c32bf77b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ecd90e49-eea8-4a11-b700-86c32bf77b74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eaa709c8-5eed-439e-ae06-73674bcf2def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eaa709c8-5eed-439e-ae06-73674bcf2def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d6d6d6e4-bf41-43b7-8f0f-e1a6be33de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d6d6d6e4-bf41-43b7-8f0f-e1a6be33de3c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended" id="i2c4a4c742f3e4ab0afc81bccd7cc255b_CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:href="ino-20221231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_82a54950-cff7-4ed0-b0d2-dfa511a0ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_82a54950-cff7-4ed0-b0d2-dfa511a0ad4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2c9948cc-46c5-4464-8e69-08e2ef58fe57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_AccruedSalariesCurrent_2c9948cc-46c5-4464-8e69-08e2ef58fe57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_9740f32e-32c4-49c6-a902-2090357c23e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_LitigationReserveCurrent_9740f32e-32c4-49c6-a902-2090357c23e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2cea180b-566b-4555-8efe-cd4711c22359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2cea180b-566b-4555-8efe-cd4711c22359" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_94579d81-fac6-4286-a9ce-c081cf5f6823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_94579d81-fac6-4286-a9ce-c081cf5f6823" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c64fb06a-00ba-437c-8f1e-d77f443d27ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c64fb06a-00ba-437c-8f1e-d77f443d27ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_de13362a-bf00-409d-ac29-36d62913d31b" xlink:href="ino-20221231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_de13362a-bf00-409d-ac29-36d62913d31b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_76e12997-0fd3-4168-8272-33a2b923f6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_76e12997-0fd3-4168-8272-33a2b923f6e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_76cbdbf3-4cc8-46c4-8d19-ce49813700d3" xlink:href="ino-20221231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_76cbdbf3-4cc8-46c4-8d19-ce49813700d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_97518882-9a21-440b-adda-6fc30cd42b92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_76cbdbf3-4cc8-46c4-8d19-ce49813700d3" xlink:to="loc_srt_LitigationCaseAxis_97518882-9a21-440b-adda-6fc30cd42b92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_97518882-9a21-440b-adda-6fc30cd42b92_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_97518882-9a21-440b-adda-6fc30cd42b92" xlink:to="loc_srt_LitigationCaseTypeDomain_97518882-9a21-440b-adda-6fc30cd42b92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1665a7cc-e26c-4ce2-8ce3-c0c3850c3549" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_97518882-9a21-440b-adda-6fc30cd42b92" xlink:to="loc_srt_LitigationCaseTypeDomain_1665a7cc-e26c-4ce2-8ce3-c0c3850c3549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_9a000aff-90f8-4167-a495-717526636ff2" xlink:href="ino-20221231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_1665a7cc-e26c-4ce2-8ce3-c0c3850c3549" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_9a000aff-90f8-4167-a495-717526636ff2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#FixedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended" id="i59088582c46f48efad02a2ba33c793fc_FixedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e307d574-f77a-4119-bf00-00b818746cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e307d574-f77a-4119-bf00-00b818746cae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a04bf799-c4d0-4cb3-869c-3a5d9d8ce5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a04bf799-c4d0-4cb3-869c-3a5d9d8ce5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7487b3f5-735b-48c9-b2f4-5cedf99770be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7487b3f5-735b-48c9-b2f4-5cedf99770be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_756cb6ec-2e72-454e-a78f-04181a7ce915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_Depreciation_756cb6ec-2e72-454e-a78f-04181a7ce915" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_ca0fe633-5189-423a-a755-425267292740" xlink:href="ino-20221231.xsd#ino_PropertyPlantAndEquipmentDisposedOfBySale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_ca0fe633-5189-423a-a755-425267292740" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_f2dbe88c-8bf6-407f-944a-be279f016399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_f2dbe88c-8bf6-407f-944a-be279f016399" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_a945d791-c4ea-439e-adcb-34bcc6d18237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_AccountsReceivableNet_a945d791-c4ea-439e-adcb-34bcc6d18237" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b942dec4-c0d2-40ac-bf5f-6ef760de603b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b942dec4-c0d2-40ac-bf5f-6ef760de603b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b942dec4-c0d2-40ac-bf5f-6ef760de603b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b942dec4-c0d2-40ac-bf5f-6ef760de603b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b942dec4-c0d2-40ac-bf5f-6ef760de603b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b942dec4-c0d2-40ac-bf5f-6ef760de603b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7b69e15f-ce58-45c2-aca7-4f2d55400516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7b69e15f-ce58-45c2-aca7-4f2d55400516" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ccada150-0c4b-49b7-928f-5822fcef449e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_OfficeEquipmentMember_ccada150-0c4b-49b7-928f-5822fcef449e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_103556a7-32f2-43e2-bcf2-66d9369c3d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_103556a7-32f2-43e2-bcf2-66d9369c3d73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_111b2509-fc28-47f3-a970-b7f125e6c8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_111b2509-fc28-47f3-a970-b7f125e6c8f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3ae0f506-1946-473c-a2d7-7f91946b023f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3ae0f506-1946-473c-a2d7-7f91946b023f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3ae0f506-1946-473c-a2d7-7f91946b023f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3ae0f506-1946-473c-a2d7-7f91946b023f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3ae0f506-1946-473c-a2d7-7f91946b023f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_747b24e7-90d7-4bde-8892-aab9df868fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3ae0f506-1946-473c-a2d7-7f91946b023f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_747b24e7-90d7-4bde-8892-aab9df868fa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_fd639712-47cb-414a-bfc5-dfed138b239f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_747b24e7-90d7-4bde-8892-aab9df868fa5" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_fd639712-47cb-414a-bfc5-dfed138b239f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended" id="ife7f324cfedd4dbc81a46a965762cafb_GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_7d45f949-e418-4b64-af98-1eb45ed218ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_7d45f949-e418-4b64-af98-1eb45ed218ec" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_651665ae-d2fc-415c-ab75-213ad07da67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:to="loc_us-gaap_GoodwillGross_651665ae-d2fc-415c-ab75-213ad07da67c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d7379084-aead-4ba6-8570-a5911881f903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:to="loc_us-gaap_Goodwill_d7379084-aead-4ba6-8570-a5911881f903" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99379ff5-0bf6-4a9c-ab79-8d3a3e39bea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99379ff5-0bf6-4a9c-ab79-8d3a3e39bea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9fa2926c-74e5-43bb-98b5-b514b4f3c8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9fa2926c-74e5-43bb-98b5-b514b4f3c8c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d158102-714a-49ae-81c7-48d5b13ddbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d158102-714a-49ae-81c7-48d5b13ddbf7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6dc7236-51f4-45e5-b7bd-95c593b95e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6dc7236-51f4-45e5-b7bd-95c593b95e07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_4100bdc9-57a5-41c3-af27-f388485fdc85" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_4100bdc9-57a5-41c3-af27-f388485fdc85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_3c047abb-268f-4af8-970e-dc656e5c95f5" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_3c047abb-268f-4af8-970e-dc656e5c95f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_7d45f949-e418-4b64-af98-1eb45ed218ec" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44388d5e-6eac-4b7f-acba-313feae9f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44388d5e-6eac-4b7f-acba-313feae9f623" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44388d5e-6eac-4b7f-acba-313feae9f623_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44388d5e-6eac-4b7f-acba-313feae9f623" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_44388d5e-6eac-4b7f-acba-313feae9f623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44388d5e-6eac-4b7f-acba-313feae9f623" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f5cb3b07-1166-4ad0-a70b-a3ad44301432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:to="loc_us-gaap_LicensingAgreementsMember_f5cb3b07-1166-4ad0-a70b-a3ad44301432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_bb9d9d1b-d5e5-40e6-9dcf-2fa1ec995381" xlink:href="ino-20221231.xsd#ino_BiojectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:to="loc_ino_BiojectMember_bb9d9d1b-d5e5-40e6-9dcf-2fa1ec995381" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_fb9005fb-0381-4b5e-91ba-a001a38d2ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_fb9005fb-0381-4b5e-91ba-a001a38d2ecf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_205b31f9-56d4-4eef-acd2-c46ad888817b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:to="loc_srt_RangeAxis_205b31f9-56d4-4eef-acd2-c46ad888817b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_205b31f9-56d4-4eef-acd2-c46ad888817b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_205b31f9-56d4-4eef-acd2-c46ad888817b" xlink:to="loc_srt_RangeMember_205b31f9-56d4-4eef-acd2-c46ad888817b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92726e7c-7e1d-455c-9649-2a6b48e6cfc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_205b31f9-56d4-4eef-acd2-c46ad888817b" xlink:to="loc_srt_RangeMember_92726e7c-7e1d-455c-9649-2a6b48e6cfc1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_7313b275-4235-4a46-bc33-2bca318af981" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_92726e7c-7e1d-455c-9649-2a6b48e6cfc1" xlink:to="loc_srt_WeightedAverageMember_7313b275-4235-4a46-bc33-2bca318af981" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended" id="ib7f39dbfcd144bdd8d750a8a0a545d4f_ConvertibleDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9f5d8ee5-c8c9-4c56-aa4d-7e02b8d45ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9f5d8ee5-c8c9-4c56-aa4d-7e02b8d45ddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9b27564-7d41-4373-9783-c9f36a0dca67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9b27564-7d41-4373-9783-c9f36a0dca67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2602ac3a-8944-4802-a706-8ea48afe5cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2602ac3a-8944-4802-a706-8ea48afe5cb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_f4fdc958-11ab-475c-a491-3a5e34364d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_f4fdc958-11ab-475c-a491-3a5e34364d9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e9b2d3ba-4e4b-4fce-b9aa-37b85dfb80ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e9b2d3ba-4e4b-4fce-b9aa-37b85dfb80ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ac34649-18e3-4241-bbc3-bfa04f9b1f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ac34649-18e3-4241-bbc3-bfa04f9b1f42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ad8e676b-b7af-4407-b531-2d8b59c860e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ad8e676b-b7af-4407-b531-2d8b59c860e1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_49ad6dc4-f3f8-48d4-8699-700ae8ca576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_49ad6dc4-f3f8-48d4-8699-700ae8ca576b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_31425479-b0b9-4b1e-b28c-a0e7c8b469c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_31425479-b0b9-4b1e-b28c-a0e7c8b469c7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ecb638a-c257-492c-bb1a-45f48d17c6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ecb638a-c257-492c-bb1a-45f48d17c6fe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ea4f16a-e88a-4b3c-97d9-4be57f19f372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ea4f16a-e88a-4b3c-97d9-4be57f19f372" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a845911b-2048-4563-a7b2-88d73128d900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a845911b-2048-4563-a7b2-88d73128d900" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f3c41725-3fd5-4331-b416-55f772b18d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f3c41725-3fd5-4331-b416-55f772b18d70" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d4f981e7-d85c-4ebb-a0fc-64a90b22a4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d4f981e7-d85c-4ebb-a0fc-64a90b22a4c7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5b68e206-8e8f-4fc4-b612-7d66bdd1af88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_ConvertibleDebt_5b68e206-8e8f-4fc4-b612-7d66bdd1af88" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17b7aeed-4c61-4786-975e-29f66aed9ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_InterestExpense_17b7aeed-4c61-4786-975e-29f66aed9ddd" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8a6b6483-4a98-480b-8912-9e095e06a592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_InterestExpenseDebt_8a6b6483-4a98-480b-8912-9e095e06a592" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a7969374-1591-43bd-a078-c7d508be09f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a7969374-1591-43bd-a078-c7d508be09f5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_b6cf60f1-6f8b-4da7-9001-cc6f00e38e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_b6cf60f1-6f8b-4da7-9001-cc6f00e38e7d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_49d2d2d2-7438-4ade-bcbc-686340fb030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_49d2d2d2-7438-4ade-bcbc-686340fb030d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_49d2d2d2-7438-4ade-bcbc-686340fb030d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_49d2d2d2-7438-4ade-bcbc-686340fb030d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_49d2d2d2-7438-4ade-bcbc-686340fb030d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f2cf470e-fd5b-4fa8-80d2-4d4f4c1a2d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_49d2d2d2-7438-4ade-bcbc-686340fb030d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f2cf470e-fd5b-4fa8-80d2-4d4f4c1a2d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1d51a561-6d0d-441e-a029-f745c598f5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f2cf470e-fd5b-4fa8-80d2-4d4f4c1a2d6a" xlink:to="loc_us-gaap_ConvertibleDebtMember_1d51a561-6d0d-441e-a029-f745c598f5e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4feb9991-17d4-474c-80da-a0906b1b6690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4feb9991-17d4-474c-80da-a0906b1b6690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_4feb9991-17d4-474c-80da-a0906b1b6690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4feb9991-17d4-474c-80da-a0906b1b6690" xlink:to="loc_us-gaap_TypeOfAdoptionMember_4feb9991-17d4-474c-80da-a0906b1b6690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ef590304-64df-4d46-b056-efdddb5abaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4feb9991-17d4-474c-80da-a0906b1b6690" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ef590304-64df-4d46-b056-efdddb5abaa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_f3f78de1-2190-4085-b50c-1f929541ca33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ef590304-64df-4d46-b056-efdddb5abaa2" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_f3f78de1-2190-4085-b50c-1f929541ca33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_85bb3c56-e52b-4740-9c91-5e74f09c08ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:to="loc_us-gaap_DebtInstrumentAxis_85bb3c56-e52b-4740-9c91-5e74f09c08ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_85bb3c56-e52b-4740-9c91-5e74f09c08ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_85bb3c56-e52b-4740-9c91-5e74f09c08ce" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_85bb3c56-e52b-4740-9c91-5e74f09c08ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_85bb3c56-e52b-4740-9c91-5e74f09c08ce" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4e8d6de1-e5b0-4871-9a7c-329ac705c002" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4e8d6de1-e5b0-4871-9a7c-329ac705c002" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a93d19e4-7d69-4d13-b4b4-3b5b27b12e32" xlink:href="ino-20221231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:to="loc_ino_December2019ConvertibleBondsMember_a93d19e4-7d69-4d13-b4b4-3b5b27b12e32" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended" id="id9dddf92cf9b4557a207435b6a7687eb_ConvertibleDebtBalanceOfConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9d2152ad-306f-44eb-ae1a-9ef8d3958001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9d2152ad-306f-44eb-ae1a-9ef8d3958001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_efe2825e-7489-4055-8110-723ec0734dde" xlink:href="ino-20221231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_efe2825e-7489-4055-8110-723ec0734dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_88d6e68a-ac5e-4825-85d8-2ee62eb25b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_88d6e68a-ac5e-4825-85d8-2ee62eb25b3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_d73b91db-5e0c-415c-b4a2-7ed38b88ea7a" xlink:href="ino-20221231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_ino_DebtinstrumentAccruedInterest_d73b91db-5e0c-415c-b4a2-7ed38b88ea7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1dbd765d-cb97-427c-8438-78cc090d0b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_us-gaap_LongTermDebt_1dbd765d-cb97-427c-8438-78cc090d0b9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b9399b25-64f3-4c5b-9fd2-77156d34f1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_us-gaap_DebtInstrumentTable_b9399b25-64f3-4c5b-9fd2-77156d34f1bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8dc9ec88-234e-4439-aa21-10e0e7028d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b9399b25-64f3-4c5b-9fd2-77156d34f1bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_8dc9ec88-234e-4439-aa21-10e0e7028d35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8dc9ec88-234e-4439-aa21-10e0e7028d35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8dc9ec88-234e-4439-aa21-10e0e7028d35" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8dc9ec88-234e-4439-aa21-10e0e7028d35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e1373ec-a52d-4fad-bda7-1c1d7faa74ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8dc9ec88-234e-4439-aa21-10e0e7028d35" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e1373ec-a52d-4fad-bda7-1c1d7faa74ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_58ff356b-d0c2-4a35-a1a3-c7939738f904" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e1373ec-a52d-4fad-bda7-1c1d7faa74ab" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_58ff356b-d0c2-4a35-a1a3-c7939738f904" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended" id="id88ecf7a648642f184ff332bced1c626_ConvertibleDebtScheduleofMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc09090d-2659-490f-9778-9a218a7e66bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc09090d-2659-490f-9778-9a218a7e66bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d5a59bc-cfcd-4dd5-85f9-63c2f4c27619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d5a59bc-cfcd-4dd5-85f9-63c2f4c27619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3b6ec686-3f53-4e2e-ba61-aefac7d54baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3b6ec686-3f53-4e2e-ba61-aefac7d54baf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ff76e984-7452-4f23-adbb-534d8b119da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_LongTermDebt_ff76e984-7452-4f23-adbb-534d8b119da0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7925fdf-a4dd-4ccc-b10c-53e191e490ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7925fdf-a4dd-4ccc-b10c-53e191e490ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_47590a14-6b27-41bd-b7b6-bed0ca68291e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7925fdf-a4dd-4ccc-b10c-53e191e490ac" xlink:to="loc_us-gaap_ConvertibleDebtMember_47590a14-6b27-41bd-b7b6-bed0ca68291e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:to="loc_us-gaap_DebtInstrumentAxis_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9cdbd1f7-559b-4b79-80bd-a3876524ea9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9cdbd1f7-559b-4b79-80bd-a3876524ea9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4b6fa0de-5e34-4589-85a4-254df53dfc27" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9cdbd1f7-559b-4b79-80bd-a3876524ea9e" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4b6fa0de-5e34-4589-85a4-254df53dfc27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended" id="if633cba8793d46bd9dde309c5a6f1cef_StockholdersEquitySummaryofPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_00e43ce7-9e62-482b-bb89-15a6f0d5f2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_00e43ce7-9e62-482b-bb89-15a6f0d5f2de" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7746b8e6-0a65-4617-97ae-f844ca789517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7746b8e6-0a65-4617-97ae-f844ca789517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4084ce16-d739-4031-ac9b-8fb094500de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4084ce16-d739-4031-ac9b-8fb094500de5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ad63348f-1d08-46f0-868b-7a37305a98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ad63348f-1d08-46f0-868b-7a37305a98b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7c78d68e-64a6-4948-8fef-f42cc109c4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7c78d68e-64a6-4948-8fef-f42cc109c4e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6f2eec88-ece9-4d76-b7e3-30c538e5116c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_00e43ce7-9e62-482b-bb89-15a6f0d5f2de" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6f2eec88-ece9-4d76-b7e3-30c538e5116c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ce35c62a-45de-4eb5-aa54-bf9e83430ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f2eec88-ece9-4d76-b7e3-30c538e5116c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ce35c62a-45de-4eb5-aa54-bf9e83430ccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ce35c62a-45de-4eb5-aa54-bf9e83430ccd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ce35c62a-45de-4eb5-aa54-bf9e83430ccd" xlink:to="loc_us-gaap_ClassOfStockDomain_ce35c62a-45de-4eb5-aa54-bf9e83430ccd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ddfce05-b649-49eb-b937-1f9217b720a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ce35c62a-45de-4eb5-aa54-bf9e83430ccd" xlink:to="loc_us-gaap_ClassOfStockDomain_5ddfce05-b649-49eb-b937-1f9217b720a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_415b731a-c307-4246-82f5-939dfda78178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5ddfce05-b649-49eb-b937-1f9217b720a3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_415b731a-c307-4246-82f5-939dfda78178" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i0bcfa2ed777f4b48aa718ba2fbef0da7_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_53ff32fe-cdd3-41fb-9fa0-9028c1b57ccb" xlink:href="ino-20221231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_53ff32fe-cdd3-41fb-9fa0-9028c1b57ccb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6f141ce7-b86f-42c9-96c9-7af06d51490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6f141ce7-b86f-42c9-96c9-7af06d51490e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_6d5d9d6b-612d-4bab-a379-57fcb8103e0b" xlink:href="ino-20221231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_6d5d9d6b-612d-4bab-a379-57fcb8103e0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_2f51e232-0ea3-47e6-a41c-a6ad80d2012f" xlink:href="ino-20221231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_2f51e232-0ea3-47e6-a41c-a6ad80d2012f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_305a0231-e139-42f5-8eef-b64b3908150c" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_305a0231-e139-42f5-8eef-b64b3908150c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_620686a1-b015-464e-b368-38551a6fd4a7" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_620686a1-b015-464e-b368-38551a6fd4a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e2b01341-8539-47e5-b092-bda6778863c3" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e2b01341-8539-47e5-b092-bda6778863c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_e65ee18b-e150-427e-b9a0-1bbc78ecfcc0" xlink:href="ino-20221231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_e65ee18b-e150-427e-b9a0-1bbc78ecfcc0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6fa71edd-0b2c-4fc9-8430-1b85658234f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6fa71edd-0b2c-4fc9-8430-1b85658234f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_471b535f-439c-439c-b45a-cb7e3ab429c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_471b535f-439c-439c-b45a-cb7e3ab429c6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7cd76f70-da36-445d-a586-0d80bc42019f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7cd76f70-da36-445d-a586-0d80bc42019f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1556636a-5c42-432c-b292-966db1cc0d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1556636a-5c42-432c-b292-966db1cc0d06" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_bc4b84f7-6a50-4ead-994f-a0c85292097e" xlink:href="ino-20221231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_bc4b84f7-6a50-4ead-994f-a0c85292097e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7ab5259e-5a80-4e4b-ac3a-ee3c265606e3" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7ab5259e-5a80-4e4b-ac3a-ee3c265606e3" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_850d7bc6-7a26-4e2d-bbf0-48bc10df3380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_850d7bc6-7a26-4e2d-bbf0-48bc10df3380" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c6a49d73-bb38-4803-a32d-5cbe4dd24566" xlink:href="ino-20221231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c6a49d73-bb38-4803-a32d-5cbe4dd24566" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_0aa1c222-0a67-4e7c-b75b-db4d4f533572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_0aa1c222-0a67-4e7c-b75b-db4d4f533572" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e5452f3-d1a2-48bc-a64c-8c78a78c6d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e5452f3-d1a2-48bc-a64c-8c78a78c6d47" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7dd76dbe-3104-46a4-83fe-8c94b7b84aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7dd76dbe-3104-46a4-83fe-8c94b7b84aed" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_6e6cbca7-e116-41e8-a516-11ceec329495" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_6e6cbca7-e116-41e8-a516-11ceec329495" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2e9834-cbae-43e3-be89-0bba824bce3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2e9834-cbae-43e3-be89-0bba824bce3c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_1f64a064-db31-4d73-9f0c-d42fb4fcf7a1" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_1f64a064-db31-4d73-9f0c-d42fb4fcf7a1" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f3786d-1eae-42c0-b0cc-445bc3129fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f3786d-1eae-42c0-b0cc-445bc3129fab" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_404d0ea3-e9b6-40fa-a9f7-9aaa31ff2c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_404d0ea3-e9b6-40fa-a9f7-9aaa31ff2c91" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79529327-71a6-4222-bcbd-2b0cc0ef6da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79529327-71a6-4222-bcbd-2b0cc0ef6da9" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_57ab4401-f5ff-4298-8505-93b59318d48c" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_57ab4401-f5ff-4298-8505-93b59318d48c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ebe7f1f0-0f27-43f7-bdf7-d383b0ad4473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ebe7f1f0-0f27-43f7-bdf7-d383b0ad4473" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_3dab29fe-6297-4835-855e-677738ba7158" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_3dab29fe-6297-4835-855e-677738ba7158" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c244a63d-c877-4d9b-9914-8ca35900decf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c244a63d-c877-4d9b-9914-8ca35900decf" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_3a3c3a85-3b80-4d81-b027-a3b24d7006ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_3a3c3a85-3b80-4d81-b027-a3b24d7006ad" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_cccf3b22-3f3e-473b-924e-8b618ce83654" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_cccf3b22-3f3e-473b-924e-8b618ce83654" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_c308a7fa-c67e-45d7-be40-52496d661139" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_c308a7fa-c67e-45d7-be40-52496d661139" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_660de18c-350a-4aa2-a635-6ee5c9dd263d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_660de18c-350a-4aa2-a635-6ee5c9dd263d" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cf268609-d296-4025-aad5-99b451301c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cf268609-d296-4025-aad5-99b451301c04" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c00aa15-4a74-4c5f-af1d-6dc59373be0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c00aa15-4a74-4c5f-af1d-6dc59373be0e" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ee67cde-b8aa-46ca-9c76-d222d2705cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ee67cde-b8aa-46ca-9c76-d222d2705cce" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_deb823e9-ace7-4d23-a963-e101018dbdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_deb823e9-ace7-4d23-a963-e101018dbdb2" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ba5bcfb-8788-4610-9460-bad0dcf37872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ba5bcfb-8788-4610-9460-bad0dcf37872" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9230df1b-a3dc-4053-bceb-c73fb414a515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a9ead3ce-1b61-423c-b080-1739ea99c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a9ead3ce-1b61-423c-b080-1739ea99c4e6" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e97ba118-75d2-4060-94f3-99199cbe1f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e97ba118-75d2-4060-94f3-99199cbe1f0e" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_78722e82-f94f-42f4-aef3-9f3dbb6b339c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_78722e82-f94f-42f4-aef3-9f3dbb6b339c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_78722e82-f94f-42f4-aef3-9f3dbb6b339c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_78722e82-f94f-42f4-aef3-9f3dbb6b339c" xlink:to="loc_us-gaap_ClassOfStockDomain_78722e82-f94f-42f4-aef3-9f3dbb6b339c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_78722e82-f94f-42f4-aef3-9f3dbb6b339c" xlink:to="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1199c839-8ef4-4ec1-b71a-5bab79726dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1199c839-8ef4-4ec1-b71a-5bab79726dfe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_16b200a3-5e81-4cbc-8634-51f3c39772fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:to="loc_us-gaap_CommonStockMember_16b200a3-5e81-4cbc-8634-51f3c39772fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_326581c2-88cc-4ca6-a427-bdb9da0789c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_326581c2-88cc-4ca6-a427-bdb9da0789c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_326581c2-88cc-4ca6-a427-bdb9da0789c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_326581c2-88cc-4ca6-a427-bdb9da0789c6" xlink:to="loc_us-gaap_EquityComponentDomain_326581c2-88cc-4ca6-a427-bdb9da0789c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62b8cdeb-1bdc-4bd1-b190-a381a80200ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_326581c2-88cc-4ca6-a427-bdb9da0789c6" xlink:to="loc_us-gaap_EquityComponentDomain_62b8cdeb-1bdc-4bd1-b190-a381a80200ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5dc85c64-e0dd-4314-8e61-74745f44233b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_62b8cdeb-1bdc-4bd1-b190-a381a80200ff" xlink:to="loc_us-gaap_CommonStockMember_5dc85c64-e0dd-4314-8e61-74745f44233b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_974e777b-a4c2-4700-85fd-78fa4f259f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_974e777b-a4c2-4700-85fd-78fa4f259f26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_974e777b-a4c2-4700-85fd-78fa4f259f26_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_974e777b-a4c2-4700-85fd-78fa4f259f26" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_974e777b-a4c2-4700-85fd-78fa4f259f26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_974e777b-a4c2-4700-85fd-78fa4f259f26" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_ac186ddf-82c1-47f5-8e63-ff40e6969769" xlink:href="ino-20221231.xsd#ino_SalesAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:to="loc_ino_SalesAgreementMember_ac186ddf-82c1-47f5-8e63-ff40e6969769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_1b5f89f4-55be-4eea-8377-5291a7855a15" xlink:href="ino-20221231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_1b5f89f4-55be-4eea-8377-5291a7855a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_02a323d1-245b-4319-ab55-0eca40ed16f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_PlanNameAxis_02a323d1-245b-4319-ab55-0eca40ed16f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_02a323d1-245b-4319-ab55-0eca40ed16f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_02a323d1-245b-4319-ab55-0eca40ed16f1" xlink:to="loc_us-gaap_PlanNameDomain_02a323d1-245b-4319-ab55-0eca40ed16f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_02a323d1-245b-4319-ab55-0eca40ed16f1" xlink:to="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_6d576965-a3c2-4fd0-9be0-fb4e2cca6a5e" xlink:href="ino-20221231.xsd#ino_A2016IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:to="loc_ino_A2016IncentivePlanMember_6d576965-a3c2-4fd0-9be0-fb4e2cca6a5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_a2df4543-64eb-45fb-830b-6a6f2f247d80" xlink:href="ino-20221231.xsd#ino_A2007IncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:to="loc_ino_A2007IncentivePlanMember_a2df4543-64eb-45fb-830b-6a6f2f247d80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_3448efdd-22c6-4b1f-afde-e81225a4a431" xlink:href="ino-20221231.xsd#ino_A2022InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:to="loc_ino_A2022InducementPlanMember_3448efdd-22c6-4b1f-afde-e81225a4a431" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e013fbf7-9cd1-45e7-b845-dbbc23e92323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e013fbf7-9cd1-45e7-b845-dbbc23e92323" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e013fbf7-9cd1-45e7-b845-dbbc23e92323_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e013fbf7-9cd1-45e7-b845-dbbc23e92323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e013fbf7-9cd1-45e7-b845-dbbc23e92323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e013fbf7-9cd1-45e7-b845-dbbc23e92323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7436a30d-dac2-4695-be49-2b641a47956e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7436a30d-dac2-4695-be49-2b641a47956e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_142898ad-e08a-47ae-8e29-77e618f09b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_142898ad-e08a-47ae-8e29-77e618f09b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_AwardTypeAxis_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_350b54b1-5288-40e8-8f90-0b5b15dfe6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_350b54b1-5288-40e8-8f90-0b5b15dfe6ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c35aeb8b-9ac7-489e-9a69-a42ea0c53014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_350b54b1-5288-40e8-8f90-0b5b15dfe6ef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c35aeb8b-9ac7-489e-9a69-a42ea0c53014" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e08429a5-e7fa-4ee8-9029-116ab4519dc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_srt_TitleOfIndividualAxis_e08429a5-e7fa-4ee8-9029-116ab4519dc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e08429a5-e7fa-4ee8-9029-116ab4519dc7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e08429a5-e7fa-4ee8-9029-116ab4519dc7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e08429a5-e7fa-4ee8-9029-116ab4519dc7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20bee0c0-4f4d-476b-9b0d-1aba6659a77d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e08429a5-e7fa-4ee8-9029-116ab4519dc7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20bee0c0-4f4d-476b-9b0d-1aba6659a77d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_c9e10649-7b46-44d2-80ff-ae0be5f0fd67" xlink:href="ino-20221231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20bee0c0-4f4d-476b-9b0d-1aba6659a77d" xlink:to="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_c9e10649-7b46-44d2-80ff-ae0be5f0fd67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_4a74a649-b147-4c12-ab5b-95654e4a4967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_GranteeStatusAxis_4a74a649-b147-4c12-ab5b-95654e4a4967" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_4a74a649-b147-4c12-ab5b-95654e4a4967_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_4a74a649-b147-4c12-ab5b-95654e4a4967" xlink:to="loc_us-gaap_GranteeStatusDomain_4a74a649-b147-4c12-ab5b-95654e4a4967_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_d4fbf894-0b9a-4802-8025-56490eaf8b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_4a74a649-b147-4c12-ab5b-95654e4a4967" xlink:to="loc_us-gaap_GranteeStatusDomain_d4fbf894-0b9a-4802-8025-56490eaf8b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_047c4059-32de-4674-89d9-2b0134bfacf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_d4fbf894-0b9a-4802-8025-56490eaf8b87" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_047c4059-32de-4674-89d9-2b0134bfacf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquitySummaryofStockOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="extended" id="ifbadb7c3aa0448c79ec34c2d2da2becd_StockholdersEquitySummaryofStockOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_3e3ea888-8f08-45db-9add-4fe25461516e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_3e3ea888-8f08-45db-9add-4fe25461516e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e7fb35ef-9124-408a-a216-e876416d1795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e7fb35ef-9124-408a-a216-e876416d1795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9d207bda-0389-4029-b518-bdd9caf64ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9d207bda-0389-4029-b518-bdd9caf64ca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_99068b29-e245-4d0e-aee9-0ac0f3e5b187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_99068b29-e245-4d0e-aee9-0ac0f3e5b187" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7b52ec07-cc0c-4ad2-92db-7393f7945137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7b52ec07-cc0c-4ad2-92db-7393f7945137" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1a55257c-44b7-405a-97a5-e8bff03a853a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1a55257c-44b7-405a-97a5-e8bff03a853a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8acc55db-53e9-4545-8d28-db610ecf406a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8acc55db-53e9-4545-8d28-db610ecf406a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9fc87bcc-c44a-4ba7-b52f-339c6615bb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9fc87bcc-c44a-4ba7-b52f-339c6615bb02" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9fc87bcc-c44a-4ba7-b52f-339c6615bb02" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_0514fb10-1940-4a48-a546-fc840eeacd2d" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesOneMember_0514fb10-1940-4a48-a546-fc840eeacd2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_7ebd8348-dba8-4fe9-bb2f-81a5e90ca045" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_7ebd8348-dba8-4fe9-bb2f-81a5e90ca045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_59d20439-e45d-4ac8-bc32-0d7fc1b220d1" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_59d20439-e45d-4ac8-bc32-0d7fc1b220d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_b81b643b-afd2-4214-844d-269a750bc7d3" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesFourMember_b81b643b-afd2-4214-844d-269a750bc7d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_b52129c1-c27a-4d9d-9f35-d25c9a4c40b6" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_b52129c1-c27a-4d9d-9f35-d25c9a4c40b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_5f300e86-a4c1-494a-bd5c-462a6d32811d" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesSixMember_5f300e86-a4c1-494a-bd5c-462a6d32811d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended" id="iae908c7ba65f4d559d7bf2c6ded9be22_StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5143aeba-e5ff-40c6-8d3d-021d812edce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5143aeba-e5ff-40c6-8d3d-021d812edce0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3300dc74-db4e-46f6-91f3-08f90daf8f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3300dc74-db4e-46f6-91f3-08f90daf8f04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92c70535-2f87-4af4-be45-61f5dbdefb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92c70535-2f87-4af4-be45-61f5dbdefb64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_72dee287-75fc-4b7b-9c46-385aaec20043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_72dee287-75fc-4b7b-9c46-385aaec20043" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8fb6f280-98e0-44db-9777-d5b9aa306489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8fb6f280-98e0-44db-9777-d5b9aa306489" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a943b2c-5283-4760-8bd3-057e0bf7b31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_287a9d34-7e58-493c-8075-5cdfbc29b85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5143aeba-e5ff-40c6-8d3d-021d812edce0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_287a9d34-7e58-493c-8075-5cdfbc29b85a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_792c46d4-682f-4682-b97d-79711fa230a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_287a9d34-7e58-493c-8075-5cdfbc29b85a" xlink:to="loc_us-gaap_AwardTypeAxis_792c46d4-682f-4682-b97d-79711fa230a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792c46d4-682f-4682-b97d-79711fa230a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_792c46d4-682f-4682-b97d-79711fa230a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_792c46d4-682f-4682-b97d-79711fa230a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3205d7cb-4a79-475b-ba10-06c1d0d56904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_792c46d4-682f-4682-b97d-79711fa230a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3205d7cb-4a79-475b-ba10-06c1d0d56904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b50c1be6-965e-4297-8f11-68f4a56d7577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3205d7cb-4a79-475b-ba10-06c1d0d56904" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b50c1be6-965e-4297-8f11-68f4a56d7577" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i15b73cf38e96491b90e86b59491ce45e_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_7a91dbf8-c53f-4f8e-8d38-1c35f64c73c3" xlink:href="ino-20221231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_7a91dbf8-c53f-4f8e-8d38-1c35f64c73c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_738d6f9f-e313-4cb2-a4de-f1751161f8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_738d6f9f-e313-4cb2-a4de-f1751161f8d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c3833864-10d0-4113-84cc-885adbc7eee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_us-gaap_LeaseCost_c3833864-10d0-4113-84cc-885adbc7eee9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_ef16b5cb-4025-4149-ad44-734eedcfdfe8" xlink:href="ino-20221231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_ef16b5cb-4025-4149-ad44-734eedcfdfe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_08c2c33c-0959-4af6-a2a7-59891892b154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_08c2c33c-0959-4af6-a2a7-59891892b154" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_41ab7359-8c73-4846-86e7-6353ee398c7b" xlink:href="ino-20221231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_41ab7359-8c73-4846-86e7-6353ee398c7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b21d1c0-90e8-49d7-a2b8-db47f2d09218" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b21d1c0-90e8-49d7-a2b8-db47f2d09218" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5b21d1c0-90e8-49d7-a2b8-db47f2d09218_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b21d1c0-90e8-49d7-a2b8-db47f2d09218" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_5b21d1c0-90e8-49d7-a2b8-db47f2d09218_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b21d1c0-90e8-49d7-a2b8-db47f2d09218" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_571dadc4-54fd-4135-9f71-decdb1a8dcd5" xlink:href="ino-20221231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:to="loc_ino_SanDiegoCaliforniaMember_571dadc4-54fd-4135-9f71-decdb1a8dcd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_59e07091-c0ba-447d-b21c-4ed85e4ca101" xlink:href="ino-20221231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_59e07091-c0ba-447d-b21c-4ed85e4ca101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_187257b4-1f9e-4240-80da-9586244e89aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:to="loc_srt_RangeAxis_187257b4-1f9e-4240-80da-9586244e89aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_187257b4-1f9e-4240-80da-9586244e89aa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_187257b4-1f9e-4240-80da-9586244e89aa" xlink:to="loc_srt_RangeMember_187257b4-1f9e-4240-80da-9586244e89aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_187257b4-1f9e-4240-80da-9586244e89aa" xlink:to="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eb4e991f-d49b-42a9-9c5d-769ba5147c54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:to="loc_srt_MinimumMember_eb4e991f-d49b-42a9-9c5d-769ba5147c54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4c9082ca-e881-4244-852c-f4a896220117" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:to="loc_srt_MaximumMember_4c9082ca-e881-4244-852c-f4a896220117" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9148390c-4062-4ff9-98ab-e54309e551ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:to="loc_srt_LitigationCaseAxis_9148390c-4062-4ff9-98ab-e54309e551ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9148390c-4062-4ff9-98ab-e54309e551ad_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9148390c-4062-4ff9-98ab-e54309e551ad" xlink:to="loc_srt_LitigationCaseTypeDomain_9148390c-4062-4ff9-98ab-e54309e551ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e4fb3933-ee0a-494c-8120-1baf95bf8d4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9148390c-4062-4ff9-98ab-e54309e551ad" xlink:to="loc_srt_LitigationCaseTypeDomain_e4fb3933-ee0a-494c-8120-1baf95bf8d4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_8cc7759f-7c87-4920-9ebe-97e83af8be45" xlink:href="ino-20221231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_e4fb3933-ee0a-494c-8120-1baf95bf8d4c" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_8cc7759f-7c87-4920-9ebe-97e83af8be45" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i6c0e29c3232d48d9ab8bedc8ea4c25a0_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3033ceb1-0c86-4e47-9815-629af83689b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3033ceb1-0c86-4e47-9815-629af83689b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_f8dc03d5-4625-406f-a031-223d9683f056" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_f8dc03d5-4625-406f-a031-223d9683f056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_50e06fe4-cee6-4dd4-ad2c-e8e6637fb123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_50e06fe4-cee6-4dd4-ad2c-e8e6637fb123" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_921a8bc9-e4d4-46b3-bcce-65fce44cd794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_921a8bc9-e4d4-46b3-bcce-65fce44cd794" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_9c9fba4b-405a-4035-9dc3-dd2a2b68223d" xlink:href="ino-20221231.xsd#ino_TaxBenefitsExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_ino_TaxBenefitsExpired_9c9fba4b-405a-4035-9dc3-dd2a2b68223d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3bd90d3b-8140-4778-bb16-f1129ebd285a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3bd90d3b-8140-4778-bb16-f1129ebd285a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b70a393f-5be7-48c0-bb1b-3ca02609d8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b70a393f-5be7-48c0-bb1b-3ca02609d8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b70a393f-5be7-48c0-bb1b-3ca02609d8ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b70a393f-5be7-48c0-bb1b-3ca02609d8ee" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b70a393f-5be7-48c0-bb1b-3ca02609d8ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b70a393f-5be7-48c0-bb1b-3ca02609d8ee" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6c57716f-5741-4571-9844-ef330ddd5fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6c57716f-5741-4571-9844-ef330ddd5fff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_7d6b0997-ad02-41f1-af10-af161cb56301" xlink:href="ino-20221231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_7d6b0997-ad02-41f1-af10-af161cb56301" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_f9c7794f-acc8-4f85-bc57-033354253fcd" xlink:href="ino-20221231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_f9c7794f-acc8-4f85-bc57-033354253fcd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_516a7ad9-7659-45d1-aaf6-78cd6c16c6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_516a7ad9-7659-45d1-aaf6-78cd6c16c6f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember_69eb5ea4-ab93-49ed-a875-38c0d870dd47" xlink:href="ino-20221231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_ino_KoreanStateIncomeTaxAuthorityMember_69eb5ea4-ab93-49ed-a875-38c0d870dd47" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_36b717d3-87ee-44be-9aa0-0cb2828625f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_36b717d3-87ee-44be-9aa0-0cb2828625f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_36b717d3-87ee-44be-9aa0-0cb2828625f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_36b717d3-87ee-44be-9aa0-0cb2828625f6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_36b717d3-87ee-44be-9aa0-0cb2828625f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_75852764-d4a6-43da-b952-a5215068c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_36b717d3-87ee-44be-9aa0-0cb2828625f6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_75852764-d4a6-43da-b952-a5215068c228" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fdf6000d-d381-4e51-83c0-b0018c846eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_75852764-d4a6-43da-b952-a5215068c228" xlink:to="loc_us-gaap_ResearchMember_fdf6000d-d381-4e51-83c0-b0018c846eb2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended" id="i233d2049b40846059b67dad170c10adf_IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f14e2373-c728-4300-9cb9-eb6849cd0436" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f14e2373-c728-4300-9cb9-eb6849cd0436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_80d565c6-9c2f-461a-88e5-368f4d4e8ca7" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_80d565c6-9c2f-461a-88e5-368f4d4e8ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_9cb80aff-1705-4d4f-b186-15b594aef3a1" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_9cb80aff-1705-4d4f-b186-15b594aef3a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_78eea631-41a1-461e-a301-a3a751ffb02a" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_78eea631-41a1-461e-a301-a3a751ffb02a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInSixYears_c4788fd7-4e16-4d89-95f1-0513878a9fe4" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringInSixYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInSixYears_c4788fd7-4e16-4d89-95f1-0513878a9fe4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_8ef140d9-a116-4029-b435-173ac0b5de41" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_8ef140d9-a116-4029-b435-173ac0b5de41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ab42fcda-04f4-412a-b991-78b7d23488b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ab42fcda-04f4-412a-b991-78b7d23488b9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_988e2dfc-25ce-4f78-a8fe-3279303d63cd" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_988e2dfc-25ce-4f78-a8fe-3279303d63cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_c598b551-a73f-4cfb-a9a7-7d75d37f55a1" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_c598b551-a73f-4cfb-a9a7-7d75d37f55a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_d7847f86-de4e-4f12-ae6b-5058347531b5" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_d7847f86-de4e-4f12-ae6b-5058347531b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_67078e32-b9d4-4644-abd3-cbe22d49f26a" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_67078e32-b9d4-4644-abd3-cbe22d49f26a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInSixYears_321b3d56-d7c3-4b8b-90f9-396a49e5dc13" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInSixYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInSixYears_321b3d56-d7c3-4b8b-90f9-396a49e5dc13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_b53ee7bd-e9db-4f42-85c5-861814469d4f" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_b53ee7bd-e9db-4f42-85c5-861814469d4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d3a1dae1-5049-4660-a0f0-88651564f69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d3a1dae1-5049-4660-a0f0-88651564f69a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d718e140-6ef0-44fe-89fa-97f0cd711b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d718e140-6ef0-44fe-89fa-97f0cd711b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_d718e140-6ef0-44fe-89fa-97f0cd711b2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d718e140-6ef0-44fe-89fa-97f0cd711b2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_d718e140-6ef0-44fe-89fa-97f0cd711b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_92dfe56a-8538-4c98-b388-87a16528a1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d718e140-6ef0-44fe-89fa-97f0cd711b2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_92dfe56a-8538-4c98-b388-87a16528a1d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_df622e7b-6de0-48ff-afae-10685f20d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_92dfe56a-8538-4c98-b388-87a16528a1d9" xlink:to="loc_us-gaap_ResearchMember_df622e7b-6de0-48ff-afae-10685f20d67d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_134e6823-d258-4bc5-8eb1-b2ce4bb56c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:to="loc_us-gaap_DomesticCountryMember_134e6823-d258-4bc5-8eb1-b2ce4bb56c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1ff73633-d0e8-4e3a-83aa-d642012c3568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1ff73633-d0e8-4e3a-83aa-d642012c3568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0e547683-f8cc-408b-9043-33f032ac2b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:to="loc_us-gaap_ForeignCountryMember_0e547683-f8cc-408b-9043-33f032ac2b5f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" id="i3c3244191c6f44a0a0764d6c4bd12d76_RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_bc3db352-9377-4387-a535-9d25d40cd757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_bc3db352-9377-4387-a535-9d25d40cd757" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e77c12bc-9515-4c32-8fcb-c7f55e61711a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e77c12bc-9515-4c32-8fcb-c7f55e61711a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a47d023b-b000-498a-8316-a6b946dae656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a47d023b-b000-498a-8316-a6b946dae656" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_951ee439-f8e0-4115-8a38-4ac65ebef2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_951ee439-f8e0-4115-8a38-4ac65ebef2f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_9b882fff-1c7c-42f5-a858-6e4763dff721" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_9b882fff-1c7c-42f5-a858-6e4763dff721" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_c95b48c1-3e7b-4e46-83dd-4d79390a5f92" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeArrangementTerm_c95b48c1-3e7b-4e46-83dd-4d79390a5f92" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_d54382d9-a970-4b45-8383-fabe7106e333" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_d54382d9-a970-4b45-8383-fabe7106e333" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_9b362b20-6b18-429d-99e5-b9d3d8a62f81" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_9b362b20-6b18-429d-99e5-b9d3d8a62f81" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_31a19c68-a8c0-40ca-8de8-1ef860bfd33e" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_31a19c68-a8c0-40ca-8de8-1ef860bfd33e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_e43da65d-66f1-4a6d-8efe-0b64b9b4273b" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_e43da65d-66f1-4a6d-8efe-0b64b9b4273b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_150f5c15-3d37-4ec7-bf4e-ba54d1b79cae" xlink:href="ino-20221231.xsd#ino_GrantProceedsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_GrantProceedsReceived_150f5c15-3d37-4ec7-bf4e-ba54d1b79cae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4ad0a417-a36e-4dcc-a5eb-3133c9b0dbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4ad0a417-a36e-4dcc-a5eb-3133c9b0dbbe" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_9974dcfe-44ba-4564-974d-a8ec02054165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_9974dcfe-44ba-4564-974d-a8ec02054165" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_85acd3db-97bb-4cc8-bf13-3dfbfb4bd61d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_85acd3db-97bb-4cc8-bf13-3dfbfb4bd61d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_0c5151a5-c767-45b7-934d-b40c98ca50ec" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_0c5151a5-c767-45b7-934d-b40c98ca50ec" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8382a83-5610-4ff4-8b5d-9fa0a39978da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8382a83-5610-4ff4-8b5d-9fa0a39978da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b8382a83-5610-4ff4-8b5d-9fa0a39978da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8382a83-5610-4ff4-8b5d-9fa0a39978da" xlink:to="loc_us-gaap_RelatedPartyDomain_b8382a83-5610-4ff4-8b5d-9fa0a39978da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8382a83-5610-4ff4-8b5d-9fa0a39978da" xlink:to="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember_732ac260-596c-4df9-ba30-03dec73b768d" xlink:href="ino-20221231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:to="loc_ino_PLSaffiliatedentityMember_732ac260-596c-4df9-ba30-03dec73b768d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_38bcbe6f-b272-4ba4-807c-38715471737e" xlink:href="ino-20221231.xsd#ino_TheWistarInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:to="loc_ino_TheWistarInstituteMember_38bcbe6f-b272-4ba4-807c-38715471737e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_38f1d456-be76-468d-9d10-ce86143e5132" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:to="loc_srt_DirectorMember_38f1d456-be76-468d-9d10-ce86143e5132" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8cf2b87f-1a88-4419-b66d-1bbda24a96bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_srt_CounterpartyNameAxis_8cf2b87f-1a88-4419-b66d-1bbda24a96bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cf2b87f-1a88-4419-b66d-1bbda24a96bf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8cf2b87f-1a88-4419-b66d-1bbda24a96bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8cf2b87f-1a88-4419-b66d-1bbda24a96bf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa1165d9-2adc-464d-9822-c1e34fb4313d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8cf2b87f-1a88-4419-b66d-1bbda24a96bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa1165d9-2adc-464d-9822-c1e34fb4313d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_b76cfe8f-b30f-4fb8-a567-c70495d668bf" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa1165d9-2adc-464d-9822-c1e34fb4313d" xlink:to="loc_ino_PlumblineLifeSciencesMember_b76cfe8f-b30f-4fb8-a567-c70495d668bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8a165111-4089-47e6-be26-67c2e07c43a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_srt_TitleOfIndividualAxis_8a165111-4089-47e6-be26-67c2e07c43a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a165111-4089-47e6-be26-67c2e07c43a9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_8a165111-4089-47e6-be26-67c2e07c43a9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_8a165111-4089-47e6-be26-67c2e07c43a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53c7df5-e922-4343-9160-bfea5e9d7e85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_8a165111-4089-47e6-be26-67c2e07c43a9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53c7df5-e922-4343-9160-bfea5e9d7e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_87be1f81-3d28-4796-aa71-ce6a2d7e0097" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53c7df5-e922-4343-9160-bfea5e9d7e85" xlink:to="loc_srt_DirectorMember_87be1f81-3d28-4796-aa71-ce6a2d7e0097" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3909196b-4a28-446e-9ab4-b75dad7e725a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_srt_OwnershipAxis_3909196b-4a28-446e-9ab4-b75dad7e725a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_3909196b-4a28-446e-9ab4-b75dad7e725a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_3909196b-4a28-446e-9ab4-b75dad7e725a" xlink:to="loc_srt_OwnershipDomain_3909196b-4a28-446e-9ab4-b75dad7e725a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_344caa7e-c894-4e16-a0ba-2b4bc53ae1de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_3909196b-4a28-446e-9ab4-b75dad7e725a" xlink:to="loc_srt_OwnershipDomain_344caa7e-c894-4e16-a0ba-2b4bc53ae1de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_6fe3b4ad-9d1d-4872-ab9f-3956e4e432ec" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_344caa7e-c894-4e16-a0ba-2b4bc53ae1de" xlink:to="loc_ino_PlumblineLifeSciencesMember_6fe3b4ad-9d1d-4872-ab9f-3956e4e432ec" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended" id="id8b4c188e39e4ca4a544781ea32b9688_GeneosTherapeuticsIncNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_e5e82608-bc49-44c7-b571-b619ce52fa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_e5e82608-bc49-44c7-b571-b619ce52fa03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f8b68d4d-e2a7-4380-a38b-7fd3cb967e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f8b68d4d-e2a7-4380-a38b-7fd3cb967e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_b0b20355-36d2-4fb9-afac-00d2bf15dcd6" xlink:href="ino-20221231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_b0b20355-36d2-4fb9-afac-00d2bf15dcd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_af7647a3-0d4d-437a-b1c4-f1d41e6f8bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_af7647a3-0d4d-437a-b1c4-f1d41e6f8bdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_2616972f-aacd-426c-a434-a983f4c36786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_2616972f-aacd-426c-a434-a983f4c36786" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_4865ee94-cf8f-4162-b9c2-8f5416f61457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_4865ee94-cf8f-4162-b9c2-8f5416f61457" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_33e58096-aeac-4892-a3c2-da90efdd33f3" xlink:href="ino-20221231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_33e58096-aeac-4892-a3c2-da90efdd33f3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a42f6f08-0b16-4bb5-aead-54ca64da67af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a42f6f08-0b16-4bb5-aead-54ca64da67af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_acaae27f-13e9-40f5-9c4a-458527e8bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_EquityMethodInvestments_acaae27f-13e9-40f5-9c4a-458527e8bd20" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6b7e0c45-e06b-44fe-9383-f1382c6c3b02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_srt_CounterpartyNameAxis_6b7e0c45-e06b-44fe-9383-f1382c6c3b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b7e0c45-e06b-44fe-9383-f1382c6c3b02_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6b7e0c45-e06b-44fe-9383-f1382c6c3b02" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6b7e0c45-e06b-44fe-9383-f1382c6c3b02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8af8d106-f28d-44d9-9a4c-aa4b7a9872b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6b7e0c45-e06b-44fe-9383-f1382c6c3b02" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8af8d106-f28d-44d9-9a4c-aa4b7a9872b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_650a2de8-7ec1-40e9-8160-975b21bb4d42" xlink:href="ino-20221231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8af8d106-f28d-44d9-9a4c-aa4b7a9872b2" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_650a2de8-7ec1-40e9-8160-975b21bb4d42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_srt_OwnershipAxis_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45" xlink:to="loc_srt_OwnershipDomain_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b6359a5e-d587-4614-8383-56e42ccf895b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45" xlink:to="loc_srt_OwnershipDomain_b6359a5e-d587-4614-8383-56e42ccf895b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_3febfefb-a48b-48e2-9754-846d20c9d649" xlink:href="ino-20221231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b6359a5e-d587-4614-8383-56e42ccf895b" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_3febfefb-a48b-48e2-9754-846d20c9d649" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d8cc40d6-fd4b-4269-8d5c-f25c224477f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d8cc40d6-fd4b-4269-8d5c-f25c224477f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d8cc40d6-fd4b-4269-8d5c-f25c224477f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d8cc40d6-fd4b-4269-8d5c-f25c224477f9" xlink:to="loc_us-gaap_ClassOfStockDomain_d8cc40d6-fd4b-4269-8d5c-f25c224477f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d8cc40d6-fd4b-4269-8d5c-f25c224477f9" xlink:to="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_acb6a1b1-7bdf-4f2e-bba0-7d1386d8b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_us-gaap_CommonStockMember_acb6a1b1-7bdf-4f2e-bba0-7d1386d8b6a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_4b3211c8-805b-45ff-b3f3-69ade33fa040" xlink:href="ino-20221231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_ino_SeriesAOnePreferredStockMember_4b3211c8-805b-45ff-b3f3-69ade33fa040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_da547b55-f9b3-4913-abc0-923922fdcd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_us-gaap_PreferredStockMember_da547b55-f9b3-4913-abc0-923922fdcd7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_893db888-0c20-4af7-bd5c-38f8e29ee57e" xlink:href="ino-20221231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_893db888-0c20-4af7-bd5c-38f8e29ee57e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd24b651-348e-46f5-8d97-d214ff7565f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd24b651-348e-46f5-8d97-d214ff7565f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_cd24b651-348e-46f5-8d97-d214ff7565f9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd24b651-348e-46f5-8d97-d214ff7565f9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_cd24b651-348e-46f5-8d97-d214ff7565f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c72c769c-8cfb-47b7-8743-d52e38548114" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd24b651-348e-46f5-8d97-d214ff7565f9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c72c769c-8cfb-47b7-8743-d52e38548114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_0f2b7b1e-3a91-45ac-a9ca-1fb997c5e2e5" xlink:href="ino-20221231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c72c769c-8cfb-47b7-8743-d52e38548114" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_0f2b7b1e-3a91-45ac-a9ca-1fb997c5e2e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GeneosTherapeuticsIncPreferredStockInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="extended" id="ib4fbdb08b2bd4e4e814356edd5a48ac9_GeneosTherapeuticsIncPreferredStockInvestmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9421c70f-6741-4d40-adb8-e7ee08db893f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_EquityMethodInvestments_9421c70f-6741-4d40-adb8-e7ee08db893f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_28c5c287-e58a-4166-8b8b-473efa358c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_28c5c287-e58a-4166-8b8b-473efa358c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8f9d3c9-de32-4950-9b68-0b6c58e743c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8f9d3c9-de32-4950-9b68-0b6c58e743c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a6678914-8ba6-40f5-be47-d4e0287bdcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_f4d58980-aee5-40dd-95dc-5a9f817e464a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_MinorityInterestTable_f4d58980-aee5-40dd-95dc-5a9f817e464a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_f4d58980-aee5-40dd-95dc-5a9f817e464a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e" xlink:to="loc_us-gaap_ClassOfStockDomain_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6eecfe94-811c-43ea-b13d-2410327fab35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e" xlink:to="loc_us-gaap_ClassOfStockDomain_6eecfe94-811c-43ea-b13d-2410327fab35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_d01bb189-7f12-474f-8ed6-c5debce9d86b" xlink:href="ino-20221231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6eecfe94-811c-43ea-b13d-2410327fab35" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_d01bb189-7f12-474f-8ed6-c5debce9d86b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended" id="i17789ab4a88e4cc1ac60de51a7c61d0e_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_2dcc74ae-5255-4c7d-8039-bd1e306931a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_2dcc74ae-5255-4c7d-8039-bd1e306931a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_4c664975-b356-475c-a0df-1530404da27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_4c664975-b356-475c-a0df-1530404da27f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestructuringAndRelatedCostExpectedAnnualSavings_20b701ac-2f69-45fe-9535-ed74fe743ff5" xlink:href="ino-20221231.xsd#ino_RestructuringAndRelatedCostExpectedAnnualSavings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_ino_RestructuringAndRelatedCostExpectedAnnualSavings_20b701ac-2f69-45fe-9535-ed74fe743ff5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c41c69d-d1c1-4e9c-83f7-1839a6b7e6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c41c69d-d1c1-4e9c-83f7-1839a6b7e6f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8dbd976a-1b2a-4780-a425-8be071e4bc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_CommonStockSharesIssued_8dbd976a-1b2a-4780-a425-8be071e4bc35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a911cd80-4c44-4f4c-992a-456aaa32ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_CommonStockValue_a911cd80-4c44-4f4c-992a-456aaa32ead7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays_a9154527-9142-41d6-b12a-68dfe03f4e73" xlink:href="ino-20221231.xsd#ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays_a9154527-9142-41d6-b12a-68dfe03f4e73" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_08c7b458-f929-4504-9b75-78eb65f9ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_08c7b458-f929-4504-9b75-78eb65f9ded9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_08c7b458-f929-4504-9b75-78eb65f9ded9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_08c7b458-f929-4504-9b75-78eb65f9ded9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_08c7b458-f929-4504-9b75-78eb65f9ded9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5eb19d03-bf35-4320-9b66-e22f2835c31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_08c7b458-f929-4504-9b75-78eb65f9ded9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5eb19d03-bf35-4320-9b66-e22f2835c31a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c2473bc7-0055-4224-a20f-33812736acac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5eb19d03-bf35-4320-9b66-e22f2835c31a" xlink:to="loc_us-gaap_SubsequentEventMember_c2473bc7-0055-4224-a20f-33812736acac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ef688809-de10-4b96-92c1-b916d78571d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:to="loc_srt_StatementScenarioAxis_ef688809-de10-4b96-92c1-b916d78571d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ef688809-de10-4b96-92c1-b916d78571d3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_ef688809-de10-4b96-92c1-b916d78571d3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ef688809-de10-4b96-92c1-b916d78571d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_52d5f656-36af-4c5a-beae-2f8fd1771636" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_ef688809-de10-4b96-92c1-b916d78571d3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_52d5f656-36af-4c5a-beae-2f8fd1771636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77293080-2025-400c-ba45-9269a852ca61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_52d5f656-36af-4c5a-beae-2f8fd1771636" xlink:to="loc_srt_ScenarioForecastMember_77293080-2025-400c-ba45-9269a852ca61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:to="loc_srt_LitigationCaseAxis_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a" xlink:to="loc_srt_LitigationCaseTypeDomain_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6c4f8c31-f1e3-4103-92e5-9b1748214d6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a" xlink:to="loc_srt_LitigationCaseTypeDomain_6c4f8c31-f1e3-4103-92e5-9b1748214d6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_926b94d7-0861-4d5e-a493-765efc383f99" xlink:href="ino-20221231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_6c4f8c31-f1e3-4103-92e5-9b1748214d6e" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_926b94d7-0861-4d5e-a493-765efc383f99" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ino-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5376b60-4920-4297-91b8-ae15a0711c84,g:73741ec8-2e2b-4617-87f5-1b9c1ea3fbd1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_fa114963-b45f-4e06-843a-629ada98c5a5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares outstanding under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockOtherSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Other Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_8c2f2237-2503-4f7c-bb3f-4b9337d9b534_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_938cffa3-e5d0-493c-a35a-d11e17cc9d0a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_76055719-a8db-4feb-b7d0-61ddd6eedc16_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d7582993-0647-4adb-bf32-93c210fbf8af_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cba8d1cc-3730-4ca2-abd0-593318d424dc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6b6deef5-4c6f-40a5-9bd2-111b5ce8268a_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7b2c7c4c-3b07-4b7c-8feb-66d64a3a6317_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_892a7e7a-ea7d-46bd-a8ec-796bc8d2e57b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_775889a6-6472-4560-a318-29407da89fc6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_b6a1f9ca-2dd5-407e-8b93-65ec5d4adc0c_terseLabel_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_label_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering [Member]</link:label>
    <link:label id="lab_ino_UnderwrittenPublicOfferingMember_documentation_en-US" xlink:label="lab_ino_UnderwrittenPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwritten Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember" xlink:href="ino-20221231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnderwrittenPublicOfferingMember" xlink:to="lab_ino_UnderwrittenPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_0ab0b6b7-e454-4ed4-a10e-781726fd369e_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$9.01-$12.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFourMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFourMember" xlink:to="lab_ino_RangeOfExercisePricesFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_71c8023d-1d2a-4a42-9a4b-7cc443f8180e_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_61137cd8-efcb-45c8-a256-a194df8b88d2_verboseLabel_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_label_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares of Vested Restricted Stock Outstanding Under Plan</link:label>
    <link:label id="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_documentation_en-US" xlink:label="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of vested restricted stock outstanding under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:href="ino-20221231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:to="lab_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_f57560d0-a45c-4d8c-ad45-2ecdae27ddc9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_d9eb1155-a628-49d6-bf52-d970dbd5b56e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_b6745e37-458b-4bb5-9467-6c1d7fe02760_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_dfccd13a-05c8-4e5d-b229-8008fc91c36d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_065b2103-5353-40b8-baa0-b86fcd60ff82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1f8d4c1f-c426-4315-bb6a-95cb6bd2376b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_807956f1-6de0-4c93-b960-94d58f73337f_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$3.01-$6.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesTwoMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesTwoMember" xlink:to="lab_ino_RangeOfExercisePricesTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5533347e-2342-4034-a1ab-74f1cc16a9cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_d183f15f-a384-4942-b811-32cf126facc0_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU's expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_26d20e06-4a46-439e-8c04-ada120edd3c4_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses related to affiliated entity</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f5dd36a8-34eb-40d6-85bf-b2c30ea0764a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_908bdc0d-31ae-427a-929b-e1c214ec047b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_ab8f056d-c3e4-4cee-93a8-9f227393c246_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1a4445d8-3571-4846-923d-543903e3138d_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_30d2fbe7-7393-460d-9fb9-f2e53829132f_negatedLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ffd00ef4-79b2-49a6-8cb8-988a75dfc697_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_243d48df-274a-40e8-b6bc-a0a318f384c0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commissions and other estimated offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_4426f46f-52a4-465d-baa1-519b7c45343c_verboseLabel_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan (in shares)</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_label_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan</link:label>
    <link:label id="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_documentation_en-US" xlink:label="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential shares authorized for issuance under a share-based compensation plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:href="ino-20221231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:to="lab_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2007IncentivePlanMember_f77d9df2-4e09-4fd6-a235-13401325c900_terseLabel_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2007IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2007IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2007 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember" xlink:href="ino-20221231.xsd#ino_A2007IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2007IncentivePlanMember" xlink:to="lab_ino_A2007IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_34a5d4ac-cc63-4369-89e4-ad42b11780a4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d97242af-4e3a-4d3d-8b07-5a23bb8c7221_verboseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_f0704f36-b5b7-4f23-ba0b-7c4eab375591_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, payment earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_label_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:label id="lab_ino_CollaborationAgreementPaymentEarned_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementPaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Payment Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementPaymentEarned" xlink:to="lab_ino_CollaborationAgreementPaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_de16aa65-8e51-487d-8247-79dfd3c5558c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations of Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2f10fe68-026b-40e1-8419-25879e1f87a2_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_69b1fac6-04d3-4e6d-b041-e9db6ee667a6_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_d5858704-7688-433e-9d76-1eb88af2a6c1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c89d44eb-0d16-4b13-a500-68816a056062_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_d8785532-fbf3-4d0b-9c12-c4cb0439e5f1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_33977e1f-d1b9-4370-b997-9e84969fcc90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_960dc7f7-a812-46bf-8d53-1685438bc3df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest based on the fixed rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantProceedsReceived_076b7e5b-14f1-4847-a58c-520beb556a90_terseLabel_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant proceeds received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_label_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:label id="lab_ino_GrantProceedsReceived_documentation_en-US" xlink:label="lab_ino_GrantProceedsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Proceeds Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived" xlink:href="ino-20221231.xsd#ino_GrantProceedsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantProceedsReceived" xlink:to="lab_ino_GrantProceedsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_fd31d22b-fe97-4109-84d6-cc3408db9a98_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_2aa23324-180c-48c9-944d-b0b660b09bc2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_7f975aa9-2c37-4487-b8ca-28e67c9f4e53_totalLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, net book value</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Net</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsNet_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets net.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsNet" xlink:to="lab_ino_GoodwillAndIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_7636fa7e-34a5-4aed-a8f4-ac031c72bf4f_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_917b430e-061f-4dd4-9c83-74307e5c7043_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinTwoYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Two Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5a4615b3-a21a-4b94-b323-e87851b9b93b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3d3c21cd-3c44-466e-84e8-f5e72c7f38fe_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss from operations</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d15a12f9-f154-4e9e-8f50-93542e47bf96_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_4a5c50f8-4ad9-4036-96b5-308b24703591_terseLabel_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lease agreements entered into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_label_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:label id="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto_documentation_en-US" xlink:label="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Number Of Lease Agreements Entered Into</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:href="ino-20221231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:to="lab_ino_LesseeNumberOfLeaseAgreementsEnteredInto" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5415f609-4741-47e3-a472-8d09b5c25dbb_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total antidilutive securities (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_92d39bc3-6680-4978-a1e4-591b1a8a229e_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_75589a43-71ac-45aa-b5fb-1b691f04ee7c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7e0a0a7e-b63b-4f58-8335-b3ab4fdfb581_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Maturities Of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_09eefcc2-c292-4589-98f4-b9b835e025fc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c3aad21a-1c69-43cd-9791-3271bf7618aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_e6331aa0-ecac-470d-a842-db11e71955cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_238787d7-d8f9-42ca-a73e-7962626a914c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_7690598c-9ce1-4fd4-a459-94caf3a6879a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_f60856cd-bb9b-42aa-b9bd-6b76cf278f59_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_e00e2d43-4d1e-4859-87f3-18e200e8a1db_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_9adc4902-f81a-4ad2-87b3-f4dbbd01e4bf_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_d1d5bbc6-2f12-4ed5-aa76-8831fd7665dd_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_04bab769-55e7-4794-889f-b423e37fd0a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_cbcc20ab-bb9f-4322-9fc3-7454de89b1f6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_b14f8eaf-5345-454b-9fe1-d20796602a94_verboseLabel_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_label_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:label id="lab_ino_ProceedsfromStockOptionandWarrantExercises_documentation_en-US" xlink:label="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Option and Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:href="ino-20221231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsfromStockOptionandWarrantExercises" xlink:to="lab_ino_ProceedsfromStockOptionandWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_1003fe5b-6f1a-40e8-9f6d-0958964ca8ef_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringinFiveYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DepartmentOfDefenceMember_8d42b3ca-f946-4bb1-87ef-dff0d01b4016_terseLabel_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_label_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence [Member]</link:label>
    <link:label id="lab_ino_DepartmentOfDefenceMember_documentation_en-US" xlink:label="lab_ino_DepartmentOfDefenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Department Of Defence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember" xlink:href="ino-20221231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DepartmentOfDefenceMember" xlink:to="lab_ino_DepartmentOfDefenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_cdcfc7c7-c928-4b17-8639-18b9b4c26a7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_331cc754-3834-4165-af90-c9751497757f_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_46054493-f62b-41a3-be8b-644ac32c0d03_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_55e009e7-2674-4d41-b7a4-d735efb87e97_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise&#160;price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_b624d41b-2375-4497-b422-b982afa15cfa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of cash settlement</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_fc4d073c-45a4-452a-8941-3e21036ee107_terseLabel_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Bonds</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_December2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_December2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember" xlink:href="ino-20221231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_December2019ConvertibleBondsMember" xlink:to="lab_ino_December2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_8dd66966-8157-41fe-a01b-50b357f91d58_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_578a4f23-8958-4dfb-9022-7d37e3150aa0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b31d68a2-b840-49c3-acc3-589d4f59815b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair&#160;Market&#160;Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a3eaaa3f-9724-4032-a607-5695f1a63e04_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_4a65f01c-2871-4a2b-bab0-ecbd10be0333_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_e8955338-e840-4f59-9a45-22778145b489_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_3aa288c9-7d98-4986-b12b-f95e19d100d6_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:to="lab_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9b880186-4c7f-45bd-b337-78b98ca1fd62_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_MutualFundsMember_b7ac2adb-a445-45da-94a9-b59141dc5577_terseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_7baf629f-2a97-4deb-9724-a667d12b6530_verboseLabel_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds</link:label>
    <link:label id="lab_ino_MutualFundsMember_label_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual Funds [Member]</link:label>
    <link:label id="lab_ino_MutualFundsMember_documentation_en-US" xlink:label="lab_ino_MutualFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mutual funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember" xlink:href="ino-20221231.xsd#ino_MutualFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_MutualFundsMember" xlink:to="lab_ino_MutualFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b95f81f4-7843-4e80-aacd-5c281939f070_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_INO4800Member_485930c9-3c36-4740-a93d-abadf28b1ea6_terseLabel_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IN O4800</link:label>
    <link:label id="lab_ino_INO4800Member_label_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I N O4800 [Member]</link:label>
    <link:label id="lab_ino_INO4800Member_documentation_en-US" xlink:label="lab_ino_INO4800Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I N O4800</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member" xlink:href="ino-20221231.xsd#ino_INO4800Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_INO4800Member" xlink:to="lab_ino_INO4800Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_a2b73414-0b48-45d2-8e20-747d4be84ed1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_c8d78e38-85b6-4075-84b3-78de305fd51f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_3c2c08d1-982c-4478-ae7a-961411c5c685_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_ba4f4260-2db4-4c17-82f8-ea5c6febea23_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_18686002-a13b-4259-aa5b-a61fe1883185_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5ca52275-1f9e-4961-a921-e1311b797a6d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BiojectMember_6316d798-5ba7-40ee-ae96-f868e50fe9da_terseLabel_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject</link:label>
    <link:label id="lab_ino_BiojectMember_label_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:label id="lab_ino_BiojectMember_documentation_en-US" xlink:label="lab_ino_BiojectMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bioject [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember" xlink:href="ino-20221231.xsd#ino_BiojectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BiojectMember" xlink:to="lab_ino_BiojectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_8798444f-0a42-4b8a-ab8a-03116202523a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_47b0a7dc-695a-4d45-b204-7bbb75ce28f4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_e3b54366-3f35-464c-986d-8180f742e105_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_80ce670e-18e4-4000-b19e-a37e7e73ff27_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b609a19b-d725-48bb-b1d8-e7381323f75f_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b715d4ed-5346-44af-94fe-b26999b01767_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2312706f-0276-4568-9298-a7a865bfd97b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expirations in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_6fdb78f5-33e0-4055-aa3c-6daa5471ab11_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_fb94a318-4131-4dc0-a202-77c4ce8873ad_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements, Upfront Payment Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:to="lab_ino_CollaborativeAgreementsUpfrontPaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostMaintenance_e4e5fa6b-6d50-4675-b65a-ac55a14635af_terseLabel_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance</link:label>
    <link:label id="lab_us-gaap_CostMaintenance_label_en-US" xlink:label="lab_us-gaap_CostMaintenance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Maintenance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostMaintenance" xlink:to="lab_us-gaap_CostMaintenance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_efcba594-2f14-48c1-be4c-35c4b91ad0ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_984eac3f-2e09-4544-aa59-b96c806a2c91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_a7cb8a70-2be3-44ab-9f59-607cb28ddb22_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected charge</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b24c02d5-85a9-4e67-a480-779d9c1d7687_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_ea4d1e0f-f5ed-49e0-9514-af999db0724c_terseLabel_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchase agreement, commitment of additional investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_label_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:label id="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_documentation_en-US" xlink:label="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement, Commitment Of Additional Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:href="ino-20221231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:to="lab_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_c6dc3e96-8db8-4675-bba0-4b928a297c4e_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_6cdbe022-991f-4a7e-a032-08cfb76e28a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_6db05a35-6a81-419d-970e-e4adbb1f9fce_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_f57e260c-b3a8-4701-b9e7-1046665f7d82_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining authorized amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementRemainingAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Remaining Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:href="ino-20221231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementRemainingAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1a3134f-ed95-468b-85d1-0f34460022b7_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_72aae535-8288-45a9-8050-5b57a871a51d_terseLabel_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_label_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:label id="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_documentation_en-US" xlink:label="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:href="ino-20221231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:to="lab_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_39fb430c-ba7d-40e2-b036-cdb8a63f4b32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_efc1fb82-4125-4891-a106-9c4108692356_terseLabel_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service-based restricted stock units</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_ino_ServiceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:href="ino-20221231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ServiceBasedRestrictedStockUnitsMember" xlink:to="lab_ino_ServiceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a7f58057-97cf-44cc-b7fb-35590c853ec2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_a6d62ff8-9686-4a33-95ac-f6da236d1352_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of (discounts) premiums on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_655e5a5c-20b0-4678-9eaa-d753b5956946_terseLabel_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_label_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:label id="lab_ino_GrantRevenuePolicyTextBlock_documentation_en-US" xlink:label="lab_ino_GrantRevenuePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock" xlink:href="ino-20221231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GrantRevenuePolicyTextBlock" xlink:to="lab_ino_GrantRevenuePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_8045b3df-e002-447b-9004-e540c058bf64_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Financing Arrangement, Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:href="ino-20221231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:to="lab_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_82f3c951-de14-4192-b829-a9c49b939337_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_71fd4c3c-9f8d-42bb-a707-37713fa00259_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_00dee60d-b319-4a39-9b6e-497f147ca7cc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_559d4436-4682-41d1-acdd-9620989a1185_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c03c5bb3-6ebd-46c2-9e9a-6c116dc9f8af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_df3e501e-7197-41f0-9edd-3a0b44c5a847_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_c0ce896c-1f63-43a9-8792-f59c3349e7ae_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expense</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_f60949cb-449b-4121-8b32-e32abc9aeda4_terseLabel_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_label_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label id="lab_ino_BillAndMelindaGatesFoundationMember_documentation_en-US" xlink:label="lab_ino_BillAndMelindaGatesFoundationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bill And Melinda Gates Foundation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember" xlink:href="ino-20221231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_BillAndMelindaGatesFoundationMember" xlink:to="lab_ino_BillAndMelindaGatesFoundationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_7ab458f0-1a86-4ac9-85ed-39126a1a15b4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_a4d06ce4-62d1-4cc6-9d7d-2e9fda1f9a61_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions reduced</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_d6e5fab7-70eb-4830-9e95-7f0cd772dc34_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e8b2f383-af89-47b2-9c32-53b78ca6971e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_3a7eadeb-ff39-4b5b-bbd0-79abbadca444_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of subsidiary</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:to="lab_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47f582be-637b-4897-be90-24852e3dd50e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_17102ce3-3db1-4fbd-b535-4cd5e04f908b_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$15.01-$25.62</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Six [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesSixMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesSixMember" xlink:to="lab_ino_RangeOfExercisePricesSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_061d8c8d-60fa-4dde-b354-5c8b2c67740f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5bbd3839-d627-475a-b4c3-63c0dbd12ffa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_d3ed7d78-f4a2-46e7-b2ec-989bbf46e532_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_0a35f687-4dbc-48af-841b-cda42ebd02d3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_69aba950-051e-4eaa-9dbf-a64a7a7aefa1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_f4815d82-20e4-4399-b93d-759643cb905b_terseLabel_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_label_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:label id="lab_ino_StockSalesAgreementMaximumAuthorizedAmount_documentation_en-US" xlink:label="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sales Agreement, Maximum Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:href="ino-20221231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:to="lab_ino_StockSalesAgreementMaximumAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_adb595cf-a2de-4016-aa9a-c252d8b2eafd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_60c34170-4893-4cfe-ae65-9c7cabd5d362_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value of december 2019 bonds</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_2d9a7450-bfe4-4129-93c9-15b1d35e70df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in cash resulting from the deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_c800a16b-6625-4745-a114-268e176757b4_terseLabel_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Korean State Income Tax Authority</link:label>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Korean State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_KoreanStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Korean State Income Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember" xlink:href="ino-20221231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_KoreanStateIncomeTaxAuthorityMember" xlink:to="lab_ino_KoreanStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e6815b1e-4f3c-4114-8004-b034947cc170_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_114e608d-95dd-43ed-86d5-d0efe72f2d15_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_b6b48a50-9cf1-4d3f-b1bf-394a86dc3616_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_007b6dcc-ac7d-4ff9-8748-16778ff26b76_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_2ceb5664-355d-458c-aba2-0c5df7a089d2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable from affiliated entities</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_a5d2e9da-af55-4e6f-8ca4-9088821a3a24_negatedTerseLabel_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement of receivable with shares of common stock from affiliated entity (PLS)</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_label_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:label id="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_documentation_en-US" xlink:label="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Of Receivable With Shares Of Common Stock From Equity Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:href="ino-20221231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:to="lab_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b4689cce-04a9-4901-9a47-9463be1bf0ef_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_8377c947-69ef-486b-8873-761c0f04894c_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eligible Item or Group for Fair Value Option [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_14d2900a-63e9-47c6-8d78-62edcab2ce28_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_79a9db29-337d-4fca-ac58-441cfc1a9988_terseLabel_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former President and Chief Executive Officer</link:label>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former President and Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former President and Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:href="ino-20221231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:to="lab_ino_FormerPresidentAndChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6b48376f-8da2-41b7-8213-db995f9d8758_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_e2e63735-eeda-478e-ba4d-756f4a8a218d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonemployee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_7d161d2d-e1e7-4b93-83ae-5cd0ab28be2c_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_9b56ac8d-29dd-470c-a587-e6d353eeef1a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_ca01b2e5-c78e-4245-8492-180adf12c91e_verboseLabel_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assumptions used to estimate the fair value of stock options</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_label_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]</link:label>
    <link:label id="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_documentation_en-US" xlink:label="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used in estimation of fair value of stock options.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:href="ino-20221231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:to="lab_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_c497d951-5810-4463-9d9f-605c20756813_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SalesAgreementMember_6a3a66f0-b6e9-4c21-b6a7-36877b680932_terseLabel_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement</link:label>
    <link:label id="lab_ino_SalesAgreementMember_label_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label id="lab_ino_SalesAgreementMember_documentation_en-US" xlink:label="lab_ino_SalesAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember" xlink:href="ino-20221231.xsd#ino_SalesAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SalesAgreementMember" xlink:to="lab_ino_SalesAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_f8a8f4f6-1ff1-4c33-afaf-f6f2508006f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_720a5e5e-c498-4ce8-adf8-5e128d2fda75_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_146e72e0-6175-449c-b714-86b36bff48f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_c1fbcf9b-eb22-4a72-9598-6ac8e02c5760_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_2dc0eef9-5d95-4d76-a16b-c9fd68dd2163_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AllOtherCustomersMember_0ad27540-2397-4453-b1cb-cc076c5f20d6_terseLabel_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other, including affiliated entities</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_label_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:label id="lab_ino_AllOtherCustomersMember_documentation_en-US" xlink:label="lab_ino_AllOtherCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other Customers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember" xlink:href="ino-20221231.xsd#ino_AllOtherCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AllOtherCustomersMember" xlink:to="lab_ino_AllOtherCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_b133d6fa-293a-44f1-a69c-28e9fc796d37_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_6f5c7a8b-8a6f-4297-8f27-7ea324f543a9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_55b70789-7fa3-48b6-bad2-5a243f5f61a5_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_19bd05ef-5c9c-4a36-b3df-9c701b79f6bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_39c1fdf3-f673-4837-bdba-e6b8034c566f_terseLabel_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total goodwill and intangible assets, gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_label_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Gross</link:label>
    <link:label id="lab_ino_GoodwillAndIntangibleAssetsGross_documentation_en-US" xlink:label="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GoodwillAndIntangibleAssetsGross" xlink:to="lab_ino_GoodwillAndIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_f66c1c99-bc0b-4e44-a5e3-4a9a94b1b9d2_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6c83e415-c49a-4667-9b3d-37227074cfb6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_05d4b575-6713-4f27-bae3-96c4566f7676_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_6dbc5cf1-f921-4a90-97b3-969d86be4d72_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_0df85f57-7b77-4252-bef3-d0c3435ad07f_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_bf4fc49e-e94a-4c3f-b3e8-7b8ca70d2a52_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_5374893d-0c51-4187-8d96-27cf61034392_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_649cfe50-9935-4ecd-8aa7-4b7c4e0f76bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_eedd55d4-6df2-4a3f-99db-5ef0062450cd_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8ee4a99f-8749-4fe6-bfeb-917bb86689c1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_a892be12-868d-4650-801d-c236d52af8fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_4cfab311-8c65-4476-a4c4-74b64471d181_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, debt</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_c194a5a8-5071-46f9-b647-4474ef1fc0e9_terseLabel_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_label_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:label id="lab_ino_EmployeesAndDirectorsMember_documentation_en-US" xlink:label="lab_ino_EmployeesAndDirectorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Directors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember" xlink:href="ino-20221231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EmployeesAndDirectorsMember" xlink:to="lab_ino_EmployeesAndDirectorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_358e3c0a-e95a-42f3-9606-62c4b8112826_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_d86e0e18-bfa0-4e4d-b77f-e5c41c9ff86c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_11e2b018-e0f2-4ec8-abe2-e4ba93e04a4f_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fba3ff7-0f95-4cfd-9444-32c0a3ba3d2d_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_2ed301d3-31a4-435f-9616-fbc1747c747c_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_9a60ee60-fd27-4ab1-9e45-7f22cd12d0b3_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_b8a62a89-5b04-4fd3-9a64-5061e7f61720_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Limited NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_63253ba7-d8df-4f7b-ab02-10479190a720_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Assumptions Used To Estimate The Fair Value Of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_a82add46-9458-4171-ac46-872ab8ecffef_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of net loss in Geneos</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillGross_6f122aad-f244-45ff-9364-3ea471f62021_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, gross</link:label>
    <link:label id="lab_us-gaap_GoodwillGross_label_en-US" xlink:label="lab_us-gaap_GoodwillGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillGross" xlink:to="lab_us-gaap_GoodwillGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_ecee20a1-f47d-4d75-871f-372224bb6023_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f761debd-b048-4080-8d20-656b3643c7ba_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0d75ba54-f4c3-42bf-9594-c346769289bb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9b543995-417e-43e8-ab81-7962dfd7d4ba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2a5b4d9d-de8a-4618-8537-c7dfddb93886_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0ac2fb4e-b000-4cd2-a11b-a6863679ecbe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_5c88822f-148c-4699-8fc0-eebc47bcc796_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a038d951-e1e3-4148-8dd0-70fd3c8a2ca8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_f8add0d5-a54a-42ee-8398-80ef98cc9a4e_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of convertible bonds and senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2432a33b-e96f-453b-a15f-83abc757a21f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of convertible bonds and senior notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_73670464-887a-4909-a540-5138cf2a813e_verboseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series&#160;C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_6bdf417c-bee0-42e2-8e5c-af9d9beb0e51_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_3eaa958c-20d1-43f0-962e-1172ab9a1f3d_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8be95465-ab31-477e-9605-7cf6c367311b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for cash, net of financing costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_3275fe29-445f-49b9-81d6-902c7e17b33a_verboseLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_86a6a016-d26b-470c-9a15-773ebffb1cc4_negatedLabel_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on equity investment in affiliated entities</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_label_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Value of Investments in Affiliated Company</link:label>
    <link:label id="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_documentation_en-US" xlink:label="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:href="ino-20221231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:to="lab_ino_ChangeInValueOfInvestmentsInAffiliatedCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_c46633ba-3343-4060-aadc-cd2f75771b47_terseLabel_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_label_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]</link:label>
    <link:label id="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_documentation_en-US" xlink:label="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:href="ino-20221231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:to="lab_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_cf619493-4f93-489b-a178-7d1d988eb6cf_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_07baf389-5fe2-4bfd-b5c9-702835f76b5d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_b5ccaf5c-e49b-491a-a824-967851ee3777_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, upper range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_12098b5a-712e-419b-b13c-e984f764a876_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement, aggregate number of shares issued (in shares)</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Number of Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:to="lab_ino_StockSaleAgreementAggregateNumberofSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_932dd70d-fc65-4f8e-a974-86999c05e7a4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a5ad17f2-e4f5-44ef-b934-b33635292236_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">401(k) Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_515ce459-5f02-4eda-8aa3-210d70b1de06_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_614a5a12-6f6b-4a1e-8ac2-b87b22d63ebc_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. (affiliated entity)</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesIncMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesIncMember" xlink:to="lab_ino_PlumblineLifeSciencesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_3d16f75f-0ba1-4a4d-91ca-6ee981010fff_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_f72cfa28-5183-44b5-a3b5-e2376d97f885_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5582a51c-a77b-46a0-9c83-3dda2c1b2684_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cca6fe29-3b15-428c-9641-a7be16eff479_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_cd57690f-448b-4371-8366-4890f5d524d1_terseLabel_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Agents will be entitled to compensation</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_label_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:label id="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_documentation_en-US" xlink:label="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:href="ino-20221231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:to="lab_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AdvaccineMember_7bcbd35d-f9a8-4b0c-8537-537c8bdff9d4_terseLabel_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:label id="lab_ino_AdvaccineMember_label_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine [Member]</link:label>
    <link:label id="lab_ino_AdvaccineMember_documentation_en-US" xlink:label="lab_ino_AdvaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember" xlink:href="ino-20221231.xsd#ino_AdvaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AdvaccineMember" xlink:to="lab_ino_AdvaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_eacb8dd8-bcce-4f56-b8e1-c32844fdfcaa_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded option amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedOptionAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Option Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedOptionAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedOptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_50737a7e-6801-41c7-b6d5-3464be650b1d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_e7401015-20e6-4ebe-b9db-20d4dd91dece_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_9cca7a5d-54f2-4f46-b735-3af50edc83c9_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_7bccd2d6-c7f5-4b53-85f9-1cc1a90c7fd2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b9000496-d1eb-4e91-b98c-86799e50509f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e8b5234a-f64a-4bc1-a594-c8901e5499dc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_961a5489-99e9-4774-ba3f-f388ac753d54_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_2227c37c-ae6a-4f57-8b80-51377e296e1d_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred grant funding from affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliate_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliate" xlink:to="lab_ino_DeferredGrantFundingFromAffiliate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_e87741ae-aafb-428f-b648-2e88eecd7b1b_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_8f6b7e46-4f6a-4c42-b25f-af72941854fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_1983d66c-92f6-41a0-95c0-9fab4435ecdb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_d0f1235a-cd0a-4ae0-af91-0a0d23e3d50d_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_474d97e5-3f37-4b1e-a9ea-6c60ddd9c03b_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55a73edb-e5d9-49ef-9741-828843bf1cb2_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_b3a90503-25f9-42d9-9253-8d07a850bca1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5f4455f4-0ec5-4b72-b729-ffbe4567a12e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TheWistarInstituteMember_ff2249c1-c074-4614-beb3-a38599c17efb_terseLabel_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_label_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:label id="lab_ino_TheWistarInstituteMember_documentation_en-US" xlink:label="lab_ino_TheWistarInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Wistar Institute [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember" xlink:href="ino-20221231.xsd#ino_TheWistarInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TheWistarInstituteMember" xlink:to="lab_ino_TheWistarInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5fccaf9c-18cb-4647-984e-10eed5377089_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_75bd9e3b-01a2-42ab-816a-3728879486ca_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0787e6b3-3d55-4663-9c6e-a9834cb3cb66_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0c5e3639-6833-4782-af5f-0df0ab321666_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_f16f51e2-23f7-4d28-a577-61346df8c6bd_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_c72dfeb4-36b5-439e-94f6-80dee480857d_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remeasurement of Geneos Series A-1 preferred stock</link:label>
    <link:label id="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_aff6ecd5-ea8e-4533-a1e7-7e274a28d7a4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_aac68195-9009-494d-9d3c-d0c6bd84cdc9_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_4bf5ea56-7af8-4718-9a8d-acd6739f14ff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining contractual life (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_cca019e4-f447-4481-92f2-4622704db0bf_terseLabel_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="ino-20221231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2204add2-8f0f-458a-83c2-ae3839803fcc_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_8b8ffdc3-781d-4dbb-84a6-bc3120ed20bb_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_d4ed1483-3698-47cf-b1e9-7bf2f56a4df8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases (decreases) related to prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_63a3c024-3aed-4f42-be3d-b903048a7081_negatedLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_39747a91-2204-4816-9697-b777b89ecde7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_fac20358-9d6c-4bf0-975b-fe6b75146c85_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3f0f1fa2-96fc-4ade-b0cc-97ccfa3f8752_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ed4ee752-d4fe-4e34-a2d1-83890a247d5f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-based restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_ca7b392f-ae18-4367-a00c-691721698ef2_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_0f96ce93-d966-4759-ba94-5adb0c0f4083_terseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_132f130e-24e7-4400-8b75-25234edd3ff9_verboseLabel_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_label_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.50% Convertible Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:to="lab_ino_A6.50ConvertibleSeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_88a0f290-ecb1-42bc-be49-fa7c79dd82d3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_26ce6763-2bb0-44f8-8dcd-4aaf722394a4_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_649ad66f-ae19-4647-932f-0ad6249d4c7a_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$6.01-$9.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesThreeMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesThreeMember" xlink:to="lab_ino_RangeOfExercisePricesThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_4c69ab31-67ae-4983-8699-489cad1a79f4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">%&#160;of&#160;Total Revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_866a557c-e5c3-403b-9ee5-20359442704f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_f7e77a5e-0a7e-40a6-b100-0f859ec5cf2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position for more than twelve months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_d4767842-3525-4728-8384-645a86c3546e_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_363b922f-d6b8-4dd5-9e18-e260a031e9fe_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertibleBondsMember_bd8a8237-e0ed-4ff8-b382-e92b820a01e7_terseLabel_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember" xlink:href="ino-20221231.xsd#ino_ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertibleBondsMember" xlink:to="lab_ino_ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_00ea597a-9dd6-4f53-899e-7dbae276f885_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_17d08fa7-bfdf-4890-a84d-ef857ddb60b0_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a57e2a66-432d-4fe2-be7e-d1cc73ca188a_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_6b2ff64c-3250-46c9-9135-79c5e1ab0b70_terseLabel_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_label_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:label id="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember_documentation_en-US" xlink:label="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coalition for Epidemic Preparedness Innovations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:href="ino-20221231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:to="lab_ino_CoalitionforEpidemicPreparednessInnovationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_351665f6-8db6-4d5d-b4f5-ef7de7689d45_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_36848ac4-ebed-4ff0-84d2-28fa514ac457_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_00442960-65bd-4a74-9a0f-4b4a4cceb33d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2ac1a7f3-2fdc-4202-b4bc-dd9074145095_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_5ebe0c54-4497-4076-a4ad-40dfb41e08eb_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability from affiliated entities</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingFromAffiliateCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, From Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:to="lab_ino_DeferredGrantFundingFromAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e8836d0c-5811-4976-97c1-1e08fa272740_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_c1d42f97-b35b-42ea-b857-e2cee22e23f9_terseLabel_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID19 Vaccine</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_label_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine [Member]</link:label>
    <link:label id="lab_ino_SARSCoV2COVID19VaccineMember_documentation_en-US" xlink:label="lab_ino_SARSCoV2COVID19VaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">S A R S Co V2 C O V I D19 Vaccine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember" xlink:href="ino-20221231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SARSCoV2COVID19VaccineMember" xlink:to="lab_ino_SARSCoV2COVID19VaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_9758836a-58fe-4c9f-bdd0-84c84aa34510_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_5d1f0675-4ff5-41cc-8dea-a0d8b1c15a31_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_4e0b0aea-d2df-4927-8980-9b8bc804aa02_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_ce1e5778-068c-4649-9adb-0bbc1dfcf0f9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_2f45a5a1-10b1-4418-906a-c81c5d75cbe2_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_966ea9da-ad4f-4bc4-8162-5750fdb23f5c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_cb1e45f5-93f3-4f82-bd6c-76b43e933915_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_f3ebff43-0f9a-413b-aabb-ba2ddf788936_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_8bfd8c4e-1d19-4bb7-aa48-35a41152214b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_52faddad-88b3-4ec4-befe-6af1a4de15eb_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_3dd2cd8c-f743-44c0-ae90-afa7be9ea659_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_002d4de9-01c6-4a16-a510-8fb726349abd_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonEmployeeMember_8fa2ca91-fb4e-4df4-a143-0dea2af5415f_terseLabel_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee</link:label>
    <link:label id="lab_ino_NonEmployeeMember_label_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee [Member]</link:label>
    <link:label id="lab_ino_NonEmployeeMember_documentation_en-US" xlink:label="lab_ino_NonEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember" xlink:href="ino-20221231.xsd#ino_NonEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonEmployeeMember" xlink:to="lab_ino_NonEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_08642ec2-6ce3-464c-bd4b-c071b4f90284_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_da102fab-8922-45d0-a3c5-9b825aec1c94_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_1fb58e1c-e246-4cb6-bbb3-da88de7e45ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_5b20e974-4d80-40c0-bf7b-17eac73629d0_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="lab_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_46ef366c-8b48-465f-b741-e9dec64faa72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_0b5782d2-d99e-424f-8032-616e75f0ed5d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_abe610f9-d785-4e98-9c03-cebb82730e77_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_dcde5eef-7728-40ff-b23b-6dd3b9179f6b_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible loss on extinguishment of debt</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:to="lab_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_3c9179d3-5b7c-4ee3-8100-ce49eea1e29e_terseLabel_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_label_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale Contractual Maturity</link:label>
    <link:label id="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity_documentation_en-US" xlink:label="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale contractual maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:href="ino-20221231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:to="lab_ino_DebtSecuritiesAvailableforSaleContractualMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_1e502436-c4e2-42e1-8f13-0a1d8bb28627_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CEPIMERSMember_2294c68c-d530-458a-8535-6c12feddeee9_terseLabel_en-US" xlink:label="lab_ino_CEPIMERSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI MERS</link:label>
    <link:label id="lab_ino_CEPIMERSMember_label_en-US" xlink:label="lab_ino_CEPIMERSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI MERS [Member]</link:label>
    <link:label id="lab_ino_CEPIMERSMember_documentation_en-US" xlink:label="lab_ino_CEPIMERSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CEPI MERS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CEPIMERSMember" xlink:href="ino-20221231.xsd#ino_CEPIMERSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CEPIMERSMember" xlink:to="lab_ino_CEPIMERSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_a0cc30d1-e89d-436c-9b49-7df3515cd9e7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of or maturity of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4094d541-f52f-44b9-b92b-8aa43d4a8efb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e5e92305-fb7a-4a6d-9b0a-238cd96d4f85_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_aa7f5dce-29c0-47ac-b28a-44919d6c6ad0_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsOperatingLeaseLiability_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:to="lab_ino_DeferredTaxAssetsOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8b00ed98-4a59-4833-b9e0-129ecb92dded_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options for cash and vesting of RSUs, net of tax payments</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3e071035-5b36-4127-af21-f75820811c0f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grants under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_b4d8d1c8-ee36-4b22-90b8-1a0c6ebb03fb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e1be61f0-c5e3-4ff8-9b3d-683278bc66cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_f46cf8e9-ab3f-4ba1-abca-5b65b1ae8d12_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ad74de99-724b-487b-98c2-12f246ce8361_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_b2f65636-aea7-4f8c-8173-02e669706e7c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6fcc4853-32e0-4aa6-a731-a63b8ae369d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_a447dde3-5d1a-4f38-82ad-fa8d797bd492_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6d0d214d-9843-41dc-b4c3-33a55dfbda08_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0fe5235b-6200-43b6-b101-58ced37d5753_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_0c4b7ae9-3221-43c6-a638-3e5a58adaa72_netLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_9293bbab-11de-4592-a548-26dadb332769_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company's contribution to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_07813407-fc28-41ba-a4ac-76be883a87a2_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_a87f8796-1483-47d8-9772-71b63f9f9484_terseLabel_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired NOLs and credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_label_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:label id="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_documentation_en-US" xlink:label="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:to="lab_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_585ecdd3-5048-4cc3-8ec1-3701e10a19cb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_08e3abe2-9332-49d7-8773-613b2d78501f_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b1cc5e79-fc1c-440d-9c3e-afb310c1356a_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2c91f183-2ab4-4078-b100-ca939209ce82_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_9ec97c5c-62f2-4b65-8e12-d364999be4f5_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3265bc1a-305f-4dd1-a670-b3482ca86e9e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f6414f87-2050-4bbb-b837-04023a65d297_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_9a7edf64-9f9f-4e17-abdb-b43c442a73d2_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_5c8b0cc9-02f6-47b6-a364-e42f9b876ec6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5502c948-d827-4fe7-8b5c-a1ce952c370a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_f37287dd-743f-42cc-aa44-a200d87fec58_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_6ce6a876-3d26-46e1-b598-ecf236df378b_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_NonCashInterestExpense_98a2fba1-0056-4b06-a967-97f76187ff94_terseLabel_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_label_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:label id="lab_ino_NonCashInterestExpense_documentation_en-US" xlink:label="lab_ino_NonCashInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense" xlink:href="ino-20221231.xsd#ino_NonCashInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_NonCashInterestExpense" xlink:to="lab_ino_NonCashInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_38399c70-197d-4141-a152-5d793c6193bd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_250d3daf-16a5-44be-99cd-f0b890c3fbb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, expirations in period, weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_de90bb26-2f2d-4f3e-9853-eb1e6c50b16e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_69b5891e-667a-4395-85c8-3120841fd2e0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd67f319-9d94-4c1d-9222-4cf838dc7925_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9d0b23f8-2ee6-4f23-a3a9-53b7be48e354_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_91b29daf-e1db-4cfb-b2e6-f8972c6e7e49_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses to reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_label_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:label id="lab_ino_CollaborativeAgreementExpensesToReimburse_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Expenses To Reimburse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementExpensesToReimburse" xlink:to="lab_ino_CollaborativeAgreementExpensesToReimburse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_13c1c0ca-c2c7-4d66-9693-3273807a14fa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c24d3ae3-d041-4954-a080-7b63156fcae4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of unvested restricted stock units and options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_89f8c722-6f4a-4199-be4c-8ce23d60d8fe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_86041cbe-19e9-49b1-8da0-f52a5320933e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_50692ffa-281f-41c8-94c2-1442d3fab3cd_terseLabel_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_label_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ino_GeneosTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_ino_GeneosTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member" xlink:href="ino-20221231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GeneosTherapeuticsInc.Member" xlink:to="lab_ino_GeneosTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_502c38ea-1e25-4179-a8ae-98e1f50789ff_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_97940710-7663-42d0-afcb-0109e604334c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_71cb1fe1-6de2-4654-97eb-c2ac507db6c7_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_21c1bda3-05d7-4b7f-b7a0-0ad968eb9c94_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_2b060522-49f0-4955-adc1-d73d09d7e0e1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryBillSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryBillSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryBillSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68d5d6ce-e878-4a0b-bc85-25ee23e32a6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2b837948-35db-4f80-b073-726f4054126d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_4bffdc65-6a51-4780-a54e-dd48499347e5_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_6247ebd4-b444-44b7-b910-9c0e52a078f3_terseLabel_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-1 Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesAOnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesAOnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A One Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember" xlink:href="ino-20221231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesAOnePreferredStockMember" xlink:to="lab_ino_SeriesAOnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_5a0335d0-0ae4-4fc2-a3bd-d5ac9aefedb1_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, funding to be received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding To Be Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingToBeReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingToBeReceived" xlink:to="lab_ino_CollaborativeAgreementFundingToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_6301af12-3382-4878-b73b-9de266720872_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_3eeb546f-ddfe-4dec-8cd4-f7f462de58e0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8639bf55-89fd-4314-8f39-05f33b7bea4f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9223b1ab-f548-43a3-8f44-27104438dfdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_51bb47fa-2f5b-49ce-9495-75eee6fb27dc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e7fed514-1630-4304-b57c-a7830d78f2c7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements - Recently Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_304f6b5e-4253-48fe-8b93-06151b10faee_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt conversion, converted instrument, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_aaa9845b-b723-4871-93b6-8c5f5bbe766f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6bbdf7c5-7603-4bb0-bf72-ddc283632707_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_19470f0e-e84b-460e-80e2-e9109521c309_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_8003f606-9530-4617-8aef-e99babe08243_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedParties_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedParties" xlink:to="lab_us-gaap_AccountsReceivableRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_11171074-e04c-470d-8918-7e7acadde1ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_b64e802b-6783-40ce-af95-51256b88a954_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_da000174-617e-4cde-9f66-b17a9edcdd9f_totalLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, net book value</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_deca35de-aac9-43aa-80c4-c0c4bbaf1455_verboseLabel_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_label_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:label id="lab_ino_AccruedClinicalTrialExpenseCurrent_documentation_en-US" xlink:label="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:href="ino-20221231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccruedClinicalTrialExpenseCurrent" xlink:to="lab_ino_AccruedClinicalTrialExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53df9228-22ad-4eea-93db-4d73352dd92e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8cdfa5af-c48f-474e-b989-b4aa76e59877_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_3a1613a8-38e0-4e92-8039-bdfd196c8380_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of non-controlling interest in Geneos, net</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8e69f4d2-9aed-48ce-9436-ba4d7f0c5918_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3d22ca3b-2e69-4588-9898-48e5dd18eda0_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ce4adf9a-f3a4-4cdf-87ed-31d1248b7567_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6a7bd793-89a8-4ac7-9a28-f6614a42e69c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_cf2d406b-a36d-4f87-b0bd-78788c86dc2b_terseLabel_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_label_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:label id="lab_ino_SanDiegoCaliforniaMember_documentation_en-US" xlink:label="lab_ino_SanDiegoCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">San Diego, California [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember" xlink:href="ino-20221231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SanDiegoCaliforniaMember" xlink:to="lab_ino_SanDiegoCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1d4769e9-130b-48ad-9a41-4d001623316c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_cf4fc664-d3e0-466c-af37-1c27eedb40a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_cc1356b8-2d16-460d-8db1-4d3f5a9c6749_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2339539a-b622-4c2e-9bb9-eed47ae2d7d8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_fa209670-ef87-4996-8707-74e7a7127f18_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c44e6431-7d80-486c-8ef9-e61ea2a95d78_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of unvested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e4125075-e4e5-47c5-b833-8212d0ccec32_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fed47f38-2c6c-4f4f-8b8c-84af3d155df4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fb286138-a132-48fa-af14-84c755ac4347_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_e5c4a6e0-c06b-4f9f-a3a8-608ccfa78492_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_ea2adf1e-d82a-4dde-a692-d22f238048eb_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_174c29a2-0a7a-4281-8bca-45ab7d13e2ef_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_9ea72d26-9f31-4a13-80f6-30d331f41514_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, remaining contractual term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_a84aac52-f262-41bb-a035-9f945b93acfa_verboseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licenses</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_077afaa1-59e0-44f7-96d1-f5fac0f47f35_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0d4cd31b-31cf-45c6-9c6b-ea9cb8d3f3c9_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_0e746da4-2f0a-4558-9f5f-d6386593d528_terseLabel_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_label_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:label id="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_documentation_en-US" xlink:label="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:href="ino-20221231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:to="lab_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_WorkingCapital_4f313256-e59d-46d5-bf59-1f3ed29b6dde_verboseLabel_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital</link:label>
    <link:label id="lab_ino_WorkingCapital_label_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital</link:label>
    <link:label id="lab_ino_WorkingCapital_documentation_en-US" xlink:label="lab_ino_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net amount of current assets and current liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital" xlink:href="ino-20221231.xsd#ino_WorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_WorkingCapital" xlink:to="lab_ino_WorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_8dbc83f7-1ac6-4576-8812-276fecea3699_terseLabel_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania State Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:href="ino-20221231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:to="lab_ino_PennsylvaniaStateIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8db4e1cf-b7ab-41e4-8d73-55dfd293fcac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, exercises in period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2022InducementPlanMember_53f79499-2946-4fc7-a4f1-4a2f649e9d00_terseLabel_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_label_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan [Member]</link:label>
    <link:label id="lab_ino_A2022InducementPlanMember_documentation_en-US" xlink:label="lab_ino_A2022InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember" xlink:href="ino-20221231.xsd#ino_A2022InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2022InducementPlanMember" xlink:to="lab_ino_A2022InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_32a6355c-f68c-4fbe-8d54-56ee33158f54_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dde79e4c-7cff-4fc7-bab4-b209acdf3324_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_3db199f5-8a87-4614-bdc3-68c782a2cd8b_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability, including from affiliated entity</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:to="lab_ino_IncreaseDecreaseinDeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7cfe41ed-6695-4d0c-84ab-66774e7d32bc_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_4f1d44a0-81b9-47ac-8d42-61f59bceefe6_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded exercised amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAwardedExercisedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Awarded Exercised Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:to="lab_ino_CollaborativeAgreementAwardedExercisedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_aa6d12a7-d02a-42db-bb0f-ed9f03a47938_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Table]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesTable_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:href="ino-20221231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb614e9c-cb5c-462b-b6c0-6356c2037551_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_48a400a8-7a4c-41f5-a766-d98631a58272_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in affiliated entity</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_83466780-e546-4cb2-b944-d2dc58b50e14_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_d7e2395e-0624-4ee7-88dd-f948f1c62643_terseLabel_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_label_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:label id="lab_ino_IncomeTaxReconciliationStatuteLimitations_documentation_en-US" xlink:label="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation, Statute Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:href="ino-20221231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeTaxReconciliationStatuteLimitations" xlink:to="lab_ino_IncomeTaxReconciliationStatuteLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dc4fe71d-b44c-47aa-b083-b1f059f08dba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_37db1c51-2342-47c6-9aa4-d328f6afab49_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInSixYears_ddaa9f2a-3c65-411a-92e9-24ea1a1d5197_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInSixYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInSixYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInSixYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Six Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInSixYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInSixYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Six Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInSixYears" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInSixYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInSixYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInSixYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_60c1b99f-8c80-48ea-ab78-ee8e9af23a6f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_d123b549-dd70-473f-9a14-27744cae8c88_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_47b768de-0077-43d7-a986-da3942ef24e6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_225a7196-cdfa-4655-9140-3d9576fddc04_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RestructuringAndRelatedCostExpectedAnnualSavings_384e0acc-6725-4aa0-b3d2-31a809468229_terseLabel_en-US" xlink:label="lab_ino_RestructuringAndRelatedCostExpectedAnnualSavings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual savings</link:label>
    <link:label id="lab_ino_RestructuringAndRelatedCostExpectedAnnualSavings_label_en-US" xlink:label="lab_ino_RestructuringAndRelatedCostExpectedAnnualSavings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Annual Savings</link:label>
    <link:label id="lab_ino_RestructuringAndRelatedCostExpectedAnnualSavings_documentation_en-US" xlink:label="lab_ino_RestructuringAndRelatedCostExpectedAnnualSavings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Annual Savings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestructuringAndRelatedCostExpectedAnnualSavings" xlink:href="ino-20221231.xsd#ino_RestructuringAndRelatedCostExpectedAnnualSavings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RestructuringAndRelatedCostExpectedAnnualSavings" xlink:to="lab_ino_RestructuringAndRelatedCostExpectedAnnualSavings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_da9b1501-a93e-47b7-b327-0e1758f944d6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December&#160;31, 2022 and 217,382,887 at December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_52792ab3-fa9c-4e35-9261-0987b24ba725_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, value, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_91d1ea34-56d7-4593-b12b-4437120e560d_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$12.01-$15.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesFiveMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesFiveMember" xlink:to="lab_ino_RangeOfExercisePricesFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_13cad243-ebe1-46db-b34e-c6e963c9c8c0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_1846219f-810a-43b8-9e6e-2bff7d39df3b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_de6de78f-d9c2-40fb-b156-2be91a670f5d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_236e8d9f-064c-4104-ac90-004f8793fec2_terseLabel_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, area of land under lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_label_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:label id="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease_documentation_en-US" xlink:label="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Area of Land Under Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:href="ino-20221231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:to="lab_ino_LesseeOperatingLeaseAreaofLandUnderLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_17fd134f-a174-4aba-8d60-cc771950fb91_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_bd5978f9-8e44-42e8-bc6a-ee10050d6948_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because Of Their Anti-Dilutive Effect</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_bb5c1ccd-0571-4066-b223-5b1c7b25740a_totalLabel_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_label_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:label id="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit_documentation_en-US" xlink:label="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:href="ino-20221231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:to="lab_ino_ComprehensiveIncomeLossTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_570f1f72-5420-49db-bd60-8f8a020a5374_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_b1d43574-dce0-4869-94ae-908c42454568_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_e246956b-c5ea-431f-842f-37817a1017c4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value for options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_79bed6a3-6a13-40d5-b42d-8ee3be9a4e0f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4685cc8-06a9-45d2-8761-3428db80c3f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6c34a0a-2c9e-457c-8ec3-6ccde1517deb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_e55f697d-8996-44fa-aa03-9cdb7018d25f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22b2ead6-ced6-4177-8268-4c58ac9d5280_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c348f013-e69f-43ca-a83f-01a16866be97_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_1592604d-c391-4fb7-bcdb-61665a731f7c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares owned (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_04568585-3fcf-450f-823d-6c0ce8e75f8d_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_21fe82e6-376b-48a4-bbdf-1d2599c23d48_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_608d3cc6-7f74-4c3b-8ab6-b323e8585585_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_label_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement , Revenue from the Procurement Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:to="lab_ino_CollaborativeArrangementRevenueFromTheProcurementContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_8d49ffc4-51e1-45ce-beeb-d8b5936fc499_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_8f0a0fbf-8ede-4f63-ac04-b785dabbe7f2_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Indefinitely Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:to="lab_ino_OperatingLossCarryforwardsIndefinitelyCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5cebabec-1edf-4ff0-87c1-c521165ef4c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_2502a0d4-6a65-4446-9db0-6f2d292cd796_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_57c6b727-9723-41ae-ad51-764847646af8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_b695cd0f-0e6e-4ea8-b6da-55c6da7d7adc_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_6270c6fa-a360-4464-8cb4-958f9c22b923_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_09443d23-20c9-4418-8e89-8906b760fb94_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_ef5a3d38-145a-458a-a872-ea8fd4172bd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantsReceivable_4b391791-bffb-44ec-9f1a-a341371a7160_terseLabel_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants receivable</link:label>
    <link:label id="lab_us-gaap_GrantsReceivable_label_en-US" xlink:label="lab_us-gaap_GrantsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grants Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantsReceivable" xlink:to="lab_us-gaap_GrantsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_7ef3480e-5af0-412d-8cb9-f0a9bf97e357_negatedTerseLabel_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:href="ino-20221231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:to="lab_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a9cbf7fc-b170-4736-adc5-c9a4ab661384_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_b23eba04-f2b4-47bc-ba4a-3b07f5fedd02_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options expected to vest (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6260a034-5374-4330-9016-e0a80c2c020f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts accrued for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5d6ecdbd-fd8d-4c78-8512-dc8d3ade70d7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution per employee, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_3df44827-6d65-4bae-8250-e06bdc249127_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized transaction (gain) loss on foreign-currency denominated debt</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_c009695a-0d8e-49a8-abd3-832ece115b4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_cf3e4bce-102d-4334-aba5-af509660dd1c_terseLabel_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Bonds</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_label_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:label id="lab_ino_August2019ConvertibleBondsMember_documentation_en-US" xlink:label="lab_ino_August2019ConvertibleBondsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2019 Convertible Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember" xlink:href="ino-20221231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_August2019ConvertibleBondsMember" xlink:to="lab_ino_August2019ConvertibleBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_5b07540c-528f-4a56-82ee-72248d7a5629_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of securities in a gross unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_2db88122-cc00-4d69-95ba-940d0fcc76fe_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial expenses</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:to="lab_ino_IncreaseDecreaseInAccruedClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_165d437b-7830-4966-864a-3619267f9690_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_80a980b0-224c-4f7b-b6a4-83743b465570_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_b8c9744f-6dce-4ac9-92aa-abd611da6184_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, procurement contract</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_label_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:label id="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:to="lab_ino_CollaborativeArrangementFixedPriceContractAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_939106ad-21e8-4b43-b575-cfa106fbb4f9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_c6989db2-1f5d-4e46-9d5a-f7aea2d358ed_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c74105c-9454-4db4-a024-352aaed19718_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_4cdf9119-64e8-4a68-a217-c944d2fa4580_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_2df78713-7177-4669-b033-08d28dc6a2e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_489d8274-8bb2-4940-adf2-5523994fb006_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_d67131e4-51a8-43c4-afa8-5464201a1483_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_ca227698-b2e6-4363-9d68-d4aca0b6dfc4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_238eb505-18b3-44b5-97c2-6e5593f9b567_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e9e771d8-58b1-45d2-9048-d8602690e589_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_62067f3b-e43f-411b-b65c-ee44f592dfda_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_edaea5ef-6a6c-4417-83e7-e039b4d7d73d_terseLabel_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_label_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:label id="lab_ino_CaliforniaIncomeTaxAuthorityMember_documentation_en-US" xlink:label="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Income Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:href="ino-20221231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CaliforniaIncomeTaxAuthorityMember" xlink:to="lab_ino_CaliforniaIncomeTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f042dfd1-63c8-4de7-92a7-6fac4841941e_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross&#160;Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_f13d4f4c-b8f9-4cbb-a027-019263399086_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement period from effective date for termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period From Effective Date For Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:to="lab_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1e5a6352-8519-4ed4-80a5-aab980b35aab_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInSixYears_626483ce-b497-4817-94eb-41fe869c0603_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInSixYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 and thereafter</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInSixYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInSixYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Six Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringInSixYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringInSixYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Six Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInSixYears" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringInSixYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringInSixYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringInSixYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_83a62e2f-184c-44ff-a246-abab7d48c01c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_55924869-7b5a-4034-ba8e-c0b94cb0e50a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_cec64377-9744-4e2a-aaa3-eecdfdf8fe78_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebt_c536f442-2e0b-4c42-ac9f-41154b312ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible senior notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebt" xlink:to="lab_us-gaap_ConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_3f7e590f-9db1-4d85-840d-9b9b0a2b63b9_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInFourYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_e33330d6-df87-46ed-ab6b-f30365faf0f0_terseLabel_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$1.56-$3.00</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_label_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:label id="lab_ino_RangeOfExercisePricesOneMember_documentation_en-US" xlink:label="lab_ino_RangeOfExercisePricesOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of Exercise Prices One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_RangeOfExercisePricesOneMember" xlink:to="lab_ino_RangeOfExercisePricesOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_e0361df8-941b-4d8c-b724-35b2f13a8c40_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1d7cd689-10db-4eca-a348-8933df81d422_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_a1c54e59-5d5b-48f2-a935-4b62e27b4e0d_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock sale agreement, aggregate proceeds from issuance of stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_label_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:label id="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:to="lab_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxBenefitsExpired_c8a487a2-93a7-4db5-8087-c4070c6e65a3_terseLabel_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_label_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:label id="lab_ino_TaxBenefitsExpired_documentation_en-US" xlink:label="lab_ino_TaxBenefitsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefits Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired" xlink:href="ino-20221231.xsd#ino_TaxBenefitsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxBenefitsExpired" xlink:to="lab_ino_TaxBenefitsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_f30e5277-3ffe-41bc-b6e2-96f6b7ca7c63_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_ad565360-2c7d-437e-9a73-0ef3f5d1bebb_terseLabel_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CELLECTRA 3PSP Proprietary Smart Device</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_label_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device [Member]</link:label>
    <link:label id="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember_documentation_en-US" xlink:label="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C E L L E C T R A3 P S P Proprietary Smart Device</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:href="ino-20221231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:to="lab_ino_CELLECTRA3PSPProprietarySmartDeviceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b96229df-eb1c-4d37-8525-b1d74b43977a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options outstanding to purchase common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_fa53aeb7-6e2d-4ad6-a03b-eaa8ffd4c774_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d873792-2169-428a-a8b5-0f93fc684f42_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PLSaffiliatedentityMember_d43c5a96-b076-4f94-b7ab-85d1f7fce9ea_terseLabel_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity)</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_label_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:label id="lab_ino_PLSaffiliatedentityMember_documentation_en-US" xlink:label="lab_ino_PLSaffiliatedentityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLS (affiliated entity) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember" xlink:href="ino-20221231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PLSaffiliatedentityMember" xlink:to="lab_ino_PLSaffiliatedentityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2f66b122-3617-4dda-9e3d-32d5dd027f6b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_d5356457-ddd1-467e-9a49-0fafcafc6d8f_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation settlement</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8e07c594-52c5-4cad-a8b0-4bd24550e17c_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6b8aafed-40be-4fbb-a97b-42d981ec0710_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_3d9ff7c3-fa21-49bc-a4e6-4870271bf873_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Liquidity</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_78272f6c-1269-4b12-8d0c-074a58de6d2e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c7d4eed3-d4e8-4330-bf8e-535f09315308_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1152c8bf-74ad-49f8-9cd4-fc667254e97c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_a4387959-4f5b-4a2e-99c5-6e98e14d0218_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite-Lived Intangible Assets, Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_53b4a513-eb95-420d-8c3d-2c6b79f24506_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d4efd117-d642-4adb-b572-578d16bbbefc_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_0ef97a69-816a-4e43-9cc5-e1a864bf83ff_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_83252374-28ee-4a2d-b47a-a195020239f1_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Carryforward Indefinitely</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:to="lab_ino_TaxCreditCarryforwardCarryforwardIndefinitely" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_649e8f8a-c8b1-434c-9e8d-23fe813a76f8_verboseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual with Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_9eca5171-6969-4c09-b58e-6fcd55fc5023_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_71fe5f8e-c048-4f9c-a790-a8a9727137bc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment disposed of</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisposals_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisposals" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dd753dbc-3cac-471f-b931-7f8b15726a6e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_19049450-25c8-44b8-abcf-1a753fcba226_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ded3547-9f7c-4453-98a6-96cd58e43b00_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c82df11e-cd8e-4d15-93f9-c71885bb59e2_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_bc1a43e9-84c8-40b6-bd3a-0250a2db1139_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_d3447e8c-d500-4a2d-8d34-787cb829f87e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_63c40987-0a05-4a52-9f75-5fc5dddc3452_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_5d5d159b-5aac-468c-ab66-7709264d32e2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3b0cb4c3-65e5-41cd-82cf-1ffc6a92c38a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_fc23e7fd-79d2-4c7e-b61e-408e0a1148da_terseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative, Gain (Loss) on Embedded Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:to="lab_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_0d065448-3f5b-4346-bb27-d72d01e999fa_terseLabel_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in number of shares authorized (in shares)</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_label_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:label id="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_documentation_en-US" xlink:label="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:to="lab_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ae8a039d-e430-4478-8c61-12514574aa42_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_d10501d0-3220-4f36-b2cf-aba7427f060d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ce180a17-0a73-41af-b76f-78bb274a4346_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6d49f437-a9d3-4965-a732-f20864bd0dba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue From External Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7e946e2e-56df-420a-820b-98eaf7d96d3a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5b83a15-5bda-478d-b3c3-a8680defe19d_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_4290663c-ee40-420c-8537-3384ddb3aeb3_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, including from affiliated entity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_dcb0d45e-6cae-4f7a-af89-8643d636d96d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_1abe9797-8d66-4ff6-9aa6-a380339803b6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_52a989d4-1739-4cd2-b339-379e89db1ad8_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of intangible assets by major asset class</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_92a8edbe-6991-4bdb-839b-8db335e99d18_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized from deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_65faaedd-4146-47e5-96df-e46a9b57de41_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_013c7a19-dc4d-42bb-82af-d14abb68791e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_25cc1980-febc-494b-bda1-96a3311173a4_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_6304adee-60ab-4cfa-b88f-c365848bf09c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3197a11b-4aad-436c-a1d0-bffef63eec3c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_48403965-cf4a-4185-9ad8-3eb85ce783f1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_43b08705-b582-4242-94b6-4007806b8117_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net book value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_daff6954-0897-4550-9f6a-30641c05b5a6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_d079af5a-a6d4-48bf-8be7-bfbdb07fd8a9_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_211cf383-539e-4017-b14f-a9f29d1c6bb3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_062e687d-36fe-4d03-a2bb-0ad9f3c452f8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliated entity</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInvestments_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInvestments" xlink:to="lab_us-gaap_DeferredTaxAssetsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2d4c1cc2-2440-4e34-84ae-f004bd8b071c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_dc1748db-47a3-4ec5-a9a1-0bde34636306_terseLabel_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets and liabilities, net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_label_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:label id="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_documentation_en-US" xlink:label="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:to="lab_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_cf5c5d4a-f002-4dab-8ec7-e062436e848b_terseLabel_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_label_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Years</link:label>
    <link:label id="lab_ino_TaxCreditCarryforwardExpiringInThreeYears_documentation_en-US" xlink:label="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Expiring in Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:to="lab_ino_TaxCreditCarryforwardExpiringInThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_3c98931a-f34c-49bb-bd7c-808f4502f08b_terseLabel_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_label_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) In Other</link:label>
    <link:label id="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_documentation_en-US" xlink:label="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) In Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:href="ino-20221231.xsd#ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:to="lab_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10878679-1b25-4e22-a0b8-5b7f82482a65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b6a01f0b-6034-466f-bbb1-36fb6c56f6fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_1d08dc88-3e5a-4de4-920c-6fc86aecc71e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIE)</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3d938512-888e-4114-b190-3f72dbb7a33f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_f28e0102-cc91-48c1-8e81-bea933796717_terseLabel_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_label_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology [Member]</link:label>
    <link:label id="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_documentation_en-US" xlink:label="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">D N A Encoded Monoclonal Antibody Technology</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:href="ino-20221231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:to="lab_ino_DNAEncodedMonoclonalAntibodyTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e2184301-a0b5-4127-8265-ae8465d253c0_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, including from affiliated entities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_d0d69d89-072d-485b-90b8-81329dab14a7_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_6ab747ae-f420-4431-abad-edf4a623ad33_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geneos Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_549d6cc3-21bd-45cc-99ae-ac7d068a10e5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_8b148be4-10f6-4424-92a9-1b5bedb7edef_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_cc49fc1f-962e-49d5-a58d-7cef46341072_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_35246295-c1a3-402a-bd73-a164e3e464c1_terseLabel_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_label_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:label id="lab_ino_PrepaidManufacturingExpensesCurrent_documentation_en-US" xlink:label="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Manufacturing Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:href="ino-20221231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidManufacturingExpensesCurrent" xlink:to="lab_ino_PrepaidManufacturingExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1ef61284-5d01-4e78-9145-f6564335c705_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Unrecognized Tax Benefits Rollforward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_f93c3132-0557-4f26-8f9f-923dcbd01b4d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_b8458ce2-ad41-46da-949d-fe1038ac4546_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e41711e3-061c-41f9-8eea-370fd1bbe4cd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of common and preferred stock authorized, issued and outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_b9d7bec3-aa84-4538-914f-7e761c89c172_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_69f668df-b8bd-4380-a64c-ef010fb66c8b_negatedTerseLabel_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on remeasurement of investment in Geneos</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_label_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:label id="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment_documentation_en-US" xlink:label="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Remeasurement Of Equity Method Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:href="ino-20221231.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:to="lab_ino_GainLossOnRemeasurementOfEquityMethodInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_a1fff6f7-9e39-41de-aa89-345b7010a49c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_626fb14d-2135-47b2-af3c-daf910447aba_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2e2f06ed-855c-4bf7-8253-264ced496fdb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e1bc17a9-12dd-4509-b615-1aa9016e8356_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_8d16781c-f8d9-4c63-b62d-bbc7f23e9632_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Intangible Assets By Major Asset Class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47561d6b-bc81-4a70-a26b-8709c123c842_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_85a79c7a-4ffb-4c68-ac2f-1712ed84459c_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c8cadeef-aa69-4ffa-954f-68a6c8c763d0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_ca86df16-753f-47e4-a8a5-b6a89186d884_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ebf51169-38bf-45d3-81c4-a87a148b32af_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_4587483f-dbcb-467e-8db1-0746a41fe4c1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f52c8fff-db73-4bea-a816-9b7bd02ad463_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6af09dd7-6861-4cbd-a603-ca42c399b6a6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_b8a40c8a-0e70-4c90-90ef-9ae44180b504_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development and other tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_9dce510a-6d9d-4d56-a000-f9b7f7526402_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_fbe4aeb2-d850-4fa5-9cac-3ec37fb596ed_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount paid to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_b84ce442-0794-4b32-95c3-c0953ff28886_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expirations of Tax Credit Carryforwards [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_37b886a2-5845-4ecf-8f93-da42c30a3104_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_a63328b2-7e38-4e3e-a093-2a9dc3bfc57f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c8d35cd3-8639-4eb6-8401-e1d5233e3409_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_e4740aee-57f3-41b6-812f-4be31a67c198_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, unamortized discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f5f99339-954a-4588-9e7a-a454142a688b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_0be8e09e-92eb-4e50-9770-50ee4e68447e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_518dedd3-0795-4814-ba31-a8610b9afa5f_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_62bb2d6c-1610-4d04-8497-8dcdb726804e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_13ff268c-c921-448e-a6d3-9b39214d8544_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4a57344d-13be-47b2-9503-4041f486e47d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6e4b3145-07da-4316-89eb-6238219c4a7d_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_5f7da83f-035d-426a-9c72-496df40023d1_verboseLabel_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets from affiliated entities</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_label_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets from Affiliated Entity</link:label>
    <link:label id="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_documentation_en-US" xlink:label="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:href="ino-20221231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:to="lab_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_51b59679-7f1e-44e7-b36b-7f3e2cd56370_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of ownership</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_84bf19c3-697f-477f-86d7-c5dc430279cb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocated share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_239e391f-2b44-4298-9909-2a6cba5e186e_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement amended amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_label_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:label id="lab_ino_CollaborativeAgreementAmendedAmount_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementAmendedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Amended Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementAmendedAmount" xlink:to="lab_ino_CollaborativeAgreementAmendedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_62762816-957d-4b84-91c8-f0bc88aec015_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2c097582-bd68-4317-b8b6-6f3ebd7b94ae_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b80f100b-2ae2-4c64-a16a-52c3c6becc54_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_64c22add-1bcc-4837-99a5-831eaa224db3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_1f254806-1985-4ae5-b801-151d2b6d46dc_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite lived:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_8f85a711-348f-4b2c-8cbe-35b8a43b7c6f_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue under collaborative research and development arrangements</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_0cf1c9d1-44a0-4c1c-a0ef-c1b7056b255a_terseLabel_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding liability</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_label_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:label id="lab_ino_DeferredGrantFundingCurrent_documentation_en-US" xlink:label="lab_ino_DeferredGrantFundingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Grant Funding, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredGrantFundingCurrent" xlink:to="lab_ino_DeferredGrantFundingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_ba5328f5-30db-4a07-830d-768f120e0407_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funding received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_label_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:label id="lab_ino_CollaborativeAgreementFundingReceived_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementFundingReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Funding Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementFundingReceived" xlink:to="lab_ino_CollaborativeAgreementFundingReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_cf162e66-2588-48f9-80e4-ee23e6a18fc6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ab0ad765-b59c-4107-8f29-535b4229ea03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_4de4b8a1-6a2e-4e5c-80e6-08310b0bd673_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2022 and 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_71f90186-ec97-43f5-a782-f6ca19ab7650_negatedTerseLabel_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount converted into common shares</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_label_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:label id="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount_documentation_en-US" xlink:label="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Converted Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:href="ino-20221231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:to="lab_ino_DebtInstrumentConvertibleDebtConvertedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c3f4ed38-276e-4862-b824-ecfd92d01c49_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_49690fad-6d71-4ca7-ae58-2be3564010e9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d5a58e9c-7e20-49ae-8013-ff65cb609d28_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from collaborative arrangements and other contracts, including affiliated entity</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d4c9e722-7dd6-4f09-8ee5-c16dc0dbe383_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of preferred stock/senior notes to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9f8199c7-9a67-4a9c-b7b8-3e675f994c8e_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_6af1651a-e6d0-4b92-9b58-3488e1c4762b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_84403c85-9272-4adc-ace2-ea7fc3b4ece7_terseLabel_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_label_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock [Member]</link:label>
    <link:label id="lab_ino_SeriesA2OnePreferredStockMember_documentation_en-US" xlink:label="lab_ino_SeriesA2OnePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A-2 One Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember" xlink:href="ino-20221231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_SeriesA2OnePreferredStockMember" xlink:to="lab_ino_SeriesA2OnePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_2ba8757d-1558-4264-acc9-ada0c10320d8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_e7ee0e8c-9f8e-4d2d-ae29-a9030b90e997_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8ca8c900-606c-4468-92cd-eb3c84fd9d02_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9b3a00f9-ec3d-4752-af08-b0f3e3d7b8c9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_857368e4-76d2-40f0-b48c-ebfb1c9cfb78_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_be1b8a0d-8aab-432d-b489-6f596d248585_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fe7dd760-1334-4072-912e-554c57810974_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_fa8b821c-513b-4d04-9780-aa9320c455cc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeArrangementTerm_089ea983-112f-495e-972a-767c3182d61d_terseLabel_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_ino_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_ino_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeArrangementTerm" xlink:to="lab_ino_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_e5cc4561-a1bd-4588-8534-16e755308b63_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_3e72b913-6e39-4cc7-9db1-b22b8531b169_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_cdccfa13-e6c5-4048-80cc-20b1f1c0c01c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_85edecf9-629a-4607-9119-821b91a08441_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_3b429a2a-86ec-4fe6-a831-85d118dbcbc8_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a69ccba3-63ac-4858-8a67-9df73a9d02ab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_52e1771f-3e4d-476e-8f7a-de1c30eedaec_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f20a50fd-1631-4e42-9390-d9927216a8f9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2ec7699b-ebc7-498e-b679-ad1b8b1de826_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_a3923c7a-56a2-4146-975a-a5e7f2f1621f_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AuditInformationAbstract_label_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ino_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ino_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract" xlink:href="ino-20221231.xsd#ino_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AuditInformationAbstract" xlink:to="lab_ino_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d462ab4e-69a1-4e6d-893b-3c8d6d9d58c0_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_e62ea3d7-2241-4cd2-8bc3-42c5d0b7d6cf_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_a4109478-806a-4069-9998-03d9a88da760_terseLabel_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from equity method investment, recorded and allocated to investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_label_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:label id="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_documentation_en-US" xlink:label="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:href="ino-20221231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:to="lab_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a431f02a-1e5d-45dc-82d2-e53b2773dd2a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_8ced7e1c-78ac-461d-80fc-9164458f83b3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_beac45ea-7a3e-415c-afad-8d244d13dab9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Components Of Pretax Loss From Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8161ef2e-5b20-4e89-a2a2-6329530e137b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Unobservable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3d8e65d0-5de4-400c-bcf2-088b109771b4_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_2d407122-c8f0-4dbd-80c1-cb5b2e6873a3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0db8f8a4-b44b-4226-86d1-f0daedc4fda0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6d4d7040-24e9-4dde-a476-a41e492d5ba7_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_dc310ac3-2db6-44e5-984c-4184de0249c9_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_83a7ee42-9bf3-40b9-970a-8f5cd3294d33_verboseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual year term of incentive plan</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_580cbd20-1d1e-44f7-bd75-ef2a135bee79_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_eeef0070-b910-4902-82a5-7e1ec9126b0d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period of incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_675144f6-6407-43da-9032-234a40cbd13f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5390dab4-8e1e-446a-82ea-020b11c45927_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_ce93b49d-751f-4dd2-b0ed-0d48ad4b4aef_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_2a327538-c1b7-4195-8471-d8134859bb17_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Preferred Stock Authorized, Issued And Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4617a5e9-1052-4c49-a0cb-c1aa0388ef5b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_4bcf8582-9b7d-4c75-9174-43d6a83579ea_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, period to receive funding for research and development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_label_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:label id="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Period to Receive Funding for Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:to="lab_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_50a5b006-0051-4007-9b77-47cb2591c82d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_fd24c0ea-6f29-437c-907c-41a6fcad6749_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d96f76be-2138-43b9-9f69-643323a30b47_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_46b5b531-7188-429f-a9de-44f3276ac8a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_eb3132ea-8e2c-4761-aa32-9369acdb0bd2_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_b8d3e989-907e-439f-9b1c-01360f7a7e3a_terseLabel_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_label_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:label id="lab_ino_PlymouthMeetingPennsylvaniaMember_documentation_en-US" xlink:label="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plymouth Meeting, Pennsylvania [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:href="ino-20221231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlymouthMeetingPennsylvaniaMember" xlink:to="lab_ino_PlymouthMeetingPennsylvaniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_61a6f5ba-9da7-4bc5-993a-596a3a369194_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2d209ccc-e1d1-4aec-8903-8bc5c88555b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of the year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_7e5df6a1-789d-4a51-adb7-fcd2de91adc5_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_ef012580-1a3c-42ef-8821-9a6ea2e603a1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1b542b3d-5db1-4132-9961-10d299e40ad9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_281d4ce0-95d0-4044-8cab-5493ea4e45fa_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_26e0eeeb-5f6f-4301-b9ec-5b04b8b79f9b_terseLabel_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_label_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses [Line Items]</link:label>
    <link:label id="lab_ino_AccountsPayableAndAccruedExpensesLineItems_documentation_en-US" xlink:label="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:href="ino-20221231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:to="lab_ino_AccountsPayableAndAccruedExpensesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_433dd9f5-3c45-41e2-a0fd-79d2e2678cd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_eabd9b0b-f667-4e83-bcab-7aee6f9055a0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5dba973d-af67-47c2-b656-7751620aec5e_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3ef8f831-ce63-46de-94d7-2401fb348e3e_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_fac0b757-64d1-4f93-8b31-07ac67570cdf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (loss) gain on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_dcf4c4a6-7f44-4a87-8010-a3232add8d67_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss (gain) on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_686b37f1-4996-4f13-991e-047244f6ed54_negatedLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on available-for-sale equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_8a061811-6e43-4cb4-9b90-d1e8db2b4def_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_02bf8635-2948-447f-9c49-d75d70252acc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Maturities Of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_d972eebf-19a0-4c2c-b052-adf2f4e7525c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_8a054c05-a53e-4c7c-a3c8-1d4c4aa03a93_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_cce2dfca-b48f-45f5-b455-f0c0ead03237_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, lower range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9fdeb4d0-3a28-4189-acd8-7dc0ee7aa395_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_e8da7b6b-fa66-4401-8ecf-65a4fa67860d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_AnnualMaintenancePeriod_b0dc1c3a-b41a-46d7-8b1e-a7346873ab34_terseLabel_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_label_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:label id="lab_ino_AnnualMaintenancePeriod_documentation_en-US" xlink:label="lab_ino_AnnualMaintenancePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Maintenance Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod" xlink:href="ino-20221231.xsd#ino_AnnualMaintenancePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_AnnualMaintenancePeriod" xlink:to="lab_ino_AnnualMaintenancePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_8b7dc93c-1f00-4715-8aa0-5c1fd1a250f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_9ddc2632-0f96-401c-a15b-9b53f5ba8816_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_d1a1479d-e605-422f-b5d8-55ca6969e330_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Geneos</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_cbb531c6-e81c-4580-b14c-e23d84956544_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_572bd37a-2e2c-4b73-b7fd-b855e57dd0af_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_bb654556-3651-478f-bd09-3f448efc9e97_verboseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities that are measured at fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="lab_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2484a4c0-1c17-47a5-80f1-b7b0403d7db4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_ce075a24-311c-4f4c-af0f-fe5d166d4595_terseLabel_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_label_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:label id="lab_ino_OperatingLossCarryforwardsExpiringinFourYears_documentation_en-US" xlink:label="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Expiring in Four Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:to="lab_ino_OperatingLossCarryforwardsExpiringinFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_3f4246be-a52a-4879-a75b-e025b6a04bd9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_c5d74aa1-3c9b-4f37-8b04-2db1bd401acc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_97875dab-8575-4d01-a6dd-28bbb887a76a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Sale [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_0b63f560-6c7d-4f2b-800e-0dc2fc0b5e99_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_c8cecc58-48ce-43b6-9aa6-397181bfc595_terseLabel_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of shares settlement</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_label_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:label id="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares_documentation_en-US" xlink:label="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss, Value of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:href="ino-20221231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:to="lab_ino_LossContingencyEstimateOfPossibleLossValueOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_58c9373b-81b2-4ee6-9b12-dd9d1b430477_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional revenue to be achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_label_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:label id="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Additional Revenue To Be Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:to="lab_ino_CollaborationAgreementAdditionalRevenueToBeAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale_64c1f571-e5bb-47f6-8ad3-b08ad393f67a_terseLabel_en-US" xlink:label="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment sold</link:label>
    <link:label id="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale_label_en-US" xlink:label="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposed Of By Sale</link:label>
    <link:label id="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale_documentation_en-US" xlink:label="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Disposed Of By Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:href="ino-20221231.xsd#ino_PropertyPlantAndEquipmentDisposedOfBySale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:to="lab_ino_PropertyPlantAndEquipmentDisposedOfBySale" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_9bfa273a-e0d2-4df1-923b-05e20e3bb801_terseLabel_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement, number of days written notice before termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_label_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:label id="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_documentation_en-US" xlink:label="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Number of Days Written Notice Before Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:to="lab_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_71164648-fc8b-4eab-a7cf-c15904916c0e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_fc9b8712-4f7b-4f7a-ab6a-05002461a0ec_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on short-term investments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_19e3e0db-a9a4-4603-8e2d-0a2abeb635ab_terseLabel_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in prepaid expenses and other current assets related to fixed assets</link:label>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_label_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Prepaid Expenses And Other Current Assets, Fixed Assets</link:label>
    <link:label id="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_documentation_en-US" xlink:label="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Prepaid Expenses And Other Current Assets, Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:href="ino-20221231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:to="lab_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_265da35a-5f3c-42de-8228-03333277ec85_terseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_label_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items [Abstract]</link:label>
    <link:label id="lab_ino_CertainBalanceSheetItemsAbstract_documentation_en-US" xlink:label="lab_ino_CertainBalanceSheetItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certain Balance Sheet Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract" xlink:href="ino-20221231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract" xlink:to="lab_ino_CertainBalanceSheetItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_5aa497dd-6f64-463f-9a76-e0427d5346cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_2b27a522-ba91-468c-8c85-6d8f0d59819d_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired intangibles</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_label_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:label id="lab_ino_DeferredTaxAssetsIntangibleAssets_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetsIntangibleAssets" xlink:to="lab_ino_DeferredTaxAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7a865f9d-1be9-4530-8805-9abe35ddcdd7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_86fa0b53-fbd0-46b4-8e61-29ac3f4dd8ed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a97fc20e-95e2-4bbb-a177-d58240554d4e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserved number of shares under the Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_05f9c03b-a0ea-4cc2-9df2-059c89db9111_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investment of GeneOne</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_234f8db6-d1c2-4ec5-9567-8e53caa2e5fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_b295f412-5dd4-4081-b7af-193abe0380e9_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options outstanding</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_A2016IncentivePlanMember_0d1fac2e-209e-40c8-9e38-ed62b5f2b918_terseLabel_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_label_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:label id="lab_ino_A2016IncentivePlanMember_documentation_en-US" xlink:label="lab_ino_A2016IncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember" xlink:href="ino-20221231.xsd#ino_A2016IncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_A2016IncentivePlanMember" xlink:to="lab_ino_A2016IncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_d42a470e-bbb5-492c-9a37-4f1a5d8a388e_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_ad57e6c0-e615-4d98-af42-95fd9a0a8f3c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_30b2adc6-e5f3-4281-842a-b3a02968c832_terseLabel_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligation period to pay royalties</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_label_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:label id="lab_ino_CollaborationAgreementRoyaltyPeriod_documentation_en-US" xlink:label="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CollaborationAgreementRoyaltyPeriod" xlink:to="lab_ino_CollaborationAgreementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_c646d002-22a8-4ce2-9f71-4fdb6c32d3c1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Geneos issuance of note payable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_e6bca8e9-942e-4d66-9bbe-e66381a2548a_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_d86482cf-2b2b-4815-a69e-b3d254830b18_negatedLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on deconsolidation of Geneos</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_00b7369d-fb92-457d-a824-3df814004a47_terseLabel_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_label_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:label id="lab_ino_PlumblineLifeSciencesMember_documentation_en-US" xlink:label="lab_ino_PlumblineLifeSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plumbline Life Sciences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_PlumblineLifeSciencesMember" xlink:to="lab_ino_PlumblineLifeSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_1598345b-cf52-4407-9abe-bd9abc721ec5_terseLabel_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards settled in cash, percentage</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_label_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</link:label>
    <link:label id="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_documentation_en-US" xlink:label="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:to="lab_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_bab3416a-13e9-4d77-bb76-d666811c8006_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a9daa06f-62fa-4f88-96dc-ec7297639cc8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease) increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_323c29ed-5057-41c7-9b5b-ac2d122c8bac_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DoDMember_467f3e3a-66f8-4f6e-b88c-1055ceb46832_terseLabel_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Department of Defense</link:label>
    <link:label id="lab_ino_DoDMember_label_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD [Member]</link:label>
    <link:label id="lab_ino_DoDMember_documentation_en-US" xlink:label="lab_ino_DoDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DoD [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember" xlink:href="ino-20221231.xsd#ino_DoDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DoDMember" xlink:to="lab_ino_DoDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_6869b200-233c-4723-9665-8d39d86c0611_terseLabel_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales made at a weighted average price (in dollars per share)</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement, Weighted Average Price Per Share</link:label>
    <link:label id="lab_ino_StockSaleAgreementWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Sale Agreement Weighted Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:to="lab_ino_StockSaleAgreementWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8fc79348-b37d-4e51-b459-d7f30494a964_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_d115b8c1-62be-4223-9f78-13668c2c15f5_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ApolloBioMember_cec3e6ae-7ce7-45d9-a82f-781195d28a6e_terseLabel_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio</link:label>
    <link:label id="lab_ino_ApolloBioMember_label_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:label id="lab_ino_ApolloBioMember_documentation_en-US" xlink:label="lab_ino_ApolloBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ApolloBio [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember" xlink:href="ino-20221231.xsd#ino_ApolloBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ApolloBioMember" xlink:to="lab_ino_ApolloBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_634ac3e0-2ef2-4713-b371-f896ba57f8e6_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_358e628c-47be-45cc-87c3-86b11556c565_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays_4db3e025-0f3f-407c-b2e1-f902be785e81_terseLabel_en-US" xlink:label="lab_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading days</link:label>
    <link:label id="lab_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays_label_en-US" xlink:label="lab_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Issued, Share Price, Consecutive Trading Days</link:label>
    <link:label id="lab_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays_documentation_en-US" xlink:label="lab_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Issued, Share Price, Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays" xlink:href="ino-20221231.xsd#ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays" xlink:to="lab_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_37ff9db1-061f-4d20-aa17-28ad2774c7b5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e293721e-30c9-4264-91e3-1a80c120d27f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_ff679cd9-ff28-4701-9179-2ccbcd479927_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_f86b264a-420a-4349-b72e-6b6d81a499f0_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_17f030fb-c5a3-4d50-a464-3a9622ac76d4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_35a68c7d-c857-4e2e-b506-5a34c4bd9774_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_ffe10ed4-b02f-419c-a49f-fbcb0db8fa31_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_939eb588-ec9e-4754-b6da-26c78f41d667_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_4a6d6250-858a-4010-b469-a07b04c8b877_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3beba626-8ed2-422c-bd5a-2f66801937ce_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_0c545936-3d3c-4994-86fe-cca4544ffa4c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_1cdec844-caa8-4270-a63e-e338f718967c_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ae0abd73-3f7f-47b0-9e6c-6fa5985e1abb_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_73a16e3e-29aa-4613-bb60-12993685edc2_terseLabel_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Operating Loss And Tax Credit Carryforward Expirations</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_label_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:label id="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_documentation_en-US" xlink:label="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:href="ino-20221231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:to="lab_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e45dc98d-e451-4263-afb0-0cdc527c21d0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_a366a81f-0de0-4e90-9e21-eb1ec3983c46_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_28901f60-041f-43cb-9534-8a2ff21fac0f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4f119177-c02d-46f2-b348-9b524b505544_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ba67d5db-5ae0-4323-b14c-a0e0a47e98c4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e5bb3685-ced7-4d48-b0e9-5c87a0a33076_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit from income taxes at statutory rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_386e1fe5-936c-4312-8ed4-1f58dc14d87d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_72375feb-70b8-4f2c-be63-ec60895e8d88_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_048c5568-12af-470c-84d6-d8bc49758692_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_0b445768-8276-49c1-a6fb-307c6f236832_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses due to affiliated entities</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_377016a5-0ee6-41ba-93ac-728eb4bd622e_terseLabel_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_label_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:label id="lab_ino_DebtinstrumentAccruedInterest_documentation_en-US" xlink:label="lab_ino_DebtinstrumentAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest" xlink:href="ino-20221231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DebtinstrumentAccruedInterest" xlink:to="lab_ino_DebtinstrumentAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_06be02ab-c00c-4d47-a4e6-3ebda0e9ac40_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_c2bd252d-8d83-4c75-8e06-24d59115c572_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_98c27791-a76e-44ee-bb49-5b830ddf95a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_621f4192-1037-4b2d-926e-5d5a448e8907_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a5c28e45-e1fb-434d-bb5f-b06bce196df0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, grants in period, weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_feafc30b-04e3-4861-9f94-dbaf1fb12720_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_16331818-a227-478f-b25f-1c98dabd4b58_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_f6485adb-6cf5-463f-8253-94581e292152_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_979f8c06-1b72-45be-94e1-8791adf4d9c0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share in current and accumulated net loss of Geneos</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_eb0dfe7c-8835-45e3-b3b7-e5d60342ecac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0297fe3a-93d9-40c0-9579-641b0bb62e62_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of capital assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_c91db69e-a5b9-4201-a63d-569ee7185a04_terseLabel_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_label_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:label id="lab_ino_DeferredTaxAssetInterestExpense_documentation_en-US" xlink:label="lab_ino_DeferredTaxAssetInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_DeferredTaxAssetInterestExpense" xlink:to="lab_ino_DeferredTaxAssetInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d4d6c996-7788-4b3b-a935-15b8230476da_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_38345665-f176-4dcc-8c44-60f812665564_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_118df828-76ce-438f-bbcc-504156acf128_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Useful Life (Yrs)</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b5320792-24e2-44b2-b231-dcfc0c299caf_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_09cc11b0-79b8-45aa-ac53-7c71fecfbf8b_terseLabel_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_label_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:label id="lab_ino_LassaFeverAndMERSVaccineMember_documentation_en-US" xlink:label="lab_ino_LassaFeverAndMERSVaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lassa Fever And MERS Vaccine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember" xlink:href="ino-20221231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ino_LassaFeverAndMERSVaccineMember" xlink:to="lab_ino_LassaFeverAndMERSVaccineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_4d255dcd-9baa-46c8-aef7-4407dfd23baf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale, realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_06eafcb2-aefa-46b3-b5e9-feb0bc61ceb8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_61484e0e-61fc-43b0-912e-57f0475b6b5e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions reduced (in percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_31469034-f534-447e-84b5-1e4adc6db339_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_4dbd8252-8e85-49a9-be95-4f9042e8cd4a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_5bfb41a8-3841-417b-b8be-24482cf9150a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ino-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:d5376b60-4920-4297-91b8-ae15a0711c84,g:73741ec8-2e2b-4617-87f5-1b9c1ea3fbd1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.inovio.com/role/CoverPage" xlink:type="simple" xlink:href="ino-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d4191184-4a77-481d-8dd4-c5b589034336" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_DocumentType_d4191184-4a77-481d-8dd4-c5b589034336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_99551678-aa53-4415-8f70-d931b79b8fe4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_DocumentAnnualReport_99551678-aa53-4415-8f70-d931b79b8fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_fd5f959a-e26e-497d-90f7-8d860ca4e809" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_DocumentPeriodEndDate_fd5f959a-e26e-497d-90f7-8d860ca4e809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_df7b68f8-87bb-4e92-bb35-8e84ec492948" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_CurrentFiscalYearEndDate_df7b68f8-87bb-4e92-bb35-8e84ec492948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5e4b2556-456e-4700-86b6-7805a944e01d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_DocumentTransitionReport_5e4b2556-456e-4700-86b6-7805a944e01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_bb9089e6-1ceb-402b-a2e3-81243c731afc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityFileNumber_bb9089e6-1ceb-402b-a2e3-81243c731afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fc45e9f3-a723-4323-9f53-58812581cf3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityRegistrantName_fc45e9f3-a723-4323-9f53-58812581cf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_68aa6231-b76b-4ef9-8ebb-4ff98aef5aa0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityIncorporationStateCountryCode_68aa6231-b76b-4ef9-8ebb-4ff98aef5aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b7fe2aec-7165-4af6-8935-f6d0ef7a203a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityTaxIdentificationNumber_b7fe2aec-7165-4af6-8935-f6d0ef7a203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d5881b99-e3a0-4faf-9788-258f33e65ace" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityAddressAddressLine1_d5881b99-e3a0-4faf-9788-258f33e65ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9bf48523-047c-401a-b942-81e8115e90b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityAddressAddressLine2_9bf48523-047c-401a-b942-81e8115e90b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_100b502d-c910-4b02-a0b0-df806128f6bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityAddressCityOrTown_100b502d-c910-4b02-a0b0-df806128f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3fa8c26d-babd-4532-b5d9-4aeaf2251eaf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityAddressStateOrProvince_3fa8c26d-babd-4532-b5d9-4aeaf2251eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ae737438-e34f-42a1-bd82-f46b3ef0e705" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityAddressPostalZipCode_ae737438-e34f-42a1-bd82-f46b3ef0e705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9d024373-d60d-410a-aa5f-43d2466e101e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_CityAreaCode_9d024373-d60d-410a-aa5f-43d2466e101e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_366ada8b-4ae0-402d-8858-3e9554ebeec3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_LocalPhoneNumber_366ada8b-4ae0-402d-8858-3e9554ebeec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_003dbd44-d641-43c5-b936-d9dd9b94ad98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_Security12bTitle_003dbd44-d641-43c5-b936-d9dd9b94ad98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_aa53324c-5e44-456d-8877-8d242696c966" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_TradingSymbol_aa53324c-5e44-456d-8877-8d242696c966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2f600a18-edd4-4196-ba2e-7e658866a644" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_SecurityExchangeName_2f600a18-edd4-4196-ba2e-7e658866a644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9a3019c8-df8b-4848-88fd-357ac2e3171b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9a3019c8-df8b-4848-88fd-357ac2e3171b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_0f825667-84d3-47dd-9e5e-02f1a33eb74c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityVoluntaryFilers_0f825667-84d3-47dd-9e5e-02f1a33eb74c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_112ff697-e7a2-4683-a3a4-17fb45ed08db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityCurrentReportingStatus_112ff697-e7a2-4683-a3a4-17fb45ed08db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6321bdd2-2dbc-48f8-ad6a-4cf841896d61" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityInteractiveDataCurrent_6321bdd2-2dbc-48f8-ad6a-4cf841896d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3cf843fa-3432-43e5-9859-b69d7b3b14da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityFilerCategory_3cf843fa-3432-43e5-9859-b69d7b3b14da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b0fadef8-7b24-4fb8-a3c5-36cc16f75718" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntitySmallBusiness_b0fadef8-7b24-4fb8-a3c5-36cc16f75718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_f23fa9a9-16f2-4714-860b-a59416304c2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityEmergingGrowthCompany_f23fa9a9-16f2-4714-860b-a59416304c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_c1a08e69-1bab-48ff-9350-c6a0842153d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_IcfrAuditorAttestationFlag_c1a08e69-1bab-48ff-9350-c6a0842153d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8206569e-1c2b-4588-923c-f6c02ecbf299" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityShellCompany_8206569e-1c2b-4588-923c-f6c02ecbf299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_b977e679-0876-4d90-a974-37c3c68f9bf0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityPublicFloat_b977e679-0876-4d90-a974-37c3c68f9bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3b92835d-b62d-4055-baba-2efaf786f40d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3b92835d-b62d-4055-baba-2efaf786f40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_4ac5c779-ea37-4f0f-a954-938ff6d71eec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_4ac5c779-ea37-4f0f-a954-938ff6d71eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9a079440-2c44-4afe-a050-dab21bf485b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_AmendmentFlag_9a079440-2c44-4afe-a050-dab21bf485b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4fad1d3d-be3c-417c-9bff-ac194ae703e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_DocumentFiscalYearFocus_4fad1d3d-be3c-417c-9bff-ac194ae703e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_080f3908-1d14-418c-8580-36b3d9838098" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_DocumentFiscalPeriodFocus_080f3908-1d14-418c-8580-36b3d9838098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_396d6bf7-e344-4629-9635-b09fd4f217f9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_6da47361-c68c-43e7-a006-20e3cf39ca10" xlink:to="loc_dei_EntityCentralIndexKey_396d6bf7-e344-4629-9635-b09fd4f217f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/AuditInformation" xlink:type="simple" xlink:href="ino-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_AuditInformationAbstract_95cf1bd3-3242-4f8c-99e2-100356abcae8" xlink:href="ino-20221231.xsd#ino_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_40b20685-46a2-4717-b9f8-277f51fbe34e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_95cf1bd3-3242-4f8c-99e2-100356abcae8" xlink:to="loc_dei_AuditorLocation_40b20685-46a2-4717-b9f8-277f51fbe34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_84aa51d0-eda5-4061-97e8-c04653bfa8eb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_95cf1bd3-3242-4f8c-99e2-100356abcae8" xlink:to="loc_dei_AuditorName_84aa51d0-eda5-4061-97e8-c04653bfa8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_269b1af1-74c6-4905-a746-849f8c4a2250" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AuditInformationAbstract_95cf1bd3-3242-4f8c-99e2-100356abcae8" xlink:to="loc_dei_AuditorFirmId_269b1af1-74c6-4905-a746-849f8c4a2250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_275c07e0-095c-4aea-9998-63f0f1cbfcf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a8710c67-34ff-412b-ae69-47d8ffea0e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_275c07e0-095c-4aea-9998-63f0f1cbfcf2" xlink:to="loc_us-gaap_StatementTable_a8710c67-34ff-412b-ae69-47d8ffea0e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3998a3fc-05e2-41a7-a847-1482e6d872dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a8710c67-34ff-412b-ae69-47d8ffea0e77" xlink:to="loc_us-gaap_DebtInstrumentAxis_3998a3fc-05e2-41a7-a847-1482e6d872dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_03ffc6b8-ebb7-4766-8b4d-04238eba7b43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3998a3fc-05e2-41a7-a847-1482e6d872dc" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_03ffc6b8-ebb7-4766-8b4d-04238eba7b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_628d9e4b-b628-473f-9d68-49a4eb2dab88" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_03ffc6b8-ebb7-4766-8b4d-04238eba7b43" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_628d9e4b-b628-473f-9d68-49a4eb2dab88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a8710c67-34ff-412b-ae69-47d8ffea0e77" xlink:to="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:to="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fcfd8189-7b06-41d5-b51d-91a056990430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_fcfd8189-7b06-41d5-b51d-91a056990430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f4518558-9add-454c-88ef-313c5e9de36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_ShortTermInvestments_f4518558-9add-454c-88ef-313c5e9de36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_39a985be-f7b5-437c-9a00-fe85c949b5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_39a985be-f7b5-437c-9a00-fe85c949b5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_5569800c-1409-4bd8-b3b0-144578f1b3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_5569800c-1409-4bd8-b3b0-144578f1b3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c9f5296-b7c8-44b2-a2cd-f57252037895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9c9f5296-b7c8-44b2-a2cd-f57252037895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_bad93ddd-5b45-4c02-8738-e461dab4c72f" xlink:href="ino-20221231.xsd#ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity_bad93ddd-5b45-4c02-8738-e461dab4c72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_08c8f693-f157-491a-85b3-9a445feee2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a3c33eb1-b85a-4989-90af-46239a247d27" xlink:to="loc_us-gaap_AssetsCurrent_08c8f693-f157-491a-85b3-9a445feee2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_504194c7-023a-4070-bce5-ba7f460844c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_504194c7-023a-4070-bce5-ba7f460844c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b6dbda27-cddd-4849-a820-73c5e6ea9543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_b6dbda27-cddd-4849-a820-73c5e6ea9543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a1d32a1-882c-4284-8a9e-cb58f9eb0b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0a1d32a1-882c-4284-8a9e-cb58f9eb0b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12844d3f-295e-4717-a935-e194361af89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_Goodwill_12844d3f-295e-4717-a935-e194361af89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7cd5c88-c398-4e7d-8163-c7e7d44d8c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d7cd5c88-c398-4e7d-8163-c7e7d44d8c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9db4aec0-6d00-483d-ac09-cfed07b988f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9db4aec0-6d00-483d-ac09-cfed07b988f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_69888162-841c-4f32-9555-034f29d7460d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_5b6bc9b0-48b3-4185-a6d1-ae98fc4b0026" xlink:to="loc_us-gaap_Assets_69888162-841c-4f32-9555-034f29d7460d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d5989275-971d-4b65-9caa-5d0268590fc8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_56284ef0-448b-4681-831d-aabd7ffa09f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_56284ef0-448b-4681-831d-aabd7ffa09f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_bcd65c83-e62f-4348-b74f-b61da98709f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_bcd65c83-e62f-4348-b74f-b61da98709f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccruedClinicalTrialExpenseCurrent_2dc5a66e-5da9-4b69-8b20-c1e9a1eeb6f1" xlink:href="ino-20221231.xsd#ino_AccruedClinicalTrialExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_ino_AccruedClinicalTrialExpenseCurrent_2dc5a66e-5da9-4b69-8b20-c1e9a1eeb6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b9e87397-18ea-46df-beb6-a701a3e060db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_b9e87397-18ea-46df-beb6-a701a3e060db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b8b4b89-80a9-4ca7-9ba9-a0a53cee8830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8b8b4b89-80a9-4ca7-9ba9-a0a53cee8830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingCurrent_38d5609b-621f-4943-8387-417347f8385f" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_ino_DeferredGrantFundingCurrent_38d5609b-621f-4943-8387-417347f8385f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63fe9595-8e87-4bcc-9ec9-9fcc2aa124c4" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingFromAffiliateCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_ino_DeferredGrantFundingFromAffiliateCurrent_63fe9595-8e87-4bcc-9ec9-9fcc2aa124c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_87dade5e-3757-4cdb-a6b8-d894515c9dff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c0a70ffc-1b30-4547-a8a8-4f6ea9ca3c41" xlink:to="loc_us-gaap_LiabilitiesCurrent_87dade5e-3757-4cdb-a6b8-d894515c9dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_71fd0d94-334c-4adb-a743-29b801426ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_71fd0d94-334c-4adb-a743-29b801426ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_d0609647-63f4-45e7-81cc-c559cdad7333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_ConvertibleDebt_d0609647-63f4-45e7-81cc-c559cdad7333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9feea21-7b79-4195-a0b3-8dbeec6f27ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a9feea21-7b79-4195-a0b3-8dbeec6f27ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_700e1d03-5392-4869-b474-ec8c6dfec257" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_700e1d03-5392-4869-b474-ec8c6dfec257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2998fb90-ec99-4601-8c05-ffbc9dbf3aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2998fb90-ec99-4601-8c05-ffbc9dbf3aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5ac65b0d-6029-4530-a05a-c80275e00766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_Liabilities_5ac65b0d-6029-4530-a05a-c80275e00766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d49ccfe-2c5f-4551-b1f0-0e638c10c8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d49ccfe-2c5f-4551-b1f0-0e638c10c8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a6d9dbfe-e80f-4c3c-bf14-f5db282e1660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_PreferredStockValue_a6d9dbfe-e80f-4c3c-bf14-f5db282e1660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3a0cdf12-ae58-4983-8e0c-9cb536ff4fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_CommonStockValue_3a0cdf12-ae58-4983-8e0c-9cb536ff4fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_00c13deb-848d-4eb3-b520-8ae0bfe1862d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_AdditionalPaidInCapital_00c13deb-848d-4eb3-b520-8ae0bfe1862d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9074fbf7-d5ab-40b1-a44b-4540a9d2e219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9074fbf7-d5ab-40b1-a44b-4540a9d2e219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9596fafb-15e9-41a9-9097-b475a0f0989b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9596fafb-15e9-41a9-9097-b475a0f0989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_02f64a17-19d7-4c2d-bc67-5c6d500271c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_eae0aab3-9735-420e-b524-9e2314d60366" xlink:to="loc_us-gaap_StockholdersEquity_02f64a17-19d7-4c2d-bc67-5c6d500271c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_724ec278-c832-47be-b86d-46e32cb00751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_00c16659-73c5-496f-8dd6-fb3d33370160" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_724ec278-c832-47be-b86d-46e32cb00751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4007daa3-2852-42d0-bdde-22c751bea71c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4007daa3-2852-42d0-bdde-22c751bea71c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_33cf55db-80e7-4da3-97a5-2a78a340809b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_33cf55db-80e7-4da3-97a5-2a78a340809b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ef6169b9-a061-44ae-b4fa-67859d2d3988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ef6169b9-a061-44ae-b4fa-67859d2d3988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fc05a3b9-c519-429d-9a57-6f2f8d9cf041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fc05a3b9-c519-429d-9a57-6f2f8d9cf041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f897f0c6-df14-45cc-8d62-d5bd2ad8642a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f897f0c6-df14-45cc-8d62-d5bd2ad8642a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f04dfe23-f09c-45f8-8b70-69713c2ba2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f04dfe23-f09c-45f8-8b70-69713c2ba2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_5ef37189-470c-4924-be98-a345887b991c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_CommonStockSharesIssued_5ef37189-470c-4924-be98-a345887b991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_02b5edde-eb1a-4b3f-ac2f-16b8cd738a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e620844f-6ec0-4d74-804c-70de62cb1e6c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_02b5edde-eb1a-4b3f-ac2f-16b8cd738a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_285d6679-4b9f-4c7d-85a9-d1db4f0b02bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3d1aa109-0523-4427-a5ce-c7ccd1bc4313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_285d6679-4b9f-4c7d-85a9-d1db4f0b02bc" xlink:to="loc_us-gaap_StatementTable_3d1aa109-0523-4427-a5ce-c7ccd1bc4313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_e08749b8-e088-4a48-a02e-56bcc96851fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3d1aa109-0523-4427-a5ce-c7ccd1bc4313" xlink:to="loc_us-gaap_DebtInstrumentAxis_e08749b8-e088-4a48-a02e-56bcc96851fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_e08749b8-e088-4a48-a02e-56bcc96851fd" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertibleBondsMember_01518598-a75b-4d2f-9b3a-170188fbf0d7" xlink:href="ino-20221231.xsd#ino_ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:to="loc_ino_ConvertibleBondsMember_01518598-a75b-4d2f-9b3a-170188fbf0d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_362f8bc9-edfc-4ec3-a6b0-55b1e7fd2c14" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_075ee7bc-4bab-45b7-bb30-417d6950ee77" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_362f8bc9-edfc-4ec3-a6b0-55b1e7fd2c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3d1aa109-0523-4427-a5ce-c7ccd1bc4313" xlink:to="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_d6b66eb0-794e-4a73-afc0-748b7931a503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_RevenuesAbstract_d6b66eb0-794e-4a73-afc0-748b7931a503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_717446a3-8418-4de6-88b9-2e7d225e1711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_d6b66eb0-794e-4a73-afc0-748b7931a503" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_717446a3-8418-4de6-88b9-2e7d225e1711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ed30cd14-49c6-4a44-abb8-efdebbf891c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ed30cd14-49c6-4a44-abb8-efdebbf891c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c1030fa4-b6f2-4b62-b8c2-d98af2b89c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c1030fa4-b6f2-4b62-b8c2-d98af2b89c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9921af2a-dec7-413b-87fe-199bc26b503d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0504faec-176c-4a6b-a614-14e8ab3b7a48" xlink:to="loc_us-gaap_OperatingExpenses_9921af2a-dec7-413b-87fe-199bc26b503d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c1b54cc8-f2ac-4514-93cf-1ed8720461e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_OperatingIncomeLoss_c1b54cc8-f2ac-4514-93cf-1ed8720461e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_30d5bea6-1097-43e6-bb11-cacab53d570f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_InterestIncomeOperating_30d5bea6-1097-43e6-bb11-cacab53d570f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f86c0ae6-209e-4360-b149-b84d5727d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_InterestExpense_f86c0ae6-209e-4360-b149-b84d5727d9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3709a127-97be-4516-be15-10f80088cffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_3709a127-97be-4516-be15-10f80088cffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_771b2ae4-89ce-49e6-a4db-1a0acfe964f5" xlink:href="ino-20221231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_771b2ae4-89ce-49e6-a4db-1a0acfe964f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8c734ae7-5fb3-411f-bb71-0799c07f7585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_8c734ae7-5fb3-411f-bb71-0799c07f7585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_29e57f33-fa4f-471c-8d44-5a24ad2586b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_29e57f33-fa4f-471c-8d44-5a24ad2586b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_30a1ce6f-2249-436d-8d05-24947db1fbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_30a1ce6f-2249-436d-8d05-24947db1fbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a12e33d-f0cf-422f-b2dc-ae03bdd2b9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_44622f62-9442-43fb-9519-c039030beb89" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9a12e33d-f0cf-422f-b2dc-ae03bdd2b9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_98d638ad-6d6f-4574-ab85-e86bbfe36e71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_98d638ad-6d6f-4574-ab85-e86bbfe36e71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_256b078d-cfea-4a81-a69e-b9bbb993a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_256b078d-cfea-4a81-a69e-b9bbb993a09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c16a25df-d410-4851-9409-828a8b2bb7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_ProfitLoss_c16a25df-d410-4851-9409-828a8b2bb7ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_451017b8-f882-4363-948f-30c5748ad426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_451017b8-f882-4363-948f-30c5748ad426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_70715d7e-3e14-4de1-a413-052868273d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_NetIncomeLoss_70715d7e-3e14-4de1-a413-052868273d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0bd66108-a83d-435e-9f52-fb1823ff2107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:to="loc_us-gaap_EarningsPerShareBasic_0bd66108-a83d-435e-9f52-fb1823ff2107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_5d3431d4-ba0e-425f-bb07-e0b2239f230d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_461d9118-ffbc-4acc-ad6f-7a79300a4044" xlink:to="loc_us-gaap_EarningsPerShareDiluted_5d3431d4-ba0e-425f-bb07-e0b2239f230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_98309324-9474-4d5c-88e9-f2ce5cbfb76b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb1754ff-effc-49e9-8a83-b4b7fc357176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fb1754ff-effc-49e9-8a83-b4b7fc357176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_529eb9ee-e381-4959-845a-dc2cc5d7b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_e3cedf4e-4f8c-4c93-ae9b-6c1099e8d50b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_529eb9ee-e381-4959-845a-dc2cc5d7b2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3b694893-5470-4b47-b1f0-54366c84e0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_364a71e6-ab28-4f96-aac0-39b7a375e601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3b694893-5470-4b47-b1f0-54366c84e0b0" xlink:to="loc_us-gaap_ProfitLoss_364a71e6-ab28-4f96-aac0-39b7a375e601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ca0c2639-5a19-4f34-97de-b43835af1d25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3b694893-5470-4b47-b1f0-54366c84e0b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ca0c2639-5a19-4f34-97de-b43835af1d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1289d605-80b0-4db0-aef6-f65f505daa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ca0c2639-5a19-4f34-97de-b43835af1d25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1289d605-80b0-4db0-aef6-f65f505daa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ece632e2-d49a-48ef-b8ff-7ecde0daef99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ca0c2639-5a19-4f34-97de-b43835af1d25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ece632e2-d49a-48ef-b8ff-7ecde0daef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d564d5c9-9195-4a6c-9213-9c6bae4598e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3b694893-5470-4b47-b1f0-54366c84e0b0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d564d5c9-9195-4a6c-9213-9c6bae4598e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b806a349-7ecc-44c5-a832-f4ee207e0bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3b694893-5470-4b47-b1f0-54366c84e0b0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b806a349-7ecc-44c5-a832-f4ee207e0bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_69dd3f58-e0c0-49f2-a117-5b4481c10ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_3b694893-5470-4b47-b1f0-54366c84e0b0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_69dd3f58-e0c0-49f2-a117-5b4481c10ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_14128b33-484d-430b-b010-641cd5f90475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_14128b33-484d-430b-b010-641cd5f90475" xlink:to="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_aafccd50-dc24-4621-aa79-18ec3e544dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_aafccd50-dc24-4621-aa79-18ec3e544dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_aafccd50-dc24-4621-aa79-18ec3e544dbb" xlink:to="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4388213a-ca2e-41db-9d0e-1d65b12306da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_PreferredStockMember_4388213a-ca2e-41db-9d0e-1d65b12306da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5665d357-21d2-48f5-a9c6-f392fbf51b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_CommonStockMember_5665d357-21d2-48f5-a9c6-f392fbf51b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_fe4258c2-da90-4b62-b88b-5f9fc34d49aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_fe4258c2-da90-4b62-b88b-5f9fc34d49aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_88f14530-af32-4ac4-9012-2e4ab63b8aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_RetainedEarningsMember_88f14530-af32-4ac4-9012-2e4ab63b8aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89268b24-48bc-4ad1-b107-f14c56402f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_89268b24-48bc-4ad1-b107-f14c56402f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f0db2c5a-8a10-4444-88de-01639cb81e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9da81d3f-406d-4a20-b5a6-9e172c848c92" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f0db2c5a-8a10-4444-88de-01639cb81e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_457c6963-6ed2-4aa6-894e-5ee836e500c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:to="loc_us-gaap_DebtInstrumentAxis_457c6963-6ed2-4aa6-894e-5ee836e500c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_457c6963-6ed2-4aa6-894e-5ee836e500c7" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_09c1a817-2e31-4d93-b573-0721441d27f9" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_09c1a817-2e31-4d93-b573-0721441d27f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_05ffb3e6-74c4-43ad-b9f8-e182afda366b" xlink:href="ino-20221231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_5fa86323-e2b3-4a02-bb9f-d9434a1fb73b" xlink:to="loc_ino_August2019ConvertibleBondsMember_05ffb3e6-74c4-43ad-b9f8-e182afda366b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_13473bdb-bd3b-4b22-87c0-075726e1d78e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_13473bdb-bd3b-4b22-87c0-075726e1d78e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5bcc6797-48f8-4af1-ba90-f054afc1198f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_13473bdb-bd3b-4b22-87c0-075726e1d78e" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5bcc6797-48f8-4af1-ba90-f054afc1198f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_17cee506-a402-4c7c-b61a-6507bfda2056" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5bcc6797-48f8-4af1-ba90-f054afc1198f" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_17cee506-a402-4c7c-b61a-6507bfda2056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1274e265-d324-4b72-8632-ab7d8280571d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_8aeef35f-c677-4f44-8e79-c4e4fa09b2fe" xlink:to="loc_us-gaap_StatementLineItems_1274e265-d324-4b72-8632-ab7d8280571d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1274e265-d324-4b72-8632-ab7d8280571d" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_50947185-5a46-4d8c-a9a4-515d414dfb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_SharesIssued_50947185-5a46-4d8c-a9a4-515d414dfb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5bfb5209-20e2-4cbd-9a34-bd07db45c83b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5bfb5209-20e2-4cbd-9a34-bd07db45c83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc636399-5348-48d4-b8af-ab0e0fbcf9ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_dc636399-5348-48d4-b8af-ab0e0fbcf9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8436f329-aace-4e13-b796-1df546e3c582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8436f329-aace-4e13-b796-1df546e3c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bdfba070-4e93-412f-9eee-260885de07fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_bdfba070-4e93-412f-9eee-260885de07fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_00836eb0-7b38-40c4-a2d0-5f9a4c010792" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_00836eb0-7b38-40c4-a2d0-5f9a4c010792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_be42e8a4-085f-48fa-b267-8ce7006badf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_be42e8a4-085f-48fa-b267-8ce7006badf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_04da6c7f-dbc7-4ef7-9c2d-51441b637d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_04da6c7f-dbc7-4ef7-9c2d-51441b637d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acebe1ad-b34d-4f7c-8f97-778a36cbcb11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_acebe1ad-b34d-4f7c-8f97-778a36cbcb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_7ab68419-ab37-4493-8735-7b53326afb26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_7ab68419-ab37-4493-8735-7b53326afb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4190e5e7-60fb-4d2d-a2d5-b0175ad99b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_4190e5e7-60fb-4d2d-a2d5-b0175ad99b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0c066ff9-ce65-4edc-bc70-d2a6388af10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_ProfitLoss_0c066ff9-ce65-4edc-bc70-d2a6388af10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47b2abef-49e4-47dc-ba3a-c44f6cb88c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_47b2abef-49e4-47dc-ba3a-c44f6cb88c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_242d91a8-452b-47e6-bf0d-b5000d28743b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_242d91a8-452b-47e6-bf0d-b5000d28743b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4c46b7d6-fb36-4f22-81ea-3f3129fdf938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_4c46b7d6-fb36-4f22-81ea-3f3129fdf938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_690c6a53-735a-46d8-84bf-32d1d8eaa0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_SharesIssued_690c6a53-735a-46d8-84bf-32d1d8eaa0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64827119-f3b7-492d-a2b7-496cf76baa6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_7acb4ada-ea1a-4427-8dec-96e0e44205a7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64827119-f3b7-492d-a2b7-496cf76baa6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d978c677-cf6d-4f7a-9f14-f0ff00f1984d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6a75dbe3-23ee-4e53-92f7-890216c29ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d978c677-cf6d-4f7a-9f14-f0ff00f1984d" xlink:to="loc_us-gaap_StatementTable_6a75dbe3-23ee-4e53-92f7-890216c29ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_897fe42b-896a-4199-9131-0e0d014a9f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a75dbe3-23ee-4e53-92f7-890216c29ddc" xlink:to="loc_us-gaap_DebtInstrumentAxis_897fe42b-896a-4199-9131-0e0d014a9f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_897fe42b-896a-4199-9131-0e0d014a9f36" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_August2019ConvertibleBondsMember_bae4153f-b653-4fef-ba20-1dd7bb56576f" xlink:href="ino-20221231.xsd#ino_August2019ConvertibleBondsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:to="loc_ino_August2019ConvertibleBondsMember_bae4153f-b653-4fef-ba20-1dd7bb56576f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_712222f0-66f5-4308-b98e-3254e6cf5d51" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_c089ebbc-3105-480c-9b5c-9da9f93d395c" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_712222f0-66f5-4308-b98e-3254e6cf5d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6a75dbe3-23ee-4e53-92f7-890216c29ddc" xlink:to="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13dc57f0-2bfe-40ad-a60a-ad7299a67e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_ProfitLoss_13dc57f0-2bfe-40ad-a60a-ad7299a67e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_cdea279e-74eb-4ae7-81b1-402a0d7cb15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_Depreciation_cdea279e-74eb-4ae7-81b1-402a0d7cb15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_7337d1fe-1ff8-466a-98be-44506f5c617c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_7337d1fe-1ff8-466a-98be-44506f5c617c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c9661e6e-7bac-462c-bb67-9cbe2521d7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c9661e6e-7bac-462c-bb67-9cbe2521d7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_aa78ff0c-bc1a-4866-99f6-ff692832e3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_aa78ff0c-bc1a-4866-99f6-ff692832e3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e4440b16-7602-4fc5-8578-926da05e9a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_ShareBasedCompensation_e4440b16-7602-4fc5-8578-926da05e9a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonCashInterestExpense_bbb4ef95-8373-407a-beaf-9cd1ada67bed" xlink:href="ino-20221231.xsd#ino_NonCashInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_NonCashInterestExpense_bbb4ef95-8373-407a-beaf-9cd1ada67bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_50ba13b4-5d91-4dc5-aab1-7e22aaf31602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_50ba13b4-5d91-4dc5-aab1-7e22aaf31602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_4b4377dc-6b76-43f3-b9dd-374ef612d57d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfOtherInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_4b4377dc-6b76-43f3-b9dd-374ef612d57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_eae4b988-e9f6-433e-bea6-336b016a0dc4" xlink:href="ino-20221231.xsd#ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity_eae4b988-e9f6-433e-bea6-336b016a0dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_7d25fd7c-4bc3-474d-8431-c5e74eee69d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_7d25fd7c-4bc3-474d-8431-c5e74eee69d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_92e82da2-acdd-4d3b-80cd-252b3f3c72b9" xlink:href="ino-20221231.xsd#ino_GainLossOnRemeasurementOfEquityMethodInvestment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_GainLossOnRemeasurementOfEquityMethodInvestment_92e82da2-acdd-4d3b-80cd-252b3f3c72b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_81e67174-d99b-4ec4-b3b5-4369bef7c9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_81e67174-d99b-4ec4-b3b5-4369bef7c9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cfe72195-d9f5-4820-bc1e-85430fbdeb9f" xlink:href="ino-20221231.xsd#ino_ChangeInValueOfInvestmentsInAffiliatedCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_ino_ChangeInValueOfInvestmentsInAffiliatedCompany_cfe72195-d9f5-4820-bc1e-85430fbdeb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_95a53aee-d8d5-418e-b01f-332865e5142a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_95a53aee-d8d5-418e-b01f-332865e5142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1976fc08-9132-41e0-a29a-7306569801cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_1976fc08-9132-41e0-a29a-7306569801cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c32ba4b9-426a-404a-ac55-eed831c11b1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c32ba4b9-426a-404a-ac55-eed831c11b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a1a167eb-f770-49bc-8eac-dd562ecaaf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ac9fcbd3-3e3f-40eb-a61b-a5b34955e877" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_a1a167eb-f770-49bc-8eac-dd562ecaaf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eaa96e4f-76f5-4396-9943-a9f036ff5eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_eaa96e4f-76f5-4396-9943-a9f036ff5eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_606f7989-0e63-4194-aaa6-4b6a9ad809b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_606f7989-0e63-4194-aaa6-4b6a9ad809b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5858a853-c690-4cf0-a5dd-628461b16625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5858a853-c690-4cf0-a5dd-628461b16625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_128a229c-40ed-43b7-9bca-baaca55a6b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_128a229c-40ed-43b7-9bca-baaca55a6b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_995ba839-5411-4c84-a00f-1ec3d610464b" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInAccruedClinicalTrialExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_ino_IncreaseDecreaseInAccruedClinicalTrialExpense_995ba839-5411-4c84-a00f-1ec3d610464b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_65d28f39-200a-480e-9350-43cb899b0101" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_65d28f39-200a-480e-9350-43cb899b0101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_cb242e88-96f5-4bbf-9baa-aa2f2c20f3f5" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet_cb242e88-96f5-4bbf-9baa-aa2f2c20f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_66a41765-9052-4783-9152-300b7e5ccf5b" xlink:href="ino-20221231.xsd#ino_IncreaseDecreaseinDeferredGrantFundingCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_ino_IncreaseDecreaseinDeferredGrantFundingCurrent_66a41765-9052-4783-9152-300b7e5ccf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_aa819f0e-24c3-4390-8f99-735b1e9643f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4700aee-07a9-4a2a-b6ca-edfb35e2aec1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_aa819f0e-24c3-4390-8f99-735b1e9643f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d2e6162-1c65-4da7-8d30-e971f086e725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cf55ba71-0fe7-42d0-a98e-52b05be09c42" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2d2e6162-1c65-4da7-8d30-e971f086e725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_37030ed3-e77f-4ef7-80da-93aec0e4caf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_37030ed3-e77f-4ef7-80da-93aec0e4caf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_070f4fa4-e87d-4525-b140-1f35d7733b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_070f4fa4-e87d-4525-b140-1f35d7733b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7b44668-93db-4b55-8510-51a3870672c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d7b44668-93db-4b55-8510-51a3870672c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_50f0966e-d93f-4f3f-a408-faf6b4050607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi_50f0966e-d93f-4f3f-a408-faf6b4050607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_3ac7ae0d-edc1-4c41-8a70-0ebe1715626f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_3ac7ae0d-edc1-4c41-8a70-0ebe1715626f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1537dfd9-e776-4aad-bd30-97737a3ee020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_1537dfd9-e776-4aad-bd30-97737a3ee020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a1c68a2-9a29-47bc-8f40-e719afc85040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_baeea3a7-1f80-4d9a-8d3e-3654ca614b3a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a1c68a2-9a29-47bc-8f40-e719afc85040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b87ef9f2-d577-4a04-89fb-d682b998cc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b87ef9f2-d577-4a04-89fb-d682b998cc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsfromStockOptionandWarrantExercises_59aed24f-3652-49c5-abea-66a4dc1c27dd" xlink:href="ino-20221231.xsd#ino_ProceedsfromStockOptionandWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_ino_ProceedsfromStockOptionandWarrantExercises_59aed24f-3652-49c5-abea-66a4dc1c27dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_517fb8ce-bdf1-4bd0-bc56-0e0d17f4efe5" xlink:href="ino-20221231.xsd#ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings_517fb8ce-bdf1-4bd0-bc56-0e0d17f4efe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_e2f85ea8-3735-42f8-8667-1e749efc6406" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_e2f85ea8-3735-42f8-8667-1e749efc6406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_dd134344-2788-4a02-8852-1e1ba1159938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_dd134344-2788-4a02-8852-1e1ba1159938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20f62bb9-69df-4861-b7be-d4d53e24c9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c8f909a6-d3db-4aff-abc9-00c340516eaf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20f62bb9-69df-4861-b7be-d4d53e24c9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22ef15dc-e534-44f6-a127-9ca8db92913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22ef15dc-e534-44f6-a127-9ca8db92913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58638712-289f-4ba4-ba58-a2eb1687e829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_58638712-289f-4ba4-ba58-a2eb1687e829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49de7372-5d52-4413-ab65-154126a1e778" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49de7372-5d52-4413-ab65-154126a1e778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09b0cc2f-b2d7-4f19-b6f9-05823937a071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09b0cc2f-b2d7-4f19-b6f9-05823937a071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3bb1a90d-95d7-49a9-a05c-6f1ccb5836c8" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a4b74c9d-d6bf-466c-b59b-fcdad75ecbd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_a4b74c9d-d6bf-466c-b59b-fcdad75ecbd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e3a10b23-8326-43a4-a6bc-3d22b8271be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:to="loc_us-gaap_InterestPaidNet_e3a10b23-8326-43a4-a6bc-3d22b8271be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_b1670552-daf7-4c4e-bc48-9da55fa33a4f" xlink:href="ino-20221231.xsd#ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_29a31462-9373-4102-a812-6290e2ce6bc5" xlink:to="loc_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets_b1670552-daf7-4c4e-bc48-9da55fa33a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ino-20221231.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_59114887-f07d-44f6-8517-c8fa4e5af598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_38f5bafc-5093-4757-bf31-3082ded0ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_59114887-f07d-44f6-8517-c8fa4e5af598" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_38f5bafc-5093-4757-bf31-3082ded0ea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/TheCompany" xlink:type="simple" xlink:href="ino-20221231.xsd#TheCompany"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/TheCompany" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9d88509-9516-4539-ad74-74347d566464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_27496223-0250-4f88-834f-64517d65592e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a9d88509-9516-4539-ad74-74347d566464" xlink:to="loc_us-gaap_NatureOfOperations_27496223-0250-4f88-834f-64517d65592e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2f8db6d9-13c1-460a-bf9c-fe5d91ecafb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_41708470-1df0-4cdd-b6cd-658a1e16013b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2f8db6d9-13c1-460a-bf9c-fe5d91ecafb6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_41708470-1df0-4cdd-b6cd-658a1e16013b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="simple" xlink:href="ino-20221231.xsd#RevenueRecognitionandConcentrationofCreditRisk"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a7e9325-49da-4bf2-a389-fe1e8a4c947f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d26b7410-fade-4aa8-ae45-4e25be5b3aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5a7e9325-49da-4bf2-a389-fe1e8a4c947f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_d26b7410-fade-4aa8-ae45-4e25be5b3aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="simple" xlink:href="ino-20221231.xsd#CollaborativeAgreements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56b86e08-b255-41f7-8940-948be1050290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1a182413-511a-4c1e-9500-7f68efc5c73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56b86e08-b255-41f7-8940-948be1050290" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_1a182413-511a-4c1e-9500-7f68efc5c73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bba90ac-549a-4c1e-9836-d6e40fcd3bea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a32b0b27-87b9-4bef-954c-2fce904393af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bba90ac-549a-4c1e-9836-d6e40fcd3bea" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_a32b0b27-87b9-4bef-954c-2fce904393af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_665beb2f-fb43-412b-80bb-85238aabb350" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8bba90ac-549a-4c1e-9836-d6e40fcd3bea" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_665beb2f-fb43-412b-80bb-85238aabb350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="simple" xlink:href="ino-20221231.xsd#CertainBalanceSheetItems"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_78ef985c-afee-4a30-8369-96aa13f0153e" xlink:href="ino-20221231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_970d83c3-b13e-4709-a2fb-18a547e9da57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_78ef985c-afee-4a30-8369-96aa13f0153e" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_970d83c3-b13e-4709-a2fb-18a547e9da57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssets" xlink:type="simple" xlink:href="ino-20221231.xsd#FixedAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2a14afd5-d979-45a9-91f9-6705e497ecc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a52d828d-e82d-4906-b0c4-9ce6600cce4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2a14afd5-d979-45a9-91f9-6705e497ecc4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a52d828d-e82d-4906-b0c4-9ce6600cce4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_29ef01d5-3d5e-4f54-844f-adae8cac3337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cf050291-5e69-4ac0-a9a9-a1aee929040a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_29ef01d5-3d5e-4f54-844f-adae8cac3337" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cf050291-5e69-4ac0-a9a9-a1aee929040a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebt" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebt"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0ebd1334-893e-443e-95ff-78df3b187796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_4edb98c3-16fa-438e-8535-67fc2d53bfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0ebd1334-893e-443e-95ff-78df3b187796" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_4edb98c3-16fa-438e-8535-67fc2d53bfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_eb998c8e-2d27-4ebe-ac7a-2a30ea804317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5ba25ccf-67c8-4144-a057-5f36cf5b67c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_eb998c8e-2d27-4ebe-ac7a-2a30ea804317" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5ba25ccf-67c8-4144-a057-5f36cf5b67c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7cd5dbe4-ed77-4a54-8a53-1429f1daa067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_50d50ae0-5bc2-4b2f-9362-6983ebee49d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7cd5dbe4-ed77-4a54-8a53-1429f1daa067" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_50d50ae0-5bc2-4b2f-9362-6983ebee49d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_78f714be-5a12-4c55-b856-7f60b6831945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a1100f36-ca18-4175-b721-bf10bedd3e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_78f714be-5a12-4c55-b856-7f60b6831945" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a1100f36-ca18-4175-b721-bf10bedd3e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlan" xlink:type="simple" xlink:href="ino-20221231.xsd#A401kPlan"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8424490f-9f0d-473f-9826-474556a287bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d815cd50-35d5-428a-89a8-ed5471a90cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8424490f-9f0d-473f-9826-474556a287bd" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_d815cd50-35d5-428a-89a8-ed5471a90cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ino-20221231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_b98e222a-3261-4ebb-877f-7e88fe884e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39423ee6-5e1c-4862-be63-85adc0b0d0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_b98e222a-3261-4ebb-877f-7e88fe884e43" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_39423ee6-5e1c-4862-be63-85adc0b0d0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="simple" xlink:href="ino-20221231.xsd#GeneosTherapeuticsInc"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_6698f3df-0726-4025-9aa8-139243b79857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8c32ea57-ec0c-4014-b829-7ef28a6cd7d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_6698f3df-0726-4025-9aa8-139243b79857" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8c32ea57-ec0c-4014-b829-7ef28a6cd7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ino-20221231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_53d2306e-aae5-43f5-9407-f4834e841fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_08a1f604-108c-4025-be94-df5c5bca2a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_53d2306e-aae5-43f5-9407-f4834e841fb1" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_08a1f604-108c-4025-be94-df5c5bca2a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9559e8cc-e313-44d0-b900-47a4355c93ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9559e8cc-e313-44d0-b900-47a4355c93ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_fc4e31a3-d5fe-43a8-a45a-bbfd07d04488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_fc4e31a3-d5fe-43a8-a45a-bbfd07d04488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9fd0bc52-a903-4a9d-a8c5-86e42f9ca11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9fd0bc52-a903-4a9d-a8c5-86e42f9ca11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ec90d94a-f7a0-48dd-bc24-0f07f41d1703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_UseOfEstimates_ec90d94a-f7a0-48dd-bc24-0f07f41d1703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_21dfc2e6-e806-45e3-bc3a-d64328d9fd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_21dfc2e6-e806-45e3-bc3a-d64328d9fd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6bebdf08-cec8-4130-af46-c105a990c288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6bebdf08-cec8-4130-af46-c105a990c288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_89dcf91b-70c3-4abb-8e25-6bbd39b8be6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_89dcf91b-70c3-4abb-8e25-6bbd39b8be6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_8a6112f3-70a8-4c83-bab4-39d3a7c6e16f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_8a6112f3-70a8-4c83-bab4-39d3a7c6e16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_044ccc9b-cee6-474b-8ead-552e1f28f310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_044ccc9b-cee6-474b-8ead-552e1f28f310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6981a8e8-6402-4322-bd22-30ba24263ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6981a8e8-6402-4322-bd22-30ba24263ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1e3d5452-d713-45f8-8a64-95ad9f5e46dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_1e3d5452-d713-45f8-8a64-95ad9f5e46dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_39f2ad2f-5aaf-45d7-b5fb-c675d61f29f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_39f2ad2f-5aaf-45d7-b5fb-c675d61f29f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_87a745ab-848e-4677-8248-67c618091e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_87a745ab-848e-4677-8248-67c618091e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bcf91614-b24a-4166-9435-6cb1a7bbf314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_bcf91614-b24a-4166-9435-6cb1a7bbf314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_29c88ea4-f4d7-4fb1-a7c5-98f8054813c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_29c88ea4-f4d7-4fb1-a7c5-98f8054813c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantRevenuePolicyTextBlock_a4ef60ff-f5db-4916-a825-4e693666ca9c" xlink:href="ino-20221231.xsd#ino_GrantRevenuePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_ino_GrantRevenuePolicyTextBlock_a4ef60ff-f5db-4916-a825-4e693666ca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6f947ea9-cb1c-4b2e-a484-0913c51587e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_6f947ea9-cb1c-4b2e-a484-0913c51587e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_ab0be974-4c09-449d-aadd-75aa378c22a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_ab0be974-4c09-449d-aadd-75aa378c22a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_97f41025-9532-4027-9ca8-43b15c5f27ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_97f41025-9532-4027-9ca8-43b15c5f27ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5bdc4426-2b34-4b61-baa3-e3d49360bf09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5bdc4426-2b34-4b61-baa3-e3d49360bf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_338c0966-e238-4dba-86ff-1c7d8acd6e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_338c0966-e238-4dba-86ff-1c7d8acd6e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_b2fdfabd-7642-449c-a3d3-fd00eefb1d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_b2fdfabd-7642-449c-a3d3-fd00eefb1d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_733cc0bf-749a-43cd-84f7-5f6b531e68d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_733cc0bf-749a-43cd-84f7-5f6b531e68d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_daf38fb3-8016-45fe-9c1b-0bc781610f11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a6f3547b-6c1f-431a-aea2-a4cd483542da" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_daf38fb3-8016-45fe-9c1b-0bc781610f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cf3c1646-fc7f-4a0f-859f-0987441655c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_49ab1909-7753-40db-b09d-cb6e6892abad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf3c1646-fc7f-4a0f-859f-0987441655c1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_49ab1909-7753-40db-b09d-cb6e6892abad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a6d23053-c970-4a8b-9bf9-74aba6322cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cf3c1646-fc7f-4a0f-859f-0987441655c1" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a6d23053-c970-4a8b-9bf9-74aba6322cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="simple" xlink:href="ino-20221231.xsd#RevenueRecognitionandConcentrationofCreditRiskTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_241e660e-b4f0-45e7-b93d-ae9ebf224307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_d84d1d9e-436f-4bf8-95b7-7ddb45d0d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_241e660e-b4f0-45e7-b93d-ae9ebf224307" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_d84d1d9e-436f-4bf8-95b7-7ddb45d0d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_838a0906-f4d7-49d4-adfb-32b6cc697b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f3e13c9a-7c26-422d-8c1b-8b8cae48cc87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_838a0906-f4d7-49d4-adfb-32b6cc697b9c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_f3e13c9a-7c26-422d-8c1b-8b8cae48cc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2a4acda2-8940-499a-9648-c114599b96f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_838a0906-f4d7-49d4-adfb-32b6cc697b9c" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2a4acda2-8940-499a-9648-c114599b96f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="simple" xlink:href="ino-20221231.xsd#CertainBalanceSheetItemsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_56c5e178-1501-4557-9b72-190e0843375f" xlink:href="ino-20221231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_46f40fb0-4292-4560-9ac7-3acc3f0ae004" xlink:href="ino-20221231.xsd#ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_56c5e178-1501-4557-9b72-190e0843375f" xlink:to="loc_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_46f40fb0-4292-4560-9ac7-3acc3f0ae004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74383c60-cebd-46fc-b621-3f35c5601a20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_56c5e178-1501-4557-9b72-190e0843375f" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_74383c60-cebd-46fc-b621-3f35c5601a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsTables" xlink:type="simple" xlink:href="ino-20221231.xsd#FixedAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bc1d45af-213f-4dfb-bd41-0155c3b1873e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9028ce21-c3bb-4d6c-bef4-6469b983a9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_bc1d45af-213f-4dfb-bd41-0155c3b1873e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9028ce21-c3bb-4d6c-bef4-6469b983a9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5a32950d-983d-41b3-a99f-33747873032b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b8a2ff85-28cd-40dc-b6b1-445f179cc014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5a32950d-983d-41b3-a99f-33747873032b" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_b8a2ff85-28cd-40dc-b6b1-445f179cc014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_eb8357f3-fbe8-48c8-b792-f89a28754740" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5a32950d-983d-41b3-a99f-33747873032b" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_eb8357f3-fbe8-48c8-b792-f89a28754740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f41aaaec-5d3a-424a-a7e2-4fe279dcc067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_270dd48d-8d6c-435b-b608-e8e5f923f8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f41aaaec-5d3a-424a-a7e2-4fe279dcc067" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_270dd48d-8d6c-435b-b608-e8e5f923f8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f2d9a252-27b1-4b1b-908b-a368d4c34325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f41aaaec-5d3a-424a-a7e2-4fe279dcc067" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_f2d9a252-27b1-4b1b-908b-a368d4c34325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f2768e1e-6699-4e6e-86ac-5e023365bb71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_427130dc-7a2f-4b85-a1a8-f9574ccd510e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f2768e1e-6699-4e6e-86ac-5e023365bb71" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_427130dc-7a2f-4b85-a1a8-f9574ccd510e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_93730d62-3ca1-447d-ba4b-9ca9729b489d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f2768e1e-6699-4e6e-86ac-5e023365bb71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_93730d62-3ca1-447d-ba4b-9ca9729b489d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f20616af-7d02-404b-9feb-24891b981a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f2768e1e-6699-4e6e-86ac-5e023365bb71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f20616af-7d02-404b-9feb-24891b981a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2837915f-ab0b-4d93-b598-f9d54c19f85f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f2768e1e-6699-4e6e-86ac-5e023365bb71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_2837915f-ab0b-4d93-b598-f9d54c19f85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f281b67a-c18e-4a0c-a13d-0fcf1ec45009" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e11aa90b-2022-4603-be26-cff0f17b93be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f281b67a-c18e-4a0c-a13d-0fcf1ec45009" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e11aa90b-2022-4603-be26-cff0f17b93be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2e02d8e3-1649-446f-b2ac-c9e6ebe0a14c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_e3ca6146-e741-49ba-bb4f-784e538c0170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e02d8e3-1649-446f-b2ac-c9e6ebe0a14c" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_e3ca6146-e741-49ba-bb4f-784e538c0170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_883e0e0b-6595-4d15-89c4-6b6b7bed7c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e02d8e3-1649-446f-b2ac-c9e6ebe0a14c" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_883e0e0b-6595-4d15-89c4-6b6b7bed7c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c7c82dc0-0925-4de7-ae56-47740a212600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e02d8e3-1649-446f-b2ac-c9e6ebe0a14c" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c7c82dc0-0925-4de7-ae56-47740a212600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_f09878d5-58e1-46c2-a0cb-a267d8d5d733" xlink:href="ino-20221231.xsd#ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e02d8e3-1649-446f-b2ac-c9e6ebe0a14c" xlink:to="loc_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock_f09878d5-58e1-46c2-a0cb-a267d8d5d733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3c986a7d-3ae4-40a9-8ef6-a7facc4917b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2e02d8e3-1649-446f-b2ac-c9e6ebe0a14c" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_3c986a7d-3ae4-40a9-8ef6-a7facc4917b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="simple" xlink:href="ino-20221231.xsd#GeneosTherapeuticsIncTables"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_08907230-cb05-43a4-84cb-0483fcee6d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_55f2215d-7b24-4021-a63d-a18cb75fc681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_08907230-cb05-43a4-84cb-0483fcee6d3c" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_55f2215d-7b24-4021-a63d-a18cb75fc681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bf5e69cf-76b9-42a6-92b1-a69351309db6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bf5e69cf-76b9-42a6-92b1-a69351309db6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1c931086-cf09-4e52-8186-96847f76b6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1c931086-cf09-4e52-8186-96847f76b6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cdbbe21a-351b-4706-98ae-b50cb479c8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1c931086-cf09-4e52-8186-96847f76b6ae" xlink:to="loc_us-gaap_ClassOfStockDomain_cdbbe21a-351b-4706-98ae-b50cb479c8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8527f5a8-f512-4084-9e1e-9974a9b83ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cdbbe21a-351b-4706-98ae-b50cb479c8c1" xlink:to="loc_us-gaap_CommonStockMember_8527f5a8-f512-4084-9e1e-9974a9b83ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a15dc7d2-7a13-4af3-8dd9-c21a3f07a749" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_8c25a328-bfee-4c93-adb6-e81d113ba82d" xlink:href="ino-20221231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:to="loc_ino_SalesAgreementMember_8c25a328-bfee-4c93-adb6-e81d113ba82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_227a1db3-767b-4113-a30a-5988ecd5fb4e" xlink:href="ino-20221231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_dac13539-4084-4711-aa15-837e06de289f" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_227a1db3-767b-4113-a30a-5988ecd5fb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:to="loc_srt_RangeAxis_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4c3c24f0-e13e-43c2-b7fc-201001e8ec8a" xlink:to="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b3e6df31-9195-4e48-a049-40a7e89dd038" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:to="loc_srt_MinimumMember_b3e6df31-9195-4e48-a049-40a7e89dd038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5d3b9f5c-13c4-4ade-9bc9-fe4f1da406fd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e0606746-4fa6-48e1-b170-69b6840e02b5" xlink:to="loc_srt_MaximumMember_5d3b9f5c-13c4-4ade-9bc9-fe4f1da406fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d7727778-4618-43a8-b3ac-10177be85f1d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_093d3be7-bfc8-4470-9a1e-b5d431b3017b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_NetIncomeLoss_093d3be7-bfc8-4470-9a1e-b5d431b3017b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_WorkingCapital_4b268fe7-1ea7-4e2c-8963-fde2d6d05427" xlink:href="ino-20221231.xsd#ino_WorkingCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_ino_WorkingCapital_4b268fe7-1ea7-4e2c-8963-fde2d6d05427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8db7453a-3974-444e-b3ea-66e4a66da01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8db7453a-3974-444e-b3ea-66e4a66da01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d9d59ca-a610-46c2-8915-f7768ff60767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_3d9d59ca-a610-46c2-8915-f7768ff60767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0a27cd69-4b7b-4461-98d8-7d92baa14015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0a27cd69-4b7b-4461-98d8-7d92baa14015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_e8d20571-45d6-48ec-8883-7c15518550f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_NumberOfOperatingSegments_e8d20571-45d6-48ec-8883-7c15518550f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9bfc1bd6-18a6-4319-90fa-adc4c74ce2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9bfc1bd6-18a6-4319-90fa-adc4c74ce2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f056aaeb-7942-4447-8e3e-5f16213e6028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_f056aaeb-7942-4447-8e3e-5f16213e6028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_335c7117-f54d-4a3e-854e-8917356a6716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_335c7117-f54d-4a3e-854e-8917356a6716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6aa3b70e-34bd-4079-9741-785845daa086" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6aa3b70e-34bd-4079-9741-785845daa086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2679b466-3816-42eb-9a06-e17e85ba41f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3f382b5d-08ec-477f-974a-1abc9abf52ee" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2679b466-3816-42eb-9a06-e17e85ba41f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c03aab1a-53cd-40d2-bf80-6f1043fcc50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c03aab1a-53cd-40d2-bf80-6f1043fcc50c" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f7f0f71-a629-4e38-8394-5b40d243496e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f7f0f71-a629-4e38-8394-5b40d243496e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4f7f0f71-a629-4e38-8394-5b40d243496e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5b2de695-92b5-4230-af00-ac92e0981b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5b2de695-92b5-4230-af00-ac92e0981b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ServiceBasedRestrictedStockUnitsMember_2d1418d6-4e0c-4855-91ca-e0b2a66ecc1f" xlink:href="ino-20221231.xsd#ino_ServiceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_ino_ServiceBasedRestrictedStockUnitsMember_2d1418d6-4e0c-4855-91ca-e0b2a66ecc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_56619617-feea-418f-b8ca-63d97c93bcff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_56619617-feea-418f-b8ca-63d97c93bcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_41b07f2a-21c3-4a48-bfe9-133542be77db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_41b07f2a-21c3-4a48-bfe9-133542be77db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_13a8ba97-bdaa-4ef9-ba97-f2ef6b9e20ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_50b816cc-5fe2-4294-9810-930731d1826e" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_13a8ba97-bdaa-4ef9-ba97-f2ef6b9e20ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_811454a3-6464-4748-96ec-3667c515e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:to="loc_us-gaap_DebtInstrumentAxis_811454a3-6464-4748-96ec-3667c515e63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_811454a3-6464-4748-96ec-3667c515e63f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d634fd93-d085-40f8-bb8b-fa8395b34bb5" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_d634fd93-d085-40f8-bb8b-fa8395b34bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_1231fbfc-2c2f-415d-aad6-1787ddd449ed" xlink:href="ino-20221231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_26f59d96-8d23-446f-b76b-60b07b5f332d" xlink:to="loc_ino_December2019ConvertibleBondsMember_1231fbfc-2c2f-415d-aad6-1787ddd449ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16ec8e50-c92d-4997-bab1-ff71e8250f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_30c01f33-d7ec-4f9d-ab40-dd751b7b541a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16ec8e50-c92d-4997-bab1-ff71e8250f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_890b0ef4-d9c0-45c9-aa35-1c83819f1cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_16ec8e50-c92d-4997-bab1-ff71e8250f30" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_890b0ef4-d9c0-45c9-aa35-1c83819f1cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82fe9f87-2df8-4d2c-8863-97dfbed60ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82fe9f87-2df8-4d2c-8863-97dfbed60ab4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:to="loc_srt_TitleOfIndividualAxis_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b3ede0dc-804b-4d8a-ba0e-536b6b55bdb3" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EmployeesAndDirectorsMember_6363d49a-21d3-48ae-8d76-a4b09593cd1e" xlink:href="ino-20221231.xsd#ino_EmployeesAndDirectorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:to="loc_ino_EmployeesAndDirectorsMember_6363d49a-21d3-48ae-8d76-a4b09593cd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NonEmployeeMember_5ba58a49-9edd-423a-8fa0-f5bce15894c4" xlink:href="ino-20221231.xsd#ino_NonEmployeeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_373cdc53-90a6-41c0-b68e-d4225676ce43" xlink:to="loc_ino_NonEmployeeMember_5ba58a49-9edd-423a-8fa0-f5bce15894c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3a7083d8-931b-4867-b6f4-0ea7c324724d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:to="loc_us-gaap_AwardTypeAxis_3a7083d8-931b-4867-b6f4-0ea7c324724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fd1e142-4c7b-424c-9bae-df2168cbfd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3a7083d8-931b-4867-b6f4-0ea7c324724d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fd1e142-4c7b-424c-9bae-df2168cbfd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5d616728-e0ea-455c-becb-405a6fa4ea81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3fd1e142-4c7b-424c-9bae-df2168cbfd6f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5d616728-e0ea-455c-becb-405a6fa4ea81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_520ad937-1ce5-4f01-946f-68ed4511509d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59ae4c2d-6208-410f-b666-94446a190bf6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_520ad937-1ce5-4f01-946f-68ed4511509d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:href="ino-20221231.xsd#ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_520ad937-1ce5-4f01-946f-68ed4511509d" xlink:to="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7460aa11-5853-4eaf-9b9d-86631058bc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7460aa11-5853-4eaf-9b9d-86631058bc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_014bb679-7429-47ba-ad29-b59490b0c7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_014bb679-7429-47ba-ad29-b59490b0c7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89e46480-85c6-4510-8c73-061fe176e07c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_89e46480-85c6-4510-8c73-061fe176e07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_782beff3-d6f4-4e04-97a9-7118c6cecf08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract_351a821f-4c34-46b0-a654-266a651ddc72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_782beff3-d6f4-4e04-97a9-7118c6cecf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd363a73-26ae-4992-a907-f756eaaeaeff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_697abcb2-7597-4310-ad67-945cf811b3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd363a73-26ae-4992-a907-f756eaaeaeff" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_697abcb2-7597-4310-ad67-945cf811b3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ebd0b6a2-2e24-46df-8f1a-a60f707fc008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_697abcb2-7597-4310-ad67-945cf811b3cc" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ebd0b6a2-2e24-46df-8f1a-a60f707fc008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_5bdd64b3-0574-463e-afe6-1e023c603f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_ebd0b6a2-2e24-46df-8f1a-a60f707fc008" xlink:to="loc_us-gaap_TypeOfAdoptionMember_5bdd64b3-0574-463e-afe6-1e023c603f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_a481b1f1-a7d8-4e78-b8e3-73f98784cc0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_5bdd64b3-0574-463e-afe6-1e023c603f9e" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_a481b1f1-a7d8-4e78-b8e3-73f98784cc0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_697abcb2-7597-4310-ad67-945cf811b3cc" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1f4a968-f468-44f2-a5cf-7219918fb767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c1f4a968-f468-44f2-a5cf-7219918fb767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f22f1162-b39d-4f89-8174-10e2e45ecaa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f22f1162-b39d-4f89-8174-10e2e45ecaa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_17ed9831-2fc8-4dba-8e4f-1e4033422127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_ConvertibleDebt_17ed9831-2fc8-4dba-8e4f-1e4033422127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2dda849a-30f9-4973-a988-876e0b044630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_fb73fad5-f7ea-4108-bfaf-38ca9a88d409" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_2dda849a-30f9-4973-a988-876e0b044630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_46a1979d-b475-45c5-a97a-ddcd41b135dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_46a1979d-b475-45c5-a97a-ddcd41b135dd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_76707195-c06c-44fa-8e8a-c3a396fc0582" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:to="loc_srt_MajorCustomersAxis_76707195-c06c-44fa-8e8a-c3a396fc0582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_76707195-c06c-44fa-8e8a-c3a396fc0582" xlink:to="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_d685b20d-ac1a-41f2-b794-3b2f18d442fa" xlink:href="ino-20221231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_AdvaccineMember_d685b20d-ac1a-41f2-b794-3b2f18d442fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesIncMember_ea0c14bb-2c6b-4139-951d-ffbea6228ea9" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_PlumblineLifeSciencesIncMember_ea0c14bb-2c6b-4139-951d-ffbea6228ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_63fdaf7e-978c-4c3f-8840-6dac7b4501bf" xlink:href="ino-20221231.xsd#ino_DoDMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_DoDMember_63fdaf7e-978c-4c3f-8840-6dac7b4501bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AllOtherCustomersMember_c4d61ccc-83d8-406d-bf70-44db512ef213" xlink:href="ino-20221231.xsd#ino_AllOtherCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96662b25-30c3-4326-a689-0124ab2800bf" xlink:to="loc_ino_AllOtherCustomersMember_c4d61ccc-83d8-406d-bf70-44db512ef213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2d59e23a-41f5-44a4-b4a6-108bf9d9de45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2d59e23a-41f5-44a4-b4a6-108bf9d9de45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05d1205f-3fcd-462c-9fbf-b75f7453258e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2d59e23a-41f5-44a4-b4a6-108bf9d9de45" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05d1205f-3fcd-462c-9fbf-b75f7453258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_7aadfc19-5ee5-40b4-a055-1739a2a43da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_05d1205f-3fcd-462c-9fbf-b75f7453258e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_7aadfc19-5ee5-40b4-a055-1739a2a43da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_e4653aa1-9d7e-4691-b006-c4deef87e69e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_e4653aa1-9d7e-4691-b006-c4deef87e69e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_97bcff58-60fe-407c-84cf-c2a56a077416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_e4653aa1-9d7e-4691-b006-c4deef87e69e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_97bcff58-60fe-407c-84cf-c2a56a077416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ba80c357-d396-4180-960b-6fc50afcbc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_97bcff58-60fe-407c-84cf-c2a56a077416" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ba80c357-d396-4180-960b-6fc50afcbc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_9ee16fb8-1ce0-4b2e-9b90-f3998ef962ba" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_207b7c85-93b0-472a-a23c-2a967f564039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_207b7c85-93b0-472a-a23c-2a967f564039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_89bb1035-19d8-4798-b321-02f129de77fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0ec442d0-57b0-4094-8532-3f0e6a912057" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_89bb1035-19d8-4798-b321-02f129de77fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ac7d48bb-a87b-4c01-aea6-022080cb056d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ac7d48bb-a87b-4c01-aea6-022080cb056d" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3d7eb849-fd46-43a6-bb82-9d33afd991a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:to="loc_srt_MajorCustomersAxis_3d7eb849-fd46-43a6-bb82-9d33afd991a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3d7eb849-fd46-43a6-bb82-9d33afd991a6" xlink:to="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DoDMember_824cb900-f698-4362-8b20-e13bd1acf9b2" xlink:href="ino-20221231.xsd#ino_DoDMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:to="loc_ino_DoDMember_824cb900-f698-4362-8b20-e13bd1acf9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CEPIMERSMember_6a23c899-d740-4c51-a447-28fc0df14bf4" xlink:href="ino-20221231.xsd#ino_CEPIMERSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5f9490b3-e474-4b60-b43b-25b966fd8dfe" xlink:to="loc_ino_CEPIMERSMember_6a23c899-d740-4c51-a447-28fc0df14bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0e7bedfc-df7f-482e-be90-f2752f9d9851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_ddbcaa0a-c732-44e6-a622-8f9631b6ae0c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0e7bedfc-df7f-482e-be90-f2752f9d9851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_855d5a3f-6450-4914-9c7f-5e0f760dc3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0e7bedfc-df7f-482e-be90-f2752f9d9851" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_855d5a3f-6450-4914-9c7f-5e0f760dc3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e43c279-5301-4c9d-8523-ddccf2810687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e43c279-5301-4c9d-8523-ddccf2810687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca299e33-a6bf-4edc-9676-e54191f4309a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_8e43c279-5301-4c9d-8523-ddccf2810687" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca299e33-a6bf-4edc-9676-e54191f4309a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_87bda4d2-6c86-437f-a38d-e6767e54549d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca299e33-a6bf-4edc-9676-e54191f4309a" xlink:to="loc_us-gaap_AccountsReceivableMember_87bda4d2-6c86-437f-a38d-e6767e54549d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_504c66a2-2ee2-4d06-9455-bfcf9ecad4af" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11bf396a-d124-4c90-aa0a-9a5424d2d75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_11bf396a-d124-4c90-aa0a-9a5424d2d75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_4dc49229-a121-470c-a76a-e1e0a577e509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:to="loc_us-gaap_AccountsReceivableNet_4dc49229-a121-470c-a76a-e1e0a577e509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_ae794d6c-c271-4b95-9c1d-7e8207738f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5068fc3b-44ff-49c1-bc8e-a1bf6f19fcae" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_ae794d6c-c271-4b95-9c1d-7e8207738f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CollaborativeAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CollaborativeAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_410a1dfc-36e6-4d77-a8f0-f18dc9dab149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_410a1dfc-36e6-4d77-a8f0-f18dc9dab149" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_srt_CounterpartyNameAxis_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b8fe9a2b-1c07-4e33-a4f4-7dc38dcb1dcc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_ea99363f-2244-42a2-837b-b498f385ee8b" xlink:href="ino-20221231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_AdvaccineMember_ea99363f-2244-42a2-837b-b498f385ee8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ApolloBioMember_f9b50035-4c74-43e1-bd92-81ef7c2f891b" xlink:href="ino-20221231.xsd#ino_ApolloBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_ApolloBioMember_f9b50035-4c74-43e1-bd92-81ef7c2f891b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_5b69834d-1180-49af-8ce1-9b3155a5b415" xlink:href="ino-20221231.xsd#ino_CoalitionforEpidemicPreparednessInnovationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_CoalitionforEpidemicPreparednessInnovationsMember_5b69834d-1180-49af-8ce1-9b3155a5b415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BillAndMelindaGatesFoundationMember_29220cf1-be92-4490-99aa-25a9b1c10b0e" xlink:href="ino-20221231.xsd#ino_BillAndMelindaGatesFoundationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_BillAndMelindaGatesFoundationMember_29220cf1-be92-4490-99aa-25a9b1c10b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DepartmentOfDefenceMember_dcbd6b7c-4687-4725-97de-51e42e1e2deb" xlink:href="ino-20221231.xsd#ino_DepartmentOfDefenceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a86ce226-bae8-4f8d-9fe7-da008ed95b45" xlink:to="loc_ino_DepartmentOfDefenceMember_dcbd6b7c-4687-4725-97de-51e42e1e2deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_764e1641-20ad-45fc-972a-f2c914d0fad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ffa23522-5e3f-46d3-9a61-ac3b1dd146ab" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_764e1641-20ad-45fc-972a-f2c914d0fad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_cdf2c7ea-2041-4906-8851-68ffff8d8981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_764e1641-20ad-45fc-972a-f2c914d0fad5" xlink:to="loc_us-gaap_CollaborativeArrangementMember_cdf2c7ea-2041-4906-8851-68ffff8d8981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_srt_MajorCustomersAxis_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_f9693f6b-e768-484d-b413-ed9c925d1c55" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_f5dc5d60-20ee-4ac1-84c4-5265fc62a6f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_f9693f6b-e768-484d-b413-ed9c925d1c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AdvaccineMember_3b384ba5-57cd-493d-9c16-5136a10e38e4" xlink:href="ino-20221231.xsd#ino_AdvaccineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_f9693f6b-e768-484d-b413-ed9c925d1c55" xlink:to="loc_ino_AdvaccineMember_3b384ba5-57cd-493d-9c16-5136a10e38e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_53b891f3-2d12-48af-a299-9340bfd42edf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_srt_ProductOrServiceAxis_53b891f3-2d12-48af-a299-9340bfd42edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_53b891f3-2d12-48af-a299-9340bfd42edf" xlink:to="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f21949a7-9f3f-4606-869d-a02ef8d8d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_us-gaap_LicenseMember_f21949a7-9f3f-4606-869d-a02ef8d8d1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LassaFeverAndMERSVaccineMember_14776411-db0d-497f-a825-1dd2ae37fa50" xlink:href="ino-20221231.xsd#ino_LassaFeverAndMERSVaccineMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_LassaFeverAndMERSVaccineMember_14776411-db0d-497f-a825-1dd2ae37fa50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SARSCoV2COVID19VaccineMember_5e94e756-5522-4574-9e9e-6b2fb956066c" xlink:href="ino-20221231.xsd#ino_SARSCoV2COVID19VaccineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_SARSCoV2COVID19VaccineMember_5e94e756-5522-4574-9e9e-6b2fb956066c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_35aef405-fd72-493f-9b41-971bd2f9fdf1" xlink:href="ino-20221231.xsd#ino_CELLECTRA3PSPProprietarySmartDeviceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_CELLECTRA3PSPProprietarySmartDeviceMember_35aef405-fd72-493f-9b41-971bd2f9fdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_INO4800Member_e91e24df-f33b-4133-8f8a-f0a0e861da1e" xlink:href="ino-20221231.xsd#ino_INO4800Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_INO4800Member_e91e24df-f33b-4133-8f8a-f0a0e861da1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_c99f6dea-3892-4181-974b-55ae2e959cfa" xlink:href="ino-20221231.xsd#ino_DNAEncodedMonoclonalAntibodyTechnologyMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e6c8449-86b4-44d9-9f51-686e26a7cf9b" xlink:to="loc_ino_DNAEncodedMonoclonalAntibodyTechnologyMember_c99f6dea-3892-4181-974b-55ae2e959cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28bd0be3-d9f1-4464-8be1-7a0a18318d96" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_a6a39fc2-4495-456a-89c2-2a4012680733" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementsUpfrontPaymentReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementsUpfrontPaymentReceived_a6a39fc2-4495-456a-89c2-2a4012680733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_294ed76b-378a-4330-ae21-fee7fdb5fc61" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementAdditionalRevenueToBeAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborationAgreementAdditionalRevenueToBeAchieved_294ed76b-378a-4330-ae21-fee7fdb5fc61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementRoyaltyPeriod_dba5cd37-bf24-4268-9f3f-a137bf2797ca" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementRoyaltyPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborationAgreementRoyaltyPeriod_dba5cd37-bf24-4268-9f3f-a137bf2797ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostMaintenance_5a4a5bce-cae0-4126-bd43-bf554d4cb1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostMaintenance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_CostMaintenance_5a4a5bce-cae0-4126-bd43-bf554d4cb1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AnnualMaintenancePeriod_a5fc88d7-d1f0-4c36-83f7-debdf518902d" xlink:href="ino-20221231.xsd#ino_AnnualMaintenancePeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_AnnualMaintenancePeriod_a5fc88d7-d1f0-4c36-83f7-debdf518902d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_6aeb2824-3e5b-4389-a070-34b426ce9fac" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination_6aeb2824-3e5b-4389-a070-34b426ce9fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborationAgreementPaymentEarned_c7d332b8-d308-48fd-bbaa-fad70e48ed66" xlink:href="ino-20221231.xsd#ino_CollaborationAgreementPaymentEarned"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborationAgreementPaymentEarned_c7d332b8-d308-48fd-bbaa-fad70e48ed66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3bafce94-0773-4f4e-aba8-504153fb75ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3bafce94-0773-4f4e-aba8-504153fb75ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_52772973-13fc-4ff9-951d-cc27ca99bb6a" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination_52772973-13fc-4ff9-951d-cc27ca99bb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingToBeReceived_ac4c6999-b54c-4808-91de-ab42679d36ad" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementFundingToBeReceived"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementFundingToBeReceived_ac4c6999-b54c-4808-91de-ab42679d36ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_1338fc70-fcbc-4fc7-a64e-27caa7afff4a" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment_1338fc70-fcbc-4fc7-a64e-27caa7afff4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_8da5c01b-8642-4504-895f-d401b9acc927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_AccountsReceivableNet_8da5c01b-8642-4504-895f-d401b9acc927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantsReceivable_912ed3ac-c59e-48e9-b478-eff4a60bf27d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_us-gaap_GrantsReceivable_912ed3ac-c59e-48e9-b478-eff4a60bf27d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementFundingReceived_04202e90-ac97-4e08-a6c9-57bc27b46cda" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementFundingReceived"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeAgreementFundingReceived_04202e90-ac97-4e08-a6c9-57bc27b46cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_675b618d-10d2-4064-902b-a6a6a2d5d6d5" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementFixedPriceContractAmountAwarded"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeArrangementFixedPriceContractAmountAwarded_675b618d-10d2-4064-902b-a6a6a2d5d6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_4af7ce5f-776a-426d-9a4b-6e420be3330e" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementRevenueFromTheProcurementContract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_CollaborativeArrangementRevenueFromTheProcurementContract_4af7ce5f-776a-426d-9a4b-6e420be3330e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_d843c05f-6145-4785-8a2b-928f4d4d15c2" xlink:href="ino-20221231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b794828e-cf9f-4ce7-a60d-964a27d9456b" xlink:to="loc_ino_GrantProceedsReceived_d843c05f-6145-4785-8a2b-928f4d4d15c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82479dc3-6316-4724-93e2-fa4d81a0c660" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_82479dc3-6316-4724-93e2-fa4d81a0c660" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_746bb208-1923-44cf-b78d-de44b74c49a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_746bb208-1923-44cf-b78d-de44b74c49a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_746bb208-1923-44cf-b78d-de44b74c49a5" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_91177d3e-40c9-4bed-9202-b240ab3d9d5d" xlink:href="ino-20221231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_ino_MutualFundsMember_91177d3e-40c9-4bed-9202-b240ab3d9d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryBillSecuritiesMember_d5c4db98-310c-4459-abfe-cdea036544df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryBillSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_USTreasuryBillSecuritiesMember_d5c4db98-310c-4459-abfe-cdea036544df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_aad75328-15bd-4326-8203-bb86e8cd47b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_CommercialPaperMember_aad75328-15bd-4326-8203-bb86e8cd47b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6ccd742a-a846-46fe-b580-2355badb2269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6ccd742a-a846-46fe-b580-2355badb2269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4276c094-103c-4f56-b7ca-275c0be9e1d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06febf2b-bf04-4ac2-9eee-c2a9e5b680fe" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_4276c094-103c-4f56-b7ca-275c0be9e1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_287cdf75-44c8-4b08-805d-6c8662fccafe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:to="loc_srt_RangeAxis_287cdf75-44c8-4b08-805d-6c8662fccafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d403ccf3-77c2-446e-971f-6e5126a360b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_287cdf75-44c8-4b08-805d-6c8662fccafe" xlink:to="loc_srt_RangeMember_d403ccf3-77c2-446e-971f-6e5126a360b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_27842c60-a650-4106-a3d1-d3eac13a39b7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d403ccf3-77c2-446e-971f-6e5126a360b6" xlink:to="loc_srt_MaximumMember_27842c60-a650-4106-a3d1-d3eac13a39b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_fa2dbef6-7ca4-44df-8be5-e03c3f4dfdb3" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_eaf7b2e6-28c2-4b36-b5d3-8a230eb5784f" xlink:href="ino-20221231.xsd#ino_DebtSecuritiesAvailableforSaleContractualMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:to="loc_ino_DebtSecuritiesAvailableforSaleContractualMaturity_eaf7b2e6-28c2-4b36-b5d3-8a230eb5784f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25e7e10c-d2bf-4e73-b58a-e448527c3da7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3e58d07-d822-49c4-8888-4311bcc85859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d3e58d07-d822-49c4-8888-4311bcc85859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae8241-12b6-4829-8139-f6c125831450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6aae8241-12b6-4829-8139-f6c125831450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed94f280-8d96-4ed8-aa27-62ca2e8f7679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ed94f280-8d96-4ed8-aa27-62ca2e8f7679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd791276-b735-4a48-90a0-bb19d506b983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_6e293d45-86a4-409e-85d3-6bb54c1faecd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cd791276-b735-4a48-90a0-bb19d506b983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a5afe94-441f-4130-9308-2a9b7b70f99b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a5afe94-441f-4130-9308-2a9b7b70f99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed692db1-72cf-46b2-a9eb-20939592dcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a5afe94-441f-4130-9308-2a9b7b70f99b" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed692db1-72cf-46b2-a9eb-20939592dcfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_a2752594-410b-4046-afd0-10ddb7fbbde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ed692db1-72cf-46b2-a9eb-20939592dcfe" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_a2752594-410b-4046-afd0-10ddb7fbbde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_bb641a84-23cc-4c06-bd9a-d069d5ef6532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:to="loc_us-gaap_InvestmentTypeAxis_bb641a84-23cc-4c06-bd9a-d069d5ef6532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_af200f3e-5276-46ae-ad4d-7ccd4c7652a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_bb641a84-23cc-4c06-bd9a-d069d5ef6532" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_af200f3e-5276-46ae-ad4d-7ccd4c7652a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1da6edb6-e93b-4685-93d9-4cccd4e64b90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_af200f3e-5276-46ae-ad4d-7ccd4c7652a7" xlink:to="loc_us-gaap_CommonStockMember_1da6edb6-e93b-4685-93d9-4cccd4e64b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_78b65704-ee42-4c39-9f6d-1646b3e79e1e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e27bc61d-e011-485b-bdbd-ffaad3c4e0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_e27bc61d-e011-485b-bdbd-ffaad3c4e0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fea2648d-0099-42fe-89e6-12b8b4294476" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fea2648d-0099-42fe-89e6-12b8b4294476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0b0ff870-67de-4f27-a0c7-4884d8a6fb40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0b0ff870-67de-4f27-a0c7-4884d8a6fb40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_54013d67-5138-4d19-9235-7ce0bfcba3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_54013d67-5138-4d19-9235-7ce0bfcba3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_d090a791-ff60-4cc2-8ae2-9dd3a227ee12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_d090a791-ff60-4cc2-8ae2-9dd3a227ee12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_edfd9b4d-3052-4665-947b-65f9370df8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_edfd9b4d-3052-4665-947b-65f9370df8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_17c0606c-682c-4fff-8cb6-715a91572189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2858b2d4-aa2f-4ac0-a9f1-e42fcf0c6097" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_17c0606c-682c-4fff-8cb6-715a91572189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_42fe4274-12ca-4ad6-a0da-37a8281e7370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_42fe4274-12ca-4ad6-a0da-37a8281e7370" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3cbd532-75c2-4cad-83e3-9265dcecc763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3cbd532-75c2-4cad-83e3-9265dcecc763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b70b8524-72dd-406a-8c97-8bb1b8960b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c3cbd532-75c2-4cad-83e3-9265dcecc763" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b70b8524-72dd-406a-8c97-8bb1b8960b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f8a1449e-dee8-457c-9157-0172938f1109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b70b8524-72dd-406a-8c97-8bb1b8960b4a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f8a1449e-dee8-457c-9157-0172938f1109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8e24dacd-1cc6-4cb8-93d8-2452f31e1469" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8e24dacd-1cc6-4cb8-93d8-2452f31e1469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8e24dacd-1cc6-4cb8-93d8-2452f31e1469" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_MutualFundsMember_8cc0556e-6dd7-4c22-9428-4f50773ecfec" xlink:href="ino-20221231.xsd#ino_MutualFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_ino_MutualFundsMember_8cc0556e-6dd7-4c22-9428-4f50773ecfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_3202189e-4f62-4357-b065-903326447c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_3202189e-4f62-4357-b065-903326447c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c4186217-9344-4577-b29a-0a644af0a5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_CommercialPaperMember_c4186217-9344-4577-b29a-0a644af0a5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ccb28076-680b-47f9-8706-bc8401077058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ccb28076-680b-47f9-8706-bc8401077058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_599d53b1-ab55-4c19-8491-fc13ea4f7ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5beccf3f-9a49-4254-93e3-e0c6278958d2" xlink:to="loc_us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember_599d53b1-ab55-4c19-8491-fc13ea4f7ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbb12af9-5de1-40bc-87d1-b5542a8d18e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbb12af9-5de1-40bc-87d1-b5542a8d18e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bbb12af9-5de1-40bc-87d1-b5542a8d18e1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_ecd90e49-eea8-4a11-b700-86c32bf77b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_ecd90e49-eea8-4a11-b700-86c32bf77b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_eaa709c8-5eed-439e-ae06-73674bcf2def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_eaa709c8-5eed-439e-ae06-73674bcf2def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d6d6d6e4-bf41-43b7-8f0f-e1a6be33de3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6d9eef18-0ed2-4bef-934f-c87cf4aedc74" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d6d6d6e4-bf41-43b7-8f0f-e1a6be33de3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24b5e3a-2a53-4c3e-be62-af89eb30be82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_96591cff-92e2-4a06-b73e-9cf815037770" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24b5e3a-2a53-4c3e-be62-af89eb30be82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_d24b5e3a-2a53-4c3e-be62-af89eb30be82" xlink:to="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a521316-883b-4db7-9018-d41017bd4d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7a521316-883b-4db7-9018-d41017bd4d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_63f2a597-b546-44fa-9f30-f597bb6e6c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_63f2a597-b546-44fa-9f30-f597bb6e6c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_224f69fd-262b-4d25-be39-9e635fcff3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_d4eec9f5-5cf7-4e47-b535-ee99e251403d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_224f69fd-262b-4d25-be39-9e635fcff3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_2f41d992-b683-45bf-816d-5ddda1a665dd" xlink:href="ino-20221231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_d4d041f2-6a1e-4a85-a5b7-2bcf4724f66c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_2f41d992-b683-45bf-816d-5ddda1a665dd" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_d4d041f2-6a1e-4a85-a5b7-2bcf4724f66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PrepaidManufacturingExpensesCurrent_e2250179-3393-444b-9fc1-c8d384070282" xlink:href="ino-20221231.xsd#ino_PrepaidManufacturingExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_2f41d992-b683-45bf-816d-5ddda1a665dd" xlink:to="loc_ino_PrepaidManufacturingExpensesCurrent_e2250179-3393-444b-9fc1-c8d384070282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_32595b07-50d6-414b-bec5-5c3eb59d2d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_2f41d992-b683-45bf-816d-5ddda1a665dd" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_32595b07-50d6-414b-bec5-5c3eb59d2d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8c4298f-cadf-4aba-ba5c-60a502c8ea74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_2f41d992-b683-45bf-816d-5ddda1a665dd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f8c4298f-cadf-4aba-ba5c-60a502c8ea74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ino_CertainBalanceSheetItemsAbstract_744fbb22-2c5a-4085-8e24-cef520ecc438" xlink:href="ino-20221231.xsd#ino_CertainBalanceSheetItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesTable_76cbdbf3-4cc8-46c4-8d19-ce49813700d3" xlink:href="ino-20221231.xsd#ino_AccountsPayableAndAccruedExpensesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_CertainBalanceSheetItemsAbstract_744fbb22-2c5a-4085-8e24-cef520ecc438" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesTable_76cbdbf3-4cc8-46c4-8d19-ce49813700d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_97518882-9a21-440b-adda-6fc30cd42b92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_76cbdbf3-4cc8-46c4-8d19-ce49813700d3" xlink:to="loc_srt_LitigationCaseAxis_97518882-9a21-440b-adda-6fc30cd42b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_1665a7cc-e26c-4ce2-8ce3-c0c3850c3549" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_97518882-9a21-440b-adda-6fc30cd42b92" xlink:to="loc_srt_LitigationCaseTypeDomain_1665a7cc-e26c-4ce2-8ce3-c0c3850c3549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_9a000aff-90f8-4167-a495-717526636ff2" xlink:href="ino-20221231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_1665a7cc-e26c-4ce2-8ce3-c0c3850c3549" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_9a000aff-90f8-4167-a495-717526636ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:href="ino-20221231.xsd#ino_AccountsPayableAndAccruedExpensesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesTable_76cbdbf3-4cc8-46c4-8d19-ce49813700d3" xlink:to="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_82a54950-cff7-4ed0-b0d2-dfa511a0ad4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_82a54950-cff7-4ed0-b0d2-dfa511a0ad4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_2c9948cc-46c5-4464-8e69-08e2ef58fe57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_AccruedSalariesCurrent_2c9948cc-46c5-4464-8e69-08e2ef58fe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_9740f32e-32c4-49c6-a902-2090357c23e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_LitigationReserveCurrent_9740f32e-32c4-49c6-a902-2090357c23e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2cea180b-566b-4555-8efe-cd4711c22359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_2cea180b-566b-4555-8efe-cd4711c22359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_94579d81-fac6-4286-a9ce-c081cf5f6823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_94579d81-fac6-4286-a9ce-c081cf5f6823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c64fb06a-00ba-437c-8f1e-d77f443d27ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c64fb06a-00ba-437c-8f1e-d77f443d27ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_de13362a-bf00-409d-ac29-36d62913d31b" xlink:href="ino-20221231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_de13362a-bf00-409d-ac29-36d62913d31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_76e12997-0fd3-4168-8272-33a2b923f6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ino_AccountsPayableAndAccruedExpensesLineItems_402fd186-e51b-4941-a8eb-036dd9086dfd" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_76e12997-0fd3-4168-8272-33a2b923f6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#FixedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/FixedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85096290-e96a-4255-b8b0-2dadba3b7084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_85096290-e96a-4255-b8b0-2dadba3b7084" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b942dec4-c0d2-40ac-bf5f-6ef760de603b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b942dec4-c0d2-40ac-bf5f-6ef760de603b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b942dec4-c0d2-40ac-bf5f-6ef760de603b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_7b69e15f-ce58-45c2-aca7-4f2d55400516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_7b69e15f-ce58-45c2-aca7-4f2d55400516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ccada150-0c4b-49b7-928f-5822fcef449e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_OfficeEquipmentMember_ccada150-0c4b-49b7-928f-5822fcef449e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_103556a7-32f2-43e2-bcf2-66d9369c3d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_103556a7-32f2-43e2-bcf2-66d9369c3d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_111b2509-fc28-47f3-a970-b7f125e6c8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b030ccd-88fd-4696-85ed-d9bdcc68c583" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_111b2509-fc28-47f3-a970-b7f125e6c8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3ae0f506-1946-473c-a2d7-7f91946b023f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3ae0f506-1946-473c-a2d7-7f91946b023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_747b24e7-90d7-4bde-8892-aab9df868fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3ae0f506-1946-473c-a2d7-7f91946b023f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_747b24e7-90d7-4bde-8892-aab9df868fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_fd639712-47cb-414a-bfc5-dfed138b239f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_747b24e7-90d7-4bde-8892-aab9df868fa5" xlink:to="loc_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_fd639712-47cb-414a-bfc5-dfed138b239f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_f10df281-d80c-4812-b610-cd8e0288134e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e307d574-f77a-4119-bf00-00b818746cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e307d574-f77a-4119-bf00-00b818746cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a04bf799-c4d0-4cb3-869c-3a5d9d8ce5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a04bf799-c4d0-4cb3-869c-3a5d9d8ce5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7487b3f5-735b-48c9-b2f4-5cedf99770be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7487b3f5-735b-48c9-b2f4-5cedf99770be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_756cb6ec-2e72-454e-a78f-04181a7ce915" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_Depreciation_756cb6ec-2e72-454e-a78f-04181a7ce915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_ca0fe633-5189-423a-a755-425267292740" xlink:href="ino-20221231.xsd#ino_PropertyPlantAndEquipmentDisposedOfBySale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_ino_PropertyPlantAndEquipmentDisposedOfBySale_ca0fe633-5189-423a-a755-425267292740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisposals_f2dbe88c-8bf6-407f-944a-be279f016399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisposals"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisposals_f2dbe88c-8bf6-407f-944a-be279f016399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_a945d791-c4ea-439e-adcb-34bcc6d18237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8afbe7d2-d9b4-460c-9b38-b6689b37af5d" xlink:to="loc_us-gaap_AccountsReceivableNet_a945d791-c4ea-439e-adcb-34bcc6d18237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cea389ac-b8be-4dc2-9670-e6f7fbc65d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cea389ac-b8be-4dc2-9670-e6f7fbc65d70" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44388d5e-6eac-4b7f-acba-313feae9f623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44388d5e-6eac-4b7f-acba-313feae9f623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_44388d5e-6eac-4b7f-acba-313feae9f623" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_f5cb3b07-1166-4ad0-a70b-a3ad44301432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:to="loc_us-gaap_LicensingAgreementsMember_f5cb3b07-1166-4ad0-a70b-a3ad44301432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_BiojectMember_bb9d9d1b-d5e5-40e6-9dcf-2fa1ec995381" xlink:href="ino-20221231.xsd#ino_BiojectMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:to="loc_ino_BiojectMember_bb9d9d1b-d5e5-40e6-9dcf-2fa1ec995381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_fb9005fb-0381-4b5e-91ba-a001a38d2ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_34e73366-44cc-469a-8c33-6a251666d684" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_fb9005fb-0381-4b5e-91ba-a001a38d2ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_205b31f9-56d4-4eef-acd2-c46ad888817b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:to="loc_srt_RangeAxis_205b31f9-56d4-4eef-acd2-c46ad888817b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_92726e7c-7e1d-455c-9649-2a6b48e6cfc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_205b31f9-56d4-4eef-acd2-c46ad888817b" xlink:to="loc_srt_RangeMember_92726e7c-7e1d-455c-9649-2a6b48e6cfc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_7313b275-4235-4a46-bc33-2bca318af981" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_92726e7c-7e1d-455c-9649-2a6b48e6cfc1" xlink:to="loc_srt_WeightedAverageMember_7313b275-4235-4a46-bc33-2bca318af981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_7d45f949-e418-4b64-af98-1eb45ed218ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1660b0f4-3cee-4726-bcb5-280ee38e75fe" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_7d45f949-e418-4b64-af98-1eb45ed218ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_7d45f949-e418-4b64-af98-1eb45ed218ec" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillGross_651665ae-d2fc-415c-ab75-213ad07da67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:to="loc_us-gaap_GoodwillGross_651665ae-d2fc-415c-ab75-213ad07da67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d7379084-aead-4ba6-8570-a5911881f903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_8e95cac4-0f99-4225-b69a-a9a5b343f2f7" xlink:to="loc_us-gaap_Goodwill_d7379084-aead-4ba6-8570-a5911881f903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99379ff5-0bf6-4a9c-ab79-8d3a3e39bea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_99379ff5-0bf6-4a9c-ab79-8d3a3e39bea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9fa2926c-74e5-43bb-98b5-b514b4f3c8c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9fa2926c-74e5-43bb-98b5-b514b4f3c8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d158102-714a-49ae-81c7-48d5b13ddbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9d158102-714a-49ae-81c7-48d5b13ddbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6dc7236-51f4-45e5-b7bd-95c593b95e07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_10aa08a7-d036-439b-a8b1-daeba6ae61a2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6dc7236-51f4-45e5-b7bd-95c593b95e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsGross_4100bdc9-57a5-41c3-af27-f388485fdc85" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_ino_GoodwillAndIntangibleAssetsGross_4100bdc9-57a5-41c3-af27-f388485fdc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GoodwillAndIntangibleAssetsNet_3c047abb-268f-4af8-970e-dc656e5c95f5" xlink:href="ino-20221231.xsd#ino_GoodwillAndIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4916f38e-5c47-44f4-802f-9c6d6351cac5" xlink:to="loc_ino_GoodwillAndIntangibleAssetsNet_3c047abb-268f-4af8-970e-dc656e5c95f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b1071d3d-a196-4585-8f6d-23fe8304fa24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b8e29d48-10c3-4d65-bc92-735fe49eafca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b1071d3d-a196-4585-8f6d-23fe8304fa24" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b8e29d48-10c3-4d65-bc92-735fe49eafca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_87a9ce01-e6ad-48f9-afd5-d4e362af959d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b1071d3d-a196-4585-8f6d-23fe8304fa24" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_87a9ce01-e6ad-48f9-afd5-d4e362af959d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_0ddcc4c7-85ed-4a8e-8c59-cb7b0dee1b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b1071d3d-a196-4585-8f6d-23fe8304fa24" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_0ddcc4c7-85ed-4a8e-8c59-cb7b0dee1b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1fed261d-35c8-4f0e-a0a0-8a60ecf15f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1fed261d-35c8-4f0e-a0a0-8a60ecf15f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9b29644f-3bfe-446e-9478-06296f4ea1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9b29644f-3bfe-446e-9478-06296f4ea1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4a0ffbea-62bd-4471-acbd-1f2f5d9b31ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_4a0ffbea-62bd-4471-acbd-1f2f5d9b31ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_466d6853-67e5-4a62-a49d-1be4a2404076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_466d6853-67e5-4a62-a49d-1be4a2404076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_707f5cf4-b023-47ea-9350-fbdb747e14f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_707f5cf4-b023-47ea-9350-fbdb747e14f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e7101ad7-4d43-4bc2-96d5-609f41692f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_e7101ad7-4d43-4bc2-96d5-609f41692f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e808d945-ae35-4e46-bea7-f96d276b036c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_690834ef-e428-4186-bc15-55eb06e54b4f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e808d945-ae35-4e46-bea7-f96d276b036c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_25e1b86f-dad4-4505-8cea-ebc8bb0de44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_25e1b86f-dad4-4505-8cea-ebc8bb0de44d" xlink:to="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_49d2d2d2-7438-4ade-bcbc-686340fb030d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_49d2d2d2-7438-4ade-bcbc-686340fb030d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f2cf470e-fd5b-4fa8-80d2-4d4f4c1a2d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_49d2d2d2-7438-4ade-bcbc-686340fb030d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f2cf470e-fd5b-4fa8-80d2-4d4f4c1a2d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1d51a561-6d0d-441e-a029-f745c598f5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f2cf470e-fd5b-4fa8-80d2-4d4f4c1a2d6a" xlink:to="loc_us-gaap_ConvertibleDebtMember_1d51a561-6d0d-441e-a029-f745c598f5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4feb9991-17d4-474c-80da-a0906b1b6690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4feb9991-17d4-474c-80da-a0906b1b6690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_ef590304-64df-4d46-b056-efdddb5abaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_4feb9991-17d4-474c-80da-a0906b1b6690" xlink:to="loc_us-gaap_TypeOfAdoptionMember_ef590304-64df-4d46-b056-efdddb5abaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member_f3f78de1-2190-4085-b50c-1f929541ca33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_ef590304-64df-4d46-b056-efdddb5abaa2" xlink:to="loc_us-gaap_AccountingStandardsUpdate202006Member_f3f78de1-2190-4085-b50c-1f929541ca33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_85bb3c56-e52b-4740-9c91-5e74f09c08ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:to="loc_us-gaap_DebtInstrumentAxis_85bb3c56-e52b-4740-9c91-5e74f09c08ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_85bb3c56-e52b-4740-9c91-5e74f09c08ce" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4e8d6de1-e5b0-4871-9a7c-329ac705c002" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4e8d6de1-e5b0-4871-9a7c-329ac705c002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_December2019ConvertibleBondsMember_a93d19e4-7d69-4d13-b4b4-3b5b27b12e32" xlink:href="ino-20221231.xsd#ino_December2019ConvertibleBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e38419f5-dae5-4727-9bc2-c20d5356d021" xlink:to="loc_ino_December2019ConvertibleBondsMember_a93d19e4-7d69-4d13-b4b4-3b5b27b12e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b03d3341-8f69-4a8c-bfa0-84c3a5c28858" xlink:to="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9f5d8ee5-c8c9-4c56-aa4d-7e02b8d45ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9f5d8ee5-c8c9-4c56-aa4d-7e02b8d45ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9b27564-7d41-4373-9783-c9f36a0dca67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9b27564-7d41-4373-9783-c9f36a0dca67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_2602ac3a-8944-4802-a706-8ea48afe5cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_2602ac3a-8944-4802-a706-8ea48afe5cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_f4fdc958-11ab-475c-a491-3a5e34364d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_f4fdc958-11ab-475c-a491-3a5e34364d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e9b2d3ba-4e4b-4fce-b9aa-37b85dfb80ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_e9b2d3ba-4e4b-4fce-b9aa-37b85dfb80ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ac34649-18e3-4241-bbc3-bfa04f9b1f42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4ac34649-18e3-4241-bbc3-bfa04f9b1f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ad8e676b-b7af-4407-b531-2d8b59c860e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_ad8e676b-b7af-4407-b531-2d8b59c860e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_49ad6dc4-f3f8-48d4-8699-700ae8ca576b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_49ad6dc4-f3f8-48d4-8699-700ae8ca576b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_31425479-b0b9-4b1e-b28c-a0e7c8b469c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_31425479-b0b9-4b1e-b28c-a0e7c8b469c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ecb638a-c257-492c-bb1a-45f48d17c6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_9ecb638a-c257-492c-bb1a-45f48d17c6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ea4f16a-e88a-4b3c-97d9-4be57f19f372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1ea4f16a-e88a-4b3c-97d9-4be57f19f372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_a845911b-2048-4563-a7b2-88d73128d900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_a845911b-2048-4563-a7b2-88d73128d900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f3c41725-3fd5-4331-b416-55f772b18d70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f3c41725-3fd5-4331-b416-55f772b18d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_d4f981e7-d85c-4ebb-a0fc-64a90b22a4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_AdditionalPaidInCapital_d4f981e7-d85c-4ebb-a0fc-64a90b22a4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebt_5b68e206-8e8f-4fc4-b612-7d66bdd1af88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebt"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_ConvertibleDebt_5b68e206-8e8f-4fc4-b612-7d66bdd1af88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_17b7aeed-4c61-4786-975e-29f66aed9ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_InterestExpense_17b7aeed-4c61-4786-975e-29f66aed9ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_8a6b6483-4a98-480b-8912-9e095e06a592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_InterestExpenseDebt_8a6b6483-4a98-480b-8912-9e095e06a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a7969374-1591-43bd-a078-c7d508be09f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_a7969374-1591-43bd-a078-c7d508be09f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_b6cf60f1-6f8b-4da7-9001-cc6f00e38e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_84f85a80-b240-4a11-916c-c9fa0c27e142" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_b6cf60f1-6f8b-4da7-9001-cc6f00e38e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtBalanceOfConvertibleDebtDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_541b3746-8261-4a3a-a9d9-75e3f259c799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b9399b25-64f3-4c5b-9fd2-77156d34f1bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_541b3746-8261-4a3a-a9d9-75e3f259c799" xlink:to="loc_us-gaap_DebtInstrumentTable_b9399b25-64f3-4c5b-9fd2-77156d34f1bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8dc9ec88-234e-4439-aa21-10e0e7028d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b9399b25-64f3-4c5b-9fd2-77156d34f1bc" xlink:to="loc_us-gaap_DebtInstrumentAxis_8dc9ec88-234e-4439-aa21-10e0e7028d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_6e1373ec-a52d-4fad-bda7-1c1d7faa74ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8dc9ec88-234e-4439-aa21-10e0e7028d35" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_6e1373ec-a52d-4fad-bda7-1c1d7faa74ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_58ff356b-d0c2-4a35-a1a3-c7939738f904" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_6e1373ec-a52d-4fad-bda7-1c1d7faa74ab" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_58ff356b-d0c2-4a35-a1a3-c7939738f904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b9399b25-64f3-4c5b-9fd2-77156d34f1bc" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9d2152ad-306f-44eb-ae1a-9ef8d3958001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9d2152ad-306f-44eb-ae1a-9ef8d3958001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_efe2825e-7489-4055-8110-723ec0734dde" xlink:href="ino-20221231.xsd#ino_DebtInstrumentConvertibleDebtConvertedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_ino_DebtInstrumentConvertibleDebtConvertedAmount_efe2825e-7489-4055-8110-723ec0734dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_88d6e68a-ac5e-4825-85d8-2ee62eb25b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_88d6e68a-ac5e-4825-85d8-2ee62eb25b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DebtinstrumentAccruedInterest_d73b91db-5e0c-415c-b4a2-7ed38b88ea7a" xlink:href="ino-20221231.xsd#ino_DebtinstrumentAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_ino_DebtinstrumentAccruedInterest_d73b91db-5e0c-415c-b4a2-7ed38b88ea7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_1dbd765d-cb97-427c-8438-78cc090d0b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4776e8a2-0716-4a7d-ab89-b94d1087c663" xlink:to="loc_us-gaap_LongTermDebt_1dbd765d-cb97-427c-8438-78cc090d0b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#ConvertibleDebtScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_134dd3b1-dcec-49ba-af73-138b6e504b61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_134dd3b1-dcec-49ba-af73-138b6e504b61" xlink:to="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f7925fdf-a4dd-4ccc-b10c-53e191e490ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a69d781d-c5d6-4fdb-a349-cdaa32cd64ea" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f7925fdf-a4dd-4ccc-b10c-53e191e490ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_47590a14-6b27-41bd-b7b6-bed0ca68291e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f7925fdf-a4dd-4ccc-b10c-53e191e490ac" xlink:to="loc_us-gaap_ConvertibleDebtMember_47590a14-6b27-41bd-b7b6-bed0ca68291e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:to="loc_us-gaap_DebtInstrumentAxis_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9cdbd1f7-559b-4b79-80bd-a3876524ea9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2a6b18fc-fa3d-4a2c-b7e7-dab0baad4775" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9cdbd1f7-559b-4b79-80bd-a3876524ea9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4b6fa0de-5e34-4589-85a4-254df53dfc27" xlink:href="ino-20221231.xsd#ino_A6.50ConvertibleSeniorNotesDue2024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9cdbd1f7-559b-4b79-80bd-a3876524ea9e" xlink:to="loc_ino_A6.50ConvertibleSeniorNotesDue2024Member_4b6fa0de-5e34-4589-85a4-254df53dfc27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5d1c2a75-2326-4cdf-9d1f-25305aba86f2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc09090d-2659-490f-9778-9a218a7e66bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_dc09090d-2659-490f-9778-9a218a7e66bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d5a59bc-cfcd-4dd5-85f9-63c2f4c27619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d5a59bc-cfcd-4dd5-85f9-63c2f4c27619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3b6ec686-3f53-4e2e-ba61-aefac7d54baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3b6ec686-3f53-4e2e-ba61-aefac7d54baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ff76e984-7452-4f23-adbb-534d8b119da0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_cb613d94-5e55-4e39-9ecb-d8512c94663c" xlink:to="loc_us-gaap_LongTermDebt_ff76e984-7452-4f23-adbb-534d8b119da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0c1c434c-9ade-4546-a5ff-051c28c0fc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6f2eec88-ece9-4d76-b7e3-30c538e5116c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0c1c434c-9ade-4546-a5ff-051c28c0fc00" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6f2eec88-ece9-4d76-b7e3-30c538e5116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ce35c62a-45de-4eb5-aa54-bf9e83430ccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f2eec88-ece9-4d76-b7e3-30c538e5116c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ce35c62a-45de-4eb5-aa54-bf9e83430ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5ddfce05-b649-49eb-b937-1f9217b720a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ce35c62a-45de-4eb5-aa54-bf9e83430ccd" xlink:to="loc_us-gaap_ClassOfStockDomain_5ddfce05-b649-49eb-b937-1f9217b720a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_415b731a-c307-4246-82f5-939dfda78178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5ddfce05-b649-49eb-b937-1f9217b720a3" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_415b731a-c307-4246-82f5-939dfda78178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_00e43ce7-9e62-482b-bb89-15a6f0d5f2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6f2eec88-ece9-4d76-b7e3-30c538e5116c" xlink:to="loc_us-gaap_ClassOfStockLineItems_00e43ce7-9e62-482b-bb89-15a6f0d5f2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_00e43ce7-9e62-482b-bb89-15a6f0d5f2de" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7746b8e6-0a65-4617-97ae-f844ca789517" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_7746b8e6-0a65-4617-97ae-f844ca789517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4084ce16-d739-4031-ac9b-8fb094500de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4084ce16-d739-4031-ac9b-8fb094500de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_ad63348f-1d08-46f0-868b-7a37305a98b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockSharesIssued_ad63348f-1d08-46f0-868b-7a37305a98b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7c78d68e-64a6-4948-8fef-f42cc109c4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_62821451-7030-4cc3-b1c3-10e8c16bff31" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7c78d68e-64a6-4948-8fef-f42cc109c4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_1a7193ab-e256-40b4-9833-1057b808283d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_1a7193ab-e256-40b4-9833-1057b808283d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_78722e82-f94f-42f4-aef3-9f3dbb6b339c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_78722e82-f94f-42f4-aef3-9f3dbb6b339c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_78722e82-f94f-42f4-aef3-9f3dbb6b339c" xlink:to="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_1199c839-8ef4-4ec1-b71a-5bab79726dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_1199c839-8ef4-4ec1-b71a-5bab79726dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_16b200a3-5e81-4cbc-8634-51f3c39772fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1fdcf333-eda9-4020-a8f1-c4e4dd85592c" xlink:to="loc_us-gaap_CommonStockMember_16b200a3-5e81-4cbc-8634-51f3c39772fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_326581c2-88cc-4ca6-a427-bdb9da0789c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_326581c2-88cc-4ca6-a427-bdb9da0789c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_62b8cdeb-1bdc-4bd1-b190-a381a80200ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_326581c2-88cc-4ca6-a427-bdb9da0789c6" xlink:to="loc_us-gaap_EquityComponentDomain_62b8cdeb-1bdc-4bd1-b190-a381a80200ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5dc85c64-e0dd-4314-8e61-74745f44233b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_62b8cdeb-1bdc-4bd1-b190-a381a80200ff" xlink:to="loc_us-gaap_CommonStockMember_5dc85c64-e0dd-4314-8e61-74745f44233b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_974e777b-a4c2-4700-85fd-78fa4f259f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_974e777b-a4c2-4700-85fd-78fa4f259f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_974e777b-a4c2-4700-85fd-78fa4f259f26" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SalesAgreementMember_ac186ddf-82c1-47f5-8e63-ff40e6969769" xlink:href="ino-20221231.xsd#ino_SalesAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:to="loc_ino_SalesAgreementMember_ac186ddf-82c1-47f5-8e63-ff40e6969769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnderwrittenPublicOfferingMember_1b5f89f4-55be-4eea-8377-5291a7855a15" xlink:href="ino-20221231.xsd#ino_UnderwrittenPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7ac68ce2-2d6e-4a39-86cc-dc7d80e26528" xlink:to="loc_ino_UnderwrittenPublicOfferingMember_1b5f89f4-55be-4eea-8377-5291a7855a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_02a323d1-245b-4319-ab55-0eca40ed16f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_PlanNameAxis_02a323d1-245b-4319-ab55-0eca40ed16f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_02a323d1-245b-4319-ab55-0eca40ed16f1" xlink:to="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2016IncentivePlanMember_6d576965-a3c2-4fd0-9be0-fb4e2cca6a5e" xlink:href="ino-20221231.xsd#ino_A2016IncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:to="loc_ino_A2016IncentivePlanMember_6d576965-a3c2-4fd0-9be0-fb4e2cca6a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2007IncentivePlanMember_a2df4543-64eb-45fb-830b-6a6f2f247d80" xlink:href="ino-20221231.xsd#ino_A2007IncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:to="loc_ino_A2007IncentivePlanMember_a2df4543-64eb-45fb-830b-6a6f2f247d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_A2022InducementPlanMember_3448efdd-22c6-4b1f-afde-e81225a4a431" xlink:href="ino-20221231.xsd#ino_A2022InducementPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_639dee8f-787d-42ef-849e-9551cad974ba" xlink:to="loc_ino_A2022InducementPlanMember_3448efdd-22c6-4b1f-afde-e81225a4a431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e013fbf7-9cd1-45e7-b845-dbbc23e92323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e013fbf7-9cd1-45e7-b845-dbbc23e92323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e013fbf7-9cd1-45e7-b845-dbbc23e92323" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7436a30d-dac2-4695-be49-2b641a47956e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7436a30d-dac2-4695-be49-2b641a47956e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_142898ad-e08a-47ae-8e29-77e618f09b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5fa8ec97-518e-4151-bca8-0a638fafd3c7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_142898ad-e08a-47ae-8e29-77e618f09b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_AwardTypeAxis_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_350b54b1-5288-40e8-8f90-0b5b15dfe6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1a9f8504-e1b5-4e5c-8eff-ea507e9969b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_350b54b1-5288-40e8-8f90-0b5b15dfe6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c35aeb8b-9ac7-489e-9a69-a42ea0c53014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_350b54b1-5288-40e8-8f90-0b5b15dfe6ef" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c35aeb8b-9ac7-489e-9a69-a42ea0c53014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e08429a5-e7fa-4ee8-9029-116ab4519dc7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_srt_TitleOfIndividualAxis_e08429a5-e7fa-4ee8-9029-116ab4519dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20bee0c0-4f4d-476b-9b0d-1aba6659a77d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e08429a5-e7fa-4ee8-9029-116ab4519dc7" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20bee0c0-4f4d-476b-9b0d-1aba6659a77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_c9e10649-7b46-44d2-80ff-ae0be5f0fd67" xlink:href="ino-20221231.xsd#ino_FormerPresidentAndChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_20bee0c0-4f4d-476b-9b0d-1aba6659a77d" xlink:to="loc_ino_FormerPresidentAndChiefExecutiveOfficerMember_c9e10649-7b46-44d2-80ff-ae0be5f0fd67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_4a74a649-b147-4c12-ab5b-95654e4a4967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_GranteeStatusAxis_4a74a649-b147-4c12-ab5b-95654e4a4967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_d4fbf894-0b9a-4802-8025-56490eaf8b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_4a74a649-b147-4c12-ab5b-95654e4a4967" xlink:to="loc_us-gaap_GranteeStatusDomain_d4fbf894-0b9a-4802-8025-56490eaf8b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_047c4059-32de-4674-89d9-2b0134bfacf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_d4fbf894-0b9a-4802-8025-56490eaf8b87" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_047c4059-32de-4674-89d9-2b0134bfacf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_990aba16-089d-424d-8f1c-db8ea71aa0e5" xlink:to="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_53ff32fe-cdd3-41fb-9fa0-9028c1b57ccb" xlink:href="ino-20221231.xsd#ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare_53ff32fe-cdd3-41fb-9fa0-9028c1b57ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6f141ce7-b86f-42c9-96c9-7af06d51490e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_6f141ce7-b86f-42c9-96c9-7af06d51490e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_6d5d9d6b-612d-4bab-a379-57fcb8103e0b" xlink:href="ino-20221231.xsd#ino_StockSalesAgreementMaximumAuthorizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSalesAgreementMaximumAuthorizedAmount_6d5d9d6b-612d-4bab-a379-57fcb8103e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_2f51e232-0ea3-47e6-a41c-a6ad80d2012f" xlink:href="ino-20221231.xsd#ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage_2f51e232-0ea3-47e6-a41c-a6ad80d2012f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_305a0231-e139-42f5-8eef-b64b3908150c" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementAggregateNumberofSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSaleAgreementAggregateNumberofSharesIssued_305a0231-e139-42f5-8eef-b64b3908150c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_620686a1-b015-464e-b368-38551a6fd4a7" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementWeightedAveragePricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSaleAgreementWeightedAveragePricePerShare_620686a1-b015-464e-b368-38551a6fd4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e2b01341-8539-47e5-b092-bda6778863c3" xlink:href="ino-20221231.xsd#ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock_e2b01341-8539-47e5-b092-bda6778863c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_e65ee18b-e150-427e-b9a0-1bbc78ecfcc0" xlink:href="ino-20221231.xsd#ino_StockSalesAgreementRemainingAuthorizedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_StockSalesAgreementRemainingAuthorizedAmount_e65ee18b-e150-427e-b9a0-1bbc78ecfcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6fa71edd-0b2c-4fc9-8430-1b85658234f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6fa71edd-0b2c-4fc9-8430-1b85658234f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_471b535f-439c-439c-b45a-cb7e3ab429c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_471b535f-439c-439c-b45a-cb7e3ab429c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7cd76f70-da36-445d-a586-0d80bc42019f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_7cd76f70-da36-445d-a586-0d80bc42019f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1556636a-5c42-432c-b292-966db1cc0d06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1556636a-5c42-432c-b292-966db1cc0d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_bc4b84f7-6a50-4ead-994f-a0c85292097e" xlink:href="ino-20221231.xsd#ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan_bc4b84f7-6a50-4ead-994f-a0c85292097e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7ab5259e-5a80-4e4b-ac3a-ee3c265606e3" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized_7ab5259e-5a80-4e4b-ac3a-ee3c265606e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_850d7bc6-7a26-4e2d-bbf0-48bc10df3380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_850d7bc6-7a26-4e2d-bbf0-48bc10df3380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c6a49d73-bb38-4803-a32d-5cbe4dd24566" xlink:href="ino-20221231.xsd#ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan_c6a49d73-bb38-4803-a32d-5cbe4dd24566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_0aa1c222-0a67-4e7c-b75b-db4d4f533572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_0aa1c222-0a67-4e7c-b75b-db4d4f533572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e5452f3-d1a2-48bc-a64c-8c78a78c6d47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e5452f3-d1a2-48bc-a64c-8c78a78c6d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7dd76dbe-3104-46a4-83fe-8c94b7b84aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7dd76dbe-3104-46a4-83fe-8c94b7b84aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_6e6cbca7-e116-41e8-a516-11ceec329495" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm_6e6cbca7-e116-41e8-a516-11ceec329495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2e9834-cbae-43e3-be89-0bba824bce3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bf2e9834-cbae-43e3-be89-0bba824bce3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_1f64a064-db31-4d73-9f0c-d42fb4fcf7a1" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash_1f64a064-db31-4d73-9f0c-d42fb4fcf7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f3786d-1eae-42c0-b0cc-445bc3129fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3f3786d-1eae-42c0-b0cc-445bc3129fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_404d0ea3-e9b6-40fa-a9f7-9aaa31ff2c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_404d0ea3-e9b6-40fa-a9f7-9aaa31ff2c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79529327-71a6-4222-bcbd-2b0cc0ef6da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_79529327-71a6-4222-bcbd-2b0cc0ef6da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_57ab4401-f5ff-4298-8505-93b59318d48c" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue_57ab4401-f5ff-4298-8505-93b59318d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ebe7f1f0-0f27-43f7-bdf7-d383b0ad4473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_ebe7f1f0-0f27-43f7-bdf7-d383b0ad4473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_3dab29fe-6297-4835-855e-677738ba7158" xlink:href="ino-20221231.xsd#ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm_3dab29fe-6297-4835-855e-677738ba7158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c244a63d-c877-4d9b-9914-8ca35900decf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_c244a63d-c877-4d9b-9914-8ca35900decf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_3a3c3a85-3b80-4d81-b027-a3b24d7006ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_3a3c3a85-3b80-4d81-b027-a3b24d7006ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_cccf3b22-3f3e-473b-924e-8b618ce83654" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber_cccf3b22-3f3e-473b-924e-8b618ce83654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_c308a7fa-c67e-45d7-be40-52496d661139" xlink:href="ino-20221231.xsd#ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber_c308a7fa-c67e-45d7-be40-52496d661139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_660de18c-350a-4aa2-a635-6ee5c9dd263d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_660de18c-350a-4aa2-a635-6ee5c9dd263d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cf268609-d296-4025-aad5-99b451301c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cf268609-d296-4025-aad5-99b451301c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c00aa15-4a74-4c5f-af1d-6dc59373be0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8c00aa15-4a74-4c5f-af1d-6dc59373be0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ee67cde-b8aa-46ca-9c76-d222d2705cce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0ee67cde-b8aa-46ca-9c76-d222d2705cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_deb823e9-ace7-4d23-a963-e101018dbdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_deb823e9-ace7-4d23-a963-e101018dbdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ba5bcfb-8788-4610-9460-bad0dcf37872" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1ba5bcfb-8788-4610-9460-bad0dcf37872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9230df1b-a3dc-4053-bceb-c73fb414a515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9230df1b-a3dc-4053-bceb-c73fb414a515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a9ead3ce-1b61-423c-b080-1739ea99c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a9ead3ce-1b61-423c-b080-1739ea99c4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e97ba118-75d2-4060-94f3-99199cbe1f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6cd1aed2-9515-440b-ab54-bc8c46caffe3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_e97ba118-75d2-4060-94f3-99199cbe1f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquitySummaryofStockOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b8f6b670-f272-4a60-a396-031694707897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9fc87bcc-c44a-4ba7-b52f-339c6615bb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b8f6b670-f272-4a60-a396-031694707897" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9fc87bcc-c44a-4ba7-b52f-339c6615bb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9fc87bcc-c44a-4ba7-b52f-339c6615bb02" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_f6fe2a3a-3d20-4319-930c-5f0434d6cd9a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesOneMember_0514fb10-1940-4a48-a546-fc840eeacd2d" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesOneMember_0514fb10-1940-4a48-a546-fc840eeacd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesTwoMember_7ebd8348-dba8-4fe9-bb2f-81a5e90ca045" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesTwoMember_7ebd8348-dba8-4fe9-bb2f-81a5e90ca045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesThreeMember_59d20439-e45d-4ac8-bc32-0d7fc1b220d1" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesThreeMember_59d20439-e45d-4ac8-bc32-0d7fc1b220d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFourMember_b81b643b-afd2-4214-844d-269a750bc7d3" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesFourMember_b81b643b-afd2-4214-844d-269a750bc7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesFiveMember_b52129c1-c27a-4d9d-9f35-d25c9a4c40b6" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesFiveMember_b52129c1-c27a-4d9d-9f35-d25c9a4c40b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RangeOfExercisePricesSixMember_5f300e86-a4c1-494a-bd5c-462a6d32811d" xlink:href="ino-20221231.xsd#ino_RangeOfExercisePricesSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_85553fbf-3aa4-41a6-b56a-45b64145a91e" xlink:to="loc_ino_RangeOfExercisePricesSixMember_5f300e86-a4c1-494a-bd5c-462a6d32811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9fc87bcc-c44a-4ba7-b52f-339c6615bb02" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_3e3ea888-8f08-45db-9add-4fe25461516e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_3e3ea888-8f08-45db-9add-4fe25461516e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e7fb35ef-9124-408a-a216-e876416d1795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_e7fb35ef-9124-408a-a216-e876416d1795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9d207bda-0389-4029-b518-bdd9caf64ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_9d207bda-0389-4029-b518-bdd9caf64ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_99068b29-e245-4d0e-aee9-0ac0f3e5b187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_99068b29-e245-4d0e-aee9-0ac0f3e5b187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7b52ec07-cc0c-4ad2-92db-7393f7945137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_7b52ec07-cc0c-4ad2-92db-7393f7945137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1a55257c-44b7-405a-97a5-e8bff03a853a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_1a55257c-44b7-405a-97a5-e8bff03a853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8acc55db-53e9-4545-8d28-db610ecf406a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_3cf84a0c-2aea-4c3f-b53c-4401b56f703a" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8acc55db-53e9-4545-8d28-db610ecf406a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_abbb7eaf-5580-4fc0-b2bb-2de1e726cba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a68880-7477-4dd0-b99e-eee82d854271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_abbb7eaf-5580-4fc0-b2bb-2de1e726cba9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a68880-7477-4dd0-b99e-eee82d854271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_511a3827-d34f-4e42-8ab1-697eeb4c4be6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a68880-7477-4dd0-b99e-eee82d854271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_511a3827-d34f-4e42-8ab1-697eeb4c4be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5ac4e3fa-d9a3-4531-ab1a-82e46bc4b000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a68880-7477-4dd0-b99e-eee82d854271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5ac4e3fa-d9a3-4531-ab1a-82e46bc4b000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5227f200-9a8b-40c5-a9ab-a8a56764f39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a68880-7477-4dd0-b99e-eee82d854271" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5227f200-9a8b-40c5-a9ab-a8a56764f39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cc2cf430-ec12-4903-8f8e-ba3aa0bdba90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a68880-7477-4dd0-b99e-eee82d854271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_cc2cf430-ec12-4903-8f8e-ba3aa0bdba90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6527ee7-3615-4092-ba00-413502d08889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b0a68880-7477-4dd0-b99e-eee82d854271" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6527ee7-3615-4092-ba00-413502d08889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8667c8da-ece3-480c-a719-a7cb0f4c77fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_abbb7eaf-5580-4fc0-b2bb-2de1e726cba9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8667c8da-ece3-480c-a719-a7cb0f4c77fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50416c8b-a91d-45a6-81c7-1fb2c0baf58b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8667c8da-ece3-480c-a719-a7cb0f4c77fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_50416c8b-a91d-45a6-81c7-1fb2c0baf58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2595bd01-a0d1-4c0d-bc0b-c1bc3fd59d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8667c8da-ece3-480c-a719-a7cb0f4c77fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2595bd01-a0d1-4c0d-bc0b-c1bc3fd59d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e200263e-c8d3-4256-b4fd-469891b1ba16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8667c8da-ece3-480c-a719-a7cb0f4c77fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e200263e-c8d3-4256-b4fd-469891b1ba16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_927a4e67-50a1-4fb2-949c-9f4b2a19b9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8667c8da-ece3-480c-a719-a7cb0f4c77fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_927a4e67-50a1-4fb2-949c-9f4b2a19b9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76efda2b-8821-4eee-859b-ba4ad5b5a867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8667c8da-ece3-480c-a719-a7cb0f4c77fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_76efda2b-8821-4eee-859b-ba4ad5b5a867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0077faa0-1e70-4f5b-a708-9ccb6e322978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_287a9d34-7e58-493c-8075-5cdfbc29b85a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0077faa0-1e70-4f5b-a708-9ccb6e322978" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_287a9d34-7e58-493c-8075-5cdfbc29b85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_792c46d4-682f-4682-b97d-79711fa230a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_287a9d34-7e58-493c-8075-5cdfbc29b85a" xlink:to="loc_us-gaap_AwardTypeAxis_792c46d4-682f-4682-b97d-79711fa230a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3205d7cb-4a79-475b-ba10-06c1d0d56904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_792c46d4-682f-4682-b97d-79711fa230a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3205d7cb-4a79-475b-ba10-06c1d0d56904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b50c1be6-965e-4297-8f11-68f4a56d7577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3205d7cb-4a79-475b-ba10-06c1d0d56904" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b50c1be6-965e-4297-8f11-68f4a56d7577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5143aeba-e5ff-40c6-8d3d-021d812edce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_287a9d34-7e58-493c-8075-5cdfbc29b85a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5143aeba-e5ff-40c6-8d3d-021d812edce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5143aeba-e5ff-40c6-8d3d-021d812edce0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3300dc74-db4e-46f6-91f3-08f90daf8f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3300dc74-db4e-46f6-91f3-08f90daf8f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92c70535-2f87-4af4-be45-61f5dbdefb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_92c70535-2f87-4af4-be45-61f5dbdefb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_72dee287-75fc-4b7b-9c46-385aaec20043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_72dee287-75fc-4b7b-9c46-385aaec20043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8fb6f280-98e0-44db-9777-d5b9aa306489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8fb6f280-98e0-44db-9777-d5b9aa306489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a943b2c-5283-4760-8bd3-057e0bf7b31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d7d8b760-9c01-404f-aaf3-f64d62bca80b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a943b2c-5283-4760-8bd3-057e0bf7b31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a151b2ff-5c23-4b53-a77b-ace8b065a0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a151b2ff-5c23-4b53-a77b-ace8b065a0ae" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b21d1c0-90e8-49d7-a2b8-db47f2d09218" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b21d1c0-90e8-49d7-a2b8-db47f2d09218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5b21d1c0-90e8-49d7-a2b8-db47f2d09218" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SanDiegoCaliforniaMember_571dadc4-54fd-4135-9f71-decdb1a8dcd5" xlink:href="ino-20221231.xsd#ino_SanDiegoCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:to="loc_ino_SanDiegoCaliforniaMember_571dadc4-54fd-4135-9f71-decdb1a8dcd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlymouthMeetingPennsylvaniaMember_59e07091-c0ba-447d-b21c-4ed85e4ca101" xlink:href="ino-20221231.xsd#ino_PlymouthMeetingPennsylvaniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cbd554fa-b623-4486-96f3-2fffd3718a7b" xlink:to="loc_ino_PlymouthMeetingPennsylvaniaMember_59e07091-c0ba-447d-b21c-4ed85e4ca101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_187257b4-1f9e-4240-80da-9586244e89aa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:to="loc_srt_RangeAxis_187257b4-1f9e-4240-80da-9586244e89aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_187257b4-1f9e-4240-80da-9586244e89aa" xlink:to="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_eb4e991f-d49b-42a9-9c5d-769ba5147c54" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:to="loc_srt_MinimumMember_eb4e991f-d49b-42a9-9c5d-769ba5147c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4c9082ca-e881-4244-852c-f4a896220117" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f991abc5-9223-4834-9ac8-b93ab2e8b0a4" xlink:to="loc_srt_MaximumMember_4c9082ca-e881-4244-852c-f4a896220117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9148390c-4062-4ff9-98ab-e54309e551ad" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:to="loc_srt_LitigationCaseAxis_9148390c-4062-4ff9-98ab-e54309e551ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_e4fb3933-ee0a-494c-8120-1baf95bf8d4c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9148390c-4062-4ff9-98ab-e54309e551ad" xlink:to="loc_srt_LitigationCaseTypeDomain_e4fb3933-ee0a-494c-8120-1baf95bf8d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_8cc7759f-7c87-4920-9ebe-97e83af8be45" xlink:href="ino-20221231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_e4fb3933-ee0a-494c-8120-1baf95bf8d4c" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_8cc7759f-7c87-4920-9ebe-97e83af8be45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_3766ed36-126a-45a7-baf3-d83df31e6fec" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_7a91dbf8-c53f-4f8e-8d38-1c35f64c73c3" xlink:href="ino-20221231.xsd#ino_LesseeOperatingLeaseAreaofLandUnderLease"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_ino_LesseeOperatingLeaseAreaofLandUnderLease_7a91dbf8-c53f-4f8e-8d38-1c35f64c73c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_738d6f9f-e313-4cb2-a4de-f1751161f8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_738d6f9f-e313-4cb2-a4de-f1751161f8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_c3833864-10d0-4113-84cc-885adbc7eee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_us-gaap_LeaseCost_c3833864-10d0-4113-84cc-885adbc7eee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_ef16b5cb-4025-4149-ad44-734eedcfdfe8" xlink:href="ino-20221231.xsd#ino_LesseeNumberOfLeaseAgreementsEnteredInto"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_ino_LesseeNumberOfLeaseAgreementsEnteredInto_ef16b5cb-4025-4149-ad44-734eedcfdfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_08c2c33c-0959-4af6-a2a7-59891892b154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_08c2c33c-0959-4af6-a2a7-59891892b154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_41ab7359-8c73-4846-86e7-6353ee398c7b" xlink:href="ino-20221231.xsd#ino_LossContingencyEstimateOfPossibleLossValueOfShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_17247fe7-6dbc-4d7c-afa5-4c5ef1cc28ec" xlink:to="loc_ino_LossContingencyEstimateOfPossibleLossValueOfShares_41ab7359-8c73-4846-86e7-6353ee398c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_fa88d4c0-4904-4a3f-b187-66c873cff948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_fa88d4c0-4904-4a3f-b187-66c873cff948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_705fb948-2563-4c45-82a3-7df272aa2970" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_705fb948-2563-4c45-82a3-7df272aa2970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5483e712-7345-4850-a29d-37c7272b6ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5483e712-7345-4850-a29d-37c7272b6ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d305425d-c2c6-475d-a2b3-9ce7749baec4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d305425d-c2c6-475d-a2b3-9ce7749baec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_12cd459d-c468-4b94-b281-6b8b86733280" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_12cd459d-c468-4b94-b281-6b8b86733280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cda5778b-0fef-4bbd-bce9-e4c04110cd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cda5778b-0fef-4bbd-bce9-e4c04110cd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10de79a3-023b-45eb-a31c-bcdf1a1b5b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_10de79a3-023b-45eb-a31c-bcdf1a1b5b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ed819f8d-57aa-4f2c-aab7-7585b7ea8bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ed819f8d-57aa-4f2c-aab7-7585b7ea8bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f29f5ada-b239-4222-a374-6a787c49e6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_OperatingLeaseLiability_f29f5ada-b239-4222-a374-6a787c49e6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2fc25b1-54b8-4431-b443-b4ab738df98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e2fc25b1-54b8-4431-b443-b4ab738df98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9207bd4c-aabf-4e01-bee6-35a10b212fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9207bd4c-aabf-4e01-bee6-35a10b212fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b9665589-56c4-438e-99b4-1f150f317cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b9665589-56c4-438e-99b4-1f150f317cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78e655e2-4850-43fb-a0d5-1c877b08a825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a41e2f80-58b7-4e92-9126-fd3165095252" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_78e655e2-4850-43fb-a0d5-1c877b08a825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ino-20221231.xsd#CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesComponentsofPretaxLossfromOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a315984e-66a5-463c-b7b0-399aebda5417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b928da48-eda4-476b-98fc-213b4e7c63db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a315984e-66a5-463c-b7b0-399aebda5417" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b928da48-eda4-476b-98fc-213b4e7c63db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_09f40b55-1d4b-4518-85af-10d6aec20a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a315984e-66a5-463c-b7b0-399aebda5417" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_09f40b55-1d4b-4518-85af-10d6aec20a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_207a27e6-2827-4343-b16b-6dd7337f0b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a315984e-66a5-463c-b7b0-399aebda5417" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_207a27e6-2827-4343-b16b-6dd7337f0b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesReconciliationofIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_bae04c8a-caf4-49f5-8dc0-3da83269bf94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_bae04c8a-caf4-49f5-8dc0-3da83269bf94" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_34c6b563-bdc5-4de9-a14d-9926091929ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_34c6b563-bdc5-4de9-a14d-9926091929ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c4b16883-0788-4d46-a7d2-669ac1a2e439" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c4b16883-0788-4d46-a7d2-669ac1a2e439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0b51c2fc-9152-4c45-abee-f5f2630d8905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_0b51c2fc-9152-4c45-abee-f5f2630d8905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_32c351d9-a051-4ff2-979f-86d4cf65564f" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt_32c351d9-a051-4ff2-979f-86d4cf65564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeTaxReconciliationStatuteLimitations_5df07acb-1d42-4bf0-a8e4-77e7646c3383" xlink:href="ino-20221231.xsd#ino_IncomeTaxReconciliationStatuteLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_ino_IncomeTaxReconciliationStatuteLimitations_5df07acb-1d42-4bf0-a8e4-77e7646c3383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_528eabd7-eac9-4107-9a9f-fad96db4cbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_528eabd7-eac9-4107-9a9f-fad96db4cbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_63c4f2e3-8f8e-431b-b0de-d8fee156a5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_63c4f2e3-8f8e-431b-b0de-d8fee156a5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_e3986491-ea40-40ab-8639-4e03d46f5d42" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary_e3986491-ea40-40ab-8639-4e03d46f5d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_6ac67b96-ff93-4a21-8a8f-3361d41cef6a" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits_6ac67b96-ff93-4a21-8a8f-3361d41cef6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_541ac290-1463-4be1-8b9a-5930fb102aa0" xlink:href="ino-20221231.xsd#ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits_541ac290-1463-4be1-8b9a-5930fb102aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_87c2938f-e4db-4d11-90f7-7282c3e18d98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_87c2938f-e4db-4d11-90f7-7282c3e18d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8b566321-3b1b-4cd0-b934-f56ff47bd437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8b566321-3b1b-4cd0-b934-f56ff47bd437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_22146a89-cd3e-4b12-9c3b-c4c9cd8e7b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_22146a89-cd3e-4b12-9c3b-c4c9cd8e7b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_f321d2b1-25a9-49bc-a308-2f4d373bcd58" xlink:href="ino-20221231.xsd#ino_ComprehensiveIncomeLossTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_54ba1eea-4c3d-4190-80df-cd65c73ba6b3" xlink:to="loc_ino_ComprehensiveIncomeLossTaxExpenseBenefit_f321d2b1-25a9-49bc-a308-2f4d373bcd58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1aa23645-1b6a-4f95-bba3-1daa7692da8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1aa23645-1b6a-4f95-bba3-1daa7692da8e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_b70a393f-5be7-48c0-bb1b-3ca02609d8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_b70a393f-5be7-48c0-bb1b-3ca02609d8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_b70a393f-5be7-48c0-bb1b-3ca02609d8ee" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6c57716f-5741-4571-9844-ef330ddd5fff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6c57716f-5741-4571-9844-ef330ddd5fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CaliforniaIncomeTaxAuthorityMember_7d6b0997-ad02-41f1-af10-af161cb56301" xlink:href="ino-20221231.xsd#ino_CaliforniaIncomeTaxAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_ino_CaliforniaIncomeTaxAuthorityMember_7d6b0997-ad02-41f1-af10-af161cb56301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_f9c7794f-acc8-4f85-bc57-033354253fcd" xlink:href="ino-20221231.xsd#ino_PennsylvaniaStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_ino_PennsylvaniaStateIncomeTaxAuthorityMember_f9c7794f-acc8-4f85-bc57-033354253fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_516a7ad9-7659-45d1-aaf6-78cd6c16c6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_516a7ad9-7659-45d1-aaf6-78cd6c16c6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_KoreanStateIncomeTaxAuthorityMember_69eb5ea4-ab93-49ed-a875-38c0d870dd47" xlink:href="ino-20221231.xsd#ino_KoreanStateIncomeTaxAuthorityMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_b0d35cba-7161-478c-8877-1ae3747b5d09" xlink:to="loc_ino_KoreanStateIncomeTaxAuthorityMember_69eb5ea4-ab93-49ed-a875-38c0d870dd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_36b717d3-87ee-44be-9aa0-0cb2828625f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_36b717d3-87ee-44be-9aa0-0cb2828625f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_75852764-d4a6-43da-b952-a5215068c228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_36b717d3-87ee-44be-9aa0-0cb2828625f6" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_75852764-d4a6-43da-b952-a5215068c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_fdf6000d-d381-4e51-83c0-b0018c846eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_75852764-d4a6-43da-b952-a5215068c228" xlink:to="loc_us-gaap_ResearchMember_fdf6000d-d381-4e51-83c0-b0018c846eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_cf756e49-d2d4-4c6b-9d05-c41da6ed7a54" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3033ceb1-0c86-4e47-9815-629af83689b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3033ceb1-0c86-4e47-9815-629af83689b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_f8dc03d5-4625-406f-a031-223d9683f056" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet_f8dc03d5-4625-406f-a031-223d9683f056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_50e06fe4-cee6-4dd4-ad2c-e8e6637fb123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_OperatingLossCarryforwards_50e06fe4-cee6-4dd4-ad2c-e8e6637fb123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_921a8bc9-e4d4-46b3-bcce-65fce44cd794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_921a8bc9-e4d4-46b3-bcce-65fce44cd794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxBenefitsExpired_9c9fba4b-405a-4035-9dc3-dd2a2b68223d" xlink:href="ino-20221231.xsd#ino_TaxBenefitsExpired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_ino_TaxBenefitsExpired_9c9fba4b-405a-4035-9dc3-dd2a2b68223d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3bd90d3b-8140-4778-bb16-f1129ebd285a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_b3201555-119b-4888-9334-5c47fe68556d" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_3bd90d3b-8140-4778-bb16-f1129ebd285a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6a48eb18-bfb1-4748-8c34-a5ac979582ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a48eb18-bfb1-4748-8c34-a5ac979582ab" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b0257dab-9cc2-4a43-80c2-39950cce6be5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b0257dab-9cc2-4a43-80c2-39950cce6be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d0460e86-1c13-448c-b0b9-7c4dc907ceef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_d0460e86-1c13-448c-b0b9-7c4dc907ceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_98d5255e-0a1b-42b9-bfdb-4061944ebc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_98d5255e-0a1b-42b9-bfdb-4061944ebc39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_fc1d1732-71b0-4039-b015-4f09ee03a1cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_fc1d1732-71b0-4039-b015-4f09ee03a1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f3ad03da-9bbb-4c15-9996-a1a6254d6830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f3ad03da-9bbb-4c15-9996-a1a6254d6830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsIntangibleAssets_7af5ed24-ef0a-40b5-952c-f1abe3cc8867" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetsIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_ino_DeferredTaxAssetsIntangibleAssets_7af5ed24-ef0a-40b5-952c-f1abe3cc8867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetInterestExpense_6c5fe893-447b-4cc3-a5f3-27734bf47d03" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetInterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_ino_DeferredTaxAssetInterestExpense_6c5fe893-447b-4cc3-a5f3-27734bf47d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInvestments_ef07b88d-c1a8-4dd4-87e3-338c80657c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsInvestments_ef07b88d-c1a8-4dd4-87e3-338c80657c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_2105904d-04f9-44fc-9144-5fecd7413e1b" xlink:href="ino-20221231.xsd#ino_DeferredTaxAssetsOperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_ino_DeferredTaxAssetsOperatingLeaseLiability_2105904d-04f9-44fc-9144-5fecd7413e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_9cfe92c7-df0e-431d-ac3c-1f37f5730df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_9cfe92c7-df0e-431d-ac3c-1f37f5730df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0e261ea2-3c52-499b-9070-3623bd96f238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0e261ea2-3c52-499b-9070-3623bd96f238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7d6344b3-668a-4d52-8f19-0f6445454701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7d6344b3-668a-4d52-8f19-0f6445454701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9de08f6c-69b8-4588-8c22-40bc2cc33e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9de08f6c-69b8-4588-8c22-40bc2cc33e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_a0a26275-e8bc-41b3-8bf5-86bce7a0d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_3c976303-579f-48f2-9688-2c016c7df874" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_a0a26275-e8bc-41b3-8bf5-86bce7a0d5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03002c5d-ef1d-4bf2-8e1f-a10082237894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a48eb18-bfb1-4748-8c34-a5ac979582ab" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03002c5d-ef1d-4bf2-8e1f-a10082237894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_608352a1-dafd-46dd-86b2-c7b575c580b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03002c5d-ef1d-4bf2-8e1f-a10082237894" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_608352a1-dafd-46dd-86b2-c7b575c580b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_cf1e2a82-84f7-4ec0-a7bb-10e4eb9da96e" xlink:href="ino-20221231.xsd#ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03002c5d-ef1d-4bf2-8e1f-a10082237894" xlink:to="loc_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset_cf1e2a82-84f7-4ec0-a7bb-10e4eb9da96e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_ecbe8747-edfc-49f9-a461-d0e5c93ed2b1" xlink:href="ino-20221231.xsd#ino_DeferredTaxLiabilitiesFinancingArrangementDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03002c5d-ef1d-4bf2-8e1f-a10082237894" xlink:to="loc_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount_ecbe8747-edfc-49f9-a461-d0e5c93ed2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0d92de6a-175f-45ca-a564-7d506bd7104b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03002c5d-ef1d-4bf2-8e1f-a10082237894" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0d92de6a-175f-45ca-a564-7d506bd7104b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ac36613f-967a-4daf-a4db-fd7edd28974c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_03002c5d-ef1d-4bf2-8e1f-a10082237894" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ac36613f-967a-4daf-a4db-fd7edd28974c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a2cd0378-3dca-42b7-9595-f24866819771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a48eb18-bfb1-4748-8c34-a5ac979582ab" xlink:to="loc_us-gaap_DeferredTaxLiabilities_a2cd0378-3dca-42b7-9595-f24866819771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a48c90f3-6b15-4c9b-8c04-c1be47ab5211" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a48c90f3-6b15-4c9b-8c04-c1be47ab5211" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_d718e140-6ef0-44fe-89fa-97f0cd711b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_d718e140-6ef0-44fe-89fa-97f0cd711b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_92dfe56a-8538-4c98-b388-87a16528a1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_d718e140-6ef0-44fe-89fa-97f0cd711b2d" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_92dfe56a-8538-4c98-b388-87a16528a1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_df622e7b-6de0-48ff-afae-10685f20d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_92dfe56a-8538-4c98-b388-87a16528a1d9" xlink:to="loc_us-gaap_ResearchMember_df622e7b-6de0-48ff-afae-10685f20d67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_e3ffd4d6-209c-4237-b8a4-bf747cd7ad73" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_134e6823-d258-4bc5-8eb1-b2ce4bb56c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:to="loc_us-gaap_DomesticCountryMember_134e6823-d258-4bc5-8eb1-b2ce4bb56c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_1ff73633-d0e8-4e3a-83aa-d642012c3568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_1ff73633-d0e8-4e3a-83aa-d642012c3568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_0e547683-f8cc-408b-9043-33f032ac2b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6d20c192-723b-49c0-81fa-f6268304fe3b" xlink:to="loc_us-gaap_ForeignCountryMember_0e547683-f8cc-408b-9043-33f032ac2b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8b74805a-9def-4724-8901-3038256b87e0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f14e2373-c728-4300-9cb9-eb6849cd0436" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinTwoYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinTwoYears_f14e2373-c728-4300-9cb9-eb6849cd0436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_80d565c6-9c2f-461a-88e5-368f4d4e8ca7" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinThreeYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinThreeYears_80d565c6-9c2f-461a-88e5-368f4d4e8ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_9cb80aff-1705-4d4f-b186-15b594aef3a1" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFourYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFourYears_9cb80aff-1705-4d4f-b186-15b594aef3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_78eea631-41a1-461e-a301-a3a751ffb02a" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringinFiveYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringinFiveYears_78eea631-41a1-461e-a301-a3a751ffb02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsExpiringInSixYears_c4788fd7-4e16-4d89-95f1-0513878a9fe4" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsExpiringInSixYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsExpiringInSixYears_c4788fd7-4e16-4d89-95f1-0513878a9fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_8ef140d9-a116-4029-b435-173ac0b5de41" xlink:href="ino-20221231.xsd#ino_OperatingLossCarryforwardsIndefinitelyCarryforward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_ino_OperatingLossCarryforwardsIndefinitelyCarryforward_8ef140d9-a116-4029-b435-173ac0b5de41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ab42fcda-04f4-412a-b991-78b7d23488b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract_0249d989-446a-4677-9a87-3a457c8e2eac" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ab42fcda-04f4-412a-b991-78b7d23488b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0ca3e19d-5de8-442a-b5ba-eedf6c2b1b51" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_988e2dfc-25ce-4f78-a8fe-3279303d63cd" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinTwoYears"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinTwoYears_988e2dfc-25ce-4f78-a8fe-3279303d63cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_c598b551-a73f-4cfb-a9a7-7d75d37f55a1" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInThreeYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInThreeYears_c598b551-a73f-4cfb-a9a7-7d75d37f55a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInFourYears_d7847f86-de4e-4f12-ae6b-5058347531b5" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInFourYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInFourYears_d7847f86-de4e-4f12-ae6b-5058347531b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_67078e32-b9d4-4644-abd3-cbe22d49f26a" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringinFiveYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringinFiveYears_67078e32-b9d4-4644-abd3-cbe22d49f26a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardExpiringInSixYears_321b3d56-d7c3-4b8b-90f9-396a49e5dc13" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardExpiringInSixYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardExpiringInSixYears_321b3d56-d7c3-4b8b-90f9-396a49e5dc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_b53ee7bd-e9db-4f42-85c5-861814469d4f" xlink:href="ino-20221231.xsd#ino_TaxCreditCarryforwardCarryforwardIndefinitely"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_ino_TaxCreditCarryforwardCarryforwardIndefinitely_b53ee7bd-e9db-4f42-85c5-861814469d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_d3a1dae1-5049-4660-a0f0-88651564f69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract_401f0130-1479-4155-8af4-85db362f8115" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_d3a1dae1-5049-4660-a0f0-88651564f69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cb0a0136-9582-464a-951e-2dea48ade7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cb0a0136-9582-464a-951e-2dea48ade7bd" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_705d8972-5456-4037-912c-e9bc37b0b0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_705d8972-5456-4037-912c-e9bc37b0b0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_acc64443-b769-44ca-8988-8c05928fc5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_acc64443-b769-44ca-8988-8c05928fc5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8005ee17-638e-49a2-aef7-abc7f4e8a76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_8005ee17-638e-49a2-aef7-abc7f4e8a76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3c785238-6f87-4238-abbc-f7ed5155e2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3c785238-6f87-4238-abbc-f7ed5155e2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_4d9422e9-5017-4348-968e-14220d430184" xlink:href="ino-20221231.xsd#ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:to="loc_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther_4d9422e9-5017-4348-968e-14220d430184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_711fe10b-ceef-4762-8dcc-b7c3cc653d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_22d82195-e8c0-452a-a75f-ff87443bf4dc" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_711fe10b-ceef-4762-8dcc-b7c3cc653d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/A401kPlanDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#A401kPlanDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/A401kPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fcaa2694-5fc6-4724-be2b-387653105207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_31b3578f-4965-4319-ab65-80ccd1d083a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fcaa2694-5fc6-4724-be2b-387653105207" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_31b3578f-4965-4319-ab65-80ccd1d083a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_dfd23475-eb79-4526-80b4-2b09ee43e2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fcaa2694-5fc6-4724-be2b-387653105207" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_dfd23475-eb79-4526-80b4-2b09ee43e2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_b3453fc6-9b0b-476e-96ea-4aa8105f1b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_fcaa2694-5fc6-4724-be2b-387653105207" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_b3453fc6-9b0b-476e-96ea-4aa8105f1b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_2a2f16c5-2560-4294-9ffc-5a8802bef225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract_2a2f16c5-2560-4294-9ffc-5a8802bef225" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8382a83-5610-4ff4-8b5d-9fa0a39978da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8382a83-5610-4ff4-8b5d-9fa0a39978da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b8382a83-5610-4ff4-8b5d-9fa0a39978da" xlink:to="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PLSaffiliatedentityMember_732ac260-596c-4df9-ba30-03dec73b768d" xlink:href="ino-20221231.xsd#ino_PLSaffiliatedentityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:to="loc_ino_PLSaffiliatedentityMember_732ac260-596c-4df9-ba30-03dec73b768d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_TheWistarInstituteMember_38bcbe6f-b272-4ba4-807c-38715471737e" xlink:href="ino-20221231.xsd#ino_TheWistarInstituteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:to="loc_ino_TheWistarInstituteMember_38bcbe6f-b272-4ba4-807c-38715471737e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_38f1d456-be76-468d-9d10-ce86143e5132" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_a2a56f0a-3d02-4521-acb4-4d0349ee8aec" xlink:to="loc_srt_DirectorMember_38f1d456-be76-468d-9d10-ce86143e5132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8cf2b87f-1a88-4419-b66d-1bbda24a96bf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_srt_CounterpartyNameAxis_8cf2b87f-1a88-4419-b66d-1bbda24a96bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa1165d9-2adc-464d-9822-c1e34fb4313d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8cf2b87f-1a88-4419-b66d-1bbda24a96bf" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa1165d9-2adc-464d-9822-c1e34fb4313d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_b76cfe8f-b30f-4fb8-a567-c70495d668bf" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa1165d9-2adc-464d-9822-c1e34fb4313d" xlink:to="loc_ino_PlumblineLifeSciencesMember_b76cfe8f-b30f-4fb8-a567-c70495d668bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_8a165111-4089-47e6-be26-67c2e07c43a9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_srt_TitleOfIndividualAxis_8a165111-4089-47e6-be26-67c2e07c43a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53c7df5-e922-4343-9160-bfea5e9d7e85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_8a165111-4089-47e6-be26-67c2e07c43a9" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53c7df5-e922-4343-9160-bfea5e9d7e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_87be1f81-3d28-4796-aa71-ce6a2d7e0097" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f53c7df5-e922-4343-9160-bfea5e9d7e85" xlink:to="loc_srt_DirectorMember_87be1f81-3d28-4796-aa71-ce6a2d7e0097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_3909196b-4a28-446e-9ab4-b75dad7e725a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_srt_OwnershipAxis_3909196b-4a28-446e-9ab4-b75dad7e725a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_344caa7e-c894-4e16-a0ba-2b4bc53ae1de" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_3909196b-4a28-446e-9ab4-b75dad7e725a" xlink:to="loc_srt_OwnershipDomain_344caa7e-c894-4e16-a0ba-2b4bc53ae1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_PlumblineLifeSciencesMember_6fe3b4ad-9d1d-4872-ab9f-3956e4e432ec" xlink:href="ino-20221231.xsd#ino_PlumblineLifeSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_344caa7e-c894-4e16-a0ba-2b4bc53ae1de" xlink:to="loc_ino_PlumblineLifeSciencesMember_6fe3b4ad-9d1d-4872-ab9f-3956e4e432ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bf727d2e-9646-4e66-a753-c4a4b62a60c7" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_bc3db352-9377-4387-a535-9d25d40cd757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_bc3db352-9377-4387-a535-9d25d40cd757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e77c12bc-9515-4c32-8fcb-c7f55e61711a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_e77c12bc-9515-4c32-8fcb-c7f55e61711a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_a47d023b-b000-498a-8316-a6b946dae656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_RevenueFromRelatedParties_a47d023b-b000-498a-8316-a6b946dae656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedParties_951ee439-f8e0-4115-8a38-4ac65ebef2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_AccountsReceivableRelatedParties_951ee439-f8e0-4115-8a38-4ac65ebef2f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementExpensesToReimburse_9b882fff-1c7c-42f5-a858-6e4763dff721" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementExpensesToReimburse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementExpensesToReimburse_9b882fff-1c7c-42f5-a858-6e4763dff721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeArrangementTerm_c95b48c1-3e7b-4e46-83dd-4d79390a5f92" xlink:href="ino-20221231.xsd#ino_CollaborativeArrangementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeArrangementTerm_c95b48c1-3e7b-4e46-83dd-4d79390a5f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedAmount_d54382d9-a970-4b45-8383-fabe7106e333" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAwardedAmount_d54382d9-a970-4b45-8383-fabe7106e333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAmendedAmount_9b362b20-6b18-429d-99e5-b9d3d8a62f81" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAmendedAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAmendedAmount_9b362b20-6b18-429d-99e5-b9d3d8a62f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedOptionAmount_31a19c68-a8c0-40ca-8de8-1ef860bfd33e" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedOptionAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAwardedOptionAmount_31a19c68-a8c0-40ca-8de8-1ef860bfd33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CollaborativeAgreementAwardedExercisedAmount_e43da65d-66f1-4a6d-8efe-0b64b9b4273b" xlink:href="ino-20221231.xsd#ino_CollaborativeAgreementAwardedExercisedAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_CollaborativeAgreementAwardedExercisedAmount_e43da65d-66f1-4a6d-8efe-0b64b9b4273b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GrantProceedsReceived_150f5c15-3d37-4ec7-bf4e-ba54d1b79cae" xlink:href="ino-20221231.xsd#ino_GrantProceedsReceived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_GrantProceedsReceived_150f5c15-3d37-4ec7-bf4e-ba54d1b79cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4ad0a417-a36e-4dcc-a5eb-3133c9b0dbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4ad0a417-a36e-4dcc-a5eb-3133c9b0dbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_9974dcfe-44ba-4564-974d-a8ec02054165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_9974dcfe-44ba-4564-974d-a8ec02054165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_85acd3db-97bb-4cc8-bf13-3dfbfb4bd61d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_85acd3db-97bb-4cc8-bf13-3dfbfb4bd61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_DeferredGrantFundingFromAffiliate_0c5151a5-c767-45b7-934d-b40c98ca50ec" xlink:href="ino-20221231.xsd#ino_DeferredGrantFundingFromAffiliate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_08c7b730-6f7f-4913-ac23-a7d3b5b666ac" xlink:to="loc_ino_DeferredGrantFundingFromAffiliate_0c5151a5-c767-45b7-934d-b40c98ca50ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GeneosTherapeuticsIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_3e5276b8-7d8c-488a-a868-8eb62cabfd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_3e5276b8-7d8c-488a-a868-8eb62cabfd10" xlink:to="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6b7e0c45-e06b-44fe-9383-f1382c6c3b02" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_srt_CounterpartyNameAxis_6b7e0c45-e06b-44fe-9383-f1382c6c3b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8af8d106-f28d-44d9-9a4c-aa4b7a9872b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6b7e0c45-e06b-44fe-9383-f1382c6c3b02" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8af8d106-f28d-44d9-9a4c-aa4b7a9872b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_650a2de8-7ec1-40e9-8160-975b21bb4d42" xlink:href="ino-20221231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8af8d106-f28d-44d9-9a4c-aa4b7a9872b2" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_650a2de8-7ec1-40e9-8160-975b21bb4d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_srt_OwnershipAxis_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b6359a5e-d587-4614-8383-56e42ccf895b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_1be4f0fa-d370-4657-8a3f-7aeafc7d3c45" xlink:to="loc_srt_OwnershipDomain_b6359a5e-d587-4614-8383-56e42ccf895b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_3febfefb-a48b-48e2-9754-846d20c9d649" xlink:href="ino-20221231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b6359a5e-d587-4614-8383-56e42ccf895b" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_3febfefb-a48b-48e2-9754-846d20c9d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_d8cc40d6-fd4b-4269-8d5c-f25c224477f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_us-gaap_StatementClassOfStockAxis_d8cc40d6-fd4b-4269-8d5c-f25c224477f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_d8cc40d6-fd4b-4269-8d5c-f25c224477f9" xlink:to="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_acb6a1b1-7bdf-4f2e-bba0-7d1386d8b6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_us-gaap_CommonStockMember_acb6a1b1-7bdf-4f2e-bba0-7d1386d8b6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesAOnePreferredStockMember_4b3211c8-805b-45ff-b3f3-69ade33fa040" xlink:href="ino-20221231.xsd#ino_SeriesAOnePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_ino_SeriesAOnePreferredStockMember_4b3211c8-805b-45ff-b3f3-69ade33fa040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_da547b55-f9b3-4913-abc0-923922fdcd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_us-gaap_PreferredStockMember_da547b55-f9b3-4913-abc0-923922fdcd7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_893db888-0c20-4af7-bd5c-38f8e29ee57e" xlink:href="ino-20221231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2a089fd3-4523-4467-a650-d77f8cb6f774" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_893db888-0c20-4af7-bd5c-38f8e29ee57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd24b651-348e-46f5-8d97-d214ff7565f9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd24b651-348e-46f5-8d97-d214ff7565f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c72c769c-8cfb-47b7-8743-d52e38548114" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_cd24b651-348e-46f5-8d97-d214ff7565f9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c72c769c-8cfb-47b7-8743-d52e38548114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_GeneosTherapeuticsInc.Member_0f2b7b1e-3a91-45ac-a9ca-1fb997c5e2e5" xlink:href="ino-20221231.xsd#ino_GeneosTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c72c769c-8cfb-47b7-8743-d52e38548114" xlink:to="loc_ino_GeneosTherapeuticsInc.Member_0f2b7b1e-3a91-45ac-a9ca-1fb997c5e2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_e1eafc51-a2ad-4dcd-8f46-caa12e253f13" xlink:to="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_e5e82608-bc49-44c7-b571-b619ce52fa03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_e5e82608-bc49-44c7-b571-b619ce52fa03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f8b68d4d-e2a7-4380-a38b-7fd3cb967e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_f8b68d4d-e2a7-4380-a38b-7fd3cb967e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_b0b20355-36d2-4fb9-afac-00d2bf15dcd6" xlink:href="ino-20221231.xsd#ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment_b0b20355-36d2-4fb9-afac-00d2bf15dcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_af7647a3-0d4d-437a-b1c4-f1d41e6f8bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_af7647a3-0d4d-437a-b1c4-f1d41e6f8bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_2616972f-aacd-426c-a434-a983f4c36786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationGainOrLossAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_2616972f-aacd-426c-a434-a983f4c36786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_4865ee94-cf8f-4162-b9c2-8f5416f61457" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_4865ee94-cf8f-4162-b9c2-8f5416f61457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_33e58096-aeac-4892-a3c2-da90efdd33f3" xlink:href="ino-20221231.xsd#ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment_33e58096-aeac-4892-a3c2-da90efdd33f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a42f6f08-0b16-4bb5-aead-54ca64da67af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_a42f6f08-0b16-4bb5-aead-54ca64da67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_acaae27f-13e9-40f5-9c4a-458527e8bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_a2f869c8-90a5-40d7-9829-6343df6eeaef" xlink:to="loc_us-gaap_EquityMethodInvestments_acaae27f-13e9-40f5-9c4a-458527e8bd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#GeneosTherapeuticsIncPreferredStockInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_28b9d6e8-0ada-4175-82af-d83ad2a3b37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_f4d58980-aee5-40dd-95dc-5a9f817e464a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_28b9d6e8-0ada-4175-82af-d83ad2a3b37a" xlink:to="loc_us-gaap_MinorityInterestTable_f4d58980-aee5-40dd-95dc-5a9f817e464a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f4d58980-aee5-40dd-95dc-5a9f817e464a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6eecfe94-811c-43ea-b13d-2410327fab35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_613f8437-5902-4b87-8ee2-fa6d1cb9fc1e" xlink:to="loc_us-gaap_ClassOfStockDomain_6eecfe94-811c-43ea-b13d-2410327fab35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_SeriesA2OnePreferredStockMember_d01bb189-7f12-474f-8ed6-c5debce9d86b" xlink:href="ino-20221231.xsd#ino_SeriesA2OnePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6eecfe94-811c-43ea-b13d-2410327fab35" xlink:to="loc_ino_SeriesA2OnePreferredStockMember_d01bb189-7f12-474f-8ed6-c5debce9d86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_f4d58980-aee5-40dd-95dc-5a9f817e464a" xlink:to="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9421c70f-6741-4d40-adb8-e7ee08db893f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_EquityMethodInvestments_9421c70f-6741-4d40-adb8-e7ee08db893f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_28c5c287-e58a-4166-8b8b-473efa358c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount_28c5c287-e58a-4166-8b8b-473efa358c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8f9d3c9-de32-4950-9b68-0b6c58e743c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c8f9d3c9-de32-4950-9b68-0b6c58e743c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_a6678914-8ba6-40f5-be47-d4e0287bdcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_e0f44bc9-db43-4b18-a321-2415981a679c" xlink:to="loc_us-gaap_EquityMethodInvestments_a6678914-8ba6-40f5-be47-d4e0287bdcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="ino-20221231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.inovio.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_b251b413-ef6c-4ee0-9b39-d18dd77d5cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_b251b413-ef6c-4ee0-9b39-d18dd77d5cfe" xlink:to="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_08c7b458-f929-4504-9b75-78eb65f9ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_08c7b458-f929-4504-9b75-78eb65f9ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5eb19d03-bf35-4320-9b66-e22f2835c31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_08c7b458-f929-4504-9b75-78eb65f9ded9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5eb19d03-bf35-4320-9b66-e22f2835c31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_c2473bc7-0055-4224-a20f-33812736acac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5eb19d03-bf35-4320-9b66-e22f2835c31a" xlink:to="loc_us-gaap_SubsequentEventMember_c2473bc7-0055-4224-a20f-33812736acac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_ef688809-de10-4b96-92c1-b916d78571d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:to="loc_srt_StatementScenarioAxis_ef688809-de10-4b96-92c1-b916d78571d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_52d5f656-36af-4c5a-beae-2f8fd1771636" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_ef688809-de10-4b96-92c1-b916d78571d3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_52d5f656-36af-4c5a-beae-2f8fd1771636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_77293080-2025-400c-ba45-9269a852ca61" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_52d5f656-36af-4c5a-beae-2f8fd1771636" xlink:to="loc_srt_ScenarioForecastMember_77293080-2025-400c-ba45-9269a852ca61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:to="loc_srt_LitigationCaseAxis_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6c4f8c31-f1e3-4103-92e5-9b1748214d6e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_1d9ca7d0-b5c3-4855-b4e7-7eef2897a67a" xlink:to="loc_srt_LitigationCaseTypeDomain_6c4f8c31-f1e3-4103-92e5-9b1748214d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_926b94d7-0861-4d5e-a493-765efc383f99" xlink:href="ino-20221231.xsd#ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_6c4f8c31-f1e3-4103-92e5-9b1748214d6e" xlink:to="loc_ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember_926b94d7-0861-4d5e-a493-765efc383f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fa222676-809b-4843-ab15-a79f07992b81" xlink:to="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_2dcc74ae-5255-4c7d-8039-bd1e306931a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_2dcc74ae-5255-4c7d-8039-bd1e306931a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_4c664975-b356-475c-a0df-1530404da27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_4c664975-b356-475c-a0df-1530404da27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_RestructuringAndRelatedCostExpectedAnnualSavings_20b701ac-2f69-45fe-9535-ed74fe743ff5" xlink:href="ino-20221231.xsd#ino_RestructuringAndRelatedCostExpectedAnnualSavings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_ino_RestructuringAndRelatedCostExpectedAnnualSavings_20b701ac-2f69-45fe-9535-ed74fe743ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c41c69d-d1c1-4e9c-83f7-1839a6b7e6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_6c41c69d-d1c1-4e9c-83f7-1839a6b7e6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8dbd976a-1b2a-4780-a425-8be071e4bc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_CommonStockSharesIssued_8dbd976a-1b2a-4780-a425-8be071e4bc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a911cd80-4c44-4f4c-992a-456aaa32ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_us-gaap_CommonStockValue_a911cd80-4c44-4f4c-992a-456aaa32ead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays_a9154527-9142-41d6-b12a-68dfe03f4e73" xlink:href="ino-20221231.xsd#ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5a3b4b81-ce7d-4b73-902d-fa59b9232ec6" xlink:to="loc_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays_a9154527-9142-41d6-b12a-68dfe03f4e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ino-20221231_g1.jpg
<TEXT>
begin 644 ino-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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MX5.2T_$F1&."E:+"18,H1F2EQ"='9H2C_\0 '@$!  (# 0 # 0
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (G*\,Z \
MHB\<H#RB\<KR@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(O'* \HB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M20"N8;*1@+W,5>$/)IZTA<#(S-'9@**U!S#-&ZR#0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0$<7>K[M
MZET1LYE]0:3S%K!9J#,:=KPY&F,!3QPV\M7@LQBUF&>+IFA,HRYC=^'Y%V?A
MVJW_ ));OU_9/U!_@L/_ +K5DSOJOB$SGV>TI^'*JIH(#./\DMWZ_LGZ@_P6
M'_W6GY);OU_9/U!_@L/_ +K6#B(#./\ )+=^O[)^H/\ !8?_ '6GY);OU_9/
MU!_@L/\ [K6#B(#./\DMWZ_LGZ@_P6'_ -UJVOW=6XN<U9LOH74.I,E/E\WD
MJ62DOY&TT33VCASN4K1%(T$<,3.$$$43=$8MT@W+<\N]$57ANZG^E^VX^Q^7
M_&3,H"0I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %66[\[O9I-$5;>S6VN38-
M996G)#K//T9C&?26+NP!X>+Q]F Q*#4>3KS/(<P$TN'HN,HO'=MUI:TEG>N=
MX'4V VTM9:D5>SKC4+R8?1.,F<2%\@8-ZSFK<+\N>.P-<_79@<>FW:]2QSE'
MZX\T5!+;#;O-;A9W(YO-7;=M[F1GR>H,W<,YK>2R%Z<[=M_'/SFO6Y3DEGE=
MW:!I/%-O:BC.N/C[XN4Z%A6XM=ZINE5SY5R?O8]$^D:Z]GO](O>RC%>\H--+
M>R$EJW%/$-.!CV666*N,8[SGZQ3Z*,5W<YMI12Z]5MU:/A[0;-W-13=0L5;'
M1%TV+KBS^?O>&!BY\2<O>[NSA'SU2>;B!R2Z7T72Q-6.G0@&&$/-^/,Y3=F9
MY99/HI)"X;DR^1F%N!9F7-,'I>K0K0U*<$=:M #!%#$+" M^U[R=W=S(N2(G
M<G<G?E<CAQWUEQZXS\0[]4M?5U8T9?54)_\ 7M:^W8U_LP3<8_>E*EO%O%N1
MJMKWWKQ82^JH3_)3MVZ2L:_V8=5#NY2XO#CO=Y+H3%0O#G,C"[<.UV9G;EO>
M3]?R?5ZO_/S4EG9O[-V:W*U-5TYAA:(2;UC)Y*2,I*V)QH&(SW9V%QZW;J:.
MM7ZXWLV"CA&2-G.0,>NVMM%0T#O;K'2F+&9L?C9<,51[!E+/)'<P6,NO-*91
MQ]4DQSG(3@#1MU<1<@PKKA_<:=(U):]Q3J<Z90TK*T:K$JOF^59&;CZA19)4
MQ:WLC17;*-MFZC&=L81<I<ZAB9Z!D?HK+SG7MBN4<:-C^_<U*;4%MUC",7SR
MZ)2E&*;>_+D7W16::CVBM.QN3#\)X75&-9G=FZ^<=Z_T^;/U?\W]7 \/[///
M#/S<Z94<.[QS/P=VBMK;#DXA+G<A0-F(A8VR>GLSCHQ+I9^IFGLQ&PNW2Y@#
MNXLW4-X]ETH]I/'Y-<QI[=+=-J;?[4<G*BU^*CR_O+0^ &3SZ%L_N95B7X.F
MB7];?[CRB(J]$X$=/>S_ $O.Y?V*H?AO&*EOBO\ FL_^Z'^AU=/[UZK)+V>]
MS1C%R<<-6E)FX;B.'+XZ64O/CR&,")V][LW#,[NJ6&+_ .:S_P"Z'^AU=CV9
MW_ZGS?\ \1G_ /IL8J-[1_\ RS3O]%#_ ']I;-[BWXC7^W74W^FBID5#=W%O
MQ&O]NFIO]-%3(JL/B;_[0ZS_ /B&3_O&60X(_P #Z9_J6-_NHA>'7E%HIM)2
M0[T+*>N=I#71"0\U"P--G!RY$J^#H/YN[^1MU^?2[,S\<>:^%V>]:9C4NI*>
MBX*4V4R=Z.T^**#I]9F>C4FN303,1"TAO7KR/ ;.TDD@C#TRR&#KC_;RR'KG
M:'W4F?KZ0U.-<6-V=Q:IBL=6=FXY;I<XC(6YY9B;GSY9=Q]TUC?7.T7I7WOZ
MKCM2W7X)F9O"Q4L?+\^]N9F9V;S=W;RX96A\>?9ZX5X]\-8:7Q-IU>3]"T*&
M5IN?7RU:CI.:M/A*.1@97*Y5-RC!7TR4\?*A%5Y%-L%%*@7$W#>/KG%N1@Y/
M,J\C,LJ=E;2LK4\B47.MM27,HK=*491?:46NA[FZ>S^.U10FQ&8KR0S0R&,,
M_AM'>QMH'<2*-I!Z@(2%PGKR-T2,SA(/RM#CNAM)D]*9.3'9*+D7<CIVP9_
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MG*OX#Q* P41$0!$1 %(KW2OTQ>V?]OU=_![JY1U*17NE?IB]L_[?J[^#W5R
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M#K/_ .(9/^\98W@C_ ^F?ZEC?[J(1%X6BFTE [M%9-KV\VZMEG%V_FA:O@Y
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MO$W#&>.MWL+9=N?,^9@R]<B9O-@&")BXX<AY<FVW1O;AX'R6ED6:IIN_=Y>
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M!+)XNU1LV:-ZO+4NTK$U2Y5F'IFJVZTA0V*\H_H9(9@.,Q^0A=O/WN!Z*(B
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MBO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_ +?J[^#W5R N]HB( B(@"(B (B(
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MFFLSJ;(NXB5;#T9K?@N3.XO:F 6KTXW82+Q;<T$3"+DYLS.[3;=G;T>+<S4
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M2]R(JV3B;R8J]Z$V$&+I8#,I$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M2JXIJQ31'[<-N>U&7F+NI,$ 1$0!$1 $1$ 6!7>@?$'N9]@X?PKCUGJL"N]
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MB(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]TK],7MG_;]7?P>ZN0%WM$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.DOQDQRIC*YSWT7Q ZD^S.DOQDQ
MRIC( B(@"(B (B( B(@"(B +GFV.YN<T=G\7J;3E^;&YG$6H[=.U"1-[0/\
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M-F$;T?/W?R_S+^'I+F94_P"7\F7Y%2^L_P#+^\JUK*^9RDAJ_IN^WR,-MS<
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M'4R2 (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(BQ+[6?;0T3LYA?A+5%TI<A9CD?#Z>HO'+F,Q*'L]-> C$(*H&[-8OV2BJP-
MS[4DW1"8&3.H]2X[#T;63RUZGC,;2A.Q<OW[,-2G5@C;J.6Q8G,(HHQ9N7(S
M%F^JJX';>[[&29[FF=G6*&%Q."SKNW%Q,;NY ;:=QMB%V 6'@H\KD&ZW<G\#
M'BP!:.*GMC]OO7.\V0-LS:^"],0V!FQ>DL?(38VKX;.,4]Z3@9<KD/,C*S:Y
MCB,G:G6K W#X/H#ZV=S]_*W;.2REZYDLC=F.Q<OY"S-=NVYY"ZI)K-JR<D\\
MID[N4DAD3N_O7R41 $1$ 1$0!$1 $1=C;6[0ZHUODQPVDL#D]09(N'*OC:QS
MM !<\2VY^&KTH7Z29IK<L,;NW2Q.7#(#KE?M6K232!##')--(_3'##&<LLA/
MY,(1QL1F3OY,PL[_ %E8,[-_<09N[X&0W1U#!AJ[O'(^GM-2!>R;ARSG#>R\
M\#X^G+PSCTT(<I&W+&UKEGC4[FP/8QVSVQ@ -'Z4Q]"T(=,F7L-)DLW9=WZB
M.?+7SL7>#+VFABEBK0\^'7@AB$(Q J=[ =T[O)KP8;4F ^8_$RN+MD-7M/BY
MRC?S\2'#/$>7,>/,'GJU8Y6<2CD('ZE--L/W&.W6!&&SK;+Y/7%\>@I*P,6G
M\$)-YD U*=F?(3 _/01SY5VD86,88')P4X"(#J[;#9'1^BJ;4-):8P6G*OO*
M/#XRI1>8^GI>6S+!$$UJ<A;@[%F26:3]'(3KM#A>40!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0'%]7Z'PNH*4N-SV'Q>;QTX]
M,]#+X^IDJ4P\L_3+5NPS02#RS/P<;MRS/QRRBTWP[EW9[5(SSX*K?T+D9&,H
MY=/S-+C!E=B<7DPMYYJS0=;LY0TI*#] ^'#) SL0RYH@*>&_/<J;L:3&:UIP
ML=K_ !T7),^(;X,S)1M[W+"WK$@O(S,Y/#2R=XR;I:/KD+PVB=U/I3*X2[-C
M<WB\EALC7(@GQ^6HVL;>A,?(AEJ7(H9XW%_>Q1M[V?W.RV.*ZBW<V%T9KV@>
M,UCIK%:@J$! +9"J!V(&)B9RJ78^B[2E%R<@FIV()HCXDC,3$28#7F(K.G:,
M[AW$6QL7MKM128>QR1Q:?U-+8O8M_+EH*^9BCFRE4>?(#N0Y4OT,A^;R# EO
MYV4=P=L;/J^M=,WL3$<GA09-F&WAK9.[L#5LM5>6F9GTNX0G+'8=O?"SL[,!
MCPB(@"(B (B( B(@/+.[.SL[L[.SB[.[.)"_+$+MYL3/YL[<.SLSL_+*9OL2
M=\-JS0/J>G]>O=UGI('&&*]-8>;4^$@9A$? M6')\S4A9N&I7I@LQQO^9KS!
M%'4DAC1 ;#O9O>W2VX&$KZBTAFJ6;Q5AF;QJDHE+5G86(Z=ZN[M/1NP\MXM6
MU'%,#.)=#@0D7:JU\_9[[2VL]KLY'G]&9B;&V7*)KU0F:?%Y>O&3OZIE:$GS
MJU"0D8#(WAVJW6\M*S6G891MS=AGO-M'[PQ0XBST:;US'#U6-/6I6]7R/0W,
MMG3]LW;UZ%OHI*DC!?K-SUPRPBUJ0"3)$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 5%KO-OC[W-^SE7\
M!XE7I51:[S;X^]S?LY5_ >)0&"B(B (B( I%>Z5^F+VS_M^KOX/=7*.I2*]T
MK],7MG_;]7?P>ZN0%WM$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!%1WT7Q ZD^S.
MDOQDQRIC*YSWT7Q ZD^S.DOQDQRIC( B(@"(B (BG$V^[L3'[@=G3":[T=!8
M'<0&RM^Q5*W+)6U%5I7KE<\9#7E)X*EYH(0.@<31C/9#U><NFQXL0$':+]K%
M:2&22&:,X9H9#BEBE HY8I8R<)(I8S9CCDC,2 P)F(29Q)F=G9?B@"(B (B(
M I+N[6[>MS9O4_J65DFLZ"U%9KQ9^IU&?P38Y:&+45"%NIO%K 3!DH(Q8[]&
M,&9SL5*@O&BB V/>#SE/)TJF1Q]F&[0O5X;=.W6D&6O9K6(QEAGAD!W$XY(R
M$@)GX=G9?555ONA.\1^9:Y4VKUK>Z=-Y&=PTGEK<PM'@<G9FZO@:Q))PT>)R
M4TDAU9"DZ:&0=H6C]7NE)4M1H#RB(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M[3W1WQ":*_NQ^&;R CD[X?N[G/U[=_1-%RE_H^N\16%N"C"-A?5%.$1Y>0&
M1S<4?]$#C*,#F%^22MBSK9%SP!*!QR ,D<@D$D9BQ 8&SB0&),XD)"[B0NSL
M[.[.SLJ>?>I=WH6UN;+5^E*9?S/L[99GKPQ_.]*Y>P9<XLNGD8\5;+@\1([
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M"(B (B( B(@(GN^J^(3.?9[2GX<JJF@KE_?5?$)G/L]I3\.55300!$1 $1$
M5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW'V/R_XR9E 2%(B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B\.@(/>_;[9TFVNU;:3PEOU?56Y$EC"P
MG&7$U#344;/J+(!P[$,L\4L&'K$W#B>1EL@7748#I-[>:6/*WH:PL[0#Q)9,
M?T$(^3LS_P!,;\ #?5?GAV%UFYWNG:BDW3WVU;?@M>-I_2TWS&Z<C&1S@"E@
MCDBR-J/R$'/(YLLC:*1AZG@*K7(Y JQFNO=J-.1XG&0-89X[>3%YI'?V3 &
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MTK$5FK,<-B NN.4/HA+W.W'T+B[<B0DSB0NXDSB_#Y[[-[Q4]11M4L=%7+Q
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B+^3-A9R)V869W=W?AF9O-W=W\F
M9F\W=_)F0$,/?9=I-])[;P:,QTXQYC7UHJ5EA?B6OIJBS3Y:4>'Y$KL[TL8/
M4'25>U>(3&6$.:AZSL[Q_M'EN;NUJ3+U[+S8+$RMIS38B?5".,Q3E%-:CZ>
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M-F5PDK9+5KA(_P ]O,1#)5PIL('6Q11Q3S,[RY3ERCI5(=T1 $1$ 1$0!$1
M%_)&PL[D[,S-R[N_#,S>]W=_)F7;6S&QVJ]PLY6T[I#"W,SD[!!UC7C=JU*
MBX*YDKA<5L?3C\W.Q9DC%W;PXFDF*.([5/8?[H326W?JFH=:^IZRUD'1-$$]
M=CT[@IV=C#X.I6&+U^["3,XY.\'(&S'3JU#%I" AG[%_=(:YW+]6S>I1GT5H
MV3ID&W<A9L]EHG\_^2<7,/,$),[<9')#%"[.SU:UUF/HM-]G/LHZ%VJQ0XO1
MF#@H=<<87LG-^:LSE3#AWFR61D;QIB,^9/!#P:<)/TU:L$0A&.1;,O* (B(
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MV[CK836A-+9O8=GAK874\SLYF3\L$>+S,Q>37>L*-HR_-\<9D5T*I>KM(Y7
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M%4>?6(8A9O$S6,AZBC\VDOT0>HWBV(*415/?Y?K?K_7^1V^1 $1$ 1$0!$1
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MC=@?R<H9QXZ@+CD)8RZ989&\XY0 V\Q95$MR=L,GMUK#-:+S/)OC[)-3M.W
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MK@W)S6)GBKPQB4LTL<8$33H]GKN/[DG@7MS=0QUH_(SP&F)'FFZ?)_"MYJS
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M;S$XS$3 F\Q)F=O-E?'[!G:-#=':[3&IY) ++-3'%:AC N7BSN,8:M\^GEW
M+I .1@!W=QKVXA(B(2=4,U.7W&_:2?3^N,KM[D+#MB]:UVN8H"=NB#4F*AD-
MQC]SC\)XII@E]_5+CJ;,P\F1 6Q41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MFL:!U!.9X&V[G*6*M.Q2S:>OR%R7BUQ8I<?.9%ZY2;S)[->RS1G( B(@"(B
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MMVY AP)LF4 P4*$,UJY9DCKP5JL1SV;5F8ACAK5H(1*6::60PCBAB$CDD(0
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M?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MTM!.3%)A")V<;!GC!<VFH11V9UK=:]B2&2.:&22&:(PEBEB,HY8I8R8XY8I
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M?\9,RJ/*O#=U/]+]MQ]C\O\ C)F4!(4B(@"(B (B( B(@"(B (B( B(@"(B
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MEM"S@]!I#YDL::R9R25' 2?J=L9>&U2D86Z(8),<W5U3=(@3?(B( B(@"(B
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M&B(@"(B +MG8W>G.[>:JP^L--V/5\IA[(S )]3U[E<O9MXZZ D+RT[T#G7L
MQ"3";21&$T<<@]3(@-@UV;.T'@=T-'8C66GI'>GDHB&Q5D?\TXS(UW\*_C+8
M\"[6*=AB#JZ6">)XK4/5!/$9=[*EUW6';?+:?6@XG-V^C0VK9H:F8>>4A@PN
M1?B*AJ .7\...-^FGE'?I%Z$C63/JH1@=T*.02%B$F(29B$A=B$A)N6)G;R=
MG;S9V\G;W(#^T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MPG%[QE%]FG_6NZ?1[-%?3O(^Q86F[=K<W1U3IPUF5IM5XFJ#\8RU*;L6<J1
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M;V2R-R4I9I781=R,S)V".(1CAB$8HHXX8P 9U-8T:&3C. @\2*>,HYP(&Z"
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MC",4DDDDD6WQ<6JBN%--<*JJHJ%==<5"$(16RC&*22279)!$1>X] 1$0!$1
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M.[.6G=S=.3:>U!"0^93XW)P,#7\1>Z'".Y3D)G;Y>FQ7/YS:AYBE;Z @J/\
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M"VEQ5:_9]8U!HTFTSEW(W*:>"H'.%O2=7).5G%/7BFD<B\6Y5M2\BQL R=H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M%FM/&[C)#/!*(2Q2 [.Q 8B3?473FJMO&-RLXX>#=^J2KRS"3^;N4+_H2_\
MN?T+OST\/Y/U*IR,7/QZ[(RHS,7(KC93;%UY&/?5.*E"R$US5V0G%IQG%N,H
MM--HTVC+E%IQG*,EVG&3B_WQV:_@2-;7=]MV@\)X-:UG\3JR/K8!#/Z?HE:-
MG9A",;6&'$2$75QQ),%B4GZNLB=V<<DM[.V7KS>FO@X-3UL?AJ.,'QRPN$*W
MZA9R,GE\(7'M2R23V((OG-<')X*K'.4 ]<TAE$]V==NH[LAY&7@[$%@ZP0/]
M%6(1;J.029G&4V/V/D$'Y9^HGZ9!V:'$U>&X:5P]_P#2\M[OUW_]EQY]M[Q?
MT]:G;PIH&!1BV8EG)JN530L>>1D[*7T6%<5&*Q:$XRLLY-[[7M!^36IW_MF\
M19U]<\:S+OEBK;S8V3E/S'%J2BY3;ERII-KFVDUU326_KYS*P8NJ48D(=(\R
M&[\,S,W+\N_EPS-YN_U/-UF5V NW?V>MMJEK*:DRV:/6N4<X+%_YE\G:IXN@
MTO 8W&6*D=DG";I&S=N.$7K!=$7LQPB)0<[X;LE?GEQ=.5W@ N+DP_\ 6FW_
M % $W_5@_'BNS-UF/1]"Q=6.HNSMP_\ +ZZDWV4/8^JJTVOB'B2.17G9T8W:
M?BP<:K<;&LCNLK(5E=FU^1%ITU<J=-&TI-V6\E/FT?6+</(CE5U4SG!-51OA
M*<8)]/,C&,X>_MTBVWLF]ENUM>;Q_?-]G>?IYUT5?J/H_-6#SD'3[O;+JH>S
M&W/F7N][KD)=[]V<V]^YN*_Q+,?[N5#*S!]9?;T-MW8SUX8(V(*\;L]F=F_H
M8>]@#GEBED]PMYL+<F7+#P5I^)O"7AK2,'*U/4-1S<3!PZI77W66X[48Q[)+
MZ-S3LG)JNJN"<[+)1KA%SDDY%K\6<U1YIU8NR[M0M7[EYK[^B_ NG[^][IH$
M]*VOYE>;AU3J6\4N/IV(:=R.CA3./V\I;*[6@"P=9C%ZE.-I6GL]+3L, 2<P
M2Q89KQVLKGR;*6[TYV[EC(B-J6Y;ED*62:=YV)C,Y"(G=VX'G@&9N&;BVV^W
MU7%TX1"(8:]>,6$&^HS-\K^9&3^9&[N1.[D[N[NN&;X[T5,!0.:1^H_.*I4!
M^#L3=+\"W]+&/T4LC^0"WN<G$2X]\7\9ZKQAQ-3I_"\=0A&67Y&DTU7..:N:
M6T;)VT>5&.1-+S;K(N->-6FO,\NMV/2.(.),G5;86Y,8\J3ACXT$^1<WVI.,
MF]YS^])M[12CT2.F;F3T'3U_2QVX.H+FF]%//Z]D+&,QF0R^2EQXL\HXW'5,
M=7L21S6Y6]2"Y,(UZ4+2V".:6*.":?G#^D$=F31&$QNGM)X'7<F&PM*"CC<=
MAM+TZ<4%:")Q",/A?,XTC-W%O%FF-Y9YI7FFDD,Y9&IFZSU#>S-Z?(Y"5YK,
M[\N_N",&=^B&(/<$4;/P _KD3D3D3\JV VQ^:C5N+Q\@.5."5LCD?J/3I&$A
M0OY>ZS+X58N."Z)3('8A9=I>+]&QL'A"C5N-]0R,A\,</?2M6LQ<A0QKKL#"
MY\S(@IU*V[)R76X0G.Q.RR25<*W8XO\ ;%XGQ.#M&U+4[(T4X^%BY&?FW<F]
MGE8]<KG34W)1V]WEJ@HISLDEU;BE8*[3N_0;HZMOZTKT\CCJ&6@H'C<=E6KQ
MY"E1BHUXH8+L-.YD*4-K@>JP%2W/"\CN32F[D3XNW:WO\EV?=J^]F9F9O=PW
MDS?M>3<?K>2XE>JK^3C6>([-3U'/U*U<MNH9N5FV04G)0GE7V7R@I/9R47/E
MBWLVDMS^=3B+C_*U_6=3UO-EOEZKG9.=?L_=C/)ME;Y</V*E)5UKIM",5V.K
M[M7W^7\OY?R=<"U!>I8^O/>R3S#CJ<96K[UFC]8:E WB6_5VE(8O'\ 3\)I2
M&/Q.GK)AY=NWKM;WK"/MJ:D^#M(2TXS<)LQ;K4AXXZG@BD:W:;ZO3)%7\$O+
MCHE)O+EE+/@7P-9Q7Q;PYP[!2:U?5\'$O<=^:O"E=&6?>MNNV/@PR+WLM^6M
MDO>#VA3U[B#1='ANUJ&H8N/9MWACRM4LJSIUVIQHVVO;T@^Q91VH])X[/)4Z
M.-NZ3W0TG6HU:U*)KF!T_D*D,%:"*&(8&P&I\I:*&,!:,6*G#)\[?YRPN#GG
MIMOWZO9:U,P^!NGC<.9\=,6IL=F-/&[DS/Q_RG1@ 7;GS8S%FX?ZCK6=KRR_
MJ1S/9QX?FMJ)9V(DDHQKOA.N*71+ENILGT6R7UB/Z2,?7+8*,%&ODBE&*46M
MHI;)+E:222V2V-O%MGOMHG6D#VM'ZPTOJFN+#US:=SV*S4<?5]"TA8ZU8:,G
M_I9.DF?R=F=G9=JK3HXJW-1N0Y"A--0R%9^JM?HS24[U<N6?JKW*Y1V(3\F=
MBBE!_)GY\E)/L3WQ/:2V[\"+![J9W(TJ_##C-6^KZMI&#.SE'(6<CM9!F/AA
M*2&_!88>?#GC+VE'^L>S+?%.6GZI5:_2O+IG1M\O-IE>I/YNJ"_=N\E5Q#%_
M;JDOG%J7\&H_ULV@Z*FAV:?2J;8>!3W?VWAE^A&?/;>6#B9V]EBD?3>H+LI!
MTLQ/TQ:AE\0B;@86'A[&G90[S[8W>F.&/0>O<7;RTC TFFLLTV U/!*3L'A%
MA<O'4MV?GG,86,>-VE8(">I:L /6H6XD\--;TI2GEX%ODQ?7)I2OQTO1RMJY
ME6GZ*U5R]'%/H9?'U&FS91FM_P!5^[+]SVW_ "W,^T1%HA[0B(@"(B (B( B
M(@"(B (B( B(@"(B *G)WR_9L?16Z4FI*%;P\%KVN68C*,.F*#/P$T&<JOTL
MPB4SO5R@>[Q"O6!%G\ R>XVH[.]#[-3[E;2YRM2@:74&G.-38#CCK.QC1(K]
M$7XY=\CBRN5HP=V#ULJLAOQ%R@*02+PS_P G\G_;;Y'7E $1$ 1$0$J'=!]I
M+Y@MV:6+NV?"P6NH8]-W@,^F"/*'.,FG[I<\-XL=PI<<#N_'AY6;EG)@Z;H"
MUN4<I@0G&9Q2 0G'+&3A)'(#L021F+L0&!,Q 8NQ"3,[.SLKZ/86[1T6ZFV6
MG-5O*!Y,J_P9J",.!>#/XU@AR E&W]#]8+P[T(\#S6MP&+=!@@,O$1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %3E[Y?M*OK7=*33-"?
MQ,%H"%\1&P2=4-K.V6CL9NVPMP/YG+U?$CRSD,E"T8&\<XL-G[MC]H&#;#;?
M5&L3>-[F/QTD.&@EY<+6=NL]7$0&+$!%$]V2*2PPD)-6BF<'8F94%\AD;%RQ
M8N6YI+-NW/-:M6)7ZI;%FQ(4UB>1^&9Y)I3.0WX;DB=_)N&8#TT1$ 1$0!$7
MAR9F=W\F9N7=_<S-[W0$I_="=FQM?;LTLI>K-/@]!!7U-?\ $!RA/*#.0Z<J
MGY./B%?@ER,8$[,8XF7Z)A("NA*,7NE^S8^WNTF*LWJ[P9[6GAZIRPR"XS0P
MW(1^!J4K%P8%6Q?@22PDS/!;LV@=NIB<I.D 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!8%=Z!\0>YGV#A_"N/6>JP*[T#X@]S/L'#^%<>@*,B(B (B( B(@+?W<8_$
MI8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MNP+.5I8X':)A<F;Z)V;RX^5F_P#-OD6(>Z/:BITRDKT'^$+;.X\1DWJL1?\
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M&9+=_2<2,8QG)^M^/TJM6_64HJNZ3;WM[(V[#U>VK9-\\.GNRZ[+Y/NOXI?
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M.<A=I(-,8UWBJ>;LSL^1R'KMTNEW ZHX]_(QD9 3<PPA& QQB(1@(@ "S"(
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M1R%'&4</B&T;.@.^41$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM(=HPB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M#<N#SU)2B>6%W87.O8%AL5I'9O%KRQ2<,Q+A*GT[]3LU/B=3X3<S'0,-#4L
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M16)A;\]Y&P9V\I==^D'=[F0GLV.7%G9I&'AN&9N^$ 1$0!$1 $1$ 1$0!$1
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M#JG?C6?P1I^QX9]-F^[4H7YX<!-G*S+_ /HZXFPNWND.-W\N5;%[LK8QMO\
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M=.34E&#PL)N%'/FXF'^AQ9ZN\,>H(1\FX>Q--6RA-R7SW(R]+B+" @1&(B(
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MR$W/46-JO6QSNQ$#G5,XWZ39 9UHB( B(@"(B (B( B(@"(B (B( B(@"(B
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M>;Z:]:P7OZ6I95L?;,^ER]7BL1CQXKJ\N@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( J+7>;?'WN;]G*OX#Q*O2JBUWFWQ][F_9RK^ \2@,%$1$
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0'AU4_[P;,O:WGUR7+N,5O$519_+I:IIW#UR9N>>&*2*0_J.1.3,S$S*V
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M>@*,B(B (B( B(@+?W<8_$I8^W?4'[TPZF24-O<8_$I8^W?4'[TPZF20!$1
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M;A8;&I,G\!X@R;VO@?"</;G'^E&UEY[%=Q?VO^2V-O8D%3]( B(@"(B (B(
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M3;RU*[GB[%75.(C)Q\Z>0?U#+A&+>UTUKL-"8R?EG+)"S.W#L@+$J(B (B(
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M>,V?GV"8?[W#^3J^GOAV/]L]QXW'66B\%F;'0X1Y0Z85<W7;EWXK9JGZOE(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MC'XE+'V[Z@_>F'4R2AM[C'XE+'V[Z@_>F'4R2 (B( B(@"(B (B( B(@"(B
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M^MT..!PM*C/)&W SW0B8[]EO)GXL73GF;JY)A-F=W=N7[J1$ 1$0!$1 $1$
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MMU/YL+.7[3-S^UY?*L"]O,]5JZOPV4O^=&MJG&9*][/B.].OF8+5OV'X8^8
ME]E_HOH7?S69H6?G4OG_ -5)_J%Q_G4=E6/Q&,?>Y]0\?5<O+_.[_P"=?;^X
MU:+#D\1<F7VK/_1O$36W-&&VN62Y7MTYG*._7JX1W70JSP!+;Z3/]7R=M_\
MG7_X3:-5+<<\44\)A+#-&$L4L9,0212"QQR 3>1 8.Q"3>3L[.R_B[?AK0RV
M+,T5>O!&<LT\\@10PQ SD<DLLCB$<8"SD1F3"+,[N_"J,:"[\36^"VTTAH_!
MZ0HV-483!5\/D]59Z[-;IS/08JE.Q2P]1J\LTTE".J<\MS(PQ16VFC"E/78#
M>/3>CM";I;I3E+KK6.9RE-S<PPP62QVGH'<G)O#PE)X,>11\],<]B&Q:$'Z&
MG=G=GOSHOLZ:OD7365;1A8T+9PC:VK[K81FXQLKIKERJ,TN9*VVJ233<?0L1
MK_C;I&%6G&4LBYQ3=<?<C&32;C*<ENVM]O<A--^I:Q[1'?"[+:!*>C7S4VM<
M["YQOB-(1!D8XI1Y;IN9F62#"UA8V89 "[8N S]8TY!4(6_7?6;P:Q*6EHVK
MCMO,1)U TU.,,QJ.4'Y;DLI>B]2I]0.W+4<8%F(QZH[[<\-%/6PF.HBW6XN[
M?H1Z6;C^7R,RY#I>OE]07H\1I7!Y/.Y.4A&.CA<?:R=PG+GI^<TXII!9^'?J
M)A%F8G=^&=VGOAWP1X?TJ*NR*_IED%S2OSW&54=N[5&T<>,5W7F1LE']?U(-
MUGQJUO4Y.G3ZI40F^6*HC*,GOV^LZVR?\SE3_51\W4=;+:@R$F:U3F,AFLI,
M[O+D,Q>L9"V3$3DX#+9DD,(NIW=H8^B(>?8 ?<O4DM8VB/DPDX_*7#,W'UO)
M2W;#]RKNSJYH;NL[U#;W&S-')ZM8\/.:@*(_-V+'T;04:DO0XOT6LEXT1$XS
MUPDC*)3==GONDMF= M!9DP):QS,/!/E]9/!EW\5N?;@Q7@0X:MTN_P [\/'O
M*+"!%,<K>([B+QOX?TN/DX]GTVVM<D:<",94QVZ)._W<=07^:E:U^H?&C^#6
MOZK)7:A;+&KF^:3NDXS>_?ZI;W-_Z3R]_P!8JM;&]F7=+= XWT1H_)9#'R/P
MV9L .+P M[3]?PM>*O6FC%Q?K]4DL2\B4<8%-TQE,[L#W",+M!>W6UA+>E]D
MY<!HXCJTF?WE#/G;U4+U@'XZ3*KC\;)TD0Q2QD(RJQQ#"$8#'& A& L(  L
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M'6+,0B[M\\("9Q(1)K_^E]24LSC,=E\;.%K'96C4R5"S&_,=BE>KQVJLX/\
M*$T$H2"_RB3+7&*W%W(W:5;5.WEO0U^?JR^@9HH:HF7)SZ;R93RXTX^KAR&A
M9BN8^00<FKPQT6/H:Q"+@37(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MXG;G_E7-''A<5RWO<6R&0KN?'F,;&?+,+NU"-FX9FY=_KN_+O]=W^5W][O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MP.0 >2LUA'(,W+6_#FH6N3T=K#)Z?RN/SF%NSX[+8JW#>Q]ZL?1/5M0$QQR
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M+HO*AY-'X.ZY1E^#A39'Y]M\[I'@'J^8U/4LI8\'U<'/GGU^%=3Y7_M6Q?\
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M1$1 $1$ 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B
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M(=FJ&<Q(R/QSX>0Q7-IX1;E_%M8NF[\.S1^;<UA-:T\QIBVV.U?I[*Z>ND1
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MNY.7#F%Y.-%M;3M]^7QV?V%_1Z[>CDT$1%#9G@B(@"(B (B( B(@"(B (B(
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M:G ?<-C,VQGR<H=7)^$5IX1,B((Q<G62J(H@S<^_)L=N1=;?;+[5EUD[9O\
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MFM-9G'UP?GA[5BA.%1WX9W]FUX1>3/[O<ZUYM:5CC V]Q@)-^L0L[(#]D1$
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MQ1P0011PP0Q ,<4,,0,$<48"S"$<8"(  LPB+,S,S,O91%S_ &R80B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( O3OT8;4$U:S#%8K6(
MI(+$$T8RPS0S \<L4L9L021R 1!(!,XF!.),[.Z]Q>'9 T4!>\7['LFSNYF8
MTU!!,VF,J/PUI&S(W(2X:X9,5)I&\GGPMQIL;(!\3^#%5M2#T6X3DQ#V[P=6
MRT\,YA'8K2.Y"3LSG$3^S(#>\FYY$N/,>1YXZF5Y?O.NQ3'O-M[/4QT<(:QT
MX<F8TI9-F9YIPCXNX64_)QK9BN+PL7N@NQTK+L00R1R41<_B[5*8S>.>G<IR
MR5;D,@'#8KS0R/#-%/$3"<<L,HE#/$;,0DS@;-TNRO\ ^$?'<=7TRMVR4LW#
M4,?+BW[T]H[59'X7QBW)_P"5A:DE'E*P^)7"EE,[*J9RHKO?FX]D5NH;/>=3
M7PCOR[=U&4);M]#OU@QE-OD-V_69N?\ /_X+V,#DKN8R5'":?Q\V1RV3L!3Q
MV.HQ/-;N6I7XC@KQC[1RGQY-[N.7?AFY6,,F7L2_1RO]?CR^I]1?K3LRQ21S
M122131&$L4T1E'+%+&3''+%(#B<<D9LQ@8$) 3,0NSLSJ3\K4VHR5<4I;/E<
MEO%2^ZW&+3DD]MTI1;71-=U#6-P14I*67;9?[R<ES;;KN]MTXI[=GR/;X,GO
MV:[EG>?5/A6=53X;0%"40/PK]N/-9I@/VO/'XB:2E"?0[.T<^4"8"=PGAB,7
M%I9MDNX[VBTV\-K4TN<U_D0X>1LU9CH83K]SO!AL4,!/&0^3Q9+(93A^2$A\
MF'%[NO.^#AS88[;O=O)!!G!\"EI[6MZ:,(,XY%X4&-S\A#''5RS?.HZV4DD>
M'+$3C;>"\+29"QRSJE7B/X@\64Y5F'F9#PH/?RUI\713=7V4ZLC>61*+7249
M7;Q;<)QC+H6GX&X*X<>/"_#QH7R6RF\K:RVN>W6-E72J,EWBXU[27O0DUU."
M;?;7:;TG1'&:8P6)T_CQX?U3$4*U"$R$>EI)1K1Q^-+QY/++UR%[R)W\USM>
M44%6W3LE*<Y2G.3WE.<G*4G\92;;;^;9+,(1BE&,5&*6RC%))+X)+HE^ 1%T
MGNWVD= Z#B\;6.L=.Z<9P*6.'*92I7N3QC]$5:@\CW;7'N=JU>5V^LOOC8MM
MTU7379;9+[-=<)3G+\(Q3D_R1\6W0KBY62C"*[RG)1BOQ;:2.[$4'>\??R[5
M81Y:^D<1J37=T'<0EK5X\#A'(??XF3RG-UQ?R<)*>&N@7+\D/'G%]NUWW&]6
MI6D@TM1P&A*LC.(S5:C9W+ SER)#;R\94!DZ?9)_@@A?WBP/YJ4="\$^(L[E
M?T+Z)7+;ZS-FJ-M_C3M/)_[$T/6/$_1<)/S,R%LH_<H7F?NGTJ_[0M[9'*5J
M<)V+=B"K7C;DY[,T<$(-YOR<LA" MPW/+DS*/O>7O6=B=$G+7N:YHYO(PNXE
MC-)QS:DLL;?11RV,:,N,JRCY=45V_6D;Y!?A^*=&X>O->:WE.QK766I-1D;D
M[QYC,6[%,>I^2"#'O*./K1<^Z"M5BA'EV",66/FN,G0PL/JU1XY<@8LS,(L\
M=4'_ .L/W>V[?T*/Z[&7L\,<RZ)[,]$-IZEJ-EG;>K#A&J._P\ZY62DOPIK>
MWJB+,OQ^^D7+&TK"\RR3V4[I.<8KUG-5\L81BNK;LE\$FVDYJN\&[]^UK'2^
M7T-MM@<KIF'-P24,KJC)7XH<P.,F;HM5,52Q_BM1EOP$4,E\\AZS6KG(,%<)
MY0L05A;HL(\,S,S#PS,W#,S-Y,S-Y,S?(S+FMZ1RZB)W(B=R(G?EW=WY=W=_
M-W=_-UPR_P"Y_P!93[PMPCI^C8[Q]/H5-<Y>99)RE.RV>R7-99-N3V2VC%;0
MCUY8K=[^F[5<G+G&S)L\R:7+TBH02[[0BNB6_P =Y/IS-G"+WR_KO_XK(OL+
M=ER[O+N[HC;^K$9TLKFJMK4<X,SM2TIC)H[NHK3N[.+2%C8IJ=/J$@+(6Z82
M#X9&XXZ7OE_7?_Q5T;T;[L0EI?1F7WDSM7IS&X 18_2P31\24='X^>4I+L+O
MYB6I,CQ.1>;'C\9C#B<1GF\3#^)G%T=%T?*RU)+(G'Z/AQ?>63<FH22]?)BI
MWR3Z-5./=I/:>'L)WWQAM[J?--_L1VW7YO:/Y[]DRR[B\;!2K5Z=6(8*M2"*
MM6@!N AKUXQBAB!O/@(XP$1;E_)F7OHBYO-[]7U;[LF$(B+X 1$0!$1 $1$
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MVMR\CK/5&H-69:0I,CJ++WLM9Y)R:%[<Y20U(N7=QKTJ[Q4ZL?+M%6KQ1,_
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MG49Q1<E\&W)I9</=L&+?T*KDI)*/47NDRE<6\G\@*R*(B (B( B(@+,_</\
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M$5JO7Y NJHOG8G+5;]6O>I6(+E.Y!%9J6JTH35[-><!DAG@FC(HY8I8R$XY
M)P,28A=V?E?10!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:" (B(
M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
M1$0!$1 $1$ 45W>@=W32WNTR-_"A4H;B8"$RP.1G?P8<I5;JDFT]DYA G&M9
M-WDI6B WH7>D_*M-; Y45X=9;0]<R=.RJ<S$L=5]$N:,N\6NTH3CVG7..\9Q
M?246T>//P:LFJ=%T>:N:V:]5\)1?I*+ZQ:[-&LGU1@<AA\A?Q.7I6,;EL7;F
MH9+&W(BKVZ5RN;A-#-"?#B0DWGQ[+L[&',1QF7$9I%>#[SONML9O-2/5.F/5
M\1N7BZ91U9Y&"'&ZIKP@[Q8C.DPN\<K?T/'95G\2FY>%.TM3AH:46Y.@<WI7
M,Y'3VHL5=P>:Q4[U\AB\A'X=FI*WR/YD$T$C>W6M0G)!9B<9899 )B>\_!/'
M6'KN-YM+5636E]+Q').=,GTYX=G91-_8L2]UODGRRVWK9Q1PE;IUSZ.=$VW7
M:EM%_LR](R77>._SC[O;@LLB^3-(OVFD7SV Y3:.,7,R?@1%N7=W^HW\N&_O
MK>DMC 5PZ=>WS[?-_@C+[L=]NW7VQV?^&-(9#Q,=:,/AS3%\CEP6<A9Q_/%=
MGYJW@$6&ME:?AW:X\QN<M62>M-:5R??R[3Y#;F//U\'E[VJ[GB4GT!?JQ\5L
MA%$!O8O9>0#Q\N <C%X<A5"Q<L,Q1-C(;4=F&M3NPVB1#B6YP<C>;0<\Q@_/
MZ-V^C+ZS/T<\\]?EQS0N&\F;CZC-[N&;AN%''%? 6DZKD57WT-7UR3G=1/R7
M?"/:NYQ6\UVVFG&V*2C"Q1Z&1Q/$'*P:YX^)9&<))I.Q>9"MOO*E/IOWZ/>M
MM[N$GU.UNT#O;D]Q-37=49>A@\;/:-V@QNG\/1P^-HUV(G"&..I#'+<EY(BF
MOY&6W>G,B8IQ@&&O#T9)[F_E]5>^?N7H2>YOY?56YXM,:X5UUQ4:ZXJ$(+M&
M$>BBE\-OWO=O=MLT^639=.5ELG.<Y<TI/NW)[M_!?@MDNR6QZ,OO_E]1?.D^
M7^7RKZ,OO_E]1?.D?W_R^596C_C^![J_3_CT/FS>[]K_ ,%]_0FW^;U7F\=I
MS3>,N9G.9BR%/'8VA$\UFS,9<>0M[,<,0\RV;,I1UZM<)+%F6*",Y!R?[(O8
M=U_O9FQQ>D,638VO.,>;U/>9X,#@H^CK)[5A^#MW2%P&OBZ V+TIRQ221UZ3
M3W8+L/8:[O/0VQ6&>O@8"RFI+\$09_5V1CB?*9(Q9B.O58!Z,9B FZBK8VL[
MLPM&=VQ>MB]HX]X^\5,+0X.J+CE:A*/U>+"72O==)Y4EOY45]I5_RMBVY5&$
MO,C(7"O"-^>U-IU8R?O727V_C&I/;G?HY?8CUW;DN5X==V)W0V&V@CJ:SUJ-
M//[ERP%X)1N5C#Z1"P+-)6Q(R,,=O*=#-':S<D R SS5L;X%:6Q)<FX9>45)
M>(>(\S5<J>7FW2NNGT6_2%<$VXU50[5UPW?+%>K<I-RE*3G_ $[3:<2J--$%
M"$?SE)^LIR[RD]NK?X+9))$1%@SW!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MLJPW)^5"QIV./H[''IWZJ"<N5;)RG)<QZ9_+^VO2/WKW3^7]M>D?O60K]/\
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MVL=>NUVEP&B(QU+DW,>8IKT4GAX*CY\LYRY#B\8NSB];'3@3B4D;O=.0!$1
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MC&^/79617O1_\2^3_@^GP;[,1$46&3"(B (B( B(@"(B (B( B(@"(B (B(
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M8Z[?@>+4&M9&U-E&,>F6O5L1C'A,>_N=AKXT8[,@ORXW+UMF)P:/IE%7XUX
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MU1$0!$1 %9R]'W_YBW.^S.F_WADE6-5G+T?C_F+<W[,Z;_>&20%AY$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %&9WQ'TNFX']OT3_"%I
M129J,7OC; AV=]= _/,UO1<8<-Y=0Z[TS._5YMPW1"?FW/M<-QP_+ 4J41$
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M<>>\+O'7(GE/#UZ]60R;%Y&;*%52HMELE5<JH5UJB;^S9RKR9/WVZFW5O$^
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M_20]RS]\HMKY,(B+3#.!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M B(@"D5[I7Z8O;/^WZN_@]U<HZE(KW2OTQ>V?]OU=_![JY 7>T1$ 1$0!$1
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M9RED(M)Y.T8C'I_)VI'9\59GD(>C#Y&<Q>J9OTX^\9"Y#5M?F8"U:B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@(GN^J^(3.?9[2GX<JJF@
MKE_?5?$)G/L]I3\.55300!$1 $1$ 5X;NI_I?MN/L?E_QDS*H\J\-W4_TOVW
M'V/R_P",F90$A2(B (B( B(@"(B (B("&?OX]<OA^SYDZ8&4<FI=4:8P(.+N
MSN(W),Y8C\G9G&6GA+$9L7+.!DW'/#M2OP;^[Y/=_I^3R;_W5K[TC[+..VVW
M6/Y;IGW%]?<>INKKH:4U#5$F'CJ=F'*R,Y,_ ]0B[.YCQ4UIVO!A.3Y1;V?^
M\_#"W]]_[ROA[/F*JN'(37>_,RKI?C%PH7Y;4+\]RN_BG)V9SAW<::JXK^=O
M-?QL_J/HYS)>-,,0O[$'L_6>3]&_U'Z>.AOJ</Q[W==EZ8T"\U6.Q89A\5FD
M 9.&9@_0%P_],WM-\O#MY<LZ^=V?MCM2;DZJQFD-*46R.;RA3%#!)-'6A"&K
M"5FU8LVI7:.O!'$!=4I^74X +$<@L]@G:_N&]P,CX<FL]<Z>TY79F_,. JW=
M07G!F86B.Q;;#4JABW+L40Y./AA'WF[Q[_K_ !QI&DR2U'-JHL<%.%3Y[+I1
M;:4E35&=G*W%Q4N51W3Z]'MH.=PIJ^935C:31)QYFKKWRQA'E2;CSSE"/-)R
MYY+??9+9/?8@_BP&.KLW7(#NWR,S?^W\OUU_89F@,HP5H7L6#]F.&,2EED?Z
MD<48O(;\-[A9U;0VS[CS9?#^%)G1U'K*P#\F^6S-C'U)'9FXZJF"^#'=F+S<
M#L&!-P)B0]3%([MCV:-O=%QC%I316F, PL+/+C<-1KV9''S8YK8P^M3R\^92
MSS22D7M$;OYJ)]8]I32JMUA8>7ER7:5GEXM3^#4F[;?G[U,7_9[=,]G;/N:E
MJ&HP@GU<:W.V7S3254/W62_\Z5FVG9)WGUIT?,QMKJ::M)YA?OT1T_C7#Y3#
M(YX\;5F86\W"O+--^A&(B<1*07;?N,-T\QX4FJ]6::TK";B\L-(+FH[\8$W)
M< #XNF4@>;$'KO1U?0R$/M*U\BBC6?:-UR_=8M>)@Q]'"MY%R_&=[E4]O3:B
M))NB^ FA8NSMC=E2Z;^9-5PZ?*M*?[[60E;6]Q-M1B>B;4V6U7K*TS-UA:O0
MX;%];<>U%2P\,-M@?SYCM92X+\^_R921[4]CS:W1#QGI;06F,39B=G"_%B:L
MV3%VX]V3M!/D&\V9W9K/3U>UQR_*R2111K/&^KZAO],U'+NC+O6[I1I_*FOD
MJ7X*").TSA?3L))8N%CTM=I1JB[/^DDI6/\ .1_+"S-PS<,WN9O<WR>3>Y>>
M%Y1:L9X(B<H B\<KY^6R]2A6GN7K5>E3K1E+9MVYHZU:O$+<E+-/,0111BWT
M1F0BWRNR^8IMI)-MO9)=6V^R2^)\-[=7T2/HHHL]]^^)V/T1XU>'4%C6>4BY
M'X-T57BRW,C?H3RL]BE@XA9^GJ=\DY]!=44<KBXJ'_>OOX]QLXTM7;_2^(T;
M7-G$,EEB;4>8!G]TD4)Q5<1!*SMU,,U7(Q#U.)!)TL;R3P]X1:_J7+*K G15
M+;Z_,_O:O9_>4;%YTX_.JJ:^!INM>(.D8"EYV77*<>]=+\V>_P -X^Y%_*<X
MG0WI#G=,1XR6[V@-N,8XU+ML3W-P-*(6"O:LNP!K.A7#I?HMV'"'45>("+UF
M:/,]/$F3D:$[L=U<A6P60J7:L]8!R?K5;U@"C(PLUH0DZ0/@Q 3KL[=0CR\A
M./+/RLT-R]U]QMP9WLZVUEJ'49.[EX.0R$@X^-WY=VKXJJU;%U0Y=W:.M3AC
M%W?I!N77$\/@HJ3$(.+D73U,/R=/U?VW?W*[?"&@ZAIVD58>HY=>9;C[1KMA
M&:Y:4XJ%4IS?-;Y?6,+'"M^7R0<?=YG7SB/Q2P=3O6)B4RBK9<SE-IR4H)SW
MY8>[#F2:?O3[O;N?:VOW^FVIWGV5U_'*45''ZN? :BZ3<!FTMJEZ>+SK3,/'
MC-2I$>5K0F3 5ZA5<G'Z)MAG%,)B)@0F!LQ 0NQ"0$S.)"3<L0DSLXDS\.S\
MLZUBO;#@Z\!C!\VYR_'+.[$W-"XW(NW#B[>]G;W.W/O97Z>ZM[0Q;H]G_;'5
M\\GB9&;3[83-$_#$^<TM;M::RTCA]%&%F[B9KE=C]HZMB"7DA,3* O:*T#>G
M3=4C'[,K,"Z6WZW/D8R?[LKJ^O9=MDIF\+\S?#\EOLYSBOESM2_C*)(,B(JK
MDH!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!5=](*W[*SJ'
M16VE25G@QF/EU=F@ V?JN9*6?&X:O(P_0'6JT\C9*.3ER"_3E$19F(ZZ6H=1
ME4@\"!^+,[/[3/YPQ\<.;?+UEYL'U/,OD;G+3O#MY_FTWMW(U!XI34ZVH;>$
MH$[L[>H:;=L+"T9-Y%%++2EFA=O(@F%_EY6!E:&:[9ZNESEGD$1!O?R[L(1C
M^LW#-[O=R_RNNDWASH:TW0]-Q>7EG]&A;<O7S\CZ^WF^+C.QP7P44ET2*I<3
M..?JF5DVM.BJQJ.[]V4:=X0^7+RQ\R7IUZ_:9SC9_;.[J[4VG-)XWJ^$=39O
M'82J0AXA1'D+,<$EIXW?VQJ1&=HQY]H8G;EN5LH=N= 8O2N!P^FL)5CI8G!8
MVGB\?6B%A"*M3@&"/GAFZI#8.N:0N3EE,Y9"(S(GU_W9 W!@VGW-TQN!E,#+
MJ6OIR2[,V(BN!1,[%G&VJ,-J&Q)!8!I*,MGUR,#C9I980C*2,7ZFMQ;$]\AL
MCK3P:]O-V]$Y23H%\=K*M'CH_%+RXBR]6>]A98^IBZ"._#+T,QS00.3 H1]H
M;1]7S+,+Z-A9-^!C53LLLH@[4LBV?++S*ZW*Q*NJN#4Y04(^;)*6[D2%X:<1
M:6XW/Z90LBV<8QC.2@W7!;KEE+:+YI2E[JEN^5-KHB51%\C!9^AE*D%_&7:F
M1HV0\2M=H68;=2P'+MUPV:YR0RARSMU 9-RSMROKJI$HM-IIII[--;--=TT^
MS1-2::W75/LUV"(B^#Y/'"Z,W5[,>WFN!=M7:*TUGY''H:UD<13FO '#-TPY
M!HAO0-PS-\YL![F^HR[T1>C&R[:)JRFVRFQ=IU3E7-?A*#37Y,_*ZB%D7"R$
M9Q?>,XJ47^*DFG^XA?W6[C#9W.>)-I^QJ;15LNH@^"<F.0QW6_N:3'YJ&\[0
MLW_5U+=(GX9_$;VNJ./<KN'MRL2YRZ1UEIW4\(\N$&2KV].7B9O-F\I,M3<R
M^A9GLQBY<=3@#NXVO$4DZ-XS<1X6RCJ$\B"^YF1AD[_)V6+STOE&U&CZMX9:
M)F;NS!JA)_>HWI:W]>6#5;?XP90[W/[(F].ANMM2;<ZDAIPN_.0QU0=08QQX
MY:4[^#DR->'K9N6&T=>5F]EXA<7%L8FU+4,RAL0M',#],D9B\4L;O[V.,F8P
M?ZQ"S_66QA6/^Z_94VVUS$\6K=#Z:SK\$(V+N)J^O0]3\N5;(Q1Q7ZIN_/SR
MM8BD\W]KAWYEO1?:;L7+'4=,C)?>MP[7';YJB_GW_#Z1'OW(GUGV<<.QN>%E
MV4R[QC='?\$[:N1K\?*90ADQN,LL_#L'/R.PO[_D_DR]O3M'+8.T-_36<RN"
MNQOS'=P65O8BX'+\OT6,?8K3CSY.[,;,_P O/RVI=T^XIVCR_B2Z8O:FT7.3
MFX1T\D>:QX._T ^KYSUNT\8E]$S7V(A?AC%V8E&WNAW%N[.%(Y=):FTQK"H+
M\A!9*UIG+%SSP+5[ Y'&&PMY%(68@<G=G&!F=V&6-)\;>&<]<EF3]&<ULZLZ
MEU1:^$K%YN-M^-W4CG/\'>)=/?/B6.^,7T=%BL?3MM%^7=^Z#V^)C9MAWI?:
M"T?X<;ZK#55.+I;U75F/AR9$ >3 ]^N]+*%U>XI)+DDQ<_1\^[O_ 'M[W+&;
MN[::NVRW5VU*M7U/A;-"+/:5R078Z.59FGQ.6'"9B""6NV-R456WS#FKEAVB
M=HNDB9VC_P!T^S1NWH)C/5F@=34*<+$4F3BQLF4Q 1B[L\LV3Q;7*5>-^'Z7
MM30.[>;#[EC]6U=0L\=8Q'S_ $KLS_YG66_] >&M1E7F8V-ANRNR%M65IUBI
M<+824X34\2<:I24DG]9&:W[K<\E7B%Q7I3\K)5\TDU*O(CSMQ[;<N1%S2_F3
M7RZ$/V9V9U)0'JFQTD["+.<E)VLCSQR7 #Q.[-Y^?A<<-R[LNLB'AW9V=G9W
M9V=N'9V?AV=G]SL[<.S^;/Y/[E.R>.QEEO)V!W^KP[?K\_\ LHJ>U!I:MB=6
MVXJO1X=JO5O$,?N&:<3:5^GAF%Y"C\1_Z8B(W\W=U)#7X?D2!P+XD/5<B6)=
MCNFZ-,K8R491C)0E!23WW6_OIII^FVQ:G]%&WI*2GNWMW/+^<[. UECXC,N7
MBR$5C"Y-J\?T+!!+C\<=@FX?KNP>]G\KA:UY/HT&NI,1VG(L>TAM#JC;K6.#
M.%B^=R35K6 U+!*8.3,\D,>G[(12<$8!8G!N!ED=;#94$\?-,6/Q'D3CT67C
MXV5M\).'D3?^U.B4_P#:V+':'8Y8\4_NRE'\M^9?NYMOR"(BA@S 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %35[XWLV_,/NK/G:-;PL%KZ"3/5R
MC!A@BSD<C1:@J-TLPM(4YULJ3]+=;91^',XI7:Y4HW.]4[-I;C;29H:-=I]0
M:5_^RC",S<R2ECP)\I1CXY=SO8E[<< -PQW JL3B/4Z I)(O#.SLSM[G9G9>
M4 1$0!$1 2X=S9VDGT5NI%IV]8:/ Z]KMA9AD/IB@SL!//@K;._LL4I^L8LF
M]EC?(0F1/ZO&*N0+6\T;]BK/!:J325K=6:*S5LPDX35[,$@RP3Q&WF$L,H!)
M&3?0F(O\BOS]C;M"0;H;<:8UA&4?K=ZB-?,PQ]/%;.4?S+E8>@?Z&+VHSFA#
MY*\T+^;.SN!D^B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B \.J@_?6=I5M7;E1Z,H3-)A]OH2IS$!]44^H\A%!/E29F=Q=\?"U7&$_D
M86X;\1"S Q%9T[5F^]3;3;[5.M+709X?%SGCJQ$(^O9BPWJV(HMU<^S9R$M<
M)2$9'BK^-/X9C$XO0*SV>N96]=R>1G*UD,C;L7KUD_H[%NW,<]B8OD9Y)I#+
MI;R%GZ19F9F0'R41$ 1$0!$7AW;S^MYN@)/>Z5[-+;A[LXVY=KO-@=#^KZIR
M;$+%#+=KS_\ (%*7J]DAGR47K91/U-/!C[$9@43R,KJ;*+'NANS8&@MIL=E+
M==HL[KQJ^I\B9#Q../L0,^ I2<LQ"-?'2^L^"_E%9R%IW$9)).93T 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 6!7>@?$'N9]
M@X?PKCUGJL"N] ^(/<S[!P_A7'H"C(B(@"(B (B("W]W&/Q*6/MWU!^],.ID
ME#;W&/Q*6/MWU!^],.IDD 1$0!$1 $1$ 1$0!$1 %6X](%T?P.VFH!#GYYJ#
M"R'PWL]04+\ .7O]OP[),W_W,G5D=0U]^9H9\ILO7R@#R6F=8X/*2.S.Y>K7
MH,CI^0/+] \^9JRG[N/!$G=F%T!4#1$0!$1 %^]7(35)8K==^FQ5ECLUR\_9
MGKF,T+^3L_E( OY.S^7D[/YK\$0&Q@V]U-!F\!@\S6-I*V6P^,R=>1B8F."_
M2@M1&Q"[L3%'*+L3.[.S\L_"Y@L&>[5UG\.[%[:V7/K.EINK@Y//EP?3Y28:
M,2?ZO@482\G]Q-Y\K.9 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 %0Q[P'639[>G<G("?7&VJ+V/B^7I#$M'B^GS9OH3J&WN\OK^][W6<S-
M?'4KF0M'X=6A5L7+,GE[%>K"<\Q^;LWLQ@1>;LWEYNS+7,Y_45C,7[^8M_GO
M+7KF4M/SS^:<C8EN6//AN?GTQOSPW/U&0'R41$ 1$0!2R]RQH_X3WRQMPAYC
MP6G\]D^KCGHEEKQ8R+];J&_,W/G]3CS432L+^C^:,\;/[DZA(?+'XG3V&A)V
M\G+*V\E=L,#^[JC'$U^OY6:8&]SN@+/*(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B *BUWFWQ][F_9RK^ \2KTJHM=YM\?>YOV<J_@/$H#!1$1 $1$ 4BO
M=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@"(B
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M$[DZ_P =I73^9U+EYF@QF"QMS*792=AX@IPG,8L[^76?0T<;?HC(6^5 5O\
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M0G<=+Y:?I <M$Q/P&.LD(1Y>,'%HQZ<B E)!-'8B+3A ;(JO8CFC"6(PEBE
M9(Y(R$XY(S9B P,7<3 Q=B$A=Q)G9V=V\U^RK7=SOWB'AO0V?UM=]EWAIZ!R
ML[OY>3B&EK4K\LS>0M@C)V;WXOGJ]1 K** (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B(")[OJOB$SGV>TI^'*JIH*Y?WU7Q"9S[/:4_#E54T$ 1$0!$1
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MYV<W,>&KB-50XC-R]+%IW4\?P%E6D)OZ'7>T7P?DG9_)RQ5^\(NXB;@9,"D
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M=G;EG;S9V?W.WUG7E $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1%X=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M B(@"O#=U/\ 2_;<?8_+_C)F51Y5X;NI_I?MN/L?E_QDS* D*1$0!$1 $1$
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M:PQV=>X>QT/@9#=G4TF<L=3')IS2\UJAAQ;_ .#8S<L=;+W6=_,SJ08AV9W
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M4I3KR8^I8?.2D[ACZU_DW?(]]_B=F:V0VXVVL5\UNQ;JS0W<A&T%O$[?#,#
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M=XL-N'%6PAL3LT4>?K'-)IZ5^2;I.Q+8MXH..IY)LC #@7 G'<90!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 %@GWCO:2;;#:C469JS!'G<I#\S^G!<F
M8_A3*B<'K8#SU%\%T_6LD_#.+G5CB/I\5G6=BJ']]IVD2U5N16T70L$6'T%5
M>"S&+MX4VI<D(39&9^GS-Z5%J-&-C=WAF:_T<-.7($,!$Y.Y$1$1.[D1$Y$1
M._+D1/RY$3^9$[N[N[N[\NO"(@"(B (B(#^A B=A #D,G80CC$CDD-WX$(P%
MG(S-W80 6<B)V$6=W9E?![ 79O':S:[3FFI81BS$U=LSJ-V8.LL]E CFNQR&
M'+2/1%H<;&?6;/#2C8"\-@9JNG=+=FW^:%NWC+-VNTV!T7&.J,J\C.\4MJO*
MT>"I>YV>2?)]-SI+@2K8VWY]72)76$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MMG0.]&#^%]'949+=80',Z?NMZKG<'9(6ZH+U(^".'JY&#(57GQ]KA_ LF0R
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MSMT8UH[LH%[<=J_8B?D8QXE/7XUJT<,<<,,8111 $<448B$<<8"PA& "S"
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M?K M-:4EMXZM9KR<MX&5R'C/D<J)1^Q/%+-#0L<F[X\!<8PPTP^F*F.=I)7
M>&-NGRY]L"%_)OE]IW\_K<^]U*?"'LW/:-VLY'S^AXDNGR5N2_W2C3'^;>1E
MQ;X_XU#=.G5^9/LK;$Y/\84Q_A*;_&LS[[2O>K;R;I/8Q]/(#H33$W(-A],2
M20W[,7R?"6H"Z<E,3^?5'CWQE1Q=AD@G(&D>/O'Z/KUN9;!-U$3R&Y.Y222&
M[G(9.[]1&9NY$9.[D3N3N[N_/]V]6UH98JM62I$<QC''+:MU*,+$;L+/-<O3
M5ZE4&?Z.:Q/%"#,Y'*P>TLNZNP^V]'1.:U5J3>K16:U56QCV,%MUH?/8[+W[
M.3E((ZX97) ]@2AIN?C7:^.IG$?AN/PH$0\RV!IJTC0*:J,;'A1&R<*X58M$
M[++9MJ*E:ZXRL:W>TK\B2C%;\]B1"=T]?X@G9=?;*JB$93G9=9&"C!)RDJU)
MQ@GLNE=2E)]-H=48(:XO"<PU(FXAK-[OJRFS$?[8MTB__:8F^NNOC#^7_BOK
M6"(R(R?DR=R)^/>[OR_E^O[F7HF/RKR.]SDY/[S;,EC[1C&"^S%*,=^Z44DN
MOX+]Y\F05\^8'^1B+G]"+.1/]01$6<B=_<S,SD[NS,SOPR^U("YQM#N;AM&:
MMTYJ?.XF'/T,'EJV5+!3Y./$196>@[V:E66^=2_ZO UP*\EAPI63.$#C"-B-
MB']O-FHR=<';.,9.-2E&+LDDW&"E-J$7-KEYI.,5OO)I+<S.''S)PAOR\THI
MRV<E!-]9.,4Y-17O;13;2Z+<O:]VIV:7VKV>TGIVU7:OG+M5M0:D#R(QSF:"
M.U9K2&PMU%CH7KXSGDA_,;^&3Q]*ST51O,^DAZLLN_P3H31%'S)A:]G\GF''
MD2Z6?U8,)UNQ=+OPP=3"0LPN3$'!K?I &\-O\[XW;NIU$)-ZOC,M+PS,XN#>
MM:BL<L3^T[O[3%Y"[#Y*HV=X+\3YV3?E9%.-7;DW676<^75+:5DG)I>4[5LM
M]DDWLDD62Q^--+Q:JZ*Y7.%,(UQVHFND$HK[:AU>V[>W5O<N.HJ9\G?E;YSE
MUQ2Z1A#AFZ(M/$8<_*75+?E/E^?=U<>7DS<^?(<=WYN]D?A^+!HRST>9^)@K
M8>+Y^XO RL/2SL_'SOH=N/?SRZ_%^ &O);[X+?P63+?^-*7\3Z__ ,2M-WV_
MOA?/RE__ %[_ ,/X]"X>BJB:=[^_<N(@^$]'Z(OQMQU-5;.8R8V\^?GLF3R<
M0D_EYM6X;CCI?EG;*#0_?]XB9P'4FV^3H>8B4N#S]3+C\C%(\5_'X4P'WGX8
MR3$+-TL<K^;X?,\%.(J4VL*%R7?R<G'D_P H2LA-_E%GKH\0M*F]GD2K?^<I
MM2_.482BOS:+#:*,?;3O=MD-1%'%/J2QIJQ)PS1ZDQMNC Q._#]>1A"UCH@'
MWO)8M01LWZ)O<I#]):YPN?J!?P67Q>:HR,Q1W,3?JY&J;/[G"Q4EFB)G^1V-
M^5H.J\/9^"]LS#R<;KLG=397&3_9G**C+_9;-FPM5QLE?WOD4W?%5V1DU^,4
M]U^:1RE$18<]X1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1>OZW%_\6/_ .<?_->0
MLQD_ R 3_4$Q=_[S/ROG9_ ^-T?NB(O@^2E[W[6RA:9W8#4,$#AC]98R#*!*
M(NT99&N[T,G!U/Y%-&5>K;E8?(0R<'+]1%Q!3;L>_P#SJZ_W\>R'S1[-OJ>O
M#UW=$92K?(Q 'E'&92:#'7!8G^>.'K,E SCC8OH&FDZ8X3(:05NQ[U>OPCUO
MZ?H>))O>S%3PK?COCI*OY[NB5+;^+96GC31_H^J9"2VA>UD0_"W=S_=;&Q+Y
M)'WZ&M+%-V9GZP']"[\$S?48O/R;Y.6?W^_A=M:;W?A)Q IN@^6;HDX'GZS.
M_LE^T7GQ[FYX6,%NQ[_-<7N3L_//[?ZWR_WV4O8^1./3?=?/T-1S.%L7+BU9
M6DW]Y);_ (M/H_Z_F21U<_0O#TRB+N7EU#Q[_=[F\G_6;C]IU]; 1Y/"Y"#-
MZ8S%_#9:HWYFR.*NST+T(LWT SUY(S>-V]DXB<HC;R,';R4[_=R=FS:;M.;#
MX&[J3$!C=?:3\?1F=U1IB2'$YZ>;$@T>&R>1Z8)J62M7<%-CI;4V4IVRLVPL
M2\L/AL&.G:'[E?=31C3Y#0]RON+B8>3]5KC'B-2QQ,_GQCK-DJ=\HQY=VI7F
ML3<?.*)R$T+:'B>+6C7963IFH26!E4VV8UE69RK'MVDXMPR']3*JR.TH^?Y+
MG&2]QF(U'P?UC A#-TJZ>14XQMCY+EYD.B>SJWYU)=5]4YI/?J?2[.W?;[G:
M0>'';A8VMK_$1^''\(QC#A]401 S [G/!$.,RCL L[/9J5;4A]9V+\Q'R,^G
M9G[R7:3=1H*V U)'CL[+P):8U& X?.#)RS>'##-(=3(\\CTR8JY>B=R8',96
M.,*4.8LWL5=FQ&H\5>Q.3K$4=G'Y:E8Q]^ A?H)I*]N.*8."%Q]H..6X;W<+
MY-S3="\W,;@SN_D).W+._P!0O<S_ %UB>*/ O0M43NQ%^C[IKFC;A\KQY;]G
M+&_DG'U^H=._=R?7?UZ#XW:QIDE1JE,LBN'NR=N_/';O]<ESI_Z6-FW;\-C*
MBHX[#]YOO'M*T%2+4T>J,# XBV!UE-/E "$6Z6@H9)YQS%(1!A:"*.U-6@Z1
M8:A Q1')KE?20-,0Z?":OMKG9]5N+A+C#S5&' 1S,S<2#G/59+\M<G?R9L$$
M_DXF CQ(5;N(/ K7<*Y5TUU9]<Y<L+:+:X-;]O-JNG7*KMUE[]2[>9OMO8?A
M_P 5=)SZ?-5DZ&ENX65S?X\DZXRC/Y+I-_J=]K+#K!'M:=Y/L]LO7F^;/5==
M\P$9%!I7""V9U-;-F?IA'&UC8*3F[,+6<O8QM&,B'QK<0DSO3M[4/?.[Z[CQ
MV*(:B#1.%GYC+%Z(:QB)CB?WQSYLK$V;-B9F:3U>Y4CD]H7B:(RB>'N_#)*<
MDDA$4DID<DLI$<DAD[N1F9.YF9.[N1$[D[N[N_*W;A7V=K;'&S5<KDCNF\;#
M]Z;7PGD3CR0?HU"NS==K$^I\9OB%![QQ*G+_ #MW1?E7%[OY.4H]>\63E]M_
MTA3=+77K>%VVB;;+3$O7$=V H+VLLC 0\.,V4,)*F$C/ER>/#0^OB0BS9?PC
ME@.NG=BL6Y9)2*2:64W.:>8R,SD)^HY)93<B,R)W(B<B,G?E^7==@STHAYZO
M;?W^?DW][_SY7Q[=CAN&\F;W,S,S?WFX\OVOVOE5G^&^$\#2J?(P<:K'@^7G
MY%O98UOM*ZV6]ELEN]G.4N5-J/*NAKEFIW7RY[9RG+TYND8[[=(Q6RBMEUVV
MWVZ[G#QP4,?M2\2G\C/Y +_K?HG;ZK^7UN?=^%RQ[_J<<-];C^7DO<N6/>I"
MN[?[L'7/:0U,U3%QV<#H7&R__91KN:N)TZ# 4?5BL.$W$>4U%9C-WKUA&6I1
M 2M90XP]7KW,IJVK8V#CVY67="C'IBY666/9)>B26\ISD_=A7!2G.3481<FD
M>[$HG;)12<I/HDO^-HKXM]%W?Q/F=V9W;VJ>TCKF/$8]I\9HG!V:TNNM6,/S
MO%TC;QFQ6-<A>.SJ+*0LP4JSNX4H97REP7@BB@M[*#9;9G3>WNE<'HO2.+AP
MVG-.T(L=B\?!RXQ01-R\DLA.4EBU8E<[%NU,1SVK4LMB8SED(GXOV:NS7H_:
M31^)T-H;$PXC XB%@CC%F.U>M$P^M9/)VND9+V3O2#XURY+R<LC\#T1A'&'?
M*H'XH^)E_$&4E!2IT_';6+CM]9/L\B_;H[IKHDMXTP?EP;;LLLDO2]-CCP^-
MDMN:7P_9C^ROXOKTZ)$1%%AE B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@(4N^Y[-_S3[<UM<4*WBY?05CQK3QB[S2Z;R4L
M-?)MPW/4&/L-4R1\LS158;LO4S,0G4<6QTU-IRGF,=?Q.1@"S0R5.S0NUY!8
M@FJVX3@GB(29V=CB,A\V?W^Y4 >TUL?=VWU[JC1=X3_Y$RMB&C.;<>NXB8O6
M,/?%V<F?UO'2UY9&$B\*=Y8"?Q(39@.B41$ 1$0!<YVRW'RFC]1875.$E:+*
MX#)5<I1(N?#.6K*TCP3,+L15[(,=:P(NQ%!*8B0N[.W!D0&Q,VDW-QNL],8+
M5>'-SQN?QE3)U>79SC"S$)E!+QY>-6DZZ\S-Y-+$;,[LS.NQ%7O[B+M)O?P6
M?VOR5CJLX.<]0:=:0W<WP]\XX\G1C9W\XZ&3=K8<<NS960'Z8X8V5A! $1$
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MF/TYA<1I_%0#6QF$QM'$X^N#<##2Q]:.K6C;_NPQ SN_+N_+N[N[N@.5(B(
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MKAR27:U%I?=_ODMK\"4E73<&6UM>!W%CQL0X[#,3.[.QY7(],IL[<.!T<=>
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M$OSW?4(B+0S(!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MW=+F;(72;@7ZKEZ6Q9?J;J;Q."=W9W?NQ $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MR[.SNQ,0DSNQ"0N)"[/PXD+\.),_DXOYL_+/[EX0!$1 %X=N?)>40%S'N?\
MM/OK_:ZMALE9\;4>A9 P-WK)GFM8E@Z\%D';ER+FFSXZ4W\RLX^60N&F#F5]
M48>[@[4;[4;HXC+V[/@:<S7_ -C^J1)W\$<9=D#P+YMSTB6)OC7N>*[.XU1N
MQ,X#8,FO-12B8B8$)@8L0&+L0D)-R)"[<LXDSL[.SNSL_+(#]$1$ 1$0!$1
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M!$1 $1$ 1$0!$1 $1$!$]WU7Q"9S[/:4_#E54T%<O[ZKXA,Y]GM*?ARJJ:"
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MR(>T-&I;F=Q"(C'*14Z>^#[7_P#-!U^6D\18\32N@YYZ,1QD)09/49"T>6R
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M;7] ;B[$+D)"[$)"3B0D+\B0D+L0D+LSB0NSB[,[.SL@-D<BAG[J/O#FW*Q
M:(U=<9]>8*HWJURQ*WBZKQ%<!'U_DN"DR](68,J')G8#HR?412VAKS,( B(@
M"(B (B( B(@"(B B>[ZKXA,Y]GM*?ARJJ:"N7]]5\0F<^SVE/PY55-! $1$
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MV?VM<%LSH?(:MS#C8M<^HZ?PS2,%C.9N>,RJT(/>0Q"P'8NV&%QJTX9IB\V
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MDW][]1_>^R]Y;;V8T1%5DWD(B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1<6UOK3&:<Q&2SV9MQ4,3B*5C(9"Y.3#%7JUHREED)W][L(\"+<D9
MN("SD3,X$=_>G=L@-JMOIZ6+M#%K+6$5S$Z>$7YFHU_#"/*YUF;Z'X,@LQA3
M,_9^$K--^B6..8%2I=W=W=W(G=W<B)W(B)WY<B)^2(B=W<B=W=W=W=^7=94=
MLOM1Y3=W7N6U9>>6&@YE0T[C3/J'%8&M+)ZC7X\A:Q.Q%<OD+,QW+$W'L#&S
M8K( B(@"(B +MK8C9[)[@:QT]HS#B3WM09&*D,@CU^JUF$Y[]XV]WA4*$-FY
M*Y>ST0.S^]=2JT%W&O9-?&X?([L9FIT7LZTV&THTT?$D6#AD#X1RD;$W4#96
M]$U6 O)RJX]Y@<H+@.X$Z>U^W6+TAIS!Z7PL/J^*P&+I8FC'Y=7J]* (!DE)
MF;Q+$W0\UB4O;FGDDE-W,R=^=HB (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B *BUWFWQ][F_9RK^ \2KTJHM=YM\?>YOV<J_@/$H#!1$1 $1$
M 4BO=*_3%[9_V_5W\'NKE'4I%>Z5^F+VS_M^KOX/=7("[VB(@"(B (B( B(@
M"(B (B( B(@"(B BH[Z+X@=2?9G27XR8Y4QE<Y[Z+X@=2?9G27XR8Y4QD 1$
M0!$1 %=I[H[XA-%?W8_#-Y4EE=I[H[XA-%?W8_#-Y 23HB( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B +U+]""U!-5LPQ6*UF*2O8KS@,L,\$P/'+#-$;
M$$D4L9$$D9BXF!.),[.[+VT0%+OO.>[^GV@U$V9T_7EEV]U!8+X+EZCF+ Y
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M,DTTIG-/*1S32'(9$_".S[L%IO;/2N,T?I6FU3%XT'<C+H>WD+LO!6\GD9@
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M5VE;TN,SF%M1WL?=KEP<$X,XD!LW#25[$125[,$G,=FM+-!*)!(3/='C'A;
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M7*4;3 [^V 9/)C9EZ>!:6M4I6!<PDC=@)T:U>.&..*(!CBB 8XXP%A (P%A
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M'!93(X7+U):.4Q-VQC\A3F%QDK7*DI0SQ$SLW/28OTDWLF#B8\B3.@./HB(
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MR>\-UM=>?R'G[K_WW:1O]#+VQ]F_.VZZEA)^OU=[7[^7^Q'DGXJXR[8F0_\
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M8RUB_A&2S&%$(G*P4S]/@.#?/(Y1?S:0?-F9N>M^/"ZF,>J*77NHFR^8RN3
M2$;UVQ/$!-[;1&;M ),WEUM$P,3,_#%RS>2NH^O5>OH0[X2U:A1=G863&?D8
MZARRFFDK92:Y.OWN2,G+;TY&^Z+M'HX\Q0OEJG#L,NW.CIS8N6(9(2;V7'R;
MWW)&]INH.&%G\R5J=5<^X!Q_JFHM35/ZET)@ZWUOG%R"+ZK_ -)]5U:,7/CQ
MOV_](\Q[=Z\5_P#P]:_J2+#^'UG-IL)>CORFOP>18_[0B(HD-V"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MF\@))T1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M7!?/E@HK=]V]MVVVV13J6M])WY-SZ)N=ELI2>WXO=OX)+\$CX99TF^AB%O\
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MW'V/R_XR9E4>5>&[J?Z7[;C['Y?\9,R@)"D1$ 1$0!$1 $1$ 1$0!$1 $1$
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M#5RH^'#GZ3.WL\G=XR@"SCTAD_! &C@9W BF1$0!$1 %X)N6=OJ_R\G;W/\
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MSE!CZY=#/U3W3ACM7;/.;: (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MZ%E\7(PC]1C+];RZ>?\ \;]I9VT/G>*-V?WB+?\ XK_RX6PZ?6DI/U_LV_\
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MRW1$5'B>@B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M2Q]N^H/WIAU,DH;>XQ^)2Q]N^H/WIAU,D@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( L->V_V.,)O/HZ? WW"GFJ+3W-,9OHZI,5E#B86:1F]N7'
M77CBAR5879YH0"0.+%> PS*1 :[+=?:K.Z(U%E=*ZEH28[-8>R5:Y6/@@?R8
MX;-:4?8LT[4)!/5LQ.\<T)B0OSRS=>*Z]WCO=\XW>; ->Q;5L=K["P&6%R9
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MCD=R#-VH96:K5DCBDP\764S/?GZ:$_C,@/*(B (B( B(@"(B (B( B(@"(B
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M5[>Q^YE[3@^(>F,N\V9T=;D<B\7"RV'$L=+*3,TMW"2F-"T_M$<7J=N3I]=
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M+%7LZ=+R;AWKYJ<1+@2=G=F>0/1G;6V?U#$,V%W/T%D8RXZ7KZKPK]74XLW
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M;OWIHZU2K$ ,Y$<L\H1LW'DY=3\,W+7>^PAV2Z.SFWN+TO'X-C-6.K*:HR@
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M1'KXE\S,UC2[I;SCD^2HR?7=U0KIY7^W%*'-\=TWUW+^>.I!6KP5H_H*\,4
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MQCX9G/3SV2=@<.7MY"[9Y=G\W?B5O:_1<=3>3LL^53_C:[S-9U:?ZVI9K_\
MB;-BU/#5?)IV!']7#QE_V, H3._IY_F+XUF^77>!Y=WXX_,F5=OU^7X;]OS\
ME-FH3._J^)?&_;U@/WKE%E?"[_VAT?\ UVK^MGAXW_P1J/\ JMO_ '2JJ;/\
M$NWN?E_?\G ^?/U./KJ[[W:_Q#[6_:I1_P!>7S_;]ZI!RF[XCA_JNWUW\O+G
MZO''E_\ 5Q=\[M?XA]K?M3H_ZTJLI[3/^"]/_P!?_P#EKBN7LX_\MU3^8_\
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M$)<2U\<8M)GK@LSL3=..8Z,1L[/'9OPRMSX3L],9F9O)O)F]S?60!$1 $1$
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M*..IQ5&C.'PVE>>/I<9S/VI)G(>6?J=WXX?@181;R9F;[>^>YM?!8R:;J%R
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M--B\"B6\7<]GESB^G1K>%&Z_5=DT]G&V.Q*NG\)2>T\^Y7/O]'I3KQE\IO\
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M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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M:G,[,[^!:CBF9F?D&X797* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M=C\,WD!).B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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M$]?6^E6ADY%B?H:UDJT[=+NX%XD$?M"71U!TF6Q,X7E;A1[1?$$%M*&G6O\
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M4D?1-%BGAZ-/TGY]KPXZ4AWQ9_=-D[#\-U*5Y $1$ 1$0!$1 $1$ 1$0!$1
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M 1$0!$1 %@5WH'Q![F?8.'\*X]9ZK KO0/B#W,^P</X5QZ HR(B( B(@"(B
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M/4FDX9JV;&U@;///#MX>7KU.>'\G<2(?<[$XNSO1>7AV9_?YH#8YZ>U5B\O
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M_"N/0%&1$1 $1$ 1$0%O[N,?B4L?;OJ#]Z8=3)*&WN,?B4L?;OJ#]Z8=3)(
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M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M$1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1
M$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
M $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
M 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!
M$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1
M$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0
M!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $
M1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
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MB (B( B(@"(B (B( B(@"(B (B( B(@"(O#(#RB(@"(B (B( B(@"(B (B(
MB(@"+PO* (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (O'*\H
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M0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$ 1$0!$1
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MOT^]ERG">EP=D.V3#/;W,QC.Y,YWMOKT@BS-RSNV-N9 ^"?V1Z1)^?HF$?-
M6=44'^W'I'_8LU//'5J[X8G$V9./8U7IS6ND*X.3DS,62U+IO%XEWX'J)X[Y
MB#./6XN3,I/MH>UEM?N!7AM:'W$T5JV"P[#7DT[J;#Y9IW+Z%HFI7)BDZOT/
M0S]7R<H#()$1 $1$ 1$0!$1 $1$ 1%XY0'E$1 $1$ 1$0!$1 $1$ 1$0!$1
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MM*[0XZ7Q BN1?_9OJB.(G;H,<CF:%#"0V8V;EB;3LT/).)1R,S$]4B.,0%A
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M6TM<8MN=UN@ +1.>N5Y*N?D&+KFLZ+S(D$6:@$F-CQ]F&AG*[MR>.DK/#;F
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M 3"K1M3W].R122028N&3U2[1 VSZ+!_L!]X5MGVD]"5]>[9Y<[=-I IYS"9
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MP<6+P0V]0:2M/I+5$,+$ 36VQ-J/(8#+V A9Y&I^M:>"Q.1/Z]6CZ0:G+RB
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M!]SS;[][91 85_D\W;'_ %0FM_\ %M+?Q=3\GF[8_P"J$UO_ (MI;^+JB21
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M(R>=RDT4NAIY8L=B*4^0NR10AIWKFD"M7E((@]J0F8!\W96;UB]VW_B6W?\
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M$0!$1 $1$ 1$0!$1 %I%^V!\;^[GW5=R/QTSBW="TB_; ^-_=S[JNY'XZ9Q
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M,?G2U^QY_P!R)?17SLQ^=+7['G_<B0&][K_T./\ [@_ZK+]E^-?^AQ_]P?\
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M;9F>"/$#-)U2WMO\]/;GPIP\@)$.!R,60P4T?7.]6H&'<CCCN5X([:: (B(
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M):[W4R7@3V\%B98-,XN>5H6SFKLBST]-8<2Z9"8+>4E@>W($<IUZ$=NUX9M
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M1 $1$ 7!-SMS=/:,T]F-5ZLS%#3^F]/T+&4S6:REB.I0QU"J#R3V;$\CL(B
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MV5LN4VK]/T:S&VD[]J<G.SJ?3]:&8\?++*4^:P40CTR7L5:GN70T 1$0!$1
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M=K7.TVI/$EOZ/S4E2K?.)X1S6"M1A>T]GH!X87ARV(L5+).#,$=I[-;@3KF
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M)W:4KV/!ADLX#,2@ !%J/ D?@V1<6')4/5<M [O/:@J7R/16OI-=$?;/K_\
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M_MP#\#T5/$L#^P-V)6V.T]FL"VIGU1\+YALMZV^&;"^K\4X*GJ_@-E<KXO\
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M-6"'X1TKJ6M&#WL7;!B+Q*\G4-S%7HR."_CIX)A,9FL002$H B(@"(B (B(
MH8O2&_I+NT!]I];\8L(IG5#%Z0W])=V@/M/K?C%A$!J+%X?W.O*\/[G0&YR[
MIWZ5CLT_< V;_@ZTXL_U@!W3OTK'9I^X!LW_  =:<6?Z (B( B(@"(B \.M6
MCZ4#V]I=WNT9?T7BK92Z+V7A/2>-".0"K9#5EH(;>L,PS1\B;P6'JZ=K$9&4
M0XB[)'X8WY0?8!=[SVYH.SOV?MPMR(YJX:BK8B;"Z'@L@4L5O6^=C/'::"2
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M]5JPW;,T76;POFJ4U#4$0NXB4&5B., C(1:7% $1$ 1$0!$1 $1$ 1$0!$1
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M4,OBK<-_&92G6R&/NUS:2O;I7(0L5;,)M]%%-#($@/Y<B3<LSH#[B(B (B(
MB(@"(B (B( HRN][[?%/LW["ZUW&>6O\T34CP&A*4[@[9'6^:@G@P,/@D_58
M@IRC)E[\0-Y8W'7#,HXP.4)-5K!?2FN\2@W?WSAVWTYD!N:+V3?)X.26M*3T
M\EK^^5:/5D_ DX6"T\]*'344[CS7N09V&#B.8Y;(%9G+YB[DKES)9*W/?R62
MN6LCDK]J1Y;-[(7[$EN]=LR/YR6+=J:6Q,;_ $4DA%Y<KY[OQ[_)D4F7="=@
MF[VC]_-$;>>JSRZ7BO!J3<&['X;18_1>#,;>1BE.7D?%SU@:NG*<8!-*4^5]
M8> JM2W+"!>-]%#[O&/;7927>+.T/!UCO5'4R-"2<3]8H;=T))RTO7A8^&@C
MSY33ZFE>(6*Y5N8=YY)1IU0KVL5\_$8JM0J5:-.".M3I5X:E2O$/3%7K5HQA
M@AB%O(8XH@$ %O<(LR^@@-'/O]\8&X'V^ZU_&?*KJ==L;_?&!N!]ONM?QGRJ
MZG0&R5]#5^EHW&^[_J3^#/:96VU4D]#5^EHW&^[_ *D_@SVF5MM $1$!B_VW
MOB6W>^Y?K_\ %3++2/8?\Z5?V/!^Y"MW#VWOB6W>^Y?K_P#%3++2/8?\Z5?V
M/!^Y"@/HK;0^C5_22['?L/6_\)FLUJ7EMH?1J_I)=COV'K?^$S6: G/1$0!$
M1 $1$ 1$0!$1 $1$ 1$0!$1 $1$!H?,+^<ZO]HB_U!7TU\S"_G.K_:(O]05]
M- ;./T0OZ4J;[K&O?]7"*T:JN7HA?TI4WW6->_ZN$5HU $1$ 1$0!$1 $1$
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M;6Z8C%L5H_!U,9ZPT;1R9*^PO-E<O9'DG>UE<E):OSN9R%XEAQ>0^GE90(B
M(B( B(@"(B (B( B(@"(B (B("M[Z4KV/Z^Y?9<S^JZ],9M1;.W(=?XRP(.5
MF/#0]-'5]:-Q'EX)<%-+>LQF8P<XR"R;%-4KN.K16\FWFVXHZQT?JO2.4KC;
MQFJM-9W3>1JFPN%FCG,7:QENN;&Q!TS5[4D9,8D/!/U,[<LM2Q>]'][8U*>>
MG'L/J^_'4FEJQWX;NE1BNQUY"BCN1C+J1I1"R -.(R-UBQLQ<NSN@(>K$(R
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M\O>WD_N?S;Y?-?J@-JKZ+KOU3UKV0-#XZ*;Q,CMWEM1[?YB'@!>M-C,@^5Q
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MD+&[>\G#@0+FB(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
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MDJ]RO7N5)XK52U#%9JV:\@306*\\8RPSP2QN02PRQD,D<@$X&!,0NXNSKW4
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M,MD];S\OYNS-+J A$'\X@$8O+HX8"85$1 $1$ 1$0!$1 $1$ 1$0!$1 $1$
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MI *3PP .KI$68#>3(M(1_/6;K?V5=SO\H6L/]\I_/6;K?V5=SO\ *%K#_?*
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M*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U_P# Q_[*\_#%3^JJ_P#AXO\
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M?*Z?U-B,=GL)DZDL<U:_BLK4BO4;<$L1'')'/6GCD$@,A=G\G= <X1$0!$1
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M[?=:_C/E5U.@-DKZ&K]+1N-]W_4G\&>TRMMJI)Z&K]+1N-]W_4G\&>TRMMH
MB(@,7^V]\2V[WW+]?_BIEEI'L/\ G2K^QX/W(5NX>V]\2V[WW+]?_BIEEI'L
M/^=*O['@_<A0'T5Z,N,K2$YG7A,WXY(H@(GX;AN7<7=^&9F_69>\O2ER5:,G
M [$($WO$Y0$FY9G;EG)G;EG9VY^3S0'Y? U3^I:_^!C_ -E/@:I_4M?_  ,?
M^RO/PQ4_JJO_ (>+_:3X8J?U57_P\7^T@/'P-4_J6O\ X&/_ &4^!JG]2U_\
M#'_LKS\,5/ZJK_X>+_:3X8J?U57_ ,/%_M(#Q\#5/ZEK_P"!C_V4^!JG]2U_
M\#'_ +*\_#%3^JJ_^'B_VD^&*G]55_\ #Q?[2 \? U3^I:_^!C_V4^!JG]2U
M_P# Q_[*\_#%3^JJ_P#AXO\ :3X8J?U57_P\7^T@/'P-4_J6O_@8_P#93X&J
M?U+7_P #'_LKS\,5/ZJK_P"'B_VD^&*G]55_\/%_M(#Q\#5/ZEK_ .!C_P!E
M/@:I_4M?_ Q_[*\_#%3^JJ_^'B_VD^&*G]55_P##Q?[2 \? U3^I:_\ @8_]
ME/@:I_4M?_ Q_P"RO/PQ4_JJO_AXO]I/ABI_55?_  \7^T@-P;W"?TG/9Y^Y
MUC/WQ;4NBB+[A-__ -3GL\_<ZQG[XMJ71 $1$!H?,+^<ZO\ :(O]05]-?,PO
MYSJ_VB+_ %!7TT!LX_1"_I2IONL:]_U<(K1JJY>B%_2E3?=8U[_JX16C4 1$
M0!$1 $1$ 1$0!$1 $1$ 1$0&J0]*#QT=;MI;D#&Y.T^GMOK9];L[M+8TM4ZV
M'AFX!N@>EGY=O/DG\E7^5BCTJ:>,^V=K$0=G*+1&W4<S,W#M(^%EE9G?AN7\
M&2)^?/R=FY\N&KKH"77N$<B=;MC[ $#DWC:RM5BZ3(.0GTSGA)BZ?HA\F=P+
MD2X^LSMM^UI].XB^G%[/7V]G^+>>6X+0!$1 5%/3)?I>=O/NPXO\4=7+6]+9
M"^F2_2\[>?=AQ?XHZN6MZ0'?G9/^-?:K[I^WGXXX5;O1:0OLG_&OM5]T_;S\
M<<*MWH@"(B IC>FB:L.':797!,9-'DMT<GEBC]OI(\+HW,4XS?@FCZHQS\@C
MU@1\2'X9@/B,>O(5_P#]-3?_ .PKL_\ VZZS_%RBJ " ]'*&XUK!"_!#!,3/
M]1VC)V?]IUNQ^P-IB'"['[0XFOT^!CMM=%5(N@/##PX-/4 'I#J+H%F9F8>I
M^/=RM)KF/SI:_8\_[D2WB79GMUI]N- 34^GU671>ESKL(>&+0EA*+QLT? ]#
M,/#=/#<>[A =WHB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"U O?W_
M $X_: ^W*I^+& 6WZ6H%[^_Z<?M ?;E4_%C ("(E7@_0IO\ I'VD/L+M+^_M
MR51\5X/T*;_I'VD/L+M+^_MR4!?M1$0!<-W%_P"CV=^PV4_>,ZYDN&[B_P#1
M[._8;*?O&= :+##_ )TJ_L>#]R%?17SL/^=*O['@_<A7T4!M0O16OI-=$?;/
MK_\ &O(JQ<JZ/HK7TFNB/MGU_P#C7D58N0!$1 %T1VFNS;H_=[0FI=N=>8F+
M,Z7U5C9\9DJANX31M*+^!>H61^>TLGCYVCN8^] 0S5+<,4T9,X>?>Z(#37=Z
M5W:VL>R[NIE=!:BBMW]/63DR.@=8R0!'3U?IHW!XK#%"[PPYG%R2/C,_CG:"
M6"]!ZY!7;%9#&V+$<"W*'>D=VKHSM1;79#0.J!"CEJQGE=%ZKBA:3(:4U+'7
MEAK7X';I.:A8"0JF8QI'ZOD*1D)BUB&K-!J(>TKV;-9[0:YU#MQN#B#PNJ],
M7"IY&KU/)5LQE[=3*XJTX@-_#Y2OTV\;= 1:: V&0(;$<\$('#-J=U=1Z%U-
M@=9Z0R]O ZITQE*N9P.9I&X6:&1IFQQ2-P[#-!*/77NTY>JM?I36*5N.6K8F
MB/;4=S#WM&F^U9MG#FA>GB-QM-M!CMP](Q3<GC\@XNU?-8T).)9]/9T *SC[
M+,7J\S6,99)K5.3JU#"S*[ _;IUSV<]S<)NAH*Q_RAC7>IF<)8FDBQ6K=.V#
M%\CIS,, FSU[(BTM.WX4LV*R457)51>6OTF!NID6)/8>[:.B>T!MKIS<_05U
M[&&SU5GL4IRB^$\!EXA!LGI[-0PR2#6RN*L$]>U$QE&;-'9KG+6G@E/+9 $1
M$ 1$0&O1]-(^,W8?[1=:_A_!JEZKH7II'QF[#_:+K7\/X-4O4!-CZ.3].SL+
M]E=<?P5:\6V_6I ]')^G9V%^RNN/X*M>+;?H B(@"U:'I77TX^H/N>;??O;*
M+:7K5H>E=?3CZ@^YYM]^]LH@*WR_"Q6CE;IEC"06?EF,1-F?AVYX)G;GAW;G
MZ[K]U^,]F.)F*60(Q=^&<R$&=_-^.2=FYX9WX^HSH#T_@:I_4M?_  ,?^RGP
M-4_J6O\ X&/_ &5Y^&*G]55_\/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?^RG
MP-4_J6O_ (&/_97GX8J?U57_ ,/%_M)\,5/ZJK_X>+_:0'CX&J?U+7_P,?\
MLI\#5/ZEK_X&/_97GX8J?U57_P /%_M)\,5/ZJK_ .'B_P!I >/@:I_4M?\
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M=G;F/+$WEY^8EDW$F^JSL[/[G9V7:6CNY=[)>"D&6AV<]GRD NH"R>AL%G'
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M/&X'_P F"_WTMPLB T]/Y!=VP_U/&X'_ ,F"_P!])^07=L/]3QN!_P#)@O\
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MPNIL!?K97 ZBQ&-SN$RE*:.Q3R6(R].'(8V_4L0D<,]:Y3L0V()HC..6*0#
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MM3^=,VK_ +&>W_WF:<_W:L@40&/W\Z9M7_8SV_\ O,TY_NU/YTS:O^QGM_\
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MQQ&XXNO6D:1JD<A 0.+YV8_.EK]CS_N1+Z*^=F/SI:_8\_[D2 WP*(B (B(
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MV@/MRJ?BQ@$!$2KP?H4W_2/M(?87:7]_;DJCXKP?H4W_ $C[2'V%VE_?VY*
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M;!?:;K[\-Z85*Q 38>CH?3G[(?9/5'XCZE6W 6H_]'0^G/V0^R>J/Q'U*MN
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M<=D:L]'(XVY;QV1H60\.S1R%"Q+4O4[ /]!/5M0RP2CYLQQOP[MYK>P+6/\
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M5</N!IWUK*;=:ME$V^"LP<+C)B\H<,<LUC3>;88ZV7JC',<3A7R5./UZC6=
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MJ%OA^B0L3B;6=RM=G^A<X6SV(D)F\P:87=^#9FO&H B(@"(B (B( B(@"(B
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M6PF]"U^+#?'[I.#_ !2I+7LK83>A:_%AOC]TG!_BE20%TI$1 $1$ 1$0!$1
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M!2<*,>GLZ^4RDT0OE-4:BRF+EAR>H<P8ES/?OR-& 1^+X5.E#4QM1XZE.N
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MG5@$YK-NU.<<%:M"!S3S&$48$9,+@=X]ESLU:KWBW#TEMCHBGZ]J?6.5CQM
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M (B( B(@"(B JX>D;]R0&_NEY=V-M<7%_-GT;BQ";'UAAKEN'IFD12R82P?
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M#1P4Z5</G5'&T*XQU<?1@9H:M:,(QZCZY# Z=7\22" D9/P("Y$_U!%N7?\
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MWXI:66N$6Q[]#7^(#<C[KM[\4M+("WJB(@"(B (B( B(@"(B (B( B(@"(B
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M,3F)*[-7''Y.]&T]X"HLLS>QMWA>\W9_R,M_:37F7TI%:L!;R.$#P<AIC+V
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M,[,(LP&\X7P\SJ;&XX>O(9"C0#AGZKEN"J/#]7#]4\@-P_0?#\^?07]*_&D
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ML,3-&#%6*$V !%@8NCI#IZ6P@S'YTM?L>?\ <B0&^!1$0!$1 $1$ 1$0!$1
M$1$!C=VR?B@W5^YOKG\6,HM(?A_SI5_8\'[D*W>';)^*#=7[F^N?Q8RBTA^'
M_.E7]CP?N0H#Z*M;]VWZ4%=[/&RVB]GH=F*^JX]'QYN,<^>N3PY7_AG4>7U
M[OCFTQD6KO7?+/5X:Y+XC0-+['B= U2$0%YO\NJY']3M5_RER?Q+3\NJY']3
MM5_RER?Q+5&1$!>;_+JN1_4[5?\ *7)_$M/RZKD?U.U7_*7)_$M49$0%YO\
M+JN1_4[5?\I<G\2T_+JN1_4[5?\ *7)_$M49$0%YO\NJY']3M5_RER?Q+3\N
MJY']3M5_RER?Q+5&1$!=5U?Z:9N!-"XX#8+1V.L<GQ-F->YK,PNSN/AN]6EI
MG!&SL+'ULUPF=R'I(6!_$CVW?]*\[7FJ8Y(,;D]N]"0RB0%\Q^C)SM"!#TLX
M7=5Y[5$L<P_1^- ,/M\NP"#M&U;-$!D#VBNUAN=N[>CR.Z&O]5Z\LPR%-6#4
MF7L7:%.4QZ#EQ^'$HL/CI##@#DH4*YF'LF1<OSC\R+WL1BK>1N5\=CJEO(Y&
MV;1U,=CJMB]?MR$[,,=6E4CFM6)'=V9@AB,G=_)D!Z*[=V(V"UINAJO%:'V]
MTUD]6ZKS4OAX_#8J(3F(&(!EMVYY2BJ8[&U>L"N9/(3UJ%0"%YYP<@$I_P#N
M[O1=]_-X9*.;W$KS[(:'F()CFU/C2GUWD:C$+D&.T;)/4L8>2<>N.*QJF3'S
M5G%[)X6[#X$5K8(=W_W86SG9ITZ6#VPTM6HWKL->/4&KL@$-[6&IY*[.X'F\
MZ4069J\<A22U<97]7Q-$YIGI48'EE<P(T>XX[@_379BQD&M]8R4]4[W9C&^!
MD\K%TSX31E2UTR6-/Z1:6&.8C?@(,OJ"9AM98HNBM#0Q_%4K&2(@"(B (B(
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MM49$0%YO\NJY']3M5_RER?Q+3\NJY']3M5_RER?Q+5&1$!>;_+JN1_4[5?\
M*7)_$M/RZKD?U.U7_*7)_$M49$0%YO\ +JN1_4[5?\I<G\2T_+JN1_4[5?\
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MJ[4<1='E[/,>3%^GR;V?=Y-Y>2]RUOMKR<'BGU[KJ:,N'>.76>II =Q=G%W
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M_P"N>R_W[ZF_B GY4,[6?]<]E_OWU-_$!;.9$!K&?RH9VL_ZY[+_ '[ZF_B
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M4TUJ;6M[.31Y'3>8Q$'J%7*;<86A,8VK\!2C8RE01KM-(!G( 0RWID1 $1$
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M  \C3HO=S]KPV-@DR&I<M)?U#DYV8S9[&0R=F<F)V*1V6:2( B(@"(B (B(
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MDN8;3V%Q-N2J<DE8[..QM:G.=>26*"4X"EA-XCD@AD*-Q<XHR=P;L)$0!$1
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MGLO]^^IOX@+9S(@-8S^5#.UG_7/9?[]]3?Q 3\J&=K/^N>R_W[ZF_B MG,B
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MS'Z'J8<-#9C4F6.L>F;&K)KQ9+X?TAI<81F'/U6J>JO<<WBL>,T##&\MGM$
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M 681%F869F9E["( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
MB(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(
MB (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B(
M B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"
M(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B
M( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@
M"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (
MB( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(
M@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
M(B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B
M(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B
J (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@"(B (B( B(@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ino-20221231_g2.jpg
<TEXT>
begin 644 ino-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $* JX# 2(  A$! Q$!_\0
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M<6Y\Q!_>]5_$?TJU:W"75O'-&<HXW"LHZ-Q8O(EHHKGO&\ES'H4GV1;M[@N
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MYGM%).:JV7IL<W:_&KQ3>0R31^&X?+@MGNI0PE!;:T \E< _.#,V>OW.G6K
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MF)DB9G(!P&S(W3BO2DET@CRXREUJ/[C@/^%V>,9=!M5.BRI>1PPO-((7#O\
MN4=F(P=JNS$#@8VGKT&]>?&?Q/9KL?POL\ES!/.XD,9EV&1 AXR&0H,_W\C!
MK5OOB)K%K<>,+R.%I[319I(8HDA3RI L,;AG?=OX+DG"]%J75O%6MVLVF6UM
MKVGW;3:I;V,LEO:[BJRQLX+#. PV\8/0C/-/W7]A?>2N=?\ +Q_<B'4_B5XC
MM/ -OKYT13>RWUU$EA&9 5CC6XV%^,DL8EZ #YQBLJ?XK^+++Q#=VMW86,-O
M#^X$C),(=P#,9<XW%3\J#W/N*JVOQHUR&*Y-Q LEQ-!<?9(Y+;8'F%R8(1%M
M8M*"1N<8!4#/>MSP7XV\:>*O$6G2OIEO'X=6!XK^3;MDBNHR5<;6.X98 @%>
MC#-/V?*FW%?>'M>=Q49N^G3\67-7^('B=-0TB"PT2WACO+:VEF%]YI>"2579
MD.T8^39@^YK 'QQUV:P@D&@V]M<D&2XAN&D!ACVHRGH 6.XX!(SC@U</[02J
MP!\.RN3:SWQ,-VC@0Q DY(7ASC[OXYINI_M"1Z7_ &L9O#[2#2_EN1#>(Y9]
MK,HC&/G7@9;@#GTJ53EM[/\ $<JT=U6?W%'6OC)XCA%K=6>D[D\US)IP@E^T
M1Q@$*TP(PHZ28!S@5L:Q\1-=N/!VEWMO;C3KN\^V'>J%@QBC<QJH/=RH(Z\*
M<9SFJ.I?'Y]+NM5L6T*5M0M'9"K3 QAL+L 8+AAEAG."!GK3;?X\)J6K:9I'
M_"-_;M0GDC6%A<*(O.V9;!9>-O(R,]>M/V<M/W?XB]M'5.KOY&9H_P 1/&UX
MR6-TLD+-J:.U[]DVA;-AM*\C&0^?FZX%=)=?%/6[+0] NDTJ.ZEN[/[1(6#C
M[2X=4V0A00&8$R#/&T^QK1A^*\>J^#[S68=#FGMXK@64EO)(O,G F!X.1&VY
M3@'.TX%8UG\>(?)69/#^S1XTC9;J.Z7;Y32I"K*FT'&YQQQQS[4N5R?P;%*4
M8+6J]?(T-2^(VOZ7X1\-:M/IML)M3C$ES#")&>#<JE51#@NWS$$9SQP#7,:'
M\7_&%W#I5O-H21ZA-^ZE6Z60;!A2)7"C&'&2,=.AYJU%^T)<:RTL&F^'"MS
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MHHNQV782EHHI#"BBB@ HHHH 0UY[JWPKFU22^;^V[F+[:7>95) \QB " ".
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M)Y426N](GA7A6\LG:3@XW=Z][ 8&685).3LEJV>/F&/AE=*$81O)Z)'Z)/\
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M16E_"]P);*.</%G:$4'[O4?-V%:VH? '1]2N$EN+^Z>6-2BN(T4A202.,<9
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MVAVVHVKAX+B,.I'N.E5WD6-7D<X1 68^@')KQ7]G/QTWES^&;J3C_6VNX_\
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M&ROI\(&\8YPRXQDXZU[=YG)KU\5&-.C3HK5]7Z-_YOU/+PTI5:LZKT71>O\
M7R%GY?/M5>XN$M8))I#M2-2Q/TJ5CDUQ/Q(\0KI]K'8H09)?G<?[/85XE>HJ
M--S/6A%U)**W9X?\2(]3UW7)XH%^P07!+F;'W%)Y(]2:XFX\#Z-;VYA^S1S'
M^-Y5#,_N2:[O6M0>:1F9M[8QD^GI7%WE\5D))[U\/5U;;/N\/'V<%%=#CY_
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M8VRP^()+8K'<1G8964917]1V_&N(^'OC_4)/"@U2YU$WT5F!;7^GW$(2>UN
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M]!Q["HDVEIN)E:W\-6$D0DOK&UN[M_FDDEA5SD]LD=!T_"I?^$9T?_H$V/\
MX#)_A6E2T*$4K6*3:5DS+_X1?1O^@18_^ R?X4?\(OHW_0(L/_ 9/\*U**?*
MNP^:7<R_^$7T;_H$6/\ X#)_A4D/A_2[=P\6FV<3C^)($!_E6A11RQ[!S/N8
M5WX$\-:A</<77AW2KF=SEI9K*)F)]22N:L6_A/0[5=L&C:?"O]V.U11^@K5H
MHY5V#F?<SO\ A&])_P"@79?^ Z?X4?\ ".:3_P! NS_\!T_PK1HHY5V#F?<K
MVNGVMA'LMK:&W3).V&,*,GKTJQ115$A1110!SGQ"\5-X)\(:AK20+<M:A"(G
M;:&W.J]?QKRO2?VJ+&9PNH:)-"O>2VF$G_CI _G7N5U:PWD#0W$,<\+?>CD4
M,I^H-<YJWPQ\+:TK+=:%9G(^]'&$8>X*XKQ,=0S"I44\'645;9J]WZG/4C5;
MO3E8E\)_$'0O&T)?2;Y)I%&7@;Y9%^JGG\>E=%7@?B[X"W?A68:]X)O9UNK4
M^:+1VR^!U"-W_P!T]:]A\$Z\WBCPKIFJNGE274(=TQC#=&'Y@U6!Q6)G-X?&
M0Y9I7NMFNZ_5!3G)OEJ*S-RBBBO9.@***Y+X@_$G2OAWIJW%\QEN9,^1:1D;
MY#Z^P]ZQK5J>'INK5=HKJ3*2BKRV.LI:^7]8^,WQ!UJSN-3LK1M,T>+EI8;;
M*J,@#+M[D5S@^-OC7_H-O_W[7_"OE*G%&#INW)*W>UK_ 'LXGC*:Z,^PZ*^/
MA\;/&G'_ !.W_P"_:_X4\?&KQG_T&G_[]K_A6/\ K;@OY)?A_F3]>I]F?7U%
M?(:_&CQG_P!!I_\ OVO^%/'QH\9'_F-/_P!^U_PH_P!;<%_)+\/\Q_7J?9GU
MS17R0OQF\9?]!E_^_:_X4Y?C)XQ_Z#+_ /?M?\*/];,%_)+\/\P^O4^S/K6B
MODP?&3QAC_D,O_W[7_"G_P#"XO&'_08?_OVO^%'^MN"_DE^'^8OKU/LSZPHK
MY1'Q@\7_ /08?_OVO^%/7XO^+O\ H,/_ -^U_P */];<%_)+\/\ ,?UZGV9]
M5T5\K#XO>+O^@N__ '[7_"G#XN>+?^@N_P#WPO\ A1_K;@OY)?A_F+Z]3[,^
MIZ*^6A\6_%G_ $%W_P"^%_PI_P#PMKQ7_P!!9_\ OA?\*/\ 6W!?R2_#_,/K
MU/LSZBHKY@'Q8\5_]!9_^^%_PIR_%?Q5_P!!9_\ OA?\*/\ 6W!?R2_#_,/K
MU/LSZ=HKYE7XK>*?^@J__?"_X4X?%3Q3_P!!5_\ OA?\*/\ 6W!?R2_#_,/K
MU/LSZ8HKYI_X6GXH_P"@JW_?"_X4X?%'Q1_T%'_[X7_"C_6W!?R2_#_,?UVG
MV9]*45\W?\+0\4?]!1_^^%_PH_X6AXGW?\A1_P#OA?\ "C_6W!?R2_#_ ##Z
M[3[,^D:*^<%^)WB;_H*/_P!\+_A3U^)OB;_H)O\ ]\+_ (4?ZVX+^27X?YB^
MO4^S/HRBOG5?B9XE_P"@FW_?"_X4_P#X67XD_P"@FW_?"_X4?ZVX+^27X?YC
M^O4^S/H>BOGK_A97B3_H)-_WPO\ A3A\2/$?_02?_OE?\*/];,%_)+\/\P^N
MT^S/H.BOG]?B-XB_Z"3?]\+_ (4[_A8WB+!_XF3?]\+_ (4?ZV8+^27X?YA]
M=I]F>_45X"OQ%\1?]!)O^^!_A3_^%B>(?^@BW_?(_P */];<%_)+\/\ ,/KM
M/LSWNBO!O^%A>(/^@BW_ 'R*?_PL'Q!_T$&_[Y%'^MN"_DE^'^8?7:?9GNU%
M>%_\+ U\_P#,0;_OD4#X@:^?^8@W_?(H_P!;<%_)+\/\P^NT^S/=**\-7Q]K
MW_00;_OD4\>/->_Z"#?]\BC_ %MP7\DOP_S#Z[3[,]OHKQ+_ (3S7<?\?[?]
M\BG?\)UKO_/^W_?(_P *?^MF"_DE^'^8?7:?9GM=%>*_\)SKG_/\_P#WR*>O
MCC7/^?YO^^11_K9@_P"27X?YA]=I]F>ST5XS_P )QK?_ #_-_P!\C_"G+XVU
MO_G];_OD4?ZV8/\ DE^'^8?7:?9GLE%>._\ ";:WC_C];_OD4O\ PFFM?\_S
M?]\BC_6S!_R2_#_,/KM/LSV&BO(!XSUK_G];_OD?X4Y?&6L_\_K?]\BC_6S!
M_P DOP_S#Z[3[,]=HKR1?&.L_P#/XW_?(IZ^,-8_Y_&_[Y%/_6S!?R2_#_,/
MKM/LSUBBO*/^$NUC_G\;_OD4\>+=6_Y_&_(4UQ5@W]B7X?YC^N4^S/5**\M_
MX2S5O^?QOR%.7Q7JI_Y>V_(5:XHPC^S+\/\ ,?UR'9GJ%%>8CQ5JO_/VWY"I
M%\4:H2/]*;\A6G^LN$?V9?A_F'UN'9GI5%>;CQ/J?_/TWY"GCQ-J?_/TWY"J
M_P!8\+_++\/\Q_6H=CT6BO.QXDU+_GY;\A3_ /A)-1_Y^3^0J_\ 6##?RR_#
M_,?UJ'8]!HK@1XBU'_GY/Y"G#Q!J'_/P?R%6L^PW\K_#_,?UF!W>:6N%_M^_
MV_\ 'P?R%.&O7Y_Y>#^0JUGF'?V7^'^8_K$#N**XI==OO^>Y_(4\:W>G_EN?
MR%6LYH/[+_#_ #']8B=C2UQZZU>Y_P!>?R%.&L7FW/G'\JO^UZ#Z/\/\Q^WB
M==17*#5[L_\ +8_D*4:M=_\ /8_E5_VI1?1C]M$ZJBN8&J77/[X_E3O[3NO^
M>I_*K694GT8_:Q.EHKGAJ5SC_6G\J<NH7/\ ST/Y5:S"F^C#VJ-^BL)=0N#_
M ,M/TIZWT_\ ST-6L;3?1C]HC:I-P)(!!(ZU@WU]>I:2FUQ)<!3L5C@$UYKI
MT'BO6FNDMI+D;I3YY+A!N[YKQL?GJP=2%.G1E4<K[+L85,1[-I*+=^QZ5XF\
M8V/ANW?S)%ENL?);J<L3[^@J?PC')'X<L?-C$4C(9&11@ LQ;^M<QX;^&"6E
MPEWJLHNYE.X0KDKGU8GK7?+QVQ71EKQ^)J/%8R/LU:T8;ONW)]]"Z7M)/GJ*
MWD+1117T)TE35-2@TC3;J^N6V6]O&TLC>B@9->0> _ <GQ$UB3QOXJB\Y;AM
MVGZ?)]Q(@?E+#T]!^-=]\1[%]:TBST921'J5Y'!/MZ^2"7?]%Q^-=1#"EO$D
M4:A(XU"JJC   P!7DUL.L7B$JJO"&MNCD^_HOS,91YY>]LOS*6L>'[#7='FT
MJ]MUEL)5"O"/E! ((''3D"N3_P"%&>"O^@+'_P!_&_QKO:*[*N%P]=J56FI/
MS29<H1E\2N<%_P *-\%?] 9/^_C?XTO_  H_P7_T!D_[^-_C7>45C_9V#_Y\
MQ^Y$^RI_RHX3_A1_@S_H#)_W\;_&E_X4CX-_Z Z?]_&_QKNJ*/[.P?\ SYC]
MR#V5/^5'#?\ "D_!O_0'3_OXW^-'_"E/!W_0'3_OXW^-=S11_9V#_P"?,?N0
M>RI_RHX?_A2O@[_H$)_W\;_&E_X4OX/_ .@0G_?QO\:[>BC^SL'_ ,^8_<@]
ME3_E1Q'_  IGPA_T"$_[[;_&E_X4SX0_Z!*_]_&_QKMJ*/[.P?\ SYC]R#V5
M/^5'%?\ "F_"/_0)7_OMO\:7_A3OA+_H$I_WVW^-=I12_L[!_P#/F/W(/94_
MY4<7_P *>\)?] E/^^V_QI?^%/\ A/\ Z!2_]]M_C79T4_[.P?\ SYC]R#V5
M/^5'&_\ "H?"G_0*7_OMO\:/^%1>%/\ H%K_ -]M_C7944?V=@_^?,?N0>RI
M_P J.._X5'X5_P"@6O\ WVW^-+_PJ7PK_P! M?\ OMO\:["BC^SL'_SYC]R#
MV5/^5'(?\*G\+_\ 0,7_ +[;_&C_ (5/X7_Z!B_]]M_C77T4O[.P?_/F/W(/
M94_Y4<C_ ,*I\+_] Q?^^V_QI?\ A5/AC_H&+_WVW^-=;11_9V#_ .?,?_ 4
M'LJ?\J.2_P"%5^&/^@8O_?;?XTO_  JOPS_T#5_[[;_&NLHI_P!G8/\ Y\Q^
MY![*G_*CD_\ A5OAG_H&K_WVW^-+_P *O\-?] Y?^^V_QKJZ*/[.P?\ SYC]
MR#V5/^5'*_\ "L?#?_0.7_OMO\:/^%8^'/\ H'K_ -]M_C7544?V=@_^?,?N
M0>RA_*CE_P#A6?AS_H'K_P!]M_C1_P *U\._] ]?^^V_QKJ**/[.P?\ SYC]
MR#V5/^5'+_\ "M?#O_0/7_OMO\:7_A6WA[_H'K_WVW^-=/11_9V#_P"?,?N0
M>RI_RHYG_A6_A[_GP7_OMO\ &C_A7/A__GP7_OH_XUTU%']G8/\ Y\Q^Y![*
MG_*CFO\ A7>@?\^ _P"^C_C1_P *[T#_ )\1_P!]'_&N1_:8\=:S\-_A!JNO
M:!<1VNJ6\UND<LD2R* \R*WRMQT)KGM=_:RT#POJ&MV=YH/B"ZBT">WMM6U*
MUM4:VMC,J[)"=X.TENPSP>*ZJ>2T*L5.%"+OY+I;_-'%4KX6C-PJ65K/;O?_
M "9Z@/AYH'_/BO\ WT?\:7_A7N@_\^(_[Z/^->+S?M72:#XR^*,>N>&;]/#'
MA&.SDCO+1$:1EE4G<^9!]_*E !]T'.#74>(/VD8?#?ANTUF\\"^*TMYX);ME
M-M"IA@3'SNQE"@D'(3.[':J>144TOJ\=;=%U5_R9"Q6#DF]-+].SMV[H] _X
M5_H7_/BO_?1_QI?^%?Z%_P ^*_\ ?1_QKRWQ!^UWX7T:0?9=$U_6X?[#A\1-
M/I]LC)'92''F-N<8V]Q^6:>G[7'A<V&NW<NC:]:1:;H8\1PBYM4C:_L2VT2P
M@OZG&&VFC^PJ=K_5E_X"A_6L%>W,CT__ (0'0_\ GR'_ 'T?\:7_ (0+0_\
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M.V.<9&?*SU/6NY9-"5N6@G>W1=;?YHX)8K"0OS-*U_PO_DSV3_A%]-_Y]_\
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M4R?M-:!JW]JZ=IUKJVG:T-)O-1TPZOITEO%>K K;FCW<D!@.N,U%#\7==?\
M9/\ ^%B$6W_"0?V&=1QY?[GS0#_#GI3_ +,BK7I)7:6W</K6'=^5WLF]/(]<
M_L.R'_+$?F:7^Q+/_GE^IKYST'XO_$[P7J?PZO?&\V@:SX9\:20VR2:9!)!<
M6,TL8>/<"<,O.#7?:;^U%X*UC6'L+0ZC+YGVE;&Z^QL+?49(%+2QV[]'8!3@
M<9QQFKEE2C\--27=*_\ 6Q$,;AI?%[K[/1_UJ>G_ -BV8_Y9?K0-'M/^>7ZU
MY=JG[2'A:Z\,Z;=:5>W'GZUHEYK-E,MH9A;P01DO+*F1]UN-N>2,9JM'^TMX
M<T30O#PO&U3Q%JE[I$6K7']CZ3([16S ?Z1+&I/EJ3T7)/UJ5EKZ4OP-/K6&
M3^)'KG]D6O\ SR_6C^R;7_GG^M>9>)OVG/!'A766L+N>_E6"*":^O+>S=X+!
M9L>5Y[?P%LCC&1GG%=7X^^(]CX#L-+GF5;F74[N.SM8_,"*S,"=Q;!PH S^5
M92P<::3E3M?R-Z=2C4;4&FUN='_9=M_SS_6E_LVW_P">?ZU@+\4/"3+J+#Q#
MI^W3QNNF\\ 1#=MR3Z;N,CO6_I>J6NM:?!?6,ZW-I,NZ.5.C#U%9^QI_RHVY
M5V%_LVW'_+/]:7^SX!_!^M6**?LJ?\J'9%?[##_<I\-O'!NV(%W')QWJ6BJ5
M.*=T@L@HHHJQA1110!3N(8Y-0LY&^_'OV#Z@ U<K'\177]GQV5X3B.*X42'T
M1OE)_,BM<'/(Z5SPJ)U)T^JL_O7_  &2GJT+111704%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!PGQK^&9^+WP]O\ PN-1_LHW4D,GVKR?-V^7(KXV[AG.W'7O
M7 ^(OV87U[1?B98?\)'Y/_"9W%I<"3['N^R>0%&,;_GW;?;'O7O-)733Q-6E
M'E@]-_Q3_1''5PE&M)SJ1N[6Z]FOR;/GSQM^RU>^*+SQ\+3Q:FGZ=XQLK*WN
M[:33O-:*6V0(DBOY@X(!RN._6K7Q@_9AE^*FLZ9>'Q*MK;6VCG29+&\L1=0@
M\D7$2EP$EYQN(;@"O3?BQJUWH'PW\1:A83/;7EO9O)%+&,LK#N!W->9V?CSQ
M'X6>XU2"VU[6="%I#&T7B.'[&YO))D1/*8IN*[68MP0,#'-:QQM>+34MO)=D
MOR2,I9?AI*47'1[ZONW^;9GV/[)LMGI6H6;>*%=KKP5#X0\P6.-OEMG[1CS.
M<_W/UJ_K'[+<&O2%+S7W^RR>"E\'R)%;!6.'W_: Q8XYQ\F/QKH+?XX7#>)G
MTN;0&:&VO5TV\GM99)3'/M!9E'E -&I(&2P;OMJW?>,)_&_C31]!TC4KK1],
MFLKF]GN5@\J>9HWC01)YB_*/WFXD#. />E]=Q%[\WY!_9^&2MR_BSB]#_9I\
M16VM7&KZMX^34-0/AK_A&H)(=&CC2&(,&1]C,ROWR&'.>U9&C_L6VT.C^*K/
M4/$4<9UJW@BCBT/3EL;6VFBD$B7/D[V#2[E&3P",C%=YXA^*%]\-=)^S75[I
MWBB\MQ=2M,]SY$S1Q'(C*1H^90IP3A5R.2,U9'QKN&O?/_L)5\/K>V=B]ZUW
M^^W7%O%,K"()@A?-"GYL]QGI5?7L0MI6VZ+IMT)_LW"O>-]^KZ[]3%\3? 7Q
M3X^\ ZIH/BKX@'4;V:ZM+RPNK;2HX(;*2W<.A\O<2^YE!8%OIBL#4_V4]7\1
M1^+Y]:\;I?:KXDO])OY[I-+$21FR;(14$G1@ .O&.]=E=_&Z_P!/\-V6MW7A
MV%+/5C"NDK'?AY)6D<*HE0)E.#N)0.!TZX%/L?C1JFJ7EG96OA;?=M#>3W"R
M731J%MS&/W6Z/+[Q(-NX+SP<5,<97AI%V^2\O+R14LOP]36:;^;\_/S9P'B+
M]CN?7O'=SXB?Q>LA;7X==A^V::)KF+8ZL;83&0$187Y54#&<G->M?"'X8GX6
MZ;KUH=1_M(ZKK5UJ^_R?+\OSB#Y>-QSC'7OZ4OPS^)Q\>0ZF;JSATN>Q$;26
MXG9I$5@3B1'1&0C:1T*GL3BN$^%_Q5U+5_B=<6.L7]P-/UB.:XT.&:W(6^@$
MA9)X<+\B)$ K!R22RGN*FIBZU6'LYRT^15+ X>C/VE.-GZLI:Y^SCXT?QAXW
MU+P[\3%\.Z5XMG62^LDT5)I@!'Y>$F:3*G&>0.]5M>_8WTE9O#<_AO4+*RFT
MC2%T9EUS2H]3BFB#EQ+L9EVR[V<[AP=W2O2+VXU;Q?\ $/7="@UJYT&STBRM
MI8_L:IYD\DWF'S&+ _(OE@;1P23GM6'K7QLF\&QZ?;WATS7VCBM?MEY9W15Y
M3+)Y9DCB5&  )!^=ESDXSBM%CL0K6EMY+M;7373N0\NPTKWC>_F]-;Z:Z:]C
M.\??LMZ7X[U+P#<R:B-/3PWMBO(+6T6./4K=65_**J0J+YBAL8(&2,<T>,?V
M88?&6L^/]0GU^2U?Q)/IMY:>3; MI]Q9*!$_+8D!89(P../>M>X^.D^DA[S4
M] 6#2'EU&&VG@O/,FD>T+YW(4 4.(VP=QQWXYJ?6_C!JWAQM-LM0\/6L>KZD
M^;6*'4&EA\H1F1F<K$74C&W&P@GH< FHCC*\4DI;?YW_ #1<L#AY-MPW_P K
M?DSG/&7[.>O?$OPS';>+_&L.M:S9ZE'J6G7!T:-;2W*H4,;6^X^8C@G.YNO3
M%>@_";X=M\-_#DEA-+IMQ=2S--)+I>EQZ?"<_=41H3T'<DDUS,?QNU2^AO9[
M#PC-/'8Z7;ZA/#)<%;C?*\B>6D8C.[!B)SGD=!GBNS^''C8>/-!EOC%;PRPW
M#V\D=M<&505 /.Y593@CY64$?E43Q%2I#V;>GHC2GA*5.I[6*][O=O\ ,X[_
M (4A?6FER:?8^((X8;[24T;4FFLO,:2%3)AHOG'EOME<<[AR#CBNV\"^#4\$
M:??6<5Q]HCN+V6[4E-I4.1A3R<D =>]=+17,=84444 ?/WQ>_9KU/XD>(/B'
MJ%MK-K9IXG\/6FBPI+&S&%X;CS2[8Z@CC J?QI^S?>^,/$'BZ];68;:WUSPA
M;^&T41%GBECD9_-/8J<@8Z]:]ZHKMCC*T4DGM_P/\D>?+ T)-MK??\?\V>(^
M /@AXBT#QPOB75];L6NO^$4A\.G^S873:\3L5F7>3_"5X]0>U>?>&?V-=:M_
M$EGJ'B+Q-9ZNBV-_IMY<QI-]KO([E&42N\CL-ZYX50% '>OJZBJCCJ\;N+WT
MV1$LMP\DE)7L[[OR_P CYJTO]F'Q7>7GA.U\3>*M-O\ 0O#NCW>A00V%F\,\
MEO-!Y(=F+$>8%P. !QW)JIX0_9#NO#OAO5M(G'A1I&T2YTBQUBUTV6.^)D0H
M)97,A XQN"CGVKZ@Q5;5(;FXTV[BLYQ:WCQ.L,Y4,(W(.UL'@X.#@^E/Z_B+
M6O\ @O-_J2LLPR=^77U?9+]$>16'P)O[/6/@_>G5+=E\#Z8UA<*(VS<L;98=
MR>@RN>:YKPM^R]JWA_1_A=9'7[<2^$+[4;N:>&)@9?M,<BKY>>C*9 >?2NOT
MGXI:KK,?AI$VQ75K8W-]XAA54R#!F(Q*6P%+S!L'(X7T-/TK]H"UUBZETZUT
MEKG63<0V]O:V]TCQRF1'?)EZ+M6-MW7MC.:S^N5DK7_K7_Y)FOU"A>]OQ_P_
M_(H\K\*_L@>)='\1VNL:GXGT_4[R+3=0TV:[,4YN+O[0C*LTKN[?,"0-J@#
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MPI!^[DX]:]&N_P!J+PIX;DLK'66O9+N*TLYM5O+.T+VNGO<(I3S6'W<D]@<
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MO-CCD0IZC;*GZUF_\+\T$>(IM+.GZN(K?5_[#GU/[&?LD5V6540OG^(LHSC
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MV2K*Z@[64D$C'6LR]_:*\/V]T+:TT[5]6N";IA#86OF.T%O)Y4LRC(W+O#*
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M#]"WWB/RKU_0_#NF>&K,6NEV,%C /X84"Y^I[_C6E172DD97;"BBBF(****
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MH **** "BBB@!-HZXI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ino-20221231_g3.jpg
<TEXT>
begin 644 ino-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #V H4# 2(  A$! Q$!_\0
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MD8(Y KZQ^+7PYT/XA>/O#/@#PQX+\'^ K2Z\*V?C'5/$EE93?:+6+[.\MPH
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MUVDG_)$;?_L:)/\ TB2LY="X]3CO.D_YZ-_WT:/.D_YZ-_WT:916A _SI/\
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MXKL_ _BBWM+*P\8P:!J.E+I3QII"W180F%C)B=592K#Y,$'&1R:^M4[Z[?\
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M_/1O^^C1YTG_ #T;_OHTRB@!_G2?\]&_[Z-'G2?\]&_[Z-,HH ?YTG_/1O\
MOHT>=)_ST;_OHTRB@!_G2?\ /1O^^C1YTG_/1O\ OHU]/_LI^#?#.K?!WXF>
M(=9TKP)=ZII>HZ;!9WOQ!DDCT^!)0XD4O&0P9L#'J<5T&D>$_AOJ'@?XQ^*-
M9L?!Z7FEW.D:1:S>#=.DU+2+-+@[3/:B2="\SEBK,2/+,8(#9Q7)+$*,G&VU
MOQM_F=,:+:3OO_7Z'R!YTG_/1O\ OHT>=)_ST;_OHU]N_%?]D+0_&GQ8\4Z?
MX4>'PIX5\*2Z?HS1Z9HC3W#W5Q$LA>8^</,1$97><E2 Y4(=N3XKKW[,>G^
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M&SQ9_P!]0?\ QJC_ (=@?"W_ *&SQ9_WU!_\:H_M"CY_<'U*MV/S*HK]-?\
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M[KX7O+/++.W_  D.O)YDKES@:O=A5R>P   [  =J],JEJ@"BBBF!-<?\LO\
MKF/ZTSRG\O?L;9_>QQ4L@RT V[CL7"],]>*^6?ACH/AGQ+\&=!^*WC7Q-J6B
M^+[F^$VH^)(M2F26RN_MIB_L]8<F,1@[8/L_EG()R-QW5%[6 ^GJ*^:E^.GC
M>/2-'\:37FDOH7B#7M3T"W\,Q6&+C3C +P13-/OS(ZM9[I8RH4+)QC;D\^OQ
MB^+\>@RWDGB;PX9U^'</C_"Z =H?)#6(_?<QMC)E/SJ>@Q1S(=CZUI64JQ#
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M5D!S>E_#O0M#UZTU73;3^SY+6WNX$M[<[83]IN!<3NR]W:4%L^KMZUTE%%,
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M^>V_._S,<;]V<<9QQ6C8_#7PII=K]FLO#NG6EO\ V6VB>5!"$7["69FM\#^
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MOQZTQ+:&.-(T@B2),[8UC4*N>N !@9R?SJSF#^[+_P!]#_"C,']V7_OH?X4
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M]EAFG>S*Q2.T4J2H2V#GYD&<]LUU,YA_=963_5CN/?VJ+,']V7_OH?X4EL!
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MM;?4+>PEN88[ZX5WAM7D EE5,;RJ]2%W+DCID9ZU8H 2BEI* "BBB@ HI:*
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MW[RJNPS(CLH( I<WD!]1Q^!]!&H6.I)X<TL7^G0BWL[Q;"+SK6(# 2-]N44
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M (4>SEV#F1N45A_\)8O_ #XC_OZ?\*/^$L7_ )\1_P!_3_A1[.78.9&Y4O\
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M(+?P5I%OXRNO%8MY9-=N+1;$W$UQ)(L4 (8I%&6*1ABJEM@!8JN<XK>5V4$
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MQTJO_P )8O\ SXC_ +^G_"DJ<K;!S(W**P_^$L7_ )\1_P!_3_A1_P )8O\
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M1;$;5>-EXV\ODALYJ?:>0^4^OK[4+73(XY+RYAM(Y)4@1IW"!I'.U$!/5F)
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MVVB<](3)CRQ)_P!,RV[/&,TTTEJ(["BG^3(%#%&"DX!QQ089%P#&P+=.#S5
M,HI_DR;PFQMYZ+@YJG-J=I;ZM!IDEQ&FHW$,EQ%:L?WCQQE1(X'HI= 3ZL*
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M44 %%%% !1110 4444 %%%% !1110 4444 3VW\5%%M_%14L""BBBJ ****
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M^_C_ .-%_("I15O[7;?\^$?_ '\?_&C[7;?\^$?_ '\?_&B_D!4HJW]KMO\
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MYL],YJG"[N*Y\=V&D>+=+\5>!K_Q!:ZUKGC18-$2?3[VUO$ECVX$KVU] Q@
M"EC<QSK\[*_.&%5_!/ACQ:=:N#J=_P"(+3Q<8-:7Q VBZ)>"\F1DF$1-U-<?
M9I,$Q-;^2N<JJ@*-QK[+#L%*AB%/49XHWL5"EB5'09XJ?9^8^8\)_93MI]-N
MO$=C'82#2$%B\.JI:7UC!=3;761?LEV6:.90J&1HV*.7'<&O(/!]GJ^K>&[*
MX^'$'B&/XB^9XC75=2NOM MY+?%XEL@ED_<M^_%MY(3)4HV<?-G[6\Q]P8L2
MR]"3FLWP]X?T_P *:-#I.DVPL].A>22.W5F8*TDC2.<DD\N['\:?)HD%SY1O
M/#]I>Z7JD?@ZU\8>'_"+:#9+K[3Z;>SO)JBWD3?O+>5EEF_="9;DPG+(PP6(
M%9>M:/>7G@#2?M.FW]E9V-UJ\>G69TW5[C2=1#>4T4D*HPO+&0G>(-X95Q)C
M@K7VIYCD@EF)'0YZ4>8X8L&;<>ISUI>S#F/CW4M-;4O&FC7_ (^\.>(_^$?7
MQ,+B]L_+NKQK9&\-6R$2-"-TD8GW(Y7AG#9R<BL[4/#?CW_A'9#9V6N0QG0H
M8O\ 2H)YKQ=&_MZ5Q X5EE>0690M&'$OEY&<U]IK(Z]&8?0TFYO4]<_CZT_9
M^8<QX_\ LVZ;<:;HGB8+=3SZ'+J@;3(3I-SIUK GDH)1:QW,KS&(OD_-M ;?
MM&.:]?I68LV6))]325HE96)"BBBF 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 3VW\5%%M_%14L""BBBJ **** "BBB@ HHHH **
M** "BBB@ JW_ ,P@?]?!_P#0!52M"%H5TG]]&\@^T'&QPO\ "/8U+ ^>/&'P
MBU76+GXJ7D&BV\U_K7B#0;[3+HM$)7@M4L_,8.3E-C1SX!()YQUYY;1_A'XU
MU[XC>%9?$WAQ;70;/4=:&JPVAT^+3OL]Y!<1JUM'&//DWB12[3-NW,?E/4?5
M?FV/_/O-_P!_A_\ $T>;8_\ /O-_W^'_ ,34<JN5<^2Y/@/X\U#P3'=ZN)+G
MQ)I>MZ9%';V-W )[W1]-22*!HWE5HA*[2M<[9!C< #@\CU'X8^ =2\/_  R\
M96<UCJ%AJ.O7&H7<=KJE]!<W&^: 1JSF!$AC9RNXHF0"Q)8DFO8_-L?^?>;_
M +_#_P")H\VQ_P"?>;_O\/\ XFA12"Y\<ZA\!O&OC#P)H%A!X1@\$77A[PM8
MZ/<6L5[:YUJ:*[M+B2%&0.@CQ;R8:8'YYCE=NXG2O/@AXLN[RV\3V^G^)K:6
M+Q&FIW.GW&K:8^J72"Q>V6X15B^R1R(S#Y2265<[E; KZT\VQ_Y]YO\ O\/_
M (FCS;'_ )]YO^_P_P#B:7(@YCYF\#_ G4=-OEFU#P[_ *+)X3UJS2#5+RWO
M9(+N\OA,(B41$4LFXD1KL4L5#'J>F\5>!?%8_9U\)6>BV23?$'PM::7>V%K+
M.J@WMO&L<D9E)VX*-*N<X.>M>Y^;8_\ /O-_W^'_ ,31YMC_ ,^\W_?X?_$T
M^56L%SXT7]E7Q9:^'_%_AZU6(:7IMI:1^&O])C4WOFW-O>ZG&2P81EY8#&"Z
ME3OY!7-=)%\&_$][=R:M%HNL6\UYJ\ES.FNZG92W+(ND75JDK);(D,9,DT<>
M%+LP 9L8P/J?S;'_ )]YO^_P_P#B:/-L?^?>;_O\/_B:7(NP<Q\]Z]\)/&=Y
M\"+G1!K4VI73>&K.RA\)2VUI'!%<Q)!N"W.W>QS&X&YMN6ZXQ5&Z^&GBC4-4
MU;3%\)I;'6O&EGXLC\6R7-OOT^W22"0P.H8R>?$L+P*L8*%7R& R*^DO-L?^
M?>;_ +_#_P")H\VQ_P"?>;_O\/\ XFGRH+GQ;'^SOXUM_#\=K>Z-JFH)JGA:
M#0Y+#2M5L+=;21)[AGCN))XY&$3"99!)!E@P/RDA2/1=2^%_BC1_"GC(:5H%
MGJ&J:AXRM]2$DR6UQ=36$<5LAGA,_P"[:=3$2@FP,@MC.*^C?-L?^?>;_O\
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M-_W^'_Q-'FV/_/O-_P!_A_\ $T7\@*E%6_-L?^?>;_O\/_B:/-L?^?>;_O\
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M_?X?_$T7\@*E%6_-L?\ GWF_[_#_ .)H\VQ_Y]YO^_P_^)HOY 5**M^;8_\
M/O-_W^'_ ,31YMC_ ,^\W_?X?_$T7\@([;^*BK5O)9?-BWF_[_#_ .)HJ6_(
M#.HHHJP"BBB@ HHHH **** "BBB@ HHHH *M_P#,('_7P?\ T 54JW_S"!_U
M\'_T 4F!Y9XH^,TNB^(]>TK2/!FM^+!X=MX;G6KC2Y+<&T62,R*(X7<23ML&
M[;&.X )/%=8GCKPZUK-=/K5I!!!/;6MPT[^6;>:X6-H(I%/*.XFBPIY^<5Y#
M\7OAGXE\4>*-8NHO!.D^)99X$30/$EIK)T74=%?R\%9I$&^:-9,R*5).&*[>
MYRM<^%/Q%VZSHXL['Q%'K6M^'];N_$<FH);G=9I9I= P%=Q=C:LZD':0^#@C
M!SYI(JR/4O ?QO\ "/C]I[:TU>SL]8MWNUGTBYNH_M,*V\SQ22, >%^3?ZA6
M!.*J:W^T3\/M'\/PZS%XFL-5L)-4MM(:2PG63RYIVPA?T7;E\]U4XS7F^F_!
MWQAJ>FZ3X>U7PKH=KIFCZQKFKF^EU 2)JBWBWB1VSQQKYB"1;I?-8GH@QD\"
M+2?A/\0+72[ACI<GV>TO]!NK+1]4UNWO+TK9W!>:-+X1J?)"$"))F9@0W*YQ
M2YI=@LCVY/BEX-D\07FA)XJTE]9LTEEN+%;I3+&L:[I21_L+RP'*CJ!7.^(?
MVBOA[H/@_6_$D/B?3]9L='$!NDTRY25U\YPD9QGHQ/WNGRGN,5Y%K7P;^*'B
M/6[![ZUA$-AJ.M7&(-4MHM.:.ZM+N&!K>UCB5D?,\?F/*Y8DN?F!XW?&'P/\
M37WA6PLM*L+$7-K\/;/P_P"2+E(E:]AN[6<Q!L8"D0R8?[N3[T<TK/0+(]5N
M/C#X2TO3[Z_U?7M,T?3[>_>PCN;B]C99V6-),J%Y!VN"4(W <G (J]H?Q!TS
MQ'XNO]"T_P#TI;72K+6$U&&17M[B&Y>98_+(/./(8YZ$,,=Z\@U3X>_$:+Q3
M>ZMIVGB"SU+7]3U*:/3M3M;;484N(+5(L7,D<@2/=%*)%CP[80C(XK6_9K^$
M_B3X7M:?\)!!;)Y'A73-(8V]R)@UQ;W5])(!CG;MN(B&(YR1@8--2DW:P65C
ML_&'QN\'^$+?Q(C:U8ZCK6@V,U]<Z':W2?:RL2;W4*3C< 02.HSDXJ6Y^,OA
M+1X+N;7M=TSP^D-W+:)]LOHR96C2-G("G(8"5<H?F&02,&O)];^$WCN3X=^(
MO 5GX=T&[M99M;N[?Q'=W:&:X-X9WB6./&Z&?=.(WD8[=B$#.[CH_!OPEUS2
M/BY:^(K^TM#IT.IZY=K)YRNZI=6]E'"0O7),$P/H,9ZT<TNP61Z%-\3O#MHV
MHSW6KZ=;:/96%MJ3:J]_$86AG+"-L Y"G;\K='SA<D&JUY\:/ &G:-I^KW7C
M30X-,U#?]DNGO$V3;#AR/93PQ.-IX.*\2\.? +QGX?LO#MW_ &=I]S=>'XM#
MN$TMKU%CO)+.:^,D ?!5,)=1NC,-NY .,9&GXU\ _%+Q0]]+!H6F:)!K&G:A
M;O:>']1MK.X@EGDRGVVZ:%VG1DPT@@QE\YSPU'-*VP61[9H/C>Q\0>(/$^EP
MHT8T!K837;.K13+-;B=70C^$*>2?PKE?#'[1?@'Q7X9TS6+;Q#96QU3S_L5C
M>7"QSSM$[(0!TY*CGH-PR:K_ +/_ ,/];^'HU0ZY## ;BST2&,0SK+\]KIT<
M$P..F)$('J.:Y7X<?"3Q3HDEI_:NF6EN^G^%M8T"*9+Q)?-DGO3-$ZXY5'0C
M.<$$8-.\M T/2[?XP>#A)H5K?^)-)TS5=9MX+BUTZ:_C:1A,H,8#*=IW9PIS
MAOX<UH^#?&EIXRT6_P!3AADL;>RU&^TV7[4RCYK6=X9),@X"DQEAGH.M?-GB
M#X'?%/4O"(\-I:0BU%CH*1FQU6VM;5C9I;^>EVOE&:XE#Q.(VWB,+LQC'/K4
MGPIU?6/@G\1?!L]S'I6H^([[7Y+6Y1]ZQQWEW-+ S%>F4==P'(R124I7V"R.
MNTCXM>"/$%H+K3/%NCW]L;R+3_-@NE9?M,IQ%%G^\YX7LW8FHM5^,O@+0DWZ
MCXRT6Q3S98-T]VJ@O$_ERJ/78_RMCA2#GI7BS?!#Q;KVA>(K2ZT*:QO==TRQ
M\.27VM>)AJCV=LLQDEN855$51#U@7_6;R"=H%5]&T'Q;X#\;>#/#L'@W2/$&
MJ:3X.U;28D%_';1SVWVR%8[O+*0IE!!FC/S99\;NA7-+J@LCZ U3XC^$]$UO
M3='U#Q+I5GJNI*CV5G-=H)+A7.$*C/1CPI_B[9JBOQ8\+W7B:#0--UG3M4U8
MW_\ 9]S:07L8EM) LA(92<LP,3+L7YN"<8!KY^C_ &7_ !1H=O=:&1<^)=*U
M;3]'M+B:W\1'3;2!K2%(I%GA\MI)44IOB,9SS@[>M=]_PIG7YM)L['$-F[>.
M=:UR>ZBF4O':727:0S#'WI )HCMZC'M34I=@LCT:U^+W@:^AU::W\8:+-#I&
M#J$B7J%;4%]@9SG 7?\ +NZ9XS3H?BUX)N/#EYX@B\6Z/)H=G/\ 9KF_6[7R
MHICC$;'^\<C"]3D8S7SI:_LV>+[GP3'HM[I,DE]I>@1Z';W&H>)A=VUP/M5L
M\BV\ C410LEN7Q*=P.% ZD^C^,/A?XD/Q>U3QOI.EV6J6]OK.E:I::9)=) U
MZL-A<6LV&(VQRH9D9"_!VD9'!H4I=@LCT&]^+_@73;'2+VZ\8Z);V>L#=I\\
MEZ@2Z 8*60YZ!B%). #P<&NNKY@\4_!/QSK6M:GKDNAPY\1:(^DW6@^'?$"Z
M7;66;B>0+<.8V^T)(DX,K1@,9%8A3D$?26AZ:-%T/3-.7[MG:PVP^=G^X@7[
MS<GIU/)[U46V]4)EVBBBK$7;Q?,:Q4<%K=!^IKRGP'\6-?\ 'WV._M_ASJ5C
MX7NIIHUUZYU:S**D;O&9#"'\S!9#QC/.:]7NF"26#'H((R?S->#_  M_9^T_
MP+X)DO$\/:3:_$5[?4%.HS.\\;2S23%/, ;:R%70, .F16>NEAG=Z7\8? FN
M?:/[.\8:->_9Y88)?(NU;8\LGEQ#W#N0JD<$G&:M>(/B9X1\)QWSZUXETS2U
ML;B.UN?M5P$,4SQ^8D9'7<4(? YV\]*\$\/_  '\;>)-2O/^$MBFL[6X\%2:
M LL^JVUR;:^6>&:)[>&"*-(8%>,,B@$C8,XXST?AWX;^.?"]]X/\=W>BZ?XD
M\9I/JMYX@TA+](!Y]Z(E5[>9P4S$D$<7.,H6P>Q2E+L.R/5IOBAX.@U*QT^3
MQ3I"WM_;"\M8?M:9FMRK,)E.<&/:C'=G'RGFL#5OV@? UCX<;7+'Q!I^MZ;#
MJ5GIMW-8W:;;,W$@1)92Q&U!G=GN <9KSGP/\"_&/@KPYXRBMHM#?6M3\*KI
M]C]HQ-917;7=[<-;%&7F!/M,:@LNUL?=P,5S]Q\%OB1J&M:GKESH_P#:4LO_
M  CS0V/B'7;:YDD^P7LDTR.T42Q1KM<;%52!CL3@+FEV"R/>(?B]X;U'5/"U
MMI-_!K-EXA-^(=4LIT:W@-I$)91(2<@X.,=B.<5K>$O'WAKQ];W,_AK7]/UZ
M*V<1SM83K+Y;$9 ..F1R#T/;->!^+/@#XQ^(E[K6HW$%EX9F\13:Y+-:QWBS
M?V>+G2X;. NR#$CR/$6D*< -U.*[GX)_#O6O#OBK4->U_2K[3;AM)M=)1]0\
M1C599%C=G*H$14CA4GY,_/\ ,<A1Q34I7LT%E8[ZV^)'A.\\6/X7@\2Z7-XC
M0L&TM+E3.&499=O]Y1R5Z@=17-0_M"^!;SQI!X>L]>L+U6M)+B74K>[C:VMW
M6XBMU@<YSO=YE"D<'!&:\IU;X,_$GQ5XKTY-2_T'3+7Q#J%XUU8ZE;Q64=M<
M07,4<UO9I$LGGJ)D9VE<L6#$;L\7]+^"_BGQ7-IFD>)O#.E^'M(TWP)<>$O[
M2L-02>2>XWP&&:-%4,D8,/F*&^8-G('4KFEV"R/;/$'Q(\*>$UOVUKQ'INEC
M3Y8H+O[5<!##)(F^-&'7<R@L%'.!GI44_P 4O!EM>:=:2^*M'2YU&W%Y9QF\
M3-Q 0Q$J'."F$<[NGRGFO$I/@GX[FT_P?XKU'SKCQO#JFH:IK]EH.LI82M)<
MPI!&;>Z92F8HX8EPV 59P".^GX%^ VI>']/\06MUH6FR6^I>$&TC^S[S5)+F
M-YY+RZGEMY)]HDV$3KEU4#).T844^:5]@LCU6U^+O@>^\.7OB"W\7:/-HEC(
ML5U?K=KY4+MC:C'J&;(P,9;/&:WM#U_3/$VCV^K:1J-KJ>EW"%XKRUE#Q.H)
M!(8<<$'/I@YKYIF^!WQ"U.UAO9!J%O'I6L:?J-EI-SX@@DU658;>>&51J218
MPGG(81+N(\M@67<,>E>$_A/J$?P6\8^&+@2Z!JOB9M2E=I]3;4I8)+E"@DEF
MVJ&<X#.$&T$G!/4D92>Z%9'8:+\6O!/B)6;2O%NCZBJW<5@3;7:O_I$A(BCX
MZER"%[,0<$T_7OBEX.\+PW,NL>*-*TR.VNS83-=7*ILN BR&(_[01E8CL""<
M5XAH/P!\1:EHNJKJNFW6EZQ:^'+?2]+O+[Q+_:7^EV\T=Q#Y*+&JPVZRPQE=
M_P XW,, 9R^\^!_C.T;PAXF$=U?>(UM-4?7['0]<339/MM],D[O%.Z,KQJ4$
M+*<$HJ$9Q@KFE;8=D>U:M\5O!6@ZE:Z=J/BW1[&^NA"T%O->(K2++_JF'/W7
M_A;H?6D\$_$W0OB!JGBO3](N#+<^&M3;2KY6[2*BMN'^R2S*,\YC;CI7C=I^
MSWK6E_#[QYH5KIFGQS:IX0TO1-/C^W&=1-!Y[21&60!MBM(N&8#.,X&*]4^&
M_AS6/#6O?$7^TK1$L=5UUM7L+R.X5_.CDM8(V5D^\C(T!SG@[ACO5)ROJA:%
MO3?C)X"UJ+4I;#QGHEY%IMK]MO'AO486]OWE8YX0=ST'0XIK?&;P"D>ER-XS
MT1$U1F2Q9[Q%%P0_EG;GMO\ EW'C/&:^:O"_PP\7?%C]GWPI:VGAS2]'M[#P
M;J=AI]PM^C'59;U%1%VA084^4O)O/+XQD<UZM\3/AIXIO-9^(":%H>F:W8>-
M_#EMH/VB\O4M_P"QVBCEB)9"I,D.)O,"Q\[TZ<@B5*35[#LC67]I+0;GQEXG
MT"SLVNAX>GDM+J\^W01F2X2U>Y>**%CO<A49<@=0W92:ZG2_B]X2OCX;MKC7
M=/TS6-?LK>^L](N[I%N2LR!XU*Y^\<D#^\0<9KRO4/@?XI^V7RP^3>PG7Y[V
M*XFN5#S0'PZNGK(P[,TZ\KU .[I7-6_[./BRWDN--N[2ZU33=9719;EX/$WV
M*TLWM+:WBD2:!8R\Q1K<O$T;8.X [>23FFN@61](>+/''AWP'8Q7GB36['0[
M65_+CDOI@GF,!DA1U) Y.!P.35+4_BIX+T5=':_\6:-:+K"++IS2WJ!;M&("
MNAS@J2P ;ID@9KFOC+H7C+6O$7AF\\,0M+8V_P!K2^:PO+>QU!&D5!&8[B:-
M]D7#>8L8#GY<9 Q7F?PW^$/C_P"&?AFVLU\-:#XDO=2\-VNAW:ZE?HUM8207
M-PVZ12N;BW=9PY5,-N3! SD4Y.]K"L>TS?&+P);QZM)+XPT9$TF407[-=+BV
ME+L@C?\ VRRLNT<Y4\5)J'Q<\#Z3IVDZA>^+]%M;'5EW6%S)>H([E<@%D;.-
MH) )/ )P<&O,]-^$_BCPSHOA+4+72['5=5\.^+]:UV32/M:0K>0WDMT(Y$E(
M*K,B31NH;IRN0:Y/6/@3XUCTV[O=/T6*'Q#K$FK3E]*UV."/3!>7'FK97$4T
M30WEH.'=0F=Y?:,'-3S2[#LCZ$7XA>%F\6_\(L/$6FGQ)C=_90N5^T?=W8V^
MNWYMO7'.,5#XE^)W@_P;J4&G:_XHTK1;^<(T=M?72Q.RNQ56P?X2RD;NF1UK
MRK3_ (7^,M.^*VGZC:V$&GZ;_:\>I:K=Q:DDVF7H%L(Y98["1#);7;, H>)E
M7:.2<D55^)FFZ]KGQG\<:-H/AK3=>FUGP#;Z7+<WUXEO]B6:YNT$C!E)DC&2
MQ5?FRBX![/F=M@L>O7GQ2\':;J6JZ?=^*=)MK[28FGU"WFNE5K2,;<M+G[H^
M=.O7<,9S44GQ:\$0^%X?$C^+=(30)I_LL>HFZ7RFFYS$#UWC!RN,C&2,5Y<W
MP/\ $&G^$]<M;6*QU._A\5Z7KUI%>3!$U>*RM[6/9,V#Y;.87*[@0&"D\5@:
MY9ZK\-_B=8_%#Q!::/I=UJVM73Q>&;_6(H(HT;3XH/.-XR^0+DB$LP)&Y&*J
MS,,$<I+=!9'M\/Q<\#W5UIUM#XOT::?4D:2S2.\1OM"*SJSI@X*@QR MTRAY
MJ.Q^,W@'4]+O]2M/&>B3Z?I[QQW=TMXGEP-(VV/>2> YX4]">AKPOX#_  \\
M37'PZO==T_3='L[G6/!UUIVEK>*)+43R:C>SHC1E<FW*31'E<,"..U11_ OX
M@>(-;N=0UFPDDAN+/P_:F'6-9MKN0?8]6CNIP%AC2-(_*#%$4'IC@G%+FE9.
MP61[WHOQ@\">)-0L+#2O&&BZA>Z@'-K;V]XC23;,[P%SG(VMP<'Y2<<5?\+?
M$+POXXFO8O#OB'3=<ELB!<I8W"R&+)(!('8D'#=#@X->5WWP=UZZU3Q#<"QT
M]UO_ (E1^)XS+*N'L1:+"6?'.[(8%/O8)]:L? GX=^*_!7B*=M2L&T;PY!H\
M6G6VFW>K1ZJ\4R2[@MK.(Q+':*F0(I6)R00%P<TI2O9H6A[91116@@HHHH *
M*** )[;^*BBV_BHJ6!!1115 %%%% !1110 4444 %%%% !1110 5;_YA _Z^
M#_Z ***3 J4444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I-B[P^Q
M=X& V!G'IGTHHH 6BBB@ HHHH **** "BBB@"WJ'2S_Z]D_F:J444EL 4444
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!$18U"(BHBC 50 !] .E+1
M10 4444 %%%% !1110 4FQ=Y?8H<C!; R1Z9]*** %J.XMX;N$Q7$,5Q$Q!,
I<R!U..G!&*** )**** "BBB@ HHHH **** "BBB@">V_BHHHJ6!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ino-20221231_g4.jpg
<TEXT>
begin 644 ino-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %% JP# 2(  A$! Q$!_\0
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M  G>E^LW_?NC_A.]+]9O^_=>=UA^+O&NE>!K&UN]6DEC@N;A;6,PQ&0F1@2
M0.@PIYII-Z(-CV#_ (3O2_6;_OW1_P )WI?K-_W[KYED_:=\!?V+I^J6MUJ6
MJ6VH0V\ULFG:>\\L@F:18U"#G=F)P5ZC ]:L_P##1_@8Z?\ :TN[^8F*.1;2
M+3Y&N7=Y&C$(B W&4,C93J,$U?LY]B.>/<^D?^$[TOUF_P"_='_"=Z7ZS?\
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MG].:[A3N4$=",BI<6MT4FGL>B?\ "=Z7ZS?]^Z/^$[TOUF_[]UYW14C/1/\
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ME_S\7'YK_A1_PKZR_P"?BX_-?\*S;<G=EI):(X*BN]_X5]9?\_%Q^:_X4?\
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M<ZD*>LW8]2K@/C)\8=.^"^@VNKZI:7%W;33>1MM0"X;&1P2..M=_7S+^WO\
M\DKTO_L(K_Z":[\MP\,5C*5"I\,FDSS,WQ53!X"MB*7Q13:(/^&_O!G_ $!=
M8_[]Q_\ Q='_  W]X,_Z NL?]^X__BZ^"J*_6/\ 5/+>TOO/Q#_7C-^\?_ 3
M[U_X;^\&?] 76/\ OW'_ /%T?\-_>#/^@+K'_?N/_P"+KX*HH_U3RWM+[P_U
MXS?O'_P$^]?^&_O!G_0%UC_OW'_\71_PW]X,_P"@+K'_ '[C_P#BZ^"J*/\
M5/+>TOO#_7C-^\?_  $^]?\ AO[P9_T!=8_[]Q__ !='_#?W@S_H"ZQ_W[C_
M /BZ^"J*/]4\M[2^\/\ 7C-^\?\ P$^]?^&_O!G_ $!=8_[]Q_\ Q=;O@?\
M;,\-?$#Q5I^@:;I&I1WM\_EQM<*BQ@XSR0Q/Z5^=M>H_LQ_\ES\*?]?/_LIK
MBQO#.7T,+5JP3O&+:U[(]#+N,<TQ.,HT*CCRRE%/3HVD?IMYVH_\^MO_ -_C
M_P#$T>=J/_/K;_\ ?X__ !-7Z*_(C]V*'G:C_P ^MO\ ]_C_ /$T>=J/_/K;
M_P#?X_\ Q-7Z* *'G:C_ ,^MO_W^/_Q-'G:C_P ^MO\ ]_C_ /$U:NKA+.UF
MGDR(XD+M@9. ,FO)%^/C:/X9TWQ/XCTF.PT#6(89-,^SW:/<O)*RB*%T8JNY
M@V[=N"C&">] 'J/G:C_SZV__ '^/_P 31YVH_P#/K;_]_C_\37FEA^TQX4U!
M7G6TU>+3E"C^T9K55@,K6HN1#G?G>8V Z8+' -2Z/^T%I>I:9+=G1=8*6T+2
MWKQVZ;+1]I=89"SC$A0 ]U!8 L* /1O.U'_GUM_^_P ?_B:/.U'_ )];?_O\
M?_B:\PT[]HC3O$7AOQ7K.C6$D\&AZ9)>E)Y%#/*GF!HB4++U0?,K$?-3G^/'
M_"):U>Z-XUTT:=>P6WVN*YTUS/!.FQF"#.&64E&54YW$<4 >F^=J/_/K;_\
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M_P#$U7]BUOYE^/\ D+_6?"_R2_#_ #/M?SM1_P"?6W_[_'_XFCSM1_Y];?\
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M7_G7X_Y!_K1A?Y)?A_F?IW)J%_'<Q0&UAWR!B/WQQQC_ &?>IO.U'_GUM_\
MO\?_ (FORSF_:E^+/F*__"=:CN4$ ^7#W_X!5>3]J[XO#IX\U(?]LX/_ (W1
M_8&(_GC^/^0?ZSX7^27X?YGZJ>=J/_/K;_\ ?X__ !-'G:C_ ,^MO_W^/_Q-
M?E')^UE\8!T\?:E_W[@_^-U5D_:V^,2]/'^I?]^H/_C=/^P,1_/'\?\ (/\
M6?"_R2_#_,_6;SM1_P"?6W_[_'_XFCSM1_Y];?\ [_'_ .)K\F;/]LGXRZ;=
MQ7 \<75UY;!O*NK>%XV]F 09'XU^E7[.?Q7G^-7PBT3Q5=V:V5[<J\5Q$F=G
MF(Q5F3/\)(R/K7GXS+*V"@IS::?8]7 9Q0S";ITTTUKJ=YYVH_\ /K;_ /?X
M_P#Q-'G:C_SZV_\ W^/_ ,35^BO(/<,N&^OYI)D6UAS$VTYF/H#_ '?>I?.U
M'_GUM_\ O\?_ (FC3_\ C\U#_KJ/_015^@"AYVH_\^MO_P!_C_\ $T>=J/\
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M'8_\^X_[Z/\ C1_8=C_S[C_OH_XT 7B,C!&17!_\*)\#&)HSH0*841YNI_\
M1PKAU$!W_N0& .(]O0>@KKO[#L?^?<?]]'_&C^P['_GW'_?1_P : .=;X0^$
M)-,;3Y-$BFLVN[:_:.:21]T]NJ+"Y)8DE1$@YZ[><Y-4]2^!7@;5B_VK0E</
MDLJW,R*S?,-Y"N 7 9@'^\ < BNN_L.Q_P"?<?\ ?1_QH_L.Q_Y]Q_WT?\:
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M/O\ ^"5V_9UT9O\ F(WG_CO^%1M^S=HC?\Q*]_\ '?\ "K#?&'P&O7[5_P"
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M_@AO^9EUO_R'_A7U?_8=C_S[C_OH_P"-']AV/_/N/^^C_C2_M3&?\_&5_8V
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MH9#*LPR>"R&6+ ZF1<]*]0^W77_0.D_[^)_C1]NNO^@=)_W\3_&@#YTNM/\
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M #[_ !_X ?ZK1_Y_?A_P3\=)O".OX/\ Q(-6_P# ";_XFJ,OA'7^?^*?U?\
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M_BJ]U5,O\ON_X!\?]7SOO+_P+_@G+2?'CQ@O2[M?_ 9:KR?'[QDN<7EK_P"
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M_LO_  "6J\G[4GQ"7I?V/_@$O^-=JW['>JM_S,UG_P" C_\ Q50M^QGJS?\
M,T6?_@(__P 55JME?]W[O^ +ZOGO>7_@2_S.(D_:J^(B]-0L?_ %?\:JR_M9
M?$=>FH6/_@"G^-=T_P"Q9J[?\S39?^ ;_P#Q=02?L1ZP_P#S-=B/^W-__BZK
MVV5?W?N_X!/U?/>\O_ E_F<%)^US\2EZ:C8?^ "?XU5D_;!^)J]-1T__ , $
M_P :[^3]AK6&_P"9ML1_VY/_ /%U7D_81UINGBZP'_;D_P#\75>VRKM'[O\
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M8*^,Q3I.M)T%[O0_0<&JT</!8AWG;4****Y3L"BBB@ HHHH H:?_ ,?FH?\
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ME_X69>_] C0O_!9'75^)]:T[2?#NLQ1P:/-?7$-M:O%'9V[&*Y9-US+&P7(
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MK0O#^L75MJ6K26DA5&56E?)&#SP*;\*-5OM2TW7H[N22>WL]:N[2RN)6+--
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M#0_F?X?Y!_K1BOY(_C_F?I W[1WPD7KX]B'_  .;_P")IC?M*?"%>OCZ$?\
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MM'[G_F?$_P"HN4]Y_>O_ )$_-C_AC3XH_P#0&M__  *2C_AC/XH_] :W_P#
MI*_2>BC_ %NS'M'[G_F/_47*N\_O7_R)^;'_  QG\4?^@-;_ /@4E'_#&?Q1
M_P"@-;_^!25^D]%'^MV8]H_<_P#,7^HN5=Y_>O\ Y$_-C_AC3XH_] :W_P#
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M23^-5TDC:_NIIM.G=9-FTM!D\#FMVB@5K[F3YUI_T"Y?_ 84GF6?_0*E_P#
M85KT4^9BY8]C(\RS_P"@5)_X"BDW67_0)D_\!16Q11S/N'+'L8^ZR_Z!,G_@
M**3-C_T"'_\  45LT4<S[ARQ[&-_H'_0(?\ \!!573;>TM[&&.71V\Q1@_Z*
M#WKHZ*?,^X<L>QB[=/\ ^@.W_@(*39I__0&;_P !!6W11S/N'+'L8GEZ=_T!
M6_\  0?X4>5IO_0%/_@&/\*VZ*.9]PY8]C#\G3?^@(?_  #7_"D^SZ9_T!/_
M "37_"MVBCF?<.6/8YC4K&PN+1DBT,;]RGFS7L03VJS]ETO_ * ?_DDO^%;U
M%',^X<L>Q@_9=*_Z 0_\ E_PI/L>D_\ 0!'_ (!+_A6_11S/N'+'L8'V/2?^
M@"O_ (!+_A2?8=(_Z "_^ *_X5T%%',^X<L>QS_V#1_^A?7_ , 5_P */L&C
MCD>'US_UXK_A7044<S[ARQ[&+)=G[?:R)9W(BB1E($6,9QC _"K?]K#_ )]+
MO_OR:OT5)10_M8?\^EW_ -^31_:P_P"?2[_[\FK]% %#^UA_SZ7?_?DT?VL/
M^?2[_P"_)J_10!0_M8?\^EW_ -^31_:P_P"?2[_[\FK]% &/:7S0W%V[6EUM
MD<,O[H]-H']*L_VL/^?2[_[\FK]% %#^UA_SZ7?_ 'Y-']K#_GTN_P#OR:OT
M4 4/[6'_ #Z7?_?DT?VL/^?2[_[\FK]% %#^UA_SZ7?_ 'Y-']K#_GTN_P#O
MR:OT4 4/[6'_ #Z7?_?DT?VL/^?2[_[\FK]% %#^UA_SZ7?_ 'Y-']K#_GTN
M_P#OR:OT4 4/[6'_ #Z7?_?DT?VL/^?2[_[\FK]% %#^UA_SZ7?_ 'Y-']K#
M_GTN_P#OR:OT4 4/[6'_ #Z7?_?DT?VL/^?2[_[\FK]% &=IA>2ZO9C%)$LC
MKM\Q<$X4"M&BB@#B?BG\1[/P!HT<>^>37=4$MOI-G:6CW4LTXC+ B- 257@L
M>@%<!XW\=#Q5^RG?^(4BA\57!TY1=Q1)-!').CJDX=%VR*J,'+)P<*153]KC
M58/"VD^&O$:S26&KZ;=2BQOK74H[:X5I$V-%'$Z/Y^\<; ., TSPKIGB6U_9
M1N8_!VDWVA^*9X9KB.WNKV*ZO7EDF+RR&0?)YKAG8#HI(':O1ITXQIPJ=;K^
MN_;^K'DU:DY5:E+HHOIZ?*^_]7)_V:/'5_XBU[QAHS6?AV31M+-N=/U/PQ#L
MMFC</B%CT+JJJQQTWX->^5X)^S;%J&G^(_%=A;QZY8^$TBM9+'3_ !.R"_2X
M8/\ :'" [A&QV\MP6#8XK>_:2^,&I?!?PC9:SIMI;WLDUR(&BN,A<$9SD?2B
M5">)Q2HT5K*UON".)AA,&\17?NQNV_*_]6/7:*^$?^'@7BO_ *%W2_\ ON3_
M !H_X>!>*_\ H7=+_P"^Y/\ &O:_U7S3_GVO_ E_F?/_ .N62_\ /U_^ R_R
M/NZBOA'_ (>!>*_^A=TO_ON3_&C_ (>!>*_^A=TO_ON3_&C_ %7S3_GVO_ E
M_F'^N62_\_7_ . R_P C[NHKX1_X>!>*_P#H7=+_ .^Y/\:/^'@7BO\ Z%W2
M_P#ON3_&C_5?-/\ GVO_  )?YA_KEDO_ #]?_@,O\C[NHKX1_P"'@7BO_H7=
M+_[[D_QH_P"'@7BO_H7=+_[[D_QH_P!5\T_Y]K_P)?YA_KEDO_/U_P#@,O\
M(^[J*^$?^'@7BO\ Z%W2_P#ON3_&NL^%/[9GB7XB_$#1_#L^CZ?90WTOEM/"
M69DX)R >*RJ\.9E1IRJS@K15WJME\S:AQ9E&(JQHTZC<I-)>[+=_(^PJ*H?8
M[W_H(?\ D%:/L=]_T$/_ ""M?,GV!?HJA]COO^@A_P"05H^QWW_00_\ (*T
M7Z*H?8[[_H(?^05H^QWW_00_\@K0!?HJA]COO^@A_P"05H^QWW_00_\ (*T
M7Z*H?8[[_H(?^05H^QWW_00_\@K0!?HJA]COO^@A_P"05H^QWW_00_\ (*T
M7Z*H?8[[_H(?^05H^QWW_00_\@K0!?HJA]COO^@A_P"05H^QWW_00_\ (*T
M7Z*H?8[[_H(?^05H^QWW_00_\@K0!?HJA]COO^@A_P"05H^QWW_00_\ (*T
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M_P R?]6<9_/'[W_D?#LUQ+_SUD_[[-4I[B7_ )ZR?]]FONQOV??A6W72(/\
MP,E_^+IC?L[_  H;KH\'_@9+_P#%U7]M8;^5_<O\Q?ZLXW^>/WO_ "/@F:XF
M_P">TG_?9JA-=38_UTG_ 'V:_0%OV<?A*W71H/\ P-E_^+IC?LU?")NNB0?^
M!LW_ ,75?VYAOY7]R_S%_JSC?YX_>_\ (_/.:ZF_Y[2?]]FJ4UU/_P ]Y?\
MOL_XU^AFI_LS_"1+1FAT.$R;EZ7LQXR,_P ?I4S?LN_!QNN@P?\ @=-_\73_
M +<PW\K^Y?YC_P!6<9_/'[W_ )'YOS74_P#SWE_[[/\ C5&:ZG_Y[R_]_#_C
M7Z5-^RK\&&ZZ! ?^WZ;_ .+J-OV3_@JW7P];_P#@?/\ _'*?]N87^5_<O\Q_
MZLXS^>/WO_(_,N:ZGP?W\O\ W\/^-49;RX_Y^)O^_A_QK]/V_9(^"3=?#MO_
M .!\_P#\<IC?LA? ]NOANW_\&$__ ,<I_P!NX7^67W+_ ##_ %9QG\\?O?\
MD?EM-=W'_/Q-_P!_&_QJFVH744@=+J='4Y#+*P(/J.:_5%OV._@8W7PU;_\
M@PG_ /CE,_X8U^!.X$^&+<_74)\?^C*?]O87^67W+_,/]6L9_/'[W_D</_P3
M[^(GBCQYX'OH/$5W<:E;Z3=-;V-]=$M(R% S(7/+;3W/3.*^NJY#P[H_ASP5
M!I>DZ!;V>EZ3:QR+';VP"HN<?F3ZGDUT?]KV7_/U#_WV*^-Q56->M*I"-D^A
M^@8.C/#X>%*I+F:6Y<HJG_:]E_S]0_\ ?8H_M>R_Y^H?^^Q7*=A<HJG_ &O9
M?\_4/_?8H_M>R_Y^H?\ OL4 7**I_P!KV7_/U#_WV*/[7LO^?J'_ +[% #-/
M_P"/S4/^NH_]!%7ZQ['5+1;J^)N8@&D!'S#GY15S^U[+_GZA_P"^Q0!<HJG_
M &O9?\_4/_?8H_M>R_Y^H?\ OL4 <;\>_%S^!?@SXQUR&5H;BUTZ402(<,LK
MC9&0?7<RU\H^']:\3?#S4Y+FYU+Q=H]QHO@VXU768O$NJ?:H[^1XQ'&UO&"0
MFV8YR3D# Q7V5XITOPWXVT6;2-<2VU'39F5I+:5_E8JP9<X(Z$ _A67XE\!^
M!_&$U[+K.GV5_)>V0TZX:20CS+<.'$9P1QN ->Q@\92P]-TYQO=Z^FG_  ?P
M/&QF#K8BHJD)6LE;UU_X'XGRKX=N?%WP\^$NJ>.;^S\6)K^DZ!]L2\U7Q,+R
MRGN'"KN^RJQ( WE@&X&*WK?4H/@_XXT&5_%OB_4-1NM!N]5OKN^O$NM-U(+;
M&1V"%LP['Q@J .@YKWCPG\'?AGX'_M$:)H6G62ZA;FTNU\QI%FA)R48.Q&*H
M:-\ /A+H$-Y%8^&]-A2\@DMILRNS-#( 'C!+$A2!T' [5VRS'#S<N9.SOT6J
MMMJW:SN^N_30XHY=B(*/*U=6W;T:?DE>ZLNFW6[/GKX7S>(M$^'4GCKQ-!XO
MCNK'1+C6#J-UXH$ME/*49HU^RAMP!W# /3%5?!GQ*\6>&X_"/@+Q-K]_/J^E
MWC>);R_>=_,N-+%D;E [9R5$C&,J?[HKZ/TG]G_X2:'#>Q6/AO3H(KV#[+<(
M)Y")(MRML(+],JO3TKHM9\ ^!?$&J/J.H:9I]S?-ISZ2T[-AC:/]Z+@]#^=$
M\RP\I2O"Z?EMVMJ^[_ 4,MQ$8QM.S5NN_>^B[+\3Y:^$,WB*'P7'XZ\3Q>+D
MFM=,NM<;5)_% >PE8*[Q+]D!W;2"H"GTK'^'NK>,-!U;P%>2WOB^SUM]'O/$
M6H'7M4,]GJMO' 7,,, )P<O'R<$"OIK2?V??A'H27B6'AO3K=+RV:SG59Y"'
MA8@LG+\ [1T]*[%O#GA-]9TO5FMK,ZAI=J]E9S[N88'"AHP,XP0J]1VIU,SH
MMRM"ZE?I;H[+=]7_ )(*>5UDH<T[.-NM[ZJ[V71:=>[/E);C5-+\#_"_XBVO
MCK6-3\?^*M7LF?3S?EK.>&9_WT MA\JI%'GD#(*\]:YZ]^+WC&STWQ?YVKZ@
MUK\1[Z2+PPZSONLG2_\ L\D<)S\H,3"08QTKZI\-_!/X7>$?$%QKFD>'],LM
M3F#@SHQ/E[\[_+4L1'G)SL ZUJ?\*[\!?V?X=LO[+T\VOAZ<7.E1EB1:2\_,
MO/7D]<TO[2PZ>L.;7JDM-TEY)V^5P_LW$N.DU'3HV]=$WZM7^=M]SL[&V^QV
M=O;^8TOE1K'YCG+-@8R3ZFIZI_VO9?\ /U#_ -]BC^U[+_GZA_[[%?-'TY<H
MJG_:]E_S]0_]]BC^U[+_ )^H?^^Q0 RQ_P"0AJ/^^G_H J_6;I<T=Q>Z@\3K
M(A=<,IR/NBM*@#YO_;2T>[USP_X<M;6PTNY+7,A:YO=)GO;BW^4?-;M$C^4_
M^T0:O>!X-4TK]E6>*V76-1U*"";RU2^:TNW(D)_UT\:%!CJ2N,9ZU]!5QWQ>
M\!/\3_AOKOAB*]_L^748!&EPREE#!@P#+D94E<$=P37;"NG"%*6R=[GGU,.U
M4G6B]6K6_K_(\<_8QDUVZTG7[K6KW5+LRRJ5CFO[>YLK<\YCA,3%BPXW,^-W
M& *^DRH;J :\H^#WPLUGP?XH\2^)-<_L6RO-7AM;4:;X=B>.TC2!6 D.X EV
MW^G  '->L5GB9*=5R1I@X2IT5&6Z[^HW:O\ ='Y4;5_NC\J=17,=HW:O]T?E
M1M7^Z/RIU% #=J_W1^5&U?[H_*G44 -VK_='Y4;5_NC\J=10 W:O]T?E08U/
M!4$?2G44"(_L\7_/-/\ OD4?9XO^>:?]\BI** (_L\7_ #S3_OD4?9XO^>:?
M]\BI** (_L\7_/-/^^11]GB_YYI_WR*DHH C^SQ?\\T_[Y%'V>+_ )YI_P!\
MBI** (_L\7_/-/\ OD4?9XO^>:?]\BI** (_L\7_ #S3_OD4?9XO^>:?]\BI
M** (_L\7_/-/^^11]GB_YYI_WR*DHH C^SQ?\\T_[Y%'V>+_ )YI_P!\BI**
M (_L\7_/-/\ OD4?9XO^>:?]\BI** (_L\7_ #S3_OD4?9XO^>:?]\BI** (
M_L\7_/-/^^11]GB_YYI_WR*DHH C^SQ?\\T_[Y%'V>+_ )YI_P!\BI** (_L
M\7_/-/\ OD4?9XO^>:?]\BI** (_L\7_ #S3_OD4?9XO^>:?]\BI** (_L\7
M_/-/^^11]GB_YYI_WR*DHH C^SQ?\\T_[Y%'V>+_ )YI_P!\BI** (_L\7_/
M-/\ OD4?9XO^>:?]\BI** (_L\7_ #S3_OD4?9XO^>:?]\BI** (_L\7_/-/
M^^11]GB_YYI_WR*DHH C^SQ?\\T_[Y%'V>+_ )YI_P!\BI** (_L\7_/-/\
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M3_KID*_YB/\ R6?_ ,B3_J[FG_/K\8_YGK_]M6WI-_WY?_"C^VK;TF_[\O\
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MK;TF_P"_+_X5Y>O[049_Y@DG_?\ '^%.'Q^C/_,%D_[_ (_PI?Z]\/?]!/\
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M6*3SY_+.XDG@8]*]X^RW_P#S_K_WX'^-8\E^FFZI=QW6M6MI*P0_O]B%ACJ
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M&1FY'^%?2G]J1?\ 0P67_CG_ ,5572=2B_L^ #7;.,;?NG8<<_[U9O@O(_\
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MG'I4_P#PHWQ5_P \;3_P(_\ K5[CJL5T^FEQ?I-&67&V(8/S#OFK_P!EOO\
MG_7_ +\#_&MO^(<Y+)74I_\ @2_^1,GQ1C^JC]S_ ,SP)?@AXI_YXVG_ ($#
M_"GCX)^*?^>-K_X$#_"O>OLM_P#\_P"O_?@?XT?9;_\ Y_U_[\#_ !J?^(;9
M*_M5/_ E_P#(D_ZS8[M'[G_F>$+\%/% _P"6-K_X$#_"GK\%_$X_Y96O_?\
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M(_\ GE;?]_\ _P"M3U^$GB(?\LK;_O\ ?_6KV/[+?_\ /^O_ 'X'^-'V6_\
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M?^_ _P :/LM__P _Z_\ ?@?XUC6Q<ZT>627W'3A\!2P\^>#=_-E^BJ'V6_\
M^?\ 7_OP/\:/LM__ ,_Z_P#?@?XUQ'HE^BJ'V6__ .?]?^_ _P :/LM__P _
MZ_\ ?@?XT 7Z*H?9;_\ Y_U_[\#_ !H^RW__ #_K_P!^!_C0 6/_ "$-1_WT
M_P#0!5^LS2DDCO+\2R>:^]<MMV_PCM6G0!\Z?MA7'B9].\/V&A:!'XDM[D71
MFL9+2&YQ*JH8I-LG0#+\CUYJNT.LM^R7KT?B;P=-/+%).(/#QA-JT=J+D>3\
MD'S*$3#_ "\_+ZT?MJ>%8-7\.Z+JMS=ZC86]C]IAEGT_[-NV2JH*XF=26)4
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M+KAEZ?=%:56<IY;\=/@HGQEM=%B>738FTV=IT;4; W6&( !3#KM8>M=+\+O
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M?B^]"^KUOY']S.FHKFAJF@'IXBA/_;^O^-+_ &EH7_0P1_\ @>O^-+ZWA_\
MGY'[T+V%7^1_<SI**YS^T-#_ .@_'_X'+_C5?3M3TF>RB>;7D$K#YA]M4=_3
M-'US#?\ /R/WH7L:O\K^XZNBN>^V:+_T'4_\#E_QI?M6CG_F.+_X&K_C2^NX
M7_G['[T'L:G\K^XZ"BL 7&D'IK8/_;Z/\:NQZ9#-&KQWEQ(C<AEG)!_&M:>(
MHUG:G-/T:9$H2C\2L:5%9_\ 8Z?\_-U_W^-']CI_S\W7_?XUN0:%%8FJ:?\
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MY=2_ ^3H43CY5_*KL*KZ#\J^IAX1\*+T\,0C_MQ_^M3O^$5\+#IX9B_\ ?\
MZU<<O#3&R_Y?P^Y_Y')+B_#R_P"74OP/F"-5X^4?E5I%7T'Y5]+_ /"+^&!T
M\-Q_^ /_ -:J^E^&_#C6$)?P_&[XY86><\^N*Y9>%^.?_,1#[G_D<\N*J#_Y
M=R_ ^>HU7T'Y59C5?05]#_\ ".^&_P#H74_\ O\ ZU+_ &!X<'_,OK_X!?\
MUJYY>%6/?_,1#[G_ )'/+B:@_P#EV_P/ (U7T%>Q?!>2[;3;Y7W&S60>5NSC
M=CY@/;I6^-#\/+TT!1_VY_\ UJU;>_M[6%8H;.XBC7@(EN0!^E?4<+>'^*R'
M,XYA6Q":BGI%/6ZMK?IU];'C9CG-/&472C"U^YIT50_MA/\ GWNO^_#4?VPG
M_/O=?]^&K]N/E1-<_P"0<W^^G_H0K0K#UC5$DL&407"_,O+0L!]X5=_M=/\
MGWNO^_#4 7Z*H?VPG_/O=?\ ?AJ/[83_ )][K_OPU %^BJ']L)_S[W7_ 'X:
MC^V$_P"?>Z_[\-0!?HJA_;"?\^]U_P!^&H_MA/\ GWNO^_#4 )<_\ABR_P"N
M<G]*T*P[C5$;5;1_(N!A)./);/:KO]L)_P ^]U_WX:@"_15#^V$_Y][K_OPU
M']L)_P ^]U_WX:@"_15#^V$_Y][K_OPU']L)_P ^]U_WX:@"_15#^V$_Y][K
M_OPU']L)_P ^]U_WX:@ T_\ X_-0_P"NH_\ 014/BKQ#;^$_#>I:Q=,JP64#
M3-N8*#@<#)Z9.!GWJ&RU1%NKX^1<G=(#Q"W'RCK1JW]GZ[8M9ZAITUW:LRLT
M,MNQ5L$$9'?D"@J-KJ^QYO#^TQH<VCZ==)IU]+=74=M(]M&@/E^:ZH0&SARA
M/.W/2KNH_'S3S:2?V99R27_V3[=%;Z@#!YL7RC"\,=Y+IA<9.X5K7GPW\%W]
MPT\_ADO(TAE'[AP%<L&+*!]TD@=/2H;[X6^!]0O%NYO##?:5*E94BD5E*A0"
M"#P?E7_OD5K>'8Z;X>^S,JW_ &D- C4P7]EJ-OJ,,+274$-LTJ0^6!Y_SC@B
M,Y!/L:OZ%\?O#?B:0KID.HW>V W;LMJ0JV^,K,22!M/;]:TK?P'X2MOM&WP_
M(1/')%('A=MRR+MD!S_>'7UJ#_A6O@O[*+8>&W$ C:'RUBD"^6W6/&?N<#Y>
MG%+W.PKT+;,XK7=:T[QAI$GBFWNKADN)FM+5" &1HWPT?EG.3N4G(Z\<UZUX
M+O-4OO#UM/J\<<5X^3B/NN?E)&3@D=16):>"?"ECI]K8P^'F2UM7>2*,0/A6
M<[G;ZD\FNDM[^WM((X8;.XBBC&U46!@ /2OFL+EL\/F-7%)VA):*[U>[<M-^
MBL]OPUK5X3I1IQ6W?HNR_4Q/BYJ&NZ3\,/%%YX8A,_B"#3YI+*-5W$RA3C [
MGN!ZBORCOM8\+>*)UN_$23/K30NES>7%U*TL\[(H\R0,3M97+' P. ,5^O?]
MKI_S[W7_ 'X:O(/B+^S+\+_B=?RZAJOA:>WU*7F2\T^-H)'/JV."?J*^ZR_&
M4\+=5$]>JW/F,PP=3%6<&M.CV]3\YGO?AG-9%3I>R:11!O627*-T\P N1D'D
MD\$ X KZ@_8+\9:Y>?$3Q-H6DO=77P\CMEN($G=I$LICM^1';GD[N/;->C:7
M^PK\(M/NA++I>N7R@Y\FXE;8?KM4']:]V\(>'_#W@'1X]+\/:&=)L(^D-M:E
M03ZDXR3[FNS&9E1JTG3I\TK_ ,W3S6^IQX3+:M*K&I.T;?R]?)^1U=</\6?$
M5QH>AQ0V]M?RO>.8EFTW)E@8#<&P,9&%.?\ Z]=3_;"?\^]U_P!^&K'\2:9I
MWBJ&"*]@U%5A?S$-N'C8-]17SL6E)-GT;VT/G7XQ>'[_ .*F@V=E>ZYJVG+9
MW'VYY9=*2Y&T(@,6P.I(#D-D?W3VKV3]G'PV?"?PCT72S?3:@UN'0S7%J+9\
M!L!3&&., #N<]:OCP'H"C_CWU7."-VZ3/+;C_A].*W=!M['PY:RV]G;WWE22
MM,1)&S88XSC/;CI71.MS4_9K9$*-I<QT-%4/[83_ )][K_OPU']L)_S[W7_?
MAJY#0+'_ )"&H_[Z?^@"K]9FE3"XO-0<*Z NO$BE3]T=JTZ "OC_ /;2U*UL
MO%.FQ:AX;\.ZC;S6<:Q:@;UX]8BD$I($<4<BR/&"%88#<YXK[ KYG_:D^$M[
MXC\4Z/XDL-$76,VLEC.;;18;ZZA(#-#R\B'8SM@\\=>^:[L'*,:R<F>;F$92
MH-15SU_X.2SS^"X)+F>2YN7?=)-,&#NQ5<E@WS9^HS7CW[>__)*]+_["*_\
MH)KV+X-Z7?Z+X'M+/5+1;&^CP)8$4*B-M7(4#C&?0FO'?V]_^25Z7_V$5_\
M0379D?\ R,J'^+]3EXG_ .17B?\ !^B/@.BBBOZ!/Y6-_P (^!M9\=74EMHU
MJMU-&T:LK2JG+DA>6(ZD5-;_  [UR:.262WCLX8BZRS7DZ0I$4<(0Q8C!W$
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MRG6WL?\ P*'^%6H_V:?&R]8++_P)'^%?ED\5Q7]E3_\  5_D?ITL+PKT</\
MP)_YG5Q_M4:HW_,#M/\ OZU68_VGM4?_ )@EK_W\:N5C_9Q\9KU@L_\ P)'^
M%6H_V>_&"]8;/_P('^%<$\9QC]E5/_ %_D<<L-PST</_  )_YG41_M*:D_\
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M_@*_R/"?^&+_ (9?] RX_P# AO\ &C_AB_X9?] RX_\  AO\:]VHH_M3'_\
M/^7_ ($_\P_L;+?^@:'_ ("O\CPG_AB_X9?] RX_\"&_QH_X8O\ AE_T#+C_
M ,"&_P :]VHH_M3'_P#/^7_@3_S#^QLM_P"@:'_@*_R/"?\ AB_X9?\ 0,N/
M_ AO\:/^&+_AE_T#+C_P(;_&O=J*/[4Q_P#S_E_X$_\ ,/[&RW_H&A_X"O\
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M<?C]#68O@N"/3TLTN)!#'%-$F0"0L@ .3WP<G\:2;P;'<I\]P8VVJH6)2L>
M&'*DG)^8T ;(U.T;9BYB.\X7#CYOEW<>O'-.;4+94+&>,+M#YW?PDX!^E<Z/
M %LH8)=W"*&WPJIXB; &1Z\ C!]35^W\.O'E7N$DC:V%JR^5C*C.#UZ_-0!H
M2ZM:0JI>=0&8J,9.2.O3TH;5;-653=1!F7<H+CD8SD?AS51/#=JL>GQD;H[*
M,QHN.N0!GZ\?K6=<^!8+Q<374FY4\N-D4 H, #\1C\: -<>(-.*EA=QL VSY
M<G)YZ>O0_E4T&J6MT\B0S+(\8RRCK6"O@>-1;9N!(;9B8@\>5P69B&&>3EO;
MI6C8Z$;.X>5I_,XD"*$V@;VW'OSS0!Y"O[6N@O(Z?V'JF58KG,78X_O5>@_:
M>T6?&-&U$?4Q_P#Q5>71_LO^,EGD8MI^&D9A^_/0DGTK7M/V<_%D.-S6/X3'
M_"OQ;$9EQ=%OV5)_^ (_6ZN7\+I>Y47_ (&STF+]HC29>FE7P_&/_P"*JW%\
M=]+EQC3;T?BG^-<%;_ ?Q-'C+6?_ ']/^%:-O\%?$,>,M:_]_#_A7@U,XX[7
MP4)?^"U_D>14P>0KX9K_ ,"9['X;\367BBQ^U63,0IVNCC#(?0UK5RW@'P<_
MA'3IDFF6:YG8,^S[JX& !74U^VY-5QU;+Z53,H*-9KWDN_X]+771GPN*C2C6
ME&@[QZ!1117M'*%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
A%% !1110 4444 %%%% "'I3=QHHH <*6BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ino-20221231_g5.jpg
<TEXT>
begin 644 ino-20221231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKJ[MO-ZL(D(<_ 7_  1C_P"5G;]N'_KRU7_T\V5<K\=_^"57[=?[(GBG7?\
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M-/\ @[U_::TCXXI)%JWB3P1K5QX0EO<YN;6:[T>YM/))^\%L(W7Y>@B=?X2
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MP_KS"*X2WFBD". 4\Q7S&6#[)-OEL ?H9^R__P %?/ /QI_;Q\9?\$S?C/\
M!?6OAK\8O"%A_:$>E7NIP:CINM69BBG$MG>0[2Y\F:.78\:-L+?Q(ZK]8>+_
M !=X7\ >$]3\=^-_$%II.BZ+I\U]J^J7\ZQ06=M"ADEFD=L!$5%9BQX !-?B
ME_P;_>*_"_[7'_!7+X^?M/?M^F\T+]L'PY)+I7_" "!+32=,TB.*"QE>QB+/
M+))"(E@8O(X\N=9 9#,SI]P_\''?AWXI^*/^"*WQVTSX0Q74FIIH%E<WT=D#
MYC:9#J=I-J&,?PBT2<OZH''>@"Q^RE_P54^-'_!1%M9^(G[ _P"QG::Y\*-)
MU:?3;/XE_$_XAR>&8]?N(3B4Z=90:9?SRQ D#S)O(&<J<.KHNAX\_P""I_Q!
M\$?LW_'?X[ZK^QAK6D:E^SY>^5XN\)>*_%4%I-J$":?%?27-C<6L5U%/$8YX
MS$6*>8-V[RF&RN4_X-F_$_@OQ+_P1+^"2>"I( FG6&JV6IP0D;H;U-6O#,'
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ML]2_X))^%-1TZ[BN+>X^-.C203PR!DD1M,U4JRL.""""".N:_1/X'?$7P?\
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M)<QL^^.(JBMM#D '\N?^#T2!H/@G^SMJ31;+:#XH7@FFQA$+6T;#)[9"L?\
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MM)<6]C':QRLB!2ZPQ@)$&()V+\JYP.!0!IT444 %%%% !1110 4444 %%%%
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M9Z^!OA7]FGX->'O@/X"U?5KKP]X4TFWTKP]%K-VMQ-9V-O"D,%L)0BM(J(@
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MG"*JCNJ* /C_ .!?_!%3]F']F;2]8^'_ , OB_\ &/PI\/->U":\U'X6Z/\
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MO/""ZA#?3Z'H^KFR2XN8MWE2221KYIV[CA X0G!*D@$-_;E_X**_LH_\$X?
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M>O/->AZ-JD6MZ1:ZS!:W,"7=NDR0WMLT,T88 A7C<!D89Y5@"#P: /._C_\
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M4M;N5;!  !^>7_!53_E;3_8X_P"Q TW_ -..OU[C^T-^V7_P4!NO^#@#2O\
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M=>_X+':5_P %>(OVOM @O]'T5M'MO C?"N9X&LFL9K0AKK^UPQEQ.S[Q&%R
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M:M)JWB'3])\"-H]QH%^;R[NXIK:9]0NED$4MWO57C^]!&22-RMZ#_P $R?\
M@FI^V-^PK\++#]G/XI_\%$9O'7PZ\)VUU:^!](TKP%#I=_;P2K(L:7-Z\\[R
M1P^:7CB0*5=(P9&C014 ?"?[4?\ P6:_X*8?LI^&?AS\4/C#X_TO1_B3+^T
M_A?XG_ C2K;1M9\.Z=H<WF26B-J-G;O<65\8H_EAEOVF<;IS"L9"+Z?^U?\
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MYX;D\56LL=OHFL27EZUQIFG^9-(CQ6MO]EBED@$4!D81! ]O*J=)_P %4_\
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M?M?V7PV^-O@3PXFA>(=5G\#_ &_1_$MF%E5A)9&[5HLB>92#+)E#& RM$LE
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M=-\ R6$WPXO)4=5N[.[;59"R) (HWRJ.PMHV62)@20#](:_&WX:2_M1?$_\
MX.R_BW\,)_VO/$%C9^"/@K'<:&(]"L)X;?2+BXT&\ETB.&:-DBC=[@;KA1Y[
M&)27[#[U_P""0'PW_:=^$O["WA[P'^UA\7/$7CGQ#8ZUJZ:1XH\86DT&KZAH
MOV^<:=->13O)-%+);".7RI7:6)9$C<AT91QUY_P2<\3:!_P5\U7_ (*L_"']
MIO\ L";Q?X)M_#7CGP?>^#TOFN[>$V?S6ETUPBVK.MA;*2\,V,2$<NIC /R\
M^'WC+]J;X4?MV?\ !5?XZ?LK_'JU\ :M\/[>;Q)+?MX4MM5N+U[-[^>.U07>
MZ"*-PDJNS1._*;=N&S]1>,?^"Z7Q^B_X)F?L<_$B,V6E?$[]I[QO9>%]8\4:
M?X?:]31;:+419:AJ=K8*LGGW1S&T5OL==TK81]JQMZAI?_!!GXE:7XX_;!\;
M1_MJ:*S_ +7&AW>FZK;GX3RX\-K.\PWQ'^V/])*PW$R8;9E]C\!3&V=\1?\
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M,)TM[JUD95N[=9<N$+H07?YMLDBN ?37Q?\ A-X"^._POUWX.?%#08M3\/\
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M:TSQRGQS^'_BKQ)?V-OX#?1_[+O7LM3E*1R-J%SYL9-XRA2H;*K\QR17C/\
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MV=KK2_A-X&O+"ZL[?]GKQ%.-*UJZOD:T OY]& WV4*SI<2&0IOC^VB,+B1J
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)("48+UP<4M%
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M]8O3+/-]IDCG=E63S+F=MR!?]:WMCZ"H _*W]M[]@S]NSXH?\%]_@]_P4O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOP#_P I!/'_ /V(
MFE?^C&KW2O"_ /\ RD$\?_\ 8B:5_P"C&H ]THHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOP#_RD$\?_P#8
MB:5_Z,:O=*\+\ _\I!/'_P#V(FE?^C&H ]THHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O"_ /_ "D$\?\ _8B:5_Z,:O=*\+\ _P#*03Q_
M_P!B)I7_ *,:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "O"_ /_*03Q__ -B)I7_HQJ]TKPOP#_RD$\?_
M /8B:5_Z,:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**_,#_@H#_P6&\<>"/\ @HAKO_!.3P7\8+#X37NC:3X4N= UR]T2&[O?%^H:
MGJUA'/;6KW0:VBBAL[B4E3&TLLB2;701$-]-:U<_\%8M0^ 7BGX8>&+CX:Q?
M$Y/'LNC>&OB;=Z5-;Z.GATV<5S'K4FGF::22[W.]I]G5O+^T+O/[E2& /J6B
MOR[_ .",W[>?_!2_Q!_P47^.W_!+G_@I#XI\/>.];^%>B0:S:?$/P[HT%C&4
ME:U,5NZV\44;+-!>13(#&LB&*96+\;?&_#O[>_\ P5H_X*(?M6^)]/\ ^"='
M_!67]E+PUX3O/%-[!X0^&GB&99O$T&EVT[P"<V[Z5(;AY8XC=;4F<*)E4LF,
M* ?M117P!\8_V[OCC\5/^"O^D_\ !([X$_%ZZ\'0^'?A!<^*_'7CNPT;3[K4
M[K4F1%M+1([RWFMHH@LT-Q*1#N?S B&(*2W8_P#!!S_@IEXC_P""J?[ 6F_'
M_P"(NCV%CXST/7KKPWXTATN,I;2WUND,JW$:$DHLL%Q Y7)"NS@< 4 ?9U%%
M% !7A?@'_E()X_\ ^Q$TK_T8U>Z5X7X!_P"4@GC_ /[$32O_ $8U 'NE%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#8B:5_Z,:O=*\+\ _\I!/'_P#V(FE?^C&H ]THHHH **** "BBB@ HHHH
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M /8B:5_Z,:O=*\+\ _\ *03Q_P#]B)I7_HQJ /=**** "BBB@ HHHH ****
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MRA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6,)+A22AQAMQ(_W37T[7A?@'_E()X_\ ^Q$TK_T8U 'NE%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<1\?_ (]>"OV>/A_/
MXY\83[WYCTW3HW EO9\<1KZ#NS=%'// /)C\?@\KP=3%XN:A3@FY2>R2_KU>
MRU,JU:EAZ3J5':*U;8?'GX_?#_\ 9X\%/XQ\=7YW/E-.TZ @SWLH&=B#TZ98
M\*#SU /R/X*^&_QQ_P""CGC\?$CXHWUQH?@6QG9;*"WR$V@\Q6P88=SC#SL"
M,\<X""Q\$/@A\2_V\?B4W[0'[0,LT/A6&8KI^GQED2Z56.+> =5A4_?DZL<@
M'=N9?M_2M*TS0M,@T;1=/AM+2UA6*VMK>,)'$BC 55'  '85^/87!9GXL8A8
MW,%*CE,7>G1UC+$6VJ5;:JGUC'KOVD_F:=*OQ'-5:UXX9?#'9S\Y>79?\.9?
MP[^&W@CX4>%K?P9\/_#MOINGVP^6&!>7;'+NQY=SCEF))K<HHK]FP^'H82A&
MC0@HPBK)))));)):)(^IA"%."A!62V2"BBBMB@HK"\:?$WX?_#RW^T^-/%ME
MI_RY6*:8&1Q_LQC+-^ -<9_PO?QQXX_=?!?X1:A?0M]S6M>/V*SQ_?4-\\H]
MA@U\_F/%&1Y97^KU*O-6_P"?<$ZE3_P7!2DEYM)=V>GA<HS#%T_:QA:'\TFH
MP_\  I67R3OY'J%<9XW^/WPM\"7/]EZCXC6\U(MM32=*0W-RS?W=B9VG_>(K
M!_X4I\2_'O[[XR_%RZ:W?[VA>&%-I;8_NM)_K)5^N#[UV?@CX7_#[X<6OV7P
M5X3L[#*[7EBBS*X_VI&RS?B37!]=XLS73"8>.%@_MUGSU/E2IRY5Y.55-=8;
MHZ/J^2X/^-5=:7\M/W8_.<E?[H6[2.,_X2C]HSXE?+X1\(VO@O37Z:CX@'G7
MI7U6W7A#[/\ G5O0OV:O!HU!/$/Q&U2_\8:HO(N=>FWPQGN$@^XJ^QW8KT:B
MKI<(9?6J*MF<Y8N:U7M6G!/O&E%1I*W1\CGWDWJ*>>8F$'#"15&+_DTD_6;;
MF_-<UO(9;VUO9P):VD"111J%CCC4*J@=  .@KE?BS\"_A5\;]'_L?XE^#K74
M0JD6]T5V7%OGO'*N&7GG .#W!KK:*^BQ>!P6/PLL-B:<9TY*SC))Q:[-/0\*
MK3IXB#A52DGNGK<^(_&_[&G[1G[*?B";XF?LG^,[_5+!3NN=*7!NO+'.R2'&
MRZ7Z -SPO&:]'_9O_P""B_@?XDW4?@CXR6L/A7Q$'\KSI6*V5S(#@KN?F!\Y
M&USCT8DXKZ5KQO\ :4_8F^%'[1,$NL36PT7Q'L_=:[8PC,AQP)TX$PZ<Y##
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MHM;*45S-XC*XRHO$X*7M*:WTM.'^..NG]Y7CYIZ':4445]4>.%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>%^ ?^4@GC_P#[$32O_1C5
M[I7A?@'_ )2">/\ _L1-*_\ 1C4 >Z4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$\?_ /8B:5_Z,:@#W2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^-OV[/CWXG^+OCRU_8]^!S/=W%U>+#K\ML_$TV<BVW#HD>-\AZ
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MB\0</91Q/ED\!F--3IR^^+Z2B]U)=&O1Z-HY,;@L-F&'=&O&\7^'FNS/D/\
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M!1116Q04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGQ_P4R\9^-/#_@>4:MXT^&OC<R&UU"P,P,\AB69K:Z'SLSKY<4BKO>.3?M%
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MI19\OE<)YKC7F=5>ZKQI)]NLO67Y?(****_8#Z<**** "BBB@ HHHH ****
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M](W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKFO&/QF^#_P /-_\
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MLTB;![E:^D_"GP\\ > X/LO@?P-H^C18QY>DZ9%;KCTQ&HK8H]ME4/AHR?\
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M"VJ7#/\ 0I;;3^==<,KS.I\%";_[=?\ D=,,NS"I\-&3_P"W7_D?4-%?*O\
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MX^N]Q7SZG_!&+]@B^<3>-? 7B/Q-(#G?K_CO5)23ZG9.@//-=/X?_P""4_\
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M_1C4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[^R3\-!!XV_::^&]IXEU55FUZYNO&M@AC./EMU+2CY4W8_VF)/0@#QC]@?\
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M[\"_B];-V2?X>S@D>O#&C_4SBCIA9/TL_P F+_7;A7KBHKUNOS1]%T5\Z?\
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MGZI;3YSCR9U;./H:XYT*]+XX->J:.RGB,/5^":?HTRS11161L%%%% !1110
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M/X%:;<$_=^S>+D/\HC7EUO%[@3#O]]7J0]:%=?\ N,AT\PB_>PE=?]R];_Y
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MJ/X)2_,^6?\ AX?^T+XTX^"?_!,/XO:EN_U3^-/LOAQ']#NG:3 /K1_PLO\
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M3]G47WN"G_Y.? QU3_@B!JMV-,\>_L[Z#X1O9./L6O\ P]NK!P<YY,46Q?\
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M*<_\,Z;_ "/DH_\ !-[]NFUYM_VC_AG>'H1=>"+J/'O\EQUJ-O\ @G[_ ,%
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M=]/-''K]*/\ 5GF^#&X=_P#<2W_I2B/_ %IY?CP.(7_<+F_])E(^BZ*^=/\
MA;'_  4LT_\ X_/V2_ ^HXZ_8/'@ASVX\U/Q^E'_  TA^WY8\:E_P3C6=?\
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M8\T?ZD\8/;+ZS]*<W^28?Z\<&+?,:"]:L%^;1]%T5\]P?\%5?V!;A \?[0,
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M$?\ N/4E_P"EN1\Z?VY_P57M?EG\#? ZZ)_BMM3U1 /P<4?\)]_P4_@^>;X
M_"Z<=-D'BJY1OKEEQ7T711_K)1?Q9?AW_P!NS7Y5$'^K-=?#F.(7_;T'^=-G
MSK_PLK_@IK_T;1\.?_"SD_\ B:0_$;_@IQ+^[C_9P^&T3'I)+XPF95^H"Y-?
M1=%'^L>%_P"A=A_NJ_\ RT/]6L7_ -#+$??2_P#E)\Z?\)G_ ,%1YOW<?P7^
M$D)/227Q'>,H^H49H_MK_@JS<\P>"O@9;8X(N=2U5\^_R"OHNBC_ %DHK; 8
M=?\ ;DW^=1A_JS6>^88A_P#;\%^5-'SJ+#_@J_>\76O? *R!R,V=IK,I'O\
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M7'_GR_\ P,WX_P!MK]E25PB_&O203_>$JC\RE2-^VA^RRJEC\;=%X&>)'/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML#;Q,IE_=@*2<$ -GUR/2OIVO"_ /_*03Q__ -B)I7_HQJ /=**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH XWXQ? #X3_'?1O[(^)/A*"\9$*VU\@\NYMO>.4?,.>=O*GN#7RE
MXH_9(_:D_9$UR?Q]^R]XRO=;TG=ON=,C0-.4'\,MM]RX&.-R#?R2%7K7V_17
MQ'$W &0<2UEBY)T<5'X:])\E2+Z7:^)>4KZ;-'DX_)<'CY>T:<*BVG'22^?7
MYGS'\ _^"E?P^\;3Q^$_C9IZ^$]:5O*>[?=]AD<'!!+?- <]GRHQR_:OIBTN
M[2_M8[ZPNHYX)D#Q30N&5U(R&!'!!'<5YA\?/V/?@M^T)!)>>)]!%CK)3$6O
M:8!'< XXW\;91TX<$XZ%>M?,]WX$_;1_8%NI-5\#:FWBKP7&Y>:%(GFMT3.2
M9(,[[8]R\9V],L>E?*_ZP\<<"^YG]'Z[A%_S$48_O(KO5I?G*.B6[;9YWUW-
M\HTQD?:TU]N*]Y?XH_JOQ/NNBO"OV?/V_P#X+_&[R-#UF['AG7Y,*-.U.<>5
M,_I#-PK>RMM8GH#UKW6OTG),_P FXCP2Q>6UXU:;ZQ>WE);Q?E))^1[N$QN%
MQU+VE":DO+]>J^84445[!U!1110 4444 %%%% !1110 4444 %>%^ ?^4@GC
M_P#[$32O_1C5[I7A?@'_ )2">/\ _L1-*_\ 1C4 >Z4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %'7K110!X/\?O^"?/P4^-4DNNZ);?\(OK<C;GO]*@7R9F[F6#(5B>
M?F4JQ)R2>E>\445X^7</Y+E&-KXO!4(TYU^7VCBK*7+S6;2TO[TKM*[OK?0Y
M:&"PN&JSJ4H*+G:]NMKVTVZOUZA1117L'4%%%% !1110 4444 %%%% !1110
M 5X7X!_Y2">/_P#L1-*_]&-7NE>%^ ?^4@GC_P#[$32O_1C4 >Z4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444WS8O-\CS%WE=VS
M/./7'I0 ZBBB@ HHHH *\+\ _P#*03Q__P!B)I7_ *,:O=*\+\ _\I!/'_\
MV(FE?^C&H ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV_\ 1O?@?_PD[/\ ^-T >6?\/:O^"=/_ $=)HG_@'=__ !FC_A[5_P $Z?\
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M  3I_P"CI-$_\ [O_P",UZG_ ,,R?LV_]&]^!_\ PD[/_P"-T?\ #,G[-O\
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M_P"C>_ __A)V?_QN@#RS_A[5_P $Z?\ HZ31/_ .[_\ C-'_  ]J_P""=/\
MT=)HG_@'=_\ QFO4_P#AF3]FW_HWOP/_ .$G9_\ QNC_ (9D_9M_Z-[\#_\
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MI-$_\ [O_P",UZG_ ,,R?LV_]&]^!_\ PD[/_P"-T?\ #,G[-O\ T;WX'_\
M"3L__C= 'EG_  ]J_P""=/\ T=)HG_@'=_\ QFC_ (>U?\$Z?^CI-$_\ [O_
M .,UZG_PS)^S;_T;WX'_ /"3L_\ XW1_PS)^S;_T;WX'_P#"3L__ (W0!Y9_
MP]J_X)T_]'2:)_X!W?\ \9H_X>U?\$Z?^CI-$_\  .[_ /C->I_\,R?LV_\
M1O?@?_PD[/\ ^-T?\,R?LV_]&]^!_P#PD[/_ .-T >6?\/:O^"=/_1TFB?\
M@'=__&:/^'M7_!.G_HZ31/\ P#N__C->I_\ #,G[-O\ T;WX'_\ "3L__C='
M_#,G[-O_ $;WX'_\).S_ /C= 'EG_#VK_@G3_P!'2:)_X!W?_P 9H_X>U?\
M!.G_ *.DT3_P#N__ (S7J?\ PS)^S;_T;WX'_P#"3L__ (W1_P ,R?LV_P#1
MO?@?_P ).S_^-T >6?\ #VK_ ()T_P#1TFB?^ =W_P#&:/\ A[5_P3I_Z.DT
M3_P#N_\ XS7J?_#,G[-O_1O?@?\ \).S_P#C='_#,G[-O_1O?@?_ ,).S_\
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MJ_X)T_\ 1TFB?^ =W_\ &:]3_P"&9/V;?^C>_ __ (2=G_\ &Z/^&9/V;?\
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M (2=G_\ &Z /+/\ A[5_P3I_Z.DT3_P#N_\ XS1_P]J_X)T_]'2:)_X!W?\
M\9KU/_AF3]FW_HWOP/\ ^$G9_P#QNC_AF3]FW_HWOP/_ .$G9_\ QN@#RS_A
M[5_P3I_Z.DT3_P  [O\ ^,T?\/:O^"=/_1TFB?\ @'=__&:]3_X9D_9M_P"C
M>_ __A)V?_QNC_AF3]FW_HWOP/\ ^$G9_P#QN@#RS_A[5_P3I_Z.DT3_ , [
MO_XS1_P]J_X)T_\ 1TFB?^ =W_\ &:]3_P"&9/V;?^C>_ __ (2=G_\ &Z/^
M&9/V;?\ HWOP/_X2=G_\;H \L_X>U?\ !.G_ *.DT3_P#N__ (S1_P /:O\
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MS,85)))CY)/>MK_AF3]FW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z.DT3_P
M[O\ ^,T?\/:O^"=/_1TFB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V?_QNC_AF
M3]FW_HWOP/\ ^$G9_P#QN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]J_X)T_\
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M!W?_ ,9KU/\ X9D_9M_Z-[\#_P#A)V?_ ,;H_P"&9/V;?^C>_ __ (2=G_\
M&Z /+/\ A[5_P3I_Z.DT3_P#N_\ XS1_P]J_X)T_]'2:)_X!W?\ \9KU/_AF
M3]FW_HWOP/\ ^$G9_P#QNC_AF3]FW_HWOP/_ .$G9_\ QN@#RS_A[5_P3I_Z
M.DT3_P  [O\ ^,T?\/:O^"=/_1TFB?\ @'=__&:]3_X9D_9M_P"C>_ __A)V
M?_QNC_AF3]FW_HWOP/\ ^$G9_P#QN@#RS_A[5_P3I_Z.DT3_ , [O_XS1_P]
MJ_X)T_\ 1TFB?^ =W_\ &:]3_P"&9/V;?^C>_ __ (2=G_\ &Z/^&9/V;?\
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MXBBV[Y(I<+M^ZH;)#"OH"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/^"5'[(WQZ\,?M)?!KX4>(K?Q3X0U#[=H=QJ/C"[NH8I]C(':)V*MC<2,]"
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M_9HO/%MA+X^U$:AXQMM7\1-J$6IW8,I6=O/5FC<--(<QLF[(W;@ !\]_$O\
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MQ)##+<;3-P(4W,CJ7RV\L"10!Y5_P;Z?\H9/V??^Q'_]NIZ^QZ\Q_9%_9/\
MAG^Q/\#](_9S^"NI:V?"'AZ%H= TS6]1%VVGQ-(\C1I,RB5E+NQQ(S[> N ,
M5Z=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^/GC/\
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M&P\8W27>I3&*")HI+H-YGD%;:',0(4[2#D,P/B'_ !"3_P#!%O\ Z([XP_\
M#@7W_P 70!^EU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 45^5W[2NA:[;?\',WP0^!.G?%SXB6?@3Q
M5\&M3\1>(O!5E\2=8ATJ^U*$ZJL<S6R700 >7"2B@(3$I*GYL_<WBK_@HO\
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M"MOXK?MW_L:? [XG:+\%OBS^TSX-T+Q;X@C>73/#M[KD0NVA2![AKB2-23!
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MK7OKZ(]# 9?4P3DY5IU+_P SO;T/S _:9(_XBN?V<1G_ )MQUO\ ]&:O6O\
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M_B__ (**_P#!LA??LB?&?4FO8-:7Q!IWPPUK4B6,,5GJ$CZ7<!CEO*BO(64
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M/"VEQZ?H6CV98I;0(, ;F)9V)RS.Q+,Q+,2220#\Z?\ @X](_P"%F_L-<_\
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M^ZK_ /+0_P!6\7_T,L1]]+_Y2?.O_"RO^"FO_1M'PY_\+.3_ .)H_P"%E?\
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MP!P7_!7[P-X-\<_\%??^">.C^,O"VGZK9W'B[QT+BUU"T26.8)I5E*@=6!#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:YTJQ;=MN[R*PAF>SMVVOB:8(C;&PQVG !ZK17F>I_MG?LD:+^S]:_M7:O\
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MZ?!RR_:$^$/Q8T+Q!X(U"QDO+7Q1I^HHUF8(]WFNTA($?EE7#AL%"C!@"I
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MC\#Z/XG^)&K7NG:'!>)J$USMAN;EH]N8(P"X.Q5P, F@#]4**^;]>_X*^_\
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MXO?$W[3\=Y,EA\,O#<D"RL(7?6F#,F>"1C@XKT>BO*S3+:V8QBJ>)J4>6_\
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MLTEGN+_X(:I+:W&CW(D<R2#1[F^BE?1G9RY\F.2.W)DRI@P2_N/_  2WU/\
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M-4U_7K:WM+SXA^-O%XUO78;*!F:&S@ENXGAM[=-\@$<<*C]X6^^%90#\^O\
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M_:J\9'4],^'_ (HL"NJ:,YM6MKL17-O<-;AC-,%O;3R)7P%\UO*0)^J/P&^
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MQHNA6>A2-J/AN+2596A_M33;MS'%<7,DKK$RH'OR2"6)'AO_  51_99^#/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-EBBGB:&:-71U*NC
M#(8'J".XIU% %2ST'0].F^T:?HUI!)C'F0VZJV/3(%6Z** "BBB@ HHHH *9
M/!!=0M;W,*21N,.CJ"&'H0>M/HH JV6AZ+IDIGTW2+6W<KM+P6ZH2/3('3@?
ME5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JMKHFBV-_/
MJMEI%K#=7./M-S%;JLDN.FY@,M^-6J* (Y+.TFN8[R6UC::$,(960%D#8W '
MJ,X&<=<5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945403936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-14888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INOVIO PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0969592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">660 W. Germantown Pike<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Plymouth Meeting<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">440-4200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">COMMON STOCK, $0.001 PAR VALUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,131,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#8217;s 2023 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8217;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#8217;s fiscal year ended December&#160;31, 2022.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001055726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945401504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946003760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 46,329,359<span></span>
</td>
<td class="nump">$ 71,143,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">206,669,397<span></span>
</td>
<td class="nump">330,170,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,701,726<span></span>
</td>
<td class="nump">5,466,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable from affiliated entities</a></td>
<td class="nump">10,036,490<span></span>
</td>
<td class="nump">2,565,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">50,130,481<span></span>
</td>
<td class="nump">38,836,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity', window );">Prepaid expenses and other current assets from affiliated entities</a></td>
<td class="nump">375,227<span></span>
</td>
<td class="nump">261,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">315,242,680<span></span>
</td>
<td class="nump">448,444,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">7,727,997<span></span>
</td>
<td class="nump">17,453,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investments in affiliated entity</a></td>
<td class="nump">2,007,142<span></span>
</td>
<td class="nump">3,906,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,129,861<span></span>
</td>
<td class="nump">2,626,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,228,207<span></span>
</td>
<td class="nump">11,571,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">684,044<span></span>
</td>
<td class="nump">1,425,794<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">348,533,302<span></span>
</td>
<td class="nump">495,941,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">79,686,885<span></span>
</td>
<td class="nump">47,644,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accounts payable and accrued expenses due to affiliated entities</a></td>
<td class="nump">1,220,439<span></span>
</td>
<td class="nump">548,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expenses</a></td>
<td class="nump">10,594,073<span></span>
</td>
<td class="nump">10,326,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">2,803,973<span></span>
</td>
<td class="nump">2,603,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingCurrent', window );">Grant funding liability</a></td>
<td class="nump">2,475,031<span></span>
</td>
<td class="nump">4,559,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliateCurrent', window );">Grant funding liability from affiliated entities</a></td>
<td class="nump">87,673<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">96,868,074<span></span>
</td>
<td class="nump">65,741,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">12,655,586<span></span>
</td>
<td class="nump">15,459,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="nump">32,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">126,170,546<span></span>
</td>
<td class="nump">96,272,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Inovio Pharmaceuticals, Inc. stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#8212;par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December&#160;31, 2022 and 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#8212;par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December&#160;31, 2022 and 217,382,887 at December&#160;31, 2021</a></td>
<td class="nump">253,090<span></span>
</td>
<td class="nump">217,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,710,656,191<span></span>
</td>
<td class="nump">1,609,589,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,487,847,784)<span></span>
</td>
<td class="num">(1,209,855,522)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(698,741)<span></span>
</td>
<td class="num">(282,236)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Inovio Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">222,362,756<span></span>
</td>
<td class="nump">399,669,421<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">348,533,302<span></span>
</td>
<td class="nump">495,941,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="nump">$ 16,614,840<span></span>
</td>
<td class="nump">$ 14,959,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947222704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">253,091,319<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">253,091,319<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945656144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 10,262,268<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">187,650,503<span></span>
</td>
<td class="nump">249,240,324<span></span>
</td>
<td class="nump">94,245,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">90,185,285<span></span>
</td>
<td class="nump">53,752,353<span></span>
</td>
<td class="nump">37,247,828<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">277,835,788<span></span>
</td>
<td class="nump">302,992,677<span></span>
</td>
<td class="nump">131,493,264<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(267,573,520)<span></span>
</td>
<td class="num">(301,217,919)<span></span>
</td>
<td class="num">(124,082,044)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">4,782,030<span></span>
</td>
<td class="nump">3,363,080<span></span>
</td>
<td class="nump">3,311,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,253,952)<span></span>
</td>
<td class="num">(1,936,447)<span></span>
</td>
<td class="num">(8,702,450)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,670,977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">(Loss) gain on investment in affiliated entities</a></td>
<td class="num">(1,899,654)<span></span>
</td>
<td class="num">(553,570)<span></span>
</td>
<td class="nump">36,556,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (loss) gain on available-for-sale equity securities</a></td>
<td class="num">(7,846,172)<span></span>
</td>
<td class="num">(3,222,838)<span></span>
</td>
<td class="nump">1,695,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(3,861,584)<span></span>
</td>
<td class="nump">343,371<span></span>
</td>
<td class="num">(704,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before share in net loss of Geneos</a></td>
<td class="num">(277,652,852)<span></span>
</td>
<td class="num">(303,224,323)<span></span>
</td>
<td class="num">(162,890,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="num">(2,165,213)<span></span>
</td>
<td class="num">(434,387)<span></span>
</td>
<td class="num">(4,584,610)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(279,818,065)<span></span>
</td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="num">(167,474,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (279,818,065)<span></span>
</td>
<td class="num">$ (303,658,710)<span></span>
</td>
<td class="num">$ (166,411,157)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (1.45)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.17)<span></span>
</td>
<td class="num">$ (1.45)<span></span>
</td>
<td class="num">$ (1.07)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted average number of common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">238,622,188<span></span>
</td>
<td class="nump">208,829,801<span></span>
</td>
<td class="nump">155,126,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">238,622,188<span></span>
</td>
<td class="nump">208,829,801<span></span>
</td>
<td class="nump">155,126,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember', window );">Convertible Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,177,043)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,762,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -URI https://asc.fasb.org/subtopic&amp;trid=2229187<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947317504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (279,818,065)<span></span>
</td>
<td class="num">$ (303,658,710)<span></span>
</td>
<td class="num">$ (167,474,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(25,556)<span></span>
</td>
<td class="num">(30,134)<span></span>
</td>
<td class="nump">27,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on short-term investments, net of tax</a></td>
<td class="num">(390,949)<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
<td class="num">(755,963)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(280,234,570)<span></span>
</td>
<td class="num">(303,684,796)<span></span>
</td>
<td class="num">(168,203,672)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,063,757<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Inovio Pharmaceuticals, Inc.</a></td>
<td class="num">$ (280,234,570)<span></span>
</td>
<td class="num">$ (303,684,796)<span></span>
</td>
<td class="num">$ (167,139,915)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941154272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>6.50% Convertible Senior Notes Due 2024</div></th>
<th class="th"><div>August 2019 Bonds</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th">
<div>Common stock </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Common stock </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Adjustment</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>6.50% Convertible Senior Notes Due 2024</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>August 2019 Bonds</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th">
<div>Accumulated deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Non- controlling interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">101,361,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 5,404,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 742,646,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (739,785,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472,608<span></span>
</td>
<td class="nump">$ 1,969,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,064,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">454,486,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454,420,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="nump">11,535,660<span></span>
</td>
<td class="nump">4,962,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,694,386<span></span>
</td>
<td class="nump">$ 102,671,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 11,536<span></span>
</td>
<td class="nump">$ 4,961<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,682,850<span></span>
</td>
<td class="nump">$ 102,666,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">8,241,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,238,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">15,647,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,655,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Acquisition of non-controlling interest in Geneos, net</a></td>
<td class="nump">2,379,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of Geneos</a></td>
<td class="num">(3,181,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,181,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(167,474,914)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166,411,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,063,757)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Dissolution of majority-owned subsidiary VGX Animal Health, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(96,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="num">(755,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(755,963)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">27,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">186,851,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">461,140,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 186,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,367,406,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(906,196,812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256,150)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,310,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">209,441,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,414,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock/senior notes to common stock</a></td>
<td class="nump">4,377,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,376,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,211,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="nump">2,057,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,055,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">26,336,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,336,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303,658,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="nump">4,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(30,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">399,669,421<span></span>
</td>
<td class="num">$ (1,468,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 217,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,609,589,797<span></span>
</td>
<td class="num">$ (3,294,019)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,209,855,522)<span></span>
</td>
<td class="nump">$ 1,825,803<span></span>
</td>
<td class="num">(282,236)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for cash, net of financing costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,445,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for cash, net of financing costs</a></td>
<td class="nump">82,955,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,920,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,262,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options for cash and vesting of RSUs, net of tax payments</a></td>
<td class="num">(1,114,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,115,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,555,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,555,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">(279,818,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(279,818,065)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on short-term investments, net of tax</a></td>
<td class="num">(390,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(390,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="num">(25,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,556)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">253,091,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 222,362,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 253,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,710,656,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,487,847,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (698,741)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946567296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (279,818,065)<span></span>
</td>
<td class="num">$ (303,658,710)<span></span>
</td>
<td class="num">$ (167,474,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,656,713<span></span>
</td>
<td class="nump">3,040,096<span></span>
</td>
<td class="nump">3,038,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">496,494<span></span>
</td>
<td class="nump">520,415<span></span>
</td>
<td class="nump">547,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">1,342,819<span></span>
</td>
<td class="nump">1,170,270<span></span>
</td>
<td class="nump">1,041,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75,670,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
<td class="nump">22,555,419<span></span>
</td>
<td class="nump">26,336,764<span></span>
</td>
<td class="nump">15,647,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NonCashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">186,977<span></span>
</td>
<td class="nump">858,644<span></span>
</td>
<td class="nump">4,077,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization of (discounts) premiums on investments</a></td>
<td class="num">(1,320,546)<span></span>
</td>
<td class="nump">1,633,286<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Loss on short-term investments</a></td>
<td class="nump">4,029,961<span></span>
</td>
<td class="nump">5,397<span></span>
</td>
<td class="nump">588,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity', window );">Settlement of receivable with shares of common stock from affiliated entity (PLS)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,713,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,121,075)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment', window );">Gain on remeasurement of investment in Geneos</a></td>
<td class="num">(165,215)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">1,074,830<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany', window );">Loss (gain) on equity investment in affiliated entities</a></td>
<td class="nump">1,899,654<span></span>
</td>
<td class="nump">553,570<span></span>
</td>
<td class="num">(36,556,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Share of net loss in Geneos</a></td>
<td class="nump">2,165,213<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">4,584,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized loss (gain) on available-for-sale equity securities</a></td>
<td class="nump">7,846,172<span></span>
</td>
<td class="nump">3,222,838<span></span>
</td>
<td class="num">(1,695,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Unrealized transaction (gain) loss on foreign-currency denominated debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(176,927)<span></span>
</td>
<td class="nump">15,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, including from affiliated entities</a></td>
<td class="num">(3,706,172)<span></span>
</td>
<td class="nump">11,031,705<span></span>
</td>
<td class="num">(17,015,471)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, including from affiliated entities</a></td>
<td class="num">(5,336,525)<span></span>
</td>
<td class="num">(6,343,632)<span></span>
</td>
<td class="num">(38,475,465)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">741,750<span></span>
</td>
<td class="nump">24,531,654<span></span>
</td>
<td class="num">(23,285,424)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses, including from affiliated entities</a></td>
<td class="nump">32,606,581<span></span>
</td>
<td class="nump">26,140,970<span></span>
</td>
<td class="nump">3,251,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense', window );">Accrued clinical trial expenses</a></td>
<td class="nump">267,807<span></span>
</td>
<td class="nump">375,921<span></span>
</td>
<td class="nump">5,962,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue, including from affiliated entity</a></td>
<td class="num">(85,989)<span></span>
</td>
<td class="num">(39,853)<span></span>
</td>
<td class="num">(62,353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet', window );">Operating lease right-of-use assets and liabilities, net</a></td>
<td class="num">(2,603,956)<span></span>
</td>
<td class="num">(2,329,394)<span></span>
</td>
<td class="num">(2,091,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent', window );">Grant funding liability, including from affiliated entity</a></td>
<td class="num">(2,034,517)<span></span>
</td>
<td class="num">(2,973,089)<span></span>
</td>
<td class="nump">624,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(14,826)<span></span>
</td>
<td class="num">(42,837)<span></span>
</td>
<td class="nump">20,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(216,215,421)<span></span>
</td>
<td class="num">(215,708,525)<span></span>
</td>
<td class="num">(177,979,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(248,528,843)<span></span>
</td>
<td class="num">(348,953,236)<span></span>
</td>
<td class="num">(156,216,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of or maturity of investments</a></td>
<td class="nump">361,083,850<span></span>
</td>
<td class="nump">174,839,758<span></span>
</td>
<td class="nump">62,991,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of capital assets</a></td>
<td class="num">(969,153)<span></span>
</td>
<td class="num">(1,231,006)<span></span>
</td>
<td class="num">(1,520,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi', window );">Proceeds from sale of investment of GeneOne</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,125,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Decrease in cash resulting from the deconsolidation of Geneos</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,774,851)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Investment in Geneos</a></td>
<td class="num">(1,999,998)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,399,999)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">109,585,856<span></span>
</td>
<td class="num">(175,344,484)<span></span>
</td>
<td class="num">(58,795,751)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">82,955,311<span></span>
</td>
<td class="nump">209,441,410<span></span>
</td>
<td class="nump">454,486,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsfromStockOptionandWarrantExercises', window );">Proceeds from stock option exercises</a></td>
<td class="nump">283,022<span></span>
</td>
<td class="nump">6,668,741<span></span>
</td>
<td class="nump">12,269,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(1,397,631)<span></span>
</td>
<td class="num">(4,611,348)<span></span>
</td>
<td class="num">(4,028,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Acquisition of non-controlling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,379,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Geneos issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">171,620<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">81,840,702<span></span>
</td>
<td class="nump">211,498,803<span></span>
</td>
<td class="nump">465,279,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(25,556)<span></span>
</td>
<td class="num">(30,134)<span></span>
</td>
<td class="nump">27,205<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(24,814,419)<span></span>
</td>
<td class="num">(179,584,340)<span></span>
</td>
<td class="nump">228,532,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">71,143,778<span></span>
</td>
<td class="nump">250,728,118<span></span>
</td>
<td class="nump">22,196,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">46,329,359<span></span>
</td>
<td class="nump">71,143,778<span></span>
</td>
<td class="nump">250,728,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Amounts accrued for purchases of property and equipment</a></td>
<td class="nump">108,181<span></span>
</td>
<td class="nump">204,815<span></span>
</td>
<td class="nump">136,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">1,066,975<span></span>
</td>
<td class="nump">1,077,803<span></span>
</td>
<td class="nump">4,624,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets', window );">Change in prepaid expenses and other current assets related to fixed assets</a></td>
<td class="nump">6,071,000<span></span>
</td>
<td class="nump">7,709,337<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember', window );">August 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,177,043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on extinguishment of convertible bonds and senior notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (8,762,030)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Prepaid Expenses And Other Current Assets, Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ChangeInValueOfInvestmentsInAffiliatedCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ChangeInValueOfInvestmentsInAffiliatedCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GainLossOnRemeasurementOfEquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Remeasurement Of Equity Method Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GainLossOnRemeasurementOfEquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInAccruedClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Accrued Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInAccruedClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncreaseDecreaseinDeferredGrantFundingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Grant Funding, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncreaseDecreaseinDeferredGrantFundingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NonCashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NonCashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ProceedsfromStockOptionandWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Option and Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ProceedsfromStockOptionandWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement Of Receivable With Shares Of Common Stock From Equity Security</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126972273&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3444-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_August2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947430576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2020-06<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951505008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">The Company</a></td>
<td class="text">The Company<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inovio Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;INOVIO&#8221;) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company&#8217;s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In clinical trials, the INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO's lead candidates are focused on diseases associated with HPV.  In 2022, INOVIO announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for Ebola; HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head &amp; neck; other HPV-related disorders, such as RRP; and GBM.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614031850080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December&#160;31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million, $47.7&#160;million and $454.5&#160;million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y also issued convertible notes and bonds in a series of private placement transactions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2022 and 2021. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounts Receivable</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December&#160;31, 2022 and 2021.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December&#160;31, 2022.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2022 and 2021, the Company&#8217;s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1&#160;million and $2.6&#160;million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2022.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations. See Note&#160;8 for further discussion of the Company&#8217;s goodwill and intangible assets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $299.1 million and $237.2 million at December&#160;31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue, in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Grants</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Investments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. </span></div><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,943,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,654,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes forfeitures as they occur. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614031769120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition and Concentration of Credit Risk</a></td>
<td class="text">Revenue Recognition and Concentration of Credit RiskDuring the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,591,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Of the total revenue recognized during the year ended December&#160;31, 2022, $14,000 was in deferred revenue as of December 31, 2021. During the year ended December 31, 2021, the Company recognized revenue of $46,000 that was included in deferred revenue at December 31, 2020. Performance obligations are generally satisfied within 12 months of the initial contract date. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of December&#160;31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. As of December&#160;31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and CEPI MERS grants, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614031769120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Agreements</a></td>
<td class="text">Collaborative Agreements <div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advaccine Biopharmaceuticals Suzhou Co., Ltd. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#8220;Advaccine&#8221;), which was amended and restated on June 7, 2021 (as amended and restated, the &#8220;Advaccine Agreement&#8221;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#8217;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#8220;Greater China&#8221;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#8217;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#8217;s clinical trial of INO-4800. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#8217;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. On October 27, 2022, the Company announced that it had discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $200.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#8217;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Advaccine Agreement, the Company will supply Advaccine&#8217;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#8217;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#8217; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18 months&#8217; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus a $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company recognized </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0, $0 and $5.0&#160;million of revenue for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the years ended December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021, and 2020, respectively, under the Advaccine Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility was assured.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2022, 2021 and 2020 the Company received funding of $1.2&#160;million, $4.5&#160;million and $0, respectively, from Advaccine that was recorded as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contra-research and development expense. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ApolloBio Corporation </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#8217;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there has been no </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significant reimbursable program costs under the ApolloBio Agreement.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Coalition for Epidemic Preparedness Innovations </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2022, 2021 and 2020, the Company received funding of $6.7 million, $10.0 million and $6.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2022 and 2021, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an accounts receivable balance of $1.7&#160;million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $1.9&#160;million, respectively, on the consolidated balance sheet related to these CEPI grants. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $6.9&#160;million </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.0&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2022, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021 and 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company received funding of $1.1 million, $6.9 million and $10.0 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2022 and 2021, the Company had $2.3&#160;million and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800, respectively</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bill &amp; Melinda Gates Foundation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, Gates awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $233,000, $182,000 and $463,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2022 and 2021, the Company had $153,000 and $384,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, Gates awarded and funded the Company a grant of $5.0&#160;million to accelerate the development of the CELLECTRA 3PSP device for the intradermal delivery of INO-4800. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $0, $893,000 and $4.1 million, respectively, as contra-research and development expense related to this Gates grant. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Defense (DoD) </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#8220;OTA Agreement&#8221;)&#160;with the DoD to fund the Company&#8217;s efforts in developing the CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5&#160;million. The Company determined that the OTA Agreement should be considered under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Not-for-Profit Entities-Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company recorded contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $6.1 million, $27.1 million and $21.2 million, respectively, as contra-research and development expense related to the OTA agreement</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#8220;Procurement Contract&#8221;) from the DoD for the purchase of the Company&#8217;s intradermal CELLECTRA</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 device and accessories. The total purchase price under the Procurement Contract was $16.8&#160;million. The</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7&#160;million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2022, 2021 </span></div>and 2020, the Company recorded revenue of $9.6&#160;million, $755,000 and $0, respectively, from the Procurement Contract.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614030661504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2022 and 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December&#160;31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8&#160;million and $3.2&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2022,&#160;2021&#160;and&#160;2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2022, the Company had&#160;29&#160;available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2022&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the </span></div>service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2022 and 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Short-term Investments and Fair Value Measurements</a></td>
<td class="text">Short-term Investments and Fair Value Measurements<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2022 and 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2022 and 2021, the Company recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gross realized ga</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December&#160;31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8&#160;million and $3.2&#160;million, respectively. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2022,&#160;2021&#160;and&#160;2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2022, the Company had&#160;29&#160;available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2022&#160;were primarily due to changes in interest rates, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#8217;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, at December&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.</span></div><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 assets at December&#160;31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#8217;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rations as unrealized gain or loss on available-for-sale equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or as a gain or loss on investment in affiliated entity. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 assets at December&#160;31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the </span></div>service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2022 and 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614031769120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Certain Balance Sheet Items</a></td>
<td class="text">Certain Balance Sheet Items<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,474,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,424,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,112,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,106,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,644,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221; The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614031769120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text">Fixed Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,036,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,295,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,428,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,291,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,563,403)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,258,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,397,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,944,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,453,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation expense for the years ended December&#160;31, 2022, 2021 and 2020 was $3.7 million, $3.0 million and $3.0 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $6.1&#160;million and disposed of fixed assets with a net book value of $1.1&#160;million. The Company has recorded a receivable from the sale of these assets of $6.1&#160;million, which is included in prepaid expenses and other current assets on the consolidated balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951505008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible Assets<div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,643,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate amortization expense on intangible assets was $496,000, $520,000 and $547,000 for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Amortization expense related to intangible assets at December&#160;31, 2022 is expected to be incurred as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no impairment or impairment indicators present and no losses were recorded during the years ended December&#160;31, 2022, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951475552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Debt</a></td>
<td class="text">Convertible Debt<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Senior Notes </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#8220;Notes&#8221;). The Notes were sold in a private offering to </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity (&#8220;ASU 2020-06&#8221;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,614,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, 2021 and 2020,&#160;the Company recognized $1.3 million, $1.9&#160;million and $6.9&#160;million, respectively, of interest expense related to the Notes, of which $1.1 million, $1.1&#160;million and $4.1&#160;million, respectively, related to the contractual interest coupon. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,015,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Convertible Bonds </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#8220;December 2019 Bonds&#8221;) with an aggregate principal amount of 4.7 billion KRW (USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.</span></div>During the year ended December 31, 2021,&#160;the Company recognized $50,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon. The effective interest rate of the December 2019 Bonds was 6.2%.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614031850080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#8217;s option, to convert all or any lesser portion of such holder&#8217;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as $27.20 per share, such</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that the outstanding shares of Series C preferred stock were convertible into an aggregate of 3,309 shares of common stock.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Issuances of Common Stock</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2021, the Company entered into an ATM Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the &#8220;2021 Sales Agreement&#8221;) with outside sales agents (collectively, the &#8220;Sales Agents&#8221;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December&#160;31, 2022 and 2021, the Company sold 34,445,743 and 6,955,341 shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $2.44 and $6.96 per share, respectively, resulting in aggregate net proceeds of $83.0&#160;million and $47.7&#160;million, respectively. As of December&#160;31, 2022 there was $167.4&#160;million of remaining capacity under the 2021 Sales Agreement.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1&#160;million. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options and Restricted Stock Units</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December&#160;31, 2022, the maximum number of shares of the Company&#8217;s common stock available for issuance over the term of the 2016 Incentive Plan was 22,000,000 shares. On the first business day of each calendar year, the maximum number of shares is increased by&#160;2,000,000 shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by 2,000,000. At December&#160;31, 2022, the Company had 3,831,240 shares of common stock available for future grant under the 2016 Incentive Plan, 2,446,257 shares underlying outstanding but unvested service-based RSUs, options outstanding to purchase 10,132,969 shares of common stock and 111,941 shares of performance-based RSUs outstanding under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#8217;s common stock that may be issued under the 2022 Inducement Plan will not exceed 2,000,000 shares. At December&#160;31, 2022 the Company had 1,703,750 shares of common stock available for future grant under the 2022 Inducement Plan, 110,000 shares underlying outstanding but unvested RSUs and options outstanding to purchase 186,250 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2022, the Company had options outstanding to purchase 1,902,329 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020 was $22.2 million, $25.0 million and $14.5 million, respectively, of which $8.8 million, $13.4 million and $8.0 million was included in research and development expenses and $13.4 million, $11.6 million and $6.5 million was included in general and administrative expenses, respectively. The Company entered into a Separation Agreement with its former President and Chief Executive Officer on May 10, 2022, under which outstanding RSUs as of the separation date were fully vested, and one-half of the RSUs were settled in the Company's common stock and the remainder settled in cash. The officer's stock options will continue to vest over a certain period and will remain exercisable until five years after the separation date. Stock-based compensation for the year ended December 31, 2022 included a $4.2&#160;million charge related to these RSU and stock option modifications.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022 and 2021, there was $10.5 million and $16.5 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.6 years and 2.0 years, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022 and 2021, there was $7.2 million and $13.4 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.7 years and 1.8 years, respectively.  </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2022, 2021 and 2020 was $1.3 million, $1.4 million and $1.2 million, respectively. As of December&#160;31, 2022, options to purchase 665,875 shares of common stock granted to non-employees remained outstanding.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.56-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,461,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,349,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,829,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the aggregate intrinsic value of options outstanding was $0, the aggregate intrinsic value of options exercisable was $0, and the weighted average remaining contractual term of options exercisable was 5.7 years.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, the aggregate intrinsic value of unvested RSUs was $4.0 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2022 was $4.6 million.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2022, options to purchase 12,221,548 shares of common stock and 2,556,257 RSUs were expected to vest.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2022 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,772,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2022 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,618,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price per share was $8.47 for the 77,250 options which expired during the year ended December&#160;31, 2022, $4.56 for the 7,000 options which expired during the year ended December&#160;31, 2021 and $4.44 for the 78,750 options which expired during the year ended December&#160;31, 2020.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share was $2.34, $7.61 and $6.87 for options granted during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value was $3.12, $10.37 and $9.12 per share for RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received $283,000, $6.7 million and $12.3 million in proceeds from the exercise of stock options during the years ended December&#160;31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $81,000, $7.0 million and $14.2 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Company</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">had</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">111,941</span><span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">performance-based RSUs outstanding, which were granted to key employees in August 2020. The underlying performance milestones of the RSUs were not probable of achievement as of December&#160;31, 2022, and no stock-based compensation expense has been recognized to date for the performance-based RSUs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945387936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2022 of 0.9 years to 7.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,090,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,630,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,460,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,804,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,656,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020 were $3.4 million, $3.4 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Class Action Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#8217; fees. The plaintiffs&#8217; complaint was later amended to include certain of the Company&#8217;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, the Company will pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers have paid the $30.0&#160;million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement. See Note 16 for events subsequent to December 31, 2022.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Derivative Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">action complaint described above. The lawsuit accuses the Company&#8217;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#8217;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#8217;s current directors as defendants. The Devarakonda complaint also names one of the Company&#8217;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VGXI Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#8217;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#8217; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#8217; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#8217;s counterclaims, disputing the allegations and the claims raised in VGXI&#8217;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#8217;s counterclaims.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GeneOne Litigation</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#8217; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#8217;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#8217;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The counterclaims seek damages, interest, expenses, attorney&#8217;s fees, and costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, GeneOne filed its answer to the Company&#8217;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#8217;s new matter. A trial date for this litigation has not been set.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#8217;s complaint. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Matters</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of </span></div>operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#8217;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951501488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,440,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,652,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no provision for or benefit from income taxes for the years ended December 31, 2022, 2021 and 2020. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,307,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,601,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,065,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,252,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,768,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,442,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,005,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,599,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,439,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,171,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,124,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,205,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,966,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,998,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of December&#160;31, 2022, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $920.6 million, $210.3 million and $89.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $625.4 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2022, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2022, respectively, unless previously utilized. </span></div><div style="margin-bottom:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also had Korean NOL carryforwards of $1.0 million as of December 31, 2022. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized. </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of December 31, 2022, the Company had federal and state research and development (R&amp;D) tax credit carryforwards of $40.5 million and $4.7 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#8217;s NOL and R&amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;D credit carryforwards as of December&#160;31, 2022. As a result of the analysis, the Company estimates that approximately $8.3 million of tax benefits related to NOL and R&amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;D carryforwards.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2022, 2021 and 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act did not have a material impact on the Company's financial statements for the years ended December 31, 2022, 2021 or 2020.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(582,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $19.7 million, $17.4 million and $10.9 million as of December&#160;31, 2022, 2021 and 2020, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2019 and state and local income tax examinations before 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#8220;IRS&#8221;), state, local or foreign tax examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614057377584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">401(k) Plan</a></td>
<td class="text">401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#8217; contributions, up to 6% of their annual compensation. The Company&#8217;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.8 million, $1.5 million and $1.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951375552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract', window );"><strong>Related Party Transaction, Due from (to) Related Party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party TransactionsPlumbline Life Sciences, Inc.<div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">T</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Company owned 597,808 shares of common stock in PLS as of December 31, 2022 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, representing a 18.7% and 18.9% ownership interest, respectively. One </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2022,  2021 and 2020, the Company recognized revenue from PLS of $34,000, $245,000 and $1.4 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $59,000 and $25,000, respectively, related to PLS.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Wistar Institute</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the Company entered into collaborative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has the exclusive right to in-license new intellectual property developed under this agreement.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, which have been completed as of September 30, 2022, the Company is reimbursing Wistar a total of $1.9&#160;million for all direct and indirect costs incurred in the conduct of the collaborative research.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2016, the Company rece</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ived a&#160;$6.1 million&#160;sub-grant through Wistar to develop a d</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MAb</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> against the Zika infectio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n, with funding through December 2021. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the National Institutes of Health&#8217;s National Institute of Allergy and Infectious Diseases, with funding through February 2023.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through March 2024, of which $3.3&#160;million has been exercised as of December 31, 2022. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2022 and 2021, the Company recorded $8.7 million and $3.0 million, respectively, as contra-research and development expense from Wistar. </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2022, 2021 and 2020 were $1.4 million, $2.9 million and $2.3&#160;million, respectively. At December&#160;31, 2022 and 2021, the Company had an accounts receivable balance of $9.9 million and $2.6 million, respectively, and an accounts payable and accrued liability balance of $1.2 million and $548,000, respectively, related to Wistar. As of December&#160;31, 2022 and 2021, the Company had a prepaid expense balance of $375,000 and $261,000, respectively, and recorded $88,000 and $37,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946526992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc.<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">Geneos Therapeutics, Inc. <div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested $1.2&#160;million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000. Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">interest. Based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1&#160;million, of which $2.4&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value. </span></div><div style="margin-top:3pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the Company&#8217;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#8217;s common stock investment and is therefore recorded as an equity security under ASC 321.  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#8217;s investment and the amount of underlying equity in Geneos&#8217;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">  </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#8217;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s share of net losses of Geneos</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f the total amount, $819,000 was allocated to the equity method investment, thereby reducing the balance to $0 as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The remaining </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.2&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loss was allocated to the Company&#8217;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o $0 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2021.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#8217;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#8217;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Geneos&#8217;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to exclusively license its SynCon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapy and CELLECTRA&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology.   </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951407952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2023, the Company committed to and communicated a corporate reorganization plan, including a reduction in force (the &#8220;Reduction&#8221;). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company reduced its overall headcount by approximately 24 employees, which represented 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3&#160;million. The Company expects to incur a one-time pre-tax charge of approximately $1.1&#160;million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. The Company expects such costs to be the only direct expense of the Reduction. The Company expects all charges associated with the Reduction to be incurred during the quarter ending March 31, 2023, with related cash payments expected to be paid out in the first half of 2023.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 18, 2023, the court for the securities class action (see Note 11) entered an order granting final approval of the settlement, as set forth in a stipulation of settlement. In February 2023, pursuant to the securities class action settlement, the Company issued 7,000,000 shares of common stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the expiration of the appeal period or resolution of an appeal if one is filed, the Company will make another contribution of common stock to the settlement fund with a value of approximately $2.1&#160;million. The number of shares will be calculated based on the average trading price of the common stock for the 10 trading days preceding the determination date pursuant to the terms of the securities class action settlement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945670560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Liquidity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Liquidity</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December&#160;31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#8217;s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#8220;Sales Agreements&#8221;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million, $47.7&#160;million and $454.5&#160;million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Compan</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y also issued convertible notes and bonds in a series of private placement transactions. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of </span></div>liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#8217;s business, results of operations and financial condition.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">ConsolidationThe consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair value of Financial Instruments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short Term Investments</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Short-term Investments</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#8217;s affiliated entity, PLS, at December 31, 2022 and 2021. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span>consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text">Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#8217; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fixed Assets</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca">three</span> to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text">Long-Lived AssetsAll long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Valuation of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Intangible Assets and Goodwill</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are amortized over their estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2">two</span> to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2022 and 2021, the Company&#8217;s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1&#160;million and $2.6&#160;million, respectively.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#8217;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#8217;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#8217; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2022.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company </span></div>cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#8217;s results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances against the Company&#8217;s deferred tax assets were $299.1 million and $237.2 million at December&#160;31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue, in accordance with Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;Topic 606&#8221;), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Fees</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Supply Services</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#8217;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Agreements</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (&#8220;Topic 808&#8221;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantRevenuePolicyTextBlock', window );">Grants</a></td>
<td class="text">Grants<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not-for-Profit Entities-Revenue Recognition</span>, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Transactions</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities (VIE)</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variable Interest Entities (VIE)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text">Equity Investments<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC Topic 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement,</span> to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.</span></div>Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. </span>For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. </span></div><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the </span></div>date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - Recently Adopted</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU No. 2020-06.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2020-06&#8221;), which simplifies the guidance on an issuer&#8217;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Revenue [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5728-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759159-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=SL6759068-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080555-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951283408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary Of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because Of Their Anti-Dilutive Effect</a></td>
<td class="text"><div style="margin-top:4.5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,906,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance-based restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">663,353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,049,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2019 Bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,009,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,943,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,654,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary Of Assumptions Used To Estimate The Fair Value Of Stock Options</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.63%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:52.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.736%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.741%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.96%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951339008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Revenue From External Customers</a></td>
<td class="text">The following table indicates the percentage of total revenues in excess of 10% with any single customer:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.733%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.945%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.967%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.201%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Customer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;of&#160;Total<br/>Revenue</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advaccine</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plumbline Life Sciences, Inc. (affiliated entity)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,370,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Department of Defense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,591,778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other, including affiliated entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">774,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,040,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,262,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774,758&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,411,220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951479920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary Of Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of available-for-sale securities as of December&#160;31, 2022 and 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,036,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,373,514)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,001,209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,977,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,450,597&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,802,431)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:25.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.812%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Maturity&#160;(in&#160;years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross&#160;Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Market&#160;Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mutual funds</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">---</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,966,772&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,069&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,614,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,193,441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 1</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,976,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency mortgage-backed securities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,608,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331,712,413&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,195&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,648,668)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*No single maturity date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:38.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.059%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.652%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,662,718&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,964,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,990,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,051,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,669,397&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202,627,228&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,007,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,676,539&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,634,370&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,042,169&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements at</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Unobservable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Mutual funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,439,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,183,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,967,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,991,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,588,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330,170,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,622,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,906,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,077,736&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,529,746&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,547,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951488848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule Of Prepaid Expenses And Other Current Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid and other current assets at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance recovery (a)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,401,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,474,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,729,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,362,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,130,481&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,836,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule Of Accounts Payable And Accrued Expenses</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,862,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,424,743&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,574,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,112,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation settlement (a)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,106,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,686,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,644,530&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#8220;Legal Proceedings.&#8221; The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Prepaid Expenses And Other Current Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951514160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule Of Fixed Assets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets at December&#160;31, 2022 and 2021 consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Depreciation<br/>and<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,036,080)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,767,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,300,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,295,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,803,800)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,360,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,428,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">932,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,291,400&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,563,403)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,727,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,803,108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,258,608)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,544,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,392,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,279,816)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,113,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,827,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,599,643)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,374,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,567,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,397,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,944,378)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,453,206&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951350464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Summary Of Intangible Assets By Major Asset Class</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following sets forth goodwill and intangible assets by major asset class:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.874%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:53pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Useful<br/>Life<br/>(Yrs)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Book<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite lived:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,513,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Definite lived:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,323,761)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,305,600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bioject (a)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,988,889)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,111,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,735,556)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,364,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (b)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,031,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,806,250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129,861&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,473,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,626,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total goodwill and intangible assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,343,900)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,643,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,987,132&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,847,406)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,139,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Other intangible assets represent the estimated fair value of acquired intellectual property.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule Of Finite-Lived Intangible Assets, Future Amortization Expense</a></td>
<td class="text">Amortization expense related to intangible assets at December&#160;31, 2022 is expected to be incurred as follows: <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,130,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945381296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule Of Convertible Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The balance of the Notes at December&#160;31, 2022 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal amount converted into common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,085,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(155,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Net carrying amount </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,614,840&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule Of Maturities Of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:85.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.346%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,067,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,948,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,015,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947516304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary Of Preferred Stock Authorized, Issued And Outstanding</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:47.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.313%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Outstanding as of<br/>December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Authorized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series&#160;C Preferred Stock, par $0.001</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total stock options outstanding at December&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:26.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.529%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life<br/>(in Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise&#160;Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Underlying Options<br/>Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted    Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.56-$3.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">830,542&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,104&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.01-$6.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,461,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01-$9.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,349,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861,909&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.01-$12.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12.01-$15.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580,947&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15.01-$25.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,829,692&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Stock Options, Activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2022 was as follows: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:70.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,488,993&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(118,694)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,772,199)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,221,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule Of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit activity under the Company&#8217;s equity incentive plans during the year ended December&#160;31, 2022 was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,448,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,485,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,618,235)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,323)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,556,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613951263888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Maturities Of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">As of December&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.351%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ending December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,089,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,050,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,063,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,139,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,526,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,223,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total remaining lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,090,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,630,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,460,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,804,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,656,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947528784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule Of Components Of Pretax Loss From Operations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of pretax loss from operations are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,440,803)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(302,614,003)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,664,355)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(211,249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(610,320)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax loss from operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(277,652,052)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303,224,323)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(162,890,304)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes at statutory rates</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,307,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,677,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,207,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income tax, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,601,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,447,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,065,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,424,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,428,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nondeductible loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,534,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,523,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,650,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,913,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">483,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,953,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,291,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,509,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deconsolidation of subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">853,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired NOLs and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Limited NOLs and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,337,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(542,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in tax rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign tax rate differential</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,246,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(819,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets And Liabilities</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are shown below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research expense</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,252,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,200,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NOL carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">212,768,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development and other tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,442,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,005,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">987,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,599,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliated entity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,793,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,062,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,973,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,439,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,171,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299,124,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(237,205,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,315,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,966,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,148,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,430,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Note discount</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(321,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,347,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,998,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32,000)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock', window );">Schedule Of Operating Loss And Tax Credit Carryforward Expirations</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiration Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign NOLs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Federal R&amp;D</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State R&amp;D</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027 and thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">249.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule Of Unrecognized Tax Benefits Rollforward</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company's unrecognized tax benefits:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of the year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,204,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,902,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,602,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases (decreases) related to prior year tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(582,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of the year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,139,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,819,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946498384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule Of Equity Method Investments</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos Series A-2 preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,999,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remeasurement of  Geneos Series A-1 preferred stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share in current and accumulated net loss of Geneos </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,165,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in Geneos as of December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946034112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss from operations</a></td>
<td class="nump">$ 279,818,065<span></span>
</td>
<td class="nump">$ 303,658,710<span></span>
</td>
<td class="nump">$ 166,411,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_WorkingCapital', window );">Working capital</a></td>
<td class="nump">218,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">1,487,847,784<span></span>
</td>
<td class="nump">1,209,855,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">253,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 82,955,311<span></span>
</td>
<td class="nump">209,441,410<span></span>
</td>
<td class="nump">454,486,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets, net</a></td>
<td class="nump">2,129,861<span></span>
</td>
<td class="nump">2,626,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, valuation allowance</a></td>
<td class="nump">$ 299,124,000<span></span>
</td>
<td class="nump">237,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant, and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="nump">47,700,000<span></span>
</td>
<td class="nump">$ 454,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of current assets and current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614040958832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">17,943,035<span></span>
</td>
<td class="nump">16,654,503<span></span>
</td>
<td class="nump">16,190,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">12,221,548<span></span>
</td>
<td class="nump">10,488,993<span></span>
</td>
<td class="nump">8,906,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember', window );">Service-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">2,556,257<span></span>
</td>
<td class="nump">2,448,868<span></span>
</td>
<td class="nump">2,558,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Performance-based restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">111,941<span></span>
</td>
<td class="nump">663,353<span></span>
</td>
<td class="nump">663,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">3,049,980<span></span>
</td>
<td class="nump">3,049,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total antidilutive securities (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,009,450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ino_ServiceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945466912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details) - Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember', window );">Employees and Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.05%<span></span>
</td>
<td class="nump">0.91%<span></span>
</td>
<td class="nump">0.63%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">93.00%<span></span>
</td>
<td class="nump">78.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember', window );">Non Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract', window );"><strong>Summary of assumptions used to estimate the fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.96%<span></span>
</td>
<td class="nump">1.45%<span></span>
</td>
<td class="nump">0.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumptions used in estimation of fair value of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_NonEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_NonEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947533408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (1,487,847,784)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,209,855,522)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="num">(1,710,656,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,609,589,797)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">32,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946575488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 10,262,268<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc. (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 33,596<span></span>
</td>
<td class="nump">$ 245,310<span></span>
</td>
<td class="nump">$ 1,370,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember', window );">Plumbline Life Sciences, Inc. (affiliated entity) | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">U.S. Department of Defense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 9,591,778<span></span>
</td>
<td class="nump">$ 754,853<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">U.S. Department of Defense | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">94.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="nump">$ 636,894<span></span>
</td>
<td class="nump">$ 774,595<span></span>
</td>
<td class="nump">$ 1,040,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember', window );">All other, including affiliated entities | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_PlumblineLifeSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AllOtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AllOtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947506768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from deferred revenue</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">U.S. Department of Defense | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_DoDMember', window );">U.S. Department of Defense | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_CEPIMERSMember', window );">CEPI MERS | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_CEPIMERSMember', window );">CEPI MERS | Customer Concentration Risk | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">%&#160;of&#160;Total Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_CEPIMERSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_CEPIMERSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613939663152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 11, 2018</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,262,268<span></span>
</td>
<td class="nump">$ 1,774,758<span></span>
</td>
<td class="nump">$ 7,411,220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ino_AdvaccineMember', window );">Advaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostMaintenance', window );">Annual maintenance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AnnualMaintenancePeriod', window );">Annual maintenance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementPaymentEarned', window );">Collaboration agreement, payment earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_AdvaccineMember', window );">Advaccine | Collaborative Arrangement | Revenue under collaborative research and development arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from collaborative arrangements and other contracts, including affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_ApolloBioMember', window );">ApolloBio | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved', window );">Additional revenue to be achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborationAgreementRoyaltyPeriod', window );">Obligation period to pay royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination', window );">Agreement, number of days written notice before termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination', window );">Agreement period from effective date for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementsUpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="nump">$ 56,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment', window );">Collaborative agreement, period to receive funding for research and development</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | Lassa Fever And MERS Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | COVID19 Vaccine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember', window );">Coalition for Epidemic Preparedness Innovations | Collaborative Arrangement | IN O4800</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">893,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember', window );">Bill And Melinda Gates Foundation | Collaborative Arrangement | D N A Encoded Monoclonal Antibody Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingToBeReceived', window );">Collaborative agreement, funding to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
<td class="nump">182,000<span></span>
</td>
<td class="nump">463,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract', window );">Procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="nump">$ 27,100,000<span></span>
</td>
<td class="nump">$ 21,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember', window );">Department Of Defence | Collaborative Arrangement | CELLECTRA 3PSP Proprietary Smart Device</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementFundingReceived', window );">Funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded', window );">Purchase price, procurement contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AnnualMaintenancePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual Maintenance Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AnnualMaintenancePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementAdditionalRevenueToBeAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Revenue To Be Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementAdditionalRevenueToBeAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementPaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Payment Earned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementPaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborationAgreementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborationAgreementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementFundingToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Funding Received for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementFundingToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Number of Days Written Notice Before Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period From Effective Date For Termination</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Period to Receive Funding for Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementsUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreements, Upfront Payment Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementsUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementFixedPriceContractAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fixed-Price Contract, Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementFixedPriceContractAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementRevenueFromTheProcurementContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement , Revenue from the Procurement Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementRevenueFromTheProcurementContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostMaintenance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of maintenance incurred and directly related to good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostMaintenance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_AdvaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_AdvaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_ApolloBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_ApolloBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_CoalitionforEpidemicPreparednessInnovationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_LassaFeverAndMERSVaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_SARSCoV2COVID19VaccineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_CELLECTRA3PSPProprietarySmartDeviceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_INO4800Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_INO4800Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ino_DNAEncodedMonoclonalAntibodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_DepartmentOfDefenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946622752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 216,450,597<span></span>
</td>
<td class="nump">$ 331,712,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">21,231<span></span>
</td>
<td class="nump">107,195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(9,802,431)<span></span>
</td>
<td class="num">(1,648,668)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">206,669,397<span></span>
</td>
<td class="nump">330,170,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">117,036,232<span></span>
</td>
<td class="nump">192,966,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">87,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(9,373,514)<span></span>
</td>
<td class="num">(1,614,411)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 107,662,718<span></span>
</td>
<td class="nump">191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 95,001,209<span></span>
</td>
<td class="nump">94,193,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">7,567<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(44,266)<span></span>
</td>
<td class="num">(9,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">94,964,510<span></span>
</td>
<td class="nump">94,183,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">2,977,564<span></span>
</td>
<td class="nump">2,976,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">13,664<span></span>
</td>
<td class="nump">15,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 2,990,908<span></span>
</td>
<td class="nump">$ 2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity', window );">Contractual Maturity</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt Securities, Available-for-sale, Sale [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 1,435,592<span></span>
</td>
<td class="nump">$ 1,608,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross&#160;Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross&#160;Unrealized Losses</a></td>
<td class="num">(384,331)<span></span>
</td>
<td class="num">(23,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair&#160;Market&#160;Value</a></td>
<td class="nump">$ 1,051,261<span></span>
</td>
<td class="nump">$ 1,588,647<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtSecuritiesAvailableforSaleContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtSecuritiesAvailableforSaleContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941053872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>position </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Debt securities, available-for-sale, realized gain</a></td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">399,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized loss on available-for-sale equity securities</a></td>
<td class="nump">$ 7,846,172<span></span>
</td>
<td class="nump">$ 3,222,838<span></span>
</td>
<td class="num">$ (1,695,497)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of securities in a gross unrealized loss position | position</a></td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">Number of securities in a gross unrealized loss position for more than twelve months | position</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on investments</a></td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares) | shares</a></td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613942501520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 206,669,397<span></span>
</td>
<td class="nump">$ 330,170,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember', window );">Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">107,662,718<span></span>
</td>
<td class="nump">191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,908<span></span>
</td>
<td class="nump">2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember', window );">U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,051,261<span></span>
</td>
<td class="nump">1,588,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">206,669,397<span></span>
</td>
<td class="nump">330,170,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">2,007,142<span></span>
</td>
<td class="nump">3,906,796<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">208,676,539<span></span>
</td>
<td class="nump">334,077,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">202,627,228<span></span>
</td>
<td class="nump">285,622,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">2,007,142<span></span>
</td>
<td class="nump">3,906,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">204,634,370<span></span>
</td>
<td class="nump">289,529,746<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">4,042,169<span></span>
</td>
<td class="nump">44,547,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">4,042,169<span></span>
</td>
<td class="nump">44,547,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in affiliated entity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">107,662,718<span></span>
</td>
<td class="nump">191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">107,662,718<span></span>
</td>
<td class="nump">191,439,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Mutual funds | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">94,964,510<span></span>
</td>
<td class="nump">94,183,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">94,964,510<span></span>
</td>
<td class="nump">94,183,520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. treasury securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,967,853<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commercial paper | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,908<span></span>
</td>
<td class="nump">2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">2,990,908<span></span>
</td>
<td class="nump">2,991,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Certificates of deposit | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,051,261<span></span>
</td>
<td class="nump">1,588,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Other Unobservable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,051,261<span></span>
</td>
<td class="nump">1,588,647<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. agency mortgage-backed securities | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Financial assets and liabilities that are measured at fair value on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=ino_MutualFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614030759968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CertainBalanceSheetItemsAbstract', window );"><strong>Certain Balance Sheet Items [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Estimated Insurance Recoveries</a></td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PrepaidManufacturingExpensesCurrent', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">1,401,028<span></span>
</td>
<td class="nump">27,474,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">18,729,453<span></span>
</td>
<td class="nump">11,362,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 50,130,481<span></span>
</td>
<td class="nump">$ 38,836,991<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CertainBalanceSheetItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Certain Balance Sheet Items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CertainBalanceSheetItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PrepaidManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PrepaidManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941152384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Accounts Payable, Trade</a></td>
<td class="nump">$ 19,862,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,424,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued Salaries, Current</a></td>
<td class="nump">12,574,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,112,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation settlement</a></td>
<td class="nump">44,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other Accrued Liabilities</a></td>
<td class="nump">3,249,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,106,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">79,686,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47,644,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_AccountsPayableAndAccruedExpensesLineItems', window );"><strong>Accounts Payable and Accrued Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Amount paid to other party</a></td>
<td class="nump">$ 252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_AccountsPayableAndAccruedExpensesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable and Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_AccountsPayableAndAccruedExpensesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613945490000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">$ 29,291,400<span></span>
</td>
<td class="nump">$ 36,397,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(21,563,403)<span></span>
</td>
<td class="num">(18,944,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">7,727,997<span></span>
</td>
<td class="nump">17,453,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">3,656,713<span></span>
</td>
<td class="nump">3,040,096<span></span>
</td>
<td class="nump">$ 3,038,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_PropertyPlantAndEquipmentDisposedOfBySale', window );">Property, plant and equipment sold</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisposals', window );">Property, plant and equipment disposed of</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">15,803,108<span></span>
</td>
<td class="nump">15,803,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(10,036,080)<span></span>
</td>
<td class="num">(8,258,608)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">5,767,028<span></span>
</td>
<td class="nump">7,544,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Research and development equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">5,300,104<span></span>
</td>
<td class="nump">12,392,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(4,295,217)<span></span>
</td>
<td class="num">(4,279,816)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">1,004,887<span></span>
</td>
<td class="nump">8,113,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Office furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">2,827,476<span></span>
</td>
<td class="nump">2,827,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(2,803,800)<span></span>
</td>
<td class="num">(2,599,643)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">23,676<span></span>
</td>
<td class="nump">227,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Computer equipment and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost</a></td>
<td class="nump">5,360,712<span></span>
</td>
<td class="nump">5,374,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation and Amortization</a></td>
<td class="num">(4,428,306)<span></span>
</td>
<td class="num">(3,806,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Book Value</a></td>
<td class="nump">$ 932,406<span></span>
</td>
<td class="nump">$ 1,567,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_PropertyPlantAndEquipmentDisposedOfBySale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Disposed Of By Sale</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_PropertyPlantAndEquipmentDisposedOfBySale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126942793&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisposals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisposals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946678368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Indefinite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillGross', window );">Goodwill, gross</a></td>
<td class="nump">$ 10,513,371<span></span>
</td>
<td class="nump">$ 10,513,371<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, net book value</a></td>
<td class="nump">10,513,371<span></span>
</td>
<td class="nump">10,513,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">10,473,761<span></span>
</td>
<td class="nump">10,473,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(8,343,900)<span></span>
</td>
<td class="num">(7,847,406)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">2,129,861<span></span>
</td>
<td class="nump">2,626,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsGross', window );">Total goodwill and intangible assets, gross</a></td>
<td class="nump">20,987,132<span></span>
</td>
<td class="nump">20,987,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GoodwillAndIntangibleAssetsNet', window );">Total goodwill and intangible assets, net book value</a></td>
<td class="nump">$ 12,643,232<span></span>
</td>
<td class="nump">13,139,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 1,323,761<span></span>
</td>
<td class="nump">1,323,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(1,323,761)<span></span>
</td>
<td class="num">(1,305,600)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licenses | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(2,988,889)<span></span>
</td>
<td class="num">(2,735,556)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 2,111,111<span></span>
</td>
<td class="nump">2,364,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember', window );">Bioject | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">$ 4,050,000<span></span>
</td>
<td class="nump">4,050,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets, accumulated amortization</a></td>
<td class="num">(4,031,250)<span></span>
</td>
<td class="num">(3,806,250)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="nump">$ 243,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other | Weighted Average Useful Life (Yrs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Definite lived:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GoodwillAndIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Goodwill and intangible assets net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GoodwillAndIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ino_BiojectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614030794080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 496,494<span></span>
</td>
<td class="nump">$ 520,415<span></span>
</td>
<td class="nump">$ 547,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613948440944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">845,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net book value</a></td>
<td class="nump">$ 2,129,861<span></span>
</td>
<td class="nump">$ 2,626,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613937824512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 01, 2019 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 26, 2019 </div>
<div>KRW (&#8361;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,487,847,784)<span></span>
</td>
<td class="num">$ (1,209,855,522)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,710,656,191)<span></span>
</td>
<td class="num">(1,609,589,797)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,253,952<span></span>
</td>
<td class="nump">1,936,447<span></span>
</td>
<td class="nump">$ 8,702,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member', window );">6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,614,840<span></span>
</td>
<td class="nump">14,959,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member', window );">Accounting Standards Update 2020-06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | 6.50% Convertible Senior Notes Due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1858045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Debt instrument, convertible, threshold consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt instrument, unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 592,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | December 2019 Bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 4,700,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense, debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt conversion, converted instrument, shares issued (in shares) | shares</a></td>
<td class="nump">1,009,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Carrying value of december 2019 bonds</a></td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_December2019ConvertibleBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614030794368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Balance Of Convertible Debt (Details) - 6.50% Convertible Senior Notes Due 2024<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 78,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtInstrumentConvertibleDebtConvertedAmount', window );">Principal amount converted into common shares</a></td>
<td class="num">(62,085,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance cost</a></td>
<td class="num">(155,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DebtinstrumentAccruedInterest', window );">Accrued interest</a></td>
<td class="nump">355,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 16,614,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtInstrumentConvertibleDebtConvertedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Converted Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtInstrumentConvertibleDebtConvertedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DebtinstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Accrued Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DebtinstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613952246432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Convertible Debt - Schedule of Maturities (Details) - Convertible Senior Notes - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 16,614,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt interest based on the fixed rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">16,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 18,015,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ino_A6.50ConvertibleSeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947496864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series&#160;C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Summary of common and preferred stock authorized, issued and outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613939187504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2021</div></th>
<th class="th"><div>Jan. 25, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 24, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>May 13, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare', window );">Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,221,548<span></span>
</td>
<td class="nump">10,488,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value for options exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm', window );">Options exercisable, remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber', window );">Number of options expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,221,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, expirations in period, weighted average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.47<span></span>
</td>
<td class="nump">$ 4.56<span></span>
</td>
<td class="nump">$ 4.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, expirations in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,250<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">78,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options, grants in period, weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 7.61<span></span>
</td>
<td class="nump">$ 6.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 283,000<span></span>
</td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="nump">$ 12,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options, exercises in period, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,000<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Nonemployee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding to purchase common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ino_FormerPresidentAndChiefExecutiveOfficerMember', window );">Former President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,556,257<span></span>
</td>
<td class="nump">2,448,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Aggregate intrinsic value of unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber', window );">RSU's expected to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,556,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.12<span></span>
</td>
<td class="nump">$ 10.37<span></span>
</td>
<td class="nump">$ 9.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Former President and Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash', window );">Awards settled in cash, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan', window );">Number of potential shares authorized for issuance under a share-based compensation plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized', window );">Increase in number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,831,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan', window );">Number of shares of vested restricted stock outstanding under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,446,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,132,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember', window );">2016 Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember', window );">2007 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,902,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm', window );">Contractual year term of incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember', window );">2022 Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Reserved number of shares under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grants under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,703,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Number of common stock shares outstanding under the Incentive Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares of unvested restricted stock units and options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Commissions and other estimated offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 162,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementMaximumAuthorizedAmount', window );">Common stock aggregate offering price</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage', window );">Sales Agents will be entitled to compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateNumberofSharesIssued', window );">Stock sale agreement, aggregate number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,445,743<span></span>
</td>
<td class="nump">6,955,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementWeightedAveragePricePerShare', window );">Sales made at a weighted average price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock', window );">Stock sale agreement, aggregate proceeds from issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000,000<span></span>
</td>
<td class="nump">$ 47,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockSalesAgreementRemainingAuthorizedAmount', window );">Remaining authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 167,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of potential shares authorized for issuance under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of vested restricted stock outstanding under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Sales Proceeds of Any Common Stock, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum contractual term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateNumberofSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Number of Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateNumberofSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSaleAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sale Agreement Weighted Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSaleAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementMaximumAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Maximum Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementMaximumAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockSalesAgreementRemainingAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Sales Agreement, Remaining Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockSalesAgreementRemainingAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ino_FormerPresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ino_FormerPresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2016IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2007IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ino_A2022InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ino_A2022InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ino_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613939160112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">12,221,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 6.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">7,829,692<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember', window );">$1.56-$3.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">1.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">830,542<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">247,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember', window );">$3.01-$6.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">3.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 6.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">5,461,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">3,059,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember', window );">$6.01-$9.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">3,349,587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 7.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">2,861,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember', window );">$9.01-$12.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">9.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">1,930,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 10.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,080,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 10.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember', window );">$12.01-$15.00</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">12.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">580,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 13.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">529,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 13.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember', window );">$15.01-$25.62</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share)</a></td>
<td class="nump">15.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share)</a></td>
<td class="nump">$ 25.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">68,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life (in Years)</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise&#160;price (in dollars per share)</a></td>
<td class="nump">$ 21.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">51,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 21.11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ino_RangeOfExercisePricesSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941025184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">10,488,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">4,623,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(118,694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(2,772,199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">12,221,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">3.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">2.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">7.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.28<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613952291392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details) - Performance-based restricted stock units<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,448,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">2,485,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(1,618,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled (in shares)</a></td>
<td class="num">(760,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,556,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941002848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>ft&#178; </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease | ft&#178;</a></td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto', window );">Number of lease agreements entered into | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember', window );">McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Estimate of cash settlement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares', window );">Estimate of shares settlement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 14.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember', window );">San Diego, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember', window );">Plymouth Meeting, Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_LesseeOperatingLeaseAreaofLandUnderLease', window );">Lessee, operating lease, area of land under lease | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeNumberOfLeaseAgreementsEnteredInto">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Number Of Lease Agreements Entered Into</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeNumberOfLeaseAgreementsEnteredInto</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LesseeOperatingLeaseAreaofLandUnderLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Area of Land Under Lease</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LesseeOperatingLeaseAreaofLandUnderLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_LossContingencyEstimateOfPossibleLossValueOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Possible Loss, Value of Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_LossContingencyEstimateOfPossibleLossValueOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_SanDiegoCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=ino_PlymouthMeetingPennsylvaniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941700064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">2,526,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total remaining lease payments</a></td>
<td class="nump">20,090,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(4,630,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">15,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,803,973)<span></span>
</td>
<td class="num">$ (2,603,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">$ 12,655,586<span></span>
</td>
<td class="nump">$ 15,459,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947014944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Pretax Loss from Operations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S. Domestic</a></td>
<td class="num">$ (277,440,803)<span></span>
</td>
<td class="num">$ (302,614,003)<span></span>
</td>
<td class="num">$ (162,664,355)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(211,249)<span></span>
</td>
<td class="num">(610,320)<span></span>
</td>
<td class="num">(225,949)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before share in net loss of Geneos</a></td>
<td class="num">$ (277,652,052)<span></span>
</td>
<td class="num">$ (303,224,323)<span></span>
</td>
<td class="num">$ (162,890,304)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946626704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Benefit from income taxes at statutory rates</a></td>
<td class="num">$ (58,307)<span></span>
</td>
<td class="num">$ (63,677)<span></span>
</td>
<td class="num">$ (34,207)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax, net of federal benefit</a></td>
<td class="num">(3,601)<span></span>
</td>
<td class="num">(3,447)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">61,065<span></span>
</td>
<td class="nump">77,424<span></span>
</td>
<td class="nump">21,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt', window );">Nondeductible loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncomeTaxReconciliationStatuteLimitations', window );">Research and development tax credits</a></td>
<td class="num">(7,534)<span></span>
</td>
<td class="num">(16,523)<span></span>
</td>
<td class="num">(2,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">483<span></span>
</td>
<td class="num">(1,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Uncertain tax positions</a></td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">6,509<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary', window );">Deconsolidation of subsidiary</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits', window );">Expired NOLs and credits</a></td>
<td class="nump">1,459<span></span>
</td>
<td class="nump">616<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits', window );">Limited NOLs and credits</a></td>
<td class="num">(1,337)<span></span>
</td>
<td class="num">(542)<span></span>
</td>
<td class="num">(368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in tax rates</a></td>
<td class="num">(187)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax rate differential</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="num">(819)<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_ComprehensiveIncomeLossTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss), Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_ComprehensiveIncomeLossTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeTaxReconciliationStatuteLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Statute Limitations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeTaxReconciliationStatuteLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613946609856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxBenefitsExpired', window );">Tax benefits expired</a></td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">19,700,000<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="nump">$ 10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">920,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">40,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">210,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">89,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">299,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember', window );">Korean State Income Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet', window );">Net operating loss carryforwards that will expire due to IRC Section 382 limitations</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxBenefitsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefits Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxBenefitsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_CaliforniaIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_PennsylvaniaStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ino_KoreanStateIncomeTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941156384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expense</a></td>
<td class="nump">$ 41,252<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">212,768<span></span>
</td>
<td class="nump">197,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">Research and development and other tax credits</a></td>
<td class="nump">26,442<span></span>
</td>
<td class="nump">23,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">538<span></span>
</td>
<td class="nump">987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,945<span></span>
</td>
<td class="nump">3,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="nump">559<span></span>
</td>
<td class="nump">637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxAssetInterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInvestments', window );">Investment in affiliated entity</a></td>
<td class="nump">1,569<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxAssetsOperatingLeaseLiability', window );">Lease liability</a></td>
<td class="nump">3,247<span></span>
</td>
<td class="nump">3,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">11,062<span></span>
</td>
<td class="nump">5,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, gross</a></td>
<td class="nump">301,439<span></span>
</td>
<td class="nump">240,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(299,124)<span></span>
</td>
<td class="num">(237,205)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">2,966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Acquired intangibles</a></td>
<td class="num">(199)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(2,148)<span></span>
</td>
<td class="num">(2,430)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount', window );">Note discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(2,347)<span></span>
</td>
<td class="num">(2,998)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="num">$ (32)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Interest Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxAssetsOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxAssetsOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesFinancingArrangementDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Financing Arrangement, Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesFinancingArrangementDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613937687472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2023</a></td>
<td class="nump">$ 5.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2024</a></td>
<td class="nump">18.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2025</a></td>
<td class="nump">9.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2026</a></td>
<td class="nump">12.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInSixYears', window );">2027 and thereafter</a></td>
<td class="nump">249.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">625.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">920.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2023</a></td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2024</a></td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2025</a></td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2026</a></td>
<td class="nump">7.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInSixYears', window );">2027 and thereafter</a></td>
<td class="nump">277.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">299.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract', window );"><strong>Expirations of Operating Loss Carryforwards, Components [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinTwoYears', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinThreeYears', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFourYears', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringinFiveYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsExpiringInSixYears', window );">2027 and thereafter</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Total</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInThreeYears', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInFourYears', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInSixYears', window );">2027 and thereafter</a></td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">40.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract', window );"><strong>Expirations of Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinTwoYears', window );">2023</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInThreeYears', window );">2024</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInFourYears', window );">2025</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringinFiveYears', window );">2026</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardExpiringInSixYears', window );">2027 and thereafter</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely', window );">Indefinite</a></td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Total</a></td>
<td class="nump">$ 4.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringInSixYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Six Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringInSixYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_OperatingLossCarryforwardsIndefinitelyCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Indefinitely Carryforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_OperatingLossCarryforwardsIndefinitelyCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardCarryforwardIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Carryforward Indefinitely</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardCarryforwardIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Four Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInSixYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Six Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInSixYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Three Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Five Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_TaxCreditCarryforwardExpiringinTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Expiring in Two Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_TaxCreditCarryforwardExpiringinTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140614030754288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of the year</a></td>
<td class="nump">$ 18,819<span></span>
</td>
<td class="nump">$ 12,210<span></span>
</td>
<td class="nump">$ 11,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">2,902<span></span>
</td>
<td class="nump">6,602<span></span>
</td>
<td class="nump">1,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="num">(582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases (decreases) related to prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 21,139<span></span>
</td>
<td class="nump">$ 18,819<span></span>
</td>
<td class="nump">$ 12,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) In Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947237760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>401(k) Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum annual contribution per employee, percent</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Company's contribution to 401(k) plan</a></td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947425680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAmendedAmount', window );">Agreement amended amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedExercisedAmount', window );">Awarded exercised amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember', window );">Plumbline Life Sciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Number of shares owned (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="nump">597,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.70%<span></span>
</td>
<td class="nump">18.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember', window );">PLS (affiliated entity)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 245<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember', window );">The Wistar Institute</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeArrangementTerm', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedOptionAmount', window );">Awarded option amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Operating expenses related to affiliated entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_DeferredGrantFundingFromAffiliate', window );">Deferred grant funding from affiliate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementExpensesToReimburse', window );">Expenses to reimburse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CollaborativeAgreementAwardedAmount', window );">Awarded amount</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_GrantProceedsReceived', window );">Grant proceeds received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAmendedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Amended Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAmendedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedExercisedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Exercised Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedExercisedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementAwardedOptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Awarded Option Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementAwardedOptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeAgreementExpensesToReimburse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Expenses To Reimburse</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeAgreementExpensesToReimburse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_DeferredGrantFundingFromAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Grant Funding, From Affiliate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_DeferredGrantFundingFromAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_GrantProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Proceeds Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_GrantProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_PlumblineLifeSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_PlumblineLifeSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_PLSaffiliatedentityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ino_TheWistarInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613941799088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,399,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,121,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,165,213<span></span>
</td>
<td class="nump">434,387<span></span>
</td>
<td class="nump">$ 4,584,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember', window );">Series A-2 One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,165,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment', window );">Stock purchase agreement, commitment of additional investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on deconsolidation of Geneos</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment', window );">Loss from equity method investment, recorded and allocated to investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">434,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Series A-1 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member', window );">Geneos Therapeutics, Inc. | Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Realized And Allocated to Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Commitment Of Additional Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ino_GeneosTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesAOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613948955584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geneos Therapeutics, Inc. - Preferred Stock Investment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in current and accumulated net loss of Geneos</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,165,213)<span></span>
</td>
<td class="num">$ (434,387)<span></span>
</td>
<td class="num">$ (4,584,610)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember', window );">Series A-2 One Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount', window );">Remeasurement of Geneos Series A-1 preferred stock</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">165,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Share in current and accumulated net loss of Geneos</a></td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="num">(2,165,213)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,999,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ino_SeriesA2OnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140613947381184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($) </div>
<div>day </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,091,319<span></span>
</td>
<td class="nump">217,382,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,090<span></span>
</td>
<td class="nump">$ 217,382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions reduced | employee</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions reduced (in percent)</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_RestructuringAndRelatedCostExpectedAnnualSavings', window );">Expected annual savings</a></td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays', window );">Trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Shares Issued, Share Price, Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ino_RestructuringAndRelatedCostExpectedAnnualSavings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Expected Annual Savings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ino_RestructuringAndRelatedCostExpectedAnnualSavings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ino_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>ino-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ino="http://www.inovio.com/20221231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ino-20221231.xsd" xlink:type="simple"/>
    <context id="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i34f3ee93005e44e4818bc81e3c428fc3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i68aed334af06455c9f43334dc07c928f_I20230224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="i0073c18a8e7f44daadd9ab703b7645a8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6327975f86354d84adb2cb38dcd5ea52_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i462df0bfe2224796bd3e4784559e9ff7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i28fdf7ad489d4fce8f004f820b342526_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8c2c1a9b72144f0a92349e7cf9e5a446_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie31c91acde4741fe900e7a84f2b0ad34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46ecffdec9a64e498429f8977ea52114_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0e3a7a0113a6439694f0af4a15e4c7dc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idae06434a74c4378bb8e66fbb38683a8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91313ea012fb4e29a82373b1216240c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic20b1cb6ae6442cfb1dd54c81a7d71f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7dc4c4c9f63349128d1754e94f5cc9e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d6cb11719d041f090cfb6c6b041e892_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i718af9ccd104415fbf64c9d32f74bb1e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8942a4a67cba41659b89e7b8521ab8eb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1bb91b86850c4019853cfafe96543ff8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if583dbf110944d9b91969553df66a181_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iad2ce681ebaa453d8289a854900c32fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i77f6191d42744cbe9b446139968001a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8cc077e8d5154506ba48d33c68a71bfe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifb9c9e86d4a54a01b3a0e8c79d8927b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9bf7e09219084016a812c88d9977fa5a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i110d8cff3e7c4910b2e0c84f0f9c65de_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7da2f113135949f6b69b0f0304007c14_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id13cf002a66c44d39492fe34b336faf0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if71c1abee2354fad9e808f4f24fbcbd2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id11369143520413d8c7da3da06fc56b1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib23b8d6624644da386cf1e538d1bd8af_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16ffc786c3c84f7ba4e698ca14539948_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i10ad082f8bde4a7a92524043edf853c1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i75216b6319924276935aa28bd9bb7dcf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i01a55d99d9834376b29d04025a363045_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4459abbf67aa4910bb765838712d9fe5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4028d9e38f094f768bb1e9452fc45472_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8cf453e9844f4d6fa74be581ed00a513_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fd95af3528440b39f64c721172b95b3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ba6177eb6b8472495d2e2a45d024f63_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8666bf368748449bb6e324e42d8b1d21_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8501fb06a5774680b79276ad409fed15_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0151eb300ba9417ca13398ee631e0a11_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc6a118a9cde4fde96c5f7c1ae0848ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4439b6c598d454e8b8ff9ceb6d62287_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if998a11fda824693a82b5630eee5944a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i75ed40a3258c4619b0d384f1c875f1b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b7a2f2ae8ab40ccae727491f64f50ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6173a75999554213bd9ef6b178b3c5a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i78e8ed6c44394b9d8730b7f657680c0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf99a57f4f0543779cb105cb89a2a1ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3e327b57b7e447c8aadc23b5385ebe2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i564f8e98e6a4437d87441f8dad2ebdb9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic1bdec8a908c4594afd92ff4781d3366_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i989ec83114ba4070a4bd52566656d740_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:August2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ff864730ea642239a8163e8e1918732_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f77b689e902453898c3df44adad4187_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib6cae987a41b4492a9781bcec7e5cea0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i851b409487e4421e97a148072ac742ed_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6a09be2c6e5c4d808f21c4869c433b68_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8c4af40c177746a9860d90e560bd8e93_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0b5c26fff9c54ee6aeec015bd77060ea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia738364cb3704782bff4583a29069493_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibf4c53fa971d4d039d0b3f9f50813d00_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i778adc9858e4413284de317978f1491e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8f6a30b1663b4a28822ba910bb5f0d2b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i385f8bc5e1ef496fa5bf4b77f4ac4c8d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ino:ServiceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i905fef709da24983a7a134952ad5cd76_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5c357726a9834da5b7f9e01126ab1934_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i793c2cf60aba4213b7dda26b6bd1d0bf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2234c920452e4ca5a201f3f44924f639_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3ea03f1cc4604b918e8a86d38eb57330_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9983d93acb00482e8d0d425200e8a260_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4acef92df1eb4002905dc17370558309_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic26efa4ca4234676aff27081710a3c9f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8b5b9fd187a54c0e8a75c5406595c067_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0b6db699219044e993eb9ea5a3b6b102_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8e7e112a8d0b4389b6475906e5e25f9a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i38c6268345f84faf98df07aa08e09d50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i666a23e01c6442398866e53b58f368d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:EmployeesAndDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6cb872fefb714074b5880db078069e39_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:NonEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie489748523ab48ef9c00350ee420a2ad_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ib54af4db6f934822936c9df96da62d29_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacebae33d2f744a48bfe3f27c87963b5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4c2ca730669f40a3b880aad76ef47eb8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iec30835ff64649d1af8bee1755bb6747_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib0233517f0744b4d84dbc2857651922e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8427d8144b8a45508082c0e9224f6b9a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if216a168540f4767a05cedea2727d91b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3508c7fdd5df49c9b3d412117527967f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba97b678f2164b7dab82b6edbc9c7f26_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i605c60f66d234792a11598c1cdedabc7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2d452e7c90114add826a2726068eca7b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i39566c733fd24bfebb62337eb808c542_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifcac4af5c7b542f9afc5cb5e93d18b8e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:PlumblineLifeSciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia146e47921c744fc956b2120c6439daf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idd3d9ccb223c4b51adcc34fee442e12e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i950175750d8f45f99adff0b9d015b817_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i990e94fbd63b4cd8aa841335ddf7a196_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifaa2ff55b5b64c87ac5b7a3c20a2340a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3e0c5185d2f4ec88fb795922202c563_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i96a3222a554c43c892ad45d36bed2135_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b4cbfef541641c29b555849b7baa86b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i87e6793803cc44808ce478887c3e8548_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i022f7c48f8c449e0984cc5c418c9249f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia4c58350d8dd4037a4eeb106f14f84bb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7a04772ad7c34b45b0fea6aab0e11b68_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:AllOtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24234386041445bca5cb6066f1a957bc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7aa7c00e7c454fc0aadae3a3b369359e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id150bf83ee8f48f998faaca40b1a30ec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icb0c56d581394886b4899de7fc50e0e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1e1e7149a8c6422490e7e06c70d28310_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i2a71317f6eea40f7b6476ead84dae594_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic78b5c6c0e794855951b9ce333c34e4d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ino:CEPIMERSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if01705c616d24d9da3e0014282dd5837_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i85a901e2e495476b83006c89b06314cf_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6d5a02ab98d44b87a3c2fe66c95e090a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i677b7c07452f40d7bb6f5a339c25fa59_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i05af6b16800c4f969cf22fdff24b2acd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d52f8c0138d4608b9e0be15696a4efd_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:AdvaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:ApolloBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia2001c79602b4f5b85e822a75b982b64_D20180411-20180411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-11</startDate>
            <endDate>2018-04-11</endDate>
        </period>
    </context>
    <context id="i90b72b34cbaa4c96b0e773c47a774b68_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iea847db8af964a5a95a30170013066a4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8e1c6e230bbb4305a74e7bd299517f02_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i624d921570e54646b679bccfad2456ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19d08d5f004243748735e0364a7ac6f0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:LassaFeverAndMERSVaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5dd47e2e24e8451fbedb25fb61279123_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="ic6e68fd9d7034356a5daff34bafca427_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i6fb8532210c34bb3b02229812e1d6ccf_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i59d6c481f47d4e698f05a3589d8d4a5f_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:INO4800Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i82d467a9444a402eab652428f5f340aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i953055247fb0438694e88e83fe092f34_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e7ae79d83454d1a94162dfaaf181c92_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0972fde3981d46cb86a06b579ea816d4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i526c4d9267ea40f59d929793e9e609e6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:CoalitionforEpidemicPreparednessInnovationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:SARSCoV2COVID19VaccineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i650513b7b0b042eba217f78ede5cb81f_D20181001-20181031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="i743b9e9db9bf47abb1bdc985839a7e95_D20190801-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i5fd06dc6be4e490f8fbf48221de75ab1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i93c96775125a4f49bee81002302c8881_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0fb85cb9a30245a59734675d97301f64_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0715a0fcc3914e2c86a2471c1d0415ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2137a35c3759425c9f6105f0eb18daad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:DNAEncodedMonoclonalAntibodyTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ife18dab7106f4cfab95e7efa34dda590_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i83eec1d80cf54e79a405e0ac8c7c3446_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia5c86a87fced4537bffa81e5585402dd_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id3e8f8ce3eb145728468142b2b4b4151_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ef3b95e79d94359931733a1d9c874ae_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ib87dc46031834cbabb9a823d652b3f5f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibdb55475f21c4c86a9e26fd186d37d72_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idd5f4f4bdca146dda0cf7316b5eddc03_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0a8536568e6643a3826b271bb765d299_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ino:CELLECTRA3PSPProprietarySmartDeviceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i115835ccef2c4c728f65ff50b203bbd4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieed26bae30344c0d930f02e46a10d2c3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i045659d16234450a8682a7768426647b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:DepartmentOfDefenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6069d61346224762a4acb6d0319cd34b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8c404065aa374228af041779ee4cc690_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i394eb6bee034494f9c9496c6ce256993_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i00707a03b34c4fcbbec4fec91c975908_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ibe96ffbd0e984b259b36f75c11046687_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib38202672cc64d6990a3e920cb9cc97e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1224aeba242c41d5ab7db7226ed80399_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id37d05cb9f5d42caa6e09898a3f84573_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3fca8c2d78840729b4acd29bd42d46b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if8231f8423e648e3831733a20c3b6e00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie753e892040f46cfa5eaaf24a0aa310d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5b2add8fd23e494f887f27eb874b2134_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib18c28bf3960424a854d14b13675393f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i93622c19682e47a18bd389447a17beb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d28cb507a504198a57d5181ce08ac8f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib904a495e82646c380154c25b095b55a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i07066c0990e24538bc05caed189f78fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3648b2d58fe42268eae0877934e1081_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b37d006f03d47b3b8e7c0a1873c00f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb9dfd820dc743fda9f61d926e90be25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc86246d2a124c419654fa1e9bf8dc32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86004616beac41238cc173e85e423ddf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i477c90290ae74d219ed8ba9ff7390f90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0dc9d150f733431f97498d614ee4a8db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i186cb4d8d2d24f43bf75c63e229647ae_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i619f71a84cc54c479c772df5eeaf3bb8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i01197e4e2ce54a9f9c6f4e01fa548a46_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72d5d82697444dd38fb5e557609c0c36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c8775bf17fa47f3b938211c08019c26_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d1f385cc4944c44a2038acebc25f9cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9de6860abc2a4ad68642fef0b295cbfb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i48fb0a0d192947be932e34702459a178_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4be9cf58cb4a4d05880ed751b4f5ec5b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84830cf68b7443bca9c062e649dd83d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">ino:MutualFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37194e785fbe427fa670a663c8578ab1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib7e279598e344efcb34f380149832910_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49986e2e16ef472cb8df7bab0e9e2546_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3867bd2a43024f87bb44709b985fcf7d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06eace206e6e4294aa395dafbbaf4688_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fceb1189d5448b79ca2bbb77264e050_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i23d3f92702014f969ac3d1af800214f7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f4ae7cd847f4617951fb8ff3f3100f1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ffb3a787b3b45cd813aa7b2f5ed87b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd4592471329482e8c0661f6abdb0594_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i936b53682ed8485d8ce3260a62f5541a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2013fc31e88d4b0bb859d16c236f4634_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0608f84c1ca4f2990271fa5a4b1c79b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i91447d855fe3401ebf5c16b61ccf4a0f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0971090c3254e23a37a6a1c85cbf09d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i176930b6d6c643fa8db9ce1084359b5d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28e0a92a960d49f88d849ddf682a08b5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67083206a9594573bb4dbe4cb68aa3af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i49b293969cc040c983dd1f2e97563558_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if6c675487b97442eb5c6a91aff241fcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3448daba76f24eb6a3f805c849575a5e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d198f1f030e444294b8ea36f6116b09_I20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="i77a209b559d5422f82009bd955139f3d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7b1117d2331b42a9a95485f3c02170c5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3b6b301ab495414cb544cfeec3509fd4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i482ffaf143e145b29a6c013341ec65b1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia8a8f742a37148a19cfc04478fa8b852_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4852db4bcad84553977888af623d132e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i373cde7a8abc406eb292a0ab2cbe85ec_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7e0234d350c34dfeac832494bdf5206c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i77ea35c5c90b42d78cff73917a5896b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id3891a2d892d444ab2b6d75d1e90d526_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1443f3e411954434acd4f1bcdb1ca5a3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie89ddab5935542b39c5b4ea28140cb13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i24e8db3eab40498a818ac04516b22b71_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ino:BiojectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e498a11c93d46d08d441fc1e554b563_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iedaf8cf0acdd46ffa0621f524655250d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib41ca5add1234f08a9091fcbd9f51b00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87ff63586a45468dad886c18594fa0da_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99b74bae4f344e8cbf89dd04418411bf_I20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-01</instant>
        </period>
    </context>
    <context id="i7bbe89ce4a474b04b398872bd94f43bc_D20190219-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-19</startDate>
            <endDate>2019-03-01</endDate>
        </period>
    </context>
    <context id="ibda181353d814282bfd46ddc089e9aed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1242ebcd358e4468bb5a2b7b601e0e98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i063303991a5041809d8211c86ef7e0d7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i316205765748470e9cebde8ab78a5ae1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1b8ef7a9972a45d68c3268ee6c9acbc2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:A6.50ConvertibleSeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-26</instant>
        </period>
    </context>
    <context id="i189926960d2b4b1c89848491c1ce2245_D20191226-20191226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-26</startDate>
            <endDate>2019-12-26</endDate>
        </period>
    </context>
    <context id="i11da8ee96782442db68b426be9a9c645_D20210317-20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="i7044f94f6dec495687d4bb1d5e39219b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5f47b0a510ab4c979a96d6c6c04992e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ino:December2019ConvertibleBondsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i29af49ccbb494cac8290ea49a3d605f0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i665787c5dd50498ba18daa109d1fa1ce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i36e51ec971e349c587d471174bf94e10_D20211109-20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-09</startDate>
            <endDate>2021-11-09</endDate>
        </period>
    </context>
    <context id="i2fca5b2439d74d788e0d439a6f383003_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3109c39c7dfe480a826f059e43510271_D20210125-20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-25</startDate>
            <endDate>2021-01-25</endDate>
        </period>
    </context>
    <context id="i256486c034e74959bea28a09407f168f_I20210125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ino:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-25</instant>
        </period>
    </context>
    <context id="i95c79bb8b10c435bb78e5dfe4b84d8d3_I20160513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-13</instant>
        </period>
    </context>
    <context id="i333db47ca7594db8809bb340e9af167b_I20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="ieaecf1d1bad04443b82d7b4be5e89ad5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4bb1b79238d54150bdfc9c781bd5fc1b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2016IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i36807b22af264de2a3e9c80926cea5b8_I20220624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-24</instant>
        </period>
    </context>
    <context id="i6a0cabe1550b4ee2905d7e3e21009431_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2022InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae9a3aca7b5e4544b7ec63dc9e3b7fdf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i10ba30993b07407997027cb283263b45_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ino:A2007IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idf2749e9d9094ef991e679e1b9cc83fe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0768a9275ad64e93b52e47eba8d93b74_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i1455c9a790944d63a8c0009471f82bcb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5b4f24c6cfc0434db99f876f8856c535_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i107f49b9f6cb4502ac08563229ac6d5f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ide5ec322e22c4863b4ec3beac0c62440_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4f6468c1ea34497783cc0f8b7387f0fb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifc1288bd631248f7b04452e9589385b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ce9a943aa164c8c8f02796513f3578c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifdb2a873738e472696885e376b3e567b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i10ced5af10f440b0bebf5936fd97f874_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibcb4a7e1962b43df901c999bf8eb65ec_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ieb960975b9964654908d00a526851994_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i432ab502425b494c81d8825eac83ad96_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i87e0aa1271764f94a354dfcb830960c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id8bf9009e8e749869810035ae3b924e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iabc9a82ce6304c689c1c2e03e7569363_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iefc5ac42f1b746c1aebd94bf8240f755_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ino:RangeOfExercisePricesSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0bfc9c5f8ce490dac127867d5e5bd45_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5f047558dce94087b1f897876f14e1f3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ino:FormerPresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d81dec2251d43bc8eec87ebd45ccbbe_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:SanDiegoCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if9eb27232eb94ef4b6dc9ca0783ab193_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">ino:PlymouthMeetingPennsylvaniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i850961a8bdd6418e89855c3fe22af042_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e5bfcb200d2499cbfc64d230771e3f2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib9df2365f9454744b557f8f6b5aa3936_I20210309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-09</instant>
        </period>
    </context>
    <context id="i84820f5d4e9a4ac2a3cac63e01a7c45c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if12b9cf6eeaa4f20aa6799810ad465db_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:CaliforniaIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i650dedeab35546edb17b1d6256119449_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:PennsylvaniaStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icfaee2d1c32b4607a08c7c73282b04f4_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic954d78339b94180a278d80e6ec99f23_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ino:KoreanStateIncomeTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i071ac54a560b456dab72ccae0e2af24a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72c37010c9d245c2a4349d20fc492085_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d82d3ec063a42378ab880fcb038f565_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbb0e730795e49dd91d896275f2661e3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2be958cfc18849ac8a625b235decac6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1c5b7985c2de404f91adb16157f71c16_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i20e06ec8473a49698ac1e8cad9679f61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i817aab3e5a42474f970fce9fc4e1a2fa_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:PlumblineLifeSciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7448c2b34ba40ff87e0d9cf69208bc4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i957537cf7fde4f90a792a8cc73b50b9c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie6b5e86588ce4204ad22f6367761229d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i64432e8f98434affba895ba9830ae610_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70087078e10b48ae9664922295bdecd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:PLSaffiliatedentityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib8718060c67641f5a4518ae2471cec53_D20160301-20160331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-31</endDate>
        </period>
    </context>
    <context id="ia687677e1a354cffa7a0cefe22646f85_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i566a6c987fa446498049b5aff48c2020_D20161101-20161130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-11-01</startDate>
            <endDate>2016-11-30</endDate>
        </period>
    </context>
    <context id="ia0abccea943c4509ba78bb57e68e1da5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibb7ba3207c4249c49792d6993d00f3d2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib65f278575cc40f2a1b542d1f3241a97_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e671e6067184545b7d91d89a7ca3096_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4c216752c5f4440ea912be5dd36dbc5c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b843063dda44b569897c0fcac97eea1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ino:TheWistarInstituteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4aaa62817594ece850f89f4ae127ddf_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i44df340754904d60b387ac967f2fee31_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i15e530f73df34c398e566264b204a2d4_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="i560af3a39c4c40d3874fed14c6721a9f_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ic7f0c3c89e134e6891c4524576f4fe89_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i876fc07681a44ee487cf4e512393be2a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i312c32046c954040884f45e992037d33_D20200601-20200601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i69253dc5f01644e79d35a7205adbc9bd_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ia6407ce5393843909b745480c6ca2554_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="ibb50f5b639ee412d94255ce7d570a547_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if32e8f4ea58f4ce98e067ea7e1754cba_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6c7c8026b35043069ab11881210ac603_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i270dcf1d2c4b423d889baab7dc6a12bc_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9b0650a02db7416e902fd5464a19fe1b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i53479a023482480fa55a43efd0b59aab_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesAOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib1281c7cd4bf4b6394985b10e622fc01_I20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i610a9153ce62445cb06cc24f93ac3001_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i523a6b123f304bd09e5c0ae91b9adde5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ino:GeneosTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i988b6f75b9e6460c956d40049e2a8e51_D20220301-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2572a2fffba544ef9e41966fc1155177_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i98148ffac5c843dab35c796318d95e41_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic8c7588fc83b4e679b3d9caf40ad0d04_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i339d243acc4a4538ae743f7ea71e863b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ino:SeriesA2OnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-31</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="if1a9994a0e9c42d682a6382e17a889cd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1b1cb2986d5240299edf1d6dd0ab9f19_I20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="ife5c59f2516940b1ba2ee6b6fca25969_D20230201-20230228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001055726</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ino:McDermidVInovioPharmaceuticalsIncAndJJosephKimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ino:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="position">
        <measure>ino:position</measure>
    </unit>
    <unit id="day">
        <measure>ino:day</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="agreement">
        <measure>ino:agreement</measure>
    </unit>
    <unit id="employee">
        <measure>ino:employee</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N180LTEtMS0xLTQ5ODI4_b9716ae4-dfeb-46d7-a56f-cd66648ab15b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N182LTEtMS0xLTQ5ODI4_0fdfed36-a2bd-416f-9772-c74b20717e1b">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N183LTEtMS0xLTQ5ODI4_82035183-9a8a-4b72-aeec-6b72050aad3f">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF80L2ZyYWc6ZDhiYzY3ZTM3OTQwNGE5NGJlNzRhODdhN2U2MWVhMDIvdGFibGU6YmYxNGUwZDgzNjI1NDU4MGI5YWMxMmUxMDczNThhNTcvdGFibGVyYW5nZTpiZjE0ZTBkODM2MjU0NTgwYjlhYzEyZTEwNzM1OGE1N185LTEtMS0xLTQ5ODI4_f24b663c-fd71-48ca-bb55-c55839a2d05d">0001055726</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy0wLTEtMS01MDQxMQ_8a092680-f934-40f5-bab2-8b87b0b9ccf7">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6a09be2c6e5c4d808f21c4869c433b68_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i6a09be2c6e5c4d808f21c4869c433b68_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i7bbe89ce4a474b04b398872bd94f43bc_D20190219-20190228"
      decimals="7"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjMvZnJhZzo2ZDZmY2FhZmI2M2M0MDlkOGExMmFiOGY3ZWYzYWRkMy90YWJsZTpmZDgyN2IxNDJiYzU0YmQxYjQ2N2M5MWJkOTJmOTczYS90YWJsZXJhbmdlOmZkODI3YjE0MmJjNTRiZDFiNDY3YzkxYmQ5MmY5NzNhXzItMS0xLTEtNDk4Mjg_2686e1ba-ee3e-41e9-8714-58f98394d693"
      unitRef="number">0.1858045</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash
      contextRef="i5f047558dce94087b1f897876f14e1f3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjE3L2ZyYWc6ZDY2NGU5YzdjMjRjNDE3YmExYzExYzM0ZjAzZTJmMzIvdGV4dHJlZ2lvbjpkNjY0ZTljN2MyNGM0MTdiYTFjMTFjMzRmMDNlMmYzMl85ODk1NjA0NjQ5OTkx_ae0a3ea2-2ea2-4a7a-97c8-36d404e7d3f2"
      unitRef="number">0.50</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash>
    <dei:DocumentType
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI5_20eb05e5-8e85-4bcd-bba7-9968f435e9fe">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6YmNlZjUxNzllNDFiNDQzYWI2MDMwZmZiMmMzZmMzNGYvdGFibGVyYW5nZTpiY2VmNTE3OWU0MWI0NDNhYjYwMzBmZmIyYzNmYzM0Zl8wLTAtMS0xLTQ5ODI4_d7c4d15f-42ae-4755-b05e-dbba1690743d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8xMjQ_6f719939-fe1f-478f-9251-381ea99466a7">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8xMjQ_b27b99ab-c232-4484-9746-d1ccaf5c59ea">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZDdjM2MwNjdiM2JhNDY0MmJlNTM1YmJkNzYxYTc4MDIvdGFibGVyYW5nZTpkN2MzYzA2N2IzYmE0NjQyYmU1MzViYmQ3NjFhNzgwMl8wLTAtMS0xLTQ5ODI4_e90f4e8f-d378-4eb4-af65-e1bf5e2bd191">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIz_0c004c70-2dcc-4383-b975-f2afbc4d8563">001-14888</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDMw_846ff1c3-7c2f-41e7-a6a4-432ba562bb91">INOVIO PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18wLTAtMS0xLTQ5ODI4_37f41a45-10f9-4118-926d-11cf759a17f7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18wLTItMS0xLTQ5ODI4_d4943833-51f4-461f-9f27-037ccc16073e">33-0969592</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfNA_010c30b0-2dd5-4190-a7c8-7ee2c730b259">660 W. Germantown Pike</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfOA_218d6cac-71d8-4dcd-8767-6df8068e1276">Suite 110</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfMTE_6e58c372-d816-47ec-8731-e0f501d1138a">Plymouth Meeting</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTAtMS0xLTQ5ODI4L3RleHRyZWdpb246Yjc5MDk1ODg5NDY5NDVhMjkyYjM1ZDgyZGQ1MWNlYTJfMTU_c4d5d95b-3cce-4f1a-98f8-a5d83c795c7f">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ODRjZjRiMDYwZWU5NGRmMzk4OTZiNDAyMmJjOWIzNjcvdGFibGVyYW5nZTo4NGNmNGIwNjBlZTk0ZGYzOTg5NmI0MDIyYmM5YjM2N18zLTItMS0xLTQ5ODI4_ef284de3-cfbe-4213-a324-bdb5604d96b8">19462</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI0_e2db9a3a-6e25-452c-a576-8fccd2999142">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI1_9b2c64c1-f1b1-4e2b-9c52-c1f31595bb77">440-4200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6Nzg3OGU1MzJjYmU2NDgxMDk3MmZlMzUzYmEyNDg1NTkvdGFibGVyYW5nZTo3ODc4ZTUzMmNiZTY0ODEwOTcyZmUzNTNiYTI0ODU1OV8xLTAtMS0xLTQ5ODI4_e8cba96d-62d3-43dd-b7a0-b15d402bda46">COMMON STOCK, $0.001 PAR VALUE</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6Nzg3OGU1MzJjYmU2NDgxMDk3MmZlMzUzYmEyNDg1NTkvdGFibGVyYW5nZTo3ODc4ZTUzMmNiZTY0ODEwOTcyZmUzNTNiYTI0ODU1OV8xLTEtMS0xLTQ5ODI4_d626b998-2978-4e19-9fbe-75b4602b1194">INO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6Nzg3OGU1MzJjYmU2NDgxMDk3MmZlMzUzYmEyNDg1NTkvdGFibGVyYW5nZTo3ODc4ZTUzMmNiZTY0ODEwOTcyZmUzNTNiYTI0ODU1OV8xLTItMS0xLTQ5ODI4_c1c80e8c-a87e-4d4f-a171-705160f47ad9">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV85ODk1NjA0NjU0NDgx_492936d3-9a6a-4c76-a913-e4cc1659d5ac">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI2_740d9940-baac-40de-885f-9598758c69e1">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDI3_f5d167f1-e314-4717-97a6-2fe9a91b2ba8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIw_8b731d02-e78b-40ca-9c78-c6872089a281">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZjQwMzU4ZjExMGZkNGRiMGE2NmI3OTc4MDZhZmI3NWEvdGFibGVyYW5nZTpmNDAzNThmMTEwZmQ0ZGIwYTY2Yjc5NzgwNmFmYjc1YV8zLTAtMS0xLTYwMzYz_0d3e85cb-6f16-4316-9e96-3f502a8a3a32">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZjQwMzU4ZjExMGZkNGRiMGE2NmI3OTc4MDZhZmI3NWEvdGFibGVyYW5nZTpmNDAzNThmMTEwZmQ0ZGIwYTY2Yjc5NzgwNmFmYjc1YV8zLTQtMS0xLTQ5ODI4_f11fd50d-1a2d-4998-a5d5-1ba2fc96e7c7">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGFibGU6ZjQwMzU4ZjExMGZkNGRiMGE2NmI3OTc4MDZhZmI3NWEvdGFibGVyYW5nZTpmNDAzNThmMTEwZmQ0ZGIwYTY2Yjc5NzgwNmFmYjc1YV80LTQtMS0xLTYwMzYx_e1d9330b-7181-4a5e-a63b-990e33b6c5d1">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIx_ba6f5bdb-55a5-4310-ae35-2a5aa1667877">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8xMDk5NTExNjMyMjY4_b908d060-314d-48e3-94a7-88d27cb9e970">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i34f3ee93005e44e4818bc81e3c428fc3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8yNzQ1_e28e81e5-b6ed-4f2b-a893-e9ba580009fe"
      unitRef="usd">425500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i68aed334af06455c9f43334dc07c928f_I20230224"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8yOTYw_244b464a-c665-4e85-9808-614540584f63"
      unitRef="shares">260131986</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xL2ZyYWc6NTEwZjc4Y2ZhZmRhNGFhYWJkZmE0OWNjMDM3M2QyNzEvdGV4dHJlZ2lvbjo1MTBmNzhjZmFmZGE0YWFhYmRmYTQ5Y2MwMzczZDI3MV8zNDIy_e29300bf-0c8c-4fc7-b435-72097de1238c">&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed with the Commission pursuant to Regulation&#160;14A in connection with the registrant&#x2019;s 2023 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x2019;) are incorporated by reference into Part&#160;III of this Report. Such Proxy Statement will be filed with the Commission not later than 120&#160;days after the conclusion of the registrant&#x2019;s fiscal year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTIvZnJhZzozZjExNTIwM2EwMDk0YTE4ODFhMDJlN2UwZTA1Zjc5Ny90YWJsZTo5MDcxMmM2YTkzMDg0NjIzOGE2NzgxZTM2ODIyNDc2Ni90YWJsZXJhbmdlOjkwNzEyYzZhOTMwODQ2MjM4YTY3ODFlMzY4MjI0NzY2XzEtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmZGE2NTA3NDczMmY0YmQ2YTYyZWEyNWQ1ZWUxMDkwM183MQ_34873fca-f2c6-4952-b19b-e95b74a066cb">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTUvZnJhZzo3NzgxZGQ4ODA5MWI0NzA5YWE1NTgzZGE0NTA5M2I3Ny90YWJsZTo1Mjg3ODUyN2Y1ZjY0ZGZkODI0ZTZhNzEyODU0ZDlmZS90YWJsZXJhbmdlOjUyODc4NTI3ZjVmNjRkZmQ4MjRlNmE3MTI4NTRkOWZlXzAtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjoyZmFkYzZlODkxNGU0M2ZkYTg5ZDVkYjQ4NzZhMzgzOF84_c4191747-dae1-4d75-bf7b-94d6fe9f31fe">Ernst&#160;&amp; Young&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTUvZnJhZzo3NzgxZGQ4ODA5MWI0NzA5YWE1NTgzZGE0NTA5M2I3Ny90YWJsZTo1Mjg3ODUyN2Y1ZjY0ZGZkODI0ZTZhNzEyODU0ZDlmZS90YWJsZXJhbmdlOjUyODc4NTI3ZjVmNjRkZmQ4MjRlNmE3MTI4NTRkOWZlXzMtMC0xLTEtNDk4Mjg_0ef37232-a434-4d2f-81aa-a9630030a2ce">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQtMS0xLTEtNDk4Mjg_c8082895-42cd-4756-ba78-87dec6f318ca"
      unitRef="usd">46329359</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQtMy0xLTEtNDk4Mjg_4a5dc3f2-9dee-4cf5-9c62-d91b81298d66"
      unitRef="usd">71143778</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUtMS0xLTEtNDk4Mjg_dc77be86-dff5-43dd-b475-28b9aa14f96e"
      unitRef="usd">206669397</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUtMy0xLTEtNDk4Mjg_876d739a-368b-4275-9253-d795fa5a6757"
      unitRef="usd">330170940</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzYtMS0xLTEtNDk4Mjg_4ea6af40-5770-4124-8d86-7c2857603496"
      unitRef="usd">1701726</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzYtMy0xLTEtNDk4Mjg_ed519a5d-c90f-46b2-b985-4fad0382a84d"
      unitRef="usd">5466850</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzctMS0xLTEtNDk4Mjg_0f3eb9ec-27b9-4b5a-b20a-be5d6bbf744b"
      unitRef="usd">10036490</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzctMy0xLTEtNDk4Mjg_7661a919-b5fa-4dd8-a88f-fe30225aaa67"
      unitRef="usd">2565194</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzgtMS0xLTEtNDk4Mjg_9305df2b-c844-4dfb-9d5a-38a5bc822c9f"
      unitRef="usd">50130481</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzgtMy0xLTEtNDk4Mjg_1fb4e562-dae2-41a5-8793-4d931d76a21e"
      unitRef="usd">38836991</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzktMS0xLTEtNDk4Mjg_dd911609-0bc6-4a3f-8d3f-a6ee9532e8d4"
      unitRef="usd">375227</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzktMy0xLTEtNDk4Mjg_40442027-ae0b-403d-a37b-a092d7786e35"
      unitRef="usd">261192</ino:PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity>
    <us-gaap:AssetsCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzExLTEtMS0xLTQ5ODI4_790194d3-ada0-4194-a7dc-92d019370b93"
      unitRef="usd">315242680</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzExLTMtMS0xLTQ5ODI4_0c1b2f81-ec6c-4469-b482-d51207d148a0"
      unitRef="usd">448444945</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzEzLTEtMS0xLTQ5ODI4_59d76d5a-f7bd-452a-a926-fe993483682d"
      unitRef="usd">7727997</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzEzLTMtMS0xLTQ5ODI4_41f3d143-d4bc-4625-bf50-1e1e26015b97"
      unitRef="usd">17453206</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE0LTEtMS0xLTQ5ODI4_3bef2783-dad7-4022-8453-18bb37dbe538"
      unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE0LTMtMS0xLTQ5ODI4_df2c732d-4e68-4b3c-95dc-a12730fdb9f1"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE2LTEtMS0xLTQ5ODI4_d4fd1dc7-991b-4890-9bbf-485ca8b49597"
      unitRef="usd">2129861</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE2LTMtMS0xLTQ5ODI4_03d52296-651b-4ee2-b22d-0137b072dfa3"
      unitRef="usd">2626355</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE3LTEtMS0xLTQ5ODI4_4cee51c5-06d8-4073-8dea-45e26b97447e"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE3LTMtMS0xLTQ5ODI4_cec4320c-5e95-4614-b236-e9ce131af478"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE4LTEtMS0xLTQ5ODI4_178cbb2f-1bb5-4a6a-987d-25dd19c14aaf"
      unitRef="usd">10228207</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE4LTMtMS0xLTQ5ODI4_b7b5898e-7545-4643-938f-c9a2f52fe9c6"
      unitRef="usd">11571026</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE5LTEtMS0xLTQ5ODI4_73857de9-f551-4aba-b347-a99bd6eabd20"
      unitRef="usd">684044</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzE5LTMtMS0xLTQ5ODI4_ddf4bab0-0e09-4996-a34d-99d9b3641af2"
      unitRef="usd">1425794</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIwLTEtMS0xLTQ5ODI4_1c34be04-4bc5-4152-aca9-14735a28e39a"
      unitRef="usd">348533302</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIwLTMtMS0xLTQ5ODI4_ceb0870e-50b8-4c2a-a8db-4242475b1a63"
      unitRef="usd">495941493</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIzLTEtMS0xLTQ5ODI4_9f853293-54ea-43c7-b727-72dc373e8647"
      unitRef="usd">79686885</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzIzLTMtMS0xLTQ5ODI4_db96d59b-0489-4b91-91be-6fc9df401bb6"
      unitRef="usd">47644530</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI0LTEtMS0xLTQ5ODI4_c7cb83aa-c919-40f8-8518-d9d5f6fa1590"
      unitRef="usd">1220439</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI0LTMtMS0xLTQ5ODI4_67d7385e-94dd-4a61-bef2-744bfd78f20e"
      unitRef="usd">548032</us-gaap:DueToRelatedPartiesCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI1LTEtMS0xLTQ5ODI4_6baf465f-6a5e-4907-a43f-9cca8e1e5783"
      unitRef="usd">10594073</ino:AccruedClinicalTrialExpenseCurrent>
    <ino:AccruedClinicalTrialExpenseCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI1LTMtMS0xLTQ5ODI4_4cfba382-acd6-409c-b754-6d96696222a1"
      unitRef="usd">10326266</ino:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI2LTEtMS0xLTQ5ODI4_f99cfa65-bb1b-4aa0-98f2-a3248aa7332e"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI2LTMtMS0xLTQ5ODI4_2318a6d8-ef75-40a9-a7e7-d392d2fb593f"
      unitRef="usd">21628</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI5LTEtMS0xLTQ5ODI4_c24dd478-12c4-419b-b9c2-0f54710667e3"
      unitRef="usd">2803973</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzI5LTMtMS0xLTQ5ODI4_53386a9c-e92f-495e-9d02-6bfeec438a25"
      unitRef="usd">2603956</us-gaap:OperatingLeaseLiabilityCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMwLTEtMS0xLTQ5ODI4_abda950d-9fdd-4124-bb9f-4ac8622cb387"
      unitRef="usd">2475031</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMwLTMtMS0xLTQ5ODI4_d550d8ae-cc8d-44e3-892b-8be5e0c5d19c"
      unitRef="usd">4559721</ino:DeferredGrantFundingCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMxLTEtMS0xLTQ5ODI4_38f3e88d-4425-4611-98c2-e21c64bdd7ce"
      unitRef="usd">87673</ino:DeferredGrantFundingFromAffiliateCurrent>
    <ino:DeferredGrantFundingFromAffiliateCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMxLTMtMS0xLTQ5ODI4_f99a8500-619c-4d58-a162-7b6e1c810c0c"
      unitRef="usd">37500</ino:DeferredGrantFundingFromAffiliateCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMyLTEtMS0xLTQ5ODI4_e55b6969-ae3b-4aa7-b786-b77ce92285a4"
      unitRef="usd">96868074</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMyLTMtMS0xLTQ5ODI4_ebf6d47e-dd4c-45fa-83af-c782e8057a97"
      unitRef="usd">65741633</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMzLTEtMS0xLTQ5ODI4_a38fd2c7-7563-4680-98e3-de5718f1b2a0"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzMzLTMtMS0xLTQ5ODI4_c35c28ea-0dae-4da8-bd95-b9228c6837ec"
      unitRef="usd">64361</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ConvertibleDebt
      contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzM1LTEtMS0xLTQ5ODI4_d9dde24f-bf4c-4a66-8b83-1c3f82ae288c"
      unitRef="usd">16614840</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebt
      contextRef="i28fdf7ad489d4fce8f004f820b342526_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzM1LTMtMS0xLTQ5ODI4_965cd22a-a10e-41a5-baea-5bbbc31a1ba2"
      unitRef="usd">14959647</us-gaap:ConvertibleDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQwLTEtMS0xLTQ5ODI4_f74bdbc3-3758-4d2e-ad3e-c7e77bc3fbb0"
      unitRef="usd">12655586</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQwLTMtMS0xLTQ5ODI4_e0ae24a9-7185-4024-947c-07e9bf5fe71f"
      unitRef="usd">15459559</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQxLTEtMS0xLTQ5ODI4_ac63f78f-1b55-4309-bb67-fdc435645a7c"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQxLTMtMS0xLTQ5ODI4_4daa5e7b-8459-4aa6-8ccb-1a61db4d391d"
      unitRef="usd">32046</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQzLTEtMS0xLTQ5ODI4_9bfa8908-5b41-4f7d-8f3c-71bcfe4416f1"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQzLTMtMS0xLTQ5ODI4_a5792fa8-4554-45cb-9393-d0bbcbefa2a1"
      unitRef="usd">14826</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ0LTEtMS0xLTQ5ODI4_af06df78-13d0-41d4-a9df-cbc405c13364"
      unitRef="usd">126170546</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ0LTMtMS0xLTQ5ODI4_748a7910-84b5-465e-ab00-a683f9e2fa5e"
      unitRef="usd">96272072</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ1LTEtMS0xLTQ5ODI4_be41e7d3-351a-4bbd-b4f6-a6a69e79ea27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ1LTMtMS0xLTQ5ODI4_19327a90-808c-460c-a213-523ac00950bb"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfMzA_084b8abe-3eb6-4748-8897-5c1581753291"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfMzA_4f27ec57-466c-44ea-800a-caff131d0cc1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfNTM_06153425-1042-4778-acc8-fb06af83c28e"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfNTM_d28432e6-bc63-412a-a782-94c02266438b"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_00bfdd30-1eee-4935-8ca9-a91f15a7c507"
      unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_e65cd6c5-3550-4217-b5db-e9d5ceb9bc3b"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_f0043209-b6f9-444b-b417-668e3403e866"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246NmJkNTQ2MGU4NmIyNDYyZjk4NTQ3Mzg3ZjkwZTZhZjJfODg_f22b2c37-ab84-4c1d-9f23-24ccfacf28f4"
      unitRef="shares">9</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTEtMS0xLTQ5ODI4_2128af53-895d-4483-ad53-824612f6e3ac"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ3LTMtMS0xLTQ5ODI4_f189feaf-f1ba-433e-933f-fa01ecc157b9"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMjc_0f44bad0-fdce-4746-b092-ea70a3062fa2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMjc_b0dbc841-7623-4e94-a53f-91d5a374df92"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfNTA_525ffb8c-0fc7-4f1f-b5cc-fe3295ba3cf9"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfNTA_ea8d0bc4-952e-478a-a1e1-6a3e1c65647b"
      unitRef="shares">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTA4_245f099f-ec82-4040-99c3-b745c9a23667"
      unitRef="shares">253091319</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTA4_ad72fc5f-2315-42f4-b23f-c8aae75a46e7"
      unitRef="shares">253091319</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTM2_59ffc067-85f2-4875-b053-dbf4e2fd5275"
      unitRef="shares">217382887</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTAtMS0xLTQ5ODI4L3RleHRyZWdpb246MzdlYWMyMWQ4NjFhNDg5NTk1NTk3YzRmOWY3NzVkN2VfMTM2_eb09d194-4a3d-46b6-a6c0-1d7edb449889"
      unitRef="shares">217382887</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTEtMS0xLTQ5ODI4_e03e7961-d771-487f-a5bf-c28627c967d4"
      unitRef="usd">253090</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ4LTMtMS0xLTQ5ODI4_de8de84d-8cfd-4d72-b1a5-b4eca4fd6a64"
      unitRef="usd">217382</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ5LTEtMS0xLTQ5ODI4_0f20047a-4e1d-44b1-8d01-0b7122df76b3"
      unitRef="usd">1710656191</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzQ5LTMtMS0xLTQ5ODI4_6ddf9883-2774-4fc2-8bc4-c0b453723045"
      unitRef="usd">1609589797</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUwLTEtMS0xLTQ5ODI4_62e4b242-ed85-44a4-9e8f-de0f9dd6de6e"
      unitRef="usd">-1487847784</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUwLTMtMS0xLTQ5ODI4_ac1a87a5-4e2c-4813-9bfc-99563400951e"
      unitRef="usd">-1209855522</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUxLTEtMS0xLTQ5ODI4_522ca994-322b-42ae-a52e-7a8abadf9c40"
      unitRef="usd">-698741</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUxLTMtMS0xLTQ5ODI4_bf20707d-c271-4c90-b2fd-43f4380cb879"
      unitRef="usd">-282236</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUyLTEtMS0xLTQ5ODI4_829fb864-0db8-494d-aedc-99514f253c52"
      unitRef="usd">222362756</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzUyLTMtMS0xLTQ5ODI4_edb3a3de-80dc-427d-aef9-686d6cfde112"
      unitRef="usd">399669421</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzU1LTEtMS0xLTQ5ODI4_483d2ce3-97f7-4ba6-b992-78cad0c06840"
      unitRef="usd">348533302</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMTgvZnJhZzphODQ3ZTBiNzA1MmI0NWU4ODU1M2U1Njk5ZTRkNzUzMy90YWJsZTowYjUwY2ZkYTQ5NTI0M2IxYTFiZWE1NTVmNDgzNGVkNy90YWJsZXJhbmdlOjBiNTBjZmRhNDk1MjQzYjFhMWJlYTU1NWY0ODM0ZWQ3XzU1LTMtMS0xLTQ5ODI4_f8ac67a9-03de-4ee4-a4ea-81480e192713"
      unitRef="usd">495941493</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzktMS0xLTEtNDk4Mjg_c8a8bdd2-2c9e-47d2-8bd7-a9bf76321d7c"
      unitRef="usd">10262268</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzktMy0xLTEtNDk4Mjg_05a31d7f-8e64-417b-ac95-f297136fee68"
      unitRef="usd">1774758</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzktNS0xLTEtNDk4Mjg_e383d37e-b1af-4a9c-8848-fe160ecea811"
      unitRef="usd">7411220</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzExLTEtMS0xLTQ5ODI4_98fa0456-9aa3-4f6e-b4a2-fb233bcc074f"
      unitRef="usd">187650503</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzExLTMtMS0xLTQ5ODI4_ffc5a166-47a9-4d53-aa33-4eb7a6975e21"
      unitRef="usd">249240324</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzExLTUtMS0xLTQ5ODI4_a57548df-8518-4e19-bec1-f2067df4f425"
      unitRef="usd">94245436</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzEyLTEtMS0xLTQ5ODI4_8f596a14-4252-423b-81ac-15101c520941"
      unitRef="usd">90185285</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzEyLTMtMS0xLTQ5ODI4_9f20c840-4764-4954-88de-fe5ce236fa72"
      unitRef="usd">53752353</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzEyLTUtMS0xLTQ5ODI4_d13daed2-4c59-468c-b938-cf21b42dc23e"
      unitRef="usd">37247828</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE1LTEtMS0xLTQ5ODI4_5f483f79-2360-4fdb-9749-0dd0c7263d23"
      unitRef="usd">277835788</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE1LTMtMS0xLTQ5ODI4_1e2d3d01-641a-443f-9b6e-0be4c476d66e"
      unitRef="usd">302992677</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE1LTUtMS0xLTQ5ODI4_dcc52791-d864-436c-b90b-07a5482ae5ae"
      unitRef="usd">131493264</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE2LTEtMS0xLTQ5ODI4_19fc4305-1bf9-472f-a113-8ca3e8e7ba2e"
      unitRef="usd">-267573520</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE2LTMtMS0xLTQ5ODI4_c1bb5523-4a3e-4954-a66b-de2cfd351607"
      unitRef="usd">-301217919</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE2LTUtMS0xLTQ5ODI4_97fa2df3-e971-4ccd-be0e-4fc7917ab879"
      unitRef="usd">-124082044</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE4LTEtMS0xLTQ5ODI4_768fc702-d184-40ec-9386-ca1e6a5ca730"
      unitRef="usd">4782030</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE4LTMtMS0xLTQ5ODI4_aa7c0a69-4876-4437-8341-43493acb3af2"
      unitRef="usd">3363080</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE4LTUtMS0xLTQ5ODI4_0d5631b5-204d-46a4-9a0c-5a7e3c252337"
      unitRef="usd">3311846</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE5LTEtMS0xLTQ5ODI4_a98bf224-32eb-4f04-9901-61f4470f0d0f"
      unitRef="usd">1253952</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE5LTMtMS0xLTQ5ODI4_6e1485d9-7f2b-45d1-8f94-0dd9b4918623"
      unitRef="usd">1936447</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzE5LTUtMS0xLTQ5ODI4_6514e5b8-5066-423e-80ab-dbdf3c4234e0"
      unitRef="usd">8702450</us-gaap:InterestExpense>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIxLTEtMS0xLTQ5ODI4_80a703a0-20dd-448f-8613-047ee35546fb"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIxLTMtMS0xLTQ5ODI4_0d1a3379-f489-4d87-8ce6-ecb937b0912d"
      unitRef="usd">0</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIxLTUtMS0xLTQ5ODI4_338fccd8-60a1-4f93-9b0e-d443313e17b2"
      unitRef="usd">-75670977</us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIyLTEtMS0xLTQ5ODI4_6fb35fb7-3fa9-4fdd-a536-f9ee08eccf30"
      unitRef="usd">-1899654</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIyLTMtMS0xLTQ5ODI4_2ea27889-2dc6-40d3-9573-d59a6f034649"
      unitRef="usd">-553570</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIyLTUtMS0xLTQ5ODI4_a6ebda71-c130-41ad-94bf-1641ca73755e"
      unitRef="usd">36556658</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIzLTEtMS0xLTQ5ODI4_d88b958b-9ed0-460a-bb97-55af18d28be6"
      unitRef="usd">-7846172</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIzLTMtMS0xLTQ5ODI4_be5da5f4-b353-47ef-bbed-f50fbccd19a5"
      unitRef="usd">-3222838</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzIzLTUtMS0xLTQ5ODI4_b485e2ca-2084-4544-a0f1-fdf6be98fc67"
      unitRef="usd">1695497</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI0LTEtMS0xLTQ5ODI4_16ad1459-8b2a-405c-86f6-7cb75423df08"
      unitRef="usd">-3861584</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI0LTMtMS0xLTQ5ODI4_8ea1bd96-8bd2-41eb-9bff-bf29c5eb11f9"
      unitRef="usd">343371</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI0LTUtMS0xLTQ5ODI4_f7b27aaa-cef1-47c2-a19e-99a18abac1a1"
      unitRef="usd">-704896</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI1LTEtMS0xLTQ5ODI4_98c413b1-5eba-409f-b842-ba76dd021a74"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI1LTMtMS0xLTQ5ODI4_e064518f-7d96-4ba9-aa5d-06d937724c2d"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI1LTUtMS0xLTQ5ODI4_eab95407-55d0-4307-953d-080eb269314a"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i8c2c1a9b72144f0a92349e7cf9e5a446_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI2LTEtMS0xLTQ5ODI4_440df533-9a0e-4dba-8ec1-46449d925fa1"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie31c91acde4741fe900e7a84f2b0ad34_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI2LTMtMS0xLTQ5ODI4_b60ad391-c69a-4835-b8df-a956780a171a"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i46ecffdec9a64e498429f8977ea52114_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI2LTUtMS0xLTQ5ODI4_831c96dd-8eb7-4d10-abd5-ad11fc805a39"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e3a7a0113a6439694f0af4a15e4c7dc_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI3LTEtMS0xLTQ5ODI4_306fb038-e1dd-422d-896d-e6b943740010"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idae06434a74c4378bb8e66fbb38683a8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI3LTMtMS0xLTQ5ODI4_3d1accbd-edf6-48a6-a228-eb3587e7b142"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI3LTUtMS0xLTQ5ODI4_c7176b8a-2c16-4ffc-a931-dbe20ba031ef"
      unitRef="usd">8762030</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI4LTEtMS0xLTQ5ODI4_90021400-01ad-4d21-a9bb-3a6c105da58c"
      unitRef="usd">-277652852</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI4LTMtMS0xLTQ5ODI4_704f1675-a083-4d2a-8a0d-a539d0081636"
      unitRef="usd">-303224323</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzI4LTUtMS0xLTQ5ODI4_66ff74c4-f3ae-424c-a07d-5faabdf53308"
      unitRef="usd">-162890304</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMwLTEtMS0xLTQ5ODI4_24985add-2cfc-43b3-a4d8-222141372959"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMwLTMtMS0xLTQ5ODI4_1a89afce-d42c-48c2-9802-02aa759c7ba6"
      unitRef="usd">-434387</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMwLTUtMS0xLTQ5ODI4_4de3f94e-f200-45c9-82c8-7289c7db7730"
      unitRef="usd">-4584610</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:ProfitLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMxLTEtMS0xLTQ5ODI4_fd05bbb7-13f0-453d-9ca4-a130866ed2f1"
      unitRef="usd">-279818065</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMxLTMtMS0xLTQ5ODI4_76f0ce08-1057-41cf-b120-0ff38740d8a4"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMxLTUtMS0xLTQ5ODI4_ec104b82-7445-4183-8f1e-0d87d74d2fab"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMyLTEtMS0xLTQ5ODI4_860de164-9663-4a69-8d78-1d1727d5702d"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMyLTMtMS0xLTQ5ODI4_6a56022f-3e1a-4b2c-8070-7695c4f21ef2"
      unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMyLTUtMS0xLTQ5ODI4_dd47785d-324c-4283-a3c2-fb609b23b393"
      unitRef="usd">-1063757</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMzLTEtMS0xLTQ5ODI4_f2a7b68e-3a60-487a-8160-6c03e2d995b6"
      unitRef="usd">-279818065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMzLTMtMS0xLTQ5ODI4_cdfa73d4-549a-406b-b811-6cd919ad0405"
      unitRef="usd">-303658710</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzMzLTUtMS0xLTQ5ODI4_19e5c0dd-2c09-4b6d-ad26-2a8b80dad117"
      unitRef="usd">-166411157</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTEtMS0xLTQ5ODI4_300e9f43-2af6-460f-b1d6-6a4c6524dfab"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTEtMS0xLTQ5ODI4_7cc2c40d-0028-4a33-9c03-7797dee3a8b3"
      unitRef="usdPerShare">-1.17</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTMtMS0xLTQ5ODI4_8e0a2a3f-29d5-4eac-9938-44dc32e4675a"
      unitRef="usdPerShare">-1.45</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTMtMS0xLTQ5ODI4_e09e4fb1-7c3b-41d9-a4b7-a78da7c827a0"
      unitRef="usdPerShare">-1.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTUtMS0xLTQ5ODI4_730f99b5-44b6-4b7d-8b9d-a7593d1a84ea"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM1LTUtMS0xLTQ5ODI4_9b8a9ebd-f9cb-481f-89f2-e4422072067b"
      unitRef="usdPerShare">-1.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTEtMS0xLTQ5ODI4_839782d8-6ede-4eb7-8a93-4a2c54807d7d"
      unitRef="shares">238622188</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTEtMS0xLTQ5ODI4_8ddb2f59-67e0-4417-8f07-a923c772b228"
      unitRef="shares">238622188</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTMtMS0xLTQ5ODI4_23d6de9e-abcc-4f38-841a-331d08666c11"
      unitRef="shares">208829801</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTMtMS0xLTQ5ODI4_8f4b0058-420f-446f-ab12-a338a8a731d8"
      unitRef="shares">208829801</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTUtMS0xLTQ5ODI4_9dc57524-d3ba-459b-88c9-e8f9e8dc3c81"
      unitRef="shares">155126857</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjEvZnJhZzo4NzhmY2U2YzFjODI0NGZmYjMxM2Y0ZWNhMmFiYTNkZC90YWJsZTpkY2U0NDhhNzJkZTU0MjQ1OWY0NTQ0ZDc4OGNhMGNhMi90YWJsZXJhbmdlOmRjZTQ0OGE3MmRlNTQyNDU5ZjQ1NDRkNzg4Y2EwY2EyXzM4LTUtMS0xLTQ5ODI4_fddcb1c1-bfc7-4d28-8fe4-f9bb5293d608"
      unitRef="shares">155126857</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzItMS0xLTEtNDk4Mjg_d917662d-55d9-495a-95b2-81fb958a81b5"
      unitRef="usd">-279818065</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzItMy0xLTEtNDk4Mjg_fe479f12-f233-4f5b-a783-369786257872"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzItNS0xLTEtNDk4Mjg_59af82b0-a36f-434a-b484-a202d114fc76"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzUtMS0xLTEtNDk4Mjg_0693f379-8d26-47f5-ba3d-485901649227"
      unitRef="usd">-25556</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzUtMy0xLTEtNDk4Mjg_a085897a-6042-4768-a5ae-2123bb1d9c7f"
      unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzUtNS0xLTEtNDk4Mjg_ab561479-30f4-4421-9146-430af6f7bc93"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzYtMS0xLTEtNDk4Mjg_ac695975-80ba-4e38-abca-32a7ce292ad5"
      unitRef="usd">-390949</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzYtMy0xLTEtNDk4Mjg_5d054d2e-3e39-462e-9d2d-d200ba21c069"
      unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzYtNS0xLTEtNDk4Mjg_73024634-442a-4338-be61-eb4c999dbb6e"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzctMS0xLTEtNDk4Mjg_9914dd41-8ac8-4951-90b8-ce7b05901c35"
      unitRef="usd">-280234570</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzctMy0xLTEtNDk4Mjg_b8542b1e-cbaf-43d8-954b-ac37d1dcd2a2"
      unitRef="usd">-303684796</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzctNS0xLTEtNDk4Mjg_a6f750e3-0406-4407-b14d-c866a31d8203"
      unitRef="usd">-168203672</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzgtMS0xLTEtNDk4Mjg_fdb52f7d-c704-4bd5-b12d-73d6556a6fca"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzgtMy0xLTEtNDk4Mjg_e7ed07ae-7e97-479e-bfaa-bde9ee35c770"
      unitRef="usd">0</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzgtNS0xLTEtNDk4Mjg_646b4fd0-74c8-47bb-915e-d202a82b22bb"
      unitRef="usd">-1063757</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzktMS0xLTEtNDk4Mjg_e8f98191-4fdf-4799-86ff-93c5f292142c"
      unitRef="usd">-280234570</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzktMy0xLTEtNDk4Mjg_697b19bb-f3d5-4c38-b88f-987ded181de1"
      unitRef="usd">-303684796</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjQvZnJhZzo3NjAxNGEwYjVhOWY0OGY4ODdkZjIxMjA5Yzg4ZTJlMi90YWJsZTpjYjk1MTNlZTQyZWU0YjljOTJiZmI3YjFmZmQ4MWZhMy90YWJsZXJhbmdlOmNiOTUxM2VlNDJlZTRiOWM5MmJmYjdiMWZmZDgxZmEzXzktNS0xLTEtNDk4Mjg_0f38115a-0ca7-471d-9b72-5bd37ec056a8"
      unitRef="usd">-167139915</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i91313ea012fb4e29a82373b1216240c7_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTEtMS0xLTQ5ODI4_c5856ee2-6124-4abd-b4a1-ee65a5af2be0"
      unitRef="shares">23</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i91313ea012fb4e29a82373b1216240c7_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTMtMS0xLTQ5ODI4_af62a1a0-5c40-4ebf-b879-e702571a39d8"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="ic20b1cb6ae6442cfb1dd54c81a7d71f1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTUtMS0xLTQ5ODI4_9ab3999c-d162-4314-8980-8f3c89e622c1"
      unitRef="shares">101361034</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic20b1cb6ae6442cfb1dd54c81a7d71f1_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTctMS0xLTQ5ODI4_25f102e1-4687-40f7-9ee5-137470f3083b"
      unitRef="usd">101361</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7dc4c4c9f63349128d1754e94f5cc9e5_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTktMS0xLTQ5ODI4_ebc781d0-b7dd-42c7-9b8d-e7caaf1b3b39"
      unitRef="usd">742646785</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d6cb11719d041f090cfb6c6b041e892_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTExLTEtMS00OTgyOA_f8287650-8941-40b9-bce2-2f5637f333de"
      unitRef="usd">-739785655</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i718af9ccd104415fbf64c9d32f74bb1e_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTEzLTEtMS00OTgyOA_f56ea3e3-5c40-45fd-aae8-d43d7f314d1b"
      unitRef="usd">472608</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8942a4a67cba41659b89e7b8521ab8eb_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTE1LTEtMS00OTgyOA_c81c6b50-aad6-4bdf-a8ab-b86c995d14b0"
      unitRef="usd">1969759</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1bb91b86850c4019853cfafe96543ff8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkxLTE3LTEtMS00OTgyOA_763660b5-eadb-4d84-8479-371cfe2db3e6"
      unitRef="usd">5404858</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTUtMS0xLTQ5ODI4_ec5e6934-10c3-4463-8094-7acc5d8cd5af"
      unitRef="shares">66064886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTctMS0xLTQ5ODI4_9d0c38ff-dc50-40a3-8d21-aaa81cd32167"
      unitRef="usd">66065</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTktMS0xLTQ5ODI4_4f8f88fe-a82d-4d04-bfa0-09579edd224d"
      unitRef="usd">454420335</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkyLTE3LTEtMS00OTgyOA_0bff0151-3a01-4ec0-aa04-1cdced834aa6"
      unitRef="usd">454486400</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="iad2ce681ebaa453d8289a854900c32fa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTEtMS0xLTQ5ODI4_bcc13deb-48d8-40d3-b5cf-9800c5b408e3"
      unitRef="shares">-14</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTUtMS0xLTQ5ODI4_cc4c61f7-47b1-4d40-a798-ec13bbe6baaf"
      unitRef="shares">5147</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTctMS0xLTQ5ODI4_e88a62bf-17b8-40fa-8cab-9e51daa73dae"
      unitRef="usd">5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTktMS0xLTQ5ODI4_e88e0800-e0c7-4ad1-b00b-849762e5ec23"
      unitRef="usd">-5</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzkzLTE3LTEtMS00OTgyOA_38d89961-9521-493f-a3c9-226815674bcd"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i77f6191d42744cbe9b446139968001a6_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTUtMS0xLTQ5ODI4_69c2d66d-dc93-4019-8fc0-69562b2df9f5"
      unitRef="shares">11535660</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i77f6191d42744cbe9b446139968001a6_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTctMS0xLTQ5ODI4_df104e3a-5895-49ca-825a-05219a14722b"
      unitRef="usd">11536</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8cc077e8d5154506ba48d33c68a71bfe_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTktMS0xLTQ5ODI4_f6286daa-7531-4a4c-8152-ae3d746c19bb"
      unitRef="usd">43682850</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk0LTE3LTEtMS00OTgyOA_98fba71d-6583-4e65-b17f-93f0a32f1fed"
      unitRef="usd">43694386</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ifb9c9e86d4a54a01b3a0e8c79d8927b3_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTUtMS0xLTQ5ODI4_7670b213-8e81-4a4a-8097-27bb0c6607a8"
      unitRef="shares">4962364</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ifb9c9e86d4a54a01b3a0e8c79d8927b3_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTctMS0xLTQ5ODI4_8fa3adf2-48e8-4c75-815c-85a9287a4f29"
      unitRef="usd">4961</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i9bf7e09219084016a812c88d9977fa5a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTktMS0xLTQ5ODI4_a954e3f3-ccfd-43bb-b35b-34b1d268a33c"
      unitRef="usd">102666349</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i110d8cff3e7c4910b2e0c84f0f9c65de_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk1LTE3LTEtMS00OTgyOA_9a7bb0c8-6009-4b0f-be3f-1a096ad4cdc8"
      unitRef="usd">102671310</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTUtMS0xLTQ5ODI4_e051bbad-d926-4af9-8bc8-a9a75e94e38c"
      unitRef="shares">2922402</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i592475c74d1d4b76b8db3db1741f1008_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTctMS0xLTQ5ODI4_50ae6f4f-95bb-4f8e-bdd0-aea0a5efc6f3"
      unitRef="usd">2923</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTktMS0xLTQ5ODI4_a757625b-c9db-44de-be2b-a149e90d27ca"
      unitRef="usd">8238701</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk2LTE3LTEtMS00OTgyOA_c2bdb784-44ca-4a31-9f1a-6eae890fff59"
      unitRef="usd">8241624</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk3LTktMS0xLTQ5ODI4_02515031-58c3-49c2-9cd4-a403da09d4bd"
      unitRef="usd">15655585</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk3LTE1LTEtMS00OTgyOA_f96c2141-69a6-4982-9e09-f4617366753f"
      unitRef="usd">-8062</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk3LTE3LTEtMS00OTgyOA_6bc99159-7c27-4c43-8b1b-3e3cc0f752ad"
      unitRef="usd">15647523</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk4LTE1LTEtMS00OTgyOA_a4903fa4-cab2-4af1-9571-54c45529e088"
      unitRef="usd">2379969</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk4LTE3LTEtMS00OTgyOA_5ac9a533-cb37-474c-aa14-97f65736027c"
      unitRef="usd">2379969</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk5LTE1LTEtMS00OTgyOA_4203f8b7-331c-45e1-9a66-f9999eeb4a87"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4Xzk5LTE3LTEtMS00OTgyOA_dfd7959e-85b0-44f9-abc6-14f138e547ef"
      unitRef="usd">3181640</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:ProfitLoss
      contextRef="i7da2f113135949f6b69b0f0304007c14_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMC0xMS0xLTEtNDk4Mjg_b1fe953e-b1e0-4ea0-bed8-228522664bf5"
      unitRef="usd">-166411157</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMC0xNS0xLTEtNDk4Mjg_241a692c-62ca-4315-b616-858d13bd9d98"
      unitRef="usd">-1063757</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMC0xNy0xLTEtNDk4Mjg_f2e0f747-ba01-42b7-8f5d-1b0a681b2e33"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="if583dbf110944d9b91969553df66a181_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMS05LTEtMS00OTgyOA_f89d904f-3455-4a8a-a64a-6e4700318873"
      unitRef="usd">-96269</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i3c53433aa6b144a9a54b6a06e2f5ac1d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMS0xNS0xLTEtNDk4Mjg_bfbc14d9-4d0f-4f43-bee7-2c9087757d75"
      unitRef="usd">96269</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMS0xNy0xLTEtNDk4Mjg_a30c0dd4-1ff0-4bbc-928b-c2b0ac152338"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="id13cf002a66c44d39492fe34b336faf0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMi0xMy0xLTEtNDk4Mjg_dd583126-0d1a-4ee6-9fcb-a82860d64189"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMi0xNy0xLTEtNDk4Mjg_bdede4d8-6906-4aa2-965f-6824ddf74370"
      unitRef="usd">-755963</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id13cf002a66c44d39492fe34b336faf0_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMy0xMy0xLTEtNDk4Mjg_3e4b5143-191c-48b4-b65f-6f6ce1b3241d"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwMy0xNy0xLTEtNDk4Mjg_cffef8de-f6e5-449d-b8c0-6c196a9abecc"
      unitRef="usd">27205</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="if71c1abee2354fad9e808f4f24fbcbd2_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xLTEtMS00OTgyOA_0acfdd63-39a8-4c53-bebd-ed854bae860c"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if71c1abee2354fad9e808f4f24fbcbd2_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0zLTEtMS00OTgyOA_ecc39816-f78f-460c-88d1-fbb7084463bc"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="id11369143520413d8c7da3da06fc56b1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC01LTEtMS00OTgyOA_aad729ad-ce1a-4ca3-a372-e41119eb3e4b"
      unitRef="shares">186851493</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id11369143520413d8c7da3da06fc56b1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC03LTEtMS00OTgyOA_320f8d17-8f7f-47b6-ae48-f0386dca9eb2"
      unitRef="usd">186851</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib23b8d6624644da386cf1e538d1bd8af_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC05LTEtMS00OTgyOA_32219911-d2a1-4480-8fda-602bb42fbf79"
      unitRef="usd">1367406869</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i16ffc786c3c84f7ba4e698ca14539948_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xMS0xLTEtNDk4Mjg_85376520-6471-40aa-9149-7ed92249b14a"
      unitRef="usd">-906196812</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10ad082f8bde4a7a92524043edf853c1_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xMy0xLTEtNDk4Mjg_7b5b9b5f-a0d4-4bc8-a52c-b2ed0d417254"
      unitRef="usd">-256150</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75216b6319924276935aa28bd9bb7dcf_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xNS0xLTEtNDk4Mjg_51a3849f-5d98-4e19-a79b-03d2c2619606"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNC0xNy0xLTEtNDk4Mjg_a2961049-378a-4973-92a3-1d1dd492e3ed"
      unitRef="usd">461140758</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS01LTEtMS00OTgyOA_4b3699ab-0ca3-4615-99a3-09337298f24a"
      unitRef="shares">27310341</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS03LTEtMS00OTgyOA_30934935-ab7e-4ea4-8d3e-a5ee0a4d8832"
      unitRef="usd">27310</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS05LTEtMS00OTgyOA_8868b90e-8199-405d-8a2b-625a8920de47"
      unitRef="usd">209414100</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNS0xNy0xLTEtNDk4Mjg_b486b0cd-351e-42e2-a44a-fb24ba743031"
      unitRef="usd">209441410</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi01LTEtMS00OTgyOA_4c9ddfe2-ba74-46bf-ba52-f9ff72a3445c"
      unitRef="shares">1009450</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi03LTEtMS00OTgyOA_0d146f63-da8b-4cf9-964b-53badf05ac81"
      unitRef="usd">1009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi05LTEtMS00OTgyOA_81635230-d215-4f87-8d7c-4cb0137e082e"
      unitRef="usd">4376883</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNi0xNy0xLTEtNDk4Mjg_276781ed-56d2-4da9-bcc7-adba12152153"
      unitRef="usd">4377892</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy01LTEtMS00OTgyOA_4fcf2984-68e9-47c8-a6cc-fe683956d80d"
      unitRef="shares">2211603</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i874f92e411d9469bb3845afa6097cb87_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy03LTEtMS00OTgyOA_e1c255da-6346-41cc-9584-5f5bc573b40f"
      unitRef="usd">2212</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy05LTEtMS00OTgyOA_f8fc1a6d-cd1e-4626-a404-f0ccaa60abd4"
      unitRef="usd">2055181</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwNy0xNy0xLTEtNDk4Mjg_245649b6-2566-456d-b6df-aadcf70982d8"
      unitRef="usd">2057393</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8bd663d3e0fd4cc9a641375000429a78_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOC05LTEtMS00OTgyOA_f261eb91-7e42-4aa1-abe4-d26e5eeee87c"
      unitRef="usd">26336764</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOC0xNy0xLTEtNDk4Mjg_b4efa0b7-e864-4551-85f1-7795c39db917"
      unitRef="usd">26336764</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="i01a55d99d9834376b29d04025a363045_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOS0xMS0xLTEtNDk4Mjg_d2ac61fe-feab-47cb-a7bb-e96279a6d2ec"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEwOS0xNy0xLTEtNDk4Mjg_a64a7608-0764-4945-9a32-7e5e17da3847"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4459abbf67aa4910bb765838712d9fe5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMC0xMy0xLTEtNDk4Mjg_cbf9b339-514c-4195-86ea-28caf38ea73f"
      unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMC0xNy0xLTEtNDk4Mjg_1175e119-999d-4357-b9c6-04ffe6ab5358"
      unitRef="usd">4048</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4459abbf67aa4910bb765838712d9fe5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMS0xMy0xLTEtNDk4Mjg_ca198c56-d0d5-4e30-b67f-832f596ce686"
      unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMS0xNy0xLTEtNDk4Mjg_b760d162-1422-492c-b2a7-c941a515e858"
      unitRef="usd">-30134</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i4028d9e38f094f768bb1e9452fc45472_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xLTEtMS00OTgyOA_120bd7c0-767a-42a4-ac12-05bd4264e846"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4028d9e38f094f768bb1e9452fc45472_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0zLTEtMS00OTgyOA_1f0116b8-4471-4e20-8b40-8a949af77548"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i8cf453e9844f4d6fa74be581ed00a513_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi01LTEtMS00OTgyOA_19a90259-7e66-4ce7-81b5-4c294a1d240e"
      unitRef="shares">217382887</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cf453e9844f4d6fa74be581ed00a513_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi03LTEtMS00OTgyOA_b3d924b6-d13d-4c2d-bd9a-268461e044d0"
      unitRef="usd">217382</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3fd95af3528440b39f64c721172b95b3_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi05LTEtMS00OTgyOA_1d89d9f5-b3db-49e7-b982-205f9a6e5dfe"
      unitRef="usd">1609589797</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2ba6177eb6b8472495d2e2a45d024f63_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xMS0xLTEtNDk4Mjg_3b9155b3-7c62-49ad-ab44-3cb472aa6150"
      unitRef="usd">-1209855522</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8666bf368748449bb6e324e42d8b1d21_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xMy0xLTEtNDk4Mjg_f20d5994-685c-4c06-80ab-ea67fb963e6a"
      unitRef="usd">-282236</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8501fb06a5774680b79276ad409fed15_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xNS0xLTEtNDk4Mjg_38330682-a89a-4d4a-b5e7-f5a7d68de956"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMi0xNy0xLTEtNDk4Mjg_6df1ac17-4e5d-4787-a255-651e974504a6"
      unitRef="usd">399669421</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0151eb300ba9417ca13398ee631e0a11_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy05LTEtMS01MDQxMQ_71b06893-ec63-4eb9-b5c4-bb29d85efc74"
      unitRef="usd">-3294019</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idc6a118a9cde4fde96c5f7c1ae0848ec_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy0xMS0xLTEtNTA0MTE_01352c9b-6084-4450-9e78-266416f34adc"
      unitRef="usd">1825803</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4439b6c598d454e8b8ff9ceb6d62287_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExMy0xNy0xLTEtNTA0MTE_435ec549-6aef-44b2-9955-07f038c62bf5"
      unitRef="usd">-1468216</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC01LTEtMS01MDQxMQ_ab4328f9-a0ee-4b9f-af5e-3cfb0b27e1c4"
      unitRef="shares">34445743</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC03LTEtMS01MDQxMQ_b1945f4a-b3c7-4933-88e2-bb4f20349e6a"
      unitRef="usd">34447</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC05LTEtMS01MDQxMQ_2e30c184-0e86-4b77-8c3a-2caccb85fdf9"
      unitRef="usd">82920864</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNC0xNy0xLTEtNTA0MTE_dc469f0f-166a-42f2-a8a2-b781dd70187d"
      unitRef="usd">82955311</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS01LTEtMS01MDQxMQ_514bd483-63b3-4e4e-9115-be849e1d1661"
      unitRef="shares">1262689</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i14c4f1206cad4d739bf9bb60cdd690c4_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS03LTEtMS01MDQxMQ_ec1e95b6-89ec-414e-bc01-e98356eae121"
      unitRef="usd">1261</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS05LTEtMS01MDQxMQ_76413546-a42f-4463-8eb0-be160772d06a"
      unitRef="usd">-1115870</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNS0xNy0xLTEtNTA0MTE_eff79bd1-2927-405e-858d-bc93114d3dcf"
      unitRef="usd">-1114609</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibc6c5b209ae94a61bf0cfcd76174f50c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNi05LTEtMS01MDQxMQ_47b7a3c6-c917-4db6-bbe5-11164480ca38"
      unitRef="usd">22555419</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNi0xNy0xLTEtNTA0MTE_68976d34-4edf-4fbe-8383-51b25f492786"
      unitRef="usd">22555419</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="if998a11fda824693a82b5630eee5944a_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNy0xMS0xLTEtNTA0MTE_aabe1fe0-881a-4548-ae8d-5f3b7a7a65a4"
      unitRef="usd">-279818065</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExNy0xNy0xLTEtNTA0MTE_e748d082-c313-4056-9408-0de0636e33f9"
      unitRef="usd">-279818065</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i75ed40a3258c4619b0d384f1c875f1b3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOC0xMy0xLTEtNTA0MTE_358a2d02-ad3d-44a8-8b66-c4d2e5064795"
      unitRef="usd">-390949</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOC0xNy0xLTEtNTA0MTE_2126d825-75a6-4274-99f5-3ec291b15fe7"
      unitRef="usd">-390949</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i75ed40a3258c4619b0d384f1c875f1b3_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOS0xMy0xLTEtNTA0MTE_5a4a647c-0c95-4144-a6cb-a226807f98cc"
      unitRef="usd">-25556</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzExOS0xNy0xLTEtNTA0MTE_741456c6-4701-4533-adad-e1b871bfae2c"
      unitRef="usd">-25556</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:SharesIssued
      contextRef="i7b7a2f2ae8ab40ccae727491f64f50ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xLTEtMS01MDQzMA_d2d21293-de1c-4bd8-970d-633f5bd25378"
      unitRef="shares">9</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7b7a2f2ae8ab40ccae727491f64f50ef_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0zLTEtMS01MDY5OQ_f3d7f690-6bdb-4bfe-bd9b-6b09d3cafcfd"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i6173a75999554213bd9ef6b178b3c5a6_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC01LTEtMS01MDY5OQ_977a5049-6d63-4464-b45d-81947a1ec126"
      unitRef="shares">253091319</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6173a75999554213bd9ef6b178b3c5a6_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC03LTEtMS01MDY5OQ_bc2ce551-321b-4f92-8d7b-d3483cf3848a"
      unitRef="usd">253090</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i78e8ed6c44394b9d8730b7f657680c0a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC05LTEtMS01MDY5OQ_a1989926-7c50-4004-85e5-dff4ca78f018"
      unitRef="usd">1710656191</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf99a57f4f0543779cb105cb89a2a1ff_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xMS0xLTEtNTA2OTk_5fa2c7ae-f851-482f-92d7-5e7d2f6d0613"
      unitRef="usd">-1487847784</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3e327b57b7e447c8aadc23b5385ebe2b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xMy0xLTEtNTA2OTk_9fe472fc-66c3-4b67-aed1-afe7243580a3"
      unitRef="usd">-698741</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i564f8e98e6a4437d87441f8dad2ebdb9_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xNS0xLTEtNTA2OTk_bfa94d26-bb49-432f-84b1-a693bee4c229"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMjcvZnJhZzphZTlhMDY2OTQ5MWY0NTFlOTBhNzljNjk4YjM3NTRhZi90YWJsZTo3NGNmZTAwOTBmZjI0NTRjOWU5MjZlYzkwZjE1YWFlOC90YWJsZXJhbmdlOjc0Y2ZlMDA5MGZmMjQ1NGM5ZTkyNmVjOTBmMTVhYWU4XzEyMC0xNy0xLTEtNTA2OTk_dc1db29f-15d9-4a6c-ae7a-f2ce59abbae2"
      unitRef="usd">222362756</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMtMS0xLTEtNDk4Mjg_6203f9ea-3a5f-4bc1-89ac-2fa4e150290b"
      unitRef="usd">-279818065</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMtMy0xLTEtNDk4Mjg_e87ff291-8be4-4531-bbbe-b8c5ace36fc3"
      unitRef="usd">-303658710</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMtNS0xLTEtNDk4Mjg_76619cc1-7c03-47d0-8742-43323b74e870"
      unitRef="usd">-167474914</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUtMS0xLTEtNDk4Mjg_dc5d0e2e-424d-496f-b155-bc85aac2d44d"
      unitRef="usd">3656713</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUtMy0xLTEtNDk4Mjg_e8fc6c86-7262-4da7-baac-1a0b5368b02d"
      unitRef="usd">3040096</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUtNS0xLTEtNDk4Mjg_8b26a64c-350e-4809-88e0-f2c72e98977e"
      unitRef="usd">3038996</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYtMS0xLTEtNDk4Mjg_b15f0d8b-d2cf-4758-b66e-4ea8dcc505b6"
      unitRef="usd">496494</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYtMy0xLTEtNDk4Mjg_42858842-2853-4a2d-8fb7-03dde7b36fe7"
      unitRef="usd">520415</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYtNS0xLTEtNDk4Mjg_ae978564-3802-495d-bed1-2b264471ec0f"
      unitRef="usd">547081</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzctMS0xLTEtNDk4Mjg_41998943-eb95-454a-821e-12d6ba99c3fc"
      unitRef="usd">1342819</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzctMy0xLTEtNDk4Mjg_6e30417f-2747-439c-99fd-0125330c80bb"
      unitRef="usd">1170270</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzctNS0xLTEtNDk4Mjg_6099a463-386b-4438-b787-fe1d5559e7e2"
      unitRef="usd">1041713</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzktMS0xLTEtNDk4Mjg_6195750f-04c3-4a1b-87cc-3437009c7768"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzktMy0xLTEtNDk4Mjg_a84b97f9-bedd-4873-952f-206a6748c91b"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzktNS0xLTEtNDk4Mjg_f0f2a97d-ce0d-49be-b01d-0326e16a61d0"
      unitRef="usd">75670977</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:ShareBasedCompensation
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzExLTEtMS0xLTQ5ODI4_3c4e930a-46fe-469b-a5d4-f103d59d6600"
      unitRef="usd">22555419</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzExLTMtMS0xLTQ5ODI4_26b9d408-58de-44c2-8fc1-1525a4947832"
      unitRef="usd">26336764</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzExLTUtMS0xLTQ5ODI4_0e9fcddb-b8dc-4925-906e-66c34cba8c3b"
      unitRef="usd">15647523</us-gaap:ShareBasedCompensation>
    <ino:NonCashInterestExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEyLTEtMS0xLTQ5ODI4_9fd816b5-f28b-4c41-8ca5-ac19ade9bdd4"
      unitRef="usd">186977</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEyLTMtMS0xLTQ5ODI4_11988b06-ad24-4ce0-9ea6-64211c3a17a2"
      unitRef="usd">858644</ino:NonCashInterestExpense>
    <ino:NonCashInterestExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEyLTUtMS0xLTQ5ODI4_25a7e138-47ff-4cc9-98d2-6366664c3942"
      unitRef="usd">4077686</ino:NonCashInterestExpense>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEzLTEtMS0xLTQ5ODI4_3706a11f-7c89-4aa2-83a9-814e0ea07ba4"
      unitRef="usd">1320546</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEzLTMtMS0xLTQ5ODI4_aab6641f-f533-44f2-9202-a33f8ec0dbee"
      unitRef="usd">-1633286</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzEzLTUtMS0xLTQ5ODI4_2fda6231-deb4-4501-9f3a-d9ed987e412c"
      unitRef="usd">0</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE4LTEtMS0xLTQ5ODI4_cfd46bba-bca9-4c5d-850e-f31a730ce9f1"
      unitRef="usd">-4029961</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE4LTMtMS0xLTQ5ODI4_af67ebe9-940d-485f-8f11-ae4b2f1f3b1e"
      unitRef="usd">-5397</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE4LTUtMS0xLTQ5ODI4_8120516a-9ea9-4f6d-aa90-b3c3ab940ae1"
      unitRef="usd">-588270</us-gaap:GainLossOnSaleOfOtherInvestments>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE5LTEtMS0xLTQ5ODI4_0e38b0c4-4e89-40f1-90f5-7f23f89b2cf3"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE5LTMtMS0xLTQ5ODI4_30e271b3-2583-4a72-a6c6-25172b6da0da"
      unitRef="usd">0</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzE5LTUtMS0xLTQ5ODI4_2ddc6e6b-a0f4-49aa-aff8-c251bb82c7b1"
      unitRef="usd">1713770</ino:SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIwLTEtMS0xLTQ5ODI4_7ba4c8eb-dd89-4f57-ba3e-ebc4388e2794"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIwLTMtMS0xLTQ5ODI4_7a12291b-a3a6-48a4-a4f9-4be58de2dec7"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIwLTUtMS0xLTQ5ODI4_cbd16ac9-4f1e-442a-a397-d8502a4c1908"
      unitRef="usd">4121075</us-gaap:DeconsolidationGainOrLossAmount>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTEtMS0xLTU2ODg0_88ceb2a7-2946-42c9-939d-b5403d241acf"
      unitRef="usd">165215</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTMtMS0xLTU2ODg0_2c24632d-8e2a-41d3-80bd-6c4b62753bff"
      unitRef="usd">0</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <ino:GainLossOnRemeasurementOfEquityMethodInvestment
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTUtMS0xLTU2ODg0_58a82949-b5ef-4f9f-b87a-5981dd6a38d9"
      unitRef="usd">0</ino:GainLossOnRemeasurementOfEquityMethodInvestment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTEtMS0xLTQ5ODI4_7a6cdddb-e7a9-46b7-b017-66cf45f36e10"
      unitRef="usd">-1074830</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTMtMS0xLTQ5ODI4_a3aa0929-c743-471f-83cc-57d3c194dae8"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIxLTUtMS0xLTQ5ODI4_d787f55b-2a83-4ecd-b0b2-ae2977e48a76"
      unitRef="usd">-26913</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIyLTEtMS0xLTQ5ODI4_12b0c61c-4682-4934-960c-a0b01a47c3ef"
      unitRef="usd">-1899654</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIyLTMtMS0xLTQ5ODI4_882970bc-6f38-4eb1-b673-681e91d2f401"
      unitRef="usd">-553570</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <ino:ChangeInValueOfInvestmentsInAffiliatedCompany
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIyLTUtMS0xLTQ5ODI4_6744b07e-bc10-41b0-9dbb-3fff2575ecb9"
      unitRef="usd">36556658</ino:ChangeInValueOfInvestmentsInAffiliatedCompany>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIzLTEtMS0xLTQ5ODI4_e12e9436-a8da-4124-9742-b8d80419b250"
      unitRef="usd">-2165213</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIzLTMtMS0xLTQ5ODI4_0e8a88cf-c03f-4f4f-a4ad-c720979f6670"
      unitRef="usd">-434387</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzIzLTUtMS0xLTQ5ODI4_b1e27db3-244c-4cb8-bced-6e2a528d1e97"
      unitRef="usd">-4584610</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ic1bdec8a908c4594afd92ff4781d3366_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI0LTEtMS0xLTQ5ODI4_76e25cf2-f324-4205-965a-0a145cc6429c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i989ec83114ba4070a4bd52566656d740_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI0LTMtMS0xLTQ5ODI4_c578b882-01fd-4b62-a611-bd4157238ffa"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i110d8cff3e7c4910b2e0c84f0f9c65de_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI0LTUtMS0xLTQ5ODI4_4a2c047a-d7b9-4545-aa9e-67bf6da8138d"
      unitRef="usd">-8177043</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i0e3a7a0113a6439694f0af4a15e4c7dc_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI1LTEtMS0xLTQ5ODI4_1d13fa42-59ac-432e-af17-bc49462557a8"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="idae06434a74c4378bb8e66fbb38683a8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI1LTMtMS0xLTQ5ODI4_5b3dcb8f-2ceb-4f01-ac38-8ef2f2a3a16c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="iaf2313dc8d634d2291808f0d5423e67b_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI1LTUtMS0xLTQ5ODI4_f5671f48-873b-4e72-9b7f-fee5d30fb21e"
      unitRef="usd">8762030</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI2LTEtMS0xLTQ5ODI4_3811752c-6cfc-44b3-b611-5d3c28fb4481"
      unitRef="usd">-7846172</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI2LTMtMS0xLTQ5ODI4_4b64bf51-e79a-470c-9243-bce36ed88a46"
      unitRef="usd">-3222838</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI2LTUtMS0xLTQ5ODI4_4707f562-7bf0-4278-a368-70a76e9a433f"
      unitRef="usd">1695497</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI4LTEtMS0xLTQ5ODI4_5a434442-1f45-4268-ae7d-4d44fb0515e5"
      unitRef="usd">0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI4LTMtMS0xLTQ5ODI4_c2bfaba7-095e-49e6-8dd0-78fce293366d"
      unitRef="usd">176927</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzI4LTUtMS0xLTQ5ODI4_ee99e65c-dacf-4a9c-bfd5-f246a9a201af"
      unitRef="usd">-15902</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMwLTEtMS0xLTQ5ODI4_a46069d4-2058-426c-9142-5e3f68906bda"
      unitRef="usd">3706172</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMwLTMtMS0xLTQ5ODI4_1bc0a671-9c53-4a7f-b7df-3ebb9390cb9f"
      unitRef="usd">-11031705</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMwLTUtMS0xLTQ5ODI4_eb0451c9-c906-481a-9445-0d1f2701cecb"
      unitRef="usd">17015471</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMyLTEtMS0xLTQ5ODI4_60f65030-2dc4-473e-9161-c69e7d7cba33"
      unitRef="usd">5336525</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMyLTMtMS0xLTQ5ODI4_571332a8-f2a8-4b76-867d-959c4037d38d"
      unitRef="usd">6343632</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzMyLTUtMS0xLTQ5ODI4_8149b1b9-568d-41c4-9832-6e0edb8483ad"
      unitRef="usd">38475465</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM1LTEtMS0xLTQ5ODI4_ce60bd0a-f9aa-499c-9470-53f5ebce1a88"
      unitRef="usd">-741750</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM1LTMtMS0xLTQ5ODI4_a502fe41-743b-4059-9a8a-264666e005c7"
      unitRef="usd">-24531654</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM1LTUtMS0xLTQ5ODI4_04fe943e-3372-40ec-ac5c-65450f610843"
      unitRef="usd">23285424</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM2LTEtMS0xLTQ5ODI4_e1edf69e-5874-4a41-a2bc-c0910a024b59"
      unitRef="usd">32606581</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM2LTMtMS0xLTQ5ODI4_0a423dac-1c57-45a7-9a25-3f2f3d03212b"
      unitRef="usd">26140970</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM2LTUtMS0xLTQ5ODI4_ed7a6599-8884-43a0-ae23-138eae0a854c"
      unitRef="usd">3251478</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM3LTEtMS0xLTQ5ODI4_0be0ca66-5c4b-4cb2-aa40-8e3e7f205f94"
      unitRef="usd">267807</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM3LTMtMS0xLTQ5ODI4_696e4648-bb28-4780-bfa7-c84d1b5fc5cd"
      unitRef="usd">375921</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <ino:IncreaseDecreaseInAccruedClinicalTrialExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM3LTUtMS0xLTQ5ODI4_820202b6-d77c-4c3b-8cc0-ecce005ddf52"
      unitRef="usd">5962381</ino:IncreaseDecreaseInAccruedClinicalTrialExpense>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM5LTEtMS0xLTQ5ODI4_a8593787-5c76-4bcd-b851-1e583b855c03"
      unitRef="usd">-85989</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM5LTMtMS0xLTQ5ODI4_1d9b75d1-d960-4c27-82f9-216fa1070410"
      unitRef="usd">-39853</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzM5LTUtMS0xLTQ5ODI4_2484c659-6c20-4ddc-a11f-1f24f47d9585"
      unitRef="usd">-62353</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQyLTEtMS0xLTQ5ODI4_dc22c966-94b0-4f4e-8ff5-1c882546fe41"
      unitRef="usd">-2603956</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQyLTMtMS0xLTQ5ODI4_dabc439e-e29a-4a65-b3c3-d07b69765e5d"
      unitRef="usd">-2329394</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQyLTUtMS0xLTQ5ODI4_7696a4e4-eb64-4762-a546-840131338498"
      unitRef="usd">-2091855</ino:IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQzLTEtMS0xLTQ5ODI4_d0123958-893a-4236-bb74-7f818d50ad7a"
      unitRef="usd">-2034517</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQzLTMtMS0xLTQ5ODI4_09f9d43a-5102-4095-b1ea-3ec194c455dd"
      unitRef="usd">-2973089</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <ino:IncreaseDecreaseinDeferredGrantFundingCurrent
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQzLTUtMS0xLTQ5ODI4_c9af0bd2-fb23-4d21-85dc-a7fe80702db3"
      unitRef="usd">624173</ino:IncreaseDecreaseinDeferredGrantFundingCurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ1LTEtMS0xLTQ5ODI4_a2d69375-a389-4b9f-808f-c51bcbe260d0"
      unitRef="usd">-14826</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ1LTMtMS0xLTQ5ODI4_ecb56052-8f98-46fa-b80a-5dc2ed0c3811"
      unitRef="usd">-42837</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ1LTUtMS0xLTQ5ODI4_3ed2d96f-aaef-470f-aed6-0551126ca1c9"
      unitRef="usd">20720</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ2LTEtMS0xLTQ5ODI4_253866f8-6fbe-4911-b643-7a5a80c82d18"
      unitRef="usd">-216215421</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ2LTMtMS0xLTQ5ODI4_1771d5ad-ead9-4605-a6a8-913e97b71559"
      unitRef="usd">-215708525</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ2LTUtMS0xLTQ5ODI4_4d2cd02c-668c-4710-8452-134d34d3338d"
      unitRef="usd">-177979046</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ4LTEtMS0xLTQ5ODI4_aa525832-43b2-47ed-8962-19117d2d4610"
      unitRef="usd">248528843</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ4LTMtMS0xLTQ5ODI4_016cb69a-d698-40ab-aee5-6d3e60002c0e"
      unitRef="usd">348953236</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ4LTUtMS0xLTQ5ODI4_4690b3bf-527f-49e8-af02-d096ce2cf794"
      unitRef="usd">156216677</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ5LTEtMS0xLTQ5ODI4_e3e86ff5-a587-4550-925b-5888143e06ed"
      unitRef="usd">361083850</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ5LTMtMS0xLTQ5ODI4_8ea53be9-a5d0-40b1-b7e2-4cf1075e0bca"
      unitRef="usd">174839758</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzQ5LTUtMS0xLTQ5ODI4_20bce427-4f16-47b3-b1bf-a2b623a72ac0"
      unitRef="usd">62991023</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUwLTEtMS0xLTQ5ODI4_008d6551-7013-457c-bfe3-2742d2e47cd6"
      unitRef="usd">969153</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUwLTMtMS0xLTQ5ODI4_8adadd1e-33fd-4c08-9391-f488f16adb93"
      unitRef="usd">1231006</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUwLTUtMS0xLTQ5ODI4_e59f8fd2-a016-4017-b149-f47ceaba0720"
      unitRef="usd">1520665</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUxLTEtMS0xLTQ5ODI4_4d8ad1a0-fff0-4fe6-b0ae-752c7cd0d0fb"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUxLTMtMS0xLTQ5ODI4_a9117750-a304-409e-b87f-07267fa87f01"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUxLTUtMS0xLTQ5ODI4_6b77ec8b-9029-4e01-95f0-f0971178c407"
      unitRef="usd">40125418</us-gaap:ProceedsFromSaleOfEquitySecuritiesFvNi>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUyLTEtMS0xLTQ5ODI4_e08bfa79-d386-4599-8189-ba989fba25f8"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUyLTMtMS0xLTQ5ODI4_761702b2-e7f2-400b-beb0-b2a774264cec"
      unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUyLTUtMS0xLTQ5ODI4_ef868b8c-373f-434d-8029-fe41ed9905ed"
      unitRef="usd">2774851</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUzLTEtMS0xLTQ5ODI4_2e2ca8fd-ec67-4c98-9175-3561e1ae3a05"
      unitRef="usd">1999998</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUzLTMtMS0xLTQ5ODI4_88547f7b-11d7-4878-a208-89b2fab6c12c"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzUzLTUtMS0xLTQ5ODI4_9a90194d-c681-460f-b7db-609a2e867ede"
      unitRef="usd">1399999</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU1LTEtMS0xLTQ5ODI4_ba5409fa-d65c-4925-b189-7f9c2a71a30c"
      unitRef="usd">109585856</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU1LTMtMS0xLTQ5ODI4_614b0fc0-606b-42a9-8452-43dbbff61a56"
      unitRef="usd">-175344484</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU1LTUtMS0xLTQ5ODI4_a8402be5-b726-4240-821f-f75fe8c36118"
      unitRef="usd">-58795751</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU5LTEtMS0xLTQ5ODI4_71a0310b-45dc-4101-a6aa-4002aba6f320"
      unitRef="usd">82955311</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU5LTMtMS0xLTQ5ODI4_6170cef8-ee58-4b7f-af78-e6d73498ee83"
      unitRef="usd">209441410</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzU5LTUtMS0xLTQ5ODI4_bfc37512-5b49-41d2-84e4-e324aa8d0ad4"
      unitRef="usd">454486400</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYwLTEtMS0xLTQ5ODI4_e8d1f72e-dbb6-487e-b0fe-965c7b37bed4"
      unitRef="usd">283022</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYwLTMtMS0xLTQ5ODI4_adc62ce5-b9c2-445e-9cf5-970c91a2d574"
      unitRef="usd">6668741</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsfromStockOptionandWarrantExercises
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYwLTUtMS0xLTQ5ODI4_1c6c4223-4b69-4d30-b94b-232893a5da78"
      unitRef="usd">12269801</ino:ProceedsfromStockOptionandWarrantExercises>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYxLTEtMS0xLTQ5ODI4_d8f46bdd-b94b-4107-b89d-45b630b0f56d"
      unitRef="usd">-1397631</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYxLTMtMS0xLTQ5ODI4_fdeb4488-bc3e-41fb-b9ef-cd507a64bf71"
      unitRef="usd">-4611348</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYxLTUtMS0xLTQ5ODI4_34de17ec-8210-4078-bf7f-6fd862ae5ccb"
      unitRef="usd">-4028177</ino:ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYyLTEtMS0xLTQ5ODI4_f98e26c2-ce3e-4578-8ea7-b1841f4a0d42"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYyLTMtMS0xLTQ5ODI4_686160f5-406f-4022-bf43-7304875a58d3"
      unitRef="usd">0</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYyLTUtMS0xLTQ5ODI4_af57941c-e6e5-47be-b190-b3facf9df942"
      unitRef="usd">2379969</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYzLTEtMS0xLTQ5ODI4_d7d101f0-0ad7-486e-950e-0c3bb5cd1283"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYzLTMtMS0xLTQ5ODI4_668b9b1e-0760-46a1-ba18-29baaa1432bf"
      unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzYzLTUtMS0xLTQ5ODI4_b1c0ca12-6983-404b-9fb4-d9aca1e70f11"
      unitRef="usd">171620</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY0LTEtMS0xLTQ5ODI4_09d3d657-c845-4eda-9843-4e2b98c130c1"
      unitRef="usd">81840702</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY0LTMtMS0xLTQ5ODI4_3a427b7d-068e-4922-8f2c-76a0acd232a5"
      unitRef="usd">211498803</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY0LTUtMS0xLTQ5ODI4_9d1fc798-283c-4112-a591-ecd3beeb8655"
      unitRef="usd">465279613</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY1LTEtMS0xLTQ5ODI4_fae68d20-3582-45ab-891b-f1b3a7497774"
      unitRef="usd">-25556</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY1LTMtMS0xLTQ5ODI4_2e265f0f-2d67-4d61-a6f3-e65caedde87f"
      unitRef="usd">-30134</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY1LTUtMS0xLTQ5ODI4_ef71e9f8-b2e6-4bee-a800-2f76df2c042a"
      unitRef="usd">27205</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY2LTEtMS0xLTQ5ODI4_b5cb4b15-629c-42f8-89b6-3c18963e412b"
      unitRef="usd">-24814419</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY2LTMtMS0xLTQ5ODI4_c14833bd-4fa9-498c-b4c2-13dbb544ab20"
      unitRef="usd">-179584340</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY2LTUtMS0xLTQ5ODI4_3b870f0d-f684-4375-a409-0ae1d5517cb2"
      unitRef="usd">228532021</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY3LTEtMS0xLTQ5ODI4_49088c69-8dd4-4404-96b9-d2f4d356c2eb"
      unitRef="usd">71143778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY3LTMtMS0xLTQ5ODI4_bcd5ec4f-efba-41b3-8f48-85d650232ff6"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1bb91b86850c4019853cfafe96543ff8_I20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY3LTUtMS0xLTQ5ODI4_8068b2b1-ce73-4e18-8dc0-7652e81e37b0"
      unitRef="usd">22196097</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY4LTEtMS0xLTQ5ODI4_5376536a-2cc1-480b-bbfe-34fdb4008805"
      unitRef="usd">46329359</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY4LTMtMS0xLTQ5ODI4_980f5454-b1f6-4a09-9a47-0c26b270e04d"
      unitRef="usd">71143778</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzY4LTUtMS0xLTQ5ODI4_f63eb5a4-6007-4e70-86b8-10eff593a5aa"
      unitRef="usd">250728118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzcyLTEtMS0xLTQ5ODI4_90876dac-f428-45bf-a0f1-fca30ddbedb7"
      unitRef="usd">108181</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzcyLTMtMS0xLTQ5ODI4_f31a477d-a8d5-4832-bc91-0701c8d10eb0"
      unitRef="usd">204815</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzcyLTUtMS0xLTQ5ODI4_782bc2aa-0799-4967-85a7-07ff6aad2ce8"
      unitRef="usd">136711</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:InterestPaidNet
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzczLTEtMS0xLTQ5ODI4_7242f4b9-d215-4c50-9726-91145b749071"
      unitRef="usd">1066975</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzczLTMtMS0xLTQ5ODI4_5908d2d3-eae6-4b69-8083-381e454b9adb"
      unitRef="usd">1077803</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3XzczLTUtMS0xLTQ5ODI4_f5e930c9-6d66-4996-86ba-e20880407330"
      unitRef="usd">4624764</us-gaap:InterestPaidNet>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3Xzc0LTEtMS0xLTQ5ODI4_5d7b4720-69e2-4ea6-8f13-50b6f30e6263"
      unitRef="usd">6071000</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3Xzc0LTMtMS0xLTQ5ODI4_2514ece6-44e5-442b-8dd2-da5983a1b5d1"
      unitRef="usd">7709337</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzAvZnJhZzo0NTE4ODMxZTM1ZmU0YzQxOWEzNDc0NTExMTcwMjhhZi90YWJsZTo4YWYyM2Q0YmM5OTI0YjM5YTRjMmE5YzVhNDJiOTQ2Ny90YWJsZXJhbmdlOjhhZjIzZDRiYzk5MjRiMzlhNGMyYTljNWE0MmI5NDY3Xzc0LTUtMS0xLTQ5ODI4_b1d33482-2600-4565-89e4-86347225f356"
      unitRef="usd">0</ino:ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets>
    <us-gaap:NatureOfOperations
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzYvZnJhZzpmY2E0NmI3YWE3Yzk0YjBkYTdiN2M2YmM1NjgyNjBkNS90ZXh0cmVnaW9uOmZjYTQ2YjdhYTdjOTRiMGRhN2I3YzZiYzU2ODI2MGQ1XzM1NjU_190a9a2b-dbb8-4552-8cf4-8ded465e1321">The Company&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inovio Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;INOVIO&#x201d;) is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with HPV, cancer, and infectious diseases. The Company&#x2019;s goal is to advance its diverse pipeline of product candidates and deliver on the promise of DNA medicines technology in treating and preventing a wide array of diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In clinical trials, the INOVIO's DNA medicine candidates have shown the ability to generate immune responses, especially CD4+, CD8+, and memory T-cell responses against targeted pathogens and cancers, via its precisely designed plasmids. These plasmids are delivered into cells using the Company's investigational proprietary smart device, CELLECTRA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO's lead candidates are focused on diseases associated with HPV.  In 2022, INOVIO announced data from a Phase 1/2 clinical trial with INO-3107 for the treatment of HPV-6 and HPV-11 associated RRP. In this trial, treatment with INO-3107 resulted in a statistically significant reduction of the median number of surgeries, a result that reinforces the Company's belief that DNA medicines may play a key role in the treatment of HPV-related diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill &amp;amp; Melinda Gates Foundation (Gates), Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), The U.S. Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute (IVI), Kaneka Eurogentec, National Cancer Institute (NCI), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its collaborators are currently evaluating the feasibility of, or conducting or planning clinical studies of, DNA medicines for Ebola; HPV-related precancers, including cervical, vulvar, and anal dysplasia; HPV-related cancers, including head &amp;amp; neck; other HPV-related disorders, such as RRP; and GBM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INOVIO was incorporated in Delaware in June 2001 and has its principal executive offices in Plymouth Meeting, Pennsylvania.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MjY2_14c8b3c9-c6ad-4ebb-a858-ce35f758f927">Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December&#160;31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million, $47.7&#160;million and $454.5&#160;million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Compan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y also issued convertible notes and bonds in a series of private placement transactions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has contracts with certain of its customers that have represented more than 10% of the Company's total revenues, as discussed in Note 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers. No allowance for doubtful accounts was deemed necessary at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets. The Company has not recognized any losses on long-lived assets through December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2"&gt;two&lt;/span&gt; to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2022 and 2021, the Company&#x2019;s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1&#160;million and $2.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations. See Note&#160;8 for further discussion of the Company&#x2019;s goodwill and intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $299.1 million and $237.2 million at December&#160;31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue, in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,221,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,943,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,654,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,190,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes forfeitures as they occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjcz_bc67cc8a-5402-464b-9177-dcbc3065b787">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation and Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred a net loss attributable to common stockholders of $279.8 million for the year ended December&#160;31, 2022. The Company had working capital of $218.4 million and an accumulated deficit of $1.5 billion as of December&#160;31, 2022. The Company has incurred losses in each year since its inception and expects to continue to incur significant expenses and operating losses for the foreseeable future in connection with the research and preclinical and clinical development of its product candidates. The Company&#x2019;s cash, cash equivalents and short-term investments of $253.0 million as of December 31, 2022 are sufficient to support the Company's operations for a period of at least 12 months from the date it is issuing these financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to fund future research and development activities, the Company will need to seek additional capital. This may occur through strategic alliance and licensing arrangements, grant agreements and/or future public or private debt or equity financings including At-the-Market Equity Offering Sales Agreements (&#x201c;Sales Agreements&#x201d;). The Company has a history of conducting debt and equity financings, including the receipt of net proceeds of $83.0&#160;million, $47.7&#160;million and $454.5&#160;million under Sales Agreements during the years ending December 31, 2022, 2021 and 2020, respectively, and $162.1&#160;million from a January 2021 underwritten public offering of common stock. During the year ended December 31, 2019, the Compan&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y also issued convertible notes and bonds in a series of private placement transactions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;However, sufficient funding may not be available in the future, or if available, may be on terms that significantly dilute or otherwise adversely affect the rights of existing stockholders. If adequate funds are not available, the Company may need to delay, reduce the scope of or put on hold one or more of its clinical and/or preclinical programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue its operations is dependent upon its ability to obtain additional capital in the future and achieve profitable operations. The Company expects to continue to rely on outside sources of financing to meet its capital needs and the Company may never achieve positive cash flow. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should Inovio be unable to continue as a going concern. The Company's consolidated financial statements as of and for the year ended December 31, 2022 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of &lt;/span&gt;&lt;/div&gt;liabilities and commitments in the normal course of business for the foreseeable future. The Company has evaluated subsequent events after the balance sheet date through the date it issued these consolidated financial statements.The Company is and, from time to time,&#160;may in the future be subject to various legal proceedings and claims arising in the ordinary course of business. The Company assesses contingencies to determine the degree of probability and range of possible loss for potential accrual in its consolidated financial statements. An estimated loss contingency is accrued in the consolidated financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal proceedings, including litigation, government investigations and enforcement actions, could result in material costs, occupy significant management resources and entail civil and criminal penalties, even if the Company ultimately prevails.&#160;Any of the foregoing consequences could result in serious harm to the Company&#x2019;s business, results of operations and financial condition.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM1MjA_1aed2210-5544-4891-b79d-53b6a0760cdd"
      unitRef="usd">-279800000</us-gaap:NetIncomeLoss>
    <ino:WorkingCapital
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM1OTQ_5e75c988-b151-4069-a30e-b0509f075692"
      unitRef="usd">218400000</ino:WorkingCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM2Mjc_a02c584f-cf17-4e33-a83e-61b542200e6d"
      unitRef="usd">-1500000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5OTU_e0118d15-552c-46d2-95d1-6c3beadd4fcc"
      unitRef="usd">253000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODEyMzY_c34a70c4-41ab-4084-b410-893ccd7e1d55"
      unitRef="usd">83000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODEyMjE_fcf0904c-7c94-412f-b4e6-d52f83514536"
      unitRef="usd">47700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib6cae987a41b4492a9781bcec7e5cea0_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0OTg5OTI_bb0c43b5-4ab1-4999-adb6-dfe2e594b02f"
      unitRef="usd">454500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i851b409487e4421e97a148072ac742ed_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzQ2MjA_6af8cc8d-9841-4114-a93c-c7926b2d3e5b"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjg4_0d7be64f-b83e-47e7-986a-0c6c2a820704">ConsolidationThe consolidated financial statements include the accounts of Inovio Pharmaceuticals, Inc. and its wholly-owned subsidiary Inovio Asia LLC.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzg4_30075b1b-0938-49a8-8919-7336327920fe">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one segment operating primarily within the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzEwMjEz_807ec1cb-797d-4e62-b1e5-7cc980860f62"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzM1_3254c615-01eb-44a7-b6b1-50a236bef0c9">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MjY4_981986e8-9ea8-448c-a863-37a589c5dfc1">Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and short-term investments. The Company limits its exposure to credit loss by placing its cash and investments with high credit quality financial institutions. Additionally, the Company has established guidelines regarding diversification of its investments and their maturities which are designed to maintain principal and maximize liquidity.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDE0_538c9dfe-08e5-4653-8e08-8c836d6f3f4e">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance regarding fair value measurements establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets that are accessible at the measurement date; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments include cash equivalents, short-term investments, investments in affiliated entities, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and convertible senior notes. The carrying amounts of cash equivalents, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses approximate the related fair values due to the short-term maturities of these instruments. Short-term investments are recorded at fair value on a recurring basis, based on current market valuations. The Company carries convertible senior notes at face value less unamortized debt discount and issuance costs on its consolidated balance sheet, and it presents the fair value of such convertible notes and bonds for disclosure purposes only.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzY3_6a6c8d70-1852-4619-a39a-45023a7c4a11">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered by the Company to be highly liquid investments purchased with original maturities of three months or less from the date of purchase. Cash and cash equivalents included certain money market accounts and U.S. treasury securities at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzQ1_6391a896-1758-4d20-8b2d-f9a2bf2e44ba">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines investments as income-yielding securities that can be readily converted into cash or equity investments classified as available-for-sale. Investments included mutual funds, U.S. treasury securities, commercial paper, certificates of deposit, U.S. agency mortgage-backed securities and an equity investment in the Company&#x2019;s affiliated entity, PLS, at December 31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments are recorded at fair value, based on current market valuations. Unrealized gains and losses on the Company's short-term debt investments are excluded from earnings and reported as a separate component of other comprehensive loss until realized. Realized gains and losses and unrealized gains and losses on available-for-sale equity securities are included in non-operating other income (expense) on the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;consolidated statements of operations and are derived using the specific identification method for determining the cost of the securities sold.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDIz_fd360ae3-16ba-47f3-a215-74edc63fd482">Accounts ReceivableAccounts receivable are recorded at invoiced amounts and do not bear interest. The Company performs ongoing credit evaluations of its customers&#x2019; financial condition. Credit is extended to customers as deemed necessary and generally does not require collateral. Management believes that the risk of loss is significantly reduced due to the quality and financial position of the Company's customers.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NDk3_1189da54-59bf-43c4-9074-470d6aa33ea0"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NDk3_d9d470e4-2d7d-4ca0-a5ad-1a55a9c3a9c4"
      unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzY5_7c0cfad3-f7cb-4269-ac38-a57261dbafb0">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fixed Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful life of the assets, generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE0NzM4_6b55f7a0-8bde-49d1-8939-997b52337bca"&gt;three&lt;/span&gt; to five years. Leasehold improvements are amortized over the shorter of the remaining term of the related leases or the estimated economic useful lives of the improvements. Repairs and maintenance are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8c4af40c177746a9860d90e560bd8e93_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzM3_3f57e01c-182c-4d9d-a71c-77e9552d1df1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjkx_e86aefed-2e56-46a1-b328-b27d731205f3">Long-Lived AssetsAll long-lived assets are reviewed for impairment in value when changes in circumstances dictate, based upon undiscounted future operating cash flows, and appropriate losses are recognized and reflected in current earnings, to the extent the carrying amount of an asset exceeds its estimated fair value determined by the use of appraisals, discounted cash flow analyses or comparable fair values of similar assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzA1_948f130b-5c69-4a10-81cd-fd6978e8301d">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are amortized over their estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjA1_a8ce23ca-a8cf-4ace-8041-e58d0af2a4c2"&gt;two&lt;/span&gt; to 18 years. Acquired intangible assets are continuously being developed for the future economic viability contemplated at the time of acquisition. The Company is concurrently conducting preclinical studies and clinical trials using the acquired intangibles and has entered into licensing agreements for the use of these acquired intangibles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;License costs are recorded based on the fair value of consideration paid and are amortized using the straight-line method over the shorter of the expected useful life of the underlying patents or the term of the related license agreement to the extent the license has an alternative future use. As of December&#160;31, 2022 and 2021, the Company&#x2019;s intangible assets resulting from prior acquisitions of other companies, and additional intangibles including license costs, net of accumulated amortization, totaled $2.1&#160;million and $2.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The determination of the value of intangible assets requires management to make estimates and assumptions that affect the Company&#x2019;s consolidated financial statements. The Company assesses potential impairments to intangible assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recovered. The Company&#x2019;s judgments regarding the existence of impairment indicators and future cash flows related to intangible assets are based on operational performance of its acquired businesses, market conditions and other factors. If impairment is indicated, the Company will reduce the carrying value of the intangible asset to fair value. While current and historical operating and cash flow losses are potential indicators of impairment, the Company believes the future cash flows to be received from its intangible assets will exceed the intangible assets&#x2019; carrying value, and accordingly, the Company has not recognized any impairment losses through December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of acquisition cost over the fair value of the net assets of acquired businesses. Goodwill is reviewed for impairment at least annually at November 30, or more frequently if an event occurs indicating the potential for impairment. During its goodwill impairment review, the Company may assess qualitative factors to determine whether it is likely that the fair value of its reporting unit is less than its carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance of the Company. If, after assessing the totality of these qualitative factors, the Company determines that it is not likely that the fair value of its reporting unit is less than its carrying amount, then no additional assessment is deemed necessary. Otherwise, the Company will proceed to perform the impairment test in which the fair value of the reporting unit is compared with its carrying amount, and an impairment charge will be recorded for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. The Company performed its annual assessment for goodwill impairment as of November 30, 2022, identifying no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although there are inherent uncertainties in this assessment process, the estimates and assumptions the Company is using are consistent with its internal planning. If these estimates or their related assumptions change in the future, the Company may be required to record an impairment charge on all or a portion of its goodwill and intangible assets. Furthermore, the Company &lt;/span&gt;&lt;/div&gt;cannot predict the occurrence of future impairment triggering events nor the impact such events might have on its reported asset values. Future events could cause the Company to conclude that impairment indicators exist and that goodwill or other intangible assets associated with its acquired businesses are impaired. Any resulting impairment loss could have an adverse impact on the Company&#x2019;s results of operations.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8c4af40c177746a9860d90e560bd8e93_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE1NjEx_c8d2eb9c-a239-4d8d-a3eb-907daf366eaf">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkx_a3bf0792-67d8-4456-a9cd-62a668fe1b92"
      unitRef="usd">2100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDk4_4a7a12fe-f3da-4078-a687-f154d28a8913"
      unitRef="usd">2600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzgz_26e60bd0-708d-4d3a-ab2b-ee1747ee4b4f">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities along with net operating loss and tax credit carry forwards. The Company records a valuation allowance against its deferred tax assets to reduce the net carrying value to an amount that it believes is more likely than not to be realized. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances against the Company&#x2019;s deferred tax assets were $299.1 million and $237.2 million at December&#160;31, 2022 and 2021, respectively. Changes in the valuation allowances, when they are recognized in the provision for income taxes, are included as a component of the estimated annual effective tax rate.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIwNDIx_6cdc1bfb-8a8a-4afa-a953-387840211cce"
      unitRef="usd">299100000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIwNDI4_febadfd0-8cdb-4a52-a79d-7f96ff71965f"
      unitRef="usd">237200000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIxOTkwMjMzMTE0OTM_a4453ab9-1a3c-4ec8-9a22-b17442f3fdf8">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue, in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;Topic 606&#x201d;), when it transfers promised goods or services to customers in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services. To determine revenue recognition for contracts with customers, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies its performance obligations. At contract inception, the Company assesses the goods or services agreed upon within each contract and assess whether each good or service is distinct and determine those that are&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;performance obligations. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Fees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If a license to intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company will recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Supply Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrangements that include a promise for future supply of drug product for either clinical development or commercial supply at the licensee&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. The Company evaluates whether it is the principal or agent in the arrangement. The Company had determined that it is the principal in the current arrangements as the Company controls the product supply before it is transferred to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes milestone payments (variable consideration), the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the Company's or its collaboration partner&#x2019;s control, such as regulatory approvals, are generally not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achieving such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration or other revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its collaborative arrangements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzIxOTkwMjMzMTE0OTQ_d3beef48-92ca-43c5-8c5b-d5ec07d46b89">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assesses whether its collaboration agreements are subject to ASC Topic 808: Collaborative Arrangements (&#x201c;Topic 808&#x201d;) based on whether they involve joint operating activities and whether both parties have active participation in the arrangement and are exposed to significant risks and rewards. To the extent that the arrangement falls within the scope of Topic 808 and the Company concludes that its collaboration partner is not a customer, the Company presents such payments as a reduction of research and development expense. If payments from the collaboration partner to the Company represent consideration from a customer, then the Company accounts for those payments within the scope of ASU Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements with partners that typically include payment of one or more of the following: (i) license fees; (ii) product supply services; (iii) milestone payments related to the achievement of developmental, regulatory, or commercial goals; and (iv) royalties on net sales of licensed products. Where a portion of non-refundable, upfront fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue when (or as) the underlying performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop estimates and assumptions that require judgment of management to determine the underlying stand-alone selling price for each performance obligation which determines how the transaction price is allocated among the performance obligation. The standalone selling price may include items such as forecasted revenues, development timelines, discount rates and probabilities of technical and regulatory success. The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time. In addition, variable consideration must be evaluated to determine if it is constrained and, therefore, excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementAccountingPolicy>
    <ino:GrantRevenuePolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzU4_4b92dca3-2663-419a-8818-c87b9bd809ba">Grants&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for various grant agreements under the contributions guidance under Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;, which is outside the scope of Topic 606, as the government agencies granting the Company funds are not receiving reciprocal value for their contributions. All contributions received from current grant agreements are recorded as a contra-expense as opposed to revenue on the consolidated statement of operations.</ino:GrantRevenuePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzA3_b2017f45-dff5-4278-a800-82e77f060f5d">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional and presentation currency of the Company is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. The cumulative translation adjustment is included in the accumulated other comprehensive income (loss) within the statement of stockholders' equity. Exchange differences are included in general and administrative expenses in the consolidated statement of operations. Non-monetary assets and liabilities measured at cost are remeasured at the exchange rate at the date of the transaction.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzM4_1fb84def-6c6f-4ba4-9d65-9891a5a7d87b">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Variable Interest Entities (VIE)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its ownership, contractual and other interests in entities that are not wholly-owned to determine if these entities are VIEs, and, if so, whether the Company is the primary beneficiary of the VIE. In determining whether the Company is the primary beneficiary of a VIE and therefore required to consolidate the VIE, the Company applies a qualitative approach that determines whether it has both (1) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and (2) the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. The Company will continuously perform this assessment, as changes to existing relationships or future transactions may result in the consolidation or deconsolidation of a VIE.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzI3_79fb72ab-d4c7-4f06-9c3e-46f8eb269581">Equity Investments&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC Topic 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the Company must measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in the consolidated statement of operations. The Company can elect a measurement alternative for equity investments that do not have readily determinable fair values and do not qualify for the practical expedient in ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement,&lt;/span&gt; to estimate fair value using the net asset value per share (or its equivalent).&#160;The Company's equity investments that do not have readily determinable fair values and do not qualify for the net asset value practical expedient for estimating fair value are measured at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identifiable or similar investments of the same issuer.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzA4_5b1fdae2-4f59-4c58-9943-d683776a6d0f">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s activities have largely consisted of research and development efforts related to developing electroporation delivery technologies, DNA vaccines, DNA immunotherapies and dMABs. Research and development expenses consist of expenses incurred in performing research and development activities including salaries and benefits, facilities and other overhead expenses, clinical trials, contract services and other outside expenses. Research and development expenses are charged to operations as they are incurred. These expenses result from the Company's independent research and development efforts as well as efforts associated with collaborations and licensing arrangements. The Company reviews and accrues clinical trial expense based on work performed, which relies on estimates of total costs incurred based on participant enrollment, completion of studies and other events. Accrued clinical trial costs are subject to revisions as trials progress. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. Historically, revisions have not resulted in material changes to research and development expense; however, a modification in the protocol of a clinical trial or cancellation of a trial could result in a charge to the Company's results of operations.&lt;/span&gt;&lt;/div&gt;Advance payments for goods or services to be rendered in the future for use in research and development activities are deferred and included in prepaid expenses and other assets. The deferred amounts are expensed as the related goods are delivered or the services are performed.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDEx_9982eefa-7669-4da9-87ec-c0b8a2fb0178">Net Loss Per Share&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss for the year by the weighted average number of shares of common stock outstanding during the year. Diluted net loss per share is calculated in accordance with the treasury stock method for the outstanding stock options and restricted stock units ("RSUs") and reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted to common stock. The dilutive impact of the outstanding Notes and Bonds issued by the Company (discussed in Note 9) has been considered using the "if-converted" method. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The calculation of diluted net loss per share requires that, to the extent the average market price of the underlying shares for the reporting period exceeds the exercise price of the options or other securities and the presumed exercise of such securities are dilutive to net loss per share for the period, an adjustment to net loss used in the calculation is required to remove the change in fair value of such securities from the numerator for the period. Likewise, an adjustment to the denominator is required to reflect the related dilutive shares, if any. &lt;/span&gt;For the years ended December 31, 2022, 2021 and 2020, basic and diluted net loss per share are the same, as the assumed exercise or settlement of stock options, RSUs and the potentially dilutive shares issuable upon conversion of the Notes and Bonds are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5NDI1_ce4444d2-08ae-4e4c-84ea-43d5894b718b">&lt;div style="margin-top:4.5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes potential shares of common stock that were excluded from diluted net loss per share calculation because of their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,221,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,906,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,558,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance-based restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;663,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,049,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2019 Bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,009,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,943,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,654,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,190,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b5c26fff9c54ee6aeec015bd77060ea_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzItMS0xLTEtNDk4Mjg_29bad806-38ac-494d-b5b2-f67dc00d4a75"
      unitRef="shares">12221548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia738364cb3704782bff4583a29069493_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzItMy0xLTEtNDk4Mjg_93fd9b73-867c-45b5-b243-6158d66232cd"
      unitRef="shares">10488993</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibf4c53fa971d4d039d0b3f9f50813d00_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzItNS0xLTEtNDk4Mjg_1f576281-75af-4a37-9a17-9ad59f99d3d2"
      unitRef="shares">8906624</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i778adc9858e4413284de317978f1491e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzQtMS0xLTEtNDk4Mjg_b22f20c0-8320-4609-9ee1-7a39bb421091"
      unitRef="shares">2556257</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8f6a30b1663b4a28822ba910bb5f0d2b_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzQtMy0xLTEtNDk4Mjg_073942c4-3dd9-445c-b34a-8056e41398d0"
      unitRef="shares">2448868</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i385f8bc5e1ef496fa5bf4b77f4ac4c8d_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzQtNS0xLTEtNDk4Mjg_d8a90a1c-c3c2-4b36-b2fc-0afb73542d7b"
      unitRef="shares">2558052</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i905fef709da24983a7a134952ad5cd76_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzUtMS0xLTEtNDk4Mjg_bc0e2c49-0797-4162-8243-3005e049635e"
      unitRef="shares">111941</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c357726a9834da5b7f9e01126ab1934_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzUtMy0xLTEtNDk4Mjg_aa19d084-bfd7-441d-8aad-cd851e3f3e3b"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i793c2cf60aba4213b7dda26b6bd1d0bf_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzUtNS0xLTEtNDk4Mjg_f91579cd-1243-4868-81e2-f418fc4cf0db"
      unitRef="shares">663353</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2234c920452e4ca5a201f3f44924f639_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzYtMS0xLTEtNDk4Mjg_5bac15a4-ce61-49c4-b04f-bb69dcfa9c62"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3ea03f1cc4604b918e8a86d38eb57330_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzYtMy0xLTEtNDk4Mjg_b46d99a9-f338-4eb0-9036-00860b8e0c55"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9983d93acb00482e8d0d425200e8a260_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzYtNS0xLTEtNDk4Mjg_86a12d75-332e-4d23-8e04-fe491c90475d"
      unitRef="shares">3309</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4acef92df1eb4002905dc17370558309_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzctMS0xLTEtNDk4Mjg_ccfae5ae-4cc5-4023-821d-04a3cb37990a"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic26efa4ca4234676aff27081710a3c9f_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzctMy0xLTEtNDk4Mjg_3d40c084-ee49-4db0-bcc9-f4fd3032c531"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8b5b9fd187a54c0e8a75c5406595c067_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzctNS0xLTEtNDk4Mjg_f8c68f65-5611-43df-becf-7535191ac277"
      unitRef="shares">3049980</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0b6db699219044e993eb9ea5a3b6b102_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzktMS0xLTEtNDk4Mjg_d51771ff-a3fc-4b74-90b0-0df3fee5beb3"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e7e112a8d0b4389b6475906e5e25f9a_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzktMy0xLTEtNDk4Mjg_37220e81-53fa-429e-99c5-90b404b482bf"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i38c6268345f84faf98df07aa08e09d50_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzktNS0xLTEtNDk4Mjg_ec0655cc-fdfc-4d32-97ca-92b813cbc7e0"
      unitRef="shares">1009450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzEwLTEtMS0xLTQ5ODI4_1ec45027-dab8-4701-b76f-8c03332f5fe1"
      unitRef="shares">17943035</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzEwLTMtMS0xLTQ5ODI4_594b6bf9-4fdf-4af5-85d3-f663dcec824d"
      unitRef="shares">16654503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTplNWI3MzEyM2RiMDM0NjI5ODBhMTQxNmYyNGVjM2Y2OS90YWJsZXJhbmdlOmU1YjczMTIzZGIwMzQ2Mjk4MGExNDE2ZjI0ZWMzZjY5XzEwLTUtMS0xLTQ5ODI4_6a1c6e4f-bf94-4fd8-814b-7128a7463a64"
      unitRef="shares">16190768</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzcw_c7a71750-f751-4fab-935a-2c302330a51f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For its long-term operating leases, the Company recognized an operating lease right-of-use asset and an operating lease liability on its consolidated balance sheets. The lease liability is determined as the present value of future lease payments using an estimated rate of interest that the Company would pay to borrow equivalent funds on a collateralized basis at the lease commencement date. The right-of-use asset is based on the liability adjusted for any prepaid or deferred rent. The Company determines the lease term at the commencement date by considering whether renewal options and termination options are reasonably assured of exercise. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed rent expense for the Company's operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses on the consolidated statements of operations. Variable lease payments including lease operating expenses are recorded as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mzc4_0eb1d75e-944b-4c6c-92a1-34989d01a921">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurs stock-based compensation expense related to RSUs and stock options. The fair value of restricted stock is determined by the closing price of the Company's common stock reported on the Nasdaq Global Select Market on the &lt;/span&gt;&lt;/div&gt;date of grant. The Company estimates the fair value of stock options granted using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of subjective assumptions, including the expected stock price volatility and expected option life. The Company amortizes the fair value of the awards on a straight-line basis over the requisite vesting period of the awards. Expected volatility is based on historical volatility. The expected life of options granted is based on historical expected life. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant. The dividend yield is based on the fact that no dividends have been paid historically and none are currently expected to be paid in the foreseeable future. The Company recognizes forfeitures as they occur.</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5MzMy_f6d6b04b-3adb-4017-a43a-231a2d02acf0">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to employees and directors are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.63%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average assumptions used in the Black-Scholes model for option grants to non-employees are presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.736%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.741%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.96%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzItMS0xLTEtNDk4Mjg_04f3d56c-0097-4d88-ba85-0517aa0a8e04"
      unitRef="number">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzItMy0xLTEtNDk4Mjg_e903fa72-63e9-4d0d-b48d-74e3d6b64769"
      unitRef="number">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzItNS0xLTEtNDk4Mjg_ce587f9a-344a-4fc7-93c4-99b37775010b"
      unitRef="number">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzMtMS0xLTEtNDk4Mjg_8369eb14-0c41-472a-8986-64d39952045a"
      unitRef="number">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzMtMy0xLTEtNDk4Mjg_2724b47c-52da-42e9-8f04-0abc4c5e6672"
      unitRef="number">0.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzMtNS0xLTEtNDk4Mjg_f08546a5-e896-46cb-a028-265c9922db93"
      unitRef="number">0.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzQtMS0xLTEtNDk4Mjg_0b9f1be4-1c02-42db-a0e9-8752e5d79b50">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzQtMy0xLTEtNDk4Mjg_bd773674-2fc2-48c7-b6a3-acdce7587d05">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzQtNS0xLTEtNDk4Mjg_ba62b967-bfa2-4e18-b717-417ad771a9af">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i666a23e01c6442398866e53b58f368d5_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzUtMS0xLTEtNDk4Mjg_d8d756b3-f12e-44d9-af70-c8a3c015d1de"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7b6ebbe842384e6692effb0b7e76058d_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzUtMy0xLTEtNDk4Mjg_681d595a-4b01-4ca3-a028-a051e261081e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i81ebdc0a7c8a49979d5eb1829589d480_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTphNmRlNGIxODMzMjE0MzRkOWRhNjQ3MGMzZDA1MGYxOS90YWJsZXJhbmdlOmE2ZGU0YjE4MzMyMTQzNGQ5ZGE2NDcwYzNkMDUwZjE5XzUtNS0xLTEtNDk4Mjg_d5d3176a-c014-480c-ad05-3d292d1e9c1c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzItMS0xLTEtNDk4Mjg_a8ba89ea-5c8a-42ac-b70d-284cb74e1659"
      unitRef="number">0.0196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzItMy0xLTEtNDk4Mjg_66bb99d8-bf35-4030-9568-e6bc891165b2"
      unitRef="number">0.0145</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzItNS0xLTEtNDk4Mjg_f98c4111-73bb-4937-8f9b-213d69d13e5c"
      unitRef="number">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzMtMS0xLTEtNDk4Mjg_fb9a9c68-ccba-471f-9940-d006a2ec2e4b"
      unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzMtMy0xLTEtNDk4Mjg_e82eae8c-b72d-4bd2-be4d-9e877b129928"
      unitRef="number">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzMtNS0xLTEtNDk4Mjg_efa06eb1-74c2-4546-9898-a50cb6179ed7"
      unitRef="number">0.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzQtMS0xLTEtNDk4Mjg_e3ea1e8b-be85-4922-b191-0ea5f103ad8a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzQtMy0xLTEtNDk4Mjg_78a26f7c-8b94-40c5-a75d-29870d4b2dd8">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzQtNS0xLTEtNDk4Mjg_39ae1195-88b5-45ac-bc9a-eed5b42cdf33">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9b76961524d04519babd13c38f8c9dc9_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzUtMS0xLTEtNDk4Mjg_7d5e722c-d92d-414e-bc54-02c994c94c76"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9b99cbe2247c4d0889152a220cde8a70_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzUtMy0xLTEtNDk4Mjg_1c71ff39-48a1-43a9-9164-b2d8a4827a93"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6cb872fefb714074b5880db078069e39_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90YWJsZTpmMjZkN2JiYTI1Y2U0NzdiOTA1ZWEyZjA5MWNkN2VkMC90YWJsZXJhbmdlOmYyNmQ3YmJhMjVjZTQ3N2I5MDVlYTJmMDkxY2Q3ZWQwXzUtNS0xLTEtNDk4Mjg_5abf7554-ec9c-45c6-995c-e09d9653356f"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzM5Mjg3_e8bdbab2-3d97-4bfd-832f-dfb5dd06a4c0">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recent accounting pronouncements below may have a significant effect on the Company's financial statements. Recent accounting pronouncements that are not anticipated to have an impact on or are unrelated to the Company's financial condition, results of operations, or related disclosures are not discussed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU No. 2020-06.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2020-06&#x201d;), which simplifies the guidance on an issuer&#x2019;s accounting for convertible instruments and contracts in its own equity. ASU 2020-06 was effective for public entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years. The Company adopted ASU 2020-06 as of January 1, 2022 on a modified retrospective basis and recorded a net reduction in accumulated deficit of $1.8&#160;million, a decrease in additional paid-in capital of $3.3&#160;million, and an increase in convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Company derecognized the related deferred tax liabilities of $1.5&#160;million with a corresponding adjustment to the valuation allowance, resulting in no net impact to the cumulative adjustment to retained earnings (see Note 9, Convertible Debt, for additional information).&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcxMzU_d7cf9543-8bca-4b3d-b7c7-184845e4243d"
      unitRef="usd">1800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcxNjI_942e3057-ac7b-4d3b-9efd-4e123e556efb"
      unitRef="usd">-3300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ConvertibleDebt
      contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcxODk_ff38ecaa-17ff-4e99-907a-9b9470bb9825"
      unitRef="usd">1500000</us-gaap:ConvertibleDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ib54af4db6f934822936c9df96da62d29_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xMzkvZnJhZzpkMjlhYTMyODQ3OTA0OTZhODc2NDMzZTkzZDRjNGVkMC90ZXh0cmVnaW9uOmQyOWFhMzI4NDc5MDQ5NmE4NzY0MzNlOTNkNGM0ZWQwXzE2NDkyNjc0ODcyMTY_bfb59b9b-6b20-4c49-93a3-f5ff5d62940a"
      unitRef="usd">1500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzExNjE_7d439786-ea92-4d97-8386-2046e2e80706">Revenue Recognition and Concentration of Credit RiskDuring the years ended December&#160;31, 2022, 2021 and 2020, the Company recognized revenue from various license and other agreements. The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advaccine&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc. (affiliated entity)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,591,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,411,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Of the total revenue recognized during the year ended December&#160;31, 2022, $14,000 was in deferred revenue as of December 31, 2021. During the year ended December 31, 2021, the Company recognized revenue of $46,000 that was included in deferred revenue at December 31, 2020. Performance obligations are generally satisfied within 12 months of the initial contract date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of December&#160;31, 2022, all of the Company's accounts receivable was attributable to the CEPI MERS grant. As of December&#160;31, 2021, $3.6 million, or 65%, and $1.9 million, or 34%, of the Company's accounts receivable was attributable to the DoD and CEPI MERS grants, respectively. There is minimal credit risk with these customers based upon collection history, their size and financial condition. Accordingly, the Company does not consider it necessary to record a reserve for uncollectible accounts receivable.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzExNjI_e760ea9c-c5fc-469f-a7fd-a29a3b1bd22c">The following table indicates the percentage of total revenues in excess of 10% with any single customer:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.945%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.967%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.201%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.678%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Customer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;%&#160;of&#160;Total&lt;br/&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Advaccine&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plumbline Life Sciences, Inc. (affiliated entity)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,370,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Department of Defense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,591,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other, including affiliated entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;774,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,040,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,262,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,411,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacebae33d2f744a48bfe3f27c87963b5_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtMS0xLTEtNDk4Mjg_a4aaf5bd-bda7-4822-bff4-30d3831dc8c7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4c2ca730669f40a3b880aad76ef47eb8_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtMy0xLTEtNDk4Mjg_43f088fe-6cff-441a-b3b1-98a84935c6d4"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec30835ff64649d1af8bee1755bb6747_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtNS0xLTEtNDk4Mjg_6719a287-f1c3-4a21-b189-27832d715bb3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib0233517f0744b4d84dbc2857651922e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtNy0xLTEtNDk4Mjg_7836313a-7f9f-4981-b52e-f69a9e08176e"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8427d8144b8a45508082c0e9224f6b9a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtOS0xLTEtNDk4Mjg_47f6eb0c-eb73-4673-932c-8a40e585fba4"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if216a168540f4767a05cedea2727d91b_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzMtMTEtMS0xLTQ5ODI4_a7a03454-3ae6-4d71-a08e-028333b000b2"
      unitRef="number">0.68</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3508c7fdd5df49c9b3d412117527967f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtMS0xLTEtNDk4Mjg_29456713-6a49-4a8e-be1a-fcb341c15223"
      unitRef="usd">33596</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iba97b678f2164b7dab82b6edbc9c7f26_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtMy0xLTEtNDk4Mjg_ad39d1af-6399-4ce8-aabc-d99129206c2d"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i605c60f66d234792a11598c1cdedabc7_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtNS0xLTEtNDk4Mjg_5de2a4d3-bc4c-49d7-8c2b-7cf64770a420"
      unitRef="usd">245310</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d452e7c90114add826a2726068eca7b_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtNy0xLTEtNDk4Mjg_24a28440-29e3-4ffd-8948-f94cfe42c892"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39566c733fd24bfebb62337eb808c542_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtOS0xLTEtNDk4Mjg_eefaadfc-af92-4f7d-b352-7f29565cbcd9"
      unitRef="usd">1370396</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifcac4af5c7b542f9afc5cb5e93d18b8e_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzQtMTEtMS0xLTQ5ODI4_3d83edac-bdda-4477-9aeb-ee79f1fd88c4"
      unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia146e47921c744fc956b2120c6439daf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtMS0xLTEtNDk4Mjg_d5b4b6e8-3bba-445c-b96d-d1a591f99dd8"
      unitRef="usd">9591778</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idd3d9ccb223c4b51adcc34fee442e12e_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtMy0xLTEtNDk4Mjg_4d29a5f7-5123-4dbd-8902-09c77686f4e0"
      unitRef="number">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i950175750d8f45f99adff0b9d015b817_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtNS0xLTEtNDk4Mjg_00fddf64-adc1-41ed-9ad8-ec99ab01b43d"
      unitRef="usd">754853</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i990e94fbd63b4cd8aa841335ddf7a196_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtNy0xLTEtNDk4Mjg_6cceec16-e03f-41bf-855c-09845c4424d1"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifaa2ff55b5b64c87ac5b7a3c20a2340a_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtOS0xLTEtNDk4Mjg_c4aa2774-5234-437a-8061-fb10d5347148"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if3e0c5185d2f4ec88fb795922202c563_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzUtMTEtMS0xLTQ5ODI4_2c4b5989-cefb-406c-838e-5d199ef67be7"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96a3222a554c43c892ad45d36bed2135_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtMS0xLTEtNDk4Mjg_1191d842-91d1-43a4-aed4-96cc9b7a57d5"
      unitRef="usd">636894</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9b4cbfef541641c29b555849b7baa86b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtMy0xLTEtNDk4Mjg_867d2fe3-49ef-4877-9287-68df2e39832b"
      unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i87e6793803cc44808ce478887c3e8548_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtNS0xLTEtNDk4Mjg_cdf7ef71-1c0b-409f-86a9-c98df264c3d6"
      unitRef="usd">774595</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i022f7c48f8c449e0984cc5c418c9249f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtNy0xLTEtNDk4Mjg_38d16470-7496-41c2-9be0-58eb0034eeef"
      unitRef="number">0.43</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4c58350d8dd4037a4eeb106f14f84bb_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtOS0xLTEtNDk4Mjg_9ef0b230-2b83-4362-a1d6-c57728e0fb0a"
      unitRef="usd">1040824</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7a04772ad7c34b45b0fea6aab0e11b68_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzYtMTEtMS0xLTQ5ODI4_60006bd6-860d-42b1-ba79-1b1f1a3b8477"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctMS0xLTEtNDk4Mjg_e416e211-0741-491e-b872-55995d6b31fb"
      unitRef="usd">10262268</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i24234386041445bca5cb6066f1a957bc_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctMy0xLTEtNDk4Mjg_78a7a5f5-cd52-4afc-8075-5fee38abeb42"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctNS0xLTEtNDk4Mjg_a426fc56-7c7b-4cd6-8622-d34e7777681b"
      unitRef="usd">1774758</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7aa7c00e7c454fc0aadae3a3b369359e_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctNy0xLTEtNDk4Mjg_c21fa1ec-5926-411c-9336-f5db6a84726f"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctOS0xLTEtNDk4Mjg_4a7a4cec-9e0d-4d94-b9a7-963f6f908342"
      unitRef="usd">7411220</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id150bf83ee8f48f998faaca40b1a30ec_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90YWJsZTpmOTRjNjljNDlhMDk0NDI4ODkwYWNkYTI0Yjg0NWU4NC90YWJsZXJhbmdlOmY5NGM2OWM0OWEwOTQ0Mjg4OTBhY2RhMjRiODQ1ZTg0XzctMTEtMS0xLTQ5ODI4_82e57218-e5f0-4dec-9b10-6040c453ba7c"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzM1Mw_f71d3380-2444-430d-9c2a-7cfff00aa414"
      unitRef="usd">14000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzQ3Ng_52e53778-7f5b-4765-87a6-26d60635158e"
      unitRef="usd">46000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:AccountsReceivableNet
      contextRef="icb0c56d581394886b4899de7fc50e0e5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzgwOQ_da32bf35-4f5c-456a-94f0-d4e95805f9f0"
      unitRef="usd">3600000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1e1e7149a8c6422490e7e06c70d28310_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzgxNg_80463e5e-23cd-4e15-a276-dded3b1f0328"
      unitRef="number">0.65</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AccountsReceivableNet
      contextRef="i2a71317f6eea40f7b6476ead84dae594_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzE2NDkyNjc0NDI4NTY_5ffaf116-f47d-4d26-a2d0-1c229c0eaa32"
      unitRef="usd">1900000</us-gaap:AccountsReceivableNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic78b5c6c0e794855951b9ce333c34e4d_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDIvZnJhZzo5NWJhMDQwOWRkNDQ0MmMwYjgwNGU1ZDgwNWM1Y2ZiZS90ZXh0cmVnaW9uOjk1YmEwNDA5ZGQ0NDQyYzBiODA0ZTVkODA1YzVjZmJlXzE2NDkyNjc0NDI4NjU_28e900f2-baa2-4c9c-89b1-9d9909a5923c"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIxOTI1_432d2ad8-e239-4e54-977e-8992ea86e7c2">Collaborative Agreements &lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Advaccine Biopharmaceuticals Suzhou Co., Ltd. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 31, 2020, the Company entered into a Collaboration and License Agreement with Advaccine Biopharmaceuticals Suzhou Co., Ltd. (&#x201c;Advaccine&#x201d;), which was amended and restated on June 7, 2021 (as amended and restated, the &#x201c;Advaccine Agreement&#x201d;). Under the terms of the Advaccine Agreement, the Company granted to Advaccine the exclusive right to develop, manufacture and commercialize the Company&#x2019;s vaccine candidate INO-4800 within the territories of China, Taiwan, Hong Kong and Macau (referred to collectively as &#x201c;Greater China&#x201d;) and 33 additional countries in Asia. Advaccine does not have the right to grant sublicenses, other than to affiliated entities, without the Company&#x2019;s express prior written consent. As part of the collaboration, Advaccine also granted to the Company a non-exclusive license to certain DNA vaccine manufacturing processes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2021 amendment related to a collaboration between the Company and Advaccine to jointly conduct a global Phase 3 segment of the Company&#x2019;s clinical trial of INO-4800. The parties were jointly participating in the trial and were to equally share the global development costs for the trial, including the Company&#x2019;s manufacturing costs to supply INO-4800. Advaccine agreed to be fully responsible for conducting the trial in Greater China, including its costs and expenses incurred. On October 27, 2022, the Company announced that it had discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. Advaccine will continue to develop INO-4800 with its own resources under the terms of the Advaccine Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, Advaccine made an upfront payment to the Company of $3.0&#160;million in January 2021. In addition to the upfront payment, the Company is entitled to receive up to an aggregate of $200.0&#160;million upon the achievement of specified milestones related to the development, regulatory approval and commercialization of INO-4800, including the achievement of specified net sales thresholds for INO-4800 in Greater China and the additional covered territories, if approved. The Company will also be entitled to receive a royalty equal to a high single-digit percentage of annual net sales in each region within the licensed territory, subject to reduction in the event of competition from biosimilar products in a particular region and in other specified circumstances. Advaccine&#x2019;s obligation to pay royalties will continue, on a licensed product-by-licensed product basis and region-by-region basis, for ten years after the first commercial sale in a particular region within Greater China or, if later, until the expiration of the last-to-expire patent covering a given licensed product in a given region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in the first calendar year following the first commercial sale of INO-4800 in the licensed territory outside of Greater China, Advaccine will pay the Company an annual maintenance fee of $1.5&#160;million for a period of five years, which fee will be creditable against any royalties payable by Advaccine with respect to sales outside of Greater China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Advaccine Agreement, the Company will supply Advaccine&#x2019;s clinical requirements of INO-4800 and devices, although Advaccine may manufacture INO-4800 for its clinical use and may procure alternate suppliers. Advaccine is responsible for the manufacture and supply of INO-4800 itself or through a contract manufacturer for commercial use. Upon Advaccine&#x2019;s reasonable request, the parties may negotiate a separate clinical and/or commercial supply agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Advaccine Agreement will continue in force on a region-by-region basis until Advaccine has no remaining royalty obligations in such region. Either party may terminate the Advaccine Agreement (i) in the event the other party shall have materially breached its obligations thereunder and such default shall have continued for a specified period after written notice thereof or (ii) upon the bankruptcy or insolvency of the other party. In addition, the Company may terminate the agreement, upon prior written notice, if Advaccine (i) ceases all development or commercialization activities for at least nine months, subject to certain exceptions, or (ii) challenges the validity, enforceability or scope of any of the patents licensed by the Company to Advaccine under the Advaccine Agreement, subject to certain conditions. Advaccine may terminate the Advaccine Agreement at any time for convenience upon nine months&#x2019; written notice to the Company, if such notice is provided before the first commercial sale of INO-4800 in the licensed territory, or&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 18 months&#x2019; written notice thereafter; provided that the Company may accelerate the effectiveness of such termination to the extent permitted by law.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the terms of the Advaccine Agreement under ASC Topics 606 and 808 at inception and determined that the contract was with a customer and therefore should be accounted for under ASC Topic 606. The license to INO-4800 in the territories was identified as the only distinct performance obligation on a standalone basis as of the inception of the Advaccine Agreement. The Company concluded that the license was distinct from potential future manufacturing and supply obligations. The Company further determined that the transaction price under the Advaccine Agreement consisted of the $3.0&#160;million upfront payment received in January 2021 plus a $2.0&#160;million milestone payment which was achieved upon contract signing. The future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained. As part of the evaluation of the development and regulatory milestones constraint, the Company determined that the achievement of such milestones is contingent upon success in future clinical trials and regulatory approvals, each of which is uncertain. Future potential milestone amounts may be recognized as revenue under the Advaccine Agreement, as well as under other collaborative research and development arrangements, if unconstrained. Reimbursable program costs will be recognized proportionately with the performance of the underlying services or delivery of drug supply and are excluded from the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under Topic 606, the entire transaction price of $5.0&#160;million was allocated to the license performance obligation. The Company recognized &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0, $0 and $5.0&#160;million of revenue for &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the years ended December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021, and 2020, respectively, under the Advaccine Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the June 2021 amendment, the Company determined that the global Phase 3 trial component of the agreement was a collaboration and not a contract with a customer and therefore accounted for the June 2021 amendment under ASC Topic 808. Reimbursements from Advaccine were recognized as contra-research development expense on the consolidated statement of operations once earned and collectibility was assured.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2022, 2021 and 2020 the Company received funding of $1.2&#160;million, $4.5&#160;million and $0, respectively, from Advaccine that was recorded as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; contra-research and development expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ApolloBio Corporation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;29, 2017, the Company entered into an Amended and Restated License and Collaboration Agreement (the "ApolloBio Agreement"),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with ApolloBio Corporation ("ApolloBio"), with an effective date of March 20, 2018. Under the terms of the ApolloBio Agreement, the Company granted to ApolloBio the exclusive right to develop and commercialize&#160;VGX-3100, its DNA immunotherapy product candidate designed to treat&#160;pre-cancers&#160;caused by HPV, within the agreed upon territories.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is entitled to receive up to an aggregate of $20.0 million, less required income, withholding or other taxes, upon the achievement of specified milestones related to the regulatory approval of&#160;VGX-3100&#160;in accordance with the ApolloBio Agreement. In the event that&#160;VGX-3100 is approved for marketing, the Company will be entitled to receive royalty payments based on a tiered percentage of annual net sales, with such percentage being in the&#160;low-&#160;to&#160;mid-teens,&#160;subject to reduction in the event of generic competition in a particular territory. ApolloBio&#x2019;s obligation to pay royalties will continue for 10 years after the first commercial sale in a particular territory or, if later, until the expiration of the&#160;last-to-expire&#160;patent covering the licensed products in the specified territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ApolloBio Agreement will continue in force until ApolloBio has no remaining royalty obligations. Either party may terminate the ApolloBio Agreement in the event the other party shall materially breach or default in the performance of its material obligations thereunder and such default continues for a specified period after written notice thereof. In addition, ApolloBio may terminate the ApolloBio Agreement at any time beginning one year after the effective date for any reason upon 90 days written notice to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 and 2020, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;there has been no &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significant reimbursable program costs under the ApolloBio Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Coalition for Epidemic Preparedness Innovations &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously entered into agreements with CEPI pursuant to which the Company intended to develop vaccine candidates against Lassa fever and MERS. The goal of the collaboration between the Company and CEPI was to conduct research and development so that investigational stockpiles would be ready for clinical efficacy trial testing during potential disease outbreaks. The agreements with CEPI contemplated&#160;preclinical&#160;studies, as well as Phase 1 and Phase 2 clinical trials, occurring over multiple years. As part of the arrangement between the parties, CEPI agreed to fund up to an aggregate of $56 million of costs over a five-year period for preclinical studies, as well as planned Phase 1 and Phase 2 clinical trials, to be conducted by the Company and collaborators, with funding from CEPI based on the achievement of identified milestones. During the years ended December&#160;31, 2022, 2021 and 2020, the Company received funding of $6.7 million, $10.0 million and $6.4 million, respectively, related to these grants and recorded those payments as contra-research and development expense. As of December&#160;31, 2022 and 2021, the Company had &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;an accounts receivable balance of $1.7&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $1.9&#160;million, respectively, on the consolidated balance sheet related to these CEPI grants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company announced that it and CEPI would discontinue the development of these product candidates targeting Lassa fever and MERS, following the initial analysis of data from the studies conducted by the Company and funded by CEPI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, CEPI awarded the Company a grant of up to $9.0&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to support preclinical and clinical development of INO-4800 through Phase 1 human testing in the United States. In April 2020, CEPI awarded the Company a grant of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $6.9&#160;million &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to work with the International Vaccine Institute ("IVI") and the Korea National Institute of Health ("KNIH") to conduct clinical trials of INO-4800 in South Korea, a grant of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $5.0&#160;million to accelerate development of the Company's next-generation intradermal electroporation device, known as CELLECTRA 3PSP, for the intradermal delivery of INO-4800, and a grant of $1.3&#160;million to support large-scale manufacturing of INO-4800. During the years ended December&#160;31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021 and 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company received funding of $1.1 million, $6.9 million and $10.0 million, respectively, from CEPI related to these grants for INO-4800 and recorded such amounts as contra-research and development expense. As of December&#160;31, 2022 and 2021, the Company had $2.3&#160;million and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $1.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded as deferred grant funding on the consolidated balance sheet related to the CEPI grants related to INO-4800, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bill &amp;amp; Melinda Gates Foundation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, Gates awarded and funded the Company a grant of $2.2&#160;million to advance the development of dMAbs to address issues in infectious disease prevention and therapy. This technology has high relevance for the control of influenza and HIV. This next-generation approach to the delivery of monoclonal antibodies would make the technology accessible to low and middle-income countries. In August 2019, Gates funded an additional $1.1&#160;million for the project. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $233,000, $182,000 and $463,000, respectively, as contra-research and development expense related to the Gates dMAb grant. As of December&#160;31, 2022 and 2021, the Company had $153,000 and $384,000 recorded as deferred grant funding on the consolidated balance sheet related to the grant, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, Gates awarded and funded the Company a grant of $5.0&#160;million to accelerate the development of the CELLECTRA 3PSP device for the intradermal delivery of INO-4800. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $0, $893,000 and $4.1 million, respectively, as contra-research and development expense related to this Gates grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Defense (DoD) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In June 2020, the Company entered into an Other Transaction Authority for Prototype Agreement (the &#x201c;OTA Agreement&#x201d;)&#160;with the DoD to fund the Company&#x2019;s efforts in developing the CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;3PSP device and associated arrays to be used for delivery of&#160;INO-4800 against&#160;COVID-19. The total amount of funding provided to the Company under the OTA Agreement was $54.5&#160;million. The Company determined that the OTA Agreement should be considered under &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Subtopic 958-605, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Not-for-Profit Entities-Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, which is outside the scope of Topic 606, as the government agency granting the Company funds was not receiving reciprocal value for their contributions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company recorded contra-research development expense on the consolidated statement of operations in the same period that the underlying expenses were incurred. During the years ended December&#160;31, 2022, 2021 and 2020, the Company recorded $6.1 million, $27.1 million and $21.2 million, respectively, as contra-research and development expense related to the OTA agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Additionally, in June 2020, the Company was awarded a fixed-price contract (the &#x201c;Procurement Contract&#x201d;) from the DoD for the purchase of the Company&#x2019;s intradermal CELLECTRA&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 device and accessories. The total purchase price under the Procurement Contract was $16.8&#160;million. The&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; Company determined that the Procurement Contract fell under the scope of ASC Topic 606 as the contract was with a customer and the Company was able to satisfy its obligations under the arrangement. Performance obligations under the Procurement Contract consisted of the delivery of a specified number of CELLECTRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;2000 devices and accessories. The total transaction price was allocated to the individual performance obligations based on the determined standalone selling price for the devices and accessories. In 2021, the DoD announced that it would discontinue funding for the Phase 3 segment of the Company's clinical trials for INO-4800 and in January 2022, the total purchase price under the Procurement Contract was reduced to $10.7&#160;million. During the year ended December 31, 2022, all performance obligations under the Procurement Contract were satisfied. During the years ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2022, 2021 &lt;/span&gt;&lt;/div&gt;and 2020, the Company recorded revenue of $9.6&#160;million, $755,000 and $0, respectively, from the Procurement Contract.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="if01705c616d24d9da3e0014282dd5837_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzI2ODU_1d2b6b14-9674-4140-891a-059e00564397"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzI3OTg_7fb43bd1-1ad0-4f2a-9988-75bb469be88f"
      unitRef="usd">200000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzM2OTY_c9d9b67d-d399-4706-b3d3-d7840bfbf8a4">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <us-gaap:CostMaintenance
      contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzQwODk_bac4a79d-00f8-439f-9a12-4f3807d3422b"
      unitRef="usd">1500000</us-gaap:CostMaintenance>
    <ino:AnnualMaintenancePeriod
      contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzQxMDg_a7134d7e-fa7e-45a8-b03b-c689b415e8d0">P5Y</ino:AnnualMaintenancePeriod>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU3NTA_af08d52d-7fbb-43eb-bacb-0c70ea2afc3b">P18M</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="if01705c616d24d9da3e0014282dd5837_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzY1MDE_055799c4-348f-40f1-b584-623c5e48bcc5"
      unitRef="usd">3000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementPaymentEarned
      contextRef="i85a901e2e495476b83006c89b06314cf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzY1NjI_d4ba425f-760c-47db-ad97-46a132e393b5"
      unitRef="usd">2000000</ino:CollaborationAgreementPaymentEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85a901e2e495476b83006c89b06314cf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2Xzc0MzQ_97443b16-f8ed-4270-84e9-cae7a0f8c881"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d5a02ab98d44b87a3c2fe66c95e090a_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NjY5MjY_55572b0e-0ada-4904-bb7c-666e0e10e3af"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i677b7c07452f40d7bb6f5a339c25fa59_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzY5MjU_57703263-6d2f-484f-9bf7-ad41bfe4a6e8"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05af6b16800c4f969cf22fdff24b2acd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzY5MDg_59044bfb-d549-4e72-b046-900a905bfe0d"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i86e77b3388fd46f29ab915f284d3e570_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzU3MTk_2ac16d5e-ef01-4bbd-b640-88bd3fa812d1"
      unitRef="usd">1200000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i85a901e2e495476b83006c89b06314cf_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NjY5NzQ_a3ed51b8-bf32-49d4-acd5-7768c52022b6"
      unitRef="usd">4500000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i9d52f8c0138d4608b9e0be15696a4efd_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcyNzI_4458b4c9-67a9-45db-bca3-b0abe0209e22"
      unitRef="usd">0</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborationAgreementAdditionalRevenueToBeAchieved
      contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzEwMjI1_2e596b96-a58a-4bea-9879-26d6f9204c59"
      unitRef="usd">20000000</ino:CollaborationAgreementAdditionalRevenueToBeAchieved>
    <ino:CollaborationAgreementRoyaltyPeriod
      contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzEwNzcx_7ecbeedf-1c6f-47a0-b12b-94b5aa3ca000">P10Y</ino:CollaborationAgreementRoyaltyPeriod>
    <ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination
      contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzExMzkz_82238cf0-5b66-4fda-8a23-b76ed661a3fe">P1Y</ino:CollaborativeAgreementPeriodFromEffectiveDateForTermination>
    <ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination
      contextRef="i25c24cb1313b4c14bcfdf164d220c2ab_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzExNDQx_9d4fa542-5b1b-43eb-aef1-5141269509fe">P90D</ino:CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ia2001c79602b4f5b85e822a75b982b64_D20180411-20180411"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE1Nzky_611b7dd5-6f9a-4eb7-8cef-b0c7650d86ad"
      unitRef="usd">56000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment
      contextRef="ia2001c79602b4f5b85e822a75b982b64_D20180411-20180411"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIxOTIx_21c3576a-277e-4335-a4d7-c69e29df45f6">P5Y</ino:CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i90b72b34cbaa4c96b0e773c47a774b68_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzU3NTg_4fd49cbc-7d30-4417-9feb-a8fdfebe01ea"
      unitRef="usd">6700000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="iea847db8af964a5a95a30170013066a4_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNTE_c423d23c-91a7-495c-b29f-634a011c38e4"
      unitRef="usd">10000000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <ino:CollaborativeAgreementsUpfrontPaymentReceived
      contextRef="i8e1c6e230bbb4305a74e7bd299517f02_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNTk_c18380e2-29d9-4fc9-ad97-fe0db0aae127"
      unitRef="usd">6400000</ino:CollaborativeAgreementsUpfrontPaymentReceived>
    <us-gaap:AccountsReceivableNet
      contextRef="i624d921570e54646b679bccfad2456ed_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2Mjc4_a428302c-4207-4e27-b140-4b4a120840c9"
      unitRef="usd">1700000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i19d08d5f004243748735e0364a7ac6f0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcwODE_b7673394-879a-4857-b58c-bb65bada0a15"
      unitRef="usd">1900000</us-gaap:AccountsReceivableNet>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i5dd47e2e24e8451fbedb25fb61279123_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDQ3_ff90ea3b-5e8f-4f37-859a-b365bdd071aa"
      unitRef="usd">9000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ic6e68fd9d7034356a5daff34bafca427_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NjEz_fd1dca69-31a6-44fb-92de-c6f916d5db34"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i6fb8532210c34bb3b02229812e1d6ccf_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2Nzkx_500ba907-26b2-4cb2-9025-9bd3e6dd1c27"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i59d6c481f47d4e698f05a3589d8d4a5f_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2OTcy_749d42fe-3df8-4be7-845f-e0851daa1f35"
      unitRef="usd">1300000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i82d467a9444a402eab652428f5f340aa_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3MDkx_3c676adf-9a01-45d3-aeb3-024e8abe5bbe"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i953055247fb0438694e88e83fe092f34_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3MDk4_d151a1aa-516d-49c1-a501-3d8c504eb3da"
      unitRef="usd">6900000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i6e7ae79d83454d1a94162dfaaf181c92_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNjU_4f4022f8-a92f-4ed9-9787-c1ba25d7f370"
      unitRef="usd">10000000</ino:CollaborativeAgreementFundingToBeReceived>
    <us-gaap:GrantsReceivable
      contextRef="i0972fde3981d46cb86a06b579ea816d4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3MjU4_57de9447-cc1c-429f-b8f3-a1ee4d758607"
      unitRef="usd">2300000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="i526c4d9267ea40f59d929793e9e609e6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzY5NTU_95024dc6-23aa-4b37-95be-f33acf16d89f"
      unitRef="usd">1800000</us-gaap:GrantsReceivable>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i650513b7b0b042eba217f78ede5cb81f_D20181001-20181031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3NTE1_f0b4a96a-1106-4efa-b9f5-e375374d3a3b"
      unitRef="usd">2200000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i743b9e9db9bf47abb1bdc985839a7e95_D20190801-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3ODc4_5ba04997-b6fb-4522-a776-d0616f30a544"
      unitRef="usd">1100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i5fd06dc6be4e490f8fbf48221de75ab1_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3OTUz_71abed3d-a8af-44ce-b63f-57b041494b4c"
      unitRef="usd">233000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i93c96775125a4f49bee81002302c8881_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE3OTYw_c208d5d2-beda-4e0c-891d-7361816d9bb0"
      unitRef="usd">182000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i0fb85cb9a30245a59734675d97301f64_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxNzU_dba8fd68-4cf4-42cf-b11e-63310770f28d"
      unitRef="usd">463000</ino:CollaborativeAgreementFundingToBeReceived>
    <us-gaap:GrantsReceivable
      contextRef="i0715a0fcc3914e2c86a2471c1d0415ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4MDgw_367bea6b-f822-4b66-b3a1-d2b31277dbc8"
      unitRef="usd">153000</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="i2137a35c3759425c9f6105f0eb18daad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcxODg_4b7cccea-1dd1-45db-892f-9cd42a829547"
      unitRef="usd">384000</us-gaap:GrantsReceivable>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ife18dab7106f4cfab95e7efa34dda590_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4MjM3_e36a3d94-f979-46a8-9cc4-28bfe3b90afb"
      unitRef="usd">5000000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="i83eec1d80cf54e79a405e0ac8c7c3446_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4Mzk3_d71c2554-e40d-49d2-8083-0c241cde7e75"
      unitRef="usd">0</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="ia5c86a87fced4537bffa81e5585402dd_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE4NDA0_b16452a7-2657-4559-bfe0-c6f6262e88ca"
      unitRef="usd">893000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingToBeReceived
      contextRef="id3e8f8ce3eb145728468142b2b4b4151_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcyMTY_a7eb44a7-1ca5-4527-862f-c32f15050b6e"
      unitRef="usd">4100000</ino:CollaborativeAgreementFundingToBeReceived>
    <ino:CollaborativeAgreementFundingReceived
      contextRef="i0ef3b95e79d94359931733a1d9c874ae_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE5NDEw_f671c17f-3125-4d1a-b2c6-23dd7d97372f"
      unitRef="usd">54500000</ino:CollaborativeAgreementFundingReceived>
    <ino:GrantProceedsReceived
      contextRef="ib87dc46031834cbabb9a823d652b3f5f_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU0OTc1NTg0OTYwMw_dbfb44f5-45ff-4db8-ac62-1af5e46de26c"
      unitRef="usd">6100000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="ibdb55475f21c4c86a9e26fd186d37d72_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU0OTc1NTg0OTYwOA_4e1275f9-88fa-4077-8160-17e652c401af"
      unitRef="usd">27100000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="idd5f4f4bdca146dda0cf7316b5eddc03_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzU0OTc1NTg0OTYxNg_02c29d01-7d14-465d-99e8-5343c2ba1cdb"
      unitRef="usd">21200000</ino:GrantProceedsReceived>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i0ef3b95e79d94359931733a1d9c874ae_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIwMjcw_1dc7c278-91b1-4ab2-97da-ea625c68167a"
      unitRef="usd">16800000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementFixedPriceContractAmountAwarded
      contextRef="i0a8536568e6643a3826b271bb765d299_D20220101-20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzM5NjU_1fb5218a-e86c-4aee-a3a2-e0874125149e"
      unitRef="usd">10700000</ino:CollaborativeArrangementFixedPriceContractAmountAwarded>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract
      contextRef="i115835ccef2c4c728f65ff50b203bbd4_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzQxODI_901e8144-ac93-4435-bfc3-33ea5ad8bd25"
      unitRef="usd">9600000</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract
      contextRef="ieed26bae30344c0d930f02e46a10d2c3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzIxMDc1_45f4832e-a166-45f2-ba81-136bd6fd17fc"
      unitRef="usd">755000</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <ino:CollaborativeArrangementRevenueFromTheProcurementContract
      contextRef="i045659d16234450a8682a7768426647b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDUvZnJhZzpmZjkzZjgzMTM1ZGU0NTdhYTI4Y2M0ODVkMTY3MmQ4Ni90ZXh0cmVnaW9uOmZmOTNmODMxMzVkZTQ1N2FhMjhjYzQ4NWQxNjcyZDg2XzE2NDkyNjc0NzcyMjY_6d0beff7-69ea-4c38-a819-cfa1f9fc4bce"
      unitRef="usd">0</ino:CollaborativeArrangementRevenueFromTheProcurementContract>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MDY_1835ff9c-ff66-488f-9ee6-f4875b6ceb99">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December&#160;31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8&#160;million and $3.2&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2022,&#160;2021&#160;and&#160;2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2022, the Company had&#160;29&#160;available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2022&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain or loss on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the &lt;/span&gt;&lt;/div&gt;service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2022 and 2021.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MDY_9729f0ce-bd38-4638-b954-85345ca405b5">Short-term Investments and Fair Value Measurements&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2022 and 2021, the Company recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gross realized ga&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in on investments of $21,000 and $394,000, respectively, and gross realized loss on investments of $4.1 million and $399,000, respectively. During the years ended December&#160;31, 2022 and 2021, the Company recorded net unrealized loss on available-for-sale equity securities of $7.8&#160;million and $3.2&#160;million, respectively. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No&#160;material balances were&#160;reclassified out of accumulated&#160;other comprehensive loss for the years ended&#160;December&#160;31, 2022,&#160;2021&#160;and&#160;2020. Interest and dividends on investments classified as available-for-sale are included in interest income in the consolidated statements of operations. As of December&#160;31, 2022, the Company had&#160;29&#160;available-for-sale securities in a gross unrealized loss position, of which 21 with an aggregate total unrealized loss of $8.7 million were in such position for longer than 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically reviews its portfolio of available-for-sale debt securities to determine if any investment is impaired due to credit loss or other potential valuation concerns. For the debt securities where the fair value of the investment is less than the amortized cost basis, the Company has assessed at the individual security level for various quantitative factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of impairment. Unrealized losses on available-for-sale debt securities as of&#160;December&#160;31, 2022&#160;were primarily due to changes in interest rates, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and not due to increased credit risks associated with specific securities. Based on the credit quality of the available-for-sale debt securities that are in an unrealized loss position, and the Company&#x2019;s estimates of future cash flows to be collected from those securities, the Company believes the unrealized losses are not credit losses.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, at December&#160;31, 2022, the Company has not recorded an allowance for credit losses related to its available-for-sale debt securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 assets at December&#160;31, 2022 and 2021 consisted of mutual funds and U.S. treasury securities held by the Company that are valued at quoted market prices, as well as the Company&#x2019;s investment in its affiliated entity, PLS. The Company accounts for its investment in 597,808 common shares of PLS based on the closing price of the shares on the Korea New Exchange Market on the applicable balance sheet date. Unrealized gains and losses on the Company's equity securities are reported in the consolidated statement of ope&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rations as unrealized gain or loss on available-for-sale equity securities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or as a gain or loss on investment in affiliated entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 assets at December&#160;31, 2022 consisted of certificates of deposit and U.S. agency mortgage-backed securities held by the Company that are initially valued at the transaction price and subsequently valued, at the end of each reporting period, typically utilizing market observable data. Level 2 assets at December&#160;31, 2021 consisted of commercial paper, certificates of deposit and U.S. agency mortgage-backed securities. The Company obtains the fair value of its Level 2 assets from a professional pricing service, which may use quoted market prices for identical or comparable instruments, or inputs other than quoted prices that are observable either directly or indirectly. The professional pricing service gathers quoted market prices and observable inputs from a variety of industry data providers. The valuation techniques used to measure the fair value of the Company's Level 2 financial instruments were derived from non-binding market consensus prices that are corroborated by observable market data, quoted market prices for similar instruments, or pricing models such as discounted cash flow techniques. The Company validates the quoted market prices provided by the primary pricing service by comparing the &lt;/span&gt;&lt;/div&gt;service's assessment of the fair values of the Company's investment portfolio balance against the fair values of the Company's investment portfolio balance obtained from an independent source.There were no Level 3 assets held as of December&#160;31, 2022 and 2021.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MTA_34ae57db-b7c3-4794-a1f3-b65c469c18b1">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of available-for-sale securities as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,036,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,373,514)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,001,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,977,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;216,450,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,802,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.839%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.812%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Maturity&#160;(in&#160;years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&#160;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Market&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;---&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,966,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,614,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,193,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,976,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,608,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331,712,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,648,668)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*No single maturity date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItMy0xLTEtNDk4Mjg_43ff01fd-f004-4a83-8909-f5fdb4c79fa1"
      unitRef="usd">117036232</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItNS0xLTEtNDk4Mjg_17ab3dca-5e01-4574-8265-ce60850e8ab1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItNy0xLTEtNDk4Mjg_d507da42-9623-4d99-a517-679c75ed422a"
      unitRef="usd">9373514</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6069d61346224762a4acb6d0319cd34b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzItOS0xLTEtNDk4Mjg_6086c2ce-8c9b-4186-b0f4-264a4b52b464"
      unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i8c404065aa374228af041779ee4cc690_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtMS0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpiY2QxMzQ5MzBhZTA0NGRiYWYxMTJmZGQ3NTEwYTI0Y18xNA_a6adfec0-a531-4be9-ab6f-b3c88e9659b7">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtMy0xLTEtNDk4Mjg_8689c49e-d8aa-4d99-b46f-99628bcd890c"
      unitRef="usd">95001209</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtNS0xLTEtNDk4Mjg_913003a2-0faf-4b5f-a407-eeb16c2480d4"
      unitRef="usd">7567</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtNy0xLTEtNDk4Mjg_89a11a16-5942-48e1-8e00-0a75f78ca191"
      unitRef="usd">44266</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i394eb6bee034494f9c9496c6ce256993_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzMtOS0xLTEtNDk4Mjg_69df9559-f2f1-48f8-985f-5843c1b53f4b"
      unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i00707a03b34c4fcbbec4fec91c975908_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtMS0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmMDZiY2JjYjdmMTM0Y2E3OTQ4NjcwYzY1Y2JmYzQyMl8xNA_c2a5600b-1455-4a5b-b81f-d0a1087deb09">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtMy0xLTEtNDk4Mjg_cd514f55-dfe9-468e-92ff-99b8f33a882e"
      unitRef="usd">2977564</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtNS0xLTEtNDk4Mjg_b41df0a5-b882-4921-ba49-108235ff208a"
      unitRef="usd">13664</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtNy0xLTEtNDk4Mjg_036daac9-f070-4fac-83fb-344db210af5a"
      unitRef="usd">320</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe96ffbd0e984b259b36f75c11046687_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzUtOS0xLTEtNDk4Mjg_83664b30-9117-4839-9a9a-1887d97907de"
      unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtMy0xLTEtNDk4Mjg_4f91267c-8bf1-44b3-82d6-f93a423146f7"
      unitRef="usd">1435592</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtNS0xLTEtNDk4Mjg_0428e72d-806d-42cc-b4c1-a4c2896d14f7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtNy0xLTEtNDk4Mjg_ed10c567-8319-4962-b0cb-0562977ab5f1"
      unitRef="usd">384331</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib38202672cc64d6990a3e920cb9cc97e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzYtOS0xLTEtNDk4Mjg_0c8c6008-3663-47d0-a475-92ff15a5194e"
      unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtMy0xLTEtNDk4Mjg_cac30a69-6681-4460-8b96-1f12c6bd7794"
      unitRef="usd">216450597</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtNS0xLTEtNDk4Mjg_34667d3f-7230-43a4-a4fd-7afbb2e57016"
      unitRef="usd">21231</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtNy0xLTEtNDk4Mjg_356ec45f-f08e-4b2e-be78-9d740971a784"
      unitRef="usd">9802431</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpkOGUxMzYwYTIzNmQ0YmE1OGY5ODcxYjNhMDhiODEyMi90YWJsZXJhbmdlOmQ4ZTEzNjBhMjM2ZDRiYTU4Zjk4NzFiM2EwOGI4MTIyXzgtOS0xLTEtNDk4Mjg_929d3c92-dc2b-4647-9477-051ccacee056"
      unitRef="usd">206669397</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItMy0xLTEtNDk4Mjg_77ef70b2-7289-4094-ac45-43948c8847a5"
      unitRef="usd">192966772</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItNS0xLTEtNDk4Mjg_4b44f34a-ca36-4f04-b2f2-0994f84fb066"
      unitRef="usd">87069</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItNy0xLTEtNDk4Mjg_65728a37-b865-43fc-9632-a422c6e4348d"
      unitRef="usd">1614411</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1224aeba242c41d5ab7db7226ed80399_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzItOS0xLTEtNDk4Mjg_23ea6208-bd0f-41dc-82de-01e06f83c8d2"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMS0xLTEtNTExNzUvdGV4dHJlZ2lvbjozYmZmNzBiYzM3Y2E0NmYzOTNmNjgxNDQ3ODM5MzUwZF8xNA_bc8a4d84-a22f-4d6c-93a3-7af07685e886">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMy0xLTEtNTExODM_5804c07b-7de0-4a35-9a36-5006f24c3156"
      unitRef="usd">94193441</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNS0xLTEtNTExODM_d26889b4-bb22-46cb-988e-648d3f44fd8e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNy0xLTEtNTExODM_f2534e1e-d070-4cf6-bd62-f38c142cd5c0"
      unitRef="usd">9921</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id37d05cb9f5d42caa6e09898a3f84573_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtOS0xLTEtNTExODM_6440b558-85b3-4332-aef7-1d54a54ae082"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMS0xLTEtNDk4MjgvdGV4dHJlZ2lvbjplNGJlMWY5ZjE4ZjE0N2NjYmFlMTBkY2M1YjIxMTJjNV8xNA_bc8a4d84-a22f-4d6c-93a3-7af07685e886">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtMy0xLTEtNDk4Mjg_7609be73-8307-48c3-8c04-be22103989fe"
      unitRef="usd">39967853</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNS0xLTEtNDk4Mjg_9c2f9086-c0c2-41a2-a707-d076a7eb12df"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtNy0xLTEtNDk4Mjg_e5661e56-198e-4c8f-affc-bd8edf7cc2b5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if3fca8c2d78840729b4acd29bd42d46b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzMtOS0xLTEtNDk4Mjg_a69fb821-6e05-49b0-9bbb-baaf8a612642"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ino:DebtSecuritiesAvailableforSaleContractualMaturity
      contextRef="i06f43110c2d940109d3faa686a89b14d_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtMS0xLTEtNTExNjQvdGV4dHJlZ2lvbjo0MGFhMWQzOWM1OWM0N2UyYTE0ZmExZDNjODY4MjI1ZF8xNA_bc8a4d84-a22f-4d6c-93a3-7af07685e886">P1Y</ino:DebtSecuritiesAvailableforSaleContractualMaturity>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtMy0xLTEtNDk4Mjg_c76855ff-1724-4df5-b5e2-f836bae0c598"
      unitRef="usd">2976210</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtNS0xLTEtNDk4Mjg_3c4c78dc-e7ce-4c00-bd6b-08f92add510e"
      unitRef="usd">15618</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtNy0xLTEtNDk4Mjg_e741bb74-7dbc-4b89-98af-8f2337f9e027"
      unitRef="usd">338</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if8231f8423e648e3831733a20c3b6e00_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzQtOS0xLTEtNDk4Mjg_1adfbb00-f773-468b-9dbd-25668977c916"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtMy0xLTEtNDk4Mjg_1686770b-7747-4792-840f-1f54119675cb"
      unitRef="usd">1608137</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtNS0xLTEtNDk4Mjg_f75e2448-c446-484a-b096-819247ae9e36"
      unitRef="usd">4508</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtNy0xLTEtNDk4Mjg_b3f0895d-41f7-400d-8559-7a518931ecd3"
      unitRef="usd">23998</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie753e892040f46cfa5eaaf24a0aa310d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzUtOS0xLTEtNDk4Mjg_41dc341b-9f76-42f3-8033-3b1756455d7d"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtMy0xLTEtNDk4Mjg_41ca6f92-05c0-4e47-b95c-d48f047377a9"
      unitRef="usd">331712413</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtNS0xLTEtNDk4Mjg_5e127820-b974-42bc-bd40-d3251809c556"
      unitRef="usd">107195</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtNy0xLTEtNDk4Mjg_8d2ca605-1e32-478b-96d2-e6af3501530e"
      unitRef="usd">1648668</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo1YjM0NzM2YTA5NTE0MzNlOGJkNDM0NDA5ZTk3NDUzZC90YWJsZXJhbmdlOjViMzQ3MzZhMDk1MTQzM2U4YmQ0MzQ0MDllOTc0NTNkXzYtOS0xLTEtNDk4Mjg_41ded366-ee13-4b60-926d-2ff6c7bc0826"
      unitRef="usd">330170940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzI2Mw_f90e96a2-d733-4885-abfc-27d039865890"
      unitRef="usd">21000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzI3MA_e4b41839-3506-4cc8-827d-590153352051"
      unitRef="usd">394000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzMzMA_1016880c-dd91-419e-ab61-219ab1c30519"
      unitRef="usd">4100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzMzNw_07b3da82-392e-405a-8c2f-9664e419462e"
      unitRef="usd">399000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MA_54886739-4ab3-40a7-a056-b0569a36edbe"
      unitRef="usd">-7800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4Nw_034e874b-ad3e-4c0a-b249-371d08956289"
      unitRef="usd">-3200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzgwNw_fe5d90b2-9d68-456e-92ff-12316edda021"
      unitRef="position">29</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4Xzg4Ng_f93234a8-d299-4098-bdeb-5c6ca808606a"
      unitRef="position">21</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzkzMg_56bd724e-8f72-4956-bcd4-3597b6eb55a6"
      unitRef="usd">-8700000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzQ4MDU_48f5e875-c159-4701-94b0-979d438abd04">&lt;div style="margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.059%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107,662,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,964,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,990,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,051,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,669,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202,627,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,007,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,676,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,634,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,042,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets that were measured at fair value on a recurring basis, determined using the following inputs as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.762%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Mutual funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,439,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,183,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,967,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,991,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. agency mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,588,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330,170,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,622,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,906,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,077,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289,529,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,547,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b2add8fd23e494f887f27eb874b2134_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtMS0xLTEtNDk4Mjg_f0ddbcd8-4080-4dc0-83bb-4799cb77db87"
      unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib18c28bf3960424a854d14b13675393f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtMy0xLTEtNDk4Mjg_330ca55e-ada2-4218-bdd2-c36c1c6f77e2"
      unitRef="usd">107662718</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i93622c19682e47a18bd389447a17beb8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtNS0xLTEtNDk4Mjg_f28c2953-7459-4be8-a4db-ed1f8df384b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d28cb507a504198a57d5181ce08ac8f_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzgtNy0xLTEtNDk4Mjg_2e2db9c0-d02d-4669-8498-adb6bfb14a5e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib904a495e82646c380154c25b095b55a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktMS0xLTEtNDk4Mjg_ad73eca8-4b22-4acd-9645-0ed14305530d"
      unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07066c0990e24538bc05caed189f78fb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktMy0xLTEtNDk4Mjg_0aeb8c08-c3ce-4fc8-9b5b-e92f2959fc13"
      unitRef="usd">94964510</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia3648b2d58fe42268eae0877934e1081_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktNS0xLTEtNDk4Mjg_7d7443ff-fa37-4848-a235-83a182efbc55"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b37d006f03d47b3b8e7c0a1873c00f5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzktNy0xLTEtNDk4Mjg_30e5063e-d8b1-4cf6-8dab-0424e48d5817"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb9dfd820dc743fda9f61d926e90be25_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTEtMS0xLTQ5ODI4_c3277ede-2e2f-416f-90b7-c1ec44918dbb"
      unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc86246d2a124c419654fa1e9bf8dc32_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTMtMS0xLTQ5ODI4_f59de93a-cdd6-4092-a3b5-afb6891fa1c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86004616beac41238cc173e85e423ddf_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTUtMS0xLTQ5ODI4_abc23289-21cb-468b-8370-7a1f9ee48e0b"
      unitRef="usd">2990908</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i477c90290ae74d219ed8ba9ff7390f90_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzExLTctMS0xLTQ5ODI4_217d8478-a6a8-46cd-a25e-124341451b48"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0dc9d150f733431f97498d614ee4a8db_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTEtMS0xLTQ5ODI4_761cba9e-0f87-42d4-b45a-44cf2b729778"
      unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i186cb4d8d2d24f43bf75c63e229647ae_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTMtMS0xLTQ5ODI4_2de28432-1474-4326-b646-bd435ff2ba1e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i619f71a84cc54c479c772df5eeaf3bb8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTUtMS0xLTQ5ODI4_291ca98d-ddf8-4a63-9bb1-618245bada5a"
      unitRef="usd">1051261</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i01197e4e2ce54a9f9c6f4e01fa548a46_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzEyLTctMS0xLTQ5ODI4_9f6026c2-0ab9-4d63-b935-c3309616d838"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i72d5d82697444dd38fb5e557609c0c36_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTEtMS0xLTQ5ODI4_ff727309-2a88-4886-a973-c8d2c3da8186"
      unitRef="usd">206669397</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c8775bf17fa47f3b938211c08019c26_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTMtMS0xLTQ5ODI4_6897ebe1-2714-40d0-b77c-7c6a3d5d0985"
      unitRef="usd">202627228</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTUtMS0xLTQ5ODI4_6fe9953e-bd42-4f79-9186-d287211e5789"
      unitRef="usd">4042169</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0d1f385cc4944c44a2038acebc25f9cb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE0LTctMS0xLTQ5ODI4_be3483de-fd6e-4986-a6de-8c74f15a9ec9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i72d5d82697444dd38fb5e557609c0c36_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTEtMS0xLTQ5ODI4_7d929e9b-ef03-4783-9257-d482c8521c1f"
      unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i7c8775bf17fa47f3b938211c08019c26_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTMtMS0xLTQ5ODI4_ecd1529f-47c5-474d-86cd-98b27aa1f47d"
      unitRef="usd">2007142</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTUtMS0xLTQ5ODI4_9f84d99a-6cca-4f29-8046-9844cfbb0c68"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i0d1f385cc4944c44a2038acebc25f9cb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE2LTctMS0xLTQ5ODI4_6f4867f0-a0b6-4524-bd9e-3895fdb67d43"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i72d5d82697444dd38fb5e557609c0c36_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTEtMS0xLTQ5ODI4_86836882-b922-411e-8e20-cf746f17aea2"
      unitRef="usd">208676539</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c8775bf17fa47f3b938211c08019c26_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTMtMS0xLTQ5ODI4_2f81eaaa-c885-4d17-a73e-409c33188645"
      unitRef="usd">204634370</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie2f1a3aa000a4c529d0ebf995559a96c_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTUtMS0xLTQ5ODI4_15666ef7-7149-4bd0-88e2-db92e5ebea85"
      unitRef="usd">4042169</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0d1f385cc4944c44a2038acebc25f9cb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTpmYzBhYjUzNTYzYmI0ZTNiOWEyMmI1ODA2YWQ4ZDg1Ni90YWJsZXJhbmdlOmZjMGFiNTM1NjNiYjRlM2I5YTIyYjU4MDZhZDhkODU2XzE3LTctMS0xLTQ5ODI4_242088cd-f607-41c4-aa9e-54c14c13d305"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9de6860abc2a4ad68642fef0b295cbfb_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMS0xLTEtNDk4Mjg_81c48efe-fc8e-4f69-9138-4b3ef1769878"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i48fb0a0d192947be932e34702459a178_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMy0xLTEtNDk4Mjg_874181aa-ef7f-49df-9287-b4d92b7de6a7"
      unitRef="usd">191439430</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4be9cf58cb4a4d05880ed751b4f5ec5b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNS0xLTEtNDk4Mjg_eb19bc73-f673-4844-be4c-737626df5c85"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84830cf68b7443bca9c062e649dd83d6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNy0xLTEtNDk4Mjg_8c409a84-292e-486b-8fc8-3e8ffc31e981"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i37194e785fbe427fa670a663c8578ab1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMS0xLTEtNTEyOTQ_c27d122e-f401-4a18-9859-5a0acc1cf1ff"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7e279598e344efcb34f380149832910_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktMy0xLTEtNTEyOTQ_e82c69a8-8223-44c6-abed-4951b88ac57f"
      unitRef="usd">94183520</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49986e2e16ef472cb8df7bab0e9e2546_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNS0xLTEtNTEyOTQ_ace4d29c-e7da-4033-9005-93671d88598d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3867bd2a43024f87bb44709b985fcf7d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzktNy0xLTEtNTEyOTQ_bbdbba86-ca29-49a0-812d-b2d093df3405"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06eace206e6e4294aa395dafbbaf4688_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTEtMS0xLTUxMjk0_52f178a7-65df-4adb-a753-e0b096266bfa"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0fceb1189d5448b79ca2bbb77264e050_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTMtMS0xLTUxMjk0_6c293b24-1e7c-488c-bd01-c16226064e77"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i23d3f92702014f969ac3d1af800214f7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTUtMS0xLTUxMjk0_69d879c7-e489-47ad-a5e7-b12de697d5af"
      unitRef="usd">39967853</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f4ae7cd847f4617951fb8ff3f3100f1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTctMS0xLTUxMjk0_8afb408b-5f07-4cfc-a3cd-b781666d7b51"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1ffb3a787b3b45cd813aa7b2f5ed87b8_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTEtMS0xLTQ5ODI4_b7d30711-b229-4dca-bba7-ee6584670536"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icd4592471329482e8c0661f6abdb0594_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTMtMS0xLTQ5ODI4_57e57b4f-ca0a-4ba2-86a2-4a343316abc8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i936b53682ed8485d8ce3260a62f5541a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTUtMS0xLTQ5ODI4_0491efb9-3a08-4345-bdde-0d097db73699"
      unitRef="usd">2991490</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2013fc31e88d4b0bb859d16c236f4634_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEwLTctMS0xLTQ5ODI4_877d1df2-7915-4808-b05e-d978f92ed684"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0608f84c1ca4f2990271fa5a4b1c79b_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTEtMS0xLTQ5ODI4_74f96529-68f5-4a81-b5a5-eba760b6b4cf"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i91447d855fe3401ebf5c16b61ccf4a0f_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTMtMS0xLTQ5ODI4_4bcccb66-9dc0-4e37-8d91-84d3b8a07d14"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0971090c3254e23a37a6a1c85cbf09d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTUtMS0xLTQ5ODI4_02492979-02a5-4471-b22a-ab6845d2d2e3"
      unitRef="usd">1588647</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i176930b6d6c643fa8db9ce1084359b5d_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzExLTctMS0xLTQ5ODI4_a175bbef-5cf0-4127-b5b2-99e8d1797cd9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i28e0a92a960d49f88d849ddf682a08b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTEtMS0xLTQ5ODI4_d23ac57e-ecff-47d8-8ffd-16c3952f2534"
      unitRef="usd">330170940</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67083206a9594573bb4dbe4cb68aa3af_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTMtMS0xLTQ5ODI4_04871afb-8720-4df8-bb6e-a1c3e4cec01c"
      unitRef="usd">285622950</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i49b293969cc040c983dd1f2e97563558_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTUtMS0xLTQ5ODI4_14f36ce6-4fa5-403d-b5f4-f54d57d9e01c"
      unitRef="usd">44547990</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6c675487b97442eb5c6a91aff241fcf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzEyLTctMS0xLTQ5ODI4_deaca99b-76d5-41d5-8dbb-7bcc908e5bc5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i28e0a92a960d49f88d849ddf682a08b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTEtMS0xLTQ5ODI4_fb11422d-55cc-4a82-aa87-1efc5e56ae44"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i67083206a9594573bb4dbe4cb68aa3af_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTMtMS0xLTQ5ODI4_f630d869-33b8-423b-af1c-c3f56be37111"
      unitRef="usd">3906796</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i49b293969cc040c983dd1f2e97563558_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTUtMS0xLTQ5ODI4_2b60ac3b-fc67-4598-b8f5-6b5fcc67ce37"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="if6c675487b97442eb5c6a91aff241fcf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE0LTctMS0xLTQ5ODI4_dce25bf6-65db-4779-9fcb-4a20360f2954"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i28e0a92a960d49f88d849ddf682a08b5_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTEtMS0xLTQ5ODI4_d1621bc6-3b0f-4680-8f3e-4741c25a36ca"
      unitRef="usd">334077736</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i67083206a9594573bb4dbe4cb68aa3af_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTMtMS0xLTQ5ODI4_0f784224-25f8-42e9-8c59-12a0fdbab0ed"
      unitRef="usd">289529746</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i49b293969cc040c983dd1f2e97563558_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTUtMS0xLTQ5ODI4_601e463e-35d5-44d5-9b38-d8ca86be333c"
      unitRef="usd">44547990</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if6c675487b97442eb5c6a91aff241fcf_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90YWJsZTo0OGI3N2Y1ZTBjYzY0NzE5YjliMzE3ZTViMzNjNDA1Zi90YWJsZXJhbmdlOjQ4Yjc3ZjVlMGNjNjQ3MTliOWIzMTdlNWIzM2M0MDVmXzE2LTctMS0xLTQ5ODI4_0a342ae3-8f8b-4f8e-a67e-9ac43e948812"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i3448daba76f24eb6a3f805c849575a5e_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNDgvZnJhZzo2YzZjOTRiMTc3MDA0OTY1YTFiMGIyNDY3ZGE5NTQyOC90ZXh0cmVnaW9uOjZjNmM5NGIxNzcwMDQ5NjVhMWIwYjI0NjdkYTk1NDI4XzI5NDA_ddec8c81-fd8e-4a90-8b0a-5969b0426a98"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzUxMg_3ec8c714-319f-4407-b7e4-ba754ab99408">Certain Balance Sheet Items&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets at December&#160;31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance recovery (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,474,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,729,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,130,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,862,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,424,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,574,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,112,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,106,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,686,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,644,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#x201c;Legal Proceedings.&#x201d; The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.</us-gaap:OtherCurrentAssetsTextBlock>
    <ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzUxMw_bbbb2c58-4f3f-4fdd-8459-2b4f10aa99b9">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid and other current assets at December&#160;31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance recovery (a)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,401,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,474,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,729,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,362,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,130,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,836,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMS0xLTEtNTEzMzM_0d0761a9-9a75-4290-b321-a04082b38b47"
      unitRef="usd">30000000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:EstimatedInsuranceRecoveries
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMy0xLTEtNTEzMzM_8756008f-c684-44b9-bca3-3af127714348"
      unitRef="usd">0</us-gaap:EstimatedInsuranceRecoveries>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMS0xLTEtNDk4Mjg_99befb13-7ce0-4a76-b954-1dcaa83dc10d"
      unitRef="usd">1401028</ino:PrepaidManufacturingExpensesCurrent>
    <ino:PrepaidManufacturingExpensesCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzEtMy0xLTEtNDk4Mjg_e10f2cd6-d32b-4b1a-b579-932e6943d3f1"
      unitRef="usd">27474159</ino:PrepaidManufacturingExpensesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzItMS0xLTEtNDk4Mjg_8d8965c9-cd28-4ddd-9ade-da252f33fdee"
      unitRef="usd">18729453</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzItMy0xLTEtNDk4Mjg_364ce9db-1375-4f31-ade6-ba227ac96bf5"
      unitRef="usd">11362832</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzQtMS0xLTEtNDk4Mjg_4b8d90d8-9404-4405-aa03-3d525a3210dc"
      unitRef="usd">50130481</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZTo3NWQ0ZTIwNDIxM2M0ZGE3YjNiZWRlYjE2NTc5ZGEzZS90YWJsZXJhbmdlOjc1ZDRlMjA0MjEzYzRkYTdiM2JlZGViMTY1NzlkYTNlXzQtMy0xLTEtNDk4Mjg_c8220ed0-4d66-4dc9-a570-ae24498ae2c0"
      unitRef="usd">38836991</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzEwOTk1MTE2Mjk1OTY_9684544a-1aad-4bcd-b372-fd721b7aded7">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses at December&#160;31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,862,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,424,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,574,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,112,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation settlement (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,106,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,686,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,644,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(a)In July 2022, the Company entered into a memorandum of understanding for the proposed settlement of the class action securities litigation described in this report under &#x201c;Legal Proceedings.&#x201d; The final judicial order for the settlement was issued in January 2023. The settlement consists of $30.0&#160;million in cash and $14.0&#160;million in shares of the Company's common stock to settle all outstanding claims. As of December 31, 2022, the Company's insurance carriers had paid the cash component of the proposed settlement, which amounts were being held in escrow. The Company's insurance carriers paid $252,000 of other expenses on behalf of the Company, which amounts are being offset against the insurers' cash commitment as part of the settlement.</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzEtMS0xLTEtNTE0MjQ_2df9a530-2e02-4667-9047-b2628e5ed954"
      unitRef="usd">19862487</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzEtMy0xLTEtNTE0MjQ_ee5993ad-9215-4fe5-af5f-4291fc097f93"
      unitRef="usd">27424743</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzItMS0xLTEtNTE0MjQ_9c8fcb9d-fd5b-441c-85e3-a31294933152"
      unitRef="usd">12574921</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzItMy0xLTEtNTE0MjQ_a1091c49-b775-438d-b372-f5154cca8f9e"
      unitRef="usd">16112912</us-gaap:AccruedSalariesCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzMtMS0xLTEtNTE0MjQ_9af89996-729d-4b3c-ac1c-42ac1c35b628"
      unitRef="usd">44000000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzMtMy0xLTEtNTE0MjQ_636f6d0e-d8af-4562-ac8a-aa0d3ba387b0"
      unitRef="usd">0</us-gaap:LitigationReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzQtMS0xLTEtNTE0MjQ_7b85e0a1-10eb-4d93-92f8-68b479b8204f"
      unitRef="usd">3249477</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzQtMy0xLTEtNTE0MjQ_2d37011b-7e0d-4ed8-864f-1faa6cdc391e"
      unitRef="usd">4106875</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzUtMS0xLTEtNTI1ODM_51bb133f-c98f-4a72-83e2-5c51aa01e9ab"
      unitRef="usd">79686885</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90YWJsZToyYWQ1ODhkNjJkMDg0NDA0ODU0NjU3ZTJlNmNkOTg5Zi90YWJsZXJhbmdlOjJhZDU4OGQ2MmQwODQ0MDQ4NTQ2NTdlMmU2Y2Q5ODlmXzUtMy0xLTEtNTI1ODM_85b05681-a604-41ac-9b3f-06128ff888c4"
      unitRef="usd">47644530</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i4d198f1f030e444294b8ea36f6116b09_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzE2NDkyNjc0NDMzMjA_c51a94ff-957e-4b12-829d-7530b46f3aff"
      unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares
      contextRef="i4d198f1f030e444294b8ea36f6116b09_I20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzE2NDkyNjc0NDMzNDk_e7ac27b7-b31e-4b13-91f8-20cee76ada60"
      unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="i77a209b559d5422f82009bd955139f3d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTEvZnJhZzoxNzI3MmE1NzNhZTI0ODhlODk2ZDllMDBiOGU4NDM2Ni90ZXh0cmVnaW9uOjE3MjcyYTU3M2FlMjQ4OGU4OTZkOWUwMGI4ZTg0MzY2XzE2NDkyNjc0NDMzNzM_e59ab9a6-7e8d-4be8-8bcc-c0d5708eeb3f"
      unitRef="usd">252000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzQ1NA_fc215da3-2eb3-4207-951d-cd625ed23a68">Fixed Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,036,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,767,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,295,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,360,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,428,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,291,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,563,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,727,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,258,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,544,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,392,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,113,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,397,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,944,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,453,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense for the years ended December&#160;31, 2022, 2021 and 2020 was $3.7 million, $3.0 million and $3.0 million, respectively. The Company determined that the carrying value of these long-lived assets was not impaired during the periods presented. During the year ended December 31, 2022 the Company sold fixed assets with a net book value of $6.1&#160;million and disposed of fixed assets with a net book value of $1.1&#160;million. The Company has recorded a receivable from the sale of these assets of $6.1&#160;million, which is included in prepaid expenses and other current assets on the consolidated balance sheet.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzQ1OA_5fd19f0d-48ff-427e-85e4-66213dfaaeba">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets at December&#160;31, 2022 and 2021 consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Depreciation&lt;br/&gt;and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,036,080)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,767,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,300,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,295,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,803,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,360,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,428,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;932,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,291,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,563,403)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,727,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,803,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,258,608)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,544,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,392,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,279,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,113,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,827,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,599,643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,374,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,567,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,397,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,944,378)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,453,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzItMS0xLTEtNDk4Mjg_57bb9d37-cfe5-4f09-913a-7ae1d4800669"
      unitRef="usd">15803108</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzItMy0xLTEtNDk4Mjg_ccd77303-3e90-485b-9046-82dd86ac0c2b"
      unitRef="usd">10036080</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a64151e1cc64174b4e4bdf3642a26ba_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzItNS0xLTEtNDk4Mjg_814994c1-98c0-4c22-9260-604086c03010"
      unitRef="usd">5767028</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7b1117d2331b42a9a95485f3c02170c5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzQtMS0xLTEtNDk4Mjg_6ceab958-6d39-4079-ab31-03bec93b7702"
      unitRef="usd">5300104</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7b1117d2331b42a9a95485f3c02170c5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzQtMy0xLTEtNDk4Mjg_99b98570-204e-441f-b58a-6cfca6e7242a"
      unitRef="usd">4295217</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7b1117d2331b42a9a95485f3c02170c5_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzQtNS0xLTEtNDk4Mjg_daf7167e-f9b0-4fcc-8e29-bbc9364b7330"
      unitRef="usd">1004887</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzUtMS0xLTEtNDk4Mjg_0b55c98b-9790-46da-928f-ffbf3aa39040"
      unitRef="usd">2827476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzUtMy0xLTEtNDk4Mjg_17330190-73e3-40dc-9b98-06ecade12227"
      unitRef="usd">2803800</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3b724ef01ab94d48b4ebda7e127fd3df_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzUtNS0xLTEtNDk4Mjg_4da92ad8-a24a-468e-b73b-cd3c416f152c"
      unitRef="usd">23676</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3b6b301ab495414cb544cfeec3509fd4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzYtMS0xLTEtNDk4Mjg_7917b458-5b26-4d50-a76d-a7b2fc9076ea"
      unitRef="usd">5360712</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3b6b301ab495414cb544cfeec3509fd4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzYtMy0xLTEtNDk4Mjg_299a03fd-bdc9-4050-b8f0-06a30be31388"
      unitRef="usd">4428306</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3b6b301ab495414cb544cfeec3509fd4_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzYtNS0xLTEtNDk4Mjg_eebe4cef-e7ac-477c-9097-ea31ea77484f"
      unitRef="usd">932406</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzctMS0xLTEtNDk4Mjg_d2db9091-ff02-44c8-8b0a-990f05e3c0a8"
      unitRef="usd">29291400</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzctMy0xLTEtNDk4Mjg_17e429b4-060d-4ca1-ae74-a8dd19c5e7fa"
      unitRef="usd">21563403</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzctNS0xLTEtNDk4Mjg_bc740997-ad6d-44b8-ae17-a4db7d850f04"
      unitRef="usd">7727997</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i482ffaf143e145b29a6c013341ec65b1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzktMS0xLTEtNDk4Mjg_d9bc9686-2260-44e7-b918-ac93c827e133"
      unitRef="usd">15803108</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i482ffaf143e145b29a6c013341ec65b1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzktMy0xLTEtNDk4Mjg_9193785d-9f70-480a-b201-7d8cd6f3b5e3"
      unitRef="usd">8258608</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i482ffaf143e145b29a6c013341ec65b1_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzktNS0xLTEtNDk4Mjg_2bb60851-a286-4dd0-b94d-39698f4ba0c4"
      unitRef="usd">7544500</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia8a8f742a37148a19cfc04478fa8b852_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEwLTEtMS0xLTQ5ODI4_2572cadf-6883-4332-8a3c-205f9209bd22"
      unitRef="usd">12392916</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia8a8f742a37148a19cfc04478fa8b852_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEwLTMtMS0xLTQ5ODI4_3debc3d7-e91b-4050-aee9-0cdce9a258aa"
      unitRef="usd">4279816</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia8a8f742a37148a19cfc04478fa8b852_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEwLTUtMS0xLTQ5ODI4_bc85f2fe-8bcd-4789-9863-40124ae6c8ac"
      unitRef="usd">8113100</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4852db4bcad84553977888af623d132e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzExLTEtMS0xLTQ5ODI4_1452f280-eb59-4636-a611-e1d600184542"
      unitRef="usd">2827476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i4852db4bcad84553977888af623d132e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzExLTMtMS0xLTQ5ODI4_8642db1f-4e5b-4e94-bdf3-96b502c838ad"
      unitRef="usd">2599643</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i4852db4bcad84553977888af623d132e_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzExLTUtMS0xLTQ5ODI4_1c497549-0172-45a0-b11b-c9cbcff552d3"
      unitRef="usd">227833</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEyLTEtMS0xLTQ5ODI4_2a985bf1-0c8e-4473-b115-e428647208b3"
      unitRef="usd">5374084</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEyLTMtMS0xLTQ5ODI4_6aaae577-7101-4e44-9ce9-1c0c5a36c713"
      unitRef="usd">3806311</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie93585d2f3774a71b8c1ed830ff7f3d7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEyLTUtMS0xLTQ5ODI4_2f649793-8165-487c-ab9c-b75d5dc8eb7e"
      unitRef="usd">1567773</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEzLTEtMS0xLTQ5ODI4_a87340bd-35a0-43b9-bb70-a16d4b4c7357"
      unitRef="usd">36397584</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEzLTMtMS0xLTQ5ODI4_09660ce1-d2df-4f16-a089-bd0b31246dc3"
      unitRef="usd">18944378</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90YWJsZTpiM2MyMGQ3YzM5OGE0YmJmODVjZWNmOTY0M2FlZDhmMy90YWJsZXJhbmdlOmIzYzIwZDdjMzk4YTRiYmY4NWNlY2Y5NjQzYWVkOGYzXzEzLTUtMS0xLTQ5ODI4_4fec220e-34a5-4f5f-a53f-5a4a2ecde48d"
      unitRef="usd">17453206</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzE2NQ_2d596de7-9b98-4d21-94f8-6faffdf3bc86"
      unitRef="usd">3700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzE2OQ_491d5194-be95-477b-b7bc-d6613b66d4dd"
      unitRef="usd">3000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzE3Ng_de6e691a-829b-4180-a633-b99212781679"
      unitRef="usd">3000000</us-gaap:Depreciation>
    <ino:PropertyPlantAndEquipmentDisposedOfBySale
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzU0OTc1NTgxNDc0OQ_5344a417-d2af-48e9-a850-49f298f549d6"
      unitRef="usd">6100000</ino:PropertyPlantAndEquipmentDisposedOfBySale>
    <us-gaap:PropertyPlantAndEquipmentDisposals
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzU0OTc1NTgxNTI0Ng_63a92eb3-5e2e-4a0b-94ca-c4058dd4d4e5"
      unitRef="usd">1100000</us-gaap:PropertyPlantAndEquipmentDisposals>
    <us-gaap:AccountsReceivableNet
      contextRef="i373cde7a8abc406eb292a0ab2cbe85ec_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTQvZnJhZzowNGU0OTY0YWEwMGU0ZDQzYTM2YzI2MDFlMGFiZjgwNC90ZXh0cmVnaW9uOjA0ZTQ5NjRhYTAwZTRkNDNhMzZjMjYwMWUwYWJmODA0XzU0OTc1NTgxNTY5Nw_cf886cd8-a5e6-42cf-a53f-a130e2ec8ce0"
      unitRef="usd">6100000</us-gaap:AccountsReceivableNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5Xzc1MQ_11a460f4-e85f-4e08-a2b4-980c88840d3e">Goodwill and Intangible Assets&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:53pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,323,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,988,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,735,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,643,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate amortization expense on intangible assets was $496,000, $520,000 and $547,000 for the years ended December&#160;31, 2022, 2021 and 2020, respectively. Amortization expense related to intangible assets at December&#160;31, 2022 is expected to be incurred as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no impairment or impairment indicators present and no losses were recorded during the years ended December&#160;31, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5Xzc1Mw_fb3385c8-32b8-40f5-bc3c-b9d11e51f421">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following sets forth goodwill and intangible assets by major asset class:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.874%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:53pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Useful&lt;br/&gt;Life&lt;br/&gt;(Yrs)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Book&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,513,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Definite lived:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,323,761)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,305,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Bioject (a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,988,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,111,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,735,556)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,364,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,031,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,806,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,129,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,473,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,626,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total goodwill and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,343,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,643,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,987,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,847,406)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,139,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt"&gt;Bioject intangible assets represent the estimated fair value of developed technology and intellectual property which were recorded from an asset acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt"&gt;Other intangible assets represent the estimated fair value of acquired intellectual property.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:GoodwillGross
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtMy0xLTEtNDk4Mjg_4b80c062-7760-49fe-a77e-fc6d515b2d73"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtNy0xLTEtNDk4Mjg_b520636a-cf21-48c9-9b89-ecbf068c97c9"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:GoodwillGross
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtOS0xLTEtNDk4Mjg_d24a913a-6a11-4810-b317-beecf10ecd17"
      unitRef="usd">10513371</us-gaap:GoodwillGross>
    <us-gaap:Goodwill
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzMtMTMtMS0xLTQ5ODI4_3256805b-a4df-4728-9979-c70d95ec8301"
      unitRef="usd">10513371</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7e0234d350c34dfeac832494bdf5206c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMS0xLTEtNDk4Mjg_55b96ae1-9bf7-4ecd-a370-a783fe6f9cbb">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i77ea35c5c90b42d78cff73917a5896b8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMy0xLTEtNDk4Mjg_c6d42cae-543f-41ae-8c85-5c94094dc802"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i77ea35c5c90b42d78cff73917a5896b8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtNS0xLTEtNDk4Mjg_7898cc07-09bb-48ec-baa5-62ac86212d2c"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i77ea35c5c90b42d78cff73917a5896b8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtNy0xLTEtNDk4Mjg_cf4e751f-4127-4a55-a055-9114b8d4e9d1"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id3891a2d892d444ab2b6d75d1e90d526_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtOS0xLTEtNDk4Mjg_2bc6640f-4352-436d-a37f-9a72f831b589"
      unitRef="usd">1323761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id3891a2d892d444ab2b6d75d1e90d526_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMTEtMS0xLTQ5ODI4_bb1b0758-089f-448b-82bc-0b7027a5a2ed"
      unitRef="usd">1305600</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id3891a2d892d444ab2b6d75d1e90d526_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzYtMTMtMS0xLTQ5ODI4_f89e9f75-9584-43f4-a469-516c564374eb"
      unitRef="usd">18161</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1443f3e411954434acd4f1bcdb1ca5a3_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMS0xLTEtNDk4Mjg_c2075cff-e692-4e7d-b642-0ee5bc082eb6">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie89ddab5935542b39c5b4ea28140cb13_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMy0xLTEtNDk4Mjg_b660eab2-e7f1-421d-bb60-3be74d4e6f72"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie89ddab5935542b39c5b4ea28140cb13_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktNS0xLTEtNDk4Mjg_f37da9eb-e2c9-407d-bee2-bcddf498cc99"
      unitRef="usd">2988889</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie89ddab5935542b39c5b4ea28140cb13_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktNy0xLTEtNDk4Mjg_d6154a40-8d8b-4ea1-955f-f63854f86f95"
      unitRef="usd">2111111</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i24e8db3eab40498a818ac04516b22b71_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktOS0xLTEtNDk4Mjg_77b1cc80-0990-48c7-a9c9-f095787f46a4"
      unitRef="usd">5100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i24e8db3eab40498a818ac04516b22b71_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMTEtMS0xLTQ5ODI4_78b8f711-d434-41c9-b9ec-ca1267a4f476"
      unitRef="usd">2735556</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i24e8db3eab40498a818ac04516b22b71_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzktMTMtMS0xLTQ5ODI4_2419fa10-fbbb-42b0-adf1-1c09fea2b5ad"
      unitRef="usd">2364444</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5e498a11c93d46d08d441fc1e554b563_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTEtMS0xLTQ5ODI4_351d6c33-1425-47aa-9e80-f676c81b9aea">P18Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iedaf8cf0acdd46ffa0621f524655250d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTMtMS0xLTQ5ODI4_ae04f5af-a629-4f10-ad57-d2ee4dc80a40"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iedaf8cf0acdd46ffa0621f524655250d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTUtMS0xLTQ5ODI4_dc816905-3a7d-4bbe-8c59-d464e06f2485"
      unitRef="usd">4031250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iedaf8cf0acdd46ffa0621f524655250d_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTctMS0xLTQ5ODI4_234395ff-6f0e-4616-b3ee-00f7ff778888"
      unitRef="usd">18750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib41ca5add1234f08a9091fcbd9f51b00_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTktMS0xLTQ5ODI4_95294b41-3b92-4d9d-a5fb-cb403582cffc"
      unitRef="usd">4050000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib41ca5add1234f08a9091fcbd9f51b00_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTExLTEtMS00OTgyOA_f1ca5308-9578-4a53-82f1-03386e2b16de"
      unitRef="usd">3806250</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib41ca5add1234f08a9091fcbd9f51b00_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEwLTEzLTEtMS00OTgyOA_2a812863-9feb-400f-8c48-4eb1b2620499"
      unitRef="usd">243750</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i87ff63586a45468dad886c18594fa0da_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTEtMS0xLTQ5ODI4_020df3fe-b045-4601-b6b1-b468a67a9017">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTMtMS0xLTQ5ODI4_2c431c60-ee1d-4547-88d7-fc964d2693fa"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTUtMS0xLTQ5ODI4_50c12251-7ed1-48fd-bba7-596ec6e8cb93"
      unitRef="usd">8343900</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTctMS0xLTQ5ODI4_c2556b98-69f5-48cd-8460-ef8546bcc879"
      unitRef="usd">2129861</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTktMS0xLTQ5ODI4_1ac578d7-8042-4fd7-b5fb-3ea44021499a"
      unitRef="usd">10473761</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTExLTEtMS00OTgyOA_6bf7bd04-f292-4b3e-9edd-a89b6b7909e9"
      unitRef="usd">7847406</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzExLTEzLTEtMS00OTgyOA_75cd0960-c32b-4122-a433-655f269981c6"
      unitRef="usd">2626355</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTMtMS0xLTQ5ODI4_3eaab947-95e9-4225-944e-bcbfb4450baf"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTUtMS0xLTQ5ODI4_7d8729d6-da7a-430c-9824-1757a59aa35b"
      unitRef="usd">8343900</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTctMS0xLTQ5ODI4_c13a4c9b-388d-451a-b462-b37672121f08"
      unitRef="usd">12643232</ino:GoodwillAndIntangibleAssetsNet>
    <ino:GoodwillAndIntangibleAssetsGross
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTktMS0xLTQ5ODI4_133ee9de-a513-49d5-8120-d2fd01fce3d5"
      unitRef="usd">20987132</ino:GoodwillAndIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTExLTEtMS00OTgyOA_54facf22-01a1-4194-a159-47eab4a42b12"
      unitRef="usd">7847406</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <ino:GoodwillAndIntangibleAssetsNet
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTowYWJjNGM0NDNjMjc0ZjVjYjIzNGU1OGUzNDQ1MzcyZS90YWJsZXJhbmdlOjBhYmM0YzQ0M2MyNzRmNWNiMjM0ZTU4ZTM0NDUzNzJlXzEyLTEzLTEtMS00OTgyOA_1149465d-375a-4571-ae54-53e985c42144"
      unitRef="usd">13139726</ino:GoodwillAndIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzQzMQ_d398f03c-1532-49bb-9fb0-d83352c4b243"
      unitRef="usd">496000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzQzNQ_943da8c9-e68d-4e8a-bc58-ea7ffa37e2a0"
      unitRef="usd">520000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzQ0Mg_40da039e-6ab2-4992-bab6-9c1ecd6f727e"
      unitRef="usd">547000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5Xzc0MQ_04152144-af79-49ab-8966-5f7135b5915f">Amortization expense related to intangible assets at December&#160;31, 2022 is expected to be incurred as follows: &lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.364%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,130,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzEtMS0xLTEtNDk4Mjg_a0e6e44e-6772-46af-9c4a-37b925aee308"
      unitRef="usd">273000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzItMS0xLTEtNDk4Mjg_e1862e92-af04-42bf-89ca-51fbc3391fd7"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzMtMS0xLTEtNDk4Mjg_835cf008-4cee-41ff-8922-d374dc83caee"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzQtMS0xLTEtNDk4Mjg_eb2dee55-f953-42dd-a21d-7864b8b7f457"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzUtMS0xLTEtNDk4Mjg_1db66301-69dc-40aa-a36d-4b131bd044f5"
      unitRef="usd">253000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzYtMS0xLTEtNDk4Mjg_77f8f7dc-d60d-47c2-8528-3f95ad874303"
      unitRef="usd">845000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90YWJsZTpmMTc5YmM2MGI2YmI0YTNkODBkMDUxZDVlYjIxNDNmYi90YWJsZXJhbmdlOmYxNzliYzYwYjZiYjRhM2Q4MGQwNTFkNWViMjE0M2ZiXzctMS0xLTEtNDk4Mjg_68f90ebc-003d-4dfe-8a04-5627652f7025"
      unitRef="usd">2130000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzYwNg_6b6eaddc-4272-4da6-8d56-d9ef9bb1f2c8"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzYwNg_94276916-9ac0-4012-9bef-a92b3ee91776"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzYwNg_eaec98fd-b54e-4f5a-8b50-84b8118d1389"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzY1Nw_2870a618-8d3c-44db-8f69-f2cf270b0daa"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzY1Nw_5523e799-c240-491b-9998-2bc0f4b5ada7"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNTcvZnJhZzplYzc5ZjVlY2U1NzE0Y2UzYjFhYjY4MGNhMDk4YTgwOS90ZXh0cmVnaW9uOmVjNzlmNWVjZTU3MTRjZTNiMWFiNjgwY2EwOThhODA5XzY1Nw_f23b7292-4a54-40d7-b07e-7650d30b624b"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNjkx_5a5e4123-8cf3-4e55-b0f8-229de0fade06">Convertible Debt&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Senior Notes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 19, 2019 and March 1, 2019, the Company completed a private placement of $78.5 million aggregate principal amount of its 6.50% convertible senior notes due 2024 (the &#x201c;Notes&#x201d;). The Notes were sold in a private offering to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Net proceeds from the offering were $75.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Notes are senior unsecured obligations of the Company and accrue interest payable in cash semi-annually in arrears on March 1 and September 1 of each year at a rate of 6.50% per annum. The Notes mature on March 1, 2024, unless earlier converted, redeemed or repurchased.&#160;Prior to the close of business on the business day immediately preceding November 1, 2023, the Notes will be convertible at the option of the holders only upon the satisfaction of certain circumstances. Thereafter, the Notes will be convertible at the option of the holders at any time until the close of business on the scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of its common stock or a combination of cash and shares of its common stock, at its election. The initial conversion rate was 185.8045 shares per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $5.38 per share), subject to adjustment upon the occurrence of specified events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may redeem all, or any portion, of the Notes for cash if the last reported sale price per share of the Company's common stock exceeds 130% of the conversion price on (i) each of at least 20 trading days (whether or not consecutive) during the 30 consecutive trading days ending on, and including, the trading day immediately before the Company sends the related redemption notice; and (ii) the trading day immediately before the date the Company sends such redemption notice.&#160;The redemption price will be equal to 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Initially, in accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of similar debt instruments, which do not have an associated convertible feature. The carrying amount of the equity component representing the conversion option for the Notes was $16.3&#160;million and was recorded as a debt discount, which was being amortized to interest expense at an effective interest rate of 13.1%. In addition, the Company allocated $592,000 of debt issuance costs to the equity component and the remaining debt issuance costs of $2.2&#160;million were allocated to the liability component, which were being amortized to interest expense under the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2022, the Company adopted ASU No. 2020-06, Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity (&#x201c;ASU 2020-06&#x201d;), which is intended to simplify the accounting for convertible instruments. The ASU eliminates the cash conversion feature models in ASC 470-20, Debt with Conversion and Other Options, which required an issuer of certain convertible debt to separately account for embedded conversion features as a component of equity. Instead, an issuer will account for these securities as a single unit of account, unless the conversion feature meets certain criteria. The Company adopted the new standard using the modified retrospective method and recorded a net reduction to accumulated deficit of $1.8&#160;million, a decrease to additional paid-in capital of $3.3&#160;million, and an increase to convertible senior notes of $1.5&#160;million to reflect the impact of the accounting change. The Notes are now accounted for as a single liability measured at amortized cost, as no other embedded features require bifurcation and recognition as derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,614,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, 2021 and 2020,&#160;the Company recognized $1.3 million, $1.9&#160;million and $6.9&#160;million, respectively, of interest expense related to the Notes, of which $1.1 million, $1.1&#160;million and $4.1&#160;million, respectively, related to the contractual interest coupon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,015,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;December 2019 Convertible Bonds &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December&#160;26, 2019, the Company closed a private placement of convertible promissory notes (the &#x201c;December 2019 Bonds&#x201d;) with an aggregate principal amount of 4.7 billion KRW (USD $4.1 million based on the exchange rate on the date of issuance) issued to a Korea-based institutional investor. Net proceeds from the offering were $4.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The December 2019 Bonds, which were unsecured obligations of the Company, were issued on December&#160;31, 2019 and accrue interest at a coupon rate of 1.00% per annum, payable quarterly. The December 2019 Bonds were scheduled to mature on December&#160;31, 2024, unless earlier converted or repurchased. On March 17, 2021, the December 2019 Bonds were converted in full into an aggregate of 1,009,450 shares of the Company's common stock, leaving no further December 2019 Bonds outstanding. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon conversion, the $4.4&#160;million carrying value of the December 2019 Bonds was reclassified to stockholders' equity.&lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2021,&#160;the Company recognized $50,000 of interest expense related to the December 2019 Bonds, of which $9,000 related to the contractual interest coupon. The effective interest rate of the December 2019 Bonds was 6.2%.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEzNg_5d90e705-59bf-4978-956e-53c8f30ffecb"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE3Mw_beb7dace-d3aa-477c-83b1-a3759d3935da"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i7bbe89ce4a474b04b398872bd94f43bc_D20190219-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQwNQ_f67394e8-1de1-4527-971f-2e267286b31e"
      unitRef="usd">75700000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzYxNA_59b9b10d-286c-4aa7-b3e0-b8233f622c99"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE0MTI_9e70e447-eeeb-4194-98e6-5d2ae7e96c39"
      unitRef="usdPerShare">5.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2MzY_78886632-3b01-43fb-83f7-17538c008885"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2ODc_2a6d3f15-b8e3-4c32-80be-a976613c0e42"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE3NDM_895bbd86-257b-4d64-950f-fcd77a265e4a"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i79932ec4bce7499281dd21389a4f63cd_D20190219-20190301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzIwMTQ_a87a7b0d-b9cf-4817-a911-f86235d9e927"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i99b74bae4f344e8cbf89dd04418411bf_I20190301"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg3ODM_445ee423-b85c-48f4-ac60-9365b58ebedc"
      unitRef="usd">16300000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4MDQ_e0388afe-2cd6-43b5-b552-ffd96f3d42f0"
      unitRef="number">0.131</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4MjA_7a07a606-3b09-488d-9891-c649d323e615"
      unitRef="usd">592000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i1242ebcd358e4468bb5a2b7b601e0e98_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4NDM_4ff6907d-43f2-4769-81c1-b38d66431a3a"
      unitRef="usd">2200000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4NzA_c6ba9928-d938-4655-8a79-5050f1ff2556"
      unitRef="usd">1800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg4OTc_4019ff5b-348e-4b33-81c7-dc86da5c7d2e"
      unitRef="usd">-3300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ConvertibleDebt
      contextRef="ie489748523ab48ef9c00350ee420a2ad_I20220101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NTg5MjQ_0d67149f-2b00-409b-9a97-1caa54e7801e"
      unitRef="usd">1500000</us-gaap:ConvertibleDebt>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNjky_5a82b38a-bb40-4d26-bd7f-59fd0f88a258">&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The balance of the Notes at December&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.327%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,500,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Principal amount converted into common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,085,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(155,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;355,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Net carrying amount &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,614,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzAtMS0xLTEtNDk4Mjg_dc858921-cca6-48ed-8957-fb0e2ae6bca3"
      unitRef="usd">78500000</us-gaap:DebtInstrumentFaceAmount>
    <ino:DebtInstrumentConvertibleDebtConvertedAmount
      contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzEtMS0xLTEtNDk4Mjg_cff7e2a9-1d86-4370-8bbc-313878af6483"
      unitRef="usd">62085000</ino:DebtInstrumentConvertibleDebtConvertedAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzMtMS0xLTEtNDk4Mjg_51f8bc39-9d48-4718-b0f1-6018f95c13c9"
      unitRef="usd">155815</us-gaap:DeferredFinanceCostsNet>
    <ino:DebtinstrumentAccruedInterest
      contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzQtMS0xLTEtNDk4Mjg_ae978f0c-7f7b-4515-8377-213ffc6a5d5a"
      unitRef="usd">355655</ino:DebtinstrumentAccruedInterest>
    <us-gaap:LongTermDebt
      contextRef="i462df0bfe2224796bd3e4784559e9ff7_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTo0MGZiMDFmNWM2ZWM0NWJmYmM0NzE2MzVmMjc5OTRhNy90YWJsZXJhbmdlOjQwZmIwMWY1YzZlYzQ1YmZiYzQ3MTYzNWYyNzk5NGE3XzUtMS0xLTEtNDk4Mjg_61ce4271-e1d1-40d3-aa87-598e8f5f1ffa"
      unitRef="usd">16614840</us-gaap:LongTermDebt>
    <us-gaap:InterestExpense
      contextRef="i063303991a5041809d8211c86ef7e0d7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ2NTY_7de89442-577b-4685-a22b-35693960df1b"
      unitRef="usd">1300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i316205765748470e9cebde8ab78a5ae1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ2NjM_5cc593be-0bf1-4dd7-8a9b-57c31fe76a9e"
      unitRef="usd">1900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1b8ef7a9972a45d68c3268ee6c9acbc2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NjYxMDI_c25f3ec8-666d-4af6-913b-cec6dadabba0"
      unitRef="usd">6900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i063303991a5041809d8211c86ef7e0d7_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ3MzI_04672d7b-1922-4e10-814e-3aa51c7aca22"
      unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i316205765748470e9cebde8ab78a5ae1_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ3Mzk_674fe883-464c-42a2-a3b0-d89117806093"
      unitRef="usd">1100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i1b8ef7a9972a45d68c3268ee6c9acbc2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NjYxMTY_54360d7d-4af7-4f53-8acf-8378e186fa49"
      unitRef="usd">4100000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNjg5_e84e5910-04e3-4c0c-8309-6be2cfa0e397">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;future minimum payments due under the Notes, representing contractual amounts due, including interest based on the fixed rate of 6.5% per annum, were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,067,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,948,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,015,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzQ5NDE_5c09b974-9135-41ac-a2f0-e7bea9d1864a"
      unitRef="number">0.065</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTpkZDFjYzg4NTZkYTc0Zjc1ODg0ZjE4MTI3YWQxMGQwNC90YWJsZXJhbmdlOmRkMWNjODg1NmRhNzRmNzU4ODRmMTgxMjdhZDEwZDA0XzQtMi0xLTEtNDk4Mjg_4dc4a109-c269-476f-9c15-2c4b156ba6b3"
      unitRef="usd">1067000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTpkZDFjYzg4NTZkYTc0Zjc1ODg0ZjE4MTI3YWQxMGQwNC90YWJsZXJhbmdlOmRkMWNjODg1NmRhNzRmNzU4ODRmMTgxMjdhZDEwZDA0XzUtMi0xLTEtNDk4Mjg_0d0b1951-db8f-4e2e-a966-e46e4cf71e19"
      unitRef="usd">16948000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebt
      contextRef="ibda181353d814282bfd46ddc089e9aed_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90YWJsZTpkZDFjYzg4NTZkYTc0Zjc1ODg0ZjE4MTI3YWQxMGQwNC90YWJsZXJhbmdlOmRkMWNjODg1NmRhNzRmNzU4ODRmMTgxMjdhZDEwZDA0XzctMi0xLTEtNDk4Mjg_505864ce-f8dd-4523-be8d-2a3b5ba2e6ce"
      unitRef="usd">18015000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk0MDk_a3d52b58-0c9b-435c-b296-3b5f05fc2533"
      unitRef="krw">4700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk0MzU_7dae63a7-35d3-45d6-a1bd-44d103c254d6"
      unitRef="usd">4100000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="i189926960d2b4b1c89848491c1ce2245_D20191226-20191226"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk1NzQ_7c1fa1b1-5c76-4d44-ad53-1f2f94258123"
      unitRef="usd">4000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibad2d76d86fe4bf4a5878f26e3bc4e48_I20191226"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk3MjU_4d44778b-d4d1-4c48-9dc3-d4b774fb4a80"
      unitRef="number">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i11da8ee96782442db68b426be9a9c645_D20210317-20210317"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1Xzk5NTc_08eecca6-aea5-4413-90f4-6aad497a226c"
      unitRef="shares">1009450</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="i11da8ee96782442db68b426be9a9c645_D20210317-20210317"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzE2NDkyNjc0NjU0NTc_a5817880-d1ba-4e3e-9b9a-057eef837685"
      unitRef="usd">4400000</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:InterestExpense
      contextRef="i7044f94f6dec495687d4bb1d5e39219b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyMzE1_67c26474-a3fc-4e23-bacf-5a4ceb228796"
      unitRef="usd">50000</us-gaap:InterestExpense>
    <us-gaap:InterestExpenseDebt
      contextRef="i7044f94f6dec495687d4bb1d5e39219b_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEyNDA1_0f571def-af44-4e4e-98d1-38c11bb474a1"
      unitRef="usd">9000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5f47b0a510ab4c979a96d6c6c04992e4_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjAvZnJhZzo0ZGI0OWU3ODViNDA0ZDQyODNkMTQ0ZmIwZDk1MmFjNS90ZXh0cmVnaW9uOjRkYjQ5ZTc4NWI0MDRkNDI4M2QxNDRmYjBkOTUyYWM1XzEwOTk1MTE2NTIyNDM_600427d2-23e6-4a23-9013-6506095bcbfd"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMzQ_5c572dc2-6e7e-4d80-9f7e-f8114494260e">Stockholders&#x2019; Equity&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The holder of a share or shares of Series C preferred stock has the right at any time, at such holder&#x2019;s option, to convert all or any lesser portion of such holder&#x2019;s shares of the preferred stock into fully paid and non-assessable shares of common stock. As of December 31, 2021, the conversion value w&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;as $27.20 per share, such&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; that the outstanding shares of Series C preferred stock were convertible into an aggregate of 3,309 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Issuances of Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2021, the Company entered into an ATM Equity Offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Sales Agreement (the &#x201c;2021 Sales Agreement&#x201d;) with outside sales agents (collectively, the &#x201c;Sales Agents&#x201d;) for the offer and sale of its common stock for an aggregate offering price of up to $300.0&#160;million. The 2021 Sales Agreement provides that the Sales Agents will be entitled to compensation in an amount equal to up to 3.0% of the gross sales proceeds of any common stock sold through the Sales Agents under the 2021 Sales Agreement. During the years ended December&#160;31, 2022 and 2021, the Company sold 34,445,743 and 6,955,341 shares, respectively, of its common stock under the 2021 Sales Agreement. The sales were made at a weighted average price of $2.44 and $6.96 per share, respectively, resulting in aggregate net proceeds of $83.0&#160;million and $47.7&#160;million, respectively. As of December&#160;31, 2022 there was $167.4&#160;million of remaining capacity under the 2021 Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 25, 2021, the Company closed an underwritten public offering of 20,355,000 shares of common stock at a public offering price of $8.50 per share. The net proceeds to the Company, after deducting the underwriters' discounts and commissions and other offering expenses, were $162.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options and Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a stock-based incentive plan, the 2016 Omnibus Incentive Plan (as amended to date, the "2016 Incentive Plan"), pursuant to which the Company may grant stock options, restricted stock awards, RSUs and other stock-based awards or short-term cash incentive awards to employees, directors and consultants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2016 Incentive Plan was originally approved by the Company's stockholders on May 13, 2016, and an amendment to the plan to increase the number of shares available for issuance was approved by the stockholders on May 8, 2019. As of December&#160;31, 2022, the maximum number of shares of the Company&#x2019;s common stock available for issuance over the term of the 2016 Incentive Plan was 22,000,000 shares. On the first business day of each calendar year, the maximum number of shares is increased by&#160;2,000,000 shares of common stock unless the Company's board of directors determines, prior to January 1 for any such calendar year, to increase the maximum amount by a lesser amount. On January 1, 2022 and again on January 1, 2023, the maximum number of shares increased by 2,000,000. At December&#160;31, 2022, the Company had 3,831,240 shares of common stock available for future grant under the 2016 Incentive Plan, 2,446,257 shares underlying outstanding but unvested service-based RSUs, options outstanding to purchase 10,132,969 shares of common stock and 111,941 shares of performance-based RSUs outstanding under the 2016 Incentive Plan. The awards granted and available for future grant under the 2016 Incentive &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plan generally vest over three years and have a maximum contractual term of ten years. The 2016 Incentive Plan terminates by its terms on March&#160;9, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 24, 2022, the Company's board of directors adopted a stock-based incentive plan (the "2022 Inducement Plan"), which provides for the discretionary grant of nonstatutory stock options, stock appreciation rights, restricted stock awards, RSU awards, performance awards, and other awards to individuals as a material inducement to entering into employment with the Company. The aggregate number of shares of the Company&#x2019;s common stock that may be issued under the 2022 Inducement Plan will not exceed 2,000,000 shares. At December&#160;31, 2022 the Company had 1,703,750 shares of common stock available for future grant under the 2022 Inducement Plan, 110,000 shares underlying outstanding but unvested RSUs and options outstanding to purchase 186,250 shares of common stock under the 2022 Inducement Plan. The 2022 Inducement Plan can be terminated by the Company's board of directors at any time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended and Restated 2007 Omnibus Incentive Plan (the "2007 Incentive Plan") was adopted on March&#160;31, 2007 and terminated by its terms on March&#160;31, 2017. At December&#160;31, 2022, the Company had options outstanding to purchase 1,902,329 shares of common stock under the 2007 Incentive Plan. The awards granted under the 2007 Incentive Plan generally vest over three years and have a maximum contractual term of ten years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total employee and director stock-based compensation expense recognized in the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020 was $22.2 million, $25.0 million and $14.5 million, respectively, of which $8.8 million, $13.4 million and $8.0 million was included in research and development expenses and $13.4 million, $11.6 million and $6.5 million was included in general and administrative expenses, respectively. The Company entered into a Separation Agreement with its former President and Chief Executive Officer on May 10, 2022, under which outstanding RSUs as of the separation date were fully vested, and one-half of the RSUs were settled in the Company's common stock and the remainder settled in cash. The officer's stock options will continue to vest over a certain period and will remain exercisable until five years after the separation date. Stock-based compensation for the year ended December 31, 2022 included a $4.2&#160;million charge related to these RSU and stock option modifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022 and 2021, there was $10.5 million and $16.5 million, respectively, of total unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted-average period of 1.6 years and 2.0 years, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022 and 2021, there was $7.2 million and $13.4 million, respectively, of total unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted-average period of 1.7 years and 1.8 years, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options granted to non-employees was estimated using the Black-Scholes pricing model. Total stock-based compensation expense for stock options and RSUs granted to non-employees for the years ended December&#160;31, 2022, 2021 and 2020 was $1.3 million, $1.4 million and $1.2 million, respectively. As of December&#160;31, 2022, options to purchase 665,875 shares of common stock granted to non-employees remained outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.56-$3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.01-$6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,461,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,059,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01-$9.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,349,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.01-$12.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.01-$15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01-$25.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,221,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,829,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the aggregate intrinsic value of options outstanding was $0, the aggregate intrinsic value of options exercisable was $0, and the weighted average remaining contractual term of options exercisable was 5.7 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, the aggregate intrinsic value of unvested RSUs was $4.0 million and the aggregate intrinsic value of RSUs which vested during the year ended December 31, 2022 was $4.6 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December 31, 2022, options to purchase 12,221,548 shares of common stock and 2,556,257 RSUs were expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2022 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,623,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,772,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,221,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,618,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(760,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price per share was $8.47 for the 77,250 options which expired during the year ended December&#160;31, 2022, $4.56 for the 7,000 options which expired during the year ended December&#160;31, 2021 and $4.44 for the 78,750 options which expired during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share was $2.34, $7.61 and $6.87 for options granted during the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value was $3.12, $10.37 and $9.12 per share for RSUs granted during the years ended December&#160;31, 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received $283,000, $6.7 million and $12.3 million in proceeds from the exercise of stock options during the years ended December&#160;31, 2022, 2021 and 2020, respectively. The aggregate intrinsic value of options exercised was $81,000, $7.0 million and $14.2 million during the years ended December&#160;31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;the&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Company&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;111,941&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;performance-based RSUs outstanding, which were granted to key employees in August 2020. The underlying performance milestones of the RSUs were not probable of achievement as of December&#160;31, 2022, and no stock-based compensation expense has been recognized to date for the performance-based RSUs.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMzI_ba01d555-94f9-4586-8ecf-c2a1cf7d7663">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Outstanding as of&lt;br/&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series&#160;C Preferred Stock, par $0.001&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjplNmNiN2UwMmM5ZTY0MjRiOGMyMWZhZmQwZTExZmYxNV8zNA_906f3e9e-254e-49cb-94ae-681f6cabd7ae"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtMS0xLTEtNDk4Mjg_914a58bc-ba99-4d0e-a394-98febfe6d71a"
      unitRef="shares">1091</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtMy0xLTEtNDk4Mjg_2b9a1b3f-86f3-4834-973e-292dcaed362e"
      unitRef="shares">1091</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i29af49ccbb494cac8290ea49a3d605f0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtNS0xLTEtNDk4Mjg_afb59a50-ad20-42e0-98ca-a6349f086b52"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i665787c5dd50498ba18daa109d1fa1ce_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpmMzZkZDM3OGE1MGM0ZTY3ODI0ZGQ3NWFjNmFmMTcxMi90YWJsZXJhbmdlOmYzNmRkMzc4YTUwYzRlNjc4MjRkZDc1YWM2YWYxNzEyXzQtNy0xLTEtNDk4Mjg_bcfc9fc5-042f-4254-8529-b64b701c8fbe"
      unitRef="shares">9</us-gaap:PreferredStockSharesOutstanding>
    <ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ5OA_ec585d93-cc8c-4532-854f-6e05a0f0883a"
      unitRef="usdPerShare">27.20</ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i665787c5dd50498ba18daa109d1fa1ce_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYxMQ_40b9d309-a96b-421d-9a5d-c58f496c239f"
      unitRef="shares">3309</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <ino:StockSalesAgreementMaximumAuthorizedAmount
      contextRef="i36e51ec971e349c587d471174bf94e10_D20211109-20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMg_b6332542-0159-49a8-88f0-2f0e89ee59f1"
      unitRef="usd">300000000</ino:StockSalesAgreementMaximumAuthorizedAmount>
    <ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage
      contextRef="i36e51ec971e349c587d471174bf94e10_D20211109-20211109"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEwMzM_1d585038-1230-4e21-bf36-d2da4bafb147"
      unitRef="number">0.030</ino:SaleOfStockSalesProceedsOfAnyCommonStockPercentage>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEyMDE_4ae7fe84-e23e-433d-b7e2-f10b7fe77375"
      unitRef="shares">34445743</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementAggregateNumberofSharesIssued
      contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwNDczMTM5Njk5NjA_c481009b-2fa0-42bb-a99a-fd2703cdd91d"
      unitRef="shares">6955341</ino:StockSaleAgreementAggregateNumberofSharesIssued>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEzMTQ_71cb4144-6cb2-465e-8c9c-15cd6c1d4c7b"
      unitRef="usdPerShare">2.44</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementWeightedAveragePricePerShare
      contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwNDczMTM5Njk5NzE_cdde8d2f-56db-457a-8962-227352793857"
      unitRef="usdPerShare">6.96</ino:StockSaleAgreementWeightedAveragePricePerShare>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i9ff864730ea642239a8163e8e1918732_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzEzNjc_8825c93c-9009-4a0a-af59-97710ce4cd5a"
      unitRef="usd">83000000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock
      contextRef="i6f77b689e902453898c3df44adad4187_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwNDczMTM5Njk5Nzg_c0c717e3-cd01-49bf-8daf-69280b33986d"
      unitRef="usd">47700000</ino:StockSaleAgreementAggregateProceedsFromIssuanceOfStock>
    <ino:StockSalesAgreementRemainingAuthorizedAmount
      contextRef="i2fca5b2439d74d788e0d439a6f383003_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE0MDU_c25ae84d-0e59-4c7c-b9b3-d4f3d3e6f134"
      unitRef="usd">167400000</ino:StockSalesAgreementRemainingAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3109c39c7dfe480a826f059e43510271_D20210125-20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE1Mzc_e6cf88d3-df9c-4ed7-9ff8-963515ffa29c"
      unitRef="shares">20355000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i256486c034e74959bea28a09407f168f_I20210125"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE1OTM_5f7e54d0-b9b9-4611-aaa2-0b7926b8273b"
      unitRef="usdPerShare">8.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="i3109c39c7dfe480a826f059e43510271_D20210125-20210125"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE3MzQ_034594bf-6351-4583-9072-48770669a2fd"
      unitRef="usd">162100000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i95c79bb8b10c435bb78e5dfe4b84d8d3_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQwODE_00de8ced-6dbc-4002-8ffe-a123e95fbace"
      unitRef="shares">22000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan
      contextRef="i95c79bb8b10c435bb78e5dfe4b84d8d3_I20160513"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQxOTM_013442ee-b21b-47a7-a7b6-52b47c34c417"
      unitRef="shares">2000000</ino:NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized
      contextRef="i333db47ca7594db8809bb340e9af167b_I20220101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ0Nzc_174360b8-3a27-4515-b547-5a24300bb7af"
      unitRef="shares">2000000</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="ieaecf1d1bad04443b82d7b4be5e89ad5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ1MDQ_367ffc3f-8c40-472c-8833-7e19a8e7b12a"
      unitRef="shares">3831240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan
      contextRef="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ1ODg_cabb89b8-ae9a-4808-a3c0-d8e918e5226d"
      unitRef="shares">2446257</ino:NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="ieaecf1d1bad04443b82d7b4be5e89ad5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ2OTM_1fa14d6f-60b7-4bce-b234-7307bc5f9e14"
      unitRef="shares">10132969</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i4bb1b79238d54150bdfc9c781bd5fc1b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU0OTc1NTgyOTY4MA_aa9cc838-abca-4fa8-8b53-5ac09101a7a6"
      unitRef="shares">111941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ4NTA_60d9257a-a42e-4f14-a4c5-483dcf465f46">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="ida2774ee3c9c40bda4ee7787dceea16b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzQ4OTI_e5ce08b3-5af5-4943-be3b-559b5becf050">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i36807b22af264de2a3e9c80926cea5b8_I20220624"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQwOTI_67ab54c4-85a3-4516-a794-41677018f2de"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i6a0cabe1550b4ee2905d7e3e21009431_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQxNTg_74c414fb-ef0d-45e5-84f8-406a07c0fc26"
      unitRef="shares">1703750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6a0cabe1550b4ee2905d7e3e21009431_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQxNzc_8d14c756-c697-426b-829c-a3d4e354c131"
      unitRef="shares">110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="i6a0cabe1550b4ee2905d7e3e21009431_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzE2NDkyNjc0NTQxOTQ_d9d96cff-9b6a-41d6-a98a-eb4fe4429445"
      unitRef="shares">186250</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="iae9a3aca7b5e4544b7ec63dc9e3b7fdf_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzUxNzU_d8be44cd-b38c-4301-a3dd-9b5f3bdd74ab"
      unitRef="shares">1902329</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i10ba30993b07407997027cb283263b45_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzUzMDE_4addf0c5-7c8c-4ca6-b5c2-076b6152d431">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm
      contextRef="i10ba30993b07407997027cb283263b45_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzUzNDM_a83ea593-24ba-4be9-b719-bff16e9f6901">P10Y</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1MTY_e50732e0-7d9e-4aa2-8428-d2cef3200b5c"
      unitRef="usd">22200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1MjA_fbf74ab1-7604-414d-a9ed-3b92d17c5ed0"
      unitRef="usd">25000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1Mjc_5473398a-9b7e-4c19-b2db-653022a68eba"
      unitRef="usd">14500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf2749e9d9094ef991e679e1b9cc83fe_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1NTQ_3a45dd48-e68e-4a13-ac19-816dbc0952f7"
      unitRef="usd">8800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0768a9275ad64e93b52e47eba8d93b74_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1NTg_6706aaa8-d84a-4d28-8970-6a1428baaaff"
      unitRef="usd">13400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1455c9a790944d63a8c0009471f82bcb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU1NjU_263992d0-d3c0-4432-8999-0182fa7ff29a"
      unitRef="usd">8000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b4f24c6cfc0434db99f876f8856c535_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU2MzA_38f64348-938c-4bf3-befa-e3cb6c6f9f98"
      unitRef="usd">13400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i107f49b9f6cb4502ac08563229ac6d5f_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU2MzQ_f84b6036-5c15-45c8-b274-9bc108a9666f"
      unitRef="usd">11600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ide5ec322e22c4863b4ec3beac0c62440_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU2NDE_7049d88a-0cc0-4bd6-8d41-18bb0dc14dea"
      unitRef="usd">6500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i4f6468c1ea34497783cc0f8b7387f0fb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU0OTc1NTgzMDIyNQ_d55f7ad0-2501-4610-bc08-56d8ef75a1be">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4f6468c1ea34497783cc0f8b7387f0fb_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU0OTc1NTgzMDMzNw_610fab21-9e06-4aeb-9232-871364e4e500"
      unitRef="usd">4200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU3NDg_fbdbd1f7-0983-4e37-9f3a-a0e1525a8ceb"
      unitRef="usd">10500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU3NjM_94461588-c4cc-4b24-b7b1-e287e21a4c46"
      unitRef="usd">16500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU5Mjg_c6d77726-4e41-46fd-be77-e9a0a447dbe3">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU5NDE_dc758dbf-93d7-4ea8-a112-6b426f17c7cc">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzU5OTY_8ee876e6-0650-4980-a4e6-c421a829761b"
      unitRef="usd">7200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i2ce9a943aa164c8c8f02796513f3578c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYwMTE_4e5630ac-b835-4184-ad06-dcd63007e74b"
      unitRef="usd">13400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYxODU_83cd5488-6526-45b5-9b35-457db004d0c7">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i10ced5af10f440b0bebf5936fd97f874_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzYxOTg_9959580e-4000-463e-9586-07c6cae9f38b">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibcb4a7e1962b43df901c999bf8eb65ec_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY0OTQ_65b18c74-8b67-4147-bcb6-665a88181f2c"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieb960975b9964654908d00a526851994_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY0OTg_f9ed27b7-edbf-4e34-acea-cd65b052f13f"
      unitRef="usd">1400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i432ab502425b494c81d8825eac83ad96_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY1MDU_8734b66c-e58f-429a-ba10-5c664f1a46a4"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i87e0aa1271764f94a354dfcb830960c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY1NjY_bc069e49-88c1-4e60-9042-4feef70e5515"
      unitRef="shares">665875</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxNTQ_af1e3817-46eb-495b-9869-01c30215d6fe">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total stock options outstanding at December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.540%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;br/&gt;(in Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&#160;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares Underlying Options&lt;br/&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted    Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.56-$3.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;830,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.01-$6.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,461,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,059,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01-$9.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,349,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.01-$12.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,930,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$12.01-$15.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$15.01-$25.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,221,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,829,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpkNzY5YjNhMTczNzM0ZmFlYTZkMDk1ODYyM2FhZjA1NF80_cbab3fa3-7e59-4ff2-9706-ff16f4eee891"
      unitRef="usdPerShare">1.56</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpkNzY5YjNhMTczNzM0ZmFlYTZkMDk1ODYyM2FhZjA1NF83_937095eb-b718-4f6b-9a07-b09009a8d9bd"
      unitRef="usdPerShare">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMi0xLTEtNDk4Mjg_990164e4-6ebb-4d4b-b188-c3c922967f4d"
      unitRef="shares">830542</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ia389047a061343b092eb2bdca2d9ffed_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItNC0xLTEtNDk4Mjg_a2504b37-9920-4444-84ee-b51bdb044e64">P8Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItNi0xLTEtNDk4Mjg_2abd9e40-38e3-4cc8-a122-a0ca1f054feb"
      unitRef="usdPerShare">2.17</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItOC0xLTEtNDk4Mjg_a666d6be-75f1-4adf-a1ea-aabe63818396"
      unitRef="shares">247104</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="id8bf9009e8e749869810035ae3b924e3_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzItMTAtMS0xLTQ5ODI4_2e3148fa-118e-4c87-b346-f4e4b56db7ec"
      unitRef="usdPerShare">2.29</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo3NjdmNGI5YzJkYWY0Nzk1OWNhMThjZTVkMTZlY2Q1Ml80_2a4433cc-f0d3-4e0a-aca7-b2cc652fd2fb"
      unitRef="usdPerShare">3.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo3NjdmNGI5YzJkYWY0Nzk1OWNhMThjZTVkMTZlY2Q1Ml83_19749d15-3122-43be-98ea-ec3fca32e537"
      unitRef="usdPerShare">6.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMi0xLTEtNDk4Mjg_e3d56264-fa5d-4ed8-be1a-1d419a695142"
      unitRef="shares">5461365</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i555d6ad502984e2dbbc57959a401df32_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtNC0xLTEtNDk4Mjg_09b7415e-d9b6-4798-afc3-5550e062c26b">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtNi0xLTEtNDk4Mjg_48d59019-5c08-4624-9109-0c7597e3af08"
      unitRef="usdPerShare">3.50</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtOC0xLTEtNDk4Mjg_1e24c0e9-b0a4-45d9-9e50-2bd64d32a89f"
      unitRef="shares">3059330</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="iabc9a82ce6304c689c1c2e03e7569363_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzMtMTAtMS0xLTQ5ODI4_b2e0fe95-7d8d-42da-ac87-254067a708b7"
      unitRef="usdPerShare">3.67</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo2NjFjOGEzMTI3NDQ0ZGYxOTQ2NDhiYjg4ZjgzM2E3MF80_cb5f5885-00ca-41a2-91ae-af587e3258c0"
      unitRef="usdPerShare">6.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjo2NjFjOGEzMTI3NDQ0ZGYxOTQ2NDhiYjg4ZjgzM2E3MF83_152f7280-d87b-4c3a-b409-51ecbe7f3dcc"
      unitRef="usdPerShare">9.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMi0xLTEtNDk4Mjg_6db86a4d-0ff5-4193-bc28-f00d04623e6d"
      unitRef="shares">3349587</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0bbf2b6d2d214283a50537db9bf1c8e8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtNC0xLTEtNDk4Mjg_7b6c8908-a6ba-433f-a9d5-3678626fc66f">P5Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtNi0xLTEtNDk4Mjg_43c3c8f2-2c70-43f5-af59-9d665432f8a6"
      unitRef="usdPerShare">7.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtOC0xLTEtNDk4Mjg_dbdbca7a-941b-40fa-b998-9c381ed2d2b4"
      unitRef="shares">2861909</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="ic84d1623798c4d50ababdf7dba3e3fc2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzQtMTAtMS0xLTQ5ODI4_d34de8aa-9500-4bd3-b8e8-0a11d7412d0e"
      unitRef="usdPerShare">7.49</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmZWI4YWMxZWFiYTc0M2JmODYzMGE5YjVjZTY0ZDMwZF80_f00ed651-7bdc-479c-b828-ea378833e89b"
      unitRef="usdPerShare">9.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjpmZWI4YWMxZWFiYTc0M2JmODYzMGE5YjVjZTY0ZDMwZF83_1663eaa1-cc8c-48a5-8ff6-4cfda8f9c07d"
      unitRef="usdPerShare">12.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMi0xLTEtNDk4Mjg_1e2fec3e-0fb8-4612-a1f3-5aa18bf0dbb7"
      unitRef="shares">1930825</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i486b8b9b78f54c48abe1ed18436482d8_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtNC0xLTEtNDk4Mjg_5af54aad-de83-4cb8-abb9-d0aacd4af1ea">P7Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtNi0xLTEtNDk4Mjg_a4259a2d-4e37-4957-944c-b303a35316d7"
      unitRef="usdPerShare">10.97</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtOC0xLTEtNDk4Mjg_9d5921ee-9370-43e3-99b2-a008b4da402f"
      unitRef="shares">1080389</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i1c8bad0df94447d2a7dc1f5eb52e2b9e_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzUtMTAtMS0xLTQ5ODI4_a11e6de2-a294-4daa-a45d-ad37be690331"
      unitRef="usdPerShare">10.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjozM2ViOGUxNmU2Mzg0MzAxYWI2Y2VlZDEyMGM3Y2IwNV80_9fa41c40-05b7-454d-a043-2620320cacfc"
      unitRef="usdPerShare">12.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjozM2ViOGUxNmU2Mzg0MzAxYWI2Y2VlZDEyMGM3Y2IwNV83_bdb7770b-ab46-472a-9c82-00d92835ca03"
      unitRef="usdPerShare">15.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMi0xLTEtNDk4Mjg_1878f5bc-f82c-46ea-a227-6c23173748e4"
      unitRef="shares">580947</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i9b960f3b520b4cc2b8b10dc0e9c4b8a2_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtNC0xLTEtNDk4Mjg_769e0796-282d-4f75-983b-d58539fa4197">P4Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtNi0xLTEtNDk4Mjg_6d4b0ac5-43d8-495d-b66b-3ea1cc7c260f"
      unitRef="usdPerShare">13.38</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtOC0xLTEtNDk4Mjg_efc2ffc0-49ea-409f-b366-5a49c0154462"
      unitRef="shares">529392</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="iefc5ac42f1b746c1aebd94bf8240f755_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzYtMTAtMS0xLTQ5ODI4_faaa21e5-95fc-41d5-9894-6c69ea7ec655"
      unitRef="usdPerShare">13.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjphMWMzNmQ5YWIzMmY0YjZkYmY0ZDk0MTYwN2I3NjM2Y180_1d09771b-3787-46e2-b42f-ff30cabb5b28"
      unitRef="usdPerShare">15.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMC0xLTEtNDk4MjgvdGV4dHJlZ2lvbjphMWMzNmQ5YWIzMmY0YjZkYmY0ZDk0MTYwN2I3NjM2Y183_102e2241-a764-44d8-b50a-003acbf99f75"
      unitRef="usdPerShare">25.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMi0xLTEtNDk4Mjg_4e8ff5ad-c467-4e5f-9a8c-52a90f7a76b3"
      unitRef="shares">68282</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="icfdac4541b954a71aaaddc001f62e767_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctNC0xLTEtNDk4Mjg_1400e8a4-50b9-4620-a20c-54075776759b">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctNi0xLTEtNDk4Mjg_3b4a183a-c374-4acd-94b1-43624e703f29"
      unitRef="usdPerShare">21.12</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctOC0xLTEtNDk4Mjg_b9d873f6-e0a9-498a-a6a3-d50b3da7f547"
      unitRef="shares">51568</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i992f2f6691ba4bd598e14bbe3bc80bb4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzctMTAtMS0xLTQ5ODI4_72d0d982-b479-43c8-a633-df6ebb294ea2"
      unitRef="usdPerShare">21.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtMi0xLTEtNDk4Mjg_877dfb9c-fe3d-4a96-bd3c-b259d9ceb2c6"
      unitRef="shares">12221548</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtNC0xLTEtNDk4Mjg_681036f4-b309-41a4-9256-54c3aa38a1ae">P6Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtNi0xLTEtNDk4Mjg_9b3722e4-f50c-4774-9d0e-5cf12ed42803"
      unitRef="usdPerShare">6.28</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtOC0xLTEtNDk4Mjg_cfcb87ff-b83e-4da9-8455-193502f1fedb"
      unitRef="shares">7829692</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjMWQzYWZkMTMyNjg0YTUwOGUyN2VkNzUzNDVlZTMzNS90YWJsZXJhbmdlOmMxZDNhZmQxMzI2ODRhNTA4ZTI3ZWQ3NTM0NWVlMzM1XzgtMTAtMS0xLTQ5ODI4_436e39ad-d909-4585-a73f-66d96ac858d6"
      unitRef="usdPerShare">6.79</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY4MDQ_6f604086-4f25-4285-95db-f096055b46e9"
      unitRef="usd">0</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY4NjU_818a72fb-5a2d-40a9-8de2-0d49238aad2c"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzY5NDg_02d4b09e-03e4-497b-b174-6c03ff8cf714">P5Y8M12D</ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcwNDc_81d6e8ef-4738-4a47-a81f-eece43c873a1"
      unitRef="usd">4000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcxNjU_6d045c75-e116-4070-9793-fdf5122e6cb2"
      unitRef="usd">4600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcyMTc_a2564ebd-c871-4002-bd94-e282a0fbff57"
      unitRef="shares">12221548</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber>
    <ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber
      contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzcyNDc_81981505-df6d-452c-b379-ac3f25d77483"
      unitRef="shares">2556257</ino:SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxMzg_1465f8f2-7de6-47cc-a541-9ca5e12e0572">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2022 was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.539%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,488,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,623,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(118,694)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,772,199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,221,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzktMS0xLTEtNDk4Mjg_57301473-ac1c-4bf9-82d9-7f7547e4f862"
      unitRef="shares">10488993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzktMy0xLTEtNDk4Mjg_14eeffdf-be55-446d-bfc9-8ecc31c7652e"
      unitRef="usdPerShare">7.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEwLTEtMS0xLTQ5ODI4_f865f185-6348-4c11-b1d1-92e51216a7ae"
      unitRef="shares">4623448</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEwLTMtMS0xLTQ5ODI4_68b0924c-67f0-4086-9696-9c88455f0946"
      unitRef="usdPerShare">3.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzExLTEtMS0xLTQ5ODI4_2df2d03c-6d5c-4847-a82d-2390d26c82d4"
      unitRef="shares">118694</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzExLTMtMS0xLTQ5ODI4_877582cf-d033-4d8c-8b31-d7baa6d99f4b"
      unitRef="usdPerShare">2.38</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEyLTEtMS0xLTQ5ODI4_5d930982-bf4e-4da3-bd8b-8b3062b25d2c"
      unitRef="shares">2772199</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEyLTMtMS0xLTQ5ODI4_b79dc2c6-6639-4e05-85a4-336b5f5526a4"
      unitRef="usdPerShare">7.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEzLTEtMS0xLTQ5ODI4_9517acdc-fb97-4878-b62c-2a3f23919834"
      unitRef="shares">12221548</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTpjYzNjNjk3NTQ4MDI0ZDAyODgyMmYxZGE3ZmE4YjE5Ni90YWJsZXJhbmdlOmNjM2M2OTc1NDgwMjRkMDI4ODIyZjFkYTdmYThiMTk2XzEzLTMtMS0xLTQ5ODI4_dd60a67e-6a2f-4fc8-8397-3e9478f0a2c9"
      unitRef="usdPerShare">6.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzkxNDQ_87c06c14-d17f-4774-8f96-ac6236c00014">&lt;div style="margin-bottom:7pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit activity under the Company&#x2019;s equity incentive plans during the year ended December&#160;31, 2022 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.303%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,448,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,485,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,618,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(760,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,556,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i2ce9a943aa164c8c8f02796513f3578c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzktMS0xLTEtNDk4Mjg_7b41dc18-015e-4a86-ae8b-2a7c8b35353b"
      unitRef="shares">2448868</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzEwLTEtMS0xLTQ5ODI4_6be178ac-ae5b-4e4d-9d05-1ba4f81d1970"
      unitRef="shares">2485947</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzExLTEtMS0xLTQ5ODI4_42389e54-ad9a-4b37-baa1-9cb719cf70ee"
      unitRef="shares">1618235</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzEyLTEtMS0xLTQ5ODI4_0a51546c-ab78-44b5-9a06-74cb31b4e215"
      unitRef="shares">760323</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90YWJsZTo4OGY3NDkyODM2OTA0MWZlYWE0Y2Y4ZDk2NTYwZDdmMC90YWJsZXJhbmdlOjg4Zjc0OTI4MzY5MDQxZmVhYTRjZjhkOTY1NjBkN2YwXzEzLTEtMS0xLTQ5ODI4_e28edb07-1049-409c-b244-67f0c9d9a3f5"
      unitRef="shares">2556257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc1NzQ_192dde16-950e-4bdf-aee4-7aca15864ca3"
      unitRef="usdPerShare">8.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc1ODU_e4b1ad14-1286-43c9-b502-9adc671b0b11"
      unitRef="shares">77250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc2NDk_39857aa9-0191-4f6f-848c-351355a76e52"
      unitRef="usdPerShare">4.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc2NjA_f72a8655-2364-4b83-a6a3-2ffc399f4595"
      unitRef="shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc3Mjc_67f9d65c-5d15-44e3-998d-2d6f05259b9e"
      unitRef="usdPerShare">4.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc3Mzg_37f4368a-560e-4353-8fd2-6195262572de"
      unitRef="shares">78750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc4NTk_fdc5719c-e33c-49ba-9e62-2774f94fa818"
      unitRef="usdPerShare">2.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc4NjM_2cbdab14-e5be-4592-ad6b-f4a90419b90d"
      unitRef="usdPerShare">7.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzc4NzA_7b280af8-46c3-43b6-968f-6c6e1079ced8"
      unitRef="usdPerShare">6.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifdb2a873738e472696885e376b3e567b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgwMDU_b919fd61-f09c-4076-a2ee-a92943ff0e59"
      unitRef="usdPerShare">3.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i10ced5af10f440b0bebf5936fd97f874_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgwMDk_bc2ab615-6397-42ae-a5f8-0228100d15c4"
      unitRef="usdPerShare">10.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ia0bfc9c5f8ce490dac127867d5e5bd45_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgwMTY_e5376d28-f768-480e-8376-ea9312dba609"
      unitRef="usdPerShare">9.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgxNTE_66b08f30-7085-41fa-a224-0218a298bfab"
      unitRef="usd">283000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgxNTU_d3716a0a-3e25-4fb8-b5ee-3ed012c2e440"
      unitRef="usd">6700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgxNjI_f73e3c0c-6ab0-4e39-b2d6-64a0db2ca0f0"
      unitRef="usd">12300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgzMzI_bfeafa3b-95ac-462d-9258-5aef779252b7"
      unitRef="usd">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgzMzY_7d659431-32c3-410d-a759-92ca91737a87"
      unitRef="usd">7000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzgzNDM_a3b43739-a73b-4792-b43b-efef5c63281d"
      unitRef="usd">14200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="ifc1288bd631248f7b04452e9589385b3_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNjkvZnJhZzo5MTJlMWU5NTVjNzQ0ZmU0YTc4YmM3M2Y4Y2JiY2YxZC90ZXh0cmVnaW9uOjkxMmUxZTk1NWM3NDRmZTRhNzhiYzczZjhjYmJjZjFkXzg0NTE_3711d807-261b-4df2-9af2-adbc6e6207f6"
      unitRef="shares">111941</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzExNzMz_3470a003-de16-4b60-b333-4904664fd250">Commitments and Contingencies&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases approximately 82,200 square feet of office, laboratory, and manufacturing space in San Diego, California and 57,360 square feet of office space in Plymouth Meeting, Pennsylvania under various non-cancellable operating lease agreements with remaining lease terms as of December&#160;31, 2022 of 0.9 years to 7.0 years, which represent the non-cancellable periods of the leases. The Company has excluded the extension options from its lease terms in the calculation of future lease payments as they are not reasonably certain to be exercised. The Company's lease payments consist primarily of fixed rental payments for the right to use the underlying leased assets over the lease terms as well as payments for common area maintenance and administrative services. The Company has received customary incentives from its landlords, such as reimbursements for tenant improvements and rent abatement periods, which effectively reduce the total lease payments owed for these leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed an evaluation of its contracts with customers and suppliers in accordance with ASC Topic 842 and determined that, except for the real estate leases described above and various copier leases, none of its other contracts contain a right-of-use asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and liabilities on the consolidated balance sheet represents the present value of the remaining lease payments over the remaining lease terms. Payments for additional monthly fees to cover the Company's share of certain facility expenses are not included in operating lease right-of-use assets and liabilities. The Company uses its incremental borrowing rate to calculate the present value of its lease payments, as the implicit rates in the leases are not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of December&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,526,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,223,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,090,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,630,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,460,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,804,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,656,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease costs included in operating expenses in the consolidated statements of operations for the years ended December&#160;31, 2022, 2021 and 2020 were $3.4 million, $3.4 million and $3.4 million, respectively. Operating lease costs consisting of the fixed lease payments included in operating lease liabilities are recorded on a straight-line basis over the lease terms. Variable lease costs are recorded as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2019, the Company entered into two agreements to sublease a total of approximately 13,500 square feet in its Plymouth Meeting headquarters with one period through March 31, 2025 and the other month-to-month after December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is a party to a variety of agreements pursuant to which it may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of the Company's obligations and the unique facts and circumstances involved in each particular agreement. Historically, payments made by the Company under these types of agreements have not had a material effect on its business, consolidated results of operations or financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Securities Class Action Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2020, a purported shareholder class action complaint, McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim, was filed in the United States District Court for the Eastern District of Pennsylvania, naming the Company and its former President and Chief Executive Officer as defendants. The lawsuit alleged that the Company made materially false and misleading statements regarding its development of a vaccine for COVID-19 in its public disclosures in violation of certain federal securities laws. The plaintiffs sought unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys&#x2019; fees. The plaintiffs&#x2019; complaint was later amended to include certain of the Company&#x2019;s other officers as defendants. After additional motions were filed in the case, in June 2022 the parties negotiated an agreement in principle to settle the shareholder class action complaint. Under the settlement, the Company will pay $30.0&#160;million in cash and $14.0&#160;million in shares of its common stock to settle all outstanding claims. The Company's insurance carriers have paid the $30.0&#160;million cash component of the settlement. On August 31, 2022, the court granted preliminary approval of the settlement. See Note 16 for events subsequent to December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Shareholder Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2020, a purported shareholder derivative complaint, Behesti v. Kim, et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The lawsuit asserts state and federal claims and is based on the same alleged misstatements as the shareholder class &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;action complaint described above. The lawsuit accuses the Company&#x2019;s board of directors of failing to exercise reasonable and prudent supervision over the Company&#x2019;s management, policies, practices, and internal controls. The plaintiff seeks unspecified monetary damages on behalf of the Company as well as governance reforms. On June 5, 2020, the court stayed the Beheshti action pending resolution of a forthcoming motion to dismiss the McDermid securities class action or until any party provides notice that they no longer consent to the stay. On June 12, 2020 and June 15, 2020, two additional shareholder derivative complaints were filed in the United States District Court for the Eastern District of Pennsylvania, captioned Isman v. Benito, et al. and Devarakonda et al. v Kim, et. al. The complaints assert substantially similar claims as the Beheshti action and name the Company&#x2019;s current directors as defendants. The Devarakonda complaint also names one of the Company&#x2019;s former directors as a defendant. On July 21, 2020, the court consolidated the three derivative cases under the caption In re Inovio Pharmaceuticals, Inc. Derivative Litigation. The consolidated action is stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, a fourth shareholder derivative complaint, Fettig v. Kim et al., was filed in the United States District Court for the Eastern District of Pennsylvania, naming eight current and former directors of the Company as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action. On August 27, 2020, the Fettig action was consolidated with the other derivative cases, which remain stayed as explained above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 28, 2022, a fifth shareholder derivative complaint, Schumacher v. Benito et al., was filed in the Delaware Court of Chancery, naming eight current and former directors as defendants. The complaint asserts substantially similar claims as those in the consolidated derivative action.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 4, 2022, the Delaware Court of Chancery entered a stay of the litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;VGXI Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2020, the Company filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., or GeneOne, and together with VGXI, Inc. collectively referred to as VGXI, alleging that VGXI had materially breached the Company&#x2019;s supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys&#x2019; fees, interest, costs and other relief from VGXI. On June 3, 2020, the Company filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, the Company filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 7, 2020, VGXI filed an answer, new matter and counterclaims against the Company, alleging that the Company had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys&#x2019; fees, interest, costs and other relief from the Company. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that the Company had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, the Company filed an answer to VGXI&#x2019;s counterclaims, disputing the allegations and the claims raised in VGXI&#x2019;s filing. On October 1, 2020, the Company filed a notice of discontinuance of appeal with the Pennsylvania Superior Court. A trial date for the litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its complaint against VGXI and to vigorously defend itself against VGXI&#x2019;s counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GeneOne Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2020, GeneOne filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against the Company, alleging that the Company had breached the CELLECTRA Device License Agreement, or the Agreement, between the Company and GeneOne. The Company terminated the Agreement on October 9, 2020. The complaint asserts claims for breach of contract, declaratory judgment, unfair competition, and unjust enrichment. The complaint seeks injunctive relief, an accounting, damages, disgorgement of profits, attorneys&#x2019; fees, interest, and other relief from the Company. On January 29, 2021, the Company filed preliminary objections to the complaint. On August 23, 2021, the court overruled the Company&#x2019;s preliminary objections to the complaint. On September 13, 2021, the Company filed an answer to the complaint, new matter, and counterclaims. The Company&#x2019;s counterclaims allege that GeneOne breached the Agreement and assert claims for breach of contract and declaratory judgment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The counterclaims seek damages, interest, expenses, attorney&#x2019;s fees, and costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 18, 2021, GeneOne filed its answer to the Company&#x2019;s counterclaims and new matter. On November 8, 2021, we filed our answer to GeneOne&#x2019;s new matter. A trial date for this litigation has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company intends to aggressively prosecute the claims set forth in its counterclaims against GeneOne and to vigorously defend itself against the claims in GeneOne&#x2019;s complaint. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of its business. Any of these claims could subject the Company to costly legal expenses and, while the Company generally believes that it has adequate insurance to cover many different types of liabilities, its insurance carriers may deny coverage or its policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on the Company's consolidated results of &lt;/span&gt;&lt;/div&gt;operations and financial position. Additionally, any such claims, whether or not successful, could damage the Company's reputation and business. Except as described above, the Company is not a party to any legal proceedings, the adverse outcome of which, in management&#x2019;s opinion, individually or in the aggregate, would be reasonably expected to have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i0d81dec2251d43bc8eec87ebd45ccbbe_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1Xzc5_50449d97-8040-48fd-a5ff-b859cd9d8162"
      unitRef="sqft">82200</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="if9eb27232eb94ef4b6dc9ca0783ab193_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE3MA_8b4c054d-774d-4286-a90c-3c41f74ff07a"
      unitRef="sqft">57360</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i850961a8bdd6418e89855c3fe22af042_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzMzMQ_d6bfd022-dc7b-4bc5-9c26-b2f8ed268699">P0Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i4e5bfcb200d2499cbfc64d230771e3f2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzMzNw_388ce4eb-58b4-4138-9a10-4c1abad959c3">P7Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzExNzM5_0dcb0216-eab9-44f8-b8ab-b10e7b187891">&lt;div style="text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;As of December&#160;31, 2022, the maturities of the Company's operating lease liabilities were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.449%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,089,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,050,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,063,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,526,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,223,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,090,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,630,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,460,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,804,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,656,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzEtMS0xLTEtNDk4Mjg_2d294132-bdda-4065-936a-8779495297c9"
      unitRef="usd">4089000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzItMS0xLTEtNDk4Mjg_b4e3bd4f-426e-43e2-b0a7-cf84b5b8c2b3"
      unitRef="usd">3050000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzMtMS0xLTEtNDk4Mjg_e985e0e8-d63a-49fc-9334-ba89a08fd583"
      unitRef="usd">3063000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzQtMS0xLTEtNDk4Mjg_e2eea168-1760-4069-935f-748daed526a7"
      unitRef="usd">3139000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzUtMS0xLTEtNDk4Mjg_b355a433-c821-44e8-8cf7-af7f76c1ef36"
      unitRef="usd">2526000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzYtMS0xLTEtNDk4Mjg_177b4bec-dd56-4083-8916-8699e312004b"
      unitRef="usd">4223000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzctMS0xLTEtNDk4Mjg_be5abb0c-bdbd-493b-82bc-fdfda6abbf86"
      unitRef="usd">20090000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzgtMS0xLTEtNDk4Mjg_da13c952-40e8-4483-b413-5dd634f9a8d2"
      unitRef="usd">4630000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzktMS0xLTEtNDk4Mjg_ba5fde3b-0f77-428d-a8ab-61b3293a40aa"
      unitRef="usd">15460000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzEwLTEtMS0xLTQ5ODI4_68d33410-097e-4721-ba68-eac5270c2dc0"
      unitRef="usd">2804000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzExLTEtMS0xLTQ5ODI4_bb079b90-6597-45e3-8223-da9c245acb83"
      unitRef="usd">12656000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzEzLTEtMS0xLTQ5ODI4_7cd1ac86-d990-4a11-90c2-9ed8a19c4e63">P5Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90YWJsZTpiMTBmMWVjODRkM2E0YmM4YWJjN2FjMDM1YzMzNTQ0YS90YWJsZXJhbmdlOmIxMGYxZWM4NGQzYTRiYzhhYmM3YWMwMzVjMzM1NDRhXzE0LTEtMS0xLTQ5ODI4_1a1b7607-7c6a-4235-a011-ed929d6eb6be"
      unitRef="number">0.086</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCost
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIwMDE_035dda03-e79d-41a6-80e2-1b13b5888120"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIwMDU_d99ce2f7-f998-4975-bcb0-edcdc13c1a15"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIwMTI_fbebed43-f9d7-4468-9fc8-7c977d1e5cb2"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <ino:LesseeNumberOfLeaseAgreementsEnteredInto
      contextRef="i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIyOTQ_1d4b03c4-b858-4101-a868-82175fa1cc4e"
      unitRef="agreement">2</ino:LesseeNumberOfLeaseAgreementsEnteredInto>
    <ino:LesseeOperatingLeaseAreaofLandUnderLease
      contextRef="i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzIzNDU_8ed2292b-d2f2-40f4-bb5f-94da61ca0f5f"
      unitRef="sqft">13500</ino:LesseeOperatingLeaseAreaofLandUnderLease>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ib9df2365f9454744b557f8f6b5aa3936_I20210309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE2NDkyNjc0NzA5MzI_54db302d-1b70-421b-b1c1-cc60248a17a6"
      unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ino:LossContingencyEstimateOfPossibleLossValueOfShares
      contextRef="ib9df2365f9454744b557f8f6b5aa3936_I20210309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE2NDkyNjc0NzA5NjE_229cac92-b389-4f9f-bca3-412ab9a3bfb4"
      unitRef="usd">14000000</ino:LossContingencyEstimateOfPossibleLossValueOfShares>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ib9df2365f9454744b557f8f6b5aa3936_I20210309"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzUvZnJhZzplYjBjZjY1MTEwYzI0OGYxYWMxNWUzNDNlMTI2OGM5NS90ZXh0cmVnaW9uOmViMGNmNjUxMTBjMjQ4ZjFhYzE1ZTM0M2UxMjY4Yzk1XzE2NDkyNjc0NzA5OTA_7513df16-f944-44e3-9c00-d5450c87d02c"
      unitRef="usd">30000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3Mjk_caa53f53-57f8-4a0d-9322-06523821bdbf">Income Taxes &lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance pursuant to accounting for income taxes, a deferred tax asset or liability is determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,440,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,614,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,664,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,652,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303,224,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,890,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no provision for or benefit from income taxes for the years ended December 31, 2022, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,307,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,677,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,207,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,601,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,065,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,534,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,650,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,337,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are shown below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,768,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,442,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,793,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,171,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,124,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,205,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,966,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,148,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,347,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,998,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of December&#160;31, 2022, the Company had federal, California and Pennsylvania tax net operating loss (NOL) carryforwards of $920.6 million, $210.3 million and $89.6 million, respectively, net of the net operating losses that will expire due to IRC Section&#160;382 limitations. The aggregate federal net operating losses generated in 2018 and after for the amount of $625.4 million will carryforward indefinitely and be available to offset up to 80% of future taxable income each year, subject to certain modifications made by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) enacted in 2020. The federal NOL carryforward began to expire in 2022, and the California and Pennsylvania NOL carryforwards will begin and have begun to expire in 2028 and 2022, respectively, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also had Korean NOL carryforwards of $1.0 million as of December 31, 2022. The Korean NOLs are available to offset up to 60% of future taxable income and will begin to expire in 2030, unless previously utilized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as of December 31, 2022, the Company had federal and state research and development (R&amp;amp;D) tax credit carryforwards of $40.5 million and $4.7 million, respectively. The federal tax credit carryforwards will begin to expire in 2029. The California research tax credits do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company&#x2019;s NOL and R&amp;amp;D credit carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has completed an IRC Section&#160;382/383 analysis regarding the limitation of NOL and R&amp;amp;D credit carryforwards as of December&#160;31, 2022. As a result of the analysis, the Company estimates that approximately $8.3 million of tax benefits related to NOL and R&amp;amp;D carryforwards will expire unused. Accordingly, the related NOL and R&amp;amp;D credit carryforwards have been removed from deferred tax assets, accompanied by a corresponding reduction of the valuation allowance. Due to the existence of the valuation allowance, limitations created by current and future ownership changes, if any, related to the Company's operations in the United States will not impact its effective tax rate. Any additional ownership changes may further limit the ability to use the NOL and R&amp;amp;D carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Tax Cuts and Jobs Act of 2017 subjects a U.S. stockholder to tax on Global Intangible Low-Taxed Income (GILTI) earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income, states that an entity can make an accounting policy election to recognize deferred taxes for temporary basis differences expected to reverse as GILTI in future years or to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. The Company has elected to provide for the tax expense related to GILTI in the year the tax is incurred as a period expense only. For 2022, 2021 and 2020, the Company did not generate any GILTI due to losses earned by its foreign subsidiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits federal NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows federal NOLs incurred in 2019, 2020, and 2021 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Due to the Company's history of net operating losses, the CARES Act did not have a material impact on the Company's financial statements for the years ended December 31, 2022, 2021 or 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(582,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unrecognized tax benefits that, if recognized and realized, would affect the effective tax rate was $19.7 million, $17.4 million and $10.9 million as of December&#160;31, 2022, 2021 and 2020, respectively, subject to valuation allowances. The Company has not recorded any interest and penalties on the unrecognized tax positions as the Company has continued to generate net operating losses after accounting for the unrecognized tax benefits. The Company does not anticipate that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve&#160;months of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its subsidiaries are subject to U.S. federal income tax as well as income tax in multiple state and foreign jurisdictions. With few exceptions, the Company is no longer subject to United States federal income tax examinations for years before 2019 and state and local income tax examinations before 2018. However, to the extent allowed by law, the tax authorities may have the right to examine prior periods where net operating losses were generated and carried forward, and make adjustments up to the amount of the NOL carryforward amount. The Company is not to its knowledge currently under Internal Revenue Service (&#x201c;IRS&#x201d;), state, local or foreign tax examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3MjM_f72f3fa1-9737-43bc-8533-1a0ddbe7c199">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of pretax loss from operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,440,803)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(302,614,003)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,664,355)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(211,249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(610,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(225,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(277,652,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303,224,323)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(162,890,304)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzItMS0xLTEtNDk4Mjg_618aee11-8344-4c61-97c1-56b7206d800a"
      unitRef="usd">-277440803</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzItMy0xLTEtNDk4Mjg_da6a2cca-9059-4d9f-9811-88e6c7d85dc2"
      unitRef="usd">-302614003</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzItNS0xLTEtNDk4Mjg_ef703400-9a84-4b88-943a-6b72939a1867"
      unitRef="usd">-162664355</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzMtMS0xLTEtNDk4Mjg_fe149952-a51e-42ba-95f4-3acf9dd2e417"
      unitRef="usd">-211249</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzMtMy0xLTEtNDk4Mjg_3b6eac19-3810-4fe5-a4d8-deb405c508a1"
      unitRef="usd">-610320</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzMtNS0xLTEtNDk4Mjg_b2125e29-3d84-4753-8395-024f991769eb"
      unitRef="usd">-225949</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzQtMS0xLTEtNDk4Mjg_d4983b88-718f-46ff-9edf-32cf22f32799"
      unitRef="usd">-277652052</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzQtMy0xLTEtNDk4Mjg_3cd74d49-b09d-488d-9e86-4f2c446a7dec"
      unitRef="usd">-303224323</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplOGMwYWJkMTkwNmI0OTNhOTY4YjEzMTYxZWIxYTdmYi90YWJsZXJhbmdlOmU4YzBhYmQxOTA2YjQ5M2E5NjhiMTMxNjFlYjFhN2ZiXzQtNS0xLTEtNDk4Mjg_726554ba-908a-4757-b3d3-4569395c4086"
      unitRef="usd">-162890304</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzYxOQ_1152d0ef-f311-4333-a961-8b6591039a51"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzYxOQ_2cb7f959-8992-49b2-9904-97051734aed7"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzYxOQ_40a28e52-f02f-4ac4-a421-8f07fa377959"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3MDM_07aabb33-a4bf-4c25-9e17-0aac00c2f15e">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of income taxes attributable to continuing operations computed at the statutory tax rates to income tax benefit, using a 21% statutory tax rate for December 31, 2022, 2021 and 2020, is as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes at statutory rates&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(58,307,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,677,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,207,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income tax, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,601,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,447,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,065,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,424,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,428,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nondeductible loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,534,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,523,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,650,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,913,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;483,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,953,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,509,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,068,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deconsolidation of subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;853,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;616,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Limited NOLs and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,337,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(542,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,246,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(819,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzItMS0xLTEtNDk4Mjg_e84d1f54-b2a4-4e6f-9a7c-44dd4d11ed76"
      unitRef="usd">-58307000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzItMy0xLTEtNDk4Mjg_e4e01e98-9669-46e5-a7f8-790377c1396b"
      unitRef="usd">-63677000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzItNS0xLTEtNDk4Mjg_3b90f034-a940-4715-8e81-a71f91eb69de"
      unitRef="usd">-34207000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzMtMS0xLTEtNDk4Mjg_9c2db69a-deeb-4637-ac5d-9f4457f5476a"
      unitRef="usd">-3601000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzMtMy0xLTEtNDk4Mjg_02001f18-f736-40a3-b499-e46f9cd16bb1"
      unitRef="usd">-3447000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzMtNS0xLTEtNDk4Mjg_ec3b8544-6c5a-4681-a391-8567e90d22a6"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzUtMS0xLTEtNDk4Mjg_335f48cd-7947-4299-8f35-4130d463e3c3"
      unitRef="usd">61065000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzUtMy0xLTEtNDk4Mjg_81e977e0-d7e0-486b-bec5-f6f02b670fd4"
      unitRef="usd">77424000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzUtNS0xLTEtNDk4Mjg_b5986848-baec-48ff-a5a4-d83483db3c3a"
      unitRef="usd">21428000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzYtMS0xLTEtNDk4Mjg_059fffb7-258a-456f-b786-1c41a856d69a"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzYtMy0xLTEtNDk4Mjg_08ecc5b0-6c4f-4556-9372-bb5d2497a2b4"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzYtNS0xLTEtNDk4Mjg_f9519ba0-f02f-4baf-bf6e-c26796fa6a28"
      unitRef="usd">14450000</ino:EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzctMS0xLTEtNDk4Mjg_8bd9026c-80f0-4b86-a838-f2e06f7ff679"
      unitRef="usd">-7534000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzctMy0xLTEtNDk4Mjg_f9a049ec-42fa-461f-8a41-8ed76d81d8f1"
      unitRef="usd">-16523000</ino:IncomeTaxReconciliationStatuteLimitations>
    <ino:IncomeTaxReconciliationStatuteLimitations
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzctNS0xLTEtNDk4Mjg_001fcc55-8ec5-41fd-8fd2-893c2b6d9601"
      unitRef="usd">-2650000</ino:IncomeTaxReconciliationStatuteLimitations>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzktMS0xLTEtNDk4Mjg_39d418f5-b38b-40b6-8c96-e8a93c25689c"
      unitRef="usd">2913000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzktMy0xLTEtNDk4Mjg_c1f7813a-2ec8-4c6d-b067-3866ab406309"
      unitRef="usd">483000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzktNS0xLTEtNDk4Mjg_76e9614f-3bec-4e7b-bf90-a253a73563be"
      unitRef="usd">-1953000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEwLTEtMS0xLTQ5ODI4_b06cf8e9-d665-494a-85ba-8f205afe15fc"
      unitRef="usd">2291000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEwLTMtMS0xLTQ5ODI4_022aa5e0-fd30-4d7f-b26b-d150ea02c258"
      unitRef="usd">6509000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEwLTUtMS0xLTQ5ODI4_b85dc7df-5417-422b-8825-040695c6b1d2"
      unitRef="usd">1068000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzExLTEtMS0xLTQ5ODI4_f69b3f9f-bf60-4dbd-87f3-0f1234201b67"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzExLTMtMS0xLTQ5ODI4_94576f9b-8e88-41a9-a999-34938d14e355"
      unitRef="usd">0</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzExLTUtMS0xLTQ5ODI4_8a36c196-c38d-459d-a15d-9bec2bafd54f"
      unitRef="usd">853000</ino:EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEyLTEtMS0xLTQ5ODI4_9b153e67-f434-4ec7-ae0b-de7dffc01b03"
      unitRef="usd">1459000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEyLTMtMS0xLTQ5ODI4_71b48378-469a-4e61-82dd-8782da6f4a07"
      unitRef="usd">616000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEyLTUtMS0xLTQ5ODI4_0587ae19-b97c-413c-b26b-5f78cc565e2c"
      unitRef="usd">468000</ino:EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEzLTEtMS0xLTQ5ODI4_9f47c217-1e5a-4955-847f-defe7ffa4102"
      unitRef="usd">-1337000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEzLTMtMS0xLTQ5ODI4_11458519-009a-4371-aa1a-354e069b8d56"
      unitRef="usd">-542000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzEzLTUtMS0xLTQ5ODI4_a2e25d99-1f96-4cb0-8766-20d5076552e7"
      unitRef="usd">-368000</ino:EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE0LTEtMS0xLTQ5ODI4_3bf296b7-12ab-4ce3-bc25-31e6dd7ff9e5"
      unitRef="usd">-187000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE0LTMtMS0xLTQ5ODI4_bace0f59-0b27-48f7-ac7d-431c119b8c33"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE0LTUtMS0xLTQ5ODI4_838d1aee-73ff-46a4-bcab-4b09eb04ba13"
      unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE1LTEtMS0xLTQ5ODI4_8717fe93-8b13-4f36-8941-e2c138554bdb"
      unitRef="usd">-8000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE1LTMtMS0xLTQ5ODI4_e30047ba-de54-4a9b-ae3d-525ed11c2f2d"
      unitRef="usd">-24000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE1LTUtMS0xLTQ5ODI4_14378fa0-47d2-4ba7-8098-f48d822f9265"
      unitRef="usd">-9000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE2LTEtMS0xLTQ5ODI4_2d298072-4cc5-4c29-867e-f986af57789f"
      unitRef="usd">3246000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE2LTMtMS0xLTQ5ODI4_219aabff-be19-4701-9719-bca4e23f9a4f"
      unitRef="usd">-819000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE2LTUtMS0xLTQ5ODI4_42ac875b-9fb7-4ebe-90cc-929a1731073f"
      unitRef="usd">920000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE3LTEtMS0xLTQ5ODI4_e1cd16eb-5eb8-4fe4-8e9f-e177ef3bfff3"
      unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE3LTMtMS0xLTQ5ODI4_218a737a-3432-4500-8201-0ac6d961df62"
      unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <ino:ComprehensiveIncomeLossTaxExpenseBenefit
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo2YzdiODFkZTMzMjA0MWI2OWM1ZTkzZTA2NzUxOTE3Yy90YWJsZXJhbmdlOjZjN2I4MWRlMzMyMDQxYjY5YzVlOTNlMDY3NTE5MTdjXzE3LTUtMS0xLTQ5ODI4_eed3550a-6837-43c5-b28c-d61856db1940"
      unitRef="usd">0</ino:ComprehensiveIncomeLossTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY2OTU_5f62d1dc-47e7-41de-a165-7b42f7b604b4">Significant components of the Company&#x2019;s deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 are shown below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,252,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;NOL carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;212,768,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,144,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,442,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;987,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,945,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,599,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;559,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliated entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,247,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,793,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,973,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301,439,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,171,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299,124,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(237,205,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,315,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,966,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,148,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,430,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Note discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(321,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,347,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,998,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzMtMS0xLTEtNDk4Mjg_14fd245c-8e01-4651-87cc-8383ca7aeb5f"
      unitRef="usd">41252000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzMtMy0xLTEtNDk4Mjg_9341be56-fe4c-4eae-8410-2fef5ad67f92"
      unitRef="usd">4200000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzQtMS0xLTEtNDk4Mjg_3a7891c7-1014-4251-b31c-be06e6843c98"
      unitRef="usd">212768000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzQtMy0xLTEtNDk4Mjg_f47e3e52-9a5f-47dd-9315-6e26e9f5e7b3"
      unitRef="usd">197144000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzUtMS0xLTEtNDk4Mjg_cef223f4-801c-4ea0-8f21-6ff5bcf1c4b8"
      unitRef="usd">26442000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzUtMy0xLTEtNDk4Mjg_3179c13c-74bd-4ca6-87f4-856fb6288d35"
      unitRef="usd">23005000</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzYtMS0xLTEtNDk4Mjg_f4d5fbd7-be46-45f2-95dc-5af94222c4ea"
      unitRef="usd">538000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzYtMy0xLTEtNDk4Mjg_c37bde72-7e25-449a-a8e9-13bba8276370"
      unitRef="usd">987000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzgtMS0xLTEtNDk4Mjg_7d5b885d-6f0a-4b8c-bfca-d97707141626"
      unitRef="usd">3945000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzgtMy0xLTEtNDk4Mjg_685e5862-de68-4736-b415-4e7f940aa00c"
      unitRef="usd">3599000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <ino:DeferredTaxAssetsIntangibleAssets
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzktMS0xLTEtNDk4Mjg_4f682f91-b51a-4984-be21-d73d8c1ff73e"
      unitRef="usd">559000</ino:DeferredTaxAssetsIntangibleAssets>
    <ino:DeferredTaxAssetsIntangibleAssets
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzktMy0xLTEtNDk4Mjg_98d398a1-cae5-492a-8c3c-906685571169"
      unitRef="usd">637000</ino:DeferredTaxAssetsIntangibleAssets>
    <ino:DeferredTaxAssetInterestExpense
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzExLTEtMS0xLTQ5ODI4_32c7bc75-5d55-4a49-959e-7c565fdaa926"
      unitRef="usd">0</ino:DeferredTaxAssetInterestExpense>
    <ino:DeferredTaxAssetInterestExpense
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzExLTMtMS0xLTQ5ODI4_b6b80488-fa32-4c98-94c5-2a3f3a55502e"
      unitRef="usd">83000</ino:DeferredTaxAssetInterestExpense>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEyLTEtMS0xLTQ5ODI4_6b2f71bc-229c-4f87-96de-cb522393bfc3"
      unitRef="usd">1569000</us-gaap:DeferredTaxAssetsInvestments>
    <us-gaap:DeferredTaxAssetsInvestments
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEyLTMtMS0xLTQ5ODI4_e358aef7-9bbb-46cf-ba66-3b3b65676a22"
      unitRef="usd">750000</us-gaap:DeferredTaxAssetsInvestments>
    <ino:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEzLTEtMS0xLTQ5ODI4_137e73b0-558b-42e8-9c3d-6134729d6e7f"
      unitRef="usd">3247000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <ino:DeferredTaxAssetsOperatingLeaseLiability
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzEzLTMtMS0xLTQ5ODI4_e9ce9901-0763-4cc9-b950-fcfe6abffd16"
      unitRef="usd">3793000</ino:DeferredTaxAssetsOperatingLeaseLiability>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE0LTEtMS0xLTQ5ODI4_5b7c9592-5740-47ee-a27f-e3c8b62a693a"
      unitRef="usd">57000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE0LTMtMS0xLTQ5ODI4_be9d0064-fe20-476c-8145-ad00b16df4e8"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE1LTEtMS0xLTQ5ODI4_ad45c261-fa5c-42f4-a535-5835804f473f"
      unitRef="usd">11062000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE1LTMtMS0xLTQ5ODI4_718df49d-da2c-4904-8b78-8c3ed2595713"
      unitRef="usd">5973000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE2LTEtMS0xLTQ5ODI4_6b193dd6-1d5b-4d40-bc8c-0bba00984660"
      unitRef="usd">301439000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE2LTMtMS0xLTQ5ODI4_c6c31523-07d7-4f18-aa4d-52c2d8a5bfb1"
      unitRef="usd">240171000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE3LTEtMS0xLTQ5ODI4_650ab7ec-e6f1-4bcf-8231-6e8fb3da2726"
      unitRef="usd">299124000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE3LTMtMS0xLTQ5ODI4_41c169ae-6d31-40ed-9b8c-2092c095eed2"
      unitRef="usd">237205000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE4LTEtMS0xLTQ5ODI4_fc71af34-e6c7-45e7-aec6-7c1486e3a2a2"
      unitRef="usd">2315000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzE4LTMtMS0xLTQ5ODI4_2c5105a4-7482-49e2-8bce-d0beda15ecdc"
      unitRef="usd">2966000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIwLTEtMS0xLTQ5ODI4_0bba33be-337e-43b8-890d-1fe678d882ad"
      unitRef="usd">199000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIwLTMtMS0xLTQ5ODI4_13dcacfa-5668-4f35-8026-c6cc2fef89dc"
      unitRef="usd">194000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIyLTEtMS0xLTQ5ODI4_0c42b622-5462-4d9c-b076-d4c5047dfc89"
      unitRef="usd">2148000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIyLTMtMS0xLTQ5ODI4_f537df5c-154a-4e0c-8eb5-f5ae9cfa0e72"
      unitRef="usd">2430000</ino:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset>
    <ino:DeferredTaxLiabilitiesFinancingArrangementDiscount
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIzLTEtMS0xLTQ5ODI4_c2905af6-6821-4f1b-a56d-a67d184bb5e9"
      unitRef="usd">0</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
    <ino:DeferredTaxLiabilitiesFinancingArrangementDiscount
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzIzLTMtMS0xLTQ5ODI4_b1d8a518-0c72-4b8d-87b2-6a1997c0a4ff"
      unitRef="usd">321000</ino:DeferredTaxLiabilitiesFinancingArrangementDiscount>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI1LTEtMS0xLTQ5ODI4_a0cbfb80-85d1-45b0-b7f6-684e0284dff0"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI1LTMtMS0xLTQ5ODI4_2a39b1aa-bb41-46e9-af41-2274716aa164"
      unitRef="usd">53000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTEtMS0xLTYwMzM1_1913eadd-0482-4775-a50d-c894c348466a"
      unitRef="usd">2347000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTMtMS0xLTYwMzM3_a4bca52c-6663-4e71-9cb6-443c647ca9a1"
      unitRef="usd">2998000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTEtMS0xLTQ5ODI4_fb5a2bc1-24c1-4c95-afc5-b38eb0b9edce"
      unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTo1ZGI1ZjQyMDRkZTA0ZWI4YmU4NTM0OGUzY2Y5ZGNhNi90YWJsZXJhbmdlOjVkYjVmNDIwNGRlMDRlYjhiZTg1MzQ4ZTNjZjlkY2E2XzI2LTMtMS0xLTQ5ODI4_4447da7b-1482-4f99-8fb7-eb90b78453ea"
      unitRef="usd">32000</us-gaap:DeferredTaxLiabilities>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="i84820f5d4e9a4ac2a3cac63e01a7c45c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzE4MTM_23bff36b-d9b5-44d4-9f26-d16cd9c3697a"
      unitRef="usd">920600000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="if12b9cf6eeaa4f20aa6799810ad465db_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzE4MTc_d2e7f53d-6ad6-4d0f-bda1-18bfe7fd7ce5"
      unitRef="usd">210300000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="i650dedeab35546edb17b1d6256119449_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzE4MjQ_7a460b05-d9ae-46e9-9c89-7ffc8a2eb645"
      unitRef="usd">89600000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="icfaee2d1c32b4607a08c7c73282b04f4_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzIwMTY_fa11742a-1364-49ed-b0db-35c039eb82e4"
      unitRef="usd">625400000</us-gaap:OperatingLossCarryforwards>
    <ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet
      contextRef="ic954d78339b94180a278d80e6ec99f23_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzIzNzM_dd18b20d-196c-4be2-b9fd-c8e829fc577e"
      unitRef="usd">1000000</ino:OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i071ac54a560b456dab72ccae0e2af24a_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzI2Njc_c4cb46c2-a3e9-41bb-805f-805c7fe813db"
      unitRef="usd">40500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzI2NzQ_332c0894-d591-49d0-bfd6-64bb6a8f7d35"
      unitRef="usd">4700000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY2OTc_d0385e5a-fb69-4f2a-97c5-0dc55a1e687c">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based upon statute, federal and state losses and credits are expected to expire as follows (in millions):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.335%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiration Date:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign NOLs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Federal R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;State R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;249.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;625.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtMS0xLTEtNDk4Mjg_e6d934d1-1dd8-4833-bbe4-43f231d26cd5"
      unitRef="usd">5300000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtMy0xLTEtNDk4Mjg_31b5fa12-b574-4979-9bd9-c5866c79b146"
      unitRef="usd">1200000</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinTwoYears
      contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtNS0xLTEtNDk4Mjg_e28f447d-3d3e-49cf-a059-474a13596351"
      unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears
      contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtNy0xLTEtNDk4Mjg_badfd5ec-2574-4fe8-989e-f311924c8f4c"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:TaxCreditCarryforwardExpiringinTwoYears
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzMtOS0xLTEtNDk4Mjg_732abad1-b93d-42ff-b43b-0eead0f005bb"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinTwoYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtMS0xLTEtNDk4Mjg_a40a93de-04c1-4842-a9ca-e9c537ff4f5c"
      unitRef="usd">18900000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtMy0xLTEtNDk4Mjg_780d6fe1-d348-4492-ad14-d23f8b359b6d"
      unitRef="usd">9100000</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinThreeYears
      contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtNS0xLTEtNDk4Mjg_aec17fcc-45c2-4717-a6d8-c48adca2f060"
      unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinThreeYears>
    <ino:TaxCreditCarryforwardExpiringInThreeYears
      contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtNy0xLTEtNDk4Mjg_e03ef20c-01c3-4146-ac20-78b6e665b240"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInThreeYears>
    <ino:TaxCreditCarryforwardExpiringInThreeYears
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzQtOS0xLTEtNDk4Mjg_9609ed01-4d38-4ac9-83ee-67d1da7a4baa"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInThreeYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtMS0xLTEtNDk4Mjg_9aef4c5b-17c9-4729-b1b1-bd973e9a6f5f"
      unitRef="usd">9600000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtMy0xLTEtNDk4Mjg_18a70f3e-5e82-40e9-8988-a062b25ab848"
      unitRef="usd">5200000</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFourYears
      contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtNS0xLTEtNDk4Mjg_911fd7b9-806c-434e-bfb1-116c95517082"
      unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinFourYears>
    <ino:TaxCreditCarryforwardExpiringInFourYears
      contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtNy0xLTEtNDk4Mjg_c68cbdde-7687-4db5-b246-90c07f058de8"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInFourYears>
    <ino:TaxCreditCarryforwardExpiringInFourYears
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzUtOS0xLTEtNDk4Mjg_815c48ef-4fdd-4a28-a1db-143dddbb0de2"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInFourYears>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMS0xLTEtNTgyNzU_a03a6c8b-bad2-44c9-aa04-83acc26069f1"
      unitRef="usd">12200000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMy0xLTEtNTgyNzU_5393acf9-24bb-4527-8c72-f2c31914938d"
      unitRef="usd">7100000</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsExpiringinFiveYears
      contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNS0xLTEtNTgyNzU_d58c701d-b3de-4005-9b30-0c8165d47cdf"
      unitRef="usd">0</ino:OperatingLossCarryforwardsExpiringinFiveYears>
    <ino:TaxCreditCarryforwardExpiringinFiveYears
      contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNy0xLTEtNTgyNzU_b370adef-72af-4eaa-ac75-698efd7ab62c"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFiveYears>
    <ino:TaxCreditCarryforwardExpiringinFiveYears
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtOS0xLTEtNTgyNzU_96632591-fa1b-4ac9-a14c-758ed5a6a54c"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringinFiveYears>
    <ino:OperatingLossCarryforwardsExpiringInSixYears
      contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMS0xLTEtNDk4Mjg_538ce952-30a3-4f4f-be9d-1010d3fc7bd3"
      unitRef="usd">249200000</ino:OperatingLossCarryforwardsExpiringInSixYears>
    <ino:OperatingLossCarryforwardsExpiringInSixYears
      contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtMy0xLTEtNDk4Mjg_45fcfdaa-912a-4670-837f-4a4f63f65f22"
      unitRef="usd">277300000</ino:OperatingLossCarryforwardsExpiringInSixYears>
    <ino:OperatingLossCarryforwardsExpiringInSixYears
      contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNS0xLTEtNDk4Mjg_cda2dbba-1f12-47be-ac49-873ca35ad87f"
      unitRef="usd">1000000.0</ino:OperatingLossCarryforwardsExpiringInSixYears>
    <ino:TaxCreditCarryforwardExpiringInSixYears
      contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtNy0xLTEtNDk4Mjg_c3c5cc8f-9402-413a-b1c9-0078210599f3"
      unitRef="usd">40500000</ino:TaxCreditCarryforwardExpiringInSixYears>
    <ino:TaxCreditCarryforwardExpiringInSixYears
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzYtOS0xLTEtNDk4Mjg_cf880bb2-4d22-4512-b968-0b571fb4ddc9"
      unitRef="usd">0</ino:TaxCreditCarryforwardExpiringInSixYears>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctMS0xLTEtNDk4Mjg_12fd41df-27f7-4bf6-a81e-0710441fa79f"
      unitRef="usd">625400000</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctMy0xLTEtNDk4Mjg_b32aac25-34e4-45c9-8b4b-addff6d4b773"
      unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:OperatingLossCarryforwardsIndefinitelyCarryforward
      contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctNS0xLTEtNDk4Mjg_4892b4d7-b2ea-4b00-88e9-290b271e8b33"
      unitRef="usd">0</ino:OperatingLossCarryforwardsIndefinitelyCarryforward>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely
      contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctNy0xLTEtNDk4Mjg_132e765b-24b9-4e12-9d3b-11a3bc414011"
      unitRef="usd">0</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <ino:TaxCreditCarryforwardCarryforwardIndefinitely
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzctOS0xLTEtNDk4Mjg_d385e6e3-81c7-4b65-a01d-9e6202eefa59"
      unitRef="usd">4700000</ino:TaxCreditCarryforwardCarryforwardIndefinitely>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i3d82d3ec063a42378ab880fcb038f565_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtMS0xLTEtNDk4Mjg_386525bf-afd9-4ee8-8cda-7f109db2833e"
      unitRef="usd">920600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="icbb0e730795e49dd91d896275f2661e3_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtMy0xLTEtNDk4Mjg_bf0cf124-19de-4a17-acfd-363d6d1d094e"
      unitRef="usd">299900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i2be958cfc18849ac8a625b235decac6d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtNS0xLTEtNDk4Mjg_44a48b2d-c1ac-4587-8f7e-ef64fbaf43ed"
      unitRef="usd">1000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i1c5b7985c2de404f91adb16157f71c16_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtNy0xLTEtNDk4Mjg_3ac435cb-6885-4acd-9280-ac64ea3d2e05"
      unitRef="usd">40500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i72c37010c9d245c2a4349d20fc492085_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplNGVkZmIwMDVkNGU0Mzc4ODA0NzRhYTNjMDE5NzJmYy90YWJsZXJhbmdlOmU0ZWRmYjAwNWQ0ZTQzNzg4MDQ3NGFhM2MwMTk3MmZjXzgtOS0xLTEtNDk4Mjg_be83d35b-4aaa-43b7-8ae1-fedf02fb3f1a"
      unitRef="usd">4700000</us-gaap:TaxCreditCarryforwardAmount>
    <ino:TaxBenefitsExpired
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzMzNzI_a928095a-00f5-4dd2-a404-758e4f41ebbd"
      unitRef="usd">8300000</ino:TaxBenefitsExpired>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzY3Mjg_fb54c792-e4e1-4b6f-b486-fa19065a7fe4">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company's unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,204,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,902,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,602,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases (decreases) related to prior year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(582,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,139,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,819,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzItMS0xLTEtNDk4Mjg_3ec718eb-1680-453e-bd98-805514f2cd47"
      unitRef="usd">18819000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzItMy0xLTEtNDk4Mjg_452a3ae3-d224-4008-a8d3-15b7867e6c9a"
      unitRef="usd">12210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1bb91b86850c4019853cfafe96543ff8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzItNS0xLTEtNDk4Mjg_a7f1c564-936d-4827-8c11-bf79c1369b82"
      unitRef="usd">11204000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzMtMS0xLTEtNDk4Mjg_f901e3fd-12d3-4806-9b09-3e77417587e3"
      unitRef="usd">2902000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzMtMy0xLTEtNDk4Mjg_d2516d6c-1121-4dfc-bb8f-a083a16625d6"
      unitRef="usd">6602000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzMtNS0xLTEtNDk4Mjg_8a14c0d8-c07d-447b-a096-ac905797fcd0"
      unitRef="usd">1043000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzQtMS0xLTEtNDk4Mjg_74060f18-5b85-4797-b1b3-58e16a73781d"
      unitRef="usd">582000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzQtMy0xLTEtNDk4Mjg_c4f9ccb9-d7c1-4b01-b199-b72ff19ba43e"
      unitRef="usd">7000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzQtNS0xLTEtNDk4Mjg_cb567e05-3f6c-4ba0-97b0-af9208d237e2"
      unitRef="usd">27000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzUtMS0xLTEtNDk4Mjg_31bdea95-8b93-4845-9e2f-2012e83b5dc2"
      unitRef="usd">0</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzUtMy0xLTEtNDk4Mjg_2fb4b374-98df-4323-9a69-aa7999564739"
      unitRef="usd">0</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzUtNS0xLTEtNDk4Mjg_51003ed3-c411-4f55-89bd-2642b10fea1e"
      unitRef="usd">-64000</ino:UnrecognizedTaxBenefitsIncreaseDecreaseInOther>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzYtMS0xLTEtNDk4Mjg_b319d769-b9b4-4dbc-bfcb-5748e2793c35"
      unitRef="usd">21139000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzYtMy0xLTEtNDk4Mjg_14f20953-a00c-4458-9f04-889ece7447a6"
      unitRef="usd">18819000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90YWJsZTplMWIzYTQyYjNlNGE0NjlkYmU2ZTFhY2JmYmI5N2RlNy90YWJsZXJhbmdlOmUxYjNhNDJiM2U0YTQ2OWRiZTZlMWFjYmZiYjk3ZGU3XzYtNS0xLTEtNDk4Mjg_82dee665-6971-4b09-bae4-7b50fad0d80f"
      unitRef="usd">12210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzU0Nzk_7bd3a889-0194-4586-b6cd-8b5b33614b0a"
      unitRef="usd">19700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i6327975f86354d84adb2cb38dcd5ea52_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzU0ODM_d971dde3-0139-4f3d-9545-21d37c3114da"
      unitRef="usd">17400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i98afe0fd1d5b4561bdccee4641e1c13f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xNzgvZnJhZzo5NTliZGE4YTkyYmI0N2RhOGIxNzZkNjI1ZGJlMTc5MS90ZXh0cmVnaW9uOjk1OWJkYThhOTJiYjQ3ZGE4YjE3NmQ2MjVkYmUxNzkxXzU0OTA_cab691af-9cd7-408c-863d-62acebfccd82"
      unitRef="usd">10900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzU0MA_6ea4a334-a417-4a3f-983b-cbac636c940e">401(k) PlanThe Company has adopted a 401(k) Profit Sharing Plan covering substantially all of its employees. The defined contribution plan allows the employees to contribute a percentage of their compensation each year. The Company currently matches 50% of its employees&#x2019; contributions, up to 6% of their annual compensation. The Company&#x2019;s contributions are recorded as expense in the accompanying consolidated statements of operations and totaled $1.8 million, $1.5 million and $1.1 million for the years ended December&#160;31, 2022, 2021 and 2020, respectively.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzI2MA_115cafbe-7b35-4541-9db1-8c41356a1095"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzMwMg_4e3b3ca3-8dc0-4573-b44c-40c361871a4a"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzQ1Nw_ed6f3897-d217-48d1-99b6-f3719699e1d1"
      unitRef="usd">1800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzQ2MQ_96c6bf9f-24f8-45d4-b07a-48621fcfaf18"
      unitRef="usd">1500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i50eb63a5939e4608ba48a07e5ab932a1_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODEvZnJhZzo4MTA0MDQ4ZThmMjY0OGViOTNmYTQ5YjA5ZjhiN2VmNy90ZXh0cmVnaW9uOjgxMDQwNDhlOGYyNjQ4ZWI5M2ZhNDliMDlmOGI3ZWY3XzQ3Ng_a276ac72-04e5-401d-99b4-4af3db3ab657"
      unitRef="usd">1100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM2MjE_7ed9cfa6-1597-4f28-a58e-d0785770e29f">Related Party TransactionsPlumbline Life Sciences, Inc.&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;T&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Company owned 597,808 shares of common stock in PLS as of December 31, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, representing a 18.7% and 18.9% ownership interest, respectively. One &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Company's directors, Dr.&#160;David B. Weiner, acts as a consultant to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from PLS consists of milestone, license and patent fees. For the years ended December&#160;31, 2022,  2021 and 2020, the Company recognized revenue from PLS of $34,000, $245,000 and $1.4 million, respectively. At December 31, 2022 and 2021, the Company had an accounts receivable balance of $59,000 and $25,000, respectively, related to PLS.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;The Wistar Institute&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's director Dr.&#160;David B. Weiner is a director of the Vaccine Center of The Wistar Institute ("Wistar"). Dr. Weiner is also the Executive Vice President of Wistar.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2016, the Company entered into collaborative &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;research agreements with Wistar&#160;for preventive and therapeutic DNA-based immunotherapy applications and products developed by&#160;Dr. Weiner and Wistar for the treatment of cancers and infectious diseases. Under the terms of the agreement, the Company reimbursed Wistar for all direct and indirect costs incurred in the conduct of the collaborative research, not to exceed $3.1 million during the five-year term of the agreement. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, upon expiration of the March 2016 agreements, the Company entered into new collaborative research agreements with Wistar&#160;with the same terms. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has the exclusive right to in-license new intellectual property developed under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company entered into collaborative research agreements with Wistar in support of the clinical development of INO-4800. Under the terms of these collaborative research agreements, which have been completed as of September 30, 2022, the Company is reimbursing Wistar a total of $1.9&#160;million for all direct and indirect costs incurred in the conduct of the collaborative research.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2016, the Company rece&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ived a&#160;$6.1 million&#160;sub-grant through Wistar to develop a d&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MAb&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; against the Zika infectio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;n, with funding through December 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a collaborator with Wistar on an Integrated Preclinical/Clinical AIDS Vaccine Development grant from the National Institutes of Health&#x2019;s National Institute of Allergy and Infectious Diseases, with funding through February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company received a $10.7&#160;million sub-grant through Wistar, which was amended in 2021 to $13.6&#160;million, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the preclinical development and translational studies of dMAbs as countermeasures for COVID-19, with funding through November 2022. The sub-grant also includes an option for an additional $6.0&#160;million in funding through March 2024, of which $3.3&#160;million has been exercised as of December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred grant funding recognized from Wistar and recorded as contra-research and development expense is related to work performed by the Company on the research sub-contract agreements. For the years ended December&#160;31, 2022 and 2021, the Company recorded $8.7 million and $3.0 million, respectively, as contra-research and development expense from Wistar. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses recorded from Wistar relate primarily to the collaborative research agreements and sub-contract agreements related to Gates and CEPI (see Note 4). Research and development expenses recorded from Wistar for the years ended December&#160;31, 2022, 2021 and 2020 were $1.4 million, $2.9 million and $2.3&#160;million, respectively. At December&#160;31, 2022 and 2021, the Company had an accounts receivable balance of $9.9 million and $2.6 million, respectively, and an accounts payable and accrued liability balance of $1.2 million and $548,000, respectively, related to Wistar. As of December&#160;31, 2022 and 2021, the Company had a prepaid expense balance of $375,000 and $261,000, respectively, and recorded $88,000 and $37,000, respectively, as deferred grant funding on its consolidated balance sheet related to Wistar.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i20e06ec8473a49698ac1e8cad9679f61_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3Xzg0_99754574-c623-407c-87b0-a424de973812"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i817aab3e5a42474f970fce9fc4e1a2fa_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3Xzg0_bf54f0f6-24f4-4d50-989d-4446f7084856"
      unitRef="shares">597808</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i817aab3e5a42474f970fce9fc4e1a2fa_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE5OA_074d43c6-99cb-41fe-a52d-2659677082f4"
      unitRef="number">0.187</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i20e06ec8473a49698ac1e8cad9679f61_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzIwNQ_2ef34878-019f-4da2-a064-895f76d42e5a"
      unitRef="number">0.189</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:RevenueFromRelatedParties
      contextRef="id7448c2b34ba40ff87e0d9cf69208bc4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzQ4Nw_416b4437-af86-4689-95d5-1a8be09c4d65"
      unitRef="usd">34000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i957537cf7fde4f90a792a8cc73b50b9c_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzQ5NA_67a75f72-1fdc-4c0a-baf7-f7106c0d3395"
      unitRef="usd">245000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="ie6b5e86588ce4204ad22f6367761229d_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDU5MjQ_604fa521-3c57-49bb-bf54-2ab0f46912eb"
      unitRef="usd">1400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i64432e8f98434affba895ba9830ae610_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzU4OQ_0893cc6f-1d2d-4260-8ca5-6a6fccf028c9"
      unitRef="usd">59000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i70087078e10b48ae9664922295bdecd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzU5Ng_4b64b2c3-0d20-4be7-81eb-78cb821f3c6d"
      unitRef="usd">25000</us-gaap:AccountsReceivableRelatedParties>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="ib8718060c67641f5a4518ae2471cec53_D20160301-20160331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzEyNDk_559bbfe0-e065-4a5c-884e-abaa96e879a3"
      unitRef="usd">3100000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeArrangementTerm
      contextRef="ib8718060c67641f5a4518ae2471cec53_D20160301-20160331"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM2MTg_0eaac8ee-aac2-4ae7-aa0e-62c7bbf90e6c">P5Y</ino:CollaborativeArrangementTerm>
    <ino:CollaborativeAgreementExpensesToReimburse
      contextRef="ia687677e1a354cffa7a0cefe22646f85_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE4OTE_64c1ac2b-f860-4ab6-b8f1-82b228304996"
      unitRef="usd">1900000</ino:CollaborativeAgreementExpensesToReimburse>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="i566a6c987fa446498049b5aff48c2020_D20161101-20161130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE5Nzg_6ad22f11-cc38-4aa9-baac-8ee1e05ef77d"
      unitRef="usd">6100000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAwardedAmount
      contextRef="ia0abccea943c4509ba78bb57e68e1da5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzIyODk_080248d8-701a-474c-935e-3fb3e512f52a"
      unitRef="usd">10700000</ino:CollaborativeAgreementAwardedAmount>
    <ino:CollaborativeAgreementAmendedAmount
      contextRef="i14d427675b944f909bde3b903e23ceb5_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzIzNDc_7414b03c-a799-438c-9a40-8a150494097c"
      unitRef="usd">13600000</ino:CollaborativeAgreementAmendedAmount>
    <ino:CollaborativeAgreementAwardedOptionAmount
      contextRef="ibb7ba3207c4249c49792d6993d00f3d2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI1NDQ_bee5094b-915f-4672-9760-b5ca8f8a5e71"
      unitRef="usd">6000000</ino:CollaborativeAgreementAwardedOptionAmount>
    <ino:CollaborativeAgreementAwardedExercisedAmount
      contextRef="i0073c18a8e7f44daadd9ab703b7645a8_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI1OTE_f7b998db-3404-4598-89ff-97532593a598"
      unitRef="usd">3300000</ino:CollaborativeAgreementAwardedExercisedAmount>
    <ino:GrantProceedsReceived
      contextRef="ib65f278575cc40f2a1b542d1f3241a97_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI4Nzg_b5c693f0-c5e8-4729-9198-4a48f9d4170a"
      unitRef="usd">8700000</ino:GrantProceedsReceived>
    <ino:GrantProceedsReceived
      contextRef="ia687677e1a354cffa7a0cefe22646f85_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzI4ODU_6466b188-a23a-4b56-aaea-eb03321debe4"
      unitRef="usd">3000000</ino:GrantProceedsReceived>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ibb7ba3207c4249c49792d6993d00f3d2_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMyMzE_98110ec9-d347-4e8d-85cd-8a15171aef89"
      unitRef="usd">1400000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="i3e671e6067184545b7d91d89a7ca3096_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMyNDY_8d3034d8-74f9-4faa-9fca-1f7a086fdadb"
      unitRef="usd">2900000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ia0abccea943c4509ba78bb57e68e1da5_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDU5OTA_b8de6292-a3e2-4c6c-bd9a-8c455de1513c"
      unitRef="usd">2300000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMzMzY_317f49bd-3e40-4c34-bd27-ec2b697296af"
      unitRef="usd">9900000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzMzNDM_215193db-253c-491b-9750-d47c89d83757"
      unitRef="usd">2600000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM0MTg_7a789330-58f9-4643-8d47-9752fff23f3a"
      unitRef="usd">1200000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM0MjU_af72c170-92ec-4f3e-a010-9671ae1085d7"
      unitRef="usd">548000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM1MTc_aba5483e-bfaf-4004-bdbd-8ac249b012d4"
      unitRef="usd">375000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDYxMTg_40c9837c-51f7-4403-9b22-5ee04d07589a"
      unitRef="usd">261000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="i4c216752c5f4440ea912be5dd36dbc5c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzM1MzM_cfa59128-64e5-4c15-a47e-601aad19df81"
      unitRef="usd">88000</ino:DeferredGrantFundingFromAffiliate>
    <ino:DeferredGrantFundingFromAffiliate
      contextRef="i4b843063dda44b569897c0fcac97eea1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODQvZnJhZzpiMzYwZWJlODQwNzE0MTA2YTA3YjQ1MTZlY2I0NDNiNy90ZXh0cmVnaW9uOmIzNjBlYmU4NDA3MTQxMDZhMDdiNDUxNmVjYjQ0M2I3XzE2NDkyNjc0NDYxMDk_43e5e843-2bbe-40e9-9334-e9b70dac5527"
      unitRef="usd">37000</ino:DeferredGrantFundingFromAffiliate>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzk4NzM_f86cf012-311c-4e27-a69d-320569043bb9">Geneos Therapeutics, Inc. &lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, the Company formed Geneos to develop and commercialize neoantigen-based personalized cancer therapies. Geneos was considered a variable interest entity (VIE) for which the Company was the primary beneficiary. In 2019, Geneos completed the initial closing of a&#160;Series A preferred stock financing. The Company invested $1.2&#160;million in the Series A preferred stock financing, which was led by an outside investor. Following this transaction, the Company held&#160;61%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos under ASC 810, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, Geneos completed the second closing of the&#160;Series A preferred stock financing, in which the Company invested $800,000. Following this transaction, the Company held&#160;52%&#160;of the outstanding equity, on an as-converted to common stock basis, of Geneos and continued to consolidate its investment in Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Geneos closed an additional&#160;Series A preferred stock financing round, in which the Company invested $800,000. Following this transaction, the Company owned 47% of the outstanding equity of Geneos on an as-converted to common stock basis. This transaction triggered a VIE reconsideration, as the Company no longer held a controlling financial &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;interest. Based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. However, the Company was not the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance. Accordingly, the Company deconsolidated its investment in Geneos as of June 1, 2020, resulting in a gain of $4.1&#160;million, of which $2.4&#160;million related to the remeasurement of the retained noncontrolling interest investment to fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. Since the Company&#x2019;s Series A preferred stock investment in Geneos has a substantive liquidation preference, it is not substantially similar to the Company&#x2019;s common stock investment and is therefore recorded as an equity security under ASC 321.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the deconsolidation, the Company accounts for its common stock investment in Geneos, in which the Company lacks control but does have the ability to exercise significant influence over operating and financial policies, using the equity method. Generally, the ability to exercise significant influence is presumed when the investor possesses more than 20% of the voting interests of the investee. This presumption may be overcome based on specific facts and circumstances that demonstrate that the ability to exercise significant influence is restricted. In applying the equity method, the Company records the investment at cost unless the initial recognition is the result of the deconsolidation of a subsidiary, in which case it is recorded at fair value. The Company's proportionate share of net loss of Geneos is recorded in&#160;equity in net earnings of Geneos in the Company's consolidated statements of operations. The Company's equity method investments are reviewed for indicators of impairment at each reporting period and are written down to fair value if there is evidence of a loss in value that is other-than-temporary.&#160;Any difference between the carrying amount of the Company&#x2019;s investment and the amount of underlying equity in Geneos&#x2019;s net assets is amortized into income or expense accordingly. There were no basis differences identified as of the deconsolidation date that would need to be amortized.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon deconsolidation, the Company recorded its Series A preferred stock investment at fair value based on the per share price paid by third party investors in connection with the preferred stock financing on June 1, 2020. The Company determined that its Series A preferred stock investment in Geneos did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer.&#160;When fair value becomes determinable, from observable price changes in orderly transactions, the Company&#x2019;s investment will be marked to fair value.&#160; There have been no observable price changes or impairments identified since the deconsolidation date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Geneos completed the closing of a Series A-1 preferred stock financing. The Company invested $1.4&#160;million in the Series A-1 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 36% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continued to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s share of net losses of Geneos&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the three months ended March 31, 2021 was $1.5&#160;million; however, only $434,000 was recorded, reducing the Company's total investment in Geneos to $0. O&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;f the total amount, $819,000 was allocated to the equity method investment, thereby reducing the balance to $0 as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The remaining &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$4.2&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; loss was allocated to the Company&#x2019;s Series A and Series A-1 preferred stock investments in Geneos, on a ratable basis, thereby reducing the investment balance t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;o $0 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, Geneos completed a second closing of the Series A-1 preferred stock financing, in which the Company did not participate. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following this transaction, the Company held approximately 35% of the outstanding equity, on an as-converted to common stock basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, Geneos completed the closing of a Series A-2 preferred stock financing. The Company invested $2.0&#160;million in the Series A-2 preferred stock financing, which was led by outside investors. The closing date of this transaction was determined to be a VIE reconsideration event; based on the Company&#x2019;s assessment, Geneos continued to be a VIE as it did not have sufficient equity at risk to finance its activities without additional subordinated financial support. The Company continued to not be the primary beneficiary of Geneos, as it did not have the power to direct the activities that most significantly impact Geneos&#x2019;s economic performance and should not consolidate Geneos. Following this transaction, the Company held approximately 28% of the outstanding equity, on an as-converted to common stock basis. Accordingly, the Company continues to account for its common stock investment in Geneos as an equity method investment under ASC 323 and its preferred stock investments as equity securities under ASC 321.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Geneos&#x2019;s Series A-2 preferred stock was based on the per share price paid by third-party investors in connection with the closing on March 21, 2022. The Company concluded that its Series A-2 preferred stock investment is a similar financial instrument as its Series A-1 preferred stock, and therefore remeasured the carrying value of the Series A-1 preferred stock investment at the Series A-2 preferred stock price, resulting in a gain on remeasurement of $165,000.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-2 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remeasurement of  Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in current and accumulated net loss of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will not reduce its investment below $0 and will not record its share of further net losses of Geneos as the Company has no obligation to fund Geneos.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company continues to exclusively license its SynCon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapy and CELLECTRA&#160;technology platform to Geneos to be used in the field of personalized, neoantigen-based therapy for cancer. The license agreement provides for potential royalty payments to the Company in the event that Geneos commercializes any products using the licensed technology.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Chief Scientific Officer Dr. Laurent Humeau is on the Board of Directors of Geneos. The Company's director Dr.&#160;David B. Weiner is the Chairman of the Scientific Advisory Board of Geneos.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ie4aaa62817594ece850f89f4ae127ddf_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzM3OA_40d8fb8f-f38a-4778-9368-31d35365a271"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i44df340754904d60b387ac967f2fee31_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzUwNw_4382f73f-4ff3-4518-882e-a44de223dfab"
      unitRef="number">0.61</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="i15e530f73df34c398e566264b204a2d4_I20200131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzc5OQ_58adbfda-039d-4c80-8b87-f177a9cf206d"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i560af3a39c4c40d3874fed14c6721a9f_I20200131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg3MA_6e26c562-4e5e-4f68-bfe3-217c02734c7f"
      unitRef="number">0.52</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment
      contextRef="ic7f0c3c89e134e6891c4524576f4fe89_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzExMjE_e4b1b2f9-28f3-4410-b065-c39e78a32dda"
      unitRef="usd">800000</ino:StockPurchaseAgreementCommitmentOfAdditionalInvestment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i876fc07681a44ee487cf4e512393be2a_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzExNzE_40c8d2f2-b996-433b-adc0-d904849776f9"
      unitRef="number">0.47</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="i312c32046c954040884f45e992037d33_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE4Mzk_fa3daeb1-a725-458d-b769-497fabd96e7f"
      unitRef="usd">4100000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="i312c32046c954040884f45e992037d33_D20200601-20200601"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE4NTI_4ebb0421-5596-41d6-be34-77c3260493f8"
      unitRef="usd">2400000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i69253dc5f01644e79d35a7205adbc9bd_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzY4NjE_c434ee42-dc3b-46cb-80a8-4b2d9806d9f7"
      unitRef="usd">1400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ia6407ce5393843909b745480c6ca2554_I20201130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzc0OTY_68fe8697-937c-42a8-91ae-9057b26bcc48"
      unitRef="number">0.36</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment
      contextRef="ibb50f5b639ee412d94255ce7d570a547_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg1MzE_344bd77f-5249-4da2-8ddf-df5947ca6a99"
      unitRef="usd">1500000</ino:IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ibb50f5b639ee412d94255ce7d570a547_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg1NDk_472a931a-bb9f-476b-ba06-faa394269294"
      unitRef="usd">-434000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if32e8f4ea58f4ce98e067ea7e1754cba_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg2MTk_9d8d39a2-9bc1-485b-b9da-1a07c96f8ee9"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6c7c8026b35043069ab11881210ac603_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg2Mzk_4d8031a3-1b29-4e1e-986b-17c544b514b3"
      unitRef="usd">-819000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i270dcf1d2c4b423d889baab7dc6a12bc_I20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg3MjY_748ad1cb-d4e4-4478-af68-4488789110e2"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9b0650a02db7416e902fd5464a19fe1b_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg3NjU_0581f488-12f7-4f9f-8d29-9e002cede3b2"
      unitRef="usd">-4200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i53479a023482480fa55a43efd0b59aab_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3Xzg5MzU_5461c892-58b9-405c-9005-c9cd227345dc"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="ib1281c7cd4bf4b6394985b10e622fc01_I20210228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzkzNTI_91bd26c4-9a7f-49e2-97c2-0ca50fb269db"
      unitRef="number">0.35</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i610a9153ce62445cb06cc24f93ac3001_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ1ODU_5435344a-1276-431d-8f82-ae60df74c9b6"
      unitRef="usd">2000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i523a6b123f304bd09e5c0ae91b9adde5_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2MDM_e3873f96-bf24-4b5d-8509-1f53778a34dd"
      unitRef="number">0.28</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="i988b6f75b9e6460c956d40049e2a8e51_D20220301-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2MTc_1fb92d67-c5a3-416b-8134-94288c4eac67"
      unitRef="usd">165000</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzIxOTkwMjMyNzg1NDg_925b4f6e-e544-45f8-bf9e-906d9d5cbf4c">&lt;div style="margin-top:5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its current and accumulated share of net losses of Geneos of $2.2&#160;million, which was allocated to the Series A-1 and Series A-2 preferred stock investment in Geneos, thereby reducing the balance to $0 as of December 31, 2022 as shown in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos Series A-2 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,999,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remeasurement of  Geneos Series A-1 preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share in current and accumulated net loss of Geneos &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,165,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in Geneos as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i988b6f75b9e6460c956d40049e2a8e51_D20220301-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2NDA_cd223e46-5b3e-4dc0-8b0d-d3a52ea4229f"
      unitRef="usd">-2200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2572a2fffba544ef9e41966fc1155177_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjQ2NTc_b8ead2d4-ff37-4441-9f41-2c9f0416c567"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i98148ffac5c843dab35c796318d95e41_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzEtMi0xLTEtNTI2Mjk_0b2d27ed-3a98-468d-8385-7c107290be7c"
      unitRef="usd">1999998</us-gaap:EquityMethodInvestments>
    <us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount
      contextRef="ic8c7588fc83b4e679b3d9caf40ad0d04_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzItMi0xLTEtNTI2Mjk_5b50771e-a002-4fc5-a28f-c069797892f7"
      unitRef="usd">165215</us-gaap:DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic8c7588fc83b4e679b3d9caf40ad0d04_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzMtMi0xLTEtNTI2Mjk_991bad5d-668b-419f-bed3-a02ecb8b7d3b"
      unitRef="usd">-2165213</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i339d243acc4a4538ae743f7ea71e863b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90YWJsZTowODI0ZjFhNWFhNTE0ZDEwOTA5ZWYyMDNkNDQxN2Q5Ny90YWJsZXJhbmdlOjA4MjRmMWE1YWE1MTRkMTA5MDllZjIwM2Q0NDE3ZDk3XzQtMi0xLTEtNTI2Mjk_f2f99ecf-46a5-48b9-b706-b1c353508e17"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i339d243acc4a4538ae743f7ea71e863b_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xODcvZnJhZzo0M2JiNTQxNjA3Yzc0YTNhODA2ZDk2NzBjM2YxYmExNy90ZXh0cmVnaW9uOjQzYmI1NDE2MDdjNzRhM2E4MDZkOTY3MGMzZjFiYTE3XzE2NDkyNjc0NjU1MzE_1970aee7-2a50-4c82-912f-91759f4ebb57"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzMw_d3e57f90-e30b-4c11-bc84-d135bc55785b">Subsequent Events&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2023, the Company committed to and communicated a corporate reorganization plan, including a reduction in force (the &#x201c;Reduction&#x201d;). The purpose of the Reduction is to decrease expenses and maintain a streamlined organization to support key clinical programs that are expected to drive long-term growth. As part of the Reduction, the Company reduced its overall headcount by approximately 24 employees, which represented 11% of its full-time employees. Along with other planned cost-saving measures, the Reduction is expected to provide annual savings of approximately $4.3&#160;million. The Company expects to incur a one-time pre-tax charge of approximately $1.1&#160;million in the first quarter of 2023 related to the Reduction, consisting primarily of one-time severance payments upon termination, continued benefits for a specific period of time, and outplacement services. The Company expects such costs to be the only direct expense of the Reduction. The Company expects all charges associated with the Reduction to be incurred during the quarter ending March 31, 2023, with related cash payments expected to be paid out in the first half of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 18, 2023, the court for the securities class action (see Note 11) entered an order granting final approval of the settlement, as set forth in a stipulation of settlement. In February 2023, pursuant to the securities class action settlement, the Company issued 7,000,000 shares of common stock. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Following the expiration of the appeal period or resolution of an appeal if one is filed, the Company will make another contribution of common stock to the settlement fund with a value of approximately $2.1&#160;million. The number of shares will be calculated based on the average trading price of the common stock for the 10 trading days preceding the determination date pursuant to the terms of the securities class action settlement.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM2OA_525a3c12-fae8-4a6e-9167-04f1a36a0a43"
      unitRef="employee">24</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM3Mg_8fbce565-2a7f-4ccc-b17b-4e9c58d4aa8f"
      unitRef="number">0.11</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <ino:RestructuringAndRelatedCostExpectedAnnualSavings
      contextRef="icc2152cae0c24f81b93236af03f8d35e_D20230131-20230131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM3Nw_6b64b349-fab7-47ce-976b-f882afb381c2"
      unitRef="usd">4300000</ino:RestructuringAndRelatedCostExpectedAnnualSavings>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="if1a9994a0e9c42d682a6382e17a889cd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMDM5MQ_1d4b0dfb-2c5b-4022-8334-0803b1897b76"
      unitRef="usd">1100000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1b1cb2986d5240299edf1d6dd0ab9f19_I20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMjQ3NA_248c3646-c91b-48b6-b58f-6fc6d691f475"
      unitRef="shares">7000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i1b1cb2986d5240299edf1d6dd0ab9f19_I20230228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyNDUzMA_95e2c8cb-5b4e-4a05-9592-e1e52585489f"
      unitRef="usd">2100000</us-gaap:CommonStockValue>
    <ino:CommonStockSharesIssuedSharePriceConsecutiveTradingDays
      contextRef="ife5c59f2516940b1ba2ee6b6fca25969_D20230201-20230228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAyZDRiZWYxNWM2ZDQ2MTliMTdiZmU1NTgyOGM5NWM4L3NlYzowMmQ0YmVmMTVjNmQ0NjE5YjE3YmZlNTU4MjhjOTVjOF8xOTMvZnJhZzpmZDdiMzVmZjBlYTg0MmEyOGQwNmYwYmU3YjY5NDRkNC90ZXh0cmVnaW9uOmZkN2IzNWZmMGVhODQyYTI4ZDA2ZjBiZTdiNjk0NGQ0XzU0OTc1NTgyMzk1Mw_14a53d0e-eb06-413b-98bd-e1f2632cff88"
      unitRef="day">10</ino:CommonStockSharesIssuedSharePriceConsecutiveTradingDays>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKB^JW@X50?MG\J*UV<!:T] '4X0^BU@181G?IEDCYX=&[G6^(!B <-4R7G;
M"]] &Z>8<30:C7(:0;(W$I=HGGIK]$X8&@T+I;+_,>4(^@QY(E]CZ+=E(!_O
M$H27^6=$,/#"-#NY^A=8YA4K.U&Q0D1-(AH0CXBG@L>J0NEFMWI\U%XO/L+B
MV87%L]6&S 'F?L:]\BZN%JB^,6GU=+K4RI@*3V>?61KVMLSI'CZ4)MDGQ*IJ
MPM1AM8E]A)^S"S]GJWW8>V+[FKIJ9FJY^]]28EH]G"ZU,K'"P]EG>3@7H#$
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MCR@LTC,BB5/BN]"C^5HC:][+\<1G14(IYFRHQ0.&@B>8C= \[;F3QKGS\RZ
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M06@F!5$P'SM7_N7$]RR@C/C&8*TWVL1:>9#RT7:^I&/'LXJ 0V(L!<7'"B;
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MP\H/E W ^;F4YKEC:XNFEHS_ E!+ P04    " !MA&%6<?7G>+\'  "C)
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MNHNNXO^[9-M/[OJ)W'U5M[,VKW=24?9W:/>W85_?F^4FW'BE^<S0-$L?W<:
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M!YB^-]8\\]O.+J_367.7'U ^:BX")I8NI0MUB%!*+D>@@^@60,!207$T8?<
M.]1/.W<VW=A)/!0X_O <DPEKP]-E<40HN.#A*,LB.AD*12<BE0VDPV9(!PS:
M%95)\NQWF+'\=(*3QR3+;=9=K,IJ 8%L]G->FW1734XN&V.+MK>KF>, 1,@9
M8R$/'0\@0ECQD131!.RQ 828'X1^&<QOJ@0 KVO\]5[(^Z4,#C#9 R#3KJI,
MD7Z%E%R4FZQH WUI[AO4#V/,<5<S(H'-0T7,C0%$2&5$V(3Y S QYN_SM"1?
M.Q5ZFZ:"I%@>,'ZJ6F=>'GMMN7[6T>)SC7;JVH'.F)_./J8=>1[ARUOP<YKO
MEM;)**U,K:@Q9RVX)MB2&BLI)1R*0[<.QL8$&85J>*(69@.^,3^^?:G,-LF6
M^YJB"Z6R69LJZ%90T\?8'W8( ET2:BC)7 ; E JRK.+,=0BBY"%46T)-, \;
M2([Y2>ZGUO;I[9^-<4M#G2Y'^6*L8T)R.MHX8T2Y8%"72,$F^G]L(#CF)[A#
M9&^3KRV5V^E-TK3:F6'.__#4(JTGI@CLXVZ-@BB9HH)$(SI QY14Z DV8 /K
ML9F&5F]U"G_(4F"]ILK@W[T34 ,Q/-,A<:MI1,>UC!AUC4,Z6I%B?*JEQ0;@
M8W[@B\W*P&I=0@9[-,5N/GVAS1Z&H%DHH]#MBV Z'H62N_8B.C!73O M&SB/
M^3GOI_F>G;LGOK5,B!H]9K8%1#&/I-M!0)6<1=QM<,:HDD0TE!/YB0\@R/T@
M^!G0IPE6NZ*=VT/O[H]-.$=HC1$N)'5#'%5&FA,W.&)$J1ADR(E)YP/_<3__
M=9GY:$I1BS!,$R%SYQ+3">!9E^80'2.:3? \'VB.^]M?/[[DU 4U$&EX0=$"
M);5P\\TMKH62+!SMOC&FI5I'.B)BHMG'CXXH7W=&V56B+SFC/.\AY7E/*?^,
M8TH^D!N?(;==E:Z3NNNNS303.0),3$ 4A*%P:UU,RT482<ZXVRK%M%1","HU
MU=SG XEQ/XE]J<K4F&4?,FU1:X]KJF"3-+:F_?H2P\=LQ:$:A[IU!&R(E-JV
M3J2E6^0B4L6BB)*I;C\?@(W[@>UD5M-DFS7 *-,TRI$&6Z0BZF[%MYB0,DX)
M&<TIII2,J"FVY@."<3^"X3-ZU);JVZ4_%>CA!I]MJ-W.2V)$(@AE4M )Q.0#
MA?$Y"DNKED<@G[?)'=;]+F\.>S)L8*_K$/,Q0(TLGI7$B&3!-,2VG.!./H 8
M]X/8=R]L!',$B&AD_PM=>^;/$]'!>#L:;H\8Z$K,M]G:F=M6Y6.VA*WY_FMP
MV>_1;]!]"WU0!#D.))$,X7\71! I[+N2"R%"%RLQK0QU)/743(J!K@1]U1:]
MRHJD2%^P10LOM;UVBS[K:/&Y1COUZ0!YP@]YI_DNJ^L=N-2XIV%M9=(FPKT@
M+6L\W8LQI(4LDI)3%_T0)10@0E Q?OYH+!42HD\),H&Y8@ _X>^L.1F_/?PK
MMVWB,\^F2K.)REN,6UX Y^WC>J=FCG5*J5 +M_1&A)0Q%85D:N4</3#F![%_
M)<_&-E@R6WWG;<75/U;5GGX&]<D):=^73YZ2:HF;CC$54(CBHSE&E$)1"K3F
M6H\I"0OI%*6)@=*$G](^IF!0G>WWLL(^K5 6357FN4T>^X<64$OGSS_G)3$B
M85Q'0$$3I@TL)F98["1XN\WM9!4796/VG374P-E3S=MY28Q(J(:*;VIQ#C@F
M_#B&;G98WD=M&V-42$-!-!FM4:2+1JF(PI"X#2-$*I1D.E)39Z)B@#/AA[-O
M5BN3=DOP.>V>BH*"&Y)M?ZY2]LQF^T;M-W:E/@*C3I06 J,J*<<;/-8L([!(
M7=O'.J89F8!N,2":\"/:Y9Y*+;XX?/IB6[%^E@BI&#\SA4DI( H4FF(4V<CY
M*PNAT"1L(BO+@>2DG^1NI^Q[&]R;AZPH;(A#,&Q-E95+S&B)'(Y"W'*M769%
ME$P2#?F5NID8DS(:*3)U/BH'@I/^_IC'8F,/=;RV(L]Y*=O:E.[\(DK<*S&B
M''OEU-:!K*3_,/1NM]UV>RJ4Q_;)L;RTSZ?@CRF?]>#SK*/%YQKMU(T#GLF9
M@\]-=SJT/Q%:E56P/>Y P,X 06-Y!2+(AM36^ASU,@)8!'8$%UH0'2.02MQ^
M)#8>5YI.)88!UZ0?U[[;/T9IB0VU9 Q+E"@5:?? $A7".AAM:XA0*":.'R,]
M->;H 7\_?0V/]VY?>I![#*ESSSI)I-%%-"7$Q1A$J#6)^*B?C@@G.$8.G"9G
M#CEW#SN83T9H%'PJ"QRK_6.\.@N<<[3X7*.=^F_@0*F]R?3/?DW$2Z&O]OPY
M1XO/-=JIYP<FE7XF;1^PO+0N[I[3>[;^A')JO:\6828>(?^VKUW<V]!NEW5M
MB@PRM2T_\%B?;QO.2V)$8@M&(B907 Y(*OU(JMY)\K?@]LBVN\ZB'ZU%0;PS
M]N4X@9KF'?G5P73.T>)SC7;ZVM% O(K\/Y>Q\O+V:SU_UM'B<XUVZOF!O)6?
MO/^D9=Q_JO8LXWE)C$@6H5:,<'?CO3IZ"WACJH?V;>HZ:)\@ZMZN/?SV\,;V
MQ_8]9>?WG^C[N'OO>ABF>PW\AZ2"VJL.<K."(<D[#3A0=6]6=S\TY;9]U_B^
M;)IRTWZ[-LG25%8 ?U^5X*W^!_L!A_?;;_X'4$L#!!0    ( &V$8592#J<Z
M0 (  !$%   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULG51-C]HP$/TK
MEBOU0VI)""RM*$0"=JOVL!):M.UAU8-)!F+AV%E[LF'_?<<.I%0"#KW$'F?F
MS7OC&4\:8W>N $"V+Y5V4UX@5N,H<ED!I7 ]4X&F/QMC2X%DVFWD*@LB#T&E
MBI(X'D6ED)JGDW"VM.G$U*BDAJ5EKBY+85_GH$PSY7U^/'B0VP+]091.*K&%
M%>!CM;1D11U*+DO03AK-+&RF?-8?SX?>/SC\E-"XDSWS2M;&[+SQ(Y_RV!,"
M!1EZ!$'+"RQ *0]$-)X/F+Q+Z0-/]T?T;T$[:5D+!PNC?LD<BRG_PED.&U$K
M?##-=SCHN?%XF5$N?%G3^HZ&G&6U0U,>@HE!*76[BOVA#B<!@]&%@.00D 3>
M;:+ \E:@2"?6-,QZ;T+SFR U1!,YJ?VEK-#27TEQF"Z,=D;)7"#D;(6T4,71
M,;,ARV2[PJ@<K'O'[IYKB:_L_5)8<B@ 92;4ATF$1,)#1=DAX;Q-F%Q(V$_8
MO2$ Q^YT#OF_ !&Q[R0D1PGSY"KB+60]-NA_9$F<]*_@#;J2# +>X )>5X6+
M17B:K1U::JC?Y_2WZ,/SZ'[(QJX2&4PY39$#^P(\??NF/XJ_7N$^[+@/KZ&G
MLRPSM4:IM_XR=2YL[MACY:^7/=WMT4_36@'5OB[!"C\89S7\?Q:ZA/A3/#JG
M)3II4\J^#</H6,!J.[8[[>9]UK;Y7_?VL;@7=BNU8PHV%!KW/M]P9ML!; TT
M56CZM4$:H; MZ,T"ZQWH_\88/!H^0?<*IG\ 4$L#!!0    ( &V$859!.=W)
MO 8  'P.   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;(U7:V_;-A3]
M*X0'="GJQ(^D#S0/P+'3QEN2&DZ; AOV@9:N+2X2J9&47?77[UQ2=NPLS?HE
MD>C[/N?>*YZLC+UW&9$7WXI<N]-6YGWYOM-Q24:%= >F)(U?YL86TN/5+CJN
MM"33H%3DG7ZW^Z932*5;9R?A;&+/3DSE<Z5I8H6KBD+:^IQRLSIM]5KK@ZE:
M9)X/.F<GI5S0+?DOY<3BK;.QDJJ"M%-&"TOST]:@]_[\B.6#P)VBE=MZ%IS)
MS)A[?AFGIZTN!T0Y)9XM2/Q;TI#RG TAC'\:FZV-2U;<?EY;_Q!R1RXSZ6AH
M\J\J]=EIZUU+I#275>ZG9G5)33ZOV5YB<A?^BE4CVVV)I'+>%(TR(BB4CO_E
MMZ8./Z/0;Q3Z(>[H*$0YDEZ>G5BS$I:E88T?0JI!&\$IS:#<>HM?%?3\V>>,
MQ- 4I=3U2<?#(!]WDD;Y/"KW?Z#<ZXMKHWWFQ(5.*=TUT$$DFW#ZZW#.^\]:
M'%%R( Y[;='O]OO/V#O<I'<8[!W^P-XGNY!:?9?,@#82U<[D*I61$#H5$TN.
MM(\'9BX^*"UUHF0N;G%(8)]WXL_!S'D+_OSU5(EB $=/!\ ]]=Z5,J'35LF^
M[)):9R]^Z;WI'C^3WM$FO:/GK/\?>C^M+,;:+)41DTR"Z0E57B4R=VV< X\]
M#\D7O[SK][O'C4)XZQT+8]<_C&\^W8T_-><OA7)"BIDRGI),F]PL:I$TON8&
MO*94H.(I+3$62J47 0U(%&2Y_.H[GXUN!J*@5"6(W EO1$9Y*3R&CP_RI67[
M7I1DRIS$W)I"I,H1NA3NG3,PY>%II7PF+B=W;9$ 7;+MH*WT/(R&RFV4#L16
M43B7WMMC)Q8&?% A )DNV8)0GI669!V)4I7$M67^(**T0D3PDS+/. ZX2B$
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M 9FU89FU:IL-+8"[@KTF0/2EM3WB&3ZV@-*RSNJ\!,188 )#8,^2]W72M$#
MPT-<];!7.84(W2%624F5';!9&@(/!U55P#U 3K@[8[XF60&,!GN!IPMA(^(!
MQDT&7)PCP737;=.OKQ,49YU9EWF2 2(S)#U\+K S*E?83M:V6;WF#:3)ND4*
MR]:MX4_PXB> +X%]VR_A3M@CG#V<(^"F,,L._\:#!=X7M-1KHNZJ+_ 1EW#"
MU^;PEZS]"C+@+5_YZVH%)P#?7@$YV.32/_(1$L[1_/GP"_IX\?SQF-^R!#;?
M-2S" .](E;@T 4>\-80N#<!C'LA-N27*1CD%E)T#PID0SP,Z3)/O3I[.GD;2
MX[N3TQ.0$OH1'#40P&A71=_JPU ,6)1A^,&(I.GG@E:&7^8I$@Q*!C!@JEW*
M3UR<'<T67C0BM6;)?V5UCV*<;B<H;MNRZTSMCDU13ECR0G>6O(F!FY:OBXN0
M+I,=4)1MB"W@6L#ZC6F[$L5-W70BG99P%B3^,B#<%A4(/%I)9UN!LB3*!QJM
M;49B"9CHY^86N*)-0[Y&!D((D<!A^60)9'R3E16)-UB?)![1:(K46*[\URG=
M!#? =E'0@(2]!I8/)&JU2XJRZ@$DN+6!I=K;$E@\*P *L"%AHX"XG"5*BY8>
M;<-\ YI#F$+%!2( 'ET O>$.$6I+(@IA#B *V9NV)-Q=F"K;X8D#!1NZRN8@
MN?!QR'-]AYO 1\&_!.T&I+R*XU!N/R$6]:(<"!I8>[-'0&>@X9 _0JF%*P9"
M$X1+8;9(%W :_1; P N"&YMEE^%!CT13?#RL;_/K$HX8H5J5; ?X1\7LO4<K
MMG@L  2X&K8L $U-W^9,7H[)\;H-^C:$' &F)K9&(,9G ,?M06MLB2S':FL%
M_@O!!60!8%@PAPHR%:;40%(T=-XL87#'0$'%'[TJ-P"+3A8VA@289!LTLZRH
MV\Q:(DM&.ZHG4.OR+0AP0CBIB-OK$I3(!ND1J1O4NK$6^1]T:@\4\KYN;LH&
MO^IK;VH)"DEHKALRC1I0"FT=H1T4YOW;9)6,<#W$-@-!#=A<&A1'K=EF:!ZA
M (VA0"^K=)M#<,UFBU:9%3&=5>6?;'3&J"&,FJZKC%HH ;(8M2#Q2CD"(<D:
M?3L@5" >2VRT[$$G AKOL*+&VL> 0=,3FFR_M,#Z" #0$.%HU1E>:9E5I'W9
MW2:[0G5T;&B0..T>1FHQ,"5M-!7K!=QG(C7XET5@S(=+M)N6?Y!<:Y*;#*RA
MWH(AM&9I@>J/U+A09;E!05:2R2 +@:4#( '!C?$7PX7'1+8ID]_:U.1+D+Q#
MB0RW, X,JDM6$<U290L"0"8*?0%&+ND8\B3PE+:@;&!5%'MYWO8L;XCC[T?>
M)=CE(,,W= FMZ"%D=.*2\)WL^'Z>*%=B+?(.D.M0V62.&IEDB V\;R3TRX(
MMXE_,3R@:)=$][9!+MYY@&?)A^%AA58-4OZ:. 6LN@9$6TV,P5:V?,.G:VK
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M<7*CSK",\9)J!(A2Y^NIT/B$0@L.1/9^AQIS.LK%H:T0)9IM+(F<E!/[715
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M(IN>;H[LU%=5!AB[RJ\;JI78NA(8*@EIP+/B9]U_G8P0)-]08^;L/09!RS&
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M^IQ+MWAZ8\HO=J54);ZNL]P^VUM55?';P8%-5FHM[;XI5(XG"U.N986OY?+
M%J62*4]:9P>SR>3D8"UUOO?\*?]V53Y_:NHJT[FZ*H6MUVM9;EZHS-P\VYON
MA1\^Z.6JHA\.GC\MY%)]5-5?Q56);P?-*JE>J]QJDXM2+9[MG4]_>W%$XWG
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M<VAE970Q-"YX;6SM6UN/VS86_BO$M.@FA<:CFRTK30;(K;O%MD6VTW8?%OM
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M/WH0%4E^TI7E051R.?-8O0%[]_W=8?F.]DRU9 [*P-(>DYGFP".",1HA%/]
M !AU0 0A]SOXOB!"WB:G=]SV]5"_OEOR=P65L!_% WO[6U>R];_1^ 5\LZF
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MH?$ >K_5VIT,'V"Z'E?_ E!+ P04    " !MA&%6/0E8]&8#  "&!P  &0
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M0R\AMRSIZ8G**I!\):79$7:#X3$[_Q=02P,$%     @ ;81A5FQR^#:["@
MZAL  !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&ULI5EK<]LV%OTK&-5M
M[1E:)O6PY3CQC!,WTVRG229NMA]V]@-$0A8:DF  T(KVU^^Y%WQ)EMWL[!=;
MI("+^SSW7.CEQM@O;JV4%]^*O'2O1FOOJQ=G9RY=JT*ZL:E4B6]6QA;2X]'>
MG[G**IGQIB(_F\3Q^5DA=3FZ?LGO/MKKEZ;VN2[51RM<7132;E^KW&Q>C9)1
M^^*3OE][>G%V_;*2]^I.^<_51XNGLTY*I@M5.FU*8=7JU>@F>?%Z1NMYP3^U
MVKC!9T&6+(WY0@_OLE>CF!12N4H]29#X]Z#>J#PG05#C:R-SU!U)&X>?6^EO
MV7;8LI1.O3'YGSKSZU>CQ4AD:B7KW'\RFU]58\^<Y*4F=_Q7;,+:R<5(I+7S
MIF@V0X-"E^&__-;X8;!A$3^Q8=)LF+#>X2#6\E9Z>?W2FHVPM!K2Z .;RKNA
MG"XI*'?>XEN-??[ZC2D?E/5ZF2MQJY;^Y9F'5/KN+&TDO X2)D](2";B=U/Z
MM1._E)G*=@6<09U.ITFKT^O)LQ)O53H6TR02DW@R>4;>M+-QRO*F3\I;>G&K
M79H;5ULE_G6S=-XB'_Y]R-H@:W98%M7("U?)5+T:H0B<L@]J=/W3#\EY?/6,
MIK-.T]ESTK\K&O^;!#%\<:=*;:QX;[QRXD,IWJJEK5&*(KDD9R>70I:9^%W:
M="V2\"82?JT@I*ADN14I_N?*JTQ(45G](+T250YOH$R],"MQ=+$8SY&G><XE
M=W]OU3TOLKI,=25S(0M3A[7:.W$^GL<_0FROHPLZEJQC5BM*@IDX)BU^^F$Q
MF<17K#Y_3JY.QN(/?!,LVB@$UYD\$[H<*&A6*X7C[X4WXFLM<[W2BI8XKWU-
MT "MEO5662>JVKI:0CTL_51#FV0VNQ$U\MJR'^Y46EOM-0Z[2=F(Y'(ZC81T
ML$M1^H_%>R!I94VJ5.;$RIJ"=W9*L))'%_/Q1>NFH0G2=AZH2T>G056SS#6\
MB*6.CAP&A.(ET]3"3[KT$.UPN-Q*\B2<D$JWAKQ"G\JRA.GYEEUC =^P%A%J
M8LUR[E3E5;&$J0D=HR2^V6*AD![>M,&53<0JK"*1Q5!Y8"255R^6*W@6P91<
M.0>)-M?8V(1;91%@/5-('MAH\1GN3]> 6'CQHR4?( QD+14N'[ZL'?+=L>KT
M1?><25A60)"&FK 2M9GB ?Y^;QX:HUB;:4CH)F$0 +%4._D'8SE>%3>-QMUK
M))5BCT%V736G.\3$K63:KDPA0Y+7M4WKPGE9ILJQ@^#O%:+S?YU-44#$/5HB
M'.IU_KQKJ'UG2.%, .K8$_L^6BKT=,6+.7+:;['&J['X3!8&Q:CY[F( *XX<
MHY!E*D=/M5P K V"!V$D.^+DBX1;(Z==6^\ D *RT=;2+R1 TINE+F7G0\I8
MRL:G]T7D"GK9MO:0@[I$8:*4>[U#SFZ@6[*8CQ?Q;-Y*I?0]2J(XC@\B4XC0
ML?I: T%R%?! EH>.P/:4_2\K%/TW703?'LW'TP4?PR>>P _U\B^HRY*RO]#8
M&3*[7#(I:MVJ,@ASE4H#3*D'+ M)U$6 '!P*1Z"D(_8C7E?&>HY6DSC!"L0X
M.%6'M[D$1*#4#!4@4CA7C0V=LGL8\_->U-2W &W)%#C0+'WLD%(<ZY. (>0<
M+W)%!T_B83K"QYNU@@ K N23($(]8FHG0/\ VSA@&@^_VI4!W*7/9#DE#L*9
MU_0FI.UW9'_K5P!O%O+8JER2>\C+1:A&: ?#KOB(8PW;OE,X5=2!4UP-SSP2
M'^(\>!V\V6*%HO9%&93$O>\/)7 ??BQ>J@YF(W3KVC4=(V-;ZK*2.NN[AS<1
ML,13F(=N'.@4,.)=J(5\&W%+25,ZFWQ!"4<[M*-6FJH=?:(]5U32LJ-[A:&(
M$;F62YT3()&*5(<^D ]3]N60HH]MZ<1=N_N]W0;&@%3F:1W"ND0-(1W[]%I)
M;05*O0[5I]&9):$;^!/Q!%M3L4+YS5HC;)GA7%U+9")003IG4LV"AV"^4MP.
MG]5UWS(J3&*5P9-[E=6TA=:_31N!94?)^7C:DRYXC-ZB QJ;4901\&!+!@Y,
MQ[>&T+*E:M2"VO^A2)@^%]0WS'Y.A=8C%"@,SU#]@I84)--Q\B/E!+ MT_Y1
MST">F)0]=#2_G##N8E?P;YLFJ7'>M1W_D6/(JI"'-&ERS1W830QT,IYTOF"R
MU1_>"#^0(9U':,/WN*3GA$^YI0"P&3 9\.Q_R#+0[##2[/DF0V!QRLW=9\1T
M3"OBT_@\8OI.-#>97#&3WVB_;NB\:P/]@<'S0Q7(X?%=O?2FTJF87<2GD_B$
MU]PJ)L+0T/'SKRJ[AX&-: CD68@J#Q,<./&6O[FXPHBPP:L0B5[T(IF?SN*3
M%V# .S4_'#3>]47#1^X<(I\]IR'YY(W&$RW5;V.D&228;5-H4*T5./V6G;J'
M0\-Z'!1RJ$DZ ORE(/:A.OZR'I9<4\.B,& ZK/S-W9O&N2% ?Q^55FU+.6T9
M=3EMJ>D-..- 4\YLLJR!1S24QBXVBNALEG5H,U34A6+ORX9X/#MVS#%1,HL&
MYW-?&8J&WHX&D&[*87$@EO<YI;QF@<V&CM;OP53G,Z6(N+7V02#R4.XRF3;W
M242I-H(X<R8MNI)K 1"N#TS(*F\-$2.NM5!=[.T>Z""#(#2K R4GJ@5:532H
MGZF53H,)1\EXT8)$Q.B8@J+#=&9G <$DL5R=G?(856F/9]HY[:$V\ WFA?WV
M)V?9<&P_'&.M5:N<.2&U2W@D[1K#((\Q$97W:G](+,VF7033*';#4/4(%_H<
M.<</$(W0DDE[:83A9.V2JLND)E_%4J\PE@6"WKK[OM3A&9-7CRY!QZ7,'[5]
M.OT6$QD/8NW-#K<?20P5 +UQ+VCFVV4R1^)B$<WCF!O&HV^[,3)PAI:D!H9_
M?(XVLYC3SA/QN>Q-?]PVQ'$RGT> M1."-"9&'9)/\<WY?,Y#_7X//Q+)>72>
MS*+%+!9OFZZ\Y<DZ@-,CB_EO&+8)VW;[0.-7TA%Y,D@R/%WN=/>C\_X%C=!M
M41 7HWEIOU>U;+9I?PT1P\H 3)"?[)R6[)XV&WZ]>]J>Y+2!>6*IG1;(T8IF
MM!LN@0,^6=4!+]#6B[J@T3(T#KK\Z=MLH_4.01J>%X+"NZ)^!NC5H*O;K!V.
M5_H;(4I_I3&XT8@:UC!(3+HW0/..SR\X$_E&"K&_G"WX^0]#X(!TP&/"*=>;
MR;=JP];XVA#]!RGHEYP?O&JCP?[)>[8ARF#N+)#0!@0C(,WPLFQ7$3Z\[:>A
M=<F_NZ:;C2^  2$??OOTISC^?'>[DQ2[KL7<P(#5>+?LAR!*S:;N3D('XL21
MXC?,2O(T2-F]EM.P$E.G_<Y;M=DXWKU4.V#]#M/[GCNV)A\:A4VYG\+-K>G^
M+1Q?FH7<[VGR.(YW,JV]JL-<!R"S^?9)M9O+S?Y2QPRNV_:+ZIDKMT<7;1^Z
MV[J+ $\A#9]488BZ*-T\#^B[DT9D*LK@,IK-X\%%SM.7"A%=#SQ0(-&0T&ZX
M)1U2P=2>.0*6/G%-A228=9G9078WVSUI6YB8<@QS@6X0_R+5FNNWGUL>=>B6
M_VSP^TNA[#W_RD06HH3"3S'=V^Z'K)OP^TV_//P*AEB G#OX8X6M\?AB/A(V
M_+(4'D#"^=><I?'>%/QQ#5JG+"W ]RL##&@>Z(#NY[WK_P)02P,$%     @
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MU$L+\'Q3EDUW00?TO_!]]5]02P,$%     @ ;81A5IG.\)+($   0S$  !D
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M6TL."J?<>H2=HR'M4&36R8 ODQB7$[[\P9$0*M03I#ZV4  PSQ0^*^M7',Q
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M6FD!_KZT<'/]"QW0OE!Y]1]02P,$%     @ ;81A5C^CGD\W!0  $PP  !D
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M7!\C8/J:TGD;0[# QXZC871[CZ,1"\W522P+8O0B(&/7E0O+$GG!A;%2"40
M M%B"; JP;A%&<EV T>8\$\L5ZPD"DW!)PH<8M5/ (3(9H4/ITRCJ+'!BIWM
MX_*6;%M/( KBD+XNX>3P)"E;O@-AB]KY#<X6B/=C"Z=?WMH78FN71V2^8S*/
MLP(:FH!JKG]'6H9$O:<#%Q+TU-LB^ZEK$+,HM%,0IOR_4$UV-5T+]I:#?;^K
M+^.%0U_Q>L*!7K/B1=YHZLEHU9=3M3=T,_0>4(.Q+BYXT613KG5[J[40PDO$
M<",HZ>9E)VZQ=ITRHU'J$[4_&.9@%B(W(NGMX-5A98G[T55%D&_!%NU9W<P$
M& L.Q6Q8?W;+#0 4N.6ZV#&T$!=Y4P\AZ9E[\ #:SRPBG)#VQA;V(:!N#^*Z
M(O'MS"T79_ZGF/FAUC<J<*@;@<%Z-^<KCS%S/2HW5)/'-@,S2DN,PF*GRC&1
M0?GZ0O/?_9)[N8#2,4(IR-07H\Z+ @S</X9@6@_G&".,H?\6!=@WR^?/!_[A
MPZ>+9?AH*J/1]Q]?!V?I!#JIZ)8)<NP'L1P"3N)REH;T*0N1)!_2J*2H DU>
M)AH">'K,6$Q&DT(EXM5T(>%'KGC#L#R>X%3Q[M>O<DJV2(G=C*M.\.H1@])%
MCCH)KT&J%GA9LT\'2J:Z3I?5]2?7W()]%H_FE\]GF=N?W)+7=46MAU+8]=H'
MZ=T2O]<',/:>7#YQ"PDYC717;/!A(.#>H$N)TI[N& ;#J%XFB?SC,=+[+2%,
MZ^L10Q0*WF3[P;1QM3Y<=4K E<P_8$BP-F/K \L'!T" #(NM;L&J0W3K&"]/
M<>'!3O623Y>0R*Z1S2G\@^P&JOI@O\O.S84W*=S!:.5S>\%K*[_Z"WBZ_WAB
M$(/@VKI>B2I9C5Z%=\/)2$>$GA>N6<+';BY<F?")AUPD[=Y;HT XAV4]MWJT
M$GN<HRT IXTQ9V$MNS%27WQB)["X6K]-Z&1,:>"#/_CAD.<H/BAQ=RE-IC9)
MOVRHD_8N&#V 2T4KD9U.S3BYRYD$3".G^=*ODX>)+S;Y!-'M5OZ"QV:S"+41
M"I$^M)Z0A:-9D,@GX!B2Y,1SF# 3(H$>=:'DGS0 B^U'/B3)@25=XM7MN N(
M,T_DV/@T =]6CT%?\,&QHI.L%LKRA>NB5L+1Z%&/ Z6T!)._(%XZ$(U4I-4=
MYO YN@=:CV#1G<TI*_\!G,E)NF;PN/:VF?\ 221M,9@@H1(B7>F-B3 @#X/Y
MB]4P_(^HDG -0)>^IH:QQ2*V)XRZUI3$2RZ&2"84<S;96(H33:[>>[\FPIP@
M_VALXCXOQGPC82"S)],'#P0N@9'""OP4$$)NG7^.CQ2GO%Q&81,5DE*G&=4-
M4<>:*[_:>/IS4P1Q0*_5BZT2$1=2!LH-@[(D7?Y^N;H'U/OH,VFW&BX4H843
M<^QTC6B:!:9IJ;OYNCL<P(R]=E)K%37,RF5WC5Z.^G1VB3=:?AU+7YINZWNF
MJ=.$"U''6ZR;N)A&%E%)[D0'*Y);7,B>@RU#9C<J&$.G>J2&-,AHX[Q3>8S-
M/3H66FT-.3S4;39VM>!M6\^"]2@E7A)N@,U]4<J]9'#@A33VQF:HJPG'E;=1
M,5 D@(:C &*!%^)*Z8).?;H(=4QJE08 2$G5I5N!J2IT6G-YK^PP%$K.J%AD
MOYH2S&+LV_F@CKS/JI40LQL.@+VFBHKD/30)WUET"625@UOE_$8!Q5"^)=;:
M12J7AFBF&^.6&U0=PCG7W*ZY@4/R30;0),\=PAJ1GF3E$E?[C*O-D+7<8Y!:
MG$=9A 4-IRL(J1X0EL7)?(1PF[$E :AZ2_TKZ()27%GDF+6UE%4$]+%[:^S=
M\,:D\TCWB@'WBIJMHC$$C13!EJ5:USZ/V[1P8^,4&[+6S%?3-WJ+J41L<"?Q
M>T,Y_/2JXY:3E)+.UD+JO=@R\LLYEX]2(7QYAC3B^U*E2IEX\X3"D=+DDL.]
MF* KYACDP-)B\&*Y.2W7KF89146(19YVM$B8-<$$.&6B<"M^;!!SE4VPG>2R
MZ:KPUPP;)SDI,5 ULQY<\U1E,<Z-BW<SPJE\LZ-.W7"K*L[T./V#=,-4O8OC
MCBNSN.+#F0HN2C_"GRLTY8F!HM[CI-" J"-I:FYU;O/=O#ND3;A\>R0C+#)_
MUN-@US??:S9S)8II  51XT%:9!_KHRHI_(5&ECJI7;&6T,XY)=JX=^+4R8@4
M3$HI2NKDP H67&GF.Y<#QT6FI,3]67HQ<7518\0'U4VK]\'O)=O>'X)IVN>4
M(0>+*E=2@8&^J.=GQQ<$J!-: "FYH'=P?8#+UF+;E:7/+!"8G'FD5NQPD_U'
MP4)$3P1ED_3#N<\OV$\?G/)$.M/M&<1R4HJ!C[BRQ<!3-XDRGZXR"AV&5W<U
M!<8\&V9SC :'[KT4@)J8A*/&5;!B^L(_GK5"YJ)T'=;9ZOIUQF&=9Y?/OLLF
MMDR#0/"TCR;Y"Q#I=RJCKDM8Y$\R^*/$NY] 0Y?#O;.&N\V, %]0&[^T5M%G
M:#FQ=S$PPGQQ$G4R\G5*-+6QGUT!LXMB]RJ%Y)[$BVZ '6VL7OV,#'_^P8 '
M[-ID6TELOQ,ZV*4:0^"G%U5R.7:2K%[.4,"3XM7.8CLYY4?JF<F6\>][AW,<
M*#$;@S@1,'J1.)D#DT">1MA]XT6(PGD8QA"ZNOZ4^<ABST+'_):5AH.3%Y==
M8SF'J_\]'M#=*8]>M L,5(.5SC5)@G<<L7-"&L,#$I7KF=\NP.0";R.*(2J]
M(?9BV\@!$=%+E;/(_)KU_+)M#::3!-DP>!?4 ) #$R<BP3<.ZL+!:BG_T>@T
M$S>,A42A$*]DHU-(Z0IY7+%1)H,^>N,%3AA'/!4'U?)I2D:N7:AEC_(77J_1
M90X*(&B\07 K+BJ\3YQK98F1?!US"*Q+1MNFO-=+E<*M\)V5=Y2_N7)V'ZW!
M"$=21)?&<J.3G+9QR>.?L)59:4?5#SO0;^.^4A)=!!?)U<>,+LS7EN : PM3
MR.X>HET3>GC1A\V5C0(D6#@<B3(,"E$?>*@GIBR.E4ERSAIVW64ZWX7!<I%/
M QNBL7LJ C"%M(04AKQ#Z8T*9LQ(; NOD@MKT=0V5_\QR\;]9F8?S&D(6,78
MUL8&4UY+8*IUW;ZS7@//N%LY9>B$AO:KZ>;SGW&*V[A9<Y\74Q,F5AF(G+JS
MPS%Q/4\+QSO2=?+M[3(5K5NWI$Z>/WXV?W+Y>):]KUOJ%/I HZ"R-])G/+\S
MAY>."0W=F\OICDOP,318(-EK"O'DQ^SW:/;8&,;^SGJ$2)#FN2LMX@&+87!F
M[MY*ZP1<8(IZY H4R<TB7;C0%3DCTE2@HI5:WQ'?IKO[1_I.((>;3,LE#2'9
M)K:73]U1^&YD/DG$Q2"EJ0IL9+D9]8"VU$4T7O[0.]1&4)O 37N5KDNF[[L/
M8L-DGIS$P\GS*1X]( WGP4-VNQ-VO \[%C"*Z[_'.N]<>QM6=EPDMI<KI"9/
M-1HM]ZTTTBVR-P[@N$*EWU,GD2&I80>T&AH%B7O[-O:0+0PEW<G^\52V]SCP
MZ X*2JP]ZF B5HL__FJ.FKKVH=%W.=WH^X>3ZF^EM\Y+FNS\C[=O1F<8_\TE
M3V@S&>H !-V9P\P'ICHAE6M^Y"5Y=*Q;-@TOQL.^^KJ(C2'_(KX#('',8^9B
M]7'(MR=X>'S-41)BN9&9T/@5K$,:T^V'E^WK5U*XCO/2DFD8WGYU+.EV[:66
MP=*GHR4%I13.5!23P2L<;*DHBT"!#O1HSZ\DR5K?LH_%,T#D^GI/.)R;5Z7P
M=-JOB)5V\B(\YN.XO@:WGW<Z7_+.J2&CUK9NUKZ7=C-S/38R<Y*+^]#@=XE*
M=AQG*7P\K2F>9(364.1UDT2$!XF2,9-2FE8\!]#RY3$J8DT*)F<TB$U*BC $
M[$9A<J@7: >\30Z+),'B 9]D<7(0:"B ))A8Z-Y'PC&3PB!T_RZG^W9E NVO
MG+V\H_'_?FO%7?.?R-0)T9N'6(X5/S!W,W"OH];Y@:_B\I8C7?SG6)9[:%T,
M/TFU!4M,7N3<R2R+2B$"]@=H9EL MY+$GAO@X 23A^*B-X8D\?PHK!=UZ$3/
M?972B=D3#7N:WX\9R6A(4-([-C[V@,4!MUA3 ,M-3O!U?/U&QZ@GFP3,YNCK
MI@\HK\F/045:&$E 1N$ZG-H;#8#Z-0 [FV+@T(V\G&XG_A@'EWZ,/+(WHME'
M&?EOKCD^.3;(2<)KB77&+O%,KN-D+&P#.$VC,?(U"A.B=5,?7#0,AXZ!TW9D
M1[(NZRU=G!_?KX!H><Z.*/[+[/==1?RJ#BZ66?RZ>F5QML%T6,[Z"6XTX=?;
M23+/'2>2L4B4T8YW3?*.TA-6 7(<.$Z S[ 'PI?_>OV/SND.6#0:C.2K!%K,
MQ-M@.43U5.%]&8OK7K_/P2G52W7B1(AXY*0-P1^'"C<ES+\N,L6[MB'G::HP
M.?A.5E!8_XIEZ#;ZR&=JN> OCI$Z&W1LG'F_)IKG:8:!3K:'5'>8*&I>-Y]#
M&X/+B#6ZE!!?5,B_X5X7:>CU'..7\K%R/&S5P!E8DZ);4&HG?FT+S)*0DAL>
M<28CSZ#J@1SZAZ/, 1[5>M(1O_@B&F0%_VU*<G?\-%W7:U;)G3C=HKREL:N^
MODVJ@]>:?)O/%1BGB^P7W^)7TFAKMSG)"\X7(>?P[?*5)I%U<5<H_05&RGAB
M."B&N@A#"$/=,OA1=2DASA2!&-!%PZPL(U/#X18MJ: LE>NC2./QWSKFMSWM
M-27KPTB%Y?0XA/>ZS=YA^?\'C)_ _J.32J87&>^ 'ZZ<X<][Y.&7.N HF:4O
MI >I:WFJ0 'BS?>_^L>3,= R>^"6?@@'73_,5 /NJHXJUI'7<67;'T9/L@N#
ME315,IU+O\A^I#GMQ2D059F+SSU2B<V.I9M:1'M) 9L#/-Y:@#D$(8,.&? Q
MVROX);9!@3%V]O'ZDSV[B$<]B._C^Q5IO#R9^7AS.*/.O]. OE@8C.-#_*'&
MN941^RF2J$= ?\$T!,F7)IH!U?M)%6D>)PANM/-57/U =.+W?I3:*Q[;SY/]
M>Y/&SC'4VUD9((GO9,\O0O8X*D$)%3UG9C/W\)WY:AX*K@C)Y.H5I^GKV]D1
MAV-3,QR'26,CA[>' PR$[1S-!R&CN.7-83A=S#&%IU9O7I64"]@.*PC\$FYZ
M76\.DB<,'&CDU-[HE (4E02>XG?<3,^VAU5CL[0_;%_?2!.W[R\;&;(7@>EU
M.MQ=%&[HUR5@80WR9\T]D0, *;;C(GMU,X2';DQ2]^!QPK0*W853$C4,&UE.
M#QMYAST^XR;R?5ZD,A6\^#23AN=?A$8M>N1$]0=UY?6>9>=^7F_F5(1,7?/2
MRME_T@7:CG>/4A33I_]>6O:MK.=4))4GO_CL_++/-4JW8Q6U\302L7/1JI"N
M]Q$%CD4H'E!8-TBK,"90?A^#RY#\Y"A"E/3329$,04)IURH/@V'YC"/X,_W"
M'X\ YDQ7E,KY?)JB0C$'G\KLEX\F+<D.'J*\&S#1APVEIA.%<80,UM:W-.P@
MZ)5DJH?[G 2>LC5ZIA1NI?@I.24L3Q89#Y5J(DO(7\O![QYYUN3KYQF2<)^.
MB9'&Q1L]'/#"!^?9GDFP.>SB_8%ZRLWO6TJ9#Z;VN"X:L\)=>L.-^BEI[Z%,
M"8O0F;J\XU<*4(7.7Q$[(59ASY._!C&]U(D9D2?6'_Z*FF5U+A5P>?RL(W_D
M1Z--0I1*[!AFZU3:#\R:5$JXWT  '1.2QL-Q:[%QXJ<1"@^\5[90_\I^+FL0
M4MDUQW#DUZ#NGNJW#'U_R[LZ]G R>_)KA4U=U9U<3 R\\2-PHU8%H*3_TX-"
MQK^Y"TDE?BBJ43BD#ZWQ%S I%,H%5>DOO'&QY6!"Y/BXG8]W[97D#6!]+MEB
M/N'=*V\64O@5G\4YCTF-S!@8?KC$;-P%FG$?K]/JX:<0'#3>F%Q0K='[>D$_
M>C7':J.W5;;JMA@*Y=_!0B!^6EV_<H9I[X59]J->MQ296K[ /Z55DNQ.ZYIH
M:7I#]IN(V7.?D'[T]'*^O+R0Z!?]0A4-[L)__Z(+'-XE2X=63!!\E/()X;#?
M;BL7VPU+/[MZ/']T>?%=S#(HJ%]'8XSCL? T#SC>1$WN$WI('2;B%E J! 7B
MEF9C7".>R\D32AB;31312X",9RV;'I!Y#*0;5NZ2E!$\V2U'<Z3YC1N#Z!?)
M?(:*&F: %X"G^-?1UAI03LDE'BOB6YVO'L^DPUDF%0"Q]F*'1D5L-?U&7UBP
MU_3"MS\!DJ=.N!]1<PW5I" YJ$#*MFUJW\47FOZ#_B%[/%0"FJE?EGP6IGTI
MWWR>I3^BA=;)' /UT0]8/EP\C-Z4N1]5>/WD".]:?M#2M9#WS._4-8P8@1V%
MODT4F1&)\1ZWM,?)X?[NKL,6S$)M#S4[H4/?8:17W4D;FOE#\UL0ZRX+YWIL
M?-8^71-HR.4YOCS]')N8V).=);<2I0AW)213X/R/!UV,VA@/HM_?!7]I2[\R
M3+^B4K7\4[S^T\S]DO&*?[\W/,X_@PQ*<HLS=DN]@5<O%T_!06GXEX7Y'R!A
MZ-=\UW7;UGOZ$^/&NL$'X/M-#<>2?^ &_O>=7_X?4$L#!!0    ( &V$85;0
MU&\B< 0  *$*   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;+56;6_;
M-A#^*P<7*39 L259LJ74-A#G!1NPKD&<MAB&?:"EDTV$$E62BI/]^ATI67,P
MU\N7(@Y%4KSG[KD7ZF8[J1[U%M' <RDJ/1]LC:DO1B.=;;%D>BAKK.A-(57)
M#"W59J1KA2QW0J48A;X_&96,5X/%S.W=J<5,-D;P"N\4Z*8LF7I9HI"[^2 8
M[#?N^69K[,9H,:O9!E=H/M=WBE:C'B7G)5::RPH4%O/!97"QC.UY=^ +QYT^
MF(-ELI;RT2Y^S><#WQJ$ C-C$1@]GO *A;! 9,:W#G/0J[2"A_,]^JWC3ES6
M3..5%%]Y;K;S03* ' O6"',O=[]@Q\<9F$FAW0B[[JP_@*S11I:=,%E0\JI]
MLN?.#V\1"#N!T-G=*G)67C/#%C,E=Z#L:4*S$T?529-QO+)!61E%;SG)F<6J
M#0;( E9\4_&"9ZPR<)EELJD,KS9P)P7/.&KXZ8&M!>J?9R-#BJWX*.N4+%LE
MX7>4!"%\E)79:KBI<LQ? XS(XM[L<&_V,CR)>(W9$,:!!Z$?AB?PQKT;Q@YO
M_!V\8WS_O%QKHRAM_CK&N,6+CN/94KK0-<MP/J!:T:B><+!X_RZ8^!].6!OU
MUD:GT/N@?2K@2I8E)?=JRT@-/&R9@:^H$&Z>,]&0K^%6R9+V$:ZY: QM_$Z5
M_IO4&NY0M7)PQ436".;*9(D9:S1:;)+B"B[)+>=.F,H';HJ"ZNF80TZ:?-PA
MUJQ""KH8K..-3:_N=N!_$YM:&B3E3(!NZ5&29BU?JHOL$8REN[-T<4^WL'3S
MCFI%5(6E6A-5AP'9 =5U1Y5@C:/*+-5\3Q4=U0OX YEJ$Q<H[;!<$]@^]>P0
MV,&'3[4%U6 DU(W*MG15O+8V"+TP#+PX2B#PO2A)O#0= XW^Q)N$$:S(*3S#
M<WO)Y'3A4?+QS-)HQ9N*&PVA%\<3+XRG-(NBQ$LFB=M+/#\.;4C=/5W]'TP0
M!%X:!3"9C+UQ/.Z?5[)Z0F6XC03%J4"E>DDZX:>OQL/3%05+T[X?I5Z:^$=G
MO?M"/TAA*:M<P_MW21B$'_IGX/E^ZD6Q#P_24.B#*1E*$.,8 O)3''FQ/[;3
M(/6]*;$_44]Q7T_Q6^OI4E,"=I'\;!WX(.%&&T[W/[HRNF64*%^8:%R)K)QG
MNM ?JXK3BBW@SGTX2!,C7])W$-B!"8TU@5<V/V$I6/9XOLJVDFYA*&6.@JI'
M@71G8:,H?5WZ85D+^8)TB%4Y%8.B-):*5LH%55-1$>K:?I#?G-WW7#^>%PJ1
MK#%HLPJ4=4DX].,S\(=I8,?)^(QNGAI=OCU)6V>"FQ=(HS-(Z=TT.7@O>&'1
MX(4LT! /IS"AOVO^Q',DNU\XBOP_Z;%__AC/5;(Z/_#>#_!7,$PG9S1&SFM)
M>-Q?R?3,_4\GW_57X'>_MSGL6)6,#MJ&$M7&-4<:W)>P[2#ZW;[_NFS;CG^/
MM\W;1Z8VG+PNL"!1?SBEO%=M0]0NC*Q=$[*6AEH:-]U2#XG*'J#WA:3[HUM8
M!7U7NO@'4$L#!!0    ( &V$859T.YF,4P,  !('   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;(55VV[;.!#]E8&Z*5I L*ZVE-0VX#@M6F +!';:
M/A3[0$LCBPA%>DDJ3OY^AY*M>G<=]T$2.9PY/'.&'$WW2C^:&M'"<R.DF7FU
MM;N;(#!%C0TS([5#22N5T@VS--7;P.PTLK(+:D00A^$D:!B7WGS:V>[U?*I:
M*[C$>PVF;1JF7VY1J/W,B[RC8<6WM76&8#[=L2VNT7[;W6N:!0-*R1N4ABL)
M&JN9MXAN;E/GWSE\Y[@W)V-PF6R4>G23+^7,"QTA%%A8A\#H\X1+%,(!$8V_
M#YC>L*4+/!T?T3]UN5,N&V9PJ<0/7MIZYN4>E%BQ5MB5VG_&0SYCAU<H8;HW
M['O?2>Q!T1JKFD,P,6BX[+_L^:##24 >OA(0'P+BCG>_4<?RCEDVGVJU!^V\
M"<T-NE2[:"+'I2O*VFI:Y11GYRM\0MDBK+!06\E[I60)2R4+E%:SSJ(J6&HL
MN845-X_P[H%M!)KWT\ 2!0<4%(?M;OOMXE>VBV+XJJ2M#7R4)9;_!@B(^Y!
M?$S@-KZ(>(?%")+(ASB,XPMXR2!(TN$EOQ&DTJIQ*I $A:6BV!J673E0P\_%
MQG3VO\XIT..GY_'=);LQ.U;@S*-;9% _H3=_^R::A!\NL$\']NDE]/F:+FW9
M"G05.V;RR67R\=FBEDP,29ASU"^#/]0DBQ)TC[G<@G5G +@L><$L&K"TND/M
M3@W=9D? *DL;ZIZ&(5? YP*-<6M1>-6+RN0+&,(CK.) [>:7TJZH0R)7+O"A
M R5[](H]/&=?E$^L*"@?^ />OLGC*/XP?*]>L8W], S= Y.<#/>B;39.$OB3
M5PCK@B-=$>/#%TDG\!VK*BXX*5$"*<#MRWM($G]\/1DPXW3L)U$(40J1GV2A
MG]!BE,.WT7H$=[ACVE*WLX[T'5;4]Q"N"2#RLRR'ZQ2R<>KGXP32Y']T%T*
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MHQ_.\)$NM=N WR<UIOYRXA2LG_W#?P%02P,$%     @ ;81A5A?1Y%!= P
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M46ATE9'$>GA;!L.JSM_G6V7I=?## SW'J)T#K>^4LB?#$4P/_.IO4$L#!!0
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M[#&),P\/%EP62+_^V0L"6R;AS'5<UP./N.GAF>+?0/S"/G[A</QPE.5-R4T
MGUO[@)4JNW#>;NVLN"M9K0A<[>'FB<NL4!Q-+C(.]ZQ>\U,1'33@=$0_;3BL
M1(ECT<12FY;K9B.:I4 +S4I0UBQAS<)H'P=? _8&KY9H_*$_+CL'?DS3@=;Y
M8A7]Y%<7%1N*<G\L],7.-9Y?S!^YQ#'=$UX@ P>9,\\)HXLS'Q,,B>^2,*"0
M.#Z< 76\&&@0$\\-[)*F8/B\B[/(<(<DB#SB1R'$CH<,OA.ZX!,W3(GONY80
MQ6!X42(U$C[Q@Y2$20RAU1 [(6H@"<*D;FH) ;Y2*^%1(X([:%1"#TH\UTEC
M4X*)2_PD;2GF;=B-5&A-P]TTB"%H97S'3R"D:%=*NS5Z9%A1@H9.1"%*"$TH
M*HF,JYZ#TS+T2!@EW1++GA)*D10D$%FNR*$)Q&A;2B*+&SGQ8$]$?4]$+^^)
MH]K'LI^;DQ+'XJDZ'P0]7>>+HQ)N3V$S<AO;=1I[X%I46U;O7[]*J!>_5<#;
MF5S4&:_-D0U;TXV0-]+V"4KL.8X+;@Z8YRT .YQ*^-]VEKJ$CXW=QT'UK)2O
M&")GG#Q#P42X)$@2DJ9M">'K#\EJ4],!B:A/ LR0;S)V:*0<WGA>@DD*SK&*
ML12N#719F@U*XI@2+TW/3?%%O]9+CPN@2_Y KN,^U_&+<WW/\9 K,MV?( ]U
MH0=3/HA].N5'2MH!UA@E_V?N!U)-33)Q/B1]BI&2A+:W/Z,C-K4DPN12/SP_
MSFL<X7R@_OE00BD)PXA0G$&G$CD^NKE57*[M_51!)II:MY>XGMI?@>?MS>\[
M>WM__L#DNL!8E7R%HJX3XY$DVSMIN]!B:^^!2Z'Q5FD_-WB-Y](PX/Y*X"VH
M6Q@%_0^#V;]02P,$%     @ ;81A5E:C'0L2 P  QP8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL?57O;],\$/Y73@%>AA2:-+_H]K:5M@$":1,3
M&R"$W@]N<FG\XMC!=E;VWW-VVJS UB^M[WSWW'-G^\E\H_1WTR!:^-D*:19!
M8VUW$D6F;+!E9J(ZE+13*]TR2Z9>1Z;3R"J?U(HHB>,B:AF7P7+N?5=Z.5>]
M%5SBE0;3MRW3=V<HU&813(.=XR-?-]8YHN6\8VN\1ONIN])D12-*Q5N4ABL)
M&NM%<#H].<M<O _XS'%C]M;@.EDI]=T9[ZM%$#M"*+"T#H'1WRV>HQ .B&C\
MV&(&8TF7N+_>H;_UO5,O*V;P7(DOO++-(I@%4&'->F$_JLT[W/:3.[Q2">-_
M83/$YED 96^L:K?)Q*#E<OAG/[=SV$N8Q8\D)-N$Q/,>"GF6KYEER[E6&] N
MFM#<PK?JLXD<E^Y0KJVF74YY=GFNVI9;FK(UP&0%YTI:+M<H2XX&CF[82J!Y
M,8\LU7(94;G%/1MPDT=PIPE<$E1CX(VLL/H=("*2(]-DQ_0L.8CX&LL)I-,0
MDCA)#N"E8^>IQTL?P;M .DP#WTY7QFJZ'/\]U.0 D3T,X1[,B>E8B8N 7H1!
M?8O!\I\GTR+^]P#!;"28'4)?7M,#K'J!\*&&2V9[S:T[$[(^=*B9.R;P3< %
M9RLN_/9#31PN<VI U4#3Q7:%>IQP"+9!NFEC70IR'KHP'9-WS\DQLA">A;AG
M 1O4",Q K00]>W,"7Y%I0%FY\#]KI? 4LC">'8=Q'#M'!FD8Y_'.S)U9I#NS
M('.:CL&O( GSI/#F34-U66T).PN39$BY498)$A G4?=L.W8WW/J$ZAP/M2[0
M$%5_E-+"+1,]-5']3Z_0A<)1%A:ICWRQ!3TT@FD>9L4^;MEK[6 ZI;T@'27A
M+,X&N LEUR^)=GL0\BE,D[#(AUZ_>,'!ZB6[I8PU_M6AA\LGQW!'LS=_QU?<
ME*HG0E0/838IX-E#MS;:$Y<6]=I+J &?.NC,Z!U5^G00I_OP0>(OF5YS:8A?
M3:GQY%4>@!YD<S"LZKQ4K90EX?/+AKXTJ%T [==*V9WA"HS?KN4O4$L#!!0
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M6:GY*7LZ.'T^'-S!]<#$SX=Q^F$ZV;K-B+DEKGL"=\;5HN?R^P68I7JH<+X
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M=V[4J-TG#!I%P>$4Z0L,4.#Z_B$/QGZ^E ?4\H",/,1D23A7'$C\U"2OM+3
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M(ZEU_%V!6O4SM6/[^!G]QR)X%<PR$N26)7_0E=Q>65,+K,@ZRA/YF>U_(E5
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M43$:F[E"9R#MB:6?9Y(#T1PE>2+7*3TBYS:F;3_3M-.%X!/ FBCS4I1Y+U-
MCS0"G6G/%%C4)L:\92X:D_JQ2=!K4O-\47J^Z/7\3WU&7PZ+-K][T?\U60U)
M%@Q$5E,->]=[DO=_G0_%FP?2?%"V8"BVNNJ5VRD>ZI HF)I9'2^FC6W793AN
M'"=!AZ$WUT55Y8/;-R3VKT'Z0YP;!4LCO<]GS?!N,@O:S6;3CF"N]U#\P47T
MYN/B R+L=4*WGX<&GX+6M;A>*7'O!>J&4Z(@Z#TF;K )^FUR]]U*E9B V-EJ
M6R);Z.5E4SE:5O2/MHYMC&],I6^KSRM-_C?!5R)V5&=%!K&FU,M)W[1$7GGG
M'<4S6XN^<J4K6]O< XE & /]/.9<73KF!>7_'^M_ 5!+ P04    " !MA&%6
M]+6\H8@#  "D#P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6S%EVV/
MHS80Q[^*1:OJ3NHNAO"4O03I+JCJ56VUVFCO7E3WPH%)8IVQJ>TDVV]?&U@:
M=@EWD9 :*<'&GO_,_&R&>'$2\JO: VCT5#*NELY>Z^K.=56^AY*H6U$!-R-;
M(4NB35?N7%5)($5M5#+7QSAR2T*YDR[J>_<R78B#9I3#O43J4)9$_O,!F#@M
M'<]YOO% =WMM;[CIHB([6(-^K.ZEZ;F=2D%+X(H*CB1LE\Y[[R[S:H-ZQB<*
M)W761C:5C1!?;>=CL72PC0@8Y-I*$',YP@H8LTHFCK];4:?S:0W/V\_JO]3)
MFV0V1,%*L,^TT/NEDSBH@"TY,/T@3K]"FU!H]7+!5/V+3NU<[*#\H+0H6V,3
M04EY<R5/+8@S Z,S;."W!OY+@^""P:PUF'VOAZ U"&HR32HUAXQHDBZD."%I
M9QLUVZAAUM8F?<KMNJ^U-*/4V.ETW:PW$ENTICM.MS0G7*/W>2X.7%.^0_>"
MT9R"0C?H 7)X,2@%-^T<S%;0"KW)0!/*U%LS^7&=H3<_OEVXVH1IG;EY&]*'
M)B3_0D@9Y+=HYOV,?.S[ ^:K<?/?"+]%^+)Y]OW>O;ZY:]AV@/T.L%_KS2[H
M_6FV_F5@0J+5GO =(,K[TRC/:<4 _?6[$40?-93JRQ#+QGLP[-U6C3M5D1R6
MCBD+"N01G/2G'[P(OQLB.Z58-I%8C_JLHSX;4T\-RD-Y8$1#8:N V<!Z"%XC
M$M<BMD(>TQLO2.(DB,UWX1[/V8PZO);-D&,?SY,P#.VF/0ZD'G2I!^.I%P6U
M)94P5!%:W)B-E9.*:L*&"#1:42^0V,-1&'ES[P6!4;_7$AAR'.%YF,SC>3Q,
M(.P(A*,$,MB"E&;E-7E"C)(-988(J*'\PU=AS'P<1"\R'_5W;>;AJ[7ON^SE
M''4Y1]_:\,^U8ZT)+X@L%'JL"O,$V$J&;W TE/ZHZ+758TJQ;"*Q'LRX@QG_
MKS4[GI+ZE&+91&(]ZDE'/9FB9H^*7 LO>?4L>@FVGWX!R"9RVN,R[[C,)RSH
MHUK7XIF_KHZS(3P3.>WA\?!_?V'Q**"5X$>0FF[,HZ> 4_. <J&'Z_VXU+5\
M6K7>_@F' $WEMD_H[$^^-]D;L97Z9DZK<9_75IZIU!I"[MF)R)Y?_R!R1[E"
M#+9&'M_&YB4LFR-AT]&BJ@])&Z'-D:MN[LTQ&J2=8,:WPNRHMF//7=W!//T7
M4$L#!!0    ( &V$858O]Y'VK 4  (4H   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;,U:76_;-A3]*X3W@19H;9&2+#MS#"1FAQ5H@2!9MX=A#XQ$
MVT(DT2-IIP7VXT=]1#)EFK4!.E@>8HF^]^CRD(>7U^+LF?$GL:94@J]Y5HCK
MP5K*S=5H).(US8D8L@TMU#=+QG,BU2U?C<2&4Y)43GDV0IXW'N4D+0;S6=5V
MQ^<SMI596M [#L0VSPG_=DLS]GP]@(.7AOMTM99EPV@^VY 5?:#RR^:.J[M1
MBY*D.2U$R@K Z?)Z< .OL%\Y5!9_I/19[%V#LBN/C#V5-Q^3ZX%71D0S&LL2
M@JB/'5W0+"N15!S_-*"#]IFEX_[U"_JO5>=59QZ)H N6_9DF<GT]F Q 0I=D
MF\E[]OP;;3H4EG@QRT3U'SPWMMX Q%LA6=XXJPCRM*@_R=>&B#T'.#[B@!H'
MU'<(CCCXC8-_JD/0. 05,W57*AXPD60^X^P9\-):H947%9F5M^I^6I3C_B"Y
M^C95?G)^3W>TV%)P3V.V*M)Z+(H$+%@1TT)R4K6P)5APFJ02W*?BZ3UX\5IR
MEH,/7R7E!<G H@J7<@'>8"I)FHFWX#WX\H#!FQ_?SD92A5L^=!0WH=W6H:$C
MH4$$/K-"K@7X4"0TT0%&JI]M9]%+9V^1%1'3> A\^ X@#R%#0(O3W:'!'9_N
M[EEZX[=#YU=X_C&\5)#5BM-5.T8OP_+7)V4*/DJ:B[]-O->X@1FW7&FNQ(;$
M]'J@EA)!^8X.YC__ ,?>+R;.7()A1V :GT'+9V!#GVN36NDJ(X^LG/\["@CG
MI%A1M=Y)4<F#R37ERJA42"S%.Y 6<;9-TF(%R'*99BF1- '*/)7?3"-01Q)5
MD91+\VX./31&:#R9C7;[[!H,HRB(PIX=/K2+ @A1.=%V!D["EI/P=$X637?5
M$B77K=K!+2WBM4H:3^#?KE%?/\I5PT2#]>'G3D278-@1F$;ZN"5]?"%ACUWR
MZ1(,.P+3^(Q:/B/K)/ZI1F++^O-W)E6R:B@UL5BC0;@ONIXLOV^"K29:/R9M
M/R;6?MPD.Q+'JM$4M-7UW*%W"88=@6F435O*IA>2TM0EGR[!L",PC4_H=?M%
M[W^3)9M0]K.:UQ/B]TVPP23TJC^S'.'>WAF>)DB5^2Z<*>V1G#L?G:)A5VCZ
M**!N%-"%--X NR+5)1IVA::3VM46T+K5/CMG-G!:NCO0ZO=ML-%FN+<MUOO3
M[>VA?7-_EVWSQ[(1?$J7%#S$J=(B54O2QT)596\.EB-SO6I]QMGSQ24:=H6F
M\]O5"3"\E B=%@%.T; K-)W4K@Z UFWQZ^;:\4&6]/UP.NYK^- ,!:$/#W1\
M: ?]R//W '52NLT\M._FSU;R*R1G:\1G3V&7:-@5FCY:7<D")Y=:%YQ6-$[1
ML"LTG=2NJ('6/?[YR7EZ0G(VV0QAT->UV>Q(?D9=68'L9<67X<,08+HA7)9K
M6CE1,%W20A@[9 <[=VXX1<.NT'0BNYH$P0L)#CDM,9RB85=H.JE=B8&LN^U7
M3<1-*/N9<QI.813U?QHV&$9A, G]GF0-=D<J7]25!\A>'AR7Z^6SK3VTL^>I
MT_<7KM#T8>FJ'!1<2OQ.2QNG:-@5FDYJ5]H@^SN0<[-M ]=+D5-_JOWUQ6QT
M"@ZT;#([(N:NS$#V,N,FR^I5R[96I508.^OTE8-3-.P*3:>U*U10="DQ.JTG
MG*)A5V@ZJ5T]@>SO0%XU$T\.$N?8'T^F05^[AW91%(33L"_>0SOH!=X$!4<4
MW!4$R%X0G*K@5TC.3M^;.$7#KM#TTQI=B>-[ESJOX;3<<8J&7:'II';ECF]_
M!7-N<F[@>GG6Z__,938[2,=F,]C7\VCO?):2TJHZYR;4RK0M9'UZJ6UMS]+=
M5"?(>NVW\ K7)^(ZF/J WF?"5VDA0$:7"M(;1FJCP.LS;_6-9)OJ%-@CDTK/
MU>6:DH3RTD!]OV1,OMR4#VA/'L[_ U!+ P04    " !MA&%61UMN2+0#  "Q
M$0  &0   'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6RU6%&/XC80_BM6>E?=
M22V)$PB[6T#:A:VZ4E=:P6WOX70/WF0(T28VM0U<J_[XVDX(A W61@HO$-LS
MG^?[/+;&'NT8?Q4K (E^Y!D58V<EY?K&=46T@IR('EL#52-+QG,B59,GKEAS
M(+%QRC/7][S0S4E*G<G(]#WQR8AM9)92>.)(;/*<\'_N(&.[L8.=?<<\3592
M=[B3T9HDL #YO'[BJN56*'&: Q4IHXC#<NS<XILI#K6#L?@KA9TX^D::R@MC
MK[KQ$(\=3T<$&4120Q#UMX4I9)E&4G'\78(ZU9S:\?A[C_Z[(:_(O! !4Y9]
M36.Y&CM7#HIA23:9G+/='U 2&FB\B&7"_*)=:>LY*-H(R?+26460I[3X)S]*
M(8X<%-%F![]T\$\=^F<<@M(A,$2+R RM&9%D,N)LA[BV5FCZPVACO!6;E.IE
M7$BN1E/E)R=SV += )I#Q!*:%M+2&$T9C8!*3DP/6Z(IASB5:)Z*5_0KNHUC
M8TLR]$"+9-)VGV8@29J)S\KD>3%#GSY\1A]02M&7%=L(A2M&KE11Z[G=J(SP
MKHC0/Q,A]M$CHW(ET#V-(:X#N(INQ=G?<[[SK8@SB'HHP+\@W_/]AH"F[W?'
MEG"":@D"@Q><PTL%21(.2:7U?E&^_:E,T8.$7'QO$J[ [3?CZ@/@1JQ)!&-'
M[7 !? O.Y.>?<.C]UD2Z([":!/U*@KX-O<I"7F3AOQ"C)6>YWH_ 5>*I 6/0
M)$*!/#3(^M#:3G!_Y&Z/J;TUZ8>522W@017PP!KP<V_10S-8$R[5F2;UHLU4
MK%0 ^@]-S;8%?K*)]-9I(F"=J>TJ=@16$R6L1 DOE,AAEQ)T!%:38%A),+3F
MQ6T4L0V50F<RI%ORDC7FK!6D+=_AF^P.0L]KSN^KBL?51?);C582S*T26.=O
M*T%'8#6IKBNIKB^4]===2M 16$T"[!VJ",^:+Q\+++8L_K\PJ2J#^?E#VP[7
MEGN)AO'1'O!ZX:!Y#^"CV@A;64WOGQ[0X_U\T?Y0MR.W)M@16ET'_Z"#?Z$4
M+X&[DJ$CM+H,ASH-6VN@]Q[N=I36G(.W]<WUN>,='PHN;*^XWIG:[S_/[?.U
M9MT16EV=0W6'!Y=*^$ZKN:[0ZC(<ZCELK97:G^J=UG$EVLFI'O1/4M\]NORJ
M)$[,FX! )FF+.V'56[T[W)K;]DG_G7Z/,)?J TSQF/%(>))2@3)8*DBO-U3+
MPHOW@:(AV=I<L5^85#O)?*Z Q,"U@1I?,B;W#3U!]4HS^1]02P,$%     @
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M>;#F66Z@SF_25+[LY!>H/G&:_0M02P,$%     @ ;81A5HRX15KZ P  U1
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MD]8"J;3I/@.D\W&D.S]1]HK.2123*)XH/N"4CQ?B+DH4JE4Q;IOUT(\!63Y
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MO:GR3?N0_H>\JO)U^_))Q4M5- +U]ZN\9J_]F^:Y_X>_\W#[?U!+ P04
M" !MA&%6&\A1I+0"  !)!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6RME5UOFS 4AO^*Q::ID[8"YB.D(TAMLFF]F!8UZG8Q[<*!D\0JV,PV2??O
M9QO"TH1&U;1<!!O.^_*<8_N0[KAXD!L A1ZKDLF)LU&JOG)=F6^@(O*2U\#T
MDQ47%5%Z*M:NK 60PHJJTL6>%[L5H<S)4GMO+K*4-ZJD#.8"R::JB/A] R7?
M31S?V=^XH^N-,C?<+*W)&A:@[NNYT#.W=REH!4Q2SI" U<2Y]J^FL8FW =\H
M[.3!&)E,EIP_F,EM,7$\ P0EY,HX$'W9PA3*TAAIC%^=I]._T@@/QWOW3S9W
MG<N22)CR\CLMU&;B) XJ8$6:4MWQW6?H\HF,7\Y+:?_1KHOU')0W4O&J$VN"
MBK+V2AZ[.AP(_/ 9 >X$^*6"H!,$-M&6S*8U(XIDJ> [)$RT=C,#6QNKUME0
M9E9QH81^2K5.95,02J\UNB$E83F@A=TZMPHJB=ZCN8":T (15J"O:@,"31LA
M@"ET+24HB2YFH.6E?*N#[Q<S=/'Z;>HJS67<W;QCN&D9\#,,,\@O4>"_0]C#
M>$ ^?;G<?RIW=37ZDN"^)-CZ!?]0DA_72ZF$WGL_A])L?<-A7W,>KV1-<I@X
M^L!)$%MPLC>O_-C[,)3T?S)[4H*@+T%PSCW[*!751P0*=,MD(VP9[B#G6Q 4
MY%#JK=_(^IG.L<T"K_VE[O8PK=/ OQ%/6,.>-3S+NM^C%6'-2J],(RA;(WC4
M?4X.L[9^\0&"'WJ^AY,CU-,X/ I'H1^-AXFCGC@Z2]R>I+KC/D<:G9(F(SP.
MH^ (=2#0#V*<!'@8->Y1XQ<5=P]I.P&W_'G7"8CM!$/T\<E21YX?>&'B']&?
M!@9)$L3CL7]$[QXT.O.1^4+$FC*)2EAIJ7<YTG40;>-N)XK7MO<MN=*=U XW
M^EL'P@3HYRO.U7YBVFG_]<S^ %!+ P04    " !MA&%6JQWPFCL$  !^%
M&0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R]6%UOHT84_2LC6E6[4M;
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MN5S+*+OO1^B><MC$Z(\DZS*Z5^O2!<*09/Z09,% 9(V$F<;;DMWX']9RE<A
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M ($IP\OG,#Z1=!DF&8CH0J1:%Z[886GY:$-YPMFZ>#K@F7'.XN+EBI* IGF
M^'S!&'\YR2]0/V R_Q]02P,$%     @ ;81A5F1+)5&Y @  (@@  !D   !X
M;"]W;W)K<VAE971S+W-H965T-3(N>&ULK59=;]HP%/TK5C9-K;0U'X3T8R$2
M-/O@H5/5JMO#M >37(A5Q\YL0[K]^ME.2(&F%$U](;9SSKGW'L.]Q#47][(
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M965T-30N>&ULM=UO;YM('@?PMS+R[JU:*8T9_MGN)I':\&_8ZZIJU=L'IWM
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M2["-(5<UG[1'SF.^W97'HXZKDQTJ61>H_;%= -6<5A/WG,ZZ #JC!]5\J!9
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M4J%I,51SH9IG]*_.I51:J5;_&$.V8"!9T)0MR* O)$1I8J5V :\Q_.KA]OH
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MS3!1;RS M8%ZOF1,/DYT3UR] X5_ 5!+ P04    " !MA&%6.U:LD?42
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MJ*>]E<F:AEJ*4%H&I>50&H'2*)3&4#1=Y\I2#*&)>2'4+X324B@M@])R*(U
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M(S'4*(324B@M@])R*(U :11*8RB:KF=E'L9V&VT4E<A#:79W/[1B(MD4\^X
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M\NL"F-C-/>SM-SZ4ZT+;#3^=U70-#Z _UDMI5GYG)2\KX*H4'$E8S;T;?+W
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M1)O-0ROJ;9.-G^0HI9/1N;K#1]T>_W3E74+5_IE$1UCA".,S6.2 15Y0B9>
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M2[I9H]]9VJ8/:UOG#G1(F \)"R!A(20L H(UI#2NI#1^E37F&%(TD# ?$A9
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M@@.TODPH@3ZV%,#O*\[5^TWY!\UKEMG_4$L#!!0    ( &V$858RF %]E04
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MI,77%6<1EWD#\_M""/VXD1^@7D(]_1=02P,$%     @ ;81A5IY2SFNU!
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M]>&*T3F3Q@"N+P1,V,/ ?&=HOBO-_@=02P,$%     @ ;81A5L3$K'/"!
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MN-S,O-![65BP56'L@I],UW0%]V"^K.\4SOR6)6<E",VD( J6,^\FO$XG%N\
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MY0@+C*J[PWIBY-KU2P_28/?EA@4VU* L />74IJ7B3V@;=&3_P!02P,$%
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M>VC!EG03J@>^^XL5/VB4\N8\E-DKVN5EQ[B'YANI>%0$ZQ9$09R_TY<B$94
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M,.?Y+!+%-SJ49<>JL)\)R>(J6+4@#I/RE[Q4'7$28.,+ 5858)T'V!<"["K
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( &V$85:I#K:-A 4  .(P   /
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M2VZC0!2%X:U8+""X[JN25IQ13S*-L@'DE!^*;1#02K+[MIR!?5 />A)Q1JA
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ ;81A5KWZB\Q8"   @S$  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &V$85:)LL;O/0(  ,<%   8
M              " @9L0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " !MA&%6720MCMH'   /(P  &               @($.$P  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ;81A5L]HITG[ @
M5PH  !@              ("!'AL  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( &V$859Q]>=XOP<  *,D   8              " @4\>
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !MA&%6\M!2
M0;P#  !W#   &               @(%$)@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ ;81A5H[7[C.2$   2=H  !@
M ("!-BH  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( &V$
M858 IL(MS P  .L^   8              " @?XZ  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " !MA&%64@ZG.D "   1!0  &
M        @($ 2   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ ;81A5D$YW<F\!@  ? X  !D              ("!=DH  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !MA&%61$YHF$<I  #J@@
M&0              @(%I40  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( &V$85:$O3NOOP0  #H+   9              " @>=Z  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ;81A5MWXUD-)
M%   ]$$  !D              ("!W7\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " !MA&%6Z$AJ5>0*  #^.0  &0
M@(%=E   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( &V$
M859AYS;4)P,  "H'   9              " @7B?  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ ;81A5CT)6/1F P  A@<  !D
M         ("!UJ(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " !MA&%6N L__78$  #8"@  &0              @(%SI@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &V$859L<O@VNPH  .H;
M   9              " @2"K  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ ;81A5F] TRG'#0  [2L  !D              ("!$K8
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !MA&%6F<[P
MDL@0  !#,0  &0              @($0Q   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( &V$8599N8EIX X  /PG   9
M  " @0_5  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M;81A5@MZBC0, P  PP8  !D              ("!)N0  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " !MA&%6>SQ$?54'  !P%   &0
M            @(%IYP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( &V$85;W L %Z0L  %PI   9              " @?7N  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ;81A5C^CGD\W!0
M$PP  !D              ("!%?L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " !MA&%6TGLU!,4D  #K>0  &0              @(&#
M  $ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( &V$85;0
MU&\B< 0  *$*   9              " @7\E 0!X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ ;81A5G0[F8Q3 P  $@<  !D
M     ("!)BH! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M" !MA&%63:TI<:$%   "$   &0              @(&P+0$ >&PO=V]R:W-H
M965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &V$8587T>1070,  .P'   9
M              " @8@S 0!X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L!
M A0#%     @ ;81A5F0T)))W P  C@<  !D              ("!'#<! 'AL
M+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !MA&%6<7+]VU4$
M  !["@  &0              @('*.@$ >&PO=V]R:W-H965T<R]S:&5E=#,R
M+GAM;%!+ 0(4 Q0    ( &V$85:+1R:K/0,  $P'   9              "
M@58_ 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ;81A
M5B4I+WBO!   ) P  !D              ("!RD(! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " !MA&%65J,="Q(#  #'!@  &0
M        @(&P1P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( &V$858?=#N&Z@<  )$4   9              " @?E* 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ;81A5IX3ASL+ P  S@8
M !D              ("!&E,! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " !MA&%66A)UP\X%  #$(   &0              @(%<5@$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( &V$85;V68<<
MU00  & =   9              " @6%< 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ ;81A5F;.(N_8 P  "Q$  !D
M ("!;6$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !M
MA&%6]+6\H8@#  "D#P  &0              @(%\90$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &V$858O]Y'VK 4  (4H   9
M          " @3MI 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ ;81A5D=;;DBT P  L1$  !D              ("!'F\! 'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !MA&%6;??&88T/   D
M[0  &0              @($)<P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( &V$859-7,+\208  .XD   9              " @<V"
M 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ;81A5HRX
M15KZ P  U1   !D              ("!38D! 'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " !MA&%6A#H&QHP)  #S80  &0
M    @(%^C0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M &V$858;R%&DM (  $D'   9              " @4&7 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ ;81A5JL=\)H[!   ?A0  !D
M             ("!+)H! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " !MA&%6HDWV0?0%  #$)0  &0              @(&>G@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( &V$85;5%AS?@ 4
M &PB   9              " @<FD 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ ;81A5F1+)5&Y @  (@@  !D              ("!
M@*H! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " !MA&%6
MQ;U/*<0"  "O"0  &0              @(%PK0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( &V$8593W'/#5 L  !N(   9
M      " @6NP 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ ;81A5A\0LD&= @  708  !D              ("!]KL! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " !MA&%6H4#@X-$"   /"@
M&0              @('*O@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( &V$85:B  !$"@,   \-   9              " @=+! 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ;81A5CM6K)'U
M$@   .\  !D              ("!$\4! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " !MA&%6QSCB.;0&  !V*P  &0
M@($_V $ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( &V$
M85;5HU$&1 ,  ,H*   9              " @2K? 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ ;81A5@8_X*$# P  ?0<  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( &V$858RF %]E04  $XM   9
M  " @0_X 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
M;81A5IY2SFNU!   8Q(  !D              ("!V_T! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " !MA&%6Q,2L<\($  #=&0  &0
M            @('' @( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( &V$85;$"06P? ,  *X+   9              " @< ' @!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ ;81A5O%U?&/4 @
MZ @  !D              ("!<PL" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " !MA&%6L1T@GHT&  #O,P  &0              @(%^
M#@( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( &V$85:M
MD)P@+PH  (R&   9              " @4(5 @!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ ;81A5AT"H]VN P  =Q   !D
M     ("!J!\" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &V$85;'UW-/1P(  -4K   :
M          "  <TR @!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( &V$858?G85O"0(  -@J   3              "  4PU @!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !2 %( =18  (8W @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>365</ContextCount>
  <ElementCount>477</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>104</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - The Company</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/TheCompany</Role>
      <ShortName>The Company</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Revenue Recognition and Concentration of Credit Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Collaborative Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreements</Role>
      <ShortName>Collaborative Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Short-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</Role>
      <ShortName>Short-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Certain Balance Sheet Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItems</Role>
      <ShortName>Certain Balance Sheet Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebt</Role>
      <ShortName>Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlan</Role>
      <ShortName>401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Geneos Therapeutics, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsInc</Role>
      <ShortName>Geneos Therapeutics, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</Role>
      <ShortName>Short-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Certain Balance Sheet Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsTables</Role>
      <ShortName>Certain Balance Sheet Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CertainBalanceSheetItems</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GoodwillandIntangibleAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtTables</Role>
      <ShortName>Convertible Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ConvertibleDebt</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/StockholdersEquity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Geneos Therapeutics, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncTables</Role>
      <ShortName>Geneos Therapeutics, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inovio.com/role/GeneosTherapeuticsInc</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails</Role>
      <ShortName>Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Collaborative Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CollaborativeAgreementsDetails</Role>
      <ShortName>Collaborative Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/CollaborativeAgreements</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails</Role>
      <ShortName>Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Fixed Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/FixedAssetsDetails</Role>
      <ShortName>Fixed Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/FixedAssetsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Convertible Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtNarrativeDetails</Role>
      <ShortName>Convertible Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails</Role>
      <ShortName>Convertible Debt - Balance Of Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Convertible Debt - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails</Role>
      <ShortName>Convertible Debt - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails</Role>
      <ShortName>Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails</Role>
      <ShortName>Income Taxes - Components of Pretax Loss from Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails</Role>
      <ShortName>Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - 401(k) Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/A401kPlanDetails</Role>
      <ShortName>401(k) Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/A401kPlan</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/RelatedPartyTransactions</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails</Role>
      <ShortName>Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ino-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inovio.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inovio.com/role/SubsequentEvents</ParentRole>
      <Position>74</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: ino:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash, us-gaap:DebtInstrumentConvertibleConversionRatio1, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:PropertyPlantAndEquipmentUsefulLife -  ino-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="ino-20221231.htm">ino-20221231.htm</File>
    <File>ino-12312022x10kex211.htm</File>
    <File>ino-12312022x10kex231.htm</File>
    <File>ino-12312022x10kex311.htm</File>
    <File>ino-12312022x10kex312.htm</File>
    <File>ino-12312022x10kex321.htm</File>
    <File>ino-20221231.xsd</File>
    <File>ino-20221231_cal.xml</File>
    <File>ino-20221231_def.xml</File>
    <File>ino-20221231_lab.xml</File>
    <File>ino-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ino-20221231_g1.jpg</File>
    <File>ino-20221231_g2.jpg</File>
    <File>ino-20221231_g3.jpg</File>
    <File>ino-20221231_g4.jpg</File>
    <File>ino-20221231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1115">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ino-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 37,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 1115,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 365,
   "dts": {
    "calculationLink": {
     "local": [
      "ino-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ino-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ino-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ino-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ino-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ino-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 741,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://www.inovio.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 9
   },
   "keyCustom": 94,
   "keyStandard": 383,
   "memberCustom": 47,
   "memberStandard": 49,
   "nsprefix": "ino",
   "nsuri": "http://www.inovio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.inovio.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - The Company",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.inovio.com/role/TheCompany",
     "shortName": "The Company",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Revenue Recognition and Concentration of Credit Risk",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk",
     "shortName": "Revenue Recognition and Concentration of Credit Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Collaborative Agreements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.inovio.com/role/CollaborativeAgreements",
     "shortName": "Collaborative Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Short-term Investments and Fair Value Measurements",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements",
     "shortName": "Short-term Investments and Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Certain Balance Sheet Items",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItems",
     "shortName": "Certain Balance Sheet Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Fixed Assets",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.inovio.com/role/FixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Goodwill and Intangible Assets",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Convertible Debt",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.inovio.com/role/ConvertibleDebt",
     "shortName": "Convertible Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.inovio.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorLocation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.inovio.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorLocation",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.inovio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.inovio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - 401(k) Plan",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.inovio.com/role/A401kPlan",
     "shortName": "401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.inovio.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Geneos Therapeutics, Inc.",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsInc",
     "shortName": "Geneos Therapeutics, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.inovio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Revenue Recognition and Concentration of Credit Risk (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables",
     "shortName": "Revenue Recognition and Concentration of Credit Risk (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Short-term Investments and Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables",
     "shortName": "Short-term Investments and Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Certain Balance Sheet Items (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsTables",
     "shortName": "Certain Balance Sheet Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Fixed Assets (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.inovio.com/role/FixedAssetsTables",
     "shortName": "Fixed Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Convertible Debt (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.inovio.com/role/ConvertibleDebtTables",
     "shortName": "Convertible Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.inovio.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.inovio.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Geneos Therapeutics, Inc. (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncTables",
     "shortName": "Geneos Therapeutics, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:WorkingCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Table (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i666a23e01c6442398866e53b58f368d5_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails",
     "shortName": "Summary of Significant Accounting Policies - Summary of Stock-Based Compensation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i666a23e01c6442398866e53b58f368d5_D20220101-20221231",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails",
     "shortName": "Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ib54af4db6f934822936c9df96da62d29_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxLiabilitiesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails",
     "shortName": "Revenue Recognition and Concentration of Credit Risk- Revenue from External Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i24234386041445bca5cb6066f1a957bc_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
     "shortName": "Revenue Recognition and Concentration of Credit Risk - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Collaborative Agreements (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.inovio.com/role/CollaborativeAgreementsDetails",
     "shortName": "Collaborative Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "if01705c616d24d9da3e0014282dd5837_D20210101-20210131",
      "decimals": "-5",
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementsUpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Summary of Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Short-term Investments and Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i72d5d82697444dd38fb5e557609c0c36_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EstimatedInsuranceRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
     "shortName": "Certain Balance Sheet Items - Prepaid and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EstimatedInsuranceRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
     "shortName": "Certain Balance Sheet Items - Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableTradeCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Fixed Assets (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.inovio.com/role/FixedAssetsDetails",
     "shortName": "Fixed Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Summary of Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Convertible Debt - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
     "shortName": "Convertible Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i1242ebcd358e4468bb5a2b7b601e0e98_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i462df0bfe2224796bd3e4784559e9ff7_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Convertible Debt - Balance Of Convertible Debt (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
     "shortName": "Convertible Debt - Balance Of Convertible Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i462df0bfe2224796bd3e4784559e9ff7_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "ino:DebtInstrumentConvertibleDebtConvertedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i462df0bfe2224796bd3e4784559e9ff7_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Convertible Debt - Schedule of Maturities (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
     "shortName": "Convertible Debt - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ibda181353d814282bfd46ddc089e9aed_I20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i29af49ccbb494cac8290ea49a3d605f0_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ino:ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i6327975f86354d84adb2cb38dcd5ea52_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity Under Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i2ce9a943aa164c8c8f02796513f3578c_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
     "shortName": "Stockholders' Equity - Summary of RSU Activity Under Equity Incentive Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ifdb2a873738e472696885e376b3e567b_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i03dda587e7244ca090249a8e7cfe2932_D20191001-20191231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "ino:LesseeOperatingLeaseAreaofLandUnderLease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
     "shortName": "Commitments and Contingencies - Summary of Maturities of Operating Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Income Taxes - Components of Pretax Loss from Operations (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails",
     "shortName": "Income Taxes - Components of Pretax Loss from Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Income Taxes - Reconciliation of Income Taxes (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails",
     "shortName": "Income Taxes - Reconciliation of Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.inovio.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxExpenseBenefit",
       "us-gaap:IncomeTaxExpenseBenefit",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i3d82d3ec063a42378ab880fcb038f565_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:OperatingLossCarryforwardsExpiringinTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
     "shortName": "Income Taxes - Expected Expirations of Federal and State Losses and Credits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ino:ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i3d82d3ec063a42378ab880fcb038f565_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:OperatingLossCarryforwardsExpiringinTwoYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i6327975f86354d84adb2cb38dcd5ea52_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i1bb91b86850c4019853cfafe96543ff8_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i91313ea012fb4e29a82373b1216240c7_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i91313ea012fb4e29a82373b1216240c7_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - 401(k) Plan (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.inovio.com/role/A401kPlanDetails",
     "shortName": "401(k) Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementAmendedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Related Party Transactions (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
     "shortName": "Related Party Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i14d427675b944f909bde3b903e23ceb5_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "ino:CollaborativeAgreementAmendedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Geneos Therapeutics, Inc. - Narrative (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
     "shortName": "Geneos Therapeutics, Inc. - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i876fc07681a44ee487cf4e512393be2a_I20200630",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
     "shortName": "Geneos Therapeutics, Inc. - Preferred Stock Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "i0073c18a8e7f44daadd9ab703b7645a8_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Subsequent Events (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.inovio.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "if1a9994a0e9c42d682a6382e17a889cd_I20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ino-20221231.htm",
      "contextRef": "ief1d49a8c3d94e6795dc03ce528f0473_D20220101-20221231",
      "decimals": "0",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 104,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r822",
      "r823",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.inovio.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ino_A2007IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2007 Incentive Plan [Member]",
        "label": "2007 Incentive Plan [Member]",
        "terseLabel": "2007 Incentive Plan"
       }
      }
     },
     "localname": "A2007IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2016IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Incentive Plan [Member]",
        "label": "2016 Incentive Plan [Member]",
        "terseLabel": "2016 Incentive Plan"
       }
      }
     },
     "localname": "A2016IncentivePlanMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A2022InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Inducement Plan",
        "label": "2022 Inducement Plan [Member]",
        "terseLabel": "2022 Inducement Plan"
       }
      }
     },
     "localname": "A2022InducementPlanMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_A6.50ConvertibleSeniorNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "label": "6.50% Convertible Senior Notes Due 2024 [Member]",
        "terseLabel": "6.50% Convertible Senior Notes Due 2024",
        "verboseLabel": "Convertible Senior Notes"
       }
      }
     },
     "localname": "A6.50ConvertibleSeniorNotesDue2024Member",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AccountsPayableAndAccruedExpensesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Expenses [Line Items]",
        "terseLabel": "Accounts Payable and Accrued Expenses [Line Items]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesLineItems",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_AccountsPayableAndAccruedExpensesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Payable and Accrued Expenses",
        "label": "Accounts Payable and Accrued Expenses [Table]",
        "terseLabel": "Accounts Payable and Accrued Expenses [Table]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesTable",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expense, Current",
        "label": "Accrued Clinical Trial Expense, Current",
        "verboseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_AdvaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advaccine",
        "label": "Advaccine [Member]",
        "terseLabel": "Advaccine"
       }
      }
     },
     "localname": "AdvaccineMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AllOtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All Other Customers [Member]",
        "label": "All Other Customers [Member]",
        "terseLabel": "All other, including affiliated entities"
       }
      }
     },
     "localname": "AllOtherCustomersMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AnnualMaintenancePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Maintenance Period",
        "label": "Annual Maintenance Period",
        "terseLabel": "Annual maintenance period"
       }
      }
     },
     "localname": "AnnualMaintenancePeriod",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ApolloBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ApolloBio [Member]",
        "label": "ApolloBio [Member]",
        "terseLabel": "ApolloBio"
       }
      }
     },
     "localname": "ApolloBioMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumptions used in estimation of fair value of stock options.",
        "label": "Assumptions Used In Estimation Of Fair Value Of Stock Options [Abstract]",
        "verboseLabel": "Summary of assumptions used to estimate the fair value of stock options"
       }
      }
     },
     "localname": "AssumptionsUsedInEstimationOfFairValueOfStockOptionsAbstract",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ino_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.inovio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ino_August2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August 2019 Convertible Bonds [Member]",
        "label": "August 2019 Convertible Bonds [Member]",
        "terseLabel": "August 2019 Bonds"
       }
      }
     },
     "localname": "August2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill And Melinda Gates Foundation",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_BiojectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bioject [Member]",
        "label": "Bioject [Member]",
        "terseLabel": "Bioject"
       }
      }
     },
     "localname": "BiojectMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CELLECTRA3PSPProprietarySmartDeviceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C E L L E C T R A3 P S P Proprietary Smart Device",
        "label": "C E L L E C T R A3 P S P Proprietary Smart Device [Member]",
        "terseLabel": "CELLECTRA 3PSP Proprietary Smart Device"
       }
      }
     },
     "localname": "CELLECTRA3PSPProprietarySmartDeviceMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CEPIMERSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CEPI MERS",
        "label": "CEPI MERS [Member]",
        "terseLabel": "CEPI MERS"
       }
      }
     },
     "localname": "CEPIMERSMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CaliforniaIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Income Tax Authority [Member]",
        "label": "California Income Tax Authority [Member]",
        "terseLabel": "California"
       }
      }
     },
     "localname": "CaliforniaIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CertainBalanceSheetItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certain Balance Sheet Items",
        "label": "Certain Balance Sheet Items [Abstract]"
       }
      }
     },
     "localname": "CertainBalanceSheetItemsAbstract",
     "nsuri": "http://www.inovio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "ino_ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets",
        "label": "Change In Prepaid Expenses And Other Current Assets, Fixed Assets",
        "terseLabel": "Change in prepaid expenses and other current assets related to fixed assets"
       }
      }
     },
     "localname": "ChangeInPrepaidExpensesAndOtherCurrentAssetsFixedAssets",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ChangeInValueOfInvestmentsInAffiliatedCompany": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 25.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of the change in fair value of the investment in affiliated entity. This investment is measured at fair value on a recurring basis.",
        "label": "Change in Value of Investments in Affiliated Company",
        "negatedLabel": "Loss (gain) on equity investment in affiliated entities",
        "verboseLabel": "(Loss) gain on investment in affiliated entities"
       }
      }
     },
     "localname": "ChangeInValueOfInvestmentsInAffiliatedCompany",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CoalitionforEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Coalition for Epidemic Preparedness Innovations [Member]",
        "label": "Coalition for Epidemic Preparedness Innovations [Member]",
        "terseLabel": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionforEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_CollaborationAgreementAdditionalRevenueToBeAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "label": "Collaboration Agreement, Additional Revenue To Be Achieved",
        "terseLabel": "Additional revenue to be achieved"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalRevenueToBeAchieved",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementPaymentEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Payment Earned",
        "label": "Collaboration Agreement, Payment Earned",
        "terseLabel": "Collaboration agreement, payment earned"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentEarned",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborationAgreementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Royalty Period",
        "label": "Collaboration Agreement, Royalty Period",
        "terseLabel": "Obligation period to pay royalties"
       }
      }
     },
     "localname": "CollaborationAgreementRoyaltyPeriod",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementAmendedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Amended Amount",
        "label": "Collaborative Agreement, Amended Amount",
        "terseLabel": "Agreement amended amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAmendedAmount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Amount",
        "label": "Collaborative Agreement, Awarded Amount",
        "terseLabel": "Awarded amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedAmount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedExercisedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Exercised Amount",
        "label": "Collaborative Agreement, Awarded Exercised Amount",
        "terseLabel": "Awarded exercised amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedExercisedAmount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementAwardedOptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Awarded Option Amount",
        "label": "Collaborative Agreement, Awarded Option Amount",
        "terseLabel": "Awarded option amount"
       }
      }
     },
     "localname": "CollaborativeAgreementAwardedOptionAmount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementExpensesToReimburse": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Expenses To Reimburse",
        "label": "Collaborative Agreement, Expenses To Reimburse",
        "terseLabel": "Expenses to reimburse"
       }
      }
     },
     "localname": "CollaborativeAgreementExpensesToReimburse",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received",
        "label": "Collaborative Agreement, Funding Received",
        "terseLabel": "Funding received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingReceived",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementFundingToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Funding Received for Research and Development",
        "label": "Collaborative Agreement, Funding To Be Received",
        "terseLabel": "Collaborative agreement, funding to be received"
       }
      }
     },
     "localname": "CollaborativeAgreementFundingToBeReceived",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "label": "Collaborative Agreement, Number of Days Written Notice Before Termination",
        "terseLabel": "Agreement, number of days written notice before termination"
       }
      }
     },
     "localname": "CollaborativeAgreementNumberofDaysWrittenNoticeBeforeTermination",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodFromEffectiveDateForTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period From Effective Date For Termination",
        "label": "Collaborative Agreement, Period From Effective Date For Termination",
        "terseLabel": "Agreement period from effective date for termination"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodFromEffectiveDateForTermination",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "label": "Collaborative Agreement, Period to Receive Funding for Research and Development",
        "terseLabel": "Collaborative agreement, period to receive funding for research and development"
       }
      }
     },
     "localname": "CollaborativeAgreementPeriodtoReceiveFundingforResearchandDevelopment",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CollaborativeAgreementsUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreements, Upfront Payment Received",
        "label": "Collaborative Agreements, Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "CollaborativeAgreementsUpfrontPaymentReceived",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementFixedPriceContractAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "label": "Collaborative Arrangement, Fixed-Price Contract, Amount Awarded",
        "terseLabel": "Purchase price, procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementFixedPriceContractAmountAwarded",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementRevenueFromTheProcurementContract": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "label": "Collaborative Arrangement , Revenue from the Procurement Contract",
        "terseLabel": "Procurement contract"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueFromTheProcurementContract",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_CommonStockSharesIssuedSharePriceConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Shares Issued, Share Price, Consecutive Trading Days",
        "label": "Common Stock, Shares Issued, Share Price, Consecutive Trading Days",
        "terseLabel": "Trading days"
       }
      }
     },
     "localname": "CommonStockSharesIssuedSharePriceConsecutiveTradingDays",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_ComprehensiveIncomeLossTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss), Tax Expense (Benefit)",
        "label": "Comprehensive Income (Loss), Tax Expense (Benefit)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossTaxExpenseBenefit",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Bonds [Member]",
        "label": "Convertible Bonds [Member]",
        "terseLabel": "Convertible Bonds"
       }
      }
     },
     "localname": "ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion, Conversion Price Per Share",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversionConversionPricePerShare",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_DNAEncodedMonoclonalAntibodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "D N A Encoded Monoclonal Antibody Technology",
        "label": "D N A Encoded Monoclonal Antibody Technology [Member]",
        "terseLabel": "D N A Encoded Monoclonal Antibody Technology"
       }
      }
     },
     "localname": "DNAEncodedMonoclonalAntibodyTechnologyMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DebtInstrumentConvertibleDebtConvertedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Converted Amount",
        "label": "Debt Instrument, Convertible Debt, Converted Amount",
        "negatedTerseLabel": "Principal amount converted into common shares"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtConvertedAmount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DebtSecuritiesAvailableforSaleContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale contractual maturity.",
        "label": "Debt Securities, Available-for-Sale Contractual Maturity",
        "terseLabel": "Contractual Maturity"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableforSaleContractualMaturity",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_DebtinstrumentAccruedInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Accrued Interest",
        "label": "Debt instrument, Accrued Interest",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "DebtinstrumentAccruedInterest",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_December2019ConvertibleBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2019 Convertible Bonds [Member]",
        "label": "December 2019 Convertible Bonds [Member]",
        "terseLabel": "December 2019 Bonds"
       }
      }
     },
     "localname": "December2019ConvertibleBondsMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, Current",
        "label": "Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability"
       }
      }
     },
     "localname": "DeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate",
        "label": "Deferred Grant Funding, From Affiliate",
        "terseLabel": "Deferred grant funding from affiliate"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliate",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredGrantFundingFromAffiliateCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Grant Funding, From Affiliate, Current",
        "label": "Deferred Grant Funding, From Affiliate, Current",
        "terseLabel": "Grant funding liability from affiliated entities"
       }
      }
     },
     "localname": "DeferredGrantFundingFromAffiliateCurrent",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset, Interest Expense",
        "label": "Deferred Tax Asset, Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestExpense",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetsIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Intangible Assets",
        "label": "Deferred Tax Assets, Intangible Assets",
        "terseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsIntangibleAssets",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxAssetsOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Lease Liability",
        "label": "Deferred Tax Assets, Operating Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiability",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxLiabilitiesFinancingArrangementDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Financing Arrangement, Discount",
        "label": "Deferred Tax Liabilities, Financing Arrangement, Discount",
        "negatedTerseLabel": "Note discount"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangementDiscount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_DepartmentOfDefenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Department Of Defence",
        "label": "Department Of Defence [Member]",
        "terseLabel": "Department Of Defence"
       }
      }
     },
     "localname": "DepartmentOfDefenceMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_DoDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DoD [Member]",
        "label": "DoD [Member]",
        "terseLabel": "U.S. Department of Defense"
       }
      }
     },
     "localname": "DoDMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 12.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary",
        "label": "Effective Income Tax Rate Reconciliation, Deconsolidation of Subsidiary",
        "terseLabel": "Deconsolidation of subsidiary"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationOfSubsidiary",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible, Loss on Extinguishment of Debt",
        "terseLabel": "Nondeductible loss on extinguishment of debt"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleLossOnExtinguishmentOfDebt",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "label": "Effective Income Tax Reconciliation, Expired Net Operating Losses and Credits",
        "terseLabel": "Expired NOLs and credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationExpiredNetOperatingLossesandCredits",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 13.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "label": "Effective Income Tax Reconciliation, Limited Net Operating Losses and Credits",
        "terseLabel": "Limited NOLs and credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationLimitedNetOperatingLossesandCredits",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_EmployeesAndDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Directors [Member]",
        "label": "Employees and Directors [Member]",
        "terseLabel": "Employees and Directors"
       }
      }
     },
     "localname": "EmployeesAndDirectorsMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_FormerPresidentAndChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former President and Chief Executive Officer",
        "label": "Former President and Chief Executive Officer [Member]",
        "terseLabel": "Former President and Chief Executive Officer"
       }
      }
     },
     "localname": "FormerPresidentAndChiefExecutiveOfficerMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GainLossOnRemeasurementOfEquityMethodInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Remeasurement Of Equity Method Investment",
        "label": "Gain (Loss) On Remeasurement Of Equity Method Investment",
        "negatedTerseLabel": "Gain on remeasurement of investment in Geneos"
       }
      }
     },
     "localname": "GainLossOnRemeasurementOfEquityMethodInvestment",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GeneosTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geneos Therapeutics, Inc. [Member]",
        "label": "Geneos Therapeutics, Inc. [Member]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "GeneosTherapeuticsInc.Member",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_GoodwillAndIntangibleAssetsGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets gross.",
        "label": "Goodwill and Intangible Assets Gross",
        "terseLabel": "Total goodwill and intangible assets, gross"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGross",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GoodwillAndIntangibleAssetsNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets net.",
        "label": "Goodwill and Intangible Assets Net",
        "totalLabel": "Total goodwill and intangible assets, net book value"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsNet",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantProceedsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Proceeds Received",
        "label": "Grant Proceeds Received",
        "terseLabel": "Grant proceeds received"
       }
      }
     },
     "localname": "GrantProceedsReceived",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_GrantRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Revenue [Policy Text Block]",
        "label": "Grant Revenue [Policy Text Block]",
        "terseLabel": "Grants"
       }
      }
     },
     "localname": "GrantRevenuePolicyTextBlock",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_INO4800Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I N O4800",
        "label": "I N O4800 [Member]",
        "terseLabel": "IN O4800"
       }
      }
     },
     "localname": "INO4800Member",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "label": "Income (Loss) From Equity Method Investments, Realized And Allocated to Investment",
        "terseLabel": "Loss from equity method investment, recorded and allocated to investment"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsRealizedAndAllocatedToInvestment",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncomeTaxReconciliationStatuteLimitations": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Reconciliation, Statute Limitations",
        "label": "Income Tax Reconciliation, Statute Limitations",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStatuteLimitations",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInAccruedClinicalTrialExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "label": "Increase (Decrease) In Accrued Clinical Trial Expense",
        "terseLabel": "Accrued clinical trial expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalTrialExpense",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset (Lease Liability), Net",
        "terseLabel": "Operating lease right-of-use assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetLeaseLiabilityNet",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_IncreaseDecreaseinDeferredGrantFundingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Grant Funding, Current",
        "label": "Increase (Decrease) in Deferred Grant Funding, Current",
        "terseLabel": "Grant funding liability, including from affiliated entity"
       }
      }
     },
     "localname": "IncreaseDecreaseinDeferredGrantFundingCurrent",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_KoreanStateIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Korean State Income Tax Authority",
        "label": "Korean State Income Tax Authority [Member]",
        "terseLabel": "Korean State Income Tax Authority"
       }
      }
     },
     "localname": "KoreanStateIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LassaFeverAndMERSVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lassa Fever And MERS Vaccine [Member]",
        "label": "Lassa Fever And MERS Vaccine [Member]",
        "terseLabel": "Lassa Fever And MERS Vaccine"
       }
      }
     },
     "localname": "LassaFeverAndMERSVaccineMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_LesseeNumberOfLeaseAgreementsEnteredInto": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Number Of Lease Agreements Entered Into",
        "label": "Lessee, Number Of Lease Agreements Entered Into",
        "terseLabel": "Number of lease agreements entered into"
       }
      }
     },
     "localname": "LesseeNumberOfLeaseAgreementsEnteredInto",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ino_LesseeOperatingLeaseAreaofLandUnderLease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Area of Land Under Lease",
        "label": "Lessee, Operating Lease, Area of Land Under Lease",
        "terseLabel": "Lessee, operating lease, area of land under lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAreaofLandUnderLease",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "ino_LossContingencyEstimateOfPossibleLossValueOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Possible Loss, Value of Shares",
        "label": "Loss Contingency, Estimate of Possible Loss, Value of Shares",
        "terseLabel": "Estimate of shares settlement"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLossValueOfShares",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_McDermidVInovioPharmaceuticalsIncAndJJosephKimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim",
        "label": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim [Member]",
        "terseLabel": "McDermid v. Inovio Pharmaceuticals, Inc. and J. Joseph Kim"
       }
      }
     },
     "localname": "McDermidVInovioPharmaceuticalsIncAndJJosephKimMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_MutualFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mutual funds.",
        "label": "Mutual Funds [Member]",
        "terseLabel": "Mutual funds",
        "verboseLabel": "Mutual funds"
       }
      }
     },
     "localname": "MutualFundsMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NonCashInterestExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash Interest Expense",
        "label": "Non-Cash Interest Expense",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "NonCashInterestExpense",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_NonEmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non employee.",
        "label": "Non Employee [Member]",
        "terseLabel": "Non Employee"
       }
      }
     },
     "localname": "NonEmployeeMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of potential shares authorized for issuance under a share-based compensation plan.",
        "label": "Number Of Potential Shares Authorized For Issuance Under Share Based Compensation Plan",
        "verboseLabel": "Number of potential shares authorized for issuance under a share-based compensation plan (in shares)"
       }
      }
     },
     "localname": "NumberOfPotentialSharesAuthorizedForIssuanceUnderShareBasedCompensationPlan",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of vested restricted stock outstanding under the plan.",
        "label": "Number of Shares of Vested Restricted Stock Outstanding Under Plan",
        "verboseLabel": "Number of shares of vested restricted stock outstanding under the plan (in shares)"
       }
      }
     },
     "localname": "NumberOfSharesOfVestedRestrictedStockOutstandingUnderPlan",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "label": "Operating Loss Carryforwards, Expiration in Period, Statute Limitations, Net",
        "terseLabel": "Net operating loss carryforwards that will expire due to IRC Section 382 limitations"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationinPeriodStatuteLimitationsNet",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringInSixYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Six Years",
        "label": "Operating Loss Carryforwards, Expiring in Six Years",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringInSixYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Five Years",
        "label": "Operating Loss Carryforwards, Expiring in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinFiveYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Four Years",
        "label": "Operating Loss Carryforwards, Expiring in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinFourYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Three Years",
        "label": "Operating Loss Carryforwards, Expiring in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinThreeYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsExpiringinTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Expiring in Two Years",
        "label": "Operating Loss Carryforwards, Expiring in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpiringinTwoYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_OperatingLossCarryforwardsIndefinitelyCarryforward": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLossCarryforwards",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "label": "Operating Loss Carryforwards, Indefinitely Carryforward",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIndefinitelyCarryforward",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PLSaffiliatedentityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PLS (affiliated entity) [Member]",
        "label": "PLS (affiliated entity) [Member]",
        "terseLabel": "PLS (affiliated entity)"
       }
      }
     },
     "localname": "PLSaffiliatedentityMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PennsylvaniaStateIncomeTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pennsylvania State Income Tax Authority [Member]",
        "label": "Pennsylvania State Income Tax Authority [Member]",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PennsylvaniaStateIncomeTaxAuthorityMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences, Inc. [Member]",
        "label": "Plumbline Life Sciences, Inc. [Member]",
        "terseLabel": "Plumbline Life Sciences, Inc. (affiliated entity)"
       }
      }
     },
     "localname": "PlumblineLifeSciencesIncMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlumblineLifeSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plumbline Life Sciences [Member]",
        "label": "Plumbline Life Sciences [Member]",
        "terseLabel": "Plumbline Life Sciences"
       }
      }
     },
     "localname": "PlumblineLifeSciencesMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PlymouthMeetingPennsylvaniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plymouth Meeting, Pennsylvania [Member]",
        "label": "Plymouth Meeting, Pennsylvania [Member]",
        "terseLabel": "Plymouth Meeting, Pennsylvania"
       }
      }
     },
     "localname": "PlymouthMeetingPennsylvaniaMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amounts paid to related parties in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event.",
        "label": "Prepaid Expenses and Other Current Assets from Affiliated Entity",
        "verboseLabel": "Prepaid expenses and other current assets from affiliated entities"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsFromAffiliatedEntity",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PrepaidManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Manufacturing Expenses, Current",
        "label": "Prepaid Manufacturing Expenses, Current",
        "terseLabel": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpensesCurrent",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "label": "Proceeds From (Payments For) Stock Options Exercised and Exercise Of Warrants, Net Of Tax Withholdings",
        "terseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForStockOptionsExercisedandExerciseOfWarrantsNetOfTaxWithholdings",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ProceedsfromStockOptionandWarrantExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Stock Option and Warrant Exercises",
        "label": "Proceeds from Stock Option and Warrant Exercises",
        "verboseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsfromStockOptionandWarrantExercises",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_PropertyPlantAndEquipmentDisposedOfBySale": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property, Plant and Equipment, Disposed Of By Sale",
        "label": "Property, Plant and Equipment, Disposed Of By Sale",
        "terseLabel": "Property, plant and equipment sold"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposedOfBySale",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_RangeOfExercisePricesFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Five [Member]",
        "label": "Range of Exercise Prices Five [Member]",
        "terseLabel": "$12.01-$15.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesFiveMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Four [Member]",
        "label": "Range of Exercise Prices Four [Member]",
        "terseLabel": "$9.01-$12.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesFourMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices One [Member]",
        "label": "Range of Exercise Prices One [Member]",
        "terseLabel": "$1.56-$3.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesOneMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesSixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Five [Member]",
        "label": "Range of Exercise Prices Six [Member]",
        "terseLabel": "$15.01-$25.62"
       }
      }
     },
     "localname": "RangeOfExercisePricesSixMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Three [Member]",
        "label": "Range of Exercise Prices Three [Member]",
        "terseLabel": "$6.01-$9.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesThreeMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RangeOfExercisePricesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of Exercise Prices Two [Member]",
        "label": "Range of Exercise Prices Two [Member]",
        "terseLabel": "$3.01-$6.00"
       }
      }
     },
     "localname": "RangeOfExercisePricesTwoMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_RestructuringAndRelatedCostExpectedAnnualSavings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and Related Cost, Expected Annual Savings",
        "label": "Restructuring and Related Cost, Expected Annual Savings",
        "terseLabel": "Expected annual savings"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedAnnualSavings",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_SARSCoV2COVID19VaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "S A R S Co V2 C O V I D19 Vaccine",
        "label": "S A R S Co V2 C O V I D19 Vaccine [Member]",
        "terseLabel": "COVID19 Vaccine"
       }
      }
     },
     "localname": "SARSCoV2COVID19VaccineMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SaleOfStockSalesProceedsOfAnyCommonStockPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "label": "Sale of Stock, Sales Proceeds of Any Common Stock, Percentage",
        "terseLabel": "Sales Agents will be entitled to compensation"
       }
      }
     },
     "localname": "SaleOfStockSalesProceedsOfAnyCommonStockPercentage",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement [Member]",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SanDiegoCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "San Diego, California [Member]",
        "label": "San Diego, California [Member]",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "SanDiegoCaliforniaMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Prepaid Expenses And Other Current Assets",
        "label": "Schedule Of Prepaid Expenses And Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "label": "Schedule of Operating Loss and Tax Credit Carryforward Expirations [Table Text Block]",
        "terseLabel": "Schedule Of Operating Loss And Tax Credit Carryforward Expirations"
       }
      }
     },
     "localname": "ScheduleofOperatingLossandTaxCreditCarryforwardExpirationsTableTextBlock",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ino_SeriesA2OnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 One Preferred Stock",
        "label": "Series A-2 One Preferred Stock [Member]",
        "terseLabel": "Series A-2 One Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2OnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SeriesAOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A One Preferred Stock [Member]",
        "label": "Series A One Preferred Stock [Member]",
        "terseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesAOnePreferredStockMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_ServiceBasedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Based Restricted Stock Units",
        "label": "Service Based Restricted Stock Units [Member]",
        "terseLabel": "Service-based restricted stock units"
       }
      }
     },
     "localname": "ServiceBasedRestrictedStockUnitsMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "label": "Settlement Of Receivable With Shares Of Common Stock From Equity Security",
        "negatedTerseLabel": "Settlement of receivable with shares of common stock from affiliated entity (PLS)"
       }
      }
     },
     "localname": "SettlementOfReceivableWithSharesOfCommonStockFromEquitySecurity",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Other Than Options, Percentage Settled In Cash",
        "terseLabel": "Awards settled in cash, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityOtherThanOptionsPercentageSettledInCash",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum contractual term.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Maximum Contractual Term",
        "verboseLabel": "Contractual year term of incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumContractualTerm",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ino_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Outstanding, Aggregate intrinsic value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized",
        "terseLabel": "Increase in number of shares authorized (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseInNumberofSharesAuthorized",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of options expected to vest (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsExpectedtoVestOutstandingNumber",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Other Than Options, Expected to Vest, Outstanding, Number",
        "terseLabel": "RSU's expected to vest (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOtherThanOptionsExpectedtoVestOutstandingNumber",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockPurchaseAgreementCommitmentOfAdditionalInvestment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "label": "Stock Purchase Agreement, Commitment Of Additional Investment",
        "terseLabel": "Stock purchase agreement, commitment of additional investment"
       }
      }
     },
     "localname": "StockPurchaseAgreementCommitmentOfAdditionalInvestment",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementAggregateNumberofSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "label": "Stock Sale Agreement, Aggregate Number of Shares Issued",
        "terseLabel": "Stock sale agreement, aggregate number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateNumberofSharesIssued",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ino_StockSaleAgreementAggregateProceedsFromIssuanceOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "label": "Stock Sale Agreement, Aggregate Proceeds From Issuance Of Stock",
        "terseLabel": "Stock sale agreement, aggregate proceeds from issuance of stock"
       }
      }
     },
     "localname": "StockSaleAgreementAggregateProceedsFromIssuanceOfStock",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSaleAgreementWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sale Agreement Weighted Average Price Per Share",
        "label": "Stock Sale Agreement, Weighted Average Price Per Share",
        "terseLabel": "Sales made at a weighted average price (in dollars per share)"
       }
      }
     },
     "localname": "StockSaleAgreementWeightedAveragePricePerShare",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ino_StockSalesAgreementMaximumAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Maximum Authorized Amount",
        "label": "Stock Sales Agreement, Maximum Authorized Amount",
        "terseLabel": "Common stock aggregate offering price"
       }
      }
     },
     "localname": "StockSalesAgreementMaximumAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_StockSalesAgreementRemainingAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Sales Agreement, Remaining Authorized Amount",
        "label": "Stock Sales Agreement, Remaining Authorized Amount",
        "terseLabel": "Remaining authorized amount"
       }
      }
     },
     "localname": "StockSalesAgreementRemainingAuthorizedAmount",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxBenefitsExpired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Benefits Expired",
        "label": "Tax Benefits Expired",
        "terseLabel": "Tax benefits expired"
       }
      }
     },
     "localname": "TaxBenefitsExpired",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardCarryforwardIndefinitely": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Carryforward Indefinitely",
        "label": "Tax Credit Carryforward, Carryforward Indefinitely",
        "terseLabel": "Indefinite"
       }
      }
     },
     "localname": "TaxCreditCarryforwardCarryforwardIndefinitely",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringInFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Four Years",
        "label": "Tax Credit Carryforward, Expiring in Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringInFourYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringInSixYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Six Years",
        "label": "Tax Credit Carryforward, Expiring in Six Years",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringInSixYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringInThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Three Years",
        "label": "Tax Credit Carryforward, Expiring in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringInThreeYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Five Years",
        "label": "Tax Credit Carryforward, Expiring in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinFiveYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TaxCreditCarryforwardExpiringinTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxCreditCarryforwardAmount",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Expiring in Two Years",
        "label": "Tax Credit Carryforward, Expiring in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpiringinTwoYears",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_TheWistarInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Wistar Institute [Member]",
        "label": "The Wistar Institute [Member]",
        "terseLabel": "The Wistar Institute"
       }
      }
     },
     "localname": "TheWistarInstituteMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten Public Offering",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ino_UnrecognizedTaxBenefitsIncreaseDecreaseInOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) In Other",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) In Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseInOther",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ino_WorkingCapital": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of current assets and current liabilities.",
        "label": "Working Capital",
        "verboseLabel": "Working capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.inovio.com/20221231",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r288",
      "r289",
      "r425",
      "r454",
      "r780",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r238",
      "r294",
      "r301",
      "r307",
      "r374",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r602",
      "r605",
      "r607",
      "r608",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r238",
      "r294",
      "r301",
      "r307",
      "r374",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r602",
      "r605",
      "r607",
      "r608",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r238",
      "r294",
      "r301",
      "r307",
      "r374",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r602",
      "r605",
      "r607",
      "r608",
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r859"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r351",
      "r799",
      "r879",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r512",
      "r700",
      "r736",
      "r773",
      "r774",
      "r796",
      "r807",
      "r817",
      "r876",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r512",
      "r700",
      "r736",
      "r773",
      "r774",
      "r796",
      "r807",
      "r817",
      "r876",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r351",
      "r799",
      "r879",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r349",
      "r702",
      "r797",
      "r816",
      "r871",
      "r872",
      "r879",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r349",
      "r702",
      "r797",
      "r816",
      "r871",
      "r872",
      "r879",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r494",
      "r512",
      "r540",
      "r541",
      "r542",
      "r676",
      "r700",
      "r736",
      "r773",
      "r774",
      "r796",
      "r807",
      "r817",
      "r869",
      "r876",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r409",
      "r494",
      "r512",
      "r540",
      "r541",
      "r542",
      "r676",
      "r700",
      "r736",
      "r773",
      "r774",
      "r796",
      "r807",
      "r817",
      "r869",
      "r876",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r772",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r772",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r288",
      "r289",
      "r425",
      "r454",
      "r781",
      "r782"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r513",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r307",
      "r513",
      "r829",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r307",
      "r513",
      "r829",
      "r830",
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r859",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]",
        "verboseLabel": "Title of Individual with Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r773",
      "r774",
      "r922",
      "r924",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average Useful Life (Yrs)"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "auth_ref": [
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity.",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "Accounting Standards Update 2020-06"
       }
      }
     },
     "localname": "AccountingStandardsUpdate202006Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r295",
      "r296",
      "r297",
      "r358",
      "r359",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r582",
      "r583",
      "r584",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r640",
      "r641",
      "r644",
      "r645",
      "r646",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "totalLabel": "Accounts payable and accrued liabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r202",
      "r224"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Accounts Payable, Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r728",
      "r766"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r352",
      "r353"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r188",
      "r190",
      "r220",
      "r255",
      "r850"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable, Related Parties",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r188",
      "r190",
      "r255",
      "r850"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts receivable from affiliated entities"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r17",
      "r779"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued Salaries, Current"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r96",
      "r246"
     ],
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Accumulated Depreciation and Amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r256",
      "r729",
      "r744",
      "r748"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r28",
      "r31",
      "r161",
      "r660",
      "r739",
      "r740",
      "r839",
      "r840",
      "r841",
      "r851",
      "r852",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r9",
      "r815"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "negatedLabel": "Additional paid-in capital",
        "negatedTerseLabel": "Additional paid-in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r546",
      "r547",
      "r548",
      "r851",
      "r852",
      "r853",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r295",
      "r296",
      "r297",
      "r298",
      "r307",
      "r358",
      "r359",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r546",
      "r547",
      "r548",
      "r570",
      "r571",
      "r572",
      "r573",
      "r582",
      "r583",
      "r584",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r640",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r704",
      "r705",
      "r706",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r140",
      "r141",
      "r516"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r544"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r257",
      "r356",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r53",
      "r83",
      "r89"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "verboseLabel": "Total antidilutive securities (shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r193",
      "r216",
      "r250",
      "r284",
      "r333",
      "r343",
      "r347",
      "r370",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r591",
      "r595",
      "r618",
      "r815",
      "r874",
      "r875",
      "r920"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r242",
      "r259",
      "r284",
      "r370",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r591",
      "r595",
      "r618",
      "r815",
      "r874",
      "r875",
      "r920"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "verboseLabel": "Gross\u00a0Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross\u00a0Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r361",
      "r383"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Sale [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r73",
      "r360",
      "r383",
      "r721"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair\u00a0Market\u00a0Value",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Liquidity"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r57",
      "r58",
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Amounts accrued for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r55",
      "r244",
      "r777"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r838"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r50",
      "r55",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r50",
      "r182"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.",
        "label": "Cash Divested from Deconsolidation",
        "negatedTerseLabel": "Decrease in cash resulting from the deconsolidation of Geneos"
       }
      }
     },
     "localname": "CashDivestedFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r284",
      "r310",
      "r311",
      "r313",
      "r315",
      "r319",
      "r320",
      "r370",
      "r411",
      "r414",
      "r415",
      "r416",
      "r420",
      "r421",
      "r452",
      "r453",
      "r456",
      "r460",
      "r468",
      "r618",
      "r775",
      "r828",
      "r846",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r585",
      "r586",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r203",
      "r222"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r100",
      "r404",
      "r405",
      "r768",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r851",
      "r852",
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "verboseLabel": "Summary of common and preferred stock authorized, issued and outstanding"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "verboseLabel": "Number of common stock shares outstanding under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r8",
      "r815"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, value, issued",
        "verboseLabel": "Common stock\u2014par value $0.001; Authorized shares: 600,000,000 at December 31, 2022 and 2021, issued and outstanding: 253,091,319 at December\u00a031, 2022 and 217,382,887 at December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r32",
      "r263",
      "r265",
      "r273",
      "r724",
      "r732"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r154",
      "r155",
      "r170",
      "r263",
      "r265",
      "r272",
      "r723",
      "r731"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r153",
      "r170",
      "r263",
      "r265",
      "r271",
      "r722",
      "r730"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r351",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r351",
      "r749",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r351",
      "r767",
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r212",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "%\u00a0of\u00a0Total Revenue"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r179",
      "r180",
      "r351",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "auth_ref": [
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities (VIE)"
       }
      }
     },
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r470",
      "r471",
      "r490"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r470",
      "r471",
      "r490"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "verboseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r491"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebt": {
     "auth_ref": [
      "r3",
      "r196",
      "r217"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.",
        "label": "Convertible Debt",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r104",
      "r422",
      "r423",
      "r434",
      "r435",
      "r436",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "verboseLabel": "Convertible Debt Securities"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule Of Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r452",
      "r453",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "verboseLabel": "Convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r6",
      "r7",
      "r114",
      "r117",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostMaintenance": {
     "auth_ref": [
      "r842"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of maintenance incurred and directly related to good produced and service rendered.",
        "label": "Cost, Maintenance",
        "terseLabel": "Annual maintenance"
       }
      }
     },
     "localname": "CostMaintenance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r65",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r57",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt conversion, converted instrument, shares issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r282",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r438",
      "r445",
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r194",
      "r196",
      "r214",
      "r290",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r643",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r105",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r20",
      "r114",
      "r117",
      "r119",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r184",
      "r186",
      "r422",
      "r643",
      "r792",
      "r793"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "netLabel": "Principal amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r19",
      "r184",
      "r450",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Debt instrument, interest rate, effective percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r19",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt interest based on the fixed rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r21",
      "r290",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r643",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r21",
      "r114",
      "r118",
      "r119",
      "r120",
      "r183",
      "r184",
      "r186",
      "r211",
      "r290",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r447",
      "r643",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r847"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r183",
      "r186",
      "r877"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "terseLabel": "Debt instrument, unamortized discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r865"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position for more than twelve months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "terseLabel": "Debt securities, available-for-sale, realized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Debt securities, available-for-sale, realized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r364",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of securities in a gross unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedLabel": "Gain on deconsolidation of Geneos",
        "terseLabel": "Gain on deconsolidation of Geneos"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from remeasurement to fair value of retained investment in former subsidiary and group of assets constituting business or nonprofit activity deconsolidated and derecognized, excluding conveyance of oil and gas mineral rights and transfer of product or service in contract with customer.",
        "label": "Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount",
        "terseLabel": "Remeasurement of Geneos Series A-1 preferred stock"
       }
      }
     },
     "localname": "DeconsolidationRevaluationOfRetainedInvestmentGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r185",
      "r877"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "negatedLabel": "Unamortized debt issuance cost",
        "terseLabel": "Debt issuance costs, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r4",
      "r5",
      "r195",
      "r213",
      "r564"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r553",
      "r554"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r565"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets, gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from investments (excludes investments in subsidiaries and equity method investments).",
        "label": "Deferred Tax Assets, Investments",
        "terseLabel": "Investment in affiliated entity"
       }
      }
     },
     "localname": "DeferredTaxAssetsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r910"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "NOL carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Components [Abstract]",
        "terseLabel": "Expirations of Operating Loss Carryforwards, Components [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsComponentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Other Tax Carryforwards",
        "terseLabel": "Research and development and other tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherTaxCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards [Abstract]",
        "terseLabel": "Expirations of Tax Credit Carryforwards [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "terseLabel": "Deferred tax assets, valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r143",
      "r910"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Acquired intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r149",
      "r911"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r511"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Company's contribution to 401(k) plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Maximum annual contribution per employee, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/A401kPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r53",
      "r94"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r489",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskAdditionalInformationDetails",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r14",
      "r413",
      "r414",
      "r415",
      "r419",
      "r420",
      "r421",
      "r664",
      "r850"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Accounts payable and accrued expenses due to affiliated entities"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r201",
      "r225",
      "r413",
      "r414",
      "r415",
      "r419",
      "r420",
      "r421",
      "r664",
      "r850"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net loss per share attributable to Inovio Pharmaceuticals, Inc. stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r274",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r308",
      "r310",
      "r313",
      "r314",
      "r315",
      "r317",
      "r608",
      "r609",
      "r725",
      "r733",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r274",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r310",
      "r313",
      "r314",
      "r315",
      "r317",
      "r608",
      "r609",
      "r725",
      "r733",
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r631"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": {
     "auth_ref": [
      "r913"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.",
        "label": "Embedded Derivative, Gain (Loss) on Embedded Derivative, Net",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r113",
      "r238",
      "r267",
      "r268",
      "r269",
      "r291",
      "r292",
      "r293",
      "r296",
      "r304",
      "r306",
      "r318",
      "r374",
      "r469",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r607",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r660",
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Percentage of ownership"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r77",
      "r334",
      "r831"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Investment in Geneos"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "auth_ref": [
      "r49",
      "r79",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.",
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Schedule Of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r251",
      "r617",
      "r778"
     ],
     "calculation": {
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Investments in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "auth_ref": [
      "r251",
      "r617"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Investments in affiliated entity"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r734",
      "r863"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "negatedLabel": "Net unrealized loss on available-for-sale equity securities",
        "negatedTerseLabel": "Net unrealized loss (gain) on available-for-sale equity securities",
        "terseLabel": "Net unrealized (loss) gain on available-for-sale equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "auth_ref": [
      "r832"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.",
        "label": "Estimated Insurance Recoveries",
        "terseLabel": "Estimated Insurance Recoveries"
       }
      }
     },
     "localname": "EstimatedInsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r174",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r436",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r612",
      "r673",
      "r674",
      "r675",
      "r792",
      "r793",
      "r804",
      "r805",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r611",
      "r612",
      "r613",
      "r614",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r436",
      "r496",
      "r501",
      "r612",
      "r673",
      "r804",
      "r805",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r436",
      "r496",
      "r501",
      "r612",
      "r674",
      "r792",
      "r793",
      "r804",
      "r805",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Unobservable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r436",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r612",
      "r675",
      "r792",
      "r793",
      "r804",
      "r805",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r436",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r673",
      "r674",
      "r675",
      "r792",
      "r793",
      "r804",
      "r805",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r362",
      "r363",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r386",
      "r387",
      "r447",
      "r466",
      "r597",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r789",
      "r860",
      "r861",
      "r862",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]",
        "verboseLabel": "Eligible Item or Group for Fair Value Option [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "verboseLabel": "Financial assets and liabilities that are measured at fair value on recurring basis"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset, useful life",
        "verboseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r248",
      "r396"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails_1": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r397",
      "r703",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r88",
      "r707"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r84",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r88",
      "r703"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite lived intangible assets, net",
        "totalLabel": "Intangible assets, net book value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsScheduleofAmortizationExpenseDetails",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Indefinite lived:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r627",
      "r628",
      "r629",
      "r630"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedTerseLabel": "Unrealized transaction (gain) loss on foreign-currency denominated debt"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Office furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r845"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "negatedLabel": "Share of net loss in Geneos"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedTerseLabel": "Loss on short-term investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r53",
      "r106",
      "r107"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Gain (loss) on extinguishment of convertible bonds and senior notes",
        "terseLabel": "Gain (loss) on extinguishment of convertible bonds and senior notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative Expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r247",
      "r388",
      "r720",
      "r790",
      "r815",
      "r867",
      "r868"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "ino_GoodwillAndIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "totalLabel": "Goodwill, net book value",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r81",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillGross": {
     "auth_ref": [
      "r390",
      "r392",
      "r790"
     ],
     "calculation": {
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Goodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Gross",
        "terseLabel": "Goodwill, gross"
       }
      }
     },
     "localname": "GoodwillGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r53",
      "r389",
      "r391",
      "r393",
      "r790"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r835"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r53",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r285",
      "r576"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S. Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r33",
      "r191",
      "r205",
      "r228",
      "r333",
      "r342",
      "r346",
      "r348",
      "r726",
      "r788"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r285",
      "r576"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesComponentsofPretaxLossfromOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r333",
      "r342",
      "r346",
      "r348",
      "r788"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before share in net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r34",
      "r53",
      "r77",
      "r204",
      "r226",
      "r331"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Share in net loss of Geneos",
        "terseLabel": "Share in net loss of Geneos",
        "verboseLabel": "Share in current and accumulated net loss of Geneos"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r286",
      "r557",
      "r562",
      "r568",
      "r574",
      "r577",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r287",
      "r305",
      "r306",
      "r332",
      "r555",
      "r575",
      "r578",
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r266",
      "r551",
      "r552",
      "r562",
      "r563",
      "r567",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r908"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r550",
      "r556"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Change in tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r908"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r556"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Benefit from income taxes at statutory rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r908"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r908"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r908"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax, net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "auth_ref": [
      "r908"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "ino_ComprehensiveIncomeLossTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesReconciliationofIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable and accrued expenses, including from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, including from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r701",
      "r844"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue, including from affiliated entity"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r844"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in fair value of derivative liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets, including from affiliated entities"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Definite lived:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r82",
      "r86"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Schedule of intangible assets by major asset class"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r185",
      "r207",
      "r270",
      "r330",
      "r642"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r40",
      "r442",
      "r451",
      "r794",
      "r795"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Interest expense, debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r275",
      "r279",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "negatedTerseLabel": "Amortization of (discounts) premiums on investments"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r229",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Number of shares owned (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r369",
      "r930"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Short Term Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r750",
      "r751",
      "r752",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r192",
      "r208",
      "r231",
      "r776"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Short-term Investments and Fair Value Measurements"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r653",
      "r814"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Lease, cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r917"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule Of Maturities Of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r917"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling 12 Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r654"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r284",
      "r370",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r592",
      "r595",
      "r596",
      "r618",
      "r787",
      "r874",
      "r920",
      "r921"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r197",
      "r219",
      "r815",
      "r848",
      "r864",
      "r915"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r243",
      "r284",
      "r370",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r592",
      "r595",
      "r596",
      "r618",
      "r815",
      "r874",
      "r920",
      "r921"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r880"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Revenue under collaborative research and development arrangements"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "verboseLabel": "Licenses"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r23",
      "r870"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Estimated Litigation Liability, Current",
        "terseLabel": "Accrued litigation settlement"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Amount paid to other party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r196",
      "r217",
      "r435",
      "r449",
      "r792",
      "r793"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtBalanceOfConvertibleDebtDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r102",
      "r290",
      "r440"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r102",
      "r290",
      "r440"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r21",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/ConvertibleDebtScheduleofMaturitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r406",
      "r407",
      "r410"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Estimate of cash settlement"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails",
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r121",
      "r156",
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Dissolution of majority-owned subsidiary VGX Animal Health, Inc."
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r26",
      "r38",
      "r152",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember": {
     "auth_ref": [
      "r881"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities collateralized by real estate mortgage loans (mortgages), issued by US Government Sponsored Enterprises, such as Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac).",
        "label": "Mortgage-Backed Securities, Issued by US Government Sponsored Enterprises [Member]",
        "terseLabel": "U.S. agency mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r321",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "The Company"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/TheCompany"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r50",
      "r51",
      "r54"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r35",
      "r54",
      "r206",
      "r227",
      "r241",
      "r262",
      "r264",
      "r269",
      "r284",
      "r295",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r306",
      "r312",
      "r333",
      "r342",
      "r346",
      "r348",
      "r370",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r609",
      "r618",
      "r788",
      "r874"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss from operations",
        "totalLabel": "Net loss attributable to Inovio Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r159",
      "r169",
      "r262",
      "r264",
      "r305",
      "r306",
      "r841"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r62",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r307",
      "r317",
      "r358",
      "r359",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r546",
      "r547",
      "r548",
      "r570",
      "r571",
      "r572",
      "r573",
      "r582",
      "r583",
      "r584",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r640",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r704",
      "r705",
      "r706",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements - Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "auth_ref": [
      "r122",
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "negatedTerseLabel": "Deconsolidation of Geneos"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r122",
      "r156",
      "r160"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Acquisition of non-controlling interest in Geneos, net"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r151",
      "r469",
      "r851",
      "r852",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- controlling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]",
        "terseLabel": "Research and development equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r333",
      "r342",
      "r346",
      "r348",
      "r788"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "netLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r845"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r652",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r651",
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesSummaryofMaturitiesofOperatingLeasePaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Geneos Therapeutics, Inc."
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r202",
      "r224"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other Accrued Liabilities",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized (loss) gain on short-term investments, net of tax",
        "verboseLabel": "Unrealized loss on short-term investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Certain Balance Sheet Items"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r836",
      "r866"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Investment in Geneos",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of capital assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r494",
      "r495",
      "r501",
      "r502",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r514",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/A401kPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r815"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u2014par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 9 at December\u00a031, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r838"
     ],
     "calculation": {
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "totalLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsPrepaidandOtherCurrentAssetsDetails",
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r200",
      "r223",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expense"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r843"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from issuance of debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Commissions and other estimated offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Acquisition of non-controlling interest"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from Geneos issuance of note payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": {
     "auth_ref": [
      "r276",
      "r367"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.",
        "label": "Proceeds from Sale of Equity Securities, FV-NI",
        "terseLabel": "Proceeds from sale of investment of GeneOne"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "verboseLabel": "Proceeds from sale of or maturity of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from stock options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r241",
      "r262",
      "r264",
      "r277",
      "r284",
      "r295",
      "r305",
      "r306",
      "r333",
      "r342",
      "r346",
      "r348",
      "r370",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r420",
      "r421",
      "r590",
      "r593",
      "r594",
      "r609",
      "r618",
      "r726",
      "r788",
      "r812",
      "r813",
      "r841",
      "r874"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r769",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisposals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Disposals",
        "terseLabel": "Property, plant and equipment disposed of"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisposals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r95",
      "r245"
     ],
     "calculation": {
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r97",
      "r221",
      "r727",
      "r815"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.inovio.com/role/FixedAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net Book Value",
        "verboseLabel": "Fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other.",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "terseLabel": "Computer equipment and other"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule Of Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property, plant, and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r503",
      "r663",
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction, Due from (to) Related Party [Abstract]",
        "terseLabel": "Related Party Transaction, Due from (to) Related Party [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "verboseLabel": "Operating expenses related to affiliated entity"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r503",
      "r663",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r919"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r661",
      "r662",
      "r664",
      "r665",
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r142",
      "r232",
      "r928"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Performance-based restricted stock units",
        "verboseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r399",
      "r401",
      "r402",
      "r403"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected charge"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions reduced"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions reduced (in percent)"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r121",
      "r218",
      "r743",
      "r748",
      "r815"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r238",
      "r291",
      "r292",
      "r293",
      "r296",
      "r304",
      "r306",
      "r374",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r607",
      "r739",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r328",
      "r329",
      "r341",
      "r344",
      "r345",
      "r349",
      "r350",
      "r351",
      "r488",
      "r489",
      "r702"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue from collaborative arrangements and other contracts, including affiliated entity"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r351",
      "r857"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer Benchmark"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskRevenuefromExternalCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r493",
      "r784"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r492",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue Recognition and Concentration of Credit Risk"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r37",
      "r230",
      "r413",
      "r414",
      "r415",
      "r419",
      "r420",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "verboseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenues [Abstract]"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule Of Accounts Payable And Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CertainBalanceSheetItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsSummaryofGoodwillandIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesTableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "verboseLabel": "Summary Of Common Shares That Were Excluded From The Diluted Net Loss Per Share Calculation Because Of Their Anti-Dilutive Effect"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "verboseLabel": "Summary Of Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule Of Deferred Tax Assets And Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule Of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Revenue From External Customers"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RevenueRecognitionandConcentrationofCreditRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r611",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule Of Fair Value, Assets And Liabilities Measured On Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r849"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule Of Components Of Pretax Loss From Operations"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "verboseLabel": "Summary Of Intangible Assets By Major Asset Class"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule Of Maturities Of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/FixedAssetsDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/RelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r515",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule Of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule Of Shares Authorized Under Stock Option Plans, By Exercise Price Range"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r125",
      "r131",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule Of Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary Of Assumptions Used To Estimate The Fair Value Of Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r109",
      "r111",
      "r112",
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121",
      "r252",
      "r253",
      "r254",
      "r319",
      "r452",
      "r453",
      "r454",
      "r456",
      "r460",
      "r466",
      "r468",
      "r796",
      "r828",
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r110",
      "r111",
      "r112",
      "r114",
      "r115",
      "r116",
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "verboseLabel": "Summary Of Preferred Stock Authorized, Issued And Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r811",
      "r909"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule Of Unrecognized Tax Benefits Rollforward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule Of Finite-Lived Intangible Assets, Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GoodwillandIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [
      "r833",
      "r834",
      "r878"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C preferred stock.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock",
        "verboseLabel": "Series\u00a0C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 27.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Non-cash stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)",
        "verboseLabel": "Vesting period of incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r529",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Number of shares of unvested restricted stock units and options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r126",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, non-option equity instruments, outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Reserved number of shares under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for grants under the Incentive Plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options, exercises in period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Options, expirations in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r888"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options, grants in period, weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Number of options outstanding to purchase common stock (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "verboseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofRSUActivityUnderEquityIncentivePlanDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, expirations in period, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Exercise price, lower range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Exercise price, upper range limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r515",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "terseLabel": "Nonemployee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Aggregate intrinsic value of unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate intrinsic value of vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Award exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesSummaryofStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r138"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value for options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise\u00a0price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average remaining contractual life (in Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r198",
      "r199",
      "r215",
      "r837"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r61",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r284",
      "r310",
      "r311",
      "r313",
      "r315",
      "r319",
      "r320",
      "r370",
      "r411",
      "r414",
      "r415",
      "r416",
      "r420",
      "r421",
      "r452",
      "r453",
      "r456",
      "r460",
      "r468",
      "r618",
      "r775",
      "r828",
      "r846",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/GeneosTherapeuticsIncNarrativeDetails",
      "http://www.inovio.com/role/GeneosTherapeuticsIncPreferredStockInvestmentDetails",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/StockholdersEquitySummaryofPreferredStockDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r25",
      "r113",
      "r238",
      "r267",
      "r268",
      "r269",
      "r291",
      "r292",
      "r293",
      "r296",
      "r304",
      "r306",
      "r318",
      "r374",
      "r469",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r607",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r660",
      "r739",
      "r740",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r318",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets",
      "http://www.inovio.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations",
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r24",
      "r113",
      "r114",
      "r121",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock/senior notes to common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r113",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r113",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and warrants for cash and vesting of RSUs, net of tax payments (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r113",
      "r121",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquitySummaryofStockOptionActivityUnderEquityIncentivePlanDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r25",
      "r113",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of preferred stock/senior notes to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "auth_ref": [
      "r25",
      "r113",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).",
        "label": "Stock Issued During Period, Value, Conversion of Units",
        "terseLabel": "Carrying value of december 2019 bonds"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r7",
      "r8",
      "r113",
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock for cash, net of financing costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r121",
      "r132"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options for cash and vesting of RSUs, net of tax payments"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r72",
      "r815",
      "r848",
      "r864",
      "r915"
     ],
     "calculation": {
      "http://www.inovio.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Inovio Pharmaceuticals, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Inovio Pharmaceuticals, Inc. stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r151",
      "r152",
      "r168",
      "r238",
      "r239",
      "r268",
      "r291",
      "r292",
      "r293",
      "r296",
      "r304",
      "r374",
      "r469",
      "r546",
      "r547",
      "r548",
      "r572",
      "r573",
      "r607",
      "r632",
      "r633",
      "r637",
      "r660",
      "r740",
      "r741",
      "r848",
      "r864",
      "r915"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r123",
      "r283",
      "r453",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r469",
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r638",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r638",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r638",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r638",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r667",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/StockholdersEquityNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesExpectedExpirationsofFederalandStateLossesandCreditsDetails",
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r233",
      "r234",
      "r235",
      "r354",
      "r355",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r362",
      "r363",
      "r447",
      "r466",
      "r597",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r860",
      "r861",
      "r862",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "verboseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r295",
      "r296",
      "r297",
      "r298",
      "r307",
      "r358",
      "r359",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r546",
      "r547",
      "r548",
      "r570",
      "r571",
      "r572",
      "r573",
      "r582",
      "r583",
      "r584",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r640",
      "r641",
      "r644",
      "r645",
      "r646",
      "r647",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r704",
      "r705",
      "r706",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConvertibleDebtNarrativeDetails",
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesRecentAccountingPronouncementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r912"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/CollaborativeAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "auth_ref": [
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Bill Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasuryBillSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r785",
      "r804",
      "r806",
      "r929"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedTerseLabel": "Unrealized loss on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ShorttermInvestmentsandFairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r549",
      "r558"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of the year",
        "periodStartLabel": "Balance at beginning of the year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases (decreases) related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesUnrecognizedTaxBenefitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r322",
      "r323",
      "r325",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r309",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r308",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted average number of common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.inovio.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569655-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4616395-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2AA",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759068-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3444-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080555-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32059-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942793&loc=d3e3073-115593",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r818": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r819": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r821": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r822": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r823": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r824": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r825": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r826": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r827": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "https://asc.fasb.org/subtopic&trid=2229187",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r933": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r934": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r935": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r936": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r937": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r938": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r939": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r941": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r942": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r943": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r944": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001055726-23-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001055726-23-000010-xbrl.zip
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MX[!,K.6PBJ=3J[;=B<J4'AYYU6]D>YP5RT6V'SY=B)P7<,YW<*%R)I]V"\3
M*;@6JWI@(?[DZ!.Z5S5WC;]H)Q.2M_[[Q#I]^GXCE@*S27O^IQY_+9I[^NZ(
M,4%$N'ZD(*=*%I99:@6O9,JW'#_8O.!K4:!7R+5YN<Q$ B=)HDII+.]>")T_
M6$*^==C!YV'' 89]Q2%I(C<*S(:#D(G26Z697;&PW(/F*XQ?)K:K&K%26:9V
M-@%U=IJAEP:7I%U5Q?%1V!]]$?$M2U-4=C*^,D,:H9L5!T25\*'C][?_@.@G
M6K#L7Z>@0M[OM:[^QP#@[*-/DC'H1;$-_NZTPB\OE,[ATJ'?QE_RM[(%\'C9
MZDS.50\HI0[N11%N[L_JY:JNA8+YANF<);PT(F%9T<7_DU[W8%A(#HZ%T()!
M0D+"Z ?"@AX:%GW$HJC!\ ,RH/UN+8=>' T:.?+#\(,<#;RHD>. AK21^WY(
M22,/"/5;.X.(DK"6B3= 0UU@,JW;?N1%_C/8<FV8D/94: X2XGDQO,FE6):%
M)0 Z+*XYS#,F4;T EMLS-NW^.+P)#I@W%L>6'X30.&[X0:A':=S*?C\FK8P;
ML-_((8UI=$.)B/I1?#<E_.C_18GP$"G1,"(*!T%P%XQ?@\;>N8@MH<ND-ER!
M^WU7PCY!I)!RJM18[6+M:PI(J_OE:Z:3S?$1KHT1<MU>)[NP$V:#PXHM3SX4
MS;:&5IFHE59",ID@=3"$MB2^C]&V[,Y*Y'Y=9(L"3J0LT<1%Y4\#C^\YO]U[
MSF)]KBNG]IQIJ!84S#BBL>0::!W&3;5QH/>6XZ,@'A75%TZU+ P<']'^"-[B
MW6P-9V?S XCADDF8";Y679CB#1AADX)])[[=)O[C._;9_>.!F/NP?6TZ/GX
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M2E,@IJU7)7&LC? &>)DZAAS%AD)H8PGXDP6J@A(\P!?7EBP\B;\, ,?;!.!
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M-YDN%OFS[:-T>C#\[?#@W?'AP5Z?D=U7C+S9?K7/:#SN[^P]/.R^ZQ]UC][
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M\LC-6J#:O=G//YFQ[^*/ \+)R9A^O<P=/WBQNW%U^=6AJ^_U^B^VIO5(66O
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M(*0$S-DK6V64%=930M>&@BXK8]468[68N:O!6)N<UB4KB(5BM$KKFD1EQ65
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MY(/"#"9K&RDKJ5L_>;+?O]C\]NK04BI95D*Q4#$@+<BD0C3&> C1199'-K8
MP\89I!9,$[@+U/:.K O:"YT20,UD$SCOO4N:O '? KG?) P7HG*9#\4EJ*LT
M 0*)X"$EDT#Z%!2TJHC;RCRMJ'TMC0W)>%U32#F#T Z!*$IABX3B(;9A@EZ3
M,%S,5D HP#F6O>Q3((*)HA!:Q"A(RJL=&YN-X<H\K:C])6JK6C95>RM  A,[
MH4G1"LOF"8-Q,:T"@X92NY5:W2&Z) 2QUC-04EW'AZ111VV#-F&U>&99V;80
MZ96E$;%X3>0+QQ8A^(*8$$24J 6EE=M>4K8MQ).F*)*QV7BI WAO(_@0,KF2
MC"!!9E8BH)$F[8YFUC^J-"#G5FE DB0G(:!/%I2"P,Z.A$U.9.6U;$,UH6^W
M.9=%(B;/*5'O%&/_NXO&W%%*+MYG*G122U<L$3O*XFK=94M8ESDCF0#-M6+-
M#R@?;3[;VMY\OML24Y:<CR;9Q!:,'9HQP<@8$FFMDP:"-E3Q;((IN\N\7+P]
M*T*ZND1+VJP@AXR:F&&@O,HLU?2G4_B$;!Z)*W2/*BEI?,Q-=M[% 7W[4N ;
M\[22<J>LC\<X?#VK"/5I/>]^'^.H,O.4/CJK2>3A4^<SM&C)N:BU]R6#+2I@
M#-*4NA6\)G-9&K+9R;$5>18V+FTP"$F*(!C64-%KP7& #U%8+2&U84QS19Y%
MN2V;#0K%YL;G6I9E-N.SD+4I&!+A<MIG\RW/L_$HGZ3ISOAR@_?K@#[EOPPG
M<XD5[SQ+%[/XG;VC2\*!405$=C':8E#KD)0I:$)+3-R*I4MM2X7!8J.T7H@$
M)=B0BE(EEZ(@*DRY!<, *Y;^2)8N9I9U9B/J$P>@[/*M\#&0B"2-#1:!2EM8
MNB+/0F9QF*0@1:EE7?(F(2:V;])"KML8L(QLB5S\$_(<,YJCA[W1<I-G(2H.
MJUE)+EBA(A03O2&O%#K#T8>*%BIYI!<@*WDN/C2-/+>+ZG=R]]$(^[V:QRVC
M\>8Q_\Q!+ST;$Y])>4B3R=9P.#J=)7IO>8:9]!T!'7D3>GUZZO<X-A&=BIK-
M$R*D8*,@YW0"A\[!U>3)9MNF%;V::[T(/;@</;*R!S08. "M.7\64L*R=&I!
M#+JB5W.#1T\R65):Q!A!<RCI@%S,*H19#? VE,Q:T:NYPMW604DEC1-DP(*-
MUH684L&LP%C*S=]79H&L^G)&I++J*4XF^)A.:;P^S'5H^^5\0L\&<_E6]LV1
M(0N?31$"%&@'WFE#0K.C=9AL$<V?#;2B9^/H.;\92B9G<*1( 7DPLD3*49D2
MK50N,"L_<<Y-G=SQ=:+LKC_??31ZJ1[MO-S:D&%.-&E WV@H2_^^()C7E!,6
MF]:7'+(3&K2Q:#*6HB%B20C*75(:KBC-FK1IE%[1ZZ;T@IO3"SI:S$-OENB-
M9D4IZDK6J".K!16\5"2S39>34II-KS^WF(\VGS[=?+3W?%T_VWW&IQV/>\0M
M>[X[J,U+]>25^5Q>?IO - 8O"[@,9(,O'++KNG.\SX"F_?S>ZNZ %V+%X>7E
ML%<9K,, =:=2H0BC-0J4+Z;4BG_MGONU4K5W,4D?C&9R*7 EBEIM('# YLGK
M0B(H9G4+DO0K2C>6THN9H4L.R;&NT& @2S;7TJI<$(OT,H4V# RL*-U82B]D
M,$($ITHFS?$@*Y 4O45AHW&!T$N;H;F#$2LF-XG)MS(4810'=CDHZV8+DSG0
M"RJXH"F0%?QO<X<B5N1L*#GG-Q!AC3!21Q<%ZUM%$95TQ7G*9-B,RG(QA4X*
M<3&%3HKFL;0!C/EZ)]GHKF\.TRA3WAX-1ZD_&F)_G7]J'.7S/4J'PU%_]/K\
M=EG[L-?OU^$ZZO>&&9^PCYT\YI/SC*BW/G%/BIO)@8M3YU.L"W0,%'(,L8##
M&&7,*7CC=4!'85;W6P;A+TC-'YJ72UN1NL&D#AWA;TCJV:GS21"7+&Q.-A(0
M!%%\87)[5K69G,$H6Y!<6Y&ZN:1>4'I-IV"=,U(9A (A$E6QH;10R7LO6Y!>
M6Y&ZP:1>S++-.E2=8D!F,1@TP6FPSF3^OY#E8EE*PQ-L*U(WF-2+2;$Y:5"4
ME'200&R=+2IP,LDL0)K5?-\5EQ>:9%-2.]0F:6<"*)-"L4RA(BA*GQ%S<Y-L
M*WHVEI[S2[,5JC2,KFZ? :E@#(8<%=20,PL$<2D)]-7L'MT\GJYFKS6(I)_J
M 7WSN3YZ3LO+-!$[?R]2,4 N( A# I-/=:L1L"U(1ZP8W51&+Z::@*FBUKN2
M*(/1+I:"7I(QWH!0N0U58U>,;BJC%[.-A*:Z,1UI5L' '/-@O005583(09ML
M02)BQ>BF,GHQ60@J>J:=0PZ@30A:.JU1YI"\ Z1+1MLK'6V;-[+WYXANU,D$
MTWJKG;)!A8;?S^ E[T)SX+&]N7JV\QG,B][E!%9HZ6?U96(,Z)7.UJBHR^5J
MC^:KYQ_*XV;3:"&2->9H##A3E$Q0U6L@94N6WF;MLE,MD:PK&BU8)V93H$#,
M"278G)&#>J>EC89R3N+3U>@K&C6>1HL19^B-ML9ZLA8T:J]L5$[&Z*RI=8<^
M<6I-+6JP$F?-X?$W>=5Y53*0LNY[G1(5Q5Z5P^9B32E&1"5TC$U?37"WK>"M
M#"X2939E2%IH@"1RT*((16!1BJR2;N[@XHH0MS*<)\!8$[*TB@EAV.]9K] Y
MZT&QZW-Q1HB53FHZ(<3\EE$(&[*5&JQ2X*Q"P!1MYO@^I*PA-M=E7 'PN#?$
M8>IA?XM;87SR :'*B^V3Z0GV'Y\,<UL67?D$ H0UB-J!4AZ+ .E<((*4;&C#
M!EA_B<S5"2]V]\:$DY/Q><T'[U(Z&?>F/5K*]?@Z $4;B:HK#E!""A!LLHF4
ML2'H%G>T'P_GK?0\(9QPR$I90X*28B3^'Z4@4W FB#95S?Y+J![1N#XCU8&7
MZC&/1Y/>7[FL&[GHY]7_73SK8O_+L][@9+",'3I2L*7$+"AXB,J$J&UQ)DDI
MP%KOEJ!#_QV6-*4W1^WY?M8I]IJ0V<(*U!242#$D[M"T!/!LC\;3U_B:'F)Z
M0_F#O=V:3$XH/SQ_L?MD=$KC8;UR]W@TG(S&E#=G"GK<F[3&+DM6IE@7^()*
M(+/!Z')T2EG*7N@0FAO$-DJBSC&(M 4TF[FD<@!NKY!U0;1U#E*(LE6[5-\Q
M1[F@R3PNB[JLJ)C,79B90B+XX%$7#\8U. G5;.4[QTG>NB3TW)V=]R"<"A$P
M9?X?XY7!QB5 Z-%H,*!Q/>,9<LNT!1C/;<Z]1&FRX$G[BUE#K&)TY%[4@F+P
M#=28\X.'G-'D652"*&!304.(A=6*0-12M&#M3KLUYG<A>3+L7< X8QRWRGN,
M!C-33C-U=G7PZB97QZZ^U[M\D1LF*LS9E\Q]M^9[O'=%.8K><; H=8/'XN:L
M6F_^/.R-7V+_A!Z>;U^T<GWDXS']YX2&Z?PZ+]^?_-&ID^>5GN/>\'5+(ILH
MV>GZ6'2P=;</]+6L(42I+1N6H$L+./(!L_<?_\EWQ'$Z/']*I]3_"FQ;P^.3
MZ61VAIP;@5:$O67"!FV52C)8KP@<2A^S]@'J1Q?9MMT-PJH58=M"6)V53]$(
MAT: Y)C3N&QJM5@2'I-O@X5='$?^=@?1*\+^;4D0!""$NA^PY9!">R$-)&6B
M""8:@RTF[.?)DALG2E:$^9/R)L+:)$(0I,!H'Y,P"2E+'XKSI<T3.'XP81H@
M8.\<>U%;\%%EXPN!4M83LF=V+F@@*;Q<L;=%:O;.L3?$.K0A;!$Z@XLZ>G))
M<%CD=!*BF!5[5U*SN>R-,>22O1(Y.= E8RT]5<N]4Q"1U#*P]U9&;^\N8TKR
M5H'-"J6"Q/&T-5!04HC%YZ35BC$KL=E@^GHK!%AI(R&35VF?DG2:O&'IJ7-N
M<S*H-?1=J<V_35]P+@6A@D!RD)4,E'UDIUV<#J($L:+O2FXVF+XL,T.61C!=
M-6A9@H/@LY5 !.CS,B2J;GFRQ(I<7Y\C[&V*D'U664$!'>M,?*M)J6#!X6JV
M=[.B]I6(_?L+-F4H3J*'E S'8"XDYU0NA@B+CJT8@K]+3%_IW;\O&*0,CFK)
M?C+ .C<D6X"$+&C (]@5TQO%])4T_MM,9P-NLE>6)3% SMJ7:(C9:$5((NDV
M,/WN89:\<R86Z0J"J\4]M5=2IKHY7TBJ79BMA-P":O.H(E$C,K@(R:B0!<42
M@C$F8+#I;A!HI8^^(Z$BB_8F)0C D0"@$MICHIB48;'4AH3*2G8L=/I")NNM
M0"8, F;^#*I0$5$%DV)I\[*_.SZ!>GY+W("UJ$ V-4$%<)&"5J3!U?T! TKG
M6\"11LF<%6%OF[#,T52,3Q$0LC#>"\K.R C%4#)M,&J-DE4KPMXR83UX+5*Q
M/G+TKV-"COFM(@LA9Z^S;0%A5TM4[A)AM9,!R'E3(H%R!:T3:*U.WCA?]W-O
M+V%72U1N@S#1D7+!!,_*$:BDJ*'4A4T0O%9!+D,5BZ9/D[YS>;HY"LH0O"5%
MTE(!IU+TN;B(45 @9:#-_KDM[+US2<(Y.FMO7<P*07/(7KR+$3AZ#S&P^T[%
M+4.)FJ:S=R4UOZ/2(&$BQ?^S+#4#(.I@,I88L8#U;<@^S;<PV8HK7^=*212E
M]"$;  ZF0T(58W0,*) PRZ R;Y\K*X'YXXFK=-8E*%<WWH 2;,"DL\3B!3\%
MBEL1=Z4M&TE<*(#D4O;@V!M+#O%EB;X47;04HBQ#(JC!Q%W)RK^_6J"4J-'Y
MNF0?#!-8:D0753&4^8]+(2M7*Y_GR9B4P00%3FJ.0KPBGX2ULEB,.0H38,68
ME<1L,'V#MM'H6K61G;4WV2?2R@JT;/(,2%S1=R4T&TS?NN-N25J2]QFBB-'/
M]C!,2EL6GGIE?5=RL\GTC<(*7SPDF1"*"D$H5U<Q(4297&C#E*06+F2Z(^0*
M$L!E;TPA#4)2+"9)&ZU,B<-S45;D:M1@T$K$_FVF9Q&<%$$DK0R0TJ@=6I3)
MU\GJ(BS#4.8R,7VE=_]^?LK9H$6TV28+NM3J*"'5>JB@38AFQ?1F,7TEC?]^
M9.=)8% 8K,@0"L=WOLY[+G5;>N&C:0'3[QQFU@FOE; 83*C[]\4(.1*D:#VB
MQC8HSI606^R,RJB"#C:D)$"DX'7.LB@*SEAM3!N&7U;Z:)$$*JR+G 'O8JV8
MH2B:Q-9(8BD*9$EWQ *M9,??GQ4+X#-&=)890]'6K6B%2:P]C#-H6E N;FMX
M2I-IO6CO_)@^G[0P&NY.1^E-DV3R7WG,[R/''.NL9AE\D45H00!UVFGTA-H6
M*Z6-XF*_<25<\\A1-Y)^RF'4:ZQ;5C[""7VT#B]MT'C0RR^WAJ/3WNC9(8X'
MF.ADVDO8GVP-T_HP__;;:$+'A__JW<(^U->@$FY.17@<*L$1L:F3/I4J7@G^
MFH,Q4H>B+W8B5U<[D3>R0S<9LVM[AZN;[QW^25_\CKW##5J01I),B3\XB$ 0
M<]$6%"H;6[ =UK/QB'_O]/Q9GSG.>&W^YZ1W7._Q\/QSR_V4?2H=COIY:W \
M'IU>.->6F$T7I90N*ZUE9'0"AX?@3=&)';<3J07;27P35#NE]!*]/Z4E(.GH
M6/ 4(3$&R."Y/\6,CJ1R)>LVE,#_)I >GXR'O2FK5#[Q<>^L?FI+=]+11EUQ
M8DT*$E(T *D0)6U$*+D%^T=_$U)?/7EG>DCC>GY;@ .O2L$B09,$$U5 FX34
M&B0E:]JP/+[A+FM^82!Z],6QL]).@D<94DD"P/F"/GJCE@RJ'^FRYEF!RJ@<
M(2;,'HS1P3GO/1:K=)9:T9*!],-=UOR0HJ"--UD5[1R@D]$G2=EK48KC8*P%
M"YE:Y;+F6=%%ITR.S6%,("RQTU(H,*H4Z^Y(+2A%^A 9A$2[AT33IZ,TBZ4_
M18N.L9<WSX[Y6IHP7C.8'IV,QW5P>C*A]D1:))2&S$(P\?\*8?):0:B!L5'"
MIA9D/3Z:)]";TM/>*>6M(;?'ZU[LTP48#\^W\6@T?M3'R>03R<%>C.\S?+W^
M>DPW$AQ_^3XU"_.<'W_9Q>O75]1[?3BEO'Y*8WQ-RYA=<8Y0FV12$!RR9^?3
M;#,IZ=#X8%NRE\2/X$]3>G[6/DA4V0>5 8 M=+39F2PIB&Q4.VK1-!^P.<[D
M M!%$TC)43QHP)2AR)ARE D-ZF4UU35[_; W.J+TW8L8[J9I)A]RQFA84AM0
M48=D(A J+T&D*/62F>:;\Z4IIE@!^1PU800!P:.7'I, (VU4*KH6I'D:"=#\
M3*^A"HN4*>@,-@O/'E,6CDBY0T5CVV!ZO]OTW:Y;G@50GYZ^E,8X8V%M+-A[
M,Y5*06&5Y%@+K#'*B+QDQO@'XWLKYCG"3&#ES*A $1Z#"-S[8P[%R"C:40VJ
M#9#-L1"V*\5JXRV" >LS9N]MDMX$X!Z7\2X8[%::QQ"B@X@$I=;W]2F6*EX%
MNUO/@4^<#2K+(+1H'%Y7W6:#XO1+Q<O7[4]&/!H-3^OJ;.Y/NS3LC<;=T90F
M&R?$C0CS<L!/1\/74QH/ZIM\:4;?^U>H)]QFAY:A(_1'%/JN&2&1PYA$@,#\
M$,!1C/=.L0V>;=$[RU,R+Q0_\N*#\BN"-)0@'UN92A&V'N$&5N;B5.7GD:P,
M=>^9!#&1@Q X$LY92>T# KN-E#]ET\K<+"6;/K9-W\:F$]93,RIE/'_/C,'%
M+/99\_/?KRZ]^O/5]WKMEW5F1NFE-CI["<JK6&JPF9/P@0)2"T*#.T_&V]F0
M7M5U*2FSGB5@-1NC015=M$*2H-""H95E1$58K84.0:(1K$Y%R+,]6[VEXDAD
MUX(08]5M&Q/W:&F5,,X:!QX<]^I$,9/'Z#P:)#ECD[QB4Z.3#2LV?<PF>7,V
MR;FQ24;/5@A#< K!9.N35M83V10PQ:1F;!)7;!(K-K6%3>+F;!)S8U/$K+*S
MV=M"$ N@\<X798GC;B#P%SD9J91M*HGF">%W,W>#TNR:VF@?/?KAZ*^WM?O>
M; PSXJ.&_2;M\S[B>3-^^WG$,QF!DN[!OYZ_^N:H1WH.P&TMVJ%B+6+G@V<7
M&&22B90"<Q&+5W9U5C1K+,T^B<*O$>W/H_!KIWZ/SY,9V<4%Z[P"4#ERH 3*
M1@Z=0[(7/&(%I:7K7'U8\:C1/*K:27>DNYEVNG;J]^0&!4 )4&RF!,%8[S+$
M*+,A'90,L45QW8I'BUQN7,!%@48*C)""8S,T*\*61,TX4PL*#=]A^MQ.@;*
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M5#;/*)U4<"\*BX^7T427))7WD0665."+BP* I70P/FAO8@OFGBQEKE2END0
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MB.;ISV.Y]C[#</V1EJLR7 T:7 PNA^?'UHO+\U/>P>__OTCW'_7LKU&^/X"
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MV1.GY3=K]8GO-MO<_G!^9HW&YT?_JEC_0'7C6!?]2^M-_^3UX-L6 3T^^?2
M+"Q%'TN^/?_>@W\'I1J9=KT]Z?6Z=KU'W7U.S^YAH*;3FC3;P+^.TVM2O?">
M2;]:SBKEQ;7IY?R!@&]W/G7P_?BX%&;T'*]; V%LN]V.L)M^<VJ[3L>Q.[46
M>"?39L?U>VA+I+[['^ME&$_<T!J)4'A+Z]1-KL7RT\''QQ[3N;?#9H&O]K+@
MJUEGYV>#>SFHM5WWV/;=7CO:[15$6+KV>[U9[;3HA]\WBDU';!CY6#DGK,G*
M\F;"N[: >:^M8&HM9\)*=/>1%:26:]V*,+2O(RS9286;QI'PX8LT$TG%<E/+
M%]. /HJLRRP4'$9IUEKH[.#MI-H(8/5];UG=U@G\3J2;&H._%\:#;BWK/DQK
MV?T74&J0?N@$X5N@[K^0N"-)VR&1=B>5]Q<'1D'Y7CMG[_NPIM<U5/9_-WOU
M7J,-OE#/;;MVT^NT;;?G-&S1Q)+K5L]ON1XHXKBL;W\X#W_XK(#EKDFC*%["
M)__)@@0DSC*VID&(ER!:2FHMLB3-\$+X J0.5@9K((LX*7U$J!921.WETF?+
MI>\DG=[$818MW83P#Y+TUY)*F*ZI_]UIUOQ>KUFS)Z[KV?"'L+O=UM3NM7K=
M3JOKM7O"V4NBAY1$MS-!_24E<73@R'SE#*P@%$2^Y8:AED:FF)H(>0'<>(-D
M*@@CPU[286(04/@UHNM8/GP;7=&EBT1X@F+F3IWO1TAVJ74 -P7'W$HS;V:E
M,U@/+)]!\^&'[I)^G7>96[=NNBY6Z<?R;0[!U(M\ZZ!NO/($?'RX:/(>O4_X
M$5T/O\3UR)LAJE5**Z'ENNG2ZM7X#KZ[2K<*W0>7*Q(<D'&V,/*V=)?9+RA>
M&G]/6[[3[DP=6S2<IMWL.!V[UW';=GTJ>F#Q3.H3M_OD#]""CU>^_&"%>!9_
M"MWH!QH+/ZGL1?D#HF<>+)<@L2@ EL01!EO"E25N1+*RAAC2<3TJ1CMVEZ[U
M@FW%@E3.[V$:CVM^+(C*+'1SL3VRQ]].#B?;Y3 O3TM6D1[^.)%I["=NIY2@
MOY[(O/V[.^DT'+]6MT6G.P&+S'/MGM?IVEZ[VZG7NCVWWG7V(O.^/D11?.Y%
MYD.)3(KEA? JPG(]#T1FXJ+<0[&"@;QHXZ?@<$?VQB_2.<A:>$JB3"@0.7/8
M@U4%+5JP_'#/KJRK)+Y=SM1W5;!N!4<,">>4JH>Q=+,.[[=E:?2U\TQ=]LD+
MMB],78B6[),M*WQ2C&,Z]8E=5Y:Y:8Y7K8,CVO(X$H>_1I%8W:EV:ITOR@W<
M]5V]VJE_^XQ#LUUUZO5OCQG4J-:^\+:?VH/[U<D]4._X#RBE/]E\WG]\O\"W
MP8LNZ91OBB:P ]3MYW1E2?JS$_=1(T[L%([%#^#6[P+?FQS!:;B*D]6&HAFZ
MB(Z()R_:Z?J9O][_&]RFU\V_W@\^G+[\Z_KLY65P^G)0/YL/&^>$[H[W&C;.
MW@[**._SL^/^Q[/Q#-8(SX4U_O5R>/MN_*Z.;;2([GX&;AK\VWGWQFR]Q=E%
M[S[^7?,;HMOR)G9[BCW9#?B?GNBU[<:T5:N[7;?A-NH8+-]@U#X^#+-O(ZL^
M_+(Z:,2> .L?[0[PG]+<_UF(_. "C/;R>9;"D]/T)YRF]OTDUK^+%7]3QYGZ
MK9IO.V[=MYM8P^JV_):-$["G7J\M.EZ'#O'7-Q7_<.MA!V3&8'-88"\G[BDG
MU/Z]I.T[4D&5GW"0S?<1&+5<8)")\^%OX?B]1J,VL3M.U[&;;DO8;KLQL7N]
MFF@T)FVOY3NYA_)UU<"/(LHYQ>#DEG!=Q0KN6SV$*2-*%('!AV5$R]C*4D%7
MP:L*>%/?6NH)3"I+@]D;?%:XPH??!O!H>*P5P:O%&&.\"5(R(",W\@(WQ'@&
M(A/CQ>G2C7PW\5,+X70"OY1DDG4 EM,X< \WAAA57%R.)/JIH]-&#86,W&)O
M'$9JW>52("@1[A5L6[!,X4:1>T7%!;+M/[7<- 7#!#]26RFF4T'9JDBB5. O
M PRZ1D GE'Q)'%HQB&6#?'G0.(,MU#5C5K/6/)CD)1IN,G'AMO;YAU"LJ#KC
MP&E9KZLCG.#>J;?K</$AOGC^EMC:!_2?A"!V#2:9!LF<4X$+>+:+%P%?47FM
M3RMV,S]8RG55?TAVY %UQM";)GU\P3CIYV1^$;I7/Y?*^*J$XX>_)VY[VIKX
M$[O5<EOHU=9L5S1:=MUMN:[3;G>ZV+'_J=EE.R,XIE::UT#!D2B>H T2M&Z<
M33B,6Y6"*7OR,T^(9URI%*_7G$9>F/E<WLX_D_5-4VJZP8^\.$F$ ATF794D
M6/$4XY&^">(L#5?J1&]Z:M7:51%O?4+&HZ:D+8U!T?*NY)NE2&ML/\E!7?^
MBL"+J98#Y'VX2@,6XQ&FSD"NVQ,7=2]J9Q&EK""P$ .^HD([_723H%IAE)&*
MDM2LZ$C 4KA!^NLE2'O Y#_4SYUG]6:MZM2.;0>8<'=)^06YY'0FPE 98M;!
MME:00@H53N?V$I;'46I=H-^^3N*[#CX:(4O]E$[C5TQG/KYNP;,^P!U7I^_?
M-?^>]&I=O]:NV0VGZ=O-KFC8O:;;L;M=O][Q)CW1Z]3NBACMBD@:@[QPKZY
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MC=S1YX%Y/AHA?XYBT5T3E%ADIW>66GJ"E)4K4 Z(IBKKW-PL,PPVYB8$H,8
M.K8W@-1,",Z;_I42F#=Y6 3(J"HGU$P3N@SV7N%0&[:2485:MM%8X13+ <E5
M4^V:I@>8T#P)PT8PH1W70O";+$MJ5*-@.]6#&>O+.9?K#M\6> 9G#+ ]XKD+
M3H50@RCB_TI8#JF,U LNV'0UVAFDTC)"9K+?A1":7%J12+A&C>&_>(^,15*[
M3<+O@5V?JH%=09/A63"5G8AFV*0I+34,YKEXP/.D=A#1PQDN*0V2=66W>Z<#
MS>B"$T)'P(B3R]KI"9>5(E*/2#!%P_%*:7!*)P3#[<0O^>^+V<S<7F (8G*'
M*.N#PI6(:J\"0;VUYAW48]BLO37Q)>2C@3QF<'^MZI4=AL)[;2JJE6JAD!'C
M[%04)W-X>Q&!L1L3,H[9S9MNSI'A.09JW=LT?C01#AV$V@<Y'BC(H9,A>6!C
M]QRHDV)JI&*%P74Q,EFQ\$C( \79E7S0CF<F8-CO)$VF9+!49>7,RBQ+_)#;
MM%FG4"U]Q#B1 1I@I8S)IJ0S&3JR(EI)('RFYOP\;[..B2R_2M>T<2K]?4+4
MU\U((B#(4H3-<.=92M8$7'$P/#UD3Y] "5"^T*?'A]7",AA>#^W!28+-)9PT
M(H-QD84I=X9BMV22!A.,"RPP"8]W _V6Y+"$A>VN\-ZI+E.M TCIDRVC3 C:
M<QU94#<J;>]:1%JF98O6J4II^47E3/@.[X7NP"E&QL(XHG@/K"*82VSC\@K8
M"$)Q[9NNKU';BH 1$D<TAUV8D)7&HZ 0\&2]%NRSJ@4?S;G$B&.9@Y 7EM,X
M#&(#!\C,6RQGB<###,R=F@Q8A[42.4&K489@$F./U2GMZ? X)QWO,I*B4&$7
M97.1H..S;7N-9[4N1A=HB",U,-X"3Y&KS[!2ZR-WTH")-PU"I+6?9%<X50GN
MZ%^MWVEM+7A?[E]KJ%4<7 [>#/HGSE/^;_V0Q(E'LWA@K6237!%H2/J?S)WC
MB]"!%0L\U2&:1"#ZZ/4/7HV&)X<:;AGN3E74420M%#S"I16J+CFZ#-986!Q]
MJYK9UAN%#2!FNO+R\J)*DR1I&&#^H$9A4X%%5<4AG#:@GY9S<J=S><A0HMF"
MA@OIL6JOJZ,JJ"^,6:J>M6,Q18PA(V,%Q]SG^D=.GS,DJFH75_@G&,>$7::_
M05+, [;<29SEP+D2@)#N9LS-4H"Z.QAX7)?NR"_P+D1,7P)Q&;8JVZ!'LC_R
M)<[Y.RU8R!?8]T5W.O!>GEX<YI8VG!2&\4;:SET"U<;/TCRV3A1]@3<E#%<\
M4_U"B:MU\.*X?PC2XB97SAF7U.2O4D2#W1[<*$D6?"0=!98\N7L0H&0^&E@X
ML(KB*-2MN93^)RYA\'KW1/.8X1#(G2&[I;C1FSOVX/^!OE-=6WH2BU+@()X6
M</"^M$OT5ZS4:#ZV2HVM#F$P!\<Z\?[W21#%-K9F._6&\_=5O?I^<?4$H4VW
M?%,D;KW=6GQ08]DEW38X340>_EJ^1+O;7'S -[[7"=M V3MKB+ZG([:Y5J58
MFZ(ZTU6Z\UC&:G=.S+S:.HN.*C2L5'S(T$ZP,<<,AO9RB5'0!;H0*8;$,*>'
M(# R;!VQLC!3H608T1@PT,_Q<K40:BHJ/)@@"$"-WX)*P# ;R'-*%Z/UI*RE
M OB#*H@#&Z:BC:\*C3F5XP&\ZPHE-.G/FRR\P43Y*D4_(7 +Z,3N1 9K"H^5
M:0#CJ56KCR;$!QH.#<9PK_8;A1+!2X*-RM\]Y88W*\("9(9[,VN?"0L@B/(L
M[:OX%IVQBC3N$)N;\%$E^!??C'#BB2KZMH7]SW?>W$]>N3%0V1<4GZ3V$72_
MI\)&.Q[C]<:(A53"TN%'8,2JVG2\?/<T*-*&V6V*I.+2I]L8M&"<+8"H)_$M
M\R5>^+BB/@<_,BTFJE?5"FV*1N"P'.>0"J$5?TV ;:XBW,K;Y0P$!IU?AH.7
MDB0]S$^Y N>6*)$Z%FH<9C@-6DX<O+H\W!-E&U$<@RK=(E4H<(.)D"NIHK3#
M&51%M21>M4PT""4!?>>DGET)OI_?7;JZ?(\J+8'RCR";!$6J\)R5+DN5D[+2
M'\@PT(V+*<<*RVB4:5% <A>' 6!L+)NS%(Z3>#%SDU7TX?X5S8]'"KV=8=4D
MCSXJ8BO+"4:P03=N$"JIKV:$%C1+!:D:AH((R[62'@Z_P0VMT+]U+R'OV0($
M/04X<18(3]V6_E(.=$,TD8NPP;>_"G )$B(N$7,)2))%?(UV.+&0!8YIU6*8
M3"Q7G4N4"/@*5Z\\C]<1C1L<X4!M!###,=ZMFMUF_4FY3/W8>"'15_-@C/E<
MF3M7T$,*9[JB]E/#P,%+XM;IS?40G&@IL?!BC:(I]:T;<@!"MZ5K7S=UYWPG
M;;6 &9!J4)^*)"EUTR'&(R(X)C1)A0;OJ7A-:2P6Z23X(4A)TPSBU8D/ 7>
M&A:%@7"WY7X;0(#0=U3[@E%5'ZO'L,C E4U:1/K-Y7IY$8X^R%I2%(OYR 2C
M8;@(>;12U<0: 4F%=@-@H!3IDL.&TQX1Y#OVR0KLQYD8I0P4Q0A7N(C",<"G
M(3$%#K(DQE#QWM0$LULF&;^F-TOB*/!RZ\90.!)VTWR] F<Q\#2]647:4/%"
MTB3!-#:N3GQ8A+%.'2,-/[6I'!&AKC>@QPRLU44<D!DW@P-,0U5RHXVBT['F
M%RR!WCT!V(=MY!'0\LPCJI6W&>O) 'S<4#>9 TQLQ0PK;SW]+@S2N\(AVP&.
MS#W$GJTOQ$;=XIDWMGKFC8V>>;/]A9YYL[7%,_\5 SJMG0GH_)".G+4N'#@U
MQ[G.>432IWZ_IOD?VH%*BGB&X6Z08_&MZB-%&4^Y:M7\M![*5=BYV),*.DN*
M3O@]"*UYJHK. S2-N"#%2X*)M.MB^F2)X^#HL?=UW;>+JN964=7<)*H:]6\6
M1'PLX;\"7*6I:>Z/1OF(SL[]N!>M) H"4K@(8;7 ,2-VDUU=N1;_F!=K<$R
M.)91GZ3>38SMX7F+BP0<AR3 ]+)+B=?)*@?^?"KWV7$*%GC(P%/ Y(2GSG$(
M&1;,8P]<"D_V9(HA-G"24G!L&?]G+?CE!LDM D9/>&21,71!+YC]*$\.7K#Z
MN 5HJF=!2J6Q+EJ?9(7(32/KA,:G>ZL\>:L6R)E+#\><H'HA0Y/K-##CXV>)
MJM68QUPJ.0?;E.\M'0"]K6$67:';/)4.##!. #(FPY0U)>/-RL4/6'!&9:V)
M9MM%)(!.$5GWTE[&>VHB'TS@0QS9Y"UQ%.4A[DW%PK8/#H=66"JA!XI36;,0
M;H;6'HZCA!<AHQHX&MX%8Z?$/QY;Q?@Z:^$AG3SG8(:;@#R$'8,]ST<+I:OY
M H1&JO8;;R+1*K$Z,'81??PFIC9)/<6!D,/34 B-HI[>JM(6&>Z5K^\AAQ$8
M!=Y</XQ[KBD:SC*668O @<#)]V$W&4\*"R%]+!S9O9CI,/)0M7A".YYNJ/I1
M)&=3K\=$UE7Y F=0T[!IV@VL19#C2,F"OT%.F+@24?A*Q-+FML+8DX.=QCHT
M8D02J S,+43=G2;!=-%$&,E">7H_OZK:I8(0_GZ!V%^U&O^02+(Q-,'-/2OA
M)E7K91A/T"DD(&,NEB#W$L,:3'7D23G1.H_<I$OP[]##G(&:=^'+Q!>1@4%/
M3!&BU*+YUGI0M?RACY*59TPP>C(QM"0%W*56=;IWOM.)2,%1C''G:M56<\M5
M9S%).MRV6K56WW!'S<EP=9\RR6% XJH.&[OMPO$,MR'R.?+@(A^ @[OBF" A
M9J VT+Z:N:UWDOP?G3H^:P<+-T#FG<,Q0%#H#2C9<*XX@I'D-6:*[%B49P-/
MB;#"S77L+1EHVESR(\'R5$QA??9U8? U-5]2- &4*?8[DC>>EPRY6R8+R,I[
M&8G9#LE]>?% *"+WM/)_I)'_@K1[#C).QTU%8%/9)4HAK5L*R"E=3]K=#:5M
M'QBYDP/6LEQCKTM<L@4>DBE-V(CQW!8H2$T?+%JX0.]6B&L9"T090R VRQ@V
MA>O-I+Z4V+YKQ25XXY[CU%6^E"#'9&T5U^O0I*U09-=P_IRZ=3 \@?\<ZL9"
M[I(0FZHL>5%L_6$[A<\A,)Z?DRJ0>+#BF)5Y*PQN1I,"C<YY\?!P0 A_BT(8
MWDS;[)LA)RF,CK6OBE)DY E]I%1I'=H(=K: 52L)9H,MP[%>/7?GANYP,![T
M!T \LV TO]4M*CJNJ4,; F]+!8.RYZS;IK"X7HZVULA>66(>!B4I;"0^I4(F
M,/Y -3O S5]2_:%#-;E"Y+<Z<)J_'1KF'S91\+4->3/49A'>F^[CXY!?WU(^
MCHINKB/GRW8)7 G.I*$(?R(P3 <_H\W@&^9ENRGH75@8;,Q!H_L;\_D4UGF5
M@:GI]'[#BC1.F=SB5%YNL"MM,]U2/:8B6XGH0V)MN7H<UJ;7KQ>\<ZIDK/F'
M7@ZD+K>RFU+?% 787+9%O7 !=;#D 7,SK-:$']:=G%'DR;G?# 3)W/GP S*7
ME7@C^4 I&3D2#Z]%F\"(P&Z7/71N=?&WSLK0[T%RQ$F!*964NI5P)+J6L"A<
MY$96K7/^RWCS"N95#SIMX,@9EI( $TE4)?0:ON$[J=BJ*FC?,#JB<./\94O+
MQ_05K#E_@33XH!#V?#C+FU=M^5E2%'#<@_3KJF_V/Y!S7#7.0]->5[MOX8"#
M7NLWZVAH.16K<:B A==/V1T&[*\8@F_O1@C^\:B H6%%5')1DF,IZ#:7]6E*
MU(11+N8!8;&0[0;T_=%QD[X].N[FC?!YTO(:FR@2]4U5C6Z2PUE79G:^\!@Z
M51+R BV8I;9%!<:0<IG=;+"Y*L-ARA"3'<ZYE"<W)J48E\=2E'!%C'(XO1.R
MK?_SH9$?#]45G7&'P%",D-+GR0)#3%1[SXA'LO#^_/CX4(5@7QSW48?\F8'J
M!O>SMGM&#W#\"S%),C1AX T:90>:9!Z&&^\R=5*<S>L;ED[>U;-A*I7A4']R
M-E6!R^VB(VR$_Q1"TMI"',/DNIW%TG8U8>OU$A!.7';]A[&,1J<(&D/--EA'
M$8(#X=24A6/>^J#G:'NF8+9]ED&C=)EI;:$]-@<5F24\5WDB@(TBZ:@<NRNK
M5I&GW4UD](=N0:4,*V6 (2%JA@7#OFW@%\""S?(2K:BWFZ>?J\)I\@ ;FLHN
M*AMTFOC2"LOMLA]K-?U0LVFXT4;-663=MMVP^?)\I46VQ4@H9H/$\A;+P.IT
MUKH5%1)1)$9.:.V>:!MO]J0E:L27Z'+ZI=;EI)5)&"FMGG\2KA"4RM#RU?7I
M+KD?K:,8<*;?@GJV6O4[E/:4\&.VQ DJ6F=S8^8]%/;.$;:@KTO!IJ!@P>G0
MD\GUWRCZ](7!IREI4ZTXFFTS7K0Q /6,Q77^FP;^1@=_"M>K0 S'FO#--\:M
ML#ZSSB$EBB25WD_?>[(RIK?@_56YZ_98$T:3U%(YZ(0M(XCN4OI.1DSSR.-:
M-[@R"HI:G1XMVZ0U^ZN?Y):+^C%'A>5O@V*V8)WU=Z)#ZLW+_T/^K^EW'&^K
MSCM2E:78![USY[RP>BZ0 #/4-CJ(--)MH:XAKV-5(4Z*FV)"!C%B2JU$E"?'
M#B ,YNB&(FG@(R[E?S.F5 $'J5*4K'*==S1GO;JT"S7.E$JGX\9Y[K7:?Z/-
M7=?-RGYV/BWY;S>U#.P>L665!-S(O6);5Y4!%]K_B1>XV'0>Z$IYU*0EC-(<
M*3F+;MFG(W->4 &'3-A(^*];1%ZSX4[VK1LL%0:8Z@HNWUF+]'L $)S <JGO
M;"XH1^L22D)^AYRV\))'PS/+.50(KE1)8ZUBK!&YA7]*KH*+ZA55\HT&.E:$
M3+,<1NL>9>E>^63I FR)%Q#=Q.$-&D23D$T)_%&VE$7SA,)&2\*M<CK/4K[C
MAV(M3>FTRCW18-A*:*6%UIH4!;4-=LX\UTI,,2-.(CX0828A>&6ZJL1HXF C
M&0NI1,+W0D101CK YHP@O<YKU'&5=,TD2):SBC4/L/( =/F5D#T>(IFY5 @T
MQ;HZSHRI<C0N&S!.Z\;62B17[!7KD#"#J(KQU=]^++CR/N])W%:COWMVVY'J
MR#%Z.J)8PD8H[#99A;]"&A*82*%IAVO_#=E;;%LHL_8.RD&MW&%S3/@S/0I6
M^A'K@#IJJCOB,+#?,NA@MIHK$7*\9\6NNB63%9)L=W.Z9I>:#BJ"."*GI\#=
M>>NN[N>UJ'V9Y)TJ5$Q%_I2JL30:T\S+4WT(>L(EB.NKQ(!IU'=5!1+%\98L
MDSZU-F2[#*7-M0;9I%&)(?UI0$3S%MN,'%5F3!:O5S$7%)CD0NFU#.;87B5,
MZZ&,,9W3TBU[A?@M!H$UJE,J$5J4MS)H/X6MT\C@X\)( /+_47P7#M)MG(7H
MY!N],RCU<Y-IC48[=V@4M(IT[3"C#O2/"36S FH"UXC=]*'KB4ELXQ1PX*Q0
MP_O4)\0O"NNGC(MDTMG$R9+W(XQS0T-3V8Y1P=,M"R49TM'/5MXJW8)(I$P-
M_5CR>LB21$0W-OJ,R='(0)B3DI'\DK4D0QBD4ZA6A"*W^B*EI,C+XWPG+X4K
M8@COD=^TU!*X!N4NN5D.JM:[<L<K7=%7B?GLPM7ZP7VXK]QCWHH(F[BDH^?F
MJX+W:=5EO*28*UZK@UFJ)#_=@SW19\;ZUJ,+,C"6R"((S/VR_YJ/CY0Q =@I
M/O7J:6:\1Y<6X/WD2]&K*THDXDKAZ./U&%B6^*K3A/%R Z$G >C=/SKN_H^*
M-TE#SHOM'),?^\'RJ4EYDY<,7TCBH?BAKD07S"!?5I\J##TO3I1O2>3)\__2
M>6=T0+!SKJ/X%@X8VE!4;%1D=EU P.XYYZJ(*R6>'U:%4E(K@].;SF2]M8YK
M\8+T<I#M511SC2D+VV+ HD?637 3LZ)8>XU=PP?57"O9[D@1BC7A\R!&U"9@
MH!%ELJCP?1?%/(%?9TF:,1],]'NEZKUX$"%PH-X2V<Q#PNO4Q3R7TZ,\ET)I
M5KC2("[<B9K\1?S][V'_Y>#,.JN^J9*;'=NJAAZ;-?Z3!3XN89&N;*Z]]L%K
MB'"\K">#,SAW;,,:$;Q8C;-8TQQ/RQJ#XQ>YX&=K@520>DEZ.3.3YY0R>6[$
M:+@*SII#BLD2C@/.A"R\KAP2A.7=$I^LN#4N2">A$C5J0S9M!RG+B*IA\HV1
MCEB:EZOOBS8,)N_L1M'&#]J=,ERBA(\OS>A=QM(4Y#A2EN18 %7%Y#C%2T-8
MHBH:AF&&&6Y8ZH?E2/SGG__5;7;KSZQ6JW;\(1_'M7ZN*X8F,V$#-'^[A9,F
MGT]@G>J1!4E4B%([O1VTQX?8R^J)N0RTEV61ZCG'+9"[@2:.T6N9U\5OD)YL
MK^5VFJI91*^18^ \0X=5!*?+<M'+A2P8\]%1<S(%P",PI13BEPLA2VF4*5'N
MIE>H\P\@SL<E%@NF.1QEA2)FY/$L9Z69<'H=IB&/I0_NN@-!=X =<F] LE.$
M)4\D9$M$J*GH=^=(,[477AE3$=8]#<8IT[[&SEE2R@D<%]%H&8E#(M+NW($\
M-V!VI3E4L2(7@S3\3I4"\K"KG26VUM4F/".6;M0<SD' 3T#JS56KJ7%E75W9
MD'D^_E@YU&3%)3'U<H(:KQCNNG50_QUCX'+D&OGN&SUW>2NCFHC[08KGS^+S
MI^N8I'E"$<>HQ+T'&'^O/U5+7O,7@_0^S(\:"$6%=K:EF^84NVV[.0@X1L[-
M?+\K,YY%9Y5D)GZ++:(&1G;1L:I:YSPGHV*$&!KFOAL;IM>_#-(T$SFBU;+4
M']:3([UE]-HH0N*:'QO[9'!S@CDWXVGA7*BU@OO*^]0J%I^HQNZ%L<F+2(!6
M&S6;T+EH62>FY >?#V-OF,MD;;AL&0+W O05&P*RCEQ'[0Z&X_&AB=]T</:_
M=3R*NL,(\_W&2>(A=L'"Y9S^E8LH_2D?< ZJ!PIX4+,9.=[<<#J5^#"D1N2(
MHM)U&+^/;*F_",!QG$=':,]4P[BQDH/4A*[*50[!!58H:RJ_DZ>>OSE4G\(V
M&+M0M<#S47FAPG.X=@X1K#%C9"Z<S\9")&CH2XB@PD]1\V\-&^$A1 ;\S3IH
M.$^=1O=PZ[M@_BI++<>I.G!UYVF[<;CQW:R#Q?]BGVCOF=5K_78T_-VR:]5F
MI>Y4ZX>F9,#,T-:*/(Z1K8L.%7E2<@.39XNE!.^^0YPAS#\5WLOUM"OU9K5U
MN(/FZ L%"U ^9?,B+^&)<GJ-PSP-:ARL==XJ\50N\]1.F^Q#?? ;:.."1+RB
M![!@)HPVXU&( YYL9D1*Y*2PVRX<3M(ZU.QHDO2+%!,9Y^+::K0W'93\M/-)
M:%0[ZB0X]SD)#3X)];M/0EV?!#H(P#V%@W#_0Z"*BK:=!EH$SM,P) HGJ(N_
M^-UR#^\\+\M8C212VI3'._O:%F%3I&0?5ZS)W?>E<PCFV><]G3/7_J%A Y4>
MG,_Q,./9FG"ZAFA+:^#!B!HP"6H.W9GRU_0MW16<L:E-^8D;!0B1UW#Q^!GN
M&X633_]$W'F,T5;6RKRPT3T0:W-!6),RD@#&D)7*-;HBV/J@7C30VE9_+G!>
M2V2-8B_  #Y*PZ,X!#O1BQ=\6G7YT4%_='1T@>\:9>A*TD@;\@>EGJ@HN$:\
M?Z.)Y9CHST=JMOA%$?7Y*(YH+B'0X&!X\>;HD!$#;G)_>?>,HK=F\@VWH56W
M28C(!(FNKUS3M?#NIHLE&R/)W-42E4$R\2@5\S%+.1&'BF:[W5)ZJO"8+3FH
M&;KYR\WR557C-MKY K@NXP[)J9:R<Q24CIN:2R*++HOC3PJ;1[O=AUT+)?3"
M<LV<98=ESC/8<-X*!=R$&;BW];QC0P^K8?>2(ODWE3RHQK7P-%$9D9^P*U:R
MD3+ T^SJ2J32D*/322U--_C9E3J;>7P)0U#;PRGL5I8"*$;DIE2/G6\2#9\I
MAK[,[GM*SD>J6 G%X)I<!&\\N(F7NH&&LX;\NZ4NG'*MYR=]'"1"V":X-7=O
M<D7M,C8Q@?0.<%^S5*W0B+S9>1=03J)\ 3142D_Z(C1/'E"CYL'(B(+>5KHK
M>^S&N!DSIL<"'1>&TY'GDH%XL*#B4S?EG$;>K9/O#E>PQ!$5?&'U&E=B8OVQ
MD2<F8;(>49!FR=T<JHLJ2APA@>= #4I,F:W[L7$7=D]LC/G ;Y3H]=R"KM<:
M?(0J6&&$S2SLAUX18>+0QQ@G2F/.=8-5*PW:<&7+,!,5^Q0LHU)=YB:1S( +
MNO6+BF)N@=6Q*CU<SE954,X%+UEB@,@)<5I1(*"QM%.!M6H5BSL^'%5J<&#X
MW1C VAQ"HC,GY6%%Y\"+]O4FOEMS/1XL#O4+-UKU-X7=-M-HLS]H$&4+#7;O
M>)O!KG)S:&YPH\&@CKP,0XYR#\WPSSRAXQA%#TQL5\P;Y:]J?3"=8:Z>V4"&
M0CXBGP:2WK7$\O* Y':!Y-]F,;L73!G?'3K[(FJ:\;9BG*U;;?]F';2?UC\=
M6ZC!A;6GS;OB"H[3>J;'PGL49S1>!1]6T0&X>A/_:M6JS<\)P>U+&0Q6Z>Y&
M*</C.EMR?I','MPE=A!2",RJ8G#=:30W'LBU4]/N;0FSWQE?DUV,]0Z=RT;G
M*3SO4*,F;XNAYRFTNX]PEV*)[:?MWIW1P9ISQREVNM6>/L6=*EB >*X/=U+U
M\H9BUV[E/GI(^\#@C)>C?4A5LV&UT:%(;*O&%-Q,F/O2I6J]#&Z$E/RRKI0M
MSO(R@H@;A/2(AKR[A3MA)"MM'N] CC.9';H 0ONF@0$<K'*C/-W!O)<"]MX]
M=NAC:,N:Q9[JCL#7T>%M,PYB)B'1-*'&C0UE#!1K2[>;0=L=83GI>QLC\F/O
M:0&I](8.E]]M*L#[]>HEF=?NWD_DU9N;1=[7YP-;S6J3Y6&[^RDAY\C<X=/Z
M';;*/\/ELT])NJ9C2+HZYDFL5J=:.]RPIY^0&LU:26D<U#OU^^VITZ@_U*;6
M6U6TZ=K=I[B:3^QJK]K]#;4?B+,[4DOWV5:G5:T;"@1V%<X]>O2[.!1F&&T]
M_I6[6AV^."^T+2%TOY3/[HEEJM/3YXQT4RHP"!SB4 B><XX&%<< 45'1-8A=
M%*VL:48UB<9P;<)M<3VEQFYDUBR/C+X5?',,7 911A%&6=,C"J*?:K.QL16!
MAK%N%K9&+$K%DU)18I90JT9\!(X_Y]CE9![(B5@*J9MZ,O+!SX@R L*:!X'#
MV[Z'&Z++%\K&'M@?0OS>M4+ NV$6^OB*\,4%/(ZF6U'L;>?8=T.O&C938=<1
MVV,;VYF5<Q+A#%O]]B@B3\04,9AEMDT.B.6B5W>E!QCDDU/A)Z,%K-*-!#Z@
M&-?,?QP4C==B=5J]5L#SK2)-UJ>VWC$OMXC,0&5^U(Y) _,XE1)B>RA!@9EK
M4^\PW#B&SYU@R50+E#V\;E?.LM6OY.FQ69OCV$\=B<1T&R>A?XM)!;[AE]QI
MVQ)Q-HX>LYN_$8%M+)=),,F6JO4:[B7SW+R*CIPM&,O>4>/G<C'K-Y#5T&9-
M\0Z6$XWU( 50C+HHVTJ]1/"<$]A:'M+J*B @TGPB0D.%>@WUI3J_91C.FK(&
M%I$>B&&6Z:JI?A*F 7-Z)81HUP]BU3*XTI=9!Y<O^H<X_#-5*"AHKP,;J4:)
ME1$F37*D@X0;RN3AJ4BD]&;O-SI8!%'&%:(FE&2:/_<SX TJ4H\QX@1-?8PP
M4T_0^; _",BW@[RSWJGLJ@K>,DXB#@>WZ[7&84'#FYJ[F(*0-?ZOAF_L2%PQ
M:B=)@6(ZS<K3::[480M3AQ%Z!OU5!C6)<&(IX]#TAV>(4W*/!)SL9,BG+2@4
MR$AF7>O-]??0:3A&%-0H_/KE?5C1#=F1DQ49,$>#DY/!T?BR;[<N1C2\)_#N
MQ+_7<%W G_D&%=-E>)6![&'.2=^28%.A"UUQ1=@PM)U/]2[+^K#4119@\$JS
M6Z962K,H]EC'QV+\355+4+7.D=O<<+KF:FTN?CEPG*=U<)9DR4VQA5R_A8FZ
MF>L<=TDPV+*<N]AH;6!12BE0O;.KVH1/V\$C79IE:G3V&_O%S):/CP,EBGT/
MZ"P I?!@Q]%5C#NH?BLG+* =$B<:J,'J#X]'UJF<&PW,<$3?+X-L#J?R],AV
M4& $A;Z([2+C\Z7#O<Y\01:I -VZ(,!RCE#8;C)794/@=)!MR,*AW(106Q<4
MY E):;%Q;L=FB5&2%ND<&?;^,B-("[M6LEH-B4';IN$58@/W";<2]DO6;*J[
MW=\:VA$OZ0V.'$]V$W[N\URC(MY,R5&BR>NJKGB31T5*]R;?K I;"=2N0= 8
MK@5N!,N)*0D%Y3$A$S%J73G2NC3-U!?'?5L#+>706U5KI)"_<)V&]6B:<,$Z
M!AHRN30'C=E;AJDH]T-N%5PP#:XDB'&%BMT8<PM!(R7*5KKR\C)V'/N7*&B.
MO(F1K,6K6%7S\PB_JG461[9&OE6P<0K?"Z^-IU,I=%2.(5XP9-\<V];GL<20
M(W0.!3BU@[KH+O.R8%4ZAVMQ(W/&R=TJPV!4\-])K)MX.X:(WV+:;IVM8CZW
MT3![^0K/+%@3A18S]O)-@]#Z,AE_EUWX139A;@W*5RF;@7DW&+&AH@UOTI8)
M3<5^,K!$_G2C;0@0G[8?^U8=I(R*CQ2 S#>:@P9-BOE%/+3MQF\Y'GDI1UTG
M;/;>X1;#5!J7^UH*XV3W=J.6X@?MCO1#@*Q+V_ Z>#J7/(/ULOUH6K\K#F\?
M."W"5L9F%3YY04$O,Z"Q2Q7;93\/@^T>1[ND1X,UIH(TBWLO#Z@@J>_0/EO5
MS1;@XD=C0FX?^=QJUIS-)N3+,(@GH0MDFKO6*4:$"%W0.GCY_/1P]S1TX77F
MY=>1 XU-.\R]TC-_,3Y-)<()0FW+X/,O.T]J<T2;MH_G%F R%U2)!/4(*++?
M;G'Q>3[D(!__2N8U_$GS+%*VGTF,XJ2W.+]'/F1Y$<>)#(IK/.)\%@/B)RT5
M[@S;91-"*%-V.$7?<0W(#SBA@Y;V3*T_YDY^!(>]"6X(I#ZQ7E='56."@T;H
M6\/YE8%<,MZ+DWMKNIM?;@%BTML4O=6/PJW"C#K%H]$51UP E>:4XV>Y':XP
M/A>8^-/39ITZ#[;5,W$Y<$P0OK3Y-!)ZYTXV8FQ(;"L#OT8+MX#Z58K0G#*8
M3RTJ:GP*SH?%,.L\\%.>!JH:>OA[&O9>#,H1X%WZNYP7.A8AF,T)JI)+P3GX
M,<*G>DFP6-*@\=EX<#D^K%AO@W">6F.\(24J;,<Z>#N6X![ \E@9).R10K\Y
M%7.0/)&P^OQ$Z^!B=-K?Q8;P[6X2SBMB&MF(3<MH4@JY0=.2L)MP<&M-#V15
M-#O<[#*!+ #.EZ((G@<'A4KZ^$@9B'.>F <+D"7NQ#HX"29+=Q4_B)!M5YN=
M>^S5!N,:J6DWJLTN_/P& ;'!KY,6,C;GX1V>_/'/_W(ZS6<_4CU@?L*Z. :>
M#J)9,$&T4(7.Q4' 2T').=AX('TR=SV1T;NDVU(6$W'%0^?!?>XR"+]*8K3J
MFRA<:N3?Z'3>,7XWUU$;W<+2F.G""(T#B0*#X1T2Z!1@.A_MXF'5J(URO'?>
MT7T^DC@DNK.[OM[9#>?V2$4?SM61QI;N\T/V@(%0=@T.=<GZ!G%'6A@?DB6Z
MVB4?)T8@B3(M.5MQ4=3IR],Q*H%YC%G0@R,>.]+GHFJG4U5 .A6-STIHPJG&
MX&)<+G1*$I[GP .S4AHFX#2K;0Q)\CV EL8295%1:7D6K\A8X=KBGA]R)UH#
M:/Q5JZLWJG6[WLI7IY&(M-S\GUQJ&N#%I9#&AA'J-#ML/<XCY2,7M8V?CD__
MPCX\V)*ECH'"4SX"R4$P"XIX;3ZEJG#D+$;_;66L&,29%QA:MHQU+/MEL;@E
MB*9!R&C,>%?2TYO M!_[C!EP@:5/YK3 ()#_JAG$.]SLJ2F+P3KB(I+=DS3J
MI<TBBX(]QBCQE*93+ZO-(\,JZA=-*.M3)E2E!!:2#X4GP"/3OJALGI6X4(_:
MV0$PPR@'YC5@:_/0\09XW@ONW!^"( F6V9*+M23W#0N6]L'%\&AXJ!6JO.82
M- EU-^9W.#BZQ.M2TMWY]"S-&HC***A=H4 Q5P\(FH,'0+6<<*OC_T.PO(KU
MXF3<  <1S <LB0/9%_E)@"B3A+@]CR<$BY <2E>2K1:^G3<3WK5JGE%VS$$4
MW,0A6/N3+>8F"'R7ZOH]=+/D>&P$80E2@OPNL8MU,#^ZO#@ZK' ])^Z5G6>>
M-?2IS"!<G%^" W$HS233@M7I4?1>M?E4890P(T-@=NV7[F[.O)#H[*7X-TIB
M$J[Y7%P@$X52%AA[,^F>XQ"K-:9;-@S?7S:@WXB\ (51)O+&8%A @GI)$4/A
M!15GFYI=#"1$)#'S0;XFZ+C$VDPEP($,"]FP65Y%_AMK!.98S&M,^7F-N3"N
MPU1XS!4B7;Z'$J0175*91R@F8G#F0'(M2ZPVG*]@2;Z\JS#8(['$'U",0=W(
M191X6*ITX/T,V&VE^(I#YJF:?9=%Y,PJ0 0RO^"\[::T,A%[0%)+(]0$%"J*
M(#1$Y6D;#<='AVRORBB*1A(B I:A<FF(65'F:SW!4DG.M-PVD4&/B:D8?2'R
MS.;+T[?['TL+&/BW%&.Z_=5'9O,U@*P!_F$PA61T6;7" /]2I'#@B4HW)'X(
MR .7(#YPUZ990FU;])O/+8CXWF;5W8%M6<R8I=:QS)!?R #1D0H0I;L8K6]V
M9<''T?F;(2BKWLZ5K4AG[VDC=PX9R80FFCG/X"R<G;_ICP<[*9JTKUQ$)O6#
M5':-J-PTA@@"QBK#XB\4T'"MINJ-ZWG8/:):0UBJ20:0J&L@:%(&0< :0#;9
MP"U,Q R'#9 NQ<80?)K$O,GG-K(DN KC"6G^.?Y58"NY@-28W7#/-\,: $U#
M#7F<]_%/8R^32%(R*J0&DA-SNZD!@JRV(8_JJF%;:J%5JR\A>I<!HF;CTW,(
M5P(1B?..'?Q63.%%59<.3U H/GR&ZAZC%2@^)G%,<QC44HSR[-),TWMMSI(*
MD38^0;VK6I])<5S8.@G5:\GQ?<%TJ<9NWF+"(T08#=X;?9^9F_<7J-E?GD)4
MFHA(H$*A.I$"<)1:FRPV+"^Y3)2*+@%".T:%%[#LA9SZ#2/46(7/T+B42%)Z
M:C+--*H8,PC!@J?$BP>F= JFM<NS!=?&/*M5:0/UQL5Z2G8NY=P@9AA]E)!?
M\/9@9H+^Q+$=U% UA4?$B1Z@J+&5Q") "TS73H&1$/FIN58JY2CDIA"#-Q'Y
M0?.XP1J;(K'A?+EBBU C:&WDE1PP"RMB0G50W&++;EK9P#2*,HIV,;5Q+A88
M?$$Q<D?TX%>L_G!J^_*/.[8'A)1 /Q<%_7O5TH*22[$7UP/+,@MNNN3HNKI@
M"JQSI6!3%0XZ@17HSDR4["%A8N,UV%03<#UC2DTN6-*!__4#"E/.\-1<(5M'
M9*_C&(J(A)KT?G:N'_*3)M/H_&1XW+\<CM]9X\MA_\1ZTS\Z&IX-1N#PC-_L
MWM $K:XP&12QXKS%\2P!::,U*TF;!VDNFR7+O<4>/NL58<Y9Y\F5&P4?92O6
MVU?GAT:9_RC&?K($-17O[AMI FE0ZN)<T,TEG(2DRB$3#@[. XHM8$E";L4H
MZ\K20 L3.7[3%PM!%#!,P"#&F)5<-@%&XJG@UGJT^"B>3LA7+GOYC).;RJ9P
M&G*/0?9S4]6A^:/-$Z'MIJ(]^DE;29/B3I-&=Y^Y-%"8=TRV27#I?D[QR"R,
MW+63:K[&T0SG"^W<V4,FR0-2(,G[OB(C&H]YXIY3L"H,CH9>O58SL2ZL63Q7
M'(%\6&]WBE_?Q3*YA4/[:(3ZN URXTGD@U?Y9%;+9#@V^?.5JH7<4A&_OFRM
MWKF$E&M8R'=X$7Q3.NADM7(QK_SI/1^Q>YTJ6DCXI_W) ]54M+YH;=N++%KW
MK['8F:/]FC012OK1*CI"': 'M['SBKPI>\8]J@_G@5V@,;!Z3!\Y(S'''B05
M2\GI8&X^M&L>1[$7$@HAAD=Q*+-U,.]/#@GH(A%3D<B^O;14?>4R%#;RRWIE
M%^-DR+8RA39#B]'34FF:&V>)90TR/3S3&Y W*:CV!+K;2LZ*KL K8>Q=H:BA
MDD[B1<Q)<YE^CL&[BC+T#6FP)/7CP]NE>L#I05"%TRH#L;0 D)(BG!Y6K"Q"
MY&+TRVXX5(&1:'A9<Y0>[JPT=M/"H^)LB6 NYJO1EN0NORH]='$$# ,CI[D[
M7P260XO")0 >MM-%,N?6(B(W7$GP7E05@P65OAI<\T%XF4[WL^<H284?>B#P
MF%!H?GAR8"7=<0M5R4"@YGED([275'.3FA!..\)M5?!#-=,>>T"Q3I<XERNY
MS%VE/G^,N<.;(G48EY@J>M1]Z6VX&I#RP7.1>+Q-NB.)B*/F9^YFUF2MT[E"
M@RBN5,'*4KAS"E#DUB.EB5#QOL7LI9'NK5A]S&W^)2+P_BJJ&A@C"9([+D04
MI:L0&"MPV;4;1E@QXQK75?)DGVO]H]&IMA&5*$3NN4J07+)-1G#I[3'("QS4
MCO8(1=AT#OF"?<_4ZE\1VL(!^$(7?2I#2]0U/%DI'Q'I\J7R"!W'QSI#_>?%
MX-P^>GYY=EPAY/Q4Y+*H..E23Z2%[;)'_<N1?12_L>MY#@A_(]D6#&I/(>P3
M+I0K\S]4^\9]> DA-E&]N<XVF4'9'>2[?I[.)Z+\=XJ>')<\$Y%56DSW4GM4
MG,1YTX+A8(J*>9 DX!0!\QI\B/?&(J1-!W^#)C)NE\L2KC! &!%V(<L#Z?5,
ML!VF"3:K9:&*Z,NC70I<QZDNC58#5DW3G8L5N&ZW4B@XD*WE'+-#X#\;G,^4
M$$@0DBR%O30K%LI^]%8+?L&5HO$UO(Z<93S%2+<,#<B\PWRS9JD4[>KA:9XS
M <\ 2_FH/!Y#OH:FQU5NLACJ->IJQWY&W@C'9O^F.(SOX-A=I5:-A^U1M8A$
MON=QB:EU<'8TKK7JO4:]V=N DOK8J]5RA[<N.X@&DSATK3?4DR73KCMW.%#;
M\7MP;QEU4>=1*-4BA%^&%*4A5,T<*)4-$#P84Q<W<;E2V#U8DWDEITX8/1FM
MVF]LD4A[#:]@/ 5$AZ*2F92FPE)XF4%-L%5#5K?'6%Y,S=EV7F/-C$;=*%7Y
M-EB8FX*&<?/9/=2T !2PN7MAB:T*-+4OINP'&].49 *[,Q_V.PGCV*]@94XB
MEJJ%_LIE*".0K %:<&&&9CQA6TED(9*GP "!GZE)*GC'-$O K!7T8]P1*6;E
M&)&EJV8DX+_G,L.Q^>XL9_+4TT3XOAI[!;)_.:/FEB%-$_7<!5EUU++#9]P'
MJ3ZC-6&=.>Y_W;%\/,)D'H*C2 WOQ?(33'7E$E)G6=PP'SF"7CWU&_O2/3+4
M?#E_9C">K/$JW$;;0X,,1)2 E\<R9 XD*M-G<-K/BT35_0>7;P;/SQ_:\WYH
M/_M'B ,D S9%NW/!Y=5,[[>OSFF2]7^ EWEN-G&LSFG@F:1$H8%UY\6(SA?(
ME#K>A: AC;O2/" -%6'<T$@Z%[ EY#!=05'5X$843,H<:R(7SJ4Y79@0Q? 4
M18A1:2T5YX(@4IUS;HA28R4[Z$IH%"AYTH!G6)-/RFOA@)]JS#,2P*C_A>',
MXIG<.1WQB2'K*D1:BI"Z5K-=B']*^VFBBC<CF6= :P.C(7-YN$L];:1N*5:H
ML!RVQQL-HP.KRL FP[)(E$!(]V+>F">IO!F]L?\"8?$&1,E>:GQ%!U1$R"]T
M#D FV_G!9HOA1F!)@:R2E7)?2@^R"YN]6KM=[V&M;XP])J*2$W]&V@WQ.8K-
M[-PBKTH%C2X/#FJ!3,#1D;F&G+)(>4\USCD>#!C&R(E+J>JYK(*D%Q4Q@EC*
M.VH3@1E5B0TJ98,N8DUCD)J?>EW3^PHBTT??2<'P0DP2A0-2+@DJP7^(D@2H
M%H_W!N+RL?9UG4Q>ZP([AT4$UD&CC;*FT3[4,'#"+W7#O>4L15Q*]*0:>IA@
MAM-9CCU\!]8P!RYX]%JV8'<K-M1;CGRL7FZ7/9V.K+X\#7P?]-@ 3?-+($(@
M2^I'*ZQ21U"!T\'E:'OB_9>LI'%VHY+F\8@3]$7OR6G4^B%E;6)<%H1A1&!>
MY*"8TGKD9GY@]3'(XLK6VGK5PINAJJ(Q@:K.G"2]= ^7Y("A $.<ARB8\P-%
M<A,'E,TA9U)&V:5C&5L;/$RMQ#3N(1FGV.&[WHFTWB!Q-+@8LM\KK2;Z@(=#
M8O&"]*'_T<J#RE3UEW(U@VJ$B DZ0-AY_;S9'^)RJ)DL..4UJV95&7%:KU!5
M@F('(X-ON5Y+M:]LR/0KSS(/"5H'%/6:!K+#!!-)>BY1"0'-*0T0.=29^(ZJ
M:N:N&Q94I9^3S5O ._-CT%0@+L* YSK*J1-KHT6WU^ULBC=6[BH90 VPW@];
M"@ZN :6WL/36C/Z5<+G(XFMUN\UZ]_!N7)DN_-^?%5<F[^:ZI4H3U3Y%J&1<
MW&7]&2>^"X;JB9BX42PMUG^):.7NGKGX7$U45H5MYBRA?,:C:N,)*+[(QAM)
M.^H^\\N57&:6R^1:LEM0O)=FGH/4[P-CDG#3%V\P0">KM;DT9$*6,B345T#8
MZQHJ092[H# %5(B5@^@DKP6;L>C=_EN5QE$N.0DH,%AH4C(=A=UK]<Y-RI8D
MS0FX3RZX#^"2[1PC\]JE.TFI]>LHOJ5<)W\U V\T268N0C3*R[A7U?6P];<0
M1%=1$ _\PI2B[>P9OA6@<?I3Q#_80=4Z+#2+<,AH6RV=:]6+D'GE4!'RRQW&
M1XM54-_S$K=BO9R!6#$;<'+]K7]?! DML:,AB8MDJ,AZ-@HU$PF5N8E(5!$U
MIYH]NA3#YL)2@H*^&,I.)LXV*F' LW=0L%'-+^9T!8$UJV 5]R\M96ZMWN4P
M/2EB.3W:J=:L^17F%.K\+RI#WTVV*76[EIJ,L$GUBU3"!KE3,>#DBRI)E%22
M5$=ES=$R-(>UHYIC=YI<CPI>$>Y>'QP==%CNV]KZ>/B<(-R 1R(AFY2+D2E9
MU6_4(C\/XD41/,H:91^!%ZVCN&+U%\C(< W\E:AD?JEH"27/<VR%_J<[7SRS
M3C%Z[+O62PIAO8 #YLL^ ?KDL *WPGRN&CL]X-XOS[I(<)" \$GP#>%HWD@)
M=8#L"+_[@L*E<5[TA+NB#JZZT\%Q? Q7O1J^T4T*LF?AC'$"*K 0JN67V4AY
ME8FV,7R#:_N7&XEKEQ**5^AS>17K3/U(P7GDOSD[PM_H"_0W)!UDC\7!V?#5
MQHMH=A?X9,G52A:$E7NTT1$:]H?'<H+AO3%&*M9%F,W1"Q3623 5U@A+V#R4
M&5NAQN KT(>P1_8K$<Z1G4ZPB2^EO4_FL?4"@1<2OM42J[D^7>9&F4'8!,(W
M 3KWD_FJ^/Z*\NRV;*JLVSTO!H\NU42H]'TI7.,F"39U<282$Y=I-H=W00\>
M*U;CVYWK\M!2:/=H960N&V"$ZJ$W%&\A P_17ZQUU7(2>"S$%.()VUOW$\A5
M\->7?M4ZP(:U>NV9_A7][3PKS'EW<2B7C$$E@L!RR$G^$\V!#JW9L0ZV7,B'
ML/R8?-7J@2:(BZYXIBDOZ[^A#:)B1;:L\DNH-OP#J"9NM\>--NI"*X6B;1E2
MD[7%0+.[+'CJ..%2%+G"!.&' I:TU!$#@LH-;C$4\@J+>/\5RU*74]=S,^N
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MKY1Y7BGL_$47HVL1/ZN_TC+?T!%M9^\@(/#VH>U+@FXTP&CV./O<K8#ID+6
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MUZ88=IQG1E-$*%"2#>+*OJXU:V0&O*>ZJJ=.:.UQPF@,!TO==TH2,8I+-/=
MVOJ.C7SK.4-&RN4KVO%GL=%NBM#&]TH/L/I\OX+=LQ.<T<,9OSH....G(G]C
M)?+"M9$,%G<26HK[T<HZ7_NXD@Z"V]MS_;E$3&&O_7J1+Z_BV,VTWA5] $:;
MT^D#G%R]E>1!^-MUW@I)L8M4LR1)R>P3B1L::VU,L[;'CQ)V/^*F"LZ@6*R!
ML^%%0YT),WNJ/'<L\ZV+:)S+*(<I5@V)8[7A^,Z6*<\WA@#1!X9'T1349@M7
M$&<U3:TC$Z>C:)UOL]A/_P:3?Y')/QYC6OG?3X:#>:[?'HWR* ='3;Q$'3"K
M>B@FAOG1Z"=\3KH]Y$'=7M=X'29,II\3G8<XQQ.AM^8#N=-@VS>(VGGNV[$S
M5;:NWH-837H20+ F *^N7A,9AR,K9P=\;R"G)*_AWFC30)8*E/BDQT 91RK/
M+,#_:"D:ULO5,1Y%Y+NMY'9T^!QZ1;9L.V8*HQ[,Y&"6,I>T6[0,IC*O\%((
M 8D'CA5,7*P1?+8U0(1)SA08'BUG4YH-8TF>]9XE,K$2UN1XRSIHA7JN5%SO
MAJBF20X#9@:AJ/TIDMS\'BD\TLNCA-IUB/:,JY/_1(JY+5[#N>M_,/^9F;=L
MC(P2#SG) 16;<K$(UGE<R\=RT,+]H%4Q_$7&M*SX3X@!AV !;1>3N?DCQ0OF
MUK?7Y79X.Z$OP(-3]E +A1#KD#XA^:;4+/;/$#.4BXYPL(N4WZ&T'T=&E-";
MUUJP4K:A#5I*R7E7>2>),D)<'/,>)OU$(4&PNU647Z%@-RROA6Y#(MCL>>_&
M?2XI-"NE)(0[5$4XB!G9][Z)]^J@A4@4NPH/BA?'=SR\26B3^)T/0%MXE)X.
M1RF+K#!ZGO#)*:;9LR[9"F,4N!MFS6NP0(BH70A!=MC(9!0CG:X7"C.3(&'Q
M9!]EQ,8@<:S1C9, TIPN*&WQ*OH$HXG6+/TP*69<>]REP/49]RJC<5/.*#Z"
MMI.S$2ZUXE2*/XTTPK)[IQBB>'#(5-!3V^ ?WSIMZC"T@/ENH0!@.;JIHM3(
M:(U25T2Z6>0MV<:*>]-],HOL0T-?E (-CZS>^G B3+)VB;L+:T%O7HND05]9
MES RW[QE&#L.@#_3?6*YLQ75([WMKZZX"#C@G<0I8!4G[PKAK$+7=GIA@< R
M\?5-&2RAUA?O>Y>80]01IY/;2&EQ#H;#HBER-=8Z"*.WIBR5P'5N"BXLS-:4
M)S",MF8B15W'1I<8[!?7?5.<?Y [ZEFW8[8D<N]+P502RC'DY.(34^L+%?>/
M6B?K.'.6*?6BU5#1*H0*1U+?\!TH'.[XZE 8"U+;HN&Z:H(WLTPR++G.9H0)
M36?2<ZCN(1_JW..*"*<CHS2[UYC>$$*%LW9-WFB&(M';[U#]FGZ!Q#*.7X:]
MG)B!+?<%>3P34HR+,<FPLB C[-J 7*Z,%L;*EOLLS#M+8 2K62]*1("XB-]]
MLAY)5XI)T/DH"?ZN66T:!Q""3_D&-59ON,DX94V3MDUK,3C*\*3*N2<NQ1#;
MPPO'15HYNYMBBAR_(7+@@)*!>#:$1K0@RU9N+WY?.ZQJ4_=2*MZ2:V8^I^O?
M %YZ2]<&HP(9 8%DA-E'_Z"Q*D2^=CU5\:SNL$811O1MI-WQ/KO![E!0,("W
M-1;V6(!1>)33JPK7V2#B>U97"L7#U(\.8'BG%5G6ONTE)F9CX,_MB6X!G )X
M%^.;C=]WB2A1NL0D*W*$/7+A(D-Q(=B^L!))HVFDE>%BQX@IH0Y)4-KFU@"S
M@J'Q2(L!@,CAC<**) C@G@X' B4F.XM-W!#&R+?5TW"1;UFW8,5%CK9COCY^
M /J%,H+.\RZ,Q*'WI!AYJO*&>^EP*Q 2I4 YK'#R[H<W\K@SPM$4):M(,3/<
M];[]U:A*X_F/$IX46N@)Y)^& DI1.(E[/ H6E<5W-!C+NF#KB"KE59W:;83T
MI=*ZX.A$&'E=K%?A_%P='P<"_-0PBN1,"=OF&UYJ1^>TOM2&,<606!Y1TZ,,
MU6P9!O7/!&$\T1+ V]#YNI.0+P^!\R<5TJAW%6]S;LW+U[3YM-HYX'M2+A"?
M7I@V>-,6 [U6$7+-C*%2?=48L*@ 6]%;&#S9O;R#CNGVC_M+XK-H<?<9&Y^)
M;L*&)IU#_S8\Y@),'.#$+%"K)<!- C-\IZZ*2&#HV*\T%G5G"24CA&F5BGLK
M60$*R<X4CYTL"5?F</8$;D7LGMN+D$SQA%X_5U(\[8RK:#?%('8X<$E9<4ZS
M?3,OKWKRLIBAGBN[,I/GL^>T!Z"I V%$T6L)VW5W)F[0!'PLAO@<M!SJHLE'
MN2(XZ!P#N12SD^.=">N =[AC4I7U^3#(29@7AC&B6<<I#Y-MSMTVC,$D/7')
M4(?DO)*S>O=!74,CV&"$)/(OI9G"@8Z(//?H3&QD*7O30/MFBU<BDK+9WUHB
M+BD<,<GSO[V\9,&>#5:/0%-H=UMO\T(]0M$]]M%OWX*8HW"[CO6<Q0^N))W
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M..T8%<RXYO*& @BAXRB!LB-[9S["8%C82L1-33YW3-O[7?T#HG$)M?@_2FJ
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MM^\  4]7G0@6M6Z+6^IP.ZV@S\]2:,;'0QKWM0P0H7H4?%-A'R048@]!TCK
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MSHY08E,^V-A]TFR)-&A&MEG:$A57GT#Z4A.;*4./%KT)_(V]T\&8#$6N!NX
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MHZ_NO73O2+I*=%]=8.G)=<?I3V".<E:D$J=_:0Q,;O>A1#'M;J%I.*Z;Q-C
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M:.2"86"8<SXYL9DT)<120\*QL-?EX$G8!S&RO@&;)]7FJUBR:,F5MI(<?>\
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M -%AQM5[\ MV5,)'W[-5?=.&9T]&[;J<CBO[F@Q3@@>;)H)L'=F4?:%U(\8
MKB%Q;41# =(I<_&[5D71T8942!Y=V=&8X("N%B+3>D0-3NO5MQ+3#B"VY/ _
M9_; HL,!S&";LI!#29%&P:2B?>\C/_)()I%P"&?,9\-4-:4BYR(E H@914'2
ML<+K2Q""/WF1R"E'CJ+RH%,OYN)]?L6=BF&4P?J.ZFA'+&Y7@&]O:JUD$]P^
M1.C%UHCE#"N,O!NCM"/))<9).+]*:C+8"#P_Z5#3E@/K=E3\9ZOP*GX",+-$
MUGL94?!;,J$;4JV>A)W:T>*(9ZYQSA50^?I2.<8*,:HB^H9O M<GS6GEKM:<
M@E)J(+YR9#W3W^E@G\_>7._:,H1?H/K@7_$X7:,MAIYI&];!HBGG42V';>9J
M=8;KX '/9Y?K[AKM&?9$-N9^2Q'')=0TF9=5QY7&01_%GG=Q78O.$<"C45T7
M ZPO.?H9&1=%U^GX_]POK[A+':9N6=OV3">S)HY_R\B*-K.J'MC)RI2!Z% 9
M;95T7!QH4E5EJ7@8=[M)D$ /@>>?S!+E"Y>NI2\^!0L8S(2B>+8HFT6_(=P+
M%=;::UHD7=-WUZ3K  *W<,VP(PA1PH3;MNB%#M<WHR[":Y<M69=(*CA<1IC<
M\5(:ZGFES2Z8P2'55]GX1AX(^CHY"<F" V=>$NBI4NA$N7!=/XDVY/2B<UR%
MTLZ=-+(8(75=C_%\Q.VTD-0MH903\+0C5<Q'RWQG*DF^W;6OJ &QBFWCC!O6
ML8D48P-RLS"&?47@ID6YS9F&BC!CC,];D65E]EB&=[A+,YYYP<[/+?>8Q%F=
M,6^G3M8RFWP1K#D^E(;'&M:0/?P 4P.(4XIHYC. _I4"DOTS8=]%SE!&(/JV
MGV229!*RPZW!@NQ.I]>MOKMZ%*?:M*?9M%(Z\CW#^:=[(9<_VU *#M2G#:7"
M(^Q)&I/MG/V4LW/QEZ+K! S;4X,-T?:O^6_?GN;@P>: C06W)I#EM$X ;5,X
M#?Z##;Z(JT^2G)Z&_<&''3D+B7H&&.G3Z#_8Z(?HA]#_W#X+547MZ)=3.O:*
M42ZM,'[(Y.-5N>:XJC_-U8.?#D-7TH/170L<)SB(9F'(F!K]K&]I8D_S]5"6
MK4#G,V',$'-ZBLR4%:,D=1R)YTW FMH'CZI33[O'\IC_!!V7-(=-P5 'C.N4
MB*JI=W<#D#W]FA9PL$C;<"X(=+8(8>E2=1Q5-")F.2AJ9B;V-FJ"F$B*DC88
M,;!IL [8A1S[[\'(6/-/2 $LI5/=/? D$8LGH=*/J.Y>Y.1\4PI"FDU.ZH,)
MEO_B.+#\GPO5O77%$9N5J))*W[WEHQ-N>^PBUBZB?OWUCHFC-"4'N7G;7$J*
M%9M%\Q ?;K8=TW(L&V@N-Z++SO^I7/,HDOP?]MZUR8WCV!;]*PC?ZR,[HH?F
MD'I>Q?TP(BF+VJ;((&GIQOYRHP==&+39Z(;[,4/XUY_*E9E56=T-S)"*$8FS
M$;&W)0V ?M0C*Q\KU]*V/4KA(7VG>M8CRB&CDZS;?423F2JN=LFKT(D)BV2,
M0F@0%+*.D"*^R;E]'>F'H-H6G@2O7/%8I>KVG&I-;ZMWC.\9Y%_))*Y+2M1;
MJV!(:2CET7<A[[GC'POEJQFA:&E"KAL,\2D]02)[C>_)?(RFFDO;,Y:P<%2C
M$5B)2$E,R$?H3_M[O&8M=1@H03C$1&3\&[T]6A59#RI#K:!IG;@XR%%=RFM'
M,>B1X!%D/)AX9B2,.9ZKI*(QVRP"EKS'YP^_H0.%F0CDFE)[>/WZ%3)8S(LA
MW0 FC]W;?1GV7]W49]W@[0B/J(S2M/81?[U<DYXB"MIC/%A^U3HG':E12E-7
M2TQQTA$W.S/^'23M2;:#RJ"H#+CW?M4>G>;'LR@ECC>&GAGZZ!@EP/KP2W^D
M4XU<Y2P&(]'M-SKFODAT')(S.^$64DYYSL^Z,R&=(6E"G0/,3.%HHE!S(Z!)
MQY+1L2"*UF?F2BJOFYY[%T=: VH] NFF*&QY,Y\J3-##Z?8U!7S("@12GBB\
M3BHSS8$WT?'B;2)/P;4O)H'4CME@FH;:7\$;A%X[IWV\,E,Z2?3$9+/[5XJT
M<**@8ZR?2CO30S"7,^H:5%AE9,(59.^O7=N6B(]XO40-DIEKH@8QW3S) .GH
MF-FC>G!:T.:7D:1_O$P88EHP_A]=H_S_'>G.%[CIY+%&;X?W8$,N2B8L8A4I
MN*Y\[-'UX']C*(C27= U:+I0)NJ-,E%X9AE5JBGYC6PKPUIT8[D/2'QB@%?"
MBX+C_>4AQ]E?^]G0>ILYJZ5(S[4AHZ\4-;1;J6MJ4CED^QV'YP@#)ISM"I58
MO&R].U.#SVCQ%.=N'LX/PPBQCPR?#F\]^1)Y$-7="W9*U0*9E<&].WAGT^BY
MMUB44I\-=>1,0^/EI=)*4DQ7Q.L'+S$AUYJ1\D@6^?C$V_/P8X+UR,/%Q&[X
M$;PW]]Y_KRNOB6GVR,ZWNZ\A+1'JN1]<F7U.0.0[9,W,T '\0:MG1L^&=_S^
MM:3 B/T+JF@XO;!76K 43YOH]KJB7$Z29!->*[P=FZ5,M$KX11S6"'NQAE6D
MVQ!OIV@\^;6UC?Q@G5U<?EO^L];L@!VHBZ7)-:0WE* "TEW)0F5-5I(UD/^N
MA2$AQ!]Y$O(PQ4AH2F4?E !.' 6!*&,5:0BG;T-3MG(W>/R<>*$?9@\AP>LW
M1ED,=.S/B?Y*W];,]519:G2YF?D(E?>@<6OZ3EA;RH RE-76N/E!6(%&2OF;
M"0#E#W<G\$\&ILSK%C^??;%]:]UQK92'L6789.P,]@N/OG#MHJQ9G[]GD0>F
MEH>N1T<"XMXIO,D)S$J(L8F$-I3J(';-/KZ/6V?4Q;K>R&LF<KNS-.4KN\9M
MR SPAK\#0BQ0D#GI8]9MP2D_6;E%,":R:OT;C8 NI?50,'64!-@WJL10 Z0&
M8\J R&279U6V?K8CM$;,.AY,%G\,NTJ^B\@KFQ-B!.QP6O!&:^GL :&[B+S_
MR(@>-K&!FUG=/5LRB1J:3(NZ,3@.>0/\43"/:D@[^)X[EU.7AW\@MT40&S(G
M%M;TD9S(G^X8NS V_^X^T:U'&#LFQFD7U^+@@77;"87#19A$S21-&&;C*HT^
MC='T-4DD=F0/"0O$+75F-IM9(8)RYZR.0-T8)#9REHQQ3'-G%G*YDJ9:YAT;
M(:X""JYP3,T]8IUN].6QBNDTO-5UE>'IYL;GTA$O,Y5+]NT.2>.!\E51K7K!
MO;MX/K]C27DT.T,HF(HM16 X-Y>B *3S7X*)'!'V%&[C%P:\;QZU^;L2"7+,
M*_B@BN[3BI@U,MG&A3:\*L$_4B,@)"=3M5YSWY$]UC>Q>M,M[<SY8W%RQU7@
M;$GL<%[;&;ILF[S04__6M1QC@HI.=).]J> [A'5G["_P?!U;4&/A_4D:&R J
MV\'3J"A:"K\C9? 0B(#,/.'XLZ3#*00OZELXIOI#=EHE0&."8Y]W-I^%":'0
M["KFD;9@0LHRF,]U.5MV9O_MWJGTI,4/ZH;'A#GFFZ:.!0>L)Y_V;$+"'[>M
M=VS*+65[F\HA2TG!)G7F$-'?REMCD***LD;84LE.-D-@%GST?,WYK!>(CC-=
M.7$2]/ -EQ?W3\9?CMN[/?;\8]H%27+DQ))O5J*L4;CG';(F?DH1_L04-5;X
M.SB+F_Q?O R"H!E*A.(Y+W-D4_8<5[4K<5!!H,C5W2SIB9'E9+ E)WW*C3/U
MBYH\R^!;<?1!&H_JGZHMF%ZH:>/&%YJTD86Y468G='_<%B_:FO'>$%$/6D+T
MAD:=L7=WA&2W%PM4+U6XH1>58VO0"+R<DT_1$A^#_<2<P6P7,(UJ I0@,<?/
M74I_,[M$9F8V4UY(X0EK^E17I"K?N:I<$RP\[(<8?NE$30_Y4[$[*78_.L9B
M]Z=J?'RDHIIB7/+;]]">O-0!_N ]&Q-.L$F@<"U8W&--SE!&2^[&;'"!'YZK
MOO9!N !*1VUF<SJJH$T$N.7*G?GGH#1*+>2Y,ZD>YB9U%5#$?D\;/6Q1*->6
MNFZT53D5%?U62Q);;G"XLLT@VXNBH"1:!%5 -LJ\DG5LK3JF9NUC_X:]40SD
M^-"D"(&XW:B*IIJ#1G$[6#(NXK*O(LD%K;P;7Y-0!]/I+)DHWF\EEB</[-.A
MP<E?J+^A:]GN&3@()+*-'J]8BX)KLG;5%C OVB/E:B=5K:[GB@MGQW*_"I*T
MC#7-?'KZ6?0S^1]-:47"NN!A@LP1$8!?CJO8I\X2-2Q;34?B4XS-708C:1-J
M10G6KZBK4O-(0EP03HQRI14A#@GC"^5]OI!%II['R)V(;8C'U7=-YL?Z,+ #
M^XR%[K.R\X>FYE=EC+V165)S)G%:[I(@@!K&N Y+$61]N[U"),*N7*ALCP.C
MO<\Y2DJ7'0 %0K#N/8>\B $8/ !$F>^F_A>[@=Z+1$-6)A/N78 M"]S>S4Z/
MW)C('SKKR 0_A5=DEC@Q: E4AGEL X7N*>>P?I,U2_RG].0\N#0@N'J!T&#B
M!TFL2,W=&^3P0_YB%V?XF2D?(["<KY(1_V=%T%[:GJ&G>BX:1Y-.H73P+5.&
M>GMR(T1L?*",JB!6K'LBCX7 7C.5P'FA3WF.;3ER7T_D*B5^#P%?4U<:K8*E
M(28L-.I/LF=CR25(O46%@+1W6_6/L/X,%D&PF:NRY<)7L$922-1M5$ ^QDZ_
M;,JP\"Y=Z+VKQ^D3I0[X '="69H.G4-V#VK68\F"+&)$]EV>*B6,E[)F0#T#
M#FH3'B X)KV<^^D]8*LEZT6_XY[T271@90PD%OT<6" .%M]? Q#Q.K(OO3:\
MLE .6KQBF<M/_AX?""O@#EM(3]$DM;:T+E*A*3BHB5JWF>3%F")LSY<4N)(S
M_9^RQ7FS*!3&G(@NM5[J5]VZW':J/)'F7L=T&6F5WG_+[U3-9V*=43;.M<>H
M^JCE=,26,'Y]D\U6U?$-^3S5NE\V9X;.06?$#V^F3J@#R;;WDLFK#OB:"4FC
M&7?;?<XT$E05S6R<;G Z8_TX<I:O.27*T\W0PY'LFST?E(B TA@W,V,2!);8
M ==5B)N1+Q(ZD:(^SV$1OXF,S.'&9<I"!:A;4N")^ %_M^14#8)9<G:,:LD$
MW!*%#<0,%)9=L?YEX/T&85&@D4IW']"]?ET[D'J'._$7X>(?XX:(?$5X$6$5
M:(* 2CH&=%0NUT(KH9JP'1<\PK+(.$%65J(Y*XCE9$ !$HZK=I8/<U;!V')3
M!-:C@N:2I1L(CEPURW<L5!CT:7]SQGWE%%APBX4D9IOOY/'],/MCG=P)_1NR
M<\TN)Q!S^!M[?3/O%3?(Q(S3Y\&&1YE%EEH*+S8=#APC_0)-2<^1VO .6(<H
M4)C2[33!2#/;EIP"$92Z:I:#BC.ZA,&P=\MUK:T]T3PEWS$2E9SW9@(68NZZ
MJ4-ZQ9J+"*NW*-?HGXIF+D$U!A9S 2)6'%]"GA@B"OK*GOV9 .!HGLFF*3P]
M5).6')IPA4BUM@7)P28B!.ZUX"VL#CUC)^H=#*BA/YHG%3)^NLI.<C&<V_R/
MD7_J-T::M*,C$J#"?;O ,,+,Z[\FH4;MKAIIQT/U(P ?1Y>WAREX?_S,!%DD
M*4^A7].Z/^;F'3(_\,#IMHTU-J@ ZS,Q9Y3"U),>&A%H8[YMH#XGQ=^P\7!5
M,V+&2IC.DZ:]RFNQ=4J%)96[*  E0 /DR6ADL*;>RW\L.6M8FH144&D87?T-
MZCSV;['9I:Q-R34O8%]['7OTZ5=2,UZUN1;N9%5@7A,KT*FZ>;TSK$!(I2Q=
M4"<)>D,Q\/%!48\JG74UPA+)*!O*;=$R""38Z("<,'?W,RBBYYTT*'H3R**?
M#*T"$D/MZ>C!Z=AG]AN9>J5GDK1DOSL$T,(]*>NT]$<KGMBJ)]=U,T"G>]_>
M4088@*)V7W3A)PJPR>>LK>K3\:]&,M5*T4/NE2("F?=KZ%1F2[PK"&],R3B5
MG# J/1V?'7M:=OY]G/H0;*Y;8I/2_/+0A1<-&?8];E$&+"'5]8@47Q2V-SGX
M6JS#&K&(G,GSK@F1GPU<W/,Q/B8K4+^(1? &[4K68O0XK'5]JSU4]HV\P8#>
M+Z$TZTYW+>VI,[(0PT9CBG1U1/V <1U[[,#/*E>S&1TINUD3K#@F.WY'52-.
MHLBQ#8^DA8$T3HW;B"A,G6?=3P$PI@M,?))4N8EO2O:/[02S?<Z<.NJZZ45U
MFLHM!%A&JIU_F[3$<Q7/^'T*=C7I!0 3EFZ*I3I*@S"7&+C;_ 8PL=\POV@F
M\'DM2I8X$5A".Y#13;]%7[KPQJ"]8M['YS6<4*HW/@TPX*<7KU]=9(L7<OX\
M^>'U+XNG;H4P_0GR#GTY;$)![*DCET0/"OWBS^A^>\5>]N(9#DR:X)=TV'-)
MZ<G:;>@.V>('$=:F?W^=%^&_<(]?!O  ZI7A:C]MG@8_G&NOAA5/!I</E] [
MU.^V/$@V;$H;E5_:1IJ2&VP42V8DB;59BFY5G'3X$CC#X^. ,WRBX?%'+P@F
MR9QQK<@OS)G-+IDE9%61ZBLOE8IOT :3SB6I$*,ZKTG:N$;5JDK"*MPF4DW&
M!E$U4'43*LHH_W-)+V2PZGA51-!S;\%EANNF5[SRZ)ECWWM*B^N=3Z:V]%ZM
M& '^:NQED1^%W%" )<\]!R4T2#[93^4T/7FQ;<MJ\>CAHW,R)C?<"]US0E"N
MZ:V-(#UZ(T%EQE7!@Z](U'GQV!]K5VH/Z3A\_LLO+W^]>/N,*U;ZWNP,:1V?
MD54%^U$^%D7E$5Q+1QB]_WW/8M!$E.R##UWC<;TP8M5_8Z,8]+LLA#%8T<T^
M%+N2=WJD!XL7)JF9W#&<,2.'+/>;-'V7AD*V()B-I@_!Q1H<.BEZ*ZL 7T,B
M8X'PU_)' 9_0(UL(SN"]@*JYD8"YZ[DR+*J2-=T_#]!I2NBU41U!DT@,'%1%
M$T&?+_-NO=!C:L0HL:>E3\]F+C_5 62B>9Z,#VUQ3V?']"@=>0WRT@QJZUAT
MJ4<5<LM5R$DZ.^WAPHR+4Y/\3&IU:44];UO4$62SP:;G' P60R\I6,#9N=$.
M*FUY4;&,\<V^!Y])K]U2F6G2-/O!PLP1VKR]4WR[N__D]<N$+&K3U"5^J@4M
MP&YJBG.!K@JM2_79B$DQ.<;50<?E93W-\"Y:DH@MI14H5=UM*,WH#V]RUNE"
M^RIH9-X"6&-$ 9QP1YMGM+31?W_RJDMHHW&WJZ$L1,+3U9*Y'V.>JVJ2%=B+
M%'PK/Y2+=;CM0K$8L\39Y"O!'$JME6H9H9<@ C(:X;.1[Y9JD9FGXR[#?TN[
MU"W<RCQ^">8%:X1=)4-X/[ZMV.:"5B+E!5B1L8K+1B$I,R+0XVM)WQ9O=T[X
M[%+H=VB)/,:876J7,P@'WKGJ>V2&G>56:VE3]+;&P!-L4B)TCY'G8HS_&7<@
MXT&4X K'ME\MS<X9PH8EY73[X-1K]M@_+Y!]H/YG9]UDY)$<YSR\2<D<-C[
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M=P[/<Y-#%)XT\[19)]S?>%9T#[JP'[Q.'S92<X,<:!<>]_P[/DNBF63?F$\
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MB>X=3AO^L%LW+;ETG6RMR?"/\ 8"@+6))BW!1T"L19I66 GI$.K?)8VQ\;O
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MG$O7^]"X[0Y-J>!G#>>3Z4Y&AO2FYA;MDV#B/9O+A&\O=$!&1L;]LWB,\69
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M^5'5Q*!*E6A!SMT9"S&E*1E1ZX"YR4J::!"M[?QVHCJ6:1V=U,P2"D-IO[R
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M\8[9O%@ \/\YN:?WE[9KT/M'"Z8>4'U9@I0R?T_3]>C!XS^#-*X&JT!H83#
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M[)%QEN3$;_ATY+%C92/K<@AN2,L$F>"BX+>9A:P.:4!XXJ^Q2J6.]9[.5LD
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M85DV?^@JV#.&^'L2G&%)1/T)[TP.3&U #(6*,Z7[L.ZPGVGI(\9-&Y \YH+
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M$D$AG#(<E@Q!<1?+821[&COS_2KR'EVUD974.A7(%>1%.N]&.#9BO0YPM,\
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MOQQ:MPE P[(/D+0#8"A+5\2]WGG ',JO$YTW^^L1+I_O8N[.H#A5Z>5>5P7
M1L37!/BHU!:*!$10BB<Z*F7J\T>F>X:IVB%,[)COD<<6S?4R!GFWSO"_AI1/
MS'N$BG99P!L2.(]^#YA]D&VO=D?:&6/DA0&MW#-B"8_41XR<M'!M ST$=T7
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M'*7T(86 F5>Q52\WT*%Q5*^^'VE<?*QF]"<UAC\*(=5H@#GGQEXH,\N@C^=
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MXWGBR7(>*"%8A5<X>TDO:B9-&>FF)+5I#Z2#+KLAV0[6NBM(Q9]058*/3H!
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MT:Q&C$EB>A'9)S KO&&!Q@W<>H*Q#)B33%>I%*:*I^>:&U[U(C;.J:[T=BP
MDIU)Y"),@^1%8&&C]\&7<ZX?K\(YUA 9O6H2'D8B23P+>6<PXS"@/Q\%*!17
M5+MCI*_[<YGM4VQ+9[BHC2%=!5X/6_95P3P 1#VK#](CDN6*DB[S91''.?^Q
M5/ZIC+7(+2>7U9$BV4HF:VU8T-(-^Z?!\K(MUE@-Y%E!&+I$%/72L30=]'+2
M#<]=2\CDD=7>N  Q ^PE!CJH((SF^8*4+\<YKI+I6CPFA5Y/ZBB>RB3I0+4F
ME.TCE>(B<_X+^8T9?% L7*7@%1!'5W4KY)^;4PLQQ,54@EXLZKB&U@P@MW]W
MG$XYLJ#3*(AT92Q%2B1[#IUZ7).6LW07O2B@C%/EF-?YEMF69"*RZ@@D<T,.
MFT&2X2U'P6BKW$RP+N"@^EZ3DH#:/W7UQI689% ,,L+F5)0!JGZJ7E'&1[#=
M3H","DT-_"K[9>8F8.(L5J3F4#IO?;%G 3D=.9,':AW=H=-04^D>T$MG!M_$
MD!*9DCR::I9%<I:Y_G:29C:=6&<ZL4\-&^],I4D=6R<JT9T+4[K]?I0"-]O%
MTR^='M.0#=:-6 >1QABS<,<SE4 K!JL]^[(\S'"N&H-F'I_91;=N:>M9?-F7
M[J\QJ^)S,P"R7+,L(JEBD))'R\ F(0>W.*-X<18\'DK+C?L]ZN3DK$=?5FMN
M#)>SU6PT:9":0^N8!7.]<H4)0\R/LI.OFXN%8?UKS'D5L>KEIO1BG*>IOT55
MC%*E"=H2"G/,P \,=C+T]#S#$;6PQ09BVI'&ZP)CHM%NWX+P 72+WVA((KOL
M;6-K!O/(IB)DV82R#(\["ZX,!7U GPZU7_6P<#L+^.D LNS 2#5<<_#CV5@X
M?4,[!3P-6A1CL@4.%:_(M/*LI>AB)DM!,.99\K8ZV\_;NA88*LAE;8&93;6@
M=&-V<L;H(TF5V4!:T%"]:,#V!YW3S&+(G5/5ZGEF0I"<X;YV5I"=&02+ W ?
M2Q!ZJ>S AKL+5*9OU:6^5?M'6K?+B4 W+T!"X?Z/W-5S64=E^%_NE '_J+*M
MJ@IN]!Q;G19+)I/R51DLBAWX>EYI)'))-D8R'SE9*<RVG !_RE!E:S]"E1^*
M ,9DH9& %2/'I'M/8_%>_>,#4 &.!'KO!W1\^M&'Q8RIN7%>]#[^6IZBTZG4
M22G\KR2"_P[4B^49*W3&=\E@\3O7J73:[:5?5RO.TN]6+>M4*\UF_4G+KOZN
M46N4FRTW^Q*;;5:<ZM-6??V]=BH=M[,G>P6XTKC3QU=]1]R+.1CP2.3!__U+
M[9>,U0]07WQ?M1Q2,]1Z^E&GL?"L._V.3R_RZ(49B<1/GUO4M1]3P4C\_!-T
M$NLLIY)0+55FVLR?= .@=/83)N<!-S9X=W0J6QR\M?1_J'[X'FP_U-1*("T%
MDJ. 5,T!Z4?O6?:HU&Q0$X)G+=*^+77LO0(EDM0:E+36@7\VP*US!4O %0"N
M^AR\ZQ!A\Z:DJ"= [6\E.97D]%+D))6&.8^44R=X+ '%LNKU3<"Y;(UGPU>Y
MR7*3!_&"O=CD#K[@$7-(.6F#,!"K]U0^63Y9$E7Y9$E4Y9/[\^0C1+4H:/M]
M(0QUH\"6&8OA8M0RG#ZW&=-9RXS)57NO*'W.4L#T_.]<U]XA#CCE3FE!XB>S
M?*0X']M8"VA5:TW0O8P1. ^]A2A\L>F\T0G-DT6XZBX=S:G:;M.%_[8Y >1'
M3HJJYH8GWDBYG7OEO()<DMT>D9W=:M7M5J.DNI+J7N]H+;ON.+;K5DNJ*ZGN
MU8[6MNOMEMUP]I_J]!KN9IIQ(07N')[JK>U(HRT<=9T@6<F3#I@G'37L9JUI
MUYONVY(?[2J.6LW71L[66='&?IBYL,^N^V$N=8M&5?WW_DFLN RGE9LL-UEN
M<K,H[AZYL8N%Q?62JMRE//0@%0,'S,EFHVHWJK72I-QI3+GUCNW6JW;-K9>8
MVFE,=>J J(9=KS5+1.TTHHZ:CMUH=^RVZY2FZ\XBR6V4R-E5Y#B-NMT!?M=N
M[W_T[< QU=RBVG XKIABX'[B'H#<1V\P\0,<B4DI,4^R)@I.OQ]$UJG:3KMA
MN^W&AK16C.\7Y0;K&M<'B:A&S6XU7+O6V-3J*Q'UNHBJM<"6:(&&NJE\+1'U
MRHAJ@L'GVIV:6R)JIQ&U<79BB:#7UE3M1K5N-]Q2B=AM1-4WM2B>$4%EY4;Y
MY+,_61)5^>1K$]4>Q5&+TU!NJ6MTN)",\B-QU*71ZCV4DFX+S+=:PVX]U46Z
M'C#VR'EZ2-BM5<'FZ[AVL]4JL7MPV'5JCEWOU&SWJ<[S$KL[C-TCMV$[C:;=
M;G<VCC"6B-UEQ+9+?!X2/IT6LN&.77>>F*168G>7L5M[8C7;RV+U<&+6Q7;;
MYS"6XT?#Q3$53_!?'A))'KG-EMUHU>R&6UU?E&P$B#WR3!\49FM5QW:=EMUQ
M-E#Z2LSN 68=MVY7VZY=K==+S!X29FLUNUFOV[5.YVGQIA*Y.XQ<QRF1>G!(
M/7):+=NI->QV:X/D[1*S^X#9>FW','HX ;9BD)]C'W,1T[SF</*TC.*]35NO
MVRU4Z9[J(MA3]\[^X:EFUYHU4+]+/.T\GAS';M?+TL3=QI-CUYVVW6F4]VFW
M\53?--V[1-#K(JCAV&ZMK)C?;21M\1(=3ICG$>M!YN7]7 6)1W#[&S60HQOT
MIBO+"%X=1QVLGJJW2ASM+([:=JOJVO7&YN'0$D>OA*-F&Q#4*8NF=AM+1[7-
M/>(E<E[K"MFM9M.N;MP+K<33*U^BU@89GL^(G+) K'SRV9\\]/C5R1W.A++\
MP!IZ?F3=>^-46.'0&L!J]SPW:NQ[/7^,,Z!^JN#6?_ROMNNX'TKG5(FE$DL_
MK!(T[&:K:G=:&[@12B255^F'L/1C8GKG\/._7V*6RV&3=,9V2JK>413EJ?K0
M SY'6-CSUAIYH'"' :C=]R).L+$]:N"+0U=_MG!0N].QFXW-*P1*W\YKX:C1
MJ-F-5AEHV%D,U9IVH]&$6U1VTMMM1 &[J]6;=K5]&.SNQX3TSF'G:<KVSTW0
MM9;MX)AQ=SO^_Y*B7U+1WC._]H5(K#2(!&SC+]"GC\8YO=N[]_RQUQN+XV$8
M'<?>6%CBWREHW%8L^FGD)_Z/M4C;P\O;PKQSVVF5<T)W%T<UX*VNW:YMWD&G
MQ-$KX<BQFYV&7>\<D,/I(/%T5+>;;LVNU3;0OG<81P?M%"P)>CV"[CAM(.C#
M&,AUT 1]Z%[NR^1.1-:1+&IX*VNC;2L03QO@NL<FL=VF,8:'X>,Y2!S5ZJ &
MM)[8Z*3$TJO9I]6ZW>XTRWNTLQBJVR[@J-,XC!3Z@_;^E02]EBE?K;=MM[FI
M*5\2]9YHU7OFTOXDG=<#T0\#:M-$?6$Q6QM'G(8_F<?ZX-(52RR56-I:(R_'
M!7'7VK0^M<13>9M*-U_IM_XQLU'RGM)OO7O8^;G\UC1U 31JV!YL-_7C.TK-
M!@4;-&[:9&\LK%X8#'YH&,/^7=*GR9T=-H1++)58VEZW'FS 77U"J^821^5-
M*AU_I3?[*2#37*<DZAW%T,_IS5ZM:\<B\,/("L+D9TO(/CA73XFE$DM;DWVM
M9CFG8O?Q='"WZ:"]@25)KV?M2]Y3NK=W#SN'ZMXN'BJ,-9%8!VGUQ#",0+F^
M\R)J_1>H+WXLE42"XZ FJKE@-#<;KMU^0I/Z<E;>+F.V5L5RRKI=<W=M9EZ)
MV1]LK $"M]VIVK5J.6OXH##K-NQ&R['K3ZW6*)&[P\A]8K^B$J<[C-,CIU[%
M&FN[ZG1*5GQ0F&UO7HJUU4G#N]=:OGQR]Y\\]"C<S3.[ /;73^?:3K-AN\X&
MQN .^^D.$T=UT"1J[;*%_ YC"'L=V$WG,+S=AXDCQV[5JG;;W4"!VV$<'71$
MHB3H]8K7&MAU=-/,MI*HRS#;2X;97B2&MJ?> K?5L=M.VZXV-^\.LC8L#L$5
MM*?XQ6!:L]&V6YMH?B5^]P:_3K-EUUO88O 90VHE?G<%OV[-;M>K=K/^Q '5
M/Q6*]Q"_1YMWY"^C+[N,3Z?6M)UVS6X]H2->B=D=QFQ[)U,;#CT,HC,CO22)
M_%Z:X&P(*PFM( S@2$$2A6/XU<CR@T1$(GY:&UL)E /3'7XH:7]G%(=G]*"5
M^"WQNT?X=>QJ$Q2)QA,G5I08WGD,_UPW>(TUUE:6=AJM6P\5'=@U.=*<<./
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M"MK;0 P%<1I2G;PI,>J_<'\HM(P/+&\",KS@1/A^10&\7UYW#!O$A:5*I4^
MWTJ>!J]9BF\)Y+I+ZNB':1C[2"WOZ56PM$S.Y01H\X<RM;>:_<3KQ>$X39;_
MQ,CM[@MLH[<E8=%HY\%A_N^=SMZ<>B-QW /]X=NQ-X3-OO?&#]XL_N5=_K[
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MME/=5,DID?3:S+G3VF#J=(F>5]=NG*U@9W]GF6T@.!OUJF,$>LXGDS0(C\,
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M74VWBDR9KN8'1'9Y 5\.547L5<T96S:DRU!<:1X@_XS?CI.94#\>"6L4><"
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MI_=^K *H7RLW%67[)00Z\A<',\6)F&)0HR=*$X.*]34!-2:+X")A%NX$UK/
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M X)+XIE;$F1YIC!R&UM$I,);$U)6B:57W?,QL]X1_2$OK)#46^TQY.H.H6L
M6B6"O?7GLGU]+'OA5*XBG,T/SKY.)GA8B3P>20"UR0!5) ?"^A\J<TXR@IVP
MU,,99RG&,;EC=1G\F>I)9/#*,/AX$BFDU!\=!\I!#2@D%BC"-5!08LNYR!QA
M&ULX0RF2N$(,_H"R,KRA[B?K[L>$EQJY.EZ=Z5?83LK"G7-SX,Q\D77EL'9>
MP:5H]"T&1/<* "TUI8_L<'>?_LTE1)): I15(7-%4J"X-<!CJ/^ <*@E\6H2
M\FH2Q6DFYA7P?LQM[V5Q\ZPOX\\K_!09?W&,?W";\:%!&N<" 6<R RC-)-!4
M8& 9PI!;1(6"&UN4BI12FDK*EH7Q5U^_6C+OU=OZCZ+(9>#M-&FY7G1&+3HZ
M%EH$]ZX^-)0W3ULV7',LNIG47$35>:+JSPEUBDG+LQ (R[FV@#(<2E'B#.1.
M2D(%R02V&UL\Y9BG,EXJ6F%>GEM8+/+R2_'RF(9$44Z\'D2 I=IK2!D.-; 9
M!,@AAS.(F)9\8POQE#*28OCLK/Z8B#,S'X[<L"M:68T%O*Z2F("S6!4CP%#O
MZJ;'^=MOM?K0']ZRM7;+1"-N[A %)]0-HEV.N? 0I2P'U)\<$!Z- !):$VZU
M8T2$5$%_ZBFBS_:"QRR<RO+UG-2-R->OP]=CJH?-L>$$>PO"90)030P([06
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MY'X!A8;Q+-UB'0S*.02=AIZX8NO?ECL?86CN,'0P>155::LD@Q;(/$3 $:9
M:^D!21F1X4*J%)7)*6<I)+$R^>JR\1R"39&-7XR-Q]-HF>=AH1PP1G@VIHX
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M_+P^7M5V/[$S__W:;H@5GM-3O/?=_WOU[Y]?!_&[O5YM]ZN?__G?1BBAK<4
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M\1DK94!/%P+[H6*DZ_8&M!732E\JQ#?<^%+N78O!*/SF*/SHA&',,^'%',3
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MI-7NK=WMBT= %W1$<041(AZZB,QD,#1RJA!SU'!KHHU14; B$S8&@5FN(1'
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M^"_9T/Y7)?&?V]G^@.!!.?MX/JPL>)%C_=;YL%TG"=QU!.[]2I^9$".7*0=
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MQN?-JQZ,/W3_>SP=SNJ7/CY"MY_G!^70OR-+NT%+^V[O"7NWMV1I8R@N2.E
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MJ*/56H<BM358XT87@LY28$:1;.!)<%+'>Z*.2Y4/1;"DG$/05L5JJ9D&RWR
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MI+L+W959"A.4"28CFFB]3U'(H&0-@4(6@73WGNCNZ:>ZZTI&(TH$K:,$#-J
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M:MMTP[2O9C>%;NM2?+D^383B@S? G,J +FNP*3$PML0L7"L@3C5T,[IS8IW
MC=C=VZ7[QH[$$,OOC.5+!BUG5YFM(B0?"Z!W$4))"HI [9VOH/IFT%3GV-J[
MK/W+(/76E)SUKE@<PV_]!'W+JY[W:![X<1J,ACX,1XM]C4>?=1Z;V):BUWA
M5OAQC&TRUVPPO9P+W-6W8!R=M/L8E.GD>&,MZK9V_;R+^407Z^;S<9QF/\M/
M\]G?S\<7D'V8Y$P+YN86S+W5^:>^!D+:):R *=N<;P3'6ZUDED5;QW1H,]EE
M9]C5F4D*C/M*[#XD)8G@MT_P)=_+0V1>&PXN*EDC8E,@F%1 YE!=CV,QN!81
M\XY)7EF^.GR,=K=Z3?.[S$D2O6^?WLN&-S!4/#J(=:T&M-Q#U7 %+/$B#.,Q
MQ]"VM3I632\:WH\%G%*2#ZEL](=I?N.'U6"]>Y/'LWQF^2?SHSP=G.4?Y^=[
M 3?FSAY$Q<G-N[-S()_FDBMLZ=D9GH_'Z:"!27U_-J[WJUW$-2M:,<E I(A0
M4<W5KVD.4;MLDHG!2[FSJSK9FH\*&B5[/ZF^Z30E4;T/5%\^Y&:XK%&YA=+^
MP& T6&T2..4B,FG2XL"][B3*3LMUMF:(ZOVE^LU[-J+Z[5-]R<59CB[PX$!I
MFP!Y7=J=E0)T9CD%BU;Z2G5IJX.K+D[W9%DG%T</X8&E%!>22-.%[^@LX^K:
MM<#CX**D@-:JC:]5J^U48M8L).:A..\!G8O@T#!0LJ@<8N;>VIU=@[PSJD]]
M9RF;L+5)0V+YS;-\>=*P8J)DY&"P-6)@RD%5= ]"H]8U+&4JFIU=@9V2?!/C
MZHCH#]F"$L%OGN!+EI-A:0-A,DAI1"5XCN"CBE"YK%C1G%F4E>"R$[9:3K%*
M\#XF#N]/SNRR=O&-/VUI]$7.S,<X/<D?$FF4+^O10;[/%T/\< ;AXW%Z? ;@
M]Q_*G4GE-JARJXU7,L^I:)=!68. O@8T7H0(D3G./!,85!O4)SK-=*?L:GD$
M=62X+WR_^9P9\?WV^;X\_<JCD,E'X%$90.5-M2U"@2RBR,1DE?%0HQK=<62=
MH^&[]YCOMU?L2'R_/;XOES\FX[5R#JRU=7V7GH&O>@Y<VNPS\U9A7#1<4KQ#
MTZ>&2P\F97+.B4&L7VK7,YA/A_7/"P]#690;]B=M=OB5VM50>7(.RF'#Y#SS
M3Y*U0<F2*Y:$A<RBUQI4Q- F]PGP'AG8++,I@JGBL(4HIK.,!G3>7WYORH\0
MO^^8WTL61#M=XTVT$(*P4(,.!J%4'Q(M)AY4B2JV6AZC.B?6WF\@?O>6WYOR
M'\3O.^;W<JU>0TL$#<F8-GE7!K Q,LCU3<V82JDHT2KPG1:=7']'D4Y=T:FK
MKY*JBWK>P32_S>.3/V]]<?JP4D6W>[3JBVM=GM3?VZ[HE^'\Z,G)K#Z>/+W8
M3SHE:=^@M*O59ABVKM;&FFK-C 8,,4&PB@//RLKZD:J@[^S:JNW6]:,$FS:-
M>W>RBIC>1Z8O=\5(+AB5."2G60WBA $KB@/!=?&<&8:<59/F.JM6)YD2T^\#
MTV^L&R0Q_4Z9OF37!%J,6CG0452FIQ3!<UZ %X$%37+*JIW=YM7ZPG2R:?00
M'EB.\++T=S!JBCE8L 0F!4[J)U?W">T&X_S IA3<J6.]>AOR$KCOV^<_M8L]
M*#_/\J*$>_%OE^O<?J;AF1M<ZGY<[0V2HA#1:0T.0UWJ"F:PI2C@T5JA4+?S
M'#N[K=91=D[I?E1T4]JA[PZ6F-\_YB_9V>1#Q.IC((LV=\YK!4%&"8F9H)W1
M*JO4F"^%ZZ3KR5D.8G[?'2TQOW_,7[*W1COM,2-4Z%L_,"W UZ4>+#(NN906
MG6W,9XYW5JW3.(1.<5V?O=]-_7@^*/5.%M[F@A:4BNNYL1F.+[*G"P2_/0/P
M;+X+*=HF%>W]JHMI"Y-3%JR3-9814D,(!L$4RVU2S"?C%XHFL5.\)S,V:7=^
M&UT,T?P6:;Y\4LL5E[ R7''6SI^[:EEX]B!SY XC*I46EL49V3%*MV\1S7M2
M(TGDOD5R+[F2Z'QA(0DH04C )#A8U3)OIF3+#!,IR)9TPXZ;U:Q;;P]E]2]#
M1%FGM9OY?913HG12#PH@/^T%1$=I;T:S5_OZ>9&TDT:!E]8!!E? ,EL@*AYB
MR$*SQ'9V.7964.KH?K+\SEKZ$<MOC.5+MBO'H#13 FQQ%E 7#\&RZL)2%#FQ
M*"WG.[LH.BMI"O;VL+Q7?3&(V[?$[277)7,2R>D"WN<":%C]*"<-3*FJU3IZ
M'MW.KF"=$7UJS'M_AE^;*[FYG^>#Z&='@Y-93DLCL.NS?[MVF[XPF:8\A7J#
MCQH&L\EHF 87M[5]6M8+7U)!>U(Q^V$Z>3M,.7US^G,%[Z/<]^-+Y$C4-BAJ
MJQW\A))6ZV)!EY !'><0-$HP7GG+HA6)MP0WUYUH$PZO.%)_[9WB+^;3%FTC
M/V"-N#%70QIQ5QJQ?)K+&)Z43Y!]<M74, 5>>PN.R^Q,,%RU+I]-'PRSFQF+
M1QIQKS3BQ@Z#D4;<E48LF2-,(B8F(FAM8S5'G(%%)8!+3.U_<C%-KRI)YXSK
M&*ZSQWE;&K&A3$UOG5-CSJ",)G_,SLKDAN.W>;9DG!Y]UCE]P8/X(H0^*ZF;
MV(UZN!=Y?VS_9Z9>GTSCD6_CKB?E_)U[G,=?.39L:XM![G* ]0_^=/'$#R>/
MXS]/AM/\XF@RG1_FZ?'S#W#0LKO!91=7LXJ^AMMME"7*4/\P.8%UNBZ[U<B;
M)!+JUFA!8 O+;6>Q)V>PJ="K=R:<N'WGW%XNX>0Z!NT\)-URB<P'\#DKT$EF
M7=]Y(K*\LRLKMYV2G9 ;"*F)VSWD]J8SBL3M.^#VLEW6C@49"BAA"J#+%GQA
M A)S.F81BVE=JKEJV^ZZTZ8GYS#NCR/^C*F83NH%IW,_/*OO\>8N)M-!9<+)
M=#@_W839> A5$!OW&N? ?%MQ>5%A.2@D6C<L6JO]&[/,5K>.%U[9-OU',7!"
M!5#66HXR,YU;ZVW-.V9E9VD\\3TF^,8-!Q'\#@B^Y#AL]DJ&["K!$ZN.(W (
M)@O 6#@S*K,0?=O$Q\Y*UQFU]L ?(GAO";YQUT$$OP."+W=KK S.5;<!"]>
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M2!QL>]\?)*XI^[;(C,P%)06H!*#LES%AA60DB8'D<VQ*)<2-VO:^<:Y?,Y#
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M46,$;#\S2%SCB^CQ$_I_1O O^S^>%L[,V71^$;TBRHS'JWLB<2*J2;V(%K"
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M[[O)R B/SKV] D>+<WWOYGIF!$*Z1\05JF*(SN)T;@P!5)QW;SB%OS$!Z")
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M)M<O6A/:#^P,.OAX;'56Q,)D)"FD(+2T&1%IDI.2&JV*S&K*TLV\ ".94:H
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M=<E57;$FF#'66I[W9'.7+]7F1_E(T,MW<M0WM<V#X:PU]S>"F >?571N?;F
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M:"X[#P ;?A>F"F:+G.1%DF#5)DND49:4>98G/!$J+<O["0!#>M"/X'YJ*^8
MW'!?36YP.WVR[$2A9<%YFO"84L-Y9B0W(A>9+&02I_= B;/5!Z/)1S.?#NC]
M6>C];D-_TWE2EHFU1&16$2I+2G@,,ERL;6:-R:61V8-'KOM&^LL]LCP-9N=;
M$-Y,:4 G$TS'DF:,RX*6.8\+DYLTMUS< ^UMX/POY_QUQ:T$%#<L(9CK3VC*
M#>%<Y<C^-*:28M&0@?-_#,[/0(9/"Y;1W#)JA>5,V[@4(F8FYCH?'$Z[S_[K
M:IL!=3S/E2)6X\&OLY3P4@G"4\F23$E5FOC!HV04QWQ$\Z]6V^Z?T\GS,;_/
MJLLK[.]T P7T0N7=;(8M29?HRVK&_F-7NOFB.N #[.T.[#T]1\CS.L^?\/P#
M>IP8!7"6ED0+R0@M86]E65C"8.>S++6Y-0G@7CGB-!O%67ZSM6YN@!-WR-P]
MP,\GX2>AFJ9E4>:24VIYS*4VF>1Q9E( (9G? WUK@)^OA9_#/OSDG,I"6DXH
MR%V$"IL3ENN,V*+(M#**I12K]!6C(J>C/+[A*GT#_ SPLTJ1C(TL,I'SC!M:
MQ$P*RD1<FEQ(GJ4B&92^[P!^7O?AIQ")*@QF%%A.$8,P28I*4B8I$R4%<BBH
M@Y^$QZ/RZ^N^W!OX<4KCOUP_DD^T1[V\B_WM=A/ZP]2U,7\849MZ:$)Y^%&=
M'ZM2E$F9Q\26>0*4*B3A62Y(JK(XS;)8Y(G=UA;HOK0N]9NY.PW7W:"QOQBV
M2QQ/)R=D8>9G37/AR4DT=A,:]?H,SHV:GDS@!=@#=_W:R+$EF5J"?8A<XUO?
M"GOSRG$E)/8DO\"^U3@ [%"(&.":NDDQ=@TBZU/3]LY=OZ^JX6C"$<.<VMZY
MV$H/^Y2U_>E"KU]_<]LMV/= %*OFVCJ"T;D;*FPP 1_[;DS=J?O^D/ ,UU9X
M.I]/SR-L3@?OPE?:)78MF[H6SM@<"1X#A//1]^>&P8:G^9%@OP0#,W1-U7#.
M?HY;U@_N;/M[N_O;!?"M\XSODXD#;)H0PY]MH^$YO*#?H[Q=M+HS'K?S880;
M8\->DTT#25RW\U/C6AG"L\TYMK?N=./TSPX]&IO/74=&44\G ,87KL6<ZV5L
MVRYS>]?M4WQOV :]4FYQVX[F39O#5<?N=4[R[0Q;_G&D4B_FPFTZOB-0RA3.
M-=\6U?&C[>R3ZSM=]UI/K][2-I\.I-)CJ1JD,-^R?JV#>/27F%>NU=<:D_B7
MK%AVRXO\SF(_5\^"34OZ*]J2W^[1BAL PW/3>^&[1#[&#O;#,0O'+#T&'2#1
M96X(IR &4E4HPD'V)QGEC.LX$3Q-UOLBIRD#M<"R,M<YY2!))H6R-.%<2VYI
MN?58WL[ M\>OGWE:O\1L=/*K@]8NQ7P1$-&]\E;G=F7;P0;<'0/6/M4^5!)3
MG<FU8-5T3X63K&W@V6OLZ<^,?J_7C9ID_2,X="16XZD[77MM<%>@V.MXZ!OJ
MK@ZW(U%K\3_1[^,I2 #12^.ZO1[Z'KWADD\CRV:SU\X.AE6CJ=NM7V8P3KSF
M9[<8H,*&3H1!L^[<&+28>'6+D("LR\7EMVSTK+JK@XHD=&W).O^>SIOQS,2)
M(1).Z7=$6!CNSV)\+B[J!__J\P PP-HJKB_ Y0I5JU9M]L$M:"R$-(#W<4*%
MT%P4.DV830!K$I.RNT&4+VCH>S50]H$UQ[:_J6*:QCG-TE+H1"D.JDY:%'F1
M\P>/=)!+3^9B79)KA%<OR*WU9>[U27<W]WI__SH&S9V\5*?3,0H,[CK'LGC!
MV52;L7_7U==%YP)AX+T9@X#@A5&47JM6N&Y>V1\@R#TH-+1]A,]/*W4:G8KW
MF'87O<=[X;X&<EKYTO6Y7F)_87C I 8I%T67O>@ 6TEKQYRC9ICX+K\W;J!M
M+VDWFFHR6_I^QDOY%F &6Z2ZYL?-@%;BC^_N/3,=Y//@]GZ*P.&%\8E>71/>
M/ZZLZ>^8.,/^X1^W[ICKOGPNYHT2\4G)T,T$L,BT*Q4ZDO<>M!<];8;4&6I7
MHSBM8#YSM*%TKO!C;F>#T_ R8Y^8+GE.[[Y&K:G?$3LW9J5=.75K7;=YO?<2
M;D!583F_B"XJ,W82KN]<VZ@G0%/K# '8 +H)[$"X9>VQ5JB@S@%E-=?6GM8
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M!6JL2 H)V C$@\L> TP1-EXIJ67B$0/O?K7'H&':E\*TRPK:"$R44 ('G;@
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M.0D*(=J@>;!1&-[P\2/L\ENZLWERL7/LBYF\L[=_(%*RB1")$E?9_44E;'G
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MW(<7#B-\DW^]6@,8[;_GWU>/W5YYW>X0!S"APYHF."UQHS^=@7&0K_FQV'?
M?S^==\+H:))Y-'-CG3&"I[=8-^QWQZ/K;YG)"_'E..WIPU0+Z?^*B%Q8HIE_
MCP;3-)##B!SLV DJ,/1'VSVW%\.U?\]S/K#]PBHN+L#U01<WG%7?>O:\<%;-
MA?8JQJ2#%-QBI;6(QHEHG6!&)/9U9]5/>6:R0B M.*L[1:_GL.M>"9)991#6
M '_ZL".;C]O@ZHP+,T2=F.RSL=OPY.'XR@1?;[WM%.LWL^=%8<[L\NX4<7.-
M[&S]T/G7O!F>?^O//&9XE$.ARZG?:=8MG>+GSX3FCVK__^R0\IVQ\KE7D@J&
M%V*RX^YH]E'3 X0*\DP-]AK\5*;4Y.BO!R+&Q^KA_2+E?NC P*^<0,[V3@;C
MLY&_R-^!.NUW83+^8F(BS4QHSE<YKSJ65\Q.=4QYU_R!9#6J8J9-ES8OJ >Y
M"5269SM[DC0G""=>I8P#/Y4ST6HI1JTNW#UJ]8JR*:'W<]Z3R>ED_.SC65GS
M]M5Z^+S L7=8W$VQ]0G> O.\:+=BKU!@G;*1KQ_Z_EGMU[E:I<IR'$X-'#=O
MK,R=D8]O5LDK1GP5;3:G\NY&IK;"1R/@WLEA&&QP)V9KJ>S,S'+5ZFN)>.9.
M-,JN%>JLO^[DX^;^ITX^OG(1WA&_UBK,^S(1H"\*33V1XVGFL&:GA,#VTR9H
MI'^J;=DIR_YS6>F]>O^!-E;:'V5?OSOKXP/;V=LXL GK(&A *CD'IF5T" C(
M(>P5CI;:Y%DV+?62,^IF9LB2M,C8GZ9D7PYY%P4BL&+LQL&$.6-*58A)+P=H
M]&L>&DTW<,)G0%"9<<_R-Z-1)4RZ]OP;,DIF?>X19.VX.F.XPTES+3PW_OJE
MM=<_Z_AA2V)9]*7&.LNZ3J\6[K4Y4JWO[!9=8?L<8U7L0GL5$#PY0AA48FP(
M)DPW"[5)&&ZM=1<&D<=0'23,Q,(L2KG9"*62B);WIU+<ME(Z_1[ @] 9@GKW
M9?M79)U52"@[Y8/M]GMQXB^?23*;S/^FX_K9#8#UJ%/BKI9H,HT\SJL!E6.%
MLWZFS2S-T[@85?,!&[,FUA3:S+\OC0<%4ZS:&]B8WK!VV0%B\+<HRRJR>ECB
MXJK9-D?MKUEN[Y/MS;<'6 AEC.>(<9T0QXD@)S1'DC(O(M<.+*:['+4O!F;4
MAWAA\0R^==8=Y\B:>SF-A3681##5C.!*.LTPEEX;AR4CW-_6[^HNA^4US;RU
M@UY#,==3S,[QUD'@SG(J$E(2>\15<,@&HQ"7EK#<;I(YH!AZ*\5<'7Q?T<Q,
M-&X=IC!)%JF5R+!SF(W,2L35,G$J)*</M*=5&D<)H,O1H+.)R"M%7[O6"Q?5
M/95)-!69,_%N60K"[?GSI1#/6KW.*(19NZH^9YT<X\\<_%\]<\%)N$IJ+Y[A
M9UPS\ZC.L#9:#XL"S\L'E^0PT&+@5VLV'ZPX7!S9),  3+9R= ZOJ;:F. !J
M.VF]]>OM&Y"1F9NK:&&'5PG@MYAF&3#$'"(P"8ZKK&,_E[J0<WGL (96^T.G
MBSW-+:F"$'*FS\S._1D[IVX\&!:O(4SW<&!/ZS#$B?-[9M1PP5E_4,(<1CEJ
M>9+>- \<JBTO@^U>9 V=\XRRAS9;LB%V8<"#8L6&P?CPRL,( \]AG27&-Y-H
M4?TKB?0; J65I_P*T%5DG\EHL J7W/>0\:'TQ:.7@OO^=(C'VY?O#XSBG+F<
MRZIC[KBD,-(\&N1M5!8G[;4F:V_$K3JDZ(INM^]GXZ8F@'HUJ)_'QS,\OLH'
M\E3L<!_JED%83*TS.G#NM++,TQ2E]$9$;+"]]Q'Z%U'WBZF/\M0$/).I>[PO
MMH_W#P1 :.IP1-@&B[C!'#FG/))21AP)CLRFM3?+I'R_:AI2*7@H5ES0Q'%0
MSLDD+&/& Q:SPCR-4&NV'>]<YFW_<""4PHQ*AL"BS5W7>4+&)05@F!.7(K<R
MZE7;?N_Z"UC8)$%8:HP]3T8:GRA-(27*';4^W%)ML%%G3T<6FX<' OB?N^10
M$#RG[RJ*'.82&8P!E0B@#!SNHMH \TR <@G"?(D>^DG)L.$MA>F>4[56=8LR
MSU7YI[-%#-HWVR /A[>?:K);Q5CNU945KJR4%0ESMQN:"_EO52)7#GT& V^:
M!V>GI\DE8\HOY?!F^WLFR.-F)_"\Z_>:L2^YA#764XNN#I8I9M1,3%(VZ^?M
MT&I(Z,J$G#4?ZS2T5GUPFTW'7*2SP,R2\SNQO_MG<5"?*>?2)F P9P]2'9I?
M5Y:H3C/+^@QSB8.P_C@,0>]XK/:,W+A0:W B.%ZD=%M,7J=U%OA$EBS60ZS\
MG3FU,$_QA20$-?[QAU#M']CVWLD!@"T"UE=$,<$V<.<"<C+GIFD76+*:T$!R
M^"R]6;7?#_<_EO.[(8R'L0!W+M\?6!:#($XCEQ@%"S!P!+A<H-Q=R8O,KT[F
MZCJWQ57?US(P 8Q![3%A.I26!R9B%XF01EH>T]TM@R^@C<82!+G@+W8NMPXX
M%]IQ;Y!4%B"_" XY;QG@?NLBK+N)E*YV ,R#T07(<E5&M:I<54#+<^KN)<"T
MZ'.O0=,#)J@_8]&>LYQU\W.G#QI^<#;!LR]Q8G>MP5.)&FHRBB'JID(\O=;&
M3)&;/R?5<";%>$IQN#F8/Q.GF9^Z-EV\JV_6_M5^&MI=7=GL64%O5;-H)4']
M,%VKM7^U:^.H-PU?*F6+,Y;<+AR7#5C8/7U](:'EE;^^D-#5M3<7$EJN'521
MTM_O_H,8*5G&8&_E,C2=T]-QKQS3V;.+JP2^:3&A$/,);NVISSD@U8/.!A'Y
M[*8?#*L/O!W7<9W__<??[=F<W;H 2151.PWR>7V6^NPAQ*-5&:#"4^X=882!
M?B+<^102D3R )>&I=4V5@6>"$.?;QUOD@$9AI#,26:$MV!/1(J.5*576DZ&8
M>V&R VN%KW!:TK6;C_;K-*$LP(%18\4R.8N_6**3H_.1_9RSA;ZF)L&J,@3]
M-"\/JK]RVFXIUEG.WZY<42L$5 EUGXWLG\B%R0,S@TQJ"!2_$##U2<PQ#BMR
MJJXI)C#)2ZAC32;%2$N$WZA3E-_-A01JX5SB+6:N='&:O5N-NML_1]5OH_X$
MW@<TBJ [V]7?=RHR4(K=EZCG:;&!Q<3LJQCN]>FZWK]BP*U)_E\D1KX^R3\[
MB+Y#T0!6Q><#%;T#19<0\3(AKBQ&CE"'#'?"6N8M:*?<LF@IG+KRJMTWPW\F
M1?RN^?PUL<\E]=?J?"&S?R[M8+8^1OYB*G1FB/E5:O,5DNVZ#*LZB^KJAKMD
M4=V>-K7B_7=(F5K*EJJ"E:I4J/K^A2BG3HGLJFZ[<U;59!6&7Y)*M9 --9WJ
MW99A-BW'795<>!J1-^-+J61=/G9].\'WFS#L7_N#VS)+OM?,]K=PS<GE@::4
M:9\P$DY*Q%.P2%O*D%,R!BF)92FNO<F!AUG\W5#O9,&N*I18G/<Y@;@"1D].
M%5^9=!3LQ7=(%CN;[S\?F,"3%9P"69 ZY\C&1) @G%!I!#:9+,RRDH0U&]Z<
M=_=E!J5Z-@7T:WU:^FH.U5Y:B,!,A,"+7+>B" M0<+$0[;.N6 G$3QUO2Z;'
MM9'4,]$5*\R^EXCR[NDE_J4/%XXF)7'>GG5"/ 6E\<<@5YB(H20?;O5Z8"97
M *DI(G%;$0GU\HM(W%H48J&(! !@DS@63B7!L8IPGS(F6AH2"S3IUU-$8N)H
M.1O$3YW^>-A=/#F8-I(HSI+20N8,9,/85K5ZJS22N0JKN:Y3J'PU$W_S4A7Z
MX57UH=_M<&A;"2ZL3(S<GZ:*Z#[LVZM6>'>K_UU&E\_72DWZJNSWM6=;PWY=
M7+KW*0Y'M<63S>E1WY^<97]9ZWR2OPJ$&2ZJ_/])H@T 3_CI+^HPJE%^!I@@
M=7_7:0I-Z QS489<+*G0=YW.N7)A"S0]/2O^N2M'^N2-M:=I- ZE"N=,,DT5
MT%4IO.IWNI@0U&[U?:Z^7;R'>:E/P8+KG'5K?+&4]S23;#.WVG4!GG8UWFGQ
M\!PC\P#N;9O/MKTR$E/'DW# AV IV-Q15%,G>8;C1&-.,ARO?IES;\O;P?FO
M531/=FHW81&W@'*R<WER<2 )<2H$@60R%O'H%-(^)N2P5U+@H*7-\:_7MQZL
M*JQF^%!(S]YHD7T1"=S-3A_UZQVO:0!V_<]:.@#K;$YE0V.Q+S8Q^GQ B6="
M28MH;EW$&1/(\J"0ER92$Q(725;%Z-!*D[WV"649.B/46JOD&0C 7CY3O)-<
MJS(Y:VF_7#IF$K99T41_,/'Z3X+Z2H1&$697QP<K#E)FJ@U,3U*6^BS?%C2]
M8)4\9+"AP4Y1Q[AWUG)OI,-1*>:YLDIQ)W43;/B\P88P_@.> C?>>:0"PXAS
MHI!)V<.A4X"?$9-HU][(=77#V>"]&L);G7.YM4U&<BNL$9;EF@V8,"REY4V<
MX;,&FGW>V7M[X#D%BX%Y9(A5B!OAD:,F(<G #B$@<G7,C>%O.C"^=XRACL3+
M2!EVSG&&A54\*A>H,8*HA.ECQA@V='$7NC@Y\$0SC2-%H%H-XLF;JB1#SC5R
MV-I(J,JR8KE9Z%16S(<BSA_[@RZM>H#6E0+J<,3147\8IR?J*U(JKHT0O*FK
M^43ID7FEEWOZO$C7G.VM[*_J;'=R8':O/,]<'H<2H7 47'+II#+.^V0#Y4+&
M4+HMWR&K]U5W6WYZEMH^]OS <JH9IAYQBD&^1JJ0R\UGN.,6]EIS[$T.\%_6
MN7-QW,\:I'M?^4Y,R)7;$L:<<J:X5DQ$S  #*.MEPM]%=^]G%>'GNYMO#YR2
MBC'#D5;9;-9"Y3I,H-^=%,X&BRT1J[M[+^26S,OQ5?EK$\$T/(IQM"SIBWE3
MB?MOJ=785J^UT_]4)73=I87<U$-8W'HSW>26"OM47K!A7(YX';9&L$XE5&VE
MZ[*]T-P!K-51U?W/=B]RK;E<+,:.[+0H3&T!WVS"UNWMX)L\@V^H;,S67#$Q
M/'$LGML:C\PVSJSZ?<("5H[&^\A$$0)7D4;*H^:")!>#HR(Y"3C*@"A<P+Q?
M4JRN<2S>2UB^9P<I&1PM<TC$7*DN,86T %GI&$C($+ B%@QB<VMB_7-JY[J[
M9G\PFG-K%;?3Y(\%R7)5VG)2,'_BYSH:G^:^M?5)0AVI]0&(&CCAKYRQ,2Q1
M4QMG@T[W[MSR(A'VO9@7K%6I4S!!8<:9D%8$FQ+CSB8/ $_5S,LGS M&;<.\
MC\F\QV\O#U(@P5MI$"-6(LZ30X:&B !AFIQ3&QSCV4*]!=X\-_.>]P<GTUCV
MK:JA;'T2^'=]:KG5 XX<C4>Q]</:UM];:_^Z:I7W?_N#:%L[DQNF%P*;_W?,
M33S@EO^[L_7?<,_,F>1BM;Z%JMY_]<=P8WEV^YMB9)F<%@QL7>R!>QUS@-JH
MT81&$J2O,Y\;1GXZ1KX\^7P@,';6@'5,I:.(>_C'8"J0<8%%&0+QV=5T>WF;
M?/0[+=F]C*8GJNG_';9Z&9:6=(@Z""/[F$*$3>JV8JZP48HS5M]5+7':K9->
M;J]LAZ#R?O_][2][?VZTV!]__=&^*BLR^Y#9THS3UIFE,.,41=X+/QH@4*Y)
MXBKP*(U.6%@FM DZ<"L:RGUBRMW=\Q<'*N?ETQ01"[GYF8N '[E(*&(M2+"6
M)%8L;'8[Y4XP7#<;=Z@L[$)M[KG^[_<\^'LQH9 O4H4\[$FHIH'GK'W.N>68
M1NNDH)SJ)  Q8GOW8HH-ISX$I[+M3= QS$LE;<C-"7.=%1$8LM$QA+,];ET4
MSL7,J>2!CCZ-8%C MJOD0!1K:> U.FJ6(C84Z. !CCX;(K@?$?"#0 2Q8-(C
M ?8!XL839 7L  O:"\R!'H)=;3%\\5&GC,I&!4J:<<$# :E ) W)VD0T\>8A
MCCH;.OC28\[C#P<\@8BFH+RMR14W8S#(**V0)\Y2$51B"M]R_+VRY$IQBUQW
MXCG7!7WN^+.DMTTJG3_!X>>]:H8:15.(#,PE4'#>:6FQ=$*9:#7P$[_K*>*[
ML@C3,YV&6*\56L<?^(%0(0*6 )+T))\BFH2<3J"^2(P\**$E5KDWPFT8$XC@
M60\1[V7L4+!U@J%218!0"6P?0XTR+)HH,?Q_UP/$AM2^I.0LC.? "$!&P4M$
MF<UU))A"1KB($F/6)V!W;5+&2_K^Q];/#O=GBU_E7.(XR-D&E55^A?GO><@Y
M>\0Y^]74]I]5$@^4"?@4*WG/[*6?<W;Z_V-/SWYJ;4?X.MC6NW)H^6L>9G&H
MO*+)WW9PN.M'_>KPE^AV/=')6<C,H>DUAXCWPI$""\*<<ACL"1H!G!"5E(XA
M"M#$)%5!Z03C*BB=X 9'/JIJWME[2PX2=MP::1$A6 )X3!8YDP2*3 FF>& V
M-RBDMQ7O+([+\*G(EA5Q &%[PPVK:\*@--T9#G/-@TYV6Y;<\_YX>)7E<U8J
M?%]52JX+9^64GPX\)/JC'K#'X45)^SP":L["*E;OGO@Q"^CLE\PG>$%W''N7
MMCSLO[?^KA^TZ#\MI71RH8=:&LZZ/T_[O;[OEN,)(/R.ZY=@@RH$XM2>Q+KB
MV-7(;&DM5+J P].Z_?.JE7@GA&Y$53&B5HD+*E6ZRGGD^' \'&4N-!,NK#G/
M3DL\P.OOPW"*,V>B"<ZXQ)5UCKC@C1::&:NB$87A#-85P\$OC;_U41EN=],#
M%G86<V,4<C(YQ 6ER"HE4<"2R,2P%9RO]N+,,]R$TH%H<]6D!\ZCJ+#%O?!N
M@AD VG*11VYPT@F(3H,Q%:(2UI';7(;L$8GM.ZS&RG;W/EP>*&)=#"P@JVU"
MG/L(9,<2$J"$.>&&.^Y!NC/6!ISQE9U8#/-&*B4(%98G;ER,69G3'#FJM2:W
MN0L; GAH M@_/_ T1[$&BH ,<MHA]D@;$I!BDF2/AW$N^X8T74D ]^_)DL^F
MO3,6-IT+*XQB7"H1X"<FJ<H[O,E5V-# ([H*+S\<!)?SI*1&W">../4).4(B
MDHP1K!1.5(>U-UQ>)P_FO81W=^XM6IH5P,FHL#(EGL;YIXBP.'G/#.$1A)*T
ME"OB20!9**Y-(6 /XY'Y#LF/;V\>GA\PJ5RTTJ$$: #Q7*K*,4M0H(X1JE1P
M7H,($JMI[MXBB!*F+!,>[!?#J? F28)%PM$1':P-U_C=FEU^$"&SNWEXP)WR
M8/^ 21D"J>J^ZWPR87S@U&J:&S:LO6&:K][PQ_!LE=OGQ==#E;)Z"3Z<217L
M#.0?TX.38N8AIPB6"32(=49$%9-E/ 10]KA6[VP2P,,:#\[CRM?C;780F;0L
M&(Z242:WF]; :9XCJEV*S!ELD[M_Z-GJ9(Z%N+$ZKNS.T6//;J1J%B/H>XU]
M$CPJ8SD6$5NOO?*,<_E81NKWJQWX]N4).P@ LZ@0'$6.<]0"&"0::X:PIYSX
M $)$B:_O!6I%QG1:)1\#%TRYE+L/12&TX)B&T%B@3[OU.YL;^, 1R06U.3)6
M*$ #PJ#<[#&'N$LJ:=3:V[4WVCP0_ LLZJ1]9(#WN%!4<ZD)IXXZ[@#EDR98
MY?F: L$S#ZR*CG,@!^*MR.Y/A;0$<.@9341@@9V,N2?434%L#V.%=H8U5JHM
MT%>5#GC/(\W-7'AQ-%'DFX"J\W+\L-G?_-?KFO=ULR2B3H.LVV+BFQOY[)9Z
MWWNP\<-:I&R,1T?]06Y(F<','X/^J#^Z.(N+/7QR&P&*?]K=VYA^4SXC/_VK
M B]7:3"PN%=%W6;&<M6(("9X4U7QO:;5"3*Z EE/&WH@\Y[>NLPK2FYF"D&L
MW V(;Y23<NJRF;D<5'[ 6L::BO_TTF(I"MG4H',&SY8<A^&P[SM%7.0Z?A?#
MNDA6:<&32C'X*X!;/6$:#E=59:P^_67W[ZU-1$Q5L1"H*I\AENBXS(H3BS9W
M\>B$F5",FG"GI6+G2*[49[R7[RLF5JPU Y8"$\8PHABS)!BO%;>Q5HMR8KG)
M+SX*;%3B+2I1[&R^/3](,GL>54*,4-"#@5CD:(E5"D%E?[FB":RV6YLC5F1U
M4\/B><(9'DW*<6;O"9!<%HL5E3U3:%WAP;_&;E1Z%ANAD<3BT=,][JY R_AV
M@':!GA$HAM09M=[F5CJ=.$1U=Z?6GU4+Y=G8H.=8QG9=2C:72!B/\O96U1%\
M_ZRD4U9]H266!385SUBN)MFKVD$<QIZO6Z%=J:*:L+*<&A:ID_M65^DEI2,'
M\#/(KIR&^<EVQU>N@,Z@ F4=-Z[;=+Q(T;^WRJ'PT VP)RU=0'Y."CA>,6?A
MO.Y%7LKZT<.J)W>GERO-QO#L+A.G5?!<8D9TJ8SHG+$:I)04U+%4)^W=-16H
M.-6!AWR,8=AHBILUQ0>\N^?SN'$^RMT^/P@N@>V4LMF4$N@,IY'UDB)BDXA<
MADBES[D?#Y4 Y((3@BN1*/$\NU8,O"$%HF5@*BAZKP2@9NN_>.MW-PYXKE4G
MDD%:)XLX5F V ]\CHB(PHN<8:&#M#54W[/W]72E!))ZX"]X2H*Y@L4^*$>E$
M#,'CQ7(OS?8_SO9_WCD\P-13$V"A52 <<2D",B9J)!AGGCI+?,A1FJMZK#^T
MVZ0"E%>5U[\=[\&T96=>GLZUOH0,@JZ.UUJI\SD&=#;(9F.UGG[>59!I?CRH
M<,$O]043C\&T?E5V%EQ%](US+>UA7$CYOW(<S)ZR-*Z"9W 5@-##<ZZ"$NU;
M==R=L?*O]K&BCJDIOXHD7I)%/VU;\&NF[C_R\"?CW"BNBXV*_AOY?4VU]_/M
M8W]^0()7GBJ-#'$$<9N+@JA@4;22"B]!@2N[]H;(VS*0"E$]IUEYHW]A)36G
M7(5^2O%7!NC&7[],C=")#>IG>:#J]=WRX^&H?UK7!%P2OW5@_1#H=9@N2N?%
MV8:+TQ?/M.!8;_TQVZ]QY>4KYU(<)<.L &N!/'NT/=NQL5=:UN5/;Q3+KU7Z
M/IN0'=XD94<S3OQ*T!8*Z7;[?A:T /3H?.J$W+OX[!HRF.M=,$/I8-?W@NWF
M/HJP2-W*73L;]G#M*+=Z,V&+6<4OU]-<+J-YU52A?GI5V([!NP]7%P):+(2U
ME)K=F2L/69?X_%(=55HS5^MZ+W5EM6!22!VEY,PRG0LE*>*< C!+C5EP(]RG
M=F2CKA[PE!;&??SA@"0G*-&@JK3TH+EB1)99FHL"*4ZH(-S$4E+@EI+/2]ZK
M!>=5:^JWRDUWK^/,V\@R.\PJ7="YP6/V(A'EC6Z\IB_>;7WQ](OJBW>M^?O2
M;-W5'?QN[<BWT,$O*!:"(9(D@ S!,$T(EX;X''O-532Y!\"D9-82[3XCP%@]
M^]MG<XTW?5"? =TSF!;&HID N)"HYUY1G:1(26!',7/N]EHD-RG"^E@J]]0&
MI#0C-"<RLU&%MZO"]Y]W-[<.#"91$\Z1]88A#J8V<LDSQ%BTP@;M A6YOO)R
MY[:%"O3WZCH4 ^ C&QEFG'L,U(@3II%+2W"@GMV6Q/ $M/']!31N?=[>].2
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M(@)?/)[0P&M)<\JBY#HRS8ABS%+LF0.MA!MGX&M@U\5F(9FI1$J(*,J!WY)
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MT>?>H)*\>1YH-;,+<9[))0RU;X_&\=7BC]>+4[6]077'ZDNOY]>:RSA<;NE
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M;#Y:833\\GAM@VD@RK)MS.,CZTKW"9>+8US,4;_?(PKG*>-OYF4<_F-/\G!
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MU@)0H:$#9*WP8YQ5X2(3S435>@^N355X*YOWUI$]J4H9@!'Q=KP'USOL(3L
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M*0 =T:^9MAO3QZYT!1>?JD_:'TU.H\N-6L>-1HO93D_:&:%J_GM?92Z:VQ_
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M(0W:%''-X/PK!DK5T.!M#$S26(% !0+/!@)3/M'JL-_QL#?G!],F)XP5&-E
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MI<MX,H9G4$C4[J'MCOR$S=[HA#1'F>B5:"T3K6]X9]>7Z][=XXVMEK7&>\T
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M66$@%.E?@]-C6"Y<9##R LUR_>DT.7M5WL*[!5-KQ?=G;G5[HR% MY[*-]J
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M_H!M+_9R>NO'F%#JRPH8[@T,5RF62D+O)J$U^+]E KI$:=V@LYWU/P[Z/5"
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M]6UP9[A-GE"M79",4*Z3<IAS0:,1VC M''MTN/WP/Z?MX?GG[F#8/\U_'.S
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M/)*21_>>X67[;&?KU4%!N?>FH"A([1'#1B!5!(*PQ=1RI11(6"H5SJZL>/3
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M9?67R5O_E[ZR;!V6U8P/TXRWZSBWZM38?,V^EV&BIK&.EXG:A\IYF Y;)@/
MQ[JA"U.NR$M:NX@(KVPK>$&=?R=6;ZKVK*G\/: 3 A&/^M7!3FHN=$U%QO!X
M/T=OU<>MZ89B5A['9 P[6;?6HR^[EK:J3-G3[M"+6$^3RY75.UFGTSO+$SBV
M];IAN&"&4CA?)U_4K^9C=%K/B/EBRDZ.X VI]7RD7^;L"2>]?CJ&^9R,55#
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MS;SR2G]P@_55,O$:K"\/ZS,6'K4B&(<UH@H7B,7 D6%>P:Q:5G#'"V7PVH;
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M[QGM]VO6+!'C3RCF[[[A/9=8S5&K.&-(.&Y@,T]6"M48*2YDT(4GQ(@4TZ-
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MD+)7%P'T ZT4,H4@EG"@7:92*/@3C,)L8'O?WK@)V#;J_E+@/.N,TQA'+RV
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MN&4\NNA!Y=>8&,2$+)"B$LP PZ*@4<#"$<"ME$\Q96J#V_OUS36XO;T+;AQ
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M?S!YCN E\_>2G,%WDL8BN <(O!\\#[-M\HQMH[/2CC68@X /+T.]EYSI]Y.
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M)V6EI)UOAL@4]X6(W!6:"OBC2Z8**:V*JG#6B_G$R<F$M_*,+]C.\\FQBZ4
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M;CYI^KZYD\1J[J2?;,]?P?].A^>=%_\?4$L#!!0    ( &V$858G/S9>*1D
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M, _/_XA)M-H-P@I^2@R/]#',L_]?)ZG@%47_%(7SBX ][#K_UFR4F'TPF'?
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M;ZJ=1,>^8S*;@W\[!.<!-/$8BV$7^RIIG#R&@0$#[^G7A/8M>?%P1-VF0^-
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MWNP65VU;!&HV"T>^3H#/<&JW8VK'=%;N\E\!J()-V#I/(,?AI<]PU <LLKT
M,5&SHW?I290V\8]&=I8NA9DSHA4"%YO?BB>76O.S='SRF*:IV.$%X_G32MGV
ML ?+>_;WR$_WCL5.XLB'54_$D><L$.N">BOZB6NS=&QK+,OR;9Z*9$0M#I:.
M@;B_$_-H)>(;XMYHL:>P3'.,EDP\[.F?K(2Z:9(970ZVAA+JHZOY6TGR/[0(
MU-:SLM.YN\*@&7$6+)/GZ#>'0\[E7IU(6V#U1ZNU&;STXPPG21+&-09CTD-?
M8"D5;Q#2Y/+29AM4B]0"6U3K)4Y5FHX9$SO%6FLG1;DC:<C%SJ$8OG_S[B!W
MC=8$4\+X#0,9/HOQX&#P5A%:U::W8 *873-F\>5BZ3MG@W;/H]636= U91"C
M??C#VKA'FS>F=WQ1^H6.+"Z6',_!&UO'=(7N!-LY]='2;8ZFIY\T&5AJ:HNC
MII?KHZ8Y#2-^2#\J#XB9,;%SW;G%E(:KX!Y1@EK=MV[ P *M=ANL (YH?HVQ
ML!CRC5?%-Y6$%G2O(J.@</G66.S>C?RO89+:7+R0JRD]>G?&EBH"F6H0IUM]
MX#R,<9#LN">YCR('(3G6-T'WC>$:<T:V>N RQ^(A>=#W-IX&Q!WYL,9!HYNG
MB)K.@AER"CH9"IXD(SF9PW26H6G5U45JNA<.;5>>SYF0QQ:G>G)4-B#6=$?"
M.@*ZRT4+)2:6FFWMKZ!\J:LO_VHW7N;.>C:N;X;G1A6\+!6W)&98;/L05G_F
M7P%\4MO+[Q1!1QT&SZAF0 :0QM0J7O.@> F\JJQ=FC)WL&?,5BB(5HJ["[1H
M7SP?MUJ-K\^CLS$FBVG,&V32@(.E%NMU+&Z\$Y$&1=RLHJ %0GI"V/_#:J"*
MY!<*6=#L&T:S*[*;FUY1\*<V_[=]:'WHSO$"??[E/U!+ P04    " !MA&%6
MU \:75LP   X[P$ %    &EN;RTR,#(R,3(S,5]C86PN>&UL[7U9DULWDNY[
M_PI=W]>;;>Q+1W=/R)+EJPC94DCR]-PG!I:$B],L4D.RM,ROOPDN5:R="PYY
M2CT.NUSKP0?D=Q*9B43F7__MZ_GHV6><SH:3\=]^X']F/SS#<9KDX?B/O_WP
M^\=7X'[XM[__Z4]__5\ __'3^S?/7D[2Q3F.Y\]>3#',,3_[,IR?/?M'QMD_
MGY7IY/S9/R;3?PX_!X"_+_[HQ>33M^GPC[/Y,\&$O/G3Z5^REM9$PT!Y01^$
MM^!Y=!"0Z\ LY\FI__/'7ZRTBF-R(%!$4(9;<+9HX-$GCD&6F/GBH:/A^)]_
MJ1]BF.$SFMQXMOCR;S^<S>>?_O+CCU^^?/GSUS@=_7DR_>-'P9C\<?W;/ZQ^
M_>NMW_\B%[_-O?<_+GYZ^:NSX5V_2(_E/_['KV\^I#,\#S <S^9AG.H L^%?
M9HMOOIFD,%^L^:.XGMW[&_4K6/\:U&\!%R#YG[_.\@]__].S9\OEF$Y&^![+
ML_K_W]^_OC;D<#SY/)S\.4W.?ZP__O'%9#R;C(:YRO:G,*JP/YPASF<$?O&P
M^;=/^+<?9L/S3R-<?^]LBN5O/]"C"(,07"P1_._[G_7C%;@41NEBM%B+-_3U
MZHD52PN<^'6.XXS+U5@/.9JD:[\TJK*83-=_.0H11XOO#BYF\$<(GP8?YI/T
MS[/)*-.+\O-_70SGWP:E:,;19BB,.5 \98@H'!0,C%FCT,1X?7WJ;&8TG84,
M2YC%A2!70_Q85^Y'',UGZ^\LUG*QCO>C6"[D_O-Z,3D_GXP7S_WW,+K 0;&%
M9J+H[4(;0#''(,0H@!OM3)(R1M]Z5C<Q7)_3!CV>3].SR90F3WKJAV=?L&J5
ME<I: @K3=(LWUU^8U6_\.+LX/U\\$X9S/%__?=5?3>4^GS1<[J5,:0:'"OUY
MSL,Z]S!Z%X;Y]?A%^#2<A]' !"Q*% .)*=*QQ7GPSC)(R:J,6B3!66/9WP-E
M&PJ(ITF!%HO?C GO2(HXG6+>H*2.@F<3##!>"BC-$ (+Q,M@5 Q9>Q5M8Q;<
M 6,;!LBGR8!#%[V='DADRM5EQ?QV?H93TDZ?IGB&X]GP,[XF(_ <WTQFL]]P
M_K9\#%\'FG,=.1D8R>@,RJD$SID"QF,I3D0L4K?6#[M!W(8UZFFRIDMA-6/4
M>YR'X1CSSV$Z)@=BM@'Z)99A&LX'VMCBE3,@1*$U8*C !2<J\3$K86QTH3&)
M'D>U#6_TT^1-8Y$TH\J;88C#$6V%.'L^SG=,FJ%WCAL#G*$%I0P923E[X,GG
MQ+)%64QCHCR&Z= YWS'+'&((V9$L;20#T%D.7CH+W/D8R0=&%M61O8C36MQ-
M>7'S93A0 %V0?^"TX-P'!2@]&7[>TGP832]&J95@G#G9VNK>&+Y/EG:GHM]W
MR9O)O/I^PWD-G=79O9B,YZ2.<9PJH.B54HF,/L5H.BH( 4%$"ZA]\L5E*UD7
M7O<]</ID>W?*B58BZ4(OO+@@%V$\'YB4T(;H(&E).+*(Y!DP!<DIPF"%T:+#
M;7"%XG#NC^?3D.;_&,[/7ES,YF2L3M>C?%O/-&J3.2<ES%.BF6H9P:'1$(WU
M6? 4?&RM"+?!U=/-<1]^W.9_8[$<_"(,QY/JZ4PO,+^@GPUIN3].AV'T\]=/
MY.G@&E.BESXYPR$XU/2&%IJT]@X0K2A8>'%X0U_>BDUO-U)/M\=#A-_!$C?3
M?V\_X314)?P&PPQO4;$(I14G)*3@!2B+!7Q4'"SI?X$JY"BQL89X&%%/=\H6
MNJ&A*)K1X^4%?IR\QX7S^BY,-Z=J41=AR8<-I))HN^8*8N$,LG(RH\Q,-3^W
MN!]-G\)0C6G12 1--HJ7JSCJ+],PGK^Z&-<SZS48QT6)J@B:HRZ@T"/01D:V
MH=#19$4FOG_L]/*1(?H4,VJX-;1:U)91ZLD%6>COPK<01TB&^FKWNF/27COE
MG16@LZB;EK(0T3B0(B3-$;72K;7 #O"V88QY6HSI6DB=Z8E7M"+/2R%HI,G6
MR%1T4F'*H#G+H)+)X%5R9.\&,G@D8]&X/97&7>-MPP?[M/C0V7*W4R>S&<XO
MYQB%3LK0S$JVQ$54!ISULF89\>BRPBQ]:X6Q">!@QSK,SFKH@OY7XR&?PV@1
MS)B_"-/I-UKWU>FB9&2O604A2 XJ!B2KOB2:JG*1)558RJT]ZVV ]<FUWI\7
MM[SJYC)I>=[_*0SSRM4CD(NCQ!M3MX5<OYC EIJ2$I&!YRF"H<U?!=KN'4_M
MS_\?@]4G1[P=55K+HQE1/IQ-IO./.#U_/?Z,LV6(=""8,CFZ!$(7HFR@SWS*
M"4PTVG'FN4^MW>^[</3)Z6Y'A8-7O+G!_1X3DO:*-7?T+G_/%60"::*(Y!(H
M;3BXQ,F8XSID'A%3%^D@VT#KD__=CB%=R*6)?7U=B\W6:FR%9[D UPS _/-X
M7L]NK-+6U<BB5Y;\R>@X!&D]"%^\+ DS1[:%O;WO^'WRX ^GR=$DT:&B^0WG
MZR4(QF2?L1ZXB01*& ]1TP9H&99":H_+W#H-\2$\??+=NU0I>TJ@F\P(9GS6
MI4"RC-4CB$*DE!8X2N-#T#3OHV5&-#G+=;$HAK2BT0C:SE'36U:0_%_T7A0M
M>4JM<]_VBT*=X#QS)VD_D-RQSUHWS/%XX$#UM\DXK4-@60MAH@*;O0-E:(OV
M)7HP2(AY%D*+<LRC[BMH??*S6K&C"ZFT.]-:1<N6*;P?P]>-69,R'BA?6-'"
M@0V*)FXMN7_9^:KCD]"N!%+XK0^V'H;4)_^K%45:2J'KT_ -QC(1,@LN@_.$
M346OP$<N(* )VHC,E':-R?$HJ#XY7ZWHT582[0A2C?M-IE[A*<SFK&BB6L@
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MD#E9"ZX6^W(:@J.9VNRLIQ_YTKQ%Q-U&V?YS6+G\ 8-VFN; 4BTA7*N6257
M2.V<<-$9TWKON :@#R;F0=*]SZ#<?7E[[ZD.;AC 1_15:>B^>*LW5Z%[?Y49
MKF64"#DX4G6%5&A$G8 IETT(.JJ;QRI']%<?>?+R->"DK0V7!E#6=X&CHIV
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MO\'JO7A9TV4,1$$?I&=.:X\L-P]H[@7T2<9E=F';3AJUB3B[#IL/!-: D##
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M-\$[\%$[L%X%H:2,/F_3/[4AI*V"PNRI4_"4<NQ:558C%I^/\QMZP&CC@&?
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M 2_W4WG"J?^]G5W;Z^+!I/ZO Y+/?IQ^^7^&."5D7WZ\P6\X6G4)! ,%0[U
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M^-9\V O@N9@*PVEE@-3V^GJ\*:_R?)W!<4/K+I@&LB VX3F._3"@&N<#Z6"
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M+2[6*YE82Z^]0P,L& W*<!*4#0C%*96"=5[SUJ,@NB$[ G]&T_:3L=/-536
M<?T0Y;5D7EVM/LT7=:K61#&G$G(#V<I:6"4YA$1FABN1>:49F06M?>WG$7VW
M!.JEF@'<]$WHKOM>3T(F^T.Y CPS1Y0N#)QQ$6R0MD8DO(O#[C[WT7SGA#E
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MQK:(3B7NOP]/[E]V'DDW ]P '+ 2,NJYXM4UC*XV2A/)@S?TAPV%F:RY\FS
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MCT&\>(WW$^L0;_OMKG;MUU2O:#ZK;LUZ9Y/":,>3 .=JW7@*=8R6J%4RT>?
MK!M@2L!S@,[6_NLM_8;C[;Z5:C_$=,/^+J &,@,W CJR)=A?<8\+Y)M)?8#=
M8C,X(Z)+&2/P6./<,=-1Q3WMBM+QX&A_9*5US<V(5.AJ%H[$A'V$/81+\.0
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MU3\,3U$;V2GC>/>37KBV!Q!GXXO;^UG.-=J*6T$6GZSUM3EQ2G50J-,0B:3
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M64Z5O%Q 0!-!,^VDLEKRQ\TP#N'%*85>CD.+PR3>OA3YN1WMSK$WEI%O+^O
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MN$-P=W<G.(_O?'/GG+EWWMR9<\^];]ZZLUFKUX_:5?7?M?>N_N^J!<^SSZL
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M#"< )PVG 0>"<X#SA@N#2X$K@*N%ZX*;@%N#.X5[@D>')X5GA.>'EX'7AK>
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M8"/!=6("8('4 !AL("PV\+D+0/%2SKPH88%_K6J049!0$1"!</"P,"\=H%@
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M[RS1""5 6IN5_+V42XBTL%-^'<'(SH+&JB7CRTDB^T.'IOIF^ >$C V\G+V
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MH6FR3[+=I;BIBH\3YW,FJ32ML!*I4&_5ET.%#P1;ZU/N&1Q@LD:EZ?78_&=
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M@=T50.D\"1P*$=6=\029#2<[2%*2.D,E9OJC8X/)5]12IO#1C034UU>E("T
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M:E#R[V;9<YR<#9G/&#(L35D>065IBS()GS"RLIYX/%[YIPNMBXA?O#.9W^T
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M8&, HHVC$,;8\_DYYZSE"17T>[JT>ZX(:FMDV'-Q? & 2_@J\)U"..!AHE]
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M4>WGT.457Q W3MO9M]B.D3C@CEW<U7-MB,3+X&N-"(\03 /8@D1VE?DLV>C
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M#RP5FZS;^QXXH#0 E,Z^R=4H![TJ)NAE>7EA84X3^]<>9:3,1WR*++"_\*M
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MFW@9V>TCJBUN7?:UA,/,CZL??B]\5@)/I7C.9@/<*/EFX;:;DP/:V68YQ>5
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M]#32?YFLL9;EUR9/*S_L-C.3F! ?Z\N.NR56G\J\XRZ;NU&&Z?N64-0F4D"
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MS,>HAJ3U\U/Y10@?K=^3YL'V3Z+HYYS43JRK,41F,>B[6@(_O]\&B,5@\Z?
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M=?1%E->6[2XT@-CXH\U%=Q<AZ8Q=JL?P-ZL2:Q65/CY#"VOM1#ON[&$Y5^)
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MM)NCT:1;)/=<*F/C($&W[O"7;0V@.5N,A2$E8;Y\55=QR>+YSVQX7*NYEGI
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M)?^M-;(F5ZPARELA\B$?HMA"/@QT*1=$I6[$ ]P$Q8?>_LH84DE##2>=WK^
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M/[\[8&IY_6=*#C+D_7^&:F#_^]3_%RR&GL]_9>SX]#W_?PNZK+CVM4\064!
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M;W HQU^'_923D+!*CHX8CA@>B-[F<^?G!S'R\_USL+K]TQE K" 0R/C  P
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MIOBGTNC";$S*G]]Z>SKGVR-S<I96D.<!@?E3OMB*7PVUEJ-$]7\QON+P,;H
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M-B?.$=PTN]V_)U2->+2>6BOYBT)3>JFZKOOC'O"CV9F@VJ!?L:=U9LF^_L
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MQ+BDO](LHO/+\ ,J3'Z?J280.Y.ZEZBY9V3:ZK<Y_8-(>4X98[R*_6/*L3:
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ML?$_A^Q[+D09N?*\,NW^[9'2*' )X-+^-<K;W*XW*\04+@S7^Q.8;/9UWW&
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MKX1\F>Y9_,^2)J76O3]8&U^SKBS.^W!['U8.6[^I6$OZM6@2[I^QX!M#W;3
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M8*V/&I[-OI=W,Q'D&KF899$A>GOIN+YR<FRY)ZDG('HE>F;A*ZXBX,=5L=%
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M#'$"5(^9!D3G?UYEA5W?UB]_Z=>]KTC"ND$\GEFGZQ#^XF6L?M78OIO&;K?
MT-QL>AZ"_:W?*DK$TL4%5=@7V6\P9,:9H5-K+,3#KY,534SD!-$JKAKX+!,L
MAV!-%1(VL\4BU3Y:TFY<QMO_,KN5[U205S55A4Y$U&+LZ\A^)?3!8S4OKJ]
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M\_J]GA8:>:YQV;(<#8A;/.CZ,>!@1>UPKF^OKA9V=T,?.77R&GK5N32 F$-
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MD3G(]8ZX$16?<=X= 0[H#=(1^E\8]*&IF)\3-^U5PE(UK63)I4@/(V_#3_5
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MX[]QZ[4-9@;=!70-S;=)=.0;C(,Y5#XLSV847\0M7!IEWA&Z6ZJEHA+;,FU
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M(,DR$#?+;Y8N#K6$4TB0R(H=+@*<?5ME:V6JOQ/[<")Q(TT94%>LPU<IKBK
MWQ$OM.WG6KC[7%P&6::1>E7: 1AY>,ZWD%YM+,MTQO>)+$8G^6NFJ904=J@N
M<OY%S<S"8;0SMOZ.H9/Z &:_"8#P)L<MS?N8WYU?A"I(#=ZA\_$LV4T,;X6>
M$#I89]S*>7M2$3WWVT#ZIV_7O#7[?NR*(#_3&>I"'"_+[C"HO*7)P+!%@52&
M+RAUE%=9?%$KOP[D"BWOS([*F;%3S=#'G+$H.NO% HN2@\%4_'P8)^:UAI%Q
M?0)[JW*R10PI[F[9D@2-/^SP.>)%F.LGF_W!26$1O,69W\R#^L?7MW2WHLR;
M#3,_1TS+<VIE@"C,4N2BE"]?N[2,>4(M%.RS#)L<38I/]$,I6./:# OE*NJ<
ME/LC]=6=:0H_G;+N3Z=0ODR+BI<CPDA4O6,X("DU=YLNG::62*X]RT>J&)JW
M ]BTH.C+)#,AT>NJ70D_O5\JJ=DC$.8K'4];@.W4QBGZ.OGHEM=5L3X@I#W3
M!QJ]LLF"#3O;!@C=5\=?78LU$BS3(U7&J%L;(VU&67E>)XR:/")\(6RA01W5
M1V5!MK&:OS8ZZ_KF(: /@-:ERBI@)9#=U2"<UVARIQ2/C9^GEM'E$&GN+_*4
MCDP][AD]/,(W_"4+ TIGIFQSQ$&\S6R&OY1NQN""$!8P7'O'8.H?$[^/QY$,
MW3H,;X);N=:LH3O%:67J$RD2*P-OO/._KXX:X^)R4!:<A!*X2HO+;O8/N!NY
MN-,]6R9K])JV\)N(V-NT&+(32V%.?[)U7$SL,M+NS]O@\>,/!I?2!JO;T;A0
M+U?BP:"'60>DP=_!&Y7?P>#D*?D^=O9\:R%J\KL,U''86Y1+I$/B5#8MHI5O
MK7,P;9$WZ5<(G%9R*8N>XRE6VY[FR?<C[>)!LZ/)P55/+A'FPF]Q_?.5T.2!
M6L$YBQ2[&3M%3F*)RW(5!D;(JH.HWZUA.RF)DO_)]4(8(:CY:NT/1GKN=:"_
M2VM5: ;S]>#+2/<)^KLO;BJJG=>1GH1"XOB;AZIC@,.RW+K^&BXJHP).?TSA
M-A!O5!-D;3)W$_U%J*N\S .\IVUE(6.WB8ZAB!8L^-;H2-N[Q(2(.A?VB.I7
M$7 "> K-78,DM$H56MQ8L[7+IO*2X]LZ>%ON9Y\>*L(:L3OLEYH?%HFS.</]
M<C@B Q Z9+ _&.(W =+3S2V).DZ6--@Y0DY>&W\P3%)7EI'#N2/W1Z?0AMEI
MOI[1D\BL%):L=Y1+,IWC&(VS]+\,]A[F\V@& O#M#=G6\%^+-4=2.1QP*$VY
M<ZTWD(Y#!&1HXV64R;2ON8H&K=ZS3*@E9$.[$/99#-A>:EUZKP-?=F6%]>K%
MQL9;K"=D,>%,K%!(N.ZP#LZUXXNN,19D&+R"KCW$F@9TK?[!\.ILSKB^RL!4
MK[3[-CFNW\K?7>"#743>)["#!=MVPO[K;VAPDY-?ZD]MYNM2%3>CK(+97PO6
M%KLQXQ$!\8J_N3[3<P_<_N>\]/_G(G:HEO@1UG!;Y=8L$[*IUYE04^^N1;\H
MNWN6V<E[)4*N0+QD745IN&>X\N-^Z>\%<^0?#/[['QOHJREM@]2S4YNO$.<9
MR$IZN\Q?UV^TZ.<U[<03[$;%/22Z?S!>GQ]( /]@^-+CGIP&WL )7NPCQ;BJ
M8P$""@L/B,#X<6!NLT]SQ93NC?:1TIVT2MT,XQD$9I//L$,3*.4TC#&V,:6$
M/*T&<1T9X<^;J-_DY#XW-51,KB.Y:\W^]:G5>WGY''" )]TO/AY\E^[NB]KJ
MICC)I3SNQY563-6= 0+=#$&;U:I1=_<*VW?;DSN#S8%\D\W2]2K/8J 0?AQ_
MH]\2O/8MY?X'@5'V&H'Q4]39O_=T;"I5W75V],IFIA+'!]4CV2!)>IB][::?
M*A?[I:UBGAWY-"'5*8HBS"+J,Q^MD&EXW!LI ]S5UZU&=^\.=<13LA<W![9X
M26MU<,+1=X(;C9S5)"XWY/;O5V9"!,B_1@AV2K<L.#O7^XQ+/N'5ZPA8D-9O
M)22)%&!D(3>M-FXU=QL1J;UXZRKUE#-(Z<WHX7#A+3S4 ^O@$&=F8!<:Z?QV
MO8(HJ3ELJ*\ CB.N@<^)YT13L4XC+6",)OXTC&>[Z)I ^#!^=O96E*#$<KU5
MA$:?H[^TJ4_@GB;L0)O_99319%5)VS=EM828(_3N0I93]RR_8?C.O!6T'Y?&
MKJFO/?E]21]OXK)=^1Z-%EO]82_3N$=DNMNY+=\3>A8&!(\W7SSQ-2Y&(V!=
MM9L/!#A:'QE[_LX7]-O\B'1'A,RR-R=TTEVPHSNCJCXC<0P'.XS/@H?QY_J1
MC,2OXS$.M4)QW580GKX$+M>EZ>'PO&/%<=7J=X;,*5,J^=(+.@$=EJD[3U%6
M*]HO-0Q(EV6LR4JV%_@B9XF>I8_6K@.YS\MN^V@F-%)%A0$@^H/SX:9B[KX*
MRT6=/MX6-V7_,HUM14.6_=M8C>CYRC'ZI<.,]>M G,6)Q.N^IFYGQ=='I$:I
MB#R!?*<V [J$;V?>I:;'5GY])=7&O<*7JY<9?MI/YPT#Q(M,<G2$V@+V"8#B
MU?*,CNQ)36NFI(000M*_3PCD%/)WN8V_*VY8W>=5ZL^^A.R"P&>U54/U1W65
MF79L]W.2!1RQ721]0..P[\*0^,A@_6+2B.U*Q\-9$NK+B\1;C=0#^69Q;4)"
ML^$P*4,#W3T_@>S^L90Q*^"5@Y79;DT@B]-S?GHG:E2$+S:5OW3W=VQ1R$$G
MCCA>^\^@0B;RWB%U6QF@\F#CW^3U#JG8BH*\3$?&E(/&6GF?AAM&M^2U9!SJ
M;^!S@6YE>3&PM-J0$ZDVR,5>\PDP \( "? Y(POD-_R5165"%M6L+[-'A,#[
M-'$<W4&]=;O1S,+OG/$B;?C5L.0Q<USTR:$K(A7?73  X#9XCNBS>#K_=@.+
MC%W48?/T#P;N%76UG2$\&_=QN,/=(GHO,W;?HE?A\G*W><605M6?I9G*E39B
M7B"KH#"NEC-F#]EO9Q^8'5TV<74ZI!Q0:G_X4[19H-P!(U37GE.9\XN,NO3G
M<K!E_9-5SCL1+SL:T5^84!>*?>FGUN)66^:G'VP[VA[T,GM%\<O'XW]^&<94
MM]L1A: Z=/ \/2Z([(Y?)+Y4AK&91LGW*?D]X53%Y-F1LTA0!%EY.RC3*8M,
M#+CKYJB?"4&2%@M2- )Y$R096,Y88"9U+9^3=9Y]BU*0QV,(TVLI2) ,B(OA
M<3(<'IR3>B(7C@[26PXVOS)!'<ET;<#Y4:6&+1U"U[J#=Q:Q!NCJB):%K[=-
MU7+8)B>W:DBW<J7\@2^^;#_<QYRSX0;<?4TRBA.REH=+1X> #0/?^3.=S;,U
M9))FY:(@SS1Y]G)1#FGCIXBR.S"./(E,CAJ&[69R;[AGCV"K)_-EEEQPYL#_
MQ=U;0+75=6NCU$NAI3@I5ISBD.+64J1X@>)6+'CP!*<M6AR"!VG1XA(@0' +
M3G$"!'=WA][W.]][[OW><[YSSOW'^>6.FS$RQMH9R<K::^X]]YS/>M8S=9.;
MFM9N S-0 &Q8(V7H+TS4/9JH-N6%Q-:Z'OD#E9/^U'2%R9!"O3Y5EG>2 40C
M^;CRPWR84L!YE@#EHQFG:A&?[[7%.\O(>RRT;^/(<C*>YG6:+&#1Y)$5 IS2
M[;,?S)W)MKJXWHE[Z$>FWM8NYCU=U[RA0=E4:!9G!>=.&*9&^$RLU)B-3E@"
M='&YWR-P<\]MVZ>VK[=K,3(NF)Z^Y(%&B_-NA8V]"4L*^Z--+5%PI5;!.%2.
M],=QHZ7:#(/5K!B72$?-@A]4LS?SJ4J <B_O9(-I/2$"T?T2<5CDA85AQVI$
MG@WD=>]2U; ZB;0I=N<=OE!XE=VC+[1-T35L7$XN*R(8"N#4%*)+V*+43=4S
M 1''@BM]@UHW-M7,'(52P>34>#P=<J0*54]BRA \QV^UA++ @&3XES,@WPH5
M&Q;M*[:Z.6H8&!6FQ4S=+0M6GHOA!^2CYZ9()RJS %P*,TM,=67I-0PMRI+O
MZXIJ]4&RALH]Q+<J-=T=K:J)'BI>G>I&QQ=Z/I_<F#O )'I9"J8(PO?#R54S
M;JU;!X^=D\0"ZVF, *K9PNF-&M3.]3O#6*#,2Z?MDADU8JQ;W8*M&B1R&AEM
M4/T;QX??KM+T]&U6A\T&7+*=!Z\IF*"-;Y6)Y3=.$4)LY?!"L2*XQE_EDMEB
M='L4&EBU-]?=50(@$3QRG7[8'48S8"5S^^J6%\QW^RI 6L?L]-\05]?WWF^/
M70]#$OD?B Q*^"GQVJ0^"B3N!>E33!V);WOC2XH)=INIC#E]IKBVY=2< B8(
MI9H;ND/>V(+OFH(@1Y8@".1,5-1YH/=2=VY6!H.\2 (/?&\;*YW_=+@KDJCB
MBAS0)X]/L(PM,GY9+<I .L5)[+30AG^_F5>17.CEWT="8)K37=A+&GJ82L;>
M2[6O#!#JQM^'RY.4PSR^H5]^^R:8%(VH:(PR:1Q2 T=.;OAH+=/B*LJ77YQ+
MIZ8W>@$N8(R#@Y5T()VI&PB+\XF^HYNDL?H/OK3&):[A0/]Q79^:+I6=B+&3
M#*8@(J<-?S7316CZRY4.3(5[;LQ@)/*@/#[ S.&%+@6>WG^$#_T/-O&M=_RF
M'E9/V@_DC;O$.4@(A'6$?I[1W0654HQT:!%"N!I1,&EGQ!V>B4AKU9 EOA>X
M*WP0!ST$9'E8MQ;2=\:E^T=B;J=?]6H0U%Y!7$L%4Z;KI8/5 F QHBA4_NG>
MU XKAO/=UZEM[P'-RF,U&VJIYML6$-]S>1JV9$'MU#@G9WG'BV<)5%60>RZ
M-^RG?PYP?P\-OTKVT$V<)$9X[:9O6/<#7ZMRT> V4HW:[[A>WPM- ' VJTB8
M"J[&5@,+8Q9V$=]XCP\?_+C*\7K=.&LO(-*_+L;YMFB96C5A*RK3BAT3P-!F
M%I9AFUORVBPU\'P#"5E"5BAE7_@ZM;^DQ^' N=OZ\F]%!OI:Z3G^>/?U]<T
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M"E(X0RR*CI0F?QUK,CDW6\5)Q/AE7I+[\2?_L%Q3O_B-,R9_^\/IUHTZWNR
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MG.BW7Y\94''$U56A-6>?J"]8OUWM7-$M&9XGL#RWV T.]]S\6O)3JD8NV\3
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M=]N^/]"7[IM.Y-1@.7,F9[EQ7=&[7@W#R6SK3]OYC8/0.\FR!];H^8Y]HTQ
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M^N2^6OHWSMU7J]XI7).X9Z_>U#>W!UYC[FS]G<+7?[M[.\Q235F8>^2BX+3
M!S$;J8O6J2'XRG?4<<<@)NW<J4/OQ"[9<<"!5#?K6]TR2.=-_7,$ G&5EI9Q
MDC'[&4/SL+U/ZL^LH'U@YN_U^>"B'J+<&[)Y;BS6ZC/VV6U55T\%?@R#+\T$
M>U'=[&JT%_0'A[N[VDX$'_($%T*/M44>9'U2U_IO0FQ1 T<JP\75HLJI76,9
M+0-K-2,BT)SI#JH@%4"]E\EAF%EYN2%JT8.GEX2P'#\6W47JO/=ZAWD:CA*>
M"12ED<!3/<HYOKC#^XY)S."HJK#L&/7EX3LF)A1OW\ >OW9A[_']3X2W33$T
M@.2&OK[^R_[EINP_RS0LGU%#;"Y^3 ASMG8ULX0-:8:6<(9[ -R8U07O).EB
M.J8!X5[,UQ<1\,K51Z:!V+>C/*E!A.T/&&,IT%2?9E)C 3PX>-[9YML<<YH8
M8Y8R2\N74_TE(WHZ+<&O-E<21HE\0PUV-:?&5EGF/6SL]I=>KM3:5'XB<J9S
M=@3B)L;]IT'?_QI8F/3Q7N],9N_> RH29V'-84\-6LW%35.<[I5MO1ZC./=+
M\H1O"YG1QHFKA:+7X;_Z*ARJ@Y:O)\"=\VNMJF1XGGGL#X"6T+M9$:GE<0,2
MI=99"0U"JP]]J5-4!2Q7X( _6:[3\#O(6)L=MRS7>M.5_=N?+:8Y$+"W2,*A
M9F:#* *("K11%4\6LH1$TON*);36Q3.4DGR0>DK%TTDH0W&![R3+@7-WCN$Q
M N@#^KBXJS.M&@RM3E!:VO*7GS_$Y'%S,2!,Z=HT6=9Z!Q< -4N)*\G3D<*V
ML/]3H/"_-',<O,G&JU/FE.5!%-<BG@7I+!K:(/"]3H02[P6SY0U)K/G!>(G"
M[*F7_Z'KSQ:M#\>?(4MKE- BAHAS2F%[7K"1$)GP/'ZCB*!?7+CUBI+N33^A
MTYXON]&?^\RKMJEK_?A$.Y#)$S&+H9QRZH&98,HC9CNFEBGR%4QR*/ZW/_P.
M_L#N[:[FZ3B2M4@1%__7>S550OPR!1H9DB$8E3K!S?>8@.3;0L'826CYU*VX
M=N9Q0EY$@-R'C7IFR^_4,Z8<"0)5B.!$*+.[>5PF'8LST2.BT^1?U-G_R7D_
M^8O*<0/;7_0>/K?\G9_^5P!XA5I!QBO'-ZD!<3M7V.2/-?B,FOJGW3_^^5<]
M!X.UOX@@F_^)ZOZ#S/&*O,4_JCW<85S_K^PF\AO'];3I4?'K6PTE&P5"\S),
M:(?6CJYN?<<YZVK N7-0O[4T2^$GH?^+N[>.BJO9]D7)1Q)"< @6-&@(%MPA
MN$. X!:L<7<GA!"D<6F<! WN--! )T#30"-!&]=NW-UYV6?O<\?99]QWSWCG
MW7/??7>-&FM4_;'FJ%IKS9I2<_YF,@X1G,.Z%W<[KJ/IAFY#T-9@>GR&/'V?
M82G64VW#C#R>NIF[QQT@Y&*)FT;[8Z5_"C,47R;^Y[.I)M.!:U6RP(\^VC]=
MG\9U%#>\^ST+8#>@;B$0=,L, V8U3;>LH,)R;ZDFE1?%=/&5[J*-* O^"O\!
M40QH]I0 7Q=R%GD+:.H,6NSZZ<1ZBY-9".Y4A:06O=IYX=*U)F /R_Y!]VV:
M.5ZIN^(?Z"^F>S/01H6"V3W3V,EKEU]/RGFCY@L\,K0'U]1@^Y8>?]$I&DU8
M_<Q7IC'&Q&LQ+ DCERO _%@#J!X-"/1JC.?3WVJ=WEY,*%A@?,ON!TQ5&_(D
M#\+Z&@^SI_O$2D1%^$)P93O<#PC9TTJ /&" G^K8>-LMLC8$*MDLOIDMQ2:I
M:Z_%YI-/_TZ4^-G&O7+]$/P>KVU#0"2Z;24=I]WNS@(X05$9XHKC@YO.RJ9'
MU7(SF5"-HVO[5+@X[M+61?Z2GH4$F!$N34),AIG\OQ'(P[/I Z<YQ0D(>871
MZUM5X;_@#@[S.$F8JRX*>GV4[=>QE *;IO?O4O-1'XR1[\_P_(U'PH47[NOX
M2#QO+&]#(%6I64AEG9&5XQ;Q,/%4/N&=%DC8HIQNS51RY2[W-?$AFBO9E8<+
MNP-ALKZW21V9UV?+/_7!P",KD-F3TOM+;EB5%4>_GC_#]HE?B=VP$LZIN]*3
M?1^]I9EQ YWND5^NBP67UEV<9VY]7YFN]+M(OHL$L#K< 63,V#X>HZRLB\<&
MBM7R"]*TUXUOT52T2Z^E/OUVHU2P=,]49 *P4H=I\"I\W'WW4?87]J>_!8$+
MI_"!\0=6@\-P;"&:>Y?IG;^O-5^UBMJ]@CD@CG[7R+Y'8<@5PAQ8$%:]Z48&
MO-X%MK6\!LD4'K4+7S_'%8C8S^+],;#];>BL\2?\]W*1!E6.X1Z@2=-M $^\
MTUO H8\&+S0VNRQ''F57F%4Y/#\%>>(/F_DT@SH@] ,LJ&+?$>_P-.&&.+H=
ME,_H2#IW7#-;,Y-5=##EFQ8*(X7&\"38(\^RCGC)\TVX>L!VUOK""GW'!V,P
M2I:<BH6F<5]RX>HJ =N.N7VBWX;<Q,ZD%6>T\?7[]S2!H[+E[G\=;&P8]4P/
MYHM?$5"6$-F&6$E21:W.+Z+OCL:=F5HH&^_!E30:F,"^()+$5..\_$'#_*<M
M2B9"[_%5WI'[ %*S08X&3GG'6W>_QJ:=+4JX!.8%/3*,*Q@/^60T=T<TYM7D
METV+A?N-4/CR*P8QTI:O +Q[\OK\T)>7V1K9)?/Y1?[:;KDBI[W]O5I!]< ]
M,S--7D= L>=,]=Q!>T6YG]8W!Z*-:R;V$X9B*IZ2%7)*SHE"@H#<K,"2BFW'
MS7F:-N1+2<N:RE/)DO%>IK4UP%O#YXWHK6N&BN0W#QA8"W'YB-Y2!S]_6Y=.
MPYFV6>K(-W.>NPE2KUM20KG1!\:DU6.1@XI/HBSK'L>-,_$I$,/H;ZXU1!Z'
MS:7;+F?.]5L\/?1U<(IL\6<9<KYGZ-BB1JR(/S(>-R0@O)TU=/KH9'7G_+/C
M6_RA4?7(R-N6)!R$$6OC K?=MJASXN7<5VMG\YB" [;B!PPI5C L2:%F=^E)
M>^/NA4G;<=?D:^[TDYI<J6M29(U,PGFC#3O>H"V1VVV"A'A=X,Q<ON<?;;3]
MZDK?W;GZRJ4D_#5Z[.4#AMZ*%3!G#?X+U.2*&^(R[/GQ&,L5F_UP&%=[;5@A
M)$#)#[T!]A;[Y*9]F6)G&IK93=?YQB@^S0FML))[33LI!)LC8UAIFP>XT0EA
M*[>O)7C<%$/>V?,D[JSPB/86::!(ML1;#%,+0_S^@J_3=Z/$];8L7R]7 8@\
M61R)Q<"\\5@QXIP54^4-W.3VI^F2A4;EDA<:>O56*,V0(1G/N[F7M)I?@XR+
M$/ET0TV*E;9Q0B)>9]>@=46;F0$<J*9.G0\4*N7GAD=M5/BHI*G*;UINI*0W
MNW_@%6K_XC4LL8B72H@I]#'%\>X:E5!*?\BH[_&>AGW!5UU+ <&H%E/&5S/E
ME(-*?;>>*R@>DUD_^=90LBFN;"C^$%VVIX&ZHR9/"6>SF/[6;G5>F]P[@1._
M.8-6&_=KUIH=+1E!^>S[^E85@F.2^K7=2X@ZPHUK#[WO<R59^("Q<7>V,1E$
MNE*E0&MC4 ?WX5P+>3+<TG@C+!O(D[6THH\(F0N9IN5SQ\_GYN8MF_T^]KZS
M6*+YH#WYR\T][VWLKC.=(TT#,GR)]^6!ZL;ZEJ7H!\\72ZS/(!XC5J0<2:@*
MS^, F-+5RN6%:)^"$:KD]^&+3Q*>3],9*5^E\[JELSVYPF847%[C\4$I/5..
M;K6U21%SG&,/\F)4>.GJWD0M4+!1$J]M)T"*#UK[$:SS7K^_BT9M4,*=7_MS
MJ$RRD(5/=!,4H*IW/-[T6CE -ULG<BGNE%UHZ<Y,C!@0O4?ZV644T9NK?9;&
MJWD_O*C0_("AA-@N*->;N+C<N;7]@M\R2L$I3^BO&HAI.?7740,?G]AD_96*
M(B.TT1K+2"B4/HHJG@EJ)W8HJ*C5[@9PMFT4&#N$K4U,)XL2O J5\ZN?-O1H
M['J&0/3V=0KW^7$_-O^A0#_53KO*06LK(8K82;@<%*).1<*32_95)T]T:4#Z
M]<QQ[#VF5'R@@:%R8M!\ZQ5W:.3)+-X]26!G3S>'Z9[-+$3#F194ES^L3HVT
MH;3X];'+(O[<D^'7H'=%@G*.]Z]YC3,D<+44\S*RQ^:%MC?^W47RGD_<F'J9
MG8.X1G6=9SDU"Z,&:FNQ*;$)?N<OR]8LFB,.3*\R(MR,G0D7(\.G8"K-=Y2<
MIEQPS*DK;TI[P##K'WR"STUNVO[&;UO-Q?W]=RRNR;(>S<%F)L\Z@ *;;;+_
ME%6W*W9]D_'D3)IQPJ</YUDY-J8S?)\ORLJ4V138JHV=-[]/O5T,//9O:8AS
M[/Z:$K,68EIW(6*4^D;=J]Y9(GNN\A74+#G]]USVS9[R;"Q;>8._LVNE2UKV
M!=J]0D6$9J7*1#2OA)'T$>3R1?GGPWFA[/;FW=1TUBSE5TOFVSN9D/K%-I=U
M]=$73@<K^A'^[I%DH6Y"7/NW?)FM2F:CHNBVI0\F"$,Q?8(?[;W"\('7C+;G
M5E$ATJYI2\E"YW'S[<@/*/,^J.$#QI%^J=KX&U@YJ>ZS+M(N@2Y"99D6>6<*
M::Y^)A!*?M:,$5CL7>]C[NA1[Q'8@;H Z2,K7#.O[Q]'74B=JTDL+@U1QC9@
M#I4V-FT*=);Z1J/#CF9=)LC9UISXH(I?,@;QI6B$J<"FE"ZG=811Z0-IYJZ*
MH#IIY\4)]1:1K#C:D@6?/[L*&^6M4197I;9RB2.6_JE@O\"<?W_.X^<]OC\B
M8*_'*H^FF;7,J?V:' (6TG2YG)Q%I>3*:AK8+2_ZZYQ'#WS.V%@;OZLQ05)
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M$%%T[T<-)J;AD:ZI;E=9@X1-_[MFWWOS)6^NX"6:G8 $FR,/>T[UKQV57DZ
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M,@AF3^"K+,FIK+]W]ZBOWF5@S[-&,I*3I3LG[XO-<@H>SDZ,;0C<RPG[4PD
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M[FF]^T&'^K.W=8ZR&[;IIGRI:3D#K5Z7#<LU"#@M5+[MSDS&A_WTG3,??R%
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MOCJBF<^.IWZ^]7?R!RZ(@+3#N6RPH5DI$7RGBAF@;[N6P3CR/I#^X(XC[=8
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MY0.'2Y/7[GLW)A?+&>I!N<=-D&V?\>7:4_\U/] [\O_?Z4?^MSFYK-[?$@Z
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M.XQH%XA5:E&O $=RJJ9#2?VOI(,M6)'CHI=]LY#@CM5E2*&!<+4NS'&?_ZF
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M7KK!/9[_B)"4MT,&MK3FY#!H#5( (#*V$!PCV">1D)JYHV)G(MXZSC7>YW+
M*,F*,!VV07:U4?TI&9PCTG;V55 J-MJG]%-F\=FK@X7=&[7< Y[&E9KX()&.
MK\%5IO:$<UT(8G?FC5YQ>6I3PABS&KZ.58INZ9\?"?[2)4Y+2-H52X'KG(-B
M8.HWV <7+=Y&-'8R9JV*:0)#BO2GJ"<IQMCXU7BAQ@H,.]25.KC2F-W*:7 E
M1\A$(ZY!B'@+^%O/U(".HU<8C6YHF/X$B;PKAU[+NXDK>@2C3!>HJW)("W%
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M;FS'7F?.8@2F'%(LT<&'#N\.90':3<]F'*5-I%CQ^]15B(,6!$9".B _>#M
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MV0)JS@)AIIXO2EUFJ]9O#J:TR:(GS4 ?NU4&M66^UD[5#!..9%-*&6MSD
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M_ JIVU'F%KPGEO#L ;PAJ6:5H^UW5I1NE'NB7W&6ILAL<7-Q&\=YLIZF<&8
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M0+M:?*1LE&Y?IR.%-3&5U7UB"A!TA_2U4]X"#V["V,7V5!:R8]^67T)])NH
M ' '?<G@4K%"BID)M@0*$S? A 65.0"?HMH)]7K1WV;K]IL1N$V4E]? $V?"
MOS(',3C!U^X.F5+ABL$%?_9(\$>VS8NU5ZY$W:L1D4^H_NT =ZW":HW%E=>/
M:3(FP%;6:O$3>KNGG/6,QM,D2SH'M_<F+^(S%[D65GZ/E6F!(?$Q;PS\SAQ/
M$WAJ4)6R27"KY9]K0\=3!<1!.?X,R?S/ZY&+/XT6ONHV'NZOB@0O<+\FZ=-X
MM*;C;?U7Q/]K8'-:9F=OAM'&T\G_5%U0A+U62/,/<S#X?64LFE< Z,V>/ASZ
M5"60I_%C68DM2=;]',J'OT4K/L(GEL1&KW4?/(%R_5[HT2I6"]]5V@%%9H_P
M/E CVO!G4#^B'9+3=:X\N*"KPDH#.T0/)=W>\?DEQ@K__9<H&,<D#4Z]>*)^
MK2S[44D-*Z5R,># $4->C"#)%""(''*ZEDPS:Q<H/;C;>)BUB-D=BBD5V96W
M7.5J21_")?P<P\R0HUX*F<2&BM%[4['T8 BZ@QE<?Z9BG^5\7'SPVC@+'CN
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M?XF /?RHL7U[AR-#ES$[V[;RWU8L^]?7<-YSBPXLPN2IQPSU%]'&WZ/F?2O
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MC8,L!H@$SSMF>ECL#;$[0DZ7 ,^ZP8*$8\'F'D>?ZH8RR3Y!94%_Q3:74W5
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M&Y4_R0L-?:02=6%\<4BV,S,^6:^2GWQYU;RP;QT1-;%L)P+%M/(E3W;!T5U
MC?"0FC@<>MSIJ="Y%G )&\@CHC4OP"-TE+&Y0D@H'+.8 9E^YQ4HLCZRF)?.
M?;F@$@;BE[QE./GS:TZ'>G3(KXM?5XB"<X)E,(5$I!'548(K:"TE__PG59VE
MD[5'D)H9 VIH.N)DK9/UJF@1.2T*O(!@%^:X5CJOS[Y==AX5WP%N9"Z^M/A^
MY=^.E\J.F4VSC.=+O _R7#I_4<^[-H*]W6/S##1"N!@0I7ML#MC3'BRQ31!O
M7_$%33FDJ-OOH4IV5.X  LU\)OF-MQ(_2K=CS=X'E^1O;ZGV!M ][*=U<1LJ
M:F$-\I/*W%%E\*8\6YYOU_ 0JGG0\V0.J9$<8]"RE,E5:!*9D9$UO;&R,#(G
M=A019JHRQF^F(NB@\L8@.M;F4OE5YO5%P?""<&&JV11B(/R(IXGAS"KRT9C)
M%LU*)OHBA[>TT2- +@1ER6/!K\/?ZJ86.21SXEHE;FGS++K?$/<Y/V-<S[!V
M2,W$J%C$<=])%8/Q;9C2NVV!Z/W%)BFV,>/>:(QIV;/.K1IP>O&*>5FEJJ]+
MH2B'NJ#.4TO1XF:!6)<8XZ;-CMD,T:UISQ98O1.TRY':Q&$GQ;+CBD-_]?1D
M-B"N%M:\B[VEZY"LZT.=S:FUW $P'KU5.\A)+_-,*'!\2SAH%AS/N]>Z]T!H
M4]'>O/SB6OM:ZQ;9S"\R4WQPA;CEBS]EMLESAX.'<K+=9NI5^X77"D=G*JA5
MV7J7=_2^(AU.^=$2^$76?CW5K],D1Y1S?I%2LWG!TYF%J#YTV\4K;K'&9!$U
MLBW[N"LEC_\2.<*@=.R\%8)XRR?:%_R!4)VU=[=FFK[\#'< +71C'H&@B0J/
M#_2;W5PTA9VKGI4>M8_S^VCG\BFYH:178HWC<F!';W^G,AVM[Q4I+YJG7VTG
M&R.;(=E65^V_>.;+_1;<LFKBQ<%NCDWH\6Q5SNGVZ $0__EMD\O!04:0"7P.
M;F@>^-RNB&#/XCZ.BW<%MZXCBG2XYX8++,.UR.23+*4BX#R7*#7X!Q>U^(>U
M4Q/= 3P:-[)%([]H_-K?]C[>ZTS%XW)9'*_V4=J]\=V]494L%%W70 ZEY]B
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MJVV(QT.N ^6(K<D"HU(%,Z=/-O2Z.QI?VX JZ0.-S^-05Z;=Q]PV@Z CPMS
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M[&<,LK^8@UWE+.YI'TNRD(FB-PX>#%>Y(,\13:!&V[.ES&PNBI$P:OZ2=>(
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MH=@X# S>< S,IMC8!-YP3&@-)E2H1524%UJ+H"A_M/P,B3P2N_1T>C\>^/5
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MVTK^AK_1>+5#&1(KS'ZC<3<-X0D2</.2J'YO(XS2GTM++7EWF)":+_B=V#R
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M1Q2JK*S&]V;M5)(N,9OML5>CUV"[&%.M:QZ%51>9(:-_D[!2@*E/AN8\&:'
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M5= NUISJW(+$?Z,-_4:S=.5 &A>[4!:W,*,&.&3UR%I$U?4AGFZX [R6W$V
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M IL!WE 'O8&2:O%>!.!#56X8P,)?- O_D@<<R$(NAF4-A&5=N](&? C+^NO
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MN2?QR?#]LV]Z__*$/LD3CA"6YY=YD+EP$'QX<;8[7,Q[1>Y/14IK%UW@%="
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MI/[Z]H;QPQ3,EO I(BU3HH.6FM;]I$_(])55W?MY0Q>D;H'+]9*1) ZXC/C
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MFR:;)LJ1QF$]+[>URPMGV2M\6=DD4V]&7'L-W5M<AK8Z-,X9#XJ_5>TT]/;
M\S]!-RHX\GZP7A:USIM)1U'PKH,)=R'8161&E)6Z<+E("BV_CWV; E1%B79:
M7U.+A4E;0\]P8]2%*1Z]%EY,, UR.IA]<J3[5Y6;-C$K&[6R@Y$_O<]CM,HI
M[6JK?+45*7/Z5.J_=-JZVK)NWYQ1D[:;-7X\O-@4PWKBU/>[A<K[Y*H_2$9H
MOGQ1&)8R>LMQ,DB0)"9,HC0E5O)XYE<GD,AES4*$?G^F)MT31TMA/GID(;7-
MG^G)D)WVD2)QZ>Q3$L^M[7C=U=@'S31K4LM-*ZDP6&SA1%-X]2-<TR4>(%Z/
M\\JVB:, VE+KU:'L@:O6@=Y*EIQJ)OF!&2\13]A?I**OSU>L@]UDR7E=1<XY
MSO-"6<N2G#7->%E?'"M8P-_;QM5TJJ2OXJ H)45TR;OQB-5^NV6[ TZ<&+G
M3)2$1<$:=16VXC00$SM<"'6N;.(;]RN+8_<H6G%\;E0>$;M@"'9$:IGV1;8[
MK9/+*)AP*WGD'W?#+TY<.N36J!1.102'YH7.!6GYRXBHJ(G:'4^D3TY1K*#+
M/61U0PQV:9^X::^W$M!YSG_[#3F+A 4J0?H:'[OC8ZSV-;E&MFT5.9'%F6K"
M(TQ34A0&FL'Y-LQ/2E1%M@?>4&)HX0B4HX.VE(R6T=?*<7B^\ </,KO_D?63
M*NQ_]'FPK\)U&KM/4P9T4>D<O4FTJCU4,-RZ/]GIMD%D=U$ FF8E/AS/EH?:
MZ(0B6%6%HQLJ->.MRBQI+J/C5<@4R(%-75E934;SGSH9P_[J2P0:T5;B--GB
M_]H_9]AJO"HB.N8>(-HIVG@G?D/!Y,OKA$OQ#;H@K#=K\G*JQ9<\&?Q.K*;*
MU:=K_USGK@6M=3Q7CNAQ/1%NY;D&>C%1GP4"LTY;)5,FD@80;I*V=GQY#T&>
M]OP^#$.;,:ME8)*VZ_0?(D!%]_XP#N.(%8/ES3>D9Z"2K)#&\7R&@5E,J$IV
MV/4DDSB\X355[EFYB%_LX5 >XN[\<*Z3N>1=>/XPE-%;>M7>@32,ZTN=7N.(
M)X0X_T1-6I?YVBE+=W#H\,2DIO)P] +),\SD<1.CGXC35].BG)"4Y<?E_*>.
MYI;J=V73(<;5J=Z$>$8]Z7/0/@-$?1$"T20>6BQZO1_G+7?0(>?3>$L'=3B3
MJQ/C$6SQV@-S;K'/Y$K_E!$M@UI%5LA72X^J*9GV;A'T$.!X4":2?85F) '3
MOXW.BJ)?OY5/B9:>_XP7F$I5O,I'AU*;X!UIR]RL?9D"WX]"/_O\>JK 4=$U
M9J*+WL/WBV>PH^7%<L8VA$D'S<U3GXI^$T%3\;T0<+1.G.#(9LD!'$]IRTQR
M'T9JA&8J47*M4TCUX_6W(IS*[@%A2']-FR;@+Q$](LZ9BANEY;>_BS/SX_2/
MACW&$;7SG#HS^Q6\LWPUO@DO.C<T,E*\%!) IS^3RP,%8$=DG)G)!76&[^ P
M),7BCL>EFK>"UCYET@8\9G,R-8/0E'=+0F6+/K*(S<588#$AMD_U2"\FO$_P
M*]U[/V&[<6EX-\?!DG.W*/NMP0G&$G-S9R2.N.M,XI LJH^)3HY^*>(2U[R5
ME"UFG/O2BB:P8FM5<U['$/@BVF=3FD%40Y,JH3)RTX!T#/R<U7.Y'>K0.$^T
MI[<JMYKD]B<C"SRDYAO "<)@<W;1KH/=,_Z8DMP#VI2-MRW?SEYB%NZ,576=
M<JT7[P'M@8'3IQZ7#1Q);.Y9^.^'=_II7E %EF\90"'3* .Y#5UL.1B2ODZ<
M4O'F,-BAXK1;P6O8$FH<G&AW274Y(MIW*1*X]O<U?&<U-^EWM=$?W@L28L(-
M=#,0.V$[^]=NYY#- EZ0MFB B!8.:<*(!<-IU)OP BM:GX^(M ';R4B;-BY/
MQQ(1L6\[B0Q.?&"?_6JM?6M1H+&!W1M&,^4O5@,:L%^ZPLEF \..QPKL+E<<
MK-PKL<!G=+2)UGF ]>!VZ*Z1L(>B7D5I1E5>F5-B")^N@W/CO$)M)5Z)4J=2
MDFAMZ:"Z1\,T<U^QO%JF77+N"XT55**^S*GUWEJ/>5!1!<7OA Q,^?->\[]P
M8YQ %GX/J!3A>/.BHYSA9#Y4!]>PM\6P\"GH9G-">>3<1V3>4Z/S5.6O&77-
M\LLPNC7I(M  .1,W<P.>J88F3:5Z<4-9-$>T<F,C;> W>4$"7%4V^99/2?::
MI(X"O$&[/2=04IL;8F)SR[*VUG+4C^*P-$8Q.96Z9%,(F['6Q=*O*R=E1ZBC
M(?LLHZ2K$E(MFBA9[5)]M<S8HS/-H-Q2KZ)PNSV\8'.D5ZZE'W/FU!6W'W]\
M#Z!MV=(<+@I;S]D7#N0\906-'S(=K.+@"VF+\@8=(@7W_0TI.YRVEC3AVA$M
M^H.9IE:@&T;&4T/?=G3?HF]\'Z'#A23SSU."?ICSX);3'JY4G96G28LNMCWB
MBYO5[GGD#-S,\M6YG&%$+!?LY/1#5DV0]QFS:!;43*LT;E0Y,ZI\\;@$N==(
MUW8/>'Z:Y;IL9M2X.J2ED'67/Z9!W7FK>DT<UANLWBE[RXBF/1[%&.=B,N)2
M,L;VZCA,C/'N 5;_V#6/C&G=&Q>9\QJ4W62WVYZ=^CC>;J)HU3RSGZ;E1?;R
M:&=UTR:V1TY*6C9G?AY<EZ=B^SP (PNX<OABRDX<^V;Q#_UZVM7U:V4QXUO%
MU<NV:WJ!#5OGQB8E.642"9[* =%- 646U42[?+4H979WFZ.Y2DKU;F_>5L:H
M$7HLIL5/G2F5J@YR,@%U")L2J=N3Q2./Q?1-YF$MG8,NMI3R3XJJ*H]#'H\3
M.A^HCE $?T4B>B)XZJ[_PE5FNCF.,_;^WT@\Q8*C#'L1PT=[/D'PHL18:M"6
MW<Z-51ML<B!B%3<^ZN270)Q$5)3N4>5PG.ZH[]T]8.RN6<<P4'&RX766X%P]
M0OM/12@J%KT,8B\O53DO2Z8_Y6-_I#WMS*&];FD<8556JB1M_,3"0;[5[)9?
MPN5/"ZGRP<C?-><$%,TMBAD,I565Y9PNK./NT:>Q9)^F-1NK^C7T-4H08\J3
M:F8E^",D>,[-PZ[U.@_,3)M.;AYJ'4T?:OV3"1&I,QA.%_G!16#KH>6[]R N
MAG_4GM$8!;T_RAK9=2TK@HK/G'-DFT8^OXDDZU:2# L#Q[2[/]FT1S#)?*<-
MO#9X\-,EB28 #U2:Z;*65)1#*Y-96>'$;*)/=QBY>B>515SB(^&K6SNO/"\:
MY?(K0,![*75ABE8ISKJ?OQBIF'-]T]*2<5[;OK=\'L*E#RZ6Z@9=NCC[U+U4
M$"]$)9\*^ 4K\8F$8(?:HL+^9( O\A.Y+^B#M+!S$R(%/^ :0O@U#X<0V *C
M'-Q1+LGFF1;DC'5*HNDV9S85DVQ*(&F7Z'5ZID%F:55;U62]98&&%IO*DLJ8
M)Y/^/RXA;Z$MC!IV!OEA);MM?/ T::OQ?4))P@9Y4Z-[P"MD;6BY/9NT#%,U
M=D9UIRO+QHUD5F['BPD]=?M=Y4TK]:T.ZSI5K+;J.1J37".CMT/"@FDFC6R*
MO6JFWWYE2G_45WGDO#_=8,]&U08QR!KQC!6UF?<UQD)(R(O7C\?,\A%'1/AC
MJK]OK<X,^E8;3]@%@A$ZYX[5@WL&,\:?M^WEG-@S!Y:'MY"RRE)\!S%I[',<
M_MU4=#^YI'&Y8(2/5<.E'[*CI-_^U1(WD)-'N%_8,/< [X!6*(;JZ+32[FE*
M:C'>3@ 8 @FG&)NS IERWBZYLJ,9GXS5#^<NQ0YZN\.8M*ET8.SY9/WFC8:-
M?Q(7:^>);K6F3<A+=,4T!5$?!]'-[2NW-]"ZI, GTYDJN1FK]X#96WGWV]!;
MH%0I\"USY=&,C4NKO_S;SX)FIJ%*<IFQTSX%+TD?NIF=5*_4^HM:Z"!5XX.?
M6^-]R"I3?J%H-!PG<HIR.0H\8MWQE $%.'3.(>DIC[T$_;5U/+)-PKTR^L=Z
M\"+?CX[U1#=PX<56T'VB^3Q(WJNX_5@*WVNX%_^1=&/38-_!+OH5A;M+I=PP
M-7+5B5F^Z!@$RS@*$V*<:'A]D*[<IGD6P2DC<%80(&:FQ1E9$0];59H;/],J
M"0.Y([7CE/=Q3J:F&LJZD4\9-2CI3K;>Y%L]8]DC6^-)ER2(J/M(FQQBQOI,
M1'#K(W(V=MF;+G3J\:M^$095%=P:@DSU'C9';BDV:1J3=P2I9!%1=75"<Q1M
M&7+!LS[&?#\]WA@;]%@5#TL?*/7(XOH1:=EEU%UIE2ISZ94!Y;RTJ*-OC(O"
M<@L/#[;=;,\[W#[:2ILUA]=NXN5B/>-N:L5%F=4V]+;U44S[F'O-#T_OV.P+
MIOU2QN0\\+H'G,7B3*"*.HR>N&@VBRY?^5-CG8+%6Q7O 2:3G#[*#G;9@LXB
M-=PFY2;]8'ZE(1C1+/VJK0URUW7%!=W 5ROGY%BY7[GPJ'4Q\)E%>9_/JAR>
M@5AI!-S/-WB<8/,<*V1KD\26C"Y1C>0XC/;)E1F(+/6U0@JN+Q,H9>"@8V/#
MHX DW4_DIP!2-3:DOXRQR$'II4'L>T;K(20WH#W.E=I)K_)]<HT4[\_9BHGT
MLC>9L,U3G0SG51C"9F; [/"7X>>%(D?J[+:3UF,T]R=3Q5&XTI@<C[ P7^!)
MSE=QB3W'!>K&IVY93;><H PAX9H.^1?RFAQ10\FFS9ET@]#N2F!L7>$L\Z!(
MN5=?ZPS:O*58_VJ0H0CCRNU+SY09XK*L_[,F[<#PCL,RQ0_,RJSF(_B:)-_&
M;K'$$ACI11^#WOBBO 1]S-GU*()'V)7N\QW#QE3>D@5) ;E4_<;D,N^LQN1>
M^EX:HSQS8;H2[Z228[K_:[MI<0U5PL8B<WAV[^'C!5>).C=%"P!*3X9'@#!F
M25?^(X-8[YV(54I/CI+=^O0&I9IZAVJP=I[%Q&MQ_6W>T-P>.T-V'T60%9:]
M*U&YY)@<I80*/<6')=XIUY>"XZT/4(0:-4R$XBP'_LV^U!O0# FC29*5UVF1
ML.-L"#S3WB)\5)OTF(Y__4X>^'$T5KDU(KI^1Q#P>HJX(#(>?)*F!$P=V165
MD9GBT?&]<!&TK:WAFH'JR<2J1H61Q6(+D)>.43J2L P3_2;L81+J#"!T0?M)
M%HZ1\H"]Z[6W++7Y2&I9,KU)9&@-*DGZO0R)TK7<G,BZAR8+ EB=E5I(<HU*
MOHT\9Q3GILRHXE"%\)1Y3,OCVVBL+/9,-PV6C8/$D0K?E]%XD3-D5F06F?*%
M=D0HKKENRWUG8$VC_D#&SZRB$N9G#:4\6O54O=VUWU1WJL7M%7S)JX+0S?8C
MN0TX/9):F^ND*7G?2](+?Y3A^*IX$GR2-GO+:/>&O66$,DE4)O+0RQYF$"($
M_3,7N<S:L 95GGK*_=&R(K7/]H(ZWK!/MC"\6Q9NV!N<FK%2FA.Y\E;EPY3%
M,V817(CP^W+?]KSTG?[,'%^F;07_Q2S7ROX9-=7:%<J3=KV5QQQJ<1.LJJ&*
M),,KBP4)1O%UEK-[@_*BB4Z[>311,7??'"\/#_.FD^T=&T-^_#5BF^1=%4IJ
MB%C:DO;:I&1[TY>]OCB1^&$8GL5UQ3)MUZ0478<_5/BL^K#<B.-,4&B$O*GY
M[)8#$Q#@!]P7OP3#H!CC6[2%AM%E[)':.+FP?D/NG_A=^X8Q0FU3YF\B/I[,
M-HME/$8OK;RJFX4IV[M(CVNN*7!5@S7*PZ<;,(^]2J"07%L2]X##++^%W>.>
MS)S^>P#(X2SP<XNWJF9/7PXN6)&^=%T2?(.^"__HX1L8%VD,R6SE.X\[@O:W
M%MYVF2_:PRG,*CAD;VB%_?L?)$.%K_04N)R;;/O4Q0F^<#<*F+VDCGJ3E(8\
MXR7E&"9N_)4VG]4$ B&RVN;GT:-CAR#0);O[S+OO[*IW(2/?YN?O 9]665U0
MU[Z8,M?RA*7K%7H&4Y9%\2K.!"N7Z05VPK1F1E7+DX:/_6L4;FE<5/H4@&]F
M6V*U Y]C9;?B'33P]=%MGL=5@3R&DV5[4'#^)U+WUFT)UNG (Q;6VM-5NY]W
MF.=7&3O20F*Y'/K[EUQ%P%7'*?[;(@Q]YUE@<11VJ;*/KOA9JREFYI+B.#M"
MVQ2A&C=1.X;;6M*0VA<@'[IJX93D:L!C<4X^2[H+VG4LZH9P<$[]M9Y['OO!
M5AYT=3!V!\07":D<>VG/=$:/?_& HI'B?6^[70+G-/-A'! JPY"[)=WED.7V
MT<TS#B1*G!(ZT,P?T0N6Y(GX23MU4<N[OFN)6%+^Q547>)FE$%D>?U!4N(*I
MS>7"?[^QWA / 0<(];VJTFUV<N'+>*G(AKD(QN1U\JN N0.?=>[MWLGNB]T#
M6*+*D8,&B.OB#LTK:*UQ@L?*.ARHY>E:]1ZJQ":6\G.LQW7UF<$HO'ML>NS%
M7(=<JEQ6K^& %XDP?3''(<L$OK'TOM\N_A/P5'W-"63(XWAN/-DXIWB&>^9;
MQI8+X[7&GTI/KZ[DB@WVCY6E^%0%5[-1B@R=NT0C^3U[;WRD:?RW*NI061?R
MXN>4$C1,\*7N_T4Z8DN&/RCN395[0-[XO,FK_&(N$)/L)]R *JXX0X6OG(?I
M,0-KS0]P:A[_?O#M07@2:.@=W\C^"''\I"Y\-&M80A/EQ59P)W45;4#I8%8^
MJ&5%$NBG1F1$QXU/S<9(69,@;:K2.X7TW $Y7.'HFD IWN@7O2G_PN9HONED
M^D8J,I2_@JX"T67!I;A""-5FC*C=F4"\-7CUSVAQ3UG()2<([&_1R%E0RT]V
MFOYT8,-+4&>GH>@ *RZD<0.S2OQWA9NJ#*1EO,4M]-?2>9I=^O&V1E@6O'"X
M\A!1AO_BD>I;>%\N*>AXH5$VE>L2.P=,VF^1GO(](:.BY&;K(YI\_E>;/"?N
M/4!]^1R2_-]C*X3HX^4"?0D'I7)V5BH23^.L&$'9#S<,<<1K-7L407"T$9&[
M1125-!N:QX*UKNF\AH\GXVY(07A66+YQXW#&B$7]:@[O-6K77C@J0DIDJHAA
MQ#BF)^%]0S)Y;I 6K<WN9-G[I,?1CU[_<Q(X/OX\:S_85J<(@?W2<M7U/>>J
M9_TN2#3+J4Q<U@=GVT*K#;#=\;0".>!W'&*%D\WX=3I[_K]:J[B)%Q2-OH>$
MAH6+P#A^#G7Q\D6DH9/80*('"YMA7FPJTH'F?30?=,OJC 9^+V;A%/(:B89L
M=)F6S=0(1#U:'DB]NA8)#AHUD/.E9L_XM/RI:^/J"_HA6^O@_W2\\#\HR[I[
MU:SMCS;PW<2Z>JZTJ;[FT_RKTN'J<I_X*[#8\CG6D:)0&CU>^[]WZ?[OOO%%
MQBO,3,AW,)?=[,LSZNE4$PCM3Q1W%%!J_:7WB=O $L$X7(I"(^W:I4J\=,4+
MX1-#E.PSLG9HQK'4MV4[)D,=UV":LJ=EQE2N =52#QJQV>0WC=6Q?!@-6P13
M@_3?$KL*[]P^N3H9:Q.2C[\Z#F]LS3<PS+8]^0HS5I,BJXL:U/E@A[@R86:]
M(I5;WI^C?5@_\,_5A TXO$2.)<\[:$W*7W!:+TU5=Y4<_S)'4P_+4-F](>P,
MGI<'W)W\ND&KLJ@-X*\I/9FO%X/V[BF* <6#VHT9PX8G0R^$T.HV[^JTG,UB
M/S"<6IVZ)'*;)#(_WDB6^$#MX,:B)UQSVU?AP*#AWE>4[:OO :F#YW6?RA6@
M"'.@D)\/.9G'LY9SV*7%BD D[6K\M80P=YQDFNLYOW:#$/G9XKE0!&N\E&5!
M*>KQ],%LYE-9JU"=Y6[9@NC@7[ E6<.LG)"SS_\;SS20GM %/=Q2[J89_?3I
MH)MF9#A!^)J'!\AQM#6RO7^K675D=<2]?Z5@"SI]I\AVNGG>F%?JQP7$)=Q=
MDDH=@UP.OK!=\\:I,?L!Y-1_]^AMZ]QM_ULCHQJH$,-^1Q1L@63$HE1GFUTW
MH?( :?0J+C3I26Q6,WXVI:YP34QEG':9FESN R]+2Y23FS=P:G,?.-#V3X9W
M[)TO>J!@K"6PVO<PM/BZ;,K]YHPA&8J;) 54ERIV2Q 8TWY%L^0U9>M,4GL'
M"?UR7DPV1'+ ^T$>XN9D8CH^Q[F=5LK4IE>DKNYUK('LFC1[4L3HS)76)[T?
MA''YRIB0*J'#-6+TD(&5/Y=\V'C@$<[[J/?A=>^C@+CPD1X>'N]_W, D8"(F
M_G]P//__=OK@)<';1YHV]B G"E]\2-%32?+$,C[6LPKIB=D&K5\B;I),XDD1
MWX1=EP@Z'W/TPI%R5,>C/>3LX.FX)RX-GE+;D0JOS;@XQRC)PR/MWUSKA]F#
M>7W>_.0B:5=<;R#/['$5NHPQI%Y@K+O(6D+2)X_?I)>I2-)2B/ _"*G8Y.Q&
MNZ/<Z4';%!X,:S#8G&4,HDQ83L\[[SW?$<W BTG_3+X7T[9WX/@IYQ-126:7
MV4W2<\51%CE<&POFI'O ].BCWNK6JQ0VW(:"BXVM&O0_3\/,"W]LU5W&+G$1
MJE,R8!',9 ?7:6GM>160OHJ%";M@XY>KM3X8U%MV!=GDQH>!.1*I&C\]N?0E
MOVC\=4054U3BPOG&/ECIC9)4\(F?W'$:*";2MN^P6TTS8]3/O^@!A::LPM=D
MADBV.@WJ YN%5>&Z]*'* I@7N&:R39./BA!VG#MBZJ><_QU"^*QR9D^P9B83
M>W]N2RX2NRCZB+5>O^';K) ;<6G]]!\4F3W,Y.]>Y+*/A>CV:30SY7R(D N5
MG]E/.N\R9:;ES$7\.DC^+U6Y?&Y,D#96MZ!^C-!4>N**N:D*5]R91S)?N986
M!OVST._Q\M0]0.%BR3]N&,-MJ4FEN=Y:@H$@FV[?0N[,X3_HF/^?) $KS!+T
MUZS];SG6YS$R%E51T([^X4;?X<KZ_N 3LU4^*^ W1%;PL> U/G/LLV9/U]?L
MIHJJ%,<[[-CXL=C@+H3>/4!6H8X-4IVN#^)RYADI*A#E*Q5Y[YFHJ*S\!8+C
M(T-R@^LH5ZZ>,)@UP/.2L*E?5UD,<"+4-3/#GH@H4JOZ@_9E"P=:\MQ9</C0
MM%NXKF[DK[YR-R[8/1RHV(GBY+.'.C8V.Q@'&32*IUC85U_C>^9 ,(%HNVVK
M;^W68_> \&X_3%.=^/6\2Z:8Y/+.72?D>I:YQ8$Q-% UT_ >H'OM=-;2#D3G
M])1H5S.A7"\/BK E;PH[#P_<EKD]]GZ?Y^^>"'*M8R1(=TKN 38PE4MWJ"==
MVJ(.>G6)Y:G 'JJA';^HZI.H(/F3U!_3Y*]1/$E3P<O#6'K2^#I@_L%!\AE;
M+/XGGO(@Y<F,FB90R5XKUUCH1-.?!J(6Y]3KJ;#]&O5GC*#U#NPBD?AL-;%"
M5D[3+.7$(%\Z4I._<_A0X*M9+!=!['L20#1 YP/@2>JGQ[JIGW2#=?]1LELK
MA[)-K>X5_J<NM\I;EJB1@?G^X<*YLT+(I/<B5CN8(_[[5I1;<ENS< \^+@O8
MXF;4<E9F+*.GI($NTZ)39#:OU) ::WK0;="U^#1@(+QDWD*"IB][IKWXO;!D
M'G?+F B&:0I?NW?SX<?8&2<^@;==5^F5BFC&+[]BO5OH;.LWZNR_=F.].O^R
MKI_DH7.FS>K8XE)9N@9-WN'/)ZN"=1SE'2[(;"8E/;?+:AR4:-G8$1S.BS:%
M.F!P[@&Y0?[(-VMX#4*&]860YK>GGZ938H547KIQ9'8/[.!5?*3%J>NW7C(O
M"WE%O=>\8; A6RQ'E$(^J>-2\5*W>DMJV]R5,$&.6CCAY4O?3Y^4M\SOF@E1
M&,?FV+8EPX]-"U5<%>>&G?KP[?+V#$8D+_&7!]9[9KO?A*]XK;7(]C5#.D*9
MYJ+2< =:3VN=+''[SNQ*7XL3R:CC:_>TE_(\Y%B/Z.IGBNZE=*6/;^^9ZNLU
MP)[G?*7\+LB,ZOLQ$'O].#O&(HTGV%X3S:@ZY)^Y27KX$3G"LK<\^TEMNU9I
M4$IY)E*ROTT%TGO3X$6FFE&5,UC:A)X3]$AN.2BR7)H1^QVIWZ'C:/76?=;D
M^Y*_'-7F7HN_'J/BLE6/1@T%T>NDSU/)LD+Y"9GTO>M;;U_-TJC.=W!I7.0'
M_2ZSX^$@;%QT"YT0H%1.FYPR[5MWKL_-C2O <2;HPO$=Q$3*%0 %RY4=43K9
M<HS)D7+/<C)9U#<8*5>K]O@MYD>>4[=[N0/O8K#/ECFR'7(<YSE0?B4H:6Q]
M9:RU&U[%YS7,<F,6;%%J^PZM'G9U6W'S%3XR99<%# /A]9+.0JN>E_HXN6=]
M;MJVK&8*.$4GDUM5RD86Z]UBO02/7-7UH#S]6@7.IN"1DMP@:F:ZESXD3I9G
MEE [8ZN&0^\!JV'=C1@@(Y,+F>WHR<:)YK6G262!(Y7VVS^7= W6'=XBL:C^
M5;M%]G.MO#!KWN7*-H:T&KQE,U-LH;P!6Q*03U/8GRUY7 ("G88IHQFU7]VJ
MWS93"T*&'POLV0,X3F7A-(#1[4.#]X HH.K+UKKW4 [E _CH47?KR@-GK-_O
ML\N2\&I/?[05T,]D NM_=*@-V.ASGMJF'':X[ZG$9KJQ'H4F17!88*-&^H^,
MIQ4"HVV58 &+.1Y#YG$6L2/7;S:7V,1"^Z^.3>?1@6I;:U@@F,U-\)BKIYB0
MQ$C=N_[?5J>LC1L<.<\%PSGE\GD#@"JF+JEL?++%ILYGMILN4VLD9&7J1<\^
M&A&07#]\1^(::)V3R.CJZ1D[NB\&.ZIO ;!MVX7O.^@=(\XI@W$GS7*]KOMV
M3VBV@EWB*5(:42?<(/:DNX-W9%N(#RN\)_> W0JYR4^7D\<&I?WSMU#]CEGS
MNZF%SR47J+R?B2 5[[ANQZ>Q484]\-AY;Q9^<_[V/PS0$/T[LT[>>\"H7&4I
M%ZU,>Y4]QOK"&&@J<*<@9$P=/75^#SC@$Z3+]\)4@5GI P>;3S>'X_CS.LH*
MULT=P^X!;;+&E7UHOWO U;!YY8&-O.XR5[%S,[-)4*@Z3E*^(RP($%I/PCQ"
M!"[@ 0&>PXV$TUJ?>?DK'XP,S9)7FC@9DNL7],'T)NOB4B&?W<]Y[LH/7QS<
M UA=^MOE,&,M9=DY&9$WY?;%NF]NF1!:LRR!S)NC^GY6G26E5PWA9<-] _K^
M_MS?,1ZO#(TW*4RAZ)R$67I\%,;([M@+,NO5:1,@];I:M3YRTT9(+*YRS^]E
MRT*8_"#KX]>M"H.\[Z0F&.,G9Z2G)!X="K;+'WX(:<>0R2,/UP_YI>&CAP=P
M^.'A/UBM&:VMMVE-IS<Q1WI'K<\=X7KX7HW[FO.U1'\V/?@$7!LMQ%^0O;_^
M L%+S38-P.JNBAG0RVRY:X[(20"9VE >21ZEM%;][/P!:D2T*8?'2E:D3L63
M3P_N;9LX)[9S.V:0(44^'8WA$Q]4?6@;,XIXH\\'[<W!<ST/H"[TJMDJ8GQ5
M@K!0$F=)4V=6NT3[TFO8:,Z2C@!;_:JC#Z(GN_R,I1E23#OT1S-V7I?$+=;R
M2^DT7DDIS8\P'L(<EIM@.T!O4O\4/US(&0-<KR1Y]'N68E^S%8Y7)EW0)Q*6
M+U+S:T,(6A>OK0X,AU!$,ZZ)XT!GV704>SPTN=.3'=QNQPX>U 5OR] G9.MK
M<^AG9B)J3+VCM])UL:_=X@?OTC)"+2W7XO5>6O[CLC3Y1[:MR[\P N\\K>DF
M1Q>D#)X@0:DFP\V, %15KZ1=W3:W8OG7!]O:MSZ(JZXN%780K+49TL3EVYP[
M"!;L;,DQ)B30[UMD$7W)F2^E;) ,&%562[:!+9F 5/BNM5F8HA8(E% ]GK5R
M]"/,XH9)R>W^RXG7^*0SQAG]?]4W1N%FX/MT9J[;_BZ:$*C"?@_PA&PN_14F
M3,N=Q*9X9]SB/6!?GRB?J4.KI3*NZBY0MT)"J8#N,CK1YN"F:+\.LYRVEG<S
MW,P_*IZ+N0=@6.?FVH.F;U/2\<3SJK7=TDA)$OO+L)04_1T+29N3VAF5#/P_
M>EJ>E ]140M+/1MF!HC'5%(+!'T^?1A7KA#F^.E[24[8^E_CZ&X^JR-OT+KY
M?5;C3!&IA6JEEM;/S'4*[SNH0%&;QETSRHU^9) =BK#L[&-QF2QB)&=25HNF
MFU3-"+J<TM=72,H6601MZU_*."/QS=%V;>G%]3/A_;-0QWJQUD0H".DC<*<E
MNOW\R.>@-@GN<C7QV.')ZUGV >5EXB4R.!OK?/[XW>\FZ>^TS;K#-Y-T-+TZ
M]BY4I$H?.=7%QYXS^O7)P=+2,@]52R5<<>L9-@0I<H6#7#H8FI;VR\=@_L+?
MRJ;742/[WL*G/%X=:XCBSI?W@!D>P<#I,JG2NDVG"*%*_HJ$0E-S?Y+(LOQT
M=P[];60>2?NAPQ"V&_(MX_#N1684]CKI,Q/=GR:(5>TL^^D,Z?YVU<^UG_6U
M$M56(9[;;N=(J&0%J-/RK#"BOY%5=G>)/[._KB[%0$RL@2 YK45/X<EC4Y"%
MR86?S:B<85K:<*BE*OOJ] EGS*W/KX"+(>:ZSVG_UF6*ZU$HLGIEPU/KFHG(
M4D_>8626:[QT3<YPN%M<2A08?1D;5RS-I1K9V\ $HTM$'"3^@:QI*MX#MN,6
M \^$6N\!H,Y>L1ETR?@]0$]3]M$](%W<X1[P>^\(O7 /(+C5ORB20=MHQE^D
MW0.>[*[NK]ZUPT 7KO< \%X.//#HA]5#&A8#?;5XPUT!<-&"C+-"K&B DJ@W
M)FIA?](KO>WZVK>4QU=L##*]I^.F3FRZ(M_!$:*O[;A$\]J#Y2-[&3^NF6"D
MP(]@<[ $67ZB\F.<N8>!OUL2E&_8K$HO0J$\P$>^<KL1]X!/=YD./C6=]4O
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M']="-7V,LL/&,,1&R7L2UF?ZX# TNSDK7N%-;E+EI&UY_/I0,M:U="]M1>I
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MEC6!*=;84MLT[AXT7H[S$[RH]0R_(QKR.M(";7@(/CV:" NXEVDW)'I"E)7
MK E#Y@BMSP[\0@C5$DLVBA3<S<CF>4>G&,U6.?M(.( "\77D _DK9C%5ML T
M'\C/C-+KXL[6A*9YW'OGO%MK7QLVP83%(EN;B72;;NV-ZF'ZU1U+_J/:*IO
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M\S^2UR,0S</'O4RU"317:$,/E)7WAE;+4UGEV!YI/@"5T-KZQ<RG_+W;^X5
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M"-"V\#!F7Y%<BJYW$4;1U !5_-+MRBP@X HU/GF05*.1$H90Q$9LQ[KE-IS
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MIDV3?>8*,BR%+#;OU7ZG?]!G%ED.>"_(5G74KJB]"*.+$G@VV;-8DUI[1HA
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M,9^E+)&5F$6^V?F5T&U?FR%SK'!D:QO>XW1@]( 8.#\R;\MN-^3YDHLAC)-
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MSGG6B-D<:)X.$PB8'XX,W4U[9Y_T9?+U%ST+YRNVUG+;)^93;NNSD+=.(*?
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M3YZL-[]L?S!%5_BUXW>X<B4S-^X&X%LVV7UP?O7H?,&DS.V$E)EK\R(6+1?
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MJLXG#G &S[\MOIL\][5\9>"?=+H?T"G'F=61:K,>G]UH2F;R'/+*]\.;-0@
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MR:9-(01M:GJ7*;WE&91[,5O"I"APRD?8'Z6$-SUUK9X=%V/L'5@;6R[LU-Q
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M..4]MJKV/&> :P"Z^Q0S$S'.Q) Q/=>KQE<5]PJ38T>ZE1.;JC-RCXX'GWD
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MD0> \^CUW,<("X/Y=RMY4=#>Q;M*:O'^!4])I5,*[ZX;"H6QMGSKQ>E[0UC
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MV%95["[HY%GU")80UYH/C\%7XNYP?6/WVBA0%+"O8PM1L;K&'.^&:2)H<GA
M!2'>'E3W#2_$TBU[3YL0V7$;P8-?HBBJDBZ]I-BC4]6!;_^>6 J#TU]%BOA'
M'QDH#"#]&,'Q%9TC&/*7=)=N[//_=+_^]QW'_QV4PK8VV&9M1]37IW3TOF+6
M4APVB^OM&&:DY\="7GF^)G,>>,]XM7XM5NH$O_H!;J(%)*R]53:I632^ZYP5
M;JLLX\@G)P&^MK D \EZ*)FB9<$MK["?$?EJH\SX%DB\T-1O:JA$4BHRLT:]
M\E-2AJE"(@942V/ZYOU+YW+!S\L_U3ZJ1\4_V\ +U8*MXQ'9.1[!7K/LZ2-<
M"B!]YIRU5X1C*8+/U^.43 WDA"P=P2Y&^:^?IF (QUSA0!8+!E=^39;]O*<B
MT)&:OUF&-^OMM;T[2IU6,+57:Q3H$%G"6[6%"'*38^2_SZ*TE\N?3R5%>7VX
MR@)*CL;^\(><!%WU8HJ(^@D#E4<(89-9;/TON2_'W)N5/Q,+; >1QT$(E!@W
M@W*DG09E[X,5&]'J8R#UL;$*10=-"WI$081>AZ^F?K37N;&8:H7'H/-CT#H^
MY2G^;4"<R8:F2OAPQ5PY8W_X6G,^YW+])<P 7P<BM6/-$O"+T0J;35CP ]I\
MTUJL8)EQ1=_SJW:<=V!S(/ +=''@[?ENRXB)L_ 39029J&S><FJ=M<UGZY,1
MK 4*@U9%5Q]&$ VE8Y5 L_"HVV\K]L75=S[![3WU,-C/J2K!-R0?*_L(0=/,
M\]^N;'5#2F59[&!N]2@;L -6>V*]GD&;KXT1]7;DMN(">ZO(D8\3=F<F55HK
MR90C"PPP5B<95[XSBPU GZUB82S5-C",R1GR69YED$4J*1(YC.#FOCW+N+WR
MX7]KR$0@Q)/D-75IXJZ#2)43H9D7,7.ZC<&K3TK+)*4-\:YD]SB!M=-U5[M\
MN'Z;ZLL'&+&IH]C\51.W?(:"\,&\9GSA H*+5>AN:55B8RV8ZET],L]3IB\4
MOCNE&V2-'WT%H=#C5]'(PO-F\*;<TD=.)MS>MA8%0:^NR^97_0^:9VX4AXQ[
MB_N$3V"SX]7]3[KP;K9FZI3V@=?8;E']W2M/VV@BRI0\"LUAGOQ#)QK\YMYA
MJ78:FL#EE,42U0Y1L(\828NY"]B;Y+8166;GAM4]"W2]D)'M&Y'9;#YX=U=W
MO%XIHS\7-7H\M'R3M^WTS":G9T>_'FP+BYZ>5VA-Z4F!YDP1XX',O4D6"TX.
M$14R,K6V,]I$0C<A.4!<[]C7M=+X\+!(5Q?2BL%;M\.O!VOZY+<G'J!KK]%%
MSP:?.^-;EO/\N0\F3&8(<B*RSXB8S(*NYV'"$.Y&T6'2(7C+O>9;ETX6D\8Y
M3?/=H!"QK;U;ZHFN:8:*GU_/Q-F&H ; =7@&O,V "&O )<3:3+$2SYGG4P86
MRWUA:GGT9FFDD.C;LLMPQ(TBN3R%EZV(. !H^7H7YE)U[I4/DVU(8&!P0TE-
MQ/YD:/SZ#LFEUJE ]/0!\&LPCSCOQ)Z+D-&V=,AE"BFE"?9C+JK6\\B,3&W#
M,/!T6'SN'@3=\] 74[CCCWVL@_O.(.=@;\[R3B%BS+V/?NT.RRCD.]NMF[-K
M_1JUK6?&C"R\$?S2AS[J%60,M>'.Q'?NU>HF4BEY8DPXS#/#:=OHDLT'N?#,
M5LS \VOU[!L_R^';NXVV7N)K(<9GV'<8V\O51"Q^/K-QC,GU>M#6>05%3O =
MJI@5_EF[6^35YDSOU/(&4P^CJ/*R;R*95^6V:;8.Z:.^+7=&"M&]#<1W=FX?
M6H,\+JU:$=[23E&'$>.W@<1^\Y-TU3A?L47<8K@]$AGWQ>TBTL<R:8$NV I/
MJ^IK=2*687,N=JX!UFIZR1%MRI\=S-<S4FX3"'B]&X<M2>[,E8$G)',L^PHF
MO/&M"1D9=W=<BYD=42R#"$YN^T&$_5 ?@1'P& BT*T-0L18WBM[,:8<[ABE^
M/@,6QWO[=GTJ]NW]L&"S+O81MOZT$0C>Z>)H:!?UK/\8>3=Q,(]H^0[%2OAI
M,<2,RQT\^P-O\Y@*<45F9UJRNAK3DA92-!<5Z16IG_[Y"(>$O2FC^D)3M\:O
MA'<_!_J>.4N?HT%@T+$FW3G,!(3[JR\<.#AX5 N,Z$E)=[4EY'[^HQYC<.B,
MI,'6V]#E:G'=<.RO+8D;<QYULT$:ILM=%N%L<J()6=?D9/JR-DKCFR=0$4Y[
M7\)E1&'ZBC])QO [H(O:*OQ]0]->86GR_&#VZHJQKT\*!DJ163U5?9TSA*1_
M]@L5ZG&HJWT/2QX[8^EZ-@,:V7-V>'GD9)I?,@961,?\\%J&_WKD=_YOBB_9
M JNB&VD#= BN6UJLU"2?(I%8DL,# Z)1'K%.^YEG\AL[2KKJ&R94F:*"'^6>
M%%A\&!Q^ I9X,06)E38PQQ^=[HWA#W1F[9TWYR'5K'EE(FE,U6$APB".$NHW
M:/GKJ[$%'1C(A(1N\I8^&QP$LT!9>@<'I9$T0S-;V'(DX>4?6WB9IGWS=8["
M>7<U@JDJG[Z=I\;GZ*8E _GQ/P:PT"S(PQ;^&0WI_]4$&+\SC.&0[W@MC.Y'
M8IR!$PN)=^]$%66(<QX]F11HT%[WE.]!5JTQ0SZXND5<N6$4]=O@CR:XNVM5
MTG')8HQ",49)>GBXOO6PJ/8JOI1B4>6 DL4D-\B2!">3"N!Q0\IC/M:U'K;.
MAR^T-L_2^#4WBEP?8'\2:7(7+5=1Q#U><W_J:-^-B",U$W(C/<8A:/Q=^_[H
MQ5=T_$=#UR/J#_\*%T>VK$76X+'FB$)V"QNCX,JD;GTL"D&IP!YAC)&EQ3Y=
MX%'18ID>@8=Z/QWJFEP)K0"L ==[!LZG9LI:XE@RNU:HGP#MM$\W.(JG)TPW
MS?HTKL!]TI2L32+1WVN?"HJGB\]]W1;!<Z' .\\5*=K67'F6.3 #2>OCS5"O
MS^=V;_M>KA6Z3TQ_\F(VM8S&1B57/%TF"?N*;^Z2G7:LUI2)QU1]Z*:U<NI$
MEYWM4VBW:H>(RLC3T72U]QP857+XOLMT#KW6RW1 MI7/UBL2^W3#PZ63<UD-
MI:C%'\\+X%<[%GJG&6#&L23%#Z=M'VWUUCP]?^(I?(5P-Q_A/+W,B<M/;25D
M,M=8[&K_\@*IOF)5KF[WH4LY'%PR(G6:+.7UZ9ZOPTW):_-5K(.].<&E<GW"
MK/M&V#R,I-U=?,OT8L.PBK6@E5YT3-W-CV,8(7P\LH:\_VU^:,(0MY6JKJA;
M.=Y2EVO>*M=#9[JWR-:A%?B\>3U)"L]]_3B<53 !51R+]/ (\T=$3ZBGUTSH
M1^U7]S/"2M+=1_Q:#@H3@PT$>M-)[0\ %*!E75GHLHV&Q, FP9N]"I5T1J)9
MY73=\)Q[III^EU.;F42Y+P.8HH5Z<5%VLE+(B:3<_39,T?!+I,M<G)YUK^$T
MSWI??4#]:T)SN<58B6[3;L/9:-19%N]W03%1M,HZ!@+HCX"$APF='E3@NU_"
ML+?H**Z@IE !"KW(F $Y#+<2+ZPNEMJ.$#^FMX9!I!--/Y^N6($FDF\??5^W
M_DY$=MO.?@]+W4;NM7@UP<G,8#QV:O&,Q>X1(<PZY1QW&#^T_'VU(EKFBI[K
MPQ&&,8SFP;?O#I-0M56;[7+,;?;7)\DGTUCC'9@7WDS6095<Y_!CU4!1M#$"
MAI$.''5!NE]N9DZ\C(Z<E2K9#9JMEQ9N>F3KZJ1_%XO:PXP0]5S^H&M"BZ,\
M:%[$,S67G-3_73$GJ.-9CB\#+N70*>)[=A((Y'*4R^*58^Y#.I6WMMCJ@;A1
MVA(=F DWNR,J!L&_VU@5 JL4!2G:5*,S]+(@/@1?C/K5J!FWQ2D:T/'JGR+?
MKANX6G4-:4JOB#)NN^Y_8KG^Y+"],&CAO-T:PJCK'=W$.W3-T!2KT=@CH'TM
MEKTVFY E6=O$,DM8Z5+9M-B2M/MN0)Q04^#O)=%&$_^;U]ENY!\ OJ<'9P?W
M!BL$?\BAS?Z>,:%4NJ5N'^Z;KX5:X<%7$-GJ^C[1MA$8[RO0EP3<X?I-ZVI4
M<9XU;\N"1$YA_ +ROXCTX,:+YLL<Y90M.>YY?7+2*$<R'=K;#,'S;PS/%'JR
MO8WV 2%90IB0 S37*NGJZ1^HNAMT-[<RY(<2#22Y,%G'[LQ*555OO;,3E&9>
M94@ZBRTJBEEX%'Z&-4I::EB86ZH6,4SVBA\,-0:E4!0 C\%\M5-]!S%AY;?0
M:<@<\Y@S0E21T/Y&M'!G[_R-1BK>A%N5GV"I67#/*EZVGOZAJZS7Y@J,T!9D
M O3?&<%35+8(W@LI6JMW9"RF:RR!).W)V2Z8,\5DZD7<X&6IB4+7T!1EGJT0
M:PD0E_9AX$KC=M-,W?P\P*A5H*2YO7NG_K&_YY@VO*"LC75>O00L8/=)-<+&
MH1>JY%9AAIEJOQCFZCCI-!D6A,TW@RB<4BX7N )+(9'Q7F84-TZ+)HS"6@,J
MVXA<_VK)XX OAEW1N4>YJ7M&B8VG<:XQ<D2ZLGC'SS#TC5>&!YC<[B^N$BTW
M[74#&AU[6)LXC:HXDSZ]%Y95+?/D/]6,5&R>+MSVCF$(-C;W8?#7"S&5AH.U
MQB\E(B>7/:?>"E#'S@2/^_\FIWS3'+#DD0ARW^2T4W+LR4FCBH$*TK/Y [BG
MMUWU[77EMQQ[S]P<B^B>@6K"M9./4+4H>F,_D+^Z0Y5'2(7"VAVI9\NV[6&6
MA8<@\$P0)>71D6L0>*<5R+6;3AJI$^&P[39_M01D?(6\;2:+9,/FT$^Y8=7N
M-_VRC8GBFT6=V)^,$43L/,*,C4E_FS]-$3I1"FF$L?20ZRS=<49I!U-8G4L@
MT<LO'";P3$K%*#_Z5Q Y*TK0O)+ ;9>/7OE^3C<PMV9 _>)6W5<:7&N)E?BR
M]@!( =41MOC1CF(1RK[+]XP?!BP_A27 AC$> *+UPMP<$G1KAVH5HY,5[#]E
MIC:I.^YI+SO"\GM=3QM,-Y$3H&76G1R#V(%4Y.HB5&DP$2K.*JME(P0,R2H?
MX&Y.(U)2W8#;9A3;C-5,3_'/#<4>KT[V<L6"A!A_^'S&H!A9U3DKK$R>)GFQ
M0*@K--K<HXC'%WVDI9*0J7,JU<L ,;IFA,H]5Q)X3]RAT1)"2Y/O/@R)*S+5
M3DBRKFB;;LEG@[I+X.I3/Z^(]E<-UY0,@2B.%W<7X)M,E9:@FQ'LW)DQ+JC&
M[3*)SGEUTK!H[_\;#Q_\;7@I5"BO,F3"1>R9\;D^<D 5$M6NH>C.HM:(-EV%
M!NJ"R.)&'[-U(X[9A@?W*C=K;/L6Y[SLBDXUI-9B];"D=2:1_5@H'J2T/)>P
M.Q%N_@KEQ):-CD$3ZN1'.%%J2#KU[H-EY-C8^\)Z0W+4EQI?G"H*J)8#=N5X
MQI?8!ECW!?:4[,CI]H=5,4MP2(Z> KZ6_R[?%-;4S%!N_^Z\42$/^+7A-"^6
M3H%HOA'-JX2\F-"S*RW/VU?X@3W0AA/791#EEX"LS\!OOR[W>/V[MY'RF+HD
M 7T3O2K^KL 7$\O/C<V74]+3WP7# G?X:5:'-/D;?"!J0W8J^YD?VSG54<=?
M?0[WS.S.X-ZL#)H.95?M^ZD $X^(?FDK25[V\U_0Q2R_MV:5G?W!1>>M2LQ_
MZ(QV^ZN4(7*4MM=^%P7D\K&!"W\@_R_R3?:A#U )%-3^:M"7C:P*FB!.!]L1
M6(L("R#+A2ZVA\7.+9CAD1]">N#!<H5%:,D],RD9WT]J+D"124,B5Z+5L+:X
M?KST+,"ZEPEU82&CMZ?0N58>=$5W)-";RQZ=&S 9T5J0N?96F;&&TJ2U;_8&
MFZ)JG&A+S4U$@-LYUV,&G;Z/AM-LEW,23;817/ZE=!;\DN%;3U,B%Z0\VHW,
MQB-:3F/>E54C_85@*3R8T?<+K#\WD40R-QK]5,)XY0' _#I[CP0Q5W,]4=CN
M6VXN 5S?8:SZ"F*1/&X^F;1",1KX[G8RH3761R(H^/$$#YT#?U:*J?7[3=:%
MGR3^>57#[/4J.J4*YAV7I!L@6*:T9./9B-3ER#=&=F7/],==T&&&SR_8JP5V
M\9$*BNMNVX@R._+0Q.78VI)C_C;!W6%J'B[^)&HJ-+?ZI-0GXW]7V;^=/CP*
MN^GV:8'=2*)N+J.>YCX !A:O&/W%QZ(NTAX ]-<T3[K0^1N3XO_N=L&5!KB:
M]-OBFI9TT=R.,72F/P]/25O81U")Y(Q0C-S--G<T5!IX:B2F88=D?6\CF\1R
ME7>4\-[."?V2!YVG2%P3E:$T"@DF"Z;EBRE4@_2!$GU_MA#5GJONU_7+=+3Q
M/8[#+)2$SU_&OCKV9'0.@H,M*KL,E*S-BU_C/?^FM9<[<V=8R?4^9'36A;G(
MMCGL@\!.K*Q!4=SAV&*3/$_5X96PZ[3U.])FIRI!X1>9;(,9W1IT[E<*4R/A
MN,V<MP/;N;LI=R/C,2/]@[BW9<Y5M707(5@*K46383R*WSHMRCP%,D1#^HQ
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MG/VK!4IG/,1832)\#2Q,K8,YA9T^+-.Z^5'16?S-$?;TD\L?G$;J<,_]D0^
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MRQ0R_6O.Q"R_;GEY3-*6Y#';!F:H)75B3VOO7 M?><?:Z4)V-I82>G(QO4@
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M#W D>OUBS/-ONT.'4CGS2"7)\CNBO2IGRTV/<M%Y)I=[8AK(%)(25S1:M",
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MT=;^26IP&:^P@*&C,=<G$XHN]2%>-6=BAQN[.,H$LKH68?G]4:/][[T,QUI
M,9G%O6CJ #90\83IS&?OHXW#!Q/.WO3IE/D1X_".\JEJ<@F1:F/Q[\"SFKEF
M*R[.6$96\8LO?!M=GX<8$O[:>FT#=_X193YQ"]UW[RG/F,3_MSK9TLE_._)Q
MP^%"FT=\%G\ /XB=>B"'XSJ]-7U]3Y:3'VS7;NN6<SS2X(!U^/>(?SW$%I((
MP43!3H0 ,".C 8F$TCB=G*-'1W<"(CP;[0IR[2I%[2;]R.$+1V3+8ET+R[GD
M B+=N0#W7>+ G6MKEUFIJR#&.,-\VP9_K_OC%8&31,%&#Q0I^V#\_&:W +&E
MU -DYKG3S!A]V"PE+#9)NX[S^P_=+5*W*@4F+?.R?F'ZUG+Z$PN5QTH:PPRT
M3S^1MUPS@!D9&9+D^!F35'"R-I)4</LWDN3 8DS\C (,C*RLX. -%'DCA71Y
MXW2%S @@</7/7,2?3[#RHT-HTIR&>Z/QS8VANW?<9T1&U*Q:W\>IAB%R2L)>
MK4D$5Y;<WMQ-C/K!)3_Q3#$WSXS FSW/VTQ)FJ7 >:")R:S^D)?,P3=-(BE_
MU:/Y4),>DARIDCPG32XJ;]M=-N#T)5E)SU ;?Z6F@6>H;95-96>FWE=_:R[F
M.A,1XH+JBDGPH4%XX8@]UUEDMIPV</N$WR_SU#O:][)\<+R7WN+K2P.VUS%/
MY4#,9X"ZT<_OLRV#ZC;$G[944,$<[O'F#E^6Y,:$8>TO3Z=V+F?FN3;%,)\_
M-8FJU>W^\2Q3I[_W>=Q!\\[-A>9\^AX-AU.U>!Z/X3?6:<![K?*:GR/8T@+)
M=H^K];/M@QJ=;:I3BL4\5J=C3 LTB.A$CU(G1;.>L54WJ%L \.-"<QY%<']R
M"63S;WUX9I(H]_CM72LA7/K%AG+DH^.67+3.;LUQZI!Z-1]TX*)&Z7A&O>EC
M5J'AMLQ>C:2$CBR9:#:A+H8CW#/IC 92*Q:W+Z0N+?)/7MY:^--2LI=T(I0<
MA-Q*YA<[>A_P*.D!SES/O6"#ZNZF+"=[_CSLRHRL97LJ)0HD?.%FMDRG62E;
M/U"/= \QD&UJAC[U\<E\N:L"OF!BI19(ZPMM[%M^NVRV/M9"X,[%Q@> :H7.
M;MJ,)^F7L&W3,,.\I%Z#1@NG-(X.MXKT4<IGY3U4Y]L1+SV2V+^DJ(K9\(&)
M8[K#PI>@4"AJKD=.ZF;KV%%PXL(>'&%AT)5]%:P0K>ZTU\C5<3 6W^NP9$E,
MW1*'5%R-FVA*>8Q9X"K(V./*"O$$LK%W4?D'[4*Z/6PT.H><UV8H3#G>#VR\
M@2P"Y; RNQ9SJ-.Z[$JUY-BC^_5%XD:HPCGHJ<Y=7S**#I!\'CMBV3!3^3;*
M?11T"AT]Z*K$,#Y$J,05K!B&ZN\<I"#4U)UQ7/@_WK3IYNL*& Z\I(TD*[]_
M?:5$HJ<ZT7*V!5=$((X.ET]=FPXEX3/GR^_JWXQ8:/?M03D2V/JD\[VR"318
M!#@P _@5F(!3-C6?WJH':<*NZNS\&&%/ OF=I9OK;GOJ^H"28]U'-/'9 :_(
MU@O*O3^:BO+Y#VE I,O7N4.KNZCWEK2\,))]LUW<%-D&8G?'0*TA(F(,?:.#
M2T7><:>N%ZF+%;B).*F9,[Y-UR]T QB!^4EH_LL\C&C$K>J%W$-J2HS:*Z6M
M#4SX#D;*-;C_J9)-MK3 NA;J$[1ULWUBPU;[X=_=$]P7-'#U><FRL:WQSFB0
MB_[JW]HPI:):#+WQ\RR_9MXB%]PN[8WWJ*?S2GQL36).];VW\J92WDQ(,1K:
M'PNUJE;<4Z?4$3^3,/>"%+1*Z[]/Z?F&:?-4O )&$\LZJ5$37'W>=YQ83D F
M]G\0WP;^D;+Z[U*(2^YQ'L:\NH/1CH(N;>P91#!:DQ?NZHSF&G?0WTNV]1K3
MQRYE0GA((K@Z5!!'SE@B]N.P1BIY?_R@]\.+B;B!-KF]O%9609'SR]C<$HG$
M A(%ZD;&*]ONIRL*!!1I :]N1%LK0,6LK=Q+$>T=,JST6Q=3K.CYQ[EXN9YU
M(>D>\X6LF.&;Z?NKW'KAZ>%'.3B;&-?JYJ7/#\;;#1!2]^Q1K?.D^UJJYQRH
M&SY'>C J Z=1VKP(W[R$(!V[UH\*OU#<'[9;PP_I98&+N*2*7)HS&Z'45;5G
MVJL^A:+121\?R,L(!CZ5/:X\C1 0)J=RUQE>?_743SUD*KM=S KK27=/C&6<
M$03: H7FC&W: __,DT!;D T9RQ>CZR/C!P6)5WIT6N47,'J?4BL18DKU_1X+
MO\7E0@Y#F^Y"*CR3UZ28+(Y;/;:;:.=JA)IR\E;&J-[9:](JSO3Y!ZL@K]H(
M\*R@AQ*Z@(I;F\7PI*WW=*O';,&'61'F$TDPBHS&LT!])^4#*Q-ZEX/ZG7X_
MSJ!.,L['U6'59&I4(?Q*3+8L1(HNW>CHW&LRL@>RLD=,HZ-C715$0!SU-?5N
MIE$F[N&#@\,N&.SZS\2P=')-VUCN]HJY_0NCAV'3LO14A*KHYH.M20Z'2T'&
MH7A=E&/]PWW)P*"I[\WY9EW!=H9NQA)+YM,EW8G/ N_\4OY> 6F4Y*PJPF:^
MY!^G;7)Z4NOJM'%6TY;%F;8X)!.T6TSPK%3>>&A.[BOWUT/\-,2-S4NUQQE5
M*H<7AA;KO%Z=&R95WUT**6*A -79> +M@?FJ3TFCPG[K,(N>IL3U HI#\*S3
MNU UWN8G%]\14"A8#JVIB4@YFN,C>?$FGW#,>I]3K A(&9^KL":<ED7(W;^6
M>/8K(_WZ_\/<6P?%]6W;PDB"!'<(+H$D.(TW[DYP=W=+&F@T!'<);L%=F\;=
MG> .P;6QX):7G'?OD=\Y]Z^OOO?>KJZN[M55:U?M7FNN.>8<8\Z+3];;9M&J
M93^&0F^*)S0]#Y>K3 N:(6.:J_+.0[JK\I\*>)EFH+HFJ&6Z%0*NHJ:MG;@]
MG%;X ?1TS(??> RN*6%YN>Z_X!SJKO>L2=>@0>-:!S6J5H2#/R[.4#"5X9,#
M#9Z,&"*JE5_Z_R1![JE!)??<C*V=M>4ZD3QU&[M67ZF&_O:5KHNT=0JD73BW
M.4C:/#I;7S7W8&EG;MXZO22+5NM%)$O-T*;@W$6ES:,CM>!>=CG3[5'>@&JF
M#$^-VZQ*1A:E=%NR0X+2^)@LQ> @2CLZ6^XD-&DD+_H6[QSU90-3^_QW!_^%
M@O_V7V0LX5;J[&!Q/UEW:ZRZ^_5(;0FDW+Z-I_'6*JR3CTA[+ ?K!680Y15$
MRU]P7RIX(4_&R!]/IVH6BT[@(7Y=<QDZS_\\\QW?(TS!@+1)(/!\-B>ZQ/)I
M63590:-4/?!8)TO5CSJ:V(P/O5V4Z%.A4^M#?<'X=Z_31J\BSJFA\-'=5\%Q
M5;392L*2)J0_5KDTJ>*"-L\/).[LQ#?$]N*&UC(VHG4B-9Z>&#'7%*%/V?(.
M-82/Y%KM>/I3W3BDG%>7BM05W UUIN.]LZ<J4"W%.,\K(?>"H,7(K3F:L8$F
M^!WSBJPA_EWF;Q7M5J&)]1=K[34-[!;\YF;>,&\%3R/M?8\%(QSJKPO^@V&M
MS.D5+&R-D"G6J68T,4LN)7>T0LXKP. >E$*/\DOW9$Q6F8Y 17&):M!JZCVM
MYRYRFM:U25!^RBT<@P,$#&GZJ:ASK.F3:"=(4Z/E^(5<7/#-!VR?D1*]#=O[
M8>W/X9J>T)1'!E[T((OBX8];M;U=C/#%.Q8WQD)SB\QA:PZMJQEFPY)Y5R^X
M73_E[JQ3%UY@CX7-W$[!6WGJ[KZZ^A'-[>AC;C>(B3M ]CDB+5O!O-I3( F/
M2T[?T0PMKBUTQ&S/Q=-Z^SS)HL W(Y#EA[3N#$?O+J:(#[E+'#Q:1Z^(D\@R
MS#-LEI>,OK!S)8(V<$8[ ^2&Y=M4T^5%E%2$<4^XP>Z.&]ZGL_D5-3L$UY&(
M38/I4K;%N[YC,;)P9+>BZ= A-0OE')$S4W5M^?'R>J\[0\ _#A.9EE#\):>/
M6YONYQ!7WJTF0Q18X?^@_WC_#/[P"TZ6_O@I8>D7W(:91!E\Z5^'OG')TK J
MT_))&GHB1Q=OQ@XD76S##S7=KS1DIR&N& WYQS8FL*,"PM :F/[;1 ECKJO(
MLWH+NT^"_%9\A(T(5#WJ6+:L%=DKZ]0O\*=?&$+#<I"*NA)3P\62UBAY=XP7
M=OF$,$=-"UR0$OUI7.#K0B:_G.(^VR\CRDO:HI<9KF!D7OF\2[X*6U.(EI<'
M*OXDRJS9)%'FHV!!Z-9O-C"$Q/;H9,E2>&[CU(*G)U:@:TA/Z4"1 T$OL*?I
MY)V*($DC^\"<R+T\T#9O)#Z>RLK3U\I5H]A*KR!<LTINV_ESQBE^^A=KHX 9
M[,4R3LT_RHZCA0"1--0?*4@RA<':*WE)[\RH>;<1J-CHJ=V)K$2\K/^#!JES
M_*?0<F/6!.F;RANU-S^4G5Z&)6$ (K(T@R!I+303RHHFO<WF]&B>LL9>KB]<
M,\$XR]"-=)'-NUUH'5AG=5-X#!G$#OR]Q,2YORYIQN\6ODZ(3+P AB7Z(\DP
M\0)KLA)Z$E2B6>\C[B*KY28X<3CA-(#Z=O;UA6.[G^C!QZEDNSDCYFZIZ1=-
M LD<J79NAFW&S:&9:?* 01%RI<D0!?M'-!:6"&%@E1>V^8/$:>&7I6%Q4P%'
M+9H[ X.X  !WKW4Y'L:3.$@<F; 2E$-<[7$7+;-8>^?]T529VA^;&"DB^V0\
MNRQTMKD!1T+F[2:786'O)"K&=NP[,T!R\0PJG1\?NET7=FI':@*?<'HEG/\B
MX[[M$S-IU(W?3'97UC2C0VD\^'6'O-26S_H5PYE5W?#RGQ(_['[U-[WUISXC
M5[_@-@MU;"AZGC^6/5!@K00Y;L#:SIE;UEV?_&Y+DG2EJ_^AR_4A\,3<]Y.J
M,KXYA50NG\Q!9H!ETJJ'A_?1^ID&?,67.V2<DJ%SKT/@=4K4V_)JDW)Q"\++
MW3CGC_D6WN43P5&%\_-4U E%&4W)UZQ77W6<I99_)V;X?R@.^7]JEG:#,,'7
M3T$+BB.=CH61,\ 2+Y6#SL&7KY9B5&Q&%CQ)W\CI<@O:5F!01D!I(P$X$N<&
M(;E21+[?#A&J;?\L>0RL%*/Q3WYUDL_?J@K;+8E^9AK!</R*&0^^L;"OB.\_
M'A?9C$4FN-X@ YMXCV_MHI0+E]H3)HS9&ZL^]'#S'<H>+C(SID&.I(]<;R_
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MVV=]IJ]_G@^\:@ S4_LD/'-=EYUD-V1'\VJT3/Y7PJN+!^CV\3IR>C%*JPR
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M<%"V<. )"2V-_JUOK$;5%/,)7U'':\.3$X=*-JJU3.KP>'G\=Y%L2-L']TP
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M_*:$IBA-0,DWU]O?6)=^;XV-EHA?<-*0#I/:[%8K_2'GU;Y?<'F+Z]6+RFN
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M?[WRSC).GX_K;]SU;4ZT9\G#0P^_J>OM%@>0FJVJ?7N6_6]EQU?\=HNRS@*
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M\QD""*E<P6Y:>L"!6^6^%NWS)EBVU@?:GOU,;5<=#&D5_-:,7BD<4H#A>L@
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M_PX*.FWJ$R$SQ;-DT8][ELP3;\ 5\Z6("WV\9_K M32B6(5P6S1._(G$;[1
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M7BB)%H9NY,L7Q="QLM^ C-F&@+T6RK=E$^^J/B.^OYG1#K)%C7&]%?U$$2Y
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MU [A;$$S1,1/&Z\WEB:2K-\];4^.U\S%R@!B.F(/1).US@3^KV3/P2(XXD<
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M>IA=%TA> ]&;(/6L!#F1([C^\.&E!6T'N:[O 3X+"/T3PNG_"M7N_\3PK']
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MW5TS#O$!M.KEA86P&$6@B(,^[7( ?41$K1'S_L'F/*WF(7/=Y,*GSX!7WR]
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M9+??_"S5CL5_"Q&R:W3<A1A.YP8O!,WM'G7;[\8EN+VW791,6N,.&IMU/A2
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M;\Q=L_JUP;MUP_[U,D0(AX#-I%'@;?<C-6,!WZ"<'+4DB*!8U]^<RO;SYGD
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MV@@K0S$E([KN,MT-*&#;F*/Z4VUR?8#L!N21GP@H.@[ V_87.]_S36J484B
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MPTYXGZ^MATP/TD(I>%;MT]LZXS5U>7;2][S>@X7*ZT\5HM^VZDY7C?NZA\H
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M_#1LWL136P!;A3$L*B=\8K!3 J,6WFLK1KLF>CA\B RGQSH-]'\T_G0?%O&
MQEG?[WNH-*8+CU]2],R]PGUQ6J<LOOOY;>$W; *)FGM<#Q(>2\3'H",UDE<9
M#=[('=[5\'R(9W3XK("AXNX^69&=$;<&"E;1\54)B;S!%BL_N"*^;]%?ZC2.
M!(]%G%D*QNX7QAM?1A1A$9([LEC+2U!=GCV5Q,#H)"B;V%9?[R_-$>, :>)H
M,H5%9I>+^%9SO^E6J1$G47N3<S 7(X&.9G5@!Y[B8^[-&U::<= BU=_OE>O@
MXQ27)M/1!46GHB+%!N/N&+,#WY(4-VY:L!X(+J(S04FBR^MY>:D&XN8\"MF+
MS4PX1=3+8NN $;W=/PZXK95HS=>^(=4XJQ>B0AU'CZK7)S,.''6M%JPX"TXN
MFS$>#[?,S9][/9MB,Z*SX+BM:[_Q$7]'+F#-WP"5)6U,H<7Z0DVF4^K+$N$=
MHFQ:/77WOMPUA$8EMZ51X)L"_A-C"EM]NMR@[8R5SS=]0/6Q(JMKVW?1'29,
M)+5PJO(SI1WK+%<:<,?JFP%/[HS^\<[58HEA5=C09ED7N/=C6/; 1A5H&#M
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M<+CG>L)U"7$;0^%Y&ST \6MM9AC7)<*:"< MA$8C8&O+KQ'5ULP&(2-RF>H
MY:CBP'F);B'"Y:+%/9AY8H5"?L?!!R-<4;&46;R0G9Z]WZ&V:GVC/\M@!8VK
M++I/+XZ>$4'R_%"<0A3U5'*264CB/M8>YH)[_]7@U"?Q5WIR6S)]2]02URO+
M"_Q<,05TR\^O(P9,QW)"^<3E52UK2IB.1>GV=!PAP<BOM_@(2=/DOK)(W*G5
MJL@RU4"EB=)K/.&^>IGIV<D#MN*'SOOA2Q0+4,OSIQ</ANRZ2N_3ISO7Q*DL
MO>0D,T>O.ZU[.;H\SA/E>!W-=1#].=SRHA#I0_^KATW6+PN=]X("[Z!'%,?1
MQ1J[DOEVS9X[D0=H5Z[+(JL4JE_81OX488'LEP4N!U7T!%\_3-K[A'^,(9#[
M3RN&9X)"?X %23W?__">HD56N22Y/EAH:RI?]N99P]^?^3I4^;W/=N1A!G1V
M4H]=#_@797FDSFFT[TMU*COD\TL/H<%LX400D. '<5+K+L+@LDD!NX_Q4IW4
MS"QOC=^#\%=,35!<J1B\VB(T-/.M"HQSEFA4=:(+2WCK[SP3,P/U#'O#P>*H
MH[:'^X!CHR^7"R$_; @=^EWX\+HU6<Y9(3!(O9VG\Q _%U%FXY3V%#[#)T;G
MV0)(=%0_48:,+[=I*?W&*#.@L[M7_]6D1LRY!#>GVH%:0LXLM794\0Q;)1_1
MJRAYUL*W@FC15201OO'-61++_7<RF!FH_U^4_G__2XI;Y<R^9GQ@[>&DL?ZH
MV$7+RF3*XNBA,?93NP:MM,H[#(>G",1U7[%KZY:EIEG6M$B+E3\_VULJQ@O-
M]W?+RT);YP,$?R*B3F-\UBF3'SGO+[/QQ)Z-QX'*]240"!(U3S(& O[&TE_5
MU/<?G J*S!BH)S]0"V\LD66ZN-LJP8T-;T*LF'*I#*H2HNK3OL$F8W<65BF!
M 8IF1)WZ+*: #*;A.7L0<HIFUV<JG:?/9H4(E>XJ4JT:LD9(JE)!4^Z"K)H6
M+L*J<Z/'_"1/>\A]VP!VKZOXB;+$)J?DF22ESJ-\D9]?.JB\K]1/"IU"IE^]
MN7FW )/-S(ZEH@+]^AB__%V%H@*!@+IO6TAL[_J^8PKA#]MZ*Z"[.GNS4: E
M5SOTT:]9Z.!PV;@\AO1,7_.9H%X@1+B8,B40?2%@Y$#20R?\#^(/9=_)*EH9
M7:4/7<O:\*NM9(3_V9JFXY9=1.9QR+L?+K*:;C];V%.'-1%V*WVI>RFU\Q,!
M8RG8-VOZMVA"RUMPCUEY'2<2E*\I_ZT3P EW['/N2YID"<NI/I,+)+GA3V2$
M^XFDR/J%,?1O9G:^AR-&5<QS6\_,W575$>K;Y%^0@Z<3<@<L'M0#!BU@<+2>
M<)*4TA'&DZN]=)$!%JN7*"P=Z%!L*"YG)3'GW.FG[E':83&%-;']T=%1F*"@
M2'Q-?7S-C2 S]&!S_HJ_4K>E')3\P6U2>U(;&$(2DYK^J#N5G!--5<@9V]]!
MJ+! *IF6;[J.@'K*OERDTL5MD1.-$T.BT4)L\+WRR!#P(.(W8.@IL Y<R:F_
MS>7?=YLK-2E2?UWK#?)NR^XG^HRIM2+H^*X"2!<QR#Z?U,U#R,Q<^^#*XIJB
MOP]M28DR,?^1_'X7.T#A4$, G_&Y(K=0;!PSW)PPJ&# PE/B1L#W:$9(;$#E
MQ8L]09N-29T:HJR>]1HWW9EJM\@6XD9F@%1&GI#\]-M._#>Z96R"@3'S_J))
MG 0K@:GCI$'_$MH(BKWO\3ZES13G5NC4<FA5&;LCO_[DC^U.EV:AV$T3_KH;
M+(L1*/HT-#,U<QPG]CO6,J)XC6V7%6:[(%MP?HU>[:Q?'E7OY :D#@#)Z9;&
M<,2(8C/)\U]VW'-3#36ITMB(><=&5ZBJRSGLJ&S9/7N@3!N_6 \03QN!JJ7*
M&\^D?J6.L\('<*:Y_[K05MC@H&9@R!:1D6]QN9,_/%GGZJF.MZ@;[;GG"7=@
M,(?@*VF$8SS6L('(J?N5D<8[.$\-G\R"=["S5'6.1>40_F.8^?S\K\E#[^&_
MIP+PH%UURCW(NP\C%V-KO2H66%V/SB5WY%BP(,1SC3]-E=#5!);8MR>]:)<8
M[BCT?-"(.Q %_S41_!+2=M6BD0S(S&@S1(D-%IJ'O7$G15Z>) BWTIKB\V_5
MU);7:DHMWDEA"0KO^T0.R1A.603@8E1WKJ@J3]H<_" _O8P9M!BF:X?D@3R:
MTVAPN-W3=!;(Q#8Q6\P2(@-^2&%O:K%AR]"Q?EBEJWS9#%KDVZMND_V1I$V;
MYEY0]>YT0"@"GY:_5*N*/:%FOHH+K*IH[*ZPF6:!^C5)C1$C= #^$X$+V<S5
M_5*MI>7N>YV@KAQ2$IE:B8/*#U/"Q?=Y7ZLN308L88&="B?G&E,7=I%43)$@
M5GG5Y% 4<S3;A*XU)I-=]1PYPCVU?)WGB4S=</8.G5IQ#.S>Y<]/?R47F&,Q
M$1QY]3E[\"M HA!P45#5Y)YA6.J6P";+?DVM1SWSQRS_=>I24EELOR2X4^6M
M:,2*=2D8Q6!$UN#,_#<[^"=@4!=5II>5I#D5%'>7:HX%YW[R!"+W)V#PK;A$
MPX/"4/%%P1UX5Z37B]QW(?2?7D<;/PTNP4N<W[N"O_>Q@<8$!$#@KY@-/ 7Y
MB!3]1,BEY,ZYE7GH]QF65M%>+JOHX3N@+Q\8H,_K'/=-(VN:(6)2IKEF1Z%"
MCAM;S'S$1!7C8W.]/<G$F<RFF/@(:9YRYNE#+./:<I*U+%5_MY4^G0)ML%ZF
MH4(=4Z:)ZA=U*5//H@8"B:AC4D,]E#AVXCB($&0A[*ZSKM*[Y(.>J=RHU#5Q
MBV7:QCWPNNE3&0W,/83:>JX"6TV<UY 73T,#9>[?#ZUF):DRO=3]G*^#(,X<
M&Q81AHX=+XC]*V\8._JM;ZA+X$5D<-<'BQ0B'_.L2-V#L?""46N1\P;U]FK*
MSP^%7P*[8%5&]_("%4I3@62;<=JE/QPHK\)&-TG]!LH3'3%I2CA2,%H9/GRJ
MQJ_B'WZA!+9"2\IC"'(E2.K5!B\+/\BZ@=#QK'M(JZ!AZ WG*2DXZ'XM[_]T
M@=+WA$E^)X@\4*FWTQ6B8P8=;S<=:\RY"3RPB<<'#;7GEU9"/#)"<%) ^! $
MESJ&-V?K_5FL'Y.\._\+/YCYW\0/GM)ZB+:T&=;\1  \:"=U+Z%RM];9CPL0
M$G] 6QL$YL5PN*>T-WVEFEKT?E>@I4?#SC3^H82Q';_9[8(:X7@8%FN_;&JZ
M(?$3@1$'MQ%'\"86%QH/_=5*F&]5]5NP0% )Y1QV@L\V1-47IE/<>>'2;^8@
MF4<O9LL&">2;'1-%AHF]BVNR XY!HGE4%S=^)1]\'VEC1&4&%@(E^S/O4U-T
MDUT? $"?15WM%N+R]LUJH?3*1M(6L8HR7N-NW:!B';?/3!\M#?-TZE(Z"*@9
M5DW88KK,VV%MF^_*5;7@N2D(W,>N7)>XCV[E$\0$=K:S3,0ZI9-[9&[,A]0Z
MO(K*2@I!LFBIU]&<,?7A[4,_2)JUM8GYQ>S09M?<*%%]J4.1^=9Q4-<1/R$@
M + 1$ $X./A&./@ ?,"O)NK]IUS!FYQ;'?U =/LZ7C*HEH"X<,%":=CW@02'
M"^WZ^H58RR8P%<C6<,6S*VSZ'8XSY T1&X(@KMB(54\/I#>\9U>!1U<9R-@3
MVP5TJ+>_L<2]<.-U6"">G(9J2#_!_935/"FU\12965]43.%MNWF#84956!@B
M[X=XOGB1QOGT$.#MZ&CU7+VFJ5YKE^TA=%%O:(BY29!7Z)W93GK D 7TG=Z4
MMO\:G]]FOQ&@F*7M.;N_X($MH5Y>J$P5/R*D9J+VX(;^^M*N?7+TNV?:#ZNM
M&[^9EXI, Y8/>L[&'KJ\G*D#5.3R2IF$Y7)F9_MES)'^.!(.W3Q/=?*]B$>7
MVX;E:[,(")):=IM879FZZF\#34&6D#,-%JY;)G::1BP)""?#6Z*OER$S+GAU
M?/V+1)2+T_]W=1Y^]W+]J^XKGYD#NLJF(3N3YU6[H26?Q[<5@E+@O<&5G6&+
M/8AR&&?BFDS=#7J!L>PQ$_W*# &"OIT>;J?7OY4Z?KV+FHG^=5O=/E-S;:P7
M(Z1!Z"^G6Y3:1<:5-:8Y.E[?U)#:=4'=R_;1M7XBY*O#X?>#]9TL<^T?W9QM
M+S(C@RHC=6>J=/VB2K0X+P+\@)'<>"K1*KW(6YLQS#M2)DCB!@AOEBM&MGVO
MPI/$\;YY\NQZ[E_:(]%7+XE5B7RL8ZMGEENL419#Z7 V<D119I<P823: ]CU
M3.@P.PM7O4^,T4\0E-W%S(2UX#01&ZA%<^=RXXOP8XC=(TMEO+QV_\P2[(C\
M)A7VKK[RLF>8[$L3D#1FD'T8P?90<I(L[>Z]1=GLN("\P[G7>+]%BUE 7D:/
M%GD!O3],X50C U5TK5ZJ?41N_R6"O '<_4O"$YE^W:;"#&JD.''"]4B9C9@!
M7P3$C,CA7[GV;Y>F7UEV)OS:])G/ \WA2<&\TMB"M2T6Y84KEHO49=C$@8$&
M^% X/PV\F*TFH3C03<C\\8 4'S&EBS6NNX^HV[%VPC(FG H1&W]%5$NR]4L$
M)Z?W%"='FM)CZ_': <$BB>J6 VBY-V"\#RAN<QV!W6-"%%DSD3)6@WLJ671F
M/]^H!S/YB1!'U>TG@8NQ2<OZ123N+='W$&_A]P34KC=/_^8BU?_K.W,A*!.>
M:A-S#H)"QWX%/N!G)&#5R12,K,=^CG@I!E CIY"@<.NCK,R0'ON)35D)\H7@
M.(3IK<R:$Q+1\PAR<*&KS*7? 7IH57K)G@"*)3I)^46D%&E7;..S8GGIG1OY
M(NG.0>#KEJ58J.P>7RF/5*KTA'E!B+5H#>=O4_EEQ</5UD)4K/^",3%)[QY.
M_!HH[)KF3K+?-&6">G\B?/YDB[)T"+D'#I87BEHGGG-[)T7UWK7M*J^,6236
MS<@*81KFYSFT'MW&7W,NFMG4_I:?:UOR7--U;=V\_8EPHL9<&_V/$F"]_>7R
M=1+\J-&[[?[C$ O-_#_KSXEOSSS00LGNL'1_(J"EC5@:Z)I[$;=]339I,]KS
M6>74_L(@])]* ?]'Y0ITYEM81I<3+QY/5BY-D!Q*5RX=T:QW<?VEWYQ9P:7E
M2J=F-B3STA1%_.+*M,/ 1A4^#+&Y1\^^)1MKJA[Y'#%V@ P7FK<:ZNET!>KI
M2*^%H.T*-G,9,W4EV<7-,6%<^>'=-?>,:4D\-S//-TFP1XR16406Q[0W+\A-
M6(IJ;M!.%V"72I= [H3J_4L.?KW,U+>&C:SD8FH+:;("2*'K!.;K.)%/M5[P
M0 V-+@U9&HE_2!T<(C,"AO<RU?PF4T[\,D<9:QK?7)_5'78:D/)=TR<]E""/
M8.I @#7\TD]5980^E$MO![GZC!1?8:E=^DT3=EXCV>WAIX[7E2*Y\5XD =#6
MIWF+:B[X6S,Z7GTTJQXAM3%1(7.C3=.96RM]]A,!I&SA0(PN;6&#XU>!I_<V
M=NHZBC_"GS 8-2\O)._9\WWL@ :),=(G!H304.CQZ/Y0[=^>ZO\A R9T0]<"
MUGEO!4#YN/Z7$SRRJMMX"F3XGEHP[G8$?YAG(R9C(N2U'Q*Y/![W/6T(5^Q/
MA.%Y-TJT%[*A(-12FB.B??6  _0:@76+L\Q?R4\OFC''NQ39X.D&*/:F\Y8Q
M(PTPQDN<7>EK'0T^9;W\;-%\N$==H?\'+DCA1_\U!WE:7"EQ6AXJ#K#E6:^"
M_7SP>Q#?EK\*FE$,&9@?04$_5'N.!S8"&35OD2^JM2W\J@67_WJ6JLB;_47O
M3(TU&,J-?H*>_.+#]?&KQ$T0(*NJB^_T)7KY2U\8%:Q^F42MMJ!S1]^.)459
M<\VOMF!5%04Q*:NR2[.<UYJ4JB_$D%=')W61MH,4J$G]! &+J(>TDD56ORMS
MMT[P[1$&SQD(X%4R%Z2,TC#=;2#5%VC&MNKBI;5P32+@,1)_\9BT-?I\5$S$
MTISQW"9KZN:67^=5=<J0R]&ZHSJ3*?O5-SG<&:C4!A4@OVFJ=Y-T9K^#UDF<
MV?0]+8#^[=K^-E;YOZ 7$2^ACI>#DX+/(+<ESA=E(=$X!3LN'7+4%/HC6\SQ
MFETK#K'Q]1$Q0X9\EIW,HQ.(LI:V:1=;;$\R6U,*[=@3SEF![S"7/5!Y41R>
M,)($FP_LF6<P#].-,7":GEWZ]C0):3X7E>!4P)0T@S_D>TI8VBS!, T;/0:'
MM*>;YOB=^./<X \&A6"%5U7.08\!%"%]?9IXT5B>'PO1TQ/  'U*WQ]WRI"%
M3*=OSLOA4Y6)D9?EHVOG6^38D9NN_68'/7)HS_FZ-UY;O:NP[)/!C7(S$TXV
M<FFZJGG1;0R"VG*]A7WJRL/-J<U"DE=Q-3))8Z;G@*#4"T9PREJNMH,.A@_F
MA%+S4^"C8JYS.]LQ5Q[XC?!W=8] B^LF*XO165SY=Z5'SUJZAXU%K<<F#SN8
M=EHXDSV?('-$:IXU+.6M+.1K2%;]K:[Y_PV+\1M+4SR SO=)'%TN[@I5S=7J
MS!((J2^BQS[U05VI'N?,XA0)R>C.*E<C !9XG$9C4M8F%IJ4&9N/?0BQ6^X4
M6*\)WMJZ[-+OG-3KPUWL^+'7P<Q7IE\(X+ &Y79?9^JSSR,?5TRZTR7CQ8%'
MA9WB.\'N]1^* H\2#C.G]$M @_I"[.I=A\B9%Z4%<,L%B:65TH[.=7K6U_9]
MS+-<RS;! @L>>:1]N$&?$_D>/** HI;/M3$7Y"%O:Q?TVZ<\D^MO9-EUTA7U
MP<,O>FV4&24BA7': 50H:UL$G%KD65+%-??[P2.NX0>6=51[9?.+-HI?+GA<
M)?<46%H$OYV/2EDK>:)Y=GD2W@=Y"ZRY4_%35F'XJHQIP"W,RAQ+*Q<JF&,&
MGSY\]H6-P9.767/OE&QL&1R<$ZIF&HZ.;<NF7FJ!];)BI\>EZ%QQ/DO[NT6%
MOC4^=,;09C:]*.LY!^#TRTU%PP67W;_=O3E,U'<(1">R84T$8TBM["#$Z C)
M%P8#$[\636%W&'Y8W:"I#VR6I*C38)^ELR1"5ZC; _E\;V%L(N94VGO 2@K@
MSW=1XFC5Q(JK&/H5LL@-^'/?TI;9UD:ZE'],D?*HRTUJ[N204FC_,/9_2W$#
M\B/G^_FH%45#K\])F^2;G!(##[*?" I;57>1P)\().>J2&:Y_[[X/L6]/ -A
MR!54.NI-IZ0BODLMYOC0B!@2\2*O>C&)__U75Q_41P(?S 48J>[\#OX.V7")
M=G+^U$*N%\.B&FX#MNA!*%P?*Z+2J>:.I;C6HA6)!2D '<-8BV-REIJ!@0F7
M;&V'XEE_^[>U)M><J$5R 1*_YG0U2R?\Z31#](K*2J(3E#*+R.CAQR_'"]_]
M(<8%.5.]$]'(ZB=UM/A4P<;/M8J?'Q8>?(%GU_]$L*V7&A@D?*>DNU*F-QXF
M2V5^?UW'^T$&!RNC4*S6+Q&,8]NXT1>)L*9:Q4:2&NOA=A^(O^(_HYU;HS/,
M/E]FC/;$G/D]&T;,"$95HS2S:J^80_]3T4]B8H>CHRW=?ZYQGMT,8:?$$(;Y
M183Y<6+'Q-N+B>WOBRG\^N6OMK]WKL^^R MZO2W4-KLXQV#.:'*>E3"VRP3:
M &%7(-,06)X,*AT.#V.BO#W<'SF%4G)EVTEJ4<XN+C[O[M/!M"K)*1<3HE9?
MFW;G6W4@)_EJP$X>"P#@KZ:F!\WNP0>V"@9T&^,KW^)S)-N:[B-!XX,BHU)M
M1X64AH^FF+=@4%X1E9:1'<JWKMMZW<I-@CL,RI4"*#*(!,D8P*+J;IH+P]@G
M/J[)Y-Z7/XR^Y27G "$<R-G?HUQ8C G+=C'I\HIT5V]IF97H9UV9]+.W]5:M
M+ZG% &?(*?K? P!6O?]JZ/OGY23K$M*ZCZOP+C3V>B=#M^DO4 @2V6Q?F[CA
M&I*C\%Y]VZO:ZCG4OT A,?@7_Q$S,;JR4^I)4Z[%G[$<^3;+CFO"34;.N/&)
M</D1B?]#6B_!!Q,Y47;T^9)5O!AC G"W(C=_]YY6&N?P*U$+Z@.O!1%M:^_U
MW:B*N83G23E3!&"4U#RV_-2>P2-ZA@]K"C<G)]K?]/%W4S*BT5Y-6V/#BBU?
MGU399![U'IJU@TK&<X!XNVZ*RY-X-B,Y$*[2DRX/SB=)-C1%&/PG;.ZZ2#C2
MG_QECZ\DWGZD LM7+LX(-0GJ%CL+YXV8/Y@%]%N4J1?:#H!'/SE67A-4S5&?
MN6WB.Z(9Q^@!2FP;AU0/3,)G9 LJF!VQR?P6 FH/ZQ=:7'QA7M 1>?\9'="0
MHE)_E?RO']E?P(2-TTF-XCHWJ;$T^]>WZ(GR'))H_&%XI1T0UR:*U@!;J/J.
MEI!4CQ!W$]\WFK=52R6\3RO4^"*-TMD+!^V>6R^G5%%)V&]\"MOXHF&<DPB&
MS.[$JW#\@.HVI:6+[Y)JE$TT[I<G3U\+8EKA9G;JQ8'E @\VCEZ=B$!>!>QK
ME;$-:4PK'2\$:X7ZM2\#PA-:9EJ30!G3V.O.FA8-1I-I(:&[<_!W^A\PR9+H
M"7W-9@@'?R*(3-87B&!O-DJU9 K<7Y"L^OG3-":%S\[;R(;U_:B]U*3(Z#2S
MDG8B2NJ&5<3T&18S.9&%NUH.L'ABIWMAQ,K\&GVPT]'^%Q_^WL\87C]A';3H
M9&.D90?S=8/%.8P0$(#4G-0@'!R *[4K  !T!=EQ:Y:?L\J1F(/L'8F5+9=;
MCP[9I&VA0Z&-:.8LG*"7YM*K#Y(87V\$A9E2^\*G8@T9B$_O:3Q?<4PR^2KZ
MV D?>U7MK^<<6)4-C_9%%XVJ5S;HM."[O"@:O#:CU<H4B3 AJM#A(>#/OWSS
MH9S!]B%\)H^?1*W"W<?==N4R'Z;-?=A(U:>2]W0>3I*[#<N:Q94R,DOOBROC
MB#%";_3<8"/W$;YX,S\LJY%AA^E!>.\BT$*U^*-.8_.HKKJQ_$K^(WSZYD[(
M09V(T,J8S1EU/@"GT/[8>;)KG7H'^=@J8,R\H\RT=+G9<3&></Q9OS,X=G 7
MHXX3R:\7/OR#TW5W[7@^TAK%\E&9#J02G/_&91W(#\Q2-<(!&.%O# >S<5($
M87#(TW[H(HU7?%?5\11;RDGYW1EA#P:V.'9"C3+75QQQ#%%5>2H,AS B3N&^
M[]),#0IU'OED9\OO/M3M;5KTWTK+P_!%MNQ"H.A]="5?NH^3:H9F8_R73EC;
M"6](R Q4&H&OM]$4#GD/BW,6@.96QAR(JK.;5EAJ8[92QM#:O.,2C9WB0G,M
M$/"=<%JX=O'TCA%XI-&1B('BY0ETA/@?(>511BNU.S7S=VO\F^&,#\/O_>6K
M,L&6"WB"/,#SP^%65'#Q;)?N-&MI;5<#=I=P]FPE<D[0'FZH7X\T@QU3D BJ
MV.L#X](N0@R'$,$PO%</G :#B+N>LJVOK#Z?DER!NE3&"'GI,&_K(6]3XCIX
M:56ZA'E%-%[2H^8FW4EM."Z%:CTG*P%X4,*_/9JZ'FG8)"XIXK.ZG(<J2Q'1
M;D=>*(4DP6\549.%-*Q73A<F7G?XYH._9 2O:_#-*,SY7*H<H"0NVHPM/8QV
M5@W$CGM T8ISOW$*@?IG^_0B3]TL /BNX#JGEYJ5LQ$A#F4>FOB[ -"3+H.D
M>JNM.:_<DSN'J#I.(QY/18T^&*J94^!%4C&JDWM6:Y@<;CQ9L)>0J'LDL,2\
M&C+<DHM0PG'X=OQN*A$6Y57FBL0#<->W^,:I$[=.&LTH=B,_.5^AF \"QK!?
M/&]!C5K(6"TC$N2$EF>*:EE-!.W'WD\+JEO 6A:C@$BUUQ'0D%A&8R(K'H/F
M2F.N,G>!GO6+D$%3VL&/*&L:[[B2<NZW/]MHJ(N<2]Q1!T?MWR7#22#$S*/'
MN_+X>_,Q;BFU23%5GD@!H?+%WV< _74^# @-$<F=SSCY^YB59MO_( 8+*609
MJFG3%1>AND,:.9I3Z:D&X(V=A2<$X(JPY"=YQ47=)H3M9U/3*7>7!?X<C$;%
M"7V*GR0/>E4/P.HXY^U0JOL9Z^!D^+"+:#PC1""W1:][GW6]+FI6&I]\[BGL
M#$]1]HS?^,..$>&+D?@8J7I9O[(+Q:,\R"*,)P0"6H:UV'S[Y')4>A#L/"H.
M1L;4%&+UW:R:VC B+\P+"OVL1!.V[]&1$D@W3,5ZR(3;Z3"FX51BVQP[7PR@
M=OCM' @H U 3_'I0HS@C1.A5:+XQ4$&.)Y?"J=%6[W\BW*I4)3!S]GM#&F^S
M$&*R<VO-7)5V9( 1VQ2S-L$Y]3B"M96M;/JIG5T"N3HCAR=*2PNC$R15:7"A
M]X;3Y6;L.G8XSRBPZ2Q=V AU&DYQ7N<%4XRXX_1OP'.#V5&:3Z X?C)N8K[Q
MAUL& T@M+04\)>*+I;.5L<  C=W02&09927SQPSX/#-&Y F>U>67O(@J4O R
M,^_HZYN$CFR'N%S-G+P%Q'9>96\.[L_[M21&7_<)DQ.UZ JS9\[:]9I-9^TD
M"RTHXN71C//)/PN^';S\Q_&2_Q53'UVT%G3#",R3NZ\K/Q%>%;-X,AGQYEB=
M&+6*.&=0K"72/IN,_4]:2TIC?W @=%6N4P+748LB4$)OJCVZ\C#$!*_@1T&0
MW6%)?7940Q"4VX)CG_=DJ<;'1;_YWJ:;9>%?#\*P&#\F@^G?P,O8IZ1GYGP
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MV%3\/IY27]^HJRLW8&JNYK?14N*,@JL[8+R*&K11D]"^X!-LOZ)@:R]L$*C
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MV[^"G/<F]%6.98XM\1+XXU?HAC>L5NX3.&F<-%SWRI8]-8L@1A+]P6W@BE7
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M<+X3<18)X;),ITN,:QZ<'(O<A4WI!#3&5WMB5*97K%3NL1Y(OQ:+MF )CK"
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MGL1C\7--PM"468RHS^+N!2'=]^+*GS(D @-\;2#Z_ND@R7!OK63F0(YAZ!3
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M=50,:LVF67BK,F-(YQ<,QM,'*-2#?ZPR#';\FK!#>Q86RRDM8$_V;51&GP;
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MLTE>_-C:&K".?6A]YO:T?BIGE58+)X@V]71 C?/HMQ 5E7E>UEO:(I1>J^Q
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MF@ME$9WLMM^(#!B:;QV1.VQ_-4WOR;IU@PR([#O0'LZDB2_ >)5(G/)&Y $
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M<X77--R##B_<,BIY]>L3K.1@6.M7M)WG^^0S6E'7L*C6>5L9!=.BBE?Y_:/
MM<.WT6F)(JK&Z_:QOD[U#;7%4C3^6*GMCWNU=V?"(KCQ6PTEIFL'DYL52P%O
M-_=JVQL"2AK.13&/TGALY]%#RLHZ-1\X?^YAEM;SM:]VNF##6W5Y05&2\?.
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M/[>>5H9=),1]Z\#R(H0 O)>0:UIP0T*D#QTP6S9>2N5+S!"B">=C*XOCP$#
M.:09!JJC9*&BVHWN0JS14ZF1STG9C]_\=(Q/_KP]1!';NVCY.2K9K+X(@N]5
MKT"MV!4^,VLP@QHDAN00Z[&*ANMV-8$]&G/KO5IUH3VD7U:YB*Q:4 />&2BC
MZ5R!LHJ6?E3BR5,&5_9X+4I$F@L\<JI8Z: 4?/*'N1D77SP7'^;0*5&+U+J?
MVXI 7D@U1Y]0&MKH=+$!5^9D"D4T3;D!E4#^ETL+RY7(H7E82E:BQL.]BQ,[
M@)1#BEK_1L6Q[49HU:UR(>2,>DV@\8W?8<7L"ZM#[8'*7N%Y&R+9B@^LW2K*
MJNOA8]R(1_AVP_#-TQ _W%SN3!*Z@E,V7[CKFSH6(6VVM2.--3_&8HVHAG11
MST3/-<=25=2XH<+OY:1Q(;ULRS$R0(I*Q8CYH=6 /*"G>8FSR1O<(5VJ_+,9
M%H"W.D,T9PQS<3]V.GRPA^6K4S;+B6,IC2!,OFIZOA)^6#6?=,B.']3.*Z\!
M+\.Q.,=^WZ-S5MY?*^\QN=KTT]_X4+5_A'GY8%DU(BGD[ $TMHNR/^#OL%N0
MGR=_TH3<G \EN,@N3JS-K2+X!X>NAZT AAL;I.:\B(,(J6.Q^X\Q IC(JJ%U
MR_:UY\5JL&[SOZUCZO$Y@L[1B]]X*O(45G)SU6'.,QW"/@HK5;MS7#[3$.NP
M/K,9I'TA;7)3RSKQJ,-HQ806WH=##/7>%2)5-*P <3:&5JMS7LV9SY6MST8J
MQT^F>3 P?='L$WMIYR"0QXSA_V&X\U5D,*%4X'N.$WR#(8,V:'"8?IAL"C08
M!H/-_:TFU#F %0D6?X':0XGYI9<6#8U%U$AA1=3D%R\4WX.R_6&/@NPHC/&:
M_M%9>UUN<E<S<^W17#@-H@-[T^5GD4M]XU'\G+S&:\V=XW\2K63#OM(B_^IQ
MB6N9<X_#$V=%LATC&Q.]8QMW9;4M.S$)]:UFB90QKS1\.WH1H?PC? [/MS<
MO*Y='B7.S)(F5UBV>5ZN/1^CW70F-:7O+=)[AL_]C(2/'@/$3>XN.[!*RNU\
M/ GP,N1ET:<2QE";L'*$42:D*Q8'?^N=-B7<5\D7^4 3UHMA!6([:71OE6I6
M4-K;;GJ.6#*)I&+IHKK\.JWR)I8O@J> W$<@%12FV$3D1&C#J>#+#=,F:F*H
MR@=FR35628/#JW5B5'84*_N5.#Z/3WGI<K ^V106B#I%2RW-[)0BY+H&'>$[
MG28G!^?XF99K]%/RZ2'9'3)BIV-Y,D@:TUP*C9U,=J VF%B_R(Y]?#1@A/(=
MVS #D7\?T6?4L-A&7E638]=R] BY>=TO!R,KZI6O_)?A*5EE-!S+<-FTD2%H
MVL)PM0(9X;M9\1#.+W6@+VUZ,-@E$ ^T P0>VY/5^3EOG/"AJWP@#_>*5QE_
MSK^5GS7XX;F ^^J/YIF>$'=WB]40=X;SQB.T$YXCY_HK[H?09E NX\5FV7R8
M#3KIX<B';JP>MJ$1X7L4=J_1N]MO?(]AL'-T0P# $7$U]^%O9N =+?LE=2$2
MAM8D=N,N*M;,WWN4I>!G!C.NQR/*4FEQ,:27ASVDE]<PU 8N4*.OK6]@Z!1/
MXI[=<&I$"(BEI:+]@_-F89 H;5.WA3UM.R%&2KRK?WPC9XC]SY:$<K-2DE?)
M)U/?)N:RO@99$&YOW3*G%,?$094[)2]O530?AL<Q>5Q.#GZ$$>>NW3%@#UA/
MAT>B*!ECBCN,T',$DAS=M-(.3=RTIAW=V3?G/"X'6%_ID>R7S2XP6+])%LIJ
M4QB3%M#$G7R[9T3/081.XTHS?N&^[2B"5D9 9<(4&CM :K^D;C^=NB]0!-;&
MDBT\%E"4*G >][@4W+ _C<S4N9EG80&5Z\5IKQFA$BY'C70$4#TQ>K*"@KH2
M<1$GAK^6$5QOL9:14L^PG#:R[@ZR</!N!',Y(WLI9A$^WV%(S3KB)+QL5^&L
M?NL,]8S*G;IT?/)&6+.S@0#G<B]5J0[*&5*_EN5ED=1@38D4B1M3Q-[LB??Y
M<;5>@O/(YRR;FC-@N,RTSBI6;)GVLS& @&*N*[0GJF^'U_+2 _GUHHFEBK^+
M7"\,:,G+Z6YW+FN[;XYXN%J-AFFW(P]9C7AO<[.F;K=S<QTC2ZJV)O[D5H)@
ME6L C8"8I[("K]*#4VZ!^1/1;9=P3!XVV,=K+KZN2UEMWT*>'#<F=$FG#3EI
MPT%0NG("S\0@:QI<YIH8VJ&.#>@5YW'"F<@Y,^_5+OSWKUW^>VD,V>7IHLI!
MD'!WRI!)>4=YG4E=W$>3B.E,SG /AA!IQO40R[#L1*9' :+4+X $((,=2A[K
M*PFR_L1&/AL).-;CJ.0S@*Y9@Q,2[V+HFYM0=YQG=>XPH1(+Z^I3Q+:\-#OI
M^\ADI@UO'B:R*WCIBNYYQ96R2[6OG]AN)(_"7>+$S&5ERD?]-M-HZV.^KU\(
MR-214U\"N@".=2.J$RI:_AU:T#05=V]EMXUB1'X#KZN&WIX%=[0>?;_='C@5
MW(/_HZT:BJV*J'RH%J.V;-A9GI']%%O(S;FB_3%+@F7V _8ON*B\PK]7BCLM
M?/@/\K\_::*EEZ:ADO"WZTR[\WW;'[,&_[#C06V_NO>WQN$\1%:]9U17H+1,
M&39KML,V ;0OG>6AZ'35A5YY.:2]V[Q))NH B5Y\55?)O>?+V&1+]^K=?Y>O
M,O^_';J*P+G6"QD]38RA::-+3,[Z1,=0IR]'@@S_(P1#_\G)&8; [KI9):&?
M)@-+G\:I18B%<1F7Q\W@H53!9UNS$XX[:C[@WHCI(;HD)1MA6!CFDWWJO>-1
MLCQ0*WO-U1AUF9I?/[&-BGHD!E,N#ZOE4"6LR3L+BUG2[&"-\9T$FC(9:RH7
M#G<GMTX<P.7L%5QI^#HP?JZT%RHK0?<AMS)T0)S%0U\SP#.,:0<3JR+.,J_0
M6@0+,<YD<$8^F@A@P,1?H?*9''CJ[>'NC72P1!*QA<]C">%K% B"EUUX]*QW
MA#B^)#)$+"L*)1$.>^$W>!#]6)%S-\4-N=5]$_$0-3?75TW\!4:0/SUV#[4)
ME+WS" [^HV($P,=-6']+.(;M'.2<N>! (GZV@XPT<T:K&9OQ'*$**8/7\5:,
M\YCWZD/!V \\O<S=GZAR79PY=;&\6O/?LGCZ.)H3#_T<IQ&G%;OS +EV\PM[
M)OP81)79C4;>C5>7=6GV+(6**+MPJS]/-AV[#IMVUB@:,Z$8G/'1-!C41KA
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M^#IW*_VS123]RV'^N9F8 0P!:B[]DZT-@-*[+W[N%:6O9;RH,11L[]>C :I
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M=PCN= C0C3N-NS?N;HW[R[UKWGLSL^;'S-39]>?L??:N[YRJKZK6.J\+K^L
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M!Q-U >C&#%6O'Z9$\4K;;#L]26/XO3/H4:)CXOK)YL1\-:"W13GVW FC,3+
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MRI=^_XET*_IZ$+'NVB'*GWU*6))'S?J3D@-V!G$2XD#%2-!ZAK.4G&_"MON
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MC7LLT4YA(ZELZ^"W1#Y\U@X:.$%V=BZ+TJ8T5%:8FJJ<,#3M9CC*2LUL2HZ
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MNQ)"H*)JQ2<SIV[FAA']22/T*U5H6?_&,Q^1160WC-@>1, <,XT4SST=V:&
MA]2R2\UAZ*WBI",R8H#=^8 =QM;[V3_- =G$U)&K96F$]LTMGZ+3F6Y4J>X_
M3ZIN9:'P8@SB#!ES"5PJ?SKT6W8:94BO[/J!G<^SG#5;RPC]3*?NAZ\4+TX&
M7?S%UO[>6*VV32L6>RK%U4#$=G74UFYN<DQW6;R ;T^XAG.N2I9+$N)382]
M'LOEQ_Q5<N%>RP2I=(FW]0^Y9S1>$%W<#]@]B2#EW>;ON*_3)LERF7X5 XAE
M;H$2 ,YZ2\JW;T53_#-/&N2],2;=B23Y)JX.A$=OB*K,E-ANQ4N=]X24*/Z5
MNW4.0,**E%"Z"-E!W#*5:<JVGT^5@P$;Y:UO'%QO;B&7VD-I;+;?)JE(3)/V
M!9]9)GP_;,7@]V<:=TPTD#20*^^@0[V0W=_#F;U ,U/JQ>BK?)"CVC9) K7W
MP]07;+-.4ZOG+^B,U#/^!;6B'ST+.-[=^0M%7'6<>)8V:F.VO&$6U;3KY2<A
M9RF987MS7=FK..6E2:D1]O[%+8\^)BVROM:A'-;O2)MT&]^X8?:O -ZK+2N9
M8;"V->=E("9I4T17N&O;$#'1P^2ZE$U<?3DPOK0M@82'^T(-?CTME[MTZ2=$
MQS.MLMR!-K Q5XWT5@[BZ"X4H?=$?93MDB95R]&I"^[X\]8'!OU/[Q]08.M-
M+T-@_.ZA@8U/7_7MQFL^<>;^,G.1+[MC$9_=;4J]E6MH2MW/S]F.QO\XR]P2
MY\ORB5K-('L&Y"/DG;TZUL%6 ]IWUEHC%N8O8<*W3JL=@B_K#A(O%@ZE9R!G
MC9WDNS!G)\4VE3>,4WMJ=8M*R);D,0L)V L?"5DMO@^U9,(9$(/>*Q/39N=B
M ?-;[P(VCHZ:3DNG-H 9E[MRZ"P46Q[O+[(QMFH$1Y5\UMNP58 635,GQ8_"
MXJ@I23O:_9+]XB@_O*FDF%S4IJ6TZ'U$M!+&L0D] ^3!TU0B:-JB\]8W:\PL
M,BG5O]?MDS!_B@9L,)1780IM>03!9$O T^R_J3E@]D1CO*C1*AK9H??)I_JX
MN2P3UQRH^[!>]\DUZPD#:=L6&EGB#UIQ:93S@5U;@0?JQR^4GC9=9MJN0 T\
MN[4F#P?85_T]0>CD/1HML_MM$D&^X<N6YI7 TEF4(69#YBS(U2L_I]HT!QD<
MGZ;G0?>M9W=LKJM3?ZN1<&G_XL#PX]2Q6V!1/TEKH,57-_M<*RWR/PMCW-G7
M9<0;':'$ED^R=HK+6\Y[HC_WRB@#-WQ,FM&!VE4GFT'(N!)XR#+S/RO> JA#
MOA>C^T":B@74%1[E]2:JG?(/YE51<KOG+,=.IL2K7++WZ-Q&944SK-T^90*M
MS),_Q(TD\EK O&MD#DXTRZIJQJ+8NYE/-E,CF3 8"R(!(S.!M8UQRBIPT.D>
M4C/^_ NBUP.^5E&H4+JN(*%Y!!3MSQMM:I5EM>T8,RDI\I105)$^2VOVN1.V
MZ#".M\)@L3[2Q]+S@SM-(XS6O%T:BTG7^P_:F=#% H-&";04<D6M:'>ZA.O2
MT6*8OKX7'-;#^HCA;PHM!E-5)G[VT:A@ ?[YRQB#K:2]&:V]A!Q>'N.;TDWX
M6(3A%+N:S!=6RI^1A:ZVR\V]2W@?A<$I["RS_C![R-B"I;%03I5D3MCK4ES<
MK$3F94W3FY\2T(PE0#4SX"KR>;DILGN.ZWY9E9!TG$'81:NLX%A0RQ1)\YPZ
M[!H*X8=IM&ZN&HGR=FG@F5'V?05DQ]Y7\TZQJHTL6=JWFQ+[?NO@IC#+%61
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M#G(-C?+AKL,"]CC&%K$KA)W03ZBD%$YJ2P=\FHY%?#?NY^)QNZQ.O145:ZL
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M =F"F<.'I*XM87HBR0A=O+M#"CR)37M3/=/EI')J=7('P,J3AZ/[W)7G/%#
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M[OYHO@(@'>MY7Y[P.\ S[8R>_NA^?--*7A_O[:OYO2+@>2V)DGY%J]0Y!'5
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MV\)FE+HV:L;X <?Y[IO0Y(U:A=G(-*ZF*M=B\)3EJCL3)K3OAL4]-K'HVUB
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M(+(6<UA$</N]E8=/&2W@T,^?G%1D$#I8>);O0CZ]N\^ZAPA1.WU;RKC_0Z]
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M7#US.%9K;=$:<.:AYR6OEMG >RP2\&_2OUQF+P6+(43$1B,<7RKO>;ZQW;J
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MSV7Q_4W!0)&M??"7*QVV0D&:4$TEY=TA*(;W^PD@Z\PNM0+!S!@.GX(D;72
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MXNLO3%5R+:O+0EXUU3?4XF[61"N5*(8\2K>7N(EB2,YR5Z8,,>\DL_8T- Q
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M 5=-^;.LU1<&1K,^T9[QEKH3G@/$.D-G.J-6:O5$<KX3:[4^9ILU)3)* T<
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M!^6@%.T1>>!U./.W8A.'1=PT]8+:'(/L-0FJ<0%7[NPU78;Q!. 9+?GC 2_
MZ_5#(A:WV2N.$<$V-D<%X9:OD2\GO=@=D/5[69J3@M@JK)/[!NYI>!RALU7F
M=W6#1H#3?MT@PZ6C$7!MCK- Q7]";>)_L??>85$VR[[H* HB29"<,TB4+#"
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MY@8X"PT"/EDGS$]N*N*NN90UR=__20,X!ISD10+4RQH;IA?\&L:SG]!/C"L
MS%J?@-E:W,ZDH$N?LL'K<:'MW+5H4)?90T1E+8+_.0B3E?6SOAE]D>$9RCLX
M,N<1Z$I#R,F6()=A K3>=P>I;C'PW01O<W+II4O6.W-M#4$^0%WCLVCLQ+;Q
MC)OL(Q/0)MR[HLA\I&S;VZ_.0[Q(9B/>1:"'=>TG?VG?7H+HHP?.MS\ZAR3U
M,)+- "56B 2(:"[4R<_VN\_I8O3UFIM3?3K,U%Z!1/A48MW):^/2'.'$BE1Q
MM<!-\>"VZB<XG$G?W0?L\"2WEV?RYT[C/IZZ]9K3@? NE&=$'R%G\['/7:J,
M%IST3P[-37G*,SQ;5+SX'\$D>&GB69B%:+YQIB'LWF$N#-&X->6&6\NVXDLL
MM>C=I2\P3INOY[J"MO2][=O4T(-V;_RG38.WV_.-&+QW[<S:'OMIK4N,'#)E
M[GO,;NL-5G1MC :*4X(Q4:9!#^&0TM\Z#QU!Z-#>7)FA1W$$)W'\2;]Y7K1\
M7_(Q_+8;>4"7645ZLW6G'Q$)&DT>RYB\Q'!4YH,[=%*/7KD4@ATJUY/Y&Y/\
M0LB^=0@ ]-FJ%M38>%((G\$T27"31]@$"&JH^T14)CLTUV45,*#P>21N!9*@
M34X+0YGS60D11-+-/[])->)LKS8WTN/QK-VT@E*\8(1T":\8M[HJTWQ*%'2_
MOZ13-F'E"=LTXIU:RHR;BWWSPUQ8*LM#)>_P<1K@ATP6U>J--;&3IFQ%BY?1
MRJL,_9%W)O $&$(8*Y*2U.:6BSV8Y"ZTQR^>EP0.R])/[NV+\8Z2UO]XRS5%
MV^^RXA[D_'+_UG+]%/0[W>N[K_:.NR\"T4R1GHL&?01>2!FW?C)3J,R4):RI
M:9)_<C!^&9Y &^40+R).X"+Y1"=6!&3"2R%Y)V17]:OPY0S;)[3_]!-3E9\'
M1&HKLKFHS<I*8!#J(3(S0I2WC7C0Y>CC$;:"K1E_7?E92VVC4)\\W^W= 9KU
M8NB]-'/,;+@@$(2LD$5V:X][#D"Y"'VTD@7=:4B*39G9DA.U'NC34\1%G@SI
M6_T<Y,*AGUPS:#0]A>FBIS>B98'B"65?:@1#[3$QG1G<&XVA^/RSW6/"N39L
MOQ4M('=NGS)XF'LQO8?J7>:4.,$Y4NNN!&O1 KF6MD%LIF)CRL>#++K:AF[)
M1B'5 4CQZ@TBD+.;2XL/0YM0-K>PB)>5[ZAQFKIL?A-F+\[>BS+-VWK*BW<Y
ME+]B,V=>O%D\JW3^.45C9)!,/CB"<6V\X%PPNV:%J*C2O 0[KS#)EG4<1^(H
MRU.G F4K,_HE81S<XI_*6_QBB%7.]T&/K1!?8Y @X[OV41'E'_0ME QT7*+X
M!7?B=PC>^&ZKS6U:K,L:*1\+8E_%ET)"KBB++CAUZ-(L?4X$L4H7_7TD%_Z7
M.3LMXL&'IQV[=G7M.%CSPRYX?Y=:W17\X78V25M2SPUZ"R\YFZ+AU(1E+*R2
M5-#2QOO>JQZ19QK? S(EQ+]ON$(*!$8^U4C':L@X-8DU5G*0:QG?^UM5VK^A
M['EL<=X-E5C(*WB 2&59?X'N7_"Z(P5)%P9=BIZSO[[EAJ,A.C$P;QWY9(K2
MQ^X)0-^GFRF:D0%;SUC9S+/E;7 &',;-+P3[05,E&IR'FX #!32WTN+]W%]M
MG9"(-.0U"88S/3QR"YV$!"[K1FFV=LSN!W9^^;GI_67=/^(9E3,WV_U2?#Z-
MV\TNVF<W0%>)$3U#2DO3/<GPCTK/='I.6V)G)_,6D-,5%2Q#H?9\IARJDO=S
M"VXV9.X(&^,8J>\)\E;.>LY+>/CN'G!&HT<P7(JKZQJ ;X9-ZGDXB)ONBND)
M'"5--6)/Z%*B95Y+3W^+LUR<=_GTUZ]*,.(:T,//A+0+DRW)IRN(A1^X2&W-
MG"UTNH.]"%Q2:30O9W1BW\="Q"8F_V?Q75G0X3VF8W30T2T]WF<TUG$JEZL$
MXJ[$$D+4IWB%:CBRD4TG9:X=%G%75QW8B8#*^2NH]36@H^I*='_UKBK/,GRW
M8Z-+[AQ[#4 I_:FM</&V1,'T7*^Z4YPT^NAR^QH0P_6__MGDW QV@56Z!@0Q
M73@J3->L&++('8]? _JB3F^]BH2=E+F=HO\V[/A)R]^;<MCQ(&8>+?VK69=K
M@"SI-6"Y_QI *_M//<%_*]:?QW7X<[LCGH*[+ C<< W(N7<-V$?=",WTMQ[U
M3>\/%:@.;A=2N.UZ+Q\BF"XO@C#Y_VCF73W5S:NX_ ,?MAM\XJY$_XP5:.!^
MLEY'_7S0Z/N@WY@;%>/^U+Y15_M&W7_H^$_J$CTOS+GTYSH4TZYWJZSX5C^2
MR'3DU;_/%*O!X%3U)]6TLS,)_UHWIZI5UO]#T?^C_7]#]/\/9NH_>__G,_7_
M5W7O[79$1M:[>;D=6O4)70-<;H8K<3G!Z>]P9")8QO8CS)8R+1&\('I>L_EA
MKSR--S.3ZK?;S2KL]$$""(B-E7OG]D2[!RBL@Z( S13EN1U$@/VZW2F1T9=T
MPH#3>Q;M%UM[MU1$;"=86_=AS[UH_M:OB%"/>.+ 1FQP)3:J.YLN\;SKBHKQ
M\;2^ M-<3(F2Y4>TFEPF,^_!"K1Q<,07UMD!5W4+#R*QP6Q$M8HYHI<[$_NJ
MK,N<C(\>5HP?,HIKY^KVR;^ZM5;[K3C9:JWLD7E_^(7T93947?B"-:XGD+#)
M[69#<JDP?7GVZ4%.S6;B"_/QR'P*P]:) E8;WD??D%]E&:]&.LBJ6#'$.4@S
M8:P3%2/C+%^]_W"QI8F9Z]Z;$8<1N>Q=[^<["?3]3"DQ]<=V-9@6I0:,7+>,
MA/*Y7+CG/OVBV;SQUHR$T]@SYN O_-^D#^LJA1_[G>E75/6Y 4".S7WY;B@7
M7'\BFA0OWN)]E,/.;_'IPWMRW/S?9/!18CR?I./2<ZB<<@B/JPCG+AZC!4+R
M!E<VL#EY)A"37BG@FF530V*?X7I3NZZB<P2+2.5%=.B=E4\&DW+U2L%>.710
MD8E6L5Q'6-H539)N?50/K6O<6D"[.H=($S]T.0UB&WU,]/8U^',FDJN++L!?
M#?-BB06=;+Q4AF-D"!8>O;]@VO756:C_T6DDWM#Q?#8/+"S((8[ *8<,:+12
MH7T-T$"?U.1MD_XZB5\&?4[2\?Y@NTC[X-[YO/L/C>?PC&AMI_,/<QL=-7%A
MLFP0 K69BT?(?1*-?,BK3KT+2=&3AK'1US&B7U0$+DH88H9Q:"P@*,G!JD+>
M_CTY!YM:C'A"OEK>O.I96F05]'&2L1/F%8OXR5)0)K?>Y3R]R^,&&K\D>+%#
M4/W&6[MF]%4FDA^DCEZO*'7X"GZ#TH[<ZH-S)%EHU'-2S(4:NE!W-;A'%C?V
M&B-]_+*7%>Q,;C+SYEFY&HMI%\X9V;Z,N)_6R:++MG;P)!>F;QJWFFDG*U3^
M;7X_[+=447PAB5W&/$<2BIB:0M[TN4B\P@A\:K)D2/JI.!A >^+ SMXNU;._
MJ.!ACHO-0KK(K>S4;@8^JAWCAY*N! @:PKXVUD<&[7Y)?<3.J12_1_J0^@,T
MC\Z?3&7%8";AE[>L:RZ/X\F577Z]F^D+$8_W!]^2XG)63WUW>SV\9?'15!%U
ME\0'D]U73--\==#Y39U^6_*$N=-7NOWX\P=W/-D<5BB.*7)XVZ/+/C*17[@'
M?=G,)JR?K*JJ,[/NT;E(-?9Z+^$SP3.?7A@I)Y-*/?3:6$7D[3T<KC@VM$9O
M1SB(K$[-H &C*T7?T$XY?6RTQS+);P\NBY)1-(%$$=8YE2?$((7E);D5/4"J
MV,S.,\'H'=17#'&4=:5Q01YD9<HEU=8(]_7*XR? ;*4*$0VT;'#!OAH1CL97
MHCNIY0TS$=0'-E8'2F]EMX7X#'+9,USYVWH]ULVX>N%])2A;#,>/_).Z&2_!
MN]\]??F1B;S6'C8''0D)388,G2:2I\T;&4<:3%#/*2B=VQ=(Z?ZSF3I!HF:0
M8QJM>8LM/15)T*KOC#"+@4>#4LQ*GZ^]N?1LL6#W-8"P/PCLUTX_,7,R\83Y
M'<)Y3(7L^54N.8I9Z<?XA4R9AN[83OTOLDGMR94I2Z/\+(OF]\IYAC^!KN1Q
MK>4X.%,/B#@H4U'-LC;MV J,@?KLL3\^5\Q>*[=GE-IQYKGX3-\9.-PR$;'A
M6Z 2+Z**Z5V-QJ$^7XUG0G708Z-Z@O!;W2I,H?+UXW<O9-DG=B\$&:+-/4$V
MD:L\O8)GXT\,@8,T5V9?&7)?39H?-9.\N_ O,89DGHN\P!#G6O*EGIS5FO0#
MJU7(HRNC6.Z$JN 0VJ]9^$]/KOSQ/P&N(#!>MQ_HI"^70-X'ZIQ_N,=J09&P
M[&JD#'C@%QRBQ+M')1O4CLV\67]8MYZS3XR",/P5DP#&)7ZR]:'%@EGH.80A
MVP @E?[RRY/6K,^B-EG]K&W6*X&%2!(*B7 Q,W\3\+9UU1:M;?;'AH1GJ?'S
MBX-D#%L2+2F:U#7].#@E,G?D""[8B$[B/)C>']FVCN<;>LZ%YC"EV]*NEO9X
MKP$&OS&(]/'\<:NTJ$D;(]TR4=NG9K/51+->V2S84/KB8.)3@W=&O\G\/TU&
M&_O5F)X6J6-+,*SG\FA<L9:19[_[TC)J:43G&:0>\>5]37T1NT121Q&3_11'
M*+[6BO-G/A?QE*PX]'G#F&=6D.:TLW/=/(.00+V1*$7U5"N,*K%G<K%[??^
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M29+7S_6LO:F<35!\T.>HJ]KV/EV!"+Z7OV?85,Z]L;?TR9]WIL#M.V;^Y"-
M ,\.;4D-67$V?4+7$>K[DL1U#P%RB;GL!<IXK2_E3D-=3O2/,H\/534AS&+>
ML_L?Q,V'M<<14QN/E0IYXT\J*F_I+AX">)("UTWZ>D[E,T%7:\C[X#N)IO;5
MV@0FKLU&R^$2%WGTKT^73M2! YL+@7/T),F$4\V)U7M&PU*ZFS-+&:<2,'CD
M?;5R3_.O1GF-5ARE 4<6GQJ8EJ LN_7#^]R$#K[E52[I^[K;,5YG$/J6I977
MT,D$_I@M(D'DB,F.[2.I4-LMMO"7NC;\*X9+R?'WQL^1$4AL(2H@<YV2HD*4
M%*/Q9AU3O#&N_]&*LI#!-F!T_TK=CXVMHK.5F"4.C?.H5&O(]MVX7U7GW#J*
M^^T&\ZPD]-^)]Z]=?]3%/[H3W*.",N2S'7%X.&1H-K\PR_,>AB85EWQ]?JG8
M/LR7G!T;**>Z_%(WE,S=1S*604:,#$JA.^H&&MSI'9&PN;I9[7!YB\+K@TC3
MLIF-8\.(\00!AN:P\6G&]^RJ=HQY(L*9T4C?-0D:)#EYX>?6!^"B_LL<>W:W
M>31((W-]0Y&_Y#A[E&Y+D>J;/8_.#/GZ^R/6V3+WI<K&D)=MC/OO*$THXIS4
MG)JGI<5<DG,'%S6"CS0U?Y;53>FV<F'@VQ\F<;7Y4T709Z?4ZBT[[I(MSCVR
MMAG5UQ^Y93"$0$%&YJ68.]T?V%+3VP?Q%P.%QDDB+WK@0GG\AGX1 N:SNHMH
M-=8)FMR]HDY2=3AG448 4Y3\K<UC!-66%(@ITY#6YVGEM?X) M>H]O%-4KLJ
M4I+X=[#\K.>.T_B#"WO05\CSTS96DR!+77<_V%QI(P?8FG(=;;=_"- :=1K2
M5?4>XRS(_3-+M4K;!,'8$JF#G9[SBF;].-QK9WU_H/_LP9),P2JWD^>D"4XS
M.104S/W/BYT?/%,(&XUSDTT;- 0B%GZOB<1M,/XK[I&JC(Q0R<\R^.+'P0HQ
M%-8>"CG@ML,S^2M1TZZ&!017IUE/TTC12/A,#42YO,HO,-BSY<9@R$>)[=X4
MMBK3DQSP@!K*2T>?(>HL'/=$0?9L!QQMOI73$KB U6#'MY*7?F=)+_.5)D\V
M_V>'9T&F3,4WY2+P71+!JH[NZU"HHL&>"A,<4,KLT;DY':FB)AJ97%X@>G3'
M$8#(N'H/"+5)5B-:.CPN$$BP^WK-7.B"S&*=T/@1PBT3;!U2T$9/'!A)63MR
MAK1AQFI)1@-V)LCP'<R6Z/DFSQ*Y46P;H$+)#/O"Z=ZGV%.1C#YQVUMN8M\4
M$5T9W I?]19$*NX9;[GD+^N50]XW+'7D)U9!T^Q?1SM>MO^<+OJ[-C%E= ?N
M@^GA[F$L;=Y3W_>J'JN"C;9X^321?SMV^=[66@6V7M(J_ AL6A?PF0!!JV=7
MR9;5B 9Z[$GOB^_=S0=73W%DR(29?JSC1RP7]W GF$VNW^S.NRW.I'L,5SR;
M"=8SED^!NOZ5,8_R=VI0@KV)&[TIO*'X_H9[+&^\6QI;9%5H7YQY/T.#HY/K
M.35@LC:FPAEI"U-Z;99B$T"N+%W43I,V5>;84?)7[A1[\"6H5YP@0CT70"3
MJU<O=(3#1) Q6/:#LPHJK%7/%(DVP3"HB?<10F_R#$1JM%!S+MKEDM>^V$V[
M77BB<5PM0Y']R=)5\:5\J=N](!-  K@AJ+-QM1-)*GKAP8I8@! W-0F0@UIV
M4:A.K.!OE9;&@9#6 >#1RZ#_=0 0J$E@R=&,+!G_9*;%NLTKPJ%..WNR I[0
M*P[M"W8/NX:,JB\.UW*HU7-450*'3R\7M,L^6/?H& KE##(L:"Y[QNJP:NGI
M%,2);WDKX#":?^ID#J;9XBN)P2 1IIX9*[D1A74@:O!V&$M-SMKVN*XK5+53
MV&_5WFF/^X88NN60T1_C246,O9$2L>;B^I$K#10^38L)VEYXF<6GN'4E2W<
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M_;0MTB3J#WL@#,, NV=$=#_$\&\;%Q?^HY[L5_*M"6-^<\. \Q@!%W+H94E
M'XQA*">JG ZW1_<[C$>16P@4/H18=N\/&+,F_NM,S_\&+Z=J?K TZW^#2&@$
M/S$PAMAK1]#TH61#_E"10PB$[@_-$J__+3'GL3T3YELS67F(W]-0 @;%3 )L
M)K+_E8F(]JM(>VB$HB42SV<2_9V"_'OC))',8(Y04"]*FR;?'T(H#20!43V$
MIZ%$+^(AGHI_XIGW'WCJMN*,_>ZRR_OG@:T<@ATWB-^MP#;5R</ ZUSP&K)Z
M0G4+!<;\/ DP1B-;11OQW8/.OSZ3F];=NZW8]NSQYD?R+N[NW]\["RQ/,$75
MO:)@X8P*2 CH@C$N8 ?0$;]A#,:31RR^%32[G+:Q>15I\%H"SQT94^2-[2BI
MH*9VM<L9WGG$TGRBP2E5LL]DV3/M/[NXX!>%1A'6E?W,UV<'V9K&M*P5GY
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MM%"[T*_.A3.ORS709C91]<B;/<XQ<%JC @O8E%""7OOL7F.5,)=Z&OH+54=
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M,>_.EB[*M+#U\2B2'#SP2!<4^M"!^7:,NDK+BB>4BXNYE?ON8!1J[>24G&L
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M_M])P%/1K:N7(+;0<PB-=FT\!2AMC6DV:,D7Y!I/(LQ=B>T^\;".SX>R.TE
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M.SH3T=[GWJ6TRG>IR,!1$9U^8RVYA_09YXLWY#[G&V1Z,"#S_4@[1I#R?ZN
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M[V])E71S8,6#3$(2@^7Z0@:U8R),WIPX-TNGMNT[4[4M&AT=^^U=GA$P!LH
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M1K\0=O6'4S=,HD_434Q%]M\JZ6?1BJO;L\1U-VM-8&#/<-ZSCQ<V,P"_DL(
M$3:#2MW0$7Q%NX$7^T:M_M/^_.LRL>FVK-0MERH/5C4W-%;MK8CL LQ&7[@?
M-^;R\]U<="HKL+K<:_;&S^?EQ6@,;)E-!I%M2^>JLA4CH&-E)9QB\1C]P$QV
MQ>1IM6_ X<E]O%MLJ3TM<X6(:PNZ\S9!S2Z]%%@HK9O1_4^M4A)#F:MII0-.
M^LXK[>_")K6Z2/18S 0?.B@_4*T!Y.U=BMC<\-9O<WT(C%[A\VM*97";.ORL
M;"O+?7MB.^#1YB@38;#B8Q_FV&KBZQJZW(I%;DB/YS:R<B-Y!"^],65#+,0=
M(9W &XW#CQI:12KX;3;SJ=X=:PM0"\=(D?(OWG!K;*N4[$LF(3![ #/\XV:B
M@)I8!7NTX;QZ&*>^<GM+V=;45JO \D5)]YHHXU0^<44W;MOW-43QXY.)/4YS
M0_TW1M-U"4->;6WU0TN/'^- 4^5I^6Q"D$/KTX"W"Y;N?^M-,&XH=(?SI/VA
M>GA^^M57#O]Z$*W/)ES$A:GD>>WB.29#H>C@$H32$UE;<EZ>1[EC#<B:G_^E
M:T79\*O^S+9B+&YB=!HN6GHC>!I)O'&Z?,Q55 6!TXY%/.@395,Z<'Z]5R"R
M:_GKF[BM[GJ?_9*A1?7N_1W:#9[&V!,D-;QM%OX>8G2)X'QJGX5=D][U_8>I
M^.6UWE>Q58D.T<Y7,R3EN!3/]M3D:SC';UGV@9BO:^W?ZE4>+RKVK^2G#VLL
M-?.^#[(B>D0A'-M,7]36O:83%YYT.;6WXBTO2\K^LH2Q[>I6LRJ09TW@E6C[
MD@&BU9C%0/TS_C%W4)?(TSL'Z<8./AZ=KX0Y&F?K3=Q/UFX\?7><UTGK0<GJ
M@K@E!>;DK66-6@ENBI%S9$MXC-Y6F);O!>=(J3VWJ?Z7I:N!:M17X4K.# >"
ME]: =A%(A<K!S5Z#;LGD=5XEGKW(W#H*3+H;)#!XQ0H09N*VOZ;R?#P MC.1
M-M2(4^HX5\QL)#!Z+C'^"0=1&K71BEP-41B /+!82-EY^H?ZP_Y_V/\?]G\T
M[.F4U.H4]25!U7A_V+IM<*S$VNASDP[-JM-45AJH5KZR=;Y2E:G+MZ[=H5K_
MC&N^/+:/H]R"Q+7F6\Q=G>*,?LE'%P[8;.^=69@0R.&H#<U); D 'C-?*Y A
M+WX@)^?S(6]U;>XO[WRT-<!5XIJYS-W#GSGC<B'Z1MA"^]E*SH"[>R(G2.62
M-3B!8LF9C)&S72NGBHNZ;3Z0(^Z7LW HGJ<.#E5Z/G,87'J&Z P4E;RD,SQ(
M=H^]M= 4XU9A-<@WN..TOGL<'$6'GZP!^4M[,IV,'C9K%77?/V8L9R54>F56
MXC#-]2I2H/($DLD</%88-*G7<Z;[;DA!1N&1?,7-]DS/42+;@O&)LC6%5QS8
M[^++O/,%Z:)U6RT.84/V#B]BGGBVC4]Q0JS>4YF.*6SXY:CM$/VSP$=.EP+S
M$KLP1K<$+P=\(3C?LE0L^KS<??T;9MS%]1#H6RY @>VEAF-+RZ@IL.N[F2N>
M[L7PF*.AD$V3AP)KG]WFV*#'OY0(WJ%!>2!U_[->?&52XUZ:=>&!5HD#^<O5
M/EQ'GURYR.#,@?] 7Y]Y?8S/W<K/CR@ZZ11JGK@187IG\%S\E>F7A_)*UK^Q
M]JF]L,M^''9V=!I\V#F9\2CTG5UJ\@P%]I6,I,!\AL<$=DYO8D@'&(#J%2P3
M^8@["MQ'2RJPI5U(GSC@I/:E:3"CBU/=X,SA+N%)FRZ),U-W@PY<SCQ0P8(/
M\G"*E.%5"$RV,LE_*U7S3MKL[/4+1J,N')G<U1(W!\KDP;@9B;4V25WU:N,1
MS)1W- 7VRQ#(7V?K;6)$DNU?LA;@?]@=<3=_1N'XV7UWV9J?;V0=((2?,<MT
M[%4?(XEL!3X&E4E?X]@GYDO5#H>G U/>Z%^ISDXF&6,?9KJQ)86_7+)9292X
M>?>=5#:.*M/[UF]_EAE)_^O/L@Q!0RX%>K]4/6W;]^(Y<UE.8ZXS%0*,RG1S
M7.V<:)?>;V0Q<+!@,PHD8?#JY'SK>7$R <"F;^K.^"U.TR^GVRIB5IMWTWP/
MZ8R\!4;#=S/?[[X%_9L^6VJZO1F;;/R+ZCW\Q[N:^L3"+!*1O#S,YY\P_]$H
M@6@YU&5+A&1YW#"'=!\[Q'O!8[HL](8_"].7")N'%WWE+C ;YBSI2/E16;0)
M*INN157KAX6GHH86'HQUDS[9?3YX4LZ"KD?EA<U%@PN%S(</+/!0I?P-,5F\
M#9.CS_,1<YECY26N(W?.$,V^)1$E%06'CHM$/4Y]6,DL<Y.M[I%KU 3:IPR>
M"=Q?&"S3*0G^QMU[F$4OPOH3K/%LI0051U!R@3F5RT^:%7"]A8FCVU"X6IV]
MY,UI+NGK8Y_.U5UG;>M0X)C84>90)\5PB.4LRW.X()U@Y]-YO1)D/9IF$?7(
M-=_$VMKZ6 Q:X)Z'ATN ;/4\XDF&^%$)F89,F#/J)V^1!9GE4)"-$0 9GV$8
MR\X/OE]^:_4X6R;2[:TRQPL?W4>WZ#]X:QR(O7B7 F,\K5L73&-U4G!X"!^L
M<DSQD2TL<MS4_@ G,VWV/GX%S3J8+6!MX [%F]XH$L\?3-)%QI,,L2XOG1M%
M/.B/W6E/;3A0)%9A1W=/ZLNDS%5:5063V/>E'R'$-=&R[OEP11<&H0]L"7.L
M,'N"T!L/W_U/X'^WFKO)'>%_.P]O?]BG/WI\#G3OC'C'K"R@/E4(3S+O#_+4
MPL_#JP%&+Y]-EY[ [X?$MJ(5"IE/5>TO6G-MDCBM6G%.QW\1C;I>2O.L]B%C
M&/P(NX5L)%^YFM;?+#HZ3F$Y$ J<(_1M28=0X/E$U!#M"0I,J&P4?Q)#4G%%
M+LK?QDQOCPNLRSXG:[8!LPV@"GQ#AOBWZUMVU+N_(XX0QD6!5>938!,6D[CB
M%Q182ZX 2(VFP$YH@OGW%T$4!38%N:SG@%[#2= 3F.J$E/3(S\DS_%P 1'4X
M+O\59D8?8L_>W5.-R>AEDQ- 2R&$1P^>3R!;-^J2('W9^ "\08&E$3 D E1(
M ,V*?V)<2$7KW_STKJG)_=@AP,<U%.P-@1/"(:U=^6DW$:\[L"S#F)1A!U$O
MP_'HU# N9'$3"IX-UM4(NUDG0IMW3YWJ.-H2-O -I';'O^,@$VHP%"(]XK$:
MZ2"<I"(#6!X()C5W 6,W=[,X(/LO!H//D.MZP#HT:+H;FD0@F8)F$ /^3LZ"
MT,OBT 0QW."^8/!\+"8O#VIRZ2 2RPGXJ.W,OT$37D(S-(/T\ULP:R9N8W$M
MF!"+^3OA,I9'6D@$DRKO0S-]"C*,$V_> &:H(%QZ; H%9I1#OW/@#R3T0^ W
MI"\[6XE6Q0%I%9]/0@+I\LO*/B/BG@7M?*\543S!R4H8VSRSHXW&FZ=@YFA^
M0":!91 +R?N@I<V%?G(@>@;U&V3ZWQ)W!VGNVDZJG/J-. RV(X0"ZSBN1CH
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M9C#C9[!H,BTT^ACDL.#]-U$#LW<Z!&0%\98(.+VBR>/^4T'CZ,';?C0Q2?*
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M/O*DY>G,\ICO]:<&NR[8T(V5!EVC>OJTIZ^]!F R1S&2X*83 +WQ@K"%>&F
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MKJ,:IWAU9LD ^[))^;*6V^YPBO?Y-!C+7MI(:&(LP.^9,6SZ&X^-0T<_HG[
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MG.0@CWFMK\*YQI_]IXS]_S$[)I TV18E3-64\CW3HB:/_@-02P,$%     @
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M.GA2> JGT]-UJ\^IKIF2K];5F9+D--XI^,N"W<*K0B'XPZ06NVQT""+=0O4
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M0&D19Q]0=J+V$(>V8"T^N4S<-@**5;4%2UJ:^@U/77WTC;K^.[VLBR.4UO1
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ML/IECQ[98:JUJ$!>P2[=8^.9QL$_>IY1W*IKUW_\7J*UX=;]@$"V/FCYF$
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M5L+7F;T,M. #^=*3VH,#,A>V8 %_$('F0[:WDX5W#+^X]SKA-(]F=A4+8'Z
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M!=Y*2F'GZQ5]*K)&7_H\.A?]RSM)Z2GG 8'RB;R;K<FS7"Q[>YO;-<QU3I5
MGO411L10&K'Q!\DK"=&$-S5P#6X?#11+O-Y\IV!*0.1G4'SZ4#+C.UR(AR"Y
MO1I=G&=8?NPTLJUXQ$5CV O1@AM\UFT,;J]XIP1/7^[J='RKX]5[:/&,KX?\
M"=6\<,UT>(*H*@R$SX]PA?U8H6P=3B\AG #I;-#'&$R6-T,N&:/!P8/"B4:#
MBG;9I"_=>&ZVADA$,XV+;%N9K PR#;CXZFQ:]-@3UG_<240;>6V[^H 5)WD[
M)4T!<VF2'8'(K2F8'E%L;Z.(*53)/:'3NG!G2B)E(W;?/SV:_@EN>+A?<SWD
MWS)S.[_=%R/)>;RMWP0 2D6 =FP>$2YLZF)/7-F"A8AVMA#&:[IS\O.:G0P^
MU?:/O4G+><@;AQT 6S*-%^/;H^DK()RY,,F36_5& UF@CIM%*3)E'0L???;(
MTZ%<-T3R4XZ]N,$IXHLGE[6<-(N^PVQ\9PF4.GB[!=T(CUTB2&/Y,)=M=H 3
M:\#%6:X@R.E(_?WC8[=K0DBL=G>91\'ZDE/WJST/1A7]G*+<=785_+BWN<F6
M@C/?1$/[C=;DP EF_TOPDZ4=.?NW;/&Y:8.2;//-]ZX&]5-$[Z*?;$AK_N6]
MU@:G(V:_ .($I+;^*I*V04H$0HQ(<J= ((40D24?"!561F E[KGC'+H,KAFN
M_U[1Z$IQ>NF\\'3R5*5FKK*QFP:^$0@"Y@%JWIH/RPQMPO2&+"*OPE/94D\=
M:E 3\:KQZX):G\O/POB=@E%:UV!*E5=@!V$"GRWH^VB /-J**RX%XM*M^<!W
MOX;^M2($-65+=Z=61**TQO9)LH'Z5_D:=K!US8<49?[# EZ#"/ 4@J3$U.#<
M)E">(MIUZ$X-:.S($*#"%J,E^F!$J/M..'<9""_><^^>UZ0K7T;%+=YWRVJ3
MM%X/5!/Z0\A 4'(1LK$;D/Z-0IY;H+.8O>]5"9._/2?IW8)DX:]HQ=&ZD%:U
M!D+;H,)5*QN&_(5;YH%'_B4P:9R'L3C2%HQY$LI@&7P']AIT&Q@1Q84#PDS0
M23].1MI=>?(J>T@O*_9E<L):R *KC^_BW;Y(57@&O"F//L**X?;QQ@I;JN(\
M&#IR5)U%[1@B*_I#'@%0&%>L7;#=J$$PIY^0.*?]@Z,=NEOQ<*JZAQ+]QCWZ
M%@PZ -"[6''8":1TK^E*$5GR*72>@A-ABW4SC/H6HP=%*B(4.[*[;4/#HQH>
M=T\;UD<;%KTYVJQY;T1:XKBRO9,.9_5OO(H:#U!B;=1_X%IP:RTL&SM6;!@X
MPC)"-W\+F#+SA&SUVGOT2[/CFD9,@06-T7/SC?00HRZ$X<$$@*3#%40R^);G
MZ*,,'J2T<7K-)L3#"$J]XJ[@%HR(E>@ [:H^MQ=)?ARZPO#S7SQ%$[E1(&'B
MH.RL=NC-KA=O-6%P&^X,&?2!+Z2.<,4F(>?M8B 0<GF1%RLEVQ9OBED0U2<&
MF<6><I0 I/>;KTK/*G^.*=G=%YP_41S\Y3^!;HP3 \^6^4$56$M@+# _0RTL
M;\A&3 5^*XM&2"T7 R>2(E-&4OYD)9C$ZUM(71A4[<DI/'G6"KXD&Y)K=6&W
M];<< F4)2+?9)F>'(017:%\M]M.-@Q\ACR%\+3Y[9&!98S2:659VO]7YTG/M
M*:W.NR6^#OH'=S:8((.XD_!F9 X0)@[ID#. RPFXK-*0XA?H&NJ'7BD"(Q-]
MQNEQ[I'(WG$#X@WM/][&V4WG+7;I[76Z:'Y7?%1\+R^N!@"4>MP>0B#BXQQS
ME<"I89O4(X8G5"Z@XXA+.UY!,8'\N%C!WB+!;Z4T8V9*L>"\.5UXQY><[/,D
M9#WOJ85DYOPD@M*]!9,#* ^0K:XC"4;I2WNG>N46T/C!FQE@8OD]\^+K8]5=
M"\,&]@%\S/E;4M;-L'PN>'>HD1V[!>/_CCG)P*VYLRRQP[6LV!791NR$BO$K
M!G\)C0],]4H,<>A*>'"Y"$Z_JW[ND&63Y^5EE-+!N(2XVSST+B#LM3;@]=9-
M!L"6"3W+>7']1X9U( 4)V45U2UP"_SF'M+7),O/KFI#F5=K:XB%Y1;<:%(K#
MJ+<$!H V,ELVFBL<RM*$E/H!N5Y#:-/Y?:_6".L$7)1M"XE5^7TGD=.N=!\U
MC7$.:PXWOS%UP9ML_1^[R3GQFV/7M[WZZ)/_OC%S.%T(E&LN#O2,!+A"1UD'
M,!=<4SNPDI ,0/M!D!VI]%[R#[=D)^UN;!))C+XJ[&O?X3:AZYV-3ST?)%($
M^FU 9@FT@.<LI2W8H$8XC][UG&5.N$(36S 1D6-=71 R_'5'GDB_R1*\+;%Z
M/<Y^EQ/SSC%;/J4H3]<G6[ K!$A#8"@Z&]Z^.;@!Z7JME;$"\8/P;*[,>_5)
MC/L+,F1@=M2$./M#BCAA\+C<R*!$\WK0IS?G[#K&T'?N\(W;((#^TP#E,:Z9
M-_J (/B\ +/&16^ K(P]C*Y>GZ#%96+$GQJV_CM3&'@],ZBQ-5>!5L!=57@\
MK%Z^GSQ./"DM<IMUFN=#=@"E!KX3H)0@VHR&.%B$#!1().S&:G@;#2 RL/K0
M5?YR3#2U=M%7R;MT]<WJN\/9DT,F?_-$S;=@%G=OZ+S#;P"@.QS2<,T!HL73
MX$+LL^1VF]K'F%C(C!8ZQ]9BH##&.](7G?1-G(2F:=<=*>+1D5\,-\.(&@EG
M NRQ/Y8WV%+%M&_T[<4]%@_^X-R/\#840RX#JXXR;Y]3T7MOK5EZXU&E<X1U
MG'GUPIE?Y ,Z&0&>\=GW@IZ%35YV[+,Y]@&@/(=W:!?_+T_8TGHO0?YQ\7%.
M)5?J^\V)(3%MI!B*91A=-4TIC;^8?U%R(4/E\JE:NO_C_>[Y%S;6ZG@<7&<(
M"5D&,K- &SSK(I0IR(L7O\[X[>N4Q9E&/W4RS[M),KWJ(E75:K7^0*%B9XA>
MS\,68YLV"@"I>M'%!88VY@.7 >(&M%\E[_DJO/EK2N@3=,*)9LCART?R2M%S
M96,U@&Y\X,PE%[R)G*>:,+',VXD>P/.:)!<(3^6AS]@P&3R'O(-L75W9BW$&
MAXKREX%=2,C,2,7]2OL!L7KJ*_>H9A%!OM14>^%?NX)"<Z@P",]TXKV@EQW.
M*<<J OT.O4<P%UNV=[XH402(5=,87::K$.K?:=+0Y\[R)]5^+L]&:_J%.N,*
M]!"'/)7::^D+#[UFMF"-Q5D\90)(V*AA!#E/,*Z,O&-0,FA%P_=E&4E@3J2=
MG6Y=M%D>#-#H;+.X:E>5Y8RN+ICI_H$^]C+^HWZ,R>'(6[]P, *%W"/71Y*C
MAU(0/#+:^@B?VVW!\@F?"E]2F_Z-VVF>=_4QLFRLZV5U>\D?D:J[=@9+?[SR
M-HXK:.:\6>(QIUT\S9H4COU(;L0/C(G/3]!P;&G[Z'T82_!1VPS^]N\<O3ZW
ME3@F>*I9'Q5S\]>[GP[BI0&'[^IZ.?;G5QR7@6%T6.Z\C@\A4*KAS;A4K#+;
M#1I<YA@Y0/>,Z#"N'(0#-4ZU3[;A]JR0E)>"BM)).8^Z/OD@Y2O^7BKB5%_M
MC!$>/F%4P^79X^?+B>T%R9 ?P!;L*<;'YQ?07X>4BB($<A!,MP\$2HUE#IV0
MQCV$@T,W5G]0@VM/=+A*V9GXY_UOA._V=HPZ+[>GVOQ3'>X\Y@3OKYPQI_XG
MN&,A)._N]X$0SM'W9YN!!R!OM!E7V9C[H3W,3/!;R?K<67?IAG_WU[LN[B\+
M/(M/\N;[L@%I3[!EY99YTNLX*]J?^X;06D,7>8XQASJ>8KQG5.=ZA= U S>#
M%.V?4S]G4FQ1E4L&+Q;KUW1>EPP1?\8S*EI]/ >P!=Q%WF\%DA6 M?O;ZMNE
M6.8G>PL&VKO*L,]RJGIW\8)0F\ (0@2J]8+$GYLQ"VGU2GW75I;4&9+#.YJ;
M/^!]F>?+E5"P1&[ WZM3AWZVXORQ'^!"W3Z,;TP,H[@?P8]>=@6_D+.ZS1(K
MS-N>A[D^=T#MFVF]:YJTZU6'X1O-3P@TO\.1<1C6&N@G$"2QZFQ9'F(%<BTQ
M5R [VM_K1E*0]J_A7O7WL8?KZM=WQ7DJVK5]"F=\<M",5FI54Y9Y-Q=9Y2=J
MC+'@63"#9]-GD"TSF)..B,Q3P4YU[NFJQER#</'4/"6T)#RM7?;]XKQ#W=''
M)0V%IY]?_5)7=MKF=*!$E(.>AC.S9NT2S]L04 YK'\]?#'OU@7[CUHT%*?NY
M5G)&D>67-D)6*.1GT/W/;>9*1<M+ ]A,"4^[-7A\R]M#>=1_H^/1#S(8!2<:
M!#)M.&5 4#HBBJZN!,P/CL@M:4VU#4/'-7K;]/_=[LG5O<R=WZEE'[^W\/(%
M&82:QTN^.FB>%8N=XV&-*UMZ>3F/+67+U(?Z!08?^5'F^C;G6G/.7\^Q68_>
M"[V@6>E&JKV,8"6DTZ8K_%X'WG50?.,_?^<6K(TYLI8(L,Z$ RUR2=' E461
MD]-879LT>48;+DU'TJ?JNZ9QSOW"O_?U#IX]9\*[^)!:V \ :(_(LCG ,UP^
M"@#/$3ZF,0<[(!?&@0W;+'L&IZ&&DE^W4J[6[AB8G' LZG*PS3FWY]E-NQ8&
M5B<[9://0",L/NP,3I(0%GT+H6#-HSF[U1B]695LO=Z7G5 R-<M/0JPC3]''
MT]-GN:-H?V V]8E$=XP@[5)CVMGU'7]2L">V]VZ4:T&;$:P ["!9!"/$.A;.
M50;G<KB6J,E/WTF).5U#LE6H%RNXD _(MQ[,HNS%=6^MMVI/1<_=R_\]PI;R
M8F(X>!MA[@(/6^SQ#!WF% ,8VH*ED+A/=G]+_<PX7]>T\+V46%Q<?[4:Q0V:
MTAB*B&9Z5Q7LD.:WE]@E'GV@QFF[,A'/ E[^0+^]M0/H1<M+MK'2N=4="IK0
M=@7L!]N?)%)Q] 2E&BF_T^\_^8EDQ6F\;;V=K%^1$COR3N&8C<QV;2&TR;)6
M'EMY'TL,K60/3>R;R[[7]R^EB?&NC?I=N3N-=<SI^NR-K_M/EUG('&\_2HW;
M^<ICCDLD@[YD4AIU"[;VBG6-I[Y?,0QPQ/%0ICNCYVLQM?YZ6!'I7.GWB-HN
M*\>HRRTG,^3HLL^<U:.$3(*:W")6""0!KI : ['\C2T=1_%B2UN<YS3\AHQZ
MA<,&1K@2+%SJ$FI.T15!/]1#]+WC'-U]X:"=M[=#6\S77^4()HK7;($5A(BI
M$6FPC\QS>I1(]'9B<>.'=3.XQ$>4S>Y(Q43A=;^L46+1]%'.^[OVFREW+?][
M_T0S^SGL&^*2T4(M5UB*840#UL9HG&L3PP0I+!P3#46:US!"W>]134O/%/)B
MCE?1C-&5T@'&E<<LNPH%L>>'7&+S]]YW+MK!'>$U(/U[)R(#$8A0YK%22_\>
M)@X(C8A,#(X3+-!+#_BY&[THO_?-&T=5\+AZ=RA7B >\NZB<1L3%"5@8 F:C
MAR5G, 2H^-N5)1BIQQ\AL>M=RWQR/Q_W=%MXF,XRXE,*=IVW2N+3.)FDL4%N
M-^H7ST2T>O75>U#E!G!9EA9)&VT^JK]B>T('SD;H*CI8QURZZ+S@^N!OPK4+
MM^09Q^!9< D>0_'CBO%T0]+=$48M]=VCVA^$IHGA<9_(-KJ*Y*^.M*A#;]5W
MW>/F7Q$9Y3,>'WI9H*VU?,AHU;7/Z#9Y-R(Z&M*T20-M1_*UZRFX#*1X +SU
MQ,._4EVCT7&RU)^C2O$>]HYO.G5'9-: 5J^U>G"..<(I^4.>3V.^F+R^!9/\
MOJ0SE5/]\LJ5TLF3A'C#R,+/)?5?<@9&E:*O9=_Z_/O%%JPI;VT.L0:P5-$B
M3*\I]L7204A\X,8_K>I75R^[74B7NGP:3%M6W7D.\4QLZ19B'X*2@M@+A(L+
M0R.T$;92 @-+"XV&H4N9ZZRAV;BNW37)=@,--1%7X@0\X@V&G@YXB4O?;/O0
ME4]?]F1Y<$4ZMHM$<JJW8.%P/K8:M$W+?D"%U>C 97A?3M0/(ER<?7#N/U_M
MJG"-]M2@V\&<]V&9I,>2>:IU=*5"2=$5[%L$:&^4N05KR6/+)--<V3)'>61W
M'Y_O!QN=%2_?@#8*&3KOX6<;B=*?/71;;(39U9B/[1=<>MVW'M,:M..W -V9
MI<>^"G6QCF.,.$^Q?-BI@VB1<U!TU0]FG&7D%BQUS_- VOY8[>F,MJZ<*-5+
M.\M@6S"-V@SK:E%SF8OB*0"E@"<(R7 >]'7LN<>2 OI=@: ,K@)VBJL +M5&
M4!,OZ6NW)GNUYJN]ZKFU\,;YV$^'2S)]UU&J]_U,U/($\8RXOHEL9.L6K \'
MZ46SI4=H7FOWP%2$'+K%!9S+^)IJ@L]2N$[T=W+JS3AE_*I .3YI]_XI:5*=
MD Q+@V>X?AN,,T.$N09NLJ41S#P&+C6Z.X("W[T$Q5%[[U'SQ%UV%Q4S":87
M CZ-F=+-/M<5C"K:BQH3"YQNK7,O@AOS %>PA&6'?0/OF!A&+BSWX3H$DLQ<
M_)8]R%NP:"B4".>+JFYJS?W*B$HB!C)V12V<NC,FJ>#T6D >QIKH#Q '0U/;
M_ .1[Z]#!G^BI<8CGZ-33]X[Y/^NJ)'D8))T\Z_YI,-#T?2TJJNX]@ZZ6B7V
M#;(E+AUKA(PH-<OY)V@Z(>9$4_K=UIP8P QJ;?+Y<F/G89M)TTB];Y\S@F(&
M%/LY]PDA>)(.U6((F8Y31*#R2'EGH/QZ--6TUL5PXCBHA ;.@.N/+AJ^O5$$
MFOU9?JWH//H9I7+B<[N0ZGX_G (0FI=#ED:@"*D$^>MYN>4JTYA](//KS[_=
MXHD4IX9O'V)%LGP,=I,7BMW33TX>/SI@;_.N+_'IV85WX[?@N63082-WB4<A
MDB)XIL9@=;C][MCIFW'$B30DG!G.E6>,X],-\+.__(,27BZA(A<K?#Z']K;%
MRJ.T_&+>UR>F\6*!#^<E(<IHGL45?L4RXH[B6AQ&]ED=!\G#)88&UL<#&]"G
M)MQ3YVDE'A/9=*?1!34M:XJ(_<L#(J';96AZ>9^5M;;CO<86PH.X9>0MWEC)
M<KU3OA]R +36;]/TC&#FM=A?"H_+]4<Y3Z*>J!<M!AUS3P_!_D?<9T0B<(6,
M&,G,1DX'(12_ !#);?BTUAXDY9@/W*X9\C/IQU^P?K$IWM.6./N,>N(I]O?P
M-6>GJ5LVQO^KK"?&:P >:G!=^$;1&J'CJ[,VYEU=9O[P)"?[&)!JZ3X3*T^_
M1"A2$D@)E'62$CFH8LLW5D3ML1)SX(H06':\5N]*X]RW.7QAM&:>[<FIZ,:6
MBWVP=H^@_HJ5S1?KK3^:LEXOEAT^D%"0;S\:)7%WU'C@H+M4@@./IE-2<%+=
M^WAT=$%\I)W0GIIFBFN;2_NS3^]<.W#GYVUJ52?K-#;(@17(T:RTB#%4"KF@
M 4H/?^))$MZSGR+UAI&@TT0: CQC$,-L*L2X@W%#Q5A5*((1Z #&^#@'6V\6
M6]@?H8NM]5Y>[[SZ2CL[65F4/_"2ZFZ\-)>$ -TVT@B[MF"1@K$$R%5ULE<"
MK>@JA]D-S=-XD)"/LE!<U7XPYZ68.%,_=$?VYP/#P(/K?F&+RZ'6>YL5>7S7
M"9&)!+WQT'YX'_DVT)Y&G" M])/$!^OCCC%V=^1:&U6C53Y$6-:-&M#KRZOV
M#0Z 0^KOFCH'GN77W5@-DN,//?E/A(AH)-!3&"U,%2B+9<+]@.A0*:,AY3 G
M0(.1%*4AW[C!VZ'5J!OW!L#Q_SJOQV5&&7[VD6^M/Z1>>%S9_=E=YUF>Y_!8
M[.5HGF [2K@$%^$.NV'"IJW]XBD+5C\2I89<J4+Z@9?,WLY)E-!W_ZYVR3/A
M:P[;? :[@C"#8=VQ(SC0'T_2H+BR]\K1R'3"LI$XVM8#2HE@'0] 6_3_MQ(@
MWC)E.AE[M69ESG[UZ]+PX0)/#X//:R/?"I/TS(_ GY*%UA 4/$*8>X3M=,^7
M,9?&-<7HEU'6;A(&>IS]N6-3;4?8%XL8RZ>!1K^%I_.N^TO8\S+98>!MO;U_
MJ-N3!"0X/YJ/*W2;8<$5RF-D,:NV8'<&'1D3>0CJH?<8_VI(G&7X:Y#4U]&6
M$BS1QAFX,))U<K>)@J[^V$M93]<83AG/%1Z2VVN2"8$N -.64XV@5&PN&;3C
MJ/6;26RU>G1@OP1*SO>TE&]9&+[FP81^1[&;0ZN]+1'V"3E^M^[9#H;G]LQJ
M*J>[5Y8[2V@:N66CQ0YMG8M%YM@<)(#%(T!J_LI-NZ]IU$3WZ#5Z1=[IF>L+
MP0;6J)O-SE?FBJ/Y-7(O*_Q<*F;8,GEJ+RD'W<45*6-$<X6ZP#1F8PO8D70]
M+[D 76O?TPORESU;0EGPS[YS4PU4%#+6_RR.&$<:/) )(0T0MC.G2,A,KA08
MMS98\0GH=ZSI)G >6$?'UD,G$0,)A]=<VH8X/>R[^D[7M Z5T.>N3[L<5+VE
M<4&2RXGCC<$4Z#X./(]7 ?K=35U)!/ND[;P/'?".BE@GA-)O^M@WVV@K3;_>
M^53A45!'KOW.PX//@Y2$]L!4MV=:"=$;>3C0G0QI<W&,:>:#&?TV(WE4N>&'
MZP8./LW3M%;%S#ZUHB-+\N<O.\P?/J%QWJ-%S=X%$[-=VF8+-AK'20?6JE<)
M_\X_\2(C0?MH2(O;PFM3 :?(##Y_[=?RGPZBE15.]M./(M]6K'BDBK<HPU:)
M^#W:\&3RP21YZ6&:H+4B%:#@": ]  ?ZS_?J8+08BQWTX"H,H@4Z7G=AM53[
M(5FL<J:J^U7)VJ/NOX0V@^&^6><4[P_4!?W_Q&#_$4"OB85BYB*G%$&I(C>G
MK4VS#K*O3/_>)[",[; II%F)Q0S<*,WIUM:K=22N%#IG%W9&OM9QP[3"JKW+
MY9AP7M=U8V<0XF;XA<U^7+L 40G(>,]]([48KB(Y.Y)&-RVK/[6(:$V:?UMT
MM?*8B4^?#'.=WTG$1*P+F\MYB:#<(T@A(N$+"&8\IPD/A$>*#W8 /&5&ES?=
MCU5RB5'IL/K4;]I?9?E"Z7IPQ\GS(FIG?;)L3N3&,7E]EZ1,8A^$EEE>&'MH
MG'72![TPB&PK;/M"R,+H!E*\IJJF A^M@P;K"VXO/WE:C<I=39=\DRM,>0YC
M-_ >[F<C.<V$"#QD<8^J0Q]EN7 G)WEQ#&SN-=%:@/9,#WC*W@329J3\DB:O
MA":9O;JHGL+NC]7JCSD0&<9N_P6X(B(0D*X1<2P/TM-)Y7GA X0H5@V=UU=Z
M%#>0A9.%",,J8B"<K>D[,_ZY)/?=\-)\'?[LX;TRY3ZG1?W4^.QRQI=Q>[>]
METS2HW6PI18&".!II )/%_U^ D[S9 I18*Y[7VPD^."1H]^1WAM)Z_8?;KQ]
M/=>@_I-XZLEG\M<\W<N;A 4CKN &(VO9BYX/#G*%C[(.8>>82+%><TAJ,.,)
M.NT\KH]'52;9SB&RYR]IY7=Y9JG'WT_6+[&5%ZV7'#VF8L48^=]J\*<(,GBR
M"U@('2BUKP!KEW&#'G$Z1!S?#YL=;6$8VRH_QY.=V;*;=TWO'NZ8CTFY>,?A
MOR="/YD<J^TQQ*GFJF.7<+!Z1-0^UV7/YP#55<['%D7=V+'DB[+Z'9'E_;2#
M4+2:X.S]&?6Y)_-+OL4=;\V<3/[_\F\*Y '!>)(X#3[@(D+5R2"$&UB=:^^>
M?=H%U<;401)?>+#V8NRM5YES>Z82%#A]Y8O=7M.$*!';5_Z5\5KY7!_./0(E
M$Y C4,J1,$(8D$P6 2B5R8,J,*AJS_/G4/QU,FSTDL5@UJC[3-3:^L+YN\V:
M._>3#^0.D,Q]U"\ZP3AJ^&%R:@'W U**UQ=KA"Q 5(>#YU&/4$I>4M.GL,M'
MA0?0D;^SLG+X?_JK'P[)*=B_N,[_(T4E0?Y^\9H-+]XG'<-8<&JPDMR!)140
M3K_$B"$&'&&(Y;;55N?3\N1]7?CQS\((T0]1TP%V5J.F9T>O:!2_*21Y%YW,
M>7T]6#GV&ULRAD@28,O\.L][61U;;9OR-VHS@*1(MMDR3F ).FI4NKXD%?K+
MU]]LP*#6\J.?KI'H1^*=:ZN!,'8WE+AL1"JC.M#G>7#L!:WP*/O--I"_'N0N
M14LZ8Y>DVV>BC +&-[[ESNQ>^JZ>,W"J85R*H-L1I81P1X]P1:H8_XP@[="U
M&(:Z"0\WSG!JNJ.#J8F!0XI &NF/J5]8FT3PL_ ;[<+-\9L.QJV>K'UQISXZ
MD)HZGJ$ \#@NPQ>9B[@"5W)@A8=M3^ .I\55K[9_HUJ_!$GO?HDQX/2\WP6-
MGTX_B"Q)S.OS4 K%V&TCYY5>M?]-_$AC^RW(;?=GR\TA)9IN&RX5)]L*"+25
MD<:UWG:H7)@-89[M*['WUSZA*']!O#"_[^@R5VB:L05C#C+((_B<[1K9^-WH
M.3?0Z\Z?6B7\':0,)I!B\3[*VKEZ\81O NH)RZ NQ,^G^.+UI$/?^PJ78[;9
MH@LGTT:0]_D3L7EIY.:.$;I"@REB[T?TO=?='7VOIC8DWV@G,1?S%HMT!O>\
MM=#@MP^V&6)ILS4Y-5PEZ/SZ%BPBCW1M@>:5^;4MZ>/B]W)I%W&7CMRC9$O?
MNN;B<OLKHWJ'/=ID#]-V)%O0-OOP.5QK3H4-'!,$>@T3Q+Z7RB45N\LM*7W
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M6;+)K%/0M4A+%PL:/*E7Z7CE2JY^1EB G_>Z(LVY+?)!IX6\B*3JG?TP6((
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MUZ5IKY?^?@&]Y=0GO7FGVSO:RCXW'W >5;-BJ)T34F'^+>8*PY>C]WT"^B>
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M+?&?15#59;&>_4':2M9)7%3>H2#XHIO 2J+,WR^L<[RGK_3J84<0H#L'P92
M%ED'4.:*#MF8(_'/,8:,/QW9AE%2Q X]44+P].X7WB%6KQHJ_)#Z5G=_V78
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M+FS!A6# ]+O,\S:?+$CB:J)30@-BI,"V=/%P-[N3!=BHUU<Z'L<]1$28"J]
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M@B9=:NO$W;>!\PX0DQ54(I10B2E9H_-U,KEDB5ZB" $@?LPHCM)&-,\ANFN
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M<G[V2[7@<OIY:Y.\TNQ(>YCKP)J0>VU"C2FIP?EG+.3<@PV!3A5RU_XX&ZE
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MM2NUX4Q=:MK=T_8V;K[TVO"YK26":% HO-3K-<80&C\(V^M8@/2G;'Q5=A7
MV::8)@$GT"QOY/@BFOH53S?SW?^E6E@MID%A/L.'Y%_Z ?4SP)Z7G(0^F!#N
MO@OT-P+NNDJTI*P_MY_M7;<56R%P57M8RJ28S5[B'60D5FKB9W!T>]^D-YOW
MPA@00BW!6:H2,<1I!2B91JG-,1/(,LV2VRN79,$0(51_''HT!2WCZ 62MN#B
M,^!>R;#= AB(O/I\MA &LI5[AJ&)L61(<*.14WF2.Y^4;%#IT&\75D[2^V?X
MX%\&.$<TZR9JK-SI/Q DG7&6&L3N6=HKVV[>4ZK_<1S(0Q:0Y1BW;ZW8(L"1
M?Y^?0#R#2,G\S^<G!807 'GPBTOQ*HL*,7CN>C<)*TR(7986'-A%?7H30?!<
M <;FF'MX3XGNQ&C?0E:'O@>%M'_!K/=>QB,B VZ9VITJW7TDR<;0\>"AM8ZF
M!'>Y[F[&+YUG;I5^+*Y3X@G/%4^)3>5.+>_?:<L5R3VQ:99/WIX87*P\M# 6
MR8?IJ"4OH.F6A'$!%%W\&>!.@K&BMC-VEA_"7<_0>P%W]^'N,M$W/:Z]OBN
M:V9$&-5H07RB+:72?YZG^HYYD>OS8P-M'2H7,PF2(W\G4&>JK?IP+[1<>>_E
MUX[ #_$>0PP "5NY2PE9G>%+C6Z,=_J]KOWXYT,O3F:4[=-59NRV5/EJND ;
M*3.K&6']&T^W((X@FUD<P:4(.H.YIM4@6E4#V=]O@_0ZM90[K_X\^$P\K+OR
MG.PINF"5CQKI#[>R]>3T.]8XZQFD/'*Q0$=T^@43EG7+"L;MGKKM:D\SC L8
MW%C>$*TD;+VFO.W-3BU2)?&)_/CPDF/G#=#%8FE8$3)[C6Y;#3TEK^#=?<<<
MA5^9-AGELWQM/I\,WY8T@ANJSS7BO>+#W.%[GV'T.,C@H\T>F]A6LKGV)RBI
MVY0_]%7L%;R Z_BY9FZNV7;6T4G%5?;E-0/!&73>ZC2##TL/1/"(8GQ8E<;D
M7.?PR!;;Y1"9;9A&/@P>RTOQW:1'13#D6G0XQ!'B/@(IJ#]4D3A]CP^++G#P
M1*L]1=[T';.V5_S3#6^B2B/CZZB(=$]V41QPO7-H /$CB)L3,3ZSZ*DVAUR)
M,[2%CGH,]CNV<V-)='-"W.H?#GX\*,WQ4;A&?:8,$6V&)'] 3KUW'.;&0\0_
M79; &\_RHIY,([XVE25O<NP';:S8?_9BM.]A)DPVKPH.T8OOZV-]@'?)6VD&
M9ZG(0O?B"''4E[PS.AL_[J)5\V5\G:.;L+:\8+ 7,8JG.R8&Q?>(@-UL4>^?
M\TS'B8$B VZ?:#;7KZ^A* >W?(@0M;4QW ?2UKRS"+0Y.7?'BN_J_4U[4-2$
M*Y;K?'@0\$7^]=OH2Z((^:&]$Q9_SP_?AF/=!L;;':AM -V6)FH!)X'-+.^\
M^1IVR/T1*M=KH>@X.-A"B#KE\GP>Q%3#EU4NL%PAMO"YN#I3 UVVGEY[Z# W
MB42WPHW)+B+#'P*'6_.50Q-,A/V6U]=S01DX!^F)7M'CWF-U4.[S^+!E4FRU
MOR][\Y;>ZCJAJ""?]^F56E1>_4%TRGE>(<[)8C)6K4-NIEL/W 5A\79RV6>.
M-U2YV>RL'L:-A0;E0<6[[*B:\<7Q^D>Z@EP1/>8V^A!IB3:*^+KB/<][FY-'
MFINC=8>]$'N]>N-'?JN++SB9OIFLWWX*W^J( B>!V0=8!"\-N OA^I8+9_K3
M95^52P'EW+_=]JGW2QT5&YT//9GX=IR7:M3G_8'RE3?Q05B2T1\)L\U03@GT
M'&!-DXIUW.WR4'%7V1]SXI1/_S^_-9-7&HQKGCQ< ?YD'*MWRX?BTH!6FB+/
MAS6\?.P20,&/AS'/T[TT0S>6Y:;(1\-9)6>^E3J'QS5=CUB.6VYR>Y5F,"YL
M'(ALEE#KT(@^G.'V*K3A1)T2'Q9GB9OM77AH_V,#3;?APT9*\KV0^S!& ^NC
M U/-.<'VUU[._1399<V2=.?JXQHEZEAHIBMKHE1@0\J4%2 7)9N+B0>-PLR?
ML$J'LX7>(=LEX+P3[3$LTE.G"O6!.7 W=(IY"</X4C4J:HE')U#_/.9%,A#-
MEK\J/(W>OX5W!'JB@J<%Y(8].E_[[PTQX6JEXR#\GX9S!+@>F#6.;_3MZCGB
MY',JNY</VTM@#/EF=X&[&0SUU/?N*4-G>WY6+]YX^0?VO5Q%Y>-(I^B<A=D/
MC4+CGD&SN[;!M5%^HA,ZG=;Q$V&2?>C(LR&(&.PV[!#R8U4Y,LEP>W <<(!U
MG?@J[,['PSNA^42*?UU]W)YY^!LLY9J?RS!'&Y*<\X8',=XK^CJ46.MFPZ.I
MNU0([Q'N-0#;5?UKA\&!CZ/:4E\&$2QOQ)@ F+S(D.+#!%21K"(Z;DRMB=W3
MQL2W9 !<D2Z*2=29X2[3POFC?9?_2 TY/5B03AU\7AR0XG2(T)D_18O!B%E2
MM(WS=)]K!9M]CCMIB&W++0PV[*C5*O:]A%GLH1^VGNORM'FP:&'C-0Y.I.;G
M]UC,_=XKMEE#[V+^Y%4 =Z2<G)6I$DL\ZEZ3IJ4FY>#*1;M$\MIUG\LW=PGP
MG'P.'=H6.ES#D@"%"M]SS3+,D7^!'8#(F;"7KB0_[_<.3E<82:^.7*WU":.*
M;3@<D]#JEI.\GJ'>3 GMS<+H9:S-%&VFN^=6S<LVB+082I8^]^Q\.,<MR[>"
M['L >O'BHI#R'(KE2Q)M7G'!-A)E[,X/7)R:3@9H;[4@L]:<ATH!1IR8,?L,
MZ3ARZ4S/)X[)F372@N^!M1S\NWEBI\E;\ M]V+$[M"F'.Q4N8829AS17EEX'
MG*$MX1ECHX*3*4#4'['P) 5HM"Y#<9-6VE=B_%#WJ"(K3%L^E-Z&6]>(T[UU
MAZ?"AQU36Q^/#*7DU/L0-?^/H?1YV7_/6=+S6Y3/:=^MH2N,"(7O$UTUX1KH
M,2]$@Q<,CS!47R$6=_1$G-DV@[..P1V:Q:TKQV>/2!+Z#@(IKGR8B[:!+^Y=
MO;O89L76F M$2.-&U*^;A##*O.P59YQP0IYQE]?Y,-QM=7MOXE0!\-%[Y#NZ
M0C6FL9WV,'.:#_OY1NSTU(]34823!(BM/($5!9/$SZ=#34XW0Q5M > FTRKL
MXQRA<#,FWA9NCB%"=06>Y,<9>H%<DQ?+\^ $8=O2W^T"// [2YU\:8'?<N?
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M 5E>'?\0)=Q()SJ6ISWJK0CK"G?I7+6KJ:F*6:KYHMX<</B;!^5IRVWGLK.
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M=R/0&])VMC3N02)3D-B!9X97W:#R+.H+($UZ<T.(+12W%"W!<%.+.%5:?V(
MS?%KMXX(OD!H3[^&K? @\BHV^T$9>\XA)S[LF]17]F06KI:I=FA!N;I?*M]
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M"K E-,.!@+J0Z$J'LP-0DS+4;0[9XL6RYP&[V\9HGN!*!\ (6= :O0$L/T@
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M-HF('K/:ESI45F)Y6WQ^WX8%HV^JC'.!4H?*VJ(QY_L;V,0&L-3KRM0ZC *
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MTGQ&R$ZR3Z\C#Z3M@BC9S_3RA=T-=#2RY$Z]";XCROWS] .N =G^37=M3NE
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MDY,J(^G3T)T<)?>>.A^H52(9CK%J;X+H4RY[M/[<4E:]V8!>UI6^_@1<*.$
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M@7BZS9_LV!28\IF6AVDE&],&BOMRDK;CAY]]X+L/ON[*"0]MB$^%;O<M?ZC
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MX,UT7C0Q3>'&1=2%&%\UW1E0?Z$/M(FVH(Y@3A(W$C1/4N(H#3_)=[\ E:^
MAHX6?2"VJIXZ0]($-C,\2L+MX#TO7[4<:Z_ ^JHH6)I&O79I@XSH;=Q4&7J
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M;F<6<>PS_ [ARA?0*Z\2%A8%'G#&4HWY?=OC15TJQXE$T0[  /Q\C1'"SG\
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MS\_AUY7.U1;IP":23)-6@"!.LPRB.):0")S"4+(LHRJB*;?:U5\*VC2ED+U
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MFGRDIBQ4]>"Q@HP5$+Z.)$[.,>WI0Y^:1P<-O1>[&U1Z#5_JG59>=3.%ZFQ
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MJ'57IOUUJLSQ0" S3?2I@ %),I(B3C-I=3S@,NG<-N'ZH4N]=5'80WN>P,<
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M:B="W@DPYBM>-0TT-J;=D'Z1]ZFZ=">T*]-:KX,MI8Z![NC<635Q;%NQ 7L
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M;U>FI&A]G%!75?A\2U=MH.OUER]%O8%]NZHT)Y8YK_GPK[+4>]I%$ @ITT!
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M<9)KT<%]*[OA+;65&]"=X&X?+(>UL/O8C(/PR!\* ZZ1&GSH@/OC[TTKG9_
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M@,-()C&-N.-<P6MEGIZGK)$.O&9BP1WG#%X]Q89T-Z5I&YHV6S'<;6W;@=R
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M^GTBI'&XRKE!IL8D2DY0"0JVDIK'3YR%LILB7 $T,#.<PJ9'&<2S()F'D[@
M:Z3 D7Z@606(7$*C(Q3D[*VC!7U<$KX=WG'QVBM;]9RHNB49(S)ET,=,]]A
M"4PQ$M#WA.!1F"0>-JI4<7FHJ1'A9[$&JVW0TT('/5U1<ZL#XB2B/!4AA9Y/
M K4+)Q1B/R8P3 *,DQ3AF)'Y>K4FBU$AW@XX(#7H,9SA:&:%_E-4)ANG"-EH
M-<>F4F+,OJ*8\P)B^LSC(2<Z!OO;ZS-=+>9>@A,14]VV*%+[UC@.8<IB?2J(
M0\1HR&@<FQX([CUY:H1:"P<JZ<P/!??ANGPLV!N$H:U',_VMC@9/ZMKK<'#_
M2:,=#YY4H'U >/J"ODGK'[.%^+PIC6V/12*,PQ3&. PA2G  B=0-1;GT" T#
M/S;_[@X?/K5/KTZYU@*"2D+;E/06<)>_P&O@&/@CM$"B1\+YL<I79)FW'C9R
M:OFQ&L?YY">NZ5U*LRF;HZ.>O@FVR;-U)HK&">/',O)% (-0)A#Q $,2)0F,
M_1#%7&(64V[7+?3"B#9OZS@]0UL"@S(R;">R=8G-3JS-3&B'^ W\M7< Y] %
M88F+NS*;G:.-76G31/43Q3:-;NL;V,S:Q3R_"EUVH?SQB_PJUB1;BM:I_._J
MWU]R;>?7I?=9$G I*()A3)5A'J8"IDC&$'M<"(0]'"66!<>O$6=J)L57\;P[
M3=+%H7X72[$JU!>6ZZ_K!OK@)6\R?<O2%[81OE=-GAF3C3<E Q/=@2(ST%)%
M3TZC#&A'&VE]P"]:GU_=9Y^X@=99&/)5PHP<K>P"N..@9B=/[7EPGRVSM?B4
M_=!CK-5[JPF_JM!^4Z4$E)+4B2XZ-?&C^C+F1,I8,!Y!0;" *%+;-.*+!"8B
M2! ),$\(LK/\^@DR/8-0O>"QY0%^ORDPH]'A81V8/BL%8*D!V*E0-84HLYL%
MT]6%VMK,RA1GH#5Q& YP%9*NX@3Z"3%N ,%50!U%%ESWM-X;W[(2X]^S]=/M
M1IE(SR+_E!&:+=3V6O<"WBC;29DRA+ 8^VD$4\_3\>F(PY2'#')/;WTQ8IRE
MUAM@DY&GQWO;TC&Y^"&6&U$FYFG[II88O%1]E:UWQ4838;P[=@WN\+OD4F+P
M5Z;K,-8RS\!6ZC*GN9;;Z7;9!BAWVV:C4<?>/MM <6(;;75[SRK4.@&9'B8@
ME[\M;C;KIU6N4SN_+]43RW(%59^P>_6J%1]^BIQEA;C/,R:^ZI3W+YMUH>-^
ML^5C=5WQ=Y$]/JE%]D91"7D4:G^IC%#UYT:Y#5D\B/PYF",J(T&B&"9$8H@2
M'\.48 X)XW$2IM)'TJ[0]33TFMH&OY$;DDIPQ;FUY(#M1 >+3%:5+,N*(I85
M+"<"O6GI[FE(.Z&5XV)-BTHU;4%7^H,2 % BH/ZZPV &&O5!K3_8 @!:"  -
M@<-2X].:4E?5S">BU;@%TR>B])DU>FKBV8=)[]+:[G/Q0C)>;X>*FR7_LGX2
M^6UE9E3[I@>BME"[% '&B.>G D&)4 (1PKXN*Q) % =!XB%./6JT:%\KR-16
MV487\$6"6INF9% !E#Z@5 C4&M5=*LU#C:^:L^Y5<<R9&'H9ZS,)X,]2'Z-V
M?6[GQ3Q,?*SY&2F4W.W'8A5B[@+)CC#TJQX_6JBZ"Q#:X>Q.GM=O,_M5%&J_
MPI[42._%#[%8O929V=7X\R#P$.$\@%AZ$J(($XA#%D B0ARFV LE8W8NM\[Q
MIN=H:\0M,PCY3F"[[5TWR&:;+F? #;R&["'6DK0A*'=[%B-$'.TDNL<:U;XW
M4OO0ZC:[J1^%U!O>XF%UP_[?)LM%F82KK>Q6"NX<4RPE9R%,L,^A,G0IQ(C$
MD++0#SS! X]2NX)O1N,:?1FCEG^[5P]Z(GJE7DF0[22UHQ0ST,VHQ1V0XU!,
M(R]8KT M,:@2OQ\.$K_=D8T51HY(QVS,4<G'"H9#$K*[N1\9?5_F@JT>E]J)
M\$!^OA-+(;-U<;=DN= ?G2+"S6)=5_Z_S[-5?B_4?_6U36>X8LZ1X#["(0SC
M5'O6F834%RE,J QD%!/$);;QK+L0:FH;]JWPX!<NZA]_!;E8E.V'U)?YHO4
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MG-"T#TRU!PV59F"K+%1S"K6Z,[!3&.PTKKJ:-CK-@!^ 2FU%"*!2? 9V+]0
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M*V@+.]-=R7XS=TIVXGK9O^L*K8%I^RQ0E\N9V"%F[KEUA=Q(SMHK$+1RT)K
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MJV<6Y)+IU'#Q7E3_KWN]B!>2\0.YE"QE-F8E]SRFE,N$13")/;4V4.I!*I,
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M;:0$?U9R&NZ@KYJ/;MH<"^6A"=,:8&,B=(%0%P6JY[?H3_UK1WU7#3T*Z;D
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M%&J/-&<(B1B%/E1&D]I.8[6=QD(J8RKV!0E(&O'$RIAZ.U6F9IYMY=4)1I7
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M@&-?41CQPT"WGB50EQ=5%,:2*"(,A:A'+:FC<:;&5+6_<"NG2=*@%:YF/.4
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MR-3$U&;F/&QCY*]_8Q^2M%Z'RW'=$.@&WJ6VP.Z$!I]K8&\:8(WDH!*]_DT
M8.V#OB$ 'BCZZP]HIT"P*V(=$6'KH08+#;LJUXX1.S_K(UC\?C'7.\FZ9#-9
M_W55M:8LN8RG<:Y$G"(%:9PCB"BCD @<0<[S/"XR[=L53G6=K6<>&]=7 =*R
M%2#E>]FW_S#2@V<COA=_RWZ5^H2A/6$_=%SZ?1OVO>#UJ56H.+4%5D$"UUWS
MOF$DVP*.[M"VS0!75WJ9KTMA&JF7/UH%#C[^--U<I?BD5316^J;>8>_41[J<
MFS0U;6)71OJ^I @369$354 BD:; 1!+(.*90RCB*LDC@ I'>M5\\"3F^N%2K
M&LPV0Z=*1@/:K5F#_Y)+";9J J.G_KD$3>-[\$6NP>?%:F5"!_5SX#V=<=-8
MV;SK[R2GFY4T8^NGRB4P,,(/#8[@H]+.AV,=UP#?&\L@U9M^%T)'F]K%:5KJ
MM<O2[+X%57OEEHI54D*C9.N+,%#=&L^+X;^2C2\!WZJVC6> .ZK=^)ZI3_/#
MI^>E?)3SE9:AKNUHZ.V>_FQZMKR3<ZG*]92QC,><"QAE>0Q1A#%D29+"C,4\
M9TF6HXC:W-9SF=3)TA[@FEY3B]34RVVN1X)?6"VJI0'M!/GE $H(( ,3[X'(
MH$'T%R/UKY.JRNO'+;+OPB'KTNW0/\*#=3KTAK1CJT,WR#K;'%H.-6"+0S?E
M#ML;.CY[K:/1[IHKJW8SK0N2OTNZVBREN)M_,UN/N2OSCJ[*U:NRA5D>J5CE
M"<Q0$D%4F"0]$V8ABM HB6B6YDZ]&+Q*-[90S,ZJU/;__MQP FH-M:%Y<-\8
M;)4$=W.P4Q-4>O;U$7PLN:M[,/!"#N@9G%A#>FX-%T=K.)!#X!%^[[Z #]G>
MR WP".MY#\#G)'UO+^X"7B82UF0/LEB@5-OT4'!IJJCA A:(2EA$A*,$92C#
M5I63.F<9&WNWA 1&2M?[:Z> M./2J^$);K0?(A.DJ4X'!-XNLYV:8^ ;;1UJ
M'E]KZ_KP%<F8['(J"'N="M(D?#271 P%W<[7FI-6):\8+)[*!.$BPPSR3)K$
M[5A!@A(%TYS$.8VC..=NIF(P4<?&/#</#TOY8++-RJV@37:D6BS!HE8'R+T^
M/=(CPZRYI:TXBI4,;3A>G\"X2U%L*3P!.Y6#I"$&71:?>85A!!T^43 HX"<S
M_\+.Z./J3WT"MZ\/,<T+)@6F*<0T3B&*1 892@0D4J9,%A3)R*F,;_=T8]L/
M7ET'FC3E,@#=%] P:1SU3QUS-RX ;T?H_N ,3,JO;A!-MF>]>V%#W24Z!TJ0
M6T5'D[WA_:)SBG??-#K[5$^WEJX>S?], K.VI&15<WBE"<Q4_S&_J.H"M7_0
M^N14($PRS@F,,"T@RD0"28YCF**$"$8BGJID^ERE/']?T^7:T@F^1B:7=^JU
M9 $=0RUD%1+CYB]R+^X$,/E0SLUYI0FDU1(Y.M17+:'"/$4THC#AA=1+F'.]
M=W"]GW N9)S%N9"L6<*/<S'*!=S*]2;+)TV9I;=8.,N(R5!+$3JRHB6;@&H=
M/K;AW\L.ZH_41><.?MA^PF,@Q@>RO@(V5\DR;&#'!VQ' 2 O@_;;0:N;/F>.
M+#\MEK)\F-<U5OG+O?8F5I17GL5<5/^J\^%NQ/_=U-W6OLCUG;JG/Z<RRQ0N
M<FW)%P6&""D**8U26'#!\B@F(LF<#/LP8H[-(6@T ;Q1!:SWTKN1<Z!E31*6
M2"HPY-IM@RC.<T@23"#B&:&\$%E"(K=4U+=?V&'244>_M'8;\MLO5^"=NKY)
MW)E4LUW*K:*@I6FU@;=T!7ME)U56L3:VM,+^]O&P"^)I@P\DY* [?UB@7YL$
M@6?K9RNT1*B25N?K<K[1KE]S76PQ7[V32@NW:QXNM[).M9=&5!2G4.)"091R
M;0^05,$HIC$F&#-IUUCQ>E%&NN>[[0%7K(0=SP^#;V N/^#M;7K_5A.P5P6P
M2I<MSU?:[&C>'U5?CZDG.KY"D$$I]WK 7M.JAQ'[4N>V(?7=7W,IWE']1>6R
MCH9.XZQ(<(0$Y&D10Z1,)7'M)T$<8YS1/(U5SMW(\?QD8Z._+YNJ$+@VBYK#
MCX41N?^Y1R?0MMSG![[@[+85$U1R3D CZ?;TPR=S74;$&S=U3#4P^UQ6^IA?
M+)[IQR#:AMNSU\UZO2S99EVE""Z^:(4TE6GE9E7S5?W>:BFFD4G?RT@&4\6U
MS95%2COKJ8"81UP2F6>*B.F\2DBQC(P[RV#UNA3UZ]*6)"#?:!]L9FYVTI;X
M8+T \\4<MC0P*3J5"F[TX[Y*=IP4!OEAB,I ?FB*W;S"_E %<'L)>F<"ZPV?
M)U9SGW]0JNL-SVO^ZS]0_Z8L9<6W)JFZMN<>M%-<RM6'<L7UB[YIWXA.8B5)
M(C%,<\P@(A1!QH2"L4BRHN":')%COK/+]&,SO5K25V&K _G=NWHXK(/EX5\P
M=$.?]G4!"_:R@S^#W!GIAYO'3B(.DP_>9\0=F%-=2'J,TN?2]DS_=6$<TQ^R
ME<OW3?Z0\XTT'NS]H_RZ7' ]85/59+VD?#W%$1$IYQCFRA1-XBF#A#)L^E.E
MTIB$^O]L:^/UEF)L=-<2$?!&1I=+QWT7HYOL!H,X..>U=#C(A399#I4>=01N
M_6@Z?.R7XOV 2^%R(7R )1GLAGBHI7&\,'XEI)TWR/N./>"5\BO5/[QC?NU@
M_>SMX\Z[-VQ5OUM$H$(ICF 6FS8O&9>02<F@("PK4JQ_4Q1NJ0'G)QO?\7XC
M8+N+]W^XF= =T-J9RW[@"KQ-G.K##?[<"NK1"+Z,AB>#MV.B08W;RPJ_-F0M
MGG W6O>E0Q>KU7NZ7+ZHQ=+<-%G=SH54Y;Q<R]E+^Q=3HB(:*:8@D4)"I' *
M*8^T:YZ33%#&9*ZL*SF[3S\V,W4OI[U%U /TRU9I6"@#\TRKGK )]AZ(;Z[:
M[14X^%U0R.VMS[#0#V1V^EX")V.S/X(=5F:/00<S+_LKW+8KKQBE[_W !9=2
M5,?QU06APPN)4DRU(<GTHQS&4BB].Z@(DIS'D&=)'.-,*N1VW?SBC&/;$+8"
MUSY:=5/P]5UQUR;,EU&W,SF]8AEX1SB$L6XTUHB[:SWJ]9:@)33>+@I>FF_@
MNX*6ZA]?%[1]L!_AU*U.?I?KQX78G]:O6F=$69302""(*<X@0@C#0K (8I6(
MI$BXR OLPC>7)AP;W;2+FS6=EFKA04MZ-[JYB+D=V_A$,C#9G 4N:+$P6X \
M4<[%Z09E'%OE7Q..]7/]3ZB;GO5U&M#M:K4Q9DW.,<N3'!9YDD(44PFIR&*8
M8T20_@^FRODH^L0\8V.7IA3[8;V#LA*U?\[?.8SM:,4#<L'/5NKZ]>W2!MJ#
MJL3T>VS<@8/'\^%3LPQ^$-RAZJD3WZZ/>[5$I@P7&1>1@I%IAXPD)9!A06&6
M<?U'+G(JG+*!S\PS-F9HI;-J'OB;G,N%'S-CBI,\XMC<0$UQI"TZC"#A#,$B
M(ZK@2<**)'4O\^ !UN$*.+S;56E@=4JJ'V2C J%4Z/TKB7BAD8T)))(4D!21
MWMRP:<Z$7*LO>,,U?%T%/8-W2*\RA4>T9[F[#K[,W6&LW%$8MXXV[94;UNY2
MS#=IQ"YG9=VQPEQ5W-\U7$VERF@J4@)CE%&(,F+N^N4)U#N9$BC.$R:LLH\<
MYQW;AE;)U^=:WV6$[4@B &ZA2:-JG-2Z<FWZ%WPS!3,/59@T#9];6DS S=-B
M,_>8,^X(G]>[>9=G?8.+>-90G+YU9_]X/WJJ>Q3K*63YP\18IHBE19P7,61*
M,6V=2 X+%1LS$,5I'M,\QI$+#[V>8&R$TS0\7^X$=".?(_SL6.8:5 +320/(
MM\N .)/#.:T]L<#1\(.^[N>4>_U>G_V<>]K(AZ9(H":)5EK*81_:;Z;K^)WZ
M8U67T9_F4J6(1!)F5&F_+C9U0SDKH(IHP521RS3+M_?;[NW21WJ(8?5]/[SB
M=C\ &512FFNUID\A-8+:YS;T68QNL@B)[5!]8)L"H\8D.<AB.VI=72D![Q34
M:M3]1,)";Y]7$G@)!DHL";,43NDE5P#9D5_29]3!$DRN4+F=87+-,+U;GU1)
MC?]5KA_?:UM3FZ++[=0O3>+CE!:<J5QQR.)<[R5YBB$5/(.\H(@RC..4(+?L
M99MI75ZN8?*8=^_6LLXD=VZ.<AEJVU,9O_ %/Z*IQ05_:7G!5N#)CIY>=MG.
M7GNI6$/DK[7*Y2F'[K1B#<*)QBOVS[K;M!>+\K-+1?F?I2GXN5[\7:[6=YOU
M:DVKB'-=,V7*DE0_&R&H$H8T9S'-7IJM8,JB7&5*"A%9YTT'EG5LKO*^ZLP^
MDZY6P)0C, %3]]/H(9;\LI4]HH4,3+EU@Q5FV8B%76C$LE]]H[?^U5[S":AU
M'\_7P-[B']'782#O8#Q?"R>/8J"%ZO ^0DLPF*<R$)1MKV:H*?MVR7@NUW16
MM1\6Y7IC,ECF52%B\6ZS_K)8_T.NO])23'&"(QJE")IVOQ"E:02+*,901I1$
M/.%1XM:.QW;BL9D']5'2"E#.ER8SS;1G>]:#/^KE6U7]$I8+[;&N7ZKR'J:A
MPO-3EVE_W:I8.DP!L [M--4B@[;,8"LT8)LUT&*#%[D&1G"?O0_<H/+6YL!R
MVH$[&KB!<=R\P/'Y?ASVP=P^DE6YE:JHE&;-K_K+]/'I>;9XD<O?Z9H_:KX\
M^+W4W]/Y>IH)++E@ BI!!$0\)Y!D<0(%)R*E0N:1<*H]W%^4L?'<[_1G^;1Y
MTBPVW^CWD+<D-BUA@*Q5DA/S+^[,<%>LF1WG#;,2X4\6C!*@+24P:FC[LU$$
M;#4Y^- $-,J8':GYJ%S]'_"WI;EOJ:T,?XQY/=">./0*009EU>L!>\VS'D;L
MQ[SGR\W_C99S<U&TKIELFDBD0B%$DAQB82Y/,2HA2;)(&Y"8"9Z@(DY<CF1[
MB##2X]@_YDM)9U5+QW6K6\0O#UK^7^N"I/J?JM83[IJ$"#E?/)5S(Z7^NVNO
M<I>5LR-<WPLQ#,-V-NPP@N]:>S2%X+UVZ.B!F2>R=)EY4';L <EK.NPSQ#5I
MK]_7^B4T3MYGL^!ZF@^+)SW1E&LVP45&822(A*B@!%(F4DC21'(9QQE#CK7;
M.V8;F_W89&GNI 5;<<&?M<#G+S?V@-J.HKP!&)B4KL"N9RKK!4R\)K">F^L-
MTE8OJ'TZ6?720^ZG@3>;A\UJG41QH4VT'W*Y+ME,OEO,Q>IW607UN4HE8ES"
M.$J$";XAS20T@U1EFF)P)$1LQ20VDXV-2&IY@1$85&+:G[5<Q/7RF9E/M *S
M1ANHEK U:.#/6EY+UK5"S_ZHR2>* YT578FFTP&/+3P=)S07AQCLB,56F?89
MB?4S?0.$;/U=:L^I2BB[^4'+F<E)UG;B=SJ3>__+F(9?%ZO2?+/JTY4[M?WW
M:IJQ*,]0Q&&6$ 41S;!V8*6$>9(@(G+][Z1PBQ5ZD&IL;-WJV;-3S5S:I>"A
M"CUM]LYNY=D^-XJX1@]]+*AM(''@90H>4V1KL%=H G8J0>T40:/4!+1B$E6%
MMJTBVX-ML\ [Y7S&$CUB[2VLZ$.F@2.,'F$\#C;Z'-S=6-9&^-)D G^0]9^W
M\YOZ*/:]?J#D=':_+)LSIY6<)H(1$B<)Y-H;ATC@ A89H[! D8@4YSE6TM9R
M=IIY;,3<B IX(RM8&V&KW#8MK8-1[8;_90L[&*KAG?1*7O#+5O)?P>T<;''>
M2@\J\4$C?RB8[4WQ8' /9)?[A=W)3.\%78?-[C;>8 9\+S7;UGR_ =QV B'+
MZ8W^N@GSE?LTHP_3&&<"I3F#.4DUTQ=8F^?8I#SCN$APK@I<6%WI/1IY=$R^
M%0X8Z>P8Y1BN;F*^"H30<0X[_:U?[;.ZGC @M5/SV\/BQ[_K9VK;4?]E;S(>
MCS3(2WM6@>U+>?X#/5L]R-5*RE<7LZ0)@F[_=2^73U,2T8)$+(+:0>80*?UN
M,DP1)&F.4H9PEN5.E^SMIAW;Z[J_>#BK+QXNMR+7/P!:B"?'?A!V^-OYM_Y1
M#?S^UP*?NM&Y [;Z ;CO M:]:X033KXZ2-A-.FPW"2<@CCI+N#WMKS7:I_*G
M%%^7)9?;NUUU*F^5:RW%E!%>Y @IB 67$%&N/<6$4G-DB^-84!P3JV+B5\@P
M-NKZVN0U@V<C\L2D-@=HDW9I82Z[D / '9C3SO;AFH!*"5AIL>NZM:UH!!I-
MPB_"]>W1/"[&6S='NW)1O+1&LX2S1V.T2R._>5LT2]5MFJ+9#M4S/;)JBO%9
M3REN];=U_F".M:JZ!7^LI-K,/I=*3HNTB"-,!4QB22!B*(4LRS/(%=4_5XPA
MY72L9#/IV#::O:!U/9J)*4VC904S+:QC8J,-YAP7I! L@;'*!$2R*N2?4:AR
M*FDBTHQHRG,JZ> ;]6%*.ORQ1[FZU/PBZ=*UPK85X':NB&\0 V_:M;BPDA>T
MOL(W]5>X ?=SUU?8/6/4 2)?J:(V4PZ;(^H PE%RJ,NS_6C_BUR_IZO'K\O%
MCU)O(N]>],AZLKK:JO9R;DP=R^KT;)KS',51QF&!,@218 C2*$$PS;3K(45<
MY#&9KA=K.K.C(?NIG;: G0 !$P>D]BFTZ,;)J&0W%[%_V9@KV"8-OMQJ .A.
M!3>><E@5.[8*@W5@SC(P&ZG!US;,?VQAW@D/;B[#[$Q>[HAYHC"'B0<E,G=
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MXE ATG6!"LEI%N<QQ(5)A>%1H5TE(B%67&29XGI;MJ[!&7!Y!JDH?&)QPB]
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M%]F?%\12X3@A"&8BBB&2.8%%C#*H<(91FF8\C]PN(_<696STO=4$W"EPMCP
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MXD)A3(2"C)@LY91$D&+$H511'"F&,2=L>R/VWNY4V5$$J]?A\';L_0 D8K0
M>J]?MG4P>WUYT%BSOK)B?V3JNCZ7SZ!#P#T,^U00_V)D_Q7<S<&!^.: J%8
MU!JT,EK"H6U_6!T0]8$.KKVC[W22W1._CE-MUQ$'.^'NJ6K[M+OO$#WO01HK
M]8;SI?8L/^\[H#7'ZMJ,-6GB37H'C9526.6PD&FA/7HAC;%9P!1E+-=;"$6%
M4Y]3A[G'9G;6[EXC.V@)[WA[T0%].SLT$*:!=P=W.-TO#+H#X^LNH,/,PU[S
M<X?DZ 9?CR%ZQB)-4%.[V<;GWCMG.,&*Q4C )$XSB'*60*I2#@5511PAE%-&
MG4JFGIIE;.131_U-**H*$?9W>4]C:AGENQ:IT.&['B"Y!^2Z0/ 5:3LYQ[ A
MM"XUCV)CG1_N>4)L!KNMPM\?JO2_KW)9+D0=<SM=M7Z:R$1%6 I(LHQ#Q)2I
M_Y2E,-$NKQ2HP$I8]9.Z0H:Q$<?'GW+)RU5UU%@?+RSJPOU5"/LO:@K]KU=
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M6-T\+9;KIG)G<Q7_'Y(N[_]:3#GA5$BI(*6X,$Q!89$A!3&A6/\NQZF(W%S
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M^D-/O_?%/]?EZ1E5\0?Z6X17KD']^E"+'7:A8BX79G_;X(L=-!>C,);#>"+
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M: [X5;E#4WQ:+7+Q_%7]V+S2^OUS3@0C@@8!3()$0(P3 BD2$BH>"8(S266
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M(VW]9 X;E7SU_-ELKRD-Z_[8*48J3-,P@Y'")B<V49!D*8-2A2(*E)),6>V
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M ZO&!N-PUD88;^:I-,.-Q5S&QH[*!D)\8#Z[T/-W!G;J@T\'8'_J!MN9T'K
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M*"*SG@R9"==.(>&A@BR-<$+2B/$(6Y?9."]C:G10J0D>]WJ"I^[,,&LTNUG
M$T8#$T -3TO%:XESUO X%+JX'::QJEHXP^56R:(;B*ZR%1?N'*]&1;?J!P4I
MKEPZ3"%/JV7:J^?3A5IY&CHG7"^::"1@F 4!Q&D80\)8 &,19C)D* XRMZVX
M0=6=&@M7FS>\W^9-'7[@Z+P-_#Y8[LU-9I2GO#MW=8"]5P3U@_M(!4)O5'92
M]4+] .]:/M23U/[51 _#I.^7[Y??596H6<RIE (E$8)!9I(Q@E! %L8<4AY'
MIN\2(6'2(V_FBE@K[A@_8>:WTUR,?*^T>S70+N#M*-P'CN/5]SQ-I3 0OK>
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M"6091I#&F:0L8"2+G#(0+>5.S=-JZOV7YXR-XN!/K3EH5._=--)V*.S(9@"
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M2D=3,49H+6=FX[16?X1P2;=!OSX?3&\H!YY:/(1)UDD@536AKP?5A/;V@QH
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ME[=XG-YZ^EU*W7R5GD-@Y\P,#^O 9%D9 $L+P-Z$:E4U T;Q,JBE;<T,&$.
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M][5%LTR%@9(8\@!E$(=4:(^79C#C@@>2DXQ%3@WB'&1/C=8/5-\G2[O6 W0
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MHM"$_97]J/;:7[/U^CE;K<NVMC^>\FHOOCAJ1II&+$R4=@L090SBQ)0YXTD
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M1F5&=7G\ '?L$'EZJOLV^P=6%.R==K_6>N7WZ]O/7WYG0F@WK)[D RI$&/(
MIM24FXX9@TS$$4Q%&F9*9#PCW':7O5O4U!RH4EM0J@NTOL H#&J-[;>-K\![
M?;_='V@#$UL77M<=*U?@[+?;_0$XTF[[;4 Z;;?;8=.QVW[E :-MMML9TMYK
MM[RCYU:7XILO2M35-NZ^LWQA"IZ^6ZU-AZG/BBWR?REIHM;F6*(XED)"RC6W
MXD00R%26:M\T2&4F4<294V==>]%3(]RRVEZQ4WT&6*,\S%9K6&CU9V!=&P >
M6.Z8L.TP*):;8H- /?BIJ$;Y2POENP.4OY0H-[J7->(\;I4Y ^9KT\Q>\+C;
M9\Z G&RDN3^A;[?PI>;*C7%+RR[D1DJ[G*+)7=.K:<U=AL5X!'FL*,P4#[A(
M0J&X4TI*I[2I$=<7\4W)K5[#W6>@I7A9:<NU'W@7R':LY VZ@8GH&"GP1ZGJ
M,'44K4#QUNJ[2];(S;TMS#YMYVUS4^\8A,UZ*TP=LK((3ETM^_6JV'S<&L?K
M/ONT*O(R+_?M(G_,EV4Q[3(S5_\I3)QD$F*"5:!@$F:F9YI>G-(0*1BG68#3
MF">:>1QC%&[5:6J,5.EMSKZ>&LVUYR2W0D_I/U55(HS:CH4>? R>'8>-/"0#
M,]V!-65 1%.NWQ@T _O1VAD%]E;-ZM(+H#;,:\"$+Y3]!53<K-'8 1>^(#P3
MD.'MT3?V+SYLEJGGATV^W&JMZHP%K<"%=IN[$H%1B!,:1!AFL?X#XU1!@GD,
M0X69%(GD441[-2^^6;6I47>KJVT3*O53;=W/,[ W$.PMG!VTPCWLG&M1:7#H
ML;>C_)<9T8&9OWLP;=L?-YV-!RD;Z1]WWQV.;U?L9=H;>P/T8F]C?Q+<PVP^
MZM?^/ON5_>=J_7I;;+24]9O5(\N7<RRY)"@VG8Q)##%E%')%]=\R&F"DB)#8
M*H:X4\K4:-LH:CRX4E70Z K^J+2U)-]N7+MYU!M:0R_[K:%QBK6Y:OH-\3:7
MGSU:S,U5\]IQ-]<O[N</UOW;-,%\V>A5#%O+XK<G4U'P[8^-YB&S8? A+S;S
MF&<<AXS B. 0XC#ED!.N(,*8()'1, Z<D@@LY4Z-$O9J@YW>H%(<_+%7';Q=
M;A]KOG9TTFP'Q,X#&P#F@;G$*\+.GI,C7I[<(ENIH_H\CE <.S2NMU^BK_;8
M?M!_^]__K?F)_L/4>_[?_^W_ 5!+ P04    " !MA&%6@4\?=@K5  !EA0D
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MHB2G+'#E!)KLK,@/I9\/ <QM*CH!S0$Z7305<'<0J7[3R\5IF,XG3):23'2
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M]?[<YO%"YA YLT#L)FT4$X6U+GS>F[AQ4XL#&*9!M-(!W.[.NE\87):C2#J
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M@;R1^V1T!]NA--L/=F]7L%S*\KQ+\U4; &49J]X-LX%V:! !HDD!,)<H-8J
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M\LMB1KI:;>_N#B\TN>^C6I23[$5FJX& MQ9[NUA?0YBPQB%',,;[VH4%P9E
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M8_)04)%Y"XJ9LE=._S'%7U]T'/>@F>(/EE\'0>B]1][OTSEN.LU.9)&.6,_
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M/6)Q5YW?GR;31 &3UMAL.IIP^6.6+L;R/S:*_ZIM)7/%74U,(:/[Q&GBCJ<
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MS;Y_6;RET[O^>1DE2RM33IH.*:O=A9R<FF@<0E9":&--0C4*V)XG:[I!<PT
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MB7=B<-0NH _E#@^734'>&&)9:/((ZGAM*0P$0R$.XT*%*!QC<5 2^P6,/$G
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MBX 7X;6'.CJ UPLO0I?FV(:02^(>--;.:Q85!*8U<"M]$$')'%H/BAU$6&]
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M(6OG6BK"<6;<"+WY^Q=:3E-*TOC>VUT574+K7C57"L)[E)+L>:1CB#F!-]8
M:L4]+THRW[J3],@++;="P+:%EMNHHP-X78XHV$S>G?VHI^_* MN8@\H"3'+U
M&8*,;Y N Q(SEIC1JOGVJZ=HZ0U.^VC\\3%S^XF_ QB]F#;4=*A*HK!7J4)"
M\HE#3 XA\%A,X;ZDT+J,\HAK2O:Y )NJH@-H/99TN1IW\O-NGO%_,)]PXD)Z
M$R#S.D4TD4.ZB7M\T$K0@<I6CU"ONP6%7>8E=D3'P\MQ+%5U ,2'MKJ.VE$Y
M*2^$)P$)<B8L2Q L\80<6="6;'7SB9B/$M+E,U8;6.TO^ [0\VSM2T#K538)
MR"TE7J+7%.[R#!:=8-9*5V1W)4B'#@V;F:@V:NBS!.G-XI2PMZCL_<!7),1]
MUXB\\ ,;E IM0W*C\I\/RZ^!KJ -J02(U>)TEB_@/<\?;['QH;R;S<,\S<+I
M9_J=RUGEU].(. N\OG])@^2B9VLAN,*@SH"@F#)$KEI;_B:$[[TFZGK)[UW5
MW=KM2^3\3@?MB3_^0K]:$2%$Z.K"WQ6NSGY'"L%]H8.GC (7D8,E=X [20+U
MK1MCVG,QK6-W>$P_V HU+2XFKFYY4UT47)*RUC]K,GCSTA1=01]$!)Z8!;5Y
M)%!%@<V)@OD4>1ZV+^>%PI;'OCWQ6N6)L;!HJ)B)@?4)OY\OT[>PNKD<[[-T
M^1 5G$DHA($8T-4)QAE\00LY,.8P>QV'37-X 6V#"9JNY&9_G2_&5L#4,V+N
MS;3"X+TTLH 0BF)Q$00X:2-$Y<GK=1K1Q1=<Q:ZF@(VDM&>F@FTCP:F5_YVL
M[N+U;'%)>O%1L]IZH5(M49)D56/V1#_'8I,HSO-!RK_[8Z<KQCJ \O>0X-1U
M>(MPNNFV*(OEV^^SC&>S1 YBE6J>XVKU?DX!VD9-5U./=#3>296!U]96Y4,!
MEXA#'R77.I",N!X CZT_/-T@L?$!-*X6)H;8Z]GI*;EWOR']80[_H"AC]8[$
M=Q&/7+(CO! LD2<7T=>"),_ ^Q! Z. C3YQ%]M+;Q,!/33>8;'P8M9;TU.7?
M]0!L%L9]*'7&_3Q=S]Q,,9MH$RCC;&TXU>!M1M <E4".(N.0*^K)#PP"B3Y.
MD+21:@=OZ)=;WFZBQ(U?7TH04@L!&LG[4B9+\,%P"$F23Y^Y,J'UX_FCA$R;
M@>DDXFZGJ@[P]E!XX7%Y78V],@JY49P $S(H71(=)Q&@B.2YRJRN^VB="]R.
MQ"ZV-.X#BONIP1$UU $ GSK*5^-(,]%=M\<(1BS1Q6[ .<W!N$+_<=EYU[[X
M_3F*)EXW.R88'N01FVFFOY[=HG/2V3"B'A%42+P.2U*@A2$A&1%,&82K<7IV
M1TL\=W*%-E!*MYV^Q1LOBXF MNYR=*KN<N$2R'M-7NC,DV[Q1'T<G;Y;:710
MI^\VXIWZ#?+>\ZF,TJD8-&A;AY)ZF6OMA:%01)K &4J'0_I!NWF ;J2D9QZ<
MMY'8Q ;AXW*1S]/ZP_(S+G_,TD4^1LOH/"\21.:"Y! *U$IJ\%*Q6#(%H+G%
M2IK'OCUMZ6]']\S>BND#6%5>EQRLK@8^HDE.*0_.1%4']!/]9>.!&10FV-H:
MWPY=#PF8SO+LK].' -E3P!V$4K\2Z?/5E>TL@GOE@R62-S%G]<^-SQ"8P.J>
MYX%3:;:(G.X0,#DZ]E7HHI5T)W9#?@VK57B'/W!9G]'??OK\SSMW+%>6HD3.
M(4=6[]C:AN.$!IZS""AM"9H-\$J>_\ITB=*V8&@LSXF1\?G5I\]O%O\4;S[\
M\_TOW-_E0Z-7:#4Y6_7A2FFKP*-',%&4Z#4AWJ0!N'CN&]-E/]NCHIDLI\Z=
MO_WUU[=OOGQZ)3]^_DAB^KZ<X3HL?WX^"\OU+UA%=>6<ZX!%,0TE6U&=\P*>
MO'SPEL<LBB_Y_A/*$^-M!GYPNB1G>[2,(^6)H?/^]P_*,795+.0Y"I4+%"DW
MB^(DN.("%!88.L-SX$.RWW=^Z'0IS/80V%U:4V>P?W_UEN*VC/FWQ7R13NM0
MTU?S]2PN\L\OF+[-%Z>+KS^O7HF]+R9C .EJ9IZ[BEP5R1 &%.BU3X-6;V[S
MS4$@,<<!DM%DW4&XTN!EX-?KAJFZG=0)AT"2)'\\H85@R/_R1@5ALU?:M&\O
M:T?_-(:ML]>:R8$QM>OU>)O8']])8_/UQ_"S_NM%ARCFDV""]"5MRIWJIG@3
MP'GZ5Q$4X\(X9N6059=;?73J,153X6)Q""7U@SY2YQ5C-W/+KZ8W+%[C*U(4
M5O8$A379F@C2DJ^BI&1 5PV'@FA+CC7%,R@$V/[3TU8B]8;$4136)1X_+7Z&
MT_7/C[B<+?))CD&G+"W$4L<KT(&Z>(\+7%KZ+>MM&N)=#OC4M&G[CO&VNT*Z
M<$%7Z]_(/U]C[1?%$QU4T#&1:$)==,1K(6I6DKC16F65XH,]X0V\R#LD3)NV
MFQQG+10S==9_/C\/I[>(OSP:@8RK<]E"YJ5.-Y8&G"STKQ@SA8+.,Y$'V*HG
M?ORT <3DN&DE^'[NO%O.Y>_G-;Q?E%_"S]5_+&=K8N_WQ7J6\#66Q1*_X/)L
M-M_H^L0$C,*1Z96H(]WOSD-@EH%4D8QQ0E_"D$?[?>F8Y@FF*S0>5)7]P/:6
M9W 9"[T-RSEYGLEF*45TD"6K)4$E0XPA0 G9,E0.LS$[NVIW/C4(?/9?!7Q-
M%-*!J[;+"C\90Z&#HJ!.-@)5%$*(P8%FBFM9HM7AP+NM=MZ[Z/ZV>#V4@ONQ
MD;?N@PL7I?+\MA1,]<]^"6M\MUC>O@JTL%9XXI#+DHC-XL%KGB$E0?&4]S&:
M+</<;4D8A%'_M\7H(178)4[?G<_KV:MO23=OFTDEX[V'J!4QY>@6\3S7$TC^
MB?59FOO6=0M4/O+!88_/[%\0A/MJITO(79RL]>*2HTL>R4O^1(H/M9UXGG^A
M.^-T\;W^]1,NI2N)'.2ZC9S.6*HBI0NAGK!@0RE%[6LD!Q,S#*K_BHF2,;7:
M@9?Z^!Q7EX-.C$=P1M7R+Z; >5T@*_I-'U+RHO5JC-T'Z/*_;]:DG98Z@-H_
M2"RW63CQ7&"6(4'2'LGB(]E^91U@/2.&U>?WUM'.?1J& >SOFR9IHILN;^-+
M0WWM7C!%8*BKD$+R==(<N1?!)%]7II-/&Y5)>??;]M['AJ'J[YL4&4<K7<'L
M1FSO9G]A_KB<);QZ!7AU5HWUJS\#*3J?&*NCX2X#9YFL-#,*/!.1^*3_BJRS
MN3^ 8@#P!G]^&!3_WGF60VBN4W#>>J/Z\@T_+A?I?'DYSFA^.5TX%)N0O 9;
M!_53J$7R#"J"03J:$:64@V9^[4S ,(#^*Z5>QM+>Q!#=N!B5!\2\NKX LE,R
M,6+ <*6!/ P-KLZ#]<(5E57F.@U9*?WH#Q\&K;]W8F5_J?>Y5.'SM\5R35\X
M>S__@:O-(+451>+OPFSYSW!ZCK]A6%T>EM7G\[.SL/RY**]^A-EI=6\I?%^%
M4_R,=*!FZQGNL8QA)$(:+'$XA(@:+7^X1>$O&-=T0-[^]_EL_?/FZ]?3\)U0
MUN<DP4ANZG@\NI0E"BA!9<<#2\;<Z_[<.V@<3MW>*]OHQ]_ZJ5>Z>+=8?B9=
M7!2J%W(](A8#-H5-9T:IA>H:D,DDZ?26'&5C 0P@:]I"ZY'P\V"-6V/U=/ H
M<[UXXOV<!'1^/0#.*A.CH'",>R&)C50@6G*%,RH5K4K*A]9C\YX@9>+=;*U5
MOF@O_PY@M'%:2AVB=-5)1E'^K;4F-]RMZL#!U>-_=+7$VA2,A=R16)BJ,Y@$
M>$1R?43P2"&98Z7UNL"6]$\+V": NC\X="KM3ARR_':^/@^G]<WJ:CRAY]S:
M+!$42QY41/+ "4P0A6(ARNRS'I)"?O"#)YX!.IE^%ZV$W8$-_./SE^7&I?Y9
M)X#?7!I7<YUU4CEZ!Y*S1 =0>PBQD%PR!B:-KO=&8ZOV/$73=B1-CKD1U-8!
M"-\LSLYP6:7T,7S'Y243(62KI2#CKV,&)84!)YB$&)U!E[*RT37&WJ.$3-N4
MU WD]E=2#TC#Y7I69JGN-Z@S[+\O5K.K4;LFI6R5"!"<HB"+1 51.P9":AU#
MCD*8UFL8GR%GVA:E?E#72&$=8.^WQ7+]-7S%UR']%^8;F_U^M3K'_/KG'Y__
ML?B!RWD5W>?O=?,BT?AVL[]A.5M=VW8EK$G,*^ 4J8$JVI!/G ((JQ.+Z)'G
MUA/GVE ^;?-4-XB>  93+QZL68)-/"><3;E874,Y1\XQ17:.Z0PF.6-$22D,
M"Y)?6BQX]<&)=YF/] RSNTQ[ ,*5BZJ(PU0D6+L9W&"P#MLJ8%!S88(T+ XR
M8T.@,/6HS!V5=5_=.TAN\I4 ?\W.SL^N]D=9IT0R#(+1M;V8&0@R<Z!H.20N
M@_1Q4('FB]L ;GUT8J7OHK)%"_EUX._<S#NZ;_INC.)-KEAHM%BCU2QB 856
M5F<N "KEM+!)YM"Z>G<K J>- L=^T1]/5U./T7M<<.6"N:N2E$U'^[K^I9\G
M&(J- @T(5\]JE.18Z2QKK8%D&#4=PGM/7D\LB-ORP[WLV6X.@,6AM-&!S7M:
M>->Y7(/"RZPT.%./*?,(KG)D8NTAXB5@:EU _C)5O:R<&PM\(^FG0\3=.V)G
M%&W._@=S'?7R.JS(!25O0;O,+&17IR3[I,#1?T!)SF-*3CO=^IEK6QHGWO[5
M&",O0+"IPG8'Y&(=3@\!R)3.S\Y/PQKS/Y:+U>J/^1+#:67X'V$VOYS/$?XZ
M,2&@$XH#%]& <L*#X])#,8D+[217]^?ECXW2881/:TBGA>X(JMT9SS]P&1>'
M,;%/LOTK_=L-VYB]*L(QJ$-9Z=K*#D(0%HQ(0: KUM@#V]UAA$\;^'2*Z-U5
MNSVB_06BY_BU$C*RFWI7 "<I6\^%K6_+4H,*RH%G@4&,W&?-3/2N==WF4-JF
M39 =&)=-%'3\1?&_USVLF^D?!RE]?_"Y Q>X/\]NHS+V(4]+UD6C+5. 6)NV
MDZR#]4T&;I2)$JW'^ULF#E^^O4,9\97,7_^\_N7_-\-E'9#P\]<Z'N%BXUG0
MH=3Q1TKQ4I=&,/!UF)<(/MIH6?'#%L!M4U4\B++^BXRWP<V#(N/VVND@7'_T
MG#_D[S+/C-EXD2,'*U+=?Q8%!(^1 ..EU_1'J7E1\58$3EPU/ )"G@)A<W7U
MA,7W\^_GZ]5&8ORJKDM8+705&F>1G!=E()3,:E=QCK;$F%&,A;R'Y'2"L_8@
M> IN>VJD W#=N#>UG&9S$&,TB@>G0,B4Z#9@=;RT#Y"9(5\5B]&R-:8>4M%_
M2<@^E^:>4N\.-V\HY/VZ6,[^9Z.AJY-0Z,-%(N@:^"@3$$)6&6Q*625KM&B>
M*GZ9JEYZ"7?3^[,PVEL)'<"J5B\OYI_7B_1?5QM$<S"8HP'T=1><<9K<@NQ)
M4I4#-"KZUB_,#XCH"33[:_F1@O'=1=X!9K9,2SKMHLBJ/OV56A/*Z-XO',B(
MEU18,LS_WP*6T2Z^\735 1"?%]ZG6UF6$Q0V)L,S(.,<E-.1K'[,4$H(62:%
M++7.,@RG[JA*7+:!R%8M]SOKZVB06+,C)P6#,,IE8,R3B1<%P7DT->OGHA)>
M*=NZ3V$X=4=5[S(Z$K?65P=(O#\KX]V/WV=W,\X;KEADI3C+P-B,H(JP$%BR
M=-*<RBZ8$E5K+V\89=->QX=#X AZZB*%^OS)NILI_EB;UDBS%WMI/I2K?U^=
M:,6XS,:"YM*!RIQ<'B$U^=?(8DDQR! .:B0'$CYM\K47^SF&ECLPK<\S7:MT
M9_/SQ?GJ<?:Y^(W^QK?5A^6OB_E77#X41V:>!>LY.3FFK@I+ EQ  3YG&82P
MB+SU.^#(+/6R6'K:XW!89'1P4![>8Q_FM]+Z)YA+]E%ED$Q30&N,!J]L!*.+
MEY;EXK!U^NX%DJ9=&7<XH+;4S+[NQI<1WL8__#G'_#J<U@6,G[^1\%<GW"9F
MF$E@G-ALORG@4C1@N0Z>:RNX:QWY/T?/M/OA#H>T9CHY_NJLNC-L\Z>_SD*<
MG5X.I-G\>0[KZ__)8AX^524L9_.OFPKWPQ1S[4O=@6N_F@KS\!-/Z_N!$E8!
M%RG0D<J&XKD<0-K@A.-HR<J.9HW&GGAZJ_#D^KPCKO^Q7)Q_KQNB+I91&.UY
MHA/O!7DP*K!-C2:"3\5QS:2US24PA*Y>4DY-$?1,[5@;!77@;-[BZ9:=>+?$
M_S['>?JYR?DFF6+64H#5M5LRA0Q.HB0.C<X)4[*F=;GV +(ZJ=YIAH6GP=9$
M,3UA[3&&+NN<HF71::' BISKHHE OHVWX&+DT7G#XOU-<*/4)MXCJQNLM8'"
M@'+$??32*=16UR[-9>% <8$KY1$RH@.E;8+J/@/C5GCI"N>L=6PSA*Y.P-8*
M#$-J7_?13 ]H>V+0L$.A<D@9>$J&#F5TM3+%@5!:%,F1J^:S__:9'#Y:9G+\
MR[*! KIH"FTZ3TY'K..!2MV#4W.O>C/?7P*R9(1U7KO<^D7\[S\\?"M(C3D\
M?!OM3HKMQR=:NY28U@;!Y&Q)CD* 5\+5F8-U(3RF@NF%=YJ_^_CPK33\[/CP
M;83=A1V\F43]8 JU) QP5S=Q%D/WA"2W(++ZTLZD%$8IFUCK:/1I:OY&@\-W
M05MC=77@RCT^CSHI[HS@EB2B5/5'B0GA [! '(3"@L;64>G??6CX/G#;7TD]
M(.V9&=0I1>&8-6!<[<JRQ8.SU2%.3C%.)IOIYD/J_R6&AN^%ND8*ZP![C:9%
M:^^SEI%#B%J36\&):U7K+!*7&%2QV'PSUO\=&MX0T1/ H /P#VSPCC%R$>@@
MZXP<%(N)CG3F0#PJ$5SF#GEC<#<<T#":$W#(Q$<K]?0$ND'=WB9[Q,(=,*SK
MMB.6ZM042,ZFH@+F9-58V/O;3&C8"B%[36C81ET]8?&1>0"8LF=(-PEB<'1R
M.<G+,@;.)"EBL3:.A[SCGM"P%0BVF-"PC4:Z>+MYC!EQQ4P(EOGD0"/6Q4X>
M(2#=#E8:JV(J(F/KS6_/D--)5F02>.VBD6[A):\V(ICZ7U00BR*3+Z,%5U@!
MY,%$E#*C3 > E^SAM69:>.VBD;[@]9AW>QV'?28];B3Z)GS?-!G\>EWVFX6*
M&F4 $;2L_>8($8V 4)S'*%E$-]J,HQUIGO:!YX 1Q0%4VH-_]\AKP?7O750
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MT7  =!U $1U<L#?NZF=<KT\W_2JOSJI<7_T92'GYR^*BG",LUS]/K$$NO+?
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M8X475MV[-I\8[#;P@],NBAL)+N.)O ,/[07&PNGJI(@<T;D$+A8#BMD"7M4
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MK *YBHYB14@4-[*,R&/SOJS'*9DV#CL<R!KHX?BF UQ6VBW*;3-_.45TG+$
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M&NMNT5"0$P/ACSF)_L_E;+W&^<?S>#I+'PH1,9M_O0H5HR[.%XH-=:SUS1C
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M] I2<044-P*B3[7!9*V$+(:KYLUH#]OQM VOC@+),64XL7WW9I&67['NO1;
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MV#0WF8XAA/'[05S^HGZ)88W_]W_]?U!+ 0(4 Q0    ( &V$85;*=*#S) ,
M !\-   9              "  0    !I;F\M,3(S,3(P,C)X,3!K97@R,3$N
M:'1M4$L! A0#%     @ ;81A5GV$RB7[ P  M1,  !D              ( !
M6P,  &EN;RTQ,C,Q,C R,G@Q,&ME>#(S,2YH=&U02P$"% ,4    " !MA&%6
M;>8+O&@(  #/*@  &0              @ &-!P  :6YO+3$R,S$R,#(R>#$P
M:V5X,S$Q+FAT;5!+ 0(4 Q0    ( &V$85;)C47/5@@  )@K   9
M      "  2P0  !I;F\M,3(S,3(P,C)X,3!K97@S,3(N:'1M4$L! A0#%
M  @ ;81A5G1!M3!Y!0  :!X  !D              ( !N1@  &EN;RTQ,C,Q
M,C R,G@Q,&ME>#,R,2YH=&U02P$"% ,4    " !MA&%6>@(./\5K! !$=2H
M$               @ %I'@  :6YO+3(P,C(Q,C,Q+FAT;5!+ 0(4 Q0    (
M &V$858G/S9>*1D  ,$B 0 0              "  5R*! !I;F\M,C R,C$R
M,S$N>'-D4$L! A0#%     @ ;81A5M0/&EU;,   ..\! !0
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M;F\M,C R,C$R,S%?9S,N:G!G4$L! A0#%     @ ;81A5D=#%9!.F   VKX
M !,              ( !S=8, &EN;RTR,#(R,3(S,5]G-"YJ<&=02P$"% ,4
M    " !MA&%6!T'2_0VB 0#&Y@$ $P              @ %,;PT :6YO+3(P
M,C(Q,C,Q7V<U+FIP9U!+ 0(4 Q0    ( &V$85:E%KS5O6@!  #'#@ 4
M          "  8H1#P!I;F\M,C R,C$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M &V$85:!3Q]V"M4  &6%"0 4              "  7EZ$ !I;F\M,C R,C$R
@,S%?<')E+GAM;%!+!08     $  0 "P$  "U3Q$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
